activity_id,mol_chembl_id,compound_name,assay_chembl_id,assay_type,assay_cell_type,assay_organism,pref_name,description,standard_type,standard_relation,standard_value,standard_units,canonical_smiles,doc_chembl_id,title,journal,year,volume,issue,first_page,last_page,doi,pubmed_id,patent_id
31876,CHEMBL152968,N-Biphenyl-3-yl-2-{4-[(R)-2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-acetamide,CHEMBL660388,A,,Cavia porcellus,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9 of isolated guinea pig heart,IC50,=,24000.0,nM,Cc1nc2cc(OC[C@H](O)CN3CCN(CC(=O)Nc4cccc(-c5ccccc5)c4)CC3)ccc2s1,CHEMBL1148425,New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.,Bioorg. Med. Chem. Lett.,2004.0,14,2,549,552,10.1016/j.bmcl.2003.09.093,14698201.0,
45775,CHEMBL292759,4-Bromo-N-[4-methoxy-3-(4-methyl-piperazin-1-yl)-phenyl]-benzenesulfonamide,CHEMBL666252,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory potential of human cytochrome P450 2C9 as Tolbutamide methylhydroxylation (100 uM),IC50,>,100000.0,nM,COc1ccc(NS(=O)(=O)c2ccc(Br)cc2)cc1N1CCN(C)CC1,CHEMBL1132410,"5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.",J. Med. Chem.,1999.0,42,2,202,205,10.1021/jm980532e,9925723.0,
60245,CHEMBL153741,N-Biphenyl-4-yl-2-{4-[(R)-2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-acetamide,CHEMBL660388,A,,Cavia porcellus,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9 of isolated guinea pig heart,IC50,=,30000.0,nM,Cc1nc2cc(OC[C@H](O)CN3CCN(CC(=O)Nc4ccc(-c5ccccc5)cc4)CC3)ccc2s1,CHEMBL1148425,New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.,Bioorg. Med. Chem. Lett.,2004.0,14,2,549,552,10.1016/j.bmcl.2003.09.093,14698201.0,
61667,CHEMBL150614,N-(9-Ethyl-9H-carbazol-3-yl)-2-{4-[(R)-2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-acetamide,CHEMBL660388,A,,Cavia porcellus,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9 of isolated guinea pig heart,IC50,>,100000.0,nM,CCn1c2ccccc2c2cc(NC(=O)CN3CCN(C[C@@H](O)COc4ccc5sc(C)nc5c4)CC3)ccc21,CHEMBL1148425,New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.,Bioorg. Med. Chem. Lett.,2004.0,14,2,549,552,10.1016/j.bmcl.2003.09.093,14698201.0,
62459,CHEMBL542139,5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-yl-phenyl)-amide hydrochloride,CHEMBL666252,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory potential of human cytochrome P450 2C9 as Tolbutamide methylhydroxylation (100 uM),IC50,>,100000.0,nM,COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1.Cl,CHEMBL1132410,"5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.",J. Med. Chem.,1999.0,42,2,202,205,10.1021/jm980532e,9925723.0,
64287,CHEMBL154751,"N-(2,6-Dimethyl-phenyl)-2-{4-[(R)-2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-acetamide",CHEMBL660388,A,,Cavia porcellus,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9 of isolated guinea pig heart,IC50,>,100000.0,nM,Cc1nc2cc(OC[C@H](O)CN3CCN(CC(=O)Nc4c(C)cccc4C)CC3)ccc2s1,CHEMBL1148425,New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.,Bioorg. Med. Chem. Lett.,2004.0,14,2,549,552,10.1016/j.bmcl.2003.09.093,14698201.0,
66436,CHEMBL168471,2-(4-Fluoro-benzenesulfonylamino)-N-(1-formyl-3-methyl-butyl)-3-methyl-butyramide,CHEMBL661231,A,,,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9,IC50,=,492000.0,nM,CC(C)C[C@H](C=O)NC(=O)[C@@H](NS(=O)(=O)c1ccc(F)cc1)C(C)C,CHEMBL1145779,Structure-activity relationship study and drug profile of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) as a potent calpain inhibitor.,J. Med. Chem.,2003.0,46,5,868,871,10.1021/jm0201924,12593666.0,
76630,CHEMBL3706623,"(S)-1-[(S)-2-Hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-4-(5-pyridin-3-yl-furan-2-ylmethyl)-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",CHEMBL660395,A,,Homo sapiens,Cytochrome P450 2C9,In vitro inhibition of human liver microsome Cytochrome P450 2C9,IC50,>,30000.0,nM,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3cccnc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O,CHEMBL1136138,HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.,Bioorg. Med. Chem. Lett.,2003.0,13,15,2569,2572,10.1016/s0960-894x(03)00475-x,12852968.0,
82258,CHEMBL115,"(S)-1-[(2S,4R)-2-Hydroxy-4-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-5-phenyl-pentyl]-4-pyridin-3-ylmethyl-piperazine-2-carboxylic acid tert-butylamide",CHEMBL660395,A,,Homo sapiens,Cytochrome P450 2C9,In vitro inhibition of human liver microsome Cytochrome P450 2C9,IC50,>,30000.0,nM,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O,CHEMBL1136138,HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.,Bioorg. Med. Chem. Lett.,2003.0,13,15,2569,2572,10.1016/s0960-894x(03)00475-x,12852968.0,
85318,CHEMBL3706619,"(S)-1-[(S)-2-Hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-4-(5-pyridin-2-yl-furan-2-ylmethyl)-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",CHEMBL660395,A,,Homo sapiens,Cytochrome P450 2C9,In vitro inhibition of human liver microsome Cytochrome P450 2C9,IC50,>,30000.0,nM,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccccn3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O,CHEMBL1136138,HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.,Bioorg. Med. Chem. Lett.,2003.0,13,15,2569,2572,10.1016/s0960-894x(03)00475-x,12852968.0,
90195,CHEMBL3706620,"(S)-1-[(S)-2-Hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-4-[1-methyl-1-(5-pyridin-4-yl-furan-2-yl)-ethyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",CHEMBL660395,A,,Homo sapiens,Cytochrome P450 2C9,In vitro inhibition of human liver microsome Cytochrome P450 2C9,IC50,=,410.0,nM,CC(C)(c1ccc(-c2ccncc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1,CHEMBL1136138,HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.,Bioorg. Med. Chem. Lett.,2003.0,13,15,2569,2572,10.1016/s0960-894x(03)00475-x,12852968.0,
102346,CHEMBL114756,"(S)-1-[(S)-2-Hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-4-(5-pyridin-4-yl-furan-2-ylmethyl)-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",CHEMBL660395,A,,Homo sapiens,Cytochrome P450 2C9,In vitro inhibition of human liver microsome Cytochrome P450 2C9,IC50,=,5500.0,nM,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccncc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O,CHEMBL1136138,HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.,Bioorg. Med. Chem. Lett.,2003.0,13,15,2569,2572,10.1016/s0960-894x(03)00475-x,12852968.0,
116376,CHEMBL8153,"4-(4-tert-Butyl-benzenesulfonyl)-1-(5-methyl-3H-imidazol-4-ylmethyl)-2-phenethyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine",CHEMBL661228,A,,,Cytochrome P450 2C9,Inhibitory activity against cytochrome P450 2C9,IC50,=,3000.0,nM,Cc1[nH]cnc1CN1c2ccccc2CN(S(=O)(=O)c2ccc(C(C)(C)C)cc2)CC1CCc1ccccc1,CHEMBL1146667,Benzodiazepine-based selective inhibitors of mitochondrial F1F0 ATP hydrolase.,Bioorg. Med. Chem. Lett.,2004.0,14,4,1031,1034,10.1016/j.bmcl.2003.11.052,15013017.0,
116379,CHEMBL8414,"4-(3,4-Dichloro-benzenesulfonyl)-1-(5-methyl-3H-imidazol-4-ylmethyl)-2-phenethyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine",CHEMBL661228,A,,,Cytochrome P450 2C9,Inhibitory activity against cytochrome P450 2C9,IC50,=,2000.0,nM,Cc1[nH]cnc1CN1c2ccccc2CN(S(=O)(=O)c2ccc(Cl)c(Cl)c2)CC1CCc1ccccc1,CHEMBL1146667,Benzodiazepine-based selective inhibitors of mitochondrial F1F0 ATP hydrolase.,Bioorg. Med. Chem. Lett.,2004.0,14,4,1031,1034,10.1016/j.bmcl.2003.11.052,15013017.0,
130285,CHEMBL8332,"4-(4-tert-Butyl-benzenesulfonyl)-1-(3H-imidazol-4-ylmethyl)-2-phenethyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine",CHEMBL661226,A,,,Cytochrome P450 2C9,Inhibitory activity against ccytochrome P450 2C9,IC50,=,38.0,nM,CC(C)(C)c1ccc(S(=O)(=O)N2Cc3ccccc3N(Cc3c[nH]cn3)C(CCc3ccccc3)C2)cc1,CHEMBL1146667,Benzodiazepine-based selective inhibitors of mitochondrial F1F0 ATP hydrolase.,Bioorg. Med. Chem. Lett.,2004.0,14,4,1031,1034,10.1016/j.bmcl.2003.11.052,15013017.0,
248661,CHEMBL276140,"5-Methylsulfanyl-6-trifluoromethyl-2,3-dihydro-indole-1-carboxylic acid pyridin-3-ylamide",CHEMBL661221,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of heterologously expressed human Cytochrome P450 2C9 at 100 uM,IC50,>,100000.0,nM,CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2,CHEMBL1130195,6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.,J. Med. Chem.,1997.0,40,22,3494,3496,10.1021/jm970424c,9357513.0,
260934,CHEMBL297784,"5-Methyl-3,5-dihydro-2H-pyrrolo[2,3-f]indole-1-carboxylic acid pyridin-3-ylamide",CHEMBL660394,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of heterologously expressed human Cytochrome P450 2C9 at 100 uM,IC50,>,100000.0,nM,Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1,CHEMBL1130195,6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.,J. Med. Chem.,1997.0,40,22,3494,3496,10.1021/jm970424c,9357513.0,
260945,CHEMBL14563,"6-Chloro-5-methyl-2,3-dihydro-indole-1-carboxylic acid [6-(2-methyl-pyridin-3-yloxy)-pyridin-3-yl]-amide",CHEMBL661221,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of heterologously expressed human Cytochrome P450 2C9 at 100 uM,IC50,>,100000.0,nM,Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2,CHEMBL1130195,6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.,J. Med. Chem.,1997.0,40,22,3494,3496,10.1021/jm970424c,9357513.0,
339647,CHEMBL430841,"1N-{4-[6-chloro-16-methyl-(12S)-2,10-diazatetracyclo[11.2.1.02,12.04,9]hexadeca-4(9),5,7-trien-10-ylcarbonyl]phenyl}-2-(4-methylphenyl)benzamide",CHEMBL659092,A,,,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,7400.0,nM,Cc1ccc(-c2ccccc2C(=O)Nc2ccc(C(=O)N3C[C@@H]4C5CCC(C5)N4Cc4cc(Cl)ccc43)cc2)cc1,CHEMBL1134932,Bridged bicyclic vasopressin receptor antagonists with V(2)-selective or dual V(1a)/V(2) activity.,Bioorg. Med. Chem. Lett.,2002.0,12,21,3081,3084,10.1016/s0960-894x(02)00649-2,12372506.0,
347542,CHEMBL121241,4-(3-Amino-propyl)-N-(3-hydroxy-propyl)-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,50000.0,nM,NCCCc1ccc(S(=O)(=O)N(CCCO)c2ccnn2-c2ccccc2)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
348952,CHEMBL414238,4-Amino-N-(3-methyl-butyl)-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,60000.0,nM,CC(C)CCN(c1ccnn1-c1ccccc1)S(=O)(=O)c1ccc(N)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
348956,CHEMBL121420,3'-Nitro-biphenyl-4-sulfonic acid (4-hydroxy-butyl)-(2-phenyl-2H-pyrazol-3-yl)-amide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,15000.0,nM,O=[N+]([O-])c1cccc(-c2ccc(S(=O)(=O)N(CCCCO)c3ccnn3-c3ccccc3)cc2)c1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
351621,CHEMBL333108,3'-Amino-biphenyl-4-sulfonic acid (2-phenyl-2H-pyrazol-3-yl)-amide,CHEMBL884338,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,12000.0,nM,Nc1cccc(-c2ccc(S(=O)(=O)Nc3ccnn3-c3ccccc3)cc2)c1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
353090,CHEMBL333210,4-Allyl-N-(3-hydroxy-propyl)-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,80000.0,nM,C=CCc1ccc(S(=O)(=O)N(CCCO)c2ccnn2-c2ccccc2)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
360239,CHEMBL120797,4-Amino-N-benzyl-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,55000.0,nM,Nc1ccc(S(=O)(=O)N(Cc2ccccc2)c2ccnn2-c2ccccc2)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
360243,CHEMBL120426,3'-Nitro-biphenyl-4-sulfonic acid (2-phenyl-2H-pyrazol-3-yl)-amide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,4000.0,nM,O=[N+]([O-])c1cccc(-c2ccc(S(=O)(=O)Nc3ccnn3-c3ccccc3)cc2)c1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
362853,CHEMBL332690,4-Allyl-N-benzyl-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,>,200000.0,nM,C=CCc1ccc(S(=O)(=O)N(Cc2ccccc2)c2ccnn2-c2ccccc2)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
364481,CHEMBL331431,4-(2-Amino-ethyl)-N-(3-hydroxy-propyl)-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,10000.0,nM,NCCc1ccc(S(=O)(=O)N(CCCO)c2ccnn2-c2ccccc2)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
364485,CHEMBL121522,3'-Nitro-biphenyl-4-sulfonic acid (3-hydroxy-propyl)-(2-phenyl-2H-pyrazol-3-yl)-amide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,28000.0,nM,O=[N+]([O-])c1cccc(-c2ccc(S(=O)(=O)N(CCCO)c3ccnn3-c3ccccc3)cc2)c1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
364489,CHEMBL333704,4-Allyl-N-methyl-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,>,200000.0,nM,C=CCc1ccc(S(=O)(=O)N(C)c2ccnn2-c2ccccc2)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
365959,CHEMBL121503,3'-Amino-biphenyl-4-sulfonic acid (3-hydroxy-propyl)-(2-phenyl-2H-pyrazol-3-yl)-amide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,12000.0,nM,Nc1cccc(-c2ccc(S(=O)(=O)N(CCCO)c3ccnn3-c3ccccc3)cc2)c1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
367385,CHEMBL121048,3'-Nitro-biphenyl-4-sulfonic acid (2-hydroxy-ethyl)-(2-phenyl-2H-pyrazol-3-yl)-amide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,20000.0,nM,O=[N+]([O-])c1cccc(-c2ccc(S(=O)(=O)N(CCO)c3ccnn3-c3ccccc3)cc2)c1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
367389,CHEMBL332994,4-Allyl-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,1000.0,nM,C=CCc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
368785,CHEMBL121040,4-Methyl-N-(2-phenyl-2H-pyrazol-3-yl)-N-propyl-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,20000.0,nM,CCCN(c1ccnn1-c1ccccc1)S(=O)(=O)c1ccc(C)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
368789,CHEMBL432386,4-Methyl-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,600.0,nM,Cc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
371564,CHEMBL121323,4-Amino-N-isopropyl-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,80000.0,nM,CC(C)N(c1ccnn1-c1ccccc1)S(=O)(=O)c1ccc(N)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
374466,CHEMBL443542,4-Amino-N-methyl-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,100000.0,nM,CN(c1ccnn1-c1ccccc1)S(=O)(=O)c1ccc(N)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
375838,CHEMBL330871,4-Amino-N-ethyl-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,90000.0,nM,CCN(c1ccnn1-c1ccccc1)S(=O)(=O)c1ccc(N)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
375842,CHEMBL331485,4-Amino-N-butyl-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,50000.0,nM,CCCCN(c1ccnn1-c1ccccc1)S(=O)(=O)c1ccc(N)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
375846,CHEMBL332958,"4,N-Dimethyl-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide",CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,10000.0,nM,Cc1ccc(S(=O)(=O)N(C)c2ccnn2-c2ccccc2)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
377208,CHEMBL120825,4-Amino-N-(3-hydroxy-propyl)-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,>,100000.0,nM,Nc1ccc(S(=O)(=O)N(CCCO)c2ccnn2-c2ccccc2)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
378600,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,600.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
380036,CHEMBL120183,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-N-propyl-benzenesulfonamide,CHEMBL659091,A,,,Cytochrome P450 2C9,Inhibitory effect on human recombinant liver cytochrome P450 2C9 expressed in yeast strain,IC50,=,55000.0,nM,CCCN(c1ccnn1-c1ccccc1)S(=O)(=O)c1ccc(N)cc1,CHEMBL1134658,Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.,J. Med. Chem.,2001.0,44,22,3622,3631,10.1021/jm010861y,11606127.0,
474355,CHEMBL112532,1-(4-Butoxy-phenyl)-1H-imidazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,96.0,nM,CCCCOc1ccc(-n2ccnc2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
474361,CHEMBL151646,3-(4-Butoxy-phenyl)-pyridine,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,7520.0,nM,CCCCOc1ccc(-c2cccnc2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
475461,CHEMBL422858,5-(4-Butoxy-phenyl)-3-methyl-isoxazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,5220.0,nM,CCCCOc1ccc(-c2cc(C)no2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
475467,CHEMBL434317,5-(4-Butoxy-phenyl)-4-methyl-1H-pyrazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,8700.0,nM,CCCCOc1ccc(-c2[nH]ncc2C)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
476645,CHEMBL150681,5-(4-Butoxy-phenyl)-isoxazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,8000.0,nM,CCCCOc1ccc(-c2ccno2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
477875,CHEMBL151449,5-(3-Butoxy-phenyl)-isoxazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,7740.0,nM,CCCCOc1cccc(-c2ccno2)c1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
479206,CHEMBL345544,"1-(4-Butoxy-phenyl)-1H-[1,2,4]triazole",CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,2800.0,nM,CCCCOc1ccc(-n2cncn2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
480452,CHEMBL359116,3-(4-Butoxy-phenyl)-1H-pyrrole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,25000.0,nM,CCCCOc1ccc(-c2cc[nH]c2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
480458,CHEMBL347303,3-(4-Butoxy-phenyl)-1-methyl-2H-pyrazol-1-ium,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,19200.0,nM,CCCCOc1ccc(-c2cc[n+](C)[nH]2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
481719,CHEMBL151280,4-(4-Butoxy-phenyl)-pyridine,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,<,46.0,nM,CCCCOc1ccc(-c2ccncc2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
481725,CHEMBL150799,5-(2-Butoxy-phenyl)-isoxazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,6090.0,nM,CCCCOc1ccccc1-c1ccno1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
482944,CHEMBL358214,1-(4-Butoxy-phenyl)-2-methyl-1H-imidazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,10200.0,nM,CCCCOc1ccc(-n2ccnc2C)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
482950,CHEMBL151037,5-(4-Butoxy-phenyl)-1-methyl-1H-pyrazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,6480.0,nM,CCCCOc1ccc(-c2ccnn2C)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
485305,CHEMBL348263,N-(4-butoxyphenyl)-N'-hydroxyimidoformamide,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,19900.0,nM,CCCCOc1ccc(N/C=N\O)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
485311,CHEMBL150146,2-(4-Butoxy-phenyl)-pyrazine,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,36800.0,nM,CCCCOc1ccc(-c2cnccn2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
486442,CHEMBL151354,5-(4-Butoxy-phenyl)-isothiazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,<,46.0,nM,CCCCOc1ccc(-c2ccns2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
492390,CHEMBL358216,5-(4-Butoxy-phenyl)-oxazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,<,46.0,nM,CCCCOc1ccc(-c2cnco2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
492396,CHEMBL433737,3-(4-Butoxy-phenyl)-isoxazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,43300.0,nM,CCCCOc1ccc(-c2ccon2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
494709,CHEMBL150278,5-(4-Butoxy-phenyl)-2H-tetrazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,10200.0,nM,CCCCOc1ccc(-c2nn[nH]n2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
495781,CHEMBL151974,4-(4-Butoxy-phenyl)-pyrimidine,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,>,46.0,nM,CCCCOc1ccc(-c2ccncn2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
498027,CHEMBL149750,5-(4-Butoxy-phenyl)-1H-pyrazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,19600.0,nM,CCCCOc1ccc(-c2cc[nH]n2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
501833,CHEMBL358880,1-(4-Butoxy-phenyl)-5-methyl-1H-imidazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,88.0,nM,CCCCOc1ccc(-n2cncc2C)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
503165,CHEMBL267865,N-(4-butyl-2-methylphenyl)-N'-hydroxyimidoformamide,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,4170.0,nM,CCCCc1ccc(/N=C/NO)c(C)c1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
505522,CHEMBL356594,5-(4-Butoxy-phenyl)-3-methyl-1H-pyrazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,17800.0,nM,CCCCOc1ccc(-c2cc(C)[nH]n2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
507941,CHEMBL150653,2-(4-Butoxy-phenyl)-pyridine,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,26400.0,nM,CCCCOc1ccc(-c2ccccn2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
509135,CHEMBL151170,5-(4-Butoxy-phenyl)-1H-imidazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,>,100000.0,nM,CCCCOc1ccc(-c2c[nH]cn2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
509141,CHEMBL150999,2-(4-Butoxy-phenyl)-1H-imidazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,27200.0,nM,CCCCOc1ccc(-c2ncc[nH]2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
509147,CHEMBL151038,5-(4-Butoxy-phenyl)-4-methyl-isoxazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,8180.0,nM,CCCCOc1ccc(-c2oncc2C)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
510399,CHEMBL151207,1-(4-Butoxy-phenyl)-4-methyl-1H-imidazole,CHEMBL660392,A,,,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 2C9.,IC50,=,6880.0,nM,CCCCOc1ccc(-n2cnc(C)c2)cc1,CHEMBL1145921,"Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.",J. Med. Chem.,2003.0,46,25,5416,5427,10.1021/jm020557k,14640550.0,
563103,CHEMBL273921,"2-{2-[4-(5-Fluoro-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-ethyl}-2,3,4,5-tetrahydro-benzo[c]azepin-1-one",CHEMBL660397,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 isoform 2C9,IC50,=,35000.0,nM,O=C1c2ccccc2CCCN1CCN1CCC(n2c(O)nc3cc(F)ccc32)CC1,CHEMBL1136643,Identification of a novel series of selective 5-HT7 receptor antagonists.,Bioorg. Med. Chem. Lett.,2003.0,13,6,1055,1058,10.1016/s0960-894x(03)00077-5,12643910.0,
640255,CHEMBL10921,N-(2-Diethylamino-ethyl)-2-[2-(4-fluoro-benzylsulfanyl)-5-(1-methyl-1H-pyrazol-4-ylmethyl)-4-oxo-4H-pyrimidin-1-yl]-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-acetamide,CHEMBL659096,A,,,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,100000.0,nM,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1,CHEMBL1135959,"The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.",Bioorg. Med. Chem. Lett.,2002.0,12,18,2603,2606,10.1016/s0960-894x(02)00473-0,12182870.0,
678582,CHEMBL3706622,"(S)-4-{1-[5-(4-Chloro-pyridin-3-yl)-oxazol-2-yl]-1-methyl-ethyl}-1-[(S)-2-hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",CHEMBL660396,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome Cytochrome P450 2C9,IC50,=,21000.0,nM,CC(C)(c1ncc(-c2cnccc2Cl)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1,CHEMBL1136139,"The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.",Bioorg. Med. Chem. Lett.,2003.0,13,15,2573,2576,10.1016/s0960-894x(03)00474-8,12852969.0,
684133,CHEMBL3706615,"(S)-1-[(S)-2-Hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-4-{1-[5-(5-methoxy-pyridin-3-yl)-oxazol-2-yl]-1-methyl-ethyl}-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",CHEMBL660396,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome Cytochrome P450 2C9,IC50,=,30000.0,nM,COc1cncc(-c2cnc(C(C)(C)N3CCN(C[C@@H](O)C[C@@H](Cc4ccccc4)C(=O)N[C@H]4c5ccccc5OC[C@H]4O)[C@H](C(=O)NCC(F)(F)F)C3)o2)c1,CHEMBL1136139,"The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.",Bioorg. Med. Chem. Lett.,2003.0,13,15,2573,2576,10.1016/s0960-894x(03)00474-8,12852969.0,
685489,CHEMBL115,"(S)-1-[(2S,4R)-2-Hydroxy-4-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-5-phenyl-pentyl]-4-pyridin-3-ylmethyl-piperazine-2-carboxylic acid tert-butylamide",CHEMBL660396,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome Cytochrome P450 2C9,IC50,>,30000.0,nM,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O,CHEMBL1136139,"The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.",Bioorg. Med. Chem. Lett.,2003.0,13,15,2573,2576,10.1016/s0960-894x(03)00474-8,12852969.0,
693191,CHEMBL3706621,"(S)-1-[(S)-2-Hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-4-[1-methyl-1-(5-pyridin-2-yl-oxazol-2-yl)-ethyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",CHEMBL660396,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome Cytochrome P450 2C9,IC50,=,28000.0,nM,CC(C)(c1ncc(-c2ccccn2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1,CHEMBL1136139,"The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.",Bioorg. Med. Chem. Lett.,2003.0,13,15,2573,2576,10.1016/s0960-894x(03)00474-8,12852969.0,
711901,CHEMBL3706613,"(S)-1-[(S)-2-Hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-4-[1-methyl-1-(5-pyridin-3-yl-oxazol-2-yl)-ethyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",CHEMBL660396,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome Cytochrome P450 2C9,IC50,=,33000.0,nM,CC(C)(c1ncc(-c2cccnc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1,CHEMBL1136139,"The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.",Bioorg. Med. Chem. Lett.,2003.0,13,15,2573,2576,10.1016/s0960-894x(03)00474-8,12852969.0,
789000,CHEMBL319862,N-(5-butyl-2-methylphenyl)-N'-hydroxyimidoformamide,CHEMBL661054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human Cytochrome P450 2C9,IC50,=,24000.0,nM,CCCCc1ccc(C)c(N/C=N/O)c1,CHEMBL1133849,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,2001.0,11,23,2993,2995,10.1016/s0960-894x(01)00614-x,11714595.0,
790854,CHEMBL330425,"(S)-(4,6-Dimethyl-pyrimidin-2-yloxy)-((S)-1-methyl-2-oxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-5-yl)-acetic acid",CHEMBL660403,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 2C9,IC50,>,50000.0,nM,Cc1cc(C)nc(O[C@H](C(=O)O)[C@@]2(c3ccccc3)NCC(=O)N(C)c3ccccc32)n1,CHEMBL1149183,"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.",J. Med. Chem.,2004.0,47,11,2776,2795,10.1021/jm031115r,15139756.0,
791701,CHEMBL101180,N'-hydroxy-N-(4-isopropylphenyl)imidoformamide,CHEMBL661054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human Cytochrome P450 2C9,IC50,=,30000.0,nM,CC(C)c1ccc(N/C=N/O)cc1,CHEMBL1133849,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,2001.0,11,23,2993,2995,10.1016/s0960-894x(01)00614-x,11714595.0,
793989,CHEMBL103651,N'-hydroxy-N-(2-methylphenyl)imidoformamide,CHEMBL661054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human Cytochrome P450 2C9,IC50,=,77000.0,nM,Cc1ccccc1/N=C/NO,CHEMBL1133849,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,2001.0,11,23,2993,2995,10.1016/s0960-894x(01)00614-x,11714595.0,
796747,CHEMBL96347,"(S)-(3,5-Dimethyl-phenoxy)-[(S)-2-oxo-5-phenyl-1-(2,4,6-trifluoro-benzyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-5-yl]-acetic acid",CHEMBL660403,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 2C9,IC50,=,15000.0,nM,Cc1cc(C)cc(O[C@H](C(=O)O)[C@@]2(c3ccccc3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)c1,CHEMBL1149183,"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.",J. Med. Chem.,2004.0,47,11,2776,2795,10.1021/jm031115r,15139756.0,
800808,CHEMBL321051,N-(4-hexylphenyl)-N'-hydroxyimidoformamide,CHEMBL661054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human Cytochrome P450 2C9,IC50,=,300.0,nM,CCCCCCc1ccc(N/C=N/O)cc1,CHEMBL1133849,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,2001.0,11,23,2993,2995,10.1016/s0960-894x(01)00614-x,11714595.0,
802151,CHEMBL103320,N'-hydroxy-N-(4-methylphenyl)imidoformamide,CHEMBL661054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human Cytochrome P450 2C9,IC50,=,79000.0,nM,Cc1ccc(N/C=N/O)cc1,CHEMBL1133849,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,2001.0,11,23,2993,2995,10.1016/s0960-894x(01)00614-x,11714595.0,
802154,CHEMBL101168,"1H-1,2,3-benzotriazol-1-amine",CHEMBL661054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human Cytochrome P450 2C9,IC50,=,42900.0,nM,Nn1nnc2ccccc21,CHEMBL1133849,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,2001.0,11,23,2993,2995,10.1016/s0960-894x(01)00614-x,11714595.0,
802712,CHEMBL330354,"(S)-[(S)-5-(3-Butyl-phenyl)-2-oxo-1-(2,4,6-trifluoro-benzyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-5-yl]-(4,6-dimethyl-pyrimidin-2-yloxy)-acetic acid",CHEMBL660403,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 2C9,IC50,=,15000.0,nM,CCCCc1cccc([C@]2([C@H](Oc3nc(C)cc(C)n3)C(=O)O)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)c1,CHEMBL1149183,"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.",J. Med. Chem.,2004.0,47,11,2776,2795,10.1021/jm031115r,15139756.0,
805939,CHEMBL100899,N-(4-sec-butylphenyl)-N'-hydroxyimidoformamide,CHEMBL661054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human Cytochrome P450 2C9,IC50,=,11000.0,nM,CCC(C)c1ccc(N/C=N/O)cc1,CHEMBL1133849,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,2001.0,11,23,2993,2995,10.1016/s0960-894x(01)00614-x,11714595.0,
805943,CHEMBL103163,N-(4-tert-butylphenyl)-N'-hydroxyimidoformamide,CHEMBL661054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human Cytochrome P450 2C9,IC50,>,100000.0,nM,CC(C)(C)c1ccc(N/C=N/O)cc1,CHEMBL1133849,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,2001.0,11,23,2993,2995,10.1016/s0960-894x(01)00614-x,11714595.0,
811126,CHEMBL101296,N-(4-ethylphenyl)-N'-hydroxyimidoformamide,CHEMBL661054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human Cytochrome P450 2C9,IC50,=,17000.0,nM,CCc1ccc(N/C=N/O)cc1,CHEMBL1133849,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,2001.0,11,23,2993,2995,10.1016/s0960-894x(01)00614-x,11714595.0,
811130,CHEMBL103313,N-(4-butylphenyl)-N'-hydroxyimidoformamide,CHEMBL661054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human Cytochrome P450 2C9,IC50,=,8800.0,nM,CCCCc1ccc(N/C=N/O)cc1,CHEMBL1133849,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,2001.0,11,23,2993,2995,10.1016/s0960-894x(01)00614-x,11714595.0,
813646,CHEMBL445120,N-(4-benzylphenyl)-N'-hydroxyimidoformamide,CHEMBL661054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human Cytochrome P450 2C9,IC50,=,17000.0,nM,ON/C=N/c1ccc(Cc2ccccc2)cc1,CHEMBL1133849,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,2001.0,11,23,2993,2995,10.1016/s0960-894x(01)00614-x,11714595.0,
814831,CHEMBL267865,N-(4-butyl-2-methylphenyl)-N'-hydroxyimidoformamide,CHEMBL661054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human Cytochrome P450 2C9,IC50,=,3300.0,nM,CCCCc1ccc(/N=C/NO)c(C)c1,CHEMBL1133849,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,2001.0,11,23,2993,2995,10.1016/s0960-894x(01)00614-x,11714595.0,
817379,CHEMBL100917,N-(2-butylphenyl)-N'-hydroxyimidoformamide,CHEMBL661054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human Cytochrome P450 2C9,IC50,=,42000.0,nM,CCCCc1ccccc1/N=C/NO,CHEMBL1133849,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,2001.0,11,23,2993,2995,10.1016/s0960-894x(01)00614-x,11714595.0,
824780,CHEMBL329477,"(S)-(4,6-Dimethyl-pyrimidin-2-yloxy)-[(S)-2-oxo-5-phenyl-1-(2,4,6-trifluoro-benzyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-5-yl]-acetic acid",CHEMBL660403,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 2C9,IC50,>,50000.0,nM,Cc1cc(C)nc(O[C@H](C(=O)O)[C@@]2(c3ccccc3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)n1,CHEMBL1149183,"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.",J. Med. Chem.,2004.0,47,11,2776,2795,10.1021/jm031115r,15139756.0,
825429,CHEMBL317798,N'-hydroxy-N-(4-propoxyphenyl)imidoformamide,CHEMBL661054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human Cytochrome P450 2C9,IC50,=,35000.0,nM,CCCOc1ccc(N/C=N/O)cc1,CHEMBL1133849,Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.,Bioorg. Med. Chem. Lett.,2001.0,11,23,2993,2995,10.1016/s0960-894x(01)00614-x,11714595.0,
826030,CHEMBL319754,"(S)-[(S)-5-Biphenyl-3-yl-2-oxo-1-(2,4,6-trifluoro-benzyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-5-yl]-(4,6-dimethyl-pyrimidin-2-yloxy)-acetic acid",CHEMBL660403,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 2C9,IC50,=,28000.0,nM,Cc1cc(C)nc(O[C@H](C(=O)O)[C@@]2(c3cccc(-c4ccccc4)c3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)n1,CHEMBL1149183,"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.",J. Med. Chem.,2004.0,47,11,2776,2795,10.1021/jm031115r,15139756.0,
868985,CHEMBL262968,3-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine,CHEMBL660400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,185.0,nM,c1cncc(CCCOc2ccc(-n3ccnc3)cc2)c1,CHEMBL1137944,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,2004.0,14,2,333,336,10.1016/j.bmcl.2003.11.005,14698153.0,
870275,CHEMBL114555,4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-piperazine-1-carboxylic acid ethyl ester,CHEMBL660400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,1440.0,nM,CCOC(=O)N1CCN(CCOc2ccc(-n3ccnc3)cc2)CC1,CHEMBL1137944,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,2004.0,14,2,333,336,10.1016/j.bmcl.2003.11.005,14698153.0,
875033,CHEMBL113018,4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine,CHEMBL660400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,1810.0,nM,c1cn(-c2ccc(OCCN3CCOCC3)cc2)cn1,CHEMBL1137944,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,2004.0,14,2,333,336,10.1016/j.bmcl.2003.11.005,14698153.0,
877526,CHEMBL325429,[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-dimethyl-amine,CHEMBL660400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,40000.0,nM,CN(C)CCOc1ccc(-n2ccnc2)cc1,CHEMBL1137944,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,2004.0,14,2,333,336,10.1016/j.bmcl.2003.11.005,14698153.0,
878765,CHEMBL113227,4-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine,CHEMBL660400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,101.0,nM,c1cc(CCCOc2ccc(-n3ccnc3)cc2)ccn1,CHEMBL1137944,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,2004.0,14,2,333,336,10.1016/j.bmcl.2003.11.005,14698153.0,
880099,CHEMBL114297,[3-(4-Imidazol-1-yl-phenoxy)-propyl]-dimethyl-amine,CHEMBL660400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,32800.0,nM,CN(C)CCCOc1ccc(-n2ccnc2)cc1,CHEMBL1137944,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,2004.0,14,2,333,336,10.1016/j.bmcl.2003.11.005,14698153.0,
884950,CHEMBL115876,2-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine,CHEMBL660400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,129.0,nM,c1ccc(CCCOc2ccc(-n3ccnc3)cc2)nc1,CHEMBL1137944,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,2004.0,14,2,333,336,10.1016/j.bmcl.2003.11.005,14698153.0,
889941,CHEMBL112532,1-(4-Butoxy-phenyl)-1H-imidazole,CHEMBL660400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,96.0,nM,CCCCOc1ccc(-n2ccnc2)cc1,CHEMBL1137944,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,2004.0,14,2,333,336,10.1016/j.bmcl.2003.11.005,14698153.0,
893390,CHEMBL113275,[6-(4-Imidazol-1-yl-phenoxy)-hexyl]-dimethyl-amine,CHEMBL660400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,33200.0,nM,CN(C)CCCCCCOc1ccc(-n2ccnc2)cc1,CHEMBL1137944,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,2004.0,14,2,333,336,10.1016/j.bmcl.2003.11.005,14698153.0,
894552,CHEMBL112592,2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine,CHEMBL660400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,130.0,nM,c1ccc(COc2ccc(-n3ccnc3)cc2)nc1,CHEMBL1137944,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,2004.0,14,2,333,336,10.1016/j.bmcl.2003.11.005,14698153.0,
894559,CHEMBL320105,2-Hexyloxy-5-imidazol-1-yl-pyridine,CHEMBL660400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,>,100000.0,nM,CCCCCCOc1ccc(-n2ccnc2)cn1,CHEMBL1137944,Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.,Bioorg. Med. Chem. Lett.,2004.0,14,2,333,336,10.1016/j.bmcl.2003.11.005,14698153.0,
905106,CHEMBL276140,"5-Methylsulfanyl-6-trifluoromethyl-2,3-dihydro-indole-1-carboxylic acid pyridin-3-ylamide",CHEMBL660391,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of heterologously expressed human cytochrome P450 2C9,IC50,>,100000.0,nM,CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2,CHEMBL1132976,Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.,J. Med. Chem.,2000.0,43,6,1123,1134,10.1021/jm990388c,10737744.0,
921685,CHEMBL14563,"6-Chloro-5-methyl-2,3-dihydro-indole-1-carboxylic acid [6-(2-methyl-pyridin-3-yloxy)-pyridin-3-yl]-amide",CHEMBL660391,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of heterologously expressed human cytochrome P450 2C9,IC50,>,100000.0,nM,Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2,CHEMBL1132976,Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.,J. Med. Chem.,2000.0,43,6,1123,1134,10.1021/jm990388c,10737744.0,
927073,CHEMBL14460,"5-Methyl-6-trifluoromethyl-2,3-dihydro-indole-1-carboxylic acid [6-(2-methyl-pyridin-3-yloxy)-pyridin-3-yl]-amide",CHEMBL660391,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of heterologously expressed human cytochrome P450 2C9,IC50,=,23000.0,nM,Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2,CHEMBL1132976,Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.,J. Med. Chem.,2000.0,43,6,1123,1134,10.1021/jm990388c,10737744.0,
939559,CHEMBL14276,"5-Methoxy-6-trifluoromethyl-2,3-dihydro-indole-1-carboxylic acid (3-fluoro-5-pyridin-3-yl-phenyl)-amide",CHEMBL660391,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of heterologously expressed human cytochrome P450 2C9,IC50,=,82000.0,nM,COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(F)cc(-c3cccnc3)c1)CC2,CHEMBL1132976,Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.,J. Med. Chem.,2000.0,43,6,1123,1134,10.1021/jm990388c,10737744.0,
987547,CHEMBL444533,"(S)-1-[(2S,4R)-2-Hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-pyridin-3-yl-pentyl]-4-(5-phenyl-furan-2-ylmethyl)-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",CHEMBL660399,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of huamn liver microsome Cytochrome P450 2C9,IC50,=,83900.0,nM,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccccc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O,CHEMBL1136245,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,2003.0,13,19,3323,3326,10.1016/s0960-894x(03)00680-2,12951118.0,
997128,CHEMBL114756,"(S)-1-[(S)-2-Hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-4-(5-pyridin-4-yl-furan-2-ylmethyl)-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",CHEMBL660399,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of huamn liver microsome Cytochrome P450 2C9,IC50,=,5500.0,nM,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccncc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O,CHEMBL1136245,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,2003.0,13,19,3323,3326,10.1016/s0960-894x(03)00680-2,12951118.0,
1004539,CHEMBL326849,"(S)-4-(3a,6a-Dihydro-thieno[2,3-b]thiophen-2-ylmethyl)-1-[(2S,4R)-2-hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-pyridin-4-yl-pentyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",CHEMBL660399,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of huamn liver microsome Cytochrome P450 2C9,IC50,=,8590.0,nM,O=C(NCC(F)(F)F)[C@@H]1CN(CC2=CC3C=CSC3S2)CCN1C[C@@H](O)C[C@@H](Cc1ccncc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O,CHEMBL1136245,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,2003.0,13,19,3323,3326,10.1016/s0960-894x(03)00680-2,12951118.0,
1023769,CHEMBL419396,"(S)-4-(3a,6a-Dihydro-thieno[2,3-b]thiophen-2-ylmethyl)-1-[(2S,4R)-2-hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-pyridin-3-yl-pentyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",CHEMBL660399,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of huamn liver microsome Cytochrome P450 2C9,IC50,=,19700.0,nM,O=C(NCC(F)(F)F)[C@@H]1CN(CC2=CC3C=CSC3S2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O,CHEMBL1136245,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,2003.0,13,19,3323,3326,10.1016/s0960-894x(03)00680-2,12951118.0,
1023786,CHEMBL324461,"(S)-4-Benzofuran-2-ylmethyl-1-[(2S,4R)-2-hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-pyridin-3-yl-pentyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",CHEMBL660399,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of huamn liver microsome Cytochrome P450 2C9,IC50,=,48800.0,nM,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2cc3ccccc3o2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O,CHEMBL1136245,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,2003.0,13,19,3323,3326,10.1016/s0960-894x(03)00680-2,12951118.0,
1024874,CHEMBL321814,"(S)-4-(7-Chloro-benzofuran-2-ylmethyl)-1-[(2S,4R)-2-hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-pyridin-3-yl-pentyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",CHEMBL660398,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome Cytochrome P450 2C9,IC50,=,27300.0,nM,O=C(NCC(F)(F)F)[C@@H]1CN(Cc2cc3cccc(Cl)c3o2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O,CHEMBL1136245,HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.,Bioorg. Med. Chem. Lett.,2003.0,13,19,3323,3326,10.1016/s0960-894x(03)00680-2,12951118.0,
1088042,CHEMBL355905,"3-Benzenesulfonyl-2-methylsulfanyl-pyrido[1,2-a]pyrimidin-(4E)-ylideneamine",CHEMBL660393,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human Cytochrome P450 2C9,IC50,=,24200.0,nM,CSc1nc2ccccn2c(=N)c1S(=O)(=O)c1ccccc1,CHEMBL1145753,"Identification of a potent and selective 5-HT(6) antagonist: one-step synthesis of (E)-3-(benzenesulfonyl)-2- (methylsulfanyl)pyrido[1,2-a]pyrimidin-4-ylidenamine from 2-(benzenesulfonyl)-3,3-bis(methylsulfanyl)acrylonitrile.",J. Med. Chem.,2003.0,46,23,4834,4837,10.1021/jm034142q,14584934.0,
1106777,CHEMBL421841,"2-(2,6-Dimethyl-pyridin-4-ylsulfanylmethyl)-5-ethyl-9-methyl-5,10-dihydro-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-11-one",CHEMBL663982,A,,,Cytochrome P450 2C9,Inhibition of CYP450 (Cytochrome P450) 2C9,IC50,=,7400.0,nM,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)ccnc21,CHEMBL1137947,Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.,Bioorg. Med. Chem. Lett.,2004.0,14,3,739,742,10.1016/j.bmcl.2003.11.049,14741280.0,
1110126,CHEMBL164261,"7-Chloro-2-(2,6-dimethyl-pyridin-4-ylsulfanylmethyl)-5-ethyl-9-methyl-5,10-dihydro-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-11-one",CHEMBL661227,A,,,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,2600.0,nM,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(Cl)nc21,CHEMBL1137947,Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.,Bioorg. Med. Chem. Lett.,2004.0,14,3,739,742,10.1016/j.bmcl.2003.11.049,14741280.0,
1113799,CHEMBL162383,"2-(2,6-Dimethyl-pyridin-4-ylsulfanylmethyl)-5-ethyl-7-fluoro-9-methyl-5,10-dihydro-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-11-one",CHEMBL661227,A,,,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,4500.0,nM,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(F)nc21,CHEMBL1137947,Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.,Bioorg. Med. Chem. Lett.,2004.0,14,3,739,742,10.1016/j.bmcl.2003.11.049,14741280.0,
1151577,CHEMBL317935,(E)-N-[1-((S)-3-Morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide,CHEMBL660404,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human Cytochrome P450 2C9,IC50,=,5300.0,nM,C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1,CHEMBL1145064,Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.,J. Med. Chem.,2003.0,46,18,3778,3781,10.1021/jm034111v,12930139.0,
1191683,CHEMBL2111784,4-{4-(4-Fluoro-phenyl)-5-[2-((S)-1-phenyl-ethylamino)-pyridin-4-yl]-thiazol-2-yl}-1-methyl-piperidin-4-ol,CHEMBL660401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 2C9,IC50,>,2000.0,nM,C[C@H](Nc1cc(-c2sc(C3CCN(C)CC3)nc2-c2ccc(F)cc2)ccn1)c1ccccc1,CHEMBL1147483,Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.,Bioorg. Med. Chem. Lett.,2004.0,14,13,3595,3599,10.1016/j.bmcl.2004.03.106,15177482.0,
1197959,CHEMBL419409,"[5-(3-Amino-3-methyl-but-1-ynyl)-2-methoxy-phenyl]-[4-(2,4-difluoro-phenylamino)-phenyl]-methanone",CHEMBL660402,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 2C9,IC50,>,2000.0,nM,COc1ccc(C#CC(C)(C)N)cc1C(=O)c1ccc(Nc2ccc(F)cc2F)cc1,CHEMBL1147484,SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.,Bioorg. Med. Chem. Lett.,2004.0,14,13,3601,3605,10.1016/j.bmcl.2004.03.111,15177483.0,
1199239,CHEMBL120185,"Cyclopentyl-{4-[2-(4-fluoro-phenyl)-5-(4-methyl-piperazin-1-yl)-imidazo[4,5-b]pyridin-1-yl]-pyrimidin-2-yl}-amine",CHEMBL660401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 2C9,IC50,>,2000.0,nM,CN1CCN(c2ccc3c(n2)nc(-c2ccc(F)cc2)n3-c2ccnc(NC3CCCC3)n2)CC1,CHEMBL1147483,Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.,Bioorg. Med. Chem. Lett.,2004.0,14,13,3595,3599,10.1016/j.bmcl.2004.03.106,15177482.0,
1200641,CHEMBL121405,4-[5-(2-Cyclohexylamino-pyridin-4-yl)-4-(4-fluoro-phenyl)-oxazol-2-yl]-piperidin-4-ol,CHEMBL660401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 2C9,IC50,>,2000.0,nM,OC1(c2nc(-c3ccc(F)cc3)c(-c3ccnc(NC4CCCCC4)c3)o2)CCNCC1,CHEMBL1147483,Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.,Bioorg. Med. Chem. Lett.,2004.0,14,13,3595,3599,10.1016/j.bmcl.2004.03.106,15177482.0,
1200663,CHEMBL120067,"[4-(2,4-Difluoro-phenylamino)-phenyl]-(6-methoxy-2-methyl-3H-benzoimidazol-5-yl)-methanone",CHEMBL660402,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 2C9,IC50,>,2000.0,nM,COc1cc2[nH]c(C)nc2cc1C(=O)c1ccc(Nc2ccc(F)cc2F)cc1,CHEMBL1147484,SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.,Bioorg. Med. Chem. Lett.,2004.0,14,13,3601,3605,10.1016/j.bmcl.2004.03.111,15177483.0,
1215187,CHEMBL118258,4-[1-(2-Cyclopentylamino-pyrimidin-4-yl)-2-(3-trifluoromethyl-phenyl)-5H-imidazol-4-yl]-1-methyl-piperidin-4-ol,CHEMBL660401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 2C9,IC50,>,2000.0,nM,CN1CCC(O)(c2cn(-c3ccnc(NC4CCCC4)n3)c(-c3cccc(C(F)(F)F)c3)n2)CC1,CHEMBL1147483,Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.,Bioorg. Med. Chem. Lett.,2004.0,14,13,3595,3599,10.1016/j.bmcl.2004.03.106,15177482.0,
1416776,CHEMBL179529,Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,2100.0,nM,CNc1ccc(-c2cccnc2)s1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1416790,CHEMBL360999,3-(1-Methyl-1H-imidazol-4-yl)-pyridine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,79500.0,nM,Cn1cnc(-c2cccnc2)c1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1416804,CHEMBL361364,3-(1-Ethyl-1H-imidazol-4-yl)-pyridine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,75200.0,nM,CCn1cnc(-c2cccnc2)c1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1416915,CHEMBL178780,3-(1-Benzyl-1H-imidazol-4-yl)-pyridine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,26900.0,nM,c1ccc(Cn2cnc(-c3cccnc3)c2)cc1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1416929,CHEMBL178781,3-(4-Methyl-imidazol-1-yl)-pyridine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,>,300000.0,nM,Cc1cn(-c2cccnc2)cn1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1417302,CHEMBL179618,3-Thiophen-2-yl-pyridine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,99200.0,nM,c1cncc(-c2cccs2)c1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1417317,CHEMBL179669,3-(3-Methyl-thiophen-2-yl)-pyridine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,93100.0,nM,Cc1ccsc1-c1cccnc1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1417454,CHEMBL179398,5-Pyridin-3-yl-thiophene-2-carbaldehyde,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,55200.0,nM,O=Cc1ccc(-c2cccnc2)s1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1417468,CHEMBL362702,1-(5-Pyridin-3-yl-thiophen-2-yl)-ethanone,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,98200.0,nM,CC(=O)c1ccc(-c2cccnc2)s1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1417596,CHEMBL361153,3-Thiophen-3-yl-pyridine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,96300.0,nM,c1cncc(-c2ccsc2)c1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1417610,CHEMBL179005,2-Fluoro-5-thiophen-3-yl-pyridine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,>,400000.0,nM,Fc1ccc(-c2ccsc2)cn1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1417738,CHEMBL179704,3-(4-Methyl-thiophen-3-yl)-pyridine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,123000.0,nM,Cc1cscc1-c1cccnc1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1417752,CHEMBL425519,2-Fluoro-5-(4-methyl-thiophen-3-yl)-pyridine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,>,400000.0,nM,Cc1cscc1-c1ccc(F)nc1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1417882,CHEMBL179763,"[3,3'']Bipyridinyl",CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,>,300000.0,nM,c1cncc(-c2cccnc2)c1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1417899,CHEMBL178516,3-(1H-Imidazol-4-yl)-pyridine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,41800.0,nM,c1cncc(-c2c[nH]cn2)c1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1418020,CHEMBL178534,5-Pyridin-3-yl-thiophene-2-carbaldehyde oxime,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,223000.0,nM,O/N=C/c1ccc(-c2cccnc2)s1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1418034,CHEMBL178547,5-Pyridin-3-yl-furan-2-carbaldehyde oxime,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,86200.0,nM,O/N=C/c1ccc(-c2cccnc2)o1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1418150,CHEMBL178330,5-Pyridin-3-yl-furan-2-carbaldehyde oxime,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,398000.0,nM,O/N=C\c1ccc(-c2cccnc2)o1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1418164,CHEMBL359657,C-(5-Pyridin-3-yl-thiophen-2-yl)-methylamine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,8900.0,nM,NCc1ccc(-c2cccnc2)s1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1418178,CHEMBL178711,Bis-(5-pyridin-3-yl-thiophen-2-ylmethyl)-amine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,710.0,nM,c1cncc(-c2ccc(CNCc3ccc(-c4cccnc4)s3)s2)c1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1418298,CHEMBL178090,C-(5-Pyridin-3-yl-furan-2-yl)-methylamine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,11700.0,nM,NCc1ccc(-c2cccnc2)o1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1418430,CHEMBL179399,3-(3-Methyl-1H-imidazol-4-yl)-pyridine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,79500.0,nM,C[n+]1c[nH]cc1-c1cccnc1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1418444,CHEMBL1795039,5-Pyridin-3-yl-furan-2-carbaldehyde oxime; compound with 5-pyridin-3-yl-furan-2-carbaldehyde oxime,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,141000.0,nM,O/N=C/c1ccc(-c2cccnc2)o1.O/N=C\c1ccc(-c2cccnc2)o1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1418457,CHEMBL178681,C-(5-Pyridin-3-yl-thiophen-2-yl)-methylamine with C-[1-(5-Pyridin-3-yl-thiophen-2-yl)-meth-(E)-]-ylideneamine; compound with C-[1-(5-pyridin-3-yl-thiophen-2-yl)-meth-(E)-]-ylideneamine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,=,208000.0,nM,N=Cc1ccc(-c2cccnc2)s1.N=Cc1ccc(-c2cccnc2)s1.NCc1ccc(-c2cccnc2)s1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1419140,CHEMBL368883,3-(2-Methyl-imidazol-1-yl)-pyridine,CHEMBL829413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P-450 2C9,IC50,>,300000.0,nM,Cc1nccn1-c1cccnc1,CHEMBL1145288,"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.",J. Med. Chem.,2005.0,48,1,224,239,10.1021/jm049696n,15634016.0,
1428427,CHEMBL360771,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid",CHEMBL834449,A,,,Cytochrome P450 2C9,Selectivity towards cytochrome P450 2C9 enzyme activity,IC50,>,5000.0,nM,CC(C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C,CHEMBL1142043,Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).,Bioorg. Med. Chem. Lett.,2005.0,15,6,1669,1673,10.1016/j.bmcl.2005.01.044,15745819.0,
1462983,CHEMBL186730,"[4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[3-(3-thiophen-2-yl-[1,2,4]oxadiazol-5-yl)-phenyl]-methanone",CHEMBL830895,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory activity against cytochrome P450 determined using human liver microsome upon 15 min incubation with probes substrates Tolbutamide (2C9),IC50,=,480.0,nM,NCc1ccc(F)c(C2CCN(C(=O)c3cccc(-c4nc(-c5cccs5)no4)c3)CC2)c1,CHEMBL1138723,Design of bivalent ligands using hydrogen bond linkers: synthesis and evaluation of inhibitors for human beta-tryptase.,Bioorg. Med. Chem. Lett.,2004.0,14,24,6053,6056,10.1016/j.bmcl.2004.09.065,15546728.0,
1462992,CHEMBL188068,"3-[4-(5-Aminomethyl-2-fluoro-phenyl)-piperidine-1-carbonyl]-5-(3-thiophen-2-yl-[1,2,4]oxadiazol-5-yl)-benzoic acid",CHEMBL830895,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory activity against cytochrome P450 determined using human liver microsome upon 15 min incubation with probes substrates Tolbutamide (2C9),IC50,>,50000.0,nM,NCc1ccc(F)c(C2CCN(C(=O)c3cc(C(=O)O)cc(-c4nc(-c5cccs5)no4)c3)CC2)c1,CHEMBL1138723,Design of bivalent ligands using hydrogen bond linkers: synthesis and evaluation of inhibitors for human beta-tryptase.,Bioorg. Med. Chem. Lett.,2004.0,14,24,6053,6056,10.1016/j.bmcl.2004.09.065,15546728.0,
1463706,CHEMBL365062,"3-[4-(5-Aminomethyl-2-fluoro-phenyl)-piperidine-1-carbonyl]-5-(3-thiophen-2-yl-[1,2,4]oxadiazol-5-yl)-benzamide",CHEMBL830895,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory activity against cytochrome P450 determined using human liver microsome upon 15 min incubation with probes substrates Tolbutamide (2C9),IC50,=,5380.0,nM,NCc1ccc(F)c(C2CCN(C(=O)c3cc(C(N)=O)cc(-c4nc(-c5cccs5)no4)c3)CC2)c1,CHEMBL1138723,Design of bivalent ligands using hydrogen bond linkers: synthesis and evaluation of inhibitors for human beta-tryptase.,Bioorg. Med. Chem. Lett.,2004.0,14,24,6053,6056,10.1016/j.bmcl.2004.09.065,15546728.0,
1496088,CHEMBL192530,"4-[2-(5-Ethyl-10-methyl-11-oxo-10,11-dihydro-5H-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-2-yl)-ethoxy]-3-methyl-benzoic acid",CHEMBL830874,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration (1.5 mM) against human CYP450 2C9 dissolved in acetonitrile/methanol,IC50,=,10000.0,nM,CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2cccnc21,CHEMBL1141165,Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.,J. Med. Chem.,2005.0,48,17,5580,5588,10.1021/jm050255t,16107158.0,
1496362,CHEMBL189942,"4-[2-(5-Ethyl-7-fluoro-10-methyl-11-oxo-10,11-dihydro-5H-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-2-yl)-ethoxy]-3-methyl-benzoic acid",CHEMBL830874,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration (1.5 mM) against human CYP450 2C9 dissolved in acetonitrile/methanol,IC50,=,6000.0,nM,CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2ccc(F)nc21,CHEMBL1141165,Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.,J. Med. Chem.,2005.0,48,17,5580,5588,10.1021/jm050255t,16107158.0,
1497803,CHEMBL189785,(S)-2-[3-(2-Methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl)-phenoxy]-propionic acid,CHEMBL832696,A,,Rattus norvegicus,Cytochrome P450 2C9,Inhibitory concentration against Cytochrome P450 2C9 in rats,IC50,=,50.0,nM,Cc1[nH]c2ccc(OC(F)(F)F)cc2c1Cc1cccc(O[C@@H](C)C(=O)O)c1,CHEMBL1145238,Selective PPARgamma modulators with improved pharmacological profiles.,Bioorg. Med. Chem. Lett.,2005.0,15,10,2437,2440,10.1016/j.bmcl.2005.03.092,15863293.0,
1512400,CHEMBL193306,"2,4-Difluoro-5-[5-isopropyl-6-(5-methyl-oxazol-2-yl)-pyrrolo[2,1-f][1,2,4]triazin-4-ylamino]-N-methoxy-benzamide",CHEMBL833935,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory concentration against human cytochrome P450 2C9,IC50,=,3600.0,nM,CONC(=O)c1cc(Nc2ncnn3cc(-c4ncc(C)o4)c(C(C)C)c23)c(F)cc1F,CHEMBL1144449,"Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.",J. Med. Chem.,2005.0,48,12,3991,4008,10.1021/jm0501275,15943473.0,
1521578,CHEMBL196875,(2-{4-[3-((E)-4-Bromo-phenyl)-acryloylamino]-3-fluoro-phenyl}-benzooxazol-5-yl)-acetic acid,CHEMBL828009,A,,Homo sapiens,Cytochrome P450 2C9,In vitro inhibitory concentration against Cytochrome P450 2C9,IC50,>,30000.0,nM,O=C(O)Cc1ccc2oc(-c3ccc(NC(=O)/C=C/c4ccc(Br)cc4)c(F)c3)nc2c1,CHEMBL1144380,"Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor.",Bioorg. Med. Chem. Lett.,2005.0,15,9,2295,2299,10.1016/j.bmcl.2005.03.014,15837312.0,
1602768,CHEMBL222460,4-(5-Chloro-2-hydroxy-phenyl)-3-(2-hydroxy-ethyl)-6-trifluoromethyl-1H-quinolin-2-one,CHEMBL872193,A,,,Cytochrome P450 2C9,Inhibition against Cytochrome P450 2C9,IC50,=,1700.0,nM,O=c1[nH]c2ccc(C(F)(F)F)cc2c(-c2cc(Cl)ccc2O)c1CCO,CHEMBL1141054,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,2005.0,15,19,4286,4290,10.1016/j.bmcl.2005.06.056,16061379.0,
1602770,CHEMBL222460,4-(5-Chloro-2-hydroxy-phenyl)-3-(2-hydroxy-ethyl)-6-trifluoromethyl-1H-quinolin-2-one,CHEMBL880428,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition against Cytochrome P450 2C9 prepared from baculovirus-infected insect cells using 7-methoxy-4-trifluoromethylcoumarin,IC50,=,1700.0,nM,O=c1[nH]c2ccc(C(F)(F)F)cc2c(-c2cc(Cl)ccc2O)c1CCO,CHEMBL1141054,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,2005.0,15,19,4286,4290,10.1016/j.bmcl.2005.06.056,16061379.0,
1602776,CHEMBL381679,4-(5-Chloro-2-hydroxy-phenyl)-3-(2-hydroxy-ethyl)-1-methyl-6-trifluoromethyl-1H-quinolin-2-one,CHEMBL872198,A,,,Cytochrome P450 2C9,Inhibitory activity against Cytochrome P450 2C9,IC50,=,1100.0,nM,Cn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21,CHEMBL1141054,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,2005.0,15,19,4286,4290,10.1016/j.bmcl.2005.06.056,16061379.0,
1602788,CHEMBL94036,4-(5-Chloro-2-methoxy-phenyl)-3-(2-hydroxy-ethyl)-6-trifluoromethyl-1H-quinolin-2-one,CHEMBL872198,A,,,Cytochrome P450 2C9,Inhibitory activity against Cytochrome P450 2C9,IC50,=,5470.0,nM,COc1ccc(Cl)cc1-c1c(CCO)c(O)nc2ccc(C(F)(F)F)cc12,CHEMBL1141054,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,2005.0,15,19,4286,4290,10.1016/j.bmcl.2005.06.056,16061379.0,
1602790,CHEMBL381860,"2-Chloro-6-(2-oxo-propyl)-11-trifluoromethyl-6,8-dihydro-5-oxa-8-aza-benzo[c]phenanthren-7-one",CHEMBL872198,A,,,Cytochrome P450 2C9,Inhibitory activity against Cytochrome P450 2C9,IC50,=,19490.0,nM,CC(=O)CC1Oc2ccc(Cl)cc2-c2c1c(O)nc1ccc(C(F)(F)F)cc21,CHEMBL1141054,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,2005.0,15,19,4286,4290,10.1016/j.bmcl.2005.06.056,16061379.0,
1602791,CHEMBL194425,"12-Chloro-2-trifluoromethyl-5,7-dihydro-9-oxa-5-aza-benzo[6,7]cyclohepta[1,2-a]naphthalene-6,8-dione",CHEMBL872198,A,,,Cytochrome P450 2C9,Inhibitory activity against Cytochrome P450 2C9,IC50,=,12450.0,nM,O=C1Cc2c(O)nc3ccc(C(F)(F)F)cc3c2-c2cc(Cl)ccc2O1,CHEMBL1141054,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,2005.0,15,19,4286,4290,10.1016/j.bmcl.2005.06.056,16061379.0,
1602792,CHEMBL365787,"1-(4-Benzyl-2-oxo-1,2-dihydro-quinolin-3-yl)-pyridinium",CHEMBL872198,A,,,Cytochrome P450 2C9,Inhibitory activity against Cytochrome P450 2C9,IC50,>,100000.0,nM,Oc1nc2ccccc2c(Cc2ccccc2)c1-[n+]1ccccc1,CHEMBL1141054,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,2005.0,15,19,4286,4290,10.1016/j.bmcl.2005.06.056,16061379.0,
1602793,CHEMBL196426,4-(5-Chloro-2-hydroxy-phenyl)-3-[3-((S)-diethyl-amino)-2-hydroxy-propylsulfanyl]-6-trifluoromethyl-1H-quinolin-2-one,CHEMBL872198,A,,,Cytochrome P450 2C9,Inhibitory activity against Cytochrome P450 2C9,IC50,=,37660.0,nM,CCN(CC)C[C@H](O)CSc1c(O)nc2ccc(C(F)(F)F)cc2c1-c1cc(Cl)ccc1O,CHEMBL1141054,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,2005.0,15,19,4286,4290,10.1016/j.bmcl.2005.06.056,16061379.0,
1602794,CHEMBL196427,4-(5-Chloro-2-hydroxy-phenyl)-3-[3-((R)-diethyl-amino)-2-hydroxy-propylsulfanyl]-6-trifluoromethyl-1H-quinolin-2-one,CHEMBL872198,A,,,Cytochrome P450 2C9,Inhibitory activity against Cytochrome P450 2C9,IC50,=,50680.0,nM,CCN(CC)C[C@@H](O)CSc1c(O)nc2ccc(C(F)(F)F)cc2c1-c1cc(Cl)ccc1O,CHEMBL1141054,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,2005.0,15,19,4286,4290,10.1016/j.bmcl.2005.06.056,16061379.0,
1602797,CHEMBL195561,[4-(5-Chloro-2-hydroxy-phenyl)-3-(2-hydroxy-ethyl)-2-oxo-6-trifluoromethyl-2H-quinolin-1-yl]-acetonitrile,CHEMBL880428,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition against Cytochrome P450 2C9 prepared from baculovirus-infected insect cells using 7-methoxy-4-trifluoromethylcoumarin,IC50,=,3900.0,nM,N#CCn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21,CHEMBL1141054,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,2005.0,15,19,4286,4290,10.1016/j.bmcl.2005.06.056,16061379.0,
1602805,CHEMBL371409,2-[4-(5-Chloro-2-hydroxy-phenyl)-3-(2-hydroxy-ethyl)-2-oxo-6-trifluoromethyl-2H-quinolin-1-yl]-acetamide,CHEMBL880428,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition against Cytochrome P450 2C9 prepared from baculovirus-infected insect cells using 7-methoxy-4-trifluoromethylcoumarin,IC50,=,16000.0,nM,NC(=O)Cn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21,CHEMBL1141054,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,2005.0,15,19,4286,4290,10.1016/j.bmcl.2005.06.056,16061379.0,
1602821,CHEMBL193647,4-(5-Chloro-2-hydroxy-phenyl)-3-(2-hydroxy-ethyl)-1-(2H-tetrazol-5-ylmethyl)-6-trifluoromethyl-1H-quinolin-2-one,CHEMBL880428,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition against Cytochrome P450 2C9 prepared from baculovirus-infected insect cells using 7-methoxy-4-trifluoromethylcoumarin,IC50,=,19000.0,nM,O=c1c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc2n1Cc1nn[nH]n1,CHEMBL1141054,Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.,Bioorg. Med. Chem. Lett.,2005.0,15,19,4286,4290,10.1016/j.bmcl.2005.06.056,16061379.0,
1605355,CHEMBL231306,4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(6-imidazol-1-yl-4-methyl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one,CHEMBL881505,A,,Homo sapiens,Cytochrome P450 2C9,Concentration required to inhibit Cytochrome P450 2C9 in vitro by 50%,IC50,<,18.0,nM,Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,CHEMBL1143653,Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.,J. Med. Chem.,2005.0,48,18,5639,5643,10.1021/jm050392q,16134929.0,
1605382,CHEMBL401930,4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one,CHEMBL880641,A,,Homo sapiens,Cytochrome P450 2C9,Concentration required to inhibit cytochrome P450 isozyme CYP2C9 in vitro by 50%,IC50,=,1200.0,nM,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,CHEMBL1143653,Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.,J. Med. Chem.,2005.0,48,18,5639,5643,10.1021/jm050392q,16134929.0,
1606063,CHEMBL197202,"2-(2-Fluoro-4''-hydroxy-[1,1';4',1'']terphenyl-4-yl)-propionic acid",CHEMBL871888,A,,Homo sapiens,Cytochrome P450 2C9,Interaction with human cytochrome P450 isoform 2C9 expressed in baculovirus-insect cells,IC50,=,4700.0,nM,CC(C(=O)O)c1ccc(-c2ccc(-c3ccc(O)cc3)cc2)c(F)c1,CHEMBL1141070,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,2005.0,48,18,5705,5720,10.1021/jm0502541,16134939.0,
1606115,CHEMBL196945,"1-(3',4'-Dichloro-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid",CHEMBL871888,A,,Homo sapiens,Cytochrome P450 2C9,Interaction with human cytochrome P450 isoform 2C9 expressed in baculovirus-insect cells,IC50,=,38000.0,nM,O=C(O)C1(c2ccc(-c3ccc(Cl)c(Cl)c3)c(F)c2)CC1,CHEMBL1141070,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,2005.0,48,18,5705,5720,10.1021/jm0502541,16134939.0,
1606124,CHEMBL196946,1-(4-Benzo[b]thiophen-3-yl-3-fluoro-phenyl)-cyclopropanecarboxylic acid,CHEMBL871888,A,,Homo sapiens,Cytochrome P450 2C9,Interaction with human cytochrome P450 isoform 2C9 expressed in baculovirus-insect cells,IC50,=,19000.0,nM,O=C(O)C1(c2ccc(-c3csc4ccccc34)c(F)c2)CC1,CHEMBL1141070,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,2005.0,48,18,5705,5720,10.1021/jm0502541,16134939.0,
1606134,CHEMBL372751,"1-[4'-(4,4-Dimethyl-cyclohexyl)-2-fluoro-biphenyl-4-yl]-cyclopropanecarboxylic acid",CHEMBL871888,A,,Homo sapiens,Cytochrome P450 2C9,Interaction with human cytochrome P450 isoform 2C9 expressed in baculovirus-insect cells,IC50,=,17000.0,nM,CC1(C)CCC(c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3F)cc2)CC1,CHEMBL1141070,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,2005.0,48,18,5705,5720,10.1021/jm0502541,16134939.0,
1606159,CHEMBL364738,2-(4'-Cyclohexyl-2-fluoro-biphenyl-4-yl)-2-methyl-propionic acid,CHEMBL871888,A,,Homo sapiens,Cytochrome P450 2C9,Interaction with human cytochrome P450 isoform 2C9 expressed in baculovirus-insect cells,IC50,=,28000.0,nM,CC(C)(C(=O)O)c1ccc(-c2ccc(C3CCCCC3)cc2)c(F)c1,CHEMBL1141070,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,2005.0,48,18,5705,5720,10.1021/jm0502541,16134939.0,
1606182,CHEMBL196947,"1-(2-Fluoro-4''-hydroxy-[1,1';4',1'']terphenyl-4-yl)-cyclopropanecarboxylic acid",CHEMBL871888,A,,Homo sapiens,Cytochrome P450 2C9,Interaction with human cytochrome P450 isoform 2C9 expressed in baculovirus-insect cells,IC50,=,89000.0,nM,O=C(O)C1(c2ccc(-c3ccc(-c4ccc(O)cc4)cc3)c(F)c2)CC1,CHEMBL1141070,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,2005.0,48,18,5705,5720,10.1021/jm0502541,16134939.0,
1606200,CHEMBL427548,"1-(4,2',2''-Trifluoro-[1,1';4',1'']terphenyl-4''-yl)-cyclopropanecarboxylic acid",CHEMBL871888,A,,Homo sapiens,Cytochrome P450 2C9,Interaction with human cytochrome P450 isoform 2C9 expressed in baculovirus-insect cells,IC50,=,7000.0,nM,O=C(O)C1(c2ccc(-c3ccc(-c4ccc(F)cc4)c(F)c3)c(F)c2)CC1,CHEMBL1141070,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,2005.0,48,18,5705,5720,10.1021/jm0502541,16134939.0,
1606209,CHEMBL197140,"1-[2-Fluoro-4'-(3,3,5,5-tetramethyl-cyclohexyloxy)-biphenyl-4-yl]-cyclopropanecarboxylic acid",CHEMBL871888,A,,Homo sapiens,Cytochrome P450 2C9,Interaction with human cytochrome P450 isoform 2C9 expressed in baculovirus-insect cells,IC50,=,15000.0,nM,CC1(C)CC(Oc2ccc(-c3ccc(C4(C(=O)O)CC4)cc3F)cc2)CC(C)(C)C1,CHEMBL1141070,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,2005.0,48,18,5705,5720,10.1021/jm0502541,16134939.0,
1606231,CHEMBL436483,1-[2-Fluoro-4'-(4-trifluoromethyl-cyclohexyloxy)-biphenyl-4-yl]-cyclopropanecarboxylic acid,CHEMBL871888,A,,Homo sapiens,Cytochrome P450 2C9,Interaction with human cytochrome P450 isoform 2C9 expressed in baculovirus-insect cells,IC50,=,20000.0,nM,O=C(O)C1(c2ccc(-c3ccc(OC4CCC(C(F)(F)F)CC4)cc3)c(F)c2)CC1,CHEMBL1141070,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,2005.0,48,18,5705,5720,10.1021/jm0502541,16134939.0,
1657860,CHEMBL2113179,"N-(4-chlorophenyl)-4-(3-hydroxypropyl)-N-{2-oxo-2-[2-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazino]ethyl}benzenesulfonamide",CHEMBL864490,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory activity against cytochrome P450 2C9 isoform,IC50,=,345.0,nM,O=C(CN(c1ccc(Cl)cc1)S(=O)(=O)c1ccc(CCCO)cc1)N/N=C1\C(=O)Nc2ccccc21,CHEMBL1141231,"Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.",J. Med. Chem.,2005.0,48,24,7882,7905,10.1021/jm050645f,16302826.0,
1657866,CHEMBL2113208,"N-(4-chlorophenyl)-4-[2-(2-methoxyethoxy)ethoxy]-N-{2-oxo-2-[(2Z)-2-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazino]ethyl}benzenesulfonamide",CHEMBL864490,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory activity against cytochrome P450 2C9 isoform,IC50,=,330.0,nM,COCCOCCOc1ccc(S(=O)(=O)N(CC(=O)N/N=C2\C(=O)Nc3ccccc32)c2ccc(Cl)cc2)cc1,CHEMBL1141231,"Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.",J. Med. Chem.,2005.0,48,24,7882,7905,10.1021/jm050645f,16302826.0,
1659350,CHEMBL373039,"(S)-4-(2-(5-(4-chlorophenyl)oxazol-2-yl)propan-2-yl)-1-((2S,4S)-2-hydroxy-5-((3S,4S)-3-hydroxychroman-4-ylamino)-5-oxo-4-(thieno[3,2-c]pyridin-2-ylmethyl)pentyl)-N-(2,2,2-trifluoroethyl)piperazine-2-carboxamide",CHEMBL862983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory activity against CYP2C9,IC50,<,1000.0,nM,CC(C)(c1ncc(-c2ccc(Cl)cc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2cc3cnccc3s2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1,CHEMBL1141938,Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.,Bioorg. Med. Chem. Lett.,2005.0,15,23,5311,5314,10.1016/j.bmcl.2005.08.072,16203148.0,
1659351,CHEMBL381630,"(S)-4-(2-(5-(4-chlorophenyl)oxazol-2-yl)propan-2-yl)-1-((2S,4S)-4-(furo[2,3-c]pyridin-2-ylmethyl)-2-hydroxy-5-((3S,4S)-3-hydroxychroman-4-ylamino)-5-oxopentyl)-N-(2,2,2-trifluoroethyl)piperazine-2-carboxamide",CHEMBL862983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibitory activity against CYP2C9,IC50,<,1000.0,nM,CC(C)(c1ncc(-c2ccc(Cl)cc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2cc3ccncc3o2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1,CHEMBL1141938,Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.,Bioorg. Med. Chem. Lett.,2005.0,15,23,5311,5314,10.1016/j.bmcl.2005.08.072,16203148.0,
1679439,CHEMBL372357,"1-(2-cyclopropylethyl)-3-(1,1-dioxo-1,4-dihydrobenzo[1,2,4]-thiadiazin-3-yl)-6-fluoro-4-hydroxy-1-quinolin-2-one",CHEMBL861912,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 isozyme,IC50,=,1000.0,nM,O=c1c(C2=Nc3ccccc3S(=O)(=O)N2)c(O)c2cc(F)ccc2n1CCC1CC1,CHEMBL1148625,"3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase.",J. Med. Chem.,2006.0,49,3,971,983,10.1021/jm050855s,16451063.0,
1689242,CHEMBL203567,"5-amino-1-(4-fluorophenyl)-4-[3-{2(S),3-dihydroxypropoxy}-benzoyl]pyrazole",CHEMBL859671,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,11000.0,nM,Nc1c(C(=O)c2cccc(OC[C@@H](O)CO)c2)cnn1-c1ccc(F)cc1,CHEMBL1138177,"Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.",J. Med. Chem.,2006.0,49,5,1562,1575,10.1021/jm050736c,16509574.0,
1698597,CHEMBL206202,"(S)-2-(4-(3-(2-chloro-4-(2,2,2-trifluoroethyl)phenoxy)propoxy)benzyl)-2-methylbutanoic acid",CHEMBL868415,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,50.0,nM,CC[C@@](C)(Cc1ccc(OCCCOc2ccc(CC(F)(F)F)cc2Cl)cc1)C(=O)O,CHEMBL1139027,Design and synthesis of potent and subtype-selective PPARalpha agonists.,Bioorg. Med. Chem. Lett.,2006.0,16,6,1673,1678,10.1016/j.bmcl.2005.12.022,16384704.0,
1707799,CHEMBL205245,"(R)-6-((4,5-dichloro-2-methyl-1H-imidazol-1-yl)methyl)-5-(3-hydroxypyrrolidine-1-carbonyl)-1-isobutyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL869596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8700.0,nM,Cc1nc(Cl)c(Cl)n1Cc1sc2c(c1C(=O)N1CC[C@@H](O)C1)c(=O)n(C)c(=O)n2CC(C)C,CHEMBL1146970,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,2006.0,16,8,2260,2265,10.1016/j.bmcl.2006.01.024,16455256.0,
1707800,CHEMBL204772,"(R)-5-(3-hydroxypyrrolidine-1-carbonyl)-1-isobutyl-3-methyl-6-((2-methyl-1H-benzo[d]imidazol-1-yl)methyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL869596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2500.0,nM,Cc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CC[C@@H](O)C1)c(=O)n(C)c(=O)n2CC(C)C,CHEMBL1146970,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,2006.0,16,8,2260,2265,10.1016/j.bmcl.2006.01.024,16455256.0,
1707801,CHEMBL426851,"(R)-5-(3-hydroxypyrrolidine-1-carbonyl)-1-isobutyl-3-methyl-6-((2-(methylamino)-1H-benzo[d]imidazol-1-yl)methyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL869596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,11000.0,nM,CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CC[C@@H](O)C1)c(=O)n(C)c(=O)n2CC(C)C,CHEMBL1146970,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,2006.0,16,8,2260,2265,10.1016/j.bmcl.2006.01.024,16455256.0,
1707802,CHEMBL205092,"(R)-6-((1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)-5-(3-hydroxypyrrolidine-1-carbonyl)-1-isobutyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL869596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,35000.0,nM,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3c[nH]c4ncccc34)sc21,CHEMBL1146970,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,2006.0,16,8,2260,2265,10.1016/j.bmcl.2006.01.024,16455256.0,
1707803,CHEMBL205807,"(R)-6-((1H-indol-3-yl)methyl)-5-(3-hydroxypyrrolidine-1-carbonyl)-1-isobutyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL869596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1400.0,nM,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3c[nH]c4ccccc34)sc21,CHEMBL1146970,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,2006.0,16,8,2260,2265,10.1016/j.bmcl.2006.01.024,16455256.0,
1707804,CHEMBL207100,"(R)-5-(3-hydroxypyrrolidine-1-carbonyl)-1-isobutyl-6-(isoquinolin-4-ylmethyl)-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL869596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,13000.0,nM,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3cncc4ccccc34)sc21,CHEMBL1146970,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,2006.0,16,8,2260,2265,10.1016/j.bmcl.2006.01.024,16455256.0,
1707805,CHEMBL204476,"(R)-5-(3-hydroxypyrrolidine-1-carbonyl)-1-isobutyl-3-methyl-6-(quinolin-5-ylmethyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL869596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,6000.0,nM,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3cccc4ncccc34)sc21,CHEMBL1146970,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,2006.0,16,8,2260,2265,10.1016/j.bmcl.2006.01.024,16455256.0,
1707806,CHEMBL205742,"(R)-5-(3-hydroxypyrrolidine-1-carbonyl)-1-isobutyl-3-methyl-6-(quinolin-4-ylmethyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL869596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,16000.0,nM,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3ccnc4ccccc34)sc21,CHEMBL1146970,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,2006.0,16,8,2260,2265,10.1016/j.bmcl.2006.01.024,16455256.0,
1707807,CHEMBL208487,"(R)-6-(2-(trifluoromethyl)benzyl)-5-(3-hydroxypyrrolidine-1-carbonyl)-1-isobutyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL869596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1700.0,nM,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3ccccc3C(F)(F)F)sc21,CHEMBL1146970,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,2006.0,16,8,2260,2265,10.1016/j.bmcl.2006.01.024,16455256.0,
1707808,CHEMBL378405,"(rac)-6-(2-(trifluoromethyl)benzyl)-5-(3-hydroxypyrrolidin-1-ylsulfonyl)-1-isobutyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL869596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,200.0,nM,CC(C)Cn1c(=O)n(C)c(=O)c2c(S(=O)(=O)N3CC[C@@H](O)C3)c(Cc3ccccc3C(F)(F)F)sc21,CHEMBL1146970,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,2006.0,16,8,2260,2265,10.1016/j.bmcl.2006.01.024,16455256.0,
1707809,CHEMBL379399,"(rac)-6-(2-(trifluoromethyl)benzyl)-5-(3-hydroxycyclopentylsulfonyl)-1-isobutyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL869596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,200.0,nM,CC(C)Cn1c(=O)n(C)c(=O)c2c(S(=O)(=O)[C@@H]3CC[C@H](O)C3)c(Cc3ccccc3C(F)(F)F)sc21,CHEMBL1146970,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,2006.0,16,8,2260,2265,10.1016/j.bmcl.2006.01.024,16455256.0,
1707810,CHEMBL205845,"(rac)-6-(2-(trifluoromethyl)benzyl)-5-(3-hydroxycyclopentylthio)-1-isobutyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL869596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,200.0,nM,CC(C)Cn1c(=O)n(C)c(=O)c2c(S[C@@H]3CC[C@H](O)C3)c(Cc3ccccc3C(F)(F)F)sc21,CHEMBL1146970,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,2006.0,16,8,2260,2265,10.1016/j.bmcl.2006.01.024,16455256.0,
1707811,CHEMBL205526,"5-(3-hydroxypropylthio)-1-isobutyl-3-methyl-6-(naphthalen-1-ylmethyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL869596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,500.0,nM,CC(C)Cn1c(=O)n(C)c(=O)c2c(SCCCO)c(Cc3cccc4ccccc34)sc21,CHEMBL1146970,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,2006.0,16,8,2260,2265,10.1016/j.bmcl.2006.01.024,16455256.0,
1707812,CHEMBL380192,"7-(3-hydroxypropylthio)-4-isobutyl-2-methyl-6-(naphthalen-1-ylmethyl)-2H-pyrrolo[3,4-d]pyridazin-1(6H)-one",CHEMBL869596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2600.0,nM,CC(C)Cc1nn(C)c(=O)c2c(SCCCO)n(Cc3cccc4ccccc34)cc12,CHEMBL1146970,Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.,Bioorg. Med. Chem. Lett.,2006.0,16,8,2260,2265,10.1016/j.bmcl.2006.01.024,16455256.0,
1712404,CHEMBL377085,"3-amino-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide",CHEMBL865088,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,Cc1cc(C)c2c(N)c(C(N)=O)sc2n1,CHEMBL1147674,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,2006.0,49,10,2898,2908,10.1021/jm0510979,16686533.0,
1712405,CHEMBL207071,3-amino-5-(4-fluoro-phenyl)-thiophene-2-carboxylic acid amide,CHEMBL865088,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7000.0,nM,NC(=O)c1sc(-c2ccc(F)cc2)cc1N,CHEMBL1147674,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,2006.0,49,10,2898,2908,10.1021/jm0510979,16686533.0,
1713455,CHEMBL207012,"3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide",CHEMBL865088,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,NC(=O)c1sc2ncccc2c1N,CHEMBL1147674,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,2006.0,49,10,2898,2908,10.1021/jm0510979,16686533.0,
1713456,CHEMBL377928,5-amino-2-(4-trifluoromethyl-phenyl)-oxazole-4-carboxylic acid amide,CHEMBL865088,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,NC(=O)c1nc(-c2ccc(C(F)(F)F)cc2)oc1N,CHEMBL1147674,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,2006.0,49,10,2898,2908,10.1021/jm0510979,16686533.0,
1713457,CHEMBL207987,5-amino-2-phenyl-oxazole-4-carboxylic acid amide,CHEMBL865088,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,NC(=O)c1nc(-c2ccccc2)oc1N,CHEMBL1147674,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,2006.0,49,10,2898,2908,10.1021/jm0510979,16686533.0,
1713458,CHEMBL207028,3-amino-5-phenyl-thiophene-2-carboxylic acid amide,CHEMBL865088,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,26000.0,nM,NC(=O)c1sc(-c2ccccc2)cc1N,CHEMBL1147674,Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.,J. Med. Chem.,2006.0,49,10,2898,2908,10.1021/jm0510979,16686533.0,
1714693,CHEMBL207577,3-(2-(2-(benzyloxy)-5-chlorophenyl)cyclopent-1-enyl)benzoic acid,CHEMBL870679,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP450 2C9,IC50,=,5700.0,nM,O=C(O)c1cccc(C2=C(c3cc(Cl)ccc3OCc3ccccc3)CCC2)c1,CHEMBL1147700,Discovery of novel biaryl heterocyclic EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,2006.0,16,10,2666,2671,10.1016/j.bmcl.2006.02.014,16503138.0,
1714696,CHEMBL377852,3-(2-(2-(benzyloxy)-5-chlorophenyl)-5-methyl-1H-pyrrol-1-yl)benzoic acid,CHEMBL870679,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP450 2C9,IC50,=,6500.0,nM,Cc1ccc(-c2cc(Cl)ccc2OCc2ccccc2)n1-c1cccc(C(=O)O)c1,CHEMBL1147700,Discovery of novel biaryl heterocyclic EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,2006.0,16,10,2666,2671,10.1016/j.bmcl.2006.02.014,16503138.0,
1714699,CHEMBL377649,3-(2-(2-(benzyloxy)-5-bromophenyl)-5-methyl-1H-pyrrol-1-yl)benzoic acid,CHEMBL870679,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP450 2C9,IC50,=,6800.0,nM,Cc1ccc(-c2cc(Br)ccc2OCc2ccccc2)n1-c1cccc(C(=O)O)c1,CHEMBL1147700,Discovery of novel biaryl heterocyclic EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,2006.0,16,10,2666,2671,10.1016/j.bmcl.2006.02.014,16503138.0,
1714702,CHEMBL383090,3-(2-(2-(benzyloxy)-5-chlorophenyl)-1H-pyrrol-1-yl)benzoic acid,CHEMBL870679,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP450 2C9,IC50,=,7300.0,nM,O=C(O)c1cccc(-n2cccc2-c2cc(Cl)ccc2OCc2ccccc2)c1,CHEMBL1147700,Discovery of novel biaryl heterocyclic EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,2006.0,16,10,2666,2671,10.1016/j.bmcl.2006.02.014,16503138.0,
1714707,CHEMBL207293,3-(5-(2-(benzyloxy)-5-chlorophenyl)-1H-imidazol-1-yl)benzoic acid,CHEMBL870679,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP450 2C9,IC50,=,1900.0,nM,O=C(O)c1cccc(-n2cncc2-c2cc(Cl)ccc2OCc2ccccc2)c1,CHEMBL1147700,Discovery of novel biaryl heterocyclic EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,2006.0,16,10,2666,2671,10.1016/j.bmcl.2006.02.014,16503138.0,
1714711,CHEMBL207174,"2''-benzyloxy-5''-chloro-[1,1';2',1'']terphenyl-3-carboxylic acid",CHEMBL870679,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP450 2C9,IC50,=,3900.0,nM,O=C(O)c1cccc(-c2ccccc2-c2cc(Cl)ccc2OCc2ccccc2)c1,CHEMBL1147700,Discovery of novel biaryl heterocyclic EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,2006.0,16,10,2666,2671,10.1016/j.bmcl.2006.02.014,16503138.0,
1714714,CHEMBL206096,3-(3-(2-(benzyloxy)-5-chlorophenyl)pyridin-2-yl)benzoic acid,CHEMBL870679,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP450 2C9,IC50,>,50000.0,nM,O=C(O)c1cccc(-c2ncccc2-c2cc(Cl)ccc2OCc2ccccc2)c1,CHEMBL1147700,Discovery of novel biaryl heterocyclic EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,2006.0,16,10,2666,2671,10.1016/j.bmcl.2006.02.014,16503138.0,
1714721,CHEMBL209244,3-(3-(2-(benzyloxy)-5-chlorophenyl)pyridin-4-yl)benzoic acid,CHEMBL870679,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP450 2C9,IC50,=,4300.0,nM,O=C(O)c1cccc(-c2ccncc2-c2cc(Cl)ccc2OCc2ccccc2)c1,CHEMBL1147700,Discovery of novel biaryl heterocyclic EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,2006.0,16,10,2666,2671,10.1016/j.bmcl.2006.02.014,16503138.0,
1716555,CHEMBL208154,"3-[6-(2-dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid",CHEMBL853205,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,5000.0,nM,C[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C,CHEMBL1147708,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,2006.0,16,10,2729,2733,10.1016/j.bmcl.2006.02.020,16504501.0,
1716556,CHEMBL208443,"3-[6-(2-dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid",CHEMBL853205,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,5000.0,nM,CC[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C,CHEMBL1147708,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,2006.0,16,10,2729,2733,10.1016/j.bmcl.2006.02.020,16504501.0,
1716557,CHEMBL207942,"1-((6-((1R,2R)-2-(ethyl(methyl)amino)-1-(1H-imidazol-1-yl)propyl)naphthalen-2-yloxy)methyl)cyclopentanecarboxylic acid",CHEMBL853205,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,5000.0,nM,CCN(C)[C@H](C)[C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1,CHEMBL1147708,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,2006.0,16,10,2729,2733,10.1016/j.bmcl.2006.02.020,16504501.0,
1716558,CHEMBL207638,"1-((6-((1R,2R)-2-(dimethylamino)-1-(1H-imidazol-1-yl)propyl)naphthalen-2-yloxy)methyl)cyclohexanecarboxylic acid",CHEMBL853205,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,5000.0,nM,C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCCCC3)ccc2c1)n1ccnc1)N(C)C,CHEMBL1147708,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,2006.0,16,10,2729,2733,10.1016/j.bmcl.2006.02.020,16504501.0,
1716559,CHEMBL377177,"1-((6-((1R,2R)-2-(dimethylamino)-1-(1H-imidazol-1-yl)propyl)naphthalen-2-yloxy)methyl)cyclopentanecarboxylic acid",CHEMBL853205,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,5000.0,nM,C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1)N(C)C,CHEMBL1147708,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.",Bioorg. Med. Chem. Lett.,2006.0,16,10,2729,2733,10.1016/j.bmcl.2006.02.020,16504501.0,
1717668,CHEMBL208528,4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-propylphenyl)butan-1-one,CHEMBL869682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,26000.0,nM,CCCc1ccc(C(=O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,CHEMBL1147015,"Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2.",Bioorg. Med. Chem. Lett.,2006.0,16,10,2777,2780,10.1016/j.bmcl.2006.02.004,16495056.0,
1717669,CHEMBL207831,1-(4-allylphenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one,CHEMBL869682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,21000.0,nM,C=CCc1ccc(C(=O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,CHEMBL1147015,"Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2.",Bioorg. Med. Chem. Lett.,2006.0,16,10,2777,2780,10.1016/j.bmcl.2006.02.004,16495056.0,
1723541,CHEMBL210514,"5-(3,3,6-trimethyl-indan-5-yloxy)-furan-2-carboxylic Acid [4,6-dimethoxy-2-(3-morpholin-4-yl-propylamino)-pyrimidine-5-yl]-amide",CHEMBL853274,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3000.0,nM,COc1nc(NCCCN2CCOCC2)nc(OC)c1NC(=O)c1ccc(Oc2cc3c(cc2C)CCC3(C)C)o1,CHEMBL1148507,"Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.",J. Med. Chem.,2006.0,49,11,3362,3367,10.1021/jm060012g,16722655.0,
1732833,CHEMBL208787,"(2R)-2-(1-benzofuran-5-yl)-2-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-(2-methylpropyl)-2,5-dioxo-1-piperazinyl]-N-(1-methylethyl)ethanamide",CHEMBL870971,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP450 2C9 transfected in human microsome,IC50,=,3500.0,nM,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc2occc2c1,CHEMBL1138900,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,2006.0,49,14,4159,4170,10.1021/jm060073e,16821776.0,
1732927,CHEMBL377414,"(2R)-2-(2,4-difluorophenyl)-2-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-(2-methylpropyl)-2,5-dioxo-1-piperazinyl]-N,N-dimethylethanamide",CHEMBL870971,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP450 2C9 transfected in human microsome,IC50,=,49000.0,nM,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F,CHEMBL1138900,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,2006.0,49,14,4159,4170,10.1021/jm060073e,16821776.0,
1741042,CHEMBL212689,"(R)-N-(1-(3-(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-(methylsulfonyl)phenyl)acetamide",CHEMBL870533,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of P450 2C9,IC50,>,10000.0,nM,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@H](c2ccc(S(C)(=O)=O)cc2)c2cc(F)cc(F)c2)CC1,CHEMBL1138893,Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides.,Bioorg. Med. Chem. Lett.,2006.0,16,13,3533,3536,10.1016/j.bmcl.2006.03.089,16631366.0,
1744184,CHEMBL208791,3-(2-(2-(4-fluorobenzyloxy)-5-bromophenyl)-5-methyl-1H-pyrrol-1-yl)benzoic acid,CHEMBL864194,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP450 2C9,IC50,=,3900.0,nM,Cc1ccc(-c2cc(Br)ccc2OCc2ccc(F)cc2)n1-c1cccc(C(=O)O)c1,CHEMBL1138923,"Structure-activity relationships of 1,5-biaryl pyrroles as EP1 receptor antagonists.",Bioorg. Med. Chem. Lett.,2006.0,16,14,3657,3662,10.1016/j.bmcl.2006.04.073,16697196.0,
1746575,CHEMBL212521,(S)-2-amino-N-((S)-2-biphenyl-4-yl-1-cyano-ethyl)-butyramide,CHEMBL864716,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,20000.0,nM,CC[C@H](N)C(=O)N[C@H](C#N)Cc1ccc(-c2ccccc2)cc1,CHEMBL1138912,Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors.,Bioorg. Med. Chem. Lett.,2006.0,16,13,3614,3617,10.1016/j.bmcl.2006.01.102,16647256.0,
1753569,CHEMBL534942,1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine hydrochloride,CHEMBL864246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,23000.0,nM,Cl.Clc1ccccc1CC(c1ccccc1)N1CCNCC1,CHEMBL1145304,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2006.0,16,16,4349,4353,10.1016/j.bmcl.2006.05.049,16750363.0,
1753571,CHEMBL534723,(R)-1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine hydrochloride,CHEMBL864246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1.Cl,CHEMBL1145304,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2006.0,16,16,4349,4353,10.1016/j.bmcl.2006.05.049,16750363.0,
1753588,CHEMBL534942,1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine hydrochloride,CHEMBL864246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,23000.0,nM,Cl.Clc1ccccc1CC(c1ccccc1)N1CCNCC1,CHEMBL1145304,Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2006.0,16,16,4349,4353,10.1016/j.bmcl.2006.05.049,16750363.0,
1754371,CHEMBL209689,"2-(2,5-dimethyl-3-(8-methylquinolin-4-yl)-1H-indol-1-yl)acetic acid",CHEMBL853470,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition at CYP2C9,IC50,=,5000.0,nM,Cc1ccc2c(c1)c(-c1ccnc3c(C)cccc13)c(C)n2CC(=O)O,CHEMBL1138972,Discovery of potent CRTh2 (DP2) receptor antagonists.,Bioorg. Med. Chem. Lett.,2006.0,16,16,4287,4290,10.1016/j.bmcl.2006.05.062,16753296.0,
1761017,CHEMBL213390,6-phenyl-N-(quinolin-7-yl)nicotinamide,CHEMBL870461,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,>,18000.0,nM,O=C(Nc1ccc2cccnc2c1)c1ccc(-c2ccccc2)nc1,CHEMBL1146870,"N-Tetrahydroquinolinyl, N-quinolinyl and N-isoquinolinyl biaryl carboxamides as antagonists of TRPV1.",Bioorg. Med. Chem. Lett.,2006.0,16,17,4533,4536,10.1016/j.bmcl.2006.06.026,16806913.0,
1765001,CHEMBL213221,1-(2-(benzyloxy)-5-bromobenzyl)-5-methyl-1H-pyrazole-3-carboxylic acid,CHEMBL864262,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP450 2C9,IC50,>,100000.0,nM,Cc1cc(C(=O)O)nn1Cc1cc(Br)ccc1OCc1ccccc1,CHEMBL1149349,Identification of novel pyrazole acid antagonists for the EP1 receptor.,Bioorg. Med. Chem. Lett.,2006.0,16,18,4767,4771,10.1016/j.bmcl.2006.06.086,16843659.0,
1774963,CHEMBL386369,"(2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)-piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile",CHEMBL855007,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C#C[C@H]1CC[C@@H](C#N)N1C(=O)CNC1(C)CCN(c2cc(C(=O)O)ccn2)CC1,CHEMBL1137403,"Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.",J. Med. Chem.,2006.0,49,21,6416,6420,10.1021/jm060777o,17034148.0,
1777163,CHEMBL437341,"(1S, 6R)-3-{[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]carbonyl}-6-(2,4,5-trifluorophenyl)cyclohex-3-en-1-ammonium trifluoro acetate",CHEMBL907767,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,N[C@H]1CC(C(=O)N2CCn3c(nnc3C(F)(F)F)C2)=CC[C@@H]1c1cc(F)c(F)c(F)c1.O=C(O)C(F)(F)F,CHEMBL1138877,"Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.",J. Med. Chem.,2006.0,49,22,6439,6442,10.1021/jm060955d,17064063.0,
1801623,CHEMBL218583,2-(4-chlorophenyl)-3-hydroxy-8-phenylquinoline-4-carboxylic acid,CHEMBL908899,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,8200.0,nM,O=C(O)c1c(O)c(-c2ccc(Cl)cc2)nc2c(-c3ccccc3)cccc12,CHEMBL1139219,Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.,J. Med. Chem.,2007.0,50,1,21,39,10.1021/jm0602256,17201408.0,
1801630,CHEMBL267210,"2-(4-chlorophenyl)-3-hydroxy-7,8-dimethylquinoline-4-carboxylic acid",CHEMBL908899,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,2000.0,nM,Cc1ccc2c(C(=O)O)c(O)c(-c3ccc(Cl)cc3)nc2c1C,CHEMBL1139219,Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.,J. Med. Chem.,2007.0,50,1,21,39,10.1021/jm0602256,17201408.0,
1801717,CHEMBL205742,"(R)-5-(3-hydroxypyrrolidine-1-carbonyl)-1-isobutyl-3-methyl-6-(quinolin-4-ylmethyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL910523,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,16000.0,nM,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3ccnc4ccccc34)sc21,CHEMBL1139234,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,2007.0,50,2,254,263,10.1021/jm060995h,17228867.0,
1801734,CHEMBL375166,"(S)-6-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]-5-{[4-hydroxyisoxazolidin-2-yl]carbonyl}-1-isobutyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL910523,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,23000.0,nM,Cc1n[nH]c(C)c1Cc1sc2c(c1C(=O)N1C[C@H](O)CO1)c(=O)n(C)c(=O)n2CC(C)C,CHEMBL1139234,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,2007.0,50,2,254,263,10.1021/jm060995h,17228867.0,
1801735,CHEMBL218628,"5-{[(4S)-4-hydroxyisoxazolidin-2-yl]carbonyl}-1-isobutyl-3-methyl-6-{[2-(methylamino)-1H-benzimidazol-1-yl]methyl}thieno-[2,3-d]pyrimidine-2,4(1H,3 H)-dione",CHEMBL910523,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9100.0,nM,CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1C[C@H](O)CO1)c(=O)n(C)c(=O)n2CC(C)C,CHEMBL1139234,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,2007.0,50,2,254,263,10.1021/jm060995h,17228867.0,
1801736,CHEMBL384536,"5-{[(4S)-4-hydroxyisoxazolidin-2-yl]carbonyl}-1-isobutyl-3-methyl-6-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL910523,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,17000.0,nM,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3C[C@H](O)CO3)c(Cc3c[nH]c4ncccc34)sc21,CHEMBL1139234,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,2007.0,50,2,254,263,10.1021/jm060995h,17228867.0,
1801737,CHEMBL218573,"5-[(4S)-4-hydroxy-2-isoxazolidinylcarbonyl]-3-methyl-1-(isobutyl)-6-[2-(trifluoromethyl)phenylmethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL910523,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,830.0,nM,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3C[C@H](O)CO3)c(Cc3ccccc3C(F)(F)F)sc21,CHEMBL1139234,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,2007.0,50,2,254,263,10.1021/jm060995h,17228867.0,
1801738,CHEMBL219861,"5-{[(4S)-4-hydroxyisoxazolidin-2-yl]carbonyl}-1-isobutyl-3-methyl-6-(quinolin-4-ylmethyl)thieno[2,3-d]pyrimidin-2,4(1H,3H)dione",CHEMBL910523,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,13000.0,nM,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3C[C@H](O)CO3)c(Cc3ccnc4ccccc34)sc21,CHEMBL1139234,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,2007.0,50,2,254,263,10.1021/jm060995h,17228867.0,
1801739,CHEMBL387125,"6-[(4,5-dichloro-2-methyl-1H-imidazol-1-yl)methyl]-1-isobutyl-N-methoxy-N,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrothieno-[2,3-d]pyrimidine-5-carboxamide",CHEMBL910523,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,15000.0,nM,CON(C)C(=O)c1c(Cn2c(C)nc(Cl)c2Cl)sc2c1c(=O)n(C)c(=O)n2CC(C)C,CHEMBL1139234,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,2007.0,50,2,254,263,10.1021/jm060995h,17228867.0,
1801740,CHEMBL219098,"5-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}-1-isobutyl-3-methyl-6-(1-naphthyloxy)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL910523,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4700.0,nM,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Oc3cccc4ccccc34)sc21,CHEMBL1139234,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,2007.0,50,2,254,263,10.1021/jm060995h,17228867.0,
1801741,CHEMBL219483,"5-(azetidin-1-ylcarbonyl)-1-isobutyl-3-methyl-6-{[2-(methylamino)-1H-benzimidazol-1-yl]methyl}thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL910523,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8900.0,nM,CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CCC1)c(=O)n(C)c(=O)n2CC(C)C,CHEMBL1139234,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,2007.0,50,2,254,263,10.1021/jm060995h,17228867.0,
1801742,CHEMBL218468,"6-[(6-Fluoroquinolin-4-yl)methyl]-5-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}-1-isobutyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL910523,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3ccnc4ccc(F)cc34)sc21,CHEMBL1139234,Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.,J. Med. Chem.,2007.0,50,2,254,263,10.1021/jm060995h,17228867.0,
1809056,CHEMBL221445,N'-[3-(4-tert-butyl-piperazin-1-ylmethyl)-8-fluoro-2-phenyl-quinoline-4-carbonyl]-N-phenyl-hydrazinecarboxylic acid methyl ester,CHEMBL910702,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,COC(=O)N(NC(=O)c1c(CN2CCN(C(C)(C)C)CC2)c(-c2ccccc2)nc2c(F)cccc12)c1ccccc1,CHEMBL1139719,"N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II.",Bioorg. Med. Chem. Lett.,2006.0,16,22,5752,5756,10.1016/j.bmcl.2006.08.085,16950617.0,
1809196,CHEMBL219162,N'-(3-methoxy-2-phenyl-quinoline-4-carbonyl)-N-phenyl-hydrazinecarboxylic acid methyl ester,CHEMBL912511,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,COC(=O)N(NC(=O)c1c(OC)c(-c2ccccc2)nc2ccccc12)c1ccccc1,CHEMBL1139722,"N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.",Bioorg. Med. Chem. Lett.,2006.0,16,22,5748,5751,10.1016/j.bmcl.2006.08.086,16950620.0,
1809962,CHEMBL220862,5-(4-acetylpiperazin-1-yl)-3-(4-fluorophenyl)-1-methyl-4-(pyridin-4-yl)-1H-pyrrole-2-carbonitrile,CHEMBL853941,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4000.0,nM,CC(=O)N1CCN(c2c(-c3ccncc3)c(-c3ccc(F)cc3)c(C#N)n2C)CC1,CHEMBL1139735,Inhibitors of unactivated p38 MAP kinase.,Bioorg. Med. Chem. Lett.,2006.0,16,23,6102,6106,10.1016/j.bmcl.2006.08.101,16971122.0,
1812473,CHEMBL373751,"3-(2-(methylsulfonyl)benzyloxy)-5-(5,6-dimethoxy-1H-benzo[d]imidazol-1-yl)thiophene-2-carbonitrile",CHEMBL911356,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,50118.72,nM,COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC,CHEMBL1146152,"5-(1H-Benzimidazol-1-yl)-3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK-epsilon kinase.",Bioorg. Med. Chem. Lett.,2006.0,16,24,6236,6240,10.1016/j.bmcl.2006.09.018,16997559.0,
1813594,CHEMBL223156,"N-[(4R)-3-methyl-2,5-dioxo-1',3'-dihydrospiro[imidazolidine-4,2'-indene]-5'-yl]-2-[2-oxo-3-(pyridin-2-yl)-2,3-dihydro-1H-1,3-benzodiazol-1-yl]acetamide",CHEMBL911976,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CN1C(=O)NC(=O)[C@]12Cc1ccc(NC(=O)Cn3c(=O)n(-c4ccccn4)c4ccccc43)cc1C2,CHEMBL1146172,"Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists.",Bioorg. Med. Chem. Lett.,2006.0,16,24,6165,6169,10.1016/j.bmcl.2006.09.045,17027263.0,
1814500,CHEMBL219060,benzyl 4-[(pyridin-4-ylamino)methyl]piperidine-1-carboxylate,CHEMBL856834,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,6500.0,nM,O=C(OCc1ccccc1)N1CCC(CNc2ccncc2)CC1,CHEMBL1141373,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,2007.0,50,4,807,819,10.1021/jm060983w,17249648.0,
1814509,CHEMBL218068,benzyl 4-[(pyrimidin-4-ylamino)methyl]piperidine-1-carboxylate,CHEMBL856834,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,500.0,nM,O=C(OCc1ccccc1)N1CCC(CNc2ccncn2)CC1,CHEMBL1141373,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,2007.0,50,4,807,819,10.1021/jm060983w,17249648.0,
1814510,CHEMBL219113,"benzyl 4-[(1,3,4-thiadiazol-2-ylamino)methyl]piperidine-1-carboxylate",CHEMBL856834,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,25000.0,nM,O=C(OCc1ccccc1)N1CCC(CNc2nncs2)CC1,CHEMBL1141373,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,2007.0,50,4,807,819,10.1021/jm060983w,17249648.0,
1814511,CHEMBL218547,"benzyl 4-[(1,3-thiazol-2-ylamino)methyl]piperidine-1-carboxylate",CHEMBL856834,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,O=C(OCc1ccccc1)N1CCC(CNc2nccs2)CC1,CHEMBL1141373,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,2007.0,50,4,807,819,10.1021/jm060983w,17249648.0,
1814512,CHEMBL435316,benzyl 4-[(2-pyrimidinylamino)methyl]-1-piperidinecarboxylate,CHEMBL856834,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,25000.0,nM,O=C(OCc1ccccc1)N1CCC(CNc2ncccn2)CC1,CHEMBL1141373,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,2007.0,50,4,807,819,10.1021/jm060983w,17249648.0,
1814513,CHEMBL220660,benzyl 4-[(pyrazin-2-ylamino)methyl]piperidine-1-carboxylate,CHEMBL856834,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,12000.0,nM,O=C(OCc1ccccc1)N1CCC(CNc2cnccn2)CC1,CHEMBL1141373,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,2007.0,50,4,807,819,10.1021/jm060983w,17249648.0,
1814514,CHEMBL218067,benzyl 4-[(pyridin-3-ylamino)methyl]piperidine-1-carboxylate,CHEMBL856834,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,12000.0,nM,O=C(OCc1ccccc1)N1CCC(CNc2cccnc2)CC1,CHEMBL1141373,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,2007.0,50,4,807,819,10.1021/jm060983w,17249648.0,
1814515,CHEMBL218017,benzyl 4-[(pyridin-2-ylamino)methyl]piperidine-1-carboxylate,CHEMBL856834,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,25000.0,nM,O=C(OCc1ccccc1)N1CCC(CNc2ccccn2)CC1,CHEMBL1141373,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,2007.0,50,4,807,819,10.1021/jm060983w,17249648.0,
1814583,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL856834,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,350.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL1141373,"Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.",J. Med. Chem.,2007.0,50,4,807,819,10.1021/jm060983w,17249648.0,
1820316,CHEMBL375812,"[(1S)-5-{3-[4-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)phenoxy]propoxy}-2,3-dihydro-1H-inden-1-yl]acetic acid",CHEMBL914359,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(O)C[C@@H]1CCc2cc(OCCCOc3ccc(-c4nc5c(s4)CCCC5)cc3)ccc21,CHEMBL1142242,"Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.",J. Med. Chem.,2007.0,50,5,984,1000,10.1021/jm061299k,17274610.0,
1820327,CHEMBL221044,"[(1S)-5-{3-[4-(6,7-dihydro-5H-pyrano[2,3-d]1,3thiazol-2-yl)-2-propylphenoxy]propoxy}-2,3-dihydro-1H-inden-1-yl]acetic acid",CHEMBL914359,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CCCc1cc(C2=NC3OCCCC3S2)ccc1OCCCOc1ccc2c(c1)CC[C@H]2CC(=O)O,CHEMBL1142242,"Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.",J. Med. Chem.,2007.0,50,5,984,1000,10.1021/jm061299k,17274610.0,
1820328,CHEMBL2113263,"[(1S)-5-{3-[2-propyl-4-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)phenoxy]propoxy}-2,3-dihydro-1H-inden-1-yl]acetic acid",CHEMBL914359,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CCCc1cc(-c2nc3c(s2)CCCC3)ccc1OCCCOc1ccc2c(c1)CC[C@H]2CC(=O)O,CHEMBL1142242,"Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.",J. Med. Chem.,2007.0,50,5,984,1000,10.1021/jm061299k,17274610.0,
1827310,CHEMBL222424,"3-(1-benzyl-piperidin-4-yl)-5,5-di-(4-fluorophenyl)-imidazolidin-2-one",CHEMBL913811,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in insect cells,IC50,=,7000.0,nM,O=C1NC(c2ccc(F)cc2)(c2ccc(F)cc2)CN1C1CCN(Cc2ccccc2)CC1,CHEMBL1142992,"Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1).",J. Med. Chem.,2007.0,50,7,1571,1583,10.1021/jm061159a,17352462.0,
1827315,CHEMBL223079,"3-(1-(3-chlorobenzyl)-piperidin-4-yl)-5,5-di-(4-fluorophenyl)-imidazolidin-2-one",CHEMBL913811,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in insect cells,IC50,=,4200.0,nM,O=C1NC(c2ccc(F)cc2)(c2ccc(F)cc2)CN1C1CCN(Cc2cccc(Cl)c2)CC1,CHEMBL1142992,"Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1).",J. Med. Chem.,2007.0,50,7,1571,1583,10.1021/jm061159a,17352462.0,
1827320,CHEMBL221401,"3-(1-(3-fluorobenzyl)-piperidin-4-yl)-5,5-di-(4-fluorophenyl)-imidazolidin-2-one",CHEMBL913811,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in insect cells,IC50,=,7300.0,nM,O=C1NC(c2ccc(F)cc2)(c2ccc(F)cc2)CN1C1CCN(Cc2cccc(F)c2)CC1,CHEMBL1142992,"Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1).",J. Med. Chem.,2007.0,50,7,1571,1583,10.1021/jm061159a,17352462.0,
1839023,CHEMBL375248,4-[2-(5-cyanothiazol-2-ylamino)pyridin-4-ylmethyl]piperazine-1-carboxylic acid methylamide,CHEMBL913883,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,50000.0,nM,CNC(=O)N1CCN(Cc2ccnc(Nc3ncc(C#N)s3)c2)CC1,CHEMBL1149259,"Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.",J. Med. Chem.,2004.0,47,25,6363,6372,10.1021/jm049697f,15566305.0,
1839026,CHEMBL376722,4-[2-(5-cyanothiazol-2-ylamino)-3-methylpyridin-4-ylmethyl]piperazine-1-carboxylic acid methylamide,CHEMBL913883,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,CNC(=O)N1CCN(Cc2ccnc(Nc3ncc(C#N)s3)c2C)CC1,CHEMBL1149259,"Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.",J. Med. Chem.,2004.0,47,25,6363,6372,10.1021/jm049697f,15566305.0,
1861013,CHEMBL228133,6-(4-(4-(4-chlorophenyl)piperidin-4-yl)phenyl)-9H-purine,CHEMBL919359,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Clc1ccc(C2(c3ccc(-c4ncnc5[nH]cnc45)cc3)CCNCC2)cc1,CHEMBL1139878,Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.,J. Med. Chem.,2007.0,50,10,2289,2292,10.1021/jm0700924,17451235.0,
1861605,CHEMBL386515,"2-[1-(dimethylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide",CHEMBL915696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,20000.0,nM,CN(C)C(C)(C)c1nc(O)c(O)c(C(=O)NCc2ccc(F)cc2)n1,CHEMBL1147159,Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors.,J. Med. Chem.,2007.0,50,9,2225,2239,10.1021/jm070027u,17428043.0,
1881374,CHEMBL389908,2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide,CHEMBL904759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,8000.0,nM,O=C(NCc1ccc(F)cc1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F,CHEMBL1143658,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,2007.0,50,11,2597,2600,10.1021/jm061195+,17477516.0,
1881381,CHEMBL226067,2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide,CHEMBL904759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,9000.0,nM,O=C(NCC1CCCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F,CHEMBL1143658,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,2007.0,50,11,2597,2600,10.1021/jm061195+,17477516.0,
1881434,CHEMBL390526,"2-(3,5-difluorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide",CHEMBL904759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,O=C(NCC1CCOCC1)c1cnc(Nc2cc(F)cc(F)c2)nc1C(F)(F)F,CHEMBL1143658,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,2007.0,50,11,2597,2600,10.1021/jm061195+,17477516.0,
1881435,CHEMBL225465,2-(2-fluoro-4-chlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)amide,CHEMBL904759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2F)nc1C(F)(F)F,CHEMBL1143658,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,2007.0,50,11,2597,2600,10.1021/jm061195+,17477516.0,
1881436,CHEMBL225464,2-(2-fluoro-5-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid(tetrahydro-pyran-4-ylmethyl)-amide,CHEMBL904759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,37000.0,nM,O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)ccc2F)nc1C(F)(F)F,CHEMBL1143658,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,2007.0,50,11,2597,2600,10.1021/jm061195+,17477516.0,
1881437,CHEMBL225413,2-(2-fluoro-3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid(tetrahydro-pyran-4-ylmethyl)-amide,CHEMBL904759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,75000.0,nM,O=C(NCC1CCOCC1)c1cnc(Nc2cccc(Cl)c2F)nc1C(F)(F)F,CHEMBL1143658,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,2007.0,50,11,2597,2600,10.1021/jm061195+,17477516.0,
1881438,CHEMBL225412,"2-(3,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide",CHEMBL904759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,13000.0,nM,O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)cc(Cl)c2)nc1C(F)(F)F,CHEMBL1143658,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,2007.0,50,11,2597,2600,10.1021/jm061195+,17477516.0,
1881439,CHEMBL389408,"2-(3,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide",CHEMBL904759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,25000.0,nM,O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)c(Cl)c2)nc1C(F)(F)F,CHEMBL1143658,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,2007.0,50,11,2597,2600,10.1021/jm061195+,17477516.0,
1881440,CHEMBL225411,"2-(2,4-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide",CHEMBL904759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2Cl)nc1C(F)(F)F,CHEMBL1143658,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,2007.0,50,11,2597,2600,10.1021/jm061195+,17477516.0,
1881441,CHEMBL387620,2-(3-chlorophenylamino)-4-carboxylic acid (1-hydroxycyclohexylmethyl)-amide,CHEMBL904759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,10000.0,nM,O=C(NCC1(O)CCCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F,CHEMBL1143658,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,2007.0,50,11,2597,2600,10.1021/jm061195+,17477516.0,
1881442,CHEMBL227899,2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclobutylmethyl)amide,CHEMBL904759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,3000.0,nM,O=C(NCC1CCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F,CHEMBL1143658,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,2007.0,50,11,2597,2600,10.1021/jm061195+,17477516.0,
1881443,CHEMBL226386,2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acidcyclopentylmethylamide,CHEMBL904759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,6000.0,nM,O=C(NCC1CCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F,CHEMBL1143658,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,2007.0,50,11,2597,2600,10.1021/jm061195+,17477516.0,
1881444,CHEMBL226385,2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide,CHEMBL904759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,18000.0,nM,O=C(NCC1CCOCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F,CHEMBL1143658,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,2007.0,50,11,2597,2600,10.1021/jm061195+,17477516.0,
1881497,CHEMBL375955,2-[(3-chlorophenyl)amino]-n-(4-pyridinylmethyl)-4-(trifluoromethyl)-5-pyrimidinecarboxamide,CHEMBL904759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,900.0,nM,O=C(NCc1ccncc1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F,CHEMBL1143658,"Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.",J. Med. Chem.,2007.0,50,11,2597,2600,10.1021/jm061195+,17477516.0,
1883927,CHEMBL229176,3-[4-(2-methyl-butoxy)-phenyl]-3-phenyl-propionic acid,CHEMBL905047,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,22000.0,nM,CCC(C)COc1ccc(C(CC(=O)O)c2ccccc2)cc1,CHEMBL1143689,Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.,J. Med. Chem.,2007.0,50,12,2807,2817,10.1021/jm070130j,17500511.0,
1890501,CHEMBL231334,"4-butyl-N-(3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)benzenesulfonamide",CHEMBL905986,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,47000.0,nM,CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(C)CC3)cc1,CHEMBL1143778,Studies towards the identification of a new generation of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,2007.0,17,2,400,405,10.1016/j.bmcl.2006.10.036,17084080.0,
1890506,CHEMBL231430,"4'-chloro-biphenyl-4-sulfonic acid (3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amide",CHEMBL905986,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,45000.0,nM,CN1CCc2ccc(NS(=O)(=O)c3ccc(-c4ccc(Cl)cc4)cc3)cc2CC1,CHEMBL1143778,Studies towards the identification of a new generation of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,2007.0,17,2,400,405,10.1016/j.bmcl.2006.10.036,17084080.0,
1890511,CHEMBL231350,"4'-chloro-biphenyl-4-sulfonic acid (8-isopropylamino-3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amide",CHEMBL905986,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,17000.0,nM,CC(C)Nc1cc2c(cc1NS(=O)(=O)c1ccc(-c3ccc(Cl)cc3)cc1)CCN(C)CC2,CHEMBL1143778,Studies towards the identification of a new generation of atypical antipsychotic agents.,Bioorg. Med. Chem. Lett.,2007.0,17,2,400,405,10.1016/j.bmcl.2006.10.036,17084080.0,
1891373,CHEMBL436137,"7-(2,6-dimethylphenyl)-5-methyl-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)benzo[e][1,2,4]triazin-3-amine",CHEMBL905866,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,100000.0,nM,Cc1cccc(C)c1-c1cc(C)c2nc(Nc3ccc(OCCN4CCCC4)cc3)nnc2c1,CHEMBL1143794,"Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.",Bioorg. Med. Chem. Lett.,2007.0,17,3,602,608,10.1016/j.bmcl.2006.11.006,17113292.0,
1891378,CHEMBL230686,"7-(2,6-dichlorophenyl)-5-methyl-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)benzo[e][1,2,4]triazin-3-amine",CHEMBL905866,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,100000.0,nM,Cc1cc(-c2c(Cl)cccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12,CHEMBL1143794,"Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.",Bioorg. Med. Chem. Lett.,2007.0,17,3,602,608,10.1016/j.bmcl.2006.11.006,17113292.0,
1898504,CHEMBL397666,3-(6-(1H-imidazol-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)-4-(pyridin-2-ylmethylamino)pyridin-2(1H)-one,CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,<,30.0,nM,Cc1cc(-n2ccnc2)cc2nc(-c3c(NCc4ccccn4)cc[nH]c3=O)[nH]c12,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898505,CHEMBL231620,4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(5-methyl-1H-imidazol-2-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,=,7800.0,nM,Cc1cnc(-c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)[nH]1,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898506,CHEMBL425819,"2-(4-{[2-(3-chlorophenyl)-2-hydroxyethyl]amino}-2-oxo-1,2-dihydropyridin-3-yl)-N,4-dimethyl-1H-1,3-benzodiazole-6-carboximidamide",CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,=,76000.0,nM,CNC(=N)c1cc(C)c2nc(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)[nH]c2c1,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898507,CHEMBL230043,"4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(1,4,5,6-tetrahydropyrimidin-2-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one",CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,=,100000.0,nM,Cc1cc(C2=NCCCN2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898508,CHEMBL230042,"4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4,4-dimethyl-4,5-dihydro-1H-imidazol-2-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one",CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,=,47000.0,nM,Cc1cc(C2=NC(C)(C)CN2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898509,CHEMBL390002,"4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(4-methyl-4,5-dihydro-1H-imidazol-2-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one",CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,=,67000.0,nM,Cc1cc(C2=NC(C)CN2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898510,CHEMBL387611,"4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one",CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,=,91000.0,nM,Cc1cc(C2=NCCN2C)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898511,CHEMBL231610,"2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-N-cyclohexyl-7-methyl-3H-benzo[d]imidazole-5-carboxamide",CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,=,6600.0,nM,Cc1cc(C(=O)NC2CCCCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898512,CHEMBL231609,"2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-N-cyclopentyl-7-methyl-3H-benzo[d]imidazole-5-carboxamide",CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,=,3500.0,nM,Cc1cc(C(=O)NC2CCCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898513,CHEMBL231510,"2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-N-cyclopropyl-7-methyl-3H-benzo[d]imidazole-5-carboxamide",CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,=,8100.0,nM,Cc1cc(C(=O)NC2CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898514,CHEMBL231509,"2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-N,N,7-trimethyl-3H-benzo[d]imidazole-5-carboxamide",CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,=,2800.0,nM,Cc1cc(C(=O)N(C)C)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898515,CHEMBL231409,"2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-N,7-dimethyl-3H-benzo[d]imidazole-5-carboxamide",CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,=,2900.0,nM,CNC(=O)c1cc(C)c2nc(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)[nH]c2c1,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898517,CHEMBL230309,4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,=,1500.0,nM,Cc1cccc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898518,CHEMBL440964,(S)-4-(1-hydroxy-3-phenylpropan-2-ylamino)-3-(6-(4-methoxyphenyl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,=,11000.0,nM,COc1ccc(-c2cc(C)c3nc(-c4c(N[C@H](CO)Cc5ccccc5)cc[nH]c4=O)[nH]c3c2)cc1,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898519,CHEMBL230308,(S)-3-(6-(4-fluorophenyl)-4-methyl-1H-benzo[d]imidazol-2-yl)-4-(1-hydroxy-3-phenylpropan-2-ylamino)pyridin-2(1H)-one,CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,=,4000.0,nM,Cc1cc(-c2ccc(F)cc2)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898520,CHEMBL230205,(S)-4-(1-hydroxy-3-phenylpropan-2-ylamino)-3-(4-methyl-6-phenyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,=,2300.0,nM,Cc1cc(-c2ccccc2)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898521,CHEMBL397667,(S)-3-(6-bromo-4-methyl-1H-benzo[d]imidazol-2-yl)-4-(1-hydroxy-3-phenylpropan-2-ylamino)pyridin-2(1H)-one,CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,=,720.0,nM,Cc1cc(Br)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898522,CHEMBL231306,4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(6-imidazol-1-yl-4-methyl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one,CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,<,40.0,nM,Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1898523,CHEMBL230204,3-(6-(1H-imidazol-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)-4-((S)-1-hydroxy-3-phenylpropan-2-ylamino)pyridin-2(1H)-one,CHEMBL887696,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 in microsomes,IC50,<,40.0,nM,Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12,CHEMBL1144646,Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.,Bioorg. Med. Chem. Lett.,2007.0,17,11,3072,3076,10.1016/j.bmcl.2007.03.048,17398093.0,
1905007,CHEMBL229861,"2-chloro-4-((1S,7S,7aR)-1-ethyl-7-hydroxy-3-oxo-tetrahydro-1H-pyrrolo[1,2-e]imidazol-2(3H)-yl)-3-methylbenzonitrile",CHEMBL888449,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,40000.0,nM,CC[C@H]1[C@@H]2[C@@H](O)CCN2C(=O)N1c1ccc(C#N)c(Cl)c1C,CHEMBL1145402,Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications.,J. Med. Chem.,2007.0,50,13,3015,3025,10.1021/jm070312d,17552509.0,
1909665,CHEMBL229008,"N-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2-fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide",CHEMBL890403,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,20000.0,nM,CCN1CCN(c2ccc(C(C)(C)NC(=O)c3cc4[nH]c5ccccc5c(=O)c4cc3F)cn2)CC1,CHEMBL1146203,"Acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase: discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2- fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419).",J. Med. Chem.,2007.0,50,15,3730,3742,10.1021/jm070299x,17585753.0,
1914930,CHEMBL244403,naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone,CHEMBL895110,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,80800.0,nM,CCCCCOc1ccc(C(=O)c2cccc3ccccc23)c2ccccc12,CHEMBL1148711,"Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.",J. Med. Chem.,2007.0,50,16,3851,3856,10.1021/jm070317a,17630726.0,
1923123,CHEMBL394864,"(5R)-3-(3-fluoro-4-pyridin-3-ylphenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one",CHEMBL896269,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,20000.0,nM,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2cccnc2)c(F)c1,CHEMBL1148787,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,2007.0,50,20,4868,4881,10.1021/jm070428+,17722903.0,
1923132,CHEMBL231383,"(5R)-3-(4-{6-[(2,5-dimethyl-1H-imidazol-1-yl)acetyl]pyridin-3-yl}-3-fluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one",CHEMBL896269,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,20000.0,nM,Cc1cnc(C)n1CC(=O)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,CHEMBL1148787,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,2007.0,50,20,4868,4881,10.1021/jm070428+,17722903.0,
1923133,CHEMBL388012,"(5R)-3-(3-fluoro-4-{6-[(2-methyl-1H-imidazol-1-yl)acetyl]pyridin-3-yl}phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one",CHEMBL896269,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,20000.0,nM,Cc1nccn1CC(=O)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,CHEMBL1148787,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,2007.0,50,20,4868,4881,10.1021/jm070428+,17722903.0,
1923134,CHEMBL387785,"(5R)-3-(3-fluoro-4-{6-[(4-methyl-1H-imidazol-1-yl)acetyl]pyridin-3-yl}phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one",CHEMBL896269,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,20000.0,nM,Cc1cn(CC(=O)c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)cn1,CHEMBL1148787,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,2007.0,50,20,4868,4881,10.1021/jm070428+,17722903.0,
1923135,CHEMBL230964,"(5R)-3-{3-fluoro-4-[6-(1H-imidazol-1-ylacetyl)pyridin-3-yl]-phenyl}-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one",CHEMBL896269,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,8000.0,nM,O=C(Cn1ccnc1)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,CHEMBL1148787,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,2007.0,50,20,4868,4881,10.1021/jm070428+,17722903.0,
1923136,CHEMBL398160,"(5R)-3-{3-fluoro-4-[6-(hydroxymethyl)pyridin-3-yl]phenyl}-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one",CHEMBL896269,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,20000.0,nM,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2ccc(CO)nc2)c(F)c1,CHEMBL1148787,Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.,J. Med. Chem.,2007.0,50,20,4868,4881,10.1021/jm070428+,17722903.0,
1923937,CHEMBL541214,4-bromo-3-carboxymethoxy-5-[3-(1-phenylmethanesulfonylpiperidin-4-ylamino)phenyl]thiophene-2-carboxylic acid,CHEMBL896132,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,40000.0,nM,O=C(O)COc1c(C(=O)O)sc(-c2cccc(NC3CCN(S(=O)(=O)Cc4ccccc4)CC3)c2)c1Br,CHEMBL1148776,Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site.,J. Med. Chem.,2007.0,50,19,4681,4698,10.1021/jm0702478,17705360.0,
1943658,CHEMBL348475,"1N-{4-[2-(6,7-dimethoxy-1,2,3,4-tetrahydro-2-isoquinolinyl)ethyl]phenyl}-4,5-dimethoxy-2-(3-quinolylcarboxamido)benzamide",CHEMBL893812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in insect microsome after 45 mins,IC50,=,7100.0,nM,COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cc(OC)c(OC)cc3NC(=O)c3cnc4ccccc4c3)cc1)CC2,CHEMBL1147947,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,2007.0,15,11,3854,3868,10.1016/j.bmc.2007.03.014,17399990.0,
1943659,CHEMBL242983,"N-(2-(4-(4-(3,4-dimethoxybenzyl)piperazin-1-yl)phenylcarbamoyl)-4,5-dimethoxyphenyl)quinoline-3-carboxamide",CHEMBL893812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in insect microsome after 45 mins,IC50,=,96.8,nM,COc1ccc(CN2CCN(c3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC,CHEMBL1147947,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,2007.0,15,11,3854,3868,10.1016/j.bmc.2007.03.014,17399990.0,
1943660,CHEMBL266212,"N-(2-(4-(4-(3,4-dimethoxybenzyl)piperazin-1-yl)phenylcarbamoyl)phenyl)quinoline-3-carboxamide",CHEMBL893812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in insect microsome after 45 mins,IC50,>,10000.0,nM,COc1ccc(CN2CCN(c3ccc(NC(=O)c4ccccc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC,CHEMBL1147947,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,2007.0,15,11,3854,3868,10.1016/j.bmc.2007.03.014,17399990.0,
1943661,CHEMBL244239,"N-(2-((2-((3,4-dimethoxyphenethyl)(methyl)amino)ethyl)carbamoyl)phenyl)quinoline-3-carboxamide",CHEMBL893812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in insect microsome after 45 mins,IC50,=,2080.0,nM,COc1ccc(CCN(C)CCNC(=O)c2ccccc2NC(=O)c2cnc3ccccc3c2)cc1OC,CHEMBL1147947,In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).,Bioorg. Med. Chem.,2007.0,15,11,3854,3868,10.1016/j.bmc.2007.03.014,17399990.0,
1955295,CHEMBL427844,"3-(2-(2-(2,4-difluorobenzyloxy)-5-bromophenyl)-5-methyl-1H-pyrrol-1-yl)-5-acetamidobenzoic acid",CHEMBL890034,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>=,18000.0,nM,CC(=O)Nc1cc(C(=O)O)cc(-n2c(C)ccc2-c2cc(Br)ccc2OCc2ccc(F)cc2F)c1,CHEMBL1146289,"1,5-Biaryl pyrrole derivatives as EP1 receptor antagonists: Structure-activity relationships of 4- and 5-substituted benzoic acid derivatives.",Bioorg. Med. Chem. Lett.,2007.0,17,3,732,735,10.1016/j.bmcl.2006.10.078,17098427.0,
1955733,CHEMBL395542,2-(2-(2-(4-fluorobenzyloxy)-5-bromophenyl)cyclopent-1-enyl)isonicotinic acid,CHEMBL889923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,5000.0,nM,O=C(O)c1ccnc(C2=C(c3cc(Br)ccc3OCc3ccc(F)cc3)CCC2)c1,CHEMBL1146277,"The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain.",Bioorg. Med. Chem. Lett.,2007.0,17,2,385,389,10.1016/j.bmcl.2006.10.041,17084082.0,
1955734,CHEMBL234940,"6-(2-(2-(2,4-difluorobenzyloxy)-5-chlorophenyl)cyclopent-1-enyl)picolinic acid",CHEMBL889923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,14000.0,nM,O=C(O)c1cccc(C2=C(c3cc(Cl)ccc3OCc3ccc(F)cc3F)CCC2)n1,CHEMBL1146277,"The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain.",Bioorg. Med. Chem. Lett.,2007.0,17,2,385,389,10.1016/j.bmcl.2006.10.041,17084082.0,
1955735,CHEMBL389996,"6-(2-(2-(2,4-difluorobenzyloxy)-5-chlorophenyl)cyclopent-1-enyl)pyrazine-2-carboxylic acid",CHEMBL889923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,12000.0,nM,O=C(O)c1cncc(C2=C(c3cc(Cl)ccc3OCc3ccc(F)cc3F)CCC2)n1,CHEMBL1146277,"The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain.",Bioorg. Med. Chem. Lett.,2007.0,17,2,385,389,10.1016/j.bmcl.2006.10.041,17084082.0,
1955736,CHEMBL233245,"6-(2-(2-(2,4-difluorobenzyloxy)-5-chlorophenyl)cyclopent-1-enyl)pyridazine-4-carboxylic acid",CHEMBL889923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,5400.0,nM,O=C(O)c1cnnc(C2=C(c3cc(Cl)ccc3OCc3ccc(F)cc3F)CCC2)c1,CHEMBL1146277,"The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain.",Bioorg. Med. Chem. Lett.,2007.0,17,2,385,389,10.1016/j.bmcl.2006.10.041,17084082.0,
1955737,CHEMBL389796,5-(2-(2-(4-fluorobenzyloxy)-5-chlorophenyl)cyclopent-1-enyl)-2-methylnicotinic acid,CHEMBL889923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,9000.0,nM,Cc1ncc(C2=C(c3cc(Cl)ccc3OCc3ccc(F)cc3)CCC2)cc1C(=O)O,CHEMBL1146277,"The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain.",Bioorg. Med. Chem. Lett.,2007.0,17,2,385,389,10.1016/j.bmcl.2006.10.041,17084082.0,
1955738,CHEMBL233043,5-(2-(2-(benzyloxy)-5-(trifluoromethyl)phenyl)cyclopent-1-enyl)nicotinic acid,CHEMBL889923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,14000.0,nM,O=C(O)c1cncc(C2=C(c3cc(C(F)(F)F)ccc3OCc3ccccc3)CCC2)c1,CHEMBL1146277,"The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain.",Bioorg. Med. Chem. Lett.,2007.0,17,2,385,389,10.1016/j.bmcl.2006.10.041,17084082.0,
1960355,CHEMBL207881,3-(4-(3-phenoxybenzylamino)phenyl)propanoic acid,CHEMBL890944,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,33000.0,nM,O=C(O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1,CHEMBL1146379,Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor.,Bioorg. Med. Chem. Lett.,2007.0,17,6,1584,1589,10.1016/j.bmcl.2006.12.084,17240142.0,
1963430,CHEMBL234412,"(2S,3S,11bS)-3-butyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-amine",CHEMBL893074,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CCCC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1N,CHEMBL1147972,"1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors.",Bioorg. Med. Chem. Lett.,2007.0,17,11,2966,2970,10.1016/j.bmcl.2007.03.072,17418568.0,
1963755,CHEMBL391070,"(2S,3S,11bS)-9,10-dimethoxy-3-m-tolyl-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-amine",CHEMBL893074,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,15000.0,nM,COc1cc2c(cc1OC)[C@@H]1C[C@H](N)[C@@H](c3cccc(C)c3)CN1CC2,CHEMBL1147972,"1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors.",Bioorg. Med. Chem. Lett.,2007.0,17,11,2966,2970,10.1016/j.bmcl.2007.03.072,17418568.0,
1964567,CHEMBL400404,(S)-2-{[5-(3'-acetylamino-biphenyl-4-ylmethyl)-oxazole-4-carbonyl]-amino}-3-phenyl-propionic acid,CHEMBL897126,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5100.0,nM,CC(=O)Nc1cccc(-c2ccc(Cc3ocnc3C(=O)N[C@@H](Cc3ccccc3)C(=O)O)cc2)c1,CHEMBL1148848,Discovery and preliminary evaluation of 5-(4-phenylbenzyl)oxazole-4-carboxamides as prostacyclin receptor antagonists.,Bioorg. Med. Chem. Lett.,2007.0,17,5,1211,1215,10.1016/j.bmcl.2006.12.025,17239589.0,
1965548,CHEMBL410414,dirlotapide,CHEMBL897345,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CN(Cc1ccccc1)C(=O)[C@@H](NC(=O)c1cc2cc(NC(=O)c3ccccc3-c3ccc(C(F)(F)F)cc3)ccc2n1C)c1ccccc1,CHEMBL1148857,"In vitro and in vivo profile of 5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity.",Bioorg. Med. Chem. Lett.,2007.0,17,7,1996,1999,10.1016/j.bmcl.2007.01.018,17276061.0,
1969335,CHEMBL231924,"3-(2-chloro-phenylamino)-7-nitro-1,1-dioxo-1,4-dihydro-1lambda6-benzo[1,2,4]thiadiazin-5-ol",CHEMBL895417,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,600.0,nM,O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Cl)N2,CHEMBL1149534,"3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.",Bioorg. Med. Chem. Lett.,2007.0,17,14,3864,3867,10.1016/j.bmcl.2007.05.011,17524641.0,
1975096,CHEMBL400431,"6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-4-(3-methoxypropyl)-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one",CHEMBL898581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(C)O2,CHEMBL1149625,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,2007.0,15,17,5912,5949,10.1016/j.bmc.2007.05.069,17574423.0,
1975097,CHEMBL239085,"N-(2-((R)-6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-methyl-3-oxo-2-phenyl-2,3-dihydrobenzo[b][1,4]oxazin-4-yl)ethyl)acetamide",CHEMBL898581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)[C@@](C)(c1ccccc1)O2,CHEMBL1149625,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,2007.0,15,17,5912,5949,10.1016/j.bmc.2007.05.069,17574423.0,
1975098,CHEMBL391463,"N-(2-((S)-6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-methyl-3-oxo-2-phenyl-2,3-dihydrobenzo[b][1,4]oxazin-4-yl)ethyl)acetamide",CHEMBL898581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)[C@](C)(c1ccccc1)O2,CHEMBL1149625,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,2007.0,15,17,5912,5949,10.1016/j.bmc.2007.05.069,17574423.0,
1975099,CHEMBL239078,"N-{2-[6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-methyl-3-oxo-2-(2,5-difluoro-phenyl)-2,3-dihydro-benzo[1,4]-oxazin-4-yl]-ethyl}-acetamide",CHEMBL898581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cc(F)ccc1F)O2,CHEMBL1149625,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,2007.0,15,17,5912,5949,10.1016/j.bmc.2007.05.069,17574423.0,
1975100,CHEMBL239074,"N-{2-[6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-methyl-3-oxo-2-(4-chloro-phenyl)-2,3-dihydro-benzo[1,4]-oxazin-4-yl]-ethyl}-acetamide",CHEMBL898581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,12000.0,nM,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1ccc(Cl)cc1)O2,CHEMBL1149625,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,2007.0,15,17,5912,5949,10.1016/j.bmc.2007.05.069,17574423.0,
1975101,CHEMBL393363,"N-{2-[6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-methyl-3-oxo-2-(3-trifluoromethyl-phenyl)-2,3-dihydrobenzo[1,4]oxazin-4-yl]-ethyl}-acetamide",CHEMBL898581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,22000.0,nM,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cccc(C(F)(F)F)c1)O2,CHEMBL1149625,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,2007.0,15,17,5912,5949,10.1016/j.bmc.2007.05.069,17574423.0,
1975102,CHEMBL238866,"6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-(3,4-difluoro-phenyl)-4-(3-methoxy-propyl)-2-methyl-4Hbenzo[1,4]oxazin-3-one",CHEMBL898581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8300.0,nM,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(c1ccc(F)c(F)c1)O2,CHEMBL1149625,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,2007.0,15,17,5912,5949,10.1016/j.bmc.2007.05.069,17574423.0,
1975103,CHEMBL239497,"6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-(3,5-difluoro-phenyl)-2-ethyl-4-(3-methoxy-propyl)-4H-benzo-[1,4]oxazin-3-one",CHEMBL898581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4900.0,nM,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(CC)(c1cc(F)cc(F)c1)O2,CHEMBL1149625,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,2007.0,15,17,5912,5949,10.1016/j.bmc.2007.05.069,17574423.0,
1975104,CHEMBL398584,"N-{2-[6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-(3,5-difluoro-phenyl)-2-methyl-3-oxo-2,3-dihydro-benzo-[1,4]oxazin-4-yl]-ethyl}-acetamide",CHEMBL898581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cc(F)cc(F)c1)O2,CHEMBL1149625,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,2007.0,15,17,5912,5949,10.1016/j.bmc.2007.05.069,17574423.0,
1975105,CHEMBL239496,"6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-(3,5-difluoro-phenyl)-4-(3-methoxy-propyl)-2-methyl-4Hbenzo[1,4]oxazin-3-one",CHEMBL898581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10500.0,nM,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(c1cc(F)cc(F)c1)O2,CHEMBL1149625,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,2007.0,15,17,5912,5949,10.1016/j.bmc.2007.05.069,17574423.0,
1975106,CHEMBL398387,"N-{2-[6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2,2-[cyclopropyl]-3-oxo-benzo[1,4]oxazin-4-yl]-ethyl}-acetamide",CHEMBL898581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C1(CC1)O2,CHEMBL1149625,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,2007.0,15,17,5912,5949,10.1016/j.bmc.2007.05.069,17574423.0,
1975107,CHEMBL239495,"6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2,2-diethyl-4-(3-methoxy-propyl)-4H-benzo[1,4]oxazin-3-one",CHEMBL898581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,15000.0,nM,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(CC)(CC)O2,CHEMBL1149625,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,2007.0,15,17,5912,5949,10.1016/j.bmc.2007.05.069,17574423.0,
1975108,CHEMBL240566,"6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-ethyl-4-(3-methoxy-propyl)-2-methyl-4H-benzo[1,4]oxazin-3-one",CHEMBL898581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,30000.0,nM,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(CC)O2,CHEMBL1149625,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,2007.0,15,17,5912,5949,10.1016/j.bmc.2007.05.069,17574423.0,
1975109,CHEMBL394016,"N-{2-[6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-methyl-3-oxo-2-trifluoromethyl-2,3-dihydro-benzo[1,4]-oxazin-4-yl]-ethyl}-acetamide",CHEMBL898581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(C(F)(F)F)O2,CHEMBL1149625,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,2007.0,15,17,5912,5949,10.1016/j.bmc.2007.05.069,17574423.0,
1975110,CHEMBL240355,"N-(2-(6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2,2-dimethyl-3-oxo-2,3-dihydrobenzo[b][1,4]-oxazin-4-yl)-ethyl)-acetamide",CHEMBL898581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(C)O2,CHEMBL1149625,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,2007.0,15,17,5912,5949,10.1016/j.bmc.2007.05.069,17574423.0,
1982386,CHEMBL391963,"(3R,4S)-N-(3,5-bis(trifluoromethyl)benzyl)-1-(1-acetylpiperidine-4-carbonyl)-N-methyl-4-phenylpyrrolidine-3-carboxamide",CHEMBL899350,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,26000.0,nM,CC(=O)N1CCC(C(=O)N2C[C@H](c3ccccc3)[C@@H](C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)CC1,CHEMBL1149712,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,2007.0,17,19,5310,5315,10.1016/j.bmcl.2007.08.028,17723300.0,
1982415,CHEMBL392465,"1-(4-((3R,4S)-3-(5-(2-(3,5-bis(trifluoromethyl)phenyl)propan-2-yl)-1,2,4-oxadiazol-3-yl)-4-(4-fluoro-2-methylphenyl)pyrrolidine-1-carbonyl)piperidin-1-yl)ethanone",CHEMBL899350,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,9000.0,nM,CC(=O)N1CCC(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](c3noc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)C2)CC1,CHEMBL1149712,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,2007.0,17,19,5310,5315,10.1016/j.bmcl.2007.08.028,17723300.0,
1982416,CHEMBL392464,"1-(4-((3S,4R)-3-(3-(2-(3,5-bis(trifluoromethyl)phenyl)propan-2-yl)-1,2,4-oxadiazol-5-yl)-4-(4-fluoro-2-methylphenyl)pyrrolidine-1-carbonyl)piperidin-1-yl)ethanone",CHEMBL899350,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,89000.0,nM,CC(=O)N1CCC(C(=O)N2C[C@@H](c3nc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)no3)[C@H](c3ccc(F)cc3C)C2)CC1,CHEMBL1149712,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,2007.0,17,19,5310,5315,10.1016/j.bmcl.2007.08.028,17723300.0,
1982417,CHEMBL392463,"1-(4-((3R,4S)-3-(3-(2-(3,5-bis(trifluoromethyl)phenyl)propan-2-yl)-1,2,4-oxadiazol-5-yl)-4-(4-fluoro-2-methylphenyl)pyrrolidine-1-carbonyl)piperidin-1-yl)ethanone",CHEMBL899350,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,47000.0,nM,CC(=O)N1CCC(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](c3nc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)no3)C2)CC1,CHEMBL1149712,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,2007.0,17,19,5310,5315,10.1016/j.bmcl.2007.08.028,17723300.0,
1982418,CHEMBL235882,"(3R,4S)-N-(3,5-bis(trifluoromethyl)benzyl)-4-(4-fluoro-2-methylphenyl)-N-methyl-1-(2-methylpyrazine-5-carbonyl)pyrrolidine-3-carboxamide",CHEMBL899350,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,43000.0,nM,Cc1cnc(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)cn1,CHEMBL1149712,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,2007.0,17,19,5310,5315,10.1016/j.bmcl.2007.08.028,17723300.0,
1982419,CHEMBL391615,"(3R,4S)-N-(2-(3,5-bis(trifluoromethyl)phenyl)propan-2-yl)-1-(1-acetylpiperidine-4-carbonyl)-4-(4-fluoro-2-methylphenyl)-N-methylpyrrolidine-3-carboxamide",CHEMBL899350,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,CC(=O)N1CCC(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](C(=O)N(C)C(C)(C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)CC1,CHEMBL1149712,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,2007.0,17,19,5310,5315,10.1016/j.bmcl.2007.08.028,17723300.0,
1982420,CHEMBL391964,"(3R,4S)-N-(3,5-bis(trifluoromethyl)benzyl)-1-(1-acetylpiperidine-4-carbonyl)-4-(4-fluoro-2-methylphenyl)-N-methylpyrrolidine-3-carboxamide",CHEMBL899350,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,69000.0,nM,CC(=O)N1CCC(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)CC1,CHEMBL1149712,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,Bioorg. Med. Chem. Lett.,2007.0,17,19,5310,5315,10.1016/j.bmcl.2007.08.028,17723300.0,
1983105,CHEMBL236902,(S)-benzyl 4-(5-((2-aminophenyl)carbamoyl)pyridin-2-yl)-2-methylpiperazine-1-carboxylate,CHEMBL899446,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,24500.0,nM,C[C@H]1CN(c2ccc(C(=O)Nc3ccccc3N)cn2)CCN1C(=O)OCc1ccccc1,CHEMBL1137437,The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,2007.0,17,19,5300,5309,10.1016/j.bmcl.2007.08.023,17761416.0,
1994149,CHEMBL118,4-(5-p-Tolyl-3-trifluoromethyl-pyrazol-1-yl)-benzenesulfonamide,CHEMBL899614,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescence inhibition assay,IC50,=,10000.0,nM,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,CHEMBL1137572,"CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.",J. Med. Chem.,2007.0,50,22,5382,5391,10.1021/jm070745g,17915853.0,
1994150,CHEMBL244132,5-(4-methylphenyl)-1-(4-sulfamoylphenyl)-1H-pyrazol-3-carboxylic acid,CHEMBL899614,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescence inhibition assay,IC50,>,40000.0,nM,Cc1ccc(-c2cc(C(=O)O)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,CHEMBL1137572,"CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.",J. Med. Chem.,2007.0,50,22,5382,5391,10.1021/jm070745g,17915853.0,
1994151,CHEMBL244131,2-[4-(5-(4-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl)-phenyl]-acetic acid,CHEMBL899614,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescence inhibition assay,IC50,>,40000.0,nM,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(CC(=O)O)cc2)cc1,CHEMBL1137572,"CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.",J. Med. Chem.,2007.0,50,22,5382,5391,10.1021/jm070745g,17915853.0,
1994152,CHEMBL388226,2-[4-(5-(4-trifluoromethylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl)phenyl]-acetic acid,CHEMBL899614,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescence inhibition assay,IC50,=,25000.0,nM,O=C(O)Cc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(C(F)(F)F)cc2)cc1,CHEMBL1137572,"CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.",J. Med. Chem.,2007.0,50,22,5382,5391,10.1021/jm070745g,17915853.0,
1994153,CHEMBL244130,"1,5-bis-(4-methylphenyl)-3-trifluoromethyl-pyrazole",CHEMBL899614,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescence inhibition assay,IC50,>,40000.0,nM,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(C)cc2)cc1,CHEMBL1137572,"CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.",J. Med. Chem.,2007.0,50,22,5382,5391,10.1021/jm070745g,17915853.0,
1994154,CHEMBL285831,4-[3-Trifluoromethyl-5-(4-trifluoromethyl-phenyl)-pyrazol-1-yl]-benzenesulfonamide,CHEMBL899614,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescence inhibition assay,IC50,=,17000.0,nM,NS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(C(F)(F)F)cc2)cc1,CHEMBL1137572,"CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.",J. Med. Chem.,2007.0,50,22,5382,5391,10.1021/jm070745g,17915853.0,
1994155,CHEMBL440055,ethyl 4-[5-(4-Methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]-benzoate,CHEMBL899614,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescence inhibition assay,IC50,>,40000.0,nM,CCOC(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(C)cc2)cc1,CHEMBL1137572,"CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.",J. Med. Chem.,2007.0,50,22,5382,5391,10.1021/jm070745g,17915853.0,
1994156,CHEMBL241971,ethyl 4-[5-(4-Trifluoromethylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]-benzoate,CHEMBL899614,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescence inhibition assay,IC50,>,40000.0,nM,CCOC(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(C(F)(F)F)cc2)cc1,CHEMBL1137572,"CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.",J. Med. Chem.,2007.0,50,22,5382,5391,10.1021/jm070745g,17915853.0,
1994157,CHEMBL241970,4-[5-(4-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]-1-methylsulfonyl-benzene,CHEMBL899614,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescence inhibition assay,IC50,=,16000.0,nM,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(C)(=O)=O)cc2)cc1,CHEMBL1137572,"CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.",J. Med. Chem.,2007.0,50,22,5382,5391,10.1021/jm070745g,17915853.0,
1994158,CHEMBL397230,4-[5-(4-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]-1-methylsulfinyl-benzene,CHEMBL899614,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescence inhibition assay,IC50,=,26000.0,nM,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc([S+](C)[O-])cc2)cc1,CHEMBL1137572,"CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.",J. Med. Chem.,2007.0,50,22,5382,5391,10.1021/jm070745g,17915853.0,
1994159,CHEMBL241969,4-[5-(4-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]-1-methylthio-benzene,CHEMBL899614,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescence inhibition assay,IC50,>,40000.0,nM,CSc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(C)cc2)cc1,CHEMBL1137572,"CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.",J. Med. Chem.,2007.0,50,22,5382,5391,10.1021/jm070745g,17915853.0,
1994160,CHEMBL245196,4-[5-(4-methylphenyl)-3-phenyl-1H-pyrazol-1-yl]-benzenesulfonamide,CHEMBL899614,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescence inhibition assay,IC50,=,16000.0,nM,Cc1ccc(-c2cc(-c3ccccc3)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,CHEMBL1137572,"CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.",J. Med. Chem.,2007.0,50,22,5382,5391,10.1021/jm070745g,17915853.0,
1994161,CHEMBL397229,4-[3-trifluoromethyl-5-(4-methylphenyl)-1H-pyrazol-1-yl]-benzoic acid,CHEMBL899614,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescence inhibition assay,IC50,>,40000.0,nM,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(C(=O)O)cc2)cc1,CHEMBL1137572,"CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.",J. Med. Chem.,2007.0,50,22,5382,5391,10.1021/jm070745g,17915853.0,
1994162,CHEMBL242403,4-[3-trifluoromethyl-5-(4-trifluoromethylphenyl)-1H-pyrazol-1-yl]-benzoic acid,CHEMBL899614,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescence inhibition assay,IC50,>,40000.0,nM,O=C(O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(C(F)(F)F)cc2)cc1,CHEMBL1137572,"CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.",J. Med. Chem.,2007.0,50,22,5382,5391,10.1021/jm070745g,17915853.0,
1994917,CHEMBL427860,1-{2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl}-4-[(2R)-methyl-3-(4-chlorophenyl)propionyl]piperazine,CHEMBL900823,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3)CC2)c([C@@H](NC(=O)CCN(C)C)C(C)C)c1,CHEMBL1137579,Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.,J. Med. Chem.,2007.0,50,22,5249,5252,10.1021/jm070806a,17918824.0,
1997532,CHEMBL392525,"2-(4-(6-chloro-2-(4-(dimethylamino)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)-N-(thiazol-2-yl)acetamide",CHEMBL899974,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,=,10000.0,nM,CN(C)c1ccc(-c2nc3c(N4CCN(CC(=O)Nc5nccs5)CC4)c(Cl)cnc3[nH]2)cc1,CHEMBL1137627,"Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases.",Bioorg. Med. Chem. Lett.,2007.0,17,23,6567,6571,10.1016/j.bmcl.2007.09.076,17933533.0,
1999460,CHEMBL392760,"N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine",CHEMBL900221,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,500000.0,nM,NCCc1cn(S(=O)(=O)c2c(Cl)nc3sccn23)c2ccccc12,CHEMBL1138245,"Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist.",J. Med. Chem.,2007.0,50,23,5535,5538,10.1021/jm070521y,17948978.0,
2004072,CHEMBL398372,(S)-2-(5-(1-(2-amino-2-methylpropanamido)-2-(benzyloxy)ethyl)-1H-tetrazol-1-yl)ethyl 4-hydroxybutylcarbamate,CHEMBL901998,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,100000.0,nM,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1CCOC(=O)NCCCCO,CHEMBL1138292,Discovery of a tetrazole-based growth hormone secretagogue: 4-(hydroxybutyl)carbamic acid 2-{5-[1-(2-amino-2-methylpropionylamino)-2- benzyloxyethyl]tetrazol-1-yl}ethyl ester (BMS-317180).,J. Med. Chem.,2007.0,50,24,5890,5893,10.1021/jm7010595,17973363.0,
2006011,CHEMBL2062151,"(5R)-3-[3-fluoro-4-(1-oxidotetrahydro-2H-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide",CHEMBL901177,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9,IC50,>,900000.0,nM,NC(=O)[C@H]1CN(c2ccc([C@H]3CC[S@+]([O-])CC3)c(F)c2)C(=O)O1,CHEMBL1138317,"Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound.",J. Med. Chem.,2007.0,50,24,5886,5889,10.1021/jm070708p,17988109.0,
2006205,CHEMBL235952,2-(3-(4-(5-hydroxypyridin-2-yl)phenyl)propanamido)benzoic acid,CHEMBL900201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,1600.0,nM,O=C(CCc1ccc(-c2ccc(O)cn2)cc1)Nc1ccccc1C(=O)O,CHEMBL1138322,Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor.,J. Med. Chem.,2007.0,50,25,6303,6306,10.1021/jm700942d,17994679.0,
2006212,CHEMBL235256,2-[3-(2'-chloro-4'-hydroxy-biphenyl-4-yl)-propionylamino]-benzoic acid,CHEMBL900201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,<,400.0,nM,O=C(CCc1ccc(-c2ccc(O)cc2Cl)cc1)Nc1ccccc1C(=O)O,CHEMBL1138322,Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor.,J. Med. Chem.,2007.0,50,25,6303,6306,10.1021/jm700942d,17994679.0,
2006213,CHEMBL237248,"2-(3-(3-(5-hydroxypyridin-2-yl)-1,2,4-oxadiazol-5-yl)propanamido)benzoic acid",CHEMBL900201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,42000.0,nM,O=C(CCc1nc(-c2ccc(O)cn2)no1)Nc1ccccc1C(=O)O,CHEMBL1138322,Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor.,J. Med. Chem.,2007.0,50,25,6303,6306,10.1021/jm700942d,17994679.0,
2006214,CHEMBL237247,2-(3-(5-(5-hydroxypyridin-2-yl)thiazol-2-yl)propanamido)benzoic acid,CHEMBL900201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,4200.0,nM,O=C(CCc1ncc(-c2ccc(O)cn2)s1)Nc1ccccc1C(=O)O,CHEMBL1138322,Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor.,J. Med. Chem.,2007.0,50,25,6303,6306,10.1021/jm700942d,17994679.0,
2006215,CHEMBL237037,2-(3-(2-(5-hydroxypyridin-2-yl)thiazol-5-yl)propanamido)benzoic acid,CHEMBL900201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,5700.0,nM,O=C(CCc1cnc(-c2ccc(O)cn2)s1)Nc1ccccc1C(=O)O,CHEMBL1138322,Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor.,J. Med. Chem.,2007.0,50,25,6303,6306,10.1021/jm700942d,17994679.0,
2006216,CHEMBL236163,2-(3-(1-(4-hydroxyphenyl)-5-methyl-1H-pyrazol-4-yl)propanamido)benzoic acid,CHEMBL900201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,15000.0,nM,Cc1c(CCC(=O)Nc2ccccc2C(=O)O)cnn1-c1ccc(O)cc1,CHEMBL1138322,Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor.,J. Med. Chem.,2007.0,50,25,6303,6306,10.1021/jm700942d,17994679.0,
2006217,CHEMBL236162,2-(3-(2-(2-chloro-4-hydroxyphenyl)thiazol-5-yl)propanamido)benzoic acid,CHEMBL900201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,2800.0,nM,O=C(CCc1cnc(-c2ccc(O)cc2Cl)s1)Nc1ccccc1C(=O)O,CHEMBL1138322,Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor.,J. Med. Chem.,2007.0,50,25,6303,6306,10.1021/jm700942d,17994679.0,
2006654,CHEMBL266647,N-(1S-[2-{4-[(2R)-methyl-3-(4-chlorophenyl)propionyl]-1-piperazinyl}-5-chlorophenyl]-3-methylbutyl)-3-(dimethylamino)propionamide,CHEMBL901391,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CC(C)C[C@H](NC(=O)CCN(C)C)c1cc(Cl)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2)CC1,CHEMBL1138325,"Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor.",J. Med. Chem.,2007.0,50,25,6356,6366,10.1021/jm701137s,17994683.0,
2010739,CHEMBL240185,4-(4-fluoro-benzoyl)-1-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazin-2-one formic acid,CHEMBL903102,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,O=C(c1ccc(F)cc1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1.O=CO,CHEMBL1138361,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,2007.0,50,26,6706,6717,10.1021/jm0708228,18052318.0,
2010750,CHEMBL239099,4-(1-(4-(1-cyclobutylpiperidin-4-yloxy)phenyl)-2-oxopiperazine-4-carbonyl)benzonitrile formic acid,CHEMBL903102,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,N#Cc1ccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCC5)CC4)cc3)C(=O)C2)cc1.O=CO,CHEMBL1138361,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,2007.0,50,26,6706,6717,10.1021/jm0708228,18052318.0,
2010751,CHEMBL239299,"(R)-4-(2,4-difluorobenzoyl)-1-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)piperazin-2-one formic acid",CHEMBL903102,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3F)CC2=O)cc1.O=CO,CHEMBL1138361,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,2007.0,50,26,6706,6717,10.1021/jm0708228,18052318.0,
2010752,CHEMBL534958,4-(2-oxo-1-(4-(3-(piperidin-1-yl)propoxy)phenyl)piperazine-4-carbonyl)benzonitrile hydrochloride,CHEMBL903102,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,Cl.N#Cc1ccc(C(=O)N2CCN(c3ccc(OCCCN4CCCCC4)cc3)C(=O)C2)cc1,CHEMBL1138361,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,2007.0,50,26,6706,6717,10.1021/jm0708228,18052318.0,
2012796,CHEMBL246970,"N2-(2-chlorobenzyl)-N4-((4-(aminomethyl)cyclohexyl)methyl)-5-nitropyrimidine-2,4-diamine",CHEMBL902306,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1000.0,nM,NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1,CHEMBL1138386,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,2007.0,17,1,225,230,10.1016/j.bmcl.2006.09.056,17055721.0,
2012807,CHEMBL246161,"N2-(2-chlorobenzyl)-5-nitro-N4-(piperidin-4-ylmethyl)pyrimidine-2,4-diamine",CHEMBL902306,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,17600.0,nM,O=[N+]([O-])c1cnc(NCc2ccccc2Cl)nc1NCC1CCNCC1,CHEMBL1138386,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,2007.0,17,1,225,230,10.1016/j.bmcl.2006.09.056,17055721.0,
2012808,CHEMBL246160,"N2-(2-chlorobenzyl)-N4-((4-((dimethylamino)methyl)cyclohexyl)methyl)-5-nitropyrimidine-2,4-diamine",CHEMBL902306,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8400.0,nM,CN(C)CC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1,CHEMBL1138386,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,2007.0,17,1,225,230,10.1016/j.bmcl.2006.09.056,17055721.0,
2012809,CHEMBL392642,"N2-(2-(methylthio)benzyl)-N4-((4-(aminomethyl)cyclohexyl)methyl)-5-nitropyrimidine-2,4-diamine",CHEMBL902306,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1400.0,nM,CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1,CHEMBL1138386,Discovery of potent and selective PKC-theta inhibitors.,Bioorg. Med. Chem. Lett.,2007.0,17,1,225,230,10.1016/j.bmcl.2006.09.056,17055721.0,
2019833,CHEMBL240436,N-(4-chlorobenzyl)-2-(N-(2-ethylphenyl)-4-methylphenylsulfonamido)acetamide,CHEMBL902281,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,6309.57,nM,CCc1ccccc1N(CC(=O)NCc1ccc(Cl)cc1)S(=O)(=O)c1ccc(C)cc1,CHEMBL1139103,Identification of novel glycine sulfonamide antagonists for the EP1 receptor.,Bioorg. Med. Chem. Lett.,2007.0,17,6,1750,1754,10.1016/j.bmcl.2006.12.060,17236765.0,
2021827,CHEMBL395426,"1-(6-(thiophen-3-yl)pyrimidin-4-yl)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine",CHEMBL903589,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,NC1CN(c2cc(-c3ccsc3)ncn2)CC1c1cc(F)c(F)cc1F,CHEMBL1139138,"Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.",Bioorg. Med. Chem. Lett.,2007.0,17,7,2005,2012,10.1016/j.bmcl.2007.01.026,17276063.0,
2021828,CHEMBL246530,"1-(4-(3-(methylsulfonyl)phenyl)-1,3,5-triazin-2-yl)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine",CHEMBL903589,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CS(=O)(=O)c1cccc(-c2ncnc(N3CC(N)C(c4cc(F)c(F)cc4F)C3)n2)c1,CHEMBL1139138,"Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.",Bioorg. Med. Chem. Lett.,2007.0,17,7,2005,2012,10.1016/j.bmcl.2007.01.026,17276063.0,
2021829,CHEMBL246322,"1-(6-(3-(morpholinosulfonyl)phenyl)pyrimidin-4-yl)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine",CHEMBL903589,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,NC1CN(c2cc(-c3cccc(S(=O)(=O)N4CCOCC4)c3)ncn2)CC1c1cc(F)c(F)cc1F,CHEMBL1139138,"Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.",Bioorg. Med. Chem. Lett.,2007.0,17,7,2005,2012,10.1016/j.bmcl.2007.01.026,17276063.0,
2021830,CHEMBL245585,"3-(6-(3-amino-4-(2,4,5-trifluorophenyl)pyrrolidin-1-yl)pyrimidin-4-yl)benzoic acid",CHEMBL903589,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,NC1CN(c2cc(-c3cccc(C(=O)O)c3)ncn2)CC1c1cc(F)c(F)cc1F,CHEMBL1139138,"Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.",Bioorg. Med. Chem. Lett.,2007.0,17,7,2005,2012,10.1016/j.bmcl.2007.01.026,17276063.0,
2021831,CHEMBL536086,"1-(6-(thiophen-3-yl)pyrimidin-4-yl)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine",CHEMBL903589,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cl.NC1CN(c2cc(-c3ccsc3)ncn2)CC1c1cc(F)c(F)cc1F,CHEMBL1139138,"Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.",Bioorg. Med. Chem. Lett.,2007.0,17,7,2005,2012,10.1016/j.bmcl.2007.01.026,17276063.0,
2027585,CHEMBL248380,(R)-2-[3-cyano-2-(2'-ethoxy-biphenyl-4-yl)-6-fluoro-quinolin-4-ylamino]-propionic acid,CHEMBL886047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2000.0,nM,CCOc1ccccc1-c1ccc(-c2nc3ccc(F)cc3c(N[C@H](C)C(=O)O)c2C#N)cc1,CHEMBL1139915,PDE-10A inhibitors as insulin secretagogues.,Bioorg. Med. Chem. Lett.,2007.0,17,10,2869,2873,10.1016/j.bmcl.2007.02.061,17400452.0,
2027586,CHEMBL397600,(S)-2-[3-cyano-2-(2'-ethoxy-biphenyl-4-yl)-6-fluoro-quinolin-4-ylamino]-propionic acid,CHEMBL886047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,66.0,nM,CCOc1ccccc1-c1ccc(-c2nc3ccc(F)cc3c(N[C@@H](C)C(=O)O)c2C#N)cc1,CHEMBL1139915,PDE-10A inhibitors as insulin secretagogues.,Bioorg. Med. Chem. Lett.,2007.0,17,10,2869,2873,10.1016/j.bmcl.2007.02.061,17400452.0,
2033519,CHEMBL398126,2-(4-chloro-2-cycloheptylphenoxy)acetic acid,CHEMBL888197,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(O)COc1ccc(Cl)cc1C1CCCCCC1,CHEMBL1140006,2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists.,Bioorg. Med. Chem. Lett.,2007.0,17,15,4347,4350,10.1016/j.bmcl.2007.05.019,17531480.0,
2040058,CHEMBL399719,"4-methyl-6-((4-(2-(2-methylquinolin-5-yloxy)ethyl)piperazin-1-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",CHEMBL923329,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,20000.0,nM,Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(C)C(=O)CO5)CC3)cccc2n1,CHEMBL1139760,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,2007.0,17,18,5214,5217,10.1016/j.bmcl.2007.06.078,17629698.0,
2040066,CHEMBL248407,"6-((4-(2-(2-methylquinolin-5-yloxy)ethyl)piperazin-1-yl)methyl)-4-phenethyl-2H-benzo[b][1,4]oxazin-3(4H)-one",CHEMBL923329,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4000.0,nM,Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(CCc4ccccc4)C(=O)CO5)CC3)cccc2n1,CHEMBL1139760,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,2007.0,17,18,5214,5217,10.1016/j.bmcl.2007.06.078,17629698.0,
2040067,CHEMBL248231,"4-benzyl-6-((4-(2-(2-methylquinolin-5-yloxy)ethyl)piperazin-1-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",CHEMBL923329,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7000.0,nM,Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(Cc4ccccc4)C(=O)CO5)CC3)cccc2n1,CHEMBL1139760,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,2007.0,17,18,5214,5217,10.1016/j.bmcl.2007.06.078,17629698.0,
2040068,CHEMBL248229,"4-butyl-6-((4-(2-(2-methylquinolin-5-yloxy)ethyl)piperazin-1-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",CHEMBL923329,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,12000.0,nM,CCCCN1C(=O)COc2ccc(CN3CCN(CCOc4cccc5nc(C)ccc45)CC3)cc21,CHEMBL1139760,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,2007.0,17,18,5214,5217,10.1016/j.bmcl.2007.06.078,17629698.0,
2040069,CHEMBL246599,"6-((4-(2-(2-methylquinolin-5-yloxy)ethyl)piperazin-1-yl)methyl)-4-propyl-2H-benzo[b][1,4]oxazin-3(4H)-one",CHEMBL923329,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,18000.0,nM,CCCN1C(=O)COc2ccc(CN3CCN(CCOc4cccc5nc(C)ccc45)CC3)cc21,CHEMBL1139760,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,2007.0,17,18,5214,5217,10.1016/j.bmcl.2007.06.078,17629698.0,
2040070,CHEMBL248458,"4-ethyl-6-((4-(2-(2-methylquinolin-5-yloxy)ethyl)piperazin-1-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",CHEMBL923329,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,14000.0,nM,CCN1C(=O)COc2ccc(CN3CCN(CCOc4cccc5nc(C)ccc45)CC3)cc21,CHEMBL1139760,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,2007.0,17,18,5214,5217,10.1016/j.bmcl.2007.06.078,17629698.0,
2040112,CHEMBL247428,"8-fluoro-4-methyl-6-((4-(2-(2-methylquinolin-5-yloxy)ethyl)piperazin-1-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",CHEMBL923329,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,19000.0,nM,Cc1ccc2c(OCCN3CCN(Cc4cc(F)c5c(c4)N(C)C(=O)CO5)CC3)cccc2n1,CHEMBL1139760,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,2007.0,17,18,5214,5217,10.1016/j.bmcl.2007.06.078,17629698.0,
2040117,CHEMBL247609,"5-fluoro-4-methyl-6-((4-(2-(2-methylquinolin-5-yloxy)ethyl)piperazin-1-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",CHEMBL923329,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,16000.0,nM,Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4F)N(C)C(=O)CO5)CC3)cccc2n1,CHEMBL1139760,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,2007.0,17,18,5214,5217,10.1016/j.bmcl.2007.06.078,17629698.0,
2040122,CHEMBL443060,"4-ethyl-5-fluoro-6-((4-(2-(2-methylquinolin-5-yloxy)ethyl)piperazin-1-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",CHEMBL923329,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,9000.0,nM,CCN1C(=O)COc2ccc(CN3CCN(CCOc4cccc5nc(C)ccc45)CC3)c(F)c21,CHEMBL1139760,"Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.",Bioorg. Med. Chem. Lett.,2007.0,17,18,5214,5217,10.1016/j.bmcl.2007.06.078,17629698.0,
2046178,CHEMBL248849,(E)-2-(5-(5-chlorothiophen-2-yl)thiophen-2-yl)-N-(((R)-1-(1-(pyridin-4-yl)piperidine-4-carbonyl)pyrrolidin-3-yl)methyl)ethenesulfonamide,CHEMBL924025,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1470.0,nM,O=C(C1CCN(c2ccncc2)CC1)N1CC[C@@H](CNS(=O)(=O)/C=C/c2ccc(-c3ccc(Cl)s3)s2)C1,CHEMBL1140480,Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.,Bioorg. Med. Chem. Lett.,2007.0,17,21,5952,5958,10.1016/j.bmcl.2007.07.063,17855089.0,
2046357,CHEMBL399045,"(E)-1-(4-((4-(4-chlorophenyl)piperidin-1-yl)methyl)piperidin-1-yl)-3-(3,4-dichlorophenyl)prop-2-en-1-one",CHEMBL925088,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,40000.0,nM,O=C(/C=C/c1ccc(Cl)c(Cl)c1)N1CCC(CN2CCC(c3ccc(Cl)cc3)CC2)CC1,CHEMBL1140484,Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists.,Bioorg. Med. Chem. Lett.,2007.0,17,21,5964,5968,10.1016/j.bmcl.2007.07.065,17869105.0,
2077673,CHEMBL372575,"(E)-8-(3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-(4-(methylsulfonyl)phenyl)vinyl)phenyl)-6-(2-(methylsulfonyl)propan-2-yl)quinoline",CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,200.0,nM,Cc1noc(/C(=C/c2cccc(-c3cc(C(C)(C)S(C)(=O)=O)cc4cccnc34)c2)c2ccc(S(C)(=O)=O)cc2)n1,CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077729,CHEMBL253083,2-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid,CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3200.0,nM,CC(C)(c1cc(-c2cccc(-c3ccc(C4CC4C(=O)O)cc3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077730,CHEMBL253083,2-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid,CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1700.0,nM,CC(C)(c1cc(-c2cccc(-c3ccc(C4CC4C(=O)O)cc3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077731,CHEMBL253082,3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-3-methyl-butyric acid,CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,15000.0,nM,CC(C)(CC(=O)O)c1ccc(-c2cccc(-c3cc(C(C)(C)S(C)(=O)=O)cc4cccnc34)c2)cc1,CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077732,CHEMBL403744,"3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-2,2-dimethyl-propionic acid",CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1600.0,nM,CC(C)(Cc1ccc(-c2cccc(-c3cc(C(C)(C)S(C)(=O)=O)cc4cccnc34)c2)cc1)C(=O)O,CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077733,CHEMBL252887,3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-propionic acid,CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9800.0,nM,CC(C)(c1cc(-c2cccc(-c3ccc(CCC(=O)O)cc3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077734,CHEMBL252886,3-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-3-yl}-propionic acid,CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7200.0,nM,CC(C)(c1cc(-c2cccc(-c3cccc(CCC(=O)O)c3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077735,CHEMBL403065,5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridine-2-carboxylic acid cyclopropylamide,CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4000.0,nM,CC(C)(c1cc(-c2cccc(-c3ccc(C(=O)NC4CC4)[n+]([O-])c3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077736,CHEMBL252490,1-isopropyl-3-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridin-2-yl)-urea,CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1500.0,nM,CC(C)NC(=O)Nc1ccc(-c2cccc(-c3cc(C(C)(C)S(C)(=O)=O)cc4cccnc34)c2)c[n+]1[O-],CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077737,CHEMBL436847,2-(5-{3-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-phenyl}-1-oxy-pyridin-2-yl)-propan-2-ol,CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,15000.0,nM,CC(C)(O)c1ccc(-c2cccc(-c3cc(C(C)(C)S(C)(=O)=O)cc4cccnc34)c2)c[n+]1[O-],CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077738,CHEMBL252090,6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(6-methyl-1-oxy-pyridin-3-yl)-phenyl]-quinoline,CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,26000.0,nM,Cc1ccc(-c2cccc(-c3cc(C(C)(C)S(C)(=O)=O)cc4cccnc34)c2)c[n+]1[O-],CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077739,CHEMBL252089,"8-(3-(1H-imidazo[4,5-b]pyridin-6-yl)phenyl)-6-(2-(methylsulfonyl)propan-2-yl)quinoline",CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2900.0,nM,CC(C)(c1cc(-c2cccc(-c3cnc4nc[nH]c4c3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077740,CHEMBL403977,6-(2-(methylsulfonyl)propan-2-yl)-8-(3-(pyridin-4-yl)phenyl)quinoline,CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,110.0,nM,CC(C)(c1cc(-c2cccc(-c3ccncc3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077741,CHEMBL251883,6-(1-methanesulfonyl-1-methyl-ethyl)-8-[3-(1-oxy-pyridin-3-yl)-phenyl]-quinoline,CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,36000.0,nM,CC(C)(c1cc(-c2cccc(-c3ccc[n+]([O-])c3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077742,CHEMBL254518,6-(2-(methylsulfonyl)propan-2-yl)-8-(3-(pyridin-3-yl)phenyl)quinoline,CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,630.0,nM,CC(C)(c1cc(-c2cccc(-c3cccnc3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077743,CHEMBL251882,8-(4'-methanesulfonylmethyl-biphenyl-3-yl)-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline,CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1600.0,nM,CC(C)(c1cc(-c2cccc(-c3ccc(CS(C)(=O)=O)cc3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077744,CHEMBL402953,8-(4'-methanesulfonyl-biphenyl-3-yl)-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline,CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,730.0,nM,CC(C)(c1cc(-c2cccc(-c3ccc(S(C)(=O)=O)cc3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2077745,CHEMBL252469,8-(3'-methanesulfonyl-biphenyl-3-yl)-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline,CHEMBL945013,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,580.0,nM,CC(C)(c1cc(-c2cccc(-c3cccc(S(C)(=O)=O)c3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1141472,"Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1407,1412,10.1016/j.bmcl.2008.01.004,18207397.0,
2080975,CHEMBL255858,"(2,4-dimethyl-1-oxy-pyridin-3-yl)-[4'-methyl-4-(phenyl-pyridin-3-yl-amino)-[1,4']bipiperidinyl-1'-yl]-methanone",CHEMBL928566,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1cc[n+]([O-])c(C)c1C(=O)N1CCC(C)(N2CCC(N(c3ccccc3)c3cccnc3)CC2)CC1,CHEMBL1141522,"Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo.",Bioorg. Med. Chem. Lett.,2008.0,18,6,2000,2005,10.1016/j.bmcl.2008.01.108,18267361.0,
2082044,CHEMBL403313,4-[5-cyano-2-(4-fluorophenyl)-1H-indol-3-yl]-N-(dimethylsulfamoyl)butanamide,CHEMBL928891,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1320.0,nM,CN(C)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12,CHEMBL1141538,"Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor.",Bioorg. Med. Chem. Lett.,2008.0,18,6,1926,1930,10.1016/j.bmcl.2008.01.127,18308567.0,
2092865,CHEMBL258324,"(R)-N-((R)-1-(5-(5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl)-3-fluoropyridin-2-yl)ethyl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide",CHEMBL930620,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,C[C@@H](NC(=O)[C@@](C)(O)C(F)(F)F)c1ncc(-c2cc(Cl)cc(F)c2-c2nnn(C)n2)cc1F,CHEMBL1141559,Alpha-hydroxy amides as a novel class of bradykinin B1 selective antagonists.,Bioorg. Med. Chem. Lett.,2008.0,18,2,716,720,10.1016/j.bmcl.2007.11.050,18061443.0,
2100883,CHEMBL408479,"(R)-9-[[(dimethylamino)sulfonyl](methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide",CHEMBL932295,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,100000.0,nM,CN(C)S(=O)(=O)N(C)[C@@H]1CCCn2c1nc(C(=O)NCc1ccc(F)cc1)c(O)c2=O,CHEMBL1143246,Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors.,J. Med. Chem.,2008.0,51,4,861,874,10.1021/jm701164t,18217703.0,
2100949,CHEMBL408962,"(S)-N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepin-10-yl)-N,N,N-trimethylethanediamide",CHEMBL932295,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,75000.0,nM,CN(C)C(=O)C(=O)N(C)[C@H]1CCCCn2c1nc(C(=O)NCc1ccc(F)cc1)c(O)c2=O,CHEMBL1143246,Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors.,J. Med. Chem.,2008.0,51,4,861,874,10.1021/jm701164t,18217703.0,
2101468,CHEMBL271310,"N-cyclopropyl-5-(6-(5-(3-(dimethylamino)propylamino)-1,3,4-oxadiazol-2-yl)-5-isopropylpyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-2,4-difluorobenzamide",CHEMBL949201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,39000.0,nM,CC(C)c1c(-c2nnc(NCCCN(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12,CHEMBL1143868,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1354,1358,10.1016/j.bmcl.2008.01.012,18221875.0,
2101484,CHEMBL258046,"N-cyclopropyl-2,4-difluoro-5-(5-isopropyl-6-(5-(piperidin-4-yloxy)-1,3,4-oxadiazol-2-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)benzamide",CHEMBL949201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,40000.0,nM,CC(C)c1c(-c2nnc(OC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12,CHEMBL1143868,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1354,1358,10.1016/j.bmcl.2008.01.012,18221875.0,
2101485,CHEMBL270193,"5-(6-(5-(4-aminobutylamino)-1,3,4-oxadiazol-2-yl)-5-isopropylpyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-N-cyclopropyl-2,4-difluorobenzamide",CHEMBL949201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,21000.0,nM,CC(C)c1c(-c2nnc(NCCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12,CHEMBL1143868,"Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,4,1354,1358,10.1016/j.bmcl.2008.01.012,18221875.0,
2111385,CHEMBL255590,JNJ-27390467,CHEMBL949332,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,NCc1ccc2c(c1)C1(CCN(C(=O)c3ccc(C#Cc4ccccc4)o3)CC1)CO2,CHEMBL1143198,"Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of novel spirocyclic piperidine amide derivatives.",Bioorg. Med. Chem. Lett.,2008.0,18,6,2114,2121,10.1016/j.bmcl.2008.01.093,18272363.0,
2113709,CHEMBL271876,2-amino-N-((S)-2-(benzyloxy)-1-(1-((R)-1-cyano-3-(pyridin-2-yloxy)propan-2-yl)-1H-tetrazol-5-yl)ethyl)-2-methylpropanamide,CHEMBL934047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,100000.0,nM,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccn1,CHEMBL1141598,Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues.,Bioorg. Med. Chem. Lett.,2008.0,18,6,2067,2072,10.1016/j.bmcl.2008.01.100,18282707.0,
2113715,CHEMBL270666,2-amino-N-((S)-2-(benzyloxy)-1-(1-((R)-1-cyano-3-(2-hydroxyphenoxy)propan-2-yl)-1H-tetrazol-5-yl)ethyl)-2-methylpropanamide,CHEMBL934047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,66000.0,nM,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccc1O,CHEMBL1141598,Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues.,Bioorg. Med. Chem. Lett.,2008.0,18,6,2067,2072,10.1016/j.bmcl.2008.01.100,18282707.0,
2114064,CHEMBL377300,"(R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol",CHEMBL935251,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,40000.0,nM,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,CHEMBL1141628,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,2008.0,51,6,1976,1980,10.1021/jm7013309,18288793.0,
2114070,CHEMBL270996,"(R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl 2-aminoacetate",CHEMBL935251,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,63.0,nM,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)CN)c(C)c34)ccc2[nH]1,CHEMBL1141628,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,2008.0,51,6,1976,1980,10.1021/jm7013309,18288793.0,
2114077,CHEMBL408444,"(S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl) 2-aminopropanoate",CHEMBL935251,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,9700.0,nM,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@@H](C)N)c(C)c34)ccc2[nH]1,CHEMBL1141628,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,2008.0,51,6,1976,1980,10.1021/jm7013309,18288793.0,
2114083,CHEMBL408443,"(S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl) 2-amino-4-methylpentanoate",CHEMBL935251,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,2700.0,nM,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](N)CC(C)C)c(C)c34)ccc2[nH]1,CHEMBL1141628,"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).",J. Med. Chem.,2008.0,51,6,1976,1980,10.1021/jm7013309,18288793.0,
2114896,CHEMBL271240,"(2S,3S)-3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-methoxyphenyl)-4-oxoazetidine-2-carboxylic acid",CHEMBL933075,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2200.0,nM,COc1ccc(N2C(=O)[C@@H](Cc3cccc(OCCc4nc(-c5ccccc5)oc4C)c3)[C@H]2C(=O)O)cc1,CHEMBL1142250,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,6,1939,1944,10.1016/j.bmcl.2008.01.126,18291645.0,
2114964,CHEMBL272336,"(2S,3S)-3-(3-(2-(2-(4-chlorophenyl)-5-methyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",CHEMBL933075,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,410.0,nM,Cc1oc(-c2ccc(Cl)cc2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1,CHEMBL1142250,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,6,1939,1944,10.1016/j.bmcl.2008.01.126,18291645.0,
2114965,CHEMBL257517,"(2S,3S)-3-(3-(2-(2-(4-methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",CHEMBL933075,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,550.0,nM,COc1ccc(-c2nc(CCOc3cccc(C[C@@H]4C(=O)N(c5ccc(C(C)(C)C)cc5)[C@@H]4C(=O)O)c3)c(C)o2)cc1,CHEMBL1142250,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,6,1939,1944,10.1016/j.bmcl.2008.01.126,18291645.0,
2114966,CHEMBL429734,"(2S,3S)-3-(3-(2-(2-(3-chlorophenyl)-5-methyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",CHEMBL933075,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,670.0,nM,Cc1oc(-c2cccc(Cl)c2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1,CHEMBL1142250,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,6,1939,1944,10.1016/j.bmcl.2008.01.126,18291645.0,
2114967,CHEMBL404646,"(2S,3S)-3-(3-(2-(2-(3-methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",CHEMBL933075,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,650.0,nM,COc1cccc(-c2nc(CCOc3cccc(C[C@@H]4C(=O)N(c5ccc(C(C)(C)C)cc5)[C@@H]4C(=O)O)c3)c(C)o2)c1,CHEMBL1142250,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,6,1939,1944,10.1016/j.bmcl.2008.01.126,18291645.0,
2114968,CHEMBL404451,"(2R,3R)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",CHEMBL933075,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3000.0,nM,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@H]2C(=O)O)cc1,CHEMBL1142250,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,6,1939,1944,10.1016/j.bmcl.2008.01.126,18291645.0,
2114969,CHEMBL256468,"(2S,3S)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",CHEMBL933075,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2300.0,nM,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)cc1,CHEMBL1142250,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,6,1939,1944,10.1016/j.bmcl.2008.01.126,18291645.0,
2114970,CHEMBL272963,"(2R,3R)-3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",CHEMBL933075,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,670.0,nM,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@H]2C(=O)O)c1,CHEMBL1142250,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,6,1939,1944,10.1016/j.bmcl.2008.01.126,18291645.0,
2114971,CHEMBL255389,"(2S,3S)-3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",CHEMBL933075,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,230.0,nM,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1,CHEMBL1142250,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,6,1939,1944,10.1016/j.bmcl.2008.01.126,18291645.0,
2114973,CHEMBL411118,"(2S,3S)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-methoxyphenyl)-4-oxoazetidine-2-carboxylic acid",CHEMBL933075,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,14000.0,nM,COc1ccc(N2C(=O)[C@@H](Cc3ccc(OCCc4nc(-c5ccccc5)oc4C)cc3)[C@H]2C(=O)O)cc1,CHEMBL1142250,Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,6,1939,1944,10.1016/j.bmcl.2008.01.126,18291645.0,
2119069,CHEMBL406917,"4-(5-(benzylthio)-4-(4-bromophenyl)-4H-1,2,4-triazol-3-yl)pyridine",CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,=,4300.0,nM,Brc1ccc(-n2c(SCc3ccccc3)nnc2-c2ccncc2)cc1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119070,CHEMBL270902,"1-(2-(2,4-dichlorophenoxy)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole",CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,=,10000.0,nM,Clc1ccc(OC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119071,CHEMBL270272,(S)-methyl 2-(benzylamino)-3-(1H-imidazol-4-yl)propanoate,CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,=,20000.0,nM,COC(=O)[C@H](Cc1c[nH]cn1)NCc1ccccc1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119072,CHEMBL271579,"1-((4-bromo-2-(2,4-dichlorophenyl)-tetrahydrofuran-2-yl)methyl)-1H-1,2,4-triazole",CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,=,8100.0,nM,Clc1ccc(C2(Cn3cncn3)CC(Br)CO2)c(Cl)c1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119073,CHEMBL258502,1-(2-(4-methoxyphenyl)-2-(3-(4-methoxyphenyl)propoxy)ethyl)-1H-imidazole,CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,=,220.0,nM,COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119074,CHEMBL271580,"4-(1-(2,4-dichlorobenzyl)-1H-pyrazol-4-yl)pyridine",CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,=,500.0,nM,Clc1ccc(Cn2cc(-c3ccncc3)cn2)c(Cl)c1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119075,CHEMBL270903,4-(1-(4-(methylsulfonyl)benzyl)-1H-pyrazol-4-yl)pyridine,CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,=,1300.0,nM,CS(=O)(=O)c1ccc(Cn2cc(-c3ccncc3)cn2)cc1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119076,CHEMBL271121,N-((5-methylpyrimidin-2-yl)methyl)-6-phenyl-2-(pyridin-4-yl)pyrimidin-4-amine,CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,=,4800.0,nM,Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3ccncc3)n2)nc1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119077,CHEMBL271120,N-((5-methylpyrimidin-2-yl)methyl)-6-phenyl-2-(pyridin-3-yl)pyrimidin-4-amine,CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,=,21000.0,nM,Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3cccnc3)n2)nc1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119079,CHEMBL271622,N-((3-(4-methoxyphenyl)isoxazol-5-yl)methyl)benzenesulfonamide,CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,=,39000.0,nM,COc1ccc(-c2cc(CNS(=O)(=O)c3ccccc3)on2)cc1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119080,CHEMBL271621,"ethyl 3-(2,4-dichlorophenyl)-2-(isoxazol-5-yl)propanoate",CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,=,11000.0,nM,CCOC(=O)C(Cc1ccc(Cl)cc1Cl)c1ccno1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119081,CHEMBL271624,"4-(5-(4-methoxybenzylthio)-4-ethyl-4H-1,2,4-triazol-3-yl)pyridine",CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,>,50000.0,nM,CCn1c(SCc2ccc(OC)cc2)nnc1-c1ccncc1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119082,CHEMBL3085388,"(S)-1-(2,4-difluorophenyl)-2-(1H-pyrazol-1-yl)-1-(1H-1,2,4-triazol-1-yl)ethanol",CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,>,50000.0,nM,O[C@](Cn1cccn1)(c1ccc(F)cc1F)n1cncn1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119083,CHEMBL410503,"(2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methyl methanesulfonate",CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,>,50000.0,nM,CS(=O)(=O)OCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119084,CHEMBL270271,"1-((2-(2,4-dichlorophenyl)-4-ethyl-1,3-dioxolan-2-yl)methyl)-1H-1,2,4-triazole",CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,>,50000.0,nM,CCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119085,CHEMBL271581,"2-bromo-N-(2-(2,6-dimethylpyridin-4-yl)propan-2-yl)-3,3-dimethylbutanamide",CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,>,50000.0,nM,Cc1cc(C(C)(C)NC(=O)C(Br)C(C)(C)C)cc(C)n1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119086,CHEMBL406832,N-((5-methylpyrimidin-2-yl)methyl)-6-phenyl-2-(pyridin-2-yl)pyrimidin-4-amine,CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,>,50000.0,nM,Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3ccccn3)n2)nc1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119087,CHEMBL405565,4-(methylsulfonylmethyl)-2-(pyridin-4-yl)-6-(pyrrolidin-1-yl)pyrimidine,CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,>,50000.0,nM,CS(=O)(=O)Cc1cc(N2CCCC2)nc(-c2ccncc2)n1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119088,CHEMBL271620,4-(methylsulfonylmethyl)-2-phenyl-6-(pyrrolidin-1-yl)pyrimidine,CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,>,50000.0,nM,CS(=O)(=O)Cc1cc(N2CCCC2)nc(-c2ccccc2)n1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2119089,CHEMBL271326,N-(4-ethoxyphenyl)-4-(1H-tetrazol-1-yl)benzamide,CHEMBL951255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Saccharomyces cerevisiae by fluorescence assay,IC50,>,30000.0,nM,CCOc1ccc(NC(=O)c2ccc(-n3cnnn3)cc2)cc1,CHEMBL1144029,Characterization of type II ligands in CYP2C9 and CYP3A4.,J. Med. Chem.,2008.0,51,6,1755,1763,10.1021/jm701121y,18311908.0,
2153928,CHEMBL410333,"(1'-benzyl-5-chloro-2,2',5'-trioxo-spiro[indole-3,3'-pyrrolidin]-1-yl)acetic acid",CHEMBL937317,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,10000.0,nM,O=C(O)CN1C(=O)C2(CC(=O)N(Cc3ccccc3)C2=O)c2cc(Cl)ccc21,CHEMBL1145542,"Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.",J. Med. Chem.,2008.0,51,7,2227,2243,10.1021/jm701383e,18318469.0,
2154807,CHEMBL195217,6-(3-Hydroxy-phenyl)-naphthalen-2-ol,CHEMBL930256,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,1050.0,nM,Oc1cccc(-c2ccc3cc(O)ccc3c2)c1,CHEMBL1142381,"Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.",J. Med. Chem.,2008.0,51,7,2158,2169,10.1021/jm701447v,18324762.0,
2154813,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL930256,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,250.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL1142381,"Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.",J. Med. Chem.,2008.0,51,7,2158,2169,10.1021/jm701447v,18324762.0,
2157703,CHEMBL263664,"4-(4-Chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-",CHEMBL932660,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,CHEMBL1144694,"Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration.",J. Med. Chem.,2008.0,51,7,2147,2157,10.1021/jm701437d,18345609.0,
2158709,CHEMBL259922,"N-(isoxazol-3-yl)-4-methyl-3-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)benzamide",CHEMBL922519,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,40000.0,nM,Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1,CHEMBL1144728,Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,8,2652,2657,10.1016/j.bmcl.2008.03.019,18359226.0,
2163332,CHEMBL409494,N-(2-aminophenyl)-4-(1-(3-(2-fluorophenylamino)-3-oxopropyl)piperidin-4-yl)benzamide,CHEMBL926901,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,Nc1ccccc1NC(=O)c1ccc(C2CCN(CCC(=O)Nc3ccccc3F)CC2)cc1,CHEMBL1144842,Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,8,2580,2584,10.1016/j.bmcl.2008.03.041,18378449.0,
2163336,CHEMBL260200,N-(2-aminophenyl)-4-(1-{[4-(dimethylcarbamoyl)phenyl]methyl}piperidin-4-yl)benzamide,CHEMBL926901,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,CN(C)C(=O)c1ccc(CN2CCC(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1,CHEMBL1144842,Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,8,2580,2584,10.1016/j.bmcl.2008.03.041,18378449.0,
2163344,CHEMBL264961,N-(2-aminophenyl)-4-(1-{[4-(methylcarbamoyl)phenyl]methyl}piperidin-4-yl)benzamide,CHEMBL926901,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,CNC(=O)c1ccc(CN2CCC(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1,CHEMBL1144842,Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,8,2580,2584,10.1016/j.bmcl.2008.03.041,18378449.0,
2163345,CHEMBL412083,N-(2-aminophenyl)-4-(1-{[4-(ethylcarbamoyl)phenyl]methyl}piperidin-4-yl)benzamide,CHEMBL926901,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,CCNC(=O)c1ccc(CN2CCC(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1,CHEMBL1144842,Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,8,2580,2584,10.1016/j.bmcl.2008.03.041,18378449.0,
2163346,CHEMBL409493,N-(2-aminophenyl)-4-(1-{[4-(cyclopropylcarbamoyl)phenyl]methyl}piperidin-4-yl)benzamide,CHEMBL926901,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,Nc1ccccc1NC(=O)c1ccc(C2CCN(Cc3ccc(C(=O)NC4CC4)cc3)CC2)cc1,CHEMBL1144842,Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,8,2580,2584,10.1016/j.bmcl.2008.03.041,18378449.0,
2164035,CHEMBL260259,(S)-2-((S)-(4-chloro-2-methoxyphenoxy)(phenyl)methyl)morpholine,CHEMBL932536,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,29000.0,nM,COc1cc(Cl)ccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1,CHEMBL1144811,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,2008.0,18,8,2562,2566,10.1016/j.bmcl.2008.03.050,18387300.0,
2170214,CHEMBL258199,tert-butyl 1-(2-(benzyloxy)-5-chlorobenzyl)-5-methyl-1H-pyrazol-3-ylcarbamate,CHEMBL937618,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,16000.0,nM,Cc1cc(NC(=O)OC(C)(C)C)nn1Cc1cc(Cl)ccc1OCc1ccccc1,CHEMBL1143088,Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy.,Bioorg. Med. Chem. Lett.,2008.0,18,11,3392,3399,10.1016/j.bmcl.2008.04.018,18462938.0,
2170244,CHEMBL256092,isopropyl 1-(2-(benzyloxy)-5-chlorobenzyl)-5-methyl-1H-pyrazol-3-ylcarbamate,CHEMBL937618,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,17000.0,nM,Cc1cc(NC(=O)OC(C)C)nn1Cc1cc(Cl)ccc1OCc1ccccc1,CHEMBL1143088,Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy.,Bioorg. Med. Chem. Lett.,2008.0,18,11,3392,3399,10.1016/j.bmcl.2008.04.018,18462938.0,
2224864,CHEMBL453169,3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine,CHEMBL1002235,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in insect microsomes,IC50,=,48970.0,nM,COc1ccc2cc(-c3cnccc3N)ccc2c1,CHEMBL1156596,Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.,J. Med. Chem.,2008.0,51,16,5064,5074,10.1021/jm800377h,18672861.0,
2224880,CHEMBL500394,4-(6-Methoxynaphthalen-2-yl)isoquinoline,CHEMBL1002235,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in insect microsomes,IC50,=,1270.0,nM,COc1ccc2cc(-c3cncc4ccccc34)ccc2c1,CHEMBL1156596,Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.,J. Med. Chem.,2008.0,51,16,5064,5074,10.1021/jm800377h,18672861.0,
2224881,CHEMBL502824,1-[5-(6-Methoxynaphthalen-2-yl)pyridin-3-yl]ethanone,CHEMBL1002235,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in insect microsomes,IC50,>,200000.0,nM,COc1ccc2cc(-c3cncc(C(C)=O)c3)ccc2c1,CHEMBL1156596,Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.,J. Med. Chem.,2008.0,51,16,5064,5074,10.1021/jm800377h,18672861.0,
2224882,CHEMBL447591,3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine,CHEMBL1002235,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in insect microsomes,IC50,=,1888.0,nM,COc1cncc(-c2ccc3cc(OC)ccc3c2)c1,CHEMBL1156596,Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.,J. Med. Chem.,2008.0,51,16,5064,5074,10.1021/jm800377h,18672861.0,
2224894,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL1002235,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in insect microsomes,IC50,=,318.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL1156596,Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.,J. Med. Chem.,2008.0,51,16,5064,5074,10.1021/jm800377h,18672861.0,
2229660,CHEMBL540359,N-{(3S)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-N-{[(4-{[(1-methylethyl)oxy]carbonyl}phenyl)amino]carbonyl}-L-tyrosinamide,CHEMBL996059,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CC(C)OC(=O)c1ccc(NC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H]2CCC[N+](C)(Cc3cccc(O)c3)C2)cc1.[I-],CHEMBL1156633,Discovery of novel and long acting muscarinic acetylcholine receptor antagonists.,J. Med. Chem.,2008.0,51,16,4866,4869,10.1021/jm800634k,18680280.0,
2234458,CHEMBL372575,"(E)-8-(3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-(4-(methylsulfonyl)phenyl)vinyl)phenyl)-6-(2-(methylsulfonyl)propan-2-yl)quinoline",CHEMBL1007305,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,200.0,nM,Cc1noc(/C(=C/c2cccc(-c3cc(C(C)(C)S(C)(=O)=O)cc4cccnc34)c2)c2ccc(S(C)(=O)=O)cc2)n1,CHEMBL1157355,Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.,J. Med. Chem.,2008.0,51,18,5471,5489,10.1021/jm800582j,18686943.0,
2240574,CHEMBL523411,"1-(3-(1-ethyl-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)phenyl)-3-(4-(trifluoromethyl)phenyl)urea",CHEMBL972687,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1258.93,nM,CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(C(F)(F)F)cc3)c2)n1,CHEMBL1156556,Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,16,4610,4614,10.1016/j.bmcl.2008.07.019,18662874.0,
2240591,CHEMBL456350,"1-(3-(1-ethyl-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)phenyl)-3-(3-methoxyphenyl)urea",CHEMBL972687,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,316.23,nM,CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3cccc(OC)c3)c2)n1,CHEMBL1156556,Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,16,4610,4614,10.1016/j.bmcl.2008.07.019,18662874.0,
2243203,CHEMBL450668,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(7-methyl-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",CHEMBL1000512,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in insect microsomes,IC50,>,40000.0,nM,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12,CHEMBL1156565,"Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.",J. Med. Chem.,2008.0,51,16,4858,4861,10.1021/jm800546t,18665579.0,
2251188,CHEMBL495727,1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]urea,CHEMBL1009890,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1,CHEMBL1139387,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",J. Med. Chem.,2009.0,52,2,379,388,10.1021/jm800984v,19143567.0,
2253462,CHEMBL482409,"2,6-bis(4-hydroxybenzylidene)cyclohexanone",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,1000.0,nM,O=C1/C(=C/c2ccc(O)cc2)CCC/C1=C\c1ccc(O)cc1,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253463,CHEMBL452101,"2,5-bis(4-hydroxybenzylidene)cyclopentanone",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,9900.0,nM,O=C1/C(=C/c2ccc(O)cc2)CC/C1=C\c1ccc(O)cc1,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253464,CHEMBL270361,"2,5-bis(4-hydroxy-3-methoxybenzylidene)cyclopentanone",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,2800.0,nM,COc1cc(/C=C2\CC/C(=C\c3ccc(O)c(OC)c3)C2=O)ccc1O,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253465,CHEMBL496935,"2,5-bis(4-hydroxy-3,5-dimethylbenzylidene)cyclopentanone",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,28300.0,nM,Cc1cc(/C=C2\CC/C(=C\c3cc(C)c(O)c(C)c3)C2=O)cc(C)c1O,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253466,CHEMBL497137,"2,5-bis(3,5-diethyl-4-hydroxybenzylidene)cyclopentanone",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,37700.0,nM,CCc1cc(/C=C2\CC/C(=C\c3cc(CC)c(O)c(CC)c3)C2=O)cc(CC)c1O,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253467,CHEMBL498372,"2,5-bis(3,5-di-tert-butyl-4-hydroxybenzylidene)cyclopentanone",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,55000.0,nM,CC(C)(C)c1cc(/C=C2\CC/C(=C\c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)C2=O)cc(C(C)(C)C)c1O,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253468,CHEMBL129134,"(1E,4E)-1,5-Bis-(4-hydroxy-phenyl)-penta-1,4-dien-3-one",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,1800.0,nM,O=C(/C=C/c1ccc(O)cc1)/C=C/c1ccc(O)cc1,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253469,CHEMBL17201,"(1E,4E)-1,5-Diphenyl-penta-1,4-dien-3-one",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,67300.0,nM,O=C(/C=C/c1ccccc1)/C=C/c1ccccc1,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253470,CHEMBL497783,"1,5-bis(3-chlorophenyl)penta-1,4-dien-3-one",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,21300.0,nM,O=C(/C=C/c1cccc(Cl)c1)/C=C/c1cccc(Cl)c1,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253471,CHEMBL407034,"1,5-bis(4-hydroxy-3,5-dimethylphenyl)penta-1,4-dien-3-one",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,62800.0,nM,Cc1cc(/C=C/C(=O)/C=C/c2cc(C)c(O)c(C)c2)cc(C)c1O,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253472,CHEMBL493001,"1,5-bis(4-hydroxy-3,5-dimethoxyphenyl)penta-1,4-dien-3-one",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,59000.0,nM,COc1cc(/C=C/C(=O)/C=C/c2cc(OC)c(O)c(OC)c2)cc(OC)c1O,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253473,CHEMBL482409,"2,6-bis(4-hydroxybenzylidene)cyclohexanone",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,1000000.0,nM,O=C1/C(=C/c2ccc(O)cc2)CCC/C1=C\c1ccc(O)cc1,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253474,CHEMBL452101,"2,5-bis(4-hydroxybenzylidene)cyclopentanone",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,45603691.6,nM,O=C1/C(=C/c2ccc(O)cc2)CC/C1=C\c1ccc(O)cc1,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253475,CHEMBL270361,"2,5-bis(4-hydroxy-3-methoxybenzylidene)cyclopentanone",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,2798981.32,nM,COc1cc(/C=C2\CC/C(=C\c3ccc(O)c(OC)c3)C2=O)ccc1O,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253476,CHEMBL496935,"2,5-bis(4-hydroxy-3,5-dimethylbenzylidene)cyclopentanone",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,28313919.96,nM,Cc1cc(/C=C2\CC/C(=C\c3cc(C)c(O)c(C)c3)C2=O)cc(C)c1O,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253477,CHEMBL497137,"2,5-bis(3,5-diethyl-4-hydroxybenzylidene)cyclopentanone",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,37670379.9,nM,CCc1cc(/C=C2\CC/C(=C\c3cc(CC)c(O)c(CC)c3)C2=O)cc(CC)c1O,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253478,CHEMBL498372,"2,5-bis(3,5-di-tert-butyl-4-hydroxybenzylidene)cyclopentanone",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,54954087.39,nM,CC(C)(C)c1cc(/C=C2\CC/C(=C\c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)C2=O)cc(C(C)(C)C)c1O,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253479,CHEMBL129134,"(1E,4E)-1,5-Bis-(4-hydroxy-phenyl)-penta-1,4-dien-3-one",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,1798870.92,nM,O=C(/C=C/c1ccc(O)cc1)/C=C/c1ccc(O)cc1,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253480,CHEMBL17201,"(1E,4E)-1,5-Diphenyl-penta-1,4-dien-3-one",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,67297665.63,nM,O=C(/C=C/c1ccccc1)/C=C/c1ccccc1,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253481,CHEMBL497783,"1,5-bis(3-chlorophenyl)penta-1,4-dien-3-one",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,21281390.46,nM,O=C(/C=C/c1cccc(Cl)c1)/C=C/c1cccc(Cl)c1,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253482,CHEMBL407034,"1,5-bis(4-hydroxy-3,5-dimethylphenyl)penta-1,4-dien-3-one",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,62805835.88,nM,Cc1cc(/C=C/C(=O)/C=C/c2cc(C)c(O)c(C)c2)cc(C)c1O,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253483,CHEMBL493001,"1,5-bis(4-hydroxy-3,5-dimethoxyphenyl)penta-1,4-dien-3-one",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,59020108.02,nM,COc1cc(/C=C/C(=O)/C=C/c2cc(OC)c(O)c(OC)c2)cc(OC)c1O,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2253496,CHEMBL116438,"1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione",CHEMBL999390,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,4300.0,nM,COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,CHEMBL1141678,Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.,Eur. J. Med. Chem.,2008.0,43,8,1621,1631,10.1016/j.ejmech.2007.10.034,18249473.0,
2258450,CHEMBL497999,4-(4-(2-(cyclopropylmethoxy)-5-(methylsulfonyl)benzoyl)piperazin-1-yl)-3-fluorobenzonitrile,CHEMBL1002898,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,29100.0,nM,CS(=O)(=O)c1ccc(OCC2CC2)c(C(=O)N2CCN(c3ccc(C#N)cc3F)CC2)c1,CHEMBL1141693,Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,18,5134,5139,10.1016/j.bmcl.2008.07.086,18752953.0,
2261008,CHEMBL486757,4-cyano-N-(5-((cyclohexyl(methyl)amino)methyl)-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)benzamide,CHEMBL1006249,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,14000.0,nM,COCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(CN(C)C3CCCCC3)ccc21,CHEMBL1152240,5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).,Bioorg. Med. Chem. Lett.,2008.0,18,20,5541,5544,10.1016/j.bmcl.2008.09.016,18823779.0,
2263558,CHEMBL464234,"(1S,2S,4R)-1-(((S)-4-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)-3-methylpiperazin-1-ylsulfonyl)methyl)-7,7-dimethylbicyclo[2.2.1]heptan-2-ol",CHEMBL1011726,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4000.0,nM,C[C@H]1CN(S(=O)(=O)C[C@]23CC[C@H](C[C@@H]2O)C3(C)C)CCN1c1ncc(C(F)(F)F)cc1F,CHEMBL1139268,"Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.",Bioorg. Med. Chem. Lett.,2009.0,19,1,114,118,10.1016/j.bmcl.2008.11.008,19014886.0,
2264915,CHEMBL517440,"5-amino-N-(2-((2-chloro-N-ethylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CHEMBL963888,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4000.0,nM,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1Cl,CHEMBL1139273,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,2009.0,19,1,158,162,10.1016/j.bmcl.2008.10.128,19019676.0,
2264916,CHEMBL517440,"5-amino-N-(2-((2-chloro-N-ethylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CHEMBL963888,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1Cl,CHEMBL1139273,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,2009.0,19,1,158,162,10.1016/j.bmcl.2008.10.128,19019676.0,
2264917,CHEMBL512127,"5-amino-N-(2-((N-ethyl-2-(methylsulfonyl)benzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CHEMBL963888,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,23000.0,nM,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1S(C)(=O)=O,CHEMBL1139273,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,2009.0,19,1,158,162,10.1016/j.bmcl.2008.10.128,19019676.0,
2264918,CHEMBL461012,"5-amino-N-(2-((2,6-dichloro-N-ethylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CHEMBL963888,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,800.0,nM,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(Cl)cccc1Cl,CHEMBL1139273,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,2009.0,19,1,158,162,10.1016/j.bmcl.2008.10.128,19019676.0,
2264919,CHEMBL467633,"5-amino-N-(2-((N-ethyl-2,6-difluorobenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CHEMBL963888,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8000.0,nM,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(F)cccc1F,CHEMBL1139273,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,2009.0,19,1,158,162,10.1016/j.bmcl.2008.10.128,19019676.0,
2264920,CHEMBL520276,"N-(2-((5-amino-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-3-chloro-N-ethylpicolinamide",CHEMBL963888,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,14000.0,nM,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ncccc1Cl,CHEMBL1139273,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,2009.0,19,1,158,162,10.1016/j.bmcl.2008.10.128,19019676.0,
2264921,CHEMBL464907,"(+/-)-5-amino-N-(2-((2,6-difluoro-N-methylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CHEMBL963888,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,CN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(F)cccc1F,CHEMBL1139273,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,2009.0,19,1,158,162,10.1016/j.bmcl.2008.10.128,19019676.0,
2264922,CHEMBL464245,"(+/-)-5-amino-N-(2-((2,6-difluoro-N-(2-fluoroethyl)benzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CHEMBL963888,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4000.0,nM,Nc1c(C(=O)NCC(O)(CN(CCF)C(=O)c2c(F)cccc2F)C(F)(F)F)cnn1-c1ccc(F)cc1,CHEMBL1139273,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,2009.0,19,1,158,162,10.1016/j.bmcl.2008.10.128,19019676.0,
2264923,CHEMBL517933,"5-amino-N-(2-((2,6-difluoro-N-(2-hydroxyethyl)benzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CHEMBL963888,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,13000.0,nM,Nc1c(C(=O)NCC(O)(CN(CCO)C(=O)c2c(F)cccc2F)C(F)(F)F)cnn1-c1ccc(F)cc1,CHEMBL1139273,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,2009.0,19,1,158,162,10.1016/j.bmcl.2008.10.128,19019676.0,
2264924,CHEMBL465451,"5-amino-N-(2-((2,6-dichloro-N-(2-hydroxyethyl)benzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CHEMBL963888,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3000.0,nM,Nc1c(C(=O)NCC(O)(CN(CCO)C(=O)c2c(Cl)cccc2Cl)C(F)(F)F)cnn1-c1ccc(F)cc1,CHEMBL1139273,Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,2009.0,19,1,158,162,10.1016/j.bmcl.2008.10.128,19019676.0,
2271293,CHEMBL443098,"3-(2-(2-methoxybenzyl)-1H-benzo[d]imidazol-6-yl)-1-((trans)-4-(4-(3-methoxypropyl)piperazin-1-yl)cyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",CHEMBL964888,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,COCCCN1CCN([C@H]2CC[C@H](n3nc(-c4ccc5nc(Cc6ccccc6OC)[nH]c5c4)c4c(N)ncnc43)CC2)CC1,CHEMBL1153290,Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases.,Bioorg. Med. Chem. Lett.,2009.0,19,6,1718,1721,10.1016/j.bmcl.2009.01.086,19217287.0,
2274318,CHEMBL453384,N-(3-((tert-butylamino)methyl)-4-fluorophenyl)-7-chloroquinolin-4-amine,CHEMBL1029111,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,52000.0,nM,CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1F,CHEMBL1153384,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",J. Med. Chem.,2009.0,52,7,1828,1844,10.1021/jm8012757,19284751.0,
2274335,CHEMBL147587,5-(7-Chloro-quinolin-4-ylamino)-2-diethylaminomethyl-phenol,CHEMBL1029111,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,75000.0,nM,CCN(CC)Cc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O,CHEMBL1153384,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",J. Med. Chem.,2009.0,52,7,1828,1844,10.1021/jm8012757,19284751.0,
2274347,CHEMBL1235,4-(7-Chloro-quinolin-4-ylamino)-2-ethylaminomethyl-phenol,CHEMBL1029111,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,58000.0,nM,CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,CHEMBL1153384,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",J. Med. Chem.,2009.0,52,7,1828,1844,10.1021/jm8012757,19284751.0,
2274413,CHEMBL1630,4-(7-Chloro-quinolin-4-ylamino)-2-diethylaminomethyl-phenol (Amodiaquin),CHEMBL1029111,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,62000.0,nM,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O.Cl,CHEMBL1153384,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",J. Med. Chem.,2009.0,52,7,1828,1844,10.1021/jm8012757,19284751.0,
2279695,CHEMBL493937,"(E)-3-{3-[6-(4-Methyl[1,4]diazepan-1-yl)pyrazin-2-yl]phenyl}acrylic acid",CHEMBL960103,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 after 45 mins,IC50,>,30000.0,nM,CN1CCCN(c2cncc(-c3cccc(/C=C/C(=O)O)c3)n2)CC1,CHEMBL1153342,Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.,J. Med. Chem.,2009.0,52,7,1814,1827,10.1021/jm801242y,19256503.0,
2297556,CHEMBL253641,"N-[(1S,2R)-1-benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-3-(1,1-dioxo-1lambda*6*-[1,2]thiazinan-2-yl)-5-ethylamino-2-fluoro-benzamide",CHEMBL1036825,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9000.0,nM,CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCCS2(=O)=O)c1,CHEMBL1137769,Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.,Bioorg. Med. Chem. Lett.,2009.0,19,13,3664,3668,10.1016/j.bmcl.2009.03.165,19428244.0,
2297583,CHEMBL445734,"5-(ethylamino)-2-fluoro-N-((2S,3R)-3-hydroxy-1-phenyl-4-(3-(trifluoromethyl)benzylamino)butan-2-yl)-3-(2-oxopyrrolidin-1-yl)benzamide",CHEMBL1036825,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,60000.0,nM,CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCC2=O)c1,CHEMBL1137769,Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.,Bioorg. Med. Chem. Lett.,2009.0,19,13,3664,3668,10.1016/j.bmcl.2009.03.165,19428244.0,
2297591,CHEMBL399656,"N-{(1S,2R)-1-benzyl-3-[(1-ethyl-1H-pyrazol-4-ylmethyl)-amino]-2-hydroxy-propyl}-3-(1,1-dioxo-1lambda*6*-[1,2]thiazinan-2-yl)-5-ethylamino-benzamide",CHEMBL1036825,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,89000.0,nM,CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cnn(CC)c2)cc(N2CCCCS2(=O)=O)c1,CHEMBL1137769,Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.,Bioorg. Med. Chem. Lett.,2009.0,19,13,3664,3668,10.1016/j.bmcl.2009.03.165,19428244.0,
2340910,CHEMBL236163,2-(3-(1-(4-hydroxyphenyl)-5-methyl-1H-pyrazol-4-yl)propanamido)benzoic acid,CHEMBL1001844,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,22000.0,nM,Cc1c(CCC(=O)Nc2ccccc2C(=O)O)cnn1-c1ccc(O)cc1,CHEMBL1150380,Tetrahydro anthranilic acid as a surrogate for anthranilic acid: application to the discovery of potent niacin receptor agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,11,3163,3167,10.1016/j.bmcl.2008.04.071,18477506.0,
2340911,CHEMBL482481,2-(3-(2-(2-chloro-4-hydroxyphenyl)thiazol-4-yl)butanamido)cyclohex-1-enecarboxylic acid,CHEMBL1001844,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5100.0,nM,CC(CC(=O)NC1=C(C(=O)O)CCCC1)c1csc(-c2ccc(O)cc2Cl)n1,CHEMBL1150380,Tetrahydro anthranilic acid as a surrogate for anthranilic acid: application to the discovery of potent niacin receptor agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,11,3163,3167,10.1016/j.bmcl.2008.04.071,18477506.0,
2340912,CHEMBL482480,2-(3-(2-(2-chloro-4-hydroxyphenyl)thiazol-4-yl)propanamido)benzoic acid,CHEMBL1001844,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1200.0,nM,O=C(CCc1csc(-c2ccc(O)cc2Cl)n1)Nc1ccccc1C(=O)O,CHEMBL1150380,Tetrahydro anthranilic acid as a surrogate for anthranilic acid: application to the discovery of potent niacin receptor agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,11,3163,3167,10.1016/j.bmcl.2008.04.071,18477506.0,
2340913,CHEMBL483934,(R)-2-(3-(1-(4-hydroxyphenyl)-5-methyl-1H-pyrazol-4-yl)-2-methylpropanamido)cyclohex-1-enecarboxylic acid,CHEMBL1001844,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,100000.0,nM,Cc1c(C[C@@H](C)C(=O)NC2=C(C(=O)O)CCCC2)cnn1-c1ccc(O)cc1,CHEMBL1150380,Tetrahydro anthranilic acid as a surrogate for anthranilic acid: application to the discovery of potent niacin receptor agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,11,3163,3167,10.1016/j.bmcl.2008.04.071,18477506.0,
2360927,CHEMBL254316,"N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(2-(2-methyl-1,3,4-oxadiazole-5-carboxamido)propan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide",CHEMBL968967,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,CHEMBL1140081,"Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.",J. Med. Chem.,2008.0,51,18,5843,5855,10.1021/jm800245z,18763751.0,
2360932,CHEMBL495331,"N-[1-(4-{[(4-Fluorobenzyl)amino]carbonyl}-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1-methylethyl]-N,N-dimethylethanediamide",CHEMBL968967,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CN(C)C(=O)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C,CHEMBL1140081,"Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.",J. Med. Chem.,2008.0,51,18,5843,5855,10.1021/jm800245z,18763751.0,
2361507,CHEMBL494713,3-[6-Methoxy-3-(4-methoxybenzyl)naphthalen-2-yl]pyridine,CHEMBL971595,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes,IC50,=,64.0,nM,COc1ccc(Cc2cc3cc(OC)ccc3cc2-c2cccnc2)cc1,CHEMBL1140083,Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.,J. Med. Chem.,2008.0,51,19,6138,6149,10.1021/jm800683c,18763754.0,
2361511,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL971595,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes,IC50,=,318.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL1140083,Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.,J. Med. Chem.,2008.0,51,19,6138,6149,10.1021/jm800683c,18763754.0,
2361613,CHEMBL459729,4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-bendo[d]imidazol-2-yl)pyridine-1-(1H)-one,CHEMBL980913,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 in human liver microsomes,IC50,>,40000.0,nM,Cc1cc(C2CCN(CCCF)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12,CHEMBL1140084,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,2008.0,51,19,5897,5900,10.1021/jm800832q,18763755.0,
2361620,CHEMBL401930,4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one,CHEMBL980913,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 in human liver microsomes,IC50,=,1200.0,nM,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,CHEMBL1140084,"Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.",J. Med. Chem.,2008.0,51,19,5897,5900,10.1021/jm800832q,18763755.0,
2365075,CHEMBL521523,N-[(6-fluoro-3'-{[(3S)-3-methyl-1-piperazinyl]methyl}-3-biphenylyl)methyl]-3-(4-piperidinylmethyl)benzamide,CHEMBL1035707,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,C[C@H]1CN(Cc2cccc(-c3cc(CNC(=O)c4cccc(CC5CCNCC5)c4)ccc3F)c2)CCN1,CHEMBL1140120,Discovery of biphenyl piperazines as novel and long acting muscarinic acetylcholine receptor antagonists.,J. Med. Chem.,2008.0,51,19,5915,5918,10.1021/jm800935u,18798607.0,
2376349,CHEMBL452051,(S)-2-(3-((3-(4-chlorobenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl)methyl)phenoxy)propanoic acid,CHEMBL979921,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5600.0,nM,Cc1c(C(=O)c2ccc(Cl)cc2)c2ccc(OC(F)(F)F)cc2n1Cc1cccc(O[C@@H](C)C(=O)O)c1,CHEMBL1139415,Highly functionalized 7-azaindoles as selective PPAR gamma modulators.,Bioorg. Med. Chem. Lett.,2008.0,18,17,4798,4801,10.1016/j.bmcl.2008.07.103,18701276.0,
2380843,CHEMBL487370,"2,2,2-trifluoro-1-(5-(4-(3-methoxyphenyl)piperazine-1-carbonyl)thiophen-2-yl)ethanone",CHEMBL948447,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,5000.0,nM,COc1cccc(N2CCN(C(=O)c3ccc(C(=O)C(F)(F)F)s3)CC2)c1,CHEMBL1152285,Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,23,6078,6082,10.1016/j.bmcl.2008.10.041,18952417.0,
2380884,CHEMBL487370,"2,2,2-trifluoro-1-(5-(4-(3-methoxyphenyl)piperazine-1-carbonyl)thiophen-2-yl)ethanone",CHEMBL948448,A,Hepatocyte,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatocytes,IC50,=,8000.0,nM,COc1cccc(N2CCN(C(=O)c3ccc(C(=O)C(F)(F)F)s3)CC2)c1,CHEMBL1152285,Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,23,6078,6082,10.1016/j.bmcl.2008.10.041,18952417.0,
2380885,CHEMBL487370,"2,2,2-trifluoro-1-(5-(4-(3-methoxyphenyl)piperazine-1-carbonyl)thiophen-2-yl)ethanone",CHEMBL948449,A,Hepatocyte,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatocytes in presence of 10% fetal bovine serum,IC50,=,8000.0,nM,COc1cccc(N2CCN(C(=O)c3ccc(C(=O)C(F)(F)F)s3)CC2)c1,CHEMBL1152285,Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,23,6078,6082,10.1016/j.bmcl.2008.10.041,18952417.0,
2380886,CHEMBL485771,"2,2,2-trifluoro-1-(5-(4-(5-phenyl-1,3,4-oxadiazol-2-yl)piperidine-1-carbonyl)thiophen-2-yl)ethanone",CHEMBL948447,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,5000.0,nM,O=C(c1ccc(C(=O)C(F)(F)F)s1)N1CCC(c2nnc(-c3ccccc3)o2)CC1,CHEMBL1152285,Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,23,6078,6082,10.1016/j.bmcl.2008.10.041,18952417.0,
2380887,CHEMBL485968,"N-(1-(pyridin-4-yl)ethyl)-5-(2,2,2-trifluoroacetyl)thiophene-2-carboxamide",CHEMBL948447,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,13000.0,nM,CC(NC(=O)c1ccc(C(=O)C(F)(F)F)s1)c1ccncc1,CHEMBL1152285,Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,23,6078,6082,10.1016/j.bmcl.2008.10.041,18952417.0,
2380888,CHEMBL485967,"N-(1-(naphthalen-1-yl)ethyl)-5-(2,2,2-trifluoroacetyl)thiophene-2-carboxamide",CHEMBL948447,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,1400.0,nM,CC(NC(=O)c1ccc(C(=O)C(F)(F)F)s1)c1cccc2ccccc12,CHEMBL1152285,Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,23,6078,6082,10.1016/j.bmcl.2008.10.041,18952417.0,
2380889,CHEMBL521355,"1-(5-(4-(5-chloro-2-methoxyphenyl)piperazine-1-carbonyl)thiophen-2-yl)-2,2,2-trifluoroethanone",CHEMBL948447,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,1800.0,nM,COc1ccc(Cl)cc1N1CCN(C(=O)c2ccc(C(=O)C(F)(F)F)s2)CC1,CHEMBL1152285,Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,23,6078,6082,10.1016/j.bmcl.2008.10.041,18952417.0,
2380890,CHEMBL485771,"2,2,2-trifluoro-1-(5-(4-(5-phenyl-1,3,4-oxadiazol-2-yl)piperidine-1-carbonyl)thiophen-2-yl)ethanone",CHEMBL948448,A,Hepatocyte,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatocytes,IC50,=,8000.0,nM,O=C(c1ccc(C(=O)C(F)(F)F)s1)N1CCC(c2nnc(-c3ccccc3)o2)CC1,CHEMBL1152285,Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,23,6078,6082,10.1016/j.bmcl.2008.10.041,18952417.0,
2380891,CHEMBL485968,"N-(1-(pyridin-4-yl)ethyl)-5-(2,2,2-trifluoroacetyl)thiophene-2-carboxamide",CHEMBL948448,A,Hepatocyte,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatocytes,IC50,=,10000.0,nM,CC(NC(=O)c1ccc(C(=O)C(F)(F)F)s1)c1ccncc1,CHEMBL1152285,Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,23,6078,6082,10.1016/j.bmcl.2008.10.041,18952417.0,
2380892,CHEMBL485967,"N-(1-(naphthalen-1-yl)ethyl)-5-(2,2,2-trifluoroacetyl)thiophene-2-carboxamide",CHEMBL948448,A,Hepatocyte,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatocytes,IC50,=,11000.0,nM,CC(NC(=O)c1ccc(C(=O)C(F)(F)F)s1)c1cccc2ccccc12,CHEMBL1152285,Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,23,6078,6082,10.1016/j.bmcl.2008.10.041,18952417.0,
2380893,CHEMBL521355,"1-(5-(4-(5-chloro-2-methoxyphenyl)piperazine-1-carbonyl)thiophen-2-yl)-2,2,2-trifluoroethanone",CHEMBL948448,A,Hepatocyte,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatocytes,IC50,=,1800.0,nM,COc1ccc(Cl)cc1N1CCN(C(=O)c2ccc(C(=O)C(F)(F)F)s2)CC1,CHEMBL1152285,Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,23,6078,6082,10.1016/j.bmcl.2008.10.041,18952417.0,
2380894,CHEMBL485771,"2,2,2-trifluoro-1-(5-(4-(5-phenyl-1,3,4-oxadiazol-2-yl)piperidine-1-carbonyl)thiophen-2-yl)ethanone",CHEMBL948449,A,Hepatocyte,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatocytes in presence of 10% fetal bovine serum,IC50,=,5000.0,nM,O=C(c1ccc(C(=O)C(F)(F)F)s1)N1CCC(c2nnc(-c3ccccc3)o2)CC1,CHEMBL1152285,Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,23,6078,6082,10.1016/j.bmcl.2008.10.041,18952417.0,
2380895,CHEMBL485968,"N-(1-(pyridin-4-yl)ethyl)-5-(2,2,2-trifluoroacetyl)thiophene-2-carboxamide",CHEMBL948449,A,Hepatocyte,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatocytes in presence of 10% fetal bovine serum,IC50,=,3000.0,nM,CC(NC(=O)c1ccc(C(=O)C(F)(F)F)s1)c1ccncc1,CHEMBL1152285,Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,23,6078,6082,10.1016/j.bmcl.2008.10.041,18952417.0,
2380896,CHEMBL485967,"N-(1-(naphthalen-1-yl)ethyl)-5-(2,2,2-trifluoroacetyl)thiophene-2-carboxamide",CHEMBL948449,A,Hepatocyte,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatocytes in presence of 10% fetal bovine serum,IC50,=,17000.0,nM,CC(NC(=O)c1ccc(C(=O)C(F)(F)F)s1)c1cccc2ccccc12,CHEMBL1152285,Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,23,6078,6082,10.1016/j.bmcl.2008.10.041,18952417.0,
2387361,CHEMBL473921,"(3-(4-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)pyridin-2-yl)(4-(4-fluorophenylamino)piperidin-1-yl)methanone",CHEMBL1008903,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,23000.0,nM,C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1,CHEMBL1140927,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,2009.0,52,4,1180,1189,10.1021/jm801332q,19191554.0,
2387362,CHEMBL489095,N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine,CHEMBL1008903,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1,CHEMBL1140927,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",J. Med. Chem.,2009.0,52,4,1180,1189,10.1021/jm801332q,19191554.0,
2393452,CHEMBL490672,"(R)-6-cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2Hpyran-2-one",CHEMBL973592,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CCc1cc(CC[C@]2(C3CCCC3)CC(O)=C(Cc3nc4nc(C)cc(C)n4n3)C(=O)O2)cc(CC)n1,CHEMBL1140946,"Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor.",J. Med. Chem.,2009.0,52,5,1255,1258,10.1021/jm8014537,19209845.0,
2393700,CHEMBL462624,"N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide",CHEMBL959568,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7000.0,nM,Nc1nccc(Oc2ccc(NC(=O)c3cccn(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,CHEMBL1140952,"Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.",J. Med. Chem.,2009.0,52,5,1251,1254,10.1021/jm801586s,19260711.0,
2395337,CHEMBL1630,4-(7-Chloro-quinolin-4-ylamino)-2-diethylaminomethyl-phenol (Amodiaquin),CHEMBL949432,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,62000.0,nM,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O.Cl,CHEMBL1140918,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,2009.0,52,5,1408,1415,10.1021/jm8012618,19222165.0,
2395338,CHEMBL147587,5-(7-Chloro-quinolin-4-ylamino)-2-diethylaminomethyl-phenol,CHEMBL949432,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,75000.0,nM,CCN(CC)Cc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O,CHEMBL1140918,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,2009.0,52,5,1408,1415,10.1021/jm8012618,19222165.0,
2395339,CHEMBL147806,2-(tert-Butylamino-methyl)-5-(7-chloro-quinolin-4-ylamino)-phenol,CHEMBL949432,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>=,90000.0,nM,CC(C)(C)NCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O,CHEMBL1140918,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,2009.0,52,5,1408,1415,10.1021/jm8012618,19222165.0,
2395340,CHEMBL146826,5-(7-Chloro-quinolin-4-ylamino)-2-ethylaminomethyl-phenol,CHEMBL949432,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,100000.0,nM,CCNCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O,CHEMBL1140918,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,2009.0,52,5,1408,1415,10.1021/jm8012618,19222165.0,
2395341,CHEMBL1235,4-(7-Chloro-quinolin-4-ylamino)-2-ethylaminomethyl-phenol,CHEMBL949432,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,58000.0,nM,CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,CHEMBL1140918,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",J. Med. Chem.,2009.0,52,5,1408,1415,10.1021/jm8012618,19222165.0,
2418327,CHEMBL529213,"(4-(3-(4H-1,2,4-triazol-3-yl)-5-(trifluoromethyl)phenylsulfonyl)piperazin-1-yl)((1R,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)methanone",CHEMBL1011898,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,6000.0,nM,O=C([C@@H]1C[C@H]1c1ccc(C(F)(F)F)cc1)N1CCN(S(=O)(=O)c2cc(-c3nnc[nH]3)cc(C(F)(F)F)c2)CC1,CHEMBL1153427,1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.,J. Med. Chem.,2009.0,52,8,2550,2558,10.1021/jm900063x,19320488.0,
2418426,CHEMBL528996,"2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(pyridin-2-ylmethyl)acetamide",CHEMBL1022364,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescent P450 inhibition assay,IC50,=,9100.0,nM,Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)NCc4ccccn4)c4ccccc43)c(Cl)c2)n1,CHEMBL1153428,"Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.",Bioorg. Med. Chem.,2009.0,17,8,3130,3141,10.1016/j.bmc.2009.03.001,19321349.0,
2418427,CHEMBL475684,"(Z)-2-{1-[2-Chloro-4-(3-methyl-1H-pyrazol-1-yl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(pyridazin-3-ylmethyl)acetamide",CHEMBL1022364,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescent P450 inhibition assay,IC50,=,13000.0,nM,Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)NCc4cccnn4)c4ccccc43)c(Cl)c2)n1,CHEMBL1153428,"Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.",Bioorg. Med. Chem.,2009.0,17,8,3130,3141,10.1016/j.bmc.2009.03.001,19321349.0,
2418428,CHEMBL478902,"(2Z)-{1-[2-chloro-4-(3-methyl-1H-pyrazol-1-yl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetic acid",CHEMBL1022364,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescent P450 inhibition assay,IC50,>,20000.0,nM,Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)O)c4ccccc43)c(Cl)c2)n1,CHEMBL1153428,"Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.",Bioorg. Med. Chem.,2009.0,17,8,3130,3141,10.1016/j.bmc.2009.03.001,19321349.0,
2418429,CHEMBL478283,"(Z)-2-{1-[2-Chloro-4-(3-methyl-1H-pyrazol-1-yl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(2-hydroxyethyl)acetamide",CHEMBL1022364,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 by fluorescent P450 inhibition assay,IC50,>,20000.0,nM,Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)NCCO)c4ccccc43)c(Cl)c2)n1,CHEMBL1153428,"Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.",Bioorg. Med. Chem.,2009.0,17,8,3130,3141,10.1016/j.bmc.2009.03.001,19321349.0,
2421012,CHEMBL507731,"Methyl (S)-1-((2S,4S,5S)-5-((S)-2-(3-Benzyl-2-oxoimidazolidin-1-yl)-3,3-dimethylbutanamido)-4-hydroxy-6-phenyl-1-(4-(pyridin-2-yl)phenyl)hexan-2-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate",CHEMBL981057,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 assessed as Tolbutamide hydroxylation,IC50,>,10000.0,nM,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(-c2ccccn2)cc1)C[C@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N1CCN(Cc2ccccc2)C1=O)C(C)(C)C)C(C)(C)C,CHEMBL1153436,2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.,J. Med. Chem.,2009.0,52,8,2571,2586,10.1021/jm900044w,19323562.0,
2421018,CHEMBL470508,"Methyl (S)-1-((2R,4S,5S)-4-Hydroxy-5-((S)-2-(3-((6-(2-hydroxypropan-2-yl)pyridin-2-yl)methyl)-2-oxoimidazolidin-1-yl)-3,3-dimethylbutanamido)-6-phenyl-1-(4-(pyridin-2-yl)phenyl)hexan-2-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate",CHEMBL981057,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 assessed as Tolbutamide hydroxylation,IC50,>,5000.0,nM,COC(=O)N[C@H](C(=O)N[C@H](Cc1ccc(-c2ccccn2)cc1)C[C@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N1CCN(Cc2cccc(C(C)(C)O)n2)C1=O)C(C)(C)C)C(C)(C)C,CHEMBL1153436,2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.,J. Med. Chem.,2009.0,52,8,2571,2586,10.1021/jm900044w,19323562.0,
2462836,CHEMBL480501,trans-4-(((4-tert-butylcyclohexyl)(1-methyl-5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)amino)methyl)-N-(1H-tetrazol-5-yl)benzamide,CHEMBL945224,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cn1c(N(Cc2ccc(C(=O)Nc3nnn[nH]3)cc2)[C@H]2CC[C@H](C(C)(C)C)CC2)nc2cc(C(F)(F)F)ccc21,CHEMBL1157483,"Discovery of potent, orally active benzimidazole glucagon receptor antagonists.",Bioorg. Med. Chem. Lett.,2008.0,18,13,3701,3705,10.1016/j.bmcl.2008.05.072,18539028.0,
2465493,CHEMBL481659,"(S)-2-(2-Bromo-3-oxo-spiro[3.5]non-1-en-1-ylamino)-3-[4-(2-pyridin-3-yl-imidazo[4,5-b]pyridin-3-yl)-phenyl]-propionic acid",CHEMBL951568,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,O=C(O)[C@H](Cc1ccc(-n2c(-c3cccnc3)nc3cccnc32)cc1)NC1=C(Br)C(=O)C12CCCCC2,CHEMBL1157490,Imidazopyridines as VLA-4 integrin antagonists.,Bioorg. Med. Chem. Lett.,2008.0,18,14,4146,4149,10.1016/j.bmcl.2008.05.075,18539454.0,
2465500,CHEMBL487438,"(S)-2-(2-Bromo-3-oxo-spiro[3.5]non-1-en-1-ylamino)-3-{4-[2-(1-trifluoromethyl-cyclopropyl)-imidazo[4,5-b]pyridin-3-yl]-phenyl}-propionic acid",CHEMBL951568,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8000.0,nM,O=C(O)[C@H](Cc1ccc(-n2c(C3(C(F)(F)F)CC3)nc3cccnc32)cc1)NC1=C(Br)C(=O)C12CCCCC2,CHEMBL1157490,Imidazopyridines as VLA-4 integrin antagonists.,Bioorg. Med. Chem. Lett.,2008.0,18,14,4146,4149,10.1016/j.bmcl.2008.05.075,18539454.0,
2465501,CHEMBL486444,"(S)-2-(2-Bromo-3-oxo-spiro[3.5]non-1-en-1-ylamino)-3-[4-(2-isopropyl-imidazo[4,5-b]pyridin-3-yl)-phenyl]-propionic acid",CHEMBL951568,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,18000.0,nM,CC(C)c1nc2cccnc2n1-c1ccc(C[C@H](NC2=C(Br)C(=O)C23CCCCC3)C(=O)O)cc1,CHEMBL1157490,Imidazopyridines as VLA-4 integrin antagonists.,Bioorg. Med. Chem. Lett.,2008.0,18,14,4146,4149,10.1016/j.bmcl.2008.05.075,18539454.0,
2471184,CHEMBL372575,"(E)-8-(3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-(4-(methylsulfonyl)phenyl)vinyl)phenyl)-6-(2-(methylsulfonyl)propan-2-yl)quinoline",CHEMBL984537,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<=,1000.0,nM,Cc1noc(/C(=C/c2cccc(-c3cc(C(C)(C)S(C)(=O)=O)cc4cccnc34)c2)c2ccc(S(C)(=O)=O)cc2)n1,CHEMBL1142499,"Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5554,5558,10.1016/j.bmcl.2008.09.009,18835163.0,
2471185,CHEMBL485620,"1-{3-[6-(1-Hydroxy-1-methyl-ethyl)-1-oxy-pyridin-3-yl]-phenyl}-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid cyclopropylamide",CHEMBL984537,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,59000.0,nM,CC(C)(O)c1ccc(-c2cccc(-n3cc(C(=O)NC4CC4)c(=O)c4cccnc43)c2)c[n+]1[O-],CHEMBL1142499,"Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5554,5558,10.1016/j.bmcl.2008.09.009,18835163.0,
2471186,CHEMBL485629,"4-Oxo-1-[3-(1-oxy-pyridin-3-ylethynyl)-phenyl]-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid cyclopropylamide",CHEMBL984537,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,41000.0,nM,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O,CHEMBL1142499,"Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5554,5558,10.1016/j.bmcl.2008.09.009,18835163.0,
2476060,CHEMBL521347,"4-(4-chloro-2-fluorophenyl)-2-(2-chloropyridin-4-yl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxamide",CHEMBL986248,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2500.0,nM,CC1=C(C(=O)Nc2cc3cn[nH]c3cc2F)C(c2ccc(Cl)cc2F)N=C(c2ccnc(Cl)c2)N1,CHEMBL1142520,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,2008.0,51,21,6631,6634,10.1021/jm8005096,18842034.0,
2476063,CHEMBL485612,"4-(4-chloro-2-fluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-2-(2-methoxypyridin-4-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxamide",CHEMBL986248,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8400.0,nM,COc1cc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3cc4cn[nH]c4cc3F)=C(C)N2)ccn1,CHEMBL1142520,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,2008.0,51,21,6631,6634,10.1021/jm8005096,18842034.0,
2476083,CHEMBL519680,"4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-phenyl-1,4-dihydropyrimidine-5-carboxamide",CHEMBL986248,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,640.0,nM,CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccccc2)N1,CHEMBL1142520,"Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.",J. Med. Chem.,2008.0,51,21,6631,6634,10.1021/jm8005096,18842034.0,
2479891,CHEMBL456379,"3,3-(1,3-Thiazole-2,5-diyl)diphenol",CHEMBL1032457,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9,IC50,=,2100.0,nM,Oc1cccc(-c2cnc(-c3cccc(O)c3)s2)c1,CHEMBL1142534,"Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).",J. Med. Chem.,2008.0,51,21,6725,6739,10.1021/jm8006917,18855374.0,
2479899,CHEMBL502908,"1,1':4',1''-terphenyl-3,3''-diol",CHEMBL1032457,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9,IC50,=,1900.0,nM,Oc1cccc(-c2ccc(-c3cccc(O)c3)cc2)c1,CHEMBL1142534,"Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).",J. Med. Chem.,2008.0,51,21,6725,6739,10.1021/jm8006917,18855374.0,
2479900,CHEMBL462513,3-[5-(4-Hydroxyphenyl)-3-thienyl]phenol,CHEMBL1032457,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9,IC50,=,800.0,nM,Oc1ccc(-c2cc(-c3cccc(O)c3)cs2)cc1,CHEMBL1142534,"Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).",J. Med. Chem.,2008.0,51,21,6725,6739,10.1021/jm8006917,18855374.0,
2481652,CHEMBL3084581,N-{(3-exo)-8-[(6-Fluoro-2-naphthyl)methyl]-8-azabicyclo[3.2.1]oct-3-yl}-3-(piperidin-1-ylcarbonyl)isonicotinamide 1-oxide,CHEMBL982617,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,40000.0,nM,O=C(N[C@H]1C[C@@H]2CC[C@H](C1)N2Cc1ccc2cc(F)ccc2c1)c1cc[n+]([O-])cc1C(=O)N1CCCCC1,CHEMBL1144174,Design and synthesis of 6-fluoro-2-naphthyl derivatives as novel CCR3 antagonists with reduced CYP2D6 inhibition.,Bioorg. Med. Chem.,2008.0,16,18,8607,8618,10.1016/j.bmc.2008.08.006,18752960.0,
2481682,CHEMBL522295,"Biphenyl-2-carboxylic acid [(1R,5R)-8-(6-fluoro-naphthalen-2-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-amide",CHEMBL982617,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=C(NC1CC2CCC(C1)N2Cc1ccc2cc(F)ccc2c1)c1ccccc1-c1ccccc1,CHEMBL1144174,Design and synthesis of 6-fluoro-2-naphthyl derivatives as novel CCR3 antagonists with reduced CYP2D6 inhibition.,Bioorg. Med. Chem.,2008.0,16,18,8607,8618,10.1016/j.bmc.2008.08.006,18752960.0,
2484201,CHEMBL514681,N-(2-((4-chlorophenyl)(phenyl)methylamino)-2-oxoethyl)-3-phenylpropanamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CCc1ccccc1)NCC(=O)NC(c1ccccc1)c1ccc(Cl)cc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484202,CHEMBL476762,N-({[(4-Chloro-phenyl)-phenyl-methyl]-carbamoyl}-methyl)-2-phenyl-acetamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(Cc1ccccc1)NCC(=O)NC(c1ccccc1)c1ccc(Cl)cc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484203,CHEMBL476763,N-(2-((4-chlorophenyl)(phenyl)methylamino)-2-oxoethyl)benzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccccc1)NC(c1ccccc1)c1ccc(Cl)cc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484204,CHEMBL475928,4-chloro-N-(2-((4-chlorophenyl)(phenyl)methylamino)-2-oxoethyl)benzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccc(Cl)cc1)NC(c1ccccc1)c1ccc(Cl)cc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484205,CHEMBL475926,N-(2-((4-chlorophenyl)(phenyl)methylamino)-2-oxoethyl)-4-fluorobenzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccc(Cl)cc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484206,CHEMBL475927,N-(2-((4-chlorophenyl)(phenyl)methylamino)-2-oxoethyl)-4-cyanobenzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,14700.0,nM,N#Cc1ccc(C(=O)NCC(=O)NC(c2ccccc2)c2ccc(Cl)cc2)cc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484207,CHEMBL452423,N-(2-((4-chlorophenyl)(phenyl)methylamino)-2-oxoethyl)isonicotinamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccncc1)NC(c1ccccc1)c1ccc(Cl)cc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484208,CHEMBL476360,N-(2-((4-chlorophenyl)(phenyl)methylamino)-2-oxoethyl)thiophene-3-carboxamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccsc1)NC(c1ccccc1)c1ccc(Cl)cc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484209,CHEMBL514209,N-(2-((4-chlorophenyl)(phenyl)methylamino)-2-oxoethyl)cyclopentanecarboxamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)C1CCCC1)NC(c1ccccc1)c1ccc(Cl)cc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484210,CHEMBL476567,N-({[(4-Chloro-phenyl)-phenyl-methyl]-carbamoyl}-methyl)-acetamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(=O)NCC(=O)NC(c1ccccc1)c1ccc(Cl)cc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484211,CHEMBL476568,N-(2-(benzhydrylamino)-2-oxoethyl)-4-fluorobenzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccccc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484212,CHEMBL476775,4-fluoro-N-(2-oxo-2-(phenyl(o-tolyl)methylamino)ethyl)benzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1ccccc1C(NC(=O)CNC(=O)c1ccc(F)cc1)c1ccccc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484213,CHEMBL479084,4-fluoro-N-(2-oxo-2-(phenyl(m-tolyl)methylamino)ethyl)benzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc2)c1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484214,CHEMBL479085,4-fluoro-N-(2-oxo-2-(phenyl(p-tolyl)methylamino)ethyl)benzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1ccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc2)cc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484215,CHEMBL518287,N-(2-((3-chlorophenyl)(phenyl)methylamino)-2-oxoethyl)-4-fluorobenzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1cccc(Cl)c1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484216,CHEMBL475926,N-(2-((4-chlorophenyl)(phenyl)methylamino)-2-oxoethyl)-4-fluorobenzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccc(Cl)cc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484217,CHEMBL476557,N-(2-(bis(3-fluorophenyl)methylamino)-2-oxoethyl)-4-fluorobenzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccc(F)cc1)NC(c1cccc(F)c1)c1cccc(F)c1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484218,CHEMBL479071,4-fluoro-N-(2-oxo-2-(phenyl(3-(trifluoromethyl)phenyl)methylamino)ethyl)benzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1cccc(C(F)(F)F)c1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484219,CHEMBL479072,4-fluoro-N-(2-((4-methoxyphenyl)(phenyl)methylamino)-2-oxoethyl)benzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1ccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc2)cc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484220,CHEMBL514198,N-(2-(bis(4-methoxyphenyl)methylamino)-2-oxoethyl)-4-fluorobenzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1ccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccc(OC)cc2)cc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484221,CHEMBL478229,4-fluoro-N-(2-oxo-2-(1-phenylpropylamino)ethyl)benzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CCC(NC(=O)CNC(=O)c1ccc(F)cc1)c1ccccc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484222,CHEMBL478230,4-fluoro-N-(2-oxo-2-(phenyl(pyridin-4-yl)methylamino)ethyl)benzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccncc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484223,CHEMBL516125,4-fluoro-N-(2-oxo-2-(phenyl(pyridazin-3-yl)methylamino)ethyl)benzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1cccnn1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484224,CHEMBL514241,4-fluoro-N-(2-oxo-2-(phenyl(pyrimidin-2-yl)methylamino)ethyl)benzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ncccn1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484225,CHEMBL478037,4-fluoro-N-(2-oxo-2-(phenyl(thiazol-2-yl)methylamino)ethyl)benzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1nccs1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484226,CHEMBL478035,N-(2-((2-chloro-9H-thioxanthen-9-yl)methylamino)-2-oxoethyl)-4-fluorobenzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccc(F)cc1)NCC1c2ccccc2Sc2ccc(Cl)cc21,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484227,CHEMBL478036,"N-{[(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylmethyl)-carbamoyl]-methyl}-4-fluoro-benzamide",CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccc(F)cc1)NCC1c2ccccc2CCc2ccccc21,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484228,CHEMBL515644,"4-Fluoro-N-{[(2-fluoro-6,11-dihydro-dibenzo[b,e]oxepin-11-ylmethyl)-carbamoyl]-methyl}-benzamide",CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccc(F)cc1)NCC1c2ccccc2COc2ccc(F)cc21,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484229,CHEMBL490609,"4-Fluoro-N-{[(5-methyl-6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-ylmethyl)-carbamoyl]-methyl}-benzamide",CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CN1C(=O)c2ccccc2C(CNC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc21,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484230,CHEMBL475928,4-chloro-N-(2-((4-chlorophenyl)(phenyl)methylamino)-2-oxoethyl)benzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccc(Cl)cc1)NC(c1ccccc1)c1ccc(Cl)cc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2484231,CHEMBL475928,4-chloro-N-(2-((4-chlorophenyl)(phenyl)methylamino)-2-oxoethyl)benzamide,CHEMBL995047,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(CNC(=O)c1ccc(Cl)cc1)NC(c1ccccc1)c1ccc(Cl)cc1,CHEMBL1144246,"Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.",Bioorg. Med. Chem. Lett.,2008.0,18,20,5533,5536,10.1016/j.bmcl.2008.09.005,18805008.0,
2491498,CHEMBL481745,(4-chlorophenyl)(2-((1-isopropylpiperidin-4-yl)methoxy)-3-methyl-3H-imidazol-4-yl)methanone,CHEMBL1036553,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CC(C)N1CCC(COc2ncc(C(=O)c3ccc(Cl)cc3)n2C)CC1,CHEMBL1143321,Novel imidazole-based histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,2009.0,19,3,903,907,10.1016/j.bmcl.2008.11.114,19119007.0,
2501687,CHEMBL458224,"N-[2-(3,5-Dimethylpyrazol-1-yl)-6-(2-(R)-methoxymethylpyrrolidin-1-yl)pyrimidin-4-yl]acetamide",CHEMBL987758,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COC[C@H]1CCCN1c1cc(NC(C)=O)nc(-n2nc(C)cc2C)n1,CHEMBL1143380,N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacy.,J. Med. Chem.,2009.0,52,3,709,717,10.1021/jm800908d,19140664.0,
2507051,CHEMBL475794,N-(5-chloropyridin-3-yl)-5-(3-(2-cyanopropan-2-yl)benzamido)-2-methylbenzamide,CHEMBL947766,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,400.0,nM,Cc1ccc(NC(=O)c2cccc(C(C)(C)C#N)c2)cc1C(=O)Nc1cncc(Cl)c1,CHEMBL1143270,Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.,Bioorg. Med. Chem. Lett.,2009.0,19,3,1026,1029,10.1016/j.bmcl.2008.10.053,19097792.0,
2507062,CHEMBL475817,N-(6-amino-5-chloropyridin-3-yl)-2-chloro-5-(3-(trifluoromethyl)benzamido)benzamide,CHEMBL947766,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,700.0,nM,Nc1ncc(NC(=O)c2cc(NC(=O)c3cccc(C(F)(F)F)c3)ccc2Cl)cc1Cl,CHEMBL1143270,Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.,Bioorg. Med. Chem. Lett.,2009.0,19,3,1026,1029,10.1016/j.bmcl.2008.10.053,19097792.0,
2507088,CHEMBL519143,5-(3-(2-cyanopropan-2-yl)benzamido)-2-methyl-N-(5-methylpyridin-3-yl)benzamide,CHEMBL947766,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1800.0,nM,Cc1cncc(NC(=O)c2cc(NC(=O)c3cccc(C(C)(C)C#N)c3)ccc2C)c1,CHEMBL1143270,Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.,Bioorg. Med. Chem. Lett.,2009.0,19,3,1026,1029,10.1016/j.bmcl.2008.10.053,19097792.0,
2507089,CHEMBL514670,N-(6-amino-5-chloropyridin-3-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide,CHEMBL947766,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1800.0,nM,Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cnc(N)c(Cl)c1,CHEMBL1143270,Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.,Bioorg. Med. Chem. Lett.,2009.0,19,3,1026,1029,10.1016/j.bmcl.2008.10.053,19097792.0,
2507099,CHEMBL475799,N-(6-amino-5-chloropyridin-3-yl)-5-(3-(2-cyanopropan-2-yl)benzamido)-2-methylbenzamide,CHEMBL947766,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4000.0,nM,Cc1ccc(NC(=O)c2cccc(C(C)(C)C#N)c2)cc1C(=O)Nc1cnc(N)c(Cl)c1,CHEMBL1143270,Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.,Bioorg. Med. Chem. Lett.,2009.0,19,3,1026,1029,10.1016/j.bmcl.2008.10.053,19097792.0,
2507101,CHEMBL475045,5-(3-(2-cyanopropan-2-yl)benzamido)-2-methyl-N-(6-(methylamino)pyridin-3-yl)benzamide,CHEMBL947766,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4900.0,nM,CNc1ccc(NC(=O)c2cc(NC(=O)c3cccc(C(C)(C)C#N)c3)ccc2C)cn1,CHEMBL1143270,Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.,Bioorg. Med. Chem. Lett.,2009.0,19,3,1026,1029,10.1016/j.bmcl.2008.10.053,19097792.0,
2507107,CHEMBL503699,5-(3-(2-cyanopropan-2-yl)benzamido)-2-methyl-N-(6-methylpyridin-3-yl)benzamide,CHEMBL947766,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9800.0,nM,Cc1ccc(NC(=O)c2cc(NC(=O)c3cccc(C(C)(C)C#N)c3)ccc2C)cn1,CHEMBL1143270,Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.,Bioorg. Med. Chem. Lett.,2009.0,19,3,1026,1029,10.1016/j.bmcl.2008.10.053,19097792.0,
2508100,CHEMBL472140,(S)-2-cyclohexyl-2-(3-(3-mesitylureido)-2-naphthamido)acetic acid,CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,610.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@H](C(=O)O)C2CCCCC2)c(C)c1,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508101,CHEMBL513400,(S)-2-cyclopentyl-2-(3-(3-mesitylureido)-2-naphthamido)acetic acid,CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1200.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@H](C(=O)O)C2CCCC2)c(C)c1,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508102,CHEMBL519796,"2-(4,4-difluorocyclohexyl)-2-(3-(3-mesitylureido)-2-naphthamido)acetic acid",CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,650.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)NC(C(=O)O)C2CCC(F)(F)CC2)c(C)c1,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508103,CHEMBL480732,"(S)-2-((1r,4S)-4-methylcyclohexyl)-2-(3-(3-(2,4,6-trichlorophenyl)ureido)-2-naphthamido)acetic acid",CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,180.0,nM,C[C@H]1CC[C@H]([C@H](NC(=O)c2cc3ccccc3cc2NC(=O)Nc2c(Cl)cc(Cl)cc2Cl)C(=O)O)CC1,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508104,CHEMBL480733,"(S)-2-((1s,4R)-4-tert-butylcyclohexyl)-2-(3-(3-(2,4,6-trichlorophenyl)ureido)-2-naphthamido)acetic acid",CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,210.0,nM,CC(C)(C)[C@H]1CC[C@@H]([C@H](NC(=O)c2cc3ccccc3cc2NC(=O)Nc2c(Cl)cc(Cl)cc2Cl)C(=O)O)CC1,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508105,CHEMBL480764,2-(3-(3-mesitylureido)-2-naphthamido)-2-(tetrahydro-2H-pyran-4-yl)acetic acid,CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2400.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)NC(C(=O)O)C2CCOCC2)c(C)c1,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508106,CHEMBL473421,2-(3-(3-mesitylureido)-2-naphthamido)-2-(4-oxocyclohexyl)acetic acid,CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9400.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)NC(C(=O)O)C2CCC(=O)CC2)c(C)c1,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508109,CHEMBL475449,"2-(3-(3-mesitylureido)-2-naphthamido)-2-(1,4-dioxaspiro[4.5]decan-8-yl)acetic acid",CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,6700.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)NC(C(=O)O)C2CCC3(CC2)OCCO3)c(C)c1,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508110,CHEMBL482146,(S)-2-cyclohexyl-2-(3-(3-mesitylureido)-2-naphthamido)propanoic acid,CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9200.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@](C)(C(=O)O)C2CCCCC2)c(C)c1,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508111,CHEMBL472319,2-(3-(3-mesitylureido)-2-naphthamido)-2-propylpentanoic acid,CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,33000.0,nM,CCCC(CCC)(NC(=O)c1cc2ccccc2cc1NC(=O)Nc1c(C)cc(C)cc1C)C(=O)O,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508112,CHEMBL480367,1-(3-(3-mesitylureido)-2-naphthamido)cyclopropanecarboxylic acid,CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,33000.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)NC2(C(=O)O)CC2)c(C)c1,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508113,CHEMBL480368,1-(3-(3-mesitylureido)-2-naphthamido)cyclopentanecarboxylic acid,CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,33000.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)NC2(C(=O)O)CCCC2)c(C)c1,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508114,CHEMBL481507,1-(3-(3-mesitylureido)-2-naphthamido)cyclohexanecarboxylic acid,CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,33000.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)NC2(C(=O)O)CCCCC2)c(C)c1,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508115,CHEMBL481363,1-(3-(3-mesitylureido)-2-naphthamido)cycloheptanecarboxylic acid,CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4100.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)NC2(C(=O)O)CCCCCC2)c(C)c1,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508116,CHEMBL481534,1-(3-(3-mesitylureido)-2-naphthamido)cyclooctanecarboxylic acid,CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,33000.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)NC2(C(=O)O)CCCCCCC2)c(C)c1,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508120,CHEMBL481887,"2-(3-(3-mesitylureido)-2-naphthamido)-2,3-dihydro-1H-indene-2-carboxylic acid",CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4877.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)NC2(C(=O)O)Cc3ccccc3C2)c(C)c1,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508138,CHEMBL453311,(S)-2-(2-(3-(2-chloro-6-methylphenyl)ureido)-2-naphthamido)-2-cyclohexylacetic acid,CHEMBL1034795,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1000.0,nM,Cc1cccc(Cl)c1NC(=O)Nc1cc2ccccc2cc1C(=O)N[C@H](C(=O)O)C1CCCCC1,CHEMBL1141020,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.,Bioorg. Med. Chem. Lett.,2009.0,19,3,976,980,10.1016/j.bmcl.2008.11.085,19095442.0,
2508187,CHEMBL444032,"(2S,3R)-3-(benzyloxy)-2-(3-(3-mesitylureido)-2-naphthamido)-5-methylhexanoic acid",CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,50.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@H](C(=O)O)[C@@H](CC(C)C)OCc2ccccc2)c(C)c1,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508189,CHEMBL475639,"(S)-2-(3-(3-mesitylureido)-2-naphthamido)-5,5-dimethylhexanoic acid",CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,450.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@@H](CCC(C)(C)C)C(=O)O)c(C)c1,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508190,CHEMBL475378,"(2S,3R)-3-(benzyloxy)-2-(3-(3-mesitylureido)-2-naphthamido)pentanoic acid",CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,680.0,nM,CC[C@@H](OCc1ccccc1)[C@H](NC(=O)c1cc2ccccc2cc1NC(=O)Nc1c(C)cc(C)cc1C)C(=O)O,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508191,CHEMBL516081,(S)-2-(3-(3-mesitylureido)-2-naphthamido)-5-methylhexanoic acid,CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,740.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@@H](CCC(C)C)C(=O)O)c(C)c1,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508192,CHEMBL475217,"(2S,3R)-3-(benzyloxy)-2-(3-(3-mesitylureido)-2-naphthamido)butanoic acid",CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1900.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@H](C(=O)O)[C@@H](C)OCc2ccccc2)c(C)c1,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508193,CHEMBL475766,"(2S,3S)-2-(3-(3-mesitylureido)-2-naphthamido)-3-methylpentanoic acid",CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1940.0,nM,CC[C@H](C)[C@H](NC(=O)c1cc2ccccc2cc1NC(=O)Nc1c(C)cc(C)cc1C)C(=O)O,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508194,CHEMBL473852,"(2S,3R)-3-cyclobutoxy-2-(3-(3-mesitylureido)-2-naphthamido)butanoic acid",CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2100.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@H](C(=O)O)[C@@H](C)OC2CCC2)c(C)c1,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508195,CHEMBL475764,"(S)-2-(3-(3-mesitylureido)-2-naphthamido)-3,3-dimethylbutanoic acid",CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2300.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@H](C(=O)O)C(C)(C)C)c(C)c1,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508196,CHEMBL475834,(S)-3-butoxy-2-(3-(3-mesitylureido)-2-naphthamido)propanoic acid,CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2800.0,nM,CCCCOC[C@H](NC(=O)c1cc2ccccc2cc1NC(=O)Nc1c(C)cc(C)cc1C)C(=O)O,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508197,CHEMBL482147,(S)-2-(3-(3-mesitylureido)-2-naphthamido)hexanoic acid,CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3000.0,nM,CCCC[C@H](NC(=O)c1cc2ccccc2cc1NC(=O)Nc1c(C)cc(C)cc1C)C(=O)O,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508198,CHEMBL475807,(S)-3-ethoxy-2-(3-(3-mesitylureido)-2-naphthamido)propanoic acid,CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3300.0,nM,CCOC[C@H](NC(=O)c1cc2ccccc2cc1NC(=O)Nc1c(C)cc(C)cc1C)C(=O)O,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508199,CHEMBL475833,(S)-2-(3-(3-mesitylureido)-2-naphthamido)-3-(neopentyloxy)propanoic acid,CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4700.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@@H](COCC(C)(C)C)C(=O)O)c(C)c1,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508200,CHEMBL475822,(S)-3-tert-butoxy-2-(3-(3-mesitylureido)-2-naphthamido)propanoic acid,CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,6000.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@@H](COC(C)(C)C)C(=O)O)c(C)c1,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508201,CHEMBL473643,(S)-3-isopropoxy-2-(3-(3-mesitylureido)-2-naphthamido)propanoic acid,CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,6920.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@@H](COC(C)C)C(=O)O)c(C)c1,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508202,CHEMBL474193,"(2S,3R)-2-(3-(3-mesitylureido)-2-naphthamido)-3-(1-methylcyclopentyloxy)butanoic acid",CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7230.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@H](C(=O)O)[C@@H](C)OC2(C)CCCC2)c(C)c1,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508203,CHEMBL475765,(S)-2-(3-(3-mesitylureido)-2-naphthamido)pentanoic acid,CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8400.0,nM,CCC[C@H](NC(=O)c1cc2ccccc2cc1NC(=O)Nc1c(C)cc(C)cc1C)C(=O)O,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508204,CHEMBL473851,"(2S,3R)-3-tert-butoxy-2-(3-(3-mesitylureido)-2-naphthamido)butanoic acid",CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@H](C(=O)O)[C@@H](C)OC(C)(C)C)c(C)c1,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508205,CHEMBL480765,(S)-2-(3-(3-mesitylureido)-2-naphthamido)-3-methylbutanoic acid,CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,12000.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@H](C(=O)O)C(C)C)c(C)c1,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508206,CHEMBL473850,"(2S,3R)-3-isopropoxy-2-(3-(3-mesitylureido)-2-naphthamido)butanoic acid",CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,14000.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@H](C(=O)O)[C@@H](C)OC(C)C)c(C)c1,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2508207,CHEMBL473828,"(2S,3R)-2-(3-(3-mesitylureido)-2-naphthamido)-3-methoxybutanoic acid",CHEMBL1034809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,32000.0,nM,CO[C@H](C)[C@H](NC(=O)c1cc2ccccc2cc1NC(=O)Nc1c(C)cc(C)cc1C)C(=O)O,CHEMBL1141021,Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.,Bioorg. Med. Chem. Lett.,2009.0,19,3,981,985,10.1016/j.bmcl.2008.11.084,19095443.0,
2513182,CHEMBL490153,4-(5-(4-Chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)-benzenesulfonamide,CHEMBL967816,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CCC(=O)c1cc(-c2ccc(Cl)cc2)n(-c2ccc(S(N)(=O)=O)cc2)c1C,CHEMBL1138521,Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor.,J. Med. Chem.,2009.0,52,10,3377,3384,10.1021/jm9003818,19419141.0,
2514643,CHEMBL450061,5-amino-4-(isobutylamino)-6-morpholinopyrimidine-2-carbonitrile,CHEMBL1021999,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CC(C)CNc1nc(C#N)nc(N2CCOCC2)c1N,CHEMBL1138582,5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,6,1658,1661,10.1016/j.bmcl.2009.01.110,19231183.0,
2514644,CHEMBL471757,5-amino-4-morpholino-6-(neopentylamino)pyrimidine-2-carbonitrile,CHEMBL1021999,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CC(C)(C)CNc1nc(C#N)nc(N2CCOCC2)c1N,CHEMBL1138582,5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,6,1658,1661,10.1016/j.bmcl.2009.01.110,19231183.0,
2514645,CHEMBL474484,5-amino-4-(isobutylamino)-6-(piperazin-1-yl)pyrimidine-2-carbonitrile,CHEMBL1021999,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CC(C)CNc1nc(C#N)nc(N2CCNCC2)c1N,CHEMBL1138582,5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,6,1658,1661,10.1016/j.bmcl.2009.01.110,19231183.0,
2515561,CHEMBL515387,"cis-(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone",CHEMBL1025429,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1,CHEMBL1138584,"(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.",Bioorg. Med. Chem. Lett.,2009.0,19,7,1991,1995,10.1016/j.bmcl.2009.02.041,19275964.0,
2519789,CHEMBL512414,8-(bis(2-chlorophenyl)methyl)-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide,CHEMBL966889,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 co-incubated with substrate,IC50,=,8000.0,nM,NC(=O)C1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl,CHEMBL1138606,The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety.,Bioorg. Med. Chem. Lett.,2009.0,19,9,2519,2523,10.1016/j.bmcl.2009.03.031,19339177.0,
2519790,CHEMBL512414,8-(bis(2-chlorophenyl)methyl)-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide,CHEMBL966909,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 pre-incubated before addition of substrate,IC50,=,19000.0,nM,NC(=O)C1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl,CHEMBL1138606,The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety.,Bioorg. Med. Chem. Lett.,2009.0,19,9,2519,2523,10.1016/j.bmcl.2009.03.031,19339177.0,
2522936,CHEMBL467114,sodium 6-(5-chloro-2-(4-chloro-2-fluorobenzyloxy)benzyl)picolinate,CHEMBL969592,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,8000.0,nM,O=C([O-])c1cccc(Cc2cc(Cl)ccc2OCc2ccc(Cl)cc2F)n1.[Na+],CHEMBL1138602,Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.,Bioorg. Med. Chem. Lett.,2009.0,19,9,2599,2603,10.1016/j.bmcl.2009.02.112,19332369.0,
2522946,CHEMBL467720,"sodium 6-(5-chloro-2-(2,4-dichlorobenzyloxy)benzyl)picolinate",CHEMBL969592,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,4800.0,nM,O=C([O-])c1cccc(Cc2cc(Cl)ccc2OCc2ccc(Cl)cc2Cl)n1.[Na+],CHEMBL1138602,Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.,Bioorg. Med. Chem. Lett.,2009.0,19,9,2599,2603,10.1016/j.bmcl.2009.02.112,19332369.0,
2522947,CHEMBL513491,sodium 6-(5-chloro-2-(2-chloro-4-fluorobenzyloxy)benzyl)picolinate,CHEMBL969592,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,15000.0,nM,O=C([O-])c1cccc(Cc2cc(Cl)ccc2OCc2ccc(F)cc2Cl)n1.[Na+],CHEMBL1138602,Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.,Bioorg. Med. Chem. Lett.,2009.0,19,9,2599,2603,10.1016/j.bmcl.2009.02.112,19332369.0,
2525048,CHEMBL520136,"2-(3-(7-hydroxy-4,5-dihydro-2H-benzo[g]indazol-3-yl)propanamido)benzoic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,26000.0,nM,O=C(CCc1[nH]nc2c1CCc1cc(O)ccc1-2)Nc1ccccc1C(=O)O,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525049,CHEMBL483160,"2-(3-(7-hydroxy-1-methyl-4,5-dihydro-1H-benzo[g]indazol-3-yl)propanamido)benzoic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,17000.0,nM,Cn1nc(CCC(=O)Nc2ccccc2C(=O)O)c2c1-c1ccc(O)cc1CC2,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525050,CHEMBL483352,2-(3-(7-hydroxy-2H-benzo[g]indazol-3-yl)propanamido)benzoic acid,CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,9200.0,nM,O=C(CCc1[nH]nc2c1ccc1cc(O)ccc12)Nc1ccccc1C(=O)O,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525051,CHEMBL483353,"2-(3-(7-hydroxy-4,5-dihydronaphtho[2,1-d]isoxazol-3-yl)propanamido)benzoic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,2200.0,nM,O=C(CCc1noc2c1CCc1cc(O)ccc1-2)Nc1ccccc1C(=O)O,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525052,CHEMBL520299,"2-(3-(7-hydroxynaphtho[2,1-d]isoxazol-3-yl)propanamido)benzoic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,990.0,nM,O=C(CCc1noc2c1ccc1cc(O)ccc12)Nc1ccccc1C(=O)O,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525053,CHEMBL482768,"2-(3-(7-hydroxy-4,5-dihydropyrazolo[1,5-a]quinolin-3-yl)propanamido)benzoic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,18000.0,nM,O=C(CCc1cnn2c1CCc1cc(O)ccc1-2)Nc1ccccc1C(=O)O,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525054,CHEMBL521326,"2-(3-(7-hydroxy-[1,2,3]triazolo[1,5-a]quinolin-3-yl)propanamido)benzoic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,1500.0,nM,O=C(CCc1nnn2c1ccc1cc(O)ccc12)Nc1ccccc1C(=O)O,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525055,CHEMBL520620,"2-(3-Benzo[d]imidazo[2,1-b]thiazol-2-yl-propionylamino)-benzoic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,4400.0,nM,O=C(CCc1cn2c(n1)sc1ccccc12)Nc1ccccc1C(=O)O,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525056,CHEMBL482980,"2-(3-(6-hydroxy-4H-indeno[2,1-d]isoxazol-3-yl)propanamido)benzoic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,8500.0,nM,O=C(CCc1noc2c1Cc1cc(O)ccc1-2)Nc1ccccc1C(=O)O,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525057,CHEMBL485184,"2-(3-(8-hydroxy-5-methyl-6-oxo-5,6-dihydrophenanthridin-3-yl)propanamido)benzoic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,4700.0,nM,Cn1c(=O)c2cc(O)ccc2c2ccc(CCC(=O)Nc3ccccc3C(=O)O)cc21,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525058,CHEMBL485185,2-(3-(3H-benzo[e]indazol-7-yl)propanamido)benzoic acid,CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,<,140.0,nM,O=C(CCc1ccc2c(ccc3[nH]ncc32)c1)Nc1ccccc1C(=O)O,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525059,CHEMBL485196,"2-(3-(7-hydroxy-4,5-dihydronaphtho[2,1-d]isoxazol-3-yl)propanamido)cyclohex-1-enecarboxylic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,11000.0,nM,O=C(CCc1noc2c1CCc1cc(O)ccc1-2)NC1=C(C(=O)O)CCCC1,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525060,CHEMBL483139,"2-(3-(7-hydroxynaphtho[2,1-d]isoxazol-3-yl)propanamido)cyclohex-1-enecarboxylic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,12000.0,nM,O=C(CCc1noc2c1ccc1cc(O)ccc12)NC1=C(C(=O)O)CCCC1,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525061,CHEMBL483140,"2-(3-(6-fluoro-7-hydroxynaphtho[2,1-d]isoxazol-3-yl)propanamido)cyclohex-1-enecarboxylic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,2000.0,nM,O=C(CCc1noc2c1ccc1c(F)c(O)ccc12)NC1=C(C(=O)O)CCCC1,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525062,CHEMBL483336,"2-(3-(6-chloro-7-hydroxynaphtho[2,1-d]isoxazol-3-yl)propanamido)cyclohex-1-enecarboxylic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,1500.0,nM,O=C(CCc1noc2c1ccc1c(Cl)c(O)ccc12)NC1=C(C(=O)O)CCCC1,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525063,CHEMBL483337,"2-(3-(7-hydroxypyrazolo[1,5-a]quinolin-3-yl)propanamido)cyclohex-1-enecarboxylic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,19000.0,nM,O=C(CCc1cnn2c1ccc1cc(O)ccc12)NC1=C(C(=O)O)CCCC1,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525064,CHEMBL520513,"2-[3-(7-Hydroxy-benzo[d]imidazo[2,1-b]thiazol-2-yl)-propionylamino]-cyclohex-1-enecarboxylic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,12000.0,nM,O=C(CCc1cn2c(n1)sc1cc(O)ccc12)NC1=C(C(=O)O)CCCC1,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525065,CHEMBL485326,"2-(3-(7-hydroxy-4,5-dihydronaphtho[2,1-d]isoxazol-3-yl)propanamido)cyclopent-1-enecarboxylic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,47000.0,nM,O=C(CCc1noc2c1CCc1cc(O)ccc1-2)NC1=C(C(=O)O)CCC1,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2525066,CHEMBL485327,"2-[3-(7-Hydroxy-benzo[d]imidazo[2,1-b]thiazol-2-yl)-propionylamino]-cyclopent-1-enecarboxylic acid",CHEMBL1009689,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate,IC50,=,12000.0,nM,O=C(CCc1cn2c(n1)sc1cc(O)ccc12)NC1=C(C(=O)O)CCC1,CHEMBL1154005,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,J. Med. Chem.,2009.0,52,8,2587,2602,10.1021/jm900151e,19309152.0,
2526873,CHEMBL484345,3-amino-N-(1-(naphthalen-1-ylsulfonyl)-1H-indazol-4-yl)propanamide,CHEMBL994676,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7.0,min,NCCC(=O)Nc1cccc2c1cnn2S(=O)(=O)c1cccc2ccccc12,CHEMBL1138452,1-Sulfonylindazoles as potent and selective 5-HT6 ligands.,Bioorg. Med. Chem. Lett.,2009.0,19,9,2413,2415,10.1016/j.bmcl.2009.03.071,19345582.0,
2526874,CHEMBL482562,N-(1-(naphthalen-1-ylsulfonyl)-1H-indazol-6-yl)piperidine-4-carboxamide,CHEMBL994676,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,370.0,min,O=C(Nc1ccc2cnn(S(=O)(=O)c3cccc4ccccc34)c2c1)C1CCNCC1,CHEMBL1138452,1-Sulfonylindazoles as potent and selective 5-HT6 ligands.,Bioorg. Med. Chem. Lett.,2009.0,19,9,2413,2415,10.1016/j.bmcl.2009.03.071,19345582.0,
2526875,CHEMBL520129,rac-N-(1-(naphthalen-1-ylsulfonyl)-1H-indazol-6-yl)piperidine-3-carboxamide,CHEMBL994676,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,140.0,min,O=C(Nc1ccc2cnn(S(=O)(=O)c3cccc4ccccc34)c2c1)C1CCCNC1,CHEMBL1138452,1-Sulfonylindazoles as potent and selective 5-HT6 ligands.,Bioorg. Med. Chem. Lett.,2009.0,19,9,2413,2415,10.1016/j.bmcl.2009.03.071,19345582.0,
2527064,CHEMBL447955,"3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-1H-isoindol-2-yl]cyclopent-2-en-1-one",CHEMBL984122,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,30000.0,nM,C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,CHEMBL1138468,"Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists.",J. Med. Chem.,2009.0,52,9,3039,3046,10.1021/jm8016514,19354254.0,
2558252,CHEMBL476323,2-Methyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-5-(trifluoromethyl)-4(3H)-quinazolinone,CHEMBL986385,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,21000.0,nM,Cc1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1,CHEMBL1155810,"Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.",J. Med. Chem.,2008.0,51,15,4780,4789,10.1021/jm8003834,18598020.0,
2560743,CHEMBL478649,"6-Methyl-biphenyl-3,4'-dicarboxylic acid 3-cyclopropylamide 4'-cyclopropylmethyl-amide",CHEMBL983826,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 transfected in Escherichia coli co-expressed with human NADPH reductase,IC50,=,4400.0,nM,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1,CHEMBL1155838,Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.,Bioorg. Med. Chem. Lett.,2008.0,18,15,4428,4432,10.1016/j.bmcl.2008.06.048,18614366.0,
2561498,CHEMBL477611,3-({4-[Methyl(3-methyl-1H-indazol-6-yl)amino]-2-pyrimidinyl}amino)benzenesulfonamide,CHEMBL983781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,700.0,nM,Cc1n[nH]c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12,CHEMBL1155848,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,2008.0,51,15,4632,4640,10.1021/jm800566m,18620382.0,
2561499,CHEMBL477563,"3-({4-[(1,2-Dimethyl-1H-benzimidazol-5-yl)(methyl)amino]pyrimidin-2-yl}amino)benzenesulfonamide",CHEMBL983781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,9000.0,nM,Cc1nc2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc2n1C,CHEMBL1155848,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,2008.0,51,15,4632,4640,10.1021/jm800566m,18620382.0,
2561500,CHEMBL478612,"3-({4-[(1,2-Dimethyl-1H-benzimidazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)benzenesulfonamide",CHEMBL983781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,15000.0,nM,Cc1nc2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2n1C,CHEMBL1155848,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,2008.0,51,15,4632,4640,10.1021/jm800566m,18620382.0,
2561501,CHEMBL478402,3-({4-[Methyl(2-methyl-2H-indazol-6-yl)amino]-2-pyrimidinyl}amino)benzenesulfonamide,CHEMBL983781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,2900.0,nM,CN(c1ccc2cn(C)nc2c1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1,CHEMBL1155848,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,2008.0,51,15,4632,4640,10.1021/jm800566m,18620382.0,
2561502,CHEMBL476572,3-[(4-{Methyl[3-methyl-2-(benzyl)-2H-indazol-6-yl]amino}-2-pyrimidinyl)amino]benzenesulfonamide,CHEMBL983781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,500.0,nM,Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1Cc1ccccc1,CHEMBL1155848,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,2008.0,51,15,4632,4640,10.1021/jm800566m,18620382.0,
2561503,CHEMBL1794074,"3-({4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)benzenesulfonamide",CHEMBL983781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,1400.0,nM,Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl.Cl,CHEMBL1155848,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,2008.0,51,15,4632,4640,10.1021/jm800566m,18620382.0,
2561504,CHEMBL1794073,"3-({4-[(1,3-Dimethyl-1H-indazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)benzenesulfonamide",CHEMBL983781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,1000.0,nM,Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl,CHEMBL1155848,"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.",J. Med. Chem.,2008.0,51,15,4632,4640,10.1021/jm800566m,18620382.0,
2562167,CHEMBL476302,"6-(4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)phenyl)-1-naphthoic acid",CHEMBL982037,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in pooled human liver microsome,IC50,=,17000.0,nM,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1,CHEMBL1155854,Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.,Bioorg. Med. Chem. Lett.,2008.0,18,15,4339,4343,10.1016/j.bmcl.2008.06.073,18621523.0,
2563284,CHEMBL476116,N-Biphenyl-2-ylmethyl-N-(S)-pyrrolidin-3-yl-isobutyramide,CHEMBL993583,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,3000.0,nM,CC(C)C(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1,CHEMBL1155858,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,2008.0,18,15,4355,4359,10.1016/j.bmcl.2008.06.071,18621528.0,
2563293,CHEMBL478834,Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-carbamic acid ethyl ester,CHEMBL993583,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,3000.0,nM,CCOC(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1,CHEMBL1155858,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,2008.0,18,15,4355,4359,10.1016/j.bmcl.2008.06.071,18621528.0,
2563304,CHEMBL476312,N-Biphenyl-2-ylmethyl-N-(S)-pyrrolidin-3-yl-methanesulfonamide,CHEMBL993583,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,3000.0,nM,CS(=O)(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1,CHEMBL1155858,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,2008.0,18,15,4355,4359,10.1016/j.bmcl.2008.06.071,18621528.0,
2570479,CHEMBL477145,"3-(6-chloro-2-fluoro-3-((5-methyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenoxy)-5-fluorobenzonitrile",CHEMBL979969,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8000.0,nM,Cc1cc(Cc2ccc(Cl)c(Oc3cc(F)cc(C#N)c3)c2F)n[nH]c1=O,CHEMBL1155885,Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.,Bioorg. Med. Chem. Lett.,2008.0,18,15,4352,4354,10.1016/j.bmcl.2008.06.072,18632268.0,
2578180,CHEMBL452864,"1,3-dicyclohexyl-2-((5,6-dihydroimidazo[2,1-b]thiazol-3-yl)methyl)isothiourea",CHEMBL958147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,C1=C(CS/C(=N\C2CCCCC2)NC2CCCCC2)N2CCN=C2S1,CHEMBL1151747,Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.,J. Med. Chem.,2008.0,51,24,7915,7920,10.1021/jm801065q,19053768.0,
2578205,CHEMBL460491,"1,3-dicyclohexyl-2-((6,6-dimethyl-5,6-dihydroimidazo[2,1-b]thiazol-3-yl)methyl)isothiourea",CHEMBL958147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CC1(C)CN2C(CS/C(=N\C3CCCCC3)NC3CCCCC3)=CSC2=N1,CHEMBL1151747,Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.,J. Med. Chem.,2008.0,51,24,7915,7920,10.1021/jm801065q,19053768.0,
2588602,CHEMBL520413,4-cyclopropyl-N-((tetrahydro-2H-pyran-4-yl)methyl)-6-(3-(trifluoromethoxy)phenylamino)nicotinamide,CHEMBL1014601,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,16000.0,nM,O=C(NCC1CCOCC1)c1cnc(Nc2cccc(OC(F)(F)F)c2)cc1C1CC1,CHEMBL1139246,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,2009.0,19,1,259,263,10.1016/j.bmcl.2008.10.118,19010671.0,
2588603,CHEMBL465470,"4-tert-butyl-6-(2,4-dichlorophenylamino)-N-((tetrahydro-2H-pyran-4-yl)methyl)nicotinamide",CHEMBL1014601,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,17000.0,nM,CC(C)(C)c1cc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,CHEMBL1139246,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,2009.0,19,1,259,263,10.1016/j.bmcl.2008.10.118,19010671.0,
2588604,CHEMBL480398,6-(3-bromophenylamino)-4-cyclopropyl-N-((tetrahydro-2H-pyran-4-yl)methyl)nicotinamide,CHEMBL1014601,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,24000.0,nM,O=C(NCC1CCOCC1)c1cnc(Nc2cccc(Br)c2)cc1C1CC1,CHEMBL1139246,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,2009.0,19,1,259,263,10.1016/j.bmcl.2008.10.118,19010671.0,
2588605,CHEMBL479628,"4-cyclopropyl-6-(2,5-dichlorophenylamino)-N-((tetrahydro-2H-pyran-4-yl)methyl)nicotinamide",CHEMBL1014601,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,27000.0,nM,O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)ccc2Cl)cc1C1CC1,CHEMBL1139246,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,2009.0,19,1,259,263,10.1016/j.bmcl.2008.10.118,19010671.0,
2588606,CHEMBL466191,"6-(2,4-dichlorophenylamino)-4-isopropyl-N-((tetrahydro-2H-pyran-4-yl)methyl)nicotinamide",CHEMBL1014601,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,40000.0,nM,CC(C)c1cc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,CHEMBL1139246,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,2009.0,19,1,259,263,10.1016/j.bmcl.2008.10.118,19010671.0,
2588607,CHEMBL517646,"4-cyclopropyl-6-(2,4-dichlorophenylamino)-N-((tetrahydro-2H-pyran-4-yl)methyl)nicotinamide",CHEMBL1014601,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,43000.0,nM,O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2Cl)cc1C1CC1,CHEMBL1139246,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,Bioorg. Med. Chem. Lett.,2009.0,19,1,259,263,10.1016/j.bmcl.2008.10.118,19010671.0,
2589633,CHEMBL473921,"(3-(4-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)pyridin-2-yl)(4-(4-fluorophenylamino)piperidin-1-yl)methanone",CHEMBL1013738,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,100000.0,nM,C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1,CHEMBL1152208,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,2008.0,18,24,6429,6436,10.1016/j.bmcl.2008.10.072,19006669.0,
2589634,CHEMBL480219,"{1-[4-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-phenyl]-1H-imidazol-2-yl}-[4-(3-fluoro-phenylamino)-piperidin-1-yl]-methanone",CHEMBL1013738,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,100000.0,nM,C[C@H]1CN(Cc2ccc(-n3ccnc3C(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)C[C@@H](C)N1,CHEMBL1152208,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,2008.0,18,24,6429,6436,10.1016/j.bmcl.2008.10.072,19006669.0,
2596779,CHEMBL460178,"3-(6-Methoxy-5,6,7,8-tetrahydronaphthalen-2-yl)pyridine",CHEMBL989845,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes,IC50,=,16300.0,nM,COC1CCc2cc(-c3cccnc3)ccc2C1,CHEMBL1151717,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,2008.0,51,24,8077,8087,10.1021/jm800888q,19049427.0,
2596780,CHEMBL462093,"6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one",CHEMBL989845,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes,IC50,=,28300.0,nM,O=C1CCc2cc(-c3cccnc3)ccc2C1,CHEMBL1151717,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,2008.0,51,24,8077,8087,10.1021/jm800888q,19049427.0,
2596781,CHEMBL448743,"5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one",CHEMBL989845,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes,IC50,=,123000.0,nM,O=C1CCc2cc(-c3cccnc3)ccc21,CHEMBL1151717,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,2008.0,51,24,8077,8087,10.1021/jm800888q,19049427.0,
2596782,CHEMBL499007,"6-(5-Methoxypyridin-3-yl)-3,4-dihydronaphthalen-2(1H)-one",CHEMBL989845,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes,IC50,=,12900.0,nM,COc1cncc(-c2ccc3c(c2)CCC(=O)C3)c1,CHEMBL1151717,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,2008.0,51,24,8077,8087,10.1021/jm800888q,19049427.0,
2596783,CHEMBL62811,"6-Pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one",CHEMBL989845,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes,IC50,=,58900.0,nM,O=C1CCc2cc(-c3cccnc3)ccc2N1,CHEMBL1151717,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,2008.0,51,24,8077,8087,10.1021/jm800888q,19049427.0,
2596784,CHEMBL446083,"1-Methyl-6-pyridin-3-yl-3,4-dihydroquinolin-2(1H)-one",CHEMBL989845,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes,IC50,=,125000.0,nM,CN1C(=O)CCc2cc(-c3cccnc3)ccc21,CHEMBL1151717,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,2008.0,51,24,8077,8087,10.1021/jm800888q,19049427.0,
2596785,CHEMBL456390,"6-Isoquinolin-4-yl-3,4-dihydroquinolin-2(1H)-one",CHEMBL989845,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes,IC50,=,2900.0,nM,O=C1CCc2cc(-c3cncc4ccccc34)ccc2N1,CHEMBL1151717,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,2008.0,51,24,8077,8087,10.1021/jm800888q,19049427.0,
2596820,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL989845,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes,IC50,=,318000.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL1151717,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",J. Med. Chem.,2008.0,51,24,8077,8087,10.1021/jm800888q,19049427.0,
2603699,CHEMBL453311,(S)-2-(2-(3-(2-chloro-6-methylphenyl)ureido)-2-naphthamido)-2-cyclohexylacetic acid,CHEMBL1027313,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1000.0,nM,Cc1cccc(Cl)c1NC(=O)Nc1cc2ccccc2cc1C(=O)N[C@H](C(=O)O)C1CCCCC1,CHEMBL1136849,"Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.",Bioorg. Med. Chem. Lett.,2009.0,19,4,1177,1182,10.1016/j.bmcl.2008.12.085,19138846.0,
2603700,CHEMBL473851,"(2S,3R)-3-tert-butoxy-2-(3-(3-mesitylureido)-2-naphthamido)butanoic acid",CHEMBL1027313,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1000.0,nM,Cc1cc(C)c(NC(=O)Nc2cc3ccccc3cc2C(=O)N[C@H](C(=O)O)[C@@H](C)OC(C)(C)C)c(C)c1,CHEMBL1136849,"Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.",Bioorg. Med. Chem. Lett.,2009.0,19,4,1177,1182,10.1016/j.bmcl.2008.12.085,19138846.0,
2608063,CHEMBL514800,"(S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide",CHEMBL1011632,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,CHEMBL1152807,"Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.",J. Med. Chem.,2009.0,52,6,1522,1524,10.1021/jm900210d,19256507.0,
2618444,CHEMBL234940,"6-(2-(2-(2,4-difluorobenzyloxy)-5-chlorophenyl)cyclopent-1-enyl)picolinic acid",CHEMBL1014225,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,25000.0,nM,O=C(O)c1cccc(C2=C(c3cc(Cl)ccc3OCc3ccc(F)cc3F)CCC2)n1,CHEMBL1154508,Discovery of GSK345931A: An EP(1) receptor antagonist with efficacy in preclinical models of inflammatory pain.,Bioorg. Med. Chem. Lett.,2009.0,19,2,497,501,10.1016/j.bmcl.2008.11.032,19036582.0,
2623848,CHEMBL2448576,(S)-N-(1-(5-(2-methoxyquinolin-3-yl)-1H-imidazol-2-yl)-7-oxooctyl)-1-methylazetidine-3-carboxamide,CHEMBL1004105,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5500.0,nM,CCC(=O)CCCCC[C@H](NC(=O)C1CN(C)C1)c1ncc(-c2cc3ccccc3nc2OC)[nH]1,CHEMBL1136937,Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.,J. Med. Chem.,2009.0,52,11,3453,3456,10.1021/jm9004303,19441846.0,
2624473,CHEMBL504492,"2-[(1S,18S,21E,28S,29S,30S)-30-{[(2S,4S,5R,6S)-5-(dimethylamino)-4-hydroxy-4,6-dimethyloxan-2-yl]oxy}-52-hydroxy-18-[(1R)-1-hydroxyethyl]-9-methoxy-21-(1-methoxyethylidene)-16,19,26,31,42,46-hexaoxo-32,43,54-trioxa-3,13,23,49-tetrathia-7,17,20,27,45,51,52,55,56,57-decaazadecacyclo[26.16.6.2^{29,40}.1^{2,5}.1^{12,15}.1^{22,25}.1^{38,41}.1^{47,50}.0^{6,11}.0^{34,39}]heptapentaconta-2(57),4,6,8,10,12(56),14,22(55),24,34,36,38,40,47,50-pentadecaen-8-yl]-N-[3-(morpholin-4-yl)propyl]-1,3-thiazole-4-carboxamide",CHEMBL996337,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>=,100000.0,nM,CO/C(C)=C1/NC(=O)[C@H]([C@@H](C)O)NC(=O)c2csc(n2)-c2cc(OC)c(-c3nc(C(=O)NCCCN4CCOCC4)cs3)nc2-c2csc(n2)[C@@H]2COC(=O)c3c4c5c(cccc5n3O)COC(=O)[C@@H](O[C@H]3C[C@](C)(O)[C@H](N(C)C)[C@H](C)O3)[C@@H](OC4)[C@H](NC(=O)c3csc1n3)c1nc(cs1)C(=O)N2,CHEMBL1136943,Nocathiacin analogs: Synthesis and antibacterial activity of novel water-soluble amides.,Bioorg. Med. Chem. Lett.,2009.0,19,13,3531,3535,10.1016/j.bmcl.2009.04.144,19447613.0,
2629327,CHEMBL497828,"(6-(methylsulfonyl)spiro[chroman-2,4'-piperidine]-1'-yl)(4-(trifluoromethyl)phenyl)methanone",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7600.0,nM,CS(=O)(=O)c1ccc2c(c1)CCC1(CCN(C(=O)c3ccc(C(F)(F)F)cc3)CC1)O2,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629337,CHEMBL496189,"4-oxo-N-((tans)-2-phenylcyclopropyl)spiro[chroman-2,4'-piperidine]-1'-carboxamide",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,O=C1CC2(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC2)Oc2ccccc21,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629338,CHEMBL495793,"(+/-)-6-(1-methyl-1H-pyrazol-5-ylamino)-4-oxo-N-((trans)-2-phenylcyclopropyl)spiro[chroman-2,4'-piperidine]-1'-carboxamide",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,Cn1nccc1Nc1ccc2c(c1)C(=O)CC1(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629339,CHEMBL497829,"2-(2,4-dichlorophenyl)-1-(6-(methylsulfonyl)spiro[chroman-2,4'-piperidine]-1'-yl)ethanone",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,CS(=O)(=O)c1ccc2c(c1)CCC1(CCN(C(=O)Cc3ccc(Cl)cc3Cl)CC1)O2,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629383,CHEMBL495992,"4-oxo-N-((trans)-2-phenylcyclopropyl)-6-(pyridin-4-yl)spiro[chroman-2,4'-piperidine]-1'-carboxamide",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,O=C1CC2(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC2)Oc2ccc(-c3ccncc3)cc21,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629384,CHEMBL495995,"(+/-)-N-((trans)-2-phenylcyclopropyl)spiro[chroman-2,4'-piperidine]-1'-carboxamide",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,O=C(N[C@H]1C[C@@H]1c1ccccc1)N1CCC2(CCc3ccccc3O2)CC1,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629385,CHEMBL483876,"(+/-)-6-fluoro-N-((trans)-2-phenylcyclopropyl)spiro[chroman-2,4'-piperidine]-1'-carboxamide",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,O=C(N[C@H]1C[C@@H]1c1ccccc1)N1CCC2(CCc3cc(F)ccc3O2)CC1,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629386,CHEMBL447085,"1-(6-fluorospiro[chroman-2,4'-piperidine]-1'-yl)-3-phenylpropan-1-one",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,O=C(CCc1ccccc1)N1CCC2(CCc3cc(F)ccc3O2)CC1,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629387,CHEMBL482845,"(+/-)-N-(2,3-dihydro-1H-inden-1-yl)-4-oxospiro[chroman-2,4'-piperidine]-1'-carboxamide",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,O=C1CC2(CCN(C(=O)NC3CCc4ccccc43)CC2)Oc2ccccc21,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629388,CHEMBL519149,"(+/-)-4-oxo-N-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-yl)spiro[chroman-2,4'-piperidine]-1'-carboxamide",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,O=C1CC2(CCN(C(=O)NC3CCc4ccccc4CC3)CC2)Oc2ccccc21,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629389,CHEMBL495586,"6-(methylsulfonyl)-4-oxo-N-((trans)-3-phenylcyclopentyl)spiro[chroman-2,4'-piperidine]-1'-carboxamide",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,CS(=O)(=O)c1ccc2c(c1)C(=O)CC1(CCN(C(=O)N[C@@H]3CC[C@@H](c4ccccc4)C3)CC1)O2,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629397,CHEMBL496189,"4-oxo-N-((tans)-2-phenylcyclopropyl)spiro[chroman-2,4'-piperidine]-1'-carboxamide",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C1CC2(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC2)Oc2ccccc21,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629398,CHEMBL495792,"(+/-)-6-(1-methyl-1H-pyrazol-5-yl)-4-oxo-N-((tans)-2-phenylcyclopropyl)spiro[chroman-2,4'-piperidine]-1'-carboxamide",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cn1nccc1-c1ccc2c(c1)C(=O)CC1(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629399,CHEMBL495794,"(+/-)-6-(methylsulfonyl)-4-oxo-N-((trans)-2-phenylcyclopropyl)spiro[chroman-2,4'-piperidine]-1'-carboxamide",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CS(=O)(=O)c1ccc2c(c1)C(=O)CC1(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629400,CHEMBL519336,"6-(methylsulfonyl)-N-((trans)-2-phenylcyclopropyl)spiro[chroman-2,4'-piperidine]-1'-carboxamide",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CS(=O)(=O)c1ccc2c(c1)CCC1(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629401,CHEMBL482637,"6'-(methylsulfonyl)-N-((trans)-2-phenylcyclopropyl)spiro[azepane-4,2'-chroman]-1-carboxamide",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CS(=O)(=O)c1ccc2c(c1)CCC1(CCCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629402,CHEMBL523565,"4'-hydroxy-N-((trans)-2-phenylcyclopropyl)-3',4'-dihydrospiro[piperidine-4,2'-pyrano[3,2-b]pyridine]-1-carboxamide",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(N[C@H]1C[C@@H]1c1ccccc1)N1CCC2(CC1)CC(O)c1ncccc1O2,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629403,CHEMBL522211,"N-((trans)-2-phenylcyclopropyl)-3',4'-dihydrospiro[piperidine-4,2'-pyrano[3,2-b]pyridine]-1-carboxamide",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(N[C@H]1C[C@@H]1c1ccccc1)N1CCC2(CCc3ncccc3O2)CC1,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629404,CHEMBL524992,"spiro[chroman-2,4'-piperidine]-1'-yl(4-(trifluoromethyl)phenyl)methanone",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(c1ccc(C(F)(F)F)cc1)N1CCC2(CCc3ccccc3O2)CC1,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2629405,CHEMBL495601,"(+/-)-4-oxo-N-(1,2,3,4-tetrahydronaphthalen-2-yl)spiro[chroman-2,4'-piperidine]-1'-carboxamide",CHEMBL1001511,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C1CC2(CCN(C(=O)NC3CCc4ccccc4C3)CC2)Oc2ccccc21,CHEMBL1137005,"Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,13,3398,3404,10.1016/j.bmcl.2009.05.036,19481932.0,
2632174,CHEMBL498114,"1-(8-(2,6-dimethylphenethyl)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4200.0,nM,Cc1cccc(C)c1CCc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632175,CHEMBL498434,"1-(8-(2,6-dimethylbenzyloxy)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,21000.0,nM,Cc1cccc(C)c1COc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632176,CHEMBL498252,"(S)-2,3-dimethyl-9-phenyl-6-(1H-1,2,4-triazol-1-yl)-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,14000.0,nM,Cc1nc2c3c(c(-n4cncn4)cn2c1C)CC[C@@H](c1ccccc1)N3,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632177,CHEMBL525001,"(S)-1-(2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-6-yl)pyridin-2(1H)-one",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5600.0,nM,Cc1nc2c3c(c(-n4ccccc4=O)cn2c1C)CC[C@@H](c1ccccc1)N3,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632178,CHEMBL498251,"(1S,2S)-1-(2,3-dimethyl-6-(1H-1,2,4-triazol-1-yl)imidazo[1,2-a]pyridin-8-ylamino)-2,3-dihydro-1H-inden-2-ol",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5300.0,nM,Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3cncn3)cn2c1C,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632179,CHEMBL498840,"1-(8-((1S,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-ylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,97000.0,nM,Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3ccccc3=O)cn2c1C,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632180,CHEMBL521724,"(S)-1-(8-(2,3-dihydro-1H-inden-1-ylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2500.0,nM,Cc1nc2c(N[C@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632181,CHEMBL510171,"(R)-N-(2,3-dihydro-1H-inden-1-yl)-2,3-dimethyl-6-(1H-1,2,4-triazol-1-yl)imidazo[1,2-a]pyridin-8-amine",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4600.0,nM,Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3cncn3)cn2c1C,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632182,CHEMBL496402,"(R)-1-(8-(2,3-dihydro-1H-inden-1-ylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,23000.0,nM,Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632185,CHEMBL497419,"1-(8-(2-methoxybenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5600.0,nM,COc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632186,CHEMBL497418,"1-(8-(benzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,13000.0,nM,Cc1nc2c(NCc3ccccc3)cc(-n3ccccc3=O)cn2c1C,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632187,CHEMBL526841,"N-(2-chloro-4-fluorobenzyl)-2,3-dimethyl-6-(1H-1,2,4-triazol-1-yl)imidazo[1,2-a]pyridin-8-amine",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1100.0,nM,Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3cncn3)cn2c1C,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632188,CHEMBL498220,"1-(8-(2-chloro-4-fluorobenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3700.0,nM,Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3ccccc3=O)cn2c1C,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632189,CHEMBL498026,"2,3-dimethyl-N-(2-methylbenzyl)-6-(1H-1,2,4-triazol-1-yl)imidazo[1,2-a]pyridin-8-amine",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2900.0,nM,Cc1ccccc1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632190,CHEMBL495787,"1-(2,3-dimethyl-8-(2-methylbenzylamino)imidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,Cc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632191,CHEMBL495786,"1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-4(1H)-one",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,17000.0,nM,Cc1cccc(C)c1CNc1cc(-n2ccc(=O)cc2)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632192,CHEMBL523563,"3-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-4(3H)-one",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4700.0,nM,Cc1cccc(C)c1CNc1cc(-n2cnccc2=O)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632193,CHEMBL496387,"2-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridazin-3(2H)-one",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4200.0,nM,Cc1cccc(C)c1CNc1cc(-n2ncccc2=O)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632194,CHEMBL496386,"1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,19000.0,nM,Cc1cccc(C)c1CNc1cc(-n2cc(C(N)=O)ccc2=O)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632195,CHEMBL496227,"(1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)-1H-1,2,4-triazol-3-yl)methanol",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8600.0,nM,Cc1cccc(C)c1CNc1cc(-n2cnc(CO)n2)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632196,CHEMBL496035,"(1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)-1H-1,2,4-triazol-5-yl)methanol",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,6500.0,nM,Cc1cccc(C)c1CNc1cc(-n2ncnc2CO)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632197,CHEMBL496624,"N-(2-ethyl-6-methylbenzyl)-2,3-dimethyl-6-(1-methyl-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-8-amine",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3200.0,nM,CCc1cccc(C)c1CNc1cc(-c2ncnn2C)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632198,CHEMBL521889,"1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)imidazolidin-2-one",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5800.0,nM,Cc1cccc(C)c1CNc1cc(N2CCNC2=O)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632199,CHEMBL496426,"N-(2,6-dimethylbenzyl)-6-(furan-2-yl)-2,3-dimethylimidazo[1,2-a]pyridin-8-amine",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3200.0,nM,Cc1cccc(C)c1CNc1cc(-c2ccco2)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632200,CHEMBL496606,"N-(2,6-dimethylbenzyl)-2,3-dimethyl-6-(1H-1,2,4-triazol-1-yl)imidazo[1,2-a]pyridin-8-amine",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2500.0,nM,Cc1cccc(C)c1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632201,CHEMBL447822,"N-(2,6-dimethylbenzyl)-2,3-dimethyl-6-(pyridin-2-yl)imidazo[1,2-a]pyridin-8-amine",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,630.0,nM,Cc1cccc(C)c1CNc1cc(-c2ccccn2)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632202,CHEMBL496605,"1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,17000.0,nM,Cc1cccc(C)c1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632203,CHEMBL453246,"N-(2,6-dimethylbenzyl)-2,3-dimethyl-6-(1H-pyrazol-1-yl)imidazo[1,2-a]pyridin-8-amine",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,860.0,nM,Cc1cccc(C)c1CNc1cc(-n2cccn2)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632204,CHEMBL496400,"1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)piperidin-2-one",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,14000.0,nM,Cc1cccc(C)c1CNc1cc(N2CCCCC2=O)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632205,CHEMBL496806,"5-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyrimidine-2,4(1H,3H)-dione",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3400.0,nM,Cc1cccc(C)c1CNc1cc(-c2c[nH]c(=O)[nH]c2=O)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632865,CHEMBL523752,"N-(2-ethyl-6-methylbenzyl)-2,3-dimethylimidazo[1,2-a]pyridin-8-amine",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1500.0,nM,CCc1cccc(C)c1CNc1cccn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632866,CHEMBL497011,"8-(2,6-dimethylbenzylamino)-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,14000.0,nM,Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2632867,CHEMBL238146,"8-(2-ethyl-6-methylbenzylamino)-2,3-dimethylH-imidazo[1,2-a]pyridine-6-carboxamide",CHEMBL964393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3600.0,nM,CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12,CHEMBL1136984,"Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).",Bioorg. Med. Chem. Lett.,2009.0,19,13,3602,3606,10.1016/j.bmcl.2009.04.127,19467868.0,
2637211,CHEMBL466496,"3-((R)-1-Phenyl-ethylamino)-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione",CHEMBL1011419,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,600.0,nM,C[C@@H](Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1,CHEMBL1136863,Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).,Bioorg. Med. Chem.,2009.0,17,9,3342,3351,10.1016/j.bmc.2009.03.041,19364658.0,
2637212,CHEMBL467079,"2-{[3,4-Dioxo-2-(pyridin-4-ylamino)cyclobut-1-en-1-yl]amino}-2-phenylacetamide",CHEMBL1011419,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5100.0,nM,NC(=O)C(Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1,CHEMBL1136863,Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).,Bioorg. Med. Chem.,2009.0,17,9,3342,3351,10.1016/j.bmc.2009.03.041,19364658.0,
2637213,CHEMBL511410,"2-{[3,4-Dioxo-2-(pyridin-4-ylamino)cyclobut-1-en-1-yl]amino}-2-(3-hydroxyphenyl)acetamide",CHEMBL1011419,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,6500.0,nM,NC(=O)C(Nc1c(Nc2ccncc2)c(=O)c1=O)c1cccc(O)c1,CHEMBL1136863,Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).,Bioorg. Med. Chem.,2009.0,17,9,3342,3351,10.1016/j.bmc.2009.03.041,19364658.0,
2637215,CHEMBL524472,"3-{[(1R)-1-Phenylethyl]amino}-4-(1H-pyrazol-3-ylamino)cyclobut-3-ene-1,2-dione",CHEMBL1011419,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,12000.0,nM,C[C@@H](Nc1c(Nc2ccn[nH]2)c(=O)c1=O)c1ccccc1,CHEMBL1136863,Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).,Bioorg. Med. Chem.,2009.0,17,9,3342,3351,10.1016/j.bmc.2009.03.041,19364658.0,
2642081,CHEMBL468927,"(S)-2-amino-N-(3-(5-(5-(benzo[d]thiazol-7-yl)-1,3,4-oxadiazol-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)propanamide",CHEMBL971426,A,Hepatocyte,,Cytochrome P450 2C9,Inhibition of CYP2C9 expressed in human hepatocytes,IC50,>,100000.0,nM,C[C@H](N)C(=O)NCc1cccc(-n2nc(C(F)(F)F)cc2-c2nnc(-c3cccc4ncsc34)o2)c1,CHEMBL1136918,Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1).,Bioorg. Med. Chem. Lett.,2009.0,19,11,2924,2927,10.1016/j.bmcl.2009.04.075,19419866.0,
2646754,CHEMBL565195,2-(4-(methylsulfonyl)phenylamino)-1-(2-(trifluoromethyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide,CHEMBL1035568,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 coincubated with compound,IC50,=,15000.0,nM,CS(=O)(=O)c1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1,CHEMBL1158447,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,13,3405,3409,10.1016/j.bmcl.2009.05.040,19481450.0,
2646755,CHEMBL557885,2-(4-methoxyphenylamino)-1-(2-(trifluoromethyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide,CHEMBL1035568,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 coincubated with compound,IC50,=,8000.0,nM,COc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1,CHEMBL1158447,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,13,3405,3409,10.1016/j.bmcl.2009.05.040,19481450.0,
2646756,CHEMBL561696,2-(4-(methylthio)phenylamino)-1-(2-(trifluoromethyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide,CHEMBL1035568,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 coincubated with compound,IC50,=,14000.0,nM,CSc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1,CHEMBL1158447,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,13,3405,3409,10.1016/j.bmcl.2009.05.040,19481450.0,
2646769,CHEMBL565195,2-(4-(methylsulfonyl)phenylamino)-1-(2-(trifluoromethyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide,CHEMBL1035576,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 preincubated with compound,IC50,>,8000.0,nM,CS(=O)(=O)c1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1,CHEMBL1158447,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,13,3405,3409,10.1016/j.bmcl.2009.05.040,19481450.0,
2646770,CHEMBL557885,2-(4-methoxyphenylamino)-1-(2-(trifluoromethyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide,CHEMBL1035576,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 preincubated with compound,IC50,>,4000.0,nM,COc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1,CHEMBL1158447,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,13,3405,3409,10.1016/j.bmcl.2009.05.040,19481450.0,
2646771,CHEMBL561696,2-(4-(methylthio)phenylamino)-1-(2-(trifluoromethyl)benzyl)-1H-benzo[d]imidazole-5-carboxamide,CHEMBL1035576,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 preincubated with compound,IC50,>,7000.0,nM,CSc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1,CHEMBL1158447,Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,13,3405,3409,10.1016/j.bmcl.2009.05.040,19481450.0,
2649315,CHEMBL552240,(2R)-2-{3-[[3-(4-Chlorobenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy}butanoic Acid,CHEMBL1036140,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,CC[C@@H](Oc1cccc(Cn2c(C)c(C(=O)c3ccc(Cl)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O,CHEMBL1158459,Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.,J. Med. Chem.,2009.0,52,14,4443,4453,10.1021/jm900367w,19530681.0,
2650508,CHEMBL564840,"4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine hydrochloride",CHEMBL1025208,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as inhibition of diclofenac 4'-hydroxylation,IC50,>,100000.0,nM,Cl.O=c1n(C[C@@H](O)CO)c2ccccc2n1C1CCN(C[C@H]2[C@H]3CC[C@H](C3)C23CC3)CC1,CHEMBL1158463,"Identification of an orally active opioid receptor-like 1 (ORL1) receptor antagonist 4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine as clinical candidate.",J. Med. Chem.,2009.0,52,14,4091,4094,10.1021/jm900581g,19537798.0,
2658387,CHEMBL549749,"2-Amino-4-[2,4-dichloro-5-(2-diethylaminoethoxy)phenyl]thieno[2,3-d]pyrimidine-6-carboxylic acid ethylamide",CHEMBL1025216,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CCNC(=O)c1cc2c(-c3cc(OCCN(CC)CC)c(Cl)cc3Cl)nc(N)nc2s1,CHEMBL1158486,"Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.",J. Med. Chem.,2009.0,52,15,4794,4809,10.1021/jm900357y,19610616.0,
2678874,CHEMBL551964,"2-(4-{[(2S)-8-Methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl}piperazin-1-yl)-quinoline-6-carbonitrile",CHEMBL1063866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,358000.0,nM,Cc1ccc2c3c(ccc2n1)OC[C@H](CN1CCN(c2ccc4cc(C#N)ccc4n2)CC1)O3,CHEMBL1151947,"Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists.",J. Med. Chem.,2009.0,52,15,4955,4959,10.1021/jm900374r,19719241.0,
2679295,CHEMBL564975,"N-(2-phenylcyclopropyl)-4-(1H-1,2,3-triazol-1-yl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(NC1CC1c1ccccc1)N1CCC(n2ccnn2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679305,CHEMBL562869,"4-(1-methyl-1H-1,2,3-triazol-4-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cn1cc(C2CCN(C(=O)NC3CC3c3ccccc3)CC2)nn1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679315,CHEMBL550652,"4-(4-methyl-4H-1,2,4-triazol-3-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cn1cnnc1C1CCN(C(=O)NC2CC2c2ccccc2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679325,CHEMBL563732,"N-(2-phenylcyclopropyl)-4-(1H-1,2,4-triazol-1-yl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(NC1CC1c1ccccc1)N1CCC(n2cncn2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679335,CHEMBL559101,N-(2-phenylcyclopropyl)-4-(1H-pyrazol-1-yl)piperidine-1-carboxamide,CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(NC1CC1c1ccccc1)N1CCC(n2cccn2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679345,CHEMBL552196,4-(3-hydroxy-4-methylisoxazol-5-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide,CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1c(O)noc1C1CCN(C(=O)NC2CC2c2ccccc2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679355,CHEMBL561379,"4-(1,3,4-oxadiazol-2-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(NC1CC1c1ccccc1)N1CCC(c2nnco2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679365,CHEMBL561259,"4-(1,2,4-oxadiazol-3-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(NC1CC1c1ccccc1)N1CCC(c2ncon2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679375,CHEMBL564547,"4-(3-methyl-1,2,4-oxadiazol-5-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1noc(C2CCN(C(=O)NC3CC3c3ccccc3)CC2)n1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679385,CHEMBL552402,4-(benzo[d]oxazol-2-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide,CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,O=C(NC1CC1c1ccccc1)N1CCC(c2nc3ccccc3o2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679395,CHEMBL561788,"N-(2-phenylcyclopropyl)-4-(3-(2-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccc3C(F)(F)F)no2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679405,CHEMBL551058,"4-(3-(4-(methylsulfonyl)phenyl)-1,2,4-oxadiazol-5-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CS(=O)(=O)c1ccc(-c2noc(C3CCN(C(=O)NC4CC4c4ccccc4)CC3)n2)cc1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679415,CHEMBL559531,"4-(5-(1-(2-phenylcyclopropylcarbamoyl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)benzoic acid",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(O)c1ccc(-c2noc(C3CCN(C(=O)NC4CC4c4ccccc4)CC3)n2)cc1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679425,CHEMBL552382,"N-(2-phenylcyclopropyl)-4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccn3)no2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679435,CHEMBL564757,"N-(2-phenylcyclopropyl)-4-(3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3cccnc3)no2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679445,CHEMBL556487,"N-(2-phenylcyclopropyl)-4-(3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccncc3)no2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679455,CHEMBL557032,"N-(2-phenylcyclopropyl)-4-(3-(pyrazin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3cnccn3)no2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679465,CHEMBL551517,"N-(2-phenylcyclopropyl)-4-(3-(pyrimidin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ncccn3)no2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679475,CHEMBL552061,"4-(3-(isoquinolin-1-yl)-1,2,4-oxadiazol-5-yl)-N-(2-phenylcyclopropyl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3nccc4ccccc34)no2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679485,CHEMBL551921,"N-(2-phenylcyclopropyl)-4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679494,CHEMBL555347,"4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)-N-(4-(trifluoromethyl)phenyl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(Nc1ccc(C(F)(F)F)cc1)N1CCC(c2nc(-c3ccccn3)no2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679504,CHEMBL562926,"4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)-N-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-yl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,O=C(NC1CCc2ccccc2CC1)N1CCC(c2nc(-c3ccccn3)no2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679514,CHEMBL550242,"4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)-N-(1,2,3,4-tetrahydronaphthalen-2-yl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,O=C(NC1CCc2ccccc2C1)N1CCC(c2nc(-c3ccccn3)no2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679528,CHEMBL562822,"N-((1R,2S)-2-phenylcyclopropyl)-4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(N[C@@H]1C[C@H]1c1ccccc1)N1CCC(c2nc(-c3ccccn3)no2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2679538,CHEMBL552382,"N-(2-phenylcyclopropyl)-4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",CHEMBL1051706,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccn3)no2)CC1,CHEMBL1152451,"Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.",J. Med. Chem.,2009.0,52,16,5009,5012,10.1021/jm900725r,19645482.0,
2691506,CHEMBL560386,"1-{3-[4-((2S,3S)-8-Methoxy-3-methyl-4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-2-yl)-phenoxy]-propyl}-pyrrolidine",CHEMBL1062354,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,COc1cccc2c1O[C@@H](c1ccc(OCCCN3CCCC3)cc1)[C@H](C)S2(=O)=O,CHEMBL1152368,"Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.",Bioorg. Med. Chem. Lett.,2009.0,19,15,4232,4236,10.1016/j.bmcl.2009.05.101,19520574.0,
2693481,CHEMBL551991,(S)-2-cyano-1-(2-methylbenzofuran-5-yl)-3-(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-yl)guanidine,CHEMBL1063239,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,29200.0,nM,Cc1cc2cc(/N=C(/NC#N)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,CHEMBL1152385,Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,15,4034,4041,10.1016/j.bmcl.2009.06.014,19541481.0,
2693491,CHEMBL551991,(S)-2-cyano-1-(2-methylbenzofuran-5-yl)-3-(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-yl)guanidine,CHEMBL1063241,A,TC5,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human TC5 cells,IC50,>,200000.0,nM,Cc1cc2cc(/N=C(/NC#N)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,CHEMBL1152385,Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,15,4034,4041,10.1016/j.bmcl.2009.06.014,19541481.0,
2700454,CHEMBL16596,"3-[3-tert-Butylsulfanyl-1-(4-chloro-benzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid",CHEMBL1053351,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,0.5,nM,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12,CHEMBL1153536,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,2009.0,52,19,5803,5815,10.1021/jm900945d,19739647.0,
2700455,CHEMBL38958,"3-[3-tert-Butylsulfanyl-1-(4-chloro-benzyl)-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid",CHEMBL1053351,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1.0,nM,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccccn3)cc12,CHEMBL1153536,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,2009.0,52,19,5803,5815,10.1021/jm900945d,19739647.0,
2700461,CHEMBL539650,"3-(3-(tert-butylthio)-5-(pyridin-2-ylmethoxy)-1-(4-(thiazol-2-yl)benzyl)-1H-indol-2-yl)-2,2-dimethylpropanoic acid",CHEMBL1053351,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9.1,nM,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3nccs3)cc2)c2ccc(OCc3ccccn3)cc12,CHEMBL1153536,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,2009.0,52,19,5803,5815,10.1021/jm900945d,19739647.0,
2700462,CHEMBL553174,"3-[3-tert-Butylsulfanyl-1-[4-(6-methylpyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid",CHEMBL1053351,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10.0,nM,Cc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccccn5)ccc43)cc2)cn1,CHEMBL1153536,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,2009.0,52,19,5803,5815,10.1021/jm900945d,19739647.0,
2700466,CHEMBL538632,"3-(3-(tert-butylthio)-5-(pyridin-2-ylmethoxy)-1-(4-(pyridin-3-yl)benzyl)-1H-indol-2-yl)-2,2-dimethylpropanoic acid",CHEMBL1053351,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,15.5,nM,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3cccnc3)cc2)c2ccc(OCc3ccccn3)cc12,CHEMBL1153536,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,2009.0,52,19,5803,5815,10.1021/jm900945d,19739647.0,
2700467,CHEMBL552567,"3-(3-(tert-butylthio)-1-(4-(6-methoxypyridazin-3-yl)benzyl)-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl)-2,2-dimethylpropanoic acid",CHEMBL1053351,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,26.9,nM,COc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccccn5)ccc43)cc2)nn1,CHEMBL1153536,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,2009.0,52,19,5803,5815,10.1021/jm900945d,19739647.0,
2700469,CHEMBL557052,"3-(3-(tert-butylthio)-5-(pyridin-2-ylmethoxy)-1-(4-(pyrimidin-2-yl)benzyl)-1H-indol-2-yl)-2,2-dimethylpropanoic acid",CHEMBL1053351,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10.0,nM,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3ncccn3)cc2)c2ccc(OCc3ccccn3)cc12,CHEMBL1153536,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,2009.0,52,19,5803,5815,10.1021/jm900945d,19739647.0,
2700470,CHEMBL553175,"3-(3-(tert-butylthio)-1-(4-(5-methoxypyridin-2-yl)benzyl)-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl)-2,2-dimethylpropanoic acid",CHEMBL1053351,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10.0,nM,COc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccccn5)ccc43)cc2)nc1,CHEMBL1153536,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,2009.0,52,19,5803,5815,10.1021/jm900945d,19739647.0,
2700478,CHEMBL557527,"3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic Acid",CHEMBL1053351,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50.0,nM,COc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccccn5)ccc43)cc2)cn1,CHEMBL1153536,"5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).",J. Med. Chem.,2009.0,52,19,5803,5815,10.1021/jm900945d,19739647.0,
2700980,CHEMBL560740,"N-[3,3-Bis-(4-fluorophenyl)-propyl]-6-(2,2,2-trifluoro-ethoxy)-nicotinamide",CHEMBL1058202,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2000.0,nM,O=C(NCCC(c1ccc(F)cc1)c1ccc(F)cc1)c1ccc(OCC(F)(F)F)nc1,CHEMBL1153540,Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.,J. Med. Chem.,2009.0,52,19,5880,5895,10.1021/jm9005302,19746975.0,
2700983,CHEMBL556716,4-Cyano-N-[3-(4-fluorophenyl)-3-(4-methanesulfonyl-phenyl)-propyl]-benzamide,CHEMBL1058202,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7000.0,nM,CS(=O)(=O)c1ccc(C(CCNC(=O)c2ccc(C#N)cc2)c2ccc(F)cc2)cc1,CHEMBL1153540,Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.,J. Med. Chem.,2009.0,52,19,5880,5895,10.1021/jm9005302,19746975.0,
2700984,CHEMBL560537,"N-(3,3-diphenyl-propyl)-nicotinamide",CHEMBL1058202,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,30000.0,nM,O=C(NCCC(c1ccccc1)c1ccccc1)c1cccnc1,CHEMBL1153540,Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.,J. Med. Chem.,2009.0,52,19,5880,5895,10.1021/jm9005302,19746975.0,
2706545,CHEMBL560993,2-(5-fluoro-2-methyl-3-(quinolin-2-ylmethyl)-1H-indol-1-yl)acetic acid,CHEMBL1054930,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(=O)O,CHEMBL1153474,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2009.0,19,16,4647,4651,10.1016/j.bmcl.2009.06.085,19608418.0,
2706546,CHEMBL551813,"2-(4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl)acetic acid",CHEMBL1054930,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,CN(C)c1nc(Cc2ccc(NC(=O)c3ccc(C(F)(F)F)cc3)cc2)nc(N(C)C)c1CC(=O)O,CHEMBL1153474,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2009.0,19,16,4647,4651,10.1016/j.bmcl.2009.06.085,19608418.0,
2706547,CHEMBL361812,"3-[(S)-3-(4-Fluoro-benzenesulfonylamino)-1,2,3,4-tetrahydro-carbazol-9-yl]-propionic acid",CHEMBL1054930,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,15000.0,nM,O=C(O)CCn1c2c(c3ccccc31)C[C@H](NS(=O)(=O)c1ccc(F)cc1)CC2,CHEMBL1153474,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2009.0,19,16,4647,4651,10.1016/j.bmcl.2009.06.085,19608418.0,
2706548,CHEMBL563664,"2-((3R)-3-(4-fluoro-N-methylphenylsulfonamido)-3,4-dihydro-1H-carbazol-9(2H,4bH,8aH)-yl)acetic acid",CHEMBL1054930,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,18000.0,nM,CN([C@@H]1CCC2=C(C1)C1C=CC=CC1N2CC(=O)O)S(=O)(=O)c1ccc(F)cc1,CHEMBL1153474,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2009.0,19,16,4647,4651,10.1016/j.bmcl.2009.06.085,19608418.0,
2706549,CHEMBL561132,"(R)-2-(7-(4-fluoro-N-methylphenylsulfonamido)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetic acid",CHEMBL1054930,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,5000.0,nM,CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1153474,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2009.0,19,16,4647,4651,10.1016/j.bmcl.2009.06.085,19608418.0,
2706550,CHEMBL564920,"(R)-2-(3-(4-fluoro-N-methylphenylsulfonamido)-1,2,3,4-tetrahydropyrido[1,2-a]indol-10-yl)acetic acid",CHEMBL1054930,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,17000.0,nM,CN([C@@H]1CCc2c(CC(=O)O)c3ccccn3c2C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1153474,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2009.0,19,16,4647,4651,10.1016/j.bmcl.2009.06.085,19608418.0,
2706551,CHEMBL564845,"(R)-2-(9-(4-fluoro-N-methylphenylsulfonamido)-7,8,9,10-tetrahydropyrido[2,1-a]isoindol-6-yl)acetic acid",CHEMBL1054930,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,10000.0,nM,CN([C@@H]1CCc2c(c3ccccn3c2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1153474,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2009.0,19,16,4647,4651,10.1016/j.bmcl.2009.06.085,19608418.0,
2706552,CHEMBL550465,"(R)-2-(8-(4-fluoro-N-methylphenylsulfonamido)-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]indol-5-yl)acetic acid",CHEMBL1054930,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,CN([C@@H]1CCc2c(c3ncccc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1153474,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2009.0,19,16,4647,4651,10.1016/j.bmcl.2009.06.085,19608418.0,
2706553,CHEMBL550868,"(R)-2-(6-(4-fluoro-N-methylphenylsulfonamido)-7,8-dihydro-5H-pyrido[3,4-b]indol-9(6H)-yl)acetic acid",CHEMBL1054930,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,CN([C@@H]1CCc2c(c3ccncc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1153474,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2009.0,19,16,4647,4651,10.1016/j.bmcl.2009.06.085,19608418.0,
2706554,CHEMBL552211,"(R)-2-(6-(4-fluoro-N-methylphenylsulfonamido)-7,8-dihydro-5H-pyrido[2,3-b]indol-9(6H)-yl)acetic acid",CHEMBL1054930,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,CN([C@@H]1CCc2c(c3cccnc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1153474,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2009.0,19,16,4647,4651,10.1016/j.bmcl.2009.06.085,19608418.0,
2706555,CHEMBL556849,"(R)-2-(8-(4-fluoro-N-methylphenylsulfonamido)-6,7,8,9-tetrahydro-5H-pyrazino[2,3-b]indol-5-yl)acetic acid",CHEMBL1054930,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,15000.0,nM,CN([C@@H]1CCc2c(c3nccnc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1153474,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2009.0,19,16,4647,4651,10.1016/j.bmcl.2009.06.085,19608418.0,
2706556,CHEMBL557117,"(R)-2-(7-(4-fluoro-N-methylphenylsulfonamido)-6,7,8,9-tetrahydropyrido[2,3-b]indolizin-10-yl)acetic acid",CHEMBL1054930,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,CN([C@@H]1CCc2c(CC(=O)O)c3ncccc3n2C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1153474,Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2009.0,19,16,4647,4651,10.1016/j.bmcl.2009.06.085,19608418.0,
2708601,CHEMBL552338,(S)-N-(cyclobutylmethyl)-N-(pyrrolidin-3-yl)-2-(trifluoromethyl)benzamide,CHEMBL1062500,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)[C@H]1CCNC1,CHEMBL1153484,"Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.",Bioorg. Med. Chem. Lett.,2009.0,19,16,4579,4583,10.1016/j.bmcl.2009.06.096,19616432.0,
2711451,CHEMBL561932,"4-chloro-N-cyclopropyl-3-(1-(4-fluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-ylamino)benzamide",CHEMBL1063402,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,21000.0,nM,Cn1c(=O)cc(Nc2cc(C(=O)NC3CC3)ccc2Cl)c2cnn(-c3ccc(F)cc3)c21,CHEMBL1153060,"Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.",Bioorg. Med. Chem. Lett.,2009.0,19,16,4724,4728,10.1016/j.bmcl.2009.06.058,19574047.0,
2711454,CHEMBL558448,"4-chloro-N-cyclopropyl-3-(1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-ylamino)benzamide",CHEMBL1063402,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8400.0,nM,Cn1c(=O)cc(Nc2cc(C(=O)NC3CC3)ccc2Cl)c2cnn(-c3ccc(F)cc3F)c21,CHEMBL1153060,"Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.",Bioorg. Med. Chem. Lett.,2009.0,19,16,4724,4728,10.1016/j.bmcl.2009.06.058,19574047.0,
2714958,CHEMBL563949,"2-(1-(3,4-difluorophenylsulfonyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid",CHEMBL1054974,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1c(CC(=O)O)c2cccnc2n1S(=O)(=O)c1ccc(F)c(F)c1,CHEMBL1153075,7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists.,Bioorg. Med. Chem. Lett.,2009.0,19,16,4794,4798,10.1016/j.bmcl.2009.06.042,19592244.0,
2718649,CHEMBL557461,(4-methylpiperidin-1-yl)(6-(3-(piperidin-1-yl)propoxy)naphthalen-2-yl)methanone,CHEMBL1055916,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,12000.0,nM,CC1CCN(C(=O)c2ccc3cc(OCCCN4CCCCC4)ccc3c2)CC1,CHEMBL1153640,Selective naphthalene H(3) receptor inverse agonists with reduced potential to induce phospholipidosis and their quinoline analogs.,Bioorg. Med. Chem. Lett.,2009.0,19,15,4495,4500,10.1016/j.bmcl.2009.03.100,19524437.0,
2718667,CHEMBL541483,(6-(1-isopropylpiperidin-4-yloxy)naphthalen-2-yl)(morpholino)methanone,CHEMBL1055916,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,41000.0,nM,CC(C)N1CCC(Oc2ccc3cc(C(=O)N4CCOCC4)ccc3c2)CC1,CHEMBL1153640,Selective naphthalene H(3) receptor inverse agonists with reduced potential to induce phospholipidosis and their quinoline analogs.,Bioorg. Med. Chem. Lett.,2009.0,19,15,4495,4500,10.1016/j.bmcl.2009.03.100,19524437.0,
2925545,CHEMBL575448,"(S)-1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide",CHEMBL1036860,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,23000.0,nM,C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1,CHEMBL1154171,"Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.",J. Med. Chem.,2009.0,52,23,7360,7363,10.1021/jm900786r,19778024.0,
2927594,CHEMBL584554,"(6aR,9R)-N9,N9-diethyl-N7-phenyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-7,9(4H)-dicarboxamide",CHEMBL1046688,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C(=O)Nc2ccccc2)C1,CHEMBL1154177,"Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.",Bioorg. Med. Chem. Lett.,2009.0,19,21,6185,6188,10.1016/j.bmcl.2009.09.002,19783143.0,
2935223,CHEMBL1645462,"[4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamic acid,(3S)-3-morpholinylmethyl ester",CHEMBL1054518,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,12000.0,nM,Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,CHEMBL1154610,"Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases.",J. Med. Chem.,2009.0,52,21,6527,6530,10.1021/jm9010065,19821562.0,
2942653,CHEMBL569185,(R)-1-(Methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxy-phenyl)-2-imidazolidinone,CHEMBL1039589,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,47000.0,nM,COc1ccc(CCN2C(=O)N(NS(C)(=O)=O)C[C@H]2c2ccc(OC)cc2)cc1,CHEMBL1154688,Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia.,J. Med. Chem.,2009.0,52,21,6531,6534,10.1021/jm901042m,19888755.0,
2943322,CHEMBL585182,"8-(4-Hydroxylphenyl)-2-[(dimethylamino)methyl][1]benzothieno-[3,2-d]pyrimidin-4(3H)-one",CHEMBL1060336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,20000.0,nM,CN(C)Cc1nc2c(sc3ccc(-c4ccc(O)cc4)cc32)c(=O)[nH]1,CHEMBL1154637,"Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.",J. Med. Chem.,2009.0,52,21,6621,6636,10.1021/jm900943h,19842661.0,
2945316,CHEMBL575966,"3-(2-chlorophenyl)-N-(4-chlorophenyl)-N,5-dimethylisoxazole-4-carboxamide",CHEMBL1040537,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1onc(-c2ccccc2Cl)c1C(=O)N(C)c1ccc(Cl)cc1,CHEMBL1154698,Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists.,J. Med. Chem.,2009.0,52,24,7962,7965,10.1021/jm901434t,19902954.0,
2946314,CHEMBL576138,"N-(3-chloro-4-methylphenyl)-3-(2-chlorophenyl)-N,5-dimethylisoxazole-4-carboxamide",CHEMBL1040537,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1ccc(N(C)C(=O)c2c(-c3ccccc3Cl)noc2C)cc1Cl,CHEMBL1154698,Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists.,J. Med. Chem.,2009.0,52,24,7962,7965,10.1021/jm901434t,19902954.0,
2948569,CHEMBL593763,7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one Methanesulfonate,CHEMBL1049146,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,5000.0,nM,CNCc1cc(=O)oc2cc(OCc3cccc(Cl)c3)ccc12.CS(=O)(=O)O,CHEMBL1154599,"Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor.",J. Med. Chem.,2009.0,52,21,6685,6706,10.1021/jm9010127,19810674.0,
2986627,CHEMBL572324,"3-{5-[(6-Amino-1H-pyrazolo[3,4-b]pyridin-3-yl)methoxy]-2-chloro-3-fluorophenoxy}-5-chlorobenzonitrile",CHEMBL1038939,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10300.0,nM,N#Cc1cc(Cl)cc(Oc2cc(OCc3n[nH]c4nc(N)ccc34)cc(F)c2Cl)c1,CHEMBL1156144,Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.,J. Med. Chem.,2009.0,52,22,7163,7169,10.1021/jm901230r,19883100.0,
2991360,CHEMBL567904,"5-(2-(((1R)-3-(2-cyclopentylallyl)-2-methylenecycloheptyl)methyl)-4-phenylpenta-2,4-dienyl)-2-methyl-1H-indene",CHEMBL1049595,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,Cc1cc2cc(/N=C(/NC(=O)c3cccnc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,CHEMBL1156750,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,2009.0,19,24,6882,6889,10.1016/j.bmcl.2009.10.084,19896847.0,
2991363,CHEMBL565383,(S)-3-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylenecarbamoyl)pyridine 1-oxide,CHEMBL1049595,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,122000.0,nM,Cc1cc2cc(N/C(=N\C(=O)c3ccc[n+]([O-])c3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,CHEMBL1156750,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,2009.0,19,24,6882,6889,10.1016/j.bmcl.2009.10.084,19896847.0,
2991366,CHEMBL577965,"(S)-N3-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylene)pyridine-3,5-dicarboxamide",CHEMBL1049595,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,Cc1cc2cc(N/C(=N\C(=O)c3cncc(C(N)=O)c3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,CHEMBL1156750,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,2009.0,19,24,6882,6889,10.1016/j.bmcl.2009.10.084,19896847.0,
2991369,CHEMBL565390,(S)-6-methyl-N-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylene)nicotinamide,CHEMBL1049595,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9000.0,nM,Cc1ccc(C(=O)/N=C(\Nc2ccc3oc(C)cc3c2)N[C@H]2CCCCN(CC(=O)N3CCCC3)C2=O)cn1,CHEMBL1156750,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,2009.0,19,24,6882,6889,10.1016/j.bmcl.2009.10.084,19896847.0,
2991372,CHEMBL567487,(S)-6-chloro-N-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylene)nicotinamide,CHEMBL1049595,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,12000.0,nM,Cc1cc2cc(N/C(=N\C(=O)c3ccc(Cl)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,CHEMBL1156750,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,2009.0,19,24,6882,6889,10.1016/j.bmcl.2009.10.084,19896847.0,
2991375,CHEMBL570639,(S)-5-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylenecarbamoyl)picolinic acid,CHEMBL1049595,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,122000.0,nM,Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(=O)O)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,CHEMBL1156750,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,2009.0,19,24,6882,6889,10.1016/j.bmcl.2009.10.084,19896847.0,
2991378,CHEMBL576093,"(S)-N5-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylene)pyridine-2,5-dicarboxamide",CHEMBL1049595,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,22000.0,nM,Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(N)=O)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,CHEMBL1156750,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,2009.0,19,24,6882,6889,10.1016/j.bmcl.2009.10.084,19896847.0,
2991381,CHEMBL576094,"(S)-N2-methyl-N5-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylene)pyridine-2,5-dicarboxamide",CHEMBL1049595,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,24000.0,nM,CNC(=O)c1ccc(C(=O)/N=C(\Nc2ccc3oc(C)cc3c2)N[C@H]2CCCCN(CC(=O)N3CCCC3)C2=O)cn1,CHEMBL1156750,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,2009.0,19,24,6882,6889,10.1016/j.bmcl.2009.10.084,19896847.0,
2991384,CHEMBL570867,"(S)-N2,N2-dimethyl-N5-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylene)pyridine-2,5-dicarboxamide",CHEMBL1049595,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,43000.0,nM,Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(=O)N(C)C)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,CHEMBL1156750,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,2009.0,19,24,6882,6889,10.1016/j.bmcl.2009.10.084,19896847.0,
2991418,CHEMBL570867,"(S)-N2,N2-dimethyl-N5-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylene)pyridine-2,5-dicarboxamide",CHEMBL1049595,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,40000.0,nM,Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(=O)N(C)C)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,CHEMBL1156750,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,2009.0,19,24,6882,6889,10.1016/j.bmcl.2009.10.084,19896847.0,
2991441,CHEMBL570867,"(S)-N2,N2-dimethyl-N5-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylene)pyridine-2,5-dicarboxamide",CHEMBL1049586,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 by HHA assay,IC50,>,200000.0,nM,Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(=O)N(C)C)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,CHEMBL1156750,Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.,Bioorg. Med. Chem. Lett.,2009.0,19,24,6882,6889,10.1016/j.bmcl.2009.10.084,19896847.0,
2991592,CHEMBL565591,"3-(1-(2,4-dichlorobenzyl)-5-fluoro-3-methyl-1H-indol-7-yl)-N-(4,5-dichlorothiophen-2-ylsulfonyl)acrylamide",CHEMBL1045321,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,30.0,nM,Cc1cn(Cc2ccc(Cl)cc2Cl)c2c(/C=C/C(=O)NS(=O)(=O)c3cc(Cl)c(Cl)s3)cc(F)cc12,CHEMBL1156787,"Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding.",J. Med. Chem.,2010.0,53,1,18,36,10.1021/jm9005912,19957930.0,
3004487,CHEMBL578413,"2-Amino-9-(2-chloro-phenyl)-4-methyl-7-oxo-6,7,8,9-tetrahydro-thieno[2,3-b:4,5-b']dipyridine-3-carbonitrile",CHEMBL1045533,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1258.93,nM,Cc1c(C#N)c(N)nc2c3c(sc12)NC(=O)CC3c1ccccc1Cl,CHEMBL1155365,"2-Amino-9-aryl-3-cyano-4-methyl-7-oxo-6,7,8,9-tetrahydropyrido[2',3':4,5]thieno[2,3-b]pyridine derivatives as selective progesterone receptor agonists.",Bioorg. Med. Chem. Lett.,2009.0,19,17,4916,4919,10.1016/j.bmcl.2009.07.100,19664922.0,
3004866,CHEMBL572255,N-(4-chloro-3-(1-methyl-1H-benzo[d]imidazol-2-yl)phenyl)-2-methyl-6-(trifluoromethyl)nicotinamide,CHEMBL1044700,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2500.0,nM,Cc1nc(C(F)(F)F)ccc1C(=O)Nc1ccc(Cl)c(-c2nc3ccccc3n2C)c1,CHEMBL1156025,GDC-0449-a potent inhibitor of the hedgehog pathway.,Bioorg. Med. Chem. Lett.,2009.0,19,19,5576,5581,10.1016/j.bmcl.2009.08.049,19716296.0,
3013988,CHEMBL565558,3-(4-(methylsulfonyl)phenyl)-4-(3-(6-(2-(methylsulfonyl)propan-2-yl)quinolin-8-yl)phenyl)butan-2-one,CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,600.0,nM,CC(=O)C(Cc1cccc(-c2cc(C(C)(C)S(C)(=O)=O)cc3cccnc23)c1)c1ccc(S(C)(=O)=O)cc1,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3013989,CHEMBL570839,1-(4-fluorophenyl)-2-(4-(methylsulfonyl)phenyl)-3-(3-(6-(2-(methylsulfonyl)propan-2-yl)quinolin-8-yl)phenyl)propan-1-one,CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,200.0,nM,CC(C)(c1cc(-c2cccc(CC(C(=O)c3ccc(F)cc3)c3ccc(S(C)(=O)=O)cc3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3013990,CHEMBL571022,2-(4-(methylsulfonyl)phenyl)-3-(3-(6-(2-(methylsulfonyl)propan-2-yl)quinolin-8-yl)phenyl)-1-(pyridin-3-yl)propan-1-one,CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,200.0,nM,CC(C)(c1cc(-c2cccc(CC(C(=O)c3cccnc3)c3ccc(S(C)(=O)=O)cc3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3013991,CHEMBL586818,"4,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1-(3-(6-(2-(methylsulfonyl)propan-2-yl)quinolin-8-yl)phenyl)pentan-3-one",CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,700.0,nM,CC(C)(C)C(=O)C(Cc1cccc(-c2cc(C(C)(C)S(C)(=O)=O)cc3cccnc23)c1)c1ccc(S(C)(=O)=O)cc1,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3013992,CHEMBL579266,4-hydroxy-4-methyl-2-(4-(methylsulfonyl)phenyl)-1-(3-(6-(2-(methylsulfonyl)propan-2-yl)quinolin-8-yl)phenyl)pentan-3-one,CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,3600.0,nM,CC(C)(O)C(=O)C(Cc1cccc(-c2cc(C(C)(C)S(C)(=O)=O)cc3cccnc23)c1)c1ccc(S(C)(=O)=O)cc1,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3013993,CHEMBL567585,2-(4-(methylsulfonyl)phenyl)-3-(3-(6-(2-(methylsulfonyl)propan-2-yl)quinolin-8-yl)phenyl)propan-1-ol,CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,3600.0,nM,CC(C)(c1cc(-c2cccc(CC(CO)c3ccc(S(C)(=O)=O)cc3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3013994,CHEMBL568232,"2,2-dimethyl-3-(4-(methylsulfonyl)phenyl)-4-(3-(6-(2-(methylsulfonyl)propan-2-yl)quinolin-8-yl)phenyl)butan-1-ol",CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,1500.0,nM,CC(C)(CO)C(Cc1cccc(-c2cc(C(C)(C)S(C)(=O)=O)cc3cccnc23)c1)c1ccc(S(C)(=O)=O)cc1,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3013995,CHEMBL591662,2-methyl-3-(4-(methylsulfonyl)phenyl)-4-(3-(6-(2-(methylsulfonyl)propan-2-yl)quinolin-8-yl)phenyl)butan-2-ol,CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,6400.0,nM,CC(C)(O)C(Cc1cccc(-c2cc(C(C)(C)S(C)(=O)=O)cc3cccnc23)c1)c1ccc(S(C)(=O)=O)cc1,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3013996,CHEMBL578359,8-(3-(2-(methylsulfonyl)-2-(4-(methylsulfonyl)phenyl)ethyl)phenyl)-6-(2-(methylsulfonyl)propan-2-yl)quinoline,CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,6900.0,nM,CC(C)(c1cc(-c2cccc(CC(c3ccc(S(C)(=O)=O)cc3)S(C)(=O)=O)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3013997,CHEMBL568446,dimethyl 1-(4-(methylsulfonyl)phenyl)-2-(3-(6-(2-(methylsulfonyl)propan-2-yl)quinolin-8-yl)phenyl)ethylphosphonate,CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,11400.0,nM,COP(=O)(OC)C(Cc1cccc(-c2cc(C(C)(C)S(C)(=O)=O)cc3cccnc23)c1)c1ccc(S(C)(=O)=O)cc1,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3013998,CHEMBL372575,"(E)-8-(3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-(4-(methylsulfonyl)phenyl)vinyl)phenyl)-6-(2-(methylsulfonyl)propan-2-yl)quinoline",CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,200.0,nM,Cc1noc(/C(=C/c2cccc(-c3cc(C(C)(C)S(C)(=O)=O)cc4cccnc34)c2)c2ccc(S(C)(=O)=O)cc2)n1,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3013999,CHEMBL584475,3-fluoro-2-methyl-3-(4-(methylsulfonyl)phenyl)-4-(3-(6-(2-(methylsulfonyl)propan-2-yl)quinolin-8-yl)phenyl)butan-2-ol,CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,4600.0,nM,CC(C)(O)C(F)(Cc1cccc(-c2cc(C(C)(C)S(C)(=O)=O)cc3cccnc23)c1)c1ccc(S(C)(=O)=O)cc1,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3014000,CHEMBL585566,8-(3-(2-fluoro-2-(methylsulfonyl)-2-(4-(methylsulfonyl)phenyl)ethyl)phenyl)-6-(2-(methylsulfonyl)propan-2-yl)quinoline,CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,4500.0,nM,CC(C)(c1cc(-c2cccc(CC(F)(c3ccc(S(C)(=O)=O)cc3)S(C)(=O)=O)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3014001,CHEMBL1204129,"1,1-dicyclopropyl-2-fluoro-2-(4-(methylsulfonyl)phenyl)-3-(3-(6-(2-(methylsulfonyl)propan-2-yl)quinolin-8-yl)phenyl)propan-1-ol methylchloride",CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,2800.0,nM,CC(C)(c1cc(-c2cccc(CC(F)(c3ccc(S(C)(=O)=O)cc3)C(O)(C3CC3)C3CC3)c2)c2ncccc2c1)S(C)(=O)=O.CCl,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3014002,CHEMBL1204131,8-(3-(2-(cyclopropylsulfonyl)-2-fluoro-2-(4-(methylsulfonyl)phenyl)ethyl)phenyl)-6-(2-(methylsulfonyl)propan-2-yl)quinoline methylchloride,CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,3800.0,nM,CC(C)(c1cc(-c2cccc(CC(F)(c3ccc(S(C)(=O)=O)cc3)S(=O)(=O)C3CC3)c2)c2ncccc2c1)S(C)(=O)=O.CCl,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3014003,CHEMBL1204128,"1,1-dicyclopropyl-2-fluoro-2-(4-(methylsulfonyl)phenyl)-3-(3-(6-(2-(methylsulfonyl)propan-2-yl)quinolin-8-yl)phenyl)propan-1-ol hydrochloride",CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,2100.0,nM,CC(C)(c1cc(-c2cccc(CC(F)(c3ccc(S(C)(=O)=O)cc3)C(O)(C3CC3)C3CC3)c2)c2ncccc2c1)S(C)(=O)=O.Cl,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3014004,CHEMBL571060,"1,1-dicyclopropyl-2-fluoro-2-(4-(methylsulfonyl)phenyl)-3-(3-(6-(2-(methylsulfonyl)propan-2-yl)quinolin-8-yl)phenyl)propan-1-ol",CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,3800.0,nM,CC(C)(c1cc(-c2cccc(CC(F)(c3ccc(S(C)(=O)=O)cc3)C(O)(C3CC3)C3CC3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3014005,CHEMBL1204130,8-(3-(2-(cyclopropylsulfonyl)-2-fluoro-2-(4-(methylsulfonyl)phenyl)ethyl)phenyl)-6-(2-(methylsulfonyl)propan-2-yl)quinoline hydrochloride,CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,3700.0,nM,CC(C)(c1cc(-c2cccc(CC(F)(c3ccc(S(C)(=O)=O)cc3)S(=O)(=O)C3CC3)c2)c2ncccc2c1)S(C)(=O)=O.Cl,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3014006,CHEMBL570939,8-(3-(2-(cyclopropylsulfonyl)-2-fluoro-2-(4-(methylsulfonyl)phenyl)ethyl)phenyl)-6-(2-(methylsulfonyl)propan-2-yl)quinoline,CHEMBL1044682,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,3900.0,nM,CC(C)(c1cc(-c2cccc(CC(F)(c3ccc(S(C)(=O)=O)cc3)S(=O)(=O)C3CC3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1155332,Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5266,5269,10.1016/j.bmcl.2009.03.105,19640717.0,
3014398,CHEMBL584261,1-(2-chlorophenyl)-5-(4-chlorophenyl)-3-(1-isopropyl-1H-imidazol-4-yl)-4-methyl-1H-pyrazole,CHEMBL1046296,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1c(-c2cn(C(C)C)cn2)nn(-c2ccccc2Cl)c1-c1ccc(Cl)cc1,CHEMBL1155992,"Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5351,5354,10.1016/j.bmcl.2009.07.130,19683918.0,
3014655,CHEMBL567911,"1-[7-(3-Chloro-phenylamino)-3-methyl-1H-pyrrolo[2,3-c]pyridin-4-yl]-1-morpholin-4-yl-methanone",CHEMBL1048898,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4700.0,nM,Cc1c[nH]c2c(Nc3cccc(Cl)c3)ncc(C(=O)N3CCOCC3)c12,CHEMBL1156052,"Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.",J. Med. Chem.,2009.0,52,19,5785,5788,10.1021/jm9009857,19743867.0,
3014673,CHEMBL567292,"(4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl)(morpholino)methanone",CHEMBL1048898,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,42000.0,nM,Cn1ccc2c(Nc3cccc(Cl)c3)ncc(C(=O)N3CCOCC3)c21,CHEMBL1156052,"Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.",J. Med. Chem.,2009.0,52,19,5785,5788,10.1021/jm9009857,19743867.0,
3018651,CHEMBL576457,"N-(4-tert-butylbenzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CC1(CC(=O)NCc2ccc(C(C)(C)C)cc2)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018653,CHEMBL565361,"N-(3-methoxybenzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,4200.0,nM,COc1cccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)c1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018654,CHEMBL578968,"N-(2-ethoxybenzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CCOc1ccccc1CNC(=O)CC1(C)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018655,CHEMBL579199,"N-(3,5-dimethoxybenzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,COc1cc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc(OC)c1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018656,CHEMBL579200,"2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)-N-(3,4,5-trimethoxybenzyl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,COc1cc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc(OC)c1OC,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018657,CHEMBL567169,"2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)-N-(3-(trifluoromethyl)benzyl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,3300.0,nM,CC1(CC(=O)NCc2cccc(C(F)(F)F)c2)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018658,CHEMBL583442,"N-(4-(difluoromethoxy)benzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CC1(CC(=O)NCc2ccc(OC(F)F)cc2)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018659,CHEMBL568242,"2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)-N-(2-(trifluoromethoxy)benzyl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CC1(CC(=O)NCc2ccccc2OC(F)(F)F)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018660,CHEMBL565983,"2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)-N-(4-(trifluoromethoxy)benzyl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,4000.0,nM,CC1(CC(=O)NCc2ccc(OC(F)(F)F)cc2)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018661,CHEMBL577694,"N-(3-chlorobenzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,3400.0,nM,CC1(CC(=O)NCc2cccc(Cl)c2)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018662,CHEMBL572184,"N-(3-bromobenzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,3700.0,nM,CC1(CC(=O)NCc2cccc(Br)c2)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018666,CHEMBL565362,"N-(4-bromo-2-fluorobenzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,3900.0,nM,CC1(CC(=O)NCc2ccc(Br)cc2F)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018667,CHEMBL567374,"tert-butyl 3-(2-(2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamido)ethyl)phenylcarbamate",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CC(C)(C)OC(=O)Nc1cccc(CCNC(=O)CC2(C)CC3(CCCCC3)OO2)c1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018668,CHEMBL577470,"4-((2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamido)methyl)benzoic acid",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CC1(CC(=O)NCc2ccc(C(=O)O)cc2)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018669,CHEMBL578547,"methyl 4-((2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamido)methyl)benzoate",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,COC(=O)c1ccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018670,CHEMBL567376,"N-(2-aminobenzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CC1(CC(=O)NCc2ccccc2N)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018671,CHEMBL578588,"N-(4-(dimethylamino)benzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CN(C)c1ccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018672,CHEMBL568444,"2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)-N-(4-nitrobenzyl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CC1(CC(=O)NCc2ccc([N+](=O)[O-])cc2)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018673,CHEMBL578594,"2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)-N-(4-(methylthio)benzyl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CSc1ccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018674,CHEMBL568456,"2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)-N-(4-sulfamoylbenzyl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CC1(CC(=O)NCc2ccc(S(N)(=O)=O)cc2)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018678,CHEMBL578578,"2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)-N-(2-(piperidin-1-yl)benzyl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CC1(CC(=O)NCc2ccccc2N2CCCCC2)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018679,CHEMBL578579,"2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)-N-(4-morpholinobenzyl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CC1(CC(=O)NCc2ccc(N3CCOCC3)cc2)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018685,CHEMBL565360,"N-(2-(2-(hydroxymethyl)phenylthio)benzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,2200.0,nM,CC1(CC(=O)NCc2ccccc2Sc2ccccc2CO)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018686,CHEMBL584886,"N-((2,3-dihydrobenzofuran-6-yl)methyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CC1(CC(=O)NCc2ccc3c(c2)OCC3)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018687,CHEMBL585191,"N-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CC1(CC(=O)NCc2ccc3c(c2)OCCO3)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018688,CHEMBL567582,"N-((2H-benzo[b][1,4]dioxepin-8-yl)methyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CC1(CC(=O)NCc2ccc3c(c2)OCC=CO3)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018689,CHEMBL568438,"2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)-N-(pyridin-2-ylmethyl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CC1(CC(=O)NCc2ccccn2)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3018690,CHEMBL579016,"2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)-N-(pyridin-4-ylmethyl)acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CC1(CC(=O)NCc2ccncc2)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3019072,CHEMBL567570,"(R)-1-(4-Benzoyl-2-methylpiperazin-1-yl)-2-(1H-indol-3-yl)-ethane-1,2-dione",CHEMBL1039965,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,=,5200.0,nM,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccccc12,CHEMBL1156066,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,2009.0,52,23,7778,7787,10.1021/jm900843g,19769332.0,
3019078,CHEMBL585487,"(R)-1-(4-Benzoyl-2-methylpiperazin-1-yl)-2-(1H-pyrrolo[3,2-b]-pyridin-3-yl)ethane-1,2-dione",CHEMBL1039965,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,>,40000.0,nM,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccnc12,CHEMBL1156066,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,2009.0,52,23,7778,7787,10.1021/jm900843g,19769332.0,
3019084,CHEMBL585498,"(R)-1-(4-Benzoyl-2-methylpiperazin-1-yl)-2-(1H-pyrrolo[3,2-c]-pyridin-3-yl)ethane-1,2-dione",CHEMBL1039965,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,>,40000.0,nM,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccncc12,CHEMBL1156066,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,2009.0,52,23,7778,7787,10.1021/jm900843g,19769332.0,
3019090,CHEMBL583867,"(R)-1-(4-Benzoyl-2-methylpiperazin-1-yl)-2-(1H-pyrrolo[2,3-c]-pyridin-3-yl)ethane-1,2-dione",CHEMBL1039965,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,=,17000.0,nM,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cnccc12,CHEMBL1156066,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,2009.0,52,23,7778,7787,10.1021/jm900843g,19769332.0,
3019096,CHEMBL442078,"(R)-1-(4-benzoyl-2-methylpiperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione",CHEMBL1039965,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,=,7900.0,nM,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ncccc12,CHEMBL1156066,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,2009.0,52,23,7778,7787,10.1021/jm900843g,19769332.0,
3019102,CHEMBL337301,"1-((R)-4-Benzoyl-2-methyl-piperazin-1-yl)-2-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)-ethane-1,2-dione",CHEMBL1039965,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,>,40000.0,nM,COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)C[C@H]3C)c12,CHEMBL1156066,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,2009.0,52,23,7778,7787,10.1021/jm900843g,19769332.0,
3019108,CHEMBL238103,"1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione",CHEMBL1039965,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,=,30000.0,nM,COc1ncc(OC)c2c(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c[nH]c12,CHEMBL1156066,"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.",J. Med. Chem.,2009.0,52,23,7778,7787,10.1021/jm900843g,19769332.0,
3020126,CHEMBL462360,"N-[2-(7-Chloro-quinolin-4-ylamino)-ethyl]-2-(3-methyl-1,2-dioxa-spiro[4.5]dec-3-yl)-acetamide",CHEMBL1045201,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,CC1(CC(=O)NCCNc2ccnc3cc(Cl)ccc23)CC2(CCCCC2)OO1,CHEMBL1156001,"Synthesis and in vitro DMPK profiling of a 1,2-dioxolane-based library with activity against Plasmodium falciparum.",Bioorg. Med. Chem. Lett.,2009.0,19,19,5657,5660,10.1016/j.bmcl.2009.08.024,19699641.0,
3023244,CHEMBL571581,4-(4-methyl-1H-indol-5-ylamino)-5-(5-((4-methylpiperazin-1-yl)methyl)benzofuran-2-yl)nicotinonitrile,CHEMBL1047205,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1c(Nc2c(C#N)cncc2-c2cc3cc(CN4CCN(C)CC4)ccc3o2)ccc2[nH]ccc12,CHEMBL1156015,C-5 substituted heteroaryl-3-pyridinecarbonitriles as PKCtheta inhibitors: part II.,Bioorg. Med. Chem. Lett.,2009.0,19,19,5799,5802,10.1016/j.bmcl.2009.07.113,19703774.0,
3061390,CHEMBL595632,(2E)-3-[2-[2-(2-Naphthyl)ethoxy]-4-(1H-pyrazol-1-ylmethyl)phenyl]acrylic acid,CHEMBL1073249,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,12800.0,nM,O=C(O)/C=C/c1ccc(Cn2cccn2)cc1OCCc1ccc2ccccc2c1,CHEMBL1152570,Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists.,Bioorg. Med. Chem.,2009.0,17,18,6567,6582,10.1016/j.bmc.2009.08.007,19700331.0,
3061394,CHEMBL605833,3-[2-[2-(2-Naphthyl)ethoxy]-4-(1H-pyrazol-1-ylmethyl)phenyl]propanoic acid,CHEMBL1073249,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,30000.0,nM,O=C(O)CCc1ccc(Cn2cccn2)cc1OCCc1ccc2ccccc2c1,CHEMBL1152570,Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists.,Bioorg. Med. Chem.,2009.0,17,18,6567,6582,10.1016/j.bmc.2009.08.007,19700331.0,
3062538,CHEMBL596515,(2E)-3-{4-(1H-Imidazol-1-ylmethyl)-2-[2-(2-naphthyl)ethoxy]phenyl}acrylic acid,CHEMBL1073249,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,1000.0,nM,O=C(O)/C=C/c1ccc(Cn2ccnc2)cc1OCCc1ccc2ccccc2c1,CHEMBL1152570,Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists.,Bioorg. Med. Chem.,2009.0,17,18,6567,6582,10.1016/j.bmc.2009.08.007,19700331.0,
3079512,CHEMBL536636,"dispiro[adamantane-2,2'-[1,3,5]trioxolane-4',1''-cyclohexane]-4''-ylmethanamine",CHEMBL1050353,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,17000.0,nM,NC[C@H]1CC[C@]2(CC1)OOC1(O2)C2CC3CC(C2)CC1C3,CHEMBL1153189,The comparative antimalarial properties of weak base and neutral synthetic ozonides.,Bioorg. Med. Chem. Lett.,2010.0,20,2,563,566,10.1016/j.bmcl.2009.11.088,19962893.0,
3081305,CHEMBL578928,GNF-Pf-2094,CHEMBL1069995,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,Cc1cc(NC2CCCCC2)nc(NCc2ccccc2)n1,CHEMBL1153120,"Synthesis and antiplasmodial activity of novel 2,4-diaminopyrimidines.",Bioorg. Med. Chem. Lett.,2010.0,20,1,228,231,10.1016/j.bmcl.2009.10.133,19914064.0,
3082330,CHEMBL16596,"3-[3-tert-Butylsulfanyl-1-(4-chloro-benzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid",CHEMBL1070651,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,500.0,nM,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12,CHEMBL1153124,"5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.",Bioorg. Med. Chem. Lett.,2010.0,20,1,213,217,10.1016/j.bmcl.2009.10.131,19914828.0,
3082367,CHEMBL595092,"(S)-3-(5-((1-acetylindolin-2-yl)methoxy)-3-(tert-butylthio)-1-(4-(5-methoxypyrimidin-2-yl)benzyl)-1H-indol-2-yl)-2,2-dimethylpropanoic acid",CHEMBL1070651,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3700.0,nM,COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OC[C@@H]5Cc6ccccc6N5C(C)=O)ccc43)cc2)nc1,CHEMBL1153124,"5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.",Bioorg. Med. Chem. Lett.,2010.0,20,1,213,217,10.1016/j.bmcl.2009.10.131,19914828.0,
3082677,CHEMBL589135,"N-(2,4-dichlorobenzyl)-4-phenoxypiperidine-1-carboxamide",CHEMBL1074711,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1400.0,nM,O=C(NCc1ccc(Cl)cc1Cl)N1CCC(Oc2ccccc2)CC1,CHEMBL1153202,Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase.,Bioorg. Med. Chem. Lett.,2010.0,20,2,571,575,10.1016/j.bmcl.2009.11.091,19969453.0,
3082684,CHEMBL589136,"N-(2,4-dichlorobenzyl)-4-(pyrimidin-2-yloxy)piperidine-1-carboxamide",CHEMBL1074711,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,20000.0,nM,O=C(NCc1ccc(Cl)cc1Cl)N1CCC(Oc2ncccn2)CC1,CHEMBL1153202,Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase.,Bioorg. Med. Chem. Lett.,2010.0,20,2,571,575,10.1016/j.bmcl.2009.11.091,19969453.0,
3082691,CHEMBL590600,1-4-(1H-pyrrol-1-yl)-N-[4-(trifluoromethoxy)phenyl]-piperidinecarboxamide,CHEMBL1074711,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,11000.0,nM,O=C(Nc1ccc(OC(F)(F)F)cc1)N1CCC(n2cccc2)CC1,CHEMBL1153202,Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase.,Bioorg. Med. Chem. Lett.,2010.0,20,2,571,575,10.1016/j.bmcl.2009.11.091,19969453.0,
3082698,CHEMBL608263,"4-(1-(2,4-dichlorobenzylcarbamoyl)piperidin-4-yloxy)benzoic acid",CHEMBL1074711,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,20000.0,nM,O=C(O)c1ccc(OC2CCN(C(=O)NCc3ccc(Cl)cc3Cl)CC2)cc1,CHEMBL1153202,Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase.,Bioorg. Med. Chem. Lett.,2010.0,20,2,571,575,10.1016/j.bmcl.2009.11.091,19969453.0,
3084251,CHEMBL558664,(S)-2-chloro-4-((1-methylpyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1100.0,nM,CN1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084252,CHEMBL591092,(S)-2-chloro-4-((1-(methylsulfonyl)pyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,330.0,nM,CS(=O)(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084253,CHEMBL590863,(S)-2-chloro-4-((1-(ethylsulfonyl)pyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,350.0,nM,CCS(=O)(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084254,CHEMBL590610,(S)-2-chloro-4-((1-(isopropylsulfonyl)pyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,280.0,nM,CC(C)S(=O)(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084255,CHEMBL592755,(S)-2-chloro-4-((1-(propylsulfonyl)pyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,110.0,nM,CCCS(=O)(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084256,CHEMBL602851,(S)-2-chloro-4-((1-(isobutylsulfonyl)pyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,160.0,nM,CC(C)CS(=O)(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084258,CHEMBL591072,(S)-4-(benzyl(1-(methylsulfonyl)pyrrolidin-3-yl)amino)-2-chlorobenzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2400.0,nM,CS(=O)(=O)N1CC[C@H](N(Cc2ccccc2)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084260,CHEMBL590835,(S)-2-chloro-4-((2-cyanobenzyl)(1-(methylsulfonyl)pyrrolidin-3-yl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1500.0,nM,CS(=O)(=O)N1CC[C@H](N(Cc2ccccc2C#N)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084261,CHEMBL584422,(S)-2-chloro-4-((2-fluorobenzyl)(1-(methylsulfonyl)pyrrolidin-3-yl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1700.0,nM,CS(=O)(=O)N1CC[C@H](N(Cc2ccccc2F)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084262,CHEMBL602745,(S)-2-chloro-4-((2-chlorobenzyl)(1-(methylsulfonyl)pyrrolidin-3-yl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,870.0,nM,CS(=O)(=O)N1CC[C@H](N(Cc2ccccc2Cl)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084263,CHEMBL592017,(S)-4-((2-bromobenzyl)(1-(methylsulfonyl)pyrrolidin-3-yl)amino)-2-chlorobenzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,690.0,nM,CS(=O)(=O)N1CC[C@H](N(Cc2ccccc2Br)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084264,CHEMBL601500,(S)-2-chloro-4-((2-methylbenzyl)(1-(methylsulfonyl)pyrrolidin-3-yl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2400.0,nM,Cc1ccccc1CN(c1ccc(C#N)c(Cl)c1)[C@H]1CCN(S(C)(=O)=O)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084265,CHEMBL592509,(S)-methyl 3-(benzyl(3-chloro-4-cyanophenyl)amino)pyrrolidine-1-carboxylate,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1300.0,nM,COC(=O)N1CC[C@H](N(Cc2ccccc2)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084266,CHEMBL590853,(S)-methyl 3-((3-chloro-4-cyanophenyl)(2-(trifluoromethyl)benzyl)amino)pyrrolidine-1-carboxylate,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,160.0,nM,COC(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084267,CHEMBL592289,(S)-methyl 3-((3-chloro-4-cyanophenyl)(2-fluorobenzyl)amino)pyrrolidine-1-carboxylate,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1400.0,nM,COC(=O)N1CC[C@H](N(Cc2ccccc2F)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084268,CHEMBL592016,(S)-methyl 3-((3-chloro-4-cyanophenyl)(2-methylbenzyl)amino)pyrrolidine-1-carboxylate,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,680.0,nM,COC(=O)N1CC[C@H](N(Cc2ccccc2C)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084269,CHEMBL592510,(S)-methyl 3-((3-chloro-4-cyanophenyl)(2-chlorobenzyl)amino)pyrrolidine-1-carboxylate,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1100.0,nM,COC(=O)N1CC[C@H](N(Cc2ccccc2Cl)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084270,CHEMBL592745,"(S)-methyl 3-((3-chloro-4-cyanophenyl)(2,3-difluorobenzyl)amino)pyrrolidine-1-carboxylate",CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1200.0,nM,COC(=O)N1CC[C@H](N(Cc2cccc(F)c2F)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084271,CHEMBL591327,(S)-methyl 3-((3-chloro-4-cyanophenyl)(5-fluoro-2-methylbenzyl)amino)pyrrolidine-1-carboxylate,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1100.0,nM,COC(=O)N1CC[C@H](N(Cc2cc(F)ccc2C)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084272,CHEMBL601472,(S)-ethyl 3-((3-chloro-4-cyanophenyl)(5-fluoro-2-methylbenzyl)amino)pyrrolidine-1-carboxylate,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1500.0,nM,CCOC(=O)N1CC[C@H](N(Cc2cc(F)ccc2C)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084273,CHEMBL601055,(S)-isopropyl 3-((3-chloro-4-cyanophenyl)(5-fluoro-2-methylbenzyl)amino)pyrrolidine-1-carboxylate,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1100.0,nM,Cc1ccc(F)cc1CN(c1ccc(C#N)c(Cl)c1)[C@H]1CCN(C(=O)OC(C)C)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084274,CHEMBL590611,(S)-4-((1-acetylpyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)-2-chlorobenzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1800.0,nM,CC(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084275,CHEMBL600465,(S)-2-chloro-4-((1-propionylpyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1200.0,nM,CCC(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084276,CHEMBL589624,(S)-2-chloro-4-((1-isobutyrylpyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,720.0,nM,CC(C)C(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084277,CHEMBL592746,(S)-2-chloro-4-((1-pivaloylpyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,440.0,nM,CC(C)(C)C(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084278,CHEMBL607030,(S)-4-((2-bromobenzyl)(1-propionylpyrrolidin-3-yl)amino)-2-chlorobenzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3000.0,nM,CCC(=O)N1CC[C@H](N(Cc2ccccc2Br)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084279,CHEMBL592532,(S)-2-chloro-4-((2-methylbenzyl)(1-propionylpyrrolidin-3-yl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4000.0,nM,CCC(=O)N1CC[C@H](N(Cc2ccccc2C)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084280,CHEMBL590100,(S)-2-chloro-4-((5-fluoro-2-methylbenzyl)(1-propionylpyrrolidin-3-yl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2900.0,nM,CCC(=O)N1CC[C@H](N(Cc2cc(F)ccc2C)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084281,CHEMBL589625,"(S)-2-chloro-4-((2,5-dichlorobenzyl)(1-propionylpyrrolidin-3-yl)amino)benzonitrile",CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2900.0,nM,CCC(=O)N1CC[C@H](N(Cc2cc(Cl)ccc2Cl)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084282,CHEMBL605078,2-chloro-4-(((S)-1-((S)-2-hydroxypropanoyl)pyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2400.0,nM,C[C@H](O)C(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084283,CHEMBL600466,2-chloro-4-(((S)-1-((S)-2-hydroxypropanoyl)pyrrolidin-3-yl)(2-methylbenzyl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,14000.0,nM,Cc1ccccc1CN(c1ccc(C#N)c(Cl)c1)[C@H]1CCN(C(=O)[C@H](C)O)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084284,CHEMBL585848,2-chloro-4-((5-fluoro-2-methylbenzyl)((S)-1-((S)-2-hydroxypropanoyl)pyrrolidin-3-yl)amino)benzonitrile,CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,11000.0,nM,Cc1ccc(F)cc1CN(c1ccc(C#N)c(Cl)c1)[C@H]1CCN(C(=O)[C@H](C)O)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3084285,CHEMBL590593,"2-chloro-4-((2,5-dichlorobenzyl)((S)-1-((S)-2-hydroxypropanoyl)pyrrolidin-3-yl)amino)benzonitrile",CHEMBL1072635,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7900.0,nM,C[C@H](O)C(=O)N1CC[C@H](N(Cc2cc(Cl)ccc2Cl)c2ccc(C#N)c(Cl)c2)C1,CHEMBL1153137,Improving the developability profile of pyrrolidine progesterone receptor partial agonists.,Bioorg. Med. Chem. Lett.,2010.0,20,1,371,374,10.1016/j.bmcl.2009.10.092,19926282.0,
3087024,CHEMBL593490,(S)-1-(6-(furan-3-yl)-5-(3-methyl-1H-indazol-5-yl)pyridin-3-yloxy)-3-(1H-indol-3-yl)propan-2-amine,CHEMBL1071328,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,500.0,nM,Cc1[nH]nc2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12,CHEMBL1153227,"2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.",Bioorg. Med. Chem. Lett.,2010.0,20,2,679,683,10.1016/j.bmcl.2009.11.060,20005102.0,
3088665,CHEMBL376487,1-cyclohexyl-2-(furan-3-yl)-N-((S)-2-(5-hydroxy-1H-indol-3-yl)-1-(thiazol-4-yl)ethyl)-1H-benzo[d]imidazole-5-carboxamide,CHEMBL1049513,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9,IC50,=,2300.0,nM,O=C(N[C@@H](Cc1c[nH]c2ccc(O)cc12)c1cscn1)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1,CHEMBL1153157,Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization.,Bioorg. Med. Chem. Lett.,2010.0,20,1,196,200,10.1016/j.bmcl.2009.10.136,19945870.0,
3088666,CHEMBL590850,(R)-3-(4-(2-(1-cyclohexyl-2-(furan-3-yl)-1H-benzo[d]imidazole-5-carboxamido)propanamido)phenyl)acrylic acid,CHEMBL1049513,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9,IC50,>,30000.0,nM,C[C@@H](NC(=O)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1)C(=O)Nc1ccc(/C=C/C(=O)O)cc1,CHEMBL1153157,Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization.,Bioorg. Med. Chem. Lett.,2010.0,20,1,196,200,10.1016/j.bmcl.2009.10.136,19945870.0,
3089245,CHEMBL596579,"N-(6-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)-6-azaspiro[2.5]octan-1-yl)-1,1,1-trifluoromethanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2000.0,nM,O=S(=O)(c1ccccc1F)c1cc(Cl)ccc1S(=O)(=O)N1CCC2(CC1)CC2NS(=O)(=O)C(F)(F)F,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089252,CHEMBL245742,(S)-N-(1-(4-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)phenyl)ethyl)trifluoromethanesulfonamide,CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3500.0,nM,C[C@H](NS(=O)(=O)C(F)(F)F)c1ccc(S(=O)(=O)c2ccc(Cl)cc2S(=O)(=O)c2ccccc2F)cc1,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089253,CHEMBL603321,"N-((1-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)piperidin-4-yl)methyl)-1,1,1-trifluoromethanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,14000.0,nM,O=S(=O)(c1ccccc1F)c1cc(Cl)ccc1S(=O)(=O)N1CCC(CNS(=O)(=O)C(F)(F)F)CC1,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089254,CHEMBL596133,N-(6-(5-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)-6-azaspiro[2.5]octan-1-yl)methanesulfonamide,CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,13000.0,nM,CS(=O)(=O)NC1CC12CCN(S(=O)(=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1F)CC2,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089255,CHEMBL592896,"N-(6-(5-chloro-2-(pyridin-2-ylsulfonyl)phenylsulfonyl)-6-azaspiro[2.5]octan-1-yl)-1,1,1-trifluoromethanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,15000.0,nM,O=S(=O)(c1ccccn1)c1ccc(Cl)cc1S(=O)(=O)N1CCC2(CC1)CC2NS(=O)(=O)C(F)(F)F,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089256,CHEMBL595223,"1,1,1-trifluoro-N-(6-(2-(pyridin-2-ylsulfonyl)-5-(trifluoromethoxy)phenylsulfonyl)-6-azaspiro[2.5]octan-1-yl)methanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,30000.0,nM,O=S(=O)(c1ccccn1)c1ccc(OC(F)(F)F)cc1S(=O)(=O)N1CCC2(CC1)CC2NS(=O)(=O)C(F)(F)F,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089971,CHEMBL596387,"N-((1-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)-4-methylpiperidin-4-yl)methyl)-1,1,1-trifluoromethanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2000.0,nM,CC1(CNS(=O)(=O)C(F)(F)F)CCN(S(=O)(=O)c2ccc(Cl)cc2S(=O)(=O)c2ccccc2F)CC1,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089972,CHEMBL596388,"N-((1-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)-4-ethylpiperidin-4-yl)methyl)-1,1,1-trifluoromethanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2000.0,nM,CCC1(CNS(=O)(=O)C(F)(F)F)CCN(S(=O)(=O)c2ccc(Cl)cc2S(=O)(=O)c2ccccc2F)CC1,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089973,CHEMBL595481,"N-((1-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)-4-propylpiperidin-4-yl)methyl)-1,1,1-trifluoromethanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2000.0,nM,CCCC1(CNS(=O)(=O)C(F)(F)F)CCN(S(=O)(=O)c2ccc(Cl)cc2S(=O)(=O)c2ccccc2F)CC1,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089974,CHEMBL605932,"N-((1-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)-4-isopropylpiperidin-4-yl)methyl)-1,1,1-trifluoromethanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2000.0,nM,CC(C)C1(CNS(=O)(=O)C(F)(F)F)CCN(S(=O)(=O)c2ccc(Cl)cc2S(=O)(=O)c2ccccc2F)CC1,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089975,CHEMBL594300,"N-((1-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)-4-(hydroxymethyl)piperidin-4-yl)methyl)-1,1,1-trifluoromethanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1000.0,nM,O=S(=O)(c1ccccc1F)c1cc(Cl)ccc1S(=O)(=O)N1CCC(CO)(CNS(=O)(=O)C(F)(F)F)CC1,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089976,CHEMBL593595,"N-((1-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)-4-(1-hydroxyethyl)piperidin-4-yl)methyl)-1,1,1-trifluoromethanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1000.0,nM,CC(O)C1(CNS(=O)(=O)C(F)(F)F)CCN(S(=O)(=O)c2ccc(Cl)cc2S(=O)(=O)c2ccccc2F)CC1,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089977,CHEMBL593596,"N-((1-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)-4-fluoropiperidin-4-yl)methyl)-1,1,1-trifluoromethanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7000.0,nM,O=S(=O)(c1ccccc1F)c1cc(Cl)ccc1S(=O)(=O)N1CCC(F)(CNS(=O)(=O)C(F)(F)F)CC1,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089978,CHEMBL593838,"N-((1-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)-4-cyanopiperidin-4-yl)methyl)-1,1,1-trifluoromethanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1000.0,nM,N#CC1(CNS(=O)(=O)C(F)(F)F)CCN(S(=O)(=O)c2ccc(Cl)cc2S(=O)(=O)c2ccccc2F)CC1,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089979,CHEMBL593823,allyl(1-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)-4-((trifluoromethylsulfonamido)methyl)piperidin-4-yl)methylcarbamate,CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,13000.0,nM,C=CCOC(=O)NCC1(CNS(=O)(=O)C(F)(F)F)CCN(S(=O)(=O)c2ccc(Cl)cc2S(=O)(=O)c2ccccc2F)CC1,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089980,CHEMBL607032,"N-((4-(aminomethyl)-1-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)piperidin-4-yl)methyl)-1,1,1-trifluoromethanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,23000.0,nM,NCC1(CNS(=O)(=O)C(F)(F)F)CCN(S(=O)(=O)c2ccc(Cl)cc2S(=O)(=O)c2ccccc2F)CC1,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089981,CHEMBL595913,"N-((1-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)-4-phenylpiperidin-4-yl)methyl)-1,1,1-trifluoromethanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,300.0,nM,O=S(=O)(c1ccccc1F)c1cc(Cl)ccc1S(=O)(=O)N1CCC(CNS(=O)(=O)C(F)(F)F)(c2ccccc2)CC1,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089982,CHEMBL596133,N-(6-(5-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)-6-azaspiro[2.5]octan-1-yl)methanesulfonamide,CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,12000.0,nM,CS(=O)(=O)NC1CC12CCN(S(=O)(=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1F)CC2,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089983,CHEMBL592895,"1,1,1-trifluoro-N-(6-(2-(pyridin-2-ylsulfonyl)phenylsulfonyl)-6-azaspiro[2.5]octan-1-yl)methanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,30000.0,nM,O=S(=O)(c1ccccn1)c1ccccc1S(=O)(=O)N1CCC2(CC1)CC2NS(=O)(=O)C(F)(F)F,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089984,CHEMBL595705,"N-(6-(5-chloro-2-(4-methoxyphenylsulfonyl)phenylsulfonyl)-6-azaspiro[2.5]octan-1-yl)-1,1,1-trifluoromethanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1000.0,nM,COc1ccc(S(=O)(=O)c2ccc(Cl)cc2S(=O)(=O)N2CCC3(CC2)CC3NS(=O)(=O)C(F)(F)F)cc1,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089985,CHEMBL595706,"1,1,1-trifluoro-N-(6-(2-(2-fluorophenylsulfonyl)-5-(trifluoromethyl)phenylsulfonyl)-6-azaspiro[2.5]octan-1-yl)methanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1000.0,nM,O=S(=O)(c1ccccc1F)c1ccc(C(F)(F)F)cc1S(=O)(=O)N1CCC2(CC1)CC2NS(=O)(=O)C(F)(F)F,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089986,CHEMBL596135,"1,1,1-trifluoro-N-(6-(2-(pyridin-2-ylsulfonyl)-5-(trifluoromethyl)phenylsulfonyl)-6-azaspiro[2.5]octan-1-yl)methanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1000.0,nM,O=S(=O)(c1ccccn1)c1ccc(C(F)(F)F)cc1S(=O)(=O)N1CCC2(CC1)CC2NS(=O)(=O)C(F)(F)F,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3089987,CHEMBL596356,"1,1,1-trifluoro-N-(6-(2-(2-fluorophenylsulfonyl)-5-(trifluoromethoxy)phenylsulfonyl)-6-azaspiro[2.5]octan-1-yl)methanesulfonamide",CHEMBL1071215,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,30000.0,nM,O=S(=O)(c1ccccc1F)c1ccc(OC(F)(F)F)cc1S(=O)(=O)N1CCC2(CC1)CC2NS(=O)(=O)C(F)(F)F,CHEMBL1153236,Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,2,608,611,10.1016/j.bmcl.2009.11.084,20005710.0,
3095588,CHEMBL605162,"2-{1'-[(adamantan-2-yl)carbamoyl]-7-bromo-2,3-dihydrospiro[indene-1,4'-piperidine]-3-yl}acetic acid",CHEMBL1074765,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,15000.0,nM,O=C(O)CC1CC2(CCN(C(=O)NC3C4CC5CC(C4)CC3C5)CC2)c2c(Br)cccc21,CHEMBL1156845,Spirocyclic ureas: orally bioavailable 11 beta-HSD1 inhibitors identified by computer-aided drug design.,Bioorg. Med. Chem. Lett.,2010.0,20,3,881,886,10.1016/j.bmcl.2009.12.082,20064717.0,
3097566,CHEMBL590078,"(+)-7-methyl-3,4,4a,5-tetrahydro-1H-pyrazino[1,2-a]quinazolin-6(2H)-one",CHEMBL1067824,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,40000.0,nM,Cc1cccc2c1C(=O)NC1CNCCN21,CHEMBL1158511,Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.,Bioorg. Med. Chem. Lett.,2010.0,20,3,1128,1133,10.1016/j.bmcl.2009.12.014,20022752.0,
3099800,CHEMBL606202,3-cyclohexyl-2-(furan-3-yl)-1-(2-morpholino-2-oxoethyl)-1H-indole-6-carboxylic acid,CHEMBL1067065,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>=,24000.0,nM,O=C(O)c1ccc2c(C3CCCCC3)c(-c3ccoc3)n(CC(=O)N3CCOCC3)c2c1,CHEMBL1156857,N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies.,Bioorg. Med. Chem. Lett.,2010.0,20,3,857,861,10.1016/j.bmcl.2009.12.101,20074949.0,
3102672,CHEMBL602483,"(S)-1,1,1-trifluoro-3-((S)-3-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)-8-(3-(trifluoromethoxy)phenyl)-2H-benzo[b][1,4]oxazin-4(3H)-yl)propan-2-ol",CHEMBL1068253,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,100000.0,nM,O[C@@H](CN1c2cccc(-c3cccc(OC(F)(F)F)c3)c2OC[C@@H]1c1cccc(OC(F)(F)C(F)F)c1)C(F)(F)F,CHEMBL1156872,"Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors.",Bioorg. Med. Chem. Lett.,2010.0,20,4,1432,1435,10.1016/j.bmcl.2009.12.096,20089400.0,
3124441,CHEMBL590472,"exo-6-[(Cyclobutyloxy)methyl]-6-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane",CHEMBL1068896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,10000.0,nM,Clc1ccc([C@]2(COC3CCC3)[C@H]3CNC[C@H]32)cc1Cl,CHEMBL1157620,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,2010.0,53,6,2534,2551,10.1021/jm901818u,20170186.0,
3124442,CHEMBL598644,"exo-6-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane",CHEMBL1068896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,10000.0,nM,Clc1ccc([C@]2(COCC3CC3)[C@H]3CNC[C@H]32)cc1Cl,CHEMBL1157620,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,2010.0,53,6,2534,2551,10.1021/jm901818u,20170186.0,
3124443,CHEMBL2021582,"exo-6-(3,4-dichlorophenyl)-6-(ethoxymethyl)-3-azabicyclo[3.1.0]hexane",CHEMBL1068896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,5000.0,nM,CCOC[C@@]1(c2ccc(Cl)c(Cl)c2)[C@H]2CCC[C@H]21,CHEMBL1157620,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,2010.0,53,6,2534,2551,10.1021/jm901818u,20170186.0,
3124444,CHEMBL598215,exo-6-[(Methyloxy)methyl]-1-(2-naphthalenyl)-3-azabicyclo[3.1.0]-hexane,CHEMBL1068896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,4000.0,nM,COC[C@@H]1[C@H]2CNC[C@]21c1ccc2ccccc2c1,CHEMBL1157620,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,2010.0,53,6,2534,2551,10.1021/jm901818u,20170186.0,
3124445,CHEMBL605209,"exo-1-(3,4-Dichlorophenyl)-6-{[(1-methylethyl)oxy]methyl}-3-azabicyclo[3.1.0]hexane",CHEMBL1068896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,8000.0,nM,CC(C)OC[C@@H]1[C@H]2CNC[C@]21c1ccc(Cl)c(Cl)c1,CHEMBL1157620,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,2010.0,53,6,2534,2551,10.1021/jm901818u,20170186.0,
3124446,CHEMBL2021577,"(1R,5R,6R)-1-(3,4-dichlorophenyl)-6-(ethoxymethyl)-3-azabicyclo[3.1.0]hexane",CHEMBL1068896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,9000.0,nM,CCOC[C@H]1[C@@H]2CNC[C@@]21C,CHEMBL1157620,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,2010.0,53,6,2534,2551,10.1021/jm901818u,20170186.0,
3124447,CHEMBL608151,"exo-rac-1-(3,4-dichlorophenyl)-6-(ethoxymethyl)-3-azabicyclo[3.1.0]hexane",CHEMBL1068896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,9000.0,nM,CCOC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1,CHEMBL1157620,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,2010.0,53,6,2534,2551,10.1021/jm901818u,20170186.0,
3124448,CHEMBL608151,"exo-rac-1-(3,4-dichlorophenyl)-6-(ethoxymethyl)-3-azabicyclo[3.1.0]hexane",CHEMBL1068896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,9000.0,nM,CCOC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1,CHEMBL1157620,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,2010.0,53,6,2534,2551,10.1021/jm901818u,20170186.0,
3124449,CHEMBL596809,"exo-rac-1-(3,4-dichlorophenyl)-6-(methoxymethyl)-3-azabicyclo[3.1.0]hexane",CHEMBL1068896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,6000.0,nM,COC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1,CHEMBL1157620,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,2010.0,53,6,2534,2551,10.1021/jm901818u,20170186.0,
3124450,CHEMBL610795,"exo-6-{[(Cyclopropylmethyl)oxy]methyl}-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane",CHEMBL1068896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,10000.0,nM,Clc1ccc([C@@]23CNC[C@@H]2[C@H]3COCC2CC2)cc1Cl,CHEMBL1157620,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,2010.0,53,6,2534,2551,10.1021/jm901818u,20170186.0,
3127264,CHEMBL263664,"4-(4-Chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-",CHEMBL1074392,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsomal preparation,IC50,>,10000.0,nM,NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,CHEMBL1157584,"Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).",J. Med. Chem.,2010.0,53,5,2239,2249,10.1021/jm901788j,20151677.0,
3127272,CHEMBL598194,"4-Amino-N-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide",CHEMBL1074392,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsomal preparation,IC50,=,1000.0,nM,NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,CHEMBL1157584,"Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).",J. Med. Chem.,2010.0,53,5,2239,2249,10.1021/jm901788j,20151677.0,
3127276,CHEMBL597211,"4-(4-tert-Butylbenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amine",CHEMBL1074392,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsomal preparation,IC50,=,1000.0,nM,CC(C)(C)c1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1,CHEMBL1157584,"Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).",J. Med. Chem.,2010.0,53,5,2239,2249,10.1021/jm901788j,20151677.0,
3131609,CHEMBL598336,"3,4-Dimethoxy-N-[3-(2-pyridin-4-yl-ethylcarbamoyl)-benzyl]-benzamide",CHEMBL1066157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,=,16000.0,nM,COc1ccc(C(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)cc1OC,CHEMBL1157712,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,2010.0,53,2,759,777,10.1021/jm9014263,20000469.0,
3131610,CHEMBL590810,"3-[3-(4-Cyano-phenyl)-ureidomethyl]-N-(1,2,3,4-tetrahydro-isoquinolin-7-yl)-benzamide",CHEMBL1066157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,30000.0,nM,N#Cc1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1,CHEMBL1157712,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,2010.0,53,2,759,777,10.1021/jm9014263,20000469.0,
3131611,CHEMBL599792,"N-[3-(4-Dimethylaminomethyl-phenylcarbamoyl)-benzyl]-3,4-dimethoxy-benzamide",CHEMBL1066157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,30000.0,nM,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1OC,CHEMBL1157712,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,2010.0,53,2,759,777,10.1021/jm9014263,20000469.0,
3131612,CHEMBL599791,"3,4-Dimethoxy-N-[3-(2-methyl-1,2,3,4-tetrahydro-isoquinolin-7-ylcarbamoyl)-benzyl]-benzamide",CHEMBL1066157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,30000.0,nM,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1OC,CHEMBL1157712,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,2010.0,53,2,759,777,10.1021/jm9014263,20000469.0,
3131613,CHEMBL604087,"3,4-Dimethoxy-N-[3-(1,2,3,4-tetrahydro-isoquinolin-7-ylcarbamoyl)-benzyl]-benzamide",CHEMBL1066157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,30000.0,nM,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1OC,CHEMBL1157712,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,2010.0,53,2,759,777,10.1021/jm9014263,20000469.0,
3131614,CHEMBL597127,"3,4-Dimethoxy-N-[3-(2-piperidin-3-yl-ethylcarbamoyl)-benzyl]-benzamide",CHEMBL1066157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,30000.0,nM,COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC,CHEMBL1157712,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,2010.0,53,2,759,777,10.1021/jm9014263,20000469.0,
3131615,CHEMBL604085,"3,4-Dimethoxy-N-[3-(2-piperidin-4-yl-ethylcarbamoyl)-benzyl]-benzamide",CHEMBL1066157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,30000.0,nM,COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCNCC3)c2)cc1OC,CHEMBL1157712,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,2010.0,53,2,759,777,10.1021/jm9014263,20000469.0,
3131792,CHEMBL605360,"N-[3-(4-Hydroxymethyl-phenylcarbamoyl)-benzyl]-3,4-dimethoxybenzamide",CHEMBL1074312,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by LCMS/MS assay,IC50,>,30000.0,nM,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CO)cc3)c2)cc1OC,CHEMBL1157712,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,2010.0,53,2,759,777,10.1021/jm9014263,20000469.0,
3131793,CHEMBL592709,3-Chloro-N-[3-(4-dimethylaminomethyl-phenylcarbamoyl)-benzyl]-4-methoxy-benzamide,CHEMBL1074312,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by LCMS/MS assay,IC50,>,30000.0,nM,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1Cl,CHEMBL1157712,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,2010.0,53,2,759,777,10.1021/jm9014263,20000469.0,
3131794,CHEMBL604249,N-[3-(4-Dimethylaminomethyl-phenylcarbamoyl)-benzyl]-4-methoxy-3-methyl-benzamide,CHEMBL1074312,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by LCMS/MS assay,IC50,>,30000.0,nM,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1C,CHEMBL1157712,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,J. Med. Chem.,2010.0,53,2,759,777,10.1021/jm9014263,20000469.0,
3189314,CHEMBL1086657,"2-({3-[3-(5-hydroxypyridin-2-yl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylpropanoyl}-amino)cyclohex-1-ene-1-carboxylic acid",CHEMBL1100505,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,39000.0,nM,CC(C)(Cc1nc(-c2ccc(O)cn2)no1)C(=O)NC1=C(C(=O)O)CCCC1,CHEMBL1155429,Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.,J. Med. Chem.,2010.0,53,6,2666,2670,10.1021/jm100022r,20184326.0,
3189563,CHEMBL376487,1-cyclohexyl-2-(furan-3-yl)-N-((S)-2-(5-hydroxy-1H-indol-3-yl)-1-(thiazol-4-yl)ethyl)-1H-benzo[d]imidazole-5-carboxamide,CHEMBL1100116,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2300.0,nM,O=C(N[C@@H](Cc1c[nH]c2ccc(O)cc12)c1cscn1)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1,CHEMBL1155433,Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series.,Bioorg. Med. Chem. Lett.,2010.0,20,6,1825,1829,10.1016/j.bmcl.2010.02.003,20185309.0,
3189564,CHEMBL1077334,3-(4-(1-(1-cyclohexyl-2-(furan-3-yl)-1H-benzo[d]imidazole-5-carboxamido)cyclopentanecarboxamido)phenyl)acrylic acid,CHEMBL1100116,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,11500.0,nM,O=C(O)/C=C/c1ccc(NC(=O)C2(NC(=O)c3ccc4c(c3)nc(-c3ccoc3)n4C3CCCCC3)CCCC2)cc1,CHEMBL1155433,Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series.,Bioorg. Med. Chem. Lett.,2010.0,20,6,1825,1829,10.1016/j.bmcl.2010.02.003,20185309.0,
3189565,CHEMBL1077335,3-(4-(1-(1-cyclohexyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)cyclopentanecarboxamido)phenyl)acrylic acid,CHEMBL1100116,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4000.0,nM,O=C(O)/C=C/c1ccc(NC(=O)C2(NC(=O)c3ccc4c(c3)nc(-c3ccccn3)n4C3CCCCC3)CCCC2)cc1,CHEMBL1155433,Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series.,Bioorg. Med. Chem. Lett.,2010.0,20,6,1825,1829,10.1016/j.bmcl.2010.02.003,20185309.0,
3189987,CHEMBL1086754,"N-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propyl)-1,2-dimethyl-5-phenyl-1H-pyrrole-3-carboxamide hydrchloride",CHEMBL1101354,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9700.0,nM,Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1C,CHEMBL1154983,"Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20,5,1705,1711,10.1016/j.bmcl.2010.01.093,20149649.0,
3195155,CHEMBL1081687,"(1S,5R)-3-(3-{[4-Methyl-5-(2-methyl-3-pyridinyl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo-[3.1.0]hexane",CHEMBL1107675,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,10000.0,nM,Cc1ncccc1-c1nnc(SCCCN2C[C@@H]3C[C@]3(c3ccc(C(F)(F)F)cc3)C2)n1C,CHEMBL1153718,"1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.",J. Med. Chem.,2010.0,53,1,374,391,10.1021/jm901319p,19891474.0,
3195161,CHEMBL1081867,"(1S,5R)-3-(3-{[4-Methyl-5-(4-pyridazinyl)-4H-1,2,4-triazol-3-yl]-thio}propyl)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane",CHEMBL1107675,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,10000.0,nM,Cn1c(SCCCN2C[C@@H]3C[C@]3(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccnnc1,CHEMBL1153718,"1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.",J. Med. Chem.,2010.0,53,1,374,391,10.1021/jm901319p,19891474.0,
3195162,CHEMBL1080293,"2-methyl-5-(4-methyl-5-(3-(1-(4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexan-3-yl)propylthio)-4H-1,2,4-triazol-3-yl)quinoline",CHEMBL1107675,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,10000.0,nM,Cc1ccc2c(-c3nnc(SCCCN4CC5CC5(c5ccc(C(F)(F)F)cc5)C4)n3C)cccc2n1,CHEMBL1153718,"1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.",J. Med. Chem.,2010.0,53,1,374,391,10.1021/jm901319p,19891474.0,
3195180,CHEMBL1080003,7-methoxy-4-trifluoromethyl coumarin-3-acetic acid,CHEMBL1107675,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,50000.0,nM,COc1ccc2c(C(F)(F)F)c(CC(=O)O)c(=O)oc2c1,CHEMBL1153718,"1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.",J. Med. Chem.,2010.0,53,1,374,391,10.1021/jm901319p,19891474.0,
3201952,CHEMBL1082158,"4-chloro-N-cyclopropyl-3-(1-(2,6-difluorophenyl)-1H-pyrazolo[4,3-d]pyridazin-4-ylamino)benzamide",CHEMBL1099693,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,27000.0,nM,O=C(NC1CC1)c1ccc(Cl)c(Nc2nncc3c2cnn3-c2c(F)cccc2F)c1,CHEMBL1154963,"Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.",Bioorg. Med. Chem. Lett.,2010.0,20,5,1680,1684,10.1016/j.bmcl.2010.01.059,20138761.0,
3215926,CHEMBL372357,"1-(2-cyclopropylethyl)-3-(1,1-dioxo-1,4-dihydrobenzo[1,2,4]-thiadiazin-3-yl)-6-fluoro-4-hydroxy-1-quinolin-2-one",CHEMBL1100451,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,840.0,nM,O=c1c(C2=Nc3ccccc3S(=O)(=O)N2)c(O)c2cc(F)ccc2n1CCC1CC1,CHEMBL1153777,Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase.,Bioorg. Med. Chem. Lett.,2009.0,19,15,4350,4353,10.1016/j.bmcl.2009.05.091,19515564.0,
3215930,CHEMBL1085893,"2-{3-[1-(2-Cyclopropyl-ethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydro-quinolin-3-yl]-1,1-dioxo-1,4-dihydro-1lambda*6*-benzo[1,2,4]thiadiazin-7-yloxy}-acetamide",CHEMBL1100451,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5400.0,nM,NC(=O)COc1ccc2c(c1)S(=O)(=O)N=C(c1c(O)c3cc(F)ccc3n(CCC3CC3)c1=O)N2,CHEMBL1153777,Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase.,Bioorg. Med. Chem. Lett.,2009.0,19,15,4350,4353,10.1016/j.bmcl.2009.05.091,19515564.0,
3215934,CHEMBL1088051,"(R)-2-{3-[1-(2-Cyclopropyl-ethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydro-quinolin-3-yl]-1,1-dioxo-1,4-dihydro-1lambda*6*-benzo[1,2,4]thiadiazin-7-yloxy}-propionamide",CHEMBL1100451,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1700.0,nM,C[C@@H](Oc1ccc2c(c1)S(=O)(=O)N=C(c1c(O)c3cc(F)ccc3n(CCC3CC3)c1=O)N2)C(N)=O,CHEMBL1153777,Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase.,Bioorg. Med. Chem. Lett.,2009.0,19,15,4350,4353,10.1016/j.bmcl.2009.05.091,19515564.0,
3217194,CHEMBL1080088,"1-(1-allyl-7-(2,6-dimethylbenzylamino)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)pyridin-2(1H)-one",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,500.0,nM,C=CCn1c(C)c(C)c2cc(-n3ccccc3=O)nc(NCc3c(C)cccc3C)c21,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3217195,CHEMBL1080982,"4-(7-(2,6-dimethylbenzylamino)-1-(2-hydroxyethyl)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)morpholin-3-one",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,13000.0,nM,Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)n(CCO)c12,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3217196,CHEMBL1080803,"1-(7-(2,6-dimethylbenzylamino)-1-(2-hydroxyethyl)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)pyridin-2(1H)-one",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,11400.0,nM,Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)n(CCO)c12,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3217197,CHEMBL1079958,"1-(7-(2,6-dimethylbenzylamino)-1-ethyl-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)pyridin-2(1H)-one",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,700.0,nM,CCn1c(C)c(C)c2cc(-n3ccccc3=O)nc(NCc3c(C)cccc3C)c21,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3217198,CHEMBL1079957,"1-(7-(2,6-dimethylbenzylamino)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)imidazolidin-2-one",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2700.0,nM,Cc1cccc(C)c1CNc1nc(N2CCNC2=O)cc2c(C)c(C)[nH]c12,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3217199,CHEMBL1079437,"6-(7-(2,6-dimethylbenzylamino)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)pyridin-2(1H)-one",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2300.0,nM,Cc1cccc(C)c1CNc1nc(-c2cccc(=O)[nH]2)cc2c(C)c(C)[nH]c12,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3217200,CHEMBL1079436,"4-(7-(2,6-dimethylbenzylamino)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)morpholin-3-one",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,61000.0,nM,Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)[nH]c12,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3217201,CHEMBL1076245,"1-(7-(2,6-dimethylbenzylamino)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)pyrrolidin-2-one",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1400.0,nM,Cc1cccc(C)c1CNc1nc(N2CCCC2=O)cc2c(C)c(C)[nH]c12,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3217202,CHEMBL1080473,"N-(2,6-dimethylbenzyl)-2,3-dimethyl-5-phenyl-1H-pyrrolo[2,3-c]pyridin-7-amine",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,6700.0,nM,Cc1cccc(C)c1CNc1nc(-c2ccccc2)cc2c(C)c(C)[nH]c12,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3217203,CHEMBL1080472,"1-(7-(2,6-dimethylbenzylamino)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)pyridin-2(1H)-one",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3300.0,nM,Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)[nH]c12,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3217287,CHEMBL1076210,"N-(2,6-dimethylbenzyl)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-7-amine",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,33000.0,nM,Cc1cccc(C)c1CNc1nccc2c(C)c(C)[nH]c12,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3217288,CHEMBL1076192,"N-(2,6-dimethylbenzyl)-1,2-dimethyl-1H-pyrrolo[3,2-c]pyridin-4-amine",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,66000.0,nM,Cc1cccc(C)c1CNc1nccc2c1cc(C)n2C,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3217289,CHEMBL1081870,"N-(2,6-dimethylbenzyl)-1,2-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,68000.0,nM,Cc1cccc(C)c1CNc1nccc2c1nc(C)n2C,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3217290,CHEMBL1081505,"N-(2,6-dimethylbenzyl)-1,2-dimethyl-1H-benzo[d]imidazol-4-amine",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8800.0,nM,Cc1cccc(C)c1CNc1cccc2c1nc(C)n2C,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3217291,CHEMBL1076536,"8-(2,6-dimethylbenzyloxy)-2,3-dimethylimidazo[1,2-a]pyridine",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,16000.0,nM,Cc1cccc(C)c1COc1cccn2c(C)c(C)nc12,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3218397,CHEMBL47529,"(8-Benzyloxy-2-methyl-imidazo[1,2-a]pyridin-3-yl)-acetonitrile",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,54000.0,nM,Cc1nc2c(OCc3ccccc3)cccn2c1CC#N,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3218398,CHEMBL497011,"8-(2,6-dimethylbenzylamino)-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,31000.0,nM,Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3218399,CHEMBL238146,"8-(2-ethyl-6-methylbenzylamino)-2,3-dimethylH-imidazo[1,2-a]pyridine-6-carboxamide",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3600.0,nM,CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3218400,CHEMBL1087758,"7-(4-fluorobenzyloxy)-2,3-dimethyl-1-(((1S,2S)-2-methylcyclopropyl)methyl)-1H-pyrrolo[2,3-d]pyridazine",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,800.0,nM,Cc1c(C)n(C[C@H]2C[C@@H]2C)c2c(OCc3ccc(F)cc3)nncc12,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3218413,CHEMBL1080717,"N-(2,6-dimethylbenzyl)-6,7-dimethylpyrrolo[1,2-a]pyrazin-1-amine",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,14000.0,nM,Cc1cccc(C)c1CNc1nccn2c(C)c(C)cc12,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3218414,CHEMBL1081504,"N-(2,6-dimethylbenzyl)-6,7-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine",CHEMBL1100428,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,100000.0,nM,Cc1cccc(C)c1CNc1ncnc2c(C)c(C)[nH]c12,CHEMBL1154377,"Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).",Bioorg. Med. Chem. Lett.,2009.0,19,23,6813,6817,10.1016/j.bmcl.2009.07.002,19846298.0,
3220789,CHEMBL1080046,"N-(3-((1H-pyrazol-3-yl)methyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-4-butylbenzenesulfonamide",CHEMBL1109283,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,600.0,nM,CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(Cc2cc[nH]n2)CC3)cc1,CHEMBL1154336,The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,2009.0,19,22,6452,6458,10.1016/j.bmcl.2009.09.027,19804969.0,
3220790,CHEMBL1078595,"N-(3-((1H-pyrazol-3-yl)methyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-6-morpholinopyridine-3-sulfonamide",CHEMBL1109283,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,200.0,nM,O=S(=O)(Nc1ccc2c(c1)CCN(Cc1cc[nH]n1)CC2)c1ccc(N2CCOCC2)nc1,CHEMBL1154336,The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,2009.0,19,22,6452,6458,10.1016/j.bmcl.2009.09.027,19804969.0,
3220791,CHEMBL1078492,"N-(3-((1H-pyrazol-3-yl)methyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-5-(pyridin-2-yl)thiophene-2-sulfonamide",CHEMBL1109283,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,400.0,nM,O=S(=O)(Nc1ccc2c(c1)CCN(Cc1cc[nH]n1)CC2)c1ccc(-c2ccccn2)s1,CHEMBL1154336,The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,2009.0,19,22,6452,6458,10.1016/j.bmcl.2009.09.027,19804969.0,
3220792,CHEMBL1081860,"N-(3-((1H-pyrazol-3-yl)methyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-4-cyanobenzenesulfonamide",CHEMBL1109283,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,2500.0,nM,N#Cc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(Cc2cc[nH]n2)CC3)cc1,CHEMBL1154336,The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.,Bioorg. Med. Chem. Lett.,2009.0,19,22,6452,6458,10.1016/j.bmcl.2009.09.027,19804969.0,
3227360,CHEMBL1080787,"(S)-2,3-dichloro-N-isobutyl-N-(pyrrolidin-3-yl)benzamide",CHEMBL1112317,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CC(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1,CHEMBL1154203,N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.,Bioorg. Med. Chem. Lett.,2009.0,19,17,5078,5081,10.1016/j.bmcl.2009.07.049,19647430.0,
3230735,CHEMBL1079360,N-(4-chlorophenyl)-3-methyl-3-phenylpiperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3230743,CHEMBL1079361,N-(benzo[d]isoxazol-3-yl)-3-methyl-3-phenylpiperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,CC1(c2ccccc2)CCCN(C(=O)Nc2noc3ccccc23)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3230752,CHEMBL1079362,3-methyl-3-phenyl-N-(pyridin-4-yl)piperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CC1(c2ccccc2)CCCN(C(=O)Nc2ccncc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3230760,CHEMBL1080076,N-(biphenyl-4-yl)-3-methyl-3-phenylpiperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,CC1(c2ccccc2)CCCN(C(=O)Nc2ccc(-c3ccccc3)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3230768,CHEMBL1080973,"N-(2,4-dichlorobenzyl)-3-methyl-3-phenylpiperidine-1-carboxamide",CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(Cl)cc2Cl)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3230777,CHEMBL1080974,3-methyl-3-phenyl-N-((2'-(trifluoromethyl)biphenyl-4-yl)methyl)piperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3ccccc3C(F)(F)F)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3230786,CHEMBL1080975,N-((3'-chlorobiphenyl-4-yl)methyl)-3-methyl-3-phenylpiperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3cccc(Cl)c3)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3230796,CHEMBL1081703,3-methyl-3-phenyl-N-(4-(pyridin-2-yl)benzyl)piperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3ccccn3)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3230806,CHEMBL1078264,N-(4-(1H-indol-5-yl)benzyl)-3-methyl-3-phenylpiperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3ccc4[nH]ccc4c3)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3230815,CHEMBL1078265,N-(4-chlorophenethyl)-3-methyl-3-phenylpiperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CC1(c2ccccc2)CCCN(C(=O)NCCc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3230824,CHEMBL1078353,3-methyl-3-phenyl-N-(3-(pyridin-3-yl)propyl)piperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CC1(c2ccccc2)CCCN(C(=O)NCCCc2cccnc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3230832,CHEMBL1078354,N-(2-(1H-benzo[d]imidazol-6-yl)ethyl)-3-methyl-3-phenylpiperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,CC1(c2ccccc2)CCCN(C(=O)NCCc2ccc3nc[nH]c3c2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3230840,CHEMBL1078452,3-methyl-3-phenyl-N-(2-(quinoxalin-6-yl)ethyl)piperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,CC1(c2ccccc2)CCCN(C(=O)NCCc2ccc3nccnc3c2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3230848,CHEMBL1077780,"3-methyl-3-phenyl-N-((1S,2R)-2-phenylcyclopropyl)piperidine-1-carboxamide",CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,CC1(c2ccccc2)CCCN(C(=O)N[C@H]2C[C@@H]2c2ccccc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3231927,CHEMBL1077781,2-(1-(4-chlorophenylcarbamoyl)-3-phenylpiperidin-3-yl)acetic acid,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(O)CC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3231937,CHEMBL1079256,3-(1-(4-chlorophenylcarbamoyl)-3-phenylpiperidin-3-yl)propanoic acid,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3231947,CHEMBL1078565,4-(1-(4-chlorophenylcarbamoyl)-3-phenylpiperidin-3-yl)butanoic acid,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(O)CCCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3231957,CHEMBL1078657,5-(1-(4-chlorophenylcarbamoyl)-3-phenylpiperidin-3-yl)pentanoic acid,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(O)CCCCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3231969,CHEMBL1078755,N-(4-chlorophenyl)-3-(2-cyanoethyl)-3-phenylpiperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,N#CCCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3231979,CHEMBL1079290,N-(4-chlorophenyl)-3-(2-hydroxyethyl)-3-phenylpiperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,O=C(Nc1ccc(Cl)cc1)N1CCCC(CCO)(c2ccccc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3231989,CHEMBL1079291,N-(4-chlorophenyl)-3-(3-hydroxypropyl)-3-phenylpiperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,O=C(Nc1ccc(Cl)cc1)N1CCCC(CCCO)(c2ccccc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3231999,CHEMBL1079292,3-(3-amino-3-oxopropyl)-N-(4-chlorophenyl)-3-phenylpiperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,NC(=O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3232007,CHEMBL1079140,N-(4-chlorophenyl)-3-(2-(dimethylamino)ethyl)-3-phenylpiperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CN(C)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3232017,CHEMBL1079244,"N-(4-chlorophenyl)-3-(2-(2,3-dihydro-1H-tetrazol-5-yl)ethyl)-3-phenylpiperidine-1-carboxamide",CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(Nc1ccc(Cl)cc1)N1CCCC(CCC2=NNNN2)(c2ccccc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3232027,CHEMBL1079245,"N-(4-chlorophenyl)-3-(3-(2,3-dihydro-1H-tetrazol-5-ylamino)-3-oxopropyl)-3-phenylpiperidine-1-carboxamide",CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1)NC1=NNNN1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3232036,CHEMBL1079246,N-(4-chlorophenyl)-3-(3-(methylamino)-3-oxopropyl)-3-phenylpiperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,CNC(=O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3232044,CHEMBL1078628,N-(4-chlorophenyl)-3-(3-(diethylamino)-3-oxopropyl)-3-phenylpiperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CCN(CC)C(=O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3232053,CHEMBL1078232,N-(4-chlorophenyl)-3-(3-morpholino-3-oxopropyl)-3-phenylpiperidine-1-carboxamide,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1)N1CCOCC1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3232063,CHEMBL1079256,3-(1-(4-chlorophenylcarbamoyl)-3-phenylpiperidin-3-yl)propanoic acid,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,100000.0,nM,O=C(O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3232073,CHEMBL1079257,3-(1-(4-chlorophenylcarbamoyl)-3-(2-(trifluoromethyl)phenyl)piperidin-3-yl)propanoic acid,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(O)CCC1(c2ccccc2C(F)(F)F)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3232082,CHEMBL1079258,3-(1-(4-chlorophenylcarbamoyl)-3-(3-(trifluoromethyl)phenyl)piperidin-3-yl)propanoic acid,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(O)CCC1(c2cccc(C(F)(F)F)c2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3232092,CHEMBL1078715,3-(1-(4-chlorophenylcarbamoyl)-3-(4-(trifluoromethyl)phenyl)piperidin-3-yl)propanoic acid,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(O)CCC1(c2ccc(C(F)(F)F)cc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3232101,CHEMBL1078336,3-(1-(4-chlorophenylcarbamoyl)-3-(pyridin-4-yl)piperidin-3-yl)propanoic acid,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,O=C(O)CCC1(c2ccncc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3232109,CHEMBL1078337,3-(1-(4-chlorophenylcarbamoyl)-3-(pyridin-3-yl)piperidin-3-yl)propanoic acid,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(O)CCC1(c2cccnc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3232117,CHEMBL1077963,3-(1-(4-chlorophenylcarbamoyl)-3-(pyridin-2-yl)piperidin-3-yl)propanoic acid,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(O)CCC1(c2ccccn2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3232126,CHEMBL1079061,3-(3-(biphenyl-4-yl)-1-(4-(trifluoromethoxy)phenylcarbamoyl)piperidin-3-yl)propanoic acid,CHEMBL1100147,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,O=C(O)CCC1(c2ccc(-c3ccccc3)cc2)CCCN(C(=O)Nc2ccc(OC(F)(F)F)cc2)C1,CHEMBL1154229,"Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.",Bioorg. Med. Chem. Lett.,2009.0,19,18,5314,5320,10.1016/j.bmcl.2009.07.138,19682899.0,
3242257,CHEMBL1091356,"1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-isopropylpiperazine-1-carbonyl)phenyl)urea",CHEMBL1112477,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CC(C)N1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(C5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1,CHEMBL1156955,2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human microsomal stability.,Bioorg. Med. Chem. Lett.,2010.0,20,8,2648,2653,10.1016/j.bmcl.2010.02.031,20223663.0,
3244045,CHEMBL1092169,"N-(6-(2-chlorophenyl)-5-(4-chlorophenyl)-2-(2-hydroxy-2-methylpropanoyl)furo[2,3-b]pyridin-3-yl)-2-hydroxyacetamide",CHEMBL1114482,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,100000.0,nM,CC(C)(O)C(=O)c1oc2nc(-c3ccccc3Cl)c(-c3ccc(Cl)cc3)cc2c1NC(=O)CO,CHEMBL1156265,"Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1.",Bioorg. Med. Chem. Lett.,2010.0,20,4,1448,1452,10.1016/j.bmcl.2009.12.065,20096577.0,
3251665,CHEMBL1089865,"N-Cyclopropyl-3-(1-(2,6-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-5-yl)-4-methylbenzamide",CHEMBL1104522,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,25000.0,nM,Cc1ccc(C(=O)NC2CC2)cc1-c1cc2cnn(-c3c(F)cccc3F)c2n(C)c1=O,CHEMBL1156338,"Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.",J. Med. Chem.,2010.0,53,7,2973,2985,10.1021/jm100095x,20218619.0,
3252399,CHEMBL1089270,"(1S,2R)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-7-(1-tert-butyl-1,2,3,6-tetrahydropyridin-4-yl)-1-(4-fluorophenyl)-2,3,8,8a-tetrahydroindolizin-5(1H)-one",CHEMBL1110611,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,36500.0,nM,C[C@@H](O[C@H]1CN2C(=O)C=C(C3=CCN(C(C)(C)C)CC3)CC2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,CHEMBL1156284,Tetrahydroindolizinone NK1 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,7,2354,2358,10.1016/j.bmcl.2010.01.120,20188553.0,
3253032,CHEMBL1089210,2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,CHEMBL1110811,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1200.0,nM,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3nc(-c4ccc(Cl)cc4)oc3C)c2)cc1,CHEMBL1156340,Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).,J. Med. Chem.,2010.0,53,7,2854,2864,10.1021/jm9016812,20218621.0,
3253033,CHEMBL1090211,2-((3-((2-(4-chlorophenyl)-4-methyloxazol-5-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,CHEMBL1110811,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3400.0,nM,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3oc(-c4ccc(Cl)cc4)nc3C)c2)cc1,CHEMBL1156340,Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).,J. Med. Chem.,2010.0,53,7,2854,2864,10.1021/jm9016812,20218621.0,
3253034,CHEMBL1090212,2-((3-((2-(4-chlorophenyl)-4-methylthiazol-5-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,CHEMBL1110811,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3700.0,nM,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3sc(-c4ccc(Cl)cc4)nc3C)c2)cc1,CHEMBL1156340,Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).,J. Med. Chem.,2010.0,53,7,2854,2864,10.1021/jm9016812,20218621.0,
3253035,CHEMBL1091664,2-((3-((2-(4-chlorophenyl)-5-methylthiazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,CHEMBL1110811,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7100.0,nM,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3nc(-c4ccc(Cl)cc4)sc3C)c2)cc1,CHEMBL1156340,Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).,J. Med. Chem.,2010.0,53,7,2854,2864,10.1021/jm9016812,20218621.0,
3253036,CHEMBL1091980,2-((3-((2-(2-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,CHEMBL1110811,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3700.0,nM,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3nc(-c4ccccc4Cl)oc3C)c2)cc1,CHEMBL1156340,Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).,J. Med. Chem.,2010.0,53,7,2854,2864,10.1021/jm9016812,20218621.0,
3253037,CHEMBL1092931,2-((3-((2-(3-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,CHEMBL1110811,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,500.0,nM,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3nc(-c4cccc(Cl)c4)oc3C)c2)cc1,CHEMBL1156340,Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).,J. Med. Chem.,2010.0,53,7,2854,2864,10.1021/jm9016812,20218621.0,
3253038,CHEMBL1089164,2-((3-((2-(4-fluorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,CHEMBL1110811,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8600.0,nM,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3nc(-c4ccc(F)cc4)oc3C)c2)cc1,CHEMBL1156340,Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).,J. Med. Chem.,2010.0,53,7,2854,2864,10.1021/jm9016812,20218621.0,
3253039,CHEMBL1090188,2-((3-((2-(4-cyanophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,CHEMBL1110811,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,21000.0,nM,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3nc(-c4ccc(C#N)cc4)oc3C)c2)cc1,CHEMBL1156340,Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).,J. Med. Chem.,2010.0,53,7,2854,2864,10.1021/jm9016812,20218621.0,
3253040,CHEMBL1090189,2-((3-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,CHEMBL1110811,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2800.0,nM,COc1ccc(-c2nc(COc3cccc(CN(CC(=O)O)C(=O)Oc4ccc(C)cc4)c3)c(C)o2)cc1,CHEMBL1156340,Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).,J. Med. Chem.,2010.0,53,7,2854,2864,10.1021/jm9016812,20218621.0,
3253041,CHEMBL1090877,2-((3-((5-methyl-2-p-tolyloxazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,CHEMBL1110811,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3500.0,nM,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3nc(-c4ccc(C)cc4)oc3C)c2)cc1,CHEMBL1156340,Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).,J. Med. Chem.,2010.0,53,7,2854,2864,10.1021/jm9016812,20218621.0,
3253042,CHEMBL1091218,2-((3-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid,CHEMBL1110811,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4400.0,nM,Cc1ccc(OC(=O)N(CC(=O)O)Cc2cccc(OCc3nc(-c4ccc(C(F)(F)F)cc4)oc3C)c2)cc1,CHEMBL1156340,Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).,J. Med. Chem.,2010.0,53,7,2854,2864,10.1021/jm9016812,20218621.0,
3253928,CHEMBL1093747,N-(5-bromo-6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide,CHEMBL1111585,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,10000.0,nM,CCCC(=O)Nc1n[nH]c2cc(-c3ccc(O)cc3)c(Br)cc12,CHEMBL1156291,Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics.,Bioorg. Med. Chem. Lett.,2010.0,20,7,2344,2349,10.1016/j.bmcl.2010.01.132,20189807.0,
3253929,CHEMBL1095040,N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide,CHEMBL1111585,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,10000.0,nM,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12,CHEMBL1156291,Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics.,Bioorg. Med. Chem. Lett.,2010.0,20,7,2344,2349,10.1016/j.bmcl.2010.01.132,20189807.0,
3254190,CHEMBL1089501,2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid,CHEMBL1116216,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,40000.0,nM,COC(=O)N(CC(=O)O)Cc1cccc(OCc2nc(-c3ccc(Cl)cc3)oc2C)c1,CHEMBL1156340,Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).,J. Med. Chem.,2010.0,53,7,2854,2864,10.1021/jm9016812,20218621.0,
3262901,CHEMBL1092929,(R)-N-(2-(1-(2-(1-benzoylpiperidin-4-yl)ethyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide,CHEMBL1108770,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by P450-Glo method,IC50,>,10000.0,nM,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCC2CCN(C(=O)c3ccccc3)CC2)C1,CHEMBL1156954,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,7,2099,2102,10.1016/j.bmcl.2010.02.072,20223662.0,
3262902,CHEMBL1089881,(R)-N-(2-(1-(2-(1-(2-fluorobenzoyl)piperidin-4-yl)ethyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide,CHEMBL1108770,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by P450-Glo method,IC50,>,10000.0,nM,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCC2CCN(C(=O)c3ccccc3F)CC2)C1,CHEMBL1156954,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,7,2099,2102,10.1016/j.bmcl.2010.02.072,20223662.0,
3262903,CHEMBL1092921,"(R)-N-(2-(1-(2-(1-(2,5-difluorobenzoyl)piperidin-4-yl)ethyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide",CHEMBL1108770,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by P450-Glo method,IC50,>,10000.0,nM,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCC2CCN(C(=O)c3cc(F)ccc3F)CC2)C1,CHEMBL1156954,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,7,2099,2102,10.1016/j.bmcl.2010.02.072,20223662.0,
3262904,CHEMBL1088874,(R)-N-(2-(1-(2-(1-(2-chlorobenzoyl)piperidin-4-yl)ethyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide,CHEMBL1108770,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by P450-Glo method,IC50,>,10000.0,nM,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCC2CCN(C(=O)c3ccccc3Cl)CC2)C1,CHEMBL1156954,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,7,2099,2102,10.1016/j.bmcl.2010.02.072,20223662.0,
3262905,CHEMBL1093469,(R)-N-(2-(1-(2-(4-benzoylpiperazin-1-yl)ethyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide,CHEMBL1108770,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by P450-Glo method,IC50,>,10000.0,nM,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3ccccc3)CC2)C1,CHEMBL1156954,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,7,2099,2102,10.1016/j.bmcl.2010.02.072,20223662.0,
3262906,CHEMBL1092238,(R)-N-(2-(1-(2-(4-(2-chlorobenzoyl)piperazin-1-yl)ethyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide,CHEMBL1108770,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by P450-Glo method,IC50,>,10000.0,nM,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3ccccc3Cl)CC2)C1,CHEMBL1156954,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,7,2099,2102,10.1016/j.bmcl.2010.02.072,20223662.0,
3262907,CHEMBL1093802,(R)-N-(2-(1-(2-(4-(2-fluorobenzoyl)piperazin-1-yl)ethyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide,CHEMBL1108770,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by P450-Glo method,IC50,>,10000.0,nM,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3ccccc3F)CC2)C1,CHEMBL1156954,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,7,2099,2102,10.1016/j.bmcl.2010.02.072,20223662.0,
3262908,CHEMBL1089793,"(R)-N-(2-(1-(2-(4-(2,5-difluorobenzoyl)piperazin-1-yl)ethyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide",CHEMBL1108770,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by P450-Glo method,IC50,>,10000.0,nM,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3cc(F)ccc3F)CC2)C1,CHEMBL1156954,Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,7,2099,2102,10.1016/j.bmcl.2010.02.072,20223662.0,
3282982,CHEMBL1098726,"6-((5S,9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic Acid",CHEMBL1117461,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,35000.0,nM,CN1C(=O)N(c2cc(Cl)cc(Cl)c2)C(=O)[C@]12CN(c1ccc(C(=O)O)cn1)C[C@H]2c1ccc(C#N)cc1,CHEMBL1157744,"Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic acid (BMS-688521).",J. Med. Chem.,2010.0,53,9,3814,3830,10.1021/jm100348u,20405922.0,
3287355,CHEMBL1099326,"4-{2-(2-Carboxy-ethyl)-3-[6-(3,5-di-pyridin-4-yl-phenoxy)-hexyl]-phenoxy}-butyric acid",CHEMBL1107486,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 fluorescence method,IC50,=,340.0,nM,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccncc3)cc(-c3ccncc3)c2)c1CCC(=O)O,CHEMBL1158546,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,2010.0,53,9,3502,3516,10.1021/jm1001919,20380377.0,
3287367,CHEMBL1099326,"4-{2-(2-Carboxy-ethyl)-3-[6-(3,5-di-pyridin-4-yl-phenoxy)-hexyl]-phenoxy}-butyric acid",CHEMBL1107487,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 by LC/MS method,IC50,=,900.0,nM,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccncc3)cc(-c3ccncc3)c2)c1CCC(=O)O,CHEMBL1158546,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,2010.0,53,9,3502,3516,10.1021/jm1001919,20380377.0,
3287388,CHEMBL1098560,"4-{3-[6-(3-5-Benzo[1,3]dioxolyl-5-thiophen-3-ylphenoxy)hexyl]-2-(2-carboxyethyl)phenoxy}butyric Acid",CHEMBL1107486,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 fluorescence method,IC50,=,3900.0,nM,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccsc3)cc(-c3ccc4c(c3)OCO4)c2)c1CCC(=O)O,CHEMBL1158546,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,2010.0,53,9,3502,3516,10.1021/jm1001919,20380377.0,
3287398,CHEMBL1094349,"4-(3-(6-(5-(benzo[d][1,3]dioxol-5-yl)-2'-fluorobiphenyl-3-yloxy)hexyl)-2-(2-carboxyethyl)phenoxy)butanoic acid",CHEMBL1107486,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 fluorescence method,IC50,=,7600.0,nM,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccc4c(c3)OCO4)cc(-c3ccccc3F)c2)c1CCC(=O)O,CHEMBL1158546,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,2010.0,53,9,3502,3516,10.1021/jm1001919,20380377.0,
3287414,CHEMBL1098560,"4-{3-[6-(3-5-Benzo[1,3]dioxolyl-5-thiophen-3-ylphenoxy)hexyl]-2-(2-carboxyethyl)phenoxy}butyric Acid",CHEMBL1107487,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 by LC/MS method,IC50,=,22500.0,nM,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccsc3)cc(-c3ccc4c(c3)OCO4)c2)c1CCC(=O)O,CHEMBL1158546,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,2010.0,53,9,3502,3516,10.1021/jm1001919,20380377.0,
3287452,CHEMBL1099330,"4-(2-(2-carboxyethyl)-3-(6-(4,6-diphenylpyridin-2-yloxy)hexyl)phenoxy)butanoic acid",CHEMBL1107486,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 fluorescence method,IC50,>,12500.0,nM,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccccc3)cc(-c3ccccc3)n2)c1CCC(=O)O,CHEMBL1158546,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,2010.0,53,9,3502,3516,10.1021/jm1001919,20380377.0,
3287453,CHEMBL1099323,"4-{2-(2-Carboxyethyl)-3-[6-([1,1',3,1'']terphenyl-5'-yloxy)-hexyl]phenoxy}butyric Acid",CHEMBL1107487,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 by LC/MS method,IC50,>,12500.0,nM,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccccc3)cc(-c3ccccc3)c2)c1CCC(=O)O,CHEMBL1158546,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,2010.0,53,9,3502,3516,10.1021/jm1001919,20380377.0,
3287454,CHEMBL1094348,"4-(3-(6-(5-(benzo[d][1,3]dioxol-5-yl)-3'-fluorobiphenyl-3-yloxy)hexyl)-2-(2-carboxyethyl)phenoxy)butanoic acid",CHEMBL1107486,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 fluorescence method,IC50,>,25000.0,nM,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3cccc(F)c3)cc(-c3ccc4c(c3)OCO4)c2)c1CCC(=O)O,CHEMBL1158546,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,2010.0,53,9,3502,3516,10.1021/jm1001919,20380377.0,
3287459,CHEMBL1099323,"4-{2-(2-Carboxyethyl)-3-[6-([1,1',3,1'']terphenyl-5'-yloxy)-hexyl]phenoxy}butyric Acid",CHEMBL1107486,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 fluorescence method,IC50,>,50000.0,nM,O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccccc3)cc(-c3ccccc3)c2)c1CCC(=O)O,CHEMBL1158546,Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.,J. Med. Chem.,2010.0,53,9,3502,3516,10.1021/jm1001919,20380377.0,
3294249,CHEMBL1090479,"3-(4-(4-(2-(3-((dimethylamino)methyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl)phenyl)-1,1-dimethylurea",CHEMBL1108265,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate,IC50,=,38000.0,nM,CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1,CHEMBL1157791,"Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.",J. Med. Chem.,2010.0,53,10,3973,4001,10.1021/jm901870q,20420387.0,
3294401,CHEMBL1089116,"1-(4-(1-ethyl-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)phenyl)-3-phenylurea",CHEMBL1108284,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,100.0,nM,CCn1cc(-c2ccnc3[nH]ccc23)c(-c2ccc(NC(=O)Nc3ccccc3)cc2)n1,CHEMBL1157791,"Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.",J. Med. Chem.,2010.0,53,10,3973,4001,10.1021/jm901870q,20420387.0,
3297041,CHEMBL1096182,"N-((4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl)-5-methyl-1H-pyrazole-3-carboxamide",CHEMBL1110981,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,18000.0,nM,Cc1cc(C(=O)N[C@@H]2CC(C)(C)Oc3nc(-c4ccc(Cl)cc4Cl)c(-c4ccc(Cl)cc4)cc32)n[nH]1,CHEMBL1157794,"Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.",J. Med. Chem.,2010.0,53,10,4028,4037,10.1021/jm100023j,20423086.0,
3298487,CHEMBL1094222,"3-[(5-Chloro-1,3-benzothiazol-2-yl)methoxy]-2,6-difluorobenzamide",CHEMBL1113798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by fluorescence assay,IC50,>,12.0,ug.mL-1,NC(=O)c1c(F)ccc(OCc2nc3cc(Cl)ccc3s2)c1F,CHEMBL1157799,Creating an antibacterial with in vivo efficacy: synthesis and characterization of potent inhibitors of the bacterial cell division protein FtsZ with improved pharmaceutical properties.,J. Med. Chem.,2010.0,53,10,3927,3936,10.1021/jm9016366,20426423.0,
3298503,CHEMBL1094181,"3-((6-chlorothiazolo[4,5-b]pyridin-2-yl)methoxy)-2,6-difluorobenzamide",CHEMBL1113798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by fluorescence assay,IC50,>,12.0,ug.mL-1,NC(=O)c1c(F)ccc(OCc2nc3ncc(Cl)cc3s2)c1F,CHEMBL1157799,Creating an antibacterial with in vivo efficacy: synthesis and characterization of potent inhibitors of the bacterial cell division protein FtsZ with improved pharmaceutical properties.,J. Med. Chem.,2010.0,53,10,3927,3936,10.1021/jm9016366,20426423.0,
3302032,CHEMBL1086579,"3-((4-(6-Bromo-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo-[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole",CHEMBL1118623,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 from human liver microsome by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1cc(CN2CCN(c3c(Br)cnc4[nH]c(N5CCN(C)CC5)nc34)CC2)no1,CHEMBL1155446,"Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.",J. Med. Chem.,2010.0,53,14,5213,5228,10.1021/jm100262j,20565112.0,
3307053,CHEMBL1085107,"(S)-2-((1S,2S,4R)-Bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one",CHEMBL1118553,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,15000.0,nM,CC(C)[C@]1(C)SC(N[C@H]2C[C@@H]3CC[C@H]2C3)=NC1=O,CHEMBL1155526,"Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221).",J. Med. Chem.,2010.0,53,11,4481,4487,10.1021/jm100242d,20465278.0,
3311131,CHEMBL589136,"N-(2,4-dichlorobenzyl)-4-(pyrimidin-2-yloxy)piperidine-1-carboxamide",CHEMBL1119169,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,25500.0,nM,O=C(NCc1ccc(Cl)cc1Cl)N1CCC(Oc2ncccn2)CC1,CHEMBL1155546,Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method.,Bioorg. Med. Chem. Lett.,2010.0,20,12,3703,3707,10.1016/j.bmcl.2010.04.078,20472432.0,
3311132,CHEMBL1085746,"N-(2,4-dichlorobenzyl)-4-(pyridin-4-yloxy)piperidine-1-carboxamide",CHEMBL1119169,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,100.0,nM,O=C(NCc1ccc(Cl)cc1Cl)N1CCC(Oc2ccncc2)CC1,CHEMBL1155546,Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method.,Bioorg. Med. Chem. Lett.,2010.0,20,12,3703,3707,10.1016/j.bmcl.2010.04.078,20472432.0,
3311133,CHEMBL1085745,3-(pyridin-4-yl)-N-(2-(trifluoromethoxy)benzyl)pyrrolidine-1-carboxamide,CHEMBL1119169,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,300.0,nM,O=C(NCc1ccccc1OC(F)(F)F)N1CCC(c2ccncc2)C1,CHEMBL1155546,Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method.,Bioorg. Med. Chem. Lett.,2010.0,20,12,3703,3707,10.1016/j.bmcl.2010.04.078,20472432.0,
3311134,CHEMBL1082684,4-(pyrimidin-2-yloxy)-N-(2-(trifluoromethoxy)benzyl)piperidine-1-carboxamide,CHEMBL1119169,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10200.0,nM,O=C(NCc1ccccc1OC(F)(F)F)N1CCC(Oc2ncccn2)CC1,CHEMBL1155546,Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method.,Bioorg. Med. Chem. Lett.,2010.0,20,12,3703,3707,10.1016/j.bmcl.2010.04.078,20472432.0,
3311135,CHEMBL1085744,4-(pyridin-4-yloxy)-N-(2-(trifluoromethoxy)benzyl)piperidine-1-carboxamide,CHEMBL1119169,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,800.0,nM,O=C(NCc1ccccc1OC(F)(F)F)N1CCC(Oc2ccncc2)CC1,CHEMBL1155546,Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method.,Bioorg. Med. Chem. Lett.,2010.0,20,12,3703,3707,10.1016/j.bmcl.2010.04.078,20472432.0,
3311136,CHEMBL1083622,"N-(3,3-bis(4-fluorophenyl)propyl)-4-(pyrazin-2-yloxy)piperidine-1-carboxamide",CHEMBL1119169,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2900.0,nM,O=C(NCCC(c1ccc(F)cc1)c1ccc(F)cc1)N1CCC(Oc2cnccn2)CC1,CHEMBL1155546,Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method.,Bioorg. Med. Chem. Lett.,2010.0,20,12,3703,3707,10.1016/j.bmcl.2010.04.078,20472432.0,
3311137,CHEMBL1085743,"N-(3,3-bis(4-fluorophenyl)propyl)-3-(pyrazin-2-yl)pyrrolidine-1-carboxamide",CHEMBL1119169,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8100.0,nM,O=C(NCCC(c1ccc(F)cc1)c1ccc(F)cc1)N1CCC(c2cnccn2)C1,CHEMBL1155546,Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method.,Bioorg. Med. Chem. Lett.,2010.0,20,12,3703,3707,10.1016/j.bmcl.2010.04.078,20472432.0,
3312114,CHEMBL1086478,"(1S,3R)-5'-Chloro-6,7-difluoro-3-methyl-2,3,4,9-tetrahydrospiro-[beta-carboline-1,3'-indol]-2'(1'H)-one",CHEMBL1119997,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@@H]1Cc2c([nH]c3cc(F)c(F)cc23)[C@]2(N1)C(=O)Nc1ccc(Cl)cc12,CHEMBL1155453,Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.,J. Med. Chem.,2010.0,53,14,5155,5164,10.1021/jm100410f,20568778.0,
3312117,CHEMBL1082725,"(1R,3S)-5'-Chloro-6,7-difluoro-3-methyl-2,3,4,9-tetrahydrospiro-[beta-carboline-1,3'-indol]-2'(1'H)-one",CHEMBL1119997,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome by LC-MS/MS analysis,IC50,=,7350.0,nM,C[C@H]1Cc2c([nH]c3cc(F)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc12,CHEMBL1155453,Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.,J. Med. Chem.,2010.0,53,14,5155,5164,10.1021/jm100410f,20568778.0,
3312120,CHEMBL1082724,"(1S,3R)-5',7-Dichloro-6-fluoro-3-methyl-2,3,4,9-tetrahydrospiro-[beta-carboline-1,3'-indol]-2'(1'H)-one",CHEMBL1119997,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@]2(N1)C(=O)Nc1ccc(Cl)cc12,CHEMBL1155453,Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.,J. Med. Chem.,2010.0,53,14,5155,5164,10.1021/jm100410f,20568778.0,
3312123,CHEMBL1082723,"(1R,3S)-5',7-Dichloro-6-fluoro-3-methyl-2,3,4,9-tetrahydrospiro-[beta-carboline-1,3'-indol]-2'(1'H)-one",CHEMBL1119997,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome by LC-MS/MS analysis,IC50,=,5420.0,nM,C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc12,CHEMBL1155453,Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.,J. Med. Chem.,2010.0,53,14,5155,5164,10.1021/jm100410f,20568778.0,
3312126,CHEMBL1084948,"(1S,3R)-5',7-Dichloro-3-methyl-2,3,4,9-tetrahydrospiro[beta-carboline-1,3'-indol]-2'(1'H)-one",CHEMBL1119997,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@@H]1Cc2c([nH]c3cc(Cl)ccc23)[C@]2(N1)C(=O)Nc1ccc(Cl)cc12,CHEMBL1155453,Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.,J. Med. Chem.,2010.0,53,14,5155,5164,10.1021/jm100410f,20568778.0,
3312129,CHEMBL1086475,"(1R,3S)-5',7-Dichloro-3-methyl-2,3,4,9-tetrahydrospiro[beta-carboline-1,3'-indol]-2'(1'H)-one",CHEMBL1119997,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome by LC-MS/MS analysis,IC50,=,4110.0,nM,C[C@H]1Cc2c([nH]c3cc(Cl)ccc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc12,CHEMBL1155453,Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.,J. Med. Chem.,2010.0,53,14,5155,5164,10.1021/jm100410f,20568778.0,
3312132,CHEMBL1083219,"(1S,3R)-5'-Chloro-6-fluoro-3-methyl-2,3,4,9-tetrahydrospiro-[beta-carboline-1,3'-indol]-2'(1'H)-one",CHEMBL1119997,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@@H]1Cc2c([nH]c3ccc(F)cc23)[C@]2(N1)C(=O)Nc1ccc(Cl)cc12,CHEMBL1155453,Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.,J. Med. Chem.,2010.0,53,14,5155,5164,10.1021/jm100410f,20568778.0,
3312135,CHEMBL1084349,"(1R,3S)-5'-Chloro-6-fluoro-3-methyl-2,3,4,9-tetrahydrospiro-[beta-carboline-1,3'-indol]-2'(1'H)-one",CHEMBL1119997,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome by LC-MS/MS analysis,IC50,=,1720.0,nM,C[C@H]1Cc2c([nH]c3ccc(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc12,CHEMBL1155453,Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.,J. Med. Chem.,2010.0,53,14,5155,5164,10.1021/jm100410f,20568778.0,
3312148,CHEMBL1085369,"(1S,3R)-5'-Chloro-3-methyl-2,3,4,9-tetrahydrospiro[beta-carboline-1,3'-indol]-2'(1'H)-one",CHEMBL1119997,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@@H]1Cc2c([nH]c3ccccc23)[C@]2(N1)C(=O)Nc1ccc(Cl)cc12,CHEMBL1155453,Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.,J. Med. Chem.,2010.0,53,14,5155,5164,10.1021/jm100410f,20568778.0,
3312151,CHEMBL1083769,"(1R,3S)-5'-Chloro-3-methyl-2,3,4,9-tetrahydrospiro[beta-carboline-1,3'-indol-2'(1'H)-one",CHEMBL1119997,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome by LC-MS/MS analysis,IC50,=,1510.0,nM,C[C@H]1Cc2c([nH]c3ccccc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc12,CHEMBL1155453,Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.,J. Med. Chem.,2010.0,53,14,5155,5164,10.1021/jm100410f,20568778.0,
3313536,CHEMBL1085616,"5-(3,5-difluorophenyl)-2-(3-(1-(5-hydroxypyridin-2-yl)-1H-pyrazol-3-yl)-2-methylpropanamido)cyclohex-1-enecarboxylic acid",CHEMBL1117823,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,23000.0,nM,CC(Cc1ccn(-c2ccc(O)cn2)n1)C(=O)NC1=C(C(=O)O)CC(c2cc(F)cc(F)c2)CC1,CHEMBL1155496,Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A.,Bioorg. Med. Chem. Lett.,2010.0,20,11,3372,3375,10.1016/j.bmcl.2010.04.013,20452209.0,
3313537,CHEMBL1085150,2-(3-(1-(5-hydroxypyridin-2-yl)-1H-pyrazol-4-yl)propanamido)cyclohex-1-enecarboxylic acid,CHEMBL1117823,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,50000.0,nM,O=C(CCc1cnn(-c2ccc(O)cn2)c1)NC1=C(C(=O)O)CCCC1,CHEMBL1155496,Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A.,Bioorg. Med. Chem. Lett.,2010.0,20,11,3372,3375,10.1016/j.bmcl.2010.04.013,20452209.0,
3313538,CHEMBL1085402,2-(3-(1-(4-hydroxyphenyl)-5-methyl-1H-pyrazol-4-yl)-2-methylpropanamido)cyclohex-1-enecarboxylic acid,CHEMBL1117823,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,100000.0,nM,Cc1c(CC(C)C(=O)NC2=C(C(=O)O)CCCC2)cnn1-c1ccc(O)cc1,CHEMBL1155496,Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A.,Bioorg. Med. Chem. Lett.,2010.0,20,11,3372,3375,10.1016/j.bmcl.2010.04.013,20452209.0,
3313539,CHEMBL1086104,2-(3-(1-(4-hydroxyphenyl)-5-methyl-1H-pyrazol-4-yl)-2-methylpropanamido)benzoic acid,CHEMBL1117823,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,22000.0,nM,Cc1c(CC(C)C(=O)Nc2ccccc2C(=O)O)cnn1-c1ccc(O)cc1,CHEMBL1155496,Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A.,Bioorg. Med. Chem. Lett.,2010.0,20,11,3372,3375,10.1016/j.bmcl.2010.04.013,20452209.0,
3313540,CHEMBL1086568,2-(3-(1-phenyl-1H-pyrazol-4-yl)propanamido)benzoic acid,CHEMBL1117823,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,15000.0,nM,O=C(CCc1cnn(-c2ccccc2)c1)Nc1ccccc1C(=O)O,CHEMBL1155496,Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A.,Bioorg. Med. Chem. Lett.,2010.0,20,11,3372,3375,10.1016/j.bmcl.2010.04.013,20452209.0,
3313541,CHEMBL236163,2-(3-(1-(4-hydroxyphenyl)-5-methyl-1H-pyrazol-4-yl)propanamido)benzoic acid,CHEMBL1117823,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,15000.0,nM,Cc1c(CCC(=O)Nc2ccccc2C(=O)O)cnn1-c1ccc(O)cc1,CHEMBL1155496,Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A.,Bioorg. Med. Chem. Lett.,2010.0,20,11,3372,3375,10.1016/j.bmcl.2010.04.013,20452209.0,
3313542,CHEMBL1086567,2-(3-(1-phenyl-1H-pyrazol-3-yl)propanamido)benzoic acid,CHEMBL1117823,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,2500.0,nM,O=C(CCc1ccn(-c2ccccc2)n1)Nc1ccccc1C(=O)O,CHEMBL1155496,Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A.,Bioorg. Med. Chem. Lett.,2010.0,20,11,3372,3375,10.1016/j.bmcl.2010.04.013,20452209.0,
3313543,CHEMBL235256,2-[3-(2'-chloro-4'-hydroxy-biphenyl-4-yl)-propionylamino]-benzoic acid,CHEMBL1117823,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,<,400.0,nM,O=C(CCc1ccc(-c2ccc(O)cc2Cl)cc1)Nc1ccccc1C(=O)O,CHEMBL1155496,Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A.,Bioorg. Med. Chem. Lett.,2010.0,20,11,3372,3375,10.1016/j.bmcl.2010.04.013,20452209.0,
3354594,CHEMBL1169994,"3,4-dichloro-N-(5-chloro-2-(5-chloropyridin-3-yloxy)pyridin-3-yl)benzenesulfonamide",CHEMBL1174522,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1071.52,nM,O=S(=O)(Nc1cc(Cl)cnc1Oc1cncc(Cl)c1)c1ccc(Cl)c(Cl)c1,CHEMBL1177762,Identification of a sulfonamide series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,13,3961,3964,10.1016/j.bmcl.2010.04.142,20627722.0,
3354595,CHEMBL1170725,"3,4-dichloro-N-{5-chloro-2-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl}benzenesulfonamide",CHEMBL1174522,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1348.96,nM,Cc1ncccc1Oc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1,CHEMBL1177762,Identification of a sulfonamide series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,13,3961,3964,10.1016/j.bmcl.2010.04.142,20627722.0,
3354596,CHEMBL1169660,"2-(5-chloro-3-(3,4-dichlorophenylsulfonamido)pyridin-2-yloxy)-N-(2-hydroxyethyl)benzamide",CHEMBL1174522,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5011.87,nM,O=C(NCCO)c1ccccc1Oc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1,CHEMBL1177762,Identification of a sulfonamide series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,13,3961,3964,10.1016/j.bmcl.2010.04.142,20627722.0,
3354597,CHEMBL1171008,"2-(5-chloro-3-(3,4-dichlorophenylsulfonamido)pyridin-2-yloxy)benzoic acid",CHEMBL1174522,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,21379.62,nM,O=C(O)c1ccccc1Oc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1,CHEMBL1177762,Identification of a sulfonamide series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,13,3961,3964,10.1016/j.bmcl.2010.04.142,20627722.0,
3354598,CHEMBL1171786,"2-(4-chloro-2-(3,4-dichlorophenylsulfonamido)phenoxy)benzoic acid",CHEMBL1174522,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4168.69,nM,O=C(O)c1ccccc1Oc1ccc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1,CHEMBL1177762,Identification of a sulfonamide series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,13,3961,3964,10.1016/j.bmcl.2010.04.142,20627722.0,
3355186,CHEMBL1170305,(R)-N-(cyclopropyl(3-fluorophenyl)methyl)-3-methyl-2-phenylquinoline-4-carboxamide,CHEMBL1174131,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7943.28,nM,Cc1c(-c2ccccc2)nc2ccccc2c1C(=O)N[C@@H](c1cccc(F)c1)C1CC1,CHEMBL1177834,ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.,Bioorg. Med. Chem.,2009.0,17,16,5906,5919,10.1016/j.bmc.2009.07.002,19632124.0,
3355187,CHEMBL1170958,(R)-N-(cyclopropyl(3-fluorophenyl)methyl)-2-phenyl-3-(pyrimidin-5-ylmethyl)quinoline-4-carboxamide,CHEMBL1174131,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,O=C(N[C@@H](c1cccc(F)c1)C1CC1)c1c(Cc2cncnc2)c(-c2ccccc2)nc2ccccc12,CHEMBL1177834,ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.,Bioorg. Med. Chem.,2009.0,17,16,5906,5919,10.1016/j.bmc.2009.07.002,19632124.0,
3355188,CHEMBL1171894,(S)-N-(1-cyclohexylethyl)-3-methyl-2-(thiophen-2-yl)quinoline-4-carboxamide,CHEMBL1174131,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,19952.62,nM,Cc1c(-c2cccs2)nc2ccccc2c1C(=O)N[C@@H](C)C1CCCCC1,CHEMBL1177834,ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.,Bioorg. Med. Chem.,2009.0,17,16,5906,5919,10.1016/j.bmc.2009.07.002,19632124.0,
3355189,CHEMBL1171895,(S)-N-(1-cyclohexylethyl)-3-(pyrimidin-5-ylmethyl)-2-(thiophen-2-yl)quinoline-4-carboxamide,CHEMBL1174131,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,31622.78,nM,C[C@H](NC(=O)c1c(Cc2cncnc2)c(-c2cccs2)nc2ccccc12)C1CCCCC1,CHEMBL1177834,ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.,Bioorg. Med. Chem.,2009.0,17,16,5906,5919,10.1016/j.bmc.2009.07.002,19632124.0,
3355190,CHEMBL1171896,2-methyl-5-(4-phenethylpiperazin-1-yl)quinoline,CHEMBL1174131,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,39810.72,nM,Cc1ccc2c(N3CCN(CCc4ccccc4)CC3)cccc2n1,CHEMBL1177834,ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.,Bioorg. Med. Chem.,2009.0,17,16,5906,5919,10.1016/j.bmc.2009.07.002,19632124.0,
3355191,CHEMBL1171708,2-methyl-5-(4-(3-(pyrimidin-5-yl)phenethyl)piperazin-1-yl)quinoline,CHEMBL1174131,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,19952.62,nM,Cc1ccc2c(N3CCN(CCc4cccc(-c5cncnc5)c4)CC3)cccc2n1,CHEMBL1177834,ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.,Bioorg. Med. Chem.,2009.0,17,16,5906,5919,10.1016/j.bmc.2009.07.002,19632124.0,
3355192,CHEMBL1171709,5-(4-(4-fluorophenethyl)piperazin-1-yl)-2-methylquinoline,CHEMBL1174131,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,31622.78,nM,Cc1ccc2c(N3CCN(CCc4ccc(F)cc4)CC3)cccc2n1,CHEMBL1177834,ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.,Bioorg. Med. Chem.,2009.0,17,16,5906,5919,10.1016/j.bmc.2009.07.002,19632124.0,
3355193,CHEMBL1171887,5-(4-(4-fluoro-3-(pyrimidin-5-yl)phenethyl)piperazin-1-yl)-2-methylquinoline,CHEMBL1174131,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,Cc1ccc2c(N3CCN(CCc4ccc(F)c(-c5cncnc5)c4)CC3)cccc2n1,CHEMBL1177834,ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.,Bioorg. Med. Chem.,2009.0,17,16,5906,5919,10.1016/j.bmc.2009.07.002,19632124.0,
3355194,CHEMBL1170480,"2-(2-(2,3-difluorophenethyl)-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl)-N-(piperidin-4-yl)-N-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)acetamide",CHEMBL1174131,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,19952.62,nM,O=C(Cn1c(CCc2cccc(F)c2F)nc(=O)c2cccnc21)N(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C1CCNCC1,CHEMBL1177834,ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.,Bioorg. Med. Chem.,2009.0,17,16,5906,5919,10.1016/j.bmc.2009.07.002,19632124.0,
3355195,CHEMBL1170481,"2-(2-(2,3-difluorophenethyl)-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl)-N-(1-(pyrimidin-4-yl)piperidin-4-yl)-N-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)acetamide",CHEMBL1174131,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,100.0,nM,O=C(Cn1c(CCc2cccc(F)c2F)nc(=O)c2cccnc21)N(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C1CCN(c2ccncn2)CC1,CHEMBL1177834,ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.,Bioorg. Med. Chem.,2009.0,17,16,5906,5919,10.1016/j.bmc.2009.07.002,19632124.0,
3355196,CHEMBL1170482,"2-(2-(2,3-difluorophenethyl)-4-oxoquinazolin-1(4H)-yl)-N-(piperidin-4-yl)-N-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)acetamide",CHEMBL1174131,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,15848.93,nM,O=C(Cn1c(CCc2cccc(F)c2F)nc(=O)c2ccccc21)N(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C1CCNCC1,CHEMBL1177834,ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.,Bioorg. Med. Chem.,2009.0,17,16,5906,5919,10.1016/j.bmc.2009.07.002,19632124.0,
3355197,CHEMBL1170483,"2-(2-(2,3-difluorophenethyl)-4-oxoquinazolin-1(4H)-yl)-N-(1-(pyrimidin-4-yl)piperidin-4-yl)-N-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)acetamide",CHEMBL1174131,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,79.43,nM,O=C(Cn1c(CCc2cccc(F)c2F)nc(=O)c2ccccc21)N(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C1CCN(c2ccncn2)CC1,CHEMBL1177834,ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.,Bioorg. Med. Chem.,2009.0,17,16,5906,5919,10.1016/j.bmc.2009.07.002,19632124.0,
3355430,CHEMBL1171204,N-(furan-2-ylmethyl)-4-(2-methylbenzoyl)-1H-pyrrole-2-carboxamide,CHEMBL1174576,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,15800.0,nM,Cc1ccccc1C(=O)c1c[nH]c(C(=O)NCc2ccco2)c1,CHEMBL1177767,The discovery and initial optimisation of pyrrole-2-carboxamides as inhibitors of p38alpha MAP kinase.,Bioorg. Med. Chem. Lett.,2010.0,20,13,3936,3940,10.1016/j.bmcl.2010.05.011,20570148.0,
3355970,CHEMBL1172346,4-cyano-N-(2-cyclohexenyl-4-(pyridin-4-yl)phenyl)-1H-imidazole-2-carboxamide,CHEMBL1174620,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3.0,nM,N#Cc1c[nH]c(C(=O)Nc2ccc(-c3ccncc3)cc2C2=CCCCC2)n1,CHEMBL1177769,Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,13,3925,3929,10.1016/j.bmcl.2010.05.013,20570147.0,
3363034,CHEMBL1173087,"rac-6-(3,4-Dichlorophenyl)-1-[1-(methyloxy)-3-buten-1-yl]-3-azabicyclo[4.1.0]heptane",CHEMBL1176756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,=,3000.0,nM,C=CCC(OC)[C@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2,CHEMBL1177725,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,2010.0,53,13,4989,5001,10.1021/jm100481d,20527970.0,
3363041,CHEMBL1172744,rac-1-[(Methyloxy)methyl]-6-(2-naphthalenyl)-3-azabicyclo[4.1.0]-heptane,CHEMBL1176756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,=,8000.0,nM,COC[C@@]12CNCC[C@]1(c1ccc3ccccc3c1)C2,CHEMBL1177725,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,2010.0,53,13,4989,5001,10.1021/jm100481d,20527970.0,
3363054,CHEMBL1173532,"1-(3,4-dichlorophenyl)-6-(methoxymethyl)-3-azabicyclo[4.1.0]heptane",CHEMBL1176756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,=,10000.0,nM,COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2,CHEMBL1177725,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,2010.0,53,13,4989,5001,10.1021/jm100481d,20527970.0,
3363058,CHEMBL1173532,"1-(3,4-dichlorophenyl)-6-(methoxymethyl)-3-azabicyclo[4.1.0]heptane",CHEMBL1176756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,=,10000.0,nM,COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2,CHEMBL1177725,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,2010.0,53,13,4989,5001,10.1021/jm100481d,20527970.0,
3363062,CHEMBL1173532,"1-(3,4-dichlorophenyl)-6-(methoxymethyl)-3-azabicyclo[4.1.0]heptane",CHEMBL1176756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,=,10000.0,nM,COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2,CHEMBL1177725,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",J. Med. Chem.,2010.0,53,13,4989,5001,10.1021/jm100481d,20527970.0,
3369518,CHEMBL2021600,"(S)-4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl]-[5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl]-methanone",CHEMBL1177065,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,24000.0,nM,C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2F)CC1)C(C)(C)C,CHEMBL1177706,"Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.",J. Med. Chem.,2010.0,53,12,4603,4614,10.1021/jm100210p,20491477.0,
3372397,CHEMBL1210423,"sodium 3-(3-(tert-butylthio)-1-(4-(5-methoxypyrimidin-2-yl)benzyl)-5-((5-methylpyridin-2-yl)methoxy)-1H-indol-2-yl)-2,2-dimethylpropanoate",CHEMBL1211535,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4500.0,nM,COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)[O-])c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)nc1.[Na+],CHEMBL1208689,"5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration.",Bioorg. Med. Chem. Lett.,2010.0,20,15,4598,4601,10.1016/j.bmcl.2010.06.011,20566292.0,
3372557,CHEMBL1079481,"(1R,5S/1S,5R)-3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane",CHEMBL1211619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(C(F)(F)F)cc3)C2)n1C,CHEMBL1208692,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,2010.0,20,15,4566,4568,10.1016/j.bmcl.2010.06.018,20573506.0,
3372558,CHEMBL1210552,"3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(pentafluoro-{6}-sulfanyl)phenyl]-3-azabicyclo[3.1.0]hexane",CHEMBL1211619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C,CHEMBL1208692,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,2010.0,20,15,4566,4568,10.1016/j.bmcl.2010.06.018,20573506.0,
3372559,CHEMBL1210552,"3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(pentafluoro-{6}-sulfanyl)phenyl]-3-azabicyclo[3.1.0]hexane",CHEMBL1211619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C,CHEMBL1208692,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,2010.0,20,15,4566,4568,10.1016/j.bmcl.2010.06.018,20573506.0,
3372560,CHEMBL1210552,"3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(pentafluoro-{6}-sulfanyl)phenyl]-3-azabicyclo[3.1.0]hexane",CHEMBL1211619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C,CHEMBL1208692,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,2010.0,20,15,4566,4568,10.1016/j.bmcl.2010.06.018,20573506.0,
3372561,CHEMBL1081957,"(1R,5S/1S,5R)-3-(3-{[4-Methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-[3-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane",CHEMBL1211619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(C(F)(F)F)c3)C2)n1C,CHEMBL1208692,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,2010.0,20,15,4566,4568,10.1016/j.bmcl.2010.06.018,20573506.0,
3372562,CHEMBL1210614,"3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[3-(pentafluoro-{6}-sulfanyl)phenyl]-3-azabicyclo[3.1.0]hexane",CHEMBL1211619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C,CHEMBL1208692,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,2010.0,20,15,4566,4568,10.1016/j.bmcl.2010.06.018,20573506.0,
3372563,CHEMBL1210614,"3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[3-(pentafluoro-{6}-sulfanyl)phenyl]-3-azabicyclo[3.1.0]hexane",CHEMBL1211619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C,CHEMBL1208692,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,2010.0,20,15,4566,4568,10.1016/j.bmcl.2010.06.018,20573506.0,
3372564,CHEMBL1210614,"3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[3-(pentafluoro-{6}-sulfanyl)phenyl]-3-azabicyclo[3.1.0]hexane",CHEMBL1211619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C,CHEMBL1208692,"A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template.",Bioorg. Med. Chem. Lett.,2010.0,20,15,4566,4568,10.1016/j.bmcl.2010.06.018,20573506.0,
3373097,CHEMBL1210434,"3-cyclopentyl-N-((2S,3R)-3-hydroxy-1-phenyl-4-(3-(trifluoromethyl)benzylamino)butan-2-yl)-5-(N-phenylmethylsulfonamido)benzamide",CHEMBL1211674,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,6900.0,nM,CS(=O)(=O)N(c1ccccc1)c1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)cc(C2CCCC2)c1,CHEMBL1208699,BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4639,4644,10.1016/j.bmcl.2010.05.111,20579874.0,
3375394,CHEMBL1208959,(R)-5-(5-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide,CHEMBL1212575,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by fluorescence plate reader,IC50,=,200.0,nM,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F,CHEMBL1208730,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4587,4592,10.1016/j.bmcl.2010.06.009,20594842.0,
3375395,CHEMBL1208960,(R)-5-(5-(2-morpholinopyridin-4-yl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide,CHEMBL1212575,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by fluorescence plate reader,IC50,=,100.0,nM,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCOCC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F,CHEMBL1208730,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4587,4592,10.1016/j.bmcl.2010.06.009,20594842.0,
3375396,CHEMBL1208961,(R)-5-(5-(2-(2-(dimethylamino)ethylamino)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide,CHEMBL1212575,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by fluorescence plate reader,IC50,=,900.0,nM,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F,CHEMBL1208730,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4587,4592,10.1016/j.bmcl.2010.06.009,20594842.0,
3375397,CHEMBL1208962,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(2-(2-(methylsulfonyl)ethylamino)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,CHEMBL1212575,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by fluorescence plate reader,IC50,=,1700.0,nM,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCS(C)(=O)=O)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,CHEMBL1208730,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4587,4592,10.1016/j.bmcl.2010.06.009,20594842.0,
3375398,CHEMBL1208963,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(2-(2-hydroxyethylamino)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,CHEMBL1212575,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by fluorescence plate reader,IC50,=,200.0,nM,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCO)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,CHEMBL1208730,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4587,4592,10.1016/j.bmcl.2010.06.009,20594842.0,
3375399,CHEMBL1208964,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(2-(1-methylpiperidin-4-ylamino)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,CHEMBL1212575,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by fluorescence plate reader,IC50,=,4300.0,nM,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,CHEMBL1208730,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4587,4592,10.1016/j.bmcl.2010.06.009,20594842.0,
3375400,CHEMBL1208965,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(6-(1-methylpiperidin-4-ylamino)pyridin-3-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,CHEMBL1212575,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by fluorescence plate reader,IC50,=,8900.0,nM,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccc(NC5CCN(C)CC5)nc4)ccc32)sc1C(N)=O)c1ccccc1Cl,CHEMBL1208730,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4587,4592,10.1016/j.bmcl.2010.06.009,20594842.0,
3375401,CHEMBL1209016,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,CHEMBL1212575,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by fluorescence plate reader,IC50,=,700.0,nM,C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCN5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,CHEMBL1208730,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4587,4592,10.1016/j.bmcl.2010.06.009,20594842.0,
3375402,CHEMBL1209017,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(1-(3-(dimethylamino)propyl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,CHEMBL1212575,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by fluorescence plate reader,IC50,=,400.0,nM,C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,CHEMBL1208730,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4587,4592,10.1016/j.bmcl.2010.06.009,20594842.0,
3375403,CHEMBL1209018,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(1-(3-(4-ethylpiperazin-1-yl)propyl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,CHEMBL1212575,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by fluorescence plate reader,IC50,=,2400.0,nM,CCN1CCN(CCCn2cc(-c3ccc4c(c3)ncn4-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)cn2)CC1,CHEMBL1208730,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4587,4592,10.1016/j.bmcl.2010.06.009,20594842.0,
3375444,CHEMBL1209842,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,CHEMBL1212575,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by fluorescence plate reader,IC50,<,100.0,nM,C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,CHEMBL1208730,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4587,4592,10.1016/j.bmcl.2010.06.009,20594842.0,
3375445,CHEMBL1208892,(R)-5-(5-(2-aminopyrimidin-4-yl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide,CHEMBL1212575,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by fluorescence plate reader,IC50,<,100.0,nM,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N)n4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F,CHEMBL1208730,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4587,4592,10.1016/j.bmcl.2010.06.009,20594842.0,
3375446,CHEMBL1209674,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,CHEMBL1212578,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate by fluorescence plate reader,IC50,=,100.0,nM,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccncc4)ccc32)sc1C(N)=O)c1ccccc1Cl,CHEMBL1208730,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4587,4592,10.1016/j.bmcl.2010.06.009,20594842.0,
3375447,CHEMBL1208835,(R)-5-(5-(2-aminopyridin-4-yl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide,CHEMBL1212578,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate by fluorescence plate reader,IC50,=,200.0,nM,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F,CHEMBL1208730,Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4587,4592,10.1016/j.bmcl.2010.06.009,20594842.0,
3375734,CHEMBL1209049,endo-2-methyl-1-(6-((4-(pyridin-2-yl)thiazol-2-ylamino)methyl)-3-azabicyclo[3.1.0]hexan-3-yl)propan-1-one,CHEMBL1212043,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>=,7000.0,nM,CC(C)C(=O)N1C[C@H]2[C@@H](CNc3nc(-c4ccccn4)cs3)[C@H]2C1,CHEMBL1208767,"Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists.",Bioorg. Med. Chem. Lett.,2010.0,20,16,4741,4744,10.1016/j.bmcl.2010.06.140,20630754.0,
3375738,CHEMBL1209217,endo-(6-((4-(pyridin-2-yl)thiazol-2-ylamino)methyl)-3-azabicyclo[3.1.0]hexan-3-yl)(tetrahydrofuran-3-yl)methanone,CHEMBL1212043,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(C1CCOC1)N1C[C@H]2[C@@H](CNc3nc(-c4ccccn4)cs3)[C@H]2C1,CHEMBL1208767,"Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists.",Bioorg. Med. Chem. Lett.,2010.0,20,16,4741,4744,10.1016/j.bmcl.2010.06.140,20630754.0,
3377968,CHEMBL1209538,"(7-(2,4-dichlorophenyl)-5-methyl-2-phenylpyrazolo[1,5-a]pyrimidin-6-yl)methanamine",CHEMBL1211748,A,,,Cytochrome P450 2C9,inhibition of CYP2C9,IC50,=,12000.0,nM,Cc1nc2cc(-c3ccccc3)nn2c(-c2ccc(Cl)cc2Cl)c1CN,CHEMBL1208739,Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4395,4398,10.1016/j.bmcl.2010.06.063,20598534.0,
3377984,CHEMBL1209853,"(5-(2,4-dichlorophenyl)-7-methyl-2-phenylimidazo[1,2-a]pyrimidin-6-yl)methanamine",CHEMBL1211748,A,,,Cytochrome P450 2C9,inhibition of CYP2C9,IC50,>,40000.0,nM,Cc1nc2nc(-c3ccccc3)cn2c(-c2ccc(Cl)cc2Cl)c1CN,CHEMBL1208739,Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4395,4398,10.1016/j.bmcl.2010.06.063,20598534.0,
3378888,CHEMBL1209322,"(2S,3S)-N-(4-(5-heptyl-1,2,4-oxadiazol-3-yl)benzyl)-3-hydroxypyrrolidine-2-carboxamide",CHEMBL1211767,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,5000.0,nM,CCCCCCCc1nc(-c2ccc(CNC(=O)[C@H]3NCC[C@@H]3O)cc2)no1,CHEMBL1208743,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4550,4554,10.1016/j.bmcl.2010.06.019,20598880.0,
3378889,CHEMBL1209617,"(2S,3S)-N-((S)-1-(4-(5-(2-cyclopentylethyl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)-3-hydroxypyrrolidine-2-carboxamide",CHEMBL1211767,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,5000.0,nM,C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCC3)n2)cc1,CHEMBL1208743,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4550,4554,10.1016/j.bmcl.2010.06.019,20598880.0,
3378890,CHEMBL1209685,"(2S,3S)-N-((S)-1-(4-(5-(2-cyclohexylethyl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)-3-hydroxypyrrolidine-2-carboxamide",CHEMBL1211767,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,5000.0,nM,C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1,CHEMBL1208743,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4550,4554,10.1016/j.bmcl.2010.06.019,20598880.0,
3378891,CHEMBL1209686,"(2S,3S)-N-((S)-1-(4-(5-(2-cyclohexylethyl)-1,2,4-oxadiazol-3-yl)phenyl)propyl)-3-hydroxypyrrolidine-2-carboxamide",CHEMBL1211767,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,5000.0,nM,CC[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1,CHEMBL1208743,Discovery of novel sphingosine kinase-1 inhibitors. Part 2.,Bioorg. Med. Chem. Lett.,2010.0,20,15,4550,4554,10.1016/j.bmcl.2010.06.019,20598880.0,
3388704,CHEMBL1269597,[(40-OH) MeLeu]4-CsA derivatives,CHEMBL1216222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 after 30 mins,IC50,=,13400.0,nM,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)[C@H](SCCN(C)C)C(=O)N(C)[C@@H](CC(C)(C)O)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,CHEMBL1212786,"SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.",Antimicrob. Agents Chemother.,2010.0,54,2,660,672,10.1128/aac.00660-09,19933795.0,
3388806,CHEMBL160,"30-Ethyl-33-(1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone",CHEMBL1216222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 after 30 mins,IC50,=,38800.0,nM,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,CHEMBL1212786,"SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.",Antimicrob. Agents Chemother.,2010.0,54,2,660,672,10.1128/aac.00660-09,19933795.0,
3402722,CHEMBL1214452,"N-[(2S)-5-(5-Fluoro-2-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide",CHEMBL1217496,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,>,10000.0,nM,CC(C)S(=O)(=O)N[C@H]1Cc2ccc(-c3ccc(F)cn3)cc2C1,CHEMBL1212831,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,2010.0,53,15,5801,5812,10.1021/jm1005429,20614889.0,
3402723,CHEMBL1214451,"N-[5-(5-chloro-2-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide",CHEMBL1217496,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,>,10000.0,nM,CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(Cl)cn3)cc2C1,CHEMBL1212831,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,2010.0,53,15,5801,5812,10.1021/jm1005429,20614889.0,
3402724,CHEMBL1214450,"N-[5-(3-methyl-2-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide",CHEMBL1217496,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,>,10000.0,nM,Cc1cccnc1-c1ccc2c(c1)CC(NS(=O)(=O)C(C)C)C2,CHEMBL1212831,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,2010.0,53,15,5801,5812,10.1021/jm1005429,20614889.0,
3402725,CHEMBL1214449,"N-[5-(5-methyl-2-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide",CHEMBL1217496,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,>,10000.0,nM,Cc1ccc(-c2ccc3c(c2)CC(NS(=O)(=O)C(C)C)C3)nc1,CHEMBL1212831,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,2010.0,53,15,5801,5812,10.1021/jm1005429,20614889.0,
3402726,CHEMBL1214448,"N-[5-(5-fluoro-2-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide",CHEMBL1217496,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,>,10000.0,nM,CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(F)cn3)cc2C1,CHEMBL1212831,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,2010.0,53,15,5801,5812,10.1021/jm1005429,20614889.0,
3402727,CHEMBL1214447,"N-[(2S)-5-(6-Methyl-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide",CHEMBL1217496,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,>,10000.0,nM,Cc1ccc(-c2ccc3c(c2)C[C@@H](NS(=O)(=O)C(C)C)C3)cn1,CHEMBL1212831,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,2010.0,53,15,5801,5812,10.1021/jm1005429,20614889.0,
3402728,CHEMBL1214399,"N-[(2S)-5-(6-Fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide",CHEMBL1217496,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,>,10000.0,nM,CC(C)S(=O)(=O)N[C@H]1Cc2ccc(-c3ccc(F)nc3)cc2C1,CHEMBL1212831,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,2010.0,53,15,5801,5812,10.1021/jm1005429,20614889.0,
3402729,CHEMBL1214397,"N-[5-(6-methyl-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide",CHEMBL1217496,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,>,10000.0,nM,Cc1ccc(-c2ccc3c(c2)CC(NS(=O)(=O)C(C)C)C3)cn1,CHEMBL1212831,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,2010.0,53,15,5801,5812,10.1021/jm1005429,20614889.0,
3402730,CHEMBL1214396,"N-[5-(4-methyl-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide",CHEMBL1217496,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,>,10000.0,nM,Cc1ccncc1-c1ccc2c(c1)CC(NS(=O)(=O)C(C)C)C2,CHEMBL1212831,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,2010.0,53,15,5801,5812,10.1021/jm1005429,20614889.0,
3402731,CHEMBL1214395,"N-[5-(5-cyano-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide",CHEMBL1217496,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,>,10000.0,nM,CC(C)S(=O)(=O)NC1Cc2ccc(-c3cncc(C#N)c3)cc2C1,CHEMBL1212831,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,2010.0,53,15,5801,5812,10.1021/jm1005429,20614889.0,
3402732,CHEMBL1214394,"N-[5-(2,6-dimethyl-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide",CHEMBL1217496,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,>,10000.0,nM,Cc1ccc(-c2ccc3c(c2)CC(NS(=O)(=O)C(C)C)C3)c(C)n1,CHEMBL1212831,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,2010.0,53,15,5801,5812,10.1021/jm1005429,20614889.0,
3402733,CHEMBL1214338,"N-[5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide",CHEMBL1217496,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,>,10000.0,nM,CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(F)nc3)cc2C1,CHEMBL1212831,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,2010.0,53,15,5801,5812,10.1021/jm1005429,20614889.0,
3402734,CHEMBL1214337,"N-[5-(2-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide",CHEMBL1217496,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,>,10000.0,nM,CC(C)S(=O)(=O)NC1Cc2ccc(-c3cccnc3F)cc2C1,CHEMBL1212831,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,2010.0,53,15,5801,5812,10.1021/jm1005429,20614889.0,
3402735,CHEMBL1214336,"N-[5-(3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide",CHEMBL1217496,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 after 10 mins,IC50,>,10000.0,nM,CC(C)S(=O)(=O)NC1Cc2ccc(-c3cccnc3)cc2C1,CHEMBL1212831,"Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.",J. Med. Chem.,2010.0,53,15,5801,5812,10.1021/jm1005429,20614889.0,
3403503,CHEMBL1215552,"Methyl 2-((1H-Imidazol-1-yl)methyl)-4-(2-chloro-4-fluorophenyl)-5-cyano-6-methyl-1,4-dihydropyridine-3-carboxylate",CHEMBL1219580,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1000.0,nM,COC(=O)C1=C(Cn2ccnc2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,2010.0,53,16,5970,5978,10.1021/jm100506y,20672820.0,
3403504,CHEMBL1215620,"Methyl 2-((1H-Pyrazol-1-yl)methyl)-4-(2-chloro-4-fluorophenyl)-5-cyano-6-methyl-1,4-dihydropyridine-3-carboxylate",CHEMBL1219580,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,600.0,nM,COC(=O)C1=C(Cn2cccn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,2010.0,53,16,5970,5978,10.1021/jm100506y,20672820.0,
3403505,CHEMBL1215621,"Methyl 2-((1H-1,2,4-Triazol-1-yl)methyl)-4-(2-chloro-4-fluorophenyl)-5-cyano-6-methyl-1,4-dihydropyridine-3-carboxylate",CHEMBL1219580,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,100.0,nM,COC(=O)C1=C(Cn2cncn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,2010.0,53,16,5970,5978,10.1021/jm100506y,20672820.0,
3403506,CHEMBL1215622,"Methyl 2-((1H-Tetrazol-1-yl)methyl)-4-(2-chloro-4-fluorophenyl)-5-cyano-6-methyl-1,4-dihydropyridine-3-carboxylate",CHEMBL1219580,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1900.0,nM,COC(=O)C1=C(Cn2cnnn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,2010.0,53,16,5970,5978,10.1021/jm100506y,20672820.0,
3403507,CHEMBL1215623,"(R)-Methyl 2-((1H-Tetrazol-1-yl)methyl)-4-(2-chloro-4-fluorophenyl)-5-cyano-6-methyl-1,4-dihydropyridine-3-carboxylate",CHEMBL1219580,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,COC(=O)C1=C(Cn2cnnn2)NC(C)=C(C#N)[C@H]1c1ccc(F)cc1Cl,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,2010.0,53,16,5970,5978,10.1021/jm100506y,20672820.0,
3412555,CHEMBL1222864,1-(2-morpholinoethyl)-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,CHEMBL1228483,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,20000.0,nM,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCN3CCOCC3)c3ccccc32)CC1,CHEMBL1221311,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,17,5004,5008,10.1016/j.bmcl.2010.07.052,20685118.0,
3412556,CHEMBL1222863,1-(2-(piperidin-1-yl)ethyl)-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,CHEMBL1228483,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,20000.0,nM,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCN3CCCCC3)c3ccccc32)CC1,CHEMBL1221311,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,17,5004,5008,10.1016/j.bmcl.2010.07.052,20685118.0,
3412557,CHEMBL1222800,1-(2-(dimethylamino)ethyl)-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,CHEMBL1228483,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,20000.0,nM,CN(C)CCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21,CHEMBL1221311,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,17,5004,5008,10.1016/j.bmcl.2010.07.052,20685118.0,
3412558,CHEMBL1222485,1-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,CHEMBL1228483,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,20000.0,nM,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,CHEMBL1221311,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,17,5004,5008,10.1016/j.bmcl.2010.07.052,20685118.0,
3412659,CHEMBL1222865,1-(3-(dimethylamino)propyl)-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,CHEMBL1228483,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,20000.0,nM,CN(C)CCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21,CHEMBL1221311,The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,17,5004,5008,10.1016/j.bmcl.2010.07.052,20685118.0,
3414425,CHEMBL1224382,"(S)-3-(3,4-dichlorophenyl)-N-methyl-3-(5-methyl-2H-tetrazol-2-yl)propan-1-amine",CHEMBL1228951,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CNCC[C@@H](c1ccc(Cl)c(Cl)c1)n1nnc(C)n1,CHEMBL1221386,Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,18,5567,5571,10.1016/j.bmcl.2010.07.021,20724153.0,
3416328,CHEMBL1224194,"1-(2',4'-bis(trifluoromethyl)biphenyl-3-yl)-5-methyl-1H-pyrazole-3-carboxamide",CHEMBL1225832,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9000.0,nM,Cc1cc(C(N)=O)nn1-c1cccc(-c2ccc(C(F)(F)F)cc2C(F)(F)F)c1,CHEMBL1221355,Substituted biaryl pyrazoles as sodium channel blockers.,Bioorg. Med. Chem. Lett.,2010.0,20,18,5480,5483,10.1016/j.bmcl.2010.07.080,20709545.0,
3416332,CHEMBL1224195,"1-(2',5'-bis(trifluoromethyl)biphenyl-3-yl)-5-methyl-1H-pyrazole-3-carboxamide",CHEMBL1225832,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2600.0,nM,Cc1cc(C(N)=O)nn1-c1cccc(-c2cc(C(F)(F)F)ccc2C(F)(F)F)c1,CHEMBL1221355,Substituted biaryl pyrazoles as sodium channel blockers.,Bioorg. Med. Chem. Lett.,2010.0,20,18,5480,5483,10.1016/j.bmcl.2010.07.080,20709545.0,
3417423,CHEMBL1224524,4-(2'-(trifluoromethyl)biphenyl-3-yl)-1H-imidazole,CHEMBL1226092,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,50.0,nM,FC(F)(F)c1ccccc1-c1cccc(-c2c[nH]cn2)c1,CHEMBL1221361,"Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers.",Bioorg. Med. Chem. Lett.,2010.0,20,18,5536,5540,10.1016/j.bmcl.2010.07.064,20709552.0,
3417430,CHEMBL1224590,4-(2'-(trifluoromethyl)biphenyl-3-yl)-1H-imidazole-2-carboxamide,CHEMBL1226092,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,40000.0,nM,NC(=O)c1nc(-c2cccc(-c3ccccc3C(F)(F)F)c2)c[nH]1,CHEMBL1221361,"Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers.",Bioorg. Med. Chem. Lett.,2010.0,20,18,5536,5540,10.1016/j.bmcl.2010.07.064,20709552.0,
3417447,CHEMBL1224197,4-(2'-(trifluoromethoxy)biphenyl-3-yl)thiazole-2-carboxamide,CHEMBL1226092,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,16000.0,nM,NC(=O)c1nc(-c2cccc(-c3ccccc3OC(F)(F)F)c2)cs1,CHEMBL1221361,"Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers.",Bioorg. Med. Chem. Lett.,2010.0,20,18,5536,5540,10.1016/j.bmcl.2010.07.064,20709552.0,
3417449,CHEMBL1224655,2-(2'-(trifluoromethoxy)biphenyl-3-yl)thiazole-4-carboxamide,CHEMBL1226092,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8790.0,nM,NC(=O)c1csc(-c2cccc(-c3ccccc3OC(F)(F)F)c2)n1,CHEMBL1221361,"Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers.",Bioorg. Med. Chem. Lett.,2010.0,20,18,5536,5540,10.1016/j.bmcl.2010.07.064,20709552.0,
3425653,CHEMBL1210558,"N-(2,4-dichlorobenzyl)-2-(3,5-dimethyl-1H-pyrazol-4-yl)acetamide",CHEMBL1228414,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,100.0,nM,Cc1n[nH]c(C)c1CC(=O)NCc1ccc(Cl)cc1Cl,CHEMBL1221272,Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor.,Bioorg. Med. Chem. Lett.,2010.0,20,17,5080,5084,10.1016/j.bmcl.2010.07.033,20673717.0,
3425658,CHEMBL1222883,(S)-N-(2-chloro-3-(trifluoromethyl)benzyl)-1-methyl-5-oxopyrrolidine-2-carboxamide,CHEMBL1228414,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,100.0,nM,CN1C(=O)CC[C@H]1C(=O)NCc1cccc(C(F)(F)F)c1Cl,CHEMBL1221272,Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor.,Bioorg. Med. Chem. Lett.,2010.0,20,17,5080,5084,10.1016/j.bmcl.2010.07.033,20673717.0,
3426709,CHEMBL111,"5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide",CHEMBL1227229,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,5.3,nM,Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1,CHEMBL1221281,"Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.",Bioorg. Med. Chem.,2010.0,18,17,6377,6388,10.1016/j.bmc.2010.07.013,20673729.0,
3426711,CHEMBL1223259,"2-(4-((1H-1,2,4-Triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole",CHEMBL1227229,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,20.0,nM,CC(C)(C)c1nnc(-c2nn(-c3ccccc3Cl)c(-c3ccc(Br)cc3)c2Cn2cncn2)s1,CHEMBL1221281,"Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.",Bioorg. Med. Chem.,2010.0,18,17,6377,6388,10.1016/j.bmc.2010.07.013,20673729.0,
3426714,CHEMBL220360,"N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide",CHEMBL1227229,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,0.93,nM,C[C@H](NC(=O)C(C)(C)Oc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1,CHEMBL1221281,"Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.",Bioorg. Med. Chem.,2010.0,18,17,6377,6388,10.1016/j.bmc.2010.07.013,20673729.0,
3426720,CHEMBL1223034,"2-(4-((1H-1,2,4-Triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole",CHEMBL1227229,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,2.6,nM,CC(C)(C)c1nnc(-c2nn(-c3ccc(Cl)cc3Cl)c(-c3ccc(Br)cc3)c2Cn2cncn2)s1,CHEMBL1221281,"Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.",Bioorg. Med. Chem.,2010.0,18,17,6377,6388,10.1016/j.bmc.2010.07.013,20673729.0,
3426721,CHEMBL1222969,"2-(4-((1H-1,2,4-Triazol-1-yl)methyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl)-5-(1-(trifluoromethyl)-cyclobutyl)-1,3,4-thiadiazole",CHEMBL1227229,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,20.0,nM,FC(F)(F)C1(c2nnc(-c3nn(-c4ccc(Cl)cc4Cl)c(-c4ccc(Cl)cc4)c3Cn3cncn3)s2)CCC1,CHEMBL1221281,"Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.",Bioorg. Med. Chem.,2010.0,18,17,6377,6388,10.1016/j.bmc.2010.07.013,20673729.0,
3430857,CHEMBL1241738,"1-methyl-6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]oxazine",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,>,10000.0,nM,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nnc(C)n4-5)CC3)cccc2n1,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3430863,CHEMBL1241546,"3-methyl-6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b][1,2,3]triazolo[1,5-d][1,4]oxazine",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,>,5000.0,nM,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C)nnn4-5)CC3)cccc2n1,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3430869,CHEMBL1241736,"1-(6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazin-3-yl)ethanone",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,>,5000.0,nM,CC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3430875,CHEMBL1241824,"N,N-dimethyl-6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxamide",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,>,10000.0,nM,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N(C)C)ncn4-5)CC3)cccc2n1,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3430881,CHEMBL1241912,"N-methyl-6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxamide",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,>,9000.0,nM,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3430887,CHEMBL1241913,"6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxamide",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,>,9000.0,nM,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3430893,CHEMBL1241998,"N-isopropyl-6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxamide",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,>,8000.0,nM,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC(C)C)ncn4-5)CC3)cccc2n1,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3430899,CHEMBL1242081,"N-cyclopropyl-6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxamide",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,>,7000.0,nM,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC6CC6)ncn4-5)CC3)cccc2n1,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3430905,CHEMBL1242345,"N-(cyclopropylmethyl)-6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxamide",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,>,10000.0,nM,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NCC6CC6)ncn4-5)CC3)cccc2n1,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3430911,CHEMBL1242533,"(6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazin-3-yl)(pyrrolidin-1-yl)methanone",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,>,6000.0,nM,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCC6)ncn4-5)CC3)cccc2n1,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3430917,CHEMBL1242623,"(6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazin-3-yl)(piperidin-1-yl)methanone",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,>,10000.0,nM,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCCC6)ncn4-5)CC3)cccc2n1,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3430923,CHEMBL1242717,"(6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazin-3-yl)(morpholino)methanone",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,>,10000.0,nM,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCOCC6)ncn4-5)CC3)cccc2n1,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3431376,CHEMBL1242904,"6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,2-d][1,4]oxazine",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,=,4000.0,nM,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nccn4-5)CC3)cccc2n1,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3431378,CHEMBL1241547,"2-methyl-6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,2-d][1,4]oxazine",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,<,4000.0,nM,Cc1cn2c(n1)COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3431380,CHEMBL1241548,"1,2-dimethyl-6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,2-d][1,4]oxazine",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,<,4000.0,nM,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nc(C)c(C)n4-5)CC3)cccc2n1,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3431382,CHEMBL1241641,"6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-2-(trifluoromethyl)-4H-benzo[b]imidazo[1,2-d][1,4]oxazine",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,<,4000.0,nM,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nc(C(F)(F)F)cn4-5)CC3)cccc2n1,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3431384,CHEMBL1241642,"6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,<,2000.0,nM,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4cncn4-5)CC3)cccc2n1,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3431390,CHEMBL1241640,"ethyl 6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxylate",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,=,4000.0,nM,CCOC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3431391,CHEMBL1241737,"1-(6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazin-3-yl)ethanone O-methyl oxime",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,=,4000.0,nM,CO/N=C(\C)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3431393,CHEMBL1241825,"6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carbonitrile",CHEMBL1248644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 preincubated for 10 mins,IC50,=,2000.0,nM,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C#N)ncn4-5)CC3)cccc2n1,CHEMBL1240442,"Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).",J. Med. Chem.,2010.0,53,15,5827,5843,10.1021/jm100482n,20590088.0,
3466645,CHEMBL1230065,"4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide",CHEMBL1251100,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,40000.0,nM,CCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C,CHEMBL1250528,"Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.",J. Med. Chem.,2010.0,53,18,6629,6639,10.1021/jm100540x,20804198.0,
3498682,CHEMBL1257706,"(1S,2R,5aS,7S,8aR,8bS)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-1-(4-fluorophenyl)-7-hydroxy-7-methyloctahydrocyclopenta[a]pyrrolizin-5(5aH)-one",CHEMBL1259707,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,43120.0,nM,C[C@@H](O[C@H]1CN2C(=O)[C@H]3C[C@@](C)(O)C[C@H]3[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,CHEMBL1255526,Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor.,Bioorg. Med. Chem. Lett.,2010.0,20,19,5925,5932,10.1016/j.bmcl.2010.07.058,20729082.0,
3500287,CHEMBL497031,"(4,4-Difluoropiperidin-1-yl)[1-isopropyl-5-(1-isopropylpiperidin-4-yloxy)-1H-indol-2-yl]methanone",CHEMBL1260336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(C)N1CCC(Oc2ccc3c(c2)cc(C(=O)N2CCC(F)(F)CC2)n3C(C)C)CC1,CHEMBL1255546,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,2010.0,20,19,5713,5717,10.1016/j.bmcl.2010.08.009,20801030.0,
3500288,CHEMBL1258754,"8-(1-isopropylpiperidin-4-yloxy)-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one",CHEMBL1260336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCNC2=O)CC1,CHEMBL1255546,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,2010.0,20,19,5713,5717,10.1016/j.bmcl.2010.08.009,20801030.0,
3500289,CHEMBL1258755,"9-(1-isopropylpiperidin-4-yloxy)-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-a]indol-1-one",CHEMBL1260336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCCNC2=O)CC1,CHEMBL1255546,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,2010.0,20,19,5713,5717,10.1016/j.bmcl.2010.08.009,20801030.0,
3500290,CHEMBL1258873,"8-(1-isopropylpiperidin-4-yloxy)-2-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one",CHEMBL1260336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(C)C2=O)CC1,CHEMBL1255546,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,2010.0,20,19,5713,5717,10.1016/j.bmcl.2010.08.009,20801030.0,
3500291,CHEMBL1257138,"2-(cyclopropylmethyl)-8-(1-isopropylpiperidin-4-yloxy)-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one",CHEMBL1260336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(CC3CC3)C2=O)CC1,CHEMBL1255546,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,2010.0,20,19,5713,5717,10.1016/j.bmcl.2010.08.009,20801030.0,
3500292,CHEMBL1257376,"2-(4-fluorobenzyl)-8-(1-isopropylpiperidin-4-yloxy)-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one",CHEMBL1260336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(Cc3ccc(F)cc3)C2=O)CC1,CHEMBL1255546,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,2010.0,20,19,5713,5717,10.1016/j.bmcl.2010.08.009,20801030.0,
3500293,CHEMBL1257487,"8-(1-isopropylpiperidin-4-yloxy)-2-(pyridin-4-ylmethyl)-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one",CHEMBL1260336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(Cc3ccncc3)C2=O)CC1,CHEMBL1255546,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,2010.0,20,19,5713,5717,10.1016/j.bmcl.2010.08.009,20801030.0,
3500294,CHEMBL1257607,"2-(2-hydroxyethyl)-8-(1-isopropylpiperidin-4-yloxy)-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one",CHEMBL1260336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(CCO)C2=O)CC1,CHEMBL1255546,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,2010.0,20,19,5713,5717,10.1016/j.bmcl.2010.08.009,20801030.0,
3500295,CHEMBL1257729,"(R)-8-(1-isopropylpiperidin-4-yloxy)-3-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one",CHEMBL1260336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3C[C@@H](C)NC2=O)CC1,CHEMBL1255546,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,2010.0,20,19,5713,5717,10.1016/j.bmcl.2010.08.009,20801030.0,
3500296,CHEMBL1257850,"(S)-8-(1-isopropylpiperidin-4-yloxy)-3-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one",CHEMBL1260336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3C[C@H](C)NC2=O)CC1,CHEMBL1255546,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,2010.0,20,19,5713,5717,10.1016/j.bmcl.2010.08.009,20801030.0,
3500297,CHEMBL1257851,"(R)-8-(1-isopropylpiperidin-4-yloxy)-4-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one",CHEMBL1260336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3[C@H](C)CNC2=O)CC1,CHEMBL1255546,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,2010.0,20,19,5713,5717,10.1016/j.bmcl.2010.08.009,20801030.0,
3500298,CHEMBL1257964,"(S)-8-(1-isopropylpiperidin-4-yloxy)-4-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one",CHEMBL1260336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3[C@@H](C)CNC2=O)CC1,CHEMBL1255546,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,2010.0,20,19,5713,5717,10.1016/j.bmcl.2010.08.009,20801030.0,
3500299,CHEMBL1257965,"(R)-2-(cyclopropylmethyl)-8-(1-isopropylpiperidin-4-yloxy)-3-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one",CHEMBL1260336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3C[C@@H](C)N(CC3CC3)C2=O)CC1,CHEMBL1255546,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,2010.0,20,19,5713,5717,10.1016/j.bmcl.2010.08.009,20801030.0,
3500300,CHEMBL1258078,"(S)-7-bromo-8-(1-isopropylpiperidin-4-yloxy)-4-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one",CHEMBL1260336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(C)N1CCC(Oc2cc3cc4n(c3cc2Br)[C@@H](C)CNC4=O)CC1,CHEMBL1255546,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,2010.0,20,19,5713,5717,10.1016/j.bmcl.2010.08.009,20801030.0,
3500301,CHEMBL1258079,"(S)-7-bromo-2-(cyclopropylmethyl)-8-(1-isopropylpiperidin-4-yloxy)-4-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one",CHEMBL1260336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC(C)N1CCC(Oc2cc3cc4n(c3cc2Br)[C@@H](C)CN(CC2CC2)C4=O)CC1,CHEMBL1255546,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,2010.0,20,19,5713,5717,10.1016/j.bmcl.2010.08.009,20801030.0,
3500302,CHEMBL1258308,"(R)-8-(3-(2-methylpyrrolidin-1-yl)propoxy)-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one",CHEMBL1260336,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,C[C@@H]1CCCN1CCCOc1ccc2c(c1)cc1n2CCNC1=O,CHEMBL1255546,"Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.",Bioorg. Med. Chem. Lett.,2010.0,20,19,5713,5717,10.1016/j.bmcl.2010.08.009,20801030.0,
3502991,CHEMBL117,"5,7-Dihydroxy-2-phenyl-chromen-4-one",CHEMBL1261122,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,5225.0,nM,O=c1cc(-c2ccccc2)oc2cc(O)cc(O)c12,CHEMBL1255203,"Isoform-selective inhibition of chrysin towards human cytochrome P450 1A2. Kinetics analysis, molecular docking, and molecular dynamics simulations.",Bioorg. Med. Chem. Lett.,2010.0,20,20,6008,6012,10.1016/j.bmcl.2010.08.072,20832301.0,
3505314,CHEMBL1257215,"3-[4-(1,1-Dimethylethyl)phenyl]-8-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-8-azabicyclo-[3.2.1]octane",CHEMBL1261452,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,5000.0,nM,Cc1ncoc1-c1nnc(SCCCN2[C@H]3CC[C@@H]2C[C@H](c2ccc(C(C)(C)C)cc2)C3)n1C,CHEMBL1255216,"Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.",J. Med. Chem.,2010.0,53,19,7129,7139,10.1021/jm100832d,20839775.0,
3505315,CHEMBL1257336,"8-(3-{[4-Methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3-[4-(trifluoromethyl)phenyl]-8-azabicyclo[3.2.1]-octane",CHEMBL1261452,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,10000.0,nM,Cc1ncoc1-c1nnc(SCCCN2[C@H]3CC[C@@H]2C[C@H](c2ccc(C(F)(F)F)cc2)C3)n1C,CHEMBL1255216,"Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.",J. Med. Chem.,2010.0,53,19,7129,7139,10.1021/jm100832d,20839775.0,
3505418,CHEMBL1258034,"4-(3-{[4-Methyl-5-(4-pyridazinyl)-4H-1,2,4-triazol-3-yl]thio}-propyl)-1-[4-(trifluoromethyl)phenyl]-4-azabicyclo[5.1.0]octane",CHEMBL1261452,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,6000.0,nM,Cn1c(SCCCN2CCC3CC3(c3ccc(C(F)(F)F)cc3)CC2)nnc1-c1ccnnc1,CHEMBL1255216,"Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.",J. Med. Chem.,2010.0,53,19,7129,7139,10.1021/jm100832d,20839775.0,
3505429,CHEMBL1258035,"(2R,5S)-N-(3-(4-methyl-5-(4-methyloxazol-5-yl)-4H-1,2,4-triazol-3-ylthio)propyl)-5-(4-(trifluoromethyl)phenyl)bicyclo[3.1.0]hexan-2-amine",CHEMBL1261452,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,4000.0,nM,Cc1ncoc1-c1nnc(SCCCN[C@@H]2CC[C@]3(c4ccc(C(F)(F)F)cc4)CC23)n1C,CHEMBL1255216,"Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.",J. Med. Chem.,2010.0,53,19,7129,7139,10.1021/jm100832d,20839775.0,
3505437,CHEMBL1080003,7-methoxy-4-trifluoromethyl coumarin-3-acetic acid,CHEMBL1261452,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,50000.0,nM,COc1ccc2c(C(F)(F)F)c(CC(=O)O)c(=O)oc2c1,CHEMBL1255216,"Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.",J. Med. Chem.,2010.0,53,19,7129,7139,10.1021/jm100832d,20839775.0,
3516421,CHEMBL1270269,2-(3-(2-cyano-6-(3-(trifluoromethyl)phenyl)pyrimidin-4-yl)propylamino)-2-methylpropanamide,CHEMBL1275143,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,35000.0,nM,CC(C)(NCCCc1cc(-c2cccc(C(F)(F)F)c2)nc(C#N)n1)C(N)=O,CHEMBL1268809,Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG.,Bioorg. Med. Chem. Lett.,2010.0,20,21,6237,6241,10.1016/j.bmcl.2010.08.101,20843687.0,
3518587,CHEMBL1269858,"N2-(3,5-dimorpholinophenyl)-N4-(1H-indazol-4-yl)-N4-methylpyrimidine-2,4-diamine",CHEMBL1274267,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by fluorometric assay,IC50,=,5000.0,nM,CN(c1ccnc(Nc2cc(N3CCOCC3)cc(N3CCOCC3)c2)n1)c1cccc2[nH]ncc12,CHEMBL1268821,Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,21,6242,6245,10.1016/j.bmcl.2010.08.100,20850301.0,
3519509,CHEMBL1270738,"ethyl(1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(2,3'-bipyridin-6'-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-ylcarbamate",CHEMBL1273607,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccccn2)cn1,CHEMBL1268933,Discovery of a vorapaxar analog with increased aqueous solubility.,Bioorg. Med. Chem. Lett.,2010.0,20,22,6676,6679,10.1016/j.bmcl.2010.09.009,20888225.0,
3523041,CHEMBL1236391,N-(3-(methylthio)-1-phenyl-1H-indazol-6-yl)piperidine-4-carboxamide,CHEMBL1273544,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,10000.0,nM,CSc1nn(-c2ccccc2)c2cc(NC(=O)C3CCNCC3)ccc12,CHEMBL1269008,Electron density guided fragment-based lead discovery of ketohexokinase inhibitors.,J. Med. Chem.,2010.0,53,22,7979,7991,10.1021/jm100677s,21033679.0,
3524296,CHEMBL1270215,(R)-3-tert-Butoxycarbonylamino-pyrrolidine-1-carboxylic acid adamantan-2-yl ester,CHEMBL1273488,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,11400.0,nM,CC(C)(C)OC(=O)N[C@@H]1CCN(C(=O)OC2C3CC4CC(C3)CC2C4)C1,CHEMBL1268897,Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1.,Bioorg. Med. Chem. Lett.,2010.0,20,22,6725,6729,10.1016/j.bmcl.2010.08.142,20864344.0,
3524297,CHEMBL1270910,(R)-3-tert-Butoxycarbonylamino-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,CHEMBL1273488,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CC(C)(C)OC(=O)N[C@@H]1CCN(C(=O)O[C@H]2C3CC4CC2C[C@](C(N)=O)(C4)C3)C1,CHEMBL1268897,Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1.,Bioorg. Med. Chem. Lett.,2010.0,20,22,6725,6729,10.1016/j.bmcl.2010.08.142,20864344.0,
3524298,CHEMBL1271218,(R)-3-(3-Trifluoromethyl-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,CHEMBL1273488,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9400.0,nM,NC(=O)[C@]12CC3CC(C1)[C@@H](OC(=O)N1CC[C@@H](Nc4ncccc4C(F)(F)F)C1)C(C3)C2,CHEMBL1268897,Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1.,Bioorg. Med. Chem. Lett.,2010.0,20,22,6725,6729,10.1016/j.bmcl.2010.08.142,20864344.0,
3524299,CHEMBL1271320,(R)-3-(5-Trifluoromethyl-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,CHEMBL1273488,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4100.0,nM,NC(=O)[C@]12CC3CC(C1)[C@@H](OC(=O)N1CC[C@@H](Nc4ccc(C(F)(F)F)cn4)C1)C(C3)C2,CHEMBL1268897,Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1.,Bioorg. Med. Chem. Lett.,2010.0,20,22,6725,6729,10.1016/j.bmcl.2010.08.142,20864344.0,
3524300,CHEMBL1271427,(R)-3-(6-Trifluoromethyl-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,CHEMBL1273488,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2400.0,nM,NC(=O)[C@]12CC3CC(C1)[C@@H](OC(=O)N1CC[C@@H](Nc4cccc(C(F)(F)F)n4)C1)C(C3)C2,CHEMBL1268897,Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1.,Bioorg. Med. Chem. Lett.,2010.0,20,22,6725,6729,10.1016/j.bmcl.2010.08.142,20864344.0,
3524301,CHEMBL1271428,(S)-3-(3-Trifluoromethyl-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,CHEMBL1273488,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8000.0,nM,NC(=O)[C@]12CC3CC(C1)[C@H](OC(=O)N1CC[C@H](Nc4ncccc4C(F)(F)F)C1)C(C3)C2,CHEMBL1268897,Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1.,Bioorg. Med. Chem. Lett.,2010.0,20,22,6725,6729,10.1016/j.bmcl.2010.08.142,20864344.0,
3524302,CHEMBL1269894,(S)-3-(5-Trifluoromethyl-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,CHEMBL1273488,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2400.0,nM,NC(=O)[C@]12CC3CC(C1)[C@@H](OC(=O)N1CC[C@H](Nc4ccc(C(F)(F)F)cn4)C1)C(C3)C2,CHEMBL1268897,Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1.,Bioorg. Med. Chem. Lett.,2010.0,20,22,6725,6729,10.1016/j.bmcl.2010.08.142,20864344.0,
3524303,CHEMBL1269895,(R)-3-(3-Cyano-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,CHEMBL1273488,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,N#Cc1cccnc1N[C@@H]1CCN(C(=O)O[C@H]2C3CC4CC2C[C@](C(N)=O)(C4)C3)C1,CHEMBL1268897,Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1.,Bioorg. Med. Chem. Lett.,2010.0,20,22,6725,6729,10.1016/j.bmcl.2010.08.142,20864344.0,
3524304,CHEMBL1270001,(R)-3-(5-Cyano-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,CHEMBL1273488,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,23100.0,nM,N#Cc1ccc(N[C@@H]2CCN(C(=O)O[C@H]3C4CC5CC3C[C@](C(N)=O)(C5)C4)C2)nc1,CHEMBL1268897,Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1.,Bioorg. Med. Chem. Lett.,2010.0,20,22,6725,6729,10.1016/j.bmcl.2010.08.142,20864344.0,
3524305,CHEMBL1270002,(S)-3-(3-Cyano-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,CHEMBL1273488,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,N#Cc1cccnc1N[C@H]1CCN(C(=O)O[C@H]2C3CC4CC2C[C@](C(N)=O)(C4)C3)C1,CHEMBL1268897,Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1.,Bioorg. Med. Chem. Lett.,2010.0,20,22,6725,6729,10.1016/j.bmcl.2010.08.142,20864344.0,
3524306,CHEMBL1270110,(S)-3-(5-Cyano-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,CHEMBL1273488,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,20000.0,nM,N#Cc1ccc(N[C@H]2CCN(C(=O)O[C@H]3C4CC5CC3C[C@](C(N)=O)(C5)C4)C2)nc1,CHEMBL1268897,Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1.,Bioorg. Med. Chem. Lett.,2010.0,20,22,6725,6729,10.1016/j.bmcl.2010.08.142,20864344.0,
3524307,CHEMBL1269176,Adamantan-2-ol,CHEMBL1273488,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,22000.0,nM,OC1C2CC3CC(C2)CC1C3,CHEMBL1268897,Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1.,Bioorg. Med. Chem. Lett.,2010.0,20,22,6725,6729,10.1016/j.bmcl.2010.08.142,20864344.0,
3526531,CHEMBL1272135,"1-(1-(2-chloro-6-fluorobenzyl)-2-oxo-1,2-dihydropyridin-3-yl)-3-(3-methoxyphenyl)urea",CHEMBL1272331,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3700.0,nM,COc1cccc(NC(=O)Nc2cccn(Cc3c(F)cccc3Cl)c2=O)c1,CHEMBL1268956,"3-Urea-1-(phenylmethyl)-pyridones as novel, potent, and selective EP3 receptor antagonists.",Bioorg. Med. Chem. Lett.,2010.0,20,22,6744,6747,10.1016/j.bmcl.2010.08.137,20926294.0,
3530799,CHEMBL1271930,"N-(2-(4-(2,3-dimethylphenyl)piperazin-1-yl)ethyl)-6-methyl-2-(methylthio)pyrimidine-4-carboxamide hydrochloride",CHEMBL1272928,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,20000.0,nM,CSc1nc(C)cc(C(=O)NCCN2CCN(c3cccc(C)c3C)CC2)n1.Cl,CHEMBL1268978,"Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",Bioorg. Med. Chem. Lett.,2010.0,20,22,6439,6442,10.1016/j.bmcl.2010.09.081,20933409.0,
3531515,CHEMBL1271489,"N-(3,5-dimethylphenyl)-2-(4-(furan-2-ylmethyl)-5-(2-methylfuran-3-yl)-4H-1,2,4-triazol-3-ylthio)acetamide",CHEMBL1273051,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 by CYPEX bactosome P450 inhibition assay,IC50,>,5000.0,nM,Cc1cc(C)cc(NC(=O)CSc2nnc(-c3ccoc3C)n2Cc2ccco2)c1,CHEMBL1268981,"2-Methyl-3-furanyl-4H-1,2,4-triazol-3-ylthioamides: a new class of selective orexin 2 antagonists.",Bioorg. Med. Chem. Lett.,2010.0,20,22,6405,6407,10.1016/j.bmcl.2010.09.090,20933413.0,
3547850,CHEMBL1276654,"5-Fluoro-1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine]",CHEMBL1285226,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3000.0,nM,Fc1cccc2c1CCC1(CCN(c3ccc(-c4nnc(Cc5cccnc5)o4)nn3)CC1)O2,CHEMBL1275283,"Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine] analogs.",Eur. J. Med. Chem.,2010.0,45,11,4788,4796,10.1016/j.ejmech.2010.07.044,20801551.0,
3561279,CHEMBL1277677,"2-(2-chlorophenyl)-4-((methyl(phenyl)amino)methyl)-5-(pyridin-4-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione",CHEMBL1286981,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,4100.0,nM,CN(Cc1c2c(=O)n(-c3ccccc3Cl)[nH]c2cc(=O)n1Cc1ccncc1)c1ccccc1,CHEMBL1275350,"First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis.",J. Med. Chem.,2010.0,53,21,7715,7730,10.1021/jm100773e,20942471.0,
3561283,CHEMBL1277582,"4-((benzyl(methyl)amino)methyl)-2-(2-chloro-4-fluorophenyl)-5-(3-methoxypropyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione",CHEMBL1286981,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,900.0,nM,COCCCn1c(CN(C)Cc2ccccc2)c2c(=O)n(-c3ccc(F)cc3Cl)[nH]c2cc1=O,CHEMBL1275350,"First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis.",J. Med. Chem.,2010.0,53,21,7715,7730,10.1021/jm100773e,20942471.0,
3561379,CHEMBL1276946,"2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione",CHEMBL1286981,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,25000.0,nM,Cc1c2c(=O)n(-c3ccccc3Cl)[nH]c2cc(=O)n1Cc1ccccn1,CHEMBL1275350,"First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis.",J. Med. Chem.,2010.0,53,21,7715,7730,10.1021/jm100773e,20942471.0,
3561823,CHEMBL1277312,"1-(11'H-Spiro[cyclopentane-1,10'-dibenzo[b,f]oxepin]-3-yl)-3-azetidinecarboxylic Acid",CHEMBL1287104,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 transfected in bactosome expression system by spectrofluorimetry,IC50,>,10000.0,nM,O=C(O)C1CN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)C1,CHEMBL1275351,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,2010.0,53,21,7778,7795,10.1021/jm100856p,20942472.0,
3561824,CHEMBL1277126,"1-{2'-oxaspiro[cyclopentane-1,9'-tricyclo[9.4.0.0^{3,8}]pentadecane]-1'(11'),3'(8'),4',6',12',14'-hexaen-4-yl}-1,2,3,6-tetrahydropyridine-4-carboxylic acid",CHEMBL1287104,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 transfected in bactosome expression system by spectrofluorimetry,IC50,>,10000.0,nM,O=C(O)C1=CCN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)CC1,CHEMBL1275351,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,2010.0,53,21,7778,7795,10.1021/jm100856p,20942472.0,
3561825,CHEMBL1276948,"1-((1S)-5',11'-Dihydrospiro[cyclopentane-1,10'-dibenzo[a,d]-cyclohepten]-3-yl)-3-azetidinecarboxylic Acid",CHEMBL1287104,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 transfected in bactosome expression system by spectrofluorimetry,IC50,>,10000.0,nM,O=C(O)C1CN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1,CHEMBL1275351,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,2010.0,53,21,7778,7795,10.1021/jm100856p,20942472.0,
3561826,CHEMBL1276947,"3-((1S)-5',11'-Dihydrospiro[cyclopentane-1,10'-dibenzo[a,d]-cyclohepten]-3-yl)-3-azabicyclo[3.1.0]hexane-1-carboxylic Acid",CHEMBL1287104,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 transfected in bactosome expression system by spectrofluorimetry,IC50,>,10000.0,nM,O=C(O)[C@]12C[C@H]1CN(C1CC[C@]3(Cc4ccccc4Cc4ccccc43)C1)C2,CHEMBL1275351,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,2010.0,53,21,7778,7795,10.1021/jm100856p,20942472.0,
3561827,CHEMBL1277678,"1-((1S)-5',11'-Dihydrospiro[cyclopentane-1,10'-dibenzo[a,d]-cyclohepten]-3-yl)-4-fluoro-4-piperidinecarboxylic Acid",CHEMBL1287104,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 transfected in bactosome expression system by spectrofluorimetry,IC50,>,10000.0,nM,O=C(O)C1(F)CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)CC1,CHEMBL1275351,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,2010.0,53,21,7778,7795,10.1021/jm100856p,20942472.0,
3561828,CHEMBL1277770,"(-)-1-((1S)-5',11'-Dihydrospiro[cyclopentane-1,10'-dibenzo-[a,d]cyclohepten]-3-yl)-4-piperidinecarboxylic Acid",CHEMBL1287104,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 transfected in bactosome expression system by spectrofluorimetry,IC50,>,10000.0,nM,O=C(O)C1CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)CC1,CHEMBL1275351,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,2010.0,53,21,7778,7795,10.1021/jm100856p,20942472.0,
3561829,CHEMBL1277935,"1-((1S)-5',11'-Dihydrospiro[cyclopentane-1,10'-dibenzo[a,d]-cyclohepten]-3-yl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic Acid",CHEMBL1287104,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 transfected in bactosome expression system by spectrofluorimetry,IC50,>,10000.0,nM,O=C(O)C1=CCCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1,CHEMBL1275351,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,2010.0,53,21,7778,7795,10.1021/jm100856p,20942472.0,
3590896,CHEMBL1290746,5-amino-1-(2-fluorophenyl)-N-(5-(isoxazol-3-ylcarbamoyl)-2-methylphenyl)-1H-pyrazole-4-carboxamide,CHEMBL1292195,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,23000.0,nM,Cc1ccc(C(=O)Nc2ccon2)cc1NC(=O)c1cnn(-c2ccccc2F)c1N,CHEMBL1287714,5-amino-pyrazoles as potent and selective p38α inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,23,6886,6889,10.1016/j.bmcl.2010.10.034,21035336.0,
3591671,CHEMBL1289313,"3-{[(2S)-2-(Aminocarbonyl)pyrrolidin-1-yl]methyl}-1-(4-fluorobenzyl)-N-hydroxy-N-methyl-1H-pyrrolo[2,3-c]pyridine-5-carboxamide",CHEMBL1291073,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CN(O)C(=O)c1cc2c(CN3CCC[C@H]3C(N)=O)cn(Cc3ccc(F)cc3)c2cn1,CHEMBL1287722,Azaindole N-methyl hydroxamic acids as HIV-1 integrase inhibitors-II. The impact of physicochemical properties on ADME and PK.,Bioorg. Med. Chem. Lett.,2010.0,20,24,7429,7434,10.1016/j.bmcl.2010.10.022,21036042.0,
3597775,CHEMBL214957,"6-(4-chlorophenyl)-3-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno[3,2-d]pyrimidin-4(3H)-one",CHEMBL1293111,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000000.0,nM,COc1cc(-n2cnc3cc(-c4ccc(Cl)cc4)sc3c2=O)ccc1OCCN1CCCC1,CHEMBL1287674,Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2010.0,20,23,7020,7023,10.1016/j.bmcl.2010.09.037,20951036.0,
3597776,CHEMBL1289614,1-(5-(4-cyanophenyl)bicyclo[3.1.0]hexan-2-yl)-3-(4-fluoro-3-(trifluoromethyl)phenyl)-1-(3-(4-methylpiperazin-1-yl)propyl)urea,CHEMBL1293111,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000000.0,nM,CN1CCN(CCCN(C(=O)Nc2ccc(F)c(C(F)(F)F)c2)C2CCC3(c4ccc(C#N)cc4)CC23)CC1,CHEMBL1287674,Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2010.0,20,23,7020,7023,10.1016/j.bmcl.2010.09.037,20951036.0,
3597777,CHEMBL1290041,1-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)-4-(4-(trifluoromethyl)phenyl)pyridin-2(1H)-one,CHEMBL1293111,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000000.0,nM,O=c1cc(-c2ccc(C(F)(F)F)cc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1,CHEMBL1287674,Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2010.0,20,23,7020,7023,10.1016/j.bmcl.2010.09.037,20951036.0,
3597778,CHEMBL1290150,"4-(2,4-dichlorophenyl)-1-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)pyridin-2(1H)-one",CHEMBL1293111,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000000.0,nM,O=c1cc(-c2ccc(Cl)cc2Cl)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1,CHEMBL1287674,Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2010.0,20,23,7020,7023,10.1016/j.bmcl.2010.09.037,20951036.0,
3598711,CHEMBL1290004,"5-phenyl-2-(2-(piperidine-1-carbonyl)phenyl)-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-1-one",CHEMBL1292042,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,5000.0,nM,O=C(c1ccccc1N1Cn2c(ccc2-c2ccccc2)C1=O)N1CCCCC1,CHEMBL1287768,"Synthesis and pharmacological characterization of 5-phenyl-2-[2-(1-piperidinylcarbonyl)phenyl]-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-1-ones: a new class of Neuropeptide S antagonists.",Bioorg. Med. Chem. Lett.,2010.0,20,24,7308,7311,10.1016/j.bmcl.2010.10.067,21055936.0,
3600470,CHEMBL1289283,4-(benzyloxy)-1-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)pyridin-2(1H)-one,CHEMBL1292290,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1,CHEMBL1287681,Tetrahydrocarboline analogs as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,23,7024,7028,10.1016/j.bmcl.2010.09.122,20952195.0,
3600471,CHEMBL1290155,"4-(benzyloxy)-1-(2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-7-yl)pyridin-2(1H)-one",CHEMBL1292290,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c3c([nH]c2c1)CCNC3,CHEMBL1287681,Tetrahydrocarboline analogs as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,23,7024,7028,10.1016/j.bmcl.2010.09.122,20952195.0,
3600472,CHEMBL1290264,"4-(benzyloxy)-1-(2,5-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-7-yl)pyridin-2(1H)-one",CHEMBL1292290,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CN1CCc2c(c3ccc(-n4ccc(OCc5ccccc5)cc4=O)cc3n2C)C1,CHEMBL1287681,Tetrahydrocarboline analogs as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,23,7024,7028,10.1016/j.bmcl.2010.09.122,20952195.0,
3600473,CHEMBL1289395,"4-(benzyloxy)-1-(9-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-7-yl)pyridin-2(1H)-one",CHEMBL1292290,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cn1c2c(c3ccc(-n4ccc(OCc5ccccc5)cc4=O)cc31)CCNC2,CHEMBL1287681,Tetrahydrocarboline analogs as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,23,7024,7028,10.1016/j.bmcl.2010.09.122,20952195.0,
3600474,CHEMBL1289396,"4-(benzyloxy)-1-(2,9-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-7-yl)pyridin-2(1H)-one",CHEMBL1292290,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CN1CCc2c(n(C)c3cc(-n4ccc(OCc5ccccc5)cc4=O)ccc23)C1,CHEMBL1287681,Tetrahydrocarboline analogs as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,23,7024,7028,10.1016/j.bmcl.2010.09.122,20952195.0,
3600505,CHEMBL1289283,4-(benzyloxy)-1-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)pyridin-2(1H)-one,CHEMBL1292300,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1,CHEMBL1287684,5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,23,7015,7019,10.1016/j.bmcl.2010.09.039,20961756.0,
3600516,CHEMBL1289515,(S)-4-(benzyloxy)-1-(1-(2-(3-hydroxypyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)pyridin-2(1H)-one,CHEMBL1292300,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CC[C@H](O)C2)c1,CHEMBL1287684,5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,23,7015,7019,10.1016/j.bmcl.2010.09.039,20961756.0,
3601231,CHEMBL1289053,"4-(benzyloxy)-1-(1-((4,5-dihydro-1H-imidazol-2-yl)methyl)-1H-indazol-5-yl)pyridin-2(1H)-one",CHEMBL1292300,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CC2=NCCN2)c1,CHEMBL1287684,5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,23,7015,7019,10.1016/j.bmcl.2010.09.039,20961756.0,
3604310,CHEMBL1287846,"(S)-(1-(cyclohexylmethyl)-7-methoxy-1H-indol-3-yl)(dihydro-1H-pyrido[1,2-a]pyrazin-2(6H,7H,8H,9H,9aH)-yl)methanone",CHEMBL1292549,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,12000.0,nM,COc1cccc2c(C(=O)N3CCN4CCCC[C@H]4C3)cn(CC3CCCCC3)c12,CHEMBL1287799,"Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists.",Bioorg. Med. Chem. Lett.,2010.0,20,24,7327,7330,10.1016/j.bmcl.2010.10.061,21074434.0,
5087367,CHEMBL1631540,1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone,CHEMBL1635467,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,60000.0,nM,Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1,CHEMBL1629528,"Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist.",J. Med. Chem.,2010.0,53,23,8228,8240,10.1021/jm100714c,21053897.0,
5089007,CHEMBL638,"(2R,3S)-2-(2,4-Difluoro-phenyl)-3-(5-fluoro-pyrimidin-4-yl)-1-[1,2,4]triazol-1-yl-butan-2-ol",CHEMBL1635163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as Tolbutamide 4'-hydroxylation after 60 mins,IC50,=,3620.0,nM,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,CHEMBL1629616,"Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A.",Antimicrob. Agents Chemother.,2009.0,53,2,541,551,10.1128/aac.01123-08,19029318.0,
5089010,CHEMBL638,"(2R,3S)-2-(2,4-Difluoro-phenyl)-3-(5-fluoro-pyrimidin-4-yl)-1-[1,2,4]triazol-1-yl-butan-2-ol",CHEMBL1635166,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using Tolbutamide as probe,IC50,=,8400.0,nM,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,CHEMBL1629616,"Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A.",Antimicrob. Agents Chemother.,2009.0,53,2,541,551,10.1128/aac.01123-08,19029318.0,
5091273,CHEMBL264241,Echinocandin B analogue,CHEMBL1637355,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,17500.0,nM,CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1,CHEMBL1629624,In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.,Antimicrob. Agents Chemother.,2009.0,53,3,1149,1156,10.1128/aac.01279-08,19029327.0,
5117638,CHEMBL1631007,"(S)-(5-chloroisoindolin-2-yl)(5-(methylsulfonyl)-2-(1,1,1-trifluoropropan-2-yloxy)phenyl)methanone",CHEMBL1639757,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,38000.0,nM,C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2ccc(Cl)cc2C1)C(F)(F)F,CHEMBL1629713,"Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors.",Bioorg. Med. Chem. Lett.,2010.0,20,23,6960,6965,10.1016/j.bmcl.2010.09.124,20974532.0,
5119770,CHEMBL1631095,"1-(2',5'-bis(trifluoromethyl)biphenyl-3-yl)-1H-pyrazole-3,5-dicarboxamide",CHEMBL1633010,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,20300.0,nM,NC(=O)c1cc(C(N)=O)n(-c2cccc(-c3cc(C(F)(F)F)ccc3C(F)(F)F)c2)n1,CHEMBL1629455,Discovery of a novel class of biphenyl pyrazole sodium channel blockers for treatment of neuropathic pain.,Bioorg. Med. Chem. Lett.,2010.0,20,24,7479,7482,10.1016/j.bmcl.2010.10.017,21106456.0,
5120928,CHEMBL561132,"(R)-2-(7-(4-fluoro-N-methylphenylsulfonamido)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetic acid",CHEMBL1646951,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9400.0,nM,CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1641461,Azaindoles as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,2011.0,21,2,841,845,10.1016/j.bmcl.2010.11.084,21185722.0,
5120929,CHEMBL1641808,"(R)-2-(8-(4-fluoro-N-methylphenylsulfonamido)-6,7,8,9-tetrahydropyrido[3,2-b]indolizin-5-yl)acetic acid",CHEMBL1646951,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CN([C@@H]1CCc2c(CC(=O)O)c3cccnc3n2C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1641461,Azaindoles as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,2011.0,21,2,841,845,10.1016/j.bmcl.2010.11.084,21185722.0,
5120930,CHEMBL1641811,"2-((R)-8-((R)-2-(4-fluorophenyl)-N-methylpropanamido)-6,7,8,9-tetrahydropyrido[3,2-b]indolizin-5-yl)acetic acid",CHEMBL1646951,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,C[C@@H](C(=O)N(C)[C@@H]1CCc2c(CC(=O)O)c3cccnc3n2C1)c1ccc(F)cc1,CHEMBL1641461,Azaindoles as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,2011.0,21,2,841,845,10.1016/j.bmcl.2010.11.084,21185722.0,
5125705,CHEMBL1643880,"(R)-7-oxo-N-(quinuclidin-3-yl)-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide",CHEMBL1646224,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,<,10000.0,nM,O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O,CHEMBL1641372,Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,Bioorg. Med. Chem. Lett.,2011.0,21,1,58,61,10.1016/j.bmcl.2010.11.080,21146988.0,
5126253,CHEMBL1642258,"2-(7-(5-chloro-4-(2-methoxy-4-morpholinophenylamino)pyrimidin-2-ylamino)-8-methoxy-4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-N,N-dimethylacetamide",CHEMBL1646087,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1800.0,nM,COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccc(N4CCOCC4)cc3OC)n1)CCN(CC(=O)N(C)C)CC2,CHEMBL1641404,"Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.",Bioorg. Med. Chem. Lett.,2011.0,21,1,463,466,10.1016/j.bmcl.2010.10.115,21074994.0,
5126797,CHEMBL1643881,"(R)-7-(quinuclidin-3-yl)-7,8-dihydropyrazolo[3,4,5-de]isoquinolin-6(2H)-one",CHEMBL1646224,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,<,10000.0,nM,O=C1c2cccc3[nH]nc(c23)CN1[C@H]1CN2CCC1CC2,CHEMBL1641372,Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,Bioorg. Med. Chem. Lett.,2011.0,21,1,58,61,10.1016/j.bmcl.2010.11.080,21146988.0,
5126803,CHEMBL1643883,"(R)-2-methyl-7-(quinuclidin-3-yl)-7,8-dihydropyrazolo[3,4,5-de]isoquinolin-6(2H)-one",CHEMBL1646224,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,<,10000.0,nM,Cn1nc2c3c(cccc31)C(=O)N([C@H]1CN3CCC1CC3)C2,CHEMBL1641372,Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,Bioorg. Med. Chem. Lett.,2011.0,21,1,58,61,10.1016/j.bmcl.2010.11.080,21146988.0,
5126808,CHEMBL1110,"5-Methyl-2-(5-methyl-1H-imidazol-4-ylmethyl)-2,3,4,5-tetrahydro-pyrido[4,3-b]indol-1-one",CHEMBL1646224,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,<,10000.0,nM,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O,CHEMBL1641372,Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,Bioorg. Med. Chem. Lett.,2011.0,21,1,58,61,10.1016/j.bmcl.2010.11.080,21146988.0,
5128577,CHEMBL1644183,"3-(4-((3-(3,5-dichlorophenyl)-5-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)methyl)benzamido)propanoic acid",CHEMBL1648780,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5800.0,nM,O=C(O)CCNC(=O)c1ccc(Cn2nc(-c3cc(Cl)cc(Cl)c3)cc2-c2ccc(OC(F)(F)F)cc2)cc1,CHEMBL1641377,"Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.",Bioorg. Med. Chem. Lett.,2011.0,21,1,76,81,10.1016/j.bmcl.2010.11.074,21147532.0,
5129290,CHEMBL809,"[4-(3,4-Dichloro-phenyl)-1,2,3,4-tetrahydro-naphthalen-1-yl]-methyl-amine (Sertraline)",CHEMBL1647133,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,CHEMBL1641414,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,1,663,676,10.1016/j.bmc.2010.10.034,21093273.0,
5129291,CHEMBL1642894,"trans-(2R,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-2-amine",CHEMBL1647133,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,CN[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1,CHEMBL1641414,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,1,663,676,10.1016/j.bmc.2010.10.034,21093273.0,
5129292,CHEMBL1642895,"trans-(2S,4R)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-2-amine",CHEMBL1647133,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,CN[C@@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1,CHEMBL1641414,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,1,663,676,10.1016/j.bmc.2010.10.034,21093273.0,
5129293,CHEMBL1642896,"cis-(2S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-2-amine",CHEMBL1647133,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,CN[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1,CHEMBL1641414,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,1,663,676,10.1016/j.bmc.2010.10.034,21093273.0,
5129294,CHEMBL1642897,"cis-(2R,4R)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-2-amine",CHEMBL1647133,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,CN[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1,CHEMBL1641414,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,1,663,676,10.1016/j.bmc.2010.10.034,21093273.0,
5129295,CHEMBL1642906,"trans-1-((2R,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylmethanamine",CHEMBL1647133,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,CNC[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1,CHEMBL1641414,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,1,663,676,10.1016/j.bmc.2010.10.034,21093273.0,
5129296,CHEMBL1642907,"trans-1-((2S,4R)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylmethanamine",CHEMBL1647133,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,CNC[C@@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1,CHEMBL1641414,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,1,663,676,10.1016/j.bmc.2010.10.034,21093273.0,
5129297,CHEMBL1642908,"cis-1-((2S,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylmethanamine",CHEMBL1647133,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,CNC[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1,CHEMBL1641414,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,1,663,676,10.1016/j.bmc.2010.10.034,21093273.0,
5129298,CHEMBL1642912,"Cis-2-((2S,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-2-yl)ethanamine",CHEMBL1647133,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,NCC[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1,CHEMBL1641414,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,1,663,676,10.1016/j.bmc.2010.10.034,21093273.0,
5129299,CHEMBL1642913,"cis-2-((2R,4R)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-2-yl)ethanamine",CHEMBL1647133,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,NCC[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1,CHEMBL1641414,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,1,663,676,10.1016/j.bmc.2010.10.034,21093273.0,
5129300,CHEMBL1642914,"trans-(1S,2S)-1-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-2-amine",CHEMBL1647133,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CN[C@H]1CCc2ccccc2[C@@H]1c1ccc(Cl)c(Cl)c1,CHEMBL1641414,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,1,663,676,10.1016/j.bmc.2010.10.034,21093273.0,
5129301,CHEMBL1642915,"cis-(1S,2R)-1-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-2-amine",CHEMBL1647133,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7600.0,nM,CN[C@@H]1CCc2ccccc2[C@@H]1c1ccc(Cl)c(Cl)c1,CHEMBL1641414,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,1,663,676,10.1016/j.bmc.2010.10.034,21093273.0,
5129302,CHEMBL1642916,"trans-(1R,2R)-1-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-2-amine",CHEMBL1647133,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CN[C@@H]1CCc2ccccc2[C@H]1c1ccc(Cl)c(Cl)c1,CHEMBL1641414,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,1,663,676,10.1016/j.bmc.2010.10.034,21093273.0,
5129303,CHEMBL1642917,"cis-(1R,2S)-1-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-2-amine",CHEMBL1647133,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CN[C@H]1CCc2ccccc2[C@H]1c1ccc(Cl)c(Cl)c1,CHEMBL1641414,"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,1,663,676,10.1016/j.bmc.2010.10.034,21093273.0,
5130285,CHEMBL1643735,N-tert-butyl-2-(1-(2-(tert-butylamino)-2-oxoethyl)-2-(4-(trifluoromethoxy)phenyl)-1H-indol-5-yl)-2-methylpropanamide,CHEMBL1647993,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CC(C)(C)NC(=O)Cn1c(-c2ccc(OC(F)(F)F)cc2)cc2cc(C(C)(C)C(=O)NC(C)(C)C)ccc21,CHEMBL1641497,A potent and selective indole N-type calcium channel (Ca(v)2.2) blocker for the treatment of pain.,Bioorg. Med. Chem. Lett.,2011.0,21,2,869,873,10.1016/j.bmcl.2010.11.067,21195616.0,
5133450,CHEMBL1643512,"(R)-1-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroquinolin-4-amine",CHEMBL1647937,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,N[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21,CHEMBL1641425,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,2011.0,21,1,520,523,10.1016/j.bmcl.2010.10.086,21095126.0,
5133451,CHEMBL1643511,"1-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydroquinolin-4-amine",CHEMBL1647937,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,CNC1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21,CHEMBL1641425,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,2011.0,21,1,520,523,10.1016/j.bmcl.2010.10.086,21095126.0,
5133452,CHEMBL1643513,"(R)-1-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydroquinolin-4-amine",CHEMBL1647937,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,CN[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21,CHEMBL1641425,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,2011.0,21,1,520,523,10.1016/j.bmcl.2010.10.086,21095126.0,
5133453,CHEMBL1643514,"(R)-1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine",CHEMBL1647937,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,250.0,nM,CN(C)[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21,CHEMBL1641425,"Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,2011.0,21,1,520,523,10.1016/j.bmcl.2010.10.086,21095126.0,
5135029,CHEMBL561132,"(R)-2-(7-(4-fluoro-N-methylphenylsulfonamido)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetic acid",CHEMBL1645654,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9400.0,nM,CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1641519,"Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.",Bioorg. Med. Chem. Lett.,2011.0,21,1,288,293,10.1016/j.bmcl.2010.11.015,21106375.0,
5135030,CHEMBL1643773,"(R)-2-(3-fluoro-7-(4-fluoro-N-methylphenylsulfonamido)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetic acid",CHEMBL1645654,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,13600.0,nM,CN([C@@H]1CCc2c(CC(=O)O)c3ccc(F)cc3n2C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1641519,"Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.",Bioorg. Med. Chem. Lett.,2011.0,21,1,288,293,10.1016/j.bmcl.2010.11.015,21106375.0,
5135031,CHEMBL1643780,"(R)-2-(3,4-difluoro-7-(4-fluoro-N-methylphenylsulfonamido)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetic acid",CHEMBL1645654,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,6400.0,nM,CN([C@@H]1CCc2c(CC(=O)O)c3ccc(F)c(F)c3n2C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1641519,"Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.",Bioorg. Med. Chem. Lett.,2011.0,21,1,288,293,10.1016/j.bmcl.2010.11.015,21106375.0,
5135032,CHEMBL1643783,"(R)-2-(4-fluoro-7-(4-fluoro-N-methylphenylsulfonamido)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetic acid",CHEMBL1645654,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4200.0,nM,CN([C@@H]1CCc2c(CC(=O)O)c3cccc(F)c3n2C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1641519,"Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.",Bioorg. Med. Chem. Lett.,2011.0,21,1,288,293,10.1016/j.bmcl.2010.11.015,21106375.0,
5135033,CHEMBL1643789,"(R)-2-(7-(4-fluoro-N-(4-fluorobenzyl)phenylsulfonamido)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetic acid",CHEMBL1645654,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,21000.0,nM,O=C(O)Cc1c2n(c3ccccc13)C[C@H](N(Cc1ccc(F)cc1)S(=O)(=O)c1ccc(F)cc1)CC2,CHEMBL1641519,"Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.",Bioorg. Med. Chem. Lett.,2011.0,21,1,288,293,10.1016/j.bmcl.2010.11.015,21106375.0,
5136791,CHEMBL1641613,"(R,E)-1-(4-(2-fluorophenyl)-4-o-tolylbut-3-enyl)piperidine-3-carboxylic acid",CHEMBL1647447,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1ccccc1/C(=C\CCN1CCC[C@@H](C(=O)O)C1)c1ccccc1F,CHEMBL1641586,"Stereospecific synthesis and structure-activity relationships of unsymmetrical 4,4-diphenylbut-3-enyl derivatives of nipecotic acid as GAT-1 inhibitors.",Bioorg. Med. Chem. Lett.,2011.0,21,1,602,605,10.1016/j.bmcl.2010.09.025,21134748.0,
5142542,CHEMBL1650510,3-[5-(2-Trifluoromethyl-phenyl)-1H-benzimidazol-2-yl]-1-oxa-2-aza-spiro[4.5]dec-2-ene,CHEMBL1655529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 15 mis,IC50,=,1700.0,nM,FC(F)(F)c1ccccc1-c1ccc2[nH]c(C3=NOC4(CCCCC4)C3)nc2c1,CHEMBL1649073,Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.,J. Med. Chem.,2011.0,54,1,233,247,10.1021/jm101075v,21128593.0,
5142543,CHEMBL1650521,3-[7-Fluoro-5-(2-trifluoromethylphenyl)-1H-benzimidazol-2-yl]-1-oxa-2-aza-spiro[4.5]dec-2-ene,CHEMBL1655529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 15 mis,IC50,=,6400.0,nM,Fc1cc(-c2ccccc2C(F)(F)F)cc2nc(C3=NOC4(CCCCC4)C3)[nH]c12,CHEMBL1649073,Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.,J. Med. Chem.,2011.0,54,1,233,247,10.1021/jm101075v,21128593.0,
5142544,CHEMBL1650522,3-[7-Chloro-5-(2-trifluoromethylphenyl)-1H-benzimidazol-2-yl]-1-oxa-2-aza-spiro[4.5]dec-2-ene,CHEMBL1655529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 15 mis,IC50,=,6000.0,nM,FC(F)(F)c1ccccc1-c1cc(Cl)c2[nH]c(C3=NOC4(CCCCC4)C3)nc2c1,CHEMBL1649073,Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.,J. Med. Chem.,2011.0,54,1,233,247,10.1021/jm101075v,21128593.0,
5142545,CHEMBL1650523,2-(1-Oxa-2-aza-spiro[4.5]dec-2-en-3-yl)-6-(2-trifluoromethylphenyl)-3H-benzimidazole-4-carbonitrile,CHEMBL1655529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 15 mis,IC50,=,1900.0,nM,N#Cc1cc(-c2ccccc2C(F)(F)F)cc2nc(C3=NOC4(CCCCC4)C3)[nH]c12,CHEMBL1649073,Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.,J. Med. Chem.,2011.0,54,1,233,247,10.1021/jm101075v,21128593.0,
5142546,CHEMBL1650524,3-[7-Bromo-5-(2-trifluoromethylphenyl)-1H-benzimidazol-2-yl]-1-oxa-2-aza-spiro[4.5]dec-2-ene,CHEMBL1655529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 15 mis,IC50,=,2200.0,nM,FC(F)(F)c1ccccc1-c1cc(Br)c2[nH]c(C3=NOC4(CCCCC4)C3)nc2c1,CHEMBL1649073,Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.,J. Med. Chem.,2011.0,54,1,233,247,10.1021/jm101075v,21128593.0,
5142547,CHEMBL1650525,3-[5-(2-Fluorophenyl)-7-trifluoromethyl-1H-benzimidazol-2-yl]-1-oxa-2-aza-spiro[4.5]dec-2-ene,CHEMBL1655529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 15 mis,IC50,=,10000.0,nM,Fc1ccccc1-c1cc(C(F)(F)F)c2[nH]c(C3=NOC4(CCCCC4)C3)nc2c1,CHEMBL1649073,Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.,J. Med. Chem.,2011.0,54,1,233,247,10.1021/jm101075v,21128593.0,
5142548,CHEMBL1650511,3-[7-Trifluoromethyl-5-(2-trifluoromethyl-phenyl)-1H-benzimidazol-2-yl]-1-oxa-2-aza-spiro[4.5]dec-2-ene,CHEMBL1655529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 15 mis,IC50,=,10000.0,nM,FC(F)(F)c1ccccc1-c1cc(C(F)(F)F)c2[nH]c(C3=NOC4(CCCCC4)C3)nc2c1,CHEMBL1649073,Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.,J. Med. Chem.,2011.0,54,1,233,247,10.1021/jm101075v,21128593.0,
5142549,CHEMBL1650526,3-[5-(2-Trifluoromethoxyphenyl)-7-trifluoromethyl-1H-benzimidazol-2-yl]-1-oxa-2-aza-spiro[4.5]dec-2-ene,CHEMBL1655529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 15 mis,IC50,=,10000.0,nM,FC(F)(F)Oc1ccccc1-c1cc(C(F)(F)F)c2[nH]c(C3=NOC4(CCCCC4)C3)nc2c1,CHEMBL1649073,Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.,J. Med. Chem.,2011.0,54,1,233,247,10.1021/jm101075v,21128593.0,
5142550,CHEMBL1650527,3-[5-(2-Chlorophenyl)-7-trifluoromethyl-1H-benzimidazol-2-yl]-1-oxa-2-aza-spiro[4.5]dec-2-ene,CHEMBL1655529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 15 mis,IC50,=,10000.0,nM,FC(F)(F)c1cc(-c2ccccc2Cl)cc2nc(C3=NOC4(CCCCC4)C3)[nH]c12,CHEMBL1649073,Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.,J. Med. Chem.,2011.0,54,1,233,247,10.1021/jm101075v,21128593.0,
5142551,CHEMBL1650528,3-[2-(1-Oxa-2-aza-spiro[4.5]dec-2-en-3-yl)-6-(2-trifluoromethylphenyl)-3H-benzimidazol-4-yl]-propan-1-ol,CHEMBL1655529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 15 mis,IC50,=,6800.0,nM,OCCCc1cc(-c2ccccc2C(F)(F)F)cc2nc(C3=NOC4(CCCCC4)C3)[nH]c12,CHEMBL1649073,Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.,J. Med. Chem.,2011.0,54,1,233,247,10.1021/jm101075v,21128593.0,
5142627,CHEMBL1650511,3-[7-Trifluoromethyl-5-(2-trifluoromethyl-phenyl)-1H-benzimidazol-2-yl]-1-oxa-2-aza-spiro[4.5]dec-2-ene,CHEMBL1656174,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,FC(F)(F)c1ccccc1-c1cc(C(F)(F)F)c2[nH]c(C3=NOC4(CCCCC4)C3)nc2c1,CHEMBL1649073,Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.,J. Med. Chem.,2011.0,54,1,233,247,10.1021/jm101075v,21128593.0,
5157838,CHEMBL1649675,"1-{4-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}-2-propanone",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,<=,1000.0,nM,CC(=O)Cc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5157842,CHEMBL1649663,"N,N-Dimethyl-2-{4-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}acetamide",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,=,7000.0,nM,CN(C)C(=O)Cc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5157843,CHEMBL1649660,"N-butyl-N-methyl-4-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]benzamide",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,=,6000.0,nM,CCCCN(C)C(=O)c1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5157864,CHEMBL1649685,"1-({4-[6-Methyl-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl]phenyl}methyl)-2-pyrrolidinone",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,10000.0,nM,CN1CCc2c(C(F)(F)F)nn(-c3ccc(CN4CCCC4=O)cc3)c2C1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5157865,CHEMBL1649684,"1-({4-[3-(Trifluoromethyl)-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl]phenyl}methyl)-2-pyrrolidinone",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,10000.0,nM,O=C1CCCN1Cc1ccc(-n2nc(C(F)(F)F)c3c2COCC3)cc1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5157866,CHEMBL1649683,"1-[4-(1-Pyrrolidinylcarbonyl)phenyl]-3-(trifluoromethyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazole",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,10000.0,nM,O=C(c1ccc(-n2nc(C(F)(F)F)c3c2COCC3)cc1)N1CCCC1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5157867,CHEMBL1649682,"1-({2,6-Difluoro-4-[3-(trifluoromethyl)-6,7-dihydropyrano[4,3-c]pyrazol-1(4H)-yl]phenyl}methyl)-2-pyrrolidinone",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,10000.0,nM,O=C1CCCN1Cc1c(F)cc(-n2nc(C(F)(F)F)c3c2CCOC3)cc1F,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5157868,CHEMBL1649681,"1-({4-[3-(Trifluoromethyl)-6,7-dihydropyrano[4,3-c]pyrazol-1(4H)-yl]phenyl}methyl)-2-pyrrolidinone",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,8000.0,nM,O=C1CCCN1Cc1ccc(-n2nc(C(F)(F)F)c3c2CCOC3)cc1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5157869,CHEMBL1649656,"1-[4-(1-Pyrrolidinylcarbonyl)phenyl]-3-(trifluoromethyl)-1,4,6,7-tetrahydropyrano[4,3-c]pyrazole",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,10000.0,nM,O=C(c1ccc(-n2nc(C(F)(F)F)c3c2CCOC3)cc1)N1CCCC1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5157870,CHEMBL1649674,"1-({2-Fluoro-4-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1Hindazol-1-yl]phenyl}methyl)-2-pyrrolidinone",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,=,9000.0,nM,O=C1CCCN1Cc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1F,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5157871,CHEMBL1649672,"N-({4-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}methyl)propanamide",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,=,8000.0,nM,CCC(=O)NCc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5157872,CHEMBL1649670,"1-({4-[3-(Trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-phenyl}methyl)-2-pyrrolidinone",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,=,5000.0,nM,O=C1CCCN1Cc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5157873,CHEMBL1649669,"1-{3-Fluoro-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]phenyl}-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazole",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,=,7000.0,nM,O=C(Cc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1F)N1CCCC1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5157874,CHEMBL1649657,"1-{4-[1,1-difluoro-2-oxo-2-(1-pyrrolidinyl)ethyl]phenyl}-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazole",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,=,4000.0,nM,O=C(N1CCCC1)C(F)(F)c1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5157875,CHEMBL1649667,"1-{4-[1-(1-pyrrolidinylcarbonyl)cyclopropyl]phenyl}-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1Hindazole",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,=,300.0,nM,O=C(N1CCCC1)C1(c2ccc(-n3nc(C(F)(F)F)c4c3CCCC4)cc2)CC1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5157876,CHEMBL1649666,"1-{4-[1-methyl-2-oxo-2-(1-pyrrolidinyl)ethyl]phenyl}-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazole",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,=,1000.0,nM,CC(C(=O)N1CCCC1)c1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5157877,CHEMBL1649665,"N-cyclopentyl-2-{4-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}acetamide",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,=,200.0,nM,O=C(Cc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1)NC1CCCC1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5158917,CHEMBL1649664,"1-{4-[2-Oxo-2-(1-pyrrolidinyl)ethyl]phenyl}-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazole",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,=,3000.0,nM,O=C(Cc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1)N1CCCC1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5158918,CHEMBL1649661,"1-{4-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}ethanone",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,=,4000.0,nM,CC(=O)c1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5158919,CHEMBL1649655,"N,N-dimethyl-4-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]benzenesulfonamide",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,=,2000.0,nM,CN(C)S(=O)(=O)c1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5158920,CHEMBL1649654,"N-methyl-N-(2-phenylethyl)-4-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]benzamide",CHEMBL1656983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,=,1000.0,nM,CN(CCc1ccccc1)C(=O)c1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1,CHEMBL1649062,Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.,J. Med. Chem.,2011.0,54,1,78,94,10.1021/jm100679e,21128618.0,
5161632,CHEMBL381751,"2-{[(4-Amino-but-2-enyl)-methyl-amino]-methyl}-5-(6-amino-purin-9-yl)-tetrahydro-furan-3,4-diol",CHEMBL1653944,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 2C9,IC50,>,5000.0,nM,CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,CHEMBL1649443,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.,Antimicrob. Agents Chemother.,2009.0,53,5,2052,2058,10.1128/aac.01674-08,19289530.0,
5161637,CHEMBL466624,"(2R,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-2-((((Z)-4-aminobut-2-enyl)(methyl)amino)methyl)-4-fluorotetrahydrofuran-3-ol",CHEMBL1653944,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 2C9,IC50,>,5000.0,nM,CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](F)[C@@H]1O,CHEMBL1649443,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.,Antimicrob. Agents Chemother.,2009.0,53,5,2052,2058,10.1128/aac.01674-08,19289530.0,
5161642,CHEMBL443705,"(2R,3R,4S,5R)-5-(6-amino-9H-purin-9-yl)-2-((((Z)-4-aminobut-2-enyl)(methyl)amino)methyl)-4-fluorotetrahydrofuran-3-ol",CHEMBL1653944,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 2C9,IC50,>,5000.0,nM,CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@@H](F)[C@@H]1O,CHEMBL1649443,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.,Antimicrob. Agents Chemother.,2009.0,53,5,2052,2058,10.1128/aac.01674-08,19289530.0,
5161647,CHEMBL468092,"(2R,3R,4S,5R)-2-(6-amino-2-chloro-9H-purin-9-yl)-5-((((Z)-4-aminobut-2-enyl)(methyl)amino)methyl)tetrahydrofuran-3,4-diol",CHEMBL1653944,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 2C9,IC50,>,5000.0,nM,CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)nc(Cl)nc32)[C@H](O)[C@@H]1O,CHEMBL1649443,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.,Antimicrob. Agents Chemother.,2009.0,53,5,2052,2058,10.1128/aac.01674-08,19289530.0,
5161652,CHEMBL467047,"(2R,3R,4S,5R)-2-(6-amino-2-methyl-9H-purin-9-yl)-5-((((Z)-4-aminobut-2-enyl)(methyl)amino)methyl)tetrahydrofuran-3,4-diol",CHEMBL1653944,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human cytochrome P450 2C9,IC50,>,5000.0,nM,Cc1nc(N)c2ncn([C@@H]3O[C@H](CN(C)C/C=C\CN)[C@@H](O)[C@H]3O)c2n1,CHEMBL1649443,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.,Antimicrob. Agents Chemother.,2009.0,53,5,2052,2058,10.1128/aac.01674-08,19289530.0,
5186914,CHEMBL469227,6-(3-Hydroxyphenyl)-1-phenyl-2-naphthol,CHEMBL1664604,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,1640.0,nM,Oc1cccc(-c2ccc3c(-c4ccccc4)c(O)ccc3c2)c1,CHEMBL1649421,New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.,J. Med. Chem.,2011.0,54,2,534,547,10.1021/jm1009082,21189020.0,
5186915,CHEMBL1650645,6-(3-Hydroxyphenyl)-1-(pyridin-3-yl)-2-naphthol,CHEMBL1664604,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,150.0,nM,Oc1cccc(-c2ccc3c(-c4cccnc4)c(O)ccc3c2)c1,CHEMBL1649421,New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.,J. Med. Chem.,2011.0,54,2,534,547,10.1021/jm1009082,21189020.0,
5186916,CHEMBL1650652,"1,6-Bis(3-hydroxyphenyl)-2-naphthol",CHEMBL1664604,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,270.0,nM,Oc1cccc(-c2ccc3c(-c4cccc(O)c4)c(O)ccc3c2)c1,CHEMBL1649421,New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.,J. Med. Chem.,2011.0,54,2,534,547,10.1021/jm1009082,21189020.0,
5186917,CHEMBL1650654,1-(3-Aminophenyl)-6-(3-hydroxyphenyl)-2-naphthol,CHEMBL1664604,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,1250.0,nM,Nc1cccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)c1,CHEMBL1649421,New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.,J. Med. Chem.,2011.0,54,2,534,547,10.1021/jm1009082,21189020.0,
5186918,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL1664604,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,250.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL1649421,New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.,J. Med. Chem.,2011.0,54,2,534,547,10.1021/jm1009082,21189020.0,
5192979,CHEMBL1650404,2-[2-(3-(R)-Aminopiperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]benzonitrile,CHEMBL1664411,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)ncc(F)c1=O,CHEMBL1649419,Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.,J. Med. Chem.,2011.0,54,2,510,524,10.1021/jm101016w,21186796.0,
5192980,CHEMBL376359,"(R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile",CHEMBL1664411,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,CHEMBL1649419,Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.,J. Med. Chem.,2011.0,54,2,510,524,10.1021/jm101016w,21186796.0,
5192981,CHEMBL1650443,"2-[6-(3-Aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluorobenzonitrile",CHEMBL1664411,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O,CHEMBL1649419,Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.,J. Med. Chem.,2011.0,54,2,510,524,10.1021/jm101016w,21186796.0,
5197070,CHEMBL1667948,"trans-4-(8-amino-1-(8-fluoro-2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-N-(1H-benzo[d]imidazol-2-yl)cyclohexanecarboxamide",CHEMBL1670393,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9800.0,nM,Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1F)nc2[C@H]1CC[C@H](C(=O)Nc2nc3ccccc3[nH]2)CC1,CHEMBL1667832,Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1176,1180,10.1016/j.bmcl.2010.12.094,21251824.0,
5198642,CHEMBL537424,"1-butyl-3-(2-methylpropyl)-9-(4-phenoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undeca-2,5-dione hydrochloride",CHEMBL1670540,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5900.0,nM,CCCCN1C(=O)C(CC(C)C)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl,CHEMBL1667838,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1141,1145,10.1016/j.bmcl.2010.12.109,21256008.0,
5198643,CHEMBL536743,"1-butyl-3-cyclohexylmethyl-9-(4-phenoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undeca-2,5-dione hydrochloride",CHEMBL1670540,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5500.0,nM,CCCCN1C(=O)C(CC2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl,CHEMBL1667838,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1141,1145,10.1016/j.bmcl.2010.12.109,21256008.0,
5198644,CHEMBL559168,"(R)-1-butyl-3-((R)-1-hydroxy-2-methyl-propyl)-9-(4-phenoxy-benzyl)-1,4,9-triaza-spiro[5.5]undecane-2,5-dione hydrochloride",CHEMBL1670540,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CCCCN1C(=O)[C@@H]([C@H](O)C(C)C)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl,CHEMBL1667838,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1141,1145,10.1016/j.bmcl.2010.12.109,21256008.0,
5198645,CHEMBL536754,"(R)-1-butyl-3-((R)-cyclohexyl-hydroxy-methyl)-9-(4-phenoxy-benzyl)-1,4,9-triaza-spiro[5.5]undecane-2,5-dione hydrochloride",CHEMBL1670540,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3700.0,nM,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl,CHEMBL1667838,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1141,1145,10.1016/j.bmcl.2010.12.109,21256008.0,
5198646,CHEMBL1170878,"4-(4-{[(3S)-1-Butyl-3-(cyclohexylmethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl}phenoxy)benzoic acid hydrochloride",CHEMBL1670540,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8800.0,nM,CCCCN1C(=O)[C@H](CC2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl,CHEMBL1667838,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1141,1145,10.1016/j.bmcl.2010.12.109,21256008.0,
5198647,CHEMBL1668019,"4-(4-(((R)-1-butyl-3-((R)-cyclohexyl(hydroxy)methyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl)methyl)phenoxy)benzoic acid hydrochloride",CHEMBL1670540,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl,CHEMBL1667838,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1141,1145,10.1016/j.bmcl.2010.12.109,21256008.0,
5198648,CHEMBL1668020,"4-(4-(((R)-1-butyl-3-((S)-cyclohexyl(hydroxy)methyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl)methyl)phenoxy)benzoic acid hydrochloride",CHEMBL1670540,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,18000.0,nM,CCCCN1C(=O)[C@@H]([C@@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl,CHEMBL1667838,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1141,1145,10.1016/j.bmcl.2010.12.109,21256008.0,
5198649,CHEMBL1668021,"4-(4-(((S)-1-butyl-3-((R)-cyclohexyl(hydroxy)methyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl)methyl)phenoxy)benzoic acid hydrochloride",CHEMBL1670540,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CCCCN1C(=O)[C@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl,CHEMBL1667838,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1141,1145,10.1016/j.bmcl.2010.12.109,21256008.0,
5198650,CHEMBL1668022,"4-(4-(((S)-1-butyl-3-((S)-cyclohexyl(hydroxy)methyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl)methyl)phenoxy)benzoic acid hydrochloride",CHEMBL1670540,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CCCCN1C(=O)[C@H]([C@@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl,CHEMBL1667838,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1141,1145,10.1016/j.bmcl.2010.12.109,21256008.0,
5199727,CHEMBL1668898,Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate,CHEMBL1670978,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,50000.0,nM,CCOc1ccc(-c2ccc(-c3cc(CC(=O)[O-])ccc3OC)c(CN(CC)C(=O)C3CC3)c2)cn1.[Na+],CHEMBL1667769,"Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.",Bioorg. Med. Chem. Lett.,2011.0,21,3,1036,1040,10.1016/j.bmcl.2010.12.016,21211969.0,
5200562,CHEMBL1642362,"(S)-2-(6-chloro-2-(4-chlorophenyl)-5-fluoro-1H-benzo[d]imidazol-1-yl)-N,2-dicyclohexylacetamide",CHEMBL1670713,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(Cl)cc21,CHEMBL1667846,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1134,1140,10.1016/j.bmcl.2010.12.123,21269824.0,
5200563,CHEMBL1668238,"(S)-2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-N,2-dicyclohexylacetamide",CHEMBL1670713,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,6700.0,nM,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,CHEMBL1667846,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1134,1140,10.1016/j.bmcl.2010.12.123,21269824.0,
5200564,CHEMBL1668239,"trans-(S)-2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexyl-N-(4-hydroxycyclohexyl)acetamide",CHEMBL1670713,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,40000.0,nM,O=C(N[C@H]1CC[C@H](O)CC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,CHEMBL1667846,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1134,1140,10.1016/j.bmcl.2010.12.123,21269824.0,
5200565,CHEMBL1668240,"trans-4-((S)-2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)cyclohexanecarboxylic acid",CHEMBL1670713,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(N[C@H]1CC[C@H](C(=O)O)CC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,CHEMBL1667846,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1134,1140,10.1016/j.bmcl.2010.12.123,21269824.0,
5200566,CHEMBL1615153,"(S)-4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)benzoic acid",CHEMBL1670713,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,32000.0,nM,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)cc1,CHEMBL1667846,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1134,1140,10.1016/j.bmcl.2010.12.123,21269824.0,
5200567,CHEMBL1615152,"(S)-4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)-3-fluorobenzoic acid",CHEMBL1670713,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,14000.0,nM,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(F)c1,CHEMBL1667846,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1134,1140,10.1016/j.bmcl.2010.12.123,21269824.0,
5200568,CHEMBL1668243,"(S)-3-chloro-4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)benzoic acid",CHEMBL1670713,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,18000.0,nM,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(Cl)c1,CHEMBL1667846,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1134,1140,10.1016/j.bmcl.2010.12.123,21269824.0,
5200569,CHEMBL1615150,"(S)-4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)-3-methylbenzoic acid",CHEMBL1670713,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,19000.0,nM,Cc1cc(C(=O)O)ccc1NC(=O)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,CHEMBL1667846,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1134,1140,10.1016/j.bmcl.2010.12.123,21269824.0,
5200570,CHEMBL1668249,"(S)-1-(4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)-3-fluorophenoxy)cyclopropanecarboxylic acid",CHEMBL1670713,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,29000.0,nM,O=C(Nc1ccc(OC2(C(=O)O)CC2)cc1F)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,CHEMBL1667846,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1134,1140,10.1016/j.bmcl.2010.12.123,21269824.0,
5200571,CHEMBL1668257,"(S)-2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexyl-N-(2-fluoro-4-(1H-tetrazol-5-yl)phenyl)acetamide",CHEMBL1670713,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7100.0,nM,O=C(Nc1ccc(-c2nnn[nH]2)cc1F)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,CHEMBL1667846,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1134,1140,10.1016/j.bmcl.2010.12.123,21269824.0,
5200572,CHEMBL1668259,(S)-4-(2-(2-(4-chlorophenyl)-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)-3-(trifluoromethyl)benzoic acid,CHEMBL1670713,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,28000.0,nM,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3ccccc32)c(C(F)(F)F)c1,CHEMBL1667846,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1134,1140,10.1016/j.bmcl.2010.12.123,21269824.0,
5200573,CHEMBL1668261,"trans-4-((2S)-2-cyclohexyl-2-(2-(2,4-dimethoxypyridin-3-yl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)acetamido)cyclohexanecarboxylic acid",CHEMBL1670713,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1ccc(-c2nc3cc(F)c(F)cc3n2[C@H](C(=O)N[C@H]2CC[C@H](C(=O)O)CC2)C2CCCCC2)c(OC)n1,CHEMBL1667846,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1134,1140,10.1016/j.bmcl.2010.12.123,21269824.0,
5207217,CHEMBL1671922,"4-(3,3-Dimethyl-butyrylamino)-N-thiazol-2-yl-benzamide",CHEMBL1679258,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 after 45 mins,IC50,>,40000.0,nM,CC(C)(C)CC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1,CHEMBL1671809,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,2011.0,54,3,751,764,10.1021/jm1008659,21210664.0,
5207218,CHEMBL1671921,4-(3-Methyl-butyrylamino)-N-thiazol-2-yl-benzamide,CHEMBL1679258,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 after 45 mins,IC50,>,40000.0,nM,CC(C)CC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1,CHEMBL1671809,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,2011.0,54,3,751,764,10.1021/jm1008659,21210664.0,
5207219,CHEMBL1671918,4-Butyrylamino-N-thiazol-2-yl-benzamide,CHEMBL1679258,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 after 45 mins,IC50,>,40000.0,nM,CCCC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1,CHEMBL1671809,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,2011.0,54,3,751,764,10.1021/jm1008659,21210664.0,
5207220,CHEMBL1671916,2-methyl-N-(4-(thiazol-2-ylcarbamoyl)phenyl)benzamide,CHEMBL1679258,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 after 45 mins,IC50,>,40000.0,nM,Cc1ccccc1C(=O)Nc1ccc(C(=O)Nc2nccs2)cc1,CHEMBL1671809,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,2011.0,54,3,751,764,10.1021/jm1008659,21210664.0,
5207231,CHEMBL1671936,"4-(3,3-Dimethyl-butyrylamino)-3,5-difluoro-N-thiazol-2-yl-benzamide",CHEMBL1679258,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 after 45 mins,IC50,>,40000.0,nM,CC(C)(C)CC(=O)Nc1c(F)cc(C(=O)Nc2nccs2)cc1F,CHEMBL1671809,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,2011.0,54,3,751,764,10.1021/jm1008659,21210664.0,
5207232,CHEMBL1671917,4-pentanamido-N-(thiazol-2-yl)benzamide,CHEMBL1679258,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 after 45 mins,IC50,=,40000.0,nM,CCCCC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1,CHEMBL1671809,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,2011.0,54,3,751,764,10.1021/jm1008659,21210664.0,
5207236,CHEMBL431770,"8-[(E)-2-(3,4-Dimethoxy-phenyl)-vinyl]-1,3-diethyl-7-methyl-3,7-dihydro-purine-2,6-dione",CHEMBL1679258,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 after 45 mins,IC50,=,13000.0,nM,CCn1c(=O)c2c(nc(/C=C/c3ccc(OC)c(OC)c3)n2C)n(CC)c1=O,CHEMBL1671809,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",J. Med. Chem.,2011.0,54,3,751,764,10.1021/jm1008659,21210664.0,
5220652,CHEMBL1672611,N-[6-(2-Furyl)-5-pyridin-4-ylpyrazin-2-yl]cyclopropanecarboxamide,CHEMBL1679087,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,5000.0,nM,O=C(Nc1cnc(-c2ccncc2)c(-c2ccco2)n1)C1CC1,CHEMBL1671839,"Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist.",ACS Med. Chem. Lett.,2011.0,2,3,213,218,10.1021/ml100249e,24900298.0,
5220656,CHEMBL1672621,N-(6-Pyridin-3-yl-5-pyridin-4-ylpyrazin-2-yl)cyclopropanecarboxamide,CHEMBL1679087,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,25000.0,nM,O=C(Nc1cnc(-c2ccncc2)c(-c2cccnc2)n1)C1CC1,CHEMBL1671839,"Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist.",ACS Med. Chem. Lett.,2011.0,2,3,213,218,10.1021/ml100249e,24900298.0,
5220659,CHEMBL1672622,"N-(5,6-Dipyridin-4-ylpyrazin-2-yl)cyclopropanecarboxamide",CHEMBL1679087,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,25000.0,nM,O=C(Nc1cnc(-c2ccncc2)c(-c2ccncc2)n1)C1CC1,CHEMBL1671839,"Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist.",ACS Med. Chem. Lett.,2011.0,2,3,213,218,10.1021/ml100249e,24900298.0,
5221695,CHEMBL1672627,N-[5-(3-Fluoropyridin-4-yl)-6-pyridin-3-ylpyrazin-2-yl]cyclopropanecarboxamide,CHEMBL1679087,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,25000.0,nM,O=C(Nc1cnc(-c2ccncc2F)c(-c2cccnc2)n1)C1CC1,CHEMBL1671839,"Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist.",ACS Med. Chem. Lett.,2011.0,2,3,213,218,10.1021/ml100249e,24900298.0,
5221699,CHEMBL1672629,"N-[5-(3,5-Difluoropyridin-4-yl)-6-pyridin-3-ylpyrazin-2-yl]cyclopropane carboxamide",CHEMBL1679087,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,25000.0,nM,O=C(Nc1cnc(-c2c(F)cncc2F)c(-c2cccnc2)n1)C1CC1,CHEMBL1671839,"Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist.",ACS Med. Chem. Lett.,2011.0,2,3,213,218,10.1021/ml100249e,24900298.0,
5221703,CHEMBL1672630,N-(5-(3-chloropyridin-4-yl)-6-(pyridin-2-yl)pyrazin-2-yl)cyclopropanecarboxamide,CHEMBL1679087,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,25000.0,nM,O=C(Nc1cnc(-c2ccncc2F)c(-c2ccncc2)n1)C1CC1,CHEMBL1671839,"Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist.",ACS Med. Chem. Lett.,2011.0,2,3,213,218,10.1021/ml100249e,24900298.0,
5221709,CHEMBL1672633,"N-[5-(3-Fluoropyridin-4-yl)-6-(1,3-oxazol-5-yl)pyrazin-2-yl]cyclopropane-carboxamide",CHEMBL1679087,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,25000.0,nM,O=C(Nc1cnc(-c2ccncc2F)c(-c2cnco2)n1)C1CC1,CHEMBL1671839,"Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist.",ACS Med. Chem. Lett.,2011.0,2,3,213,218,10.1021/ml100249e,24900298.0,
5221922,CHEMBL1671877,"5-(3-cyclopropylpropyl)-2-(difluoromethyl)-3H-pyrano[2,3-d]pyrimidine-4,7-dione",CHEMBL1680958,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,50000.0,nM,O=c1cc(CCCC2CC2)c2c(=O)[nH]c(C(F)F)nc2o1,CHEMBL1671841,Discovery of a potent nicotinic Acid receptor agonist for the treatment of dyslipidemia.,ACS Med. Chem. Lett.,2011.0,2,2,171,176,10.1021/ml100251u,24900295.0,
5233929,CHEMBL1672448,"6-[4-({[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-2-quinolinecarboxylic acid",CHEMBL1678712,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome,IC50,=,4400.0,nM,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3nc(C(=O)O)ccc3c2)cc1,CHEMBL1671792,Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.,Bioorg. Med. Chem. Lett.,2011.0,21,4,1206,1213,10.1016/j.bmcl.2010.12.089,21256005.0,
5235820,CHEMBL1682904,(-)-(S)-7-(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-2-methyl-1H-benzo[e]isoindol-3(2H)-one,CHEMBL1687156,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,<,3000.0,nM,CC(C)[C@](O)(c1ccc2c3c(ccc2c1)C(=O)N(C)C3)c1c[nH]cn1,CHEMBL1681730,"17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.",Bioorg. Med. Chem.,2011.0,19,5,1751,1770,10.1016/j.bmc.2011.01.017,21316976.0,
5239426,CHEMBL1684057,"1-(1-(3,4-dichlorophenyl)cyclohexyl)-N-methylethanamine hydrochloride",CHEMBL1686747,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,CNC(C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1.Cl,CHEMBL1681689,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,2011.0,21,5,1434,1437,10.1016/j.bmcl.2011.01.019,21310612.0,
5239427,CHEMBL1684058,"1-(1-(3,4-dichlorophenyl)cyclohexyl)-N,N-dimethylethanamine hydrochloride",CHEMBL1686747,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,CC(N(C)C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1.Cl,CHEMBL1681689,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,2011.0,21,5,1434,1437,10.1016/j.bmcl.2011.01.019,21310612.0,
5239428,CHEMBL1684059,"N,N-dimethyl-1-(1-(naphthalen-2-yl)cyclohexyl)ethanamine hydrochloride",CHEMBL1686747,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,5000.0,nM,CC(N(C)C)C1(c2ccc3ccccc3c2)CCCCC1.Cl,CHEMBL1681689,"Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.",Bioorg. Med. Chem. Lett.,2011.0,21,5,1434,1437,10.1016/j.bmcl.2011.01.019,21310612.0,
5240890,CHEMBL1683571,"1-((3S,4S)-4-amino-1-(4-(3,3-difluoropyrrolidin-1-yl)-1,3,5-triazin-2-yl)pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one",CHEMBL1685357,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,15000.0,nM,N[C@H]1CN(c2ncnc(N3CCC(F)(F)C3)n2)C[C@@H]1N1CC(F)(F)CCC1=O,CHEMBL1681744,"1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes.",Bioorg. Med. Chem. Lett.,2011.0,21,6,1810,1814,10.1016/j.bmcl.2011.01.055,21324688.0,
5240939,CHEMBL1683577,5-methyl-N-(1-methyl-1H-pyrazol-3-yl)-1-(3-(trifluoromethyl)benzyl)-1H-imidazole-4-carboxamide,CHEMBL1685378,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,Cc1c(C(=O)Nc2ccn(C)n2)ncn1Cc1cccc(C(F)(F)F)c1,CHEMBL1681746,"N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.",Bioorg. Med. Chem. Lett.,2011.0,21,6,1621,1625,10.1016/j.bmcl.2011.01.113,21324691.0,
5293964,CHEMBL1688243,"5-[(4-(3S)-4-[(1R,2R)-2-ethoxy-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-3-methylpiperazin-1-yl-4-methylpiperidin-1-yl)carbonyl]-4,6-dimethylpyrimidine",CHEMBL1695234,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,CCO[C@@H]1Cc2cc(C(F)(F)F)ccc2[C@H]1N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,CHEMBL1687698,"Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity.",ACS Med. Chem. Lett.,2010.0,1,9,483,487,10.1021/ml1001536,24900235.0,
6148470,CHEMBL1760794,"2-(4-(5-(1-(4-chlorophenyl)cyclobutyl)-4-methyl-4H-1,2,4-triazol-3-yl)phenyl)pyrazine",CHEMBL1764826,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,13000.0,nM,Cn1c(-c2ccc(-c3cnccn3)cc2)nnc1C1(c2ccc(Cl)cc2)CCC1,CHEMBL1759971,Substituted phenyl triazoles as selective inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1.,Bioorg. Med. Chem. Lett.,2011.0,21,7,2141,2145,10.1016/j.bmcl.2011.01.125,21334894.0,
6148477,CHEMBL1760809,"2-(3-chloro-4-(5-(1-(4-chlorophenyl)-3-fluorocyclobutyl)-4-methyl-4H-1,2,4-triazol-3-yl)phenyl)pyrazine",CHEMBL1764826,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,26000.0,nM,Cn1c(-c2ccc(-c3cnccn3)cc2Cl)nnc1C1(c2ccc(Cl)cc2)CC(F)C1,CHEMBL1759971,Substituted phenyl triazoles as selective inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1.,Bioorg. Med. Chem. Lett.,2011.0,21,7,2141,2145,10.1016/j.bmcl.2011.01.125,21334894.0,
6149598,CHEMBL1738841,"(S)-5-methyl-1-(quinolin-4-ylmethyl)-3-(4-(trifluoromethylsulfonyl)phenyl)imidazolidine-2,4-dione",CHEMBL1764692,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,700.0,nM,C[C@H]1C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)N1Cc1ccnc2ccccc12,CHEMBL1759913,Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.,Bioorg. Med. Chem. Lett.,2011.0,21,8,2224,2228,10.1016/j.bmcl.2011.03.003,21441024.0,
6156351,CHEMBL1762427,"4-[2-(1,1-Dioxo-1lambda*6*-thiomorpholin-4-yl)-acetyl]-[1,4]diazepane-1-carboxylic acid(5-tert-butyl-isoxazol-3-yl)-amide",CHEMBL1763217,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using fluorescent probe 7-methoxy-4-trifluoromethylcoumarin,IC50,>,30000.0,nM,CC(C)(C)c1cc(NC(=O)N2CCCN(C(=O)CN3CCS(=O)(=O)CC3)CC2)no1,CHEMBL1759893,"1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.",Bioorg. Med. Chem. Lett.,2011.0,21,7,2011,2016,10.1016/j.bmcl.2011.02.017,21354795.0,
6156365,CHEMBL1762293,"N-(5-tert-butylisoxazol-3-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-1,4-diazepane-1-carboxamide",CHEMBL1763217,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using fluorescent probe 7-methoxy-4-trifluoromethylcoumarin,IC50,>,30000.0,nM,CC(C)(C)c1cc(NC(=O)N2CCCN(C(=O)C3CCOCC3)CC2)no1,CHEMBL1759893,"1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.",Bioorg. Med. Chem. Lett.,2011.0,21,7,2011,2016,10.1016/j.bmcl.2011.02.017,21354795.0,
6156863,CHEMBL1762429,"4-(1,1-Dioxo-1lambda*6*-thiomorpholine-4-carbonyl)-[1,4]diazepane-1-carboxylic acid(5-tert-butyl-isoxazol-3-yl)-amide",CHEMBL1763217,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using fluorescent probe 7-methoxy-4-trifluoromethylcoumarin,IC50,>,30000.0,nM,CC(C)(C)c1cc(NC(=O)N2CCCN(C(=O)N3CCS(=O)(=O)CC3)CC2)no1,CHEMBL1759893,"1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.",Bioorg. Med. Chem. Lett.,2011.0,21,7,2011,2016,10.1016/j.bmcl.2011.02.017,21354795.0,
6157333,CHEMBL1762808,2-(((2-(7-chloro-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-indol-3-yl)thiazol-4-yl)methyl)(isopropyl)amino)ethanol,CHEMBL1764371,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2800.0,nM,CC(C)N(CCO)Cc1csc(-c2cn(CC3CCOCC3)c3c(Cl)cccc23)n1,CHEMBL1759932,"Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.",Bioorg. Med. Chem. Lett.,2011.0,21,8,2541,2546,10.1016/j.bmcl.2011.02.023,21411321.0,
6158572,CHEMBL1760005,"2-({4-[(butyl{2-chloro-4'-[(trifluoromethyl)oxy]-3-biphenylyl}amino)sulfonyl]-2,3-dimethylphenyl}oxy)propanoic acid",CHEMBL1764911,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,794.33,nM,CCCCN(c1cccc(-c2ccc(OC(F)(F)F)cc2)c1Cl)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,CHEMBL1759972,"Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacy.",Bioorg. Med. Chem. Lett.,2011.0,21,8,2345,2350,10.1016/j.bmcl.2011.02.077,21414782.0,
6158573,CHEMBL1760428,"2-{[4-({butyl[2-chloro-4'-(trifluoromethyl)-3-biphenylyl]amino}sulfonyl)-2,3-dimethylphenyl]oxy}propanoic acid",CHEMBL1764911,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,794.33,nM,CCCCN(c1cccc(-c2ccc(C(F)(F)F)cc2)c1Cl)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,CHEMBL1759972,"Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacy.",Bioorg. Med. Chem. Lett.,2011.0,21,8,2345,2350,10.1016/j.bmcl.2011.02.077,21414782.0,
6158726,CHEMBL1760200,(4-(2-methoxyphenyl)piperazin-1-yl)(3-phenyl-1H-pyrazol-5-yl)methanone,CHEMBL1763138,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,15000.0,nM,COc1ccccc1N1CCN(C(=O)c2cc(-c3ccccc3)n[nH]2)CC1,CHEMBL1759909,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,2011.0,21,7,1991,1996,10.1016/j.bmcl.2011.02.033,21376585.0,
6158727,CHEMBL1760338,(3-(4-chlorophenyl)-1H-pyrazol-5-yl)(4-(2-methoxyphenyl)piperazin-1-yl)methanone,CHEMBL1763138,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3000.0,nM,COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)n[nH]2)CC1,CHEMBL1759909,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,2011.0,21,7,1991,1996,10.1016/j.bmcl.2011.02.033,21376585.0,
6158728,CHEMBL1760205,(3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl)(4-(2-methoxyphenyl)piperazin-1-yl)methanone,CHEMBL1763138,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3000.0,nM,COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)nn2C)CC1,CHEMBL1759909,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,2011.0,21,7,1991,1996,10.1016/j.bmcl.2011.02.033,21376585.0,
6158729,CHEMBL1760206,(5-(4-chlorophenyl)-1-methyl-1H-pyrazol-3-yl)(4-(2-methoxyphenyl)piperazin-1-yl)methanone,CHEMBL1763138,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4000.0,nM,COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)n(C)n2)CC1,CHEMBL1759909,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,2011.0,21,7,1991,1996,10.1016/j.bmcl.2011.02.033,21376585.0,
6158730,CHEMBL10188,3-Hydroxy-2-phenyl-quinoline-4-carboxylic acid ((S)-1-phenyl-propyl)-amide,CHEMBL1763138,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2000.0,nM,CC[C@H](NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1,CHEMBL1759909,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,2011.0,21,7,1991,1996,10.1016/j.bmcl.2011.02.033,21376585.0,
6158731,CHEMBL346178,"N-(3-{3-[1-Benzoyl-4-(3,4-dichloro-phenyl)-piperidin-4-yl]-propyl}-4-phenyl-piperidin-4-yl)-N-methyl-acetamide",CHEMBL1763138,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,11000.0,nM,CC(=O)N(C)C1(c2ccccc2)CCN(CCC[C@]2(c3ccc(Cl)c(Cl)c3)CCCN(C(=O)c3ccccc3)C2)CC1,CHEMBL1759909,Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.,Bioorg. Med. Chem. Lett.,2011.0,21,7,1991,1996,10.1016/j.bmcl.2011.02.033,21376585.0,
6161671,CHEMBL1170367,N-(7-(N-ethylacetamido)-4-methoxybenzo[d]thiazol-2-yl)-1-methyl-1H-pyrazole-5-carboxamide,CHEMBL1764844,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CCN(C(C)=O)c1ccc(OC)c2nc(NC(=O)c3ccnn3C)sc12,CHEMBL1759892,Discovery of benzothiazole-based adenosine A2B receptor antagonists with improved A2A selectivity.,Bioorg. Med. Chem. Lett.,2011.0,21,7,1933,1936,10.1016/j.bmcl.2011.02.053,21388809.0,
6164119,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL1768382,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect microsomes,IC50,=,318.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL1765045,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",J. Med. Chem.,2011.0,54,7,2307,2319,10.1021/jm101470k,21384875.0,
6166316,CHEMBL1766005,3-Imidazol-1-yl-2-methyl-3-[4-(naphthalen-2-ylamino)-phenyl]-propionic acid Methyl Ester,CHEMBL1769740,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,1500.0,nM,COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1ccnc1,CHEMBL1764976,Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.,J. Med. Chem.,2011.0,54,8,2778,2791,10.1021/jm101583w,21428449.0,
6166317,CHEMBL517438,"Benzothiazol-2-yl-[4-((1S,2S)-2-dimethylamino-1-imidazol-1-yl-propyl)-phenyl]-amine",CHEMBL1769740,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,5900.0,nM,C[C@H]([C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1ccnc1)N(C)C,CHEMBL1764976,Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.,J. Med. Chem.,2011.0,54,8,2778,2791,10.1021/jm101583w,21428449.0,
6172448,CHEMBL1766811,4-(4-{4-[(2-Phenyl-5-trifluoromethyloxazole-4-carbonyl)-amino]phenyl}piperidine-1-carbonyl)-trans-cyclohexanecarboxylic Acid,CHEMBL1767879,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=C(Nc1ccc(C2CCN(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)CC2)cc1)c1nc(-c2ccccc2)oc1C(F)(F)F,CHEMBL1764953,Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes.,J. Med. Chem.,2011.0,54,7,2433,2446,10.1021/jm101580m,21413799.0,
6173699,CHEMBL1230122,"6-(2,4-Difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one",CHEMBL1769479,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,40000.0,nM,Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21,CHEMBL1764984,"Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase.",J. Med. Chem.,2011.0,54,7,2255,2265,10.1021/jm101423y,21375264.0,
6173700,CHEMBL1090089,pamapimod,CHEMBL1769479,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,29000.0,nM,Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC(CCO)CCO)nc21,CHEMBL1764984,"Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase.",J. Med. Chem.,2011.0,54,7,2255,2265,10.1021/jm101423y,21375264.0,
6174659,CHEMBL1412368,SID4265076,CHEMBL1769306,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,50000.0,nM,O=C1CC(=O)N(CCc2ccccc2)C(=O)N1CCc1ccccc1,CHEMBL1765084,"Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis.",J. Med. Chem.,2011.0,54,7,2409,2421,10.1021/jm101549k,21375347.0,
6174901,CHEMBL1767164,4-[(4-Chlorophenyl)methyl]-2-({(2R)-1-[4-(4-{[3-(hexahydro-1H-azepin-1-yl)propyl]oxy}phenyl)butyl]-2-pyrrolidinyl}methyl)-1(2H)-phthalazinone,CHEMBL1769767,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,3000.0,nM,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1,CHEMBL1764974,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,2011.0,54,7,2183,2195,10.1021/jm1013874,21381763.0,
6179798,CHEMBL1770373,"2-benzyl-6,7,8,9-tetrahydro-5H-pyrimido[5,4-d]azepine",CHEMBL1772820,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,c1ccc(Cc2ncc3c(n2)CCNCC3)cc1,CHEMBL1770110,"Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.",Bioorg. Med. Chem. Lett.,2011.0,21,9,2715,2720,10.1016/j.bmcl.2010.11.120,21195614.0,
6187356,CHEMBL1774933,"2-Amino-4-{4-chloro-2-[2-(4-fluoropyrazol-1-yl)ethoxy]-6-methylphenyl}-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylic Acid(2,2-Difluoropropyl)amide",CHEMBL1777407,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,Cc1cc(Cl)cc(OCCn2cc(F)cn2)c1-c1nc(N)nc2c1CN(C(=O)NCC(C)(F)F)C2,CHEMBL1772974,"Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.",J. Med. Chem.,2011.0,54,9,3368,3385,10.1021/jm200128m,21438541.0,
6201654,CHEMBL1778587,3-(4-(2-(3-cyclohexyl-2-(furan-3-yl)-1-methyl-1H-indole-6-carboxamido)-2-methylpropanamido)phenyl)acrylic acid,CHEMBL1780835,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2400.0,nM,Cn1c(-c2ccoc2)c(C2CCCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21,CHEMBL1777795,From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3658,3663,10.1016/j.bmcl.2011.04.059,21550240.0,
6201655,CHEMBL1778481,3-(4-(2-(3-cyclohexyl-1-methyl-2-(pyridin-2-yl)-1H-indole-6-carboxamido)-2-methylpropanamido)phenyl)acrylic acid,CHEMBL1780835,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7900.0,nM,Cn1c(-c2ccccn2)c(C2CCCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21,CHEMBL1777795,From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3658,3663,10.1016/j.bmcl.2011.04.059,21550240.0,
6202447,CHEMBL1823817,"(R)-2-chloro-5-(4-(2-hydroxy-3-methoxypropyl)-3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl)-N-((1-hydroxycycloheptyl)methyl)benzamide",CHEMBL1780720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,COC[C@H](O)Cn1c(=O)cnn(-c2ccc(Cl)c(C(=O)NCC3(O)CCCCCC3)c2)c1=O,CHEMBL1777794,"Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535.",Bioorg. Med. Chem. Lett.,2011.0,21,12,3708,3711,10.1016/j.bmcl.2011.04.077,21565499.0,
6207364,CHEMBL3084389,"3-chloro-4-(6-((1S,5S)-8-(cyclopropylsulfonyl)-8-azabicyclo[3.2.1]octan-3-yloxy)-5-methylpyrimidin-4-ylamino)benzonitrile",CHEMBL1781112,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,20000.0,nM,Cc1c(Nc2ccc(C#N)cc2Cl)ncnc1O[C@@H]1C[C@@H]2CC[C@H](C1)N2S(=O)(=O)C1CC1,CHEMBL1777763,Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.,Bioorg. Med. Chem. Lett.,2011.0,21,11,3290,3296,10.1016/j.bmcl.2011.04.035,21536438.0,
6207737,CHEMBL1777861,rac-3-(4-(2-(difluoromethoxy)-4-(trifluoromethyl)phenoxy)phenyl)hex-4-ynoic acid,CHEMBL1780455,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CC#CC(CC(=O)O)c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1,CHEMBL1777807,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists.,Bioorg. Med. Chem. Lett.,2011.0,21,11,3390,3394,10.1016/j.bmcl.2011.03.114,21514824.0,
6207836,CHEMBL1777855,rac-3-(4-(2-(difluoromethoxy)-4-(trifluoromethyl)phenoxy)-2-fluorophenyl)hex-4-ynoic acid,CHEMBL1780455,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,28000.0,nM,CC#CC(CC(=O)O)c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1F,CHEMBL1777807,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists.,Bioorg. Med. Chem. Lett.,2011.0,21,11,3390,3394,10.1016/j.bmcl.2011.03.114,21514824.0,
6207837,CHEMBL1777878,"cis-rac-5-(1-(4-(2-(difluoromethoxy)-4-(trifluoromethyl)phenoxy)phenyl)but-2-ynyl)oxazolidine-2,4-dione",CHEMBL1780455,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2400.0,nM,CC#C[C@@H](c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1)[C@H]1OC(=O)NC1=O,CHEMBL1777807,3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists.,Bioorg. Med. Chem. Lett.,2011.0,21,11,3390,3394,10.1016/j.bmcl.2011.03.114,21514824.0,
6209086,CHEMBL561132,"(R)-2-(7-(4-fluoro-N-methylphenylsulfonamido)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetic acid",CHEMBL1780283,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9000.0,nM,CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1777736,New indole amide derivatives as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,2011.0,21,11,3471,3474,10.1016/j.bmcl.2011.03.085,21515053.0,
6209087,CHEMBL1778387,"2-((R)-7-((R)-2-(4-fluorophenyl)-N-methylpropanamido)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetic acid",CHEMBL1780283,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,C[C@@H](C(=O)N(C)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)c1ccc(F)cc1,CHEMBL1777736,New indole amide derivatives as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,2011.0,21,11,3471,3474,10.1016/j.bmcl.2011.03.085,21515053.0,
6209088,CHEMBL1778388,"(R)-2-(7-(1-(4-fluorophenyl)-N-methylcyclopentanecarboxamido)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetic acid",CHEMBL1780283,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CN(C(=O)C1(c2ccc(F)cc2)CCCC1)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1,CHEMBL1777736,New indole amide derivatives as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,2011.0,21,11,3471,3474,10.1016/j.bmcl.2011.03.085,21515053.0,
6209089,CHEMBL1778506,"(R)-2-(7-(2-(4-fluorophenyl)-N-methylacetamido)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetic acid",CHEMBL1780283,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CN(C(=O)Cc1ccc(F)cc1)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1,CHEMBL1777736,New indole amide derivatives as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,2011.0,21,11,3471,3474,10.1016/j.bmcl.2011.03.085,21515053.0,
6209090,CHEMBL1778524,"(R)-2-(7-(1-(4-fluorophenyl)-N-methylcyclobutanecarboxamido)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetic acid",CHEMBL1780283,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CN(C(=O)C1(c2ccc(F)cc2)CCC1)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1,CHEMBL1777736,New indole amide derivatives as potent CRTH2 receptor antagonists.,Bioorg. Med. Chem. Lett.,2011.0,21,11,3471,3474,10.1016/j.bmcl.2011.03.085,21515053.0,
6211471,CHEMBL1778639,2-(4'-(ethylsulfonyl)-2'-methyl-5-(trifluoromethyl)biphenyl-2-yloxy)acetic acid,CHEMBL1780739,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CCS(=O)(=O)c1ccc(-c2cc(C(F)(F)F)ccc2OCC(=O)O)c(C)c1,CHEMBL1777748,Switching between agonists and antagonists at CRTh2 in a series of highly potent and selective biaryl phenoxyacetic acids.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3616,3621,10.1016/j.bmcl.2011.04.101,21592791.0,
6225631,CHEMBL1782308,2-(4-(5-ethyl-2-(5-fluorothiophen-2-yl)-6-methylpyrimidin-4-ylamino)-3-fluorophenyl)acetic acid,CHEMBL1786312,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CCc1c(C)nc(-c2ccc(F)s2)nc1Nc1ccc(CC(=O)O)cc1F,CHEMBL1782001,Discovery of selective PDE4B inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,12,3174,3176,10.1016/j.bmcl.2009.04.121,19447034.0,
6225635,CHEMBL1782306,2-(4-(2-(5-chlorothiophen-2-yl)-5-ethyl-6-methylpyrimidin-4-ylamino)phenyl)acetic acid,CHEMBL1786312,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CCc1c(C)nc(-c2ccc(Cl)s2)nc1Nc1ccc(CC(=O)O)cc1,CHEMBL1782001,Discovery of selective PDE4B inhibitors.,Bioorg. Med. Chem. Lett.,2009.0,19,12,3174,3176,10.1016/j.bmcl.2009.04.121,19447034.0,
6227715,CHEMBL1782521,5-bromo-7-(piperidin-4-ylmethylamino)benzofuran-2-carboxylic acid,CHEMBL1786250,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,O=C(O)c1cc2cc(Br)cc(NCC3CCNCC3)c2o1,CHEMBL1781944,The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors.,Bioorg. Med. Chem. Lett.,2011.0,21,10,3050,3056,10.1016/j.bmcl.2011.03.030,21507633.0,
6227716,CHEMBL1782530,cis-7-(4-aminocyclohexylamino)-5-bromobenzofuran-2-carboxylic acid,CHEMBL1786250,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,N[C@H]1CC[C@@H](Nc2cc(Br)cc3cc(C(=O)O)oc23)CC1,CHEMBL1781944,The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors.,Bioorg. Med. Chem. Lett.,2011.0,21,10,3050,3056,10.1016/j.bmcl.2011.03.030,21507633.0,
6227717,CHEMBL1782531,trans-7-(4-aminocyclohexylamino)-5-bromobenzofuran-2-carboxylic acid,CHEMBL1786250,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,N[C@H]1CC[C@H](Nc2cc(Br)cc3cc(C(=O)O)oc23)CC1,CHEMBL1781944,The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors.,Bioorg. Med. Chem. Lett.,2011.0,21,10,3050,3056,10.1016/j.bmcl.2011.03.030,21507633.0,
6230207,CHEMBL478649,"6-Methyl-biphenyl-3,4'-dicarboxylic acid 3-cyclopropylamide 4'-cyclopropylmethyl-amide",CHEMBL1787756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli by fluorimetric assay,IC50,=,3981.07,nM,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1,CHEMBL1781916,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,2009.0,52,20,6257,6269,10.1021/jm9004779,19772287.0,
6230211,CHEMBL1784164,"N3-Cyclopropyl-N4'-(cyclopropylmethyl)-5-fluoro-6-methyl-3,4'-biphenyldicarboxamide",CHEMBL1787756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli by fluorimetric assay,IC50,=,1995.26,nM,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1,CHEMBL1781916,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,2009.0,52,20,6257,6269,10.1021/jm9004779,19772287.0,
6230226,CHEMBL1784168,"N3-Cyclopropyl-5-fluoro-6-methyl-N4'-(tetrahydro-2-furanylmethyl)-3,4'-biphenyldicarboxamide",CHEMBL1787756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli by fluorimetric assay,IC50,=,12589.25,nM,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CCCO2)cc1,CHEMBL1781916,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,2009.0,52,20,6257,6269,10.1021/jm9004779,19772287.0,
6230229,CHEMBL1784169,"N3-Cyclopropyl-5-fluoro-6-methyl-N4'-[(2-methyl-1,3-thiazol-4-yl)methyl]-3,4'-biphenyldicarboxamide",CHEMBL1787756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli by fluorimetric assay,IC50,>,100000.0,nM,Cc1nc(CNC(=O)c2ccc(-c3cc(C(=O)NC4CC4)cc(F)c3C)cc2)cs1,CHEMBL1781916,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,2009.0,52,20,6257,6269,10.1021/jm9004779,19772287.0,
6230232,CHEMBL1784170,"N3-Cyclopropyl-5-fluoro-6-methyl-N4'-[2-(methyloxy)ethyl]-3,4'-biphenyldicarboxamide",CHEMBL1787756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli by fluorimetric assay,IC50,=,63095.73,nM,COCCNC(=O)c1ccc(-c2cc(C(=O)NC3CC3)cc(F)c2C)cc1,CHEMBL1781916,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,2009.0,52,20,6257,6269,10.1021/jm9004779,19772287.0,
6230235,CHEMBL1784171,"N3-cyclopropyl-5-fluoro-N4'-(2-hydroxy-2-methylpropyl)-6-methyl-3,4'-biphenyldicarboxamide",CHEMBL1787756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli by fluorimetric assay,IC50,=,15848.93,nM,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)O)cc1,CHEMBL1781916,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,2009.0,52,20,6257,6269,10.1021/jm9004779,19772287.0,
6230246,CHEMBL1784173,6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-(2-methylpropyl)-3-pyridinecarboxamide,CHEMBL1787756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli by fluorimetric assay,IC50,=,31622.78,nM,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)C)cn1,CHEMBL1781916,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,2009.0,52,20,6257,6269,10.1021/jm9004779,19772287.0,
6230252,CHEMBL1784174,"6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-[(1R)-1,2-dimethylpropyl]-3-pyridinecarboxamide",CHEMBL1787756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli by fluorimetric assay,IC50,=,39810.72,nM,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)N[C@H](C)C(C)C)cn1,CHEMBL1781916,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,2009.0,52,20,6257,6269,10.1021/jm9004779,19772287.0,
6230258,CHEMBL1784175,"6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-[(1S)-1,2-dimethylpropyl]-3-pyridinecarboxamide",CHEMBL1787756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli by fluorimetric assay,IC50,=,39810.72,nM,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)N[C@@H](C)C(C)C)cn1,CHEMBL1781916,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,2009.0,52,20,6257,6269,10.1021/jm9004779,19772287.0,
6230264,CHEMBL1088752,Losmapimod,CHEMBL1787756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli by fluorimetric assay,IC50,=,31622.78,nM,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1,CHEMBL1781916,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,2009.0,52,20,6257,6269,10.1021/jm9004779,19772287.0,
6230270,CHEMBL1784176,"6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-[(1R)-1,2,2-trimethylpropyl]-3-pyridinecarboxamide",CHEMBL1787756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli by fluorimetric assay,IC50,=,39810.72,nM,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)N[C@H](C)C(C)(C)C)cn1,CHEMBL1781916,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,2009.0,52,20,6257,6269,10.1021/jm9004779,19772287.0,
6230276,CHEMBL1784177,"6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-[(1S)-1,2,2-trimethylpropyl]-3-pyridinecarboxamide",CHEMBL1787756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli by fluorimetric assay,IC50,=,31622.78,nM,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)N[C@@H](C)C(C)(C)C)cn1,CHEMBL1781916,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,2009.0,52,20,6257,6269,10.1021/jm9004779,19772287.0,
6230283,CHEMBL1232887,6-(5-Cyclopropylcarbamoyl-2-methyl-phenyl)-N-cyclopropylmethyl-nicotinamide,CHEMBL1787756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli by fluorimetric assay,IC50,=,39810.72,nM,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cn1,CHEMBL1781916,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,2009.0,52,20,6257,6269,10.1021/jm9004779,19772287.0,
6230355,CHEMBL1784172,6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-(cyclopropylmethyl)-3-pyridinecarboxamide,CHEMBL1787756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli by fluorimetric assay,IC50,=,63095.73,nM,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cn1,CHEMBL1781916,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,J. Med. Chem.,2009.0,52,20,6257,6269,10.1021/jm9004779,19772287.0,
6259419,CHEMBL1796296,(R/S)-4-(4-((3-hydroxyquinuclidin-3-yl)ethynyl)phenoxy)-N-(pyridin-4-ylmethyl)benzamide,CHEMBL1798936,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,<,10000.0,nM,O=C(NCc1ccncc1)c1ccc(Oc2ccc(C#CC3(O)CN4CCC3CC4)cc2)cc1,CHEMBL1795206,Selective non zinc binding inhibitors of MMP13.,Bioorg. Med. Chem. Lett.,2011.0,21,14,4215,4219,10.1016/j.bmcl.2011.05.075,21669521.0,
6259454,CHEMBL1796298,4-[4-[2-[(3S)-3-hydroxyquinuclidin-3-yl]ethynyl]phenoxy]-N-(pyrimidin-4-ylmethyl)benzamide,CHEMBL1798936,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(NCc1ccncn1)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1,CHEMBL1795206,Selective non zinc binding inhibitors of MMP13.,Bioorg. Med. Chem. Lett.,2011.0,21,14,4215,4219,10.1016/j.bmcl.2011.05.075,21669521.0,
6259460,CHEMBL1796298,4-[4-[2-[(3S)-3-hydroxyquinuclidin-3-yl]ethynyl]phenoxy]-N-(pyrimidin-4-ylmethyl)benzamide,CHEMBL1798940,A,,,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9,IC50,>,50118.72,nM,O=C(NCc1ccncn1)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1,CHEMBL1795206,Selective non zinc binding inhibitors of MMP13.,Bioorg. Med. Chem. Lett.,2011.0,21,14,4215,4219,10.1016/j.bmcl.2011.05.075,21669521.0,
6272673,CHEMBL372575,"(E)-8-(3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-(4-(methylsulfonyl)phenyl)vinyl)phenyl)-6-(2-(methylsulfonyl)propan-2-yl)quinoline",CHEMBL1805702,A,,,Cytochrome P450 2C9,Competitive inhibition of CYP2C9,IC50,<,1000.0,nM,Cc1noc(/C(=C/c2cccc(-c3cc(C(C)(C)S(C)(=O)=O)cc4cccnc34)c2)c2ccc(S(C)(=O)=O)cc2)n1,CHEMBL1799977,"Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.",Bioorg. Med. Chem. Lett.,2010.0,20,22,6387,6393,10.1016/j.bmcl.2010.09.087,20933411.0,
6272674,CHEMBL485629,"4-Oxo-1-[3-(1-oxy-pyridin-3-ylethynyl)-phenyl]-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid cyclopropylamide",CHEMBL1805702,A,,,Cytochrome P450 2C9,Competitive inhibition of CYP2C9,IC50,=,40000.0,nM,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O,CHEMBL1799977,"Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.",Bioorg. Med. Chem. Lett.,2010.0,20,22,6387,6393,10.1016/j.bmcl.2010.09.087,20933411.0,
6272675,CHEMBL253083,2-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid,CHEMBL1805702,A,,,Cytochrome P450 2C9,Competitive inhibition of CYP2C9,IC50,=,1700.0,nM,CC(C)(c1cc(-c2cccc(-c3ccc(C4CC4C(=O)O)cc3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1799977,"Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.",Bioorg. Med. Chem. Lett.,2010.0,20,22,6387,6393,10.1016/j.bmcl.2010.09.087,20933411.0,
6272676,CHEMBL253083,2-{3'-[6-(1-methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid,CHEMBL1805702,A,,,Cytochrome P450 2C9,Competitive inhibition of CYP2C9,IC50,=,3200.0,nM,CC(C)(c1cc(-c2cccc(-c3ccc(C4CC4C(=O)O)cc3)c2)c2ncccc2c1)S(C)(=O)=O,CHEMBL1799977,"Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.",Bioorg. Med. Chem. Lett.,2010.0,20,22,6387,6393,10.1016/j.bmcl.2010.09.087,20933411.0,
6272732,CHEMBL1801160,"(1R,2R)-2-(3'-(3-(cyclopropylcarbamoyl)-4-oxo-1,8-naphthyridin-1(4H)-yl)-3-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid",CHEMBL1806199,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,O=C(NC1CC1)c1cn(-c2cccc(-c3ccc([C@@H]4C[C@H]4C(=O)O)c(F)c3)c2)c2ncccc2c1=O,CHEMBL1799977,"Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.",Bioorg. Med. Chem. Lett.,2010.0,20,22,6387,6393,10.1016/j.bmcl.2010.09.087,20933411.0,
6280740,CHEMBL1822792,"N-[(2R)-1,4-dioxan-2-ylmethyl]-N-methyl{[5-(1-methyl-1H-pyrazol-4-yl)-2-oxo-7-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3(8),4,6,9,11,13-heptaen-13-yl]amino}sulfonamide",CHEMBL1803984,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1200.0,nM,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1,CHEMBL1800066,"Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.",J. Med. Chem.,2011.0,54,12,4092,4108,10.1021/jm200112k,21608528.0,
6280848,CHEMBL1803004,"N-(5-Oxo-3-phenyl-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl)methanesulfonamide",CHEMBL1803984,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CS(=O)(=O)Nc1ccc2ccc3ncc(-c4ccccc4)cc3c(=O)c2c1,CHEMBL1800066,"Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.",J. Med. Chem.,2011.0,54,12,4092,4108,10.1021/jm200112k,21608528.0,
6281044,CHEMBL1801364,"N-(2-chloro-4-fluorobenzyl)-2-(2-(2,4-difluorophenyl)-1,4-dimethyl-1H-imidazol-5-yl)acetamide hydrochloride",CHEMBL1805044,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1nc(-c2ccc(F)cc2F)n(C)c1CC(=O)NCc1ccc(F)cc1Cl.Cl,CHEMBL1800005,Synthesis and biological activity of a series of tetrasubstituted-imidazoles as P2X(7) antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,16,4951,4954,10.1016/j.bmcl.2010.05.018,20634071.0,
6281908,CHEMBL1738840,"2-(2-(4-methoxypyridin-2-yl)ethyl)-3H-imidazo[4,5-b]pyridine",CHEMBL1803816,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3162.28,nM,COc1ccnc(CCc2nc3cccnc3[nH]2)c1,CHEMBL1799930,"Novel nanomolar imidazo[4,5-b]pyridines as selective nitric oxide synthase (iNOS) inhibitors: SAR and structural insights.",Bioorg. Med. Chem. Lett.,2011.0,21,14,4228,4232,10.1016/j.bmcl.2011.05.073,21684157.0,
6282618,CHEMBL1800911,"N-cyclopropyl-4-methyl-3-(2'-oxospiro[cyclopentane-1,3'-indoline]-6'-yl)benzamide",CHEMBL1804852,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2c(c1)NC(=O)C21CCCC1,CHEMBL1799962,"Indolin-2-one p38α inhibitors I: design, profiling and crystallographic binding mode.",Bioorg. Med. Chem. Lett.,2011.0,21,14,4130,4133,10.1016/j.bmcl.2011.05.114,21696951.0,
6283740,CHEMBL1800774,"2-amino-1-(3-(3,4-difluorophenylamino)-2-(4-fluorophenyl)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-methylpropan-1-one",CHEMBL1803728,A,,,Cytochrome P450 2C9,Inhibition of CYP 2C9,IC50,>,8900.0,nM,CC(C)(N)C(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(F)c(F)c2)C1,CHEMBL1800027,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,J. Med. Chem.,2011.0,54,14,5116,5130,10.1021/jm2003359,21644570.0,
6283741,CHEMBL1800137,"2-amino-1-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-methylpropan-1-one",CHEMBL1803728,A,,,Cytochrome P450 2C9,Inhibition of CYP 2C9,IC50,>,8900.0,nM,CC(C)(N)C(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(F)cc2)C1,CHEMBL1800027,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,J. Med. Chem.,2011.0,54,14,5116,5130,10.1021/jm2003359,21644570.0,
6283742,CHEMBL601821,GNF-Pf-5069,CHEMBL1803728,A,,,Cytochrome P450 2C9,Inhibition of CYP 2C9,IC50,>,10000.0,nM,NCC(=O)N1CCn2c(nc(-c3ccccc3)c2Nc2ccc3c(c2)OCO3)C1,CHEMBL1800027,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,J. Med. Chem.,2011.0,54,14,5116,5130,10.1021/jm2003359,21644570.0,
6300720,CHEMBL1807440,"N-(3-(6-benzoyl-5-methylpyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-4-methylphenyl)-3-fluoro-5-morpholinobenzamide",CHEMBL1811279,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,350.0,nM,Cc1ccc(NC(=O)c2cc(F)cc(N3CCOCC3)c2)cc1Nc1ncnn2cc(C(=O)c3ccccc3)c(C)c12,CHEMBL1806462,"Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors.",Bioorg. Med. Chem. Lett.,2011.0,21,15,4633,4637,10.1016/j.bmcl.2011.05.091,21705217.0,
6305038,CHEMBL1813314,"cis-3a-(3,4-dichlorophenyl)-2-methyloctahydro-1H-isoindole",CHEMBL1816478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,25000.0,nM,CN1C[C@H]2CCCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1,CHEMBL1811752,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,2011.0,54,15,5283,5295,10.1021/jm101312a,21739935.0,
6305039,CHEMBL1813315,"cis-(3aS,7aR)-3a-(3,4-dichlorophenyl)-2-methyloctahydro-1H-isoindole",CHEMBL1816478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,25000.0,nM,CN1C[C@@H]2CCCC[C@]2(c2ccc(Cl)c(Cl)c2)C1,CHEMBL1811752,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,2011.0,54,15,5283,5295,10.1021/jm101312a,21739935.0,
6305040,CHEMBL1813471,"cis-rac-3a-(3,4-dichlorophenyl)octahydro-1H-isoindole",CHEMBL1816478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,25000.0,nM,Clc1ccc([C@]23CCCC[C@H]2CNC3)cc1Cl,CHEMBL1811752,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,2011.0,54,15,5283,5295,10.1021/jm101312a,21739935.0,
6305041,CHEMBL1813472,"(3aR,7aS)-3a-(3,4-dichlorophenyl)octahydro-1H-isoindole",CHEMBL1816478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,25000.0,nM,Clc1ccc([C@@]23CCCC[C@@H]2CNC3)cc1Cl,CHEMBL1811752,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,2011.0,54,15,5283,5295,10.1021/jm101312a,21739935.0,
6305042,CHEMBL1813316,"cis-(3aR,7aS)-3a-(3,4-dichlorophenyl)-2-ethyloctahydro-1H-isoindole",CHEMBL1816478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,5000.0,nM,CCN1C[C@H]2CCCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1,CHEMBL1811752,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,2011.0,54,15,5283,5295,10.1021/jm101312a,21739935.0,
6305043,CHEMBL1813317,"cis-3a-(3,4-dichlorophenyl)-2-ethyloctahydro-1H-isoindole",CHEMBL1816478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,5000.0,nM,CCN1C[C@@H]2CCCC[C@]2(c2ccc(Cl)c(Cl)c2)C1,CHEMBL1811752,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,2011.0,54,15,5283,5295,10.1021/jm101312a,21739935.0,
6305091,CHEMBL1813478,"cis-rac-(3aS,6aR)-3a-(3,4-dichlorophenyl)-2-methyloctahydrocyclopenta[c]pyrrole",CHEMBL1816478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,=,9830.0,nM,CN1C[C@@H]2CCC[C@]2(c2ccc(Cl)c(Cl)c2)C1,CHEMBL1811752,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,2011.0,54,15,5283,5295,10.1021/jm101312a,21739935.0,
6305099,CHEMBL1813484,"(3aR,6aS)-3a-(3,4-dichlorophenyl)-2-methyloctahydrocyclopenta[c]pyrrole",CHEMBL1816478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,25000.0,nM,CN1C[C@H]2CCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1,CHEMBL1811752,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,2011.0,54,15,5283,5295,10.1021/jm101312a,21739935.0,
6305107,CHEMBL1813474,"cis-3a-(3,4-dichlorophenyl)octahydrocyclopenta[c]pyrrole",CHEMBL1816478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,=,4010.0,nM,Clc1ccc([C@]23CCC[C@H]2CNC3)cc1Cl,CHEMBL1811752,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,2011.0,54,15,5283,5295,10.1021/jm101312a,21739935.0,
6305115,CHEMBL1813475,"(3aR,6aS)-3a-(3,4-dichlorophenyl)octahydrocyclopenta[c]pyrrole",CHEMBL1816478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,25000.0,nM,Clc1ccc([C@@]23CCC[C@@H]2CNC3)cc1Cl,CHEMBL1811752,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,2011.0,54,15,5283,5295,10.1021/jm101312a,21739935.0,
6305123,CHEMBL1813476,"cis-(3aS,6aR)-3a-(naphthalen-2-yl)octahydrocyclopenta[c]pyrrole",CHEMBL1816478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,25000.0,nM,c1ccc2cc([C@]34CCC[C@H]3CNC4)ccc2c1,CHEMBL1811752,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,2011.0,54,15,5283,5295,10.1021/jm101312a,21739935.0,
6305131,CHEMBL1813477,"(3aR,6aS)-3a-(naphthalen-2-yl)octahydrocyclopenta[c]pyrrole",CHEMBL1816478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,=,14400.0,nM,c1ccc2cc([C@@]34CCC[C@@H]3CNC4)ccc2c1,CHEMBL1811752,Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.,J. Med. Chem.,2011.0,54,15,5283,5295,10.1021/jm101312a,21739935.0,
6319221,CHEMBL1813067,(R)-6-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)pyridazin-3(2H)-one hydrochloride,CHEMBL1816653,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)[nH]n2)cc1.Cl,CHEMBL1811886,"Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.",J. Med. Chem.,2011.0,54,13,4781,4792,10.1021/jm200401v,21634396.0,
6319596,CHEMBL1813114,"(8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carboxamide",CHEMBL1815298,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,40000.0,nM,C[C@@]12CN(C(=O)Nc3ccnn3-c3ccccc3)CCN1C(=O)N([C@H]1C[C@@H]1c1ccccc1)C2=O,CHEMBL1811786,"Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo- propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 2.",Bioorg. Med. Chem. Lett.,2011.0,21,15,4429,4435,10.1016/j.bmcl.2011.06.023,21737263.0,
6327535,CHEMBL1818291,tert-Butyl[(trans-4-{[({2-[3-(aminomethyl)phenyl]-quinolin-4-yl}carbonyl)amino]methyl}cyclohexyl)methyl]-carbamate,CHEMBL1820809,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,800.0,nM,CC(C)(C)OC(=O)NC[C@H]1CC[C@H](CNC(=O)c2cc(-c3cccc(CN)c3)nc3ccccc23)CC1,CHEMBL1817551,Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats.,Bioorg. Med. Chem.,2011.0,19,10,3039,3053,10.1016/j.bmc.2011.04.014,21515056.0,
6329336,CHEMBL1818445,"2-((6S)-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptan-1-yl)-4-methylthiazole",CHEMBL1819646,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 incubated for 10 mins before substrate addition by fluorescence assay,IC50,>,6000.0,nM,Cc1csc(C23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1,CHEMBL1817647,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,11,3451,3461,10.1016/j.bmc.2011.04.032,21550808.0,
6329337,CHEMBL1818451,"(6S)-6-(3,4-dichlorophenyl)-1-((3-methyl-1H-pyrazol-1-yl)methyl)-3-azabicyclo[4.1.0]heptane",CHEMBL1819646,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 incubated for 10 mins before substrate addition by fluorescence assay,IC50,>,10000.0,nM,Cc1ccn(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1,CHEMBL1817647,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,11,3451,3461,10.1016/j.bmc.2011.04.032,21550808.0,
6329338,CHEMBL1818452,"(6S)-6-(3,4-dichlorophenyl)-1-((5-methyl-1H-pyrazol-1-yl)methyl)-3-azabicyclo[4.1.0]heptane",CHEMBL1819646,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 incubated for 10 mins before substrate addition by fluorescence assay,IC50,>,10000.0,nM,Cc1ccnn1CC12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2,CHEMBL1817647,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,11,3451,3461,10.1016/j.bmc.2011.04.032,21550808.0,
6329339,CHEMBL1818455,"(6S)-6-(3,4-dichlorophenyl)-1-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)-3-azabicyclo[4.1.0]heptane",CHEMBL1819646,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 incubated for 10 mins before substrate addition by fluorescence assay,IC50,>,8000.0,nM,Cc1cc(C)n(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1,CHEMBL1817647,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,11,3451,3461,10.1016/j.bmc.2011.04.032,21550808.0,
6329373,CHEMBL1818543,"(6S)-6-(3,4-dichlorophenyl)-1-((3,5-dimethyl-1H-1,2,4-triazol-1-yl)methyl)-3-azabicyclo[4.1.0]heptane",CHEMBL1819646,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 incubated for 10 mins before substrate addition by fluorescence assay,IC50,>,25000.0,nM,Cc1nc(C)n(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1,CHEMBL1817647,"1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: further insights into a class of triple re-uptake inhibitors.",Bioorg. Med. Chem.,2011.0,19,11,3451,3461,10.1016/j.bmc.2011.04.032,21550808.0,
6335444,CHEMBL1819090,"2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile",CHEMBL1821058,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cn1c(=O)c2c(cc(N3CCC[C@@](C)(N)C3)n2Cc2cc(F)ccc2C#N)n(C)c1=O,CHEMBL1817578,"2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.",Bioorg. Med. Chem.,2011.0,19,18,5490,5499,10.1016/j.bmc.2011.07.042,21865048.0,
6338957,CHEMBL1825089,"N-(4-(1-cycloheptyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino)phenyl)-N-(2-morpholinoethyl)methanesulfonamide",CHEMBL1825560,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using a fluorescent probe 7-methoxy-4-trifluoromethylcoumarin,IC50,=,1.0,nM,CS(=O)(=O)N(CCN1CCOCC1)c1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cc1,CHEMBL1821661,"Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).",Bioorg. Med. Chem. Lett.,2011.0,21,18,5633,5637,10.1016/j.bmcl.2011.06.129,21798738.0,
6339027,CHEMBL1825096,"N-(5-(1-cycloheptyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino)pyridin-2-yl)methanesulfonamide",CHEMBL1825560,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using a fluorescent probe 7-methoxy-4-trifluoromethylcoumarin,IC50,>,10000.0,nM,CS(=O)(=O)Nc1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cn1,CHEMBL1821661,"Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).",Bioorg. Med. Chem. Lett.,2011.0,21,18,5633,5637,10.1016/j.bmcl.2011.06.129,21798738.0,
6339113,CHEMBL1821837,"(R)-1-((3,5-difluoropyridin-2-yl)methyl)-N-(1-phenylpropyl)-1H-benzo[d]imidazole-5-carboxamide",CHEMBL1825658,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,42000.0,nM,CC[C@@H](NC(=O)c1ccc2c(c1)ncn2Cc1ncc(F)cc1F)c1ccccc1,CHEMBL1821577,Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5568,5572,10.1016/j.bmcl.2011.06.088,21798739.0,
6339177,CHEMBL3217170,"N-(3-(4-(3-Chloro-2-methylphenyl)piperazin-1-yl)propyl)-5-methyl-1,2-diphenyl-1H-imidazole-4-carboxamide dihydrochloride",CHEMBL1827886,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by luceferin-based assay,IC50,=,2900.0,nM,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(-c3ccccc3)n(-c3ccccc3)c2C)CC1.Cl.Cl.Cl,CHEMBL1821711,Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54,18,6305,6318,10.1021/jm200682b,21823597.0,
6339184,CHEMBL3215850,"5-((1H-1,2,4-Triazol-1-yl)methyl)-N-(3-(4-(3-chloro-2-methylphenyl)piperazin-1-yl)propyl)-1,2-diphenyl-1H-imidazole-4-carboxamide dihydrochloride",CHEMBL1827886,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by luceferin-based assay,IC50,=,3300.0,nM,Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(-c3ccccc3)n(-c3ccccc3)c2Cn2cncn2)CC1.Cl.Cl.Cl,CHEMBL1821711,Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54,18,6305,6318,10.1021/jm200682b,21823597.0,
6339201,CHEMBL3215864,"1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-1-yl)propyl)-2,5-dimethyl-1H-imidazole-4-carboxamide dihydrochloride",CHEMBL1827886,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by luceferin-based assay,IC50,=,4400.0,nM,Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccc5c(c4)OCCO5)c3C)CC2)c1C.Cl.Cl,CHEMBL1821711,Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,J. Med. Chem.,2011.0,54,18,6305,6318,10.1021/jm200682b,21823597.0,
6340394,CHEMBL1823410,(S)-2-methyl-6-(4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)phenyl)pyridazin-3(2H)-one,CHEMBL1826318,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,Cn1nc(-c2ccc(C(=O)N3CCC[C@H]3CN3CCCC3)cc2)ccc1=O,CHEMBL1821562,Amine-constrained pyridazinone histamine H₃ receptor antagonists.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5543,5546,10.1016/j.bmcl.2011.06.094,21824776.0,
6343528,CHEMBL1223751,"1-(((1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)methyl)(methyl)amino)-3-(4-ethoxyphenoxy)propan-2-ol",CHEMBL1827967,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as probe,IC50,=,43000.0,nM,CCOc1ccc(OCC(O)CN(C)Cc2c(C)nn(Cc3ccccc3Cl)c2C)cc1,CHEMBL1821673,Development of β-amino alcohol derivatives that inhibit Toll-like receptor 4 mediated inflammatory response as potential antiseptics.,J. Med. Chem.,2011.0,54,13,4659,4669,10.1021/jm2003365,21591694.0,
6346619,CHEMBL1823591,"N-(2-chlorophenyl)-4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperazine-1-carboxamide",CHEMBL1827536,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,O=C(Nc1ccccc1Cl)N1CCN(c2nc(-c3ccc4ccccc4n3)no2)CC1,CHEMBL1821555,"Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors.",Bioorg. Med. Chem. Lett.,2011.0,21,18,5274,5282,10.1016/j.bmcl.2011.07.031,21803580.0,
6348243,CHEMBL1822515,"[7-(2-Methoxy-phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl]-[4-(4-methyl-piperazin-1-yl)-phenyl]amine",CHEMBL1825984,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,COc1ccccc1-c1ccc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nn12,CHEMBL1821719,"2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.",J. Med. Chem.,2011.0,54,18,6328,6341,10.1021/jm200758k,21859094.0,
6349158,CHEMBL1821735,"N-Methyl-N-(2-{2-[4-(4-methyl-piperazin-1-yl)phenylamino]-pyrrolo[2,1-f][1,2,4]triazin-7-yl}phenyl)methanesulfonamide",CHEMBL1825984,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CN1CCN(c2ccc(Nc3ncc4ccc(-c5ccccc5N(C)S(C)(=O)=O)n4n3)cc2)CC1,CHEMBL1821719,"2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.",J. Med. Chem.,2011.0,54,18,6328,6341,10.1021/jm200758k,21859094.0,
6349220,CHEMBL1822525,"N-[2-(2-{4-[4-((S)-2-Hydroxy-propyl)-piperazin-1-yl]-2-methoxy-phenylamino}-pyrrolo[2,1-f][1,2,4]triazin-7-yl)-phenyl]-N-methyl-methanesulfonamide",CHEMBL1825984,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,12000.0,nM,COc1cc(N2CCN(C[C@H](C)O)CC2)ccc1Nc1ncc2ccc(-c3ccccc3N(C)S(C)(=O)=O)n2n1,CHEMBL1821719,"2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.",J. Med. Chem.,2011.0,54,18,6328,6341,10.1021/jm200758k,21859094.0,
6353416,CHEMBL1824249,trans-N-butyl-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexanamine,CHEMBL1827184,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1000.0,nM,CCCCN[C@H]1CC[C@H](c2ccc(OCCCN3CCCCC3)cc2)CC1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6353417,CHEMBL1824248,cis-N-butyl-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexanamine,CHEMBL1827184,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1000.0,nM,CCCCN[C@H]1CC[C@@H](c2ccc(OCCCN3CCCCC3)cc2)CC1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6354040,CHEMBL1824247,trans-N-benzyl-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexanamine,CHEMBL1827184,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1000.0,nM,c1ccc(CN[C@H]2CC[C@H](c3ccc(OCCCN4CCCCC4)cc3)CC2)cc1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6354041,CHEMBL1824241,trans-4-(4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexyl)morpholine,CHEMBL1827184,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,44000.0,nM,c1cc([C@H]2CC[C@H](N3CCOCC3)CC2)ccc1OCCCN1CCCCC1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6354042,CHEMBL1824235,trans-1-(3-(4-(-4-(pyrrolidin-1-yl)cyclohexyl)phenoxy)propyl)piperidine,CHEMBL1827184,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,15300.0,nM,c1cc([C@H]2CC[C@H](N3CCCC3)CC2)ccc1OCCCN1CCCCC1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6354043,CHEMBL1824234,cis-1-(3-(4(4-(pyrrolidin-1-yl)cyclohexyl)phenoxy)propyl)piperidine,CHEMBL1827184,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,22300.0,nM,c1cc([C@H]2CC[C@@H](N3CCCC3)CC2)ccc1OCCCN1CCCCC1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6354044,CHEMBL1824231,"trans-N,N-dimethyl-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexanamine",CHEMBL1827184,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,40700.0,nM,CN(C)[C@H]1CC[C@H](c2ccc(OCCCN3CCCCC3)cc2)CC1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6354045,CHEMBL1824230,"cis-N,N-dimethyl-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexanamine",CHEMBL1827184,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,11300.0,nM,CN(C)[C@H]1CC[C@@H](c2ccc(OCCCN3CCCCC3)cc2)CC1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6361173,CHEMBL1766005,3-Imidazol-1-yl-2-methyl-3-[4-(naphthalen-2-ylamino)-phenyl]-propionic acid Methyl Ester,CHEMBL1833289,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,8000.0,nM,COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1ccnc1,CHEMBL1828563,"Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).",J. Med. Chem.,2011.0,54,19,6803,6811,10.1021/jm200695m,21838328.0,
6361174,CHEMBL517438,"Benzothiazol-2-yl-[4-((1S,2S)-2-dimethylamino-1-imidazol-1-yl-propyl)-phenyl]-amine",CHEMBL1833289,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,11000.0,nM,C[C@H]([C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1ccnc1)N(C)C,CHEMBL1828563,"Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).",J. Med. Chem.,2011.0,54,19,6803,6811,10.1021/jm200695m,21838328.0,
6361175,CHEMBL1831092,"Methyl 2,2-Dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]-3-(1H-1,2,4-triazol-1-yl)propanoate",CHEMBL1833289,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,21400.0,nM,COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1cncn1,CHEMBL1828563,"Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).",J. Med. Chem.,2011.0,54,19,6803,6811,10.1021/jm200695m,21838328.0,
6366124,CHEMBL1829472,(R)-6-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-2-(pyrimidin-2-yl)pyridazin-3(2H)-one,CHEMBL1832619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)n(-c3ncccn3)n2)cc1,CHEMBL1828619,"Identification of pyridazin-3-one derivatives as potent, selective histamine H₃ receptor inverse agonists with robust wake activity.",Bioorg. Med. Chem. Lett.,2011.0,21,18,5493,5497,10.1016/j.bmcl.2011.06.108,21782432.0,
6366125,CHEMBL1829477,(R)-6-(3-fluoro-4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-2-methylpyridazin-3(2H)-one,CHEMBL1832619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)n(C)n2)cc1F,CHEMBL1828619,"Identification of pyridazin-3-one derivatives as potent, selective histamine H₃ receptor inverse agonists with robust wake activity.",Bioorg. Med. Chem. Lett.,2011.0,21,18,5493,5497,10.1016/j.bmcl.2011.06.108,21782432.0,
6366126,CHEMBL1829485,2-methyl-6-(4-((S)-2-methyl-3-((R)-2-methylpyrrolidin-1-yl)propoxy)phenyl)pyridazin-3(2H)-one,CHEMBL1832619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@H](COc1ccc(-c2ccc(=O)n(C)n2)cc1)CN1CCC[C@H]1C,CHEMBL1828619,"Identification of pyridazin-3-one derivatives as potent, selective histamine H₃ receptor inverse agonists with robust wake activity.",Bioorg. Med. Chem. Lett.,2011.0,21,18,5493,5497,10.1016/j.bmcl.2011.06.108,21782432.0,
6367181,CHEMBL1829763,"(S)-3-((S)-1-(2',4'-Difluoro-[1,1'-biphenyl]-4-yl)ethyl)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one",CHEMBL1831806,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4900.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O,CHEMBL1828622,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase type 1.",J. Med. Chem.,2011.0,54,17,6050,6062,10.1021/jm2005354,21786805.0,
6370084,CHEMBL1829433,"N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-4,5-dihydroisothiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide",CHEMBL1833740,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,10000.0,nM,Cc1ccc(C(=O)N(CCCN)C(c2nc3snc(C)c3c(=O)n2Cc2ccccc2)C(C)C)cc1,CHEMBL1828558,"Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent.",J. Med. Chem.,2011.0,54,19,6734,6750,10.1021/jm200629m,21899292.0,
6371703,CHEMBL3215861,(E)-3-[2-Butyl-1-(2-diethylaminoethyl)-1H-benzimidazol-5-yl]-N-hydroxyacrylamide Dihydrochloride Salt,CHEMBL1832818,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by fluorescence assay,IC50,>,25000.0,nM,CCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(CC)CC.Cl.Cl,CHEMBL1828590,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",J. Med. Chem.,2011.0,54,13,4694,4720,10.1021/jm2003552,21634430.0,
6371710,CHEMBL1830397,"(E)-3-[1-(3-Dimethylamino-2,2-dimethylpropyl)-2-(2,2-dimethylpropyl)-1H-benzimidazol-5-yl]-N-hydroxyacrylamide",CHEMBL1832818,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by fluorescence assay,IC50,>,25000.0,nM,CN(C)CC(C)(C)Cn1c(CC(C)(C)C)nc2cc(/C=C/C(=O)NO)ccc21,CHEMBL1828590,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",J. Med. Chem.,2011.0,54,13,4694,4720,10.1021/jm2003552,21634430.0,
6371717,CHEMBL1830424,(E)-3-[1-(2-Dimethylaminoethyl)-2-hexyl-1H-benzimidazol-5-yl]-N-hydroxyacrylamide,CHEMBL1832818,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by fluorescence assay,IC50,=,10400.0,nM,CCCCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(C)C,CHEMBL1828590,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",J. Med. Chem.,2011.0,54,13,4694,4720,10.1021/jm2003552,21634430.0,
6372963,CHEMBL1837037,"8-chloro-5-methyl-1-(1-(pyridin-2-yl)piperidin-4-yl)-5,6-dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine",CHEMBL1837363,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CN1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1,CHEMBL1833912,"Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.",Bioorg. Med. Chem. Lett.,2011.0,21,19,5684,5687,10.1016/j.bmcl.2011.08.038,21885275.0,
6372968,CHEMBL1837038,"methyl 8-chloro-1-(1-(pyridin-2-yl)piperidin-4-yl)-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine-5(6H)-carboxylate",CHEMBL1837363,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,COC(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1,CHEMBL1833912,"Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.",Bioorg. Med. Chem. Lett.,2011.0,21,19,5684,5687,10.1016/j.bmcl.2011.08.038,21885275.0,
6372973,CHEMBL1837040,"1-(8-chloro-1-(1-(pyridin-2-yl)piperidin-4-yl)-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-5(6H)-yl)ethanone",CHEMBL1837363,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CC(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1,CHEMBL1833912,"Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.",Bioorg. Med. Chem. Lett.,2011.0,21,19,5684,5687,10.1016/j.bmcl.2011.08.038,21885275.0,
6372978,CHEMBL1837041,"8-chloro-5-(methylsulfonyl)-1-(1-(pyridin-2-yl)piperidin-4-yl)-5,6-dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine",CHEMBL1837363,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CS(=O)(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1,CHEMBL1833912,"Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.",Bioorg. Med. Chem. Lett.,2011.0,21,19,5684,5687,10.1016/j.bmcl.2011.08.038,21885275.0,
6378275,CHEMBL1836317,"Trans-N-[4-(4,5-Dihydro-3,6-dithia-1-aza-benzo[e]azulen-2-ylamino)-cyclohexylmethyl]-methanesulfonamide",CHEMBL1837835,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CS(=O)(=O)NC[C@H]1CC[C@H](Nc2nc3c(s2)CCSc2ccccc2-3)CC1,CHEMBL1833793,Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5436,5441,10.1016/j.bmcl.2011.06.124,21782428.0,
6378429,CHEMBL1834345,"N'-(3-Chlorophenylsulfonyl)-N-ethyl-4,4-dimethyl-4,5-dihydro-1H-pyrazole-1-carboxamidine",CHEMBL1839287,A,,,Cytochrome P450 2C9,Inhibition of CYP 2C9,IC50,>,10000.0,nM,CCN/C(=N\S(=O)(=O)c1cccc(Cl)c1)N1CC(C)(C)C=N1,CHEMBL1833864,"N'-(arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT₆R) antagonists with unique structural features.",J. Med. Chem.,2011.0,54,20,7030,7054,10.1021/jm200466r,21866910.0,
6378947,CHEMBL1834793,cis-N-[1-(4-Hydroxy-4-thiazol-5-yl-cyclohexyl)-azetidin-3-yl]-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,CHEMBL1839024,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cn1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](c4cncs4)CC3)C2)c2cc(C(F)(F)F)ccc21,CHEMBL1833932,"Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.",Bioorg. Med. Chem. Lett.,2011.0,21,20,6042,6048,10.1016/j.bmcl.2011.08.074,21917454.0,
6381751,CHEMBL1836215,"5-(3-{2-[2-hydroxy-1-(hydroxymethyl)ethyl]-5-methyl-1,2,3,4-tetrahydro-6-isoquinolinyl}-1,2,4-oxadiazol-5-yl)-2-[(1-methylethyl)oxy]benzonitrile",CHEMBL1839237,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4300.0,nM,Cc1c(-c2noc(-c3ccc(OC(C)C)c(C#N)c3)n2)ccc2c1CCN(C(CO)CO)C2,CHEMBL1833884,Discovery of a brain-penetrant S1P₃-sparing direct agonist of the S1P₁ and S1P₅ receptors efficacious at low oral dose.,J. Med. Chem.,2011.0,54,19,6724,6733,10.1021/jm200609t,21838322.0,
6382622,CHEMBL3142316,"N-(3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-6-yl)thiophene-2-carboximidamide dihydrochloride",CHEMBL1837331,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate,IC50,=,72700.0,nM,CN1CC=C(c2c[nH]c3cc(NC(=N)c4cccs4)ccc23)CC1.Cl.Cl,CHEMBL1833804,"Discovery of N-(3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-6-yl) thiophene-2-carboximidamide as a selective inhibitor of human neuronal nitric oxide synthase (nNOS) for the treatment of pain.",J. Med. Chem.,2011.0,54,20,7408,7416,10.1021/jm201063u,21923116.0,
6383173,CHEMBL1834184,"(1R,3S)-3-Propionylamino-cyclopentanecarboxylic acid N-(4-benzooxazol-2-yl-phenyl)-N-methyl-amide",CHEMBL1839785,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,10000.0,nM,CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1,CHEMBL1833814,"Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure.",Bioorg. Med. Chem. Lett.,2011.0,21,19,5924,5927,10.1016/j.bmcl.2011.07.083,21873051.0,
6386480,CHEMBL1834663,"3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(3-dimethylaminomethyl-phenylamino)-pyrimidin-4-yl]-1-methyl-urea",CHEMBL1837643,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate,IC50,>,10000.0,nM,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN(C)C)c3)ncn2)c1Cl,CHEMBL1833940,"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.",J. Med. Chem.,2011.0,54,20,7066,7083,10.1021/jm2006222,21936542.0,
6386481,CHEMBL1834662,"3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[3-(4-methyl-piperazin-1-ylmethyl)-phenylamino]-pyrimidin-4-yl}-urea",CHEMBL1837643,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate,IC50,>,10000.0,nM,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN4CCN(C)CC4)c3)ncn2)c1Cl,CHEMBL1833940,"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.",J. Med. Chem.,2011.0,54,20,7066,7083,10.1021/jm2006222,21936542.0,
6386482,CHEMBL1834661,"3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(1-ethyl-piperidin-4-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea",CHEMBL1837643,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate,IC50,=,4000.0,nM,CCN1CCC(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,CHEMBL1833940,"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.",J. Med. Chem.,2011.0,54,20,7066,7083,10.1021/jm2006222,21936542.0,
6386483,CHEMBL1834660,"3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(3-dimethylamino-propyl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea",CHEMBL1837643,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate,IC50,>,10000.0,nM,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(CCCN(C)C)cc3)ncn2)c1Cl,CHEMBL1833940,"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.",J. Med. Chem.,2011.0,54,20,7066,7083,10.1021/jm2006222,21936542.0,
6386484,CHEMBL1834659,"3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-pyrimidin-4-yl}-urea",CHEMBL1837643,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate,IC50,>,10000.0,nM,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(OCCN4CCCC4)cc3)ncn2)c1Cl,CHEMBL1833940,"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.",J. Med. Chem.,2011.0,54,20,7066,7083,10.1021/jm2006222,21936542.0,
6386485,CHEMBL1834658,"3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[3-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea",CHEMBL1837643,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate,IC50,=,1700.0,nM,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(N4CCN(C)CC4)c3)ncn2)c1Cl,CHEMBL1833940,"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.",J. Med. Chem.,2011.0,54,20,7066,7083,10.1021/jm2006222,21936542.0,
6386486,CHEMBL1834657,"3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea monophosphate",CHEMBL1837643,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate,IC50,>,10000.0,nM,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O,CHEMBL1833940,"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.",J. Med. Chem.,2011.0,54,20,7066,7083,10.1021/jm2006222,21936542.0,
6388887,CHEMBL1835153,"7-(2-Aminopyrimidin-5-yl)-1-{[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]amino}-5H-pyrido[4,3-b]indole-4-carboxamide",CHEMBL1840138,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,75000.0,nM,NC(=O)c1cnc(N[C@H](C2CC2)C(F)(F)F)c2c1[nH]c1cc(-c3cnc(N)nc3)ccc12,CHEMBL1833803,"Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.",J. Med. Chem.,2011.0,54,20,7334,7349,10.1021/jm200909u,21942426.0,
6389772,CHEMBL1835772,"(R)-5-isopropyl-7-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)thieno[3,2-d]pyridazin-4(5H)-one",CHEMBL1839286,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CC(C)n1nc(-c2ccc(OCCCN3CCC[C@H]3C)cc2)c2sccc2c1=O,CHEMBL1833909,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.",Bioorg. Med. Chem. Lett.,2011.0,21,20,6126,6130,10.1016/j.bmcl.2011.08.045,21906941.0,
6389773,CHEMBL1835782,"(R)-2-methyl-4-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-2,5,6,7-tetrahydro-1H-cyclopenta[d]pyridazin-1-one",CHEMBL1839286,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(-c2nn(C)c(=O)c3c2CCC3)cc1,CHEMBL1833909,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.",Bioorg. Med. Chem. Lett.,2011.0,21,20,6126,6130,10.1016/j.bmcl.2011.08.045,21906941.0,
6389774,CHEMBL1835783,"2-methyl-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)-2,5,6,7-tetrahydro-1H-cyclopenta[d]pyridazin-1-one",CHEMBL1839286,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,Cn1nc(-c2ccc(OCCCN3CCCCC3)cc2)c2c(c1=O)CCC2,CHEMBL1833909,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.",Bioorg. Med. Chem. Lett.,2011.0,21,20,6126,6130,10.1016/j.bmcl.2011.08.045,21906941.0,
6389775,CHEMBL1835784,"2-methyl-4-(4-(3-((R)-2-methylpyrrolidin-1-yl)propoxy)phenyl)-2,4a,5,6,7,7a-hexahydro-1H-cyclopenta[d]pyridazin-1-one",CHEMBL1839286,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(C2=NN(C)C(=O)C3CCCC23)cc1,CHEMBL1833909,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.",Bioorg. Med. Chem. Lett.,2011.0,21,20,6126,6130,10.1016/j.bmcl.2011.08.045,21906941.0,
6389776,CHEMBL1835785,"2-methyl-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)-2,4a,5,6,7,7a-hexahydro-1H-cyclopenta[d]pyridazin-1-one",CHEMBL1839286,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CN1N=C(c2ccc(OCCCN3CCCCC3)cc2)C2CCCC2C1=O,CHEMBL1833909,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.",Bioorg. Med. Chem. Lett.,2011.0,21,20,6126,6130,10.1016/j.bmcl.2011.08.045,21906941.0,
6389777,CHEMBL1835786,"(R)-2-methyl-4-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one",CHEMBL1839286,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(-c2nn(C)c(=O)c3c2CCCC3)cc1,CHEMBL1833909,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.",Bioorg. Med. Chem. Lett.,2011.0,21,20,6126,6130,10.1016/j.bmcl.2011.08.045,21906941.0,
6389778,CHEMBL1835787,"2-methyl-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one",CHEMBL1839286,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,Cn1nc(-c2ccc(OCCCN3CCCCC3)cc2)c2c(c1=O)CCCC2,CHEMBL1833909,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.",Bioorg. Med. Chem. Lett.,2011.0,21,20,6126,6130,10.1016/j.bmcl.2011.08.045,21906941.0,
6389789,CHEMBL1835706,2-methyl-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)phthalazin-1(2H)-one,CHEMBL1839286,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,Cn1nc(-c2ccc(OCCCN3CCCCC3)cc2)c2ccccc2c1=O,CHEMBL1833909,"Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.",Bioorg. Med. Chem. Lett.,2011.0,21,20,6126,6130,10.1016/j.bmcl.2011.08.045,21906941.0,
6390874,CHEMBL1835918,"5-methyl-3-(4-((1-(6-methylpyridazin-3-yl)azetidin-3-yl)methoxy)phenyl)-1,2,4-oxadiazole",CHEMBL1839695,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1ccc(N2CC(COc3ccc(-c4noc(C)n4)cc3)C2)nn1,CHEMBL1833869,Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.,Bioorg. Med. Chem. Lett.,2011.0,21,20,6031,6035,10.1016/j.bmcl.2011.08.083,21907579.0,
6390879,CHEMBL1835918,"5-methyl-3-(4-((1-(6-methylpyridazin-3-yl)azetidin-3-yl)methoxy)phenyl)-1,2,4-oxadiazole",CHEMBL1839700,A,,,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9,IC50,>,50118.72,nM,Cc1ccc(N2CC(COc3ccc(-c4noc(C)n4)cc3)C2)nn1,CHEMBL1833869,Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.,Bioorg. Med. Chem. Lett.,2011.0,21,20,6031,6035,10.1016/j.bmcl.2011.08.083,21907579.0,
6390899,CHEMBL29609,"3-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-5-trifluoromethyl-[1,2,4]oxadiazole",CHEMBL1839695,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1,CHEMBL1833869,Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.,Bioorg. Med. Chem. Lett.,2011.0,21,20,6031,6035,10.1016/j.bmcl.2011.08.083,21907579.0,
6390904,CHEMBL29609,"3-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-5-trifluoromethyl-[1,2,4]oxadiazole",CHEMBL1839700,A,,,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9,IC50,>,50118.72,nM,Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1,CHEMBL1833869,Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.,Bioorg. Med. Chem. Lett.,2011.0,21,20,6031,6035,10.1016/j.bmcl.2011.08.083,21907579.0,
7608344,CHEMBL942,SID11112427,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,10000.0,nM,CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7610082,CHEMBL1016,2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,3000.0,nM,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7620789,CHEMBL388590,benzbromarone,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,16.0,nM,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7631243,CHEMBL1909048,1-(2-Chlorobenzoyl)-4-(Phenylmethyl)-Piperidine,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,2000.0,nM,O=C(c1ccccc1Cl)N1CCC(Cc2ccccc2)CC1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7633953,CHEMBL437002,(4-benzylpiperidin-1-yl)(2-fluorophenyl)methanone,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,2000.0,nM,O=C(c1ccccc1F)N1CCC(Cc2ccccc2)CC1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7634704,CHEMBL1403281,"7-Methyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((2R,5S,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxo-octahydro-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-amide",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,6000.0,nM,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7636687,CHEMBL1909049,1-(2-Methoxybenzoyl)-4-(Phenylmethyl)-Piperidine,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,2000.0,nM,COc1ccccc1C(=O)N1CCC(Cc2ccccc2)CC1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7639498,CHEMBL1909050,1-(2-Methylbenzoyl)-4-(Phenylmethyl)-Piperidine,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,1000.0,nM,Cc1ccccc1C(=O)N1CCC(Cc2ccccc2)CC1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7641231,CHEMBL1909051,4-(Phenylmethyl)-1-[2-(Trifluoromethyl)Benzoyl]-Piperidine,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,2000.0,nM,O=C(c1ccccc1C(F)(F)F)N1CCC(Cc2ccccc2)CC1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7650913,CHEMBL2220442,"7-[3-(4-Fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,400.0,nM,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7651960,CHEMBL808,"1-[2-(4-Chloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole (Econazole)",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,200.0,nM,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7661154,CHEMBL710,"(4aR,6aS,11aR)-4a,6a-Dimethyl-2-oxo-hexadecahydro-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,2000.0,nM,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7667439,CHEMBL1480,"4-(2,3-Dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,4579.5,nM,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7668522,CHEMBL434063,(S)-2-(2-Benzoyl-phenylamino)-3-{4-[2-(methyl-pyridin-2-yl-amino)-ethoxy]-phenyl}-propionic acid,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,4000.0,nM,CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1)c1ccccn1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7670994,CHEMBL252556,idebenone,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,5000.0,nM,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7676850,CHEMBL472,glyburide,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,1602.0,nM,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7685532,CHEMBL1466,Bishydroxycoumarin4-hydroxy-3-(4-hydroxy-2-oxo-2H-3-chromenylmethyl)-2H-2-chromenone,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,300.0,nM,O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7692884,CHEMBL799,"6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,10000.0,nM,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7693241,CHEMBL12131,"N-{5-Chloro-4-[(4-chloro-phenyl)-cyano-methyl]-2-methyl-phenyl}-2-hydroxy-3,5-diiodo-benzamide",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,2000.0,nM,Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7694157,CHEMBL1255837,Dihydroergocristine methanesulfonate,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,3000.0,nM,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CS(=O)(=O)O,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7697546,CHEMBL104,1-[(2-Chloro-phenyl)-diphenyl-methyl]-1H-imidazole,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,16.0,nM,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7708845,CHEMBL1479,"1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-7-oxa-8-aza-dicyclopenta[a,h]phenanthren-1-ol, danazol",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,300.0,nM,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7714292,CHEMBL485549,"2-hydroxy-3,5-dinitro-N'-((5-nitrofuran-2-yl)methylene)benzohydrazide",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,7000.0,nM,O=C(N/N=C/c1ccc([N+](=O)[O-])o1)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1O,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7715149,CHEMBL1089,Phenethyl-hydrazine,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,4000.0,nM,NNCCc1ccccc1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7727087,CHEMBL1428,"2,6-Dimethyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-isopropyl ester 5-(2-methoxy-ethyl) ester",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,1000.0,nM,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7730429,CHEMBL61,"(5R,5aR,8aR,9R)-9-Hydroxy-5-(3,4,5-trimethoxy-phenyl)-5,8,8a,9-tetrahydro-5aH-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6-one",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,4000.0,nM,COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7738223,CHEMBL1262,"1-(2,4-Dichloro-phenyl)-2-imidazol-1-yl-ethanone O-(2,4-dichloro-benzyl)-oxime",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,3000.0,nM,Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7739938,CHEMBL475534,"(Nitrendipine) 2,6-Dimethyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,300.0,nM,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7743092,CHEMBL456807,Phenylhydrazine,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,6000.0,nM,NNc1ccccc1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7744378,CHEMBL364713,"(S)-6,7-Dimethoxy-3-((R)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,8177.3,nM,COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7748954,CHEMBL191,{2-Butyl-5-chloro-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-yl}-methanol,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,2882.0,nM,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7751448,CHEMBL1201139,Megestrol acetate,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,10000.0,nM,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7754145,CHEMBL91,"1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,200.0,nM,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7767048,CHEMBL60889,4-Amino-5-chloro-2-ethoxy-N-[4-(4-fluoro-benzyl)-morpholin-2-ylmethyl]-benzamide,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,1000.0,nM,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7772093,CHEMBL460291,Lacidipine,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,2000.0,nM,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7781750,CHEMBL603,{3-[2-Methoxy-4-(toluene-2-sulfonylaminocarbonyl)-benzyl]-1-methyl-1H-indol-5-yl}-carbamic acid cyclopentyl ester,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,2257.5,nM,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7787789,CHEMBL24944,"3,5-Dibromo-N-(4-bromo-phenyl)-2-hydroxy-benzamide",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,2000.0,nM,O=C(Nc1ccc(Br)cc1)c1cc(Br)cc(Br)c1O,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7789782,CHEMBL408,"5-[4-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzyl]-thiazolidine-2,4-dione",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,4000.0,nM,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7793502,CHEMBL1200604,Tropicamide,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,1000.0,nM,CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7796153,CHEMBL413,Rapamycin,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,2000.0,nM,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7803394,CHEMBL1221,"1-[2-(4-Chloro-benzylsulfanyl)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,200.0,nM,Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7804726,CHEMBL165,"5-[2-((E)-4-Hydroxy-phenyl)-vinyl]-benzene-1,3-diol",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,7000.0,nM,Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7804986,CHEMBL115769,"2-(4-Fluoro-phenyl)-4-methoxy-3-pyridin-4-yl-1H-pyrrolo[2,3-b]pyridin-6-ylamine",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,1000.0,nM,COc1cc(N)[nH]c2nc(-c3ccc(F)cc3)c(-c3ccncc3)c1-2,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7806019,CHEMBL506247,"Acetic acid 4-acetoxy-2,5-dioxo-tetrahydro-furan-3-yl ester",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,4607.4,nM,O=C(OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7807593,CHEMBL2079587,Stanozolol,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,1127.6,nM,C[C@]12Cc3c[nH]nc3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7809133,CHEMBL163,"((1R,2R,4R)-1-Benzyl-2-hydroxy-4-{(R)-2-[3-(2-isopropyl-1lambda*4*-[1,3]thiazin-5-ylmethyl)-3-methyl-ureido]-3-methyl-butyrylamino}-5-phenyl-pentyl)-carbamic acid thiazol-5-ylmethyl ester",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,16.0,nM,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7812141,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,200.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7819498,CHEMBL81,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,2000.0,nM,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7822223,CHEMBL10,4-[5-(4-Fluoro-phenyl)-2-(4-methanesulfinyl-phenyl)-3H-imidazol-4-yl]-pyridine,CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,1000.0,nM,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7827349,CHEMBL1908355,"5-Chloro-2-oxo-3-(thiophene-2-carbonyl)-2,3-dihydro-indole-1-carboxylic acid amide (tenidap)",CHEMBL1909135,B,BTI-TN-5B1-4,,Cytochrome P450 2C9,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",IC50,=,700.0,nM,NC(=O)N1C(=O)/C(=C(\O)c2cccs2)c2cc(Cl)ccc21,CHEMBL1909046,DrugMatrix in vitro pharmacology data,,,,,,,,,
7850031,CHEMBL1911194,"6-(2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl)-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one",CHEMBL1912138,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,25000.0,nM,Cc1nnc(-c2ccc(C)c(-c3ccc4c(c3)NC(=O)C43CCOCC3)c2)[nH]1,CHEMBL1909512,Indolin-2-one p38α inhibitors III: bioisosteric amide replacement.,Bioorg. Med. Chem. Lett.,2011.0,21,21,6253,6257,10.1016/j.bmcl.2011.09.006,21958544.0,
7855887,CHEMBL1909725,"N,N-dimethyl-N'-{5-[(4-pyridin-2-yl-1,3-thiazol-2-yl)amino]pentyl}sulfamide",CHEMBL1912459,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,7000.0,nM,CN(C)S(=O)(=O)NCCCCCNc1nc(-c2ccccn2)cs1,CHEMBL1909589,5-(2'-Pyridyl)-2-aminothiazoles: alkyl amino sulfonamides and sulfamides as potent NPY(5) antagonists.,Bioorg. Med. Chem. Lett.,2011.0,21,21,6500,6504,10.1016/j.bmcl.2011.08.072,21924902.0,
7923337,CHEMBL1917389,{4-Chloro-2-[(3-chlorophenyl)ethynyl]phenoxy}acetic Acid,CHEMBL1920739,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus infected insect cells preincubated for 15 mins measured after 30 mins by luminescence analysis,IC50,=,1440.0,nM,O=C(O)COc1ccc(Cl)cc1C#Cc1cccc(Cl)c1,CHEMBL1914440,"Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.",J. Med. Chem.,2011.0,54,20,7299,7317,10.1021/jm200866y,21916510.0,
7928836,CHEMBL3216770,"N-(1-(2-(Dimethylamino)ethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carboximidamide dihydrochloride",CHEMBL1920789,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,CN(C)CCN1C(=O)CCc2cc(NC(=N)c3cccs3)ccc21.Cl.Cl,CHEMBL1914402,"Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.",J. Med. Chem.,2011.0,54,15,5562,5575,10.1021/jm200648s,21699209.0,
7928837,CHEMBL3216313,"N-(1-(2-(Dimethylamino)ethyl)-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carboximidamide dihydrochloride",CHEMBL1920789,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,CN(C)CCN1CCCc2cc(NC(=N)c3cccs3)ccc21.Cl.Cl,CHEMBL1914402,"Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.",J. Med. Chem.,2011.0,54,15,5562,5575,10.1021/jm200648s,21699209.0,
7928838,CHEMBL3142403,"(S)-N-(1-(2-(1-Methylpyrrolidin-2-yl)ethyl)-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carboximidamide dihydrochloride",CHEMBL1920789,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,CN1CCC[C@H]1CCN1CCCc2cc(NC(=N)c3cccs3)ccc21.Cl.Cl,CHEMBL1914402,"Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.",J. Med. Chem.,2011.0,54,15,5562,5575,10.1021/jm200648s,21699209.0,
7928839,CHEMBL3216112,"(R)-N-(1-(2-(1-Methylpyrrolidin-2-yl)ethyl)-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carboximidamide dihydrochloride",CHEMBL1920789,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,CN1CCC[C@@H]1CCN1CCCc2cc(NC(=N)c3cccs3)ccc21.Cl.Cl,CHEMBL1914402,"Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.",J. Med. Chem.,2011.0,54,15,5562,5575,10.1021/jm200648s,21699209.0,
7928840,CHEMBL3217198,"N-(1-(Piperidin-4-yl)-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carboximidamide dihydrochloride",CHEMBL1920789,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,Cl.Cl.N=C(Nc1ccc2c(c1)CCCN2C1CCNCC1)c1cccs1,CHEMBL1914402,"Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.",J. Med. Chem.,2011.0,54,15,5562,5575,10.1021/jm200648s,21699209.0,
7929344,CHEMBL1916282,"(S)-N-(3,3-dimethylbutan-2-yl)-3-methyl-5-(4-methylphenylsulfonamido)-1-phenyl-1H-pyrazole-4-carboxamide",CHEMBL1919532,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1ccc(S(=O)(=O)Nc2c(C(=O)N[C@@H](C)C(C)(C)C)c(C)nn2-c2ccccc2)cc1,CHEMBL1914348,Discovery of pyrazoles as novel FPR1 antagonists.,Bioorg. Med. Chem. Lett.,2011.0,21,21,6456,6460,10.1016/j.bmcl.2011.08.085,21955939.0,
7929345,CHEMBL1916288,"(S)-5-(4-cyanophenylsulfonamido)-N-(3,3-dimethylbutan-2-yl)-1-(4-fluorophenyl)-3-methyl-1H-pyrazole-4-carboxamide",CHEMBL1919532,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1nn(-c2ccc(F)cc2)c(NS(=O)(=O)c2ccc(C#N)cc2)c1C(=O)N[C@@H](C)C(C)(C)C,CHEMBL1914348,Discovery of pyrazoles as novel FPR1 antagonists.,Bioorg. Med. Chem. Lett.,2011.0,21,21,6456,6460,10.1016/j.bmcl.2011.08.085,21955939.0,
7930053,CHEMBL1916224,"(R)-Ethyl 3-(2-methylbenzamido)-1,4'-bipiperidine-1'-carboxylate",CHEMBL1919037,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,CCOC(=O)N1CCC(N2CCC[C@@H](NC(=O)c3ccccc3C)C2)CC1,CHEMBL1914417,"Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071.",Bioorg. Med. Chem. Lett.,2011.0,21,21,6451,6455,10.1016/j.bmcl.2011.08.084,21930376.0,
7930302,CHEMBL1916686,"2-(6-methoxy-2'-(((4S,5R)-4-methyl-2-oxo-5-phenyloxazolidin-3-yl)methyl)-4'-(trifluoromethyl)biphenyl-3-yl)acetic acid",CHEMBL1918378,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,COc1ccc(CC(=O)O)cc1-c1ccc(C(F)(F)F)cc1CN1C(=O)O[C@H](c2ccccc2)[C@@H]1C,CHEMBL1914441,Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2011.0,21,21,6608,6612,10.1016/j.bmcl.2011.01.024,21958540.0,
7930303,CHEMBL1916697,2-(2'-((benzyl(methoxycarbonyl)amino)methyl)-6-methoxy-4'-(trifluoromethyl)biphenyl-3-yl)acetic acid,CHEMBL1918378,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,COC(=O)N(Cc1ccccc1)Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC,CHEMBL1914441,Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2011.0,21,21,6608,6612,10.1016/j.bmcl.2011.01.024,21958540.0,
7930304,CHEMBL1916700,2-(2'-(((benzyloxycarbonyl)(ethyl)amino)methyl)-6-methoxy-4'-(trifluoromethyl)biphenyl-3-yl)acetic acid,CHEMBL1918378,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,18000.0,nM,CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OCc1ccccc1,CHEMBL1914441,Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2011.0,21,21,6608,6612,10.1016/j.bmcl.2011.01.024,21958540.0,
7930305,CHEMBL1916704,2-(2'-((ethyl(methoxycarbonyl)amino)methyl)-6-methoxy-4'-(trifluoromethyl)biphenyl-3-yl)acetic acid,CHEMBL1918378,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OC,CHEMBL1914441,Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2011.0,21,21,6608,6612,10.1016/j.bmcl.2011.01.024,21958540.0,
7930306,CHEMBL1916708,2-(2'-((((4-chlorobenzyloxy)carbonyl)(ethyl)amino)methyl)-6-methoxy-4'-(trifluoromethyl)biphenyl-3-yl)acetic acid,CHEMBL1918378,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,18000.0,nM,CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OCc1ccc(Cl)cc1,CHEMBL1914441,Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.,Bioorg. Med. Chem. Lett.,2011.0,21,21,6608,6612,10.1016/j.bmcl.2011.01.024,21958540.0,
7933377,CHEMBL1916399,"4-(5-(5-(3-cyano-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-3-yl)indolin-1-yl)-4-oxobutanoic acid",CHEMBL1920309,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,N#Cc1cc(OC(F)(F)F)cc(-c2nc(-c3ccc4c(c3)CCN4C(=O)CCC(=O)O)no2)c1,CHEMBL1914334,"Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P₁ agonists.",Bioorg. Med. Chem. Lett.,2011.0,21,19,6013,6018,10.1016/j.bmcl.2011.05.110,21852130.0,
7933378,CHEMBL1916559,"4-(5-(5-(3,5-bis(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl)indolin-1-yl)-4-oxobutanoic acid",CHEMBL1920309,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,34800.0,nM,O=C(O)CCC(=O)N1CCc2cc(-c3noc(-c4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)ccc21,CHEMBL1914334,"Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P₁ agonists.",Bioorg. Med. Chem. Lett.,2011.0,21,19,6013,6018,10.1016/j.bmcl.2011.05.110,21852130.0,
7933932,CHEMBL1917511,3-tert-Butyl-N-(4-(aminomethyl)thiazol-2-yl)-1-benzyl-1Hpyrazole-5-carboxamide,CHEMBL1919564,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9-mediated Tolbutamide methlyhydroxylation in human liver microsomes by LCMS analysis,IC50,=,10000.0,nM,CC(C)(C)c1cc(C(=O)Nc2nc(CN)cs2)n(Cc2ccccc2)n1,CHEMBL1914447,Novel orally active antimalarial thiazoles.,J. Med. Chem.,2011.0,54,21,7713,7719,10.1021/jm201108k,21966980.0,
7935273,CHEMBL1917418,"2-(3-(4-chlorophenylthio)-2,5-dimethyl-1H-indol-1-yl)acetic acid",CHEMBL1919388,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,800.0,nM,Cc1ccc2c(c1)c(Sc1ccc(Cl)cc1)c(C)n2CC(=O)O,CHEMBL1914459,Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981.,Bioorg. Med. Chem. Lett.,2011.0,21,21,6288,6292,10.1016/j.bmcl.2011.08.124,21944852.0,
7935274,CHEMBL1917433,2-(3-(4-chlorophenylthio)-2-methyl-4-(methylsulfonamido)-1H-indol-1-yl)acetic acid,CHEMBL1919388,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,Cc1c(Sc2ccc(Cl)cc2)c2c(NS(C)(=O)=O)cccc2n1CC(=O)O,CHEMBL1914459,Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981.,Bioorg. Med. Chem. Lett.,2011.0,21,21,6288,6292,10.1016/j.bmcl.2011.08.124,21944852.0,
7935275,CHEMBL1914489,2-(4-acetamido-3-(4-chlorophenylthio)-2-methyl-1H-indol-1-yl)acetic acid,CHEMBL1919388,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CC(=O)Nc1cccc2c1c(Sc1ccc(Cl)cc1)c(C)n2CC(=O)O,CHEMBL1914459,Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981.,Bioorg. Med. Chem. Lett.,2011.0,21,21,6288,6292,10.1016/j.bmcl.2011.08.124,21944852.0,
7935276,CHEMBL1917443,"2-(2,5-dimethyl-3-(4-(methylsulfonyl)phenylthio)-1H-indol-1-yl)acetic acid",CHEMBL1919388,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5200.0,nM,Cc1ccc2c(c1)c(Sc1ccc(S(C)(=O)=O)cc1)c(C)n2CC(=O)O,CHEMBL1914459,Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981.,Bioorg. Med. Chem. Lett.,2011.0,21,21,6288,6292,10.1016/j.bmcl.2011.08.124,21944852.0,
7935382,CHEMBL1917464,(R)-2-methyl-6-(4-(2-(2-methylpyrrolidin-1-yl)ethyl)phenyl)pyridazin-3(2H)-one,CHEMBL1917948,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCc1ccc(-c2ccc(=O)n(C)n2)cc1,CHEMBL1914283,Synthesis and evaluation of pyridazinone-phenethylamine derivatives as selective and orally bioavailable histamine H3 receptor antagonists with robust wake-promoting activity.,Bioorg. Med. Chem. Lett.,2011.0,21,21,6362,6365,10.1016/j.bmcl.2011.08.104,21944855.0,
7935408,CHEMBL1917468,(R)-2-(4-fluorophenyl)-6-(4-(2-(2-methylpyrrolidin-1-yl)ethyl)phenyl)pyridazin-3(2H)-one,CHEMBL1917948,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCc1ccc(-c2ccc(=O)n(-c3ccc(F)cc3)n2)cc1,CHEMBL1914283,Synthesis and evaluation of pyridazinone-phenethylamine derivatives as selective and orally bioavailable histamine H3 receptor antagonists with robust wake-promoting activity.,Bioorg. Med. Chem. Lett.,2011.0,21,21,6362,6365,10.1016/j.bmcl.2011.08.104,21944855.0,
7946338,CHEMBL1923729,(R)-1-methyl-5-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)pyridin-2(1H)-one,CHEMBL1925976,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)n(C)c2)cc1,CHEMBL1921690,Synthesis and evaluation of pyridone-phenoxypropyl-R-2-methylpyrrolidine analogues as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,2011.0,21,23,7076,7080,10.1016/j.bmcl.2011.09.091,22014551.0,
7946987,CHEMBL1921855,"N-(4-(1,1,3,3-Tetraoxidobenzo[d][1,3,2]dithiazol-2-yl)phenyl)picolinamide",CHEMBL1924931,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 4-hydroxydiclofenac as substrate,IC50,>,30000.0,nM,O=C(Nc1ccc(N2S(=O)(=O)c3ccccc3S2(=O)=O)cc1)c1ccccn1,CHEMBL1921795,"Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.",J. Med. Chem.,2011.0,54,21,7639,7647,10.1021/jm200956q,21966889.0,
7946988,CHEMBL1921961,"Pyridine-2-carboxylic acid [3-chloro-4-((1R,2S,6R,7S)-3,5-dioxo-4-aza-tricyclo[5.2.1.0*2,6*]dec-8-en-4-yl)-phenyl]-amide",CHEMBL1924931,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 4-hydroxydiclofenac as substrate,IC50,>,30000.0,nM,O=C(Nc1ccc(N2C(=O)[C@H]3[C@H]4C=C[C@H](C4)[C@H]3C2=O)c(Cl)c1)c1ccccn1,CHEMBL1921795,"Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.",J. Med. Chem.,2011.0,54,21,7639,7647,10.1021/jm200956q,21966889.0,
7946989,CHEMBL1705230,SID99309093,CHEMBL1924931,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 4-hydroxydiclofenac as substrate,IC50,>,30000.0,nM,O=C(Nc1ccc(N2C(=O)CC3(CCCCC3)C2=O)c(Cl)c1)c1ccccn1,CHEMBL1921795,"Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.",J. Med. Chem.,2011.0,54,21,7639,7647,10.1021/jm200956q,21966889.0,
7946990,CHEMBL1698322,SID99309094,CHEMBL1924931,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 4-hydroxydiclofenac as substrate,IC50,=,8700.0,nM,O=C(Nc1ccc(N2C(=O)CC(c3ccccc3)C2=O)c(Cl)c1)c1ccccn1,CHEMBL1921795,"Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.",J. Med. Chem.,2011.0,54,21,7639,7647,10.1021/jm200956q,21966889.0,
7946991,CHEMBL562551,N-(4-chloro-3-methoxyphenyl)picolinamide,CHEMBL1924931,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 4-hydroxydiclofenac as substrate,IC50,>,30000.0,nM,COc1cc(NC(=O)c2ccccn2)ccc1Cl,CHEMBL1921795,"Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.",J. Med. Chem.,2011.0,54,21,7639,7647,10.1021/jm200956q,21966889.0,
7947820,CHEMBL1921976,Orteronel,CHEMBL1925458,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human B-lymphoblastoid cell microsomal CYP2C9 (Arg) assessed as Tolbutamide hydroxylation preincubated for 5 mins with substrate,IC50,>,30000.0,nM,CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1,CHEMBL1921734,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,2011.0,19,21,6383,6399,10.1016/j.bmc.2011.08.066,21978946.0,
7947821,CHEMBL1921976,Orteronel,CHEMBL1925459,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human B-lymphoblastoid cell microsomal CYP2C9 (Cys) assessed as Tolbutamide hydroxylation preincubated for 5 mins with substrate,IC50,>,30000.0,nM,CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1,CHEMBL1921734,"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.",Bioorg. Med. Chem.,2011.0,19,21,6383,6399,10.1016/j.bmc.2011.08.066,21978946.0,
7947995,CHEMBL1923983,"2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide",CHEMBL1924384,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,25000.0,nM,CNc1nc2[nH]c(-c3cccc(CNC(=O)COC)n3)cc2c2c1ncn2C,CHEMBL1921674,"Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066).",Bioorg. Med. Chem. Lett.,2011.0,21,23,7006,7012,10.1016/j.bmcl.2011.09.111,22018461.0,
7950161,CHEMBL1922660,"3-[3-tert-Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid",CHEMBL1924649,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,50.0,nM,CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1,CHEMBL1921749,"5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.",J. Med. Chem.,2011.0,54,23,8013,8029,10.1021/jm2008369,22059882.0,
7950162,CHEMBL1922662,"3-(3-(tert-butylthio)-1-(4-(5-methylpyridin-2-yl)benzyl)-5-((5-methylpyridin-2-yl)methoxy)-1H-indol-2-yl)-2,2-dimethylpropanoic acid",CHEMBL1924649,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,12.0,nM,Cc1ccc(COc2ccc3c(c2)c(SC(C)(C)C)c(CC(C)(C)C(=O)O)n3Cc2ccc(-c3ccc(C)cn3)cc2)nc1,CHEMBL1921749,"5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.",J. Med. Chem.,2011.0,54,23,8013,8029,10.1021/jm2008369,22059882.0,
7950163,CHEMBL1922663,"3-[3-tert-Butylsulfanyl-1-[4-(5-fluoropyridin-2-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid",CHEMBL1924649,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,1.5,nM,Cc1ccc(COc2ccc3c(c2)c(SC(C)(C)C)c(CC(C)(C)C(=O)O)n3Cc2ccc(-c3ccc(F)cn3)cc2)nc1,CHEMBL1921749,"5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.",J. Med. Chem.,2011.0,54,23,8013,8029,10.1021/jm2008369,22059882.0,
7950164,CHEMBL1229205,"3-[3-tert-Butylsulfanyl-1-[4-(5-methoxypyrimidin-2-yl)-benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid",CHEMBL1924649,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,4.5,nM,COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)nc1,CHEMBL1921749,"5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.",J. Med. Chem.,2011.0,54,23,8013,8029,10.1021/jm2008369,22059882.0,
7953905,CHEMBL1923502,"(2R,5S,8R,11R)-5-cyclopropyl-11-(4-fluorobenzyl)-2,7,8-trimethyl-4,5,7,8,10,11,13,14,15,16-decahydro-2H-benzo[q][1,4,7,10,13]oxatetraazacyclooctadecine-6,9,12(3H)-trione hydrochloride hydrate",CHEMBL1925703,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,66000.0,nM,C[C@@H]1CN[C@@H](C2CC2)C(=O)N(C)[C@H](C)C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)NCCCc2ccccc2O1.Cl.O,CHEMBL1921692,Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.,J. Med. Chem.,2011.0,54,24,8305,8320,10.1021/jm2007062,22106937.0,
7953906,CHEMBL1923642,"(5S,8R,11R)-5-cyclopropyl-19-fluoro-11-(4-fluorobenzyl)-7,8-dimethyl-4,5,7,8,10,11,13,14,15,16-decahydro-2H-benzo[q][1,4,7,10,13]oxatetraazacyclooctadecine-6,9,12(3H)-trione",CHEMBL1925703,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,C[C@@H]1C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)NCCCc2ccc(F)cc2OCCN[C@@H](C2CC2)C(=O)N1C,CHEMBL1921692,Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.,J. Med. Chem.,2011.0,54,24,8305,8320,10.1021/jm2007062,22106937.0,
7954489,CHEMBL1922933,(S)-3-(4-(2-(5-chloro-1-(3-(trifluoromethyl)phenyl)-1H-indole-2-carbonyl)heptyl)benzamido)propanoic acid,CHEMBL1925827,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,11000.0,nM,CCCCC[C@@H](Cc1ccc(C(=O)NCCC(=O)O)cc1)C(=O)c1cc2cc(Cl)ccc2n1-c1cccc(C(F)(F)F)c1,CHEMBL1921704,Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.,Bioorg. Med. Chem. Lett.,2011.0,21,23,7124,7130,10.1016/j.bmcl.2011.09.105,22030028.0,
7962764,CHEMBL1929387,"N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride",CHEMBL1932778,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1.Cl,CHEMBL1926646,"Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor.",Bioorg. Med. Chem.,2011.0,19,23,7221,7227,10.1016/j.bmc.2011.09.043,22019046.0,
7964682,CHEMBL1928243,"2-(6-(3,3-Dimethyl-1-(4-(trifluoromethyl)piperidin-1-yl)butyl)-4'-(trifluoromethyl)biphenyl-3-yl)acetic acid",CHEMBL1931639,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,10000.0,nM,CC(C)(C)CC(c1ccc(CC(=O)O)cc1-c1ccc(C(F)(F)F)cc1)N1CCC(C(F)(F)F)CC1,CHEMBL1926647,Discovery of 4-aminomethylphenylacetic acids as γ-secretase modulators via a scaffold design approach.,Bioorg. Med. Chem. Lett.,2011.0,21,24,7277,7280,10.1016/j.bmcl.2011.10.047,22061640.0,
7970075,CHEMBL1927147,"10-benzyl-2-(2-chlorophenyl)-2,3,8,9,10,11-hexahydro-1H-pyrazolo[4',3':3,4]pyrido[1,2-a][1,4]diazepine-1,5(7H)-dione hydrochloride",CHEMBL1931599,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by mass spectrophotometry,IC50,>,25000.0,nM,Cl.O=c1c2c3n(c(=O)cc2[nH]n1-c1ccccc1Cl)CCCN(Cc1ccccc1)C3,CHEMBL1926564,"Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors.",Bioorg. Med. Chem.,2011.0,19,23,6989,6999,10.1016/j.bmc.2011.10.016,22041175.0,
7970614,CHEMBL1928092,"2-({4-[(2-cyanoethyl)(methyl)amino]benzylidene}amino)-5-(3,4-dimethoxyphenyl)-4-methylthiophene-3-carbonitrile",CHEMBL1930584,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,1200.0,nM,COc1ccc(-c2sc(/N=C/c3ccc(N(C)CCC#N)cc3)c(C#N)c2C)cc1OC,CHEMBL1926617,Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.,Eur. J. Med. Chem.,2012.0,47,,270,277,10.1016/j.ejmech.2011.10.053,22100140.0,
7970615,CHEMBL1928095,"2-[([1,1'-biphenyl]-4-ylmethylene)amino]-5-(3,4-dimethoxyphenyl)-4-methylthiophene-3-carbonitrile",CHEMBL1930584,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,1400.0,nM,COc1ccc(-c2sc(/N=C/c3ccc(-c4ccccc4)cc3)c(C#N)c2C)cc1OC,CHEMBL1926617,Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.,Eur. J. Med. Chem.,2012.0,47,,270,277,10.1016/j.ejmech.2011.10.053,22100140.0,
7981280,CHEMBL1935416,"1'-cyclobutyl-6-(3-(methylsulfonyl)propoxy)spiro[chroman-2,4'-piperidine]",CHEMBL1936243,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CS(=O)(=O)CCCOc1ccc2c(c1)CCC1(CCN(C3CCC3)CC1)O2,CHEMBL1933032,"Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.",Bioorg. Med. Chem. Lett.,2012.0,22,1,186,189,10.1016/j.bmcl.2011.11.038,22153342.0,
7982969,CHEMBL1935601,"(+/-)-7-(3-fluorophenylsulfonyl)-2',3,4,4',5',6'-hexahydro-2H-spiro[benzofuro[2,3-c]pyridine-1,3'-pyran]",CHEMBL1937636,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1900.0,nM,O=S(=O)(c1cccc(F)c1)c1ccc2c3c(oc2c1)C1(CCCOC1)NCC3,CHEMBL1933007,Novel brain penetrant benzofuropiperidine 5-HT₆ receptor antagonists.,Bioorg. Med. Chem. Lett.,2012.0,22,1,120,123,10.1016/j.bmcl.2011.11.050,22153937.0,
7992359,CHEMBL1934523,(R)-1-{2-[4'-(3-Methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine,CHEMBL1936405,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,40000.0,nM,COCCCS(=O)(=O)c1ccc(-c2ccc(CCN3CCC[C@H]3C)cc2)cc1,CHEMBL1932985,Identification of biaryl sulfone derivatives as antagonists of the histamine H₃ receptor: discovery of (R)-1-(2-(4'-(3-methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916).,Bioorg. Med. Chem. Lett.,2012.0,22,1,71,75,10.1016/j.bmcl.2011.11.075,22172695.0,
7992989,CHEMBL1934426,"(S)-5-(4-cyclopropylphenylsulfonamido)-N-(3,3-dimethylbutan-2-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carboxamide",CHEMBL1937834,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1nn(C2CCOCC2)c(NS(=O)(=O)c2ccc(C3CC3)cc2)c1C(=O)N[C@@H](C)C(C)(C)C,CHEMBL1932964,Lead optimisation of pyrazoles as novel FPR1 antagonists.,Bioorg. Med. Chem. Lett.,2012.0,22,1,532,536,10.1016/j.bmcl.2011.10.090,22094028.0,
7992990,CHEMBL1934424,"N-((S)-3,3-dimethylbutan-2-yl)-1-((cis)-4-methoxycyclohexyl)-3-methyl-5-(4-methylphenylsulfonamido)-1H-pyrazole-4-carboxamide",CHEMBL1937834,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CO[C@H]1CC[C@@H](n2nc(C)c(C(=O)N[C@@H](C)C(C)(C)C)c2NS(=O)(=O)c2ccc(C)cc2)CC1,CHEMBL1932964,Lead optimisation of pyrazoles as novel FPR1 antagonists.,Bioorg. Med. Chem. Lett.,2012.0,22,1,532,536,10.1016/j.bmcl.2011.10.090,22094028.0,
7995130,CHEMBL1935100,"(R)-6-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-4,5-dihydropyridazin-3(2H)-one",CHEMBL1937485,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)CC2)cc1,CHEMBL1932917,"4,5-dihydropyridazin-3-one derivatives as histamine H₃ receptor inverse agonists.",Bioorg. Med. Chem. Lett.,2012.0,22,1,194,198,10.1016/j.bmcl.2011.11.037,22142542.0,
7995131,CHEMBL1935114,"(R)-4,4-dimethyl-6-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-4,5-dihydropyridazin-3(2H)-one",CHEMBL1937485,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)C(C)(C)C2)cc1,CHEMBL1932917,"4,5-dihydropyridazin-3-one derivatives as histamine H₃ receptor inverse agonists.",Bioorg. Med. Chem. Lett.,2012.0,22,1,194,198,10.1016/j.bmcl.2011.11.037,22142542.0,
7995215,CHEMBL1935111,"(+/-)-5-methyl-6-(4-(3-((R)-2-methylpyrrolidin-1-yl)propoxy)phenyl)-4,5-dihydropyridazin-3(2H)-one",CHEMBL1937485,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CC1CC(=O)NN=C1c1ccc(OCCCN2CCC[C@H]2C)cc1,CHEMBL1932917,"4,5-dihydropyridazin-3-one derivatives as histamine H₃ receptor inverse agonists.",Bioorg. Med. Chem. Lett.,2012.0,22,1,194,198,10.1016/j.bmcl.2011.11.037,22142542.0,
7995216,CHEMBL1935111,"(+/-)-5-methyl-6-(4-(3-((R)-2-methylpyrrolidin-1-yl)propoxy)phenyl)-4,5-dihydropyridazin-3(2H)-one",CHEMBL1937485,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CC1CC(=O)NN=C1c1ccc(OCCCN2CCC[C@H]2C)cc1,CHEMBL1932917,"4,5-dihydropyridazin-3-one derivatives as histamine H₃ receptor inverse agonists.",Bioorg. Med. Chem. Lett.,2012.0,22,1,194,198,10.1016/j.bmcl.2011.11.037,22142542.0,
7995217,CHEMBL1829475,(R)-5-methyl-6-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)pyridazin-3(2H)-one,CHEMBL1937485,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,Cc1cc(=O)[nH]nc1-c1ccc(OCCCN2CCC[C@H]2C)cc1,CHEMBL1932917,"4,5-dihydropyridazin-3-one derivatives as histamine H₃ receptor inverse agonists.",Bioorg. Med. Chem. Lett.,2012.0,22,1,194,198,10.1016/j.bmcl.2011.11.037,22142542.0,
8000879,CHEMBL1939876,5-[5-(4-Carboxy-benzylcarbamoyl)-2-methyl-2H-pyrazol-3-yl]-1H-indole-2-carboxylic Acid Ethyl Ester,CHEMBL1942207,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using 7-methoxy-4-trifluoromethylcoumarin as substrate after 45 mins by fluorimetry,IC50,>,30000.0,nM,CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1,CHEMBL1938382,Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.,J. Med. Chem.,2011.0,54,23,8174,8187,10.1021/jm201129m,22017539.0,
8005139,CHEMBL1940274,"2-(4-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-N-(1-isopropyl-1H-pyrazol-4-yl)acetamide",CHEMBL1942932,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8000.0,nM,COc1cc2ncnc(Oc3ccc(CC(=O)Nc4cnn(C(C)C)c4)cc3)c2cc1OC,CHEMBL1938371,"Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases.",Bioorg. Med. Chem. Lett.,2012.0,22,1,262,266,10.1016/j.bmcl.2011.11.019,22153662.0,
8005864,CHEMBL1940315,"N-(1,1-Dioxo-hexahydro-1lambda[6]-thiopyran-3-yl)-4-[4-((S)-3-hydroxy-1-aza-bicyclo[2.2.2]oct-3-ylethynyl)-phenoxy]-benzamide",CHEMBL1942947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(NC1CCCS(=O)(=O)C1)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1,CHEMBL1938343,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012.0,22,1,271,277,10.1016/j.bmcl.2011.11.034,22153941.0,
8005865,CHEMBL1940308,(S)-4-(4-((3-hydroxyquinuclidin-3-yl)ethynyl)phenoxy)-N-(1-methylpiperidin-4-yl)benzamide,CHEMBL1942947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CN1CCC(NC(=O)c2ccc(Oc3ccc(C#C[C@]4(O)CN5CCC4CC5)cc3)cc2)CC1,CHEMBL1938343,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012.0,22,1,271,277,10.1016/j.bmcl.2011.11.034,22153941.0,
8005866,CHEMBL1940296,(S)-4-(4-((3-hydroxyquinuclidin-3-yl)ethynyl)phenoxy)-N-methylbenzamide,CHEMBL1942947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CNC(=O)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1,CHEMBL1938343,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012.0,22,1,271,277,10.1016/j.bmcl.2011.11.034,22153941.0,
8005867,CHEMBL1796298,4-[4-[2-[(3S)-3-hydroxyquinuclidin-3-yl]ethynyl]phenoxy]-N-(pyrimidin-4-ylmethyl)benzamide,CHEMBL1942947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(NCc1ccncn1)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1,CHEMBL1938343,Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,Bioorg. Med. Chem. Lett.,2012.0,22,1,271,277,10.1016/j.bmcl.2011.11.034,22153941.0,
8014832,CHEMBL1944698,"(16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo-[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8-(27),9,11,16,21,23-decaene",CHEMBL1948599,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using Tolbutamide as substrate after 60 mins by LC-MS/MS analysis,IC50,>,25000.0,nM,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,CHEMBL1944548,"Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer.",J. Med. Chem.,2012.0,55,1,169,196,10.1021/jm201112g,22148278.0,
8020167,CHEMBL1947144,"(R)-5-(3-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenyl)-5-methyloxazolidine-2,4-dione",CHEMBL1948332,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2000.0,nM,COc1ccc2c(-n3c(=O)n(Cc4cccc([C@@]5(C)OC(=O)NC5=O)c4)c4ccccc43)noc2c1,CHEMBL1944523,Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.,J. Med. Chem.,2011.0,54,24,8541,8554,10.1021/jm201061j,22070604.0,
8030520,CHEMBL1950643,6-(4-(1-cyclobutylpiperidin-4-yloxy)phenyl)pyridazin-3(2H)-one,CHEMBL1952478,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,O=c1ccc(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)n[nH]1,CHEMBL1949660,4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity.,Bioorg. Med. Chem. Lett.,2012.0,22,4,1504,1509,10.1016/j.bmcl.2012.01.026,22290075.0,
8030521,CHEMBL1950743,"6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one",CHEMBL1952478,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CC1(C)CC(c2ccc(OC3CCN(C4CCC4)CC3)cc2)=NNC1=O,CHEMBL1949660,4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity.,Bioorg. Med. Chem. Lett.,2012.0,22,4,1504,1509,10.1016/j.bmcl.2012.01.026,22290075.0,
8031595,CHEMBL1951055,(R)-1-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-2-morpholinoethanone,CHEMBL1953351,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(C(=O)CN2CCOCC2)cc1,CHEMBL1949633,Novel morpholine ketone analogs as potent histamine H3 receptor inverse agonists with wake activity.,Bioorg. Med. Chem. Lett.,2012.0,22,4,1546,1549,10.1016/j.bmcl.2012.01.004,22297111.0,
8033800,CHEMBL1951011,isopropyl 4-(6-(2-fluoro-4-(methylsulfonyl)phenoxy)-5-methylpyrimidin-4-yloxy)piperidine-1-carboxylate,CHEMBL1953647,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5300.0,nM,Cc1c(Oc2ccc(S(C)(=O)=O)cc2F)ncnc1OC1CCN(C(=O)OC(C)C)CC1,CHEMBL1949629,Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.,Bioorg. Med. Chem. Lett.,2012.0,22,4,1750,1755,10.1016/j.bmcl.2011.12.092,22264481.0,
8033803,CHEMBL1951022,isopropyl 4-(5-methyl-6-(2-methyl-6-(methylsulfonyl)pyridin-3-ylamino)pyrimidin-4-yloxy)piperidine-1-carboxylate,CHEMBL1953647,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2500.0,nM,Cc1nc(S(C)(=O)=O)ccc1Nc1ncnc(OC2CCN(C(=O)OC(C)C)CC2)c1C,CHEMBL1949629,Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.,Bioorg. Med. Chem. Lett.,2012.0,22,4,1750,1755,10.1016/j.bmcl.2011.12.092,22264481.0,
8033804,CHEMBL1951032,isopropyl 4-(5-methoxy-6-(2-methyl-6-(methylsulfonyl)pyridin-3-ylamino)pyrimidin-4-yloxy)piperidine-1-carboxylate,CHEMBL1953647,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8000.0,nM,COc1c(Nc2ccc(S(C)(=O)=O)nc2C)ncnc1OC1CCN(C(=O)OC(C)C)CC1,CHEMBL1949629,Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.,Bioorg. Med. Chem. Lett.,2012.0,22,4,1750,1755,10.1016/j.bmcl.2011.12.092,22264481.0,
8037342,CHEMBL1951778,N-(2-((R)-1-(trans-4-Hydroxy-4-(6-methoxypyridin-3-yl)cyclohexyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide bismethanesulfonate,CHEMBL1953974,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,COc1ccc([C@]2(O)CC[C@H](N3CC[C@@H](NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1.CS(=O)(=O)O,CHEMBL1949557,"Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist.",ACS Med. Chem. Lett.,2011.0,2,6,450,454,10.1021/ml200030q,24900329.0,
8037784,CHEMBL1951914,"(R)-N-(1-(3-(3,5-difluorophenyl)-3-(1-(methylsulfonyl)piperidin-4-yl)propyl)piperidin-4-yl)-N-ethyl-2-(4-(methylsulfonyl)phenyl)acetamide",CHEMBL1954552,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1,CHEMBL1949642,"Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.",Bioorg. Med. Chem. Lett.,2012.0,22,4,1655,1659,10.1016/j.bmcl.2011.12.117,22266038.0,
8037939,CHEMBL1952142,"7-methoxy-N-(piperidin-4-ylmethyl)-3-(3-(trifluoromethoxy)phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",CHEMBL1955098,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by luminescent assay,IC50,=,8700.0,nM,COc1cc(NCC2CCNCC2)nc2c1nnn2-c1cccc(OC(F)(F)F)c1,CHEMBL1949661,"Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.",Bioorg. Med. Chem. Lett.,2012.0,22,4,1591,1597,10.1016/j.bmcl.2011.12.130,22266039.0,
8041355,CHEMBL555563,(S)-{3-[(4-Chlorophenyl)-(2-chloropyridin-3-yl)methoxy]azetidin-1-yl}piperidin-1-ylmethanone,CHEMBL1954252,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(N1CCCCC1)N1CC(O[C@@H](c2ccc(Cl)cc2)c2cccnc2Cl)C1,CHEMBL1949530,Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity.,Bioorg. Med. Chem. Lett.,2012.0,22,2,901,906,10.1016/j.bmcl.2011.12.032,22209458.0,
8042873,CHEMBL1950351,"(5-(ethylsulfonyl)-2-(tetrahydro-2H-pyran-4-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)(4-methylpiperidin-1-yl)methanone",CHEMBL1954290,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,20000.0,nM,CCS(=O)(=O)n1c2c(c3cc(C(=O)N4CCC(C)CC4)ccc31)CN(C1CCOCC1)CC2,CHEMBL1949601,γ-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.,Bioorg. Med. Chem. Lett.,2012.0,22,4,1619,1624,10.1016/j.bmcl.2011.12.124,22284817.0,
8044656,CHEMBL1949930,"cis-7-(3-isopropoxy-5-methoxyphenylsulfonyl)-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridine hydrochloride",CHEMBL1953171,A,,,Cytochrome P450 2C9,Inhibition of CYP 2C9,IC50,>,30000.0,nM,COc1cc(OC(C)C)cc(S(=O)(=O)c2ccc3c(c2)O[C@H]2CNCC[C@@H]32)c1.Cl,CHEMBL1949541,"Discovery of 7-arylsulfonyl-1,2,3,4, 4a,9a-hexahydro-benzo[4,5]furo[2,3-c]pyridines: identification of a potent and selective 5-HT₆ receptor antagonist showing activity in rat social recognition test.",Bioorg. Med. Chem. Lett.,2012.0,22,3,1421,1426,10.1016/j.bmcl.2011.12.026,22226656.0,
8047617,CHEMBL3216551,"N-(3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl)furan-2-carboximidamide dihydrochloride",CHEMBL1960203,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,CN1CC=C(c2c[nH]c3ccc(NC(=N)c4ccco4)cc23)CC1.Cl.Cl,CHEMBL1955728,"3,5-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase (nNOS) inhibitors.",Bioorg. Med. Chem. Lett.,2012.0,22,5,1980,1984,10.1016/j.bmcl.2012.01.031,22318159.0,
8051173,CHEMBL1957816,"(4-(2,4-difluorophenethyl)piperazin-1-yl)(imidazo[1,2-a]pyridin-8-yl)methanone",CHEMBL1961173,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,40000.0,nM,O=C(c1cccn2ccnc12)N1CCN(CCc2ccc(F)cc2F)CC1,CHEMBL1955741,Identification of fused bicyclic heterocycles as potent and selective 5-HT(2A) receptor antagonists for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,2012.0,22,5,1870,1873,10.1016/j.bmcl.2012.01.080,22325948.0,
8055213,CHEMBL1945843,5-{4-[3-(R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one,CHEMBL1960240,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(-c2cnn(-c3ccccn3)c(=O)c2)cc1,CHEMBL1955733,"Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H₃ receptor antagonists with potent cognition enhancing activity.",J. Med. Chem.,2012.0,55,1,414,423,10.1021/jm201295j,22107017.0,
8055428,CHEMBL1955989,2-(2-cyclohexylvinyl)-5-(2-(trifluoromethyl)phenyl)-1H-benzo[d]imidazole,CHEMBL1958508,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,=,3500.0,nM,FC(F)(F)c1ccccc1-c1ccc2[nH]c(/C=C/C3CCCCC3)nc2c1,CHEMBL1955797,Discovery of vinylcycloalkyl-substituted benzimidazole TRPM8 antagonists effective in the treatment of cold allodynia.,Bioorg. Med. Chem. Lett.,2012.0,22,5,1903,1907,10.1016/j.bmcl.2012.01.060,22330635.0,
8057253,CHEMBL1956397,(-)-2-((4'-chlorobiphenyl-2-yl)methylsulfinyl)acetamide,CHEMBL1960692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsome,IC50,=,233000.0,nM,NC(=O)C[S+]([O-])Cc1ccccc1-c1ccc(Cl)cc1,CHEMBL1955765,Wake-promoting agents: search for next generation modafinil: part II.,Bioorg. Med. Chem. Lett.,2012.0,22,6,2315,2317,10.1016/j.bmcl.2012.01.064,22341942.0,
8057267,CHEMBL1956397,(-)-2-((4'-chlorobiphenyl-2-yl)methylsulfinyl)acetamide,CHEMBL1960692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsome,IC50,=,129000.0,nM,NC(=O)C[S+]([O-])Cc1ccccc1-c1ccc(Cl)cc1,CHEMBL1955765,Wake-promoting agents: search for next generation modafinil: part II.,Bioorg. Med. Chem. Lett.,2012.0,22,6,2315,2317,10.1016/j.bmcl.2012.01.064,22341942.0,
10836987,CHEMBL2012228,"(S)-5-(1-aminoethyl)-N-(2,4-difluorobenzyl)-2-(8-methoxy-2-(trifluoromethyl)quinolin-5-yl)oxazole-4-carboxamide",CHEMBL2015131,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,8000.0,nM,COc1ccc(-c2nc(C(=O)NCc3ccc(F)cc3F)c([C@H](C)N)o2)c2ccc(C(F)(F)F)nc12,CHEMBL2010662,Discovery of oxazole-based PDE4 inhibitors with picomolar potency.,Bioorg. Med. Chem. Lett.,2012.0,22,7,2594,2597,10.1016/j.bmcl.2012.01.115,22401864.0,
10840333,CHEMBL2012951,N-Cyclopropyl-5-(4-(difluoromethoxy)-2-methyl-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,CHEMBL2014810,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using diclofenac as substrate after 10 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1nc2c(OC(F)F)cccc2n1-c1ccc(C(=O)NC2CC2)s1,CHEMBL2010768,Optimization of Potent Inhibitors of P. falciparum Dihydroorotate Dehydrogenase for the Treatment of Malaria.,ACS Med. Chem. Lett.,2011.0,2,9,708,713,10.1021/ml200143c,24900364.0,
10840334,CHEMBL2012958,N-Cyclopropyl-5-(4-cyano-2-methyl-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,CHEMBL2014810,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using diclofenac as substrate after 10 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1nc2c(C#N)cccc2n1-c1ccc(C(=O)NC2CC2)s1,CHEMBL2010768,Optimization of Potent Inhibitors of P. falciparum Dihydroorotate Dehydrogenase for the Treatment of Malaria.,ACS Med. Chem. Lett.,2011.0,2,9,708,713,10.1021/ml200143c,24900364.0,
10842934,CHEMBL2010836,2-(4-(1H-tetrazol-1-yl)phenyl)-N-methyl-N-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)acetamide,CHEMBL2014820,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 by HTRF assay,IC50,>,25000.0,nM,CN(C(=O)Cc1ccc(-n2cnnn2)cc1)C1CCN(Cc2ccc(C(F)(F)F)cc2)CC1,CHEMBL2010696,"Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.",Bioorg. Med. Chem. Lett.,2011.0,21,24,7310,7316,10.1016/j.bmcl.2011.10.033,22061639.0,
10843260,CHEMBL2013045,"1'-cyclobutyl-6-(1-(methylsulfonyl)piperidin-4-yloxy)spiro[chroman-2,4'-piperidine]",CHEMBL2014283,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CS(=O)(=O)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1,CHEMBL2010741,"Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.",Bioorg. Med. Chem. Lett.,2012.0,22,6,2151,2153,10.1016/j.bmcl.2012.01.139,22365751.0,
10843261,CHEMBL2013050,"1'-cyclobutyl-6-(1-(cyclopropylsulfonyl)piperidin-4-yloxy)spiro[chroman-2,4'-piperidine]",CHEMBL2014283,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,O=S(=O)(C1CC1)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1,CHEMBL2010741,"Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.",Bioorg. Med. Chem. Lett.,2012.0,22,6,2151,2153,10.1016/j.bmcl.2012.01.139,22365751.0,
10843262,CHEMBL2013051,"1-(4-(1'-cyclobutylspiro[chroman-2,4'-piperidine]-6-yloxy)piperidin-1-yl)ethanone",CHEMBL2014283,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CC(=O)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1,CHEMBL2010741,"Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.",Bioorg. Med. Chem. Lett.,2012.0,22,6,2151,2153,10.1016/j.bmcl.2012.01.139,22365751.0,
10843263,CHEMBL2013052,"1-(4-(1'-cyclobutylspiro[chroman-2,4'-piperidine]-6-yloxy)piperidin-1-yl)-2-methylpropan-1-one",CHEMBL2014283,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CC(C)C(=O)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1,CHEMBL2010741,"Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.",Bioorg. Med. Chem. Lett.,2012.0,22,6,2151,2153,10.1016/j.bmcl.2012.01.139,22365751.0,
10843264,CHEMBL2013053,"(4-(1'-cyclobutylspiro[chroman-2,4'-piperidine]-6-yloxy)piperidin-1-yl)(cyclopropyl)methanone",CHEMBL2014283,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,O=C(C1CC1)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1,CHEMBL2010741,"Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.",Bioorg. Med. Chem. Lett.,2012.0,22,6,2151,2153,10.1016/j.bmcl.2012.01.139,22365751.0,
10844103,CHEMBL2011266,"(N-(Cyclopropylsulfonyl)-1-[(2,5-difluorophenyl)methyl]-3-(1,2-dihydro-2-oxo-3-pyridinyl)-6-fluoro-5-(methyl)-1H-indole-2-carboxamide",CHEMBL2014630,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 co-incubated with substrate,IC50,>,20000.0,nM,Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)NS(=O)(=O)C3CC3)n(Cc3cc(F)ccc3F)c2cc1F,CHEMBL2010765,Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase.,J. Med. Chem.,2012.0,55,2,754,765,10.1021/jm201258k,22148957.0,
10844107,CHEMBL2011266,"(N-(Cyclopropylsulfonyl)-1-[(2,5-difluorophenyl)methyl]-3-(1,2-dihydro-2-oxo-3-pyridinyl)-6-fluoro-5-(methyl)-1H-indole-2-carboxamide",CHEMBL2014634,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 preincubated prior to substrate addition,IC50,>,20000.0,nM,Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)NS(=O)(=O)C3CC3)n(Cc3cc(F)ccc3F)c2cc1F,CHEMBL2010765,Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase.,J. Med. Chem.,2012.0,55,2,754,765,10.1021/jm201258k,22148957.0,
10844351,CHEMBL2013195,2-phenyl-4-(piperidin-1-ylmethyl)-1H-benzo[d]imidazol-5-ol,CHEMBL2013458,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,Oc1ccc2[nH]c(-c3ccccc3)nc2c1CN1CCCCC1,CHEMBL2010727,A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.,Bioorg. Med. Chem. Lett.,2012.0,22,7,2620,2623,10.1016/j.bmcl.2012.01.108,22366657.0,
10844352,CHEMBL2010880,2-phenyl-4-(piperidin-1-ylmethyl)-1H-benzo[d]imidazole,CHEMBL2013458,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,c1ccc(-c2nc3c(CN4CCCCC4)cccc3[nH]2)cc1,CHEMBL2010727,A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.,Bioorg. Med. Chem. Lett.,2012.0,22,7,2620,2623,10.1016/j.bmcl.2012.01.108,22366657.0,
10844353,CHEMBL2010883,5-fluoro-2-phenyl-4-(pyrrolidin-1-ylmethyl)-1H-benzo[d]imidazole,CHEMBL2013458,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,Fc1ccc2[nH]c(-c3ccccc3)nc2c1CN1CCCC1,CHEMBL2010727,A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.,Bioorg. Med. Chem. Lett.,2012.0,22,7,2620,2623,10.1016/j.bmcl.2012.01.108,22366657.0,
10847069,CHEMBL2011113,"2-(4-acetylpiperazin-1-yl)-4-(4-chlorobenzylamino)-6-isopropyl-5H-pyrrolo[3,4-d]pyrimidin-7(6H)-one",CHEMBL2014022,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,=,2400.0,nM,CC(=O)N1CCN(c2nc(NCc3ccc(Cl)cc3)c3c(n2)C(=O)N(C(C)C)C3)CC1,CHEMBL2010731,Discovery of P2X3 selective antagonists for the treatment of chronic pain.,Bioorg. Med. Chem. Lett.,2012.0,22,7,2565,2571,10.1016/j.bmcl.2012.01.124,22370269.0,
10847070,CHEMBL2011115,"2-(4-acetylpiperazin-1-yl)-6-isopropyl-4-(4-(trifluoromethoxy)benzylamino)-5H-pyrrolo[3,4-d]pyrimidin-7(6H)-one",CHEMBL2014022,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,=,2400.0,nM,CC(=O)N1CCN(c2nc(NCc3ccc(OC(F)(F)F)cc3)c3c(n2)C(=O)N(C(C)C)C3)CC1,CHEMBL2010731,Discovery of P2X3 selective antagonists for the treatment of chronic pain.,Bioorg. Med. Chem. Lett.,2012.0,22,7,2565,2571,10.1016/j.bmcl.2012.01.124,22370269.0,
10847071,CHEMBL2011118,"(R)-2-(4-acetylpiperazin-1-yl)-6-isopropyl-4-(1-(4-(trifluoromethoxy)phenyl)ethylamino)-5H-pyrrolo[3,4-d]pyrimidin-7(6H)-one",CHEMBL2014022,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,=,7300.0,nM,CC(=O)N1CCN(c2nc(N[C@H](C)c3ccc(OC(F)(F)F)cc3)c3c(n2)C(=O)N(C(C)C)C3)CC1,CHEMBL2010731,Discovery of P2X3 selective antagonists for the treatment of chronic pain.,Bioorg. Med. Chem. Lett.,2012.0,22,7,2565,2571,10.1016/j.bmcl.2012.01.124,22370269.0,
10847072,CHEMBL2011119,"(R)-2-(4-acetylpiperazin-1-yl)-6-isopropyl-4-(1-(4-methoxyphenyl)ethylamino)-5H-pyrrolo[3,4-d]pyrimidin-7(6H)-one",CHEMBL2014022,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,=,2400.0,nM,COc1ccc([C@@H](C)Nc2nc(N3CCN(C(C)=O)CC3)nc3c2CN(C(C)C)C3=O)cc1,CHEMBL2010731,Discovery of P2X3 selective antagonists for the treatment of chronic pain.,Bioorg. Med. Chem. Lett.,2012.0,22,7,2565,2571,10.1016/j.bmcl.2012.01.124,22370269.0,
10847073,CHEMBL2011120,"(R)-2-(4-acetylpiperazin-1-yl)-4-(1-(4-ethoxyphenyl)ethylamino)-6-isopropyl-5H-pyrrolo[3,4-d]pyrimidin-7(6H)-one",CHEMBL2014022,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,>,10000.0,nM,CCOc1ccc([C@@H](C)Nc2nc(N3CCN(C(C)=O)CC3)nc3c2CN(C(C)C)C3=O)cc1,CHEMBL2010731,Discovery of P2X3 selective antagonists for the treatment of chronic pain.,Bioorg. Med. Chem. Lett.,2012.0,22,7,2565,2571,10.1016/j.bmcl.2012.01.124,22370269.0,
10847074,CHEMBL2011122,"(S)-2-(4-acetylpiperazin-1-yl)-4-(1-(4-ethoxyphenyl)-2,2,2-trifluoroethylamino)-6-isopropyl-5H-pyrrolo[3,4-d]pyrimidin-7(6H)-one",CHEMBL2014022,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,=,14000.0,nM,CCOc1ccc([C@H](Nc2nc(N3CCN(C(C)=O)CC3)nc3c2CN(C(C)C)C3=O)C(F)(F)F)cc1,CHEMBL2010731,Discovery of P2X3 selective antagonists for the treatment of chronic pain.,Bioorg. Med. Chem. Lett.,2012.0,22,7,2565,2571,10.1016/j.bmcl.2012.01.124,22370269.0,
10847075,CHEMBL2011123,"(R)-2-(4-acetylpiperazin-1-yl)-4-(1-(4-ethoxy-3-fluorophenyl)ethylamino)-6-isopropyl-5H-pyrrolo[3,4-d]pyrimidin-7(6H)-one",CHEMBL2014022,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,=,11000.0,nM,CCOc1ccc([C@@H](C)Nc2nc(N3CCN(C(C)=O)CC3)nc3c2CN(C(C)C)C3=O)cc1F,CHEMBL2010731,Discovery of P2X3 selective antagonists for the treatment of chronic pain.,Bioorg. Med. Chem. Lett.,2012.0,22,7,2565,2571,10.1016/j.bmcl.2012.01.124,22370269.0,
10847076,CHEMBL2011125,"2-(4-acetylpiperazin-1-yl)-6-isopropyl-4-(quinolin-3-ylmethylamino)-5H-pyrrolo[3,4-d]pyrimidin-7(6H)-one",CHEMBL2014022,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,=,16000.0,nM,CC(=O)N1CCN(c2nc(NCc3cnc4ccccc4c3)c3c(n2)C(=O)N(C(C)C)C3)CC1,CHEMBL2010731,Discovery of P2X3 selective antagonists for the treatment of chronic pain.,Bioorg. Med. Chem. Lett.,2012.0,22,7,2565,2571,10.1016/j.bmcl.2012.01.124,22370269.0,
10847077,CHEMBL2011126,"2-(4-acetylpiperazin-1-yl)-6-isopropyl-4-(isoquinolin-3-ylmethylamino)-5H-pyrrolo[3,4-d]pyrimidin-7(6H)-one",CHEMBL2014022,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,=,7000.0,nM,CC(=O)N1CCN(c2nc(NCc3cc4ccccc4cn3)c3c(n2)C(=O)N(C(C)C)C3)CC1,CHEMBL2010731,Discovery of P2X3 selective antagonists for the treatment of chronic pain.,Bioorg. Med. Chem. Lett.,2012.0,22,7,2565,2571,10.1016/j.bmcl.2012.01.124,22370269.0,
10847078,CHEMBL2011127,"2-(4-acetylpiperazin-1-yl)-6-isopropyl-4-((isoquinolin-3-ylmethyl)(methyl)amino)-5H-pyrrolo[3,4-d]pyrimidin-7(6H)-one",CHEMBL2014022,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,=,7000.0,nM,CC(=O)N1CCN(c2nc3c(c(N(C)Cc4cc5ccccc5cn4)n2)CN(C(C)C)C3=O)CC1,CHEMBL2010731,Discovery of P2X3 selective antagonists for the treatment of chronic pain.,Bioorg. Med. Chem. Lett.,2012.0,22,7,2565,2571,10.1016/j.bmcl.2012.01.124,22370269.0,
10847128,CHEMBL2011112,"2-(4-acetylpiperazin-1-yl)-4-(1-(4-chlorophenyl)-2-methylpropan-2-ylamino)-6-isopropyl-5H-pyrrolo[3,4-d]pyrimidin-7(6H)-one",CHEMBL2014022,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,=,2000.0,nM,CC(=O)N1CCN(c2nc(NC(C)(C)Cc3ccc(Cl)cc3)c3c(n2)C(=O)N(C(C)C)C3)CC1,CHEMBL2010731,Discovery of P2X3 selective antagonists for the treatment of chronic pain.,Bioorg. Med. Chem. Lett.,2012.0,22,7,2565,2571,10.1016/j.bmcl.2012.01.124,22370269.0,
10850646,CHEMBL1938681,5-(4-chlorophenyl)-N-(4-(piperazin-1-yl)phenyl)-N-(pyridin-2-ylmethyl)furan-2-carboxamide,CHEMBL2019981,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes co-incubated with tolbutamide,IC50,>,20000.0,nM,O=C(c1ccc(-c2ccc(Cl)cc2)o1)N(Cc1ccccn1)c1ccc(N2CCNCC2)cc1,CHEMBL2016522,Discovery and Hit-to-Lead Optimization of Non-ATP Competitive MK2 (MAPKAPK2) Inhibitors.,ACS Med. Chem. Lett.,2011.0,2,8,632,637,10.1021/ml200113y,24900358.0,
10850647,CHEMBL1938681,5-(4-chlorophenyl)-N-(4-(piperazin-1-yl)phenyl)-N-(pyridin-2-ylmethyl)furan-2-carboxamide,CHEMBL2019982,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate incubated for 30 mins prior to substrate addition,IC50,>,20000.0,nM,O=C(c1ccc(-c2ccc(Cl)cc2)o1)N(Cc1ccccn1)c1ccc(N2CCNCC2)cc1,CHEMBL2016522,Discovery and Hit-to-Lead Optimization of Non-ATP Competitive MK2 (MAPKAPK2) Inhibitors.,ACS Med. Chem. Lett.,2011.0,2,8,632,637,10.1021/ml200113y,24900358.0,
10854883,CHEMBL2018481,"(2S,4R)-1-(2-(1H-imidazol-5-yl)acetyl)-4-benzyl-N-(4-(4-fluorophenoxy)phenyl)pyrrolidine-2-carboxamide",CHEMBL2020550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using tolbutamide as substrate by LC/MS/MS analysis,IC50,<,205.0,nM,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccccc2)CN1C(=O)Cc1cnc[nH]1,CHEMBL2016445,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,2012.0,55,3,1368,1381,10.1021/jm201533b,22214363.0,
10854886,CHEMBL2018482,"(2S,4S)-1-(2-(1H-imidazol-5-yl)acetyl)-N-(4-(4-fluorophenoxy)phenyl)-4-phenylpyrrolidine-2-carboxamide",CHEMBL2020550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using tolbutamide as substrate by LC/MS/MS analysis,IC50,=,213.0,nM,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](c2ccccc2)CN1C(=O)Cc1cnc[nH]1,CHEMBL2016445,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,2012.0,55,3,1368,1381,10.1021/jm201533b,22214363.0,
10854889,CHEMBL2018484,"(2S,4R)-1-(2-(1H-1,2,4-triazol-1-yl)acetyl)-4-benzyl-N-(4-(4-fluorophenoxy)phenyl)pyrrolidine-2-carboxamide",CHEMBL2020550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using tolbutamide as substrate by LC/MS/MS analysis,IC50,=,2286.0,nM,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccccc2)CN1C(=O)Cn1cncn1,CHEMBL2016445,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,2012.0,55,3,1368,1381,10.1021/jm201533b,22214363.0,
10854892,CHEMBL2018485,"(2S,4R)-1-(2-(1H-1,2,4-Triazol-1-yl)acetyl)-4-(4-fluorobenzyl)-N-(4-(4-fluorophenoxy)phenyl)pyrrolidine-2-carboxamide",CHEMBL2020550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using tolbutamide as substrate by LC/MS/MS analysis,IC50,=,2187.0,nM,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccc(F)cc2)CN1C(=O)Cn1cncn1,CHEMBL2016445,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,2012.0,55,3,1368,1381,10.1021/jm201533b,22214363.0,
10854895,CHEMBL2018486,"(2S,4S)-1-(2-(1H-1,2,4-Triazol-1-yl)acetyl)-4-(4-fluorobenzyl)-N-(4-(4-fluorophenoxy)phenyl)pyrrolidine-2-carboxamide",CHEMBL2020550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using tolbutamide as substrate by LC/MS/MS analysis,IC50,=,1347.0,nM,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@H](Cc2ccc(F)cc2)CN1C(=O)Cn1cncn1,CHEMBL2016445,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,2012.0,55,3,1368,1381,10.1021/jm201533b,22214363.0,
10854898,CHEMBL2018571,"(2S,4R)-1-(2-(1H-1,2,3-Triazol-1-yl)acetyl)-4-(4-fluorobenzyl)-N-(4-(4-fluorophenoxy)phenyl)pyrrolidine-2-carboxamide",CHEMBL2020550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using tolbutamide as substrate by LC/MS/MS analysis,IC50,=,17253.0,nM,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccc(F)cc2)CN1C(=O)Cn1ccnn1,CHEMBL2016445,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,2012.0,55,3,1368,1381,10.1021/jm201533b,22214363.0,
10854901,CHEMBL2018573,"(2S,4R)-1-(2-(2H-1,2,3-Triazol-2-yl)acetyl)-4-(4-fluorobenzyl)-N-(4-(4-fluorophenoxy)phenyl)pyrrolidine-2-carboxamide",CHEMBL2020550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using tolbutamide as substrate by LC/MS/MS analysis,IC50,=,17390.0,nM,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccc(F)cc2)CN1C(=O)Cn1nccn1,CHEMBL2016445,Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.,J. Med. Chem.,2012.0,55,3,1368,1381,10.1021/jm201533b,22214363.0,
10857590,CHEMBL2018906,2-(ethylthio)-5-methoxy-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,CCSc1nc2cc(OC)ccc2[nH]1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857591,CHEMBL2018905,5-methoxy-2-(propylthio)-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,35800.0,nM,CCCSc1nc2cc(OC)ccc2[nH]1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857592,CHEMBL2018903,2-(butylthio)-5-methoxy-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,39900.0,nM,CCCCSc1nc2cc(OC)ccc2[nH]1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857593,CHEMBL2018904,5-methoxy-2-(pentylthio)-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,9180.0,nM,CCCCCSc1nc2cc(OC)ccc2[nH]1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857594,CHEMBL2018907,2-(hexylthio)-5-methoxy-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,2920.0,nM,CCCCCCSc1nc2cc(OC)ccc2[nH]1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857595,CHEMBL2018908,2-(heptylthio)-5-methoxy-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,4570.0,nM,CCCCCCCSc1nc2cc(OC)ccc2[nH]1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857596,CHEMBL2018909,2-(isobutylthio)-5-methoxy-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,32700.0,nM,COc1ccc2[nH]c(SCC(C)C)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857597,CHEMBL2018910,5-methoxy-2-(neopentylthio)-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,21200.0,nM,COc1ccc2[nH]c(SCC(C)(C)C)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857598,CHEMBL2018911,2-(cyclopropylmethylthio)-5-methoxy-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,22100.0,nM,COc1ccc2[nH]c(SCC3CC3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857599,CHEMBL2018912,2-(cyclohexylmethylthio)-5-methoxy-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,4410.0,nM,COc1ccc2[nH]c(SCC3CCCCC3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857600,CHEMBL2018913,3-(5-methoxy-1H-benzo[d]imidazol-2-ylthio)propan-1-ol,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,COc1ccc2[nH]c(SCCCO)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857601,CHEMBL2018914,4-(5-methoxy-1H-benzo[d]imidazol-2-ylthio)butanoic acid,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,COc1ccc2[nH]c(SCCCC(=O)O)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857602,CHEMBL2018915,2-(benzylthio)-5-methoxy-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,9730.0,nM,COc1ccc2[nH]c(SCc3ccccc3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857603,CHEMBL2018916,5-methoxy-2-(4-methylbenzylthio)-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,6730.0,nM,COc1ccc2[nH]c(SCc3ccc(C)cc3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857604,CHEMBL2018917,2-(4-isopropylbenzylthio)-5-methoxy-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,3420.0,nM,COc1ccc2[nH]c(SCc3ccc(C(C)C)cc3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857605,CHEMBL2018918,2-(4-tert-butylbenzylthio)-5-methoxy-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,2540.0,nM,COc1ccc2[nH]c(SCc3ccc(C(C)(C)C)cc3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857606,CHEMBL2018919,2-(4-chlorobenzylthio)-5-methoxy-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,5980.0,nM,COc1ccc2[nH]c(SCc3ccc(Cl)cc3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857607,CHEMBL2018920,2-(4-bromobenzylthio)-5-methoxy-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,3250.0,nM,COc1ccc2[nH]c(SCc3ccc(Br)cc3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857608,CHEMBL2018921,2-(4-iodobenzylthio)-5-methoxy-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,5150.0,nM,COc1ccc2[nH]c(SCc3ccc(I)cc3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857609,CHEMBL2018922,4-((5-methoxy-1H-benzo[d]imidazol-2-ylthio)methyl)benzoic acid,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,COc1ccc2[nH]c(SCc3ccc(C(=O)O)cc3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857610,CHEMBL488400,"2-(3,5-dimethoxybenzylthio)-6-methoxy-1H-benzo[d]imidazole",CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,2320.0,nM,COc1cc(CSc2nc3ccc(OC)cc3[nH]2)cc(OC)c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857611,CHEMBL2018923,2-(biphenyl-3-ylmethylthio)-5-methoxy-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,820.0,nM,COc1ccc2[nH]c(SCc3cccc(-c4ccccc4)c3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857612,CHEMBL502335,6-methoxy-2-(naphthalen-2-ylmethylthio)-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,2270.0,nM,COc1ccc2nc(SCc3ccc4ccccc4c3)[nH]c2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857613,CHEMBL2018924,2-((5-methoxy-1H-benzo[d]imidazol-2-ylthio)methyl)quinoline,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,6180.0,nM,COc1ccc2[nH]c(SCc3ccc4ccccc4n3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857614,CHEMBL2018925,5-methoxy-2-(3-phenoxybenzylthio)-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,960.0,nM,COc1ccc2[nH]c(SCc3cccc(Oc4ccccc4)c3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857615,CHEMBL2018926,2-(4-(benzyloxy)benzylthio)-5-methoxy-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,880.0,nM,COc1ccc2[nH]c(SCc3ccc(OCc4ccccc4)cc3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857616,CHEMBL2019022,5-methoxy-2-(pyridin-2-ylmethylthio)-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,550.0,nM,COc1ccc2[nH]c(SCc3ccccn3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857617,CHEMBL2019023,5-ethoxy-2-(pyridin-2-ylmethylthio)-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,24200.0,nM,CCOc1ccc2[nH]c(SCc3ccccn3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857618,CHEMBL296580,2-(Pyridin-2-ylmethylsulfanyl)-1H-benzoimidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,c1ccc(CSc2nc3ccccc3[nH]2)nc1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857619,CHEMBL2019024,5-methyl-2-(pyridin-2-ylmethylthio)-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,Cc1ccc2[nH]c(SCc3ccccn3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857620,CHEMBL2019025,5-(difluoromethoxy)-2-(pyridin-2-ylmethylthio)-1H-benzo[d]imidazole,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,22300.0,nM,FC(F)Oc1ccc2[nH]c(SCc3ccccn3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10857621,CHEMBL2019026,2-(pyridin-2-ylmethylthio)-1H-benzo[d]imidazol-5-amine,CHEMBL2020720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins by LC-MS/MS analysis,IC50,=,6970.0,nM,Nc1ccc2[nH]c(SCc3ccccn3)nc2c1,CHEMBL2016494,Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.,J. Med. Chem.,2012.0,55,3,1205,1214,10.1021/jm201346g,22239545.0,
10858779,CHEMBL1552719,SID24390028,CHEMBL2020823,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,990.0,nM,COc1ccc(-n2c(SCc3nc(-c4ccc(C)cc4)no3)nnc2-c2ccncc2)cc1,CHEMBL2016557,"[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.",J. Med. Chem.,2012.0,55,3,1127,1136,10.1021/jm2011222,22260203.0,
10859407,CHEMBL1086580,"2-(4-(Trifluoromethyl)phenyl)-7,8-dihydro-5H-thiopyrano-[4,3-d]pyrimidin-4-ol",CHEMBL2020823,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Oc1nc(-c2ccc(C(F)(F)F)cc2)nc2c1CSCC2,CHEMBL2016557,"[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.",J. Med. Chem.,2012.0,55,3,1127,1136,10.1021/jm2011222,22260203.0,
10859415,CHEMBL1867804,SID24390092,CHEMBL2020823,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,45000.0,nM,COc1ccc(-n2c(C)nnc2SCc2nc(-c3ccc(OC)c(OC)c3)no2)cc1,CHEMBL2016557,"[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.",J. Med. Chem.,2012.0,55,3,1127,1136,10.1021/jm2011222,22260203.0,
10859422,CHEMBL1898239,SID24390090,CHEMBL2020823,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,21000.0,nM,COc1ccc(-c2noc(CSc3nnc(C)n3-c3ccc(OC)cc3)n2)cc1,CHEMBL2016557,"[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.",J. Med. Chem.,2012.0,55,3,1127,1136,10.1021/jm2011222,22260203.0,
10859436,CHEMBL2016639,"5-((5-(4-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)methyl)-3-phenyl-1,2,4-oxadiazole",CHEMBL2020823,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Fc1ccc(-c2nnc(SCc3nc(-c4ccccc4)no3)n2-c2ccccc2)cc1,CHEMBL2016557,"[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.",J. Med. Chem.,2012.0,55,3,1127,1136,10.1021/jm2011222,22260203.0,
10860381,CHEMBL2017089,"7-(3,5-dimethylisoxazol-4-yl)-4-(phenylamino)quinoline-3-carboxamide",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2100.0,nM,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3)c(C(N)=O)cnc2c1,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860382,CHEMBL2017091,"7-(3,5-dimethylisoxazol-4-yl)-4-(phenylamino)quinoline-3-carboxylic acid",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,33000.0,nM,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3)c(C(=O)O)cnc2c1,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860383,CHEMBL2017268,"4-(2-tert-butylphenylamino)-7-(3,5-dimethylisoxazol-4-yl)quinoline-3-carboxamide",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,700.0,nM,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(N)=O)cnc2c1,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860384,CHEMBL2017269,"4-(2-tert-butylphenylamino)-7-(3,5-dimethylisoxazol-4-yl)quinoline-3-carboxylic acid",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(=O)O)cnc2c1,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860385,CHEMBL2017273,"7-(3,5-dimethylisoxazol-4-yl)-4-(2-fluorophenylamino)-6-methoxyquinoline-3-carboxamide",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,600.0,nM,COc1cc2c(Nc3ccccc3F)c(C(N)=O)cnc2cc1-c1c(C)noc1C,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860386,CHEMBL2017274,"4-(2-tert-butylphenylamino)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxyquinoline-3-carboxamide",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1200.0,nM,COc1cc2c(Nc3ccccc3C(C)(C)C)c(C(N)=O)cnc2cc1-c1c(C)noc1C,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860387,CHEMBL2017275,"7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-4-(2-(2-morpholinoethyl)phenylamino)quinoline-3-carboxamide",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2200.0,nM,COc1cc2c(Nc3ccccc3CCN3CCOCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860388,CHEMBL2017276,"7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-4-(2-picolinoylphenylamino)quinoline-3-carboxamide",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9900.0,nM,COc1cc2c(Nc3ccccc3C(=O)c3ccccn3)c(C(N)=O)cnc2cc1-c1c(C)noc1C,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860389,CHEMBL2017279,"7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-4-(2-morpholinophenylamino)quinoline-3-carboxamide",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5100.0,nM,COc1cc2c(Nc3ccccc3N3CCOCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860390,CHEMBL2017280,"7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-4-(2-(piperidine-1-carbonyl)phenylamino)quinoline-3-carboxamide",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8500.0,nM,COc1cc2c(Nc3ccccc3C(=O)N3CCCCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860391,CHEMBL2017281,"7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-4-(quinolin-8-ylamino)quinoline-3-carboxamide",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2800.0,nM,COc1cc2c(Nc3cccc4cccnc34)c(C(N)=O)cnc2cc1-c1c(C)noc1C,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860392,CHEMBL2017283,"1-(2-tert-butylphenyl)-7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1H-imidazo[4,5-c]quinolin-2(3H)-one",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,900.0,nM,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3C(C)(C)C)c12,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860393,CHEMBL2017284,"7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-(2-(trifluoromethoxy)phenyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2300.0,nM,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3OC(F)(F)F)c12,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860394,CHEMBL2017285,"1-benzyl-7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1H-imidazo[4,5-c]quinolin-2(3H)-one",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1200.0,nM,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccc3)c12,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860395,CHEMBL2017286,"7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-(pyridin-2-ylmethyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9800.0,nM,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccn3)c12,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860396,CHEMBL2017287,"rac-7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-(1-phenylethyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1300.0,nM,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(C(C)c3ccccc3)c12,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860397,CHEMBL2017288,"7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-((R)-1-phenylethyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1000.0,nM,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccc3)c12,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860398,CHEMBL2017290,"7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-((R)-1-phenylpropyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2400.0,nM,CC[C@H](c1ccccc1)n1c(=O)[nH]c2cnc3cc(-c4c(C)noc4C)c(OC)cc3c21,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10860399,CHEMBL2017291,"7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one",CHEMBL2020947,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9900.0,nM,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12,CHEMBL2016443,From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2963,2967,10.1016/j.bmcl.2012.01.125,22386529.0,
10867500,CHEMBL119385,"5-(2,6-Dichloro-phenyl)-2-(2,4-difluoro-phenylsulfanyl)-1,7,8a-triaza-naphthalen-6-one",CHEMBL2027467,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,40000.0,nM,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,CHEMBL2021894,The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor.,ACS Med. Chem. Lett.,2011.0,2,10,758,763,10.1021/ml2001455,24900264.0,
10868365,CHEMBL2023802,2-(5-(7-ethoxy-6-methoxyquinolin-4-yloxy)-3-methoxypyridin-2-yl)-N-(5-ethyl-4-methyl-1H-pyrazol-3-yl)acetamide,CHEMBL2026448,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,8600.0,nM,CCOc1cc2nccc(Oc3cnc(CC(=O)Nc4n[nH]c(CC)c4C)c(OC)c3)c2cc1OC,CHEMBL2021798,Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases.,Bioorg. Med. Chem. Lett.,2012.0,22,9,3050,3055,10.1016/j.bmcl.2012.03.074,22497760.0,
10868371,CHEMBL2023803,"N-(1,3-dimethyl-1H-pyrazol-4-yl)-2-(2-methoxy-4-(7-methoxyquinolin-4-yloxy)phenyl)acetamide sulfate",CHEMBL2026448,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,COc1ccc2c(Oc3ccc(CC(=O)Nc4cn(C)nc4C)c(OC)c3)ccnc2c1.O=S(=O)(O)O,CHEMBL2021798,Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases.,Bioorg. Med. Chem. Lett.,2012.0,22,9,3050,3055,10.1016/j.bmcl.2012.03.074,22497760.0,
10869856,CHEMBL2022495,"2-fluoro-N-(3-methoxy-4-(5-(3-(piperidin-1-yl)propylamino)-1,3,4-oxadiazol-2-yl)phenyl)benzamide",CHEMBL2024828,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,100000.0,nM,COc1cc(NC(=O)c2ccccc2F)ccc1-c1nnc(NCCCN2CCCCC2)o1,CHEMBL2021886,"Identification of a series of 1,3,4-oxadiazol-2-amines as potent alpha-7 agonists with efficacy in the novel object recognition model of cognition.",Bioorg. Med. Chem. Lett.,2012.0,22,10,3560,3563,10.1016/j.bmcl.2012.03.040,22503248.0,
10869932,CHEMBL2022570,4-(4'-Fluorobiphenyl-3-ylmethyl)-5-methyl-2H-pyrazole-3-carboxylic acid,CHEMBL2027079,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1n[nH]c(C(=O)O)c1Cc1cccc(-c2ccc(F)cc2)c1,CHEMBL2021770,Potent and Selective Inhibitors of Long Chain l-2-Hydroxy Acid Oxidase Reduced Blood Pressure in DOCA Salt-Treated Rats.,ACS Med. Chem. Lett.,2011.0,2,12,919,923,10.1021/ml2001938,24900281.0,
10869933,CHEMBL2022571,4-Benzo[b]thiophen-2-ylmethyl-5-methyl-2H-pyrazole-3-carboxylic acid,CHEMBL2027079,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1n[nH]c(C(=O)O)c1Cc1cc2ccccc2s1,CHEMBL2021770,Potent and Selective Inhibitors of Long Chain l-2-Hydroxy Acid Oxidase Reduced Blood Pressure in DOCA Salt-Treated Rats.,ACS Med. Chem. Lett.,2011.0,2,12,919,923,10.1021/ml2001938,24900281.0,
10871884,CHEMBL2022739,"2-fluoro-N-(3-fluoro-4-(5-(4-morpholinobutylamino)-1,3,4-oxadiazol-2-yl)phenyl)benzamide",CHEMBL2026873,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,51000.0,nM,O=C(Nc1ccc(-c2nnc(NCCCCN3CCOCC3)o2)c(F)c1)c1ccccc1F,CHEMBL2021786,"The discovery of 2-fluoro-N-(3-fluoro-4-(5-((4-morpholinobutyl)amino)-1,3,4-oxadiazol-2-yl)phenyl)benzamide, a full agonist of the alpha-7 nicotinic acetylcholine receptor showing efficacy in the novel object recognition model of cognition enhancement.",Bioorg. Med. Chem. Lett.,2012.0,22,10,3531,3534,10.1016/j.bmcl.2012.03.062,22503453.0,
10875808,CHEMBL2022995,"(S)-2-amino-5,5-diphenyl-5-m-tolylpentanoic acid",CHEMBL2025098,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,Cc1cccc(C(CC[C@H](N)C(=O)O)(c2ccccc2)c2ccccc2)c1,CHEMBL2021885,Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.,J. Med. Chem.,2012.0,55,4,1511,1525,10.1021/jm201195m,22248262.0,
10875809,CHEMBL2022996,"(R)-2-amino-5,5-diphenyl-5-m-tolylpentanoic acid",CHEMBL2025098,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,Cc1cccc(C(CC[C@@H](N)C(=O)O)(c2ccccc2)c2ccccc2)c1,CHEMBL2021885,Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.,J. Med. Chem.,2012.0,55,4,1511,1525,10.1021/jm201195m,22248262.0,
10875810,CHEMBL2022997,"4-(3-Methylphenyl)-4,4-diphenylbutan-1-amine",CHEMBL2025098,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4300.0,nM,Cc1cccc(C(CCCN)(c2ccccc2)c2ccccc2)c1,CHEMBL2021885,Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.,J. Med. Chem.,2012.0,55,4,1511,1525,10.1021/jm201195m,22248262.0,
10875811,CHEMBL228814,"(R)-N-(3-aminopropyl)-N-(1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl)-4-methylbenzamide",CHEMBL2025098,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,25000.0,nM,Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1,CHEMBL2021885,Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.,J. Med. Chem.,2012.0,55,4,1511,1525,10.1021/jm201195m,22248262.0,
10885414,CHEMBL2029422,(S)-N-[2-(3-{trans-4-Hydroxy-4-[5-(pyrimidin-2-yl)pyridin-2-yl]cyclohexylamino}pyrrolidin-1-yl)-2-oxoethyl]-3-(trifluoromethyl)benzamide,CHEMBL2032970,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,O=C(NCC(=O)N1CC[C@H](N[C@H]2CC[C@@](O)(c3ccc(-c4ncccn4)cn3)CC2)C1)c1cccc(C(F)(F)F)c1,CHEMBL2029240,"Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.",ACS Med. Chem. Lett.,2011.0,2,12,913,918,10.1021/ml200199c,24900280.0,
10886073,CHEMBL2029988,"1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea",CHEMBL2034051,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,10000.0,nM,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC,CHEMBL2029242,"Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.",J. Med. Chem.,2012.0,55,3,1082,1105,10.1021/jm2009925,22168626.0,
10890670,CHEMBL2029729,"(R)-N,9-dimethyl-N-(4-(methylamino)-4-oxobutyl)-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide",CHEMBL2032810,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,7000.0,nM,CNC(=O)CCCN(C)C(=O)c1ccc2c(c1)c1c(n2C)CC[C@@H](C2CCOCC2)C1,CHEMBL2029249,"N-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamides as a novel class of cannabinoid receptors agonists with low CNS penetration.",Bioorg. Med. Chem. Lett.,2012.0,22,12,3884,3889,10.1016/j.bmcl.2012.04.128,22607668.0,
10891872,CHEMBL2030436,4-(2-(1H-indol-5-yl)-6-(methylsulfonylmethyl)pyrimidin-4-yl)morpholine,CHEMBL2033334,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5000.0,nM,CS(=O)(=O)Cc1cc(N2CCOCC2)nc(-c2ccc3[nH]ccc3c2)n1,CHEMBL2029234,Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor.,Bioorg. Med. Chem. Lett.,2012.0,22,12,4163,4168,10.1016/j.bmcl.2012.04.036,22607682.0,
10893593,CHEMBL2030402,"(S)-8-chloro-2-(pyrrolidin-2-yl)benzofuro[3,2-d]pyrimidin-4(3H)-one",CHEMBL2032621,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=c1[nH]c([C@@H]2CCCN2)nc2c1oc1ccc(Cl)cc12,CHEMBL2029277,"Discovery of XL413, a potent and selective CDC7 inhibitor.",Bioorg. Med. Chem. Lett.,2012.0,22,11,3727,3731,10.1016/j.bmcl.2012.04.024,22560567.0,
10895058,CHEMBL2031470,"(R)-2-methyl-8-(3-(2-methylpyrrolidin-1-yl)propoxy)-5,6-dihydrobenzo[h]cinnolin-3(2H)-one",CHEMBL2034494,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc2c(c1)CCc1cc(=O)n(C)nc1-2,CHEMBL2029210,"Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists.",Bioorg. Med. Chem. Lett.,2012.0,22,12,4198,4202,10.1016/j.bmcl.2012.04.001,22617490.0,
10899075,CHEMBL2036268,cis-N-(3-(4-(methylamino)cyclohexyl)-1H-indol-5-yl)thiophene-2-carboximidamide hydrochloride,CHEMBL2037698,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,100000.0,nM,CN[C@H]1CC[C@@H](c2c[nH]c3ccc(NC(=N)c4cccs4)cc32)CC1.Cl,CHEMBL2034871,"First-in-class, dual-action, 3,5-disubstituted indole derivatives having human nitric oxide synthase (nNOS) and norepinephrine reuptake inhibitory (NERI) activity for the treatment of neuropathic pain.",J. Med. Chem.,2012.0,55,7,3488,3501,10.1021/jm300138g,22420844.0,
10899076,CHEMBL2036270,cis-N-(3-(4-(ethylamino)cyclohexyl)-1H-indol-5-yl)thiophene-2-carboximidamide hydrochloride,CHEMBL2037698,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,21500.0,nM,CCN[C@H]1CC[C@@H](c2c[nH]c3ccc(NC(=N)c4cccs4)cc32)CC1.Cl,CHEMBL2034871,"First-in-class, dual-action, 3,5-disubstituted indole derivatives having human nitric oxide synthase (nNOS) and norepinephrine reuptake inhibitory (NERI) activity for the treatment of neuropathic pain.",J. Med. Chem.,2012.0,55,7,3488,3501,10.1021/jm300138g,22420844.0,
10899895,CHEMBL1770317,"5-isopropyl-5-(6-(naphthalen-2-yl)-2-oxo-1,2-dihydropyridin-3-yl)oxazolidine-2,4-dione",CHEMBL2039053,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50118.72,nM,CC(C)C1(c2ccc(-c3ccc4ccccc4c3)[nH]c2=O)OC(=O)NC1=O,CHEMBL2034937,"Novel 3-Oxazolidinedione-6-aryl-pyridinones as Potent, Selective, and Orally Active EP3 Receptor Antagonists.",ACS Med. Chem. Lett.,2010.0,1,7,316,320,10.1021/ml100077x,24900213.0,
10901344,CHEMBL2036017,N-(4-methoxybenzyl)-N-[3-(1H-tetrazol-5-yl)phenyl]pentanamide,CHEMBL2039550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,IC50,=,840.0,nM,CCCCC(=O)N(Cc1ccc(OC)cc1)c1cccc(-c2nnn[nH]2)c1,CHEMBL2034935,Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids.,ACS Med. Chem. Lett.,2011.0,2,12,938,942,10.1021/ml200223s,24900284.0,
10901345,CHEMBL2036030,N-[3-fluoro-5-(1H-tetrazol-5-yl)phenyl]-N-(3-isopropoxybenzyl)propanamide,CHEMBL2039550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,IC50,=,340.0,nM,CCC(=O)N(Cc1cccc(OC(C)C)c1)c1cc(F)cc(-c2nnn[nH]2)c1,CHEMBL2034935,Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids.,ACS Med. Chem. Lett.,2011.0,2,12,938,942,10.1021/ml200223s,24900284.0,
10901489,CHEMBL1951055,(R)-1-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-2-morpholinoethanone,CHEMBL2040327,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(C(=O)CN2CCOCC2)cc1,CHEMBL2034887,Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2807,2810,10.1016/j.bmcl.2012.02.081,22450133.0,
10901490,CHEMBL2036635,(R)-2-(4-benzoylpiperazin-1-yl)-1-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)ethanone,CHEMBL2040327,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(C(=O)CN2CCN(C(=O)c3ccccc3)CC2)cc1,CHEMBL2034887,Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2807,2810,10.1016/j.bmcl.2012.02.081,22450133.0,
10901491,CHEMBL2036653,(R)-methyl 4-(2-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-2-oxoethyl)piperazine-1-carboxylate,CHEMBL2040327,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,COC(=O)N1CCN(CC(=O)c2ccc(OCCCN3CCC[C@H]3C)cc2)CC1,CHEMBL2034887,Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2807,2810,10.1016/j.bmcl.2012.02.081,22450133.0,
10901625,CHEMBL2036643,"(R)-2-(4,4-difluoropiperidin-1-yl)-1-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)ethanone",CHEMBL2040327,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(C(=O)CN2CCC(F)(F)CC2)cc1,CHEMBL2034887,Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,2012.0,22,8,2807,2810,10.1016/j.bmcl.2012.02.081,22450133.0,
10901702,CHEMBL2030386,"(R)-8-bromo-2-((3-hydroxypyrrolidin-1-yl)methyl)benzofuro[3,2-d]pyrimidin-4(3H)-one",CHEMBL2038182,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,20000.0,nM,O=c1[nH]c(CN2CC[C@@H](O)C2)nc2c1oc1ccc(Br)cc12,CHEMBL2034948,"The design, synthesis, and biological evaluation of PIM kinase inhibitors.",Bioorg. Med. Chem. Lett.,2012.0,22,11,3732,3738,10.1016/j.bmcl.2012.04.025,22542012.0,
10902225,CHEMBL2036203,"N-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-N-[3-(1H-tetrazol-5-yl)phenyl]pentanamide",CHEMBL2039550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,IC50,=,640.0,nM,CCCCC(=O)N(Cc1ccc2c(c1)OCCO2)c1cccc(-c2nnn[nH]2)c1,CHEMBL2034935,Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids.,ACS Med. Chem. Lett.,2011.0,2,12,938,942,10.1021/ml200223s,24900284.0,
10902226,CHEMBL2036210,N-[3-fluoro-5-(1H-tetrazol-5-yl)phenyl]-N-[4-(trifluoromethyl)benzyl]propanamide,CHEMBL2039550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,IC50,=,280.0,nM,CCC(=O)N(Cc1ccc(C(F)(F)F)cc1)c1cc(F)cc(-c2nnn[nH]2)c1,CHEMBL2034935,Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids.,ACS Med. Chem. Lett.,2011.0,2,12,938,942,10.1021/ml200223s,24900284.0,
10902227,CHEMBL2036213,N-[3-fluoro-5-(1H-tetrazol-5-yl)phenyl]-N-[4-(trifluoromethoxy)benzyl]propanamide,CHEMBL2039550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,IC50,=,200.0,nM,CCC(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1cc(F)cc(-c2nnn[nH]2)c1,CHEMBL2034935,Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids.,ACS Med. Chem. Lett.,2011.0,2,12,938,942,10.1021/ml200223s,24900284.0,
10902228,CHEMBL2036217,N-[3-fluoro-5-(1H-tetrazol-5-yl)phenyl]-N-(3-hydroxybenzyl)propanamide,CHEMBL2039550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,IC50,=,2000.0,nM,CCC(=O)N(Cc1cccc(O)c1)c1cc(F)cc(-c2nnn[nH]2)c1,CHEMBL2034935,Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids.,ACS Med. Chem. Lett.,2011.0,2,12,938,942,10.1021/ml200223s,24900284.0,
10902229,CHEMBL2036220,N-[3-fluoro-5-(1H-tetrazol-5-yl)phenyl]-N-[4-(methylsulfonyl)benzyl]propanamide,CHEMBL2039550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,IC50,>,20000.0,nM,CCC(=O)N(Cc1ccc(S(C)(=O)=O)cc1)c1cc(F)cc(-c2nnn[nH]2)c1,CHEMBL2034935,Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids.,ACS Med. Chem. Lett.,2011.0,2,12,938,942,10.1021/ml200223s,24900284.0,
10902230,CHEMBL2036222,N-[3-fluoro-5-(1H-tetrazol-5-yl)phenyl]-3-methyl-N-[4-(methylsulfonyl)benzyl]butanamide,CHEMBL2039550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,IC50,=,1700.0,nM,CC(C)CC(=O)N(Cc1ccc(S(C)(=O)=O)cc1)c1cc(F)cc(-c2nnn[nH]2)c1,CHEMBL2034935,Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids.,ACS Med. Chem. Lett.,2011.0,2,12,938,942,10.1021/ml200223s,24900284.0,
10902231,CHEMBL2036223,N-[3-fluoro-5-(1H-tetrazol-5-yl)phenyl]-N-[4-(methylsulfonyl)benzyl]cyclopentanecarboxamide,CHEMBL2039550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,IC50,=,7400.0,nM,CS(=O)(=O)c1ccc(CN(C(=O)C2CCCC2)c2cc(F)cc(-c3nnn[nH]3)c2)cc1,CHEMBL2034935,Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids.,ACS Med. Chem. Lett.,2011.0,2,12,938,942,10.1021/ml200223s,24900284.0,
10902232,CHEMBL2036225,N-[3-fluoro-5-(1H-tetrazol-5-yl)phenyl]-N-[4-(methylsulfonyl)benzyl]-2-phenylacetamide,CHEMBL2039550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry,IC50,=,290.0,nM,CS(=O)(=O)c1ccc(CN(C(=O)Cc2ccccc2)c2cc(F)cc(-c3nnn[nH]3)c2)cc1,CHEMBL2034935,Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids.,ACS Med. Chem. Lett.,2011.0,2,12,938,942,10.1021/ml200223s,24900284.0,
10903650,CHEMBL2036958,"5-(3-(1-methylcyclopropyl)propyl)-1H-pyrano[2,3-d]pyrimidine-2,4,7(3H)-trione",CHEMBL2038330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,50000.0,nM,CC1(CCCc2cc(=O)oc3[nH]c(=O)[nH]c(=O)c23)CC1,CHEMBL2034879,"Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia.",ACS Med. Chem. Lett.,2012.0,3,1,63,68,10.1021/ml200243g,24900372.0,
10904371,CHEMBL2037608,2-Methoxymethyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxyl]-phenyl}-2H-pyridazin-3-one,CHEMBL2038950,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,COCn1ncc(-c2ccc(OCCCN3CCC[C@H]3C)cc2)cc1=O,CHEMBL2034817,Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists.,Bioorg. Med. Chem.,2012.0,20,12,3880,3886,10.1016/j.bmc.2012.04.028,22578490.0,
10904372,CHEMBL2037604,5-{4-[(S)-2-Methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one,CHEMBL2038950,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,C[C@H](COc1ccc(-c2cn[nH]c(=O)c2)cc1)CN1CCC[C@H]1C,CHEMBL2034817,Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists.,Bioorg. Med. Chem.,2012.0,20,12,3880,3886,10.1016/j.bmc.2012.04.028,22578490.0,
10908247,CHEMBL2037511,"(3R,6R)-3-(2,3-Dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione",CHEMBL2039723,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1ccc(C)nc1C,CHEMBL2034824,"Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,2012.0,55,2,783,796,10.1021/jm201287w,22239250.0,
10908248,CHEMBL377414,"(2R)-2-(2,4-difluorophenyl)-2-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-(2-methylpropyl)-2,5-dioxo-1-piperazinyl]-N,N-dimethylethanamide",CHEMBL2039723,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,12000.0,nM,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F,CHEMBL2034824,"Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.",J. Med. Chem.,2012.0,55,2,783,796,10.1021/jm201287w,22239250.0,
10910710,CHEMBL2035185,"(9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triazatetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene",CHEMBL2040147,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate by LC-MS/MS analysis,IC50,>,10000.0,nM,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1,CHEMBL2034857,"Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis.",J. Med. Chem.,2012.0,55,6,2623,2640,10.1021/jm201454n,22339472.0,
10915272,CHEMBL2036730,"trans-2-(4-(4-(5-(3,4-difluorophenylamino)-1,3,4-oxadiazole-2-carboxamido)phenyl)cyclohexyl)acetic acid",CHEMBL2038297,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,O=C(O)C[C@H]1CC[C@H](c2ccc(NC(=O)c3nnc(Nc4ccc(F)c(F)c4)o3)cc2)CC1,CHEMBL2034922,"Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes.",Bioorg. Med. Chem. Lett.,2012.0,22,12,3873,3878,10.1016/j.bmcl.2012.04.117,22608962.0,
10922694,CHEMBL2042239,"(+)-(S)-[5'-chloro-1-(5-chloro-2-fluorobenzyl)-3-methyl-2,2',5-trioxospiro[imidazolidine-4,3'-indol]-1'(2'H)-yl]acetic acid",CHEMBL2046033,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CN1C(=O)N(Cc2cc(Cl)ccc2F)C(=O)[C@]12C(=O)N(CC(=O)O)c1ccc(Cl)cc12,CHEMBL2040789,Optimization of the Central Core of Indolinone-Acetic Acid-Based CRTH2 (DP2) Receptor Antagonists.,ACS Med. Chem. Lett.,2011.0,2,8,644,649,10.1021/ml2001196,24900359.0,
10923835,CHEMBL2043437,"1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea",CHEMBL2045157,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1,CHEMBL2040751,"Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.",ACS Med. Chem. Lett.,2012.0,3,2,106,111,10.1021/ml2002423,24900436.0,
10926986,CHEMBL2043240,"rac-2-(2-(3,4-dichlorophenoxy)benzylsulfinyl)acetamide",CHEMBL2044631,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,216000.0,nM,NC(=O)C[S+]([O-])Cc1ccccc1Oc1ccc(Cl)c(Cl)c1,CHEMBL2040782,Wake-promoting agents: search for next generation modafinil: part IV.,Eur. J. Med. Chem.,2012.0,54,,949,951,10.1016/j.ejmech.2012.05.038,22749190.0,
10926987,CHEMBL2043240,"rac-2-(2-(3,4-dichlorophenoxy)benzylsulfinyl)acetamide",CHEMBL2044631,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2443000.0,nM,NC(=O)C[S+]([O-])Cc1ccccc1Oc1ccc(Cl)c(Cl)c1,CHEMBL2040782,Wake-promoting agents: search for next generation modafinil: part IV.,Eur. J. Med. Chem.,2012.0,54,,949,951,10.1016/j.ejmech.2012.05.038,22749190.0,
10932007,CHEMBL2043004,"3-(Biphenyl-4-yl)-8-[(3-methylpyridin-2-yl)methyl]-1-(6-hydroxypyrimidin-4-yl)-1,3,8-triazaspiro[4.5]decane-2,4-dione",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,65000.0,nM,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccccc3)cc1)C(=O)N2c1cc(O)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932008,CHEMBL2043011,"4'-[1-(6-Hydroxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1cc(O)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932009,CHEMBL2043168,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932010,CHEMBL2043169,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-3-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4cccc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932011,CHEMBL2043170,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-2-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccccc4C(=O)O)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932012,CHEMBL2043171,"2-Chloro-4'-[1-(6-methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4Cl)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932013,CHEMBL2043172,"3-Chloro-4'-[1-(6-methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)c(Cl)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932014,CHEMBL2043324,"2-Fluoro-4'-[1-(6-methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4F)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932015,CHEMBL2043325,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-2-methyl-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932016,CHEMBL2043326,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-3-methyl-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)c(C)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932017,CHEMBL2041182,"2-Methyl-4'-[8-(3-methyl-pyridin-2-ylmethyl)-1-(6-methyl-pyrimidin-4-yl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932018,CHEMBL2041183,"2-Methyl-4'-[8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1-(6-trifluoromethyl-pyrimidin-4-yl)-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cc(C(F)(F)F)ncn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932019,CHEMBL2041184,"2-Methyl-4'-[8-(3-methyl-pyridin-2-ylmethyl)-1-(2-methyl-pyrimidin-4-yl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1nccc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)n1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932020,CHEMBL2041186,"2-Methyl-4'-[1-(3-methyl-pyrazin-2-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3nccnc3C)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932021,CHEMBL2041187,"4'-[8-(3-Methyl-pyridin-2-ylmethyl)-2,4-dioxo-1-pyrimidin-2-yl-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1ncccn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932022,CHEMBL2041188,"2-Methyl-4'-[8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1-pyrimidin-2-yl-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3ncccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932023,CHEMBL2041189,"4'-[8-(3-Methyl-pyridin-2-ylmethyl)-2,4-dioxo-1-pyrazin-2-yl-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1cnccn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932024,CHEMBL2041190,"2-Methyl-4'-[8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1-pyrazin-2-yl-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cnccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932025,CHEMBL2041191,"3-Methyl-4-{5-[8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1-pyrazin-2-yl-1,3,8-triaza-spiro[4.5]dec-3-yl]-pyridin-2-yl}-benzoic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cnccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932026,CHEMBL2041192,"4'-[8-(3-Methyl-pyridin-2-ylmethyl)-2,4-dioxo-1-pyrimidin-4-yl-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1ccncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932027,CHEMBL2041193,"2-Methyl-4'-[8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1-pyrimidin-4-yl-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3ccncn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932158,CHEMBL2043327,"3-(4-Cyclohexyl-phenyl)-1-(6-hydroxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(C3CCCCC3)cc1)C(=O)N2c1cc(O)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932160,CHEMBL2043328,"1-(6-Hydroxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-3-[4-(2-oxo-azetidin-1-yl)-phenyl]-1,3,8-triaza-spiro[4.5]decane-2,4-dione",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(N3CCC3=O)cc1)C(=O)N2c1cc(O)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932162,CHEMBL2040894,"1-(6-Hydroxy-pyrimidin-4-yl)-3-[4-(5-methoxymethyl-[1,2,4]oxadiazol-3-yl)-phenyl]-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COCc1nc(-c2ccc(N3C(=O)N(c4cc(O)ncn4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)no1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932164,CHEMBL2040895,"1-(6-Hydroxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-3-(4-pyrazol-1-yl-phenyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-n3cccn3)cc1)C(=O)N2c1cc(O)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932166,CHEMBL2040896,"1-(6-Hydroxy-pyrimidin-4-yl)-3-(4-isoxazol-5-yl-phenyl)-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccno3)cc1)C(=O)N2c1cc(O)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932168,CHEMBL2040897,"3-[4-(2,4-Dimethyl-thiazol-5-yl)-phenyl]-1-(6-hydroxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1nc(C)c(-c2ccc(N3C(=O)N(c4cc(O)ncn4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)s1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932170,CHEMBL2041010,"5-{4-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-phenyl}-thiophene-2-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)s4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932172,CHEMBL2041164,"4-{4-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-phenyl}-thiophene-2-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4csc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932174,CHEMBL2041165,"4-{4-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-phenyl}-furan-2-carboxylic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4coc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932179,CHEMBL2041167,"1-(6-Hydroxy-pyrimidin-4-yl)-3-[4-(2-hydroxy-pyrimidin-5-yl)-phenyl]-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3cnc(O)nc3)cc1)C(=O)N2c1cc(O)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932181,CHEMBL2041168,"1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-3-[4'-(2H-pyrazol-3-yl)-biphenyl-4-yl]-1,3,8-triaza-spiro[4.5]decane-2,4-dione",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc(-c5ccn[nH]5)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932183,CHEMBL2041169,"1-(6-Hydroxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-3-[4'-(2H-pyrazol-3-yl)-biphenyl-4-yl]-1,3,8-triaza-spiro[4.5]decane-2,4-dione",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(-c4ccn[nH]4)cc3)cc1)C(=O)N2c1cc(O)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932185,CHEMBL2041170,"1-(6-hydroxypyrimidin-4-yl)-8-((3-methylpyridin-2-yl)methyl)-3-(4'-morpholinobiphenyl-4-yl)-1,3,8-triazaspiro[4.5]decane-2,4-dione",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(N4CCOCC4)cc3)cc1)C(=O)N2c1cc(O)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932188,CHEMBL2041171,"1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-3-[4'-(5-oxo-2,5-dihydro-1H-pyrazol-3-yl)-biphenyl-4-yl]-1,3,8-triaza-spiro[4.5]decane-2,4-dione",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc(-c5cc(=O)[nH][nH]5)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932191,CHEMBL2041172,"3-[4-(1H-Indazol-6-yl)-phenyl]-1-(6-methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc5cn[nH]c5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932193,CHEMBL2041173,"3-[4-(1H-Indazol-5-yl)-phenyl]-1-(6-methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,25000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc5[nH]ncc5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932195,CHEMBL2041174,"3-[4-(3H-Benzoimidazol-5-yl)-phenyl]-1-(6-methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,30000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc5nc[nH]c5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932197,CHEMBL2041175,"3-(4-Benzothiazol-5-yl-phenyl)-1-(6-hydroxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc4scnc4c3)cc1)C(=O)N2c1cc(O)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932199,CHEMBL2041176,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carbonitrile",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C#N)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932201,CHEMBL2041177,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid amide",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(N)=O)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932205,CHEMBL2041178,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid methylamide",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,44000.0,nM,CNC(=O)c1ccc(-c2ccc(N3C(=O)N(c4cc(OC)ncn4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)cc1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932207,CHEMBL2041179,"4'-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-biphenyl-4-carboxylic acid dimethylamide",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)N(C)C)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932209,CHEMBL2041180,"4-{5-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-pyridin-2-yl}-benzoic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4)nc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932211,CHEMBL2041181,"4-{5-[1-(6-Methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-pyridin-2-yl}-3-methyl-benzoic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)nc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10932213,CHEMBL2040854,"4-{5-[1-(6-Hydroxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl]-pyridin-2-yl}-3-methyl-benzoic acid",CHEMBL2046011,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cc(O)ncn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cn1,CHEMBL2040836,"1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.",J. Med. Chem.,2012.0,55,7,2945,2959,10.1021/jm201542d,22364528.0,
10935806,CHEMBL2048183,2-(2-(5-acetyl-2-methoxybenzylthio)-1H-benzo[d]imidazol-1-yl)acetic acid,CHEMBL2051630,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,24000.0,nM,COc1ccc(C(C)=O)cc1CSc1nc2ccccc2n1CC(=O)O,CHEMBL2046289,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,2012.0,22,14,4660,4664,10.1016/j.bmcl.2012.05.087,22726929.0,
10935807,CHEMBL2048187,2-(2-(5-acetyl-2-methoxybenzylthio)-5-fluoro-1H-benzo[d]imidazol-1-yl)acetic acid,CHEMBL2051630,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,COc1ccc(C(C)=O)cc1CSc1nc2cc(F)ccc2n1CC(=O)O,CHEMBL2046289,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,2012.0,22,14,4660,4664,10.1016/j.bmcl.2012.05.087,22726929.0,
10935808,CHEMBL2048199,2-(2-(5-(butylcarbamoyl)-2-methoxybenzylthio)-5-fluoro-1H-benzo[d]imidazol-1-yl)acetic acid,CHEMBL2051630,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,6000.0,nM,CCCCNC(=O)c1ccc(OC)c(CSc2nc3cc(F)ccc3n2CC(=O)O)c1,CHEMBL2046289,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,2012.0,22,14,4660,4664,10.1016/j.bmcl.2012.05.087,22726929.0,
10935809,CHEMBL2048204,2-(5-fluoro-2-(5-(indoline-1-carbonyl)-2-methoxybenzylthio)-1H-benzo[d]imidazol-1-yl)acetic acid,CHEMBL2051630,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2000.0,nM,COc1ccc(C(=O)N2CCc3ccccc32)cc1CSc1nc2cc(F)ccc2n1CC(=O)O,CHEMBL2046289,Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.,Bioorg. Med. Chem. Lett.,2012.0,22,14,4660,4664,10.1016/j.bmcl.2012.05.087,22726929.0,
10936800,CHEMBL2048846,N-methyl-N-(4-methylthiazol-2-yl)-2-(6-phenylpyridazin-3-ylthio)acetamide,CHEMBL2049720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,Cc1csc(N(C)C(=O)CSc2ccc(-c3ccccc3)nn2)n1,CHEMBL2046355,Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: development of a highly selective and more potent in vitro probe.,Bioorg. Med. Chem. Lett.,2012.0,22,14,4532,4535,10.1016/j.bmcl.2012.05.126,22727639.0,
10936801,CHEMBL2048855,N-cyclopropyl-N-(4-methylthiazol-2-yl)-2-(6-phenylpyridazin-3-ylthio)acetamide,CHEMBL2049720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,Cc1csc(N(C(=O)CSc2ccc(-c3ccccc3)nn2)C2CC2)n1,CHEMBL2046355,Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: development of a highly selective and more potent in vitro probe.,Bioorg. Med. Chem. Lett.,2012.0,22,14,4532,4535,10.1016/j.bmcl.2012.05.126,22727639.0,
10939115,CHEMBL2048028,"(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid",CHEMBL2051022,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3000.0,nM,CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1,CHEMBL2046303,Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.,ACS Med. Chem. Lett.,2012.0,3,3,203,206,10.1021/ml2002482,24900456.0,
10942088,CHEMBL2023898,daclatasvir,CHEMBL2050708,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,59500.0,nM,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C,CHEMBL2046362,Synthesis and evaluation of novel potent HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,2012.0,22,14,4864,4868,10.1016/j.bmcl.2012.05.039,22704887.0,
10942089,CHEMBL2047188,"dimethyl-(2S,2'S)-1,1'-((2S,2'S)-2,2'-(5,5'-(biphenyl-4,4'-diyl)bis(4-chloro-1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate",CHEMBL2050708,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,81600.0,nM,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(Cl)c(-c2ccc(-c3ccc(-c4[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)nc4Cl)cc3)cc2)[nH]1)C(C)C,CHEMBL2046362,Synthesis and evaluation of novel potent HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,2012.0,22,14,4864,4868,10.1016/j.bmcl.2012.05.039,22704887.0,
10942090,CHEMBL2047191,"dimethyl-(2S,2'S)-1,1'-((2S,2'S)-2,2'-(5,5'-(biphenyl-4,4'-diyl)bis(4-fluoro-1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate",CHEMBL2050708,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,100000.0,nM,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(F)c(-c2ccc(-c3ccc(-c4[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)nc4F)cc3)cc2)[nH]1)C(C)C,CHEMBL2046362,Synthesis and evaluation of novel potent HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,2012.0,22,14,4864,4868,10.1016/j.bmcl.2012.05.039,22704887.0,
10943865,CHEMBL2047879,"4-Amino-thieno[3,2-d]pyrimidine-7-carboxylic Acid [6-Chloro-2-fluoro-3-(3-fluoro-propane-1-sulfonylamino)-phenyl]-amide",CHEMBL2049548,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9000.0,nM,Nc1ncnc2c(C(=O)Nc3c(Cl)ccc(NS(=O)(=O)CCCF)c3F)csc12,CHEMBL2046386,Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.,J. Med. Chem.,2012.0,55,6,2869,2881,10.1021/jm300016v,22335519.0,
10948287,CHEMBL2048293,"rac-2-(7-(5-(3-cyano-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid",CHEMBL2050023,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,N#Cc1cc(OC(F)(F)F)cc(-c2nc(-c3ccc4c(c3)cc3n4CCC3CC(=O)O)no2)c1,CHEMBL2046302,Fused tricyclic indoles as S1P₁ agonists with robust efficacy in animal models of autoimmune disease.,Bioorg. Med. Chem. Lett.,2012.0,22,13,4404,4409,10.1016/j.bmcl.2012.04.129,22633692.0,
10957548,CHEMBL2059906,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(benzo[b]thiophen-3-yl)-1-oxopropan-2-yl)-2'-oxo-2',3'-dihydro-1'H-spiro[piperidine-4,4'-quinazoline]-1-carboxamide",CHEMBL2062039,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9,IC50,>,40000.0,nM,O=C1Nc2ccccc2C2(CCN(C(=O)N[C@H](Cc3csc4ccccc34)C(=O)N3CCC(N4CCCCC4)CC3)CC2)N1,CHEMBL2057200,Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor.,Bioorg. Med. Chem. Lett.,2012.0,22,14,4719,4722,10.1016/j.bmcl.2012.05.118,22732695.0,
10959049,CHEMBL2059517,"4-(3-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4-thiadiazol-3-yl)-2-ethylphenyl)butanoic acid",CHEMBL2061657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5011.87,nM,CCc1c(CCCC(=O)O)cccc1-c1nsc(-c2ccc(OC(C)C)c(C#N)c2)n1,CHEMBL2057096,"Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)).",J. Med. Chem.,2012.0,55,9,4286,4296,10.1021/jm2016107,22500954.0,
10959050,CHEMBL2059519,"4-(3-(5-(3-cyano-4-isopropoxyphenyl)-1,3,4-oxadiazol-2-yl)-2-ethylphenyl)butanoic acid",CHEMBL2061657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7943.28,nM,CCc1c(CCCC(=O)O)cccc1-c1nnc(-c2ccc(OC(C)C)c(C#N)c2)o1,CHEMBL2057096,"Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)).",J. Med. Chem.,2012.0,55,9,4286,4296,10.1021/jm2016107,22500954.0,
10959051,CHEMBL2059520,4-(3-(2-(3-cyano-4-isopropoxyphenyl)thiazol-5-yl)-2-ethylphenyl)butanoic acid,CHEMBL2061657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3981.07,nM,CCc1c(CCCC(=O)O)cccc1-c1cnc(-c2ccc(OC(C)C)c(C#N)c2)s1,CHEMBL2057096,"Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)).",J. Med. Chem.,2012.0,55,9,4286,4296,10.1021/jm2016107,22500954.0,
10959052,CHEMBL2059521,4-(3-(5-(3-cyano-4-isopropoxyphenyl)thiophen-2-yl)-2-ethylphenyl)butanoic acid,CHEMBL2061657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1584.89,nM,CCc1c(CCCC(=O)O)cccc1-c1ccc(-c2ccc(OC(C)C)c(C#N)c2)s1,CHEMBL2057096,"Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)).",J. Med. Chem.,2012.0,55,9,4286,4296,10.1021/jm2016107,22500954.0,
10959053,CHEMBL2059527,"4-(3''-cyano-2-ethyl-4''-isopropoxy-[1,1':4',1''-terphenyl]-3-yl)butanoic acid",CHEMBL2061657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3981.07,nM,CCc1c(CCCC(=O)O)cccc1-c1ccc(-c2ccc(OC(C)C)c(C#N)c2)cc1,CHEMBL2057096,"Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)).",J. Med. Chem.,2012.0,55,9,4286,4296,10.1021/jm2016107,22500954.0,
10959070,CHEMBL2059515,"4-(3-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-2-ethylphenyl)butanoic acid",CHEMBL2061657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CCc1c(CCCC(=O)O)cccc1-c1noc(-c2ccc(OC(C)C)c(C#N)c2)n1,CHEMBL2057096,"Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)).",J. Med. Chem.,2012.0,55,9,4286,4296,10.1021/jm2016107,22500954.0,
10959075,CHEMBL2059516,"4-(3-(5-(3-cyano-4-isopropoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-ethylphenyl)butanoic acid",CHEMBL2061657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CCc1c(CCCC(=O)O)cccc1-c1nnc(-c2ccc(OC(C)C)c(C#N)c2)s1,CHEMBL2057096,"Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)).",J. Med. Chem.,2012.0,55,9,4286,4296,10.1021/jm2016107,22500954.0,
10959158,CHEMBL2057282,"1-(3-(5-(3-Chloro-4-isopropoxyphenyl)-1,2,4-thiadiazol-3-yl)-2-ethylphenethyl)piperidine-4-carboxylic Acid",CHEMBL2061657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CCc1c(CCN2CCC(C(=O)O)CC2)cccc1-c1nsc(-c2ccc(OC(C)C)c(Cl)c2)n1,CHEMBL2057096,"Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)).",J. Med. Chem.,2012.0,55,9,4286,4296,10.1021/jm2016107,22500954.0,
10959171,CHEMBL2057285,"1-(3-(5-(3-Cyano-4-isobutylphenyl)-1,2,4-thiadiazol-3-yl)-2-ethylphenethyl)piperidine-4-carboxylic Acid",CHEMBL2061657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CCc1c(CCN2CCC(C(=O)O)CC2)cccc1-c1nsc(-c2ccc(CC(C)C)c(C#N)c2)n1,CHEMBL2057096,"Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)).",J. Med. Chem.,2012.0,55,9,4286,4296,10.1021/jm2016107,22500954.0,
10961564,CHEMBL2058833,"2-Amino-1-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone",CHEMBL2060829,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,6000.0,nM,CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN,CHEMBL2057141,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,J. Med. Chem.,2012.0,55,9,4244,4273,10.1021/jm300041e,22524250.0,
10963152,CHEMBL2057776,"(1-(isoquinolin-5-ylsulfonyl)azetidin-3-yl)(5-(pyridin-4-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methanone",CHEMBL2061623,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CPY2C9,IC50,<,2500.0,nM,O=C(C1CN(S(=O)(=O)c2cccc3cnccc23)C1)N1CC2CN(c3ccncc3)CC2C1,CHEMBL2057199,Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.,Bioorg. Med. Chem. Lett.,2012.0,22,15,5035,5040,10.1016/j.bmcl.2012.06.018,22749871.0,
10985787,CHEMBL2069579,(S)-3-(3-phenyl-2-(thiazol-4-ylmethylamino)propanamido)-5-(pyridin-4-yl)benzoic acid,CHEMBL2072141,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,O=C(O)c1cc(NC(=O)[C@H](Cc2ccccc2)NCc2cscn2)cc(-c2ccncc2)c1,CHEMBL2069182,Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.,Bioorg. Med. Chem. Lett.,2012.0,22,18,5942,5947,10.1016/j.bmcl.2012.07.063,22884988.0,
10987920,CHEMBL2069398,"(-)-1-(4-fluorophenyl)-4-(3-m-tolyl-1,2,4-oxadiazol-5-yl)pyrrolidin-2-one",CHEMBL2072735,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,11000.0,nM,Cc1cccc(-c2noc(C3CC(=O)N(c4ccc(F)cc4)C3)n2)c1,CHEMBL2069226,N-Aryl pyrrolidinonyl oxadiazoles as potent mGluR5 positive allosteric modulators.,Bioorg. Med. Chem. Lett.,2012.0,22,17,5658,5662,10.1016/j.bmcl.2012.06.094,22832311.0,
10989337,CHEMBL589135,"N-(2,4-dichlorobenzyl)-4-phenoxypiperidine-1-carboxamide",CHEMBL2072826,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1400.0,nM,O=C(NCc1ccc(Cl)cc1Cl)N1CCC(Oc2ccccc2)CC1,CHEMBL2069173,Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.,J. Med. Chem.,2012.0,55,5,1789,1808,10.1021/jm201468j,22168898.0,
10989338,CHEMBL589136,"N-(2,4-dichlorobenzyl)-4-(pyrimidin-2-yloxy)piperidine-1-carboxamide",CHEMBL2072826,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,20000.0,nM,O=C(NCc1ccc(Cl)cc1Cl)N1CCC(Oc2ncccn2)CC1,CHEMBL2069173,Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.,J. Med. Chem.,2012.0,55,5,1789,1808,10.1021/jm201468j,22168898.0,
10989339,CHEMBL608263,"4-(1-(2,4-dichlorobenzylcarbamoyl)piperidin-4-yloxy)benzoic acid",CHEMBL2072826,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,20000.0,nM,O=C(O)c1ccc(OC2CCN(C(=O)NCc3ccc(Cl)cc3Cl)CC2)cc1,CHEMBL2069173,Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.,J. Med. Chem.,2012.0,55,5,1789,1808,10.1021/jm201468j,22168898.0,
10989340,CHEMBL1085745,3-(pyridin-4-yl)-N-(2-(trifluoromethoxy)benzyl)pyrrolidine-1-carboxamide,CHEMBL2072826,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,300.0,nM,O=C(NCc1ccccc1OC(F)(F)F)N1CCC(c2ccncc2)C1,CHEMBL2069173,Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.,J. Med. Chem.,2012.0,55,5,1789,1808,10.1021/jm201468j,22168898.0,
10989566,CHEMBL1504335,SID24815875,CHEMBL2072912,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli,IC50,>,20000.0,nM,c1ccc(CN2CCN(Cc3nnc(-c4ccccc4)o3)CC2)cc1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10990159,CHEMBL2069806,"N-cyclohexyl-5-(phenylsulfonylmethyl)-1,3,4-oxadiazole-2-carboxamide",CHEMBL2072912,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli,IC50,>,20000.0,nM,O=C(NC1CCCCC1)c1nnc(CS(=O)(=O)c2ccccc2)o1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10990160,CHEMBL2069805,"N-cyclohexyl-3-(phenylsulfonylmethyl)-1,2,4-oxadiazole-5-carboxamide",CHEMBL2072912,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli,IC50,>,20000.0,nM,O=C(NC1CCCCC1)c1nc(CS(=O)(=O)c2ccccc2)no1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10990161,CHEMBL2069804,"2-cyclohexyl-5-(pyridin-4-yl)-1,3,4-oxadiazole",CHEMBL2072912,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli,IC50,>,20000.0,nM,c1cc(-c2nnc(C3CCCCC3)o2)ccn1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10990162,CHEMBL2069803,"5-cyclohexyl-3-(pyridin-4-yl)-1,2,4-oxadiazole",CHEMBL2072912,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli,IC50,=,17600.0,nM,c1cc(-c2noc(C3CCCCC3)n2)ccn1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10990163,CHEMBL2069802,"5-(phenylsulfonylmethyl)-N-(pyridin-4-ylmethyl)-1,3,4-oxadiazole-2-carboxamide",CHEMBL2072912,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli,IC50,=,1700.0,nM,O=C(NCc1ccncc1)c1nnc(CS(=O)(=O)c2ccccc2)o1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10990164,CHEMBL2069801,"3-(phenylsulfonylmethyl)-N-(pyridin-4-ylmethyl)-1,2,4-oxadiazole-5-carboxamide",CHEMBL2072912,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli,IC50,=,2200.0,nM,O=C(NCc1ccncc1)c1nc(CS(=O)(=O)c2ccccc2)no1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10990165,CHEMBL2069800,"2-(2-chloropyridin-4-yl)-5-((4-cyclopropyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,3,4-oxadiazole",CHEMBL2072912,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli,IC50,>,20000.0,nM,Clc1cc(-c2nnc(CSc3nnc(-c4ccncc4)n3C3CC3)o2)ccn1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10990166,CHEMBL2069799,"5-(2-chloropyridin-4-yl)-3-((4-cyclopropyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole",CHEMBL2072912,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli,IC50,>,20000.0,nM,Clc1cc(-c2nc(CSc3nnc(-c4ccncc4)n3C3CC3)no2)ccn1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10992779,CHEMBL2070937,"(1R,2R)-2-(4-(benzo[d]thiazol-2-yl)piperazine-1-carbonyl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide",CHEMBL2073643,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,31622.78,nM,N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc4ccccc4s3)CC2)CC1,CHEMBL2069241,Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.,Bioorg. Med. Chem. Lett.,2012.0,22,17,5563,5568,10.1016/j.bmcl.2012.07.012,22858142.0,
10992780,CHEMBL2070947,"(1R,2R)-N-(1-cyanocyclopropyl)-2-(4-(6-(methylsulfonyl)benzo[d]thiazol-2-yl)piperazine-1-carbonyl)cyclohexanecarboxamide",CHEMBL2073643,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7943.28,nM,CS(=O)(=O)c1ccc2nc(N3CCN(C(=O)[C@@H]4CCCC[C@H]4C(=O)NC4(C#N)CC4)CC3)sc2c1,CHEMBL2069241,Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.,Bioorg. Med. Chem. Lett.,2012.0,22,17,5563,5568,10.1016/j.bmcl.2012.07.012,22858142.0,
10992781,CHEMBL2070948,"(1R,2R)-N-(1-cyanocyclopropyl)-2-(4-(5-(2-cyanopropan-2-yl)thiazol-2-yl)piperazine-1-carbonyl)cyclohexanecarboxamide",CHEMBL2073643,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3162.28,nM,CC(C)(C#N)c1cnc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3(C#N)CC3)CC2)s1,CHEMBL2069241,Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.,Bioorg. Med. Chem. Lett.,2012.0,22,17,5563,5568,10.1016/j.bmcl.2012.07.012,22858142.0,
10992782,CHEMBL2070949,"(1R,2R)-N-(1-cyanocyclopropyl)-2-(4-(thiazolo[5,4-b]pyridin-2-yl)piperazine-1-carbonyl)cyclohexanecarboxamide",CHEMBL2073643,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,31622.78,nM,N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc4cccnc4s3)CC2)CC1,CHEMBL2069241,Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.,Bioorg. Med. Chem. Lett.,2012.0,22,17,5563,5568,10.1016/j.bmcl.2012.07.012,22858142.0,
10993643,CHEMBL2070131,N-(2-Fluorobenzyl)-5-methoxy-2-(pyridin-2-yl)pyrimidin-4-amine,CHEMBL2073271,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9,IC50,>=,5000.0,nM,COc1cnc(-c2ccccn2)nc1NCc1ccccc1F,CHEMBL2069291,Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors.,Bioorg. Med. Chem. Lett.,2012.0,22,17,5681,5684,10.1016/j.bmcl.2012.06.087,22853997.0,
10993644,CHEMBL2070133,"5-Methoxy-2-(pyridin-2-yl)-N-(2,4,6-trifluorobenzyl)pyrimidin-4-amine",CHEMBL2073271,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9,IC50,>=,5000.0,nM,COc1cnc(-c2ccccn2)nc1NCc1c(F)cc(F)cc1F,CHEMBL2069291,Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors.,Bioorg. Med. Chem. Lett.,2012.0,22,17,5681,5684,10.1016/j.bmcl.2012.06.087,22853997.0,
10993645,CHEMBL2070134,N-[4-Fluoro-2-(trifluoromethyl)benzyl]-5-methoxy-2-(pyridin-2-yl)pyrimidin-4-amine,CHEMBL2073271,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9,IC50,>=,5000.0,nM,COc1cnc(-c2ccccn2)nc1NCc1ccc(F)cc1C(F)(F)F,CHEMBL2069291,Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors.,Bioorg. Med. Chem. Lett.,2012.0,22,17,5681,5684,10.1016/j.bmcl.2012.06.087,22853997.0,
10993646,CHEMBL2070131,N-(2-Fluorobenzyl)-5-methoxy-2-(pyridin-2-yl)pyrimidin-4-amine,CHEMBL2073272,A,,Homo sapiens,Cytochrome P450 2C9,Time-dependent inhibition of CYP2C9,IC50,>=,5000.0,nM,COc1cnc(-c2ccccn2)nc1NCc1ccccc1F,CHEMBL2069291,Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors.,Bioorg. Med. Chem. Lett.,2012.0,22,17,5681,5684,10.1016/j.bmcl.2012.06.087,22853997.0,
10993647,CHEMBL2070133,"5-Methoxy-2-(pyridin-2-yl)-N-(2,4,6-trifluorobenzyl)pyrimidin-4-amine",CHEMBL2073272,A,,Homo sapiens,Cytochrome P450 2C9,Time-dependent inhibition of CYP2C9,IC50,>=,5000.0,nM,COc1cnc(-c2ccccn2)nc1NCc1c(F)cc(F)cc1F,CHEMBL2069291,Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors.,Bioorg. Med. Chem. Lett.,2012.0,22,17,5681,5684,10.1016/j.bmcl.2012.06.087,22853997.0,
10993648,CHEMBL2070134,N-[4-Fluoro-2-(trifluoromethyl)benzyl]-5-methoxy-2-(pyridin-2-yl)pyrimidin-4-amine,CHEMBL2073272,A,,Homo sapiens,Cytochrome P450 2C9,Time-dependent inhibition of CYP2C9,IC50,>=,5000.0,nM,COc1cnc(-c2ccccn2)nc1NCc1ccc(F)cc1C(F)(F)F,CHEMBL2069291,Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors.,Bioorg. Med. Chem. Lett.,2012.0,22,17,5681,5684,10.1016/j.bmcl.2012.06.087,22853997.0,
10994630,CHEMBL2070162,1-phenyl-3-(5-(propylsulfonyl)-1H-benzo[d]imidazol-2-yl)pyridin-4(1H)-one,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,20000.0,nM,CCCS(=O)(=O)c1ccc2[nH]c(-c3cn(-c4ccccc4)ccc3=O)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994631,CHEMBL2070161,"1-phenyl-5-(5-(2,2,2-trifluoroethylsulfonyl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one",CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,20000.0,nM,O=c1ccc(-c2nc3cc(S(=O)(=O)CC(F)(F)F)ccc3[nH]2)cn1-c1ccccc1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994632,CHEMBL2070160,1-phenyl-5-(5-(trifluoromethylsulfonyl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7500.0,nM,O=c1ccc(-c2nc3cc(S(=O)(=O)C(F)(F)F)ccc3[nH]2)cn1-c1ccccc1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994633,CHEMBL2070159,5-(5-(tert-butylsulfonyl)-1H-benzo[d]imidazol-2-yl)-1-phenylpyridin-2(1H)-one,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,20000.0,nM,CC(C)(C)S(=O)(=O)c1ccc2[nH]c(-c3ccc(=O)n(-c4ccccc4)c3)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994634,CHEMBL2070158,1-phenyl-5-(5-(propylsulfonyl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,20000.0,nM,CCCS(=O)(=O)c1ccc2[nH]c(-c3ccc(=O)n(-c4ccccc4)c3)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994635,CHEMBL2070157,5-(ethylsulfonyl)-2-(2-phenylpyridin-4-yl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,20000.0,nM,CCS(=O)(=O)c1ccc2[nH]c(-c3ccnc(-c4ccccc4)c3)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994636,CHEMBL2070156,5-(ethylsulfonyl)-2-(5-phenylpyridin-3-yl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9800.0,nM,CCS(=O)(=O)c1ccc2[nH]c(-c3cncc(-c4ccccc4)c3)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994637,CHEMBL2070155,5-(ethylsulfonyl)-2-(4-phenylpyridin-2-yl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,CCS(=O)(=O)c1ccc2[nH]c(-c3cc(-c4ccccc4)ccn3)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994638,CHEMBL2070154,5-(ethylsulfonyl)-2-(6-phenylpyridin-2-yl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,14000.0,nM,CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)n3)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994639,CHEMBL2069316,5-(ethylsulfonyl)-2-(6-methylbiphenyl-3-yl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,8300.0,nM,CCS(=O)(=O)c1ccc2[nH]c(-c3ccc(C)c(-c4ccccc4)c3)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994640,CHEMBL2070153,5-(ethylsulfonyl)-2-(4-methylbiphenyl-3-yl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,6800.0,nM,CCS(=O)(=O)c1ccc2[nH]c(-c3cc(-c4ccccc4)ccc3C)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994641,CHEMBL2070152,5-(ethylsulfonyl)-2-(2-methylbiphenyl-3-yl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4400.0,nM,CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3C)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994642,CHEMBL2070151,2-(6-chlorobiphenyl-3-yl)-5-(ethylsulfonyl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5400.0,nM,CCS(=O)(=O)c1ccc2[nH]c(-c3ccc(Cl)c(-c4ccccc4)c3)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994643,CHEMBL2070150,2-(4-chlorobiphenyl-3-yl)-5-(ethylsulfonyl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7100.0,nM,CCS(=O)(=O)c1ccc2[nH]c(-c3cc(-c4ccccc4)ccc3Cl)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994644,CHEMBL2070149,2-(2-chlorobiphenyl-3-yl)-5-(ethylsulfonyl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4000.0,nM,CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3Cl)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994645,CHEMBL2070148,5-(ethylsulfonyl)-2-(6-fluorobiphenyl-3-yl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9500.0,nM,CCS(=O)(=O)c1ccc2[nH]c(-c3ccc(F)c(-c4ccccc4)c3)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994646,CHEMBL2070147,5-(ethylsulfonyl)-2-(4-fluorobiphenyl-3-yl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,17000.0,nM,CCS(=O)(=O)c1ccc2[nH]c(-c3cc(-c4ccccc4)ccc3F)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994647,CHEMBL2070146,5-(ethylsulfonyl)-2-(2-fluorobiphenyl-3-yl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7200.0,nM,CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3F)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994648,CHEMBL2070137,2-(biphenyl-3-yl)-5-(ethylsulfonyl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9900.0,nM,CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994649,CHEMBL2070143,5-(propylsulfonyl)-2-(3-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,5600.0,nM,CCCS(=O)(=O)c1ccc2[nH]c(-c3cccc(OC(F)(F)F)c3)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994650,CHEMBL2070142,5-(propylsulfonyl)-2-(3-(trifluoromethyl)phenyl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,7400.0,nM,CCCS(=O)(=O)c1ccc2[nH]c(-c3cccc(C(F)(F)F)c3)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994651,CHEMBL2070141,2-(biphenyl-4-yl)-5-(propylsulfonyl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2400.0,nM,CCCS(=O)(=O)c1ccc2[nH]c(-c3ccc(-c4ccccc4)cc3)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994652,CHEMBL2070140,2-(biphenyl-3-yl)-5-(propylsulfonyl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9500.0,nM,CCCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994653,CHEMBL2070139,2-(biphenyl-2-yl)-5-(propylsulfonyl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4500.0,nM,CCCS(=O)(=O)c1ccc2[nH]c(-c3ccccc3-c3ccccc3)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994654,CHEMBL2070138,2-phenyl-5-(propylsulfonyl)-1H-benzo[d]imidazole,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9500.0,nM,CCCS(=O)(=O)c1ccc2[nH]c(-c3ccccc3)nc2c1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994655,CHEMBL1585484,SID22410576,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1500.0,nM,O=S(=O)(c1ccc2[nH]c(SCc3cccc(Cl)c3)nc2c1)N1CCOCC1,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
10994765,CHEMBL2070163,1-phenyl-3-(5-(propylsulfonyl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one hydrochloride,CHEMBL2073337,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,20000.0,nM,CCCS(=O)(=O)c1ccc2[nH]c(-c3cccn(-c4ccccc4)c3=O)nc2c1.Cl,CHEMBL2069245,"Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.",Bioorg. Med. Chem. Lett.,2012.0,22,17,5498,5502,10.1016/j.bmcl.2012.07.020,22853998.0,
11009497,CHEMBL2089032,"(2R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]propane-1,2-diol",CHEMBL2089679,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,5000.0,nM,CC(C)n1cnc2c(NCc3ccc(-c4ccccn4)cc3)nc(NC[C@@H](O)CO)nc21,CHEMBL2086256,Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.,Eur. J. Med. Chem.,2012.0,56,,210,216,10.1016/j.ejmech.2012.08.033,22982525.0,
11018924,CHEMBL2086690,"4-{[(2-{(2R)-2-Methyl-4-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]piperazin-1-yl}pyrimidin-5-yl)oxy]methyl}pyridine-3-carbonitrile",CHEMBL2089923,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 by high-throughput fluorescence assay,IC50,>,30000.0,nM,CC(C)c1nc(N2CCN(c3ncc(OCc4ccncc4C#N)cn3)[C@H](C)C2)no1,CHEMBL2086249,Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.,J. Med. Chem.,2012.0,55,11,5361,5379,10.1021/jm300310c,22545772.0,
12039585,CHEMBL520648,"2,4-dichloro-N-(((cis)-1-(cyclopropylmethyl)-4-(1-methyl-1H-1,2,3-triazol-4-ylsulfonyl)cyclohexyl)methyl)benzamide",CHEMBL2149627,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cn1cc(S(=O)(=O)[C@H]2CC[C@](CNC(=O)c3ccc(Cl)cc3Cl)(CC3CC3)CC2)nn1,CHEMBL2146383,"Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1.",ACS Med. Chem. Lett.,2010.0,1,7,350,354,10.1021/ml1001085,24900218.0,
12039586,CHEMBL2146710,"trans-N-((4-(1H-1,2,3-triazol-4-ylsulfonyl)-1-(cyclopropylmethyl)cyclohexyl)methyl)-2,4-dichlorobenzamide",CHEMBL2149627,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10.0,nM,O=C(NC[C@]1(CC2CC2)CC[C@@H](S(=O)(=O)c2c[nH]nn2)CC1)c1ccc(Cl)cc1Cl,CHEMBL2146383,"Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1.",ACS Med. Chem. Lett.,2010.0,1,7,350,354,10.1021/ml1001085,24900218.0,
12040413,CHEMBL2146750,(R)-2-(6-((R)-(4-fluorophenyl)(4-methylpiperidin-1-yl)methyl)-4'-(trifluoromethyl)biphenyl-3-yl)propanoic acid,CHEMBL2150360,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,35000.0,nM,CC1CCN([C@H](c2ccc(F)cc2)c2ccc([C@@H](C)C(=O)O)cc2-c2ccc(C(F)(F)F)cc2)CC1,CHEMBL2146445,"Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable γ-Secretase Modulator.",ACS Med. Chem. Lett.,2011.0,2,10,786,791,10.1021/ml200175q,24900267.0,
12044131,CHEMBL2147070,"2-[(3R)-3-aminopiperidin-1-yl]-3-(2-chloro-5-fluorobenzyl)-5-methyl-4-oxo-4,5-dihydro-3H-imidazo[4,5-c]-quinoline-7-carboxylic acid hydrochloride",CHEMBL2149446,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,Cl.Cn1c(=O)c2c(nc(N3CCC[C@@H](N)C3)n2Cc2cc(F)ccc2Cl)c2ccc(C(=O)O)cc21,CHEMBL2146411,"Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.",Bioorg. Med. Chem.,2012.0,20,19,5864,5883,10.1016/j.bmc.2012.07.046,22938786.0,
12056877,CHEMBL2152522,"(1S,2S)-1,2-diphenyl-1,2-di(piperidin-1-yl)ethane",CHEMBL2153972,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Escherichia coli,IC50,=,19952.62,nM,c1ccc([C@@H]([C@H](c2ccccc2)N2CCCCC2)N2CCCCC2)cc1,CHEMBL2150928,Symmetric kv1.5 blockers discovered by focused screening.,ACS Med. Chem. Lett.,2012.0,3,9,769,773,10.1021/ml3001787,24900546.0,
12056878,CHEMBL2152523,"(1R,2R)-1,2-diphenyl-1,2-di(piperidin-1-yl)ethane",CHEMBL2153972,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Escherichia coli,IC50,=,19952.62,nM,c1ccc([C@H]([C@@H](c2ccccc2)N2CCCCC2)N2CCCCC2)cc1,CHEMBL2150928,Symmetric kv1.5 blockers discovered by focused screening.,ACS Med. Chem. Lett.,2012.0,3,9,769,773,10.1021/ml3001787,24900546.0,
12056879,CHEMBL2152524,"(1S,2S)-1,2-diphenyl-1,2-di(pyrrolidin-1-yl)ethane",CHEMBL2153972,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Escherichia coli,IC50,=,19952.62,nM,c1ccc([C@@H]([C@H](c2ccccc2)N2CCCC2)N2CCCC2)cc1,CHEMBL2150928,Symmetric kv1.5 blockers discovered by focused screening.,ACS Med. Chem. Lett.,2012.0,3,9,769,773,10.1021/ml3001787,24900546.0,
12056880,CHEMBL2152525,"(1R,2R)-1,2-diphenyl-1,2-di(pyrrolidin-1-yl)ethane",CHEMBL2153972,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Escherichia coli,IC50,=,19952.62,nM,c1ccc([C@H]([C@@H](c2ccccc2)N2CCCC2)N2CCCC2)cc1,CHEMBL2150928,Symmetric kv1.5 blockers discovered by focused screening.,ACS Med. Chem. Lett.,2012.0,3,9,769,773,10.1021/ml3001787,24900546.0,
12060752,CHEMBL2152252,"3-Amino-6-(4-chloro-3-(N-(2,3-difluorophenyl)sulfamoyl)-phenyl)-N-methylpyrazine-2-carboxamide",CHEMBL2156887,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using tolbutamide as substrate after 15 mins by LC/MS/MS analysis,IC50,=,591.0,nM,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N,CHEMBL2150966,Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.,J. Med. Chem.,2012.0,55,11,5467,5482,10.1021/jm300403a,22548342.0,
12068090,CHEMBL2159210,"(1R,3R)-3-(2-Methylimidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexanol",CHEMBL2162418,A,,,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 using warfarin as substrate,IC50,>,10000.0,nM,Cc1nc2cnc3[nH]ccc3c2n1[C@@H]1CCC[C@@H](O)C1,CHEMBL2157937,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,J. Med. Chem.,2012.0,55,13,6176,6193,10.1021/jm300628c,22698084.0,
12071507,CHEMBL2159071,N-Methyl-N-(thiophen-2-ylmethyl)-1-p-tolylcyclopropanecarboxamide,CHEMBL2162044,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,4500.0,nM,Cc1ccc(C2(C(=O)N(C)Cc3cccs3)CC2)cc1,CHEMBL2157887,Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem.,2012.0,20,21,6394,6402,10.1016/j.bmc.2012.08.056,23040895.0,
12071513,CHEMBL2159084,N-Methyl-N-((1-methyl-1H-pyrrol-2-yl)-methyl)adamantane-1-carboxamide,CHEMBL2162044,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,CN(Cc1cccn1C)C(=O)C12CC3CC(CC(C3)C1)C2,CHEMBL2157887,Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem.,2012.0,20,21,6394,6402,10.1016/j.bmc.2012.08.056,23040895.0,
12073749,CHEMBL2158221,4-Cyano-1H-imidazole-2-carboxylic Acid(2-Cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide Trifluoroacetic Acid Salt,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4100.0,nM,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCNCC3)cc2C2=CCCCC2)n1.O=C(O)C(F)(F)F,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073750,CHEMBL2158222,"4-Cyano-1H-imidazole-2-carboxylic Acid[2-Cyclohex-1-enyl-4-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-phenyl]-amide",CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(c4ccccn4)CC3)cc2C2=CCCCC2)n1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073751,CHEMBL2158223,4-Cyano-1H-imidazole-2-carboxylic Acid{4-[1-(2-Cyanoethyl)-piperidin-4-yl]-2-cyclohex-1-enyl-phenyl}-amide,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,N#CCCN1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073752,CHEMBL2158224,4-Cyano-1H-imidazole-2-carboxylic Acid[2-Cyclohex-1-enyl-4-(1-pyridin-2-ylmethyl-piperidin-4-yl)-phenyl]-amide,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(Cc4ccccn4)CC3)cc2C2=CCCCC2)n1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073753,CHEMBL2158225,4-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(2-hydroxy-ethyl)-piperidin-4-yl]-phenyl}-amide,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(CCO)CC3)cc2C2=CCCCC2)[nH]1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073755,CHEMBL2158227,4-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(2-methanesulfonyl-ethyl)-piperidin-4-yl]-phenyl}-amide,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CS(=O)(=O)CCN1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073756,CHEMBL2158228,4-Cyano-1H-imidazole-2-carboxylic Acid[4-(1-Carbamoylmethyl-piperidin-4-yl)-2-cyclohex-1-enyl-phenyl]-amide,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(CC(N)=O)CC3)cc2C2=CCCCC2)n1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073758,CHEMBL2158230,4-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(2-morpholin-4-yl-ethyl)-piperidin-4-yl]-phenyl}-amide,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(CCN4CCOCC4)CC3)cc2C2=CCCCC2)[nH]1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073759,CHEMBL256712,N-(4-(1-acetylpiperidin-4-yl)-2-cyclohexenylphenyl)-5-cyano-1H-imidazole-2-carboxamide,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CC(=O)N1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)CC1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073760,CHEMBL2158231,4-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(pyridine-3-carbonyl)-piperidin-4-yl]-phenyl}-amide,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,540.0,nM,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)c4cccnc4)CC3)cc2C2=CCCCC2)n1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073761,CHEMBL1908842,4-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl}-amide,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073762,CHEMBL2158287,"5-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(R)-(+)-(2,3-dihydroxy-propionyl)-piperidin-4-yl]-phenyl}-amide",CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)[C@H](O)CO)CC3)cc2C2=CCCCC2)n1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073767,CHEMBL2158292,4-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(1-oxy-pyridine-4-carbonyl)-piperidin-4-yl]-phenyl}-amide,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)c4cc[n+]([O-])cc4)CC3)cc2C2=CCCCC2)n1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073768,CHEMBL2158293,4-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(2-1H-imidazol-4-yl-acetyl)-piperidin-4-yl]-phenyl}-amide,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,330.0,nM,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)Cc4c[nH]cn4)CC3)cc2C2=CCCCC2)n1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073772,CHEMBL2158297,4-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(2-pyridin-4-yl-acetyl)-piperidin-4-yl]-phenyl}-amide,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)Cc4ccncc4)CC3)cc2C2=CCCCC2)n1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073773,CHEMBL2158298,4-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(3-morpholin-4-yl-propionyl)-piperidin-4-yl]-phenyl}-amide,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)CCN4CCOCC4)CC3)cc2C2=CCCCC2)n1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073774,CHEMBL2158299,4-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(2-morpholin-4-yl-acetyl)-piperidin-4-yl]-phenyl}-amide,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)CN4CCOCC4)CC3)cc2C2=CCCCC2)n1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073776,CHEMBL2158301,5-Cyano-1H-imidazole-2-carboxylic Acid{4-[1-(2-Amino-2-methyl-propionyl)-piperidin-4-yl]-2-cyclohex-1-enyl-phenyl}-amide,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CC(C)(N)C(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12073777,CHEMBL2158302,4-{4-[(4-Cyano-1H-imidazole-2-carbonyl)-amino]-3-cyclohex-1-enyl-phenyl}-piperidine-1-carboxylic Acid(2-Hydroxy-ethyl)-amide,CHEMBL2160395,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)NCCO)CC3)cc2C2=CCCCC2)n1,CHEMBL2157860,Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).,J. Med. Chem.,2011.0,54,22,7860,7883,10.1021/jm200900q,22039836.0,
12077458,CHEMBL1933349,"(S)-3-(4-(1-(3-(3,5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl)ethyl)benzamido)propanoic acid",CHEMBL2160812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 in liver microsomes assessed as diclofenac 4'-hydroxylation after 48 hrs,IC50,=,14000.0,nM,COc1ccc2cc(-c3cc(-c4cc(Cl)cc(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1,CHEMBL2157898,"Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.",J. Med. Chem.,2012.0,55,13,6137,6148,10.1021/jm300579z,22708876.0,
12082232,CHEMBL1939222,"5-((3,5-dichlorophenoxy)methyl)-1H-pyrazol-3(2H)-one",CHEMBL2167212,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,50000.0,nM,O=c1cc(COc2cc(Cl)cc(Cl)c2)[nH][nH]1,CHEMBL2163259,ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.,J. Med. Chem.,2012.0,55,1,515,527,10.1021/jm2014277,22191331.0,
12085854,CHEMBL2164048,(S)-2-Phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide,CHEMBL2169307,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,18900.0,nM,CC[C@H](C(=O)Nc1ccccc1N1CCCC1)c1ccccc1,CHEMBL2163245,"Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.",J. Med. Chem.,2012.0,55,15,6975,6979,10.1021/jm300700v,22793372.0,
12086614,CHEMBL2164422,"4-(2-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-N-(2-hydroxyethyl)benzenesulfonamide",CHEMBL2166005,A,,,Cytochrome P450 2C9,inhibition of CYP2C9,IC50,=,7000.0,nM,O=S(=O)(NCCO)c1ccc(-c2ccnc3[nH]c(C4CC4)cc23)cc1,CHEMBL2163232,"4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy.",Bioorg. Med. Chem. Lett.,2012.0,22,16,5222,5226,10.1016/j.bmcl.2012.06.065,22801646.0,
12093576,CHEMBL2163365,"2-amino-6-bromo-7-(trifluoromethyl)-1,8-naphthyridine-3-carboxamide",CHEMBL2166643,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,50000.0,nM,NC(=O)c1cc2cc(Br)c(C(F)(F)F)nc2nc1N,CHEMBL2163244,"Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity.",Bioorg. Med. Chem. Lett.,2012.0,22,21,6705,6711,10.1016/j.bmcl.2012.08.094,23006603.0,
12094756,CHEMBL2165189,(S)-6-((2-hydroxyethyl)(naphthalen-1-ylmethyl)amino)-4-(2-methylmorpholino)pyrimidin-2(1H)-one,CHEMBL2167600,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4000.0,nM,C[C@H]1CN(c2cc(N(CCO)Cc3cccc4ccccc34)[nH]c(=O)n2)CCO1,CHEMBL2163325,"Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance.",Bioorg. Med. Chem. Lett.,2012.0,22,21,6671,6676,10.1016/j.bmcl.2012.08.102,23010262.0,
12094757,CHEMBL2165175,6-(2-methylpyridin-4-yl)-2-(naphthalen-1-ylmethylamino)pyrimidin-4(3H)-one,CHEMBL2167600,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,400.0,nM,Cc1cc(-c2cc(=O)[nH]c(NCc3cccc4ccccc34)n2)ccn1,CHEMBL2163325,"Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance.",Bioorg. Med. Chem. Lett.,2012.0,22,21,6671,6676,10.1016/j.bmcl.2012.08.102,23010262.0,
12099429,CHEMBL2001019,SID103905666,CHEMBL2175023,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,5000.0,nM,OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1,CHEMBL2169886,"Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.",J. Med. Chem.,2012.0,55,18,8091,8109,10.1021/jm300967g,22924734.0,
12102571,CHEMBL586213,TCMDC-139046,CHEMBL2173015,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using 7-methoxy-4-triflouromethylcoumarin-3-acetic acid as substrate incubated for 30 mins prior to substrate addition measured up to 10 mins by fluorimetry,IC50,=,2000.0,nM,COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(OC(F)(F)F)cc(-c3cccnc3)c1)CC2,CHEMBL2169755,A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.,ACS Med. Chem. Lett.,2012.0,3,5,373,377,10.1021/ml300008j,24900481.0,
12108692,CHEMBL2170747,"2,6-Difluoro-3-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide",CHEMBL2173692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,54000.0,nM,O=C(Nc1nc2ccc(O)cc2s1)c1c(F)ccc(O)c1F,CHEMBL2169876,Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17β-HSD1.,J. Med. Chem.,2012.0,55,5,2469,2473,10.1021/jm201711b,22277094.0,
12108696,CHEMBL2170754,"(4-Methyl-3-hydroxyphenyl)(6-hydroxy-1,3-benzothiazol-2-yl)methanone",CHEMBL2173692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,54000.0,nM,Cc1ccc(C(=O)c2nc3ccc(O)cc3s2)cc1O,CHEMBL2169876,Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17β-HSD1.,J. Med. Chem.,2012.0,55,5,2469,2473,10.1021/jm201711b,22277094.0,
12108697,CHEMBL2170750,"(4-Fluoro-3-hydroxyphenyl)(6-hydroxy-1,3-benzothiazol-2-yl)methanone",CHEMBL2173692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,54000.0,nM,O=C(c1ccc(F)c(O)c1)c1nc2ccc(O)cc2s1,CHEMBL2169876,Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17β-HSD1.,J. Med. Chem.,2012.0,55,5,2469,2473,10.1021/jm201711b,22277094.0,
12111290,CHEMBL2170062,4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine,CHEMBL2173606,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,10000.0,nM,Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1,CHEMBL2169838,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",J. Med. Chem.,2012.0,55,19,8211,8224,10.1021/jm3007323,22784008.0,
12111298,CHEMBL2170062,4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine,CHEMBL2173610,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1,CHEMBL2169838,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",J. Med. Chem.,2012.0,55,19,8211,8224,10.1021/jm3007323,22784008.0,
12113775,CHEMBL2170610,N-[4-(1-Acetyl-piperidin-4-yl)-3-trifluoromethyl-benzoyl]-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12113776,CHEMBL2170609,N-[4-(1-Propionyl-piperidin-4-yl)-3-trifluoromethyl-benzoyl]-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,21000.0,nM,CCC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12113777,CHEMBL2170608,N-{4-[1-(2-Methoxy-acetyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,25000.0,nM,COCC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12113778,CHEMBL2170607,N-[4-(1-Cyclopropanecarbonyl-piperidin-4-yl)-3-trifluoromethylbenzoyl]-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,6000.0,nM,N=C(N)NC(=O)c1ccc(C2CCN(C(=O)C3CC3)CC2)c(C(F)(F)F)c1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12113779,CHEMBL2170606,N-[4-(1-Isobutyryl-piperidin-4-yl)-3-trifluoromethyl-benzoyl]-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,7000.0,nM,CC(C)C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12113780,CHEMBL2170605,"N-{4-[1-(2,2-Dimethyl-propionyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine",CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,17000.0,nM,CC(C)(C)C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12114164,CHEMBL2170294,"6-[(6R)-2-(4-Fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)-pyridazin-3(2H)-one",CHEMBL2172902,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,19000.0,nM,Cc1ccccc1-n1nc(-c2c(-c3ccc(F)cc3)nn3c2NC[C@@H](CO)C3)ccc1=O,CHEMBL2169749,"Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor.",J. Med. Chem.,2012.0,55,17,7772,7785,10.1021/jm3008008,22905713.0,
12114795,CHEMBL2170618,N-{4-[1-(3-Methyl-3H-imidazole-4-carbonyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,25000.0,nM,Cn1cncc1C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12114796,CHEMBL2170617,N-{4-[1-(1-Methyl-1H-imidazole-2-carbonyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,18000.0,nM,Cn1ccnc1C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12114797,CHEMBL2170615,N-{4-[1-(4-Sulfamoyl-benzoyl)-piperidin-4-yl]-3-trifluoromethylbenzoyl}-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,16000.0,nM,N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccc(S(N)(=O)=O)cc3)CC2)c(C(F)(F)F)c1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12114798,CHEMBL2170639,N-{4-[1-(6-Hydroxy-pyridine-3-carbonyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,29000.0,nM,N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccc(O)nc3)CC2)c(C(F)(F)F)c1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12114799,CHEMBL2170638,4-[4-(4-Guanidinocarbonyl-2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-benzamide,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,4000.0,nM,N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccc(C(N)=O)cc3)CC2)c(C(F)(F)F)c1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12114800,CHEMBL2170637,N-{4-[1-(Pyridine-2-carbonyl)-piperidin-4-yl]-3-trifluoromethylbenzoyl}-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,3000.0,nM,N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccccn3)CC2)c(C(F)(F)F)c1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12114801,CHEMBL2170636,N-{4-[1-(Pyridine-3-carbonyl)-piperidin-4-yl]-3-trifluoromethylbenzoyl}-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,13000.0,nM,N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3cccnc3)CC2)c(C(F)(F)F)c1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12114802,CHEMBL2170635,N-{4-[1-(Pyridine-4-carbonyl)-piperidin-4-yl]-3-trifluoromethylbenzoyl}-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,400.0,nM,N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccncc3)CC2)c(C(F)(F)F)c1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12114803,CHEMBL2170633,N-{4-[1-(3-Methylsulfonyl-benzoyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,CS(=O)(=O)c1cccc(C(=O)N2CCC(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)c1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12114804,CHEMBL2170632,N-{4-[1-(4-Methylsulfonyl-benzoyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,CS(=O)(=O)c1ccc(C(=O)N2CCC(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)cc1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12114805,CHEMBL2170631,N-{4-[1-(2-Cyano-benzoyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,4000.0,nM,N#Cc1ccccc1C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12114806,CHEMBL2170630,N-{4-[1-(3-Cyano-benzoyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,19000.0,nM,N#Cc1cccc(C(=O)N2CCC(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)c1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12114807,CHEMBL2170629,N-{4-[1-(4-Cyano-benzoyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,13000.0,nM,N#Cc1ccc(C(=O)N2CCC(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)cc1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12114808,CHEMBL2170643,N-{4-[1-(4-Fluoro-benzoyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,8000.0,nM,N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccc(F)cc3)CC2)c(C(F)(F)F)c1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12114809,CHEMBL2170642,N-[4-(1-Benzoyl-piperidin-4-yl)-3-trifluoromethyl-benzoyl]-guanidine,CHEMBL2173431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate after 45 mins by LC/MS/MS analysis,IC50,=,7000.0,nM,N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccccc3)CC2)c(C(F)(F)F)c1,CHEMBL2169836,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,J. Med. Chem.,2012.0,55,16,7114,7140,10.1021/jm300601d,22803959.0,
12135996,CHEMBL2177588,"(3S,4R)-4-(4-((E)-3-(2-aminophenylamino)-3-oxoprop-1-enyl)phenyl)-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide",CHEMBL2182316,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH by LC-MS/MS method,IC50,=,23000.0,nM,CN1C[C@@H](C(=O)Nc2ccc(Cl)cc2)[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)C1,CHEMBL2177000,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,J. Med. Chem.,2012.0,55,20,8903,8925,10.1021/jm3011838,23061376.0,
12135997,CHEMBL2177582,"rac-(trans-3,4)-4-{4-[2-(2-Amino-phenylcarbamoyl)-vinyl]-2-fluoro-phenyl}-1-methyl-pyrrolidine-3-carboxylic acid(4-chloro-phenyl)-amide",CHEMBL2182316,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH by LC-MS/MS method,IC50,=,13000.0,nM,CN1C[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2F)[C@@H](C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL2177000,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,J. Med. Chem.,2012.0,55,20,8903,8925,10.1021/jm3011838,23061376.0,
12135998,CHEMBL2178223,"rac-(trans-3,4)-4-{4-[(E)-2-(2-Amino-phenylcarbamoyl)-vinyl]-phenyl}-1-(2-hydroxy-2-methyl-propyl)-pyrrolidine-3-carboxylic acid(4-chloro-phenyl)-amide",CHEMBL2182316,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH by LC-MS/MS method,IC50,=,4000.0,nM,CC(C)(O)CN1C[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)[C@@H](C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL2177000,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,J. Med. Chem.,2012.0,55,20,8903,8925,10.1021/jm3011838,23061376.0,
12135999,CHEMBL2178221,"rac-(trans-3,4)-4-{4-[(E)-2-(2-Amino-phenylcarbamoyl)-vinyl]-phenyl}-1-(2-hydroxy-ethyl)-pyrrolidine-3-carboxylic acid(4-chloro-phenyl)-amide",CHEMBL2182316,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH by LC-MS/MS method,IC50,=,3000.0,nM,Nc1ccccc1NC(=O)/C=C/c1ccc([C@H]2CN(CCO)C[C@@H]2C(=O)Nc2ccc(Cl)cc2)cc1,CHEMBL2177000,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,J. Med. Chem.,2012.0,55,20,8903,8925,10.1021/jm3011838,23061376.0,
12136000,CHEMBL2177587,"(3R,4S)-4-{4-[(E)-2-(2-Amino-phenylcarbamoyl)-vinyl]-phenyl}-1-methyl-pyrrolidine-3-carboxylic acid(4-chloro-phenyl)-amide",CHEMBL2182316,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH by LC-MS/MS method,IC50,=,29000.0,nM,CN1C[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)[C@@H](C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL2177000,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,J. Med. Chem.,2012.0,55,20,8903,8925,10.1021/jm3011838,23061376.0,
12136842,CHEMBL2177777,"1-Methylethyl 4-({7-[2-Fluoro-4-(methylsulfonyl)phenyl]-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)-1-piperidinecarboxylate",CHEMBL2188569,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,3000.0,nM,CC(C)OC(=O)N1CCC(Oc2ncnc3c2CCN3c2ccc(S(C)(=O)=O)cc2F)CC1,CHEMBL2176966,"Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists.",J. Med. Chem.,2012.0,55,24,10972,10994,10.1021/jm301404a,23214471.0,
12139886,CHEMBL2178718,"3-(5-((4aR,7aR)-6-(5-Fluoropyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-1H-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-3-yl)benzonitrile",CHEMBL2183474,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 preincubated with substrate,IC50,=,30000.0,nM,CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O,CHEMBL2177036,Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation.,J. Med. Chem.,2012.0,55,21,9331,9345,10.1021/jm301039c,22989333.0,
12139893,CHEMBL2178718,"3-(5-((4aR,7aR)-6-(5-Fluoropyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-1H-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-3-yl)benzonitrile",CHEMBL2183481,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 coincubated with substrate,IC50,=,22400.0,nM,CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O,CHEMBL2177036,Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation.,J. Med. Chem.,2012.0,55,21,9331,9345,10.1021/jm301039c,22989333.0,
12140162,CHEMBL2178254,"5-amino-N-(3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide",CHEMBL2186605,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cn1cc(NC(=O)c2cnn3ccc(N)nc23)c(-c2cccc(Cl)c2)n1,CHEMBL2176876,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,2012.0,55,22,10090,10107,10.1021/jm3012239,23061660.0,
12140163,CHEMBL2178252,"N-(3-(3-Chlorophenyl)-1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]-pyrimidine-3-carboxamide",CHEMBL2186605,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cn1cc(NC(=O)c2cnn3cccnc23)c(-c2cccc(Cl)c2)n1,CHEMBL2176876,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,2012.0,55,22,10090,10107,10.1021/jm3012239,23061660.0,
12140164,CHEMBL2178251,"N-(4-(3-chlorophenyl)-1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide",CHEMBL2186605,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cn1cc(-c2cccc(Cl)c2)c(NC(=O)c2cnn3cccnc23)n1,CHEMBL2176876,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,2012.0,55,22,10090,10107,10.1021/jm3012239,23061660.0,
12140165,CHEMBL2178250,"N-(5-(3-chlorophenyl)-2-methylpyridin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide",CHEMBL2186605,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,Cc1cc(NC(=O)c2cnn3cccnc23)c(-c2cccc(Cl)c2)cn1,CHEMBL2176876,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,2012.0,55,22,10090,10107,10.1021/jm3012239,23061660.0,
12140166,CHEMBL2178248,"N-(2-(3-Chlorophenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide",CHEMBL2186605,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,O=C(Nc1cccnc1-c1cccc(Cl)c1)c1cnn2cccnc12,CHEMBL2176876,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,2012.0,55,22,10090,10107,10.1021/jm3012239,23061660.0,
12140286,CHEMBL2178247,"N-(1-(3-Chlorophenyl)-3-methyl-1H-pyrazol-5-yl)-5-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide",CHEMBL2186605,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CNc1ccn2ncc(C(=O)Nc3cc(C)nn3-c3cccc(Cl)c3)c2n1,CHEMBL2176876,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,2012.0,55,22,10090,10107,10.1021/jm3012239,23061660.0,
12140292,CHEMBL2178807,"5-Amino-N-(1-(3-chlorophenyl)-3-methyl-1H-pyrazol-5-yl)-pyrazolo[1,5-a]pyrimidine-3-carboxamide",CHEMBL2186605,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,5000.0,nM,Cc1cc(NC(=O)c2cnn3ccc(N)nc23)n(-c2cccc(Cl)c2)n1,CHEMBL2176876,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,J. Med. Chem.,2012.0,55,22,10090,10107,10.1021/jm3012239,23061660.0,
12142191,CHEMBL2179319,"3-Cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine",CHEMBL2186477,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,11000.0,nM,FC(F)(F)c1c(N2CCC(c3ccccc3)CC2)ccn2c(CC3CC3)nnc12,CHEMBL2176880,"Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor.",J. Med. Chem.,2012.0,55,20,8770,8789,10.1021/jm3010724,23072213.0,
12142811,CHEMBL2178422,"(5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-Oxo-2,3-dihydro-1H-imidazo-[4,5-b]pyridin-1-yl)piperidine-1-carboxylate",CHEMBL2183283,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using 7-methoxy-4-trifluoromethylcoumarin as substrate after 45 mins by fluorescence assay,IC50,>=,20000.0,nM,N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F,CHEMBL2176923,"Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine.",J. Med. Chem.,2012.0,55,23,10644,10651,10.1021/jm3013147,23153230.0,
12145217,CHEMBL2177831,"N-(4-(2-(2-Aminopyridin-3-yl)-6-(pyridin-3-yl)-3H-imidazo-[4,5-b]pyridin-3-yl)benzyl)benzamide",CHEMBL2186636,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 10 mins,IC50,>,10000.0,nM,Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1,CHEMBL2176970,"Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.",J. Med. Chem.,2012.0,55,11,5291,5310,10.1021/jm300276x,22533986.0,
12145218,CHEMBL2177819,"N-(4-(2-(2-Aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)benzamide",CHEMBL2186636,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 10 mins,IC50,>,10000.0,nM,Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1,CHEMBL2176970,"Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.",J. Med. Chem.,2012.0,55,11,5291,5310,10.1021/jm300276x,22533986.0,
12145219,CHEMBL2177818,"2-(4-(2-(2-Aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3-yl)phenyl)-N-phenylacetamide",CHEMBL2186636,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 10 mins,IC50,>,10000.0,nM,Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1,CHEMBL2176970,"Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.",J. Med. Chem.,2012.0,55,11,5291,5310,10.1021/jm300276x,22533986.0,
12145320,CHEMBL2177836,"N-(4-(5-(3-Acetamidophenyl)-2-(2-aminopyridin-3-yl)-3Himidazo[4,5-b]pyridin-3-yl)benzyl)-3-fluorobenzamide",CHEMBL2186636,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 10 mins,IC50,=,1000.0,nM,CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1,CHEMBL2176970,"Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.",J. Med. Chem.,2012.0,55,11,5291,5310,10.1021/jm300276x,22533986.0,
12145855,CHEMBL1651219,"3-Chloro-3'-((2-cyclopentyl-3-oxo-2,3-dihydrobenzo[d]isothiazol-6-yloxy)methyl)biphenyl-4-carboxylic Acid",CHEMBL2183560,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,4000.0,nM,O=C(O)c1cc(-c2cccc(COc3ccc4c(=O)n(C5CCCC5)sc4c3)c2)ccc1Cl,CHEMBL2177081,Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence.,J. Med. Chem.,2012.0,55,22,9434,9445,10.1021/jm3005306,23009245.0,
12145857,CHEMBL1651208,4-Chloro-3'-((2-cyclopentyl-1-oxoisoindolin-5-yloxy)methyl)-biphenyl-3-carboxylic Acid,CHEMBL2183560,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,8200.0,nM,O=C(O)c1cc(-c2cccc(COc3ccc4c(c3)CN(C3CCCC3)C4=O)c2)ccc1Cl,CHEMBL2177081,Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence.,J. Med. Chem.,2012.0,55,22,9434,9445,10.1021/jm3005306,23009245.0,
12147440,CHEMBL2151164,2-(4-fluorophenyl)-N-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-1-methyl-1H-benzo[d]imidazol-4-amine,CHEMBL2186746,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate,IC50,=,21900.0,nM,COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1,CHEMBL2176900,Design and synthesis of a novel series of bicyclic heterocycles as potent γ-secretase modulators.,J. Med. Chem.,2012.0,55,21,9089,9106,10.1021/jm201710f,22650177.0,
12148341,CHEMBL2180528,(R)-N-(1-(4-(4-Chlorophenyl)piperidin-1-yl)-3-methyl-1-oxobutan-2-yl)benzamide,CHEMBL2184933,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 expressed in baculovirus-infected insect cells using fluorogeinc substrate,IC50,>,40000.0,nM,CC(C)[C@@H](NC(=O)c1ccccc1)C(=O)N1CCC(c2ccc(Cl)cc2)CC1,CHEMBL2176935,Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.,J. Med. Chem.,2012.0,55,22,9643,9653,10.1021/jm300896d,23075267.0,
12150723,CHEMBL2178953,"{trans-4-[4-(6-Carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl}acetic Acid",CHEMBL2183579,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,30000.0,nM,Cc1nc(C)c(-c2ccc([C@H]3CC[C@H](CC(=O)O)CC3)cc2)nc1C(N)=O,CHEMBL2176918,Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687).,J. Med. Chem.,2012.0,55,23,10610,10629,10.1021/jm301296t,23116186.0,
12151266,CHEMBL2035187,pacritinib,CHEMBL2183772,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as decrease in formation of 4-hydroxytolbutamide from tolbutamide substrate after 60 mins by LC-MS/MS,IC50,>,5000.0,nM,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,CHEMBL2176955,"Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.",J. Med. Chem.,2011.0,54,13,4638,4658,10.1021/jm200326p,21604762.0,
12163620,CHEMBL457,"5-(2,5-Dimethyl-phenoxy)-2,2-dimethyl-pentanoic acid (gemfibrozil)",CHEMBL2185185,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes,IC50,=,9600.0,nM,Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1,CHEMBL2176960,Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.,J. Med. Chem.,2012.0,55,11,4896,4933,10.1021/jm300065h,22409598.0,
12163801,CHEMBL2017291,"7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one",CHEMBL2187898,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9900.0,nM,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12,CHEMBL2176882,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,2012.0,22,8,2968,2972,10.1016/j.bmcl.2012.02.041,22437115.0,
12163802,CHEMBL2017288,"7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-((R)-1-phenylethyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one",CHEMBL2187898,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1000.0,nM,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccc3)c12,CHEMBL2176882,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,2012.0,22,8,2968,2972,10.1016/j.bmcl.2012.02.041,22437115.0,
12163803,CHEMBL2017286,"7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-(pyridin-2-ylmethyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one",CHEMBL2187898,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,9800.0,nM,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccn3)c12,CHEMBL2176882,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,2012.0,22,8,2968,2972,10.1016/j.bmcl.2012.02.041,22437115.0,
12163804,CHEMBL2017285,"1-benzyl-7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1H-imidazo[4,5-c]quinolin-2(3H)-one",CHEMBL2187898,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,1200.0,nM,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccc3)c12,CHEMBL2176882,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,2012.0,22,8,2968,2972,10.1016/j.bmcl.2012.02.041,22437115.0,
12163805,CHEMBL2017283,"1-(2-tert-butylphenyl)-7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1H-imidazo[4,5-c]quinolin-2(3H)-one",CHEMBL2187898,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,900.0,nM,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3C(C)(C)C)c12,CHEMBL2176882,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,2012.0,22,8,2968,2972,10.1016/j.bmcl.2012.02.041,22437115.0,
12163806,CHEMBL2017277,"4-(cyclohexylamino)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxyquinoline-3-carboxamide",CHEMBL2187898,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,4300.0,nM,COc1cc2c(NC3CCCCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C,CHEMBL2176882,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,2012.0,22,8,2968,2972,10.1016/j.bmcl.2012.02.041,22437115.0,
12163807,CHEMBL2017281,"7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-4-(quinolin-8-ylamino)quinoline-3-carboxamide",CHEMBL2187898,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,2800.0,nM,COc1cc2c(Nc3cccc4cccnc34)c(C(N)=O)cnc2cc1-c1c(C)noc1C,CHEMBL2176882,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,2012.0,22,8,2968,2972,10.1016/j.bmcl.2012.02.041,22437115.0,
12163808,CHEMBL2017273,"7-(3,5-dimethylisoxazol-4-yl)-4-(2-fluorophenylamino)-6-methoxyquinoline-3-carboxamide",CHEMBL2187898,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,600.0,nM,COc1cc2c(Nc3ccccc3F)c(C(N)=O)cnc2cc1-c1c(C)noc1C,CHEMBL2176882,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,2012.0,22,8,2968,2972,10.1016/j.bmcl.2012.02.041,22437115.0,
12163809,CHEMBL2017269,"4-(2-tert-butylphenylamino)-7-(3,5-dimethylisoxazol-4-yl)quinoline-3-carboxylic acid",CHEMBL2187898,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,10000.0,nM,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(=O)O)cnc2c1,CHEMBL2176882,Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).,Bioorg. Med. Chem. Lett.,2012.0,22,8,2968,2972,10.1016/j.bmcl.2012.02.041,22437115.0,
12168398,CHEMBL2204363,1-[2-(2-Chloro-4-methyl-phenylsulfanyl)-phenyl]-piperazine Hydrochloride,CHEMBL2215827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using dibenzylfluorescein after 45 mins by fluorescence spectrophotometric analysis,IC50,=,40000.0,nM,Cc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1.Cl,CHEMBL2203036,"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.",J. Med. Chem.,2011.0,54,9,3206,3221,10.1021/jm101459g,21486038.0,
12168399,CHEMBL2204360,"1-[2-(2,4-Dimethyl-phenylsulfanyl)-phenyl]-piperazine Hydrochloride",CHEMBL2215827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using dibenzylfluorescein after 45 mins by fluorescence spectrophotometric analysis,IC50,=,39000.0,nM,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1.Cl,CHEMBL2203036,"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.",J. Med. Chem.,2011.0,54,9,3206,3221,10.1021/jm101459g,21486038.0,
12168400,CHEMBL2204359,"1-[2-(2,4-Dichloro-phenylsulfanyl)-phenyl]-piperazine Hydrochloride",CHEMBL2215827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using dibenzylfluorescein after 45 mins by fluorescence spectrophotometric analysis,IC50,=,34000.0,nM,Cl.Clc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1,CHEMBL2203036,"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.",J. Med. Chem.,2011.0,54,9,3206,3221,10.1021/jm101459g,21486038.0,
12168401,CHEMBL2204357,"1-[2-(2,3-Dimethyl-phenylsulfanyl)-phenyl]-piperazine Hydrochloride",CHEMBL2215827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using dibenzylfluorescein after 45 mins by fluorescence spectrophotometric analysis,IC50,=,40000.0,nM,Cc1cccc(Sc2ccccc2N2CCNCC2)c1C.Cl,CHEMBL2203036,"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.",J. Med. Chem.,2011.0,54,9,3206,3221,10.1021/jm101459g,21486038.0,
12168402,CHEMBL2204356,"1-[2-(2,3-Dichloro-phenylsulfanyl)-phenyl]-piperazine Hydrochloride",CHEMBL2215827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using dibenzylfluorescein after 45 mins by fluorescence spectrophotometric analysis,IC50,=,40000.0,nM,Cl.Clc1cccc(Sc2ccccc2N2CCNCC2)c1Cl,CHEMBL2203036,"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.",J. Med. Chem.,2011.0,54,9,3206,3221,10.1021/jm101459g,21486038.0,
12168403,CHEMBL2205054,"1-[2-(3,4-Dimethyl-phenylsulfanyl)-phenyl]-piperazine Hydrochloride",CHEMBL2215827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using dibenzylfluorescein after 45 mins by fluorescence spectrophotometric analysis,IC50,=,34000.0,nM,Cc1ccc(Sc2ccccc2N2CCNCC2)cc1C.Cl,CHEMBL2203036,"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.",J. Med. Chem.,2011.0,54,9,3206,3221,10.1021/jm101459g,21486038.0,
12168404,CHEMBL2205045,1-(2-p-Tolylsulfanyl-phenyl)-piperazine hydrochloride,CHEMBL2215827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using dibenzylfluorescein after 45 mins by fluorescence spectrophotometric analysis,IC50,=,40000.0,nM,Cc1ccc(Sc2ccccc2N2CCNCC2)cc1.Cl,CHEMBL2203036,"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.",J. Med. Chem.,2011.0,54,9,3206,3221,10.1021/jm101459g,21486038.0,
12168405,CHEMBL2205043,1-[2-(4-Chloro-phenylsulfanyl)-phenyl]-piperazine hydrochloride,CHEMBL2215827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using dibenzylfluorescein after 45 mins by fluorescence spectrophotometric analysis,IC50,=,31000.0,nM,Cl.Clc1ccc(Sc2ccccc2N2CCNCC2)cc1,CHEMBL2203036,"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.",J. Med. Chem.,2011.0,54,9,3206,3221,10.1021/jm101459g,21486038.0,
12175411,CHEMBL2207503,"6-Chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine",CHEMBL2214082,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 by LC-MS-MS analysis,IC50,>,10000.0,nM,Cc1nn(C)cc1-c1nc2c(N3CCN(Cc4ccc(Cl)cc4)CC3)c(Cl)cnc2[nH]1,CHEMBL2203264,"Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.",J. Med. Chem.,2012.0,55,20,8721,8734,10.1021/jm300952s,23043539.0,
12175907,CHEMBL2206278,"N-(4-(3-(5-tert-Butylisoxazol-3-yl)ureido)phenyl)-5-(1-ethyl-2,2,6,6-tetramethylpiperidin-4-yloxy)picolinamide",CHEMBL2213404,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,40000.0,nM,CCN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C,CHEMBL2203000,"Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases.",ACS Med. Chem. Lett.,2012.0,3,12,997,1002,10.1021/ml300214g,24900421.0,
12177058,CHEMBL2206277,"N-(4-(3-(5-tert-Butylisoxazol-3-yl)ureido)phenyl)-5-(1,2,2,6,6-pentamethylpiperidin-4-yloxy)picolinamide",CHEMBL2213404,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,40000.0,nM,CN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C,CHEMBL2203000,"Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases.",ACS Med. Chem. Lett.,2012.0,3,12,997,1002,10.1021/ml300214g,24900421.0,
12177059,CHEMBL2203434,N-(4-(3-(5-tert-Butylisoxazol-3-yl)ureido)phenyl)-5-(1-ethylpiperidin-4-yloxy)picolinamide,CHEMBL2213404,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,40000.0,nM,CCN1CCC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1,CHEMBL2203000,"Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases.",ACS Med. Chem. Lett.,2012.0,3,12,997,1002,10.1021/ml300214g,24900421.0,
12184272,CHEMBL2207081,"3,4-dichloro-N-[5-chloro-2-(1H-1,2,3-triazol-1-ylmethyl)phenyl]benzenesulfonamide",CHEMBL2212598,A,,,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,630.96,nM,O=S(=O)(Nc1cc(Cl)ccc1Cn1ccnn1)c1ccc(Cl)c(Cl)c1,CHEMBL2202966,In vivo activity of an azole series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,2012.0,22,23,7252,7255,10.1016/j.bmcl.2012.09.020,23079519.0,
12184283,CHEMBL2207100,"N-(2-((1H-1,2,3-triazol-1-yl)methyl)-4,5-dichlorophenyl)-5-chlorothiophene-2-sulfonamide",CHEMBL2212598,A,,,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,1258.93,nM,O=S(=O)(Nc1cc(Cl)c(Cl)cc1Cn1ccnn1)c1ccc(Cl)s1,CHEMBL2202966,In vivo activity of an azole series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,2012.0,22,23,7252,7255,10.1016/j.bmcl.2012.09.020,23079519.0,
12184289,CHEMBL2207099,"3,4-dichloro-N-{5-chloro-2-[(1-methyl-1H-tetrazol-5-yl)methyl]-3-pyridinyl}benzenesulfonamide",CHEMBL2212598,A,,,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9,IC50,=,1584.89,nM,Cn1nnnc1Cc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1,CHEMBL2202966,In vivo activity of an azole series of CCR2 antagonists.,Bioorg. Med. Chem. Lett.,2012.0,22,23,7252,7255,10.1016/j.bmcl.2012.09.020,23079519.0,
12184983,CHEMBL2204445,(R)-(3-(hydroxymethyl)piperidin-1-yl)(4-((4-methoxyphenyl)ethynyl)phenyl)methanone,CHEMBL2213664,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,COc1ccc(C#Cc2ccc(C(=O)N3CCC[C@@H](CO)C3)cc2)cc1,CHEMBL2203026,"Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM.",Bioorg. Med. Chem. Lett.,2012.0,22,12,3921,3925,10.1016/j.bmcl.2012.04.112,22607673.0,
12185280,CHEMBL2205775,"methyl-2,2-dimethyl-3-(4-(phenylamino)phenyl)-3-(1H-1,2,4-triazol-1-yl)propanoate",CHEMBL2214475,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,9100.0,nM,COC(=O)C(C)(C)C(c1ccc(Nc2ccccc2)cc1)n1cncn1,CHEMBL2203049,"Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.",Bioorg. Med. Chem.,2012.0,20,14,4201,4207,10.1016/j.bmc.2012.05.076,22727372.0,
12186419,CHEMBL2204469,"2-(3-((1-(2,4-Difluorobenzyl)-6-oxo-1,6-dihydropyridazin-3-yl)methyl)-5-fluoro-2-methyl-1H-indol-1-yl)acetic Acid",CHEMBL2209440,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,=,16000.0,nM,Cc1c(Cc2ccc(=O)n(Cc3ccc(F)cc3F)n2)c2cc(F)ccc2n1CC(=O)O,CHEMBL2203126,"Diazine indole acetic acids as potent, selective, and orally bioavailable antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases.",J. Med. Chem.,2012.0,55,11,5088,5109,10.1021/jm300007n,22651823.0,
12196691,CHEMBL2206059,"exo-N-((1-((1R,2R,4S)-bicyclo[2.2.1]heptan-2-yl)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl)methyl)methanesulfonamide",CHEMBL2214827,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,IC50,>,10000.0,nM,CS(=O)(=O)NCc1nc2cnc3[nH]ccc3c2n1[C@@H]1C[C@H]2CC[C@@H]1C2,CHEMBL2203155,Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.,Bioorg. Med. Chem. Lett.,2012.0,22,24,7627,7633,10.1016/j.bmcl.2012.10.008,23107482.0,
12615705,CHEMBL2315243,"(19S,22R)-N-[(4-carbamimidoylphenyl)methyl]-3,12,21-trioxo-22-(phenylmethane)sulfonamido-2,6,9,13,20-pentaazatetracyclo[22.2.2.2^{6,9}.2^{14,17}]dotriaconta-1(26),14,16,24,27,29-hexaene-19-carboxamide; trifluoroacetic acid",CHEMBL2318288,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Trichoplusia ni BTI-TN-5B1-4 cells preincubated for 15 mins measured after 45 mins by spectrofluorimetry,IC50,>,100000.0,nM,N=C(N)c1ccc(CNC(=O)[C@@H]2Cc3ccc(cc3)NC(=O)CCN3CCN(CCC(=O)Nc4ccc(cc4)C[C@@H](NS(=O)(=O)Cc4ccccc4)C(=O)N2)CC3)cc1.O=C(O)C(F)(F)F,CHEMBL2311491,Development of new cyclic plasmin inhibitors with excellent potency and selectivity.,J. Med. Chem.,2013.0,56,3,820,831,10.1021/jm3012917,23294255.0,
12615706,CHEMBL2315239,"(17S,20R)-N-[(4-carbamimidoylphenyl)methyl]-3,10,19-trioxo-20-(phenylmethane)sulfonamido-2,5,8,11,18-pentaazatetracyclo[20.2.2.2^{5,8}.2^{12,15}]triaconta-1(24),12,14,22,25,27-hexaene-17-carboxamide; trifluoroacetic acid",CHEMBL2318288,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Trichoplusia ni BTI-TN-5B1-4 cells preincubated for 15 mins measured after 45 mins by spectrofluorimetry,IC50,>,100000.0,nM,N=C(N)c1ccc(CNC(=O)[C@@H]2Cc3ccc(cc3)NC(=O)CN3CCN(CC3)CC(=O)Nc3ccc(cc3)C[C@@H](NS(=O)(=O)Cc3ccccc3)C(=O)N2)cc1.O=C(O)C(F)(F)F,CHEMBL2311491,Development of new cyclic plasmin inhibitors with excellent potency and selectivity.,J. Med. Chem.,2013.0,56,3,820,831,10.1021/jm3012917,23294255.0,
12618431,CHEMBL2316386,N-(Cyclobutylmethyl)-6-[2-(2-hydroxyethoxy)ethoxy]-3-({4-[(methylsulfinyl)methyl]-1-naphthoyl}amino)pyridine-2-carboxamide,CHEMBL2320437,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Escherichia coli cells,IC50,=,6700.0,nM,C[S+]([O-])Cc1ccc(C(=O)Nc2ccc(OCCOCCO)nc2C(=O)NCC2CCC2)c2ccccc12,CHEMBL2311293,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,2013.0,56,1,220,240,10.1021/jm301511h,23227781.0,
12618432,CHEMBL2316385,N-(Cyclobutylmethyl)-3-({4-[(methylsulfinyl)methyl]-1-naphthoyl}amino)pyrazine-2-carboxamide,CHEMBL2320437,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Escherichia coli cells,IC50,>,20000.0,nM,C[S+]([O-])Cc1ccc(C(=O)Nc2nccnc2C(=O)NCC2CCC2)c2ccccc12,CHEMBL2311293,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,2013.0,56,1,220,240,10.1021/jm301511h,23227781.0,
12618433,CHEMBL2316383,3-({4-[(Methylsulfinyl)methyl]-1-naphthoyl}amino)-N-(tetrahydro-2H-pyran-4-ylmethyl)pyridine-2-carboxamide,CHEMBL2320437,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Escherichia coli cells,IC50,=,19000.0,nM,C[S+]([O-])Cc1ccc(C(=O)Nc2cccnc2C(=O)NCC2CCOCC2)c2ccccc12,CHEMBL2311293,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,2013.0,56,1,220,240,10.1021/jm301511h,23227781.0,
12618434,CHEMBL2316382,6-Methoxy-3-({4-[(methylsulfinyl)methyl]-1-naphthoyl}-amino)-N-(tetrahydro-2H-pyran-4-ylmethyl)pyridine-2-carboxamide,CHEMBL2320437,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Escherichia coli cells,IC50,=,1600.0,nM,COc1ccc(NC(=O)c2ccc(C[S+](C)[O-])c3ccccc23)c(C(=O)NCC2CCOCC2)n1,CHEMBL2311293,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,2013.0,56,1,220,240,10.1021/jm301511h,23227781.0,
12618435,CHEMBL2316379,"N-[(Tetrahydro-2H-pyran-4-yl)methyl]-3-[[[4-(1H-1,2,3-triazol-1-ylmethyl)-1-naphthalenyl]carbonyl]amino]-2-pyridinecarboxamide",CHEMBL2320437,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Escherichia coli cells,IC50,=,660.0,nM,O=C(NCC1CCOCC1)c1ncccc1NC(=O)c1ccc(Cn2ccnn2)c2ccccc12,CHEMBL2311293,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,2013.0,56,1,220,240,10.1021/jm301511h,23227781.0,
12618436,CHEMBL2316378,"6-Methoxy-N-(tetrahydro-2H-pyran-4-ylmethyl)-3-{[4-(1H-1,2,3-triazol-1-ylmethyl)-1-naphthoyl]amino}pyridine-2-carboxamide",CHEMBL2320437,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in Escherichia coli cells,IC50,=,110.0,nM,COc1ccc(NC(=O)c2ccc(Cn3ccnn3)c3ccccc23)c(C(=O)NCC2CCOCC2)n1,CHEMBL2311293,Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.,J. Med. Chem.,2013.0,56,1,220,240,10.1021/jm301511h,23227781.0,
12621448,CHEMBL2316582,"3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-benzamide",CHEMBL2318534,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 after 30 mins,IC50,=,110.0,nM,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1,CHEMBL2311339,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,J. Med. Chem.,2013.0,56,3,879,894,10.1021/jm301581y,23301703.0,
12624948,CHEMBL2312555,"(R)-10-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)-5-(3,4,5-trifluorophenyl)-4,5,7,8,9,10-hexahydro-3H-pyrido[2,1-c][1,2,4]oxadiazepine",CHEMBL2318740,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,COc1cc(/C=C2\CCCN3C2=NOCC[C@@H]3c2cc(F)c(F)c(F)c2)ccc1-n1cnc(C)c1,CHEMBL2311347,The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer's disease.,Bioorg. Med. Chem. Lett.,2013.0,23,2,466,471,10.1016/j.bmcl.2012.11.055,23253441.0,
12630103,CHEMBL2313764,"((2R,3aR)-2-((3S)-3-methoxytetrahydro-2H-pyran-4-ylamino)octahydropentalen-3a-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone",CHEMBL2318181,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,10000.0,nM,CO[C@@H]1COCC[C@@H]1N[C@@H]1C[C@H]2CCC[C@@]2(C(=O)N2CCc3ncc(C(F)(F)F)cc3C2)C1,CHEMBL2311289,Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists.,Bioorg. Med. Chem. Lett.,2013.0,23,1,351,354,10.1016/j.bmcl.2012.10.069,23182090.0,
12631076,CHEMBL592675,Silybin B,CHEMBL2320747,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in pooled human liver microsomes assessed as reduction in enzyme-mediated (S)-warfarin 7-hydroxylation by HPLC/MS-MS method,IC50,=,8200.0,nM,COc1cc([C@@H]2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3O[C@H]2CO)ccc1O,CHEMBL2311246,Enhanced bioactivity of silybin B methylation products.,Bioorg. Med. Chem.,2013.0,21,3,742,747,10.1016/j.bmc.2012.11.035,23260576.0,
12648374,CHEMBL2322875,1-(4-(4-chloro-3-methoxyphenyl)piperazin-1-yl)-2-(4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)ethanone,CHEMBL2328656,A,,Homo sapiens,Cytochrome P450 2C9,Competitive inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,COc1cc(N2CCN(C(=O)Cn3nc(C(F)(F)F)c(Cl)c3C)CC2)ccc1Cl,CHEMBL2321873,1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.,Bioorg. Med. Chem. Lett.,2013.0,23,5,1228,1231,10.1016/j.bmcl.2013.01.005,23374868.0,
12650043,CHEMBL2323775,"C-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-pyridin-2-ylmethyl-methanesulfonamide",CHEMBL2327571,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,14730.0,nM,Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1,CHEMBL2321765,"Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met.",J. Med. Chem.,2013.0,56,6,2294,2310,10.1021/jm301619u,23379595.0,
12651457,CHEMBL2324491,"N-((4,4-difluoro-1-(4-(propylsulfonyl)piperazin-1-yl)cyclohexyl)methyl)-2,6-difluorobenzamide",CHEMBL2327741,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCCS(=O)(=O)N1CCN(C2(CNC(=O)c3c(F)cccc3F)CCC(F)(F)CC2)CC1,CHEMBL2321762,"Design, synthesis, and SAR of N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1.",Bioorg. Med. Chem. Lett.,2013.0,23,5,1257,1261,10.1016/j.bmcl.2013.01.006,23380375.0,
12659365,CHEMBL1907089,"3,4-Difluoro-N-(2-(1-(3-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-8yl)ethyl)benzamide",CHEMBL2330313,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,O=C(NCCN1CCC2(CC1)C(=O)NCN2c1cccc(F)c1)c1ccc(F)c(F)c1,CHEMBL2321744,"Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells.",J. Med. Chem.,2013.0,56,6,2695,2699,10.1021/jm301782e,23445448.0,
12659366,CHEMBL2325485,"(S)-4-bromo-N-(1-(4-oxo-1-m-tolyl-1,3,8-triazaspiro[4.5]decan-8-yl)propan-2-yl)benzamide",CHEMBL2330313,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,13300.0,nM,Cc1cccc(N2CNC(=O)C23CCN(C[C@H](C)NC(=O)c2ccc(Br)cc2)CC3)c1,CHEMBL2321744,"Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells.",J. Med. Chem.,2013.0,56,6,2695,2699,10.1021/jm301782e,23445448.0,
12660172,CHEMBL2325940,"cis-3-(8-amino-1-(2-methoxy-4-phenoxyphenyl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol",CHEMBL2329224,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,COc1cc(Oc2ccccc2)ccc1-c1nc([C@H]2C[C@@](C)(O)C2)n2ccnc(N)c12,CHEMBL2321683,"Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.",Bioorg. Med. Chem. Lett.,2013.0,23,4,979,984,10.1016/j.bmcl.2012.12.042,23317569.0,
12660501,CHEMBL2325697,4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)-cyclopropyl]pyrimidi-2-yl}-1H-indole,CHEMBL2330569,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1,CHEMBL2321758,Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity.,J. Med. Chem.,2013.0,56,5,2125,2138,10.1021/jm301859s,23394205.0,
12679610,CHEMBL2331648,"2-(ethylamino)-6-(3-(4-(trifluoromethoxy)phenyl)propanoyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-4-carboxamide",CHEMBL2339907,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,CCNc1nc2c(c(C(N)=O)n1)CN(C(=O)CCc1ccc(OC(F)(F)F)cc1)CC2,CHEMBL2331085,"Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists.",ACS Med. Chem. Lett.,2013.0,4,1,63,68,10.1021/ml300277t,24900564.0,
12681657,CHEMBL2336410,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(7-methyl-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide hydrochloride",CHEMBL2344715,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12.Cl,CHEMBL2331184,The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.,Bioorg. Med. Chem. Lett.,2013.0,23,6,1870,1873,10.1016/j.bmcl.2013.01.011,23402880.0,
12700587,CHEMBL2337981,"N-((1-(2-(3-tert-butylureido)ethyl)-4-(hydroxymethyl)piperidin-4-yl)methyl)-3,5-dichlorobenzamide",CHEMBL2344003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,10000.0,nM,CC(C)(C)NC(=O)NCCN1CCC(CO)(CNC(=O)c2cc(Cl)cc(Cl)c2)CC1,CHEMBL2331553,"Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor.",Bioorg. Med. Chem. Lett.,2013.0,23,1,119,124,10.1016/j.bmcl.2012.10.140,23200256.0,
12702840,CHEMBL2338343,"rac-cis(4aS,5R,10bS)-9-(isopentyloxy)-5-(tetrahydro-2H-pyran-4-yl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinoline",CHEMBL2342704,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,5000.0,nM,CC(C)CCOc1ccc2c(c1)[C@H]1OCCC[C@H]1[C@@H](C1CCOCC1)N2,CHEMBL2331108,"Synthesis and biological evaluation of a new series of hexahydro-2H-pyrano[3,2-c]quinolines as novel selective σ1 receptor ligands.",J. Med. Chem.,2013.0,56,9,3656,3665,10.1021/jm400181k,23560650.0,
12703049,CHEMBL2332055,"4-(4-(2-Pivalamidoethyl)piperidin-1-yl)thieno[3,2-d]pyrimidine-6-carboxamide",CHEMBL2343145,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,7200.0,nM,CC(C)(C)C(=O)NCCC1CCN(c2ncnc3cc(C(N)=O)sc23)CC1,CHEMBL2331260,"Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3.",J. Med. Chem.,2013.0,56,9,3666,3679,10.1021/jm400204k,23570514.0,
12703646,CHEMBL2331747,"(S)-1-(1-(3-(3-chlorophenoxy)-4-hydroxyphenylsulfonyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione",CHEMBL2342064,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,Cc1cn([C@H]2CCCN(S(=O)(=O)c3ccc(O)c(Oc4cccc(Cl)c4)c3)C2)c(=O)[nH]c1=O,CHEMBL2331361,"Sulfonylpiperidines as novel, antibacterial inhibitors of Gram-positive thymidylate kinase (TMK).",Bioorg. Med. Chem. Lett.,2013.0,23,1,169,173,10.1016/j.bmcl.2012.10.128,23206863.0,
12705952,CHEMBL2332068,3-(4-(1H-Pyrazol-4-yl)phenyl)-1-(2-(dimethylamino)ethyl)-1-(3-methoxybenzyl)urea,CHEMBL2341170,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated tolbutamide hydroxylation to hydroxy tolbutamide,IC50,=,30000.0,nM,COc1cccc(CN(CCN(C)C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1,CHEMBL2331531,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,2013.0,56,9,3568,3581,10.1021/jm400062r,23570561.0,
12706039,CHEMBL2332065,3-(4-(1H-Pyrazol-4-yl)phenyl)-1-(2-hydroxyethyl)-1-(3-methoxybenzyl)urea,CHEMBL2341170,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated tolbutamide hydroxylation to hydroxy tolbutamide,IC50,=,2000.0,nM,COc1cccc(CN(CCO)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1,CHEMBL2331531,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,2013.0,56,9,3568,3581,10.1021/jm400062r,23570561.0,
12706070,CHEMBL2332097,3-(4-(1H-Pyrazol-4-yl)phenyl)-1-(3-methoxybenzyl)-1-methylurea,CHEMBL2341170,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated tolbutamide hydroxylation to hydroxy tolbutamide,IC50,=,600.0,nM,COc1cccc(CN(C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1,CHEMBL2331531,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,2013.0,56,9,3568,3581,10.1021/jm400062r,23570561.0,
12717262,CHEMBL2347997,"N-tert-butyl-2-(6-methoxy-1H-indazol-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide",CHEMBL2350845,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,8000.0,nM,COc1ccc2cnn(-c3cnc4[nH]cc(C(=O)NC(C)(C)C)c4n3)c2c1,CHEMBL2346624,Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,2013.0,56,4,1677,1692,10.1021/jm301720p,23350847.0,
12717263,CHEMBL2347988,"N-tert-butyl-2-(5-(difluoromethoxy)-1-(3,4-dihydroxybutyl)-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide",CHEMBL2350845,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8000.0,nM,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(CCC(O)CO)c4ccc(OC(F)F)cc34)nc12,CHEMBL2346624,Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,2013.0,56,4,1677,1692,10.1021/jm301720p,23350847.0,
12717264,CHEMBL2347418,"N-tert-butyl-2-(5-(difluoromethoxy)-1-(3-morpholinopropyl)-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide",CHEMBL2350845,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,4000.0,nM,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(CCCN4CCOCC4)c4ccc(OC(F)F)cc34)nc12,CHEMBL2346624,Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,2013.0,56,4,1677,1692,10.1021/jm301720p,23350847.0,
12717265,CHEMBL2347417,"N-tert-butyl-2-(1-(3-(3-cyanoazetidin-1-yl)propyl)-5-(difluoromethoxy)-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide",CHEMBL2350845,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5000.0,nM,CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(CCCN4CC(C#N)C4)c4ccc(OC(F)F)cc34)nc12,CHEMBL2346624,Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,2013.0,56,4,1677,1692,10.1021/jm301720p,23350847.0,
12717266,CHEMBL2347413,"cis-N-(3-amino-1-methylcyclobutyl)-2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide",CHEMBL2350845,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,4000.0,nM,Cn1nc(-c2cnc3[nH]cc(C(=O)N[C@]4(C)C[C@H](N)C4)c3n2)c2ccc(F)cc21,CHEMBL2346624,Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,2013.0,56,4,1677,1692,10.1021/jm301720p,23350847.0,
12717267,CHEMBL2348850,"N-isopropyl-2-(3,4,5-trimethoxyphenyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide",CHEMBL2350845,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,16000.0,nM,COc1cc(-c2cnc3[nH]cc(C(=O)NC(C)C)c3n2)cc(OC)c1OC,CHEMBL2346624,Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.,J. Med. Chem.,2013.0,56,4,1677,1692,10.1021/jm301720p,23350847.0,
12719356,CHEMBL2347208,"N-(3-((4S,6S)-2-Amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide",CHEMBL2353193,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,25000.0,nM,C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C[C@@H](C(F)(F)F)OC(N)=N1,CHEMBL2346595,β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.,J. Med. Chem.,2013.0,56,10,3980,3995,10.1021/jm400225m,23590342.0,
12721454,CHEMBL2347337,methyl(S)-1-((S)-2-(5-(4'-(hydroxymethyl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate,CHEMBL2350276,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,31200.0,nM,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(CO)cc3)cc2)[nH]1)C(C)C,CHEMBL2346553,Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,7,2031,2034,10.1016/j.bmcl.2013.02.023,23466233.0,
12721455,CHEMBL2347328,methyl(S)-3-methyl-1-oxo-1-((S)-2-(5-(4'-(trifluoromethyl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)butan-2-ylcarbamate,CHEMBL2350276,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,9100.0,nM,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(C(F)(F)F)cc3)cc2)[nH]1)C(C)C,CHEMBL2346553,Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,7,2031,2034,10.1016/j.bmcl.2013.02.023,23466233.0,
12721456,CHEMBL2347323,methyl(S)-1-((S)-2-(5-(4-azidophenyl)-4-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate,CHEMBL2350276,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,50500.0,nM,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(Br)c(-c2ccc(N=[N+]=[N-])cc2)[nH]1)C(C)C,CHEMBL2346553,Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,7,2031,2034,10.1016/j.bmcl.2013.02.023,23466233.0,
12721457,CHEMBL2347159,methyl(S)-1-((S)-2-(5-(4-azidophenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate,CHEMBL2350276,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(N=[N+]=[N-])cc2)[nH]1)C(C)C,CHEMBL2346553,Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,7,2031,2034,10.1016/j.bmcl.2013.02.023,23466233.0,
12721458,CHEMBL2023898,daclatasvir,CHEMBL2350276,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,59500.0,nM,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C,CHEMBL2346553,Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,7,2031,2034,10.1016/j.bmcl.2013.02.023,23466233.0,
12729597,CHEMBL2348780,"(8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one",CHEMBL2351336,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL2346557,"VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.",Bioorg. Med. Chem.,2013.0,21,8,2241,2249,10.1016/j.bmc.2013.02.009,23498916.0,
13285786,CHEMBL2376562,2-(4-methylphenylsulfonamido)-4-phenoxybenzoic acid,CHEMBL2379478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3100.0,nM,Cc1ccc(S(=O)(=O)Nc2cc(Oc3ccccc3)ccc2C(=O)O)cc1,CHEMBL2375335,Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,9,2585,2589,10.1016/j.bmcl.2013.02.110,23545108.0,
13285803,CHEMBL2375371,2-(4-bromo-2-fluorophenylsulfonamido)-5-phenoxybenzoic acid,CHEMBL2379478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1100.0,nM,O=C(O)c1cc(Oc2ccccc2)ccc1NS(=O)(=O)c1ccc(Br)cc1F,CHEMBL2375335,Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,9,2585,2589,10.1016/j.bmcl.2013.02.110,23545108.0,
13285820,CHEMBL2376577,2-(4-methylphenylsulfonamido)-5-phenoxybenzoic acid,CHEMBL2379478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3000.0,nM,Cc1ccc(S(=O)(=O)Nc2ccc(Oc3ccccc3)cc2C(=O)O)cc1,CHEMBL2375335,Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,9,2585,2589,10.1016/j.bmcl.2013.02.110,23545108.0,
13294541,CHEMBL2375587,trans-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexanol,CHEMBL2378544,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,40300.0,nM,O[C@H]1CC[C@H](c2ccc(OCCCN3CCCCC3)cc2)CC1,CHEMBL2375312,Novel and highly potent histamine H3 receptor ligands. Part 3: an alcohol function to improve the pharmacokinetic profile.,Bioorg. Med. Chem. Lett.,2013.0,23,9,2548,2554,10.1016/j.bmcl.2013.02.118,23535326.0,
13295025,CHEMBL2377663,"(S)-N-((3-(3,5-Difluoro-4-(1-(hydroxyacetyl)[1,2,5]triazepan-5-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-O-methylthiocarbamate",CHEMBL2379432,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as tolbutamide hydroxylation after 20 mins by LC/MS/MS analysis,IC50,>,20000.0,nM,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,CHEMBL2375276,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.",Eur. J. Med. Chem.,2013.0,63,,811,825,10.1016/j.ejmech.2013.03.003,23584544.0,
13295026,CHEMBL2377662,"(S)-N-((3-(3-Fluoro-4-(1-(hydroxyacetyl)[1,2,5]triazepan-5-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-O-methylthiocarbamate",CHEMBL2379432,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as tolbutamide hydroxylation after 20 mins by LC/MS/MS analysis,IC50,>,20000.0,nM,COC(=S)NC[C@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,CHEMBL2375276,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.",Eur. J. Med. Chem.,2013.0,63,,811,825,10.1016/j.ejmech.2013.03.003,23584544.0,
13295027,CHEMBL47955,N-((S)-3-{3-Fluoro-4-[4-(2-hydroxy-acetyl)-piperazin-1-yl]-phenyl}-2-oxo-oxazolidin-5-ylmethyl)-acetamide,CHEMBL2379432,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as tolbutamide hydroxylation after 20 mins by LC/MS/MS analysis,IC50,>,20000.0,nM,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,CHEMBL2375276,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.",Eur. J. Med. Chem.,2013.0,63,,811,825,10.1016/j.ejmech.2013.03.003,23584544.0,
13295028,CHEMBL126,N-[(R)-3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide,CHEMBL2379432,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as tolbutamide hydroxylation after 20 mins by LC/MS/MS analysis,IC50,>,20000.0,nM,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,CHEMBL2375276,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.",Eur. J. Med. Chem.,2013.0,63,,811,825,10.1016/j.ejmech.2013.03.003,23584544.0,
13298432,CHEMBL2382415,"2,2,2-trifluoroethyl 3-(5-((3-cyanopyridin-4-yl)methoxy)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate",CHEMBL2384316,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,N#Cc1cnccc1COc1cnc(N2CC3CCC(C2)N3C(=O)OCC(F)(F)F)nc1,CHEMBL2380211,Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.,Bioorg. Med. Chem. Lett.,2013.0,23,11,3175,3179,10.1016/j.bmcl.2013.04.006,23628336.0,
13298433,CHEMBL2086687,"2,2,2-Trifluoroethyl-(3R)-4-{5-[(3-Cyanopyridin-4-yl)-methoxy]pyrimidin-2-yl}-3-methylpiperazine-1-carboxylate",CHEMBL2384316,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,C[C@@H]1CN(C(=O)OCC(F)(F)F)CCN1c1ncc(OCc2ccncc2C#N)cn1,CHEMBL2380211,Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.,Bioorg. Med. Chem. Lett.,2013.0,23,11,3175,3179,10.1016/j.bmcl.2013.04.006,23628336.0,
13298434,CHEMBL2382414,"2,2,2-trifluoroethyl 4-(5-((3-cyanopyridin-4-yl)methoxy)pyrimidin-2-yl)piperazine-1-carboxylate",CHEMBL2384316,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,N#Cc1cnccc1COc1cnc(N2CCN(C(=O)OCC(F)(F)F)CC2)nc1,CHEMBL2380211,Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.,Bioorg. Med. Chem. Lett.,2013.0,23,11,3175,3179,10.1016/j.bmcl.2013.04.006,23628336.0,
13303083,CHEMBL2380735,"(2S,4R)-1-acetyl-N-((S)-1-(benzo[d]oxazol-2-yl)-1-oxobutan-2-yl)-4-(phenylsulfonyl)pyrrolidine-2-carboxamide",CHEMBL2383921,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence detection method,IC50,=,5000.0,nM,CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2)CN1C(C)=O)C(=O)c1nc2ccccc2o1,CHEMBL2380281,Synthesis of proline analogues as potent and selective cathepsin S inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,11,3140,3144,10.1016/j.bmcl.2013.04.023,23639544.0,
13311876,CHEMBL2381116,2-(6-methoxy-1-oxoisoindolin-2-yl)-N-(4-(piperazin-1-yl)pyridin-3-yl)thiazole-4-carboxamide,CHEMBL2382849,A,,Homo sapiens,Cytochrome P450 2C9,Time-dependent inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate incubated for 30 mins prior to substrate addition measured after 30 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,COc1ccc2c(c1)C(=O)N(c1nc(C(=O)Nc3cnccc3N3CCNCC3)cs1)C2,CHEMBL2380296,Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,9,2590,2594,10.1016/j.bmcl.2013.02.108,23535330.0,
13311879,CHEMBL2381116,2-(6-methoxy-1-oxoisoindolin-2-yl)-N-(4-(piperazin-1-yl)pyridin-3-yl)thiazole-4-carboxamide,CHEMBL2382852,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate by LC-MS/MS analysis,IC50,>,30000.0,nM,COc1ccc2c(c1)C(=O)N(c1nc(C(=O)Nc3cnccc3N3CCNCC3)cs1)C2,CHEMBL2380296,Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,9,2590,2594,10.1016/j.bmcl.2013.02.108,23535330.0,
13314432,CHEMBL2385886,(R)-(2-Fluoro-4-((4-methoxyphenyl)ethynyl)phenyl)(3-hydroxypiperidin-1-yl)methanone,CHEMBL2390285,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 15 mins prior to NADPH addition measured after 8 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,COc1ccc(C#Cc2ccc(C(=O)N3CCC[C@@H](O)C3)c(F)c2)cc1,CHEMBL2384940,"Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM).",J. Med. Chem.,2013.0,56,12,5208,5212,10.1021/jm400439t,23718281.0,
13316354,CHEMBL2385902,"2-(2-(2-(1H-Indol-3-yl)acetyl)-8-fluoro-3,4-dihydro-1Hpyrido[4,3-b]indol-5(2H)-yl)acetic Acid",CHEMBL2388763,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac 4'-hydroxylation by LC-MS/MS analysis,IC50,>,50000.0,nM,O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)Cc1c[nH]c3ccccc13)CC2,CHEMBL2385063,"Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.",J. Med. Chem.,2013.0,56,12,4899,4911,10.1021/jm400122f,23721423.0,
13316355,CHEMBL2386081,"2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]-indol-5(2H)-yl)acetic Acid",CHEMBL2388763,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac 4'-hydroxylation by LC-MS/MS analysis,IC50,>,50000.0,nM,O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccc3ccccc13)CC2,CHEMBL2385063,"Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.",J. Med. Chem.,2013.0,56,12,4899,4911,10.1021/jm400122f,23721423.0,
13316356,CHEMBL2386077,"2-(2-(3-Chlorobenzoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid",CHEMBL2388763,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac 4'-hydroxylation by LC-MS/MS analysis,IC50,>,50000.0,nM,O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccc(Cl)c1)CC2,CHEMBL2385063,"Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.",J. Med. Chem.,2013.0,56,12,4899,4911,10.1021/jm400122f,23721423.0,
13316357,CHEMBL2386076,"2-(2-(3-Chlorobenzoyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid",CHEMBL2388763,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac 4'-hydroxylation by LC-MS/MS analysis,IC50,>,50000.0,nM,O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1cccc(Cl)c1)CC2,CHEMBL2385063,"Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.",J. Med. Chem.,2013.0,56,12,4899,4911,10.1021/jm400122f,23721423.0,
13316380,CHEMBL2386075,"2-(8-Fluoro-2-(thiophene-2-carbonyl)-3,4-dihydro-1Hpyrido[4,3-b]indol-5(2H)-yl)acetic Acid",CHEMBL2388763,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac 4'-hydroxylation by LC-MS/MS analysis,IC50,=,43000.0,nM,O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccs1)CC2,CHEMBL2385063,"Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.",J. Med. Chem.,2013.0,56,12,4899,4911,10.1021/jm400122f,23721423.0,
13316382,CHEMBL2386079,"2-(2-(1-Naphthoyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid",CHEMBL2388763,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac 4'-hydroxylation by LC-MS/MS analysis,IC50,=,40000.0,nM,O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1cccc3ccccc13)CC2,CHEMBL2385063,"Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.",J. Med. Chem.,2013.0,56,12,4899,4911,10.1021/jm400122f,23721423.0,
13317209,CHEMBL2387588,"2-(2-chloro-6-fluorophenyl)-7-(4-chlorophenyl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,O=c1[nH]c2cc(-c3ccc(Cl)cc3)ccc2c2[nH]c(-c3c(F)cccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317210,CHEMBL2387587,"2-(2-Chloro-6-fluorophenyl)-7-(3-chlorophenyl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,O=c1[nH]c2cc(-c3cccc(Cl)c3)ccc2c2[nH]c(-c3c(F)cccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317211,CHEMBL2387507,"2-(2-chloro-6-fluorophenyl)-7-(2-chlorophenyl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,=,21000.0,nM,O=c1[nH]c2cc(-c3ccccc3Cl)ccc2c2[nH]c(-c3c(F)cccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317212,CHEMBL2387506,"2-(2-chloro-6-fluorophenyl)-7-(4-methylphenyl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,Cc1ccc(-c2ccc3c(c2)[nH]c(=O)c2nc(-c4c(F)cccc4Cl)[nH]c23)cc1,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317213,CHEMBL2387505,"2-(2-chloro-6-fluorophenyl)-7-(3-methylphenyl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,=,9000.0,nM,Cc1cccc(-c2ccc3c(c2)[nH]c(=O)c2nc(-c4c(F)cccc4Cl)[nH]c23)c1,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317214,CHEMBL2387504,"2-(2-Chloro-6-fluorophenyl)-7-(2-methylphenyl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,=,17000.0,nM,Cc1ccccc1-c1ccc2c(c1)[nH]c(=O)c1nc(-c3c(F)cccc3Cl)[nH]c12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317215,CHEMBL2387503,"2-(2-chloro-6-fluorophenyl)-7-phenylimidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,O=c1[nH]c2cc(-c3ccccc3)ccc2c2[nH]c(-c3c(F)cccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317216,CHEMBL2387502,"2-(2-chloro-6-nitrophenyl)-7-phenylimidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,=,20000.0,nM,O=c1[nH]c2cc(-c3ccccc3)ccc2c2[nH]c(-c3c(Cl)cccc3[N+](=O)[O-])nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317217,CHEMBL2387501,"2-(2-chloro-6-(trifluoromethyl)phenyl)-7-phenylimidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,=,9800.0,nM,O=c1[nH]c2cc(-c3ccccc3)ccc2c2[nH]c(-c3c(Cl)cccc3C(F)(F)F)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317218,CHEMBL2387500,"2-(2-Chloro-6-methylphenyl)-7-phenylimidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,Cc1cccc(Cl)c1-c1nc2c(=O)[nH]c3cc(-c4ccccc4)ccc3c2[nH]1,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317219,CHEMBL2387606,"2-(2-chlorophenyl)-7-(pyridin-4-yl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,O=c1[nH]c2cc(-c3ccncc3)ccc2c2[nH]c(-c3ccccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317220,CHEMBL2387605,"2-(2-chlorophenyl)-7-(pyridin-3-yl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,=,25000.0,nM,O=c1[nH]c2cc(-c3cccnc3)ccc2c2[nH]c(-c3ccccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317221,CHEMBL2387604,"2-(2-chlorophenyl)-7-(furan-2-yl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,O=c1[nH]c2cc(-c3ccco3)ccc2c2[nH]c(-c3ccccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317222,CHEMBL2387603,"2-(2-chlorophenyl)-7-(thiophen-2-yl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,O=c1[nH]c2cc(-c3cccs3)ccc2c2[nH]c(-c3ccccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317223,CHEMBL2387602,"2-(2-Chlorophenyl)-7-(naphthalen-2-yl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,O=c1[nH]c2cc(-c3ccc4ccccc4c3)ccc2c2[nH]c(-c3ccccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317224,CHEMBL2387601,"2-(2-chlorophenyl)-7-(2-phenethyl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,O=c1[nH]c2cc(CCc3ccccc3)ccc2c2[nH]c(-c3ccccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317225,CHEMBL2387600,"7-benzyl-2-(2-chlorophenyl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,=,5200.0,nM,O=c1[nH]c2cc(Cc3ccccc3)ccc2c2[nH]c(-c3ccccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317226,CHEMBL2387599,"2-(2-Chlorophenyl)-7-phenylimidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,O=c1[nH]c2cc(-c3ccccc3)ccc2c2[nH]c(-c3ccccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317227,CHEMBL2387598,"2-(2-chlorophenyl)-7-(n-hexyl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,CCCCCCc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317228,CHEMBL2387597,"2-(2-chlorophenyl)-7-(n-pentyl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,CCCCCc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317229,CHEMBL2387596,"7-(n-Butyl)-2-(2-chlorophenyl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,CCCCc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317230,CHEMBL2387595,"2-(2-Chlorophenyl)-7-(n-propyl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,=,24000.0,nM,CCCc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317231,CHEMBL2387594,"2-(2-Chlorophenyl)-7-ethylimidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,=,21000.0,nM,CCc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317232,CHEMBL2387593,"2-(2-Chlorophenyl)-7-methylimidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,Cc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317233,CHEMBL2387592,"8-chloro-2-(2-chlorophenyl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,O=c1[nH]c2ccc(Cl)cc2c2[nH]c(-c3ccccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317234,CHEMBL2387591,"8-bromo-2-(2-chlorophenyl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,O=c1[nH]c2ccc(Br)cc2c2[nH]c(-c3ccccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317235,CHEMBL2387590,"7-Chloro-2-(2-chlorophenyl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,O=c1[nH]c2cc(Cl)ccc2c2[nH]c(-c3ccccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317236,CHEMBL2387589,"2-(2-Chlorophenyl)imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,O=c1[nH]c2ccccc2c2[nH]c(-c3ccccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317237,CHEMBL1934810,"7-bromo-2-(2-chlorophenyl)-1H-imidazo[4,5-c]quinolin-4(5H)-one",CHEMBL2389927,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,=,700.0,nM,O=c1[nH]c2cc(Br)ccc2c2[nH]c(-c3ccccc3Cl)nc12,CHEMBL2385013,7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors.,Bioorg. Med. Chem.,2013.0,21,11,2868,2878,10.1016/j.bmc.2013.03.069,23623673.0,
13317958,CHEMBL2385901,"2-(8-Fluoro-2-(2-(naphthalen-1-yl)acetyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid",CHEMBL2388763,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac 4'-hydroxylation by LC-MS/MS analysis,IC50,=,16000.0,nM,O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)Cc1cccc3ccccc13)CC2,CHEMBL2385063,"Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.",J. Med. Chem.,2013.0,56,12,4899,4911,10.1021/jm400122f,23721423.0,
13317960,CHEMBL2385906,"2-(2-Benzoyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-acetic Acid",CHEMBL2388763,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac 4'-hydroxylation by LC-MS/MS analysis,IC50,=,15000.0,nM,O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1ccccc1)CC2,CHEMBL2385063,"Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.",J. Med. Chem.,2013.0,56,12,4899,4911,10.1021/jm400122f,23721423.0,
13317964,CHEMBL2385904,"2-(2-(4'-Ethyl-[1,1'-biphenyl]-4-carbonyl)-3,4-dihydro-1Hpyrido[4,3-b]indol-5(2H)-yl)acetic Acid",CHEMBL2388763,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac 4'-hydroxylation by LC-MS/MS analysis,IC50,=,14000.0,nM,CCc1ccc(-c2ccc(C(=O)N3CCc4c(c5ccccc5n4CC(=O)O)C3)cc2)cc1,CHEMBL2385063,"Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.",J. Med. Chem.,2013.0,56,12,4899,4911,10.1021/jm400122f,23721423.0,
13325603,CHEMBL2386162,6-Methoxy-2-methyl-3-[(1S)-3-methyl-1-[(3S)-pyrrolidin-3-yl]butoxy]pyridine,CHEMBL2389152,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,COc1ccc(O[C@@H](CC(C)C)[C@H]2CCNC2)c(C)n1,CHEMBL2384999,"Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.",ACS Med. Chem. Lett.,2013.0,4,6,560,564,10.1021/ml400049p,24900709.0,
13329962,CHEMBL2386636,"3-(trans-4-(2-((R)-1-Hydroxyethyl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)propanenitrile",CHEMBL2390361,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using warfarin as substrate by LC/MS/MS analysis,IC50,>,10000.0,nM,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CCC#N)CC1,CHEMBL2385026,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,2013.0,56,11,4764,4785,10.1021/jm4004895,23659214.0,
13329963,CHEMBL2386635,"2-(trans-4-(2-((R)-1-Hydroxyethyl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile",CHEMBL2390361,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using warfarin as substrate by LC/MS/MS analysis,IC50,>,10000.0,nM,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1,CHEMBL2385026,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,2013.0,56,11,4764,4785,10.1021/jm4004895,23659214.0,
13329964,CHEMBL2386633,"trans-4-(2-((R)-1-Hydroxyethyl)imidazo[4,5-d]pyrrolo[2,3-b]-pyridin-1(6H)-yl)cyclohexanecarbonitrile",CHEMBL2390361,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using warfarin as substrate by LC/MS/MS analysis,IC50,>,10000.0,nM,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](C#N)CC1,CHEMBL2385026,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,2013.0,56,11,4764,4785,10.1021/jm4004895,23659214.0,
13329965,CHEMBL2385096,"(R)-1-(1-((1S,3R)-3-((2,2,2-Trifluoroethyl)amino)cyclopentyl)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl)ethanol",CHEMBL2390361,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using warfarin as substrate by LC/MS/MS analysis,IC50,>,10000.0,nM,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@@H](NCC(F)(F)F)C1,CHEMBL2385026,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,2013.0,56,11,4764,4785,10.1021/jm4004895,23659214.0,
13329966,CHEMBL2386629,"(R)-1-(1-(trans-4-((2,2,2-Trifluoroethyl)amino)cyclohexyl)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl)ethanol",CHEMBL2390361,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using warfarin as substrate by LC/MS/MS analysis,IC50,>,10000.0,nM,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](NCC(F)(F)F)CC1,CHEMBL2385026,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,2013.0,56,11,4764,4785,10.1021/jm4004895,23659214.0,
13329967,CHEMBL2386653,"(R)-1-(1-((S)-Tetrahydro-2H-pyran-3-yl)-1,6-dihydroimidazo-[4,5-d]pyrrolo[2,3-b]pyridin-2-yl)ethanol",CHEMBL2390361,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using warfarin as substrate by LC/MS/MS analysis,IC50,>,10000.0,nM,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CCCOC1,CHEMBL2385026,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,J. Med. Chem.,2013.0,56,11,4764,4785,10.1021/jm4004895,23659214.0,
13335768,CHEMBL2392692,"N-({4-bromo-2-[(trifluoromethyl)oxy]phenyl}methyl)-1-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,33000.0,nM,CNc1nc(C)nc(N2CCC(C(=O)NCc3ccc(Br)cc3OC(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335769,CHEMBL2392691,"1-[4-Methyl-6-(methylamino)-1,3,5-triazin-2-yl]-N-{[2-(trifluoromethyl)-4-(methoxy)-phenyl]methyl}-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CNc1nc(C)nc(N2CCC(C(=O)NCc3ccc(OC)cc3C(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335770,CHEMBL2392690,"1-[4-Methyl-6-(methylamino)-1,3,5-triazin-2-yl]-N-{[2-(trifluoromethyl)-4-(fluoro)-phenyl]methyl}-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CNc1nc(C)nc(N2CCC(C(=O)NCc3ccc(F)cc3C(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335771,CHEMBL2392689,"1-[4-Methyl-6-(methylamino)-1,3,5-triazin-2-yl]-N-{[2-(cyano)phenyl]methyl}-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CNc1nc(C)nc(N2CCC(C(=O)NCc3ccccc3C#N)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335772,CHEMBL2392688,"1-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]-N-(benzyl)-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CNc1nc(C)nc(N2CCC(C(=O)NCc3ccccc3)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335773,CHEMBL2392710,"1-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]-N-({4-[(trifluoromethyl)oxy]phenyl}methyl)-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CNc1nc(C)nc(N2CCC(C(=O)NCc3ccc(OC(F)(F)F)cc3)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335774,CHEMBL2392709,"1-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]-N-({3-[(trifluoromethyl)oxy]phenyl}methyl)-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CNc1nc(C)nc(N2CCC(C(=O)NCc3cccc(OC(F)(F)F)c3)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335775,CHEMBL2392708,"1-[4-Methyl-6-(methylamino)-1,3,5-triazin-2-yl]-N-{[2-(methoxy)phenyl]methyl}-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CNc1nc(C)nc(N2CCC(C(=O)NCc3ccccc3OC)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335776,CHEMBL2392707,"1-[4-Methyl-6-(methylamino)-1,3,5-triazin-2-yl]-N-{[2-(methyl)phenyl]methyl}-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CNc1nc(C)nc(N2CCC(C(=O)NCc3ccccc3C)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335777,CHEMBL2392706,"1-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]-N-({2-[(trifluoromethyl)oxy]phenyl}methyl)-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CNc1nc(C)nc(N2CCC(C(=O)NCc3ccccc3OC(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335778,CHEMBL2392705,1-[3-Methyl-5-(methylamino)phenyl]-N-{[2-(trifluoromethyl)phenyl]methyl}piperidine-4-carboxamide,CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2000.0,nM,CNc1cc(C)cc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)c1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335779,CHEMBL2392704,1-[4-Methyl-6-(methylamino)pyridin-2-yl]-N-{[2-(trifluoromethyl)phenyl]methyl}piperidine-4-carboxamide,CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,11000.0,nM,CNc1cc(C)cc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335780,CHEMBL2392703,1-[6-methyl-4-(methylamino)pyridin-2-yl]-N-{[2-(trifluoromethyl)phenyl]methyl}piperidine-4-carboxamide,CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CNc1cc(C)nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)c1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335781,CHEMBL2392702,1-[2-Methyl-6-(methylamino)pyridin-4-yl]-N-{[2-(trifluoromethyl)phenyl]methyl}piperidine-4-carboxamide,CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CNc1cc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)cc(C)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335782,CHEMBL2392701,1-[2-methyl-6-(methylamino)-4-pyrimidinyl]-N-{[2-(trifluoromethyl)phenyl]methyl}-4-piperidinecarboxamide,CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1000.0,nM,CNc1cc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)nc(C)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335783,CHEMBL2392700,1-[4-methyl-6-(methylamino)-2-pyrimidinyl]-N-{[2-(trifluoromethyl)phenyl]methyl}-4-piperidinecarboxamide,CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CNc1cc(C)nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335784,CHEMBL2392699,1-[6-methyl-2-(methylamino)-4-pyrimidinyl]-N-{[2-(trifluoromethyl)phenyl]methyl}-4-piperidinecarboxamide,CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CNc1nc(C)cc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335785,CHEMBL2392698,"1-[4-Methyl-6-(methoxy-ethylamino)-1,3,5-triazin-2-yl]-N-{[2-(trifluoromethyl)phenyl]methyl}-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1800.0,nM,COCCNc1nc(C)nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335786,CHEMBL2392697,"1-[4-Methyl-6-(morpholino)-1,3,5-triazin-2-yl]-N-{[2-(trifluoromethyl)phenyl]methyl}-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,400.0,nM,Cc1nc(N2CCOCC2)nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335787,CHEMBL2392696,"1-[4-Methyl-6-(isopropylamino)-1,3,5-triazin-2-yl]-N-{[2-(trifluoromethyl)phenyl]methyl}-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,400.0,nM,Cc1nc(NC(C)C)nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335788,CHEMBL2392695,"1-[4-Methyl-6-(dimethylamino)-1,3,5-triazin-2-yl]-N-{[2-(trifluoromethyl)phenyl]methyl}-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,10000.0,nM,Cc1nc(N(C)C)nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335789,CHEMBL2392694,"1-[4-(Methylamino)-6-phenyl-1,3,5-triazin-2-yl]-N-{[2-(trifluoromethyl)phenyl]methyl}-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1800.0,nM,CNc1nc(-c2ccccc2)nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335790,CHEMBL2392693,"1-[4-(Methylamino)-6-cyclohexyl-1,3,5-triazin-2-yl]-N-{[2-(trifluoromethyl)phenyl]methyl}-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,63.0,nM,CNc1nc(C2CCCCC2)nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335791,CHEMBL2392715,"1-[4-Ethyl-6-(methylamino)-1,3,5-triazin-2-yl]-N-{[2-(trifluoromethyl)phenyl]methyl}-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,9600.0,nM,CCc1nc(NC)nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335792,CHEMBL2392714,"1-[4-Methyl-6-(methylamino)-1,3,5-triazin-2-yl]-N-{[2-(trifluoromethyl)phenyl]methyl}-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,25000.0,nM,CNc1nc(C)nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335793,CHEMBL2392713,"1-[4-[[2-(Dimethylamino)ethyl](methyl)amino]-6-(methylamino)-1,3,5-triazin-2-yl]-N-{[2-(trifluoromethyl)phenyl]methyl}-4-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,17000.0,nM,CNc1nc(N(C)CCN(C)C)nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335794,CHEMBL2392712,"1-[4,6-(Dimethylamino)-1,3,5-triazin-2-yl]-N-[[2-(trifluoromethyl)phenyl]methyl]-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,25000.0,nM,CNc1nc(NC)nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13335795,CHEMBL2392711,"1-[4-(Methylamino)-6-(4-methyl-1-piperazinyl)-1,3,5-triazin-2-yl]-N-[[2-(trifluoromethyl)phenyl]methyl]-piperidinecarboxamide",CHEMBL2393701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,16000.0,nM,CNc1nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)nc(N2CCN(C)CC2)n1,CHEMBL2390902,"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,2013.0,23,12,3584,3588,10.1016/j.bmcl.2013.04.019,23664879.0,
13338356,CHEMBL2385906,"2-(2-Benzoyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-acetic Acid",CHEMBL2395618,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,15000.0,nM,O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1ccccc1)CC2,CHEMBL2390869,Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold.,Bioorg. Med. Chem. Lett.,2013.0,23,4,944,948,10.1016/j.bmcl.2012.12.050,23324405.0,
13338384,CHEMBL2391518,"(E)-2-(3-(2-cyano-3-(3,4-dihydroquinolin-1(2H)-yl)-3-oxoprop-1-enyl)-1H-indol-1-yl)acetic acid",CHEMBL2395618,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,N#C/C(=C\c1cn(CC(=O)O)c2ccccc12)C(=O)N1CCCc2ccccc21,CHEMBL2390869,Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold.,Bioorg. Med. Chem. Lett.,2013.0,23,4,944,948,10.1016/j.bmcl.2012.12.050,23324405.0,
13345998,CHEMBL2393173,"N-((1S,3S)-3-hydroxycyclohexyl)-4-(3-(pyridin-3-ylmethyl)ureido)benzenesulfonamide",CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N[C@H]2CCC[C@H](O)C2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13345999,CHEMBL2393172,trans-N-(4-hydroxycyclohexyl)-4-(3-(pyridin-3-ylmethyl)ureido)benzenesulfonamide,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N[C@H]2CC[C@H](O)CC2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346000,CHEMBL2393171,trans-N-(4-aminocyclohexyl)-4-(3-(pyridin-3-ylmethyl)ureido)benzenesulfonamide,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,N[C@H]1CC[C@H](NS(=O)(=O)c2ccc(NC(=O)NCc3cccnc3)cc2)CC1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346001,CHEMBL2393170,"N-((3S,4R)-1-ethyl-3-fluoropiperidin-4-yl)-4-(3-(pyridin-3-ylmethyl)ureido)benzenesulfonamide",CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,CCN1CC[C@@H](NS(=O)(=O)c2ccc(NC(=O)NCc3cccnc3)cc2)[C@@H](F)C1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346002,CHEMBL2393169,"N-((3R,4R)-3-fluoropiperidin-4-yl)-4-(3-(pyridin-3-ylmethyl)ureido)benzenesulfonamide",CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N[C@@H]2CCNC[C@H]2F)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346003,CHEMBL2393168,"rac-1-(pyridin-3-ylmethyl)-3-(4-(5-(trifluoromethyl)-1,4-diazepan-1-ylsulfonyl)phenyl)urea",CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,110.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N2CCNC(C(F)(F)F)CC2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346004,CHEMBL2393167,"rac-1-(4-(5-methyl-1,4-diazepan-1-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea",CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,930.0,nM,CC1CCN(S(=O)(=O)c2ccc(NC(=O)NCc3cccnc3)cc2)CCN1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346005,CHEMBL2393166,"rac-1-(4-(6-methyl-1,4-diazepan-1-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea",CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,2180.0,nM,CC1CNCCN(S(=O)(=O)c2ccc(NC(=O)NCc3cccnc3)cc2)C1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346006,CHEMBL2393165,"1-(4-(1,4-diazepan-1-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea",CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N2CCCNCC2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346007,CHEMBL2393164,"rac-1-(4-(2,8-diazaspiro[4.5]decan-2-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea",CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N2CCC3(CCNCC3)C2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346008,CHEMBL2393163,"rac-1-(4-(2,8-diazaspiro[4.5]decan-8-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea",CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N2CCC3(CCNC3)CC2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346009,CHEMBL2393162,"rac-1-(4-(1,8-diazaspiro[4.5]decan-8-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea",CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N2CCC3(CCCN3)CC2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346010,CHEMBL2393161,1-(4-(2-oxa-6-azaspiro[3.3]heptan-6-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N2CC3(COC3)C2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346011,CHEMBL2393160,1-(4-(6-oxa-1-azaspiro[3.3]heptan-1-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,1140.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N2CCC23COC3)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346012,CHEMBL2393159,"1-(4-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea",CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,554.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N2C[C@@H]3C[C@H]2CO3)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346013,CHEMBL2393158,1-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,1050.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N2C3CCC2COC3)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346014,CHEMBL2393191,"trans-rac-1-(4-(3,5-dimethylmorpholinosulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea",CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,601.0,nM,C[C@@H]1COC[C@@H](C)N1S(=O)(=O)c1ccc(NC(=O)NCc2cccnc2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346015,CHEMBL2393190,"1-(4-((2R,6S)-2,6-dimethylmorpholinosulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea",CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,750.0,nM,C[C@H]1CN(S(=O)(=O)c2ccc(NC(=O)NCc3cccnc3)cc2)C[C@@H](C)O1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346016,CHEMBL2393189,1-((2-aminopyrimidin-5-yl)methyl)-3-(4-(phenylsulfonyl)phenyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,Nc1ncc(CNC(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346017,CHEMBL2393188,1-(4-(phenylsulfonyl)phenyl)-3-(pyrimidin-5-ylmethyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,149.0,nM,O=C(NCc1cncnc1)Nc1ccc(S(=O)(=O)c2ccccc2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346018,CHEMBL2393187,1-(4-(phenylsulfonyl)phenyl)-3-(pyrazin-2-ylmethyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,460.0,nM,O=C(NCc1cnccn1)Nc1ccc(S(=O)(=O)c2ccccc2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346019,CHEMBL2393186,1-(4-(phenylsulfonyl)phenyl)-3-(pyridazin-3-ylmethyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,515.0,nM,O=C(NCc1cccnn1)Nc1ccc(S(=O)(=O)c2ccccc2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346020,CHEMBL2393185,1-((5-fluoropyridin-3-yl)methyl)-3-(4-(phenylsulfonyl)phenyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,74.0,nM,O=C(NCc1cncc(F)c1)Nc1ccc(S(=O)(=O)c2ccccc2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346022,CHEMBL2393183,1-((6-aminopyridin-3-yl)methyl)-3-(4-(phenylsulfonyl)phenyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,Nc1ccc(CNC(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346023,CHEMBL2393182,1-((6-chloropyridin-3-yl)methyl)-3-(4-(phenylsulfonyl)phenyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,1770.0,nM,O=C(NCc1ccc(Cl)nc1)Nc1ccc(S(=O)(=O)c2ccccc2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346024,CHEMBL2393181,1-((6-methoxypyridin-3-yl)methyl)-3-(4-(phenylsulfonyl)phenyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,COc1ccc(CNC(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346025,CHEMBL2393180,rac-1-(4-(morpholinosulfonyl)phenyl)-3-(1-(pyridin-3-yl)ethyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,1300.0,nM,CC(NC(=O)Nc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1cccnc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346026,CHEMBL2391551,rac-3-[4-(Benzenesulfonyl)phenyl]-1-[1-(pyridin-3-yl)ethyl]urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,139.0,nM,CC(NC(=O)Nc1ccc(S(=O)(=O)c2ccccc2)cc1)c1cccnc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346027,CHEMBL2393179,1-((4-methylpyridin-3-yl)methyl)-3-(4-(morpholinosulfonyl)phenyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,Cc1ccncc1CNC(=O)Nc1ccc(S(=O)(=O)N2CCOCC2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346028,CHEMBL2393178,1-((4-methylpyridin-3-yl)methyl)-3-(4-(phenylsulfonyl)phenyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,1960.0,nM,Cc1ccncc1CNC(=O)Nc1ccc(S(=O)(=O)c2ccccc2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346029,CHEMBL2393177,1-((5-methylpyridin-3-yl)methyl)-3-(4-(morpholinosulfonyl)phenyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,644.0,nM,Cc1cncc(CNC(=O)Nc2ccc(S(=O)(=O)N3CCOCC3)cc2)c1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346030,CHEMBL2393176,1-((5-methylpyridin-3-yl)methyl)-3-(4-(phenylsulfonyl)phenyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,125.0,nM,Cc1cncc(CNC(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)c1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346031,CHEMBL2393175,1-((6-methylpyridin-3-yl)methyl)-3-(4-(morpholinosulfonyl)phenyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,Cc1ccc(CNC(=O)Nc2ccc(S(=O)(=O)N3CCOCC3)cc2)cn1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346032,CHEMBL2393174,1-((6-methylpyridin-3-yl)methyl)-3-(4-(phenylsulfonyl)phenyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,Cc1ccc(CNC(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346033,CHEMBL2393193,1-((2-methylpyridin-3-yl)methyl)-3-(4-(morpholinosulfonyl)phenyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,>,10000.0,nM,Cc1ncccc1CNC(=O)Nc1ccc(S(=O)(=O)N2CCOCC2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346034,CHEMBL2393192,1-((2-methylpyridin-3-yl)methyl)-3-(4-(phenylsulfonyl)phenyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,4600.0,nM,Cc1ncccc1CNC(=O)Nc1ccc(S(=O)(=O)c2ccccc2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346035,CHEMBL2391567,1-[4-(Morpholine-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)-urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,200.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N2CCOCC2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13346036,CHEMBL2391572,1-[4-(Benzenesulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea,CHEMBL2396489,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 mins,IC50,=,68.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)c2ccccc2)cc1,CHEMBL2390826,Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.,Bioorg. Med. Chem. Lett.,2013.0,23,12,3531,3538,10.1016/j.bmcl.2013.04.040,23668988.0,
13358857,CHEMBL2397415,"(R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide",CHEMBL2400602,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) expressed in baculovirus-infected insect cell microsomes assessed as 7-methoxy-4-trifluoromethylcoumarin conversion to 7-hydroxy-4-trifluoromethylcoumarin after 45 mins by fluorescence assay,IC50,>,40000.0,nM,Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12,CHEMBL2396632,"Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery.",Bioorg. Med. Chem. Lett.,2013.0,23,11,3157,3161,10.1016/j.bmcl.2013.04.012,23632269.0,
13364941,CHEMBL2403551,"5-fluoro-2-methyl-N-(2-methyl-4-((2R,3'R)-2-methyl-1,3'-bipyrrolidin-1'-yl)phenyl)benzamide",CHEMBL2404999,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1cc(N2CC[C@@H](N3CCC[C@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C,CHEMBL2401654,"Synthesis, characterization, and biological assessment of the four stereoisomers of the H(3) receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.",Bioorg. Med. Chem. Lett.,2013.0,23,14,4044,4047,10.1016/j.bmcl.2013.05.068,23769643.0,
13364942,CHEMBL2403550,"5-fluoro-2-methyl-N-(2-methyl-4-((2S,3'S)-2-methyl-1,3'-bipyrrolidin-1'-yl)phenyl)benzamide",CHEMBL2404999,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1cc(N2CC[C@H](N3CCC[C@@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C,CHEMBL2401654,"Synthesis, characterization, and biological assessment of the four stereoisomers of the H(3) receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.",Bioorg. Med. Chem. Lett.,2013.0,23,14,4044,4047,10.1016/j.bmcl.2013.05.068,23769643.0,
13364943,CHEMBL2403549,"5-fluoro-2-methyl-N-(2-methyl-4-((2S,3'R)-2-methyl-1,3'-bipyrrolidin-1'-yl)phenyl)benzamide",CHEMBL2404999,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1cc(N2CC[C@@H](N3CCC[C@@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C,CHEMBL2401654,"Synthesis, characterization, and biological assessment of the four stereoisomers of the H(3) receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.",Bioorg. Med. Chem. Lett.,2013.0,23,14,4044,4047,10.1016/j.bmcl.2013.05.068,23769643.0,
13364944,CHEMBL2403548,"5-fluoro-2-methyl-N-(2-methyl-4-((2R,3'S)-2-methyl-1,3'-bipyrrolidin-1'-yl)phenyl)benzamide",CHEMBL2404999,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1cc(N2CC[C@H](N3CCC[C@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C,CHEMBL2401654,"Synthesis, characterization, and biological assessment of the four stereoisomers of the H(3) receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.",Bioorg. Med. Chem. Lett.,2013.0,23,14,4044,4047,10.1016/j.bmcl.2013.05.068,23769643.0,
13365238,CHEMBL2402509,"2-ethyl-2-(4-(methylamino)-6-(1H-1,2,4-triazol-1-yl)-1,3,5-triazin-2-ylamino)butanenitrile",CHEMBL2406773,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCC(C#N)(CC)Nc1nc(NC)nc(-n2cncn2)n1,CHEMBL2401705,"Discovery of triazines as potent, selective and orally active PDE4 inhibitors.",Bioorg. Med. Chem. Lett.,2013.0,23,15,4308,4314,10.1016/j.bmcl.2013.05.099,23806553.0,
13366683,CHEMBL2402572,"2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one",CHEMBL2403919,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,41000.0,nM,Cc1ccccc1[C@@H]1[C@@H](O[C@H](CO)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H]2CN(C3=NC(=O)CO3)C[C@H]21,CHEMBL2401672,"2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one: a potent human NK1 receptor antagonist with multiple clearance pathways.",J. Med. Chem.,2013.0,56,14,5940,5948,10.1021/jm400751p,23808489.0,
13378318,CHEMBL2403317,"6-(4-methoxy-3-(trifluoromethyl)pyridin-2-yloxy)-1-(2,4,6-trifluorobenzyl)quinazolin-4(1H)-one",CHEMBL2405378,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,11000.0,nM,COc1ccnc(Oc2ccc3c(c2)c(=O)ncn3Cc2c(F)cc(F)cc2F)c1C(F)(F)F,CHEMBL2401666,Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype.,Bioorg. Med. Chem. Lett.,2013.0,23,14,4132,4140,10.1016/j.bmcl.2013.05.037,23768906.0,
13385482,CHEMBL2409564,(cis/trans)-2-(4-(4-(5-(2-phenyl-5-(trifluoromethyl)oxazole-4-carboxamido)-1H-benzo[d]imidazol-2-yl)phenyl)cyclohexyl)acetic acid,CHEMBL2410072,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,100000.0,nM,O=C(O)CC1CCC(c2ccc(-c3nc4cc(NC(=O)c5nc(-c6ccccc6)oc5C(F)(F)F)ccc4[nH]3)cc2)CC1,CHEMBL2406997,Synthesis and biological evaluation of aminobenzimidazole derivatives with a phenylcyclohexyl acetic acid group as anti-obesity and anti-diabetic agents.,Bioorg. Med. Chem. Lett.,2013.0,23,16,4713,4718,10.1016/j.bmcl.2013.05.081,23810496.0,
13385536,CHEMBL2409691,"(S)-5-methyl-5-((4-(4-(pyridin-2-ylmethoxy)phenoxy)piperidin-1-ylsulfonyl)methyl)imidazolidine-2,4-dione",CHEMBL2410299,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,10000.0,nM,C[C@]1(CS(=O)(=O)N2CCC(Oc3ccc(OCc4ccccn4)cc3)CC2)NC(=O)NC1=O,CHEMBL2407043,Hydantoin based inhibitors of MMP13--discovery of AZD6605.,Bioorg. Med. Chem. Lett.,2013.0,23,16,4705,4712,10.1016/j.bmcl.2013.05.089,23810497.0,
13385542,CHEMBL2409710,"(S)-5-methyl-5-((4-(4-(trifluoromethyl)phenoxy)piperidin-1-ylsulfonyl)methyl)imidazolidine-2,4-dione",CHEMBL2410299,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,40000.0,nM,C[C@]1(CS(=O)(=O)N2CCC(Oc3ccc(C(F)(F)F)cc3)CC2)NC(=O)NC1=O,CHEMBL2407043,Hydantoin based inhibitors of MMP13--discovery of AZD6605.,Bioorg. Med. Chem. Lett.,2013.0,23,16,4705,4712,10.1016/j.bmcl.2013.05.089,23810497.0,
13385615,CHEMBL2409676,"(5S)-5-methyl-5-({[4-(5-{[5-(trifluoromethyl)-2-furyl]methoxy}pyrimidin-2-yl)piperazin-1-yl]sulfonyl}methyl)imidazolidine-2,4-dione",CHEMBL2410299,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,10000.0,nM,C[C@]1(CS(=O)(=O)N2CCN(c3ncc(OCc4ccc(C(F)(F)F)o4)cn3)CC2)NC(=O)NC1=O,CHEMBL2407043,Hydantoin based inhibitors of MMP13--discovery of AZD6605.,Bioorg. Med. Chem. Lett.,2013.0,23,16,4705,4712,10.1016/j.bmcl.2013.05.089,23810497.0,
13385616,CHEMBL2409707,"5S-methyl-5-[({4-[4-(1,1,2,2-tetrafluoroethoxy)phenoxy]piperidin-yl}sulfonyl)methyl]imidazolidine-2,4-dione",CHEMBL2410299,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,10000.0,nM,C[C@]1(CS(=O)(=O)N2CCC(Oc3ccc(OC(F)(F)C(F)F)cc3)CC2)NC(=O)NC1=O,CHEMBL2407043,Hydantoin based inhibitors of MMP13--discovery of AZD6605.,Bioorg. Med. Chem. Lett.,2013.0,23,16,4705,4712,10.1016/j.bmcl.2013.05.089,23810497.0,
13391015,CHEMBL2408045,4-(3-Chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline,CHEMBL2412597,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1,CHEMBL2407034,"Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.",ACS Med. Chem. Lett.,2013.0,4,8,742,746,10.1021/ml400146c,24900741.0,
13394016,CHEMBL2407717,"N-(2-Aminophenyl)-4-({[(4S)-4-phenyl-4,5-dihydro-1,3-thiazol-2-yl]amino}methyl)benzamide",CHEMBL2412947,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,16000.0,nM,Nc1ccccc1NC(=O)c1ccc(CNC2=N[C@@H](c3ccccc3)CS2)cc1,CHEMBL2407081,"Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.",J. Med. Chem.,2013.0,56,15,6156,6174,10.1021/jm400634n,23829483.0,
13395056,CHEMBL2407900,5-Methoxy-(E)-3-((3-((E)-2-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)vinyl)-1H-indazol-6-yl)methylene)indolin-2-one,CHEMBL2410117,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins by fluorescence assay,IC50,=,800.0,nM,COc1ccc2c(c1)/C(=C\c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2,CHEMBL2406977,The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.,J. Med. Chem.,2013.0,56,15,6069,6087,10.1021/jm400380m,23829549.0,
13395057,CHEMBL2407899,(E/Z)-3-((3-((E)-2-(6-(4-Methylpiperazin-1-yl)pyridin-3-yl)-vinyl)-1H-indazol-6-yl)methylene)-indolin-2-one,CHEMBL2410117,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins by fluorescence assay,IC50,=,900.0,nM,CN1CCN(c2ccc(/C=C/c3n[nH]c4cc(/C=C5/C(=O)Nc6ccccc65)ccc34)cn2)CC1,CHEMBL2406977,The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.,J. Med. Chem.,2013.0,56,15,6069,6087,10.1021/jm400380m,23829549.0,
13395058,CHEMBL2407897,3-((3-((E)-4-((Dimethylamino)methyl)styryl)-1H-indazol-6-yl)-methylene)indolin-2-one,CHEMBL2410117,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins by fluorescence assay,IC50,=,1300.0,nM,CN(C)Cc1ccc(/C=C/c2n[nH]c3cc(/C=C4/C(=O)Nc5ccccc54)ccc23)cc1,CHEMBL2406977,The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.,J. Med. Chem.,2013.0,56,15,6069,6087,10.1021/jm400380m,23829549.0,
13395060,CHEMBL2407749,(E)-3-((3-((E)-2-(Pyridin-4-yl)vinyl)-1H-indazol-6-yl)-methylene)-indolin-2-one,CHEMBL2410117,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins by fluorescence assay,IC50,=,20.0,nM,O=C1Nc2ccccc2/C1=C\c1ccc2c(/C=C/c3ccncc3)n[nH]c2c1,CHEMBL2406977,The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.,J. Med. Chem.,2013.0,56,15,6069,6087,10.1021/jm400380m,23829549.0,
13402113,CHEMBL2413882,N-{3-[(1-tert-butyl-1H-tetrazol-5-yl)(pyrrolidin-1-yl)methyl]phenyl}-7-Chloroquinolin-4-amine,CHEMBL2416911,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac 4'-hydroxylation after 20 mins by LCMS analysis,IC50,=,3140.0,nM,CC(C)(C)n1nnnc1C(c1cccc(Nc2ccnc3cc(Cl)ccc23)c1)N1CCCC1,CHEMBL2412968,"Tetrazole-based deoxyamodiaquines: synthesis, ADME/PK profiling and pharmacological evaluation as potential antimalarial agents.",Bioorg. Med. Chem.,2013.0,21,17,4904,4913,10.1016/j.bmc.2013.06.067,23896611.0,
13402114,CHEMBL2413881,N-{3-[(diethylamino)(1-tert-butyl-1H-tetrazol-5-yl)methyl]phenyl}-7-Chloroquinolin-4-amine,CHEMBL2416911,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac 4'-hydroxylation after 20 mins by LCMS analysis,IC50,=,2430.0,nM,CCN(CC)C(c1cccc(Nc2ccnc3cc(Cl)ccc23)c1)c1nnnn1C(C)(C)C,CHEMBL2412968,"Tetrazole-based deoxyamodiaquines: synthesis, ADME/PK profiling and pharmacological evaluation as potential antimalarial agents.",Bioorg. Med. Chem.,2013.0,21,17,4904,4913,10.1016/j.bmc.2013.06.067,23896611.0,
13404196,CHEMBL2413849,2-Methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol,CHEMBL2415316,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,Cc1ccc2[nH]c(C(=O)N3CCC(CC(C)(C)O)CC3)cc2c1,CHEMBL2413071,"Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.",Bioorg. Med. Chem.,2013.0,21,17,5261,5270,10.1016/j.bmc.2013.06.025,23845281.0,
13412165,CHEMBL2415099,"(S)-2-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-8-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine",CHEMBL2417294,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8510.0,nM,COc1nc(-c2nc3n(n2)CCC[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1,CHEMBL2413065,Design and synthesis of bicyclic heterocycles as potent γ-secretase modulators.,Bioorg. Med. Chem. Lett.,2013.0,23,17,4794,4800,10.1016/j.bmcl.2013.06.100,23890837.0,
13412166,CHEMBL2415098,"(S)-2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-8-(2-(trifluoromethyl)phenyl)-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazine",CHEMBL2417294,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8430.0,nM,COc1cc(-c2nc3n(n2)CCO[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1,CHEMBL2413065,Design and synthesis of bicyclic heterocycles as potent γ-secretase modulators.,Bioorg. Med. Chem. Lett.,2013.0,23,17,4794,4800,10.1016/j.bmcl.2013.06.100,23890837.0,
13412167,CHEMBL2415097,"(S)-2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-8-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine",CHEMBL2417294,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,4640.0,nM,COc1cc(-c2nc3n(n2)CCC[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1,CHEMBL2413065,Design and synthesis of bicyclic heterocycles as potent γ-secretase modulators.,Bioorg. Med. Chem. Lett.,2013.0,23,17,4794,4800,10.1016/j.bmcl.2013.06.100,23890837.0,
13412168,CHEMBL2415095,"(S)-8-(4-fluoro-2-methylphenyl)-2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine",CHEMBL2417294,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5660.0,nM,COc1cc(-c2nc3n(n2)CCC[C@H]3c2ccc(F)cc2C)ccc1-n1cnc(C)c1,CHEMBL2413065,Design and synthesis of bicyclic heterocycles as potent γ-secretase modulators.,Bioorg. Med. Chem. Lett.,2013.0,23,17,4794,4800,10.1016/j.bmcl.2013.06.100,23890837.0,
13417368,CHEMBL2397347,3-[(R)-4-(Adamantane-1-carbonyl)-3-methyl-piperazin-1-yl]-pyridine-2-carbonitrile,CHEMBL2421134,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH,IC50,>,30000.0,nM,C[C@@H]1CN(c2cccnc2C#N)CCN1C(=O)C12CC3CC(CC(C3)C1)C2,CHEMBL2417457,"Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.",Bioorg. Med. Chem. Lett.,2013.0,23,18,5091,5096,10.1016/j.bmcl.2013.07.029,23932792.0,
13417369,CHEMBL2418359,"((3aR,6aS)-5-(pyridin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(2-azaspiro[4.4]nonan-2-yl)methanone",CHEMBL2421134,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH,IC50,>,30000.0,nM,O=C(N1C[C@@H]2CN(c3ccccn3)C[C@@H]2C1)N1CCC2(CCCC2)C1,CHEMBL2417457,"Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.",Bioorg. Med. Chem. Lett.,2013.0,23,18,5091,5096,10.1016/j.bmcl.2013.07.029,23932792.0,
13417370,CHEMBL2418364,"Adamantan-1-yl-((3aR,6aS)-5-pyridin-2-yl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-methanone",CHEMBL2421134,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH,IC50,>,30000.0,nM,O=C(N1C[C@@H]2CN(c3ccccn3)C[C@@H]2C1)C12CC3CC(CC(C3)C1)C2,CHEMBL2417457,"Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.",Bioorg. Med. Chem. Lett.,2013.0,23,18,5091,5096,10.1016/j.bmcl.2013.07.029,23932792.0,
13424083,CHEMBL2418954,"N-(6-(6-amino-5-(trifluoromethyl)pyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)acetamide",CHEMBL2423248,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CC(=O)Nc1cn2cc(-c3cnc(N)c(C(F)(F)F)c3)ccc2n1,CHEMBL2417393,Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.,Bioorg. Med. Chem. Lett.,2013.0,23,16,4652,4656,10.1016/j.bmcl.2013.06.010,23820386.0,
13424315,CHEMBL2420310,"2-(4-(2-Hydroxyethyl)piperazin-1-yl)-N-(4-(2-morpholino-4-oxo-4H-chromen-8-yl)dibenzo[b,d]thiophen-1-yl)acetamide",CHEMBL2423440,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,O=C(CN1CCN(CCO)CC1)Nc1ccc(-c2cccc3c(=O)cc(N4CCOCC4)oc23)c2sc3ccccc3c12,CHEMBL2417539,"1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.",J. Med. Chem.,2013.0,56,16,6386,6401,10.1021/jm400915j,23855836.0,
13424316,CHEMBL1086377,"2-(4-ethylpiperazin-1-yl)-N-(4-(2-morpholino-4-oxo-4H-chromen-8-yl)dibenzo[b,d]thiophen-1-yl)acetamide",CHEMBL2423440,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCN1CCN(CC(=O)Nc2ccc(-c3cccc4c(=O)cc(N5CCOCC5)oc34)c3sc4ccccc4c23)CC1,CHEMBL2417539,"1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.",J. Med. Chem.,2013.0,56,16,6386,6401,10.1021/jm400915j,23855836.0,
13424317,CHEMBL2420425,"2-(4-Methylpiperazin-1-yl)-N-(4-(2-morpholino-4-oxo-4Hchromen-8-yl)dibenzo[b,d]thiophen-1-yl)acetamide",CHEMBL2423440,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CN1CCN(CC(=O)Nc2ccc(-c3cccc4c(=O)cc(N5CCOCC5)oc34)c3sc4ccccc4c23)CC1,CHEMBL2417539,"1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.",J. Med. Chem.,2013.0,56,16,6386,6401,10.1021/jm400915j,23855836.0,
13425862,CHEMBL2420615,"3-(4-Ethylphenyl)-1,6-dimethyl-pyrimido[5,4-e][1,2,4]triazine-5,7-dione",CHEMBL2423650,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,<,1000.0,nM,CCc1ccc(-c2nc3c(=O)n(C)c(=O)nc-3n(C)n2)cc1,CHEMBL2417532,Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II.,J. Med. Chem.,2013.0,56,16,6352,6370,10.1021/jm400568p,23859074.0,
13433619,CHEMBL2387224,"2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide",CHEMBL2421796,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1c(Cl)cccc1Cl,CHEMBL2417497,Lead identification of novel and selective TYK2 inhibitors.,Eur. J. Med. Chem.,2013.0,67,,175,187,10.1016/j.ejmech.2013.03.070,23867602.0,
13433620,CHEMBL1327969,SID49644368,CHEMBL2421796,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,O=C(Nc1ccncc1)c1c(Cl)cccc1Cl,CHEMBL2417497,Lead identification of novel and selective TYK2 inhibitors.,Eur. J. Med. Chem.,2013.0,67,,175,187,10.1016/j.ejmech.2013.03.070,23867602.0,
13434258,CHEMBL2419495,"Ethyl 6-[4-({[(2,4-Difluorobenzyl)sulfonyl]amino}carbonyl)-piperidin-1-yl]-5-cyano-2-methylnicotinate",CHEMBL2424023,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,4100.0,nM,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3F)CC2)nc1C,CHEMBL2417494,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,2013.0,56,17,7015,7024,10.1021/jm400820m,23899349.0,
13434259,CHEMBL2419494,Ethyl 6-[4-({[(4-Isopropylbenzyl)sulfonyl]amino}carbonyl)-piperidin-1-yl]-5-cyano-2-methylnicotinate,CHEMBL2424023,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,2400.0,nM,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(C(C)C)cc3)CC2)nc1C,CHEMBL2417494,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,2013.0,56,17,7015,7024,10.1021/jm400820m,23899349.0,
13434260,CHEMBL2419493,Ethyl 6-[4-({[(4-Methylbenzyl)sulfonyl]amino}carbonyl)-piperidin-1-yl]-5-cyano-2-methylnicotinate,CHEMBL2424023,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,18000.0,nM,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(C)cc3)CC2)nc1C,CHEMBL2417494,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,2013.0,56,17,7015,7024,10.1021/jm400820m,23899349.0,
13434261,CHEMBL2419492,Ethyl 5-Cyano-6-[4-({[(4-methoxybenzyl)sulfonyl]amino}-carbonyl)piperidin-1-yl]-2-methylnicotinate,CHEMBL2424023,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,15000.0,nM,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(OC)cc3)CC2)nc1C,CHEMBL2417494,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,2013.0,56,17,7015,7024,10.1021/jm400820m,23899349.0,
13434262,CHEMBL2419491,Ethyl 6-[4-({[(4-Fluorobenzyl)sulfonyl]amino}carbonyl)-piperidin-1-yl]-5-cyano-2-methylnicotinate,CHEMBL2424023,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,5900.0,nM,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3)CC2)nc1C,CHEMBL2417494,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,2013.0,56,17,7015,7024,10.1021/jm400820m,23899349.0,
13434263,CHEMBL2419490,Ethyl 6-(4-[(Benzylsulfonyl)carbamoyl]piperidin-1-yl)-5-cyano-2-methylnicotinate,CHEMBL2424023,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,3300.0,nM,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccccc3)CC2)nc1C,CHEMBL2417494,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,2013.0,56,17,7015,7024,10.1021/jm400820m,23899349.0,
13434264,CHEMBL2419487,Ethyl 6-(3-{[(4-Methylbenzyl)sulfonyl]carbamoyl}azetidin-1-yl)-5-cyano-2-methylnicotinate,CHEMBL2424023,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,20000.0,nM,CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(C)cc3)C2)nc1C,CHEMBL2417494,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,2013.0,56,17,7015,7024,10.1021/jm400820m,23899349.0,
13434265,CHEMBL2419486,Ethyl 6-(3-{[(4-Fluorobenzyl)sulfonyl]carbamoyl}azetidin-1-yl)-5-cyano-2-methylnicotinate,CHEMBL2424023,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,20000.0,nM,CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3)C2)nc1C,CHEMBL2417494,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,2013.0,56,17,7015,7024,10.1021/jm400820m,23899349.0,
13434266,CHEMBL2419485,Ethyl 6-(3-{[(4-Chlorobenzyl)sulfonyl]carbamoyl}azetidin-1-yl)-5-cyano-2-methylnicotinate,CHEMBL2424023,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,7100.0,nM,CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(Cl)cc3)C2)nc1C,CHEMBL2417494,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,2013.0,56,17,7015,7024,10.1021/jm400820m,23899349.0,
13434267,CHEMBL2419501,Ethyl 6-(3-[(Benzylsulfonyl)carbamoyl]azetidin-1-yl)-5-cyano-2-methylnicotinate,CHEMBL2424023,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,50000.0,nM,CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccccc3)C2)nc1C,CHEMBL2417494,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,J. Med. Chem.,2013.0,56,17,7015,7024,10.1021/jm400820m,23899349.0,
13435972,CHEMBL2419525,"N-(4-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-ylsulfonyl)benzyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL2423175,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,=,270.0,nM,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)N1Cc2ccncc2C1,CHEMBL2417549,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,2013.0,23,17,4875,4885,10.1016/j.bmcl.2013.06.090,23899614.0,
13435973,CHEMBL2419524,"N-(4-(1-(oxetan-3-yl)piperidin-4-ylsulfonyl)benzyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL2423175,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,=,300.0,nM,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3COC3)CC2)cc1)N1Cc2ccncc2C1,CHEMBL2417549,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,2013.0,23,17,4875,4885,10.1016/j.bmcl.2013.06.090,23899614.0,
13435974,CHEMBL2419518,"N-(4-(1-isopropyl-1H-pyrazol-4-ylsulfonyl)benzyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL2423175,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,=,73.0,nM,CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1,CHEMBL2417549,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,2013.0,23,17,4875,4885,10.1016/j.bmcl.2013.06.090,23899614.0,
13435975,CHEMBL2419516,"N-(4-(6-aminopyridin-3-ylsulfonyl)benzyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL2423175,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,=,65.0,nM,Nc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1,CHEMBL2417549,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,2013.0,23,17,4875,4885,10.1016/j.bmcl.2013.06.090,23899614.0,
13435976,CHEMBL2419515,"N-(4-(6-methylpyridin-3-ylsulfonyl)benzyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL2423175,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,=,77.0,nM,Cc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1,CHEMBL2417549,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,2013.0,23,17,4875,4885,10.1016/j.bmcl.2013.06.090,23899614.0,
13435977,CHEMBL2419505,"N-(4-(phenylsulfonyl)benzyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL2423175,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,=,54.0,nM,O=C(NCc1ccc(S(=O)(=O)c2ccccc2)cc1)N1Cc2ccncc2C1,CHEMBL2417549,"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).",Bioorg. Med. Chem. Lett.,2013.0,23,17,4875,4885,10.1016/j.bmcl.2013.06.090,23899614.0,
13440927,CHEMBL2425161,1-(4-(6-(benzyloxy)pyridin-3-yl)phenyl)-3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)urea,CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(OCc4ccccc4)nc3)cc2)cc1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440928,CHEMBL2425160,1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(6-methoxypyridin-3-yl)phenyl)urea,CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,COc1ccc(-c2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)cc2)cn1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440929,CHEMBL2425159,"1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(4,6-dimethoxypyrimidin-2-yl)phenyl)urea",CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,COc1cc(OC)nc(-c2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)cc2)n1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440930,CHEMBL2425158,1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(pyridin-4-yl)phenyl)urea,CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccncc3)cc2)cc1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440931,CHEMBL2425157,1-(4-(6-aminopyridin-3-yl)phenyl)-3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)urea,CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(N)nc3)cc2)cc1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440932,CHEMBL2425156,1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(pyridin-3-yl)phenyl)urea,CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cccnc3)cc2)cc1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440933,CHEMBL2425155,"1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)urea",CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3nncn3C)cc2)cc1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440934,CHEMBL2425154,1-(4-(1H-tetrazol-1-yl)phenyl)-3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)urea,CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnnn3)cc2)cc1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440935,CHEMBL2425153,1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(oxazol-5-yl)phenyl)urea,CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cnco3)cc2)cc1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440936,CHEMBL2425152,1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(5-methyl-1H-tetrazol-1-yl)phenyl)urea,CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3nnnc3C)cc2)cc1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440937,CHEMBL2425151,"1-(4-(1,2,3-thiadiazol-4-yl)phenyl)-3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)urea",CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3csnn3)cc2)cc1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440938,CHEMBL2425150,1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(5-methyl-1H-imidazol-1-yl)phenyl)urea,CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cncc3C)cc2)cc1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440939,CHEMBL2425149,"1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(4,5-dichloro-1H-imidazol-1-yl)phenyl)urea",CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(Cl)c3Cl)cc2)cc1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440940,CHEMBL2425148,"1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(5-mercapto-4-methyl-4H-1,2,4-triazol-3-yl)phenyl)urea",CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3nnc(S)n3C)cc2)cc1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440941,CHEMBL2425147,"1-(4-(4H-1,2,4-triazol-4-yl)phenyl)-3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)urea",CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,6900.0,nM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnnc3)cc2)cc1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440942,CHEMBL2425146,1-(4-(1H-imidazol-1-yl)phenyl)-3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)urea,CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,800.0,nM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3ccnc3)cc2)cc1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440943,CHEMBL2425145,1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(4-methyl-1H-imidazol-1-yl)phenyl)urea,CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(C)c3)cc2)cc1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13440944,CHEMBL2425144,1-(4-(6-amino-9H-purin-9-yl)phenyl)-3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)urea,CHEMBL2429619,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc4c(N)ncnc43)cc2)cc1,CHEMBL2424535,Fragment-based discovery of focal adhesion kinase inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,19,5401,5409,10.1016/j.bmcl.2013.07.050,23973211.0,
13448749,CHEMBL2425651,"N-(trans-4-(4-(1H-benzo[d][1,2,3]triazol-1-yl)pyrimidin-2-ylamino)cyclohexyl)acetamide",CHEMBL2429333,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,39.0,nM,CC(=O)N[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1,CHEMBL2424622,"Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.",Bioorg. Med. Chem. Lett.,2013.0,23,5,1486,1492,10.1016/j.bmcl.2012.12.047,23352510.0,
13448959,CHEMBL2425952,"4-((2-Ethyl-4-oxo-3-phenethyl-3,4-dihydroquinazolin-8-yl)-methyl)-N-hydroxybenzamide",CHEMBL2429412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using Vivid OOMR as substrate,IC50,=,2100.0,nM,CCc1nc2c(Cc3ccc(C(=O)NO)cc3)cccc2c(=O)n1CCc1ccccc1,CHEMBL2424579,Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.,J. Med. Chem.,2013.0,56,17,6775,6791,10.1021/jm400564j,23905680.0,
13448960,CHEMBL2425958,"(E)-N-Hydroxy-3-(2-methyl-4-oxo-3-phenethyl-3,4-dihydro-quinazolin-7-yl)-acrylamide",CHEMBL2429412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using Vivid OOMR as substrate,IC50,=,9100.0,nM,Cc1nc2cc(/C=C/C(=O)NO)ccc2c(=O)n1CCc1ccccc1,CHEMBL2424579,Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.,J. Med. Chem.,2013.0,56,17,6775,6791,10.1021/jm400564j,23905680.0,
13454716,CHEMBL2425654,"trans-4-(4-(1H-benzo[d][1,2,3]triazol-1-yl)pyrimidin-2-ylamino)cyclohexanol",CHEMBL2429333,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,7.8,nM,O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1,CHEMBL2424622,"Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.",Bioorg. Med. Chem. Lett.,2013.0,23,5,1486,1492,10.1016/j.bmcl.2012.12.047,23352510.0,
13455847,CHEMBL1232461,"2-((4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)-N-ethylacetamide",CHEMBL2433393,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>=,33000.0,nM,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc21,CHEMBL2429783,Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.,J. Med. Chem.,2013.0,56,19,7501,7515,10.1021/jm401088k,24015967.0,
13460065,CHEMBL2431173,5-((3-Fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)-picolinamide,CHEMBL2433742,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,CC1(NC(=O)c2ccc(C#Cc3cccc(F)c3)cn2)COC1,CHEMBL2429814,Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254).,J. Med. Chem.,2013.0,56,20,7976,7996,10.1021/jm401028t,24050755.0,
13463204,CHEMBL2431365,N-[4-[(E)-2-[3-tert-Butyl-5-(5-fluoro-2-oxo-1H-pyridin-3-yl)-2-methoxyphenyl]vinyl]phenyl]methanesulfonamide,CHEMBL2434090,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,COc1c(/C=C/c2ccc(NS(C)(=O)=O)cc2)cc(-c2cc(F)c[nH]c2=O)cc1C(C)(C)C,CHEMBL2429757,Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.,J. Med. Chem.,2013.0,56,20,8163,8182,10.1021/jm401266k,24069953.0,
13463205,CHEMBL2431456,N-[4-[2-[3-tert-Butyl-2-methoxy-5-(2-oxo-1H-pyridin-3yl)-phenyl]ethyl]phenyl]methanesulfonamide,CHEMBL2434090,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,5000.0,nM,COc1c(CCc2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C,CHEMBL2429757,Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.,J. Med. Chem.,2013.0,56,20,8163,8182,10.1021/jm401266k,24069953.0,
13472798,CHEMBL2436632,"(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidin-4-yl)(4-(6-methyl-1,2,4,5-tetrahydroazepino[4,5-b]indol-3(6H)-yl)piperidin-1-yl)methanone",CHEMBL2437986,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,Cn1c2c(c3ccccc31)CCN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)CC2,CHEMBL2434936,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2013.0,23,21,6004,6009,10.1016/j.bmcl.2013.08.013,24035485.0,
13472799,CHEMBL2436630,(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidin-4-yl)(4-(5-fluoroisoindolin-2-yl)piperidin-1-yl)methanone,CHEMBL2437986,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccc(F)cc5C4)CC3)CC2)ccn1,CHEMBL2434936,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2013.0,23,21,6004,6009,10.1016/j.bmcl.2013.08.013,24035485.0,
13472800,CHEMBL2436629,(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidin-4-yl)(4-(isoindolin-2-yl)piperidin-1-yl)methanone,CHEMBL2437986,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5C4)CC3)CC2)ccn1,CHEMBL2434936,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2013.0,23,21,6004,6009,10.1016/j.bmcl.2013.08.013,24035485.0,
13472801,CHEMBL2436628,"2-(1-(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidine-4-carbonyl)piperidin-4-yl)-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile",CHEMBL2437986,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,N#Cc1ccc2c(c1)CN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)CC2,CHEMBL2434936,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2013.0,23,21,6004,6009,10.1016/j.bmcl.2013.08.013,24035485.0,
13472802,CHEMBL2436627,"(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidin-4-yl)(4-(3,4-dihydroisoquinolin-2(1H)-yl)piperidin-1-yl)methanone",CHEMBL2437986,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCc5ccccc5C4)CC3)CC2)ccn1,CHEMBL2434936,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2013.0,23,21,6004,6009,10.1016/j.bmcl.2013.08.013,24035485.0,
13472803,CHEMBL2436626,"(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidin-4-yl)(4-(2,3-dihydro-1H-benzo[e][1,4]diazepin-4(5H)-yl)piperidin-1-yl)methanone",CHEMBL2437986,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCNc5ccccc5C4)CC3)CC2)ccn1,CHEMBL2434936,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2013.0,23,21,6004,6009,10.1016/j.bmcl.2013.08.013,24035485.0,
13472804,CHEMBL2436625,"(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidin-4-yl)(4-(7-methoxy-4,5-dihydro-1H-benzo[c]azepin-2(3H)-yl)piperidin-1-yl)methanone",CHEMBL2437986,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,COc1ccc2c(c1)CCCN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)C2,CHEMBL2434936,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2013.0,23,21,6004,6009,10.1016/j.bmcl.2013.08.013,24035485.0,
13472805,CHEMBL2436624,"(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidin-4-yl)(4-(8-methoxy-4,5-dihydro-1H-benzo[c]azepin-2(3H)-yl)piperidin-1-yl)methanone",CHEMBL2437986,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,COc1ccc2c(c1)CN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)CCC2,CHEMBL2434936,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2013.0,23,21,6004,6009,10.1016/j.bmcl.2013.08.013,24035485.0,
13472806,CHEMBL2436623,"(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidin-4-yl)(4-(4,5-dihydro-1H-benzo[c]azepin-2(3H)-yl)piperidin-1-yl)methanone",CHEMBL2437986,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCCc5ccccc5C4)CC3)CC2)ccn1,CHEMBL2434936,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2013.0,23,21,6004,6009,10.1016/j.bmcl.2013.08.013,24035485.0,
13472807,CHEMBL2436622,"(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidin-4-yl)(4-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)piperidin-1-yl)methanone",CHEMBL2437986,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCc5ccccc5CC4)CC3)CC2)ccn1,CHEMBL2434936,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2013.0,23,21,6004,6009,10.1016/j.bmcl.2013.08.013,24035485.0,
13472808,CHEMBL2436621,"5-(1-(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidine-4-carbonyl)piperidin-4-yl)-9-methyl-5,6-dihydro-4H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-one",CHEMBL2437986,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,Cc1nnc2n1-c1sccc1C(=O)N(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)C2,CHEMBL2434936,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2013.0,23,21,6004,6009,10.1016/j.bmcl.2013.08.013,24035485.0,
13472809,CHEMBL2436620,"(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidin-4-yl)(4-(9-methyl-4H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-5(6H)-yl)piperidin-1-yl)methanone",CHEMBL2437986,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,Cc1nnc2n1-c1sccc1CN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)C2,CHEMBL2434936,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2013.0,23,21,6004,6009,10.1016/j.bmcl.2013.08.013,24035485.0,
13472812,CHEMBL2436617,(4-(10H-phenothiazin-10-yl)piperidin-1-yl)(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidin-4-yl)methanone,CHEMBL2437986,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4c5ccccc5Sc5ccccc54)CC3)CC2)ccn1,CHEMBL2434936,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2013.0,23,21,6004,6009,10.1016/j.bmcl.2013.08.013,24035485.0,
13472813,CHEMBL2436616,"(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidin-4-yl)(4-(6,11-dihydro-5H-dibenzo[b,e]azepin-5-yl)piperidin-1-yl)methanone",CHEMBL2437986,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,4000.0,nM,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5Cc5ccccc54)CC3)CC2)ccn1,CHEMBL2434936,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2013.0,23,21,6004,6009,10.1016/j.bmcl.2013.08.013,24035485.0,
13472814,CHEMBL2436633,"(4-(5H-dibenzo[c,e]azepin-6(7H)-yl)piperidin-1-yl)(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidin-4-yl)methanone",CHEMBL2437986,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5-c5ccccc5C4)CC3)CC2)ccn1,CHEMBL2434936,Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.,Bioorg. Med. Chem. Lett.,2013.0,23,21,6004,6009,10.1016/j.bmcl.2013.08.013,24035485.0,
13475232,CHEMBL2436945,"cis-rac-2-(2-ethyl-8-oxo-7,8-dihydropyrido[3,4-d]pyrimidin-4-ylamino)cyclopentanecarbonitrile",CHEMBL2438568,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCc1nc(N[C@@H]2CCC[C@@H]2C#N)c2cc[nH]c(=O)c2n1,CHEMBL2434881,Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,21,5923,5930,10.1016/j.bmcl.2013.08.082,24042009.0,
13475305,CHEMBL2436976,"5-(5-(3,4,5-Trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine",CHEMBL2439899,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as inhibition of midazolam metabolism by HPLC/MS analysis,IC50,>,30000.0,nM,COc1cc(-c2cnc3[nH]cc(-c4cnc(N)nc4)c3c2)cc(OC)c1OC,CHEMBL2434948,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,2013.0,56,20,8032,8048,10.1021/jm401094t,24044867.0,
13475306,CHEMBL2436983,"5-(3-(1H-Indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-2-amine",CHEMBL2439899,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as inhibition of midazolam metabolism by HPLC/MS analysis,IC50,>,30000.0,nM,Nc1ncc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cn1,CHEMBL2434948,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,2013.0,56,20,8032,8048,10.1021/jm401094t,24044867.0,
13475307,CHEMBL2436982,"5-(5-(3,4,5-Trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2-amine",CHEMBL2439899,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as inhibition of midazolam metabolism by HPLC/MS analysis,IC50,>,30000.0,nM,COc1cc(-c2cnc3[nH]cc(-c4ccc(N)nc4)c3c2)cc(OC)c1OC,CHEMBL2434948,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,2013.0,56,20,8032,8048,10.1021/jm401094t,24044867.0,
13475308,CHEMBL2436980,"3-(1H-Indol-5-yl)-5-(3,4,5-trimethoxyphenyl)-1H-pyrrolo-[2,3-b]pyridine",CHEMBL2439899,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as inhibition of midazolam metabolism by HPLC/MS analysis,IC50,>,30000.0,nM,COc1cc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cc(OC)c1OC,CHEMBL2434948,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,2013.0,56,20,8032,8048,10.1021/jm401094t,24044867.0,
13475309,CHEMBL2436978,"3-(1H-Indol-5-yl)-5-(4-((4-methylpiperazin-1-yl)methyl)-phenyl)-1H-pyrrolo[2,3-b]pyridine",CHEMBL2439899,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as inhibition of midazolam metabolism by HPLC/MS analysis,IC50,>,30000.0,nM,CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1,CHEMBL2434948,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,2013.0,56,20,8032,8048,10.1021/jm401094t,24044867.0,
13476455,CHEMBL2436981,"5-(3-(1H-Indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2-amine",CHEMBL2439899,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as inhibition of midazolam metabolism by HPLC/MS analysis,IC50,=,13700.0,nM,Nc1ccc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cn1,CHEMBL2434948,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",J. Med. Chem.,2013.0,56,20,8032,8048,10.1021/jm401094t,24044867.0,
13476723,CHEMBL2435856,(R)-4-((6-Ethyl-5-((4-(2-oxo-5-phenyl-3-(tetrahydro-2Hpyran-4-yl)imidazolidin-1-yl)piperidin-1-yl)methyl)pyridin-2-yl)oxy)benzoic Acid,CHEMBL2439727,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,73000.0,nM,CCc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2ccccc2)CC1,CHEMBL2434870,Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.,J. Med. Chem.,2013.0,56,20,8049,8065,10.1021/jm401101p,24090135.0,
13476730,CHEMBL2434978,(R)-4-((5-((4-(2-Oxo-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-imidazolidin-1-yl)piperidin-1-yl)methyl)pyridin-2-yl)thio)-benzoic Acid,CHEMBL2439727,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,60000.0,nM,O=C(O)c1ccc(Sc2ccc(CN3CCC(N4C(=O)N(C5CCOCC5)C[C@H]4c4ccccc4)CC3)cn2)cc1,CHEMBL2434870,Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.,J. Med. Chem.,2013.0,56,20,8049,8065,10.1021/jm401101p,24090135.0,
13476737,CHEMBL2435852,(R)-4-((6-Methyl-5-((4-(2-oxo-5-phenyl-3-(tetrahydro-2Hpyran-4-yl)imidazolidin-1-yl)piperidin-1-yl)methyl)pyridin-2-yl)oxy)benzoic Acid,CHEMBL2439727,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,Cc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2ccccc2)CC1,CHEMBL2434870,Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.,J. Med. Chem.,2013.0,56,20,8049,8065,10.1021/jm401101p,24090135.0,
13476744,CHEMBL2435858,(R)-4-((6-Methyl-5-((4-(2-oxo-5-phenyl-3-(tetrahydro-2Hpyran-4-yl)imidazolidin-1-yl)piperidin-1-yl)methyl)pyridin-2-yl)oxy)benzamide,CHEMBL2439727,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,26000.0,nM,Cc1nc(Oc2ccc(C(N)=O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2ccccc2)CC1,CHEMBL2434870,Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.,J. Med. Chem.,2013.0,56,20,8049,8065,10.1021/jm401101p,24090135.0,
13476751,CHEMBL2435853,(R)-4-((5-((4-(5-(3-Chlorophenyl)-2-oxo-3-(tetrahydro-2Hpyran-4-yl)imidazolidin-1-yl)piperidin-1-yl)methyl)-6-methylpyridin-2-yl)oxy)benzoic Acid,CHEMBL2439727,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,100000.0,nM,Cc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2cccc(Cl)c2)CC1,CHEMBL2434870,Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.,J. Med. Chem.,2013.0,56,20,8049,8065,10.1021/jm401101p,24090135.0,
13478901,CHEMBL2437199,"(S)-N-((3-(3-Fluoro-4-(1-(methylcarbamoyl)-[1,2,5]triazepan-5-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-Omethylthiocarbamate",CHEMBL2438457,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation after 20 mins by LC/MS/MS analysis,IC50,>,20000.0,nM,CNC(=O)N1CCN(c2ccc(N3C[C@H](CNC(=S)OC)OC3=O)cc2F)CCN1,CHEMBL2434863,"Synthesis and in vitro/in vivo antibacterial activity of oxazolidinones having thiocarbamate at C-5 on the A-ring and an amide- or urea-substituted [1,2,5]triazepane or [1,2,5]oxadiazepane as the C-ring.",Eur. J. Med. Chem.,2013.0,69,,262,277,10.1016/j.ejmech.2013.08.002,24044938.0,
13478902,CHEMBL2437330,"(S)-N-((3-(3-Fluoro-4-(1-(difluoroacetyl)[1,2,5]triazepan-5-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-O-methylthiocarbamate",CHEMBL2438457,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation after 20 mins by LC/MS/MS analysis,IC50,>,20000.0,nM,COC(=S)NC[C@H]1CN(c2ccc(N3CCNN(C(=O)C(F)F)CC3)c(F)c2)C(=O)O1,CHEMBL2434863,"Synthesis and in vitro/in vivo antibacterial activity of oxazolidinones having thiocarbamate at C-5 on the A-ring and an amide- or urea-substituted [1,2,5]triazepane or [1,2,5]oxadiazepane as the C-ring.",Eur. J. Med. Chem.,2013.0,69,,262,277,10.1016/j.ejmech.2013.08.002,24044938.0,
13482575,CHEMBL2436226,"(S)-N-((3S,4S)-5-Acetyl-7-cyano-4-methyl-1-((2-methylnaphthalen-1-yl)methyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]-diazepin-3-yl)-2-(methylamino)propanamide Hydrochloride",CHEMBL2439941,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C.Cl,CHEMBL2434833,Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,2013.0,56,20,7788,7803,10.1021/jm400732v,24093940.0,
13482576,CHEMBL2436225,"(S)-N-((3S,4S)-5-Acetyl-7-cyano-1-((2-methoxynaphthalen-1-yl)-methyl)-4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]-diazepin-3-yl)-2-(methylamino)propanamide Hydrochloride",CHEMBL2439941,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C.Cl,CHEMBL2434833,Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,J. Med. Chem.,2013.0,56,20,7788,7803,10.1021/jm400732v,24093940.0,
13491957,CHEMBL2441346,"5-{1-[(3,5-dimethyl-1H-pyrazol-1-yl)acetyl]-4-fluoro-2,3-dihydro-1H-indol-5-yl}-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine",CHEMBL2444388,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 5 to 60 mins by LC-MS/MS analysis,IC50,>,25000.0,nM,Cc1cc(C)n(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,CHEMBL2440009,Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development.,ACS Med. Chem. Lett.,2013.0,4,10,964,968,10.1021/ml400228e,24900593.0,
13491958,CHEMBL2441342,"5-(4-fluoro-1-{[6-(trifluoromethyl)-2-pyridinyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine",CHEMBL2444388,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 5 to 60 mins by LC-MS/MS analysis,IC50,=,19200.0,nM,Cn1cc(-c2ccc3c(c2F)CCN3C(=O)Cc2cccc(C(F)(F)F)n2)c2c(N)ncnc21,CHEMBL2440009,Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development.,ACS Med. Chem. Lett.,2013.0,4,10,964,968,10.1021/ml400228e,24900593.0,
13491959,CHEMBL2441340,"5-{4-fluoro-1-[(6-methyl-2-pyridinyl)acetyl]-2,3-dihydro-1H-indol-5-yl}-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine",CHEMBL2444388,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 5 to 60 mins by LC-MS/MS analysis,IC50,=,24700.0,nM,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,CHEMBL2440009,Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development.,ACS Med. Chem. Lett.,2013.0,4,10,964,968,10.1021/ml400228e,24900593.0,
13491960,CHEMBL2171124,"7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",CHEMBL2444388,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 5 to 60 mins by LC-MS/MS analysis,IC50,=,4500.0,nM,Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21,CHEMBL2440009,Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development.,ACS Med. Chem. Lett.,2013.0,4,10,964,968,10.1021/ml400228e,24900593.0,
13492124,CHEMBL2441567,"(E)-1-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7, 8-dihydro-6H-[1, 4]oxazino[3,2-g]quinazolin-6-yl)-4-(dimethylamino)but-2-en-1-one",CHEMBL2444705,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 after 20 mins by LC/MS/MS analysis,IC50,>,10000.0,nM,CN(C)C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,CHEMBL2440024,"Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.",ACS Med. Chem. Lett.,2013.0,4,10,974,978,10.1021/ml4002437,24900594.0,
13492125,CHEMBL2441565,"(E)-1-(4-((3-chloro-4-fluorophenyl)amino)-7,8-dihydro-6H-[1,4]oxazino[3,2 g]quinazolin-6-yl)-4-(dimethylamino)but-2-en-1-one",CHEMBL2444705,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 after 20 mins by LC/MS/MS analysis,IC50,>,10000.0,nM,CN(C)C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,CHEMBL2440024,"Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.",ACS Med. Chem. Lett.,2013.0,4,10,974,978,10.1021/ml4002437,24900594.0,
13509376,CHEMBL2442750,"[1-(4-Methanesulfonylbenzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]acetic acid",CHEMBL2447521,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1,CHEMBL2440029,"Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.",Bioorg. Med. Chem.,2013.0,21,21,6582,6591,10.1016/j.bmc.2013.08.025,24021582.0,
13516054,CHEMBL2441208,N-(6-(4-(2-chlorophenylcarbamoyl)piperazin-1-yl)pyridin-3-yl)-2-(piperidin-1-yl)-4-(trifluoromethyl)oxazole-5-carboxamide,CHEMBL2444670,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) coincubated with substrate,IC50,=,6400.0,nM,O=C(Nc1ccc(N2CCN(C(=O)Nc3ccccc3Cl)CC2)nc1)c1oc(N2CCCCC2)nc1C(F)(F)F,CHEMBL2440008,Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.,Bioorg. Med. Chem. Lett.,2013.0,23,23,6410,6414,10.1016/j.bmcl.2013.09.048,24120540.0,
13516055,CHEMBL2441200,isopropyl 4-(5-(2-(piperidin-1-yl)-4-(trifluoromethyl)oxazole-5-carboxamido)pyridin-2-yl)piperazine-1-carboxylate,CHEMBL2444670,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) coincubated with substrate,IC50,>,20000.0,nM,CC(C)OC(=O)N1CCN(c2ccc(NC(=O)c3oc(N4CCCCC4)nc3C(F)(F)F)cn2)CC1,CHEMBL2440008,Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.,Bioorg. Med. Chem. Lett.,2013.0,23,23,6410,6414,10.1016/j.bmcl.2013.09.048,24120540.0,
13516056,CHEMBL2441208,N-(6-(4-(2-chlorophenylcarbamoyl)piperazin-1-yl)pyridin-3-yl)-2-(piperidin-1-yl)-4-(trifluoromethyl)oxazole-5-carboxamide,CHEMBL2444671,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) preincubated prior to substrate addition,IC50,=,9700.0,nM,O=C(Nc1ccc(N2CCN(C(=O)Nc3ccccc3Cl)CC2)nc1)c1oc(N2CCCCC2)nc1C(F)(F)F,CHEMBL2440008,Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.,Bioorg. Med. Chem. Lett.,2013.0,23,23,6410,6414,10.1016/j.bmcl.2013.09.048,24120540.0,
13516057,CHEMBL2441200,isopropyl 4-(5-(2-(piperidin-1-yl)-4-(trifluoromethyl)oxazole-5-carboxamido)pyridin-2-yl)piperazine-1-carboxylate,CHEMBL2444671,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) preincubated prior to substrate addition,IC50,>,20000.0,nM,CC(C)OC(=O)N1CCN(c2ccc(NC(=O)c3oc(N4CCCCC4)nc3C(F)(F)F)cn2)CC1,CHEMBL2440008,Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.,Bioorg. Med. Chem. Lett.,2013.0,23,23,6410,6414,10.1016/j.bmcl.2013.09.048,24120540.0,
13516474,CHEMBL2448709,,CHEMBL2448769,A,,,Cytochrome P450 2C9,DNDI: CYP Inhibition,IC50,>,20000.0,nM,CN1CCC(NCC(O)COc2ccc3cc(Br)ccc3c2)CC1,CHEMBL2448688,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,,,,,,10.6019/CHEMBL2448688,,
13516558,CHEMBL2448712,,CHEMBL2448769,A,,,Cytochrome P450 2C9,DNDI: CYP Inhibition,IC50,>,20000.0,nM,N#Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1,CHEMBL2448688,Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Exported from HEOS 25-Oct-2013. See also related datasets CHEMBL3137440 and CHEMBL3137386.,,,,,,,10.6019/CHEMBL2448688,,
13830535,CHEMBL3087669,"3,5-dimethyl-N-(2-methyl-4-((2S,3'S)-2-methyl-1,3'-bipyrrolidin-1'-yl)phenyl)isoxazole-4-carboxamide",CHEMBL3089231,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) after 4 hrs,IC50,>,100000.0,nM,Cc1cc(N2CC[C@H](N3CCC[C@@H]3C)C2)ccc1NC(=O)c1c(C)noc1C,CHEMBL3085708,"Identification and profiling of 3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3'S)-2-methyl-[1,3']bipyrrolidinyl-1'-yl)phenyl] amide as histamine H(3) receptor antagonist for the treatment of depression.",Bioorg. Med. Chem. Lett.,2013.0,23,23,6269,6273,10.1016/j.bmcl.2013.09.081,24139584.0,
13835795,CHEMBL3086045,"((1S,2S,4S)-4-(4-chlorobenzylamino)-2-o-tolylcyclohexyl)(3,3-diphenylazetidin-1-yl)methanone",CHEMBL3090537,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1ccccc1[C@H]1C[C@@H](NCc2ccc(Cl)cc2)CC[C@@H]1C(=O)N1CC(c2ccccc2)(c2ccccc2)C1,CHEMBL3085718,Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,23,6228,6233,10.1016/j.bmcl.2013.09.094,24157366.0,
13836194,CHEMBL3086078,Dimethylcarbamic acid 6-fluoro-3-[2-fluoro-3-(sulfamoylamino)benzyl]-4-methyl-2-oxo-2H-chromen-7-yl ester,CHEMBL3090620,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 30 mins post NADPH addition followed by substrate addition measured after 5 mins by LC/MS/MS analysis,IC50,=,12000.0,nM,Cc1c(Cc2cccc(NS(N)(=O)=O)c2F)c(=O)oc2cc(OC(=O)N(C)C)c(F)cc12,CHEMBL3085763,The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,23,6223,6227,10.1016/j.bmcl.2013.10.001,24157370.0,
13836195,CHEMBL3086078,Dimethylcarbamic acid 6-fluoro-3-[2-fluoro-3-(sulfamoylamino)benzyl]-4-methyl-2-oxo-2H-chromen-7-yl ester,CHEMBL3090621,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 30 mins followed by NADPH and substrate addition measured after 5 mins by LC/MS/MS analysis,IC50,=,12000.0,nM,Cc1c(Cc2cccc(NS(N)(=O)=O)c2F)c(=O)oc2cc(OC(=O)N(C)C)c(F)cc12,CHEMBL3085763,The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,23,6223,6227,10.1016/j.bmcl.2013.10.001,24157370.0,
13844497,CHEMBL3092124,"1-((2-chloroquinolin-3-yl)methyl)-6-fluoro-5-methyl-3-(2-oxo-1,2-dihydropyridin-3-yl)-1H-indole-2-carboxylic acid",CHEMBL3094691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes measured after compound pre-incubation,IC50,>,50000.0,nM,Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)O)n(Cc3cc4ccccc4nc3Cl)c2cc1F,CHEMBL3091412,Discovery of an irreversible HCV NS5B polymerase inhibitor.,Bioorg. Med. Chem. Lett.,2013.0,23,24,6585,6587,10.1016/j.bmcl.2013.10.060,24252545.0,
13844503,CHEMBL3092124,"1-((2-chloroquinolin-3-yl)methyl)-6-fluoro-5-methyl-3-(2-oxo-1,2-dihydropyridin-3-yl)-1H-indole-2-carboxylic acid",CHEMBL3094698,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes measured after concurrent incubation,IC50,>,50000.0,nM,Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)O)n(Cc3cc4ccccc4nc3Cl)c2cc1F,CHEMBL3091412,Discovery of an irreversible HCV NS5B polymerase inhibitor.,Bioorg. Med. Chem. Lett.,2013.0,23,24,6585,6587,10.1016/j.bmcl.2013.10.060,24252545.0,
13845442,CHEMBL3092130,"2-(4-amino-3,5-diphenyl-1H-pyrazol-1-yl)thiazole-4-carboxylic acid",CHEMBL3095955,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,5620.0,nM,Nc1c(-c2ccccc2)nn(-c2nc(C(=O)O)cs2)c1-c1ccccc1,CHEMBL3091274,SAR-based optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as highly potent EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,2013.0,23,24,6569,6576,10.1016/j.bmcl.2013.10.065,24252546.0,
13845443,CHEMBL2442495,"2-(4-Methyl-3,5-diphenyl-1H-pyrazol-1-yl)thiazole-4-carboxylic acid",CHEMBL3095955,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,10000.0,nM,Cc1c(-c2ccccc2)nn(-c2nc(C(=O)O)cs2)c1-c1ccccc1,CHEMBL3091274,SAR-based optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as highly potent EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,2013.0,23,24,6569,6576,10.1016/j.bmcl.2013.10.065,24252546.0,
13851489,CHEMBL3092423,"(R)-3-(3-Fluoro-4-([1,2,4]triazolo[1,5-a]pyridin-7-yl)phenyl)-5-([1,2,3]triazol-1-yl)methyloxazolidin-2-one",CHEMBL3096586,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as tolbutamide hydroxylation after 20 mins by LC-MS/MS analysis,IC50,>,20000.0,nM,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2ccn3ncnc3c2)c(F)c1,CHEMBL3091359,Potent oxazolidinone antibacterials with heteroaromatic C-ring substructure.,ACS Med. Chem. Lett.,2013.0,4,11,1074,1078,10.1021/ml400280z,24900607.0,
13851490,CHEMBL3092421,"(R)-3-(3-Fluoro-4-(imidazo[1,2-a]pyridin-7-yl)phenyl)-5-([1,2,3]triazol-1-yl)methyloxazolidin-2-one",CHEMBL3096586,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as tolbutamide hydroxylation after 20 mins by LC-MS/MS analysis,IC50,>,20000.0,nM,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2ccn3ccnc3c2)c(F)c1,CHEMBL3091359,Potent oxazolidinone antibacterials with heteroaromatic C-ring substructure.,ACS Med. Chem. Lett.,2013.0,4,11,1074,1078,10.1021/ml400280z,24900607.0,
13851491,CHEMBL3092419,"(S)-(N-3-(3-Fluoro-4-([1,2,4]triazolo[1,5-a]pyridin-7-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl acetamide",CHEMBL3096586,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as tolbutamide hydroxylation after 20 mins by LC-MS/MS analysis,IC50,>,20000.0,nM,CC(=O)NC[C@H]1CN(c2ccc(-c3ccn4ncnc4c3)c(F)c2)C(=O)O1,CHEMBL3091359,Potent oxazolidinone antibacterials with heteroaromatic C-ring substructure.,ACS Med. Chem. Lett.,2013.0,4,11,1074,1078,10.1021/ml400280z,24900607.0,
13851492,CHEMBL3092417,"(S)-(N-3-(3-Fluoro-4-(imidazo[1,2-a]pyridin-7-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl acetamide",CHEMBL3096586,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as tolbutamide hydroxylation after 20 mins by LC-MS/MS analysis,IC50,>,20000.0,nM,CC(=O)NC[C@H]1CN(c2ccc(-c3ccn4ccnc4c3)c(F)c2)C(=O)O1,CHEMBL3091359,Potent oxazolidinone antibacterials with heteroaromatic C-ring substructure.,ACS Med. Chem. Lett.,2013.0,4,11,1074,1078,10.1021/ml400280z,24900607.0,
13851493,CHEMBL126,N-[(R)-3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide,CHEMBL3096586,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as tolbutamide hydroxylation after 20 mins by LC-MS/MS analysis,IC50,>,20000.0,nM,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,CHEMBL3091359,Potent oxazolidinone antibacterials with heteroaromatic C-ring substructure.,ACS Med. Chem. Lett.,2013.0,4,11,1074,1078,10.1021/ml400280z,24900607.0,
13862584,CHEMBL2414256,"N1-((1-tert-Butyl-1H-tetrazol-5-yl)(4-chlorophenyl)methyl)-N2-(7-chloroquinolin-4-yl)ethane-1,2-diamine",CHEMBL3100524,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac 4'-hydroxylation after 20 mins by LC-MS/MS analysis,IC50,=,8910.0,nM,CC(C)(C)n1nnnc1C(NCCNc1ccnc2cc(Cl)ccc12)c1ccc(Cl)cc1,CHEMBL3098028,Synthesis and in vitro and in vivo pharmacological evaluation of new 4-aminoquinoline-based compounds.,ACS Med. Chem. Lett.,2013.0,4,12,1198,1202,10.1021/ml400311r,24900630.0,
13862586,CHEMBL3099819,"N1-((1-tert-butyl-1H-tetrazol-5-yl)(p-tolyl)methyl)-N2-(7-chloroquinolin-4-yl)ethane-1,2-diamine",CHEMBL3100524,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac 4'-hydroxylation after 20 mins by LC-MS/MS analysis,IC50,=,10300.0,nM,Cc1ccc(C(NCCNc2ccnc3cc(Cl)ccc23)c2nnnn2C(C)(C)C)cc1,CHEMBL3098028,Synthesis and in vitro and in vivo pharmacological evaluation of new 4-aminoquinoline-based compounds.,ACS Med. Chem. Lett.,2013.0,4,12,1198,1202,10.1021/ml400311r,24900630.0,
13862719,CHEMBL3099695,"(R)-4-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluorobenzonitrile",CHEMBL3101164,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,N#Cc1ccc([C@H]2CCc3cncn32)c(F)c1,CHEMBL3098017,Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors.,ACS Med. Chem. Lett.,2013.0,4,12,1203,1207,10.1021/ml400324c,24900631.0,
13863160,CHEMBL3098241,"(1R,2S,3S,4S,5S)-4-(7-((1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-fluorocyclopentane-1,2,3-triol",CHEMBL3101013,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8820.0,nM,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H]3F)c2n1,CHEMBL3098001,Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.,Bioorg. Med. Chem. Lett.,2014.0,24,1,141,146,10.1016/j.bmcl.2013.11.055,24332627.0,
13880533,CHEMBL3105228,"(-)-(S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one",CHEMBL3108383,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,IC50,=,7400.0,nM,O=C(c1ccc(F)c(F)c1)N1CCN2C(=O)c3ccccc3[C@@]12c1ccc(Cl)cc1,CHEMBL3102750,"Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375).",J. Med. Chem.,2013.0,56,22,9351,9355,10.1021/jm4013246,24164599.0,
13883971,CHEMBL3104250,(E)-N'-(1-(5-Chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)Benzohydrazide,CHEMBL3108399,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8040.0,nM,C/C(=N\NC(=O)c1cccc(S(=O)(=O)N2CCOCC2)c1)c1cc(Cl)ccc1O,CHEMBL3102716,"High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors.",J. Med. Chem.,2013.0,56,23,9496,9508,10.1021/jm400870h,24237195.0,
13889203,CHEMBL3103437,5-(2-Biphenyl-4-yl-adamantan-2-ylmethyl)-1H-tetrazole,CHEMBL3106833,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,c1ccc(-c2ccc(C3(Cc4nnn[nH]4)C4CC5CC(C4)CC3C5)cc2)cc1,CHEMBL3102707,Synthesis and structure-activity relationship of 2-adamantylmethyl tetrazoles as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).,Bioorg. Med. Chem. Lett.,2014.0,24,2,654,660,10.1016/j.bmcl.2013.11.066,24360604.0,
13890696,CHEMBL3109337,"8-(((3R,4R)-3-fluoropiperidin-4-yl)oxy)-2-(7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl)quinolone",CHEMBL3111866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@H]5F)c4n3)cnc2c1,CHEMBL3108676,"Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral Bioavailability.",ACS Med. Chem. Lett.,2014.0,5,1,78,83,10.1021/ml4003953,24900776.0,
13890697,CHEMBL3109356,"8-((cis)-3-fluoropiperidin-4-yloxy)-2-(7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl)quinolone",CHEMBL3111866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@@H]5F)c4n3)cnc2c1,CHEMBL3108676,"Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral Bioavailability.",ACS Med. Chem. Lett.,2014.0,5,1,78,83,10.1021/ml4003953,24900776.0,
13890698,CHEMBL3109338,"8-((3S,4S)-3-fluoropiperidin-4-yloxy)-2-(7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl)quinoline",CHEMBL3111866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,COCCOc1ccn2c(-c3ccc4cccc(O[C@H]5CCNC[C@@H]5F)c4n3)cnc2c1,CHEMBL3108676,"Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral Bioavailability.",ACS Med. Chem. Lett.,2014.0,5,1,78,83,10.1021/ml4003953,24900776.0,
13890699,CHEMBL3109337,"8-(((3R,4R)-3-fluoropiperidin-4-yl)oxy)-2-(7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl)quinolone",CHEMBL3111866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@H]5F)c4n3)cnc2c1,CHEMBL3108676,"Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral Bioavailability.",ACS Med. Chem. Lett.,2014.0,5,1,78,83,10.1021/ml4003953,24900776.0,
13890700,CHEMBL3109340,"2-(7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl)-8-(piperidin-4-yloxy)quinoline",CHEMBL3111866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,COCCOc1ccn2c(-c3ccc4cccc(OC5CCNCC5)c4n3)cnc2c1,CHEMBL3108676,"Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral Bioavailability.",ACS Med. Chem. Lett.,2014.0,5,1,78,83,10.1021/ml4003953,24900776.0,
13896478,CHEMBL3109985,"(1R,2R,3R)-2-(4-(2-Cyclopropyloxazol-5-yl)phenyl)-N-hydroxy-3-phenylcyclopropanecarboxamide",CHEMBL3111802,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,23000.0,nM,O=C(NO)[C@@H]1[C@H](c2ccccc2)[C@H]1c1ccc(-c2cnc(C3CC3)o2)cc1,CHEMBL3108758,"Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.",J. Med. Chem.,2013.0,56,24,9934,9954,10.1021/jm4011884,24261862.0,
13896479,CHEMBL3109984,"(1R,2R,3R)-N-Hydroxy-2-(4-(2-methyloxazol-5-yl)phenyl)-3-phenylcyclopropanecarboxamide",CHEMBL3111802,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,Cc1ncc(-c2ccc([C@H]3[C@H](C(=O)NO)[C@@H]3c3ccccc3)cc2)o1,CHEMBL3108758,"Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.",J. Med. Chem.,2013.0,56,24,9934,9954,10.1021/jm4011884,24261862.0,
13896480,CHEMBL3110021,"(1R,2R,3R)-N-Hydroxy-2-(4-(oxazol-5-yl)phenyl)-3-phenylcyclopropanecarboxamide",CHEMBL3111802,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,400.0,nM,O=C(NO)[C@@H]1[C@H](c2ccccc2)[C@H]1c1ccc(-c2cnco2)cc1,CHEMBL3108758,"Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.",J. Med. Chem.,2013.0,56,24,9934,9954,10.1021/jm4011884,24261862.0,
13902061,CHEMBL3114787,"N-(4-chloro-3-fluorobenzyl)-1-methyl-N-(((1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl)-1H-imidazole-4-carboxamide",CHEMBL3119198,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CN1C[C@H]2[C@@H](C1)[C@@H]2CN(Cc1ccc(Cl)c(F)c1)C(=O)c1cn(C)cn1,CHEMBL3112567,Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead.,Bioorg. Med. Chem. Lett.,2014.0,24,4,1067,1070,10.1016/j.bmcl.2014.01.013,24461352.0,
13902062,CHEMBL3114971,"N-(((1R,5S)-6-(cyclopropylmethyl)-3-(1-methyl-1H-imidazol-4-ylsulfonyl)-3-azabicyclo[3.1.0]hexan-6-yl)methyl)-2-(trifluoromethyl)benzamide",CHEMBL3119198,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cn1cnc(S(=O)(=O)N2C[C@H]3[C@@H](C2)[C@]3(CNC(=O)c2ccccc2C(F)(F)F)CC2CC2)c1,CHEMBL3112567,Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead.,Bioorg. Med. Chem. Lett.,2014.0,24,4,1067,1070,10.1016/j.bmcl.2014.01.013,24461352.0,
13902063,CHEMBL3114968,"N-(((1R,5S)-3-(1-methyl-1H-imidazol-4-ylsulfonyl)-6-(pyridin-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl)methyl)-2-(trifluoromethyl)benzamide",CHEMBL3119198,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cn1cnc(S(=O)(=O)N2C[C@H]3[C@@H](C2)[C@]3(CNC(=O)c2ccccc2C(F)(F)F)c2ccccn2)c1,CHEMBL3112567,Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead.,Bioorg. Med. Chem. Lett.,2014.0,24,4,1067,1070,10.1016/j.bmcl.2014.01.013,24461352.0,
13902064,CHEMBL3114967,"2,4-dichloro-N-(((1R,5S)-3-(1-methyl-1H-imidazol-4-ylsulfonyl)-6-(pyridin-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl)methyl)benzamide",CHEMBL3119198,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cn1cnc(S(=O)(=O)N2C[C@H]3[C@@H](C2)[C@]3(CNC(=O)c2ccc(Cl)cc2Cl)c2ccccn2)c1,CHEMBL3112567,Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead.,Bioorg. Med. Chem. Lett.,2014.0,24,4,1067,1070,10.1016/j.bmcl.2014.01.013,24461352.0,
13902065,CHEMBL472757,"2,4-dichloro-N-((4-(cyclopropylmethyl)-1-(ethylsulfonyl)piperidin-4-yl)methyl)benzamide",CHEMBL3119198,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCS(=O)(=O)N1CCC(CNC(=O)c2ccc(Cl)cc2Cl)(CC2CC2)CC1,CHEMBL3112567,Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead.,Bioorg. Med. Chem. Lett.,2014.0,24,4,1067,1070,10.1016/j.bmcl.2014.01.013,24461352.0,
13902066,CHEMBL3114792,"(S)-2,4-dichloro-N-(1-(4-phenyl-1-(propylsulfonyl)piperidin-4-yl)ethyl)benzamide",CHEMBL3119198,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCCS(=O)(=O)N1CCC(c2ccccc2)([C@H](C)NC(=O)c2ccc(Cl)cc2Cl)CC1,CHEMBL3112567,Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead.,Bioorg. Med. Chem. Lett.,2014.0,24,4,1067,1070,10.1016/j.bmcl.2014.01.013,24461352.0,
13903515,CHEMBL3112778,(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)(1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)methanone hydrochloride,CHEMBL3119560,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) compound preincubated with substrate,IC50,>,30000.0,nM,COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1.Cl,CHEMBL3112574,Substituted piperidines as HDM2 inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,4,1026,1030,10.1016/j.bmcl.2014.01.026,24486134.0,
13903518,CHEMBL3112778,(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)(1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)methanone hydrochloride,CHEMBL3119563,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) compound co-incubated with substrate,IC50,>,30000.0,nM,COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1.Cl,CHEMBL3112574,Substituted piperidines as HDM2 inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,4,1026,1030,10.1016/j.bmcl.2014.01.026,24486134.0,
13908290,CHEMBL3112601,"rac-6-(2,6-dimethoxyphenyl)-1-(quinolin-2-ylmethyl)piperidin-2-one",CHEMBL3119316,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,COc1cccc(OC)c1C1CCCC(=O)N1Cc1ccc2ccccc2n1,CHEMBL3112474,"Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1.",Bioorg. Med. Chem. Lett.,2014.0,24,4,1201,1208,10.1016/j.bmcl.2013.12.092,24447850.0,
13913700,CHEMBL3114738,"Thiazol-5-ylmethyl(2S,3S)-3-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,4-diphenylbutan-2-ylcarbamate",CHEMBL3118923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,25000.0,nM,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,CHEMBL3112589,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: core region.",Bioorg. Med. Chem. Lett.,2014.0,24,3,989,994,10.1016/j.bmcl.2013.12.058,24411125.0,
13913701,CHEMBL3114735,Thiazol-5-ylmethyl(S)-4-((S)-N-isobutyl-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1-phenylbutan-2-ylcarbamate,CHEMBL3118923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,25000.0,nM,CC(C)CN(CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)[C@H](CCN1CCOCC1)NC(=O)N(C)Cc1csc(C(C)C)n1,CHEMBL3112589,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: core region.",Bioorg. Med. Chem. Lett.,2014.0,24,3,989,994,10.1016/j.bmcl.2013.12.058,24411125.0,
13913702,CHEMBL3114731,Thiazol-5-ylmethyl benzyl((S)-3-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-4-phenylbutyl)carbamate,CHEMBL3118923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,8100.0,nM,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)cs1,CHEMBL3112589,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: core region.",Bioorg. Med. Chem. Lett.,2014.0,24,3,989,994,10.1016/j.bmcl.2013.12.058,24411125.0,
13913703,CHEMBL3114730,Thiazol-5-ylmethyl benzyl((S)-3-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-4-phenylbutyl)carbamate,CHEMBL3118923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,25000.0,nM,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1,CHEMBL3112589,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: core region.",Bioorg. Med. Chem. Lett.,2014.0,24,3,989,994,10.1016/j.bmcl.2013.12.058,24411125.0,
13913704,CHEMBL3114724,(S)-thiazol-5-ylmethyl benzyl(4-(N-benzyl-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)butyl)carbamate,CHEMBL3118923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,3400.0,nM,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N(CCCCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1,CHEMBL3112589,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: core region.",Bioorg. Med. Chem. Lett.,2014.0,24,3,989,994,10.1016/j.bmcl.2013.12.058,24411125.0,
13913705,CHEMBL3114722,"Thiazol-5-ylmethyl(2S,5S)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,6-diphenylhexan-2-ylcarbamate",CHEMBL3118923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,13800.0,nM,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1,CHEMBL3112589,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: core region.",Bioorg. Med. Chem. Lett.,2014.0,24,3,989,994,10.1016/j.bmcl.2013.12.058,24411125.0,
13913706,CHEMBL3114719,"Thiazol-5-ylmethyl(3S,6S)-6-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)octan-3-ylcarbamate",CHEMBL3118923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,13400.0,nM,CC[C@@H](CC[C@H](CC)NC(=O)[C@@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C)NC(=O)OCc1cncs1,CHEMBL3112589,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: core region.",Bioorg. Med. Chem. Lett.,2014.0,24,3,989,994,10.1016/j.bmcl.2013.12.058,24411125.0,
13913707,CHEMBL3114713,Desoxy-ritonavir,CHEMBL3118923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,6800.0,nM,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1,CHEMBL3112589,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: core region.",Bioorg. Med. Chem. Lett.,2014.0,24,3,989,994,10.1016/j.bmcl.2013.12.058,24411125.0,
13913708,CHEMBL163,"((1R,2R,4R)-1-Benzyl-2-hydroxy-4-{(R)-2-[3-(2-isopropyl-1lambda*4*-[1,3]thiazin-5-ylmethyl)-3-methyl-ureido]-3-methyl-butyrylamino}-5-phenyl-pentyl)-carbamic acid thiazol-5-ylmethyl ester",CHEMBL3118923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,4900.0,nM,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,CHEMBL3112589,"Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: core region.",Bioorg. Med. Chem. Lett.,2014.0,24,3,989,994,10.1016/j.bmcl.2013.12.058,24411125.0,
13913841,CHEMBL3114894,"4-(4-(methylsulfonyl)phenoxy)-1-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine",CHEMBL3117319,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,6000.0,nM,CS(=O)(=O)c1ccc(Oc2ncnc3c2cnn3C2CCN(Cc3ccc(C(F)(F)F)cc3)CC2)cc1,CHEMBL3112399,"Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.",Bioorg. Med. Chem. Lett.,2014.0,24,3,949,953,10.1016/j.bmcl.2013.12.063,24412066.0,
13913842,CHEMBL3114886,"3-methyl-1-(4-(4-(4-(methylsulfonyl)phenoxy)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)butan-1-one",CHEMBL3117319,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CC(C)CC(=O)N1CCC(n2ncc3c(Oc4ccc(S(C)(=O)=O)cc4)ncnc32)CC1,CHEMBL3112399,"Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.",Bioorg. Med. Chem. Lett.,2014.0,24,3,949,953,10.1016/j.bmcl.2013.12.063,24412066.0,
13913843,CHEMBL3114880,"isopropyl 4-(4-(4-(methylsulfonyl)phenoxy)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate",CHEMBL3117319,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,6000.0,nM,CC(C)OC(=O)N1CCC(n2ncc3c(Oc4ccc(S(C)(=O)=O)cc4)ncnc32)CC1,CHEMBL3112399,"Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.",Bioorg. Med. Chem. Lett.,2014.0,24,3,949,953,10.1016/j.bmcl.2013.12.063,24412066.0,
13913844,CHEMBL3114905,"tert-butyl 4-(4-(4-(methylsulfonyl)phenoxy)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate",CHEMBL3117319,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,3000.0,nM,CC(C)(C)OC(=O)N1CCC(n2ncc3c(Oc4ccc(S(C)(=O)=O)cc4)ncnc32)CC1,CHEMBL3112399,"Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.",Bioorg. Med. Chem. Lett.,2014.0,24,3,949,953,10.1016/j.bmcl.2013.12.063,24412066.0,
13913845,CHEMBL3114896,"tert-butyl 4-(4-(2-fluoro-4-(methylsulfonyl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate",CHEMBL3117319,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,900.0,nM,CC(C)(C)OC(=O)N1CCC(n2ncc3c(Nc4ccc(S(C)(=O)=O)cc4F)ncnc32)CC1,CHEMBL3112399,"Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.",Bioorg. Med. Chem. Lett.,2014.0,24,3,949,953,10.1016/j.bmcl.2013.12.063,24412066.0,
13914685,CHEMBL3115191,"Thiazol-5-ylmethyl(2S,5S)-5-((S)-3-(1H-imidazol-4-yl)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)propanamido)-1,6-diphenylhexan-2-ylcarbamate",CHEMBL3117570,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,4700.0,nM,CC(C)c1nc(CN(C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CHEMBL3112558,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,2014.0,24,3,995,999,10.1016/j.bmcl.2013.12.057,24412072.0,
13914686,CHEMBL3115188,"Thiazol-5-ylmethyl(2S,5S)-5-((S)-4-acetamido-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)butanamido)-1,6-diphenylhexan-2-ylcarbamate",CHEMBL3117570,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,15500.0,nM,CC(=O)NCC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,CHEMBL3112558,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,2014.0,24,3,995,999,10.1016/j.bmcl.2013.12.057,24412072.0,
13914687,CHEMBL3115187,"Thiazol-5-ylmethyl(2S,5S)-5-((S)-3-hydroxy-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)propanamido)-1,6-diphenylhexan-2-ylcarbamate",CHEMBL3117570,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,25000.0,nM,CC(C)c1nc(CN(C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CHEMBL3112558,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,2014.0,24,3,995,999,10.1016/j.bmcl.2013.12.057,24412072.0,
13914688,CHEMBL3115185,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-(1-methyl-1H-imidazol-4-yl)propanamido)-1,6-diphenylhexan-2-ylcarbamate",CHEMBL3117570,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,4700.0,nM,CC(C)c1nc(CN(C)C(=O)N[C@@H](Cc2cn(C)cn2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CHEMBL3112558,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,2014.0,24,3,995,999,10.1016/j.bmcl.2013.12.057,24412072.0,
13914689,CHEMBL3115180,"Thiazol-5-ylmethyl(2R,5R)-5-((R)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-ylcarbamate",CHEMBL3117570,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,8000.0,nM,CC(C)c1nc(CN(C)C(=O)N[C@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CHEMBL3112558,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,2014.0,24,3,995,999,10.1016/j.bmcl.2013.12.057,24412072.0,
13914690,CHEMBL2095208,COBICISTAT,CHEMBL3117570,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,25000.0,nM,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CHEMBL3112558,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,2014.0,24,3,995,999,10.1016/j.bmcl.2013.12.057,24412072.0,
13914691,CHEMBL3115177,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-4-amino-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)butanamido)-1,6-diphenylhexan-2-ylcarbamate",CHEMBL3117570,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,25000.0,nM,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CHEMBL3112558,Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).,Bioorg. Med. Chem. Lett.,2014.0,24,3,995,999,10.1016/j.bmcl.2013.12.057,24412072.0,
13916954,CHEMBL3116157,"(R)-N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-5-methyl-4-(trifluoromethyl)thiazol-2-amine",CHEMBL3119697,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,Cc1sc(N[C@](Cc2ccccc2)(c2cc(F)cc(OC(F)(F)C(F)F)c2)c2ccc(Cl)cn2)nc1C(F)(F)F,CHEMBL3112495,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,3,860,864,10.1016/j.bmcl.2013.12.088,24424134.0,
13916955,CHEMBL3116158,"(R)-N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-(trifluoromethyl)thiazol-2-amine",CHEMBL3119697,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,40000.0,nM,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc(C(F)(F)F)cs2)c2ccc(Cl)cn2)c1,CHEMBL3112495,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,3,860,864,10.1016/j.bmcl.2013.12.088,24424134.0,
13916956,CHEMBL3116160,"(R)-5-bromo-N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-(trifluoromethyl)thiazol-2-amine",CHEMBL3119697,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc(C(F)(F)F)c(Br)s2)c2ccc(Cl)cn2)c1,CHEMBL3112495,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,3,860,864,10.1016/j.bmcl.2013.12.088,24424134.0,
13916957,CHEMBL3116154,"(R)-N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-5,7-difluoro-1H-benzo[d]imidazol-2-amine",CHEMBL3119697,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,15000.0,nM,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3cc(F)cc(F)c3[nH]2)c2ccc(Cl)cn2)c1,CHEMBL3112495,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,3,860,864,10.1016/j.bmcl.2013.12.088,24424134.0,
13916958,CHEMBL3116155,"(R)-N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-5-fluoro-1H-benzo[d]imidazol-2-amine",CHEMBL3119697,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,40000.0,nM,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3cc(F)ccc3[nH]2)c2ccc(Cl)cn2)c1,CHEMBL3112495,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,3,860,864,10.1016/j.bmcl.2013.12.088,24424134.0,
13916959,CHEMBL3116156,"(R)-N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-1H-benzo[d]imidazol-2-amine",CHEMBL3119697,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,19000.0,nM,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3ccccc3[nH]2)c2ccc(Cl)cn2)c1,CHEMBL3112495,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,3,860,864,10.1016/j.bmcl.2013.12.088,24424134.0,
13916960,CHEMBL2152165,"(S)-1-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-cyclopentylurea",CHEMBL3119697,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,4400.0,nM,O=C(NC1CCCC1)N[C@@](Cc1ccccc1)(c1cc(F)cc(OC(F)(F)C(F)F)c1)c1ccc(Cl)cn1,CHEMBL3112495,Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,3,860,864,10.1016/j.bmcl.2013.12.088,24424134.0,
13925829,CHEMBL3121804,"(S)-6-(3-Cyano-6-ethyl-5-fluoro-1-(5-fluoropyrimidin-2-yl)-1Hindol-2-yl)-N-(1,1,1-trifluoropropan-2-yl)pyridine-3-sulfonamide",CHEMBL3123417,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,CCc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncc(F)cn1,CHEMBL3120098,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,2014.0,57,5,2121,2135,10.1021/jm401621g,24266880.0,
13925830,CHEMBL3121800,"(S)-6-(3-Cyano-6-ethyl-5-fluoro-1-(pyridin-2-yl)-1H-indol-2-yl)-N-(1,1,1-trifluoropropan-2-yl)pyridine-3-sulfonamide",CHEMBL3123417,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,CCc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ccccn1,CHEMBL3120098,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,2014.0,57,5,2121,2135,10.1021/jm401621g,24266880.0,
13925831,CHEMBL3120505,"(S)-6-(3-cyano-6-ethyl-5-fluoro-1-(pyrimidin-2-yl)-1H-indol-2-yl)-N-(1,1,1-trifluoropropan-2-yl)pyridine-3-sulfonamide",CHEMBL3123417,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,CCc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncccn1,CHEMBL3120098,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,2014.0,57,5,2121,2135,10.1021/jm401621g,24266880.0,
13925832,CHEMBL3121798,"(S)-6-(3-Cyano-5-fluoro-1-(3-fluoropyridin-2-yl)-6-methyl-1Hindol-2-yl)-N-(1,1,1-trifluoropropan-2-yl)pyridine-3-sulfonamide",CHEMBL3123417,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,Cc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncccc1F,CHEMBL3120098,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,2014.0,57,5,2121,2135,10.1021/jm401621g,24266880.0,
13925833,CHEMBL3121694,"(S)-6-(3-Cyano-5-fluoro-1-(5-fluoropyrimidin-2-yl)-6-methyl-1Hindol-2-yl)-N-(1,1,1-trifluoropropan-2-yl)pyridine-3-sulfonamide",CHEMBL3123417,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,Cc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncc(F)cn1,CHEMBL3120098,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,2014.0,57,5,2121,2135,10.1021/jm401621g,24266880.0,
13925834,CHEMBL3121811,"(S)-6-(3-Cyano-5-fluoro-6-methyl-1-(pyrimidin-2-yl)-1H-indol-2-yl)-N-(1,1,1-trifluoropropan-2-yl)pyridine-3-sulfonamide",CHEMBL3123417,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,Cc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncccn1,CHEMBL3120098,"Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.",J. Med. Chem.,2014.0,57,5,2121,2135,10.1021/jm401621g,24266880.0,
13926208,CHEMBL3121096,"(-)-(1S,6R)-5-(4-(1-cyclobutylpiperidin-4-yloxy)phenyl)-3,4-diazabicyclo[4.1.0]hept-4-en-2-one",CHEMBL3123344,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,O=C1NN=C(c2ccc(OC3CCN(C4CCC4)CC3)cc2)[C@@H]2C[C@H]12,CHEMBL3120141,"Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): histamine H(3) receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity.",Bioorg. Med. Chem. Lett.,2014.0,24,5,1303,1306,10.1016/j.bmcl.2014.01.061,24513042.0,
13926941,CHEMBL3121095,"(+)-(1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one",CHEMBL3123344,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,O=C1NN=C(c2ccc(OC3CCN(C4CCC4)CC3)cc2)[C@H]2C[C@@H]12,CHEMBL3120141,"Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): histamine H(3) receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity.",Bioorg. Med. Chem. Lett.,2014.0,24,5,1303,1306,10.1016/j.bmcl.2014.01.061,24513042.0,
13936979,CHEMBL3121951,"Methyl[(1S)-2-Methyl-1-({(2S)-2-[5-(4'-{2-[(8S)-7-((2S)-3-methyl-2-{[(methyloxy)carbonyl]amino}butanoyl)-1,4-dioxa-7-azaspiro[4.4]non-8-yl]-1H-imidazol-5-yl}-4-biphenylyl)-1H-imidazol-2-yl]-1-pyrrolidinyl}carbonyl)propyl]carbamate",CHEMBL3123389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,33000.0,nM,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CC6(CN5C(=O)[C@@H](NC(=O)OC)C(C)C)OCCO6)[nH]4)cc3)cc2)[nH]1)C(C)C,CHEMBL3120061,Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.,J. Med. Chem.,2014.0,57,5,2058,2073,10.1021/jm4013104,24568313.0,
13943218,CHEMBL3128188,"(S)-N-(4-(((2S,5R)-5-((R)-Hydroxy(pyridin-3-yl)methyl)-pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]-pyrazole-6-carboxamide",CHEMBL3129313,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac alpha'-hydroxylation,IC50,>,100000.0,nM,O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2ccnn21,CHEMBL3124772,"Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder.",J. Med. Chem.,2014.0,57,4,1437,1453,10.1021/jm4017224,24437735.0,
13943219,CHEMBL3128178,"(R)-N-(4-(((2S,5R)-5-((R)-Hydroxy(pyridin-3-yl)methyl)-pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4H-cyclopenta[d]-thiazole-4-carboxamide",CHEMBL3129313,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac alpha'-hydroxylation,IC50,>,100000.0,nM,O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2scnc21,CHEMBL3124772,"Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder.",J. Med. Chem.,2014.0,57,4,1437,1453,10.1021/jm4017224,24437735.0,
13943220,CHEMBL3128194,"(R)-2-Amino-N-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)-pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4H-cyclopenta[d]-thiazole-4-carboxamide",CHEMBL3129313,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac alpha'-hydroxylation,IC50,>,100000.0,nM,Nc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1,CHEMBL3124772,"Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder.",J. Med. Chem.,2014.0,57,4,1437,1453,10.1021/jm4017224,24437735.0,
13943221,CHEMBL1684585,"2-(2-aminothiazol-4-yl)-N-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)acetamide",CHEMBL3129313,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac alpha'-hydroxylation,IC50,>,100000.0,nM,Nc1nc(CC(=O)Nc2ccc(C[C@@H]3CC[C@H]([C@H](O)c4ccccc4)N3)cc2)cs1,CHEMBL3124772,"Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder.",J. Med. Chem.,2014.0,57,4,1437,1453,10.1021/jm4017224,24437735.0,
13943342,CHEMBL3128180,"(R)-N-(4-(((2S,5R)-5-((R)-Hydroxy(pyridin-3-yl)methyl)-pyrrolidin-2-yl)methyl)phenyl)-2-methyl-5,6-dihydro-4Hcyclopenta[d]thiazole-4-carboxamide",CHEMBL3129313,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac alpha'-hydroxylation,IC50,=,67200.0,nM,Cc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1,CHEMBL3124772,"Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder.",J. Med. Chem.,2014.0,57,4,1437,1453,10.1021/jm4017224,24437735.0,
13944810,CHEMBL3125655,"4-{[3-chloro-5-cyclopropyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]carbonyl}-1-[(1S,2S,3S,5S)-2-hydroxybicyclo[3.1.0]hex-3-yl]-2-piperazinone",CHEMBL3131723,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS/MS analysis,IC50,>,20000.0,nM,O=C(c1nn2c(C(F)(F)F)cc(C3CC3)cc2c1Cl)N1CCN([C@H]2C[C@@H]3C[C@@H]3[C@@H]2O)C(=O)C1,CHEMBL3124867,Hepatitis C replication inhibitors that target the viral NS4B protein.,J. Med. Chem.,2014.0,57,5,2107,2120,10.1021/jm400125h,23544424.0,
13948760,CHEMBL3125270,"N-((3R,5S)-1-(Benzofuran-3-carbonyl)-5-carbamoylpyrrolidin-3-yl)-1,3-diethyl-1H-pyrazole-5-carboxamide",CHEMBL3131783,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,50000.0,nM,CCc1cc(C(=O)N[C@@H]2C[C@@H](C(N)=O)N(C(=O)c3coc4ccccc34)C2)n(CC)n1,CHEMBL3124857,Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.,J. Med. Chem.,2014.0,57,4,1276,1288,10.1021/jm401326j,24450589.0,
13948761,CHEMBL3125272,"N-((3R,5S)-1-(Benzofuran-3-carbonyl)-5-(ethylcarbamoyl)-pyrrolidin-3-yl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide",CHEMBL3131783,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,50000.0,nM,CCNC(=O)[C@@H]1C[C@@H](NC(=O)c2cc(CC)nn2C)CN1C(=O)c1coc2ccccc12,CHEMBL3124857,Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.,J. Med. Chem.,2014.0,57,4,1276,1288,10.1021/jm401326j,24450589.0,
13949082,CHEMBL3127163,2-(3-phenyl-6-(trifluoromethyl)-1H-indazol-1-yl)thiazole-4-carboxylic acid,CHEMBL3131128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,7860.0,nM,O=C(O)c1csc(-n2nc(-c3ccccc3)c3ccc(C(F)(F)F)cc32)n1,CHEMBL3124785,Discovery of 2-(1H-indazol-1-yl)-thiazole derivatives as selective EP(1) receptor antagonists for treatment of overactive bladder by core structure replacement.,Bioorg. Med. Chem. Lett.,2014.0,24,5,1327,1333,10.1016/j.bmcl.2014.01.052,24508133.0,
13952611,CHEMBL3126382,4-((1R)-2-{[6-({4-[3-(Cyclopentylsulfonyl)phenyl]butyl}oxy)-hexyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol acetate salt,CHEMBL3131894,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli,IC50,>,10000.0,nM,CC(=O)O.O=S(=O)(c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1)C1CCCC1,CHEMBL3124822,"Discovery of a rapidly metabolized, long-acting β(2) adrenergic receptor agonist with a short onset time incorporating a sulfone group suitable for once-daily dosing.",J. Med. Chem.,2014.0,57,1,159,170,10.1021/jm401532g,24359185.0,
13954436,CHEMBL3127494,rac-trans-2-(Pyridin-3-yl)-N-(4-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)sulfonyl)phenyl)cyclopropanecarboxamide,CHEMBL3129757,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,=,910.0,nM,O=C(Nc1ccc(S(=O)(=O)c2cnn(C3CCOCC3)c2)cc1)[C@@H]1C[C@H]1c1cccnc1,CHEMBL3124860,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,J. Med. Chem.,2014.0,57,3,770,792,10.1021/jm4015108,24405419.0,
13954437,CHEMBL3127510,"trans-(S,S)-N-(4-((1-Isopropyl-1H-pyrazol-4-yl)sulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide",CHEMBL3129757,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,=,780.0,nM,CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1,CHEMBL3124860,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,J. Med. Chem.,2014.0,57,3,770,792,10.1021/jm4015108,24405419.0,
13954438,CHEMBL3127509,rac-trans-N-(4-((1-Isopropyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide,CHEMBL3129757,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,=,1000.0,nM,CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1,CHEMBL3124860,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,J. Med. Chem.,2014.0,57,3,770,792,10.1021/jm4015108,24405419.0,
13954439,CHEMBL3127507,"trans-(S,S)-N-(4-((1-Propyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide",CHEMBL3129757,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,=,1500.0,nM,CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1,CHEMBL3124860,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,J. Med. Chem.,2014.0,57,3,770,792,10.1021/jm4015108,24405419.0,
13954440,CHEMBL3127506,rac-trans-N-(4-((1-Propyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide,CHEMBL3129757,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,=,900.0,nM,CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1,CHEMBL3124860,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,J. Med. Chem.,2014.0,57,3,770,792,10.1021/jm4015108,24405419.0,
13954441,CHEMBL3127501,rac-trans-2-(Pyridin-3-yl)-N-(4-((3-(trifluoromethoxy)phenyl)-sulfonyl)phenyl)cyclopropanecarboxamide,CHEMBL3129757,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,=,450.0,nM,O=C(Nc1ccc(S(=O)(=O)c2cccc(OC(F)(F)F)c2)cc1)[C@@H]1C[C@H]1c1cccnc1,CHEMBL3124860,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,J. Med. Chem.,2014.0,57,3,770,792,10.1021/jm4015108,24405419.0,
13954442,CHEMBL3127500,rac-trans-N-(4-((3-(Methylsulfonyl)phenyl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide,CHEMBL3129757,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,=,570.0,nM,CS(=O)(=O)c1cccc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)c1,CHEMBL3124860,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,J. Med. Chem.,2014.0,57,3,770,792,10.1021/jm4015108,24405419.0,
13954443,CHEMBL3127526,rac-trans-2-(Pyridin-3-yl)-N-(4-((tetrahydro-2H-pyran-4-yl)-sulfonyl)phenyl)cyclopropanecarboxamide,CHEMBL3129757,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,>,10000.0,nM,O=C(Nc1ccc(S(=O)(=O)C2CCOCC2)cc1)[C@@H]1C[C@H]1c1cccnc1,CHEMBL3124860,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,J. Med. Chem.,2014.0,57,3,770,792,10.1021/jm4015108,24405419.0,
13954444,CHEMBL3127525,rac-trans-N-(4-(8-Oxa-3-azabicyclo[3.2.1]octan-3-ylsulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide,CHEMBL3129757,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,=,7800.0,nM,O=C(Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1)[C@@H]1C[C@H]1c1cccnc1,CHEMBL3124860,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,J. Med. Chem.,2014.0,57,3,770,792,10.1021/jm4015108,24405419.0,
13954445,CHEMBL3127522,rac-trans-2-(6-Aminopyridin-3-yl)-N-(4-(phenylsulfonyl)phenyl)-cyclopropanecarboxamide,CHEMBL3129757,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,>,10000.0,nM,Nc1ccc([C@@H]2C[C@H]2C(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1,CHEMBL3124860,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,J. Med. Chem.,2014.0,57,3,770,792,10.1021/jm4015108,24405419.0,
13954446,CHEMBL3127521,trans-N-(4-(Phenylsulfonyl)phenyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide,CHEMBL3129757,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,=,720.0,nM,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@H]1C[C@@H]1c1cccnc1,CHEMBL3124860,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,J. Med. Chem.,2014.0,57,3,770,792,10.1021/jm4015108,24405419.0,
13954447,CHEMBL3127520,rac-trans-N-(4-(Phenylsulfonyl)phenyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide,CHEMBL3129757,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)- warfarin as substrate by LC-MS/MS analysis,IC50,=,490.0,nM,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1,CHEMBL3124860,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,J. Med. Chem.,2014.0,57,3,770,792,10.1021/jm4015108,24405419.0,
13957148,CHEMBL3126842,"(8S,10R)-19-cyclohexyl-N-(dimethylsulfamoyl)-5-methoxy-10-({3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl}carbonyl)-12-azapentacyclo[10.7.0.0^{2,7}.0^{8,10}.0^{13,18}]nonadeca-1(19),2(7),3,5,13,15,17-heptaene-15-carboxamide",CHEMBL3128605,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21,CHEMBL3124792,"Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.",J. Med. Chem.,2014.0,57,5,1855,1879,10.1021/jm4016894,24397558.0,
13963111,CHEMBL3127906,"2-{2-[4-Chloro-2-(trifluoromethyl)phenoxy]ethyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione",CHEMBL3132329,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,15400.0,nM,Cc1cn(-c2ccc3n(c2=O)CCN(CCOc2ccc(Cl)cc2C(F)(F)F)C3=O)cn1,CHEMBL3124856,"Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione γ-secretase modulators.",J. Med. Chem.,2014.0,57,3,1046,1062,10.1021/jm401782h,24428186.0,
13963112,CHEMBL3127905,"2-{2-[4-Fluoro-2-(trifluoromethyl)phenoxy]ethyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione",CHEMBL3132329,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1cn(-c2ccc3n(c2=O)CCN(CCOc2ccc(F)cc2C(F)(F)F)C3=O)cn1,CHEMBL3124856,"Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione γ-secretase modulators.",J. Med. Chem.,2014.0,57,3,1046,1062,10.1021/jm401782h,24428186.0,
13965422,CHEMBL3134098,"9-chloro-N-(2,4-difluorophenyl)-3-ethyl-3-methyl-2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine-7-sulfonamide",CHEMBL3135113,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,CCC1(C)NC(=O)c2cc(S(=O)(=O)Nc3ccc(F)cc3F)cc(Cl)c2NC1=O,CHEMBL3132851,Achieving improved permeability by hydrogen bond donor modulation in a series of MGAT2 inhibitors,MedChemComm,2013.0,4,9,1305,1311,10.1039/C3MD00156C,,
13967604,CHEMBL3133005,"cis-(4-(5-(5-(3,4-difluorophenylamino)-1,3,4-oxadiazole-2-carboxamido)-pyridin-2-yloxy)cyclohexyl)acetic acid",CHEMBL3135872,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,O=C(O)C[C@H]1CC[C@@H](Oc2ccc(NC(=O)c3nnc(Nc4ccc(F)c(F)c4)o3)cn2)CC1,CHEMBL3132759,Design and synthesis of a novel series of cyclohexyloxy-pyridyl derivatives as inhibitors of diacylglycerol acyl transferase 1,MedChemComm,2013.0,4,1,151,158,10.1039/C2MD20187A,,
13979420,CHEMBL3104375,N-[4-(Trifluoromethyl)phenyl]-N-(1-[5-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl)pyridin-3-amine,CHEMBL3137495,A,,,Cytochrome P450 2C9,DNDI: CYP Inhibition,IC50,=,8100.0,nM,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1,CHEMBL3137440,DNDi T. cruzi fenarimol series dataset from which preclinical candidate EPL-BS0967 was identified (see also related datasets: CHEMBL3137386 and CHEMBL2448688),,,,,,,10.6019/CHEMBL3137440,,
14529093,CHEMBL3218854,"(1S,2S,3R,4R)-3-[6-Chloro-2-(2-methoxy-4-morpholin-4-yl-phenyl)-3H-imidazo[4,5-b]pyridin-7-ylamino]-bicyclo[2.2.1]hept-5-ene-2-carboxylicacidamide",CHEMBL3226258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human pooled liver microsomes using diclofenac as substrate by LC/MS/MS analysis,IC50,>,30000.0,nM,COc1cc(N2CCOCC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1,CHEMBL3217622,"Design of 7-amino-6-chloro-3H-imidazo[4,5-b]pyridine scaffold from 5-chloro-2,4-diaminopyrimidine pharmacophore: identification of potent inhibitors of anaplastic lymphoma kinase",MedChemComm,2012.0,3,9,1138,1142,10.1039/C2MD20061A,,
14529094,CHEMBL3218855,"(1S,2S,3R,4R)-3-{6-Chloro-2-[2-methoxy-4-(4-methyl-piperazin-1-yl)-phenyl]-3Himidazo[4,5-b]pyridin-7-ylamino}-bicyclo[2.2.1]hept-5-ene-2-carboxylic",CHEMBL3226258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human pooled liver microsomes using diclofenac as substrate by LC/MS/MS analysis,IC50,>,30000.0,nM,COc1cc(N2CCN(C)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1,CHEMBL3217622,"Design of 7-amino-6-chloro-3H-imidazo[4,5-b]pyridine scaffold from 5-chloro-2,4-diaminopyrimidine pharmacophore: identification of potent inhibitors of anaplastic lymphoma kinase",MedChemComm,2012.0,3,9,1138,1142,10.1039/C2MD20061A,,
14529095,CHEMBL3218856,"(1S,2S,3R,4R)-3-{6-Chloro-2-[2-methoxy-4-(4-morpholin-4-yl-piperidin-1-yl)-phenyl]-3H-imidazo[4,5-b]pyridin-7-ylamino}-bicyclo[2.2.1]hept-5-ene-2-carboxylicacidamide",CHEMBL3226258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human pooled liver microsomes using diclofenac as substrate by LC/MS/MS analysis,IC50,>,30000.0,nM,COc1cc(N2CCC(N3CCOCC3)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1,CHEMBL3217622,"Design of 7-amino-6-chloro-3H-imidazo[4,5-b]pyridine scaffold from 5-chloro-2,4-diaminopyrimidine pharmacophore: identification of potent inhibitors of anaplastic lymphoma kinase",MedChemComm,2012.0,3,9,1138,1142,10.1039/C2MD20061A,,
14529096,CHEMBL3218857,"(1S,2S,3R,4R)-3-(6-Chloro-2-{2-methoxy-4-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-phenyl}-3H-imidazo[4,5-b]pyridin-7-ylamino)-bicyclo[2.2.1]hept-5-ene-2-carboxylicacidamide",CHEMBL3226258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human pooled liver microsomes using diclofenac as substrate by LC/MS/MS analysis,IC50,>,30000.0,nM,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1,CHEMBL3217622,"Design of 7-amino-6-chloro-3H-imidazo[4,5-b]pyridine scaffold from 5-chloro-2,4-diaminopyrimidine pharmacophore: identification of potent inhibitors of anaplastic lymphoma kinase",MedChemComm,2012.0,3,9,1138,1142,10.1039/C2MD20061A,,
14529097,CHEMBL3218858,"(1S,2S,3R,4R)-3-[6-Chloro-2-(2-methoxy-4-morpholin-4-ylmethyl-phenyl)-3Himidazo[4,5-b]pyridin-7-ylamino]-bicyclo[2.2.1]hept-5-ene-2-carboxylicacidamide",CHEMBL3226258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human pooled liver microsomes using diclofenac as substrate by LC/MS/MS analysis,IC50,>,30000.0,nM,COc1cc(CN2CCOCC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1,CHEMBL3217622,"Design of 7-amino-6-chloro-3H-imidazo[4,5-b]pyridine scaffold from 5-chloro-2,4-diaminopyrimidine pharmacophore: identification of potent inhibitors of anaplastic lymphoma kinase",MedChemComm,2012.0,3,9,1138,1142,10.1039/C2MD20061A,,
14529098,CHEMBL3218859,"(1S,2S,3R,4R)-3-{6-Chloro-2-[2-methoxy-4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-3H-imidazo[4,5-b]pyridin-7-ylamino}-bicyclo[2.2.1]hept-5-ene-2-carboxylicacidamide",CHEMBL3226258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human pooled liver microsomes using diclofenac as substrate by LC/MS/MS analysis,IC50,>,30000.0,nM,COc1cc(CN2CCN(C)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1,CHEMBL3217622,"Design of 7-amino-6-chloro-3H-imidazo[4,5-b]pyridine scaffold from 5-chloro-2,4-diaminopyrimidine pharmacophore: identification of potent inhibitors of anaplastic lymphoma kinase",MedChemComm,2012.0,3,9,1138,1142,10.1039/C2MD20061A,,
14542700,CHEMBL3219283,"2-Dimethylaminomethyl-9-hydroxythieno[2,3-c]isoquinolin-5(4H)-one hydrobromide",CHEMBL3225212,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,<,200000.0,nM,Br.CN(C)Cc1cc2c([nH]c(=O)c3cccc(O)c32)s1,CHEMBL3217609,Discovery and characterization of novel potent PARP-1 inhibitors endowed with neuroprotective properties: From TIQ-A to HYDAMTIQ,MedChemComm,2011.0,2,6,559,565,10.1039/C1MD00021G,,
14566277,CHEMBL3234858,"(R)-5-benzyl-5-(5-(3,5-dimethoxyphenyl)-1,3,4-oxadiazol-2-yl)-3-((R)-1-phenylethyl)oxazolidine-2,4-dione",CHEMBL3241727,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,COc1cc(OC)cc(-c2nnc([C@@]3(Cc4ccccc4)OC(=O)N([C@H](C)c4ccccc4)C3=O)o2)c1,CHEMBL3232811,Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.,Bioorg. Med. Chem. Lett.,2014.0,24,7,1681,1684,10.1016/j.bmcl.2014.02.057,24630411.0,
14566278,CHEMBL3234863,"(R)-5-benzyl-5-(5-(1-phenylcyclopropyl)-1,3,4-oxadiazol-2-yl)-3-((R)-1-phenylethyl)oxazolidine-2,4-dione",CHEMBL3241727,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,19000.0,nM,C[C@H](c1ccccc1)N1C(=O)O[C@](Cc2ccccc2)(c2nnc(C3(c4ccccc4)CC3)o2)C1=O,CHEMBL3232811,Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.,Bioorg. Med. Chem. Lett.,2014.0,24,7,1681,1684,10.1016/j.bmcl.2014.02.057,24630411.0,
14566952,CHEMBL3234568,(R)-N-(4-cyanophenethyl)-1-(6-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl)piperidine-3-carboxamide,CHEMBL3239432,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,4700.0,nM,CN1CCN(c2cc(N3CCC[C@@H](C(=O)NCCc4ccc(C#N)cc4)C3)nc(C(F)(F)F)n2)CC1,CHEMBL3232835,"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,2014.0,57,8,3263,3282,10.1021/jm401731q,24666203.0,
14566993,CHEMBL3234871,trans-4-(4-{6-[(2S)-2-{[2-(4-Cyanophenyl)ethyl]carbamoyl}azetidin-1-yl]-2-(trifluoromethyl)pyrimidin-4-yl}phenyl)cyclohexane-1-carboxylic Acid,CHEMBL3239432,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,N#Cc1ccc(CCNC(=O)[C@@H]2CCN2c2cc(-c3ccc([C@H]4CC[C@H](C(=O)O)CC4)cc3)nc(C(F)(F)F)n2)cc1,CHEMBL3232835,"Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.",J. Med. Chem.,2014.0,57,8,3263,3282,10.1021/jm401731q,24666203.0,
14568075,CHEMBL3233058,"6-((1R,2S)-2-Amino-cyclohexylamino)-4-(6-methyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide",CHEMBL3240917,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomal fraction assessed as diclofenac-4'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis,IC50,>,50000.0,nM,Cc1cccc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)nnc2C(N)=O)n1,CHEMBL3232975,"Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.",J. Med. Chem.,2014.0,57,6,2683,2691,10.1021/jm401982j,24520947.0,
14568076,CHEMBL3237560,"6-((1R,2S)-2-Aminocyclohexylamino)-4-(5-fluoro-6-methylpyridin-2-ylamino pyridazine-3-carboxamide",CHEMBL3240917,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomal fraction assessed as diclofenac-4'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis,IC50,>,50000.0,nM,Cc1nc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)nnc2C(N)=O)ccc1F,CHEMBL3232975,"Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.",J. Med. Chem.,2014.0,57,6,2683,2691,10.1021/jm401982j,24520947.0,
14568077,CHEMBL3237561,"6-((1R,2S)-2-Amino-cyclohexylamino)-4-(5,6-dimethyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide",CHEMBL3240917,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomal fraction assessed as diclofenac-4'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis,IC50,>,50000.0,nM,Cc1ccc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)nnc2C(N)=O)nc1C,CHEMBL3232975,"Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.",J. Med. Chem.,2014.0,57,6,2683,2691,10.1021/jm401982j,24520947.0,
14568078,CHEMBL3237564,"6-((1R,2S)-2-aminocyclohexylamino)-4-(6,7-dihydro-5H-cyclopenta[b]pyridin-2-ylamino)pyridazine-3-carboxamide",CHEMBL3240917,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomal fraction assessed as diclofenac-4'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis,IC50,>,50000.0,nM,NC(=O)c1nnc(N[C@@H]2CCCC[C@@H]2N)cc1Nc1ccc2c(n1)CCC2,CHEMBL3232975,"Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.",J. Med. Chem.,2014.0,57,6,2683,2691,10.1021/jm401982j,24520947.0,
14574788,CHEMBL3235164,3-(4-Methanesulfonylphenoxy)-N-[1-(2-methoxyethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide,CHEMBL3243421,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,5200.0,nM,COCCOCn1ccc(NC(=O)c2cc(Oc3ccc(S(C)(=O)=O)cc3)cc(-c3ncccc3C)c2)n1,CHEMBL3232870,Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.,Bioorg. Med. Chem.,2014.0,22,7,2280,2293,10.1016/j.bmc.2014.02.009,24588963.0,
14595276,CHEMBL3236948,"2-(5-Fluoro-3-(2-isopropyl-1-oxo-1,2-dihydroisoquinolin-4-yl)-2-methyl-1H-indol-1-yl)acetic Acid",CHEMBL3242639,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,55000.0,nM,Cc1c(-c2cn(C(C)C)c(=O)c3ccccc23)c2cc(F)ccc2n1CC(=O)O,CHEMBL3232705,Discovery of isoquinolinone indole acetic acids as antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases.,J. Med. Chem.,2014.0,57,4,1299,1322,10.1021/jm401509e,24512187.0,
14645948,CHEMBL3263640,4-tert-butyl-N-(2-methyl-3-(6-(4-(morpholine-4-carbonyl)phenylamino)-9H-purin-2-yl)phenyl)benzamide,CHEMBL3270542,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,400.0,nM,Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1,CHEMBL3259754,Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.,Bioorg. Med. Chem. Lett.,2014.0,24,9,2206,2211,10.1016/j.bmcl.2014.02.075,24685542.0,
14646845,CHEMBL3260740,"8-(4-Chlorophenyl)-2-methyl-7-(pyridin-4-yl)-5-((6-(trifluoromethyl)pyridin-3-yl)methyl)-[1,2,4]triazolo[4,3-b]-pyridazine-3,6(2H,5H)-dione",CHEMBL3268564,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,1900.0,nM,Cn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3)n2c1=O,CHEMBL3259698,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,2013.0,56,23,9586,9600,10.1021/jm4010835,24182233.0,
14646846,CHEMBL3260741,"8-(4-Chlorophenyl)-2-methyl-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-7-(pyridin-4-yl)-[1,2,4]-triazolo[4,3-b]pyridazine-3,6(2H,5H)-dione",CHEMBL3268564,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,2900.0,nM,Cc1nc(C(F)(F)F)ccc1Cn1c(=O)c(-c2ccncc2)c(-c2ccc(Cl)cc2)c2nn(C)c(=O)n21,CHEMBL3259698,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,2013.0,56,23,9586,9600,10.1021/jm4010835,24182233.0,
14646847,CHEMBL3260742,"8-(4-Chlorophenyl)-2-ethyl-7-(pyridin-4-yl)-5-((6-(trifluoromethyl)pyridin-3-yl)methyl)-[1,2,4]triazolo[4,3-b]-pyridazine-3,6(2H,5H)-dione",CHEMBL3268564,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,4900.0,nM,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3)n2c1=O,CHEMBL3259698,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,2013.0,56,23,9586,9600,10.1021/jm4010835,24182233.0,
14646848,CHEMBL3260743,"8-(4-Chlorophenyl)-2-ethyl-5-((2-methyl-6-(trifluoromethyl)-pyridin-3-yl)methyl)-7-(pyridin-4-yl)-[1,2,4]triazolo[4,3-b]-pyridazine-3,6(2H,5H)-dione",CHEMBL3268564,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,4200.0,nM,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O,CHEMBL3259698,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,2013.0,56,23,9586,9600,10.1021/jm4010835,24182233.0,
14646849,CHEMBL3260744,"8-(4-chlorophenyl)-2-ethyl-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-7-(3-methylpyridin-4-yl)-[1,2,4]triazolo[4,3-b]pyridazine-3,6(2H,5H)-dione",CHEMBL3268564,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,5000.0,nM,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3C)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O,CHEMBL3259698,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,2013.0,56,23,9586,9600,10.1021/jm4010835,24182233.0,
14646850,CHEMBL3260745,"4-(8-(4-Chlorophenyl)-2-ethyl-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-3,6-dioxo-2,3,5,6-tetra-hydro-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)benzonitrile",CHEMBL3268564,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,40000.0,nM,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccc(C#N)cc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O,CHEMBL3259698,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,2013.0,56,23,9586,9600,10.1021/jm4010835,24182233.0,
14646851,CHEMBL3260753,"8-(4-Chlorophenyl)-2-ethyl-5-((2-methyl-6-(trifluoromethyl)-pyridin-3-yl)methyl)-7-(2-methylpyrimidin-5-yl)-[1,2,4]-triazolo[4,3-b]pyridazine-3,6(2H,5H)-dione",CHEMBL3268564,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,40000.0,nM,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3cnc(C)nc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O,CHEMBL3259698,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,2013.0,56,23,9586,9600,10.1021/jm4010835,24182233.0,
14646852,CHEMBL3260754,"8-(4-chlorophenyl)-2-ethyl-7-(3-fluoropyridin-4-yl)-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-[1,2,4]triazolo[4,3-b]pyridazine-3,6(2H,5H)-dione",CHEMBL3268564,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,=,14000.0,nM,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3F)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O,CHEMBL3259698,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,2013.0,56,23,9586,9600,10.1021/jm4010835,24182233.0,
14646853,CHEMBL3260755,"4-((8-(4-chlorophenyl)-2-ethyl-7-(1-methyl-1H-pyrazol-4-yl)-3,6-dioxo-2,3-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-5(6H)-yl)methyl)benzonitrile",CHEMBL3268564,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,40000.0,nM,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3cnn(C)c3)c(=O)n(Cc3ccc(C#N)cc3)n2c1=O,CHEMBL3259698,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,2013.0,56,23,9586,9600,10.1021/jm4010835,24182233.0,
14646854,CHEMBL3260756,"4-((8-(4-chlorophenyl)-7-(2-(dimethylamino)pyrimidin-5-yl)-2-ethyl-3,6-dioxo-2,3-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-5(6H)-yl)methyl)benzonitrile",CHEMBL3268564,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,40000.0,nM,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3cnc(N(C)C)nc3)c(=O)n(Cc3ccc(C#N)cc3)n2c1=O,CHEMBL3259698,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,J. Med. Chem.,2013.0,56,23,9586,9600,10.1021/jm4010835,24182233.0,
14648175,CHEMBL3264059,"trans-N-(3-{2-[(3-Fluoropyridin-2-yl)amino]pyrimidin-5-yl}-imidazo[1,2-b]pyridazin-6-yl)cyclohexane-1,4-diamine",CHEMBL3267045,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,N[C@H]1CC[C@H](Nc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)CC1,CHEMBL3259664,Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1).,J. Med. Chem.,2014.0,57,8,3570,3587,10.1021/jm500342d,24689770.0,
14653778,CHEMBL3264002,3-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]methyl]-4-methyl-7-pyrimidin-2-yloxy-chromen-2-one,CHEMBL3267837,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH,IC50,=,12000.0,nM,CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F,CHEMBL3259729,Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.,ACS Med. Chem. Lett.,2014.0,5,4,309,314,10.1021/ml400379x,24900832.0,
14653779,CHEMBL3092195,3-(2-Fluoro-3-(N-methylsulfamoylamino)benzyl)-4-methyl-7-(pyrimidin-2-yloxy)-2H-chromen-2-one,CHEMBL3267837,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH,IC50,=,19000.0,nM,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F,CHEMBL3259729,Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.,ACS Med. Chem. Lett.,2014.0,5,4,309,314,10.1021/ml400379x,24900832.0,
14653780,CHEMBL3092189,4-Methyl-3-(3-(N-methylsulfamoylamino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate,CHEMBL3267837,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH,IC50,=,29000.0,nM,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)c1,CHEMBL3259729,Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.,ACS Med. Chem. Lett.,2014.0,5,4,309,314,10.1021/ml400379x,24900832.0,
14653781,CHEMBL3263996,Dimethyl-carbamicacid 3-[2-(N-methylsulfamoylamino)-pyridin-4-ylmethyl]-4-methyl-2-oxo-2H-chromen-7-ylester,CHEMBL3267837,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH,IC50,>,100000.0,nM,CNS(=O)(=O)Nc1cc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)ccn1,CHEMBL3259729,Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.,ACS Med. Chem. Lett.,2014.0,5,4,309,314,10.1021/ml400379x,24900832.0,
14653782,CHEMBL3264002,3-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]methyl]-4-methyl-7-pyrimidin-2-yloxy-chromen-2-one,CHEMBL3267838,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH,IC50,=,60000.0,nM,CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F,CHEMBL3259729,Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.,ACS Med. Chem. Lett.,2014.0,5,4,309,314,10.1021/ml400379x,24900832.0,
14653783,CHEMBL3092195,3-(2-Fluoro-3-(N-methylsulfamoylamino)benzyl)-4-methyl-7-(pyrimidin-2-yloxy)-2H-chromen-2-one,CHEMBL3267838,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH,IC50,=,19000.0,nM,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F,CHEMBL3259729,Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.,ACS Med. Chem. Lett.,2014.0,5,4,309,314,10.1021/ml400379x,24900832.0,
14653784,CHEMBL3092189,4-Methyl-3-(3-(N-methylsulfamoylamino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate,CHEMBL3267838,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH,IC50,=,96000.0,nM,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)c1,CHEMBL3259729,Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.,ACS Med. Chem. Lett.,2014.0,5,4,309,314,10.1021/ml400379x,24900832.0,
14653785,CHEMBL3263996,Dimethyl-carbamicacid 3-[2-(N-methylsulfamoylamino)-pyridin-4-ylmethyl]-4-methyl-2-oxo-2H-chromen-7-ylester,CHEMBL3267838,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH,IC50,>,100000.0,nM,CNS(=O)(=O)Nc1cc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)ccn1,CHEMBL3259729,Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.,ACS Med. Chem. Lett.,2014.0,5,4,309,314,10.1021/ml400379x,24900832.0,
14658494,CHEMBL3259928,(R)-2-Methoxy-N-(1-methyl-3-phenyl-piperidin-3-yl)-6-methylsulfanyl-4-trifluoromethylbenzamide,CHEMBL3266596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,COc1cc(C(F)(F)F)cc(SC)c1C(=O)N[C@@]1(c2ccccc2)CCCN(C)C1,CHEMBL3259663,"3-Amido-3-aryl-piperidines: A Novel Class of Potent, Selective, and Orally Active GlyT1 Inhibitors.",ACS Med. Chem. Lett.,2014.0,5,4,428,433,10.1021/ml500005m,24900853.0,
14659007,CHEMBL3261331,"2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile",CHEMBL3266609,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,22000.0,nM,CC(C)c1cc(Oc2c(Cl)cc(-n3nc(C#N)c(=O)[nH]c3=O)cc2Cl)n[nH]c1=O,CHEMBL3259553,"Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia.",J. Med. Chem.,2014.0,57,10,3912,3923,10.1021/jm4019299,24712661.0,
14660365,CHEMBL3260567,"N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline",CHEMBL3270811,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate incubated for 5 mins prior to substrate addition measured after 10 mins by LC/MS/MS analysis,IC50,>,10000.0,nM,Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1,CHEMBL3259733,"Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.",J. Med. Chem.,2014.0,57,10,4213,4238,10.1021/jm500115w,24786585.0,
14667144,CHEMBL3261407,"(S)-N-(1-(1-(4-fluorophenyl)-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",CHEMBL3268094,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,7900.0,nM,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cccc3c2cnn3-c2ccc(F)cc2)c(C)c1,CHEMBL3259563,"The discovery of potent and selective non-steroidal glucocorticoid receptor modulators, suitable for inhalation.",Bioorg. Med. Chem. Lett.,2014.0,24,11,2571,2577,10.1016/j.bmcl.2014.03.070,24755427.0,
14667163,CHEMBL3261425,"(S)-1-cyclopentyl-N-(1-(1-(6-fluoropyridin-3-yl)-1H-indazol-4-ylamino)propan-2-yl)-3,5-dimethyl-1H-pyrazole-4-sulfonamide",CHEMBL3268094,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,17000.0,nM,Cc1nn(C2CCCC2)c(C)c1S(=O)(=O)N[C@@H](C)CNc1cccc2c1cnn2-c1ccc(F)nc1,CHEMBL3259563,"The discovery of potent and selective non-steroidal glucocorticoid receptor modulators, suitable for inhalation.",Bioorg. Med. Chem. Lett.,2014.0,24,11,2571,2577,10.1016/j.bmcl.2014.03.070,24755427.0,
14668378,CHEMBL3261479,"(S)-2-(quinuclidin-3-yl)-3,4-dihydro-[1,4]diazepino[6,7,1-hi]indol-1(2H)-one",CHEMBL3268874,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C1c2cccc3ccn(c23)CCN1[C@@H]1CN2CCC1CC2,CHEMBL3259590,The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,2014.0,24,11,2578,2581,10.1016/j.bmcl.2014.03.074,24755431.0,
14668379,CHEMBL3261481,"(S)-7-(quinuclidin-3-yl)-8,9-dihydro-[1,4]diazepino[6,7,1-hi]indazol-6(7H)-one",CHEMBL3268874,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C1c2cccc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2,CHEMBL3259590,The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,2014.0,24,11,2578,2581,10.1016/j.bmcl.2014.03.074,24755431.0,
14668380,CHEMBL3261482,"(S)-4-fluoro-7-(quinuclidin-3-yl)-8,9-dihydro-[1,4]diazepino[6,7,1-hi]indazol-6(7H)-one",CHEMBL3268874,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C1c2cc(F)cc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2,CHEMBL3259590,The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,2014.0,24,11,2578,2581,10.1016/j.bmcl.2014.03.074,24755431.0,
14668381,CHEMBL3261483,"(S)-4-chloro-7-(quinuclidin-3-yl)-8,9-dihydro-[1,4]diazepino[6,7,1-hi]indazol-6(7H)-one",CHEMBL3268874,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C1c2cc(Cl)cc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2,CHEMBL3259590,The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,2014.0,24,11,2578,2581,10.1016/j.bmcl.2014.03.074,24755431.0,
14668382,CHEMBL3261485,"(S)-4-methoxy-7-(quinuclidin-3-yl)-8,9-dihydro-[1,4]diazepino[6,7,1-hi]indazol-6(7H)-one",CHEMBL3268874,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,COc1cc2c3c(cnn3CCN([C@@H]3CN4CCC3CC4)C2=O)c1,CHEMBL3259590,The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,2014.0,24,11,2578,2581,10.1016/j.bmcl.2014.03.074,24755431.0,
14668383,CHEMBL3261486,"6-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepine-2,7(1H,4H)-dione",CHEMBL3268874,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C1c2cccc3[nH]c(=O)n(c23)CCN1[C@@H]1CN2CCC1CC2,CHEMBL3259590,The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,2014.0,24,11,2578,2581,10.1016/j.bmcl.2014.03.074,24755431.0,
14669622,CHEMBL3262028,"2-Methyl-3-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]-8-morpholin-4-ylimidazo[1,2-a]pyrazine",CHEMBL3267114,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,COCCn1cc(-c2c(C)nc3c(N4CCOCC4)nccn23)cn1,CHEMBL3259706,"Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.",J. Med. Chem.,2014.0,57,10,4196,4212,10.1021/jm500073h,24758746.0,
14670081,CHEMBL3262163,(R)-N-(4-Methoxyphenyl)-2-((pyridin-3-yloxy)methyl)piperazine-1-carboxamide Dihydrochloride,CHEMBL3268693,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,100000.0,nM,COc1ccc(NC(=O)N2CCNC[C@@H]2COc2cccnc2)cc1.Cl,CHEMBL3259628,Discovery of novel 2-((pyridin-3-yloxy)methyl)piperazines as α7 nicotinic acetylcholine receptor modulators for the treatment of inflammatory disorders.,J. Med. Chem.,2014.0,57,10,3966,3983,10.1021/jm5004599,24814197.0,
14672082,CHEMBL3265032,"6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]-pyrazin-8-amine",CHEMBL3265579,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1,CHEMBL3259702,"Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.",J. Med. Chem.,2014.0,57,9,3856,3873,10.1021/jm500228a,24779514.0,
14710053,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3294175,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) using 7-methoxy-4-trifluoromethylcoumarin as substrate,IC50,=,180.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3286274,"Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.",J. Med. Chem.,2014.0,57,11,4640,4660,10.1021/jm500109z,24793360.0,
14715563,CHEMBL3288752,"6-Chloro-2-(2-chloro-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)-7-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one",CHEMBL3292472,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,11000.0,nM,Cc1cc2nn(Cc3cc([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)ccc3Cl)c(=O)n2cc1Cl,CHEMBL3286323,The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties.,Bioorg. Med. Chem.,2014.0,22,13,3414,3422,10.1016/j.bmc.2014.04.036,24842618.0,
14715564,CHEMBL3288755,"1-(4-(2-Chloro-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)-3-ethylimidazolidine-2,4-dione",CHEMBL3292472,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,11000.0,nM,CCN1C(=O)CN(c2ccc(Cc3cc([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)ccc3Cl)cc2)C1=O,CHEMBL3286323,The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties.,Bioorg. Med. Chem.,2014.0,22,13,3414,3422,10.1016/j.bmc.2014.04.036,24842618.0,
14715656,CHEMBL3291118,14-O-(((Pyridin-2-yl)sulfanyl)acetyl)mutilin,CHEMBL3297535,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 15 mins by LC/MS/MS analysis,IC50,>,10000.0,nM,C=C[C@]1(C)C[C@@H](OC(=O)CSc2ccccn2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,CHEMBL3286253,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,2014.0,57,11,4772,4795,10.1021/jm500312x,24874438.0,
14715657,CHEMBL3291120,"(3-Hydroxymethyl-phenylsulfanyl)-acetic acid(1S,2R,3S,4S,6R,7R,8R,14R)-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-4-vinyl-tricyclo[5.4.3.0(1,8)]tetradec-6-yl ester",CHEMBL3297535,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 15 mins by LC/MS/MS analysis,IC50,=,11100.0,nM,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cccc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,CHEMBL3286253,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,2014.0,57,11,4772,4795,10.1021/jm500312x,24874438.0,
14715658,CHEMBL3291124,14-O-(((5-Hydroxymethylpyridin-3-yl)sulfanyl)acetyl)mutilin,CHEMBL3297535,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 15 mins by LC/MS/MS analysis,IC50,>,25000.0,nM,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,CHEMBL3286253,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,2014.0,57,11,4772,4795,10.1021/jm500312x,24874438.0,
14715659,CHEMBL3291127,14-O-(((5-Aminopyridin-3-yl)sulfanyl)acetyl)mutilin,CHEMBL3297535,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 15 mins by LC/MS/MS analysis,IC50,>,25000.0,nM,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(N)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,CHEMBL3286253,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,2014.0,57,11,4772,4795,10.1021/jm500312x,24874438.0,
14715660,CHEMBL3291394,14-O-(((5-((3-Hydroxylpiperidin-1-yl)acetamido)pyridin-3-yl)sulfanyl)acetyl)mutilin,CHEMBL3297535,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 15 mins by LC/MS/MS analysis,IC50,>,25000.0,nM,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCCC(O)C3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,CHEMBL3286253,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,2014.0,57,11,4772,4795,10.1021/jm500312x,24874438.0,
14715661,CHEMBL3291395,14-O-(((5-((4-Hydroxylpiperidin-1-yl)acetamido)pyridin-3-yl)-sulfanyl)acetyl)mutilin,CHEMBL3297535,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 15 mins by LC/MS/MS analysis,IC50,>,25000.0,nM,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCC(O)CC3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,CHEMBL3286253,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,2014.0,57,11,4772,4795,10.1021/jm500312x,24874438.0,
14715662,CHEMBL3291398,BC-3781,CHEMBL3297535,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 15 mins by LC/MS/MS analysis,IC50,>,25000.0,nM,C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,CHEMBL3286253,"Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.",J. Med. Chem.,2014.0,57,11,4772,4795,10.1021/jm500312x,24874438.0,
14719509,CHEMBL3289023,"trans-N-(4-Aminocyclohexyl)-3,5-bis(4-carbamimidoylphenoxy)benzamide",CHEMBL3294547,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,N=C(N)c1ccc(Oc2cc(Oc3ccc(C(=N)N)cc3)cc(C(=O)N[C@H]3CC[C@H](N)CC3)c2)cc1,CHEMBL3286254,"Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.",Bioorg. Med. Chem.,2014.0,22,12,3187,3203,10.1016/j.bmc.2014.04.013,24794746.0,
14719510,CHEMBL3289034,"trans-4-Amino-N-(3,5-bis(4-carbamimidoylphenoxy)phenyl)cyclohexanecarboxamide",CHEMBL3294547,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,N=C(N)c1ccc(Oc2cc(NC(=O)[C@H]3CC[C@H](N)CC3)cc(Oc3ccc(C(=N)N)cc3)c2)cc1,CHEMBL3286254,"Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.",Bioorg. Med. Chem.,2014.0,22,12,3187,3203,10.1016/j.bmc.2014.04.013,24794746.0,
14719511,CHEMBL3289038,"trans-4-Aminocyclohexyl 3,5-bis(4-carbamimidoylphenoxy)benzoate",CHEMBL3294547,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,N=C(N)c1ccc(Oc2cc(Oc3ccc(C(=N)N)cc3)cc(C(=O)O[C@H]3CC[C@H](N)CC3)c2)cc1,CHEMBL3286254,"Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.",Bioorg. Med. Chem.,2014.0,22,12,3187,3203,10.1016/j.bmc.2014.04.013,24794746.0,
14720436,CHEMBL3109801,"N-(2-Fluoroethyl)-1-((6-methoxy-5-methylpyrimidin-4-yl)-methyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide",CHEMBL3292128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,50000.0,nM,COc1ncnc(Cn2cc(C(=O)NCCF)c3ncc(C)cc32)c1C,CHEMBL3286390,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,2014.0,57,13,5728,5737,10.1021/jm500571f,24874895.0,
14720437,CHEMBL3109802,"N-(2-Hydroxyethyl)-1-((6-methoxy-5-methylpyrimidin-4-yl)-methyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide",CHEMBL3292128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,50000.0,nM,COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc32)c1C,CHEMBL3286390,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,2014.0,57,13,5728,5737,10.1021/jm500571f,24874895.0,
14720438,CHEMBL3291422,"N-(2,2-Difluoroethyl)-1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide",CHEMBL3292128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,50000.0,nM,COc1ncnc(Cn2cc(C(=O)NCC(F)F)c3ncc(C)cc32)c1C,CHEMBL3286390,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,2014.0,57,13,5728,5737,10.1021/jm500571f,24874895.0,
14720439,CHEMBL3291423,"1-((6-(Dimethylamino)-5-methylpyrimidin-4-yl)methyl)-N-(2-hydroxyethyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide",CHEMBL3292128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,50000.0,nM,Cc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(N(C)C)c3C)c2c1,CHEMBL3286390,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,2014.0,57,13,5728,5737,10.1021/jm500571f,24874895.0,
14720440,CHEMBL3291424,"1-((6-(Difluoromethoxy)-5-methylpyrimidin-4-yl)methyl)-N-(2-hydroxyethyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide",CHEMBL3292128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,50000.0,nM,Cc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(OC(F)F)c3C)c2c1,CHEMBL3286390,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,2014.0,57,13,5728,5737,10.1021/jm500571f,24874895.0,
14720441,CHEMBL3291427,"N-(2-Hydroxyethyl)-6-methoxy-1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-1H-pyrrolo[3,2-b]pyridine-3-carboxamide",CHEMBL3292128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,50000.0,nM,COc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(OC)c3C)c2c1,CHEMBL3286390,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,2014.0,57,13,5728,5737,10.1021/jm500571f,24874895.0,
14720442,CHEMBL3291430,"1-((6-(Dimethylamino)-5-methylpyrimidin-4-yl)methyl)-N-(2-hydroxyethyl)-6-methoxy-1H-pyrrolo[3,2-b]pyridine-3-carboxamide",CHEMBL3292128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,50000.0,nM,COc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(N(C)C)c3C)c2c1,CHEMBL3286390,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",J. Med. Chem.,2014.0,57,13,5728,5737,10.1021/jm500571f,24874895.0,
14721847,CHEMBL3286732,"N-(2-amino-5-(thiophen-2-yl)phenyl)-6-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)nicotinamide",CHEMBL3293883,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Nc1ccc(-c2cccs2)cc1NC(=O)c1ccc(N2CCC3(CC2)CNC(=O)O3)nc1,CHEMBL3286368,Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor.,ACS Med. Chem. Lett.,2014.0,5,4,340,345,10.1021/ml4004233,24900838.0,
14725690,CHEMBL3289805,"rac-2-(2-Amino-3H-imidazo[4,5-b]pyridin-3-yl)-1-(2,3-dichlorophenyl)ethanol",CHEMBL3296729,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Nc1nc2cccnc2n1CC(O)c1cccc(Cl)c1Cl,CHEMBL3286148,"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",J. Med. Chem.,2014.0,57,13,5702,5713,10.1021/jm500535j,24914738.0,
14725691,CHEMBL3289806,"rac-2-(2-Amino-5-(4-methylpiperazin-1-yl)-3H-imidazo[4,5-b]-pyridin-3-yl)-1-(2-chloro-4-(trifluoromethyl)phenyl)ethan-1-ol",CHEMBL3296729,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,CN1CCN(c2ccc3nc(N)n(CC(O)c4ccc(C(F)(F)F)cc4Cl)c3n2)CC1,CHEMBL3286148,"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",J. Med. Chem.,2014.0,57,13,5702,5713,10.1021/jm500535j,24914738.0,
14725692,CHEMBL3289811,"rac-2-(2-Amino-5-((tetrahydrofuran-3-yl)oxy)-3H-imidazo[4,5-b]-pyridin-3-yl)-1-(2-chloro-4-(trifluoromethyl)phenyl)ethanol",CHEMBL3296729,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Nc1nc2ccc(OC3CCOC3)nc2n1CC(O)c1ccc(C(F)(F)F)cc1Cl,CHEMBL3286148,"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",J. Med. Chem.,2014.0,57,13,5702,5713,10.1021/jm500535j,24914738.0,
14725837,CHEMBL3289813,"rac-2-(2-Amino-5-((1,1,1-trifluoropropan-2-yl)oxy)-3H-imidazo[4,5-b]pyridin-3-yl)-1-(2-chloro-4-(trifluoromethyl)phenyl)ethanol",CHEMBL3296729,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,22900.0,nM,CC(Oc1ccc2nc(N)n(CC(O)c3ccc(C(F)(F)F)cc3Cl)c2n1)C(F)(F)F,CHEMBL3286148,"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",J. Med. Chem.,2014.0,57,13,5702,5713,10.1021/jm500535j,24914738.0,
14725847,CHEMBL3289803,rac-2-(2-Amino-6-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl)-1-(2-chloro-4-(trifluoromethyl)phenyl)ethanol,CHEMBL3296729,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,27900.0,nM,Nc1nc2ccc(C(F)(F)F)cc2n1CC(O)c1ccc(C(F)(F)F)cc1Cl,CHEMBL3286148,"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",J. Med. Chem.,2014.0,57,13,5702,5713,10.1021/jm500535j,24914738.0,
14730354,CHEMBL3287179,"4-(1-Propanoyl-2,3-dihydro-1H-indol-5-yl)isoquinoline",CHEMBL3293055,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 2 to 45 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,CCC(=O)N1CCc2cc(-c3cncc4ccccc34)ccc21,CHEMBL3286158,Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.,J. Med. Chem.,2014.0,57,12,5179,5189,10.1021/jm500140c,24899257.0,
14730355,CHEMBL3287188,"1-Acetyl-5-(4-methylpyridin-3-yl)-2,3-dihydro-1H-indole",CHEMBL3293055,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 2 to 45 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,CC(=O)N1CCc2cc(-c3cnccc3C)ccc21,CHEMBL3286158,Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.,J. Med. Chem.,2014.0,57,12,5179,5189,10.1021/jm500140c,24899257.0,
14732712,CHEMBL3287239,2-((5-(2-chloro-4-(2-isopropoxyethoxy)phenyl)pyrimidin-2-yl)methoxy)nicotinamide,CHEMBL3293586,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,19000.0,nM,CC(C)OCCOc1ccc(-c2cnc(COc3ncccc3C(N)=O)nc2)c(Cl)c1,CHEMBL3286119,Biarylmethoxy Nicotinamides As Novel and Specific Inhibitors of Mycobacterium tuberculosis.,ACS Med. Chem. Lett.,2014.0,5,5,491,495,10.1021/ml4004815,24900867.0,
14737252,CHEMBL3287548,"5-(3-(4-chlorophenoxy)propyl)-8-fluoro-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole",CHEMBL3292549,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide conversion to 4-hydroxy tolbutamide preincubated for 10 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis,IC50,>,25000.0,nM,Fc1ccc2c(c1)c1c(n2CCCOc2ccc(Cl)cc2)CCNC1,CHEMBL3286225,"Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation.",ACS Med. Chem. Lett.,2014.0,5,5,506,511,10.1021/ml400492t,24900870.0,
14741959,CHEMBL3287849,"5-((2R,4S)-2-Benzylpiperidin-4-yl)isoxazol-3(2H)-one",CHEMBL3293937,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000000.0,nM,O=c1cc([C@H]2CCN[C@@H](Cc3ccccc3)C2)o[nH]1,CHEMBL3286179,"Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.",ACS Med. Chem. Lett.,2014.0,5,5,538,543,10.1021/ml400526d,24900876.0,
14741960,CHEMBL3287851,"5-((2R,4S)-2-Neopentylpiperidin-4-yl)isoxazol-3(2H)-one",CHEMBL3293937,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000000.0,nM,CC(C)(C)C[C@H]1C[C@@H](c2cc(=O)[nH]o2)CCN1,CHEMBL3286179,"Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.",ACS Med. Chem. Lett.,2014.0,5,5,538,543,10.1021/ml400526d,24900876.0,
14741961,CHEMBL3287854,"5-((2S,4S)-2-Phenethylpiperidin-4-yl)isoxazol-3(2H)-one",CHEMBL3293937,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000000.0,nM,O=c1cc([C@H]2CCN[C@@H](CCc3ccccc3)C2)o[nH]1,CHEMBL3286179,"Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.",ACS Med. Chem. Lett.,2014.0,5,5,538,543,10.1021/ml400526d,24900876.0,
14742008,CHEMBL3287894,"3-(5-(2-ethyl-4-(phenylcarbamoyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)pyridin-2-yloxy)-2,2-dimethylpropanoicacid",CHEMBL3294185,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,500.0,nM,CCC1CN(C(=O)Nc2ccccc2)c2ccc(-c3ccc(OCC(C)(C)C(=O)O)nc3)cc2O1,CHEMBL3286266,Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.,ACS Med. Chem. Lett.,2014.0,5,5,544,549,10.1021/ml400527n,24900877.0,
14742044,CHEMBL3287865,"2-((trans)-4-(4-((R)-2-methyl-4-(phenylcarbamoyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)phenyl)cyclohexyl)acetic acid",CHEMBL3294185,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,14000.0,nM,C[C@@H]1CN(C(=O)Nc2ccccc2)c2ccc(-c3ccc([C@H]4CC[C@H](CC(=O)O)CC4)cc3)cc2O1,CHEMBL3286266,Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.,ACS Med. Chem. Lett.,2014.0,5,5,544,549,10.1021/ml400527n,24900877.0,
14743147,CHEMBL3288009,"N-((cis)-4-(5-Fluoro-2-(4'-((4-(pyrrolidin-1-yl)piperidin-1-yl)methyl)biphenyl-3-yloxy)nicotinamido)cyclohexyl)-5-methylimidazo[1,2-a]pyridine-2-carboxamide",CHEMBL3292790,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,1000.0,nM,Cc1cccc2nc(C(=O)N[C@H]3CC[C@@H](NC(=O)c4cc(F)cnc4Oc4cccc(-c5ccc(CN6CCC(N7CCCC7)CC6)cc5)c4)CC3)cn12,CHEMBL3286180,Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.,J. Med. Chem.,2014.0,57,11,4661,4676,10.1021/jm5001216,24785301.0,
14743148,CHEMBL3288010,"N-((cis)-4-(2-(4'-(((3S,5R)-3,5-Dimethylpiperazin-1-yl)methyl)biphenyl-3-yloxy)-5-fluoronicotinamido)cyclohexyl)pyrazolo[1,5-a]pyridine-2-carboxamide",CHEMBL3292790,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,1000.0,nM,C[C@H]1CN(Cc2ccc(-c3cccc(Oc4ncc(F)cc4C(=O)N[C@H]4CC[C@@H](NC(=O)c5cc6ccccn6n5)CC4)c3)cc2)C[C@@H](C)N1,CHEMBL3286180,Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.,J. Med. Chem.,2014.0,57,11,4661,4676,10.1021/jm5001216,24785301.0,
14743149,CHEMBL3288011,"N-((cis)-4-(2-(4'-(((3S,5R)-3,5-Dimethylpiperazin-1-yl)methyl)biphenyl-3-yloxy)-5-fluoronicotinamido)cyclohexyl)-5-methylimidazo[1,2-a]pyridine-2-carboxamide",CHEMBL3292790,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,1000.0,nM,Cc1cccc2nc(C(=O)N[C@H]3CC[C@@H](NC(=O)c4cc(F)cnc4Oc4cccc(-c5ccc(CN6C[C@H](C)N[C@H](C)C6)cc5)c4)CC3)cn12,CHEMBL3286180,Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.,J. Med. Chem.,2014.0,57,11,4661,4676,10.1021/jm5001216,24785301.0,
14743244,CHEMBL3288027,"N-((cis)-4-(1,5-Dimethyl-1H-pyrazole-3-carboxamido)-cyclohexyl)-2-(4'-(3-((3S,5R)-3,5-dimethylpiperazin-1-yl)-propyl)biphenyl-3-yloxy)-5-fluoronicotinamide",CHEMBL3292790,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,1000.0,nM,Cc1cc(C(=O)N[C@H]2CC[C@@H](NC(=O)c3cc(F)cnc3Oc3cccc(-c4ccc(CCCN5C[C@H](C)N[C@H](C)C5)cc4)c3)CC2)nn1C,CHEMBL3286180,Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.,J. Med. Chem.,2014.0,57,11,4661,4676,10.1021/jm5001216,24785301.0,
14743245,CHEMBL3288028,"N-((cis)-4-(1,5-Dimethyl-1H-pyrazole-3-carboxamido)-cyclohexyl)-5-fluoro-2-(4'-(2-(4-(pyrrolidin-1-yl)piperidin-1-yl)-ethyl)biphenyl-3-yloxy)nicotinamide",CHEMBL3292790,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,1000.0,nM,Cc1cc(C(=O)N[C@H]2CC[C@@H](NC(=O)c3cc(F)cnc3Oc3cccc(-c4ccc(CCN5CCC(N6CCCC6)CC5)cc4)c3)CC2)nn1C,CHEMBL3286180,Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.,J. Med. Chem.,2014.0,57,11,4661,4676,10.1021/jm5001216,24785301.0,
14743364,CHEMBL3287739,"N-((cis)-4-(1,5-Dimethyl-1H-pyrazole-3-carboxamido)-cyclohexyl)-5-fluoro-2-(4'-hydroxy-2'-(morpholinomethyl)-biphenyl-3-yloxy)nicotinamide",CHEMBL3292790,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,251.19,nM,Cc1cc(C(=O)N[C@H]2CC[C@@H](NC(=O)c3cc(F)cnc3Oc3cccc(-c4ccc(O)cc4CN4CCOCC4)c3)CC2)nn1C,CHEMBL3286180,Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.,J. Med. Chem.,2014.0,57,11,4661,4676,10.1021/jm5001216,24785301.0,
14744550,CHEMBL3288447,(S)-(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)(1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)methanone hydrochloride,CHEMBL3292889,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) co-incubated with enzyme,IC50,>,30000.0,nM,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1.Cl,CHEMBL3286134,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,2014.0,5,5,572,575,10.1021/ml500019s,24900882.0,
14744551,CHEMBL3288448,"((2R,3S)-2-allyl-1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)methanone hydrochloride",CHEMBL3292889,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) co-incubated with enzyme,IC50,>,30000.0,nM,C=CC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1ccc(C(F)(F)F)cc1)C(=O)N1CCN(c2ccccc2OCCOC)CC1.Cl,CHEMBL3286134,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,2014.0,5,5,572,575,10.1021/ml500019s,24900882.0,
14744552,CHEMBL3288450,"((2R,3S)-2-(2,3-dihydroxypropyl)-1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)methanone hydrochloride",CHEMBL3292889,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) co-incubated with enzyme,IC50,>,30000.0,nM,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CC(O)CO)CC1.Cl,CHEMBL3286134,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,2014.0,5,5,572,575,10.1021/ml500019s,24900882.0,
14744553,CHEMBL3288451,"((2R,3S)-2-(2-hydroxyethyl)-1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)methanone hydrochloride",CHEMBL3292889,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) co-incubated with enzyme,IC50,>,30000.0,nM,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CCO)CC1.Cl,CHEMBL3286134,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,2014.0,5,5,572,575,10.1021/ml500019s,24900882.0,
14744562,CHEMBL3288447,(S)-(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)(1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)methanone hydrochloride,CHEMBL3292892,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) pre-incubated with enzyme,IC50,>,30000.0,nM,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1.Cl,CHEMBL3286134,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,2014.0,5,5,572,575,10.1021/ml500019s,24900882.0,
14744563,CHEMBL3288448,"((2R,3S)-2-allyl-1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)methanone hydrochloride",CHEMBL3292892,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) pre-incubated with enzyme,IC50,>,30000.0,nM,C=CC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1ccc(C(F)(F)F)cc1)C(=O)N1CCN(c2ccccc2OCCOC)CC1.Cl,CHEMBL3286134,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,2014.0,5,5,572,575,10.1021/ml500019s,24900882.0,
14744564,CHEMBL3288450,"((2R,3S)-2-(2,3-dihydroxypropyl)-1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)methanone hydrochloride",CHEMBL3292892,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) pre-incubated with enzyme,IC50,>,30000.0,nM,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CC(O)CO)CC1.Cl,CHEMBL3286134,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,2014.0,5,5,572,575,10.1021/ml500019s,24900882.0,
14744565,CHEMBL3288451,"((2R,3S)-2-(2-hydroxyethyl)-1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)methanone hydrochloride",CHEMBL3292892,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) pre-incubated with enzyme,IC50,>,30000.0,nM,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CCO)CC1.Cl,CHEMBL3286134,Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.,ACS Med. Chem. Lett.,2014.0,5,5,572,575,10.1021/ml500019s,24900882.0,
14748653,CHEMBL3109797,"7-chloro-2-ethyl-N-(4-(4-(4-fluorophenyl)piperazin-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide",CHEMBL3300782,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by LC/MS/MS analysis,IC50,>,40000.0,nM,CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCN(c3ccc(F)cc3)CC2)cc1,CHEMBL3297708,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,2014.0,57,12,5293,5305,10.1021/jm5003606,24870926.0,
14748654,CHEMBL3298835,"7-Chloro-2-ethyl-N-{4-[4-(4-fluorophenyl)piperidin-1-yl]benzyl}-imidazo[1,2-a]pyridine-3-carboxamide",CHEMBL3300782,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by LC/MS/MS analysis,IC50,=,500.0,nM,CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCC(c3ccc(F)cc3)CC2)cc1,CHEMBL3297708,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,2014.0,57,12,5293,5305,10.1021/jm5003606,24870926.0,
14748655,CHEMBL3298836,"6-Chloro-2-ethyl-N-{4-[4-(4-fluorophenyl)piperazin-1-yl]benzyl}-imidazo[1,2-a]pyridine-3-carboxamide",CHEMBL3300782,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by LC/MS/MS analysis,IC50,=,1330.0,nM,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCN(c3ccc(F)cc3)CC2)cc1,CHEMBL3297708,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,2014.0,57,12,5293,5305,10.1021/jm5003606,24870926.0,
14748656,CHEMBL3298837,"7-Chloro-2-ethyl-N-(4-{4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}benzyl)imidazo[1,2-a]pyridine-3-carboxamide",CHEMBL3300782,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by LC/MS/MS analysis,IC50,=,170.0,nM,CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCN(c3ccc(OC(F)(F)F)cc3)CC2)cc1,CHEMBL3297708,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,2014.0,57,12,5293,5305,10.1021/jm5003606,24870926.0,
14748657,CHEMBL3298905,"6-Chloro-2-ethyl-N-(4-{4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}benzyl)imidazo[1,2-a]pyridine-3-carboxamide",CHEMBL3300782,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by LC/MS/MS analysis,IC50,=,570.0,nM,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCN(c3ccc(OC(F)(F)F)cc3)CC2)cc1,CHEMBL3297708,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,2014.0,57,12,5293,5305,10.1021/jm5003606,24870926.0,
14748658,CHEMBL3298906,"6-Chloro-2-ethyl-N-{4-[4-(4-fluorophenyl)piperidin-1-yl]benzyl}-imidazo[1,2-a]pyridine-3-carboxamide",CHEMBL3300782,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by LC/MS/MS analysis,IC50,>,40000.0,nM,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(F)cc3)CC2)cc1,CHEMBL3297708,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,2014.0,57,12,5293,5305,10.1021/jm5003606,24870926.0,
14748659,CHEMBL3298907,"7-Chloro-N-{4-[4-(4-chlorophenyl)piperidin-1-yl]benzyl}-2-ethylimidazo[1,2-a]pyridine-3-carboxamide",CHEMBL3300782,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by LC/MS/MS analysis,IC50,=,190.0,nM,CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCC(c3ccc(Cl)cc3)CC2)cc1,CHEMBL3297708,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,2014.0,57,12,5293,5305,10.1021/jm5003606,24870926.0,
14748660,CHEMBL3298908,"6-Chloro-N-{4-[4-(4-chlorophenyl)piperidin-1-yl]benzyl}-2-ethylimidazo[1,2-a]pyridine-3-carboxamide",CHEMBL3300782,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by LC/MS/MS analysis,IC50,=,260.0,nM,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(Cl)cc3)CC2)cc1,CHEMBL3297708,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,2014.0,57,12,5293,5305,10.1021/jm5003606,24870926.0,
14748661,CHEMBL3298909,"7-Chloro-2-ethyl-N-(4-{4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl}benzyl)imidazo[1,2-a]pyridine-3-carboxamide",CHEMBL3300782,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by LC/MS/MS analysis,IC50,=,140.0,nM,CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCC(c3ccc(OC(F)(F)F)cc3)CC2)cc1,CHEMBL3297708,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,2014.0,57,12,5293,5305,10.1021/jm5003606,24870926.0,
14748662,CHEMBL3298910,"6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide",CHEMBL3300782,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by LC/MS/MS analysis,IC50,>,100000.0,nM,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(OC(F)(F)F)cc3)CC2)cc1,CHEMBL3297708,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",J. Med. Chem.,2014.0,57,12,5293,5305,10.1021/jm5003606,24870926.0,
14751932,CHEMBL3297762,"2-[(4S)-7-(3-Chlorophenyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl]-N-[(1S)-1-cyclohexyl-2-(4-methylpiperazin-1-yl)ethyl]acetamide",CHEMBL3300820,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CN1CCN(C[C@@H](NC(=O)C[C@H]2CNC(=O)c3cc(-c4cccc(Cl)c4)cn32)C2CCCCC2)CC1,CHEMBL3297733,"Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.",Bioorg. Med. Chem.,2013.0,21,23,7364,7380,10.1016/j.bmc.2013.09.054,24139169.0,
14756296,CHEMBL3298322,"1-(4-Fluorophenoxy)-6,7-dimethoxyisoquinoline",CHEMBL3300596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS/competitive screening assay,IC50,=,1900.0,nM,COc1cc2ccnc(Oc3ccc(F)cc3)c2cc1OC,CHEMBL3297644,"Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists.",Bioorg. Med. Chem. Lett.,2014.0,24,14,3199,3203,10.1016/j.bmcl.2014.04.045,24835202.0,
14756325,CHEMBL3298431,"4-(4-Fluorophenoxy)-7H-pyrrolo[2,3-d]pyrimidine",CHEMBL3300596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS/competitive screening assay,IC50,>,20000.0,nM,Fc1ccc(Oc2ncnc3[nH]ccc23)cc1,CHEMBL3297644,"Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists.",Bioorg. Med. Chem. Lett.,2014.0,24,14,3199,3203,10.1016/j.bmcl.2014.04.045,24835202.0,
14756326,CHEMBL3298760,"4-(2,4-difluorophenoxy)-1H-pyrrolo[3,2-c]pyridine",CHEMBL3300596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS/competitive screening assay,IC50,>,20000.0,nM,Fc1ccc(Oc2nccc3[nH]ccc23)c(F)c1,CHEMBL3297644,"Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists.",Bioorg. Med. Chem. Lett.,2014.0,24,14,3199,3203,10.1016/j.bmcl.2014.04.045,24835202.0,
14756327,CHEMBL3297778,"4-(2,4-Difluorophenoxy)-1H-pyrrolo[3,2-c]pyridine",CHEMBL3300596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS/competitive screening assay,IC50,>,20000.0,nM,Fc1ccc(Oc2nccc3[nH]ccc23)cc1,CHEMBL3297644,"Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists.",Bioorg. Med. Chem. Lett.,2014.0,24,14,3199,3203,10.1016/j.bmcl.2014.04.045,24835202.0,
14971347,CHEMBL3357391,2-(3-(1-(2-(dimethylamino)ethyl)-2-neopentyl-1H-benzo[d]imidazol-5-ylsulfonyl)azetidin-1-yl)ethanol,CHEMBL3378972,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,3000.0,nM,CN(C)CCn1c(CC(C)(C)C)nc2cc(S(=O)(=O)C3CN(CCO)C3)ccc21,CHEMBL3352700,"Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome.",Bioorg. Med. Chem. Lett.,2015.0,25,2,236,240,10.1016/j.bmcl.2014.11.062,25499880.0,
14971775,CHEMBL3354313,"2-((3-chlorophenylsulfonyl)methyl)-4-(6-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine",CHEMBL3387009,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) after 10 mins by LC-MS/MS analysis,IC50,=,5250.0,nM,COc1ccc(-c2nc(CS(=O)(=O)c3cccc(Cl)c3)nc3ccsc23)cn1,CHEMBL3352046,"Serendipitous discovery of 2-((phenylsulfonyl)methyl)-thieno[3,2-d]pyrimidine derivatives as novel HIV-1 replication inhibitors.",Bioorg. Med. Chem. Lett.,2014.0,24,23,5473,5477,10.1016/j.bmcl.2014.10.007,25455487.0,
14974750,CHEMBL3353862,(S)-N-(5-tert-butylisoxazol-3-yl)-1-(4-(trifluoromethyl)phenyl)pyrrolidine-2-carboxamide,CHEMBL3373572,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC(C)(C)c1cc(NC(=O)[C@@H]2CCCN2c2ccc(C(F)(F)F)cc2)no1,CHEMBL3352390,Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.,Bioorg. Med. Chem. Lett.,2015.0,25,3,581,586,10.1016/j.bmcl.2014.12.019,25556092.0,
14974751,CHEMBL3353863,(S)-N-(5-tert-butylisoxazol-3-yl)-1-(4-chlorophenyl)pyrrolidine-2-carboxamide,CHEMBL3373572,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,46000.0,nM,CC(C)(C)c1cc(NC(=O)[C@@H]2CCCN2c2ccc(Cl)cc2)no1,CHEMBL3352390,Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.,Bioorg. Med. Chem. Lett.,2015.0,25,3,581,586,10.1016/j.bmcl.2014.12.019,25556092.0,
14974753,CHEMBL3353881,(S)-N-(3-tert-butylisoxazol-5-yl)-5-oxo-1-(4-(trifluoromethyl)phenyl)pyrrolidine-2-carboxamide,CHEMBL3373572,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,17000.0,nM,CC(C)(C)c1cc(NC(=O)[C@@H]2CCC(=O)N2c2ccc(C(F)(F)F)cc2)on1,CHEMBL3352390,Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.,Bioorg. Med. Chem. Lett.,2015.0,25,3,581,586,10.1016/j.bmcl.2014.12.019,25556092.0,
14977778,CHEMBL3354553,"(S)-1-(1,1-Dioxo-1lambda*6*-thiomorpholine-4-carbonyl)-piperidine-2-carboxylic acid(5-tert-butyl-isoxazol-3-yl)-amide",CHEMBL3376657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,CC(C)(C)c1cc(NC(=O)[C@@H]2CCCCN2C(=O)N2CCS(=O)(=O)CC2)no1,CHEMBL3352656,Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model.,Bioorg. Med. Chem. Lett.,2015.0,25,3,587,592,10.1016/j.bmcl.2014.12.031,25575658.0,
14979390,CHEMBL3355474,"(R)-3-methyl-4-(1-((R)-1-(methylsulfonyl)ethyl)-6-(1H-pyrrolo[2,3-c]pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-4-yl)morpholine",CHEMBL3372418,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,C[C@@H]1COCCN1c1nc(-c2cncc3[nH]ccc23)cc2c1ncn2[C@@H](C)S(C)(=O)=O,CHEMBL3352352,"Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors.",ACS Med. Chem. Lett.,2015.0,6,1,42,46,10.1021/ml500352s,25589928.0,
14979391,CHEMBL3355480,"(R)-3-methyl-4-(1-methyl-6-(1H-pyrrolo[2,3-d]pyridazin-4-yl)-1H-imidazo[4,5-c]pyridin-4-yl)morpholine",CHEMBL3372418,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,24000.0,nM,C[C@@H]1COCCN1c1nc(-c2nncc3[nH]ccc23)cc2c1ncn2C,CHEMBL3352352,"Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors.",ACS Med. Chem. Lett.,2015.0,6,1,42,46,10.1021/ml500352s,25589928.0,
14979882,CHEMBL3356239,"1-(1-Cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-{[2-(2-methoxyphenyl)ethyl]amino}ethanone",CHEMBL3381623,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 after 45 mins,IC50,=,4800.0,nM,COc1ccccc1CCNCC(=O)N1CCc2ccccc2C1C1CCCCC1,CHEMBL3351320,Discovery of novel tetrahydroisoquinoline derivatives as orally active N-type calcium channel blockers with high selectivity for hERG potassium channels.,Bioorg. Med. Chem.,2014.0,22,24,6899,6907,10.1016/j.bmc.2014.10.020,25456079.0,
14979883,CHEMBL3356251,"(1S)-(1-Cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-{[(1-hydroxycyclohexyl)methyl]amino}ethanone",CHEMBL3381623,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 after 45 mins,IC50,>,50000.0,nM,O=C(CNCC1(O)CCCCC1)N1CCc2ccccc2[C@@H]1C1CCCCC1,CHEMBL3351320,Discovery of novel tetrahydroisoquinoline derivatives as orally active N-type calcium channel blockers with high selectivity for hERG potassium channels.,Bioorg. Med. Chem.,2014.0,22,24,6899,6907,10.1016/j.bmc.2014.10.020,25456079.0,
14985796,CHEMBL3358920,"(R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid",CHEMBL3373698,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21,CHEMBL3352115,Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.,ACS Med. Chem. Lett.,2014.0,5,12,1313,1317,10.1021/ml500389m,25516790.0,
14985942,CHEMBL3359927,"4-((1R,2S)-2-fluoro-2-methylcyclopentylamino)pyrrolo[1,2-b]pyridazine-3-carboxamide",CHEMBL3377609,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,C[C@]1(F)CCC[C@H]1Nc1c(C(N)=O)cnn2cccc12,CHEMBL3352641,"Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.",Bioorg. Med. Chem. Lett.,2014.0,24,24,5721,5726,10.1016/j.bmcl.2014.10.061,25453808.0,
14987335,CHEMBL3358953,"(R)-2-(4-((5-(ethylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)benzamide",CHEMBL3374304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,12000.0,nM,CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccccc3C(N)=O)C(F)(F)F)[nH]c2cn1,CHEMBL3352560,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,2014.0,5,12,1318,1323,10.1021/ml500387y,25516791.0,
14987336,CHEMBL3358954,"(R)-2-(4-((5-(ethylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)-5-fluorobenzamide",CHEMBL3374304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,12000.0,nM,CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1,CHEMBL3352560,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,ACS Med. Chem. Lett.,2014.0,5,12,1318,1323,10.1021/ml500387y,25516791.0,
14988712,CHEMBL3359522,"(R)-2-(9-chloro-7-(3-cyano-4-isopropoxybenzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid",CHEMBL3380167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8500.0,nM,CC(C)Oc1ccc(COc2ccc3c(c2)c(Cl)c2n3CC[C@@H]2CC(=O)O)cc1C#N,CHEMBL3352004,"(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional Antagonists.",ACS Med. Chem. Lett.,2014.0,5,12,1334,1339,10.1021/ml500422m,25516794.0,
14988713,CHEMBL3359523,"(R)-2-(9-Chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid",CHEMBL3380167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC(C)Oc1ccc(COc2ccc3c(c2)c(Cl)c2n3CC[C@@H]2CC(=O)O)cc1C(F)(F)F,CHEMBL3352004,"(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional Antagonists.",ACS Med. Chem. Lett.,2014.0,5,12,1334,1339,10.1021/ml500422m,25516794.0,
14992471,CHEMBL2151164,2-(4-fluorophenyl)-N-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-1-methyl-1H-benzo[d]imidazol-4-amine,CHEMBL3382690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,21900.0,nM,COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1,CHEMBL3351481,Anilinotriazoles as potent gamma secretase modulators.,Bioorg. Med. Chem. Lett.,2014.0,24,24,5805,5813,10.1016/j.bmcl.2014.10.024,25454273.0,
14992472,CHEMBL3353099,"N-(2-fluoro-5-(trifluoromethyl)phenyl)-3-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-1-methyl-1H-1,2,4-triazol-5-amine",CHEMBL3382690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,12300.0,nM,COc1nc(-c2nc(Nc3cc(C(F)(F)F)ccc3F)n(C)n2)ccc1-n1cnc(C)c1,CHEMBL3351481,Anilinotriazoles as potent gamma secretase modulators.,Bioorg. Med. Chem. Lett.,2014.0,24,24,5805,5813,10.1016/j.bmcl.2014.10.024,25454273.0,
14997333,CHEMBL3310294,"(S)-1-(3-(2,3-dihydroxypropyl)-5-(3-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)phenyl)cyclopropanecarbonitrile",CHEMBL3368204,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using diclofenac as substrate after 10 mins by SPE-MS analysis in presence of NADPH,IC50,>,20000.0,nM,N#CC1(c2cc(C[C@H](O)CO)cc(-c3ccnc4[nH]nc(C(F)(F)F)c34)c2)CC1,CHEMBL3351598,Strategies for the modulation of phase II metabolism in a series of PKCε inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3398,3402,10.1016/j.bmcl.2014.05.082,24939756.0,
14997334,CHEMBL3310295,"(R)-1-(3-(2,3-dihydroxypropyl)-5-(3-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)phenyl)cyclopropanecarbonitrile",CHEMBL3368204,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using diclofenac as substrate after 10 mins by SPE-MS analysis in presence of NADPH,IC50,>,20000.0,nM,N#CC1(c2cc(C[C@@H](O)CO)cc(-c3ccnc4[nH]nc(C(F)(F)F)c34)c2)CC1,CHEMBL3351598,Strategies for the modulation of phase II metabolism in a series of PKCε inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3398,3402,10.1016/j.bmcl.2014.05.082,24939756.0,
15002157,CHEMBL1175,Methyl-[(S)-3-(naphthalen-1-yloxy)-3-thiophen-2-yl-propyl]-amine,CHEMBL3363904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,IC50,=,29000.0,nM,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,CHEMBL3352322,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3234,3237,10.1016/j.bmcl.2014.06.026,24974340.0,
15002158,CHEMBL528995,"1-(3,4-dichlorophenyl)-3-aza-bicyclo[3.1.0]hexane",CHEMBL3363904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,IC50,=,99000.0,nM,Clc1ccc(C23CNCC2C3)cc1Cl,CHEMBL3352322,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3234,3237,10.1016/j.bmcl.2014.06.026,24974340.0,
15002181,CHEMBL3310483,3-(2-(4-chloro-3-fluorophenyl)-2-(3-chlorophenoxy)ethyl)azetidine,CHEMBL3363904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,IC50,=,1100.0,nM,Fc1cc(C(CC2CNC2)Oc2cccc(Cl)c2)ccc1Cl,CHEMBL3352322,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3234,3237,10.1016/j.bmcl.2014.06.026,24974340.0,
15002182,CHEMBL3310484,3-(2-(4-chloro-3-fluorophenyl)-2-(2-fluorophenoxy)ethyl)azetidine,CHEMBL3363904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,IC50,=,2200.0,nM,Fc1cc(C(CC2CNC2)Oc2ccccc2F)ccc1Cl,CHEMBL3352322,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3234,3237,10.1016/j.bmcl.2014.06.026,24974340.0,
15002183,CHEMBL3310485,3-(2-(4-chloro-3-fluorophenyl)-2-(3-fluorophenoxy)ethyl)azetidine,CHEMBL3363904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,IC50,=,3100.0,nM,Fc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1,CHEMBL3352322,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3234,3237,10.1016/j.bmcl.2014.06.026,24974340.0,
15002184,CHEMBL3310486,3-(2-(4-chloro-3-fluorophenyl)-2-(4-fluorophenoxy)ethyl)azetidine,CHEMBL3363904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,IC50,=,2400.0,nM,Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)cc1,CHEMBL3352322,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3234,3237,10.1016/j.bmcl.2014.06.026,24974340.0,
15002185,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3363904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,IC50,=,4200.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3352322,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3234,3237,10.1016/j.bmcl.2014.06.026,24974340.0,
15007950,CHEMBL3330260,"3-(5-(3-(2,6-Diethylphenyl)ureido)-1H-indazol-3-yl)benzenesulfonamide",CHEMBL3367713,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in supersomes (unknown origin) using MFC as substrate after 30 mins,IC50,=,1700.0,nM,CCc1cccc(CC)c1NC(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1,CHEMBL3352261,Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.,Bioorg. Med. Chem.,2014.0,22,17,4968,4997,10.1016/j.bmc.2014.06.027,25043312.0,
15007951,CHEMBL3330410,(+/-)-2-(Pyrrolidin-1-yl)-N-(3-(3-sulfamoylphenyl)-1Hindazol-5-yl)-2-(thiophen-3-yl)acetamide,CHEMBL3367713,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in supersomes (unknown origin) using MFC as substrate after 30 mins,IC50,=,900.0,nM,NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)C(c4ccsc4)N4CCCC4)cc23)c1,CHEMBL3352261,Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.,Bioorg. Med. Chem.,2014.0,22,17,4968,4997,10.1016/j.bmc.2014.06.027,25043312.0,
15007952,CHEMBL3330409,(+/-)-2-(Dimethylamino)-2-(2-ethylphenyl)-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide,CHEMBL3367713,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in supersomes (unknown origin) using MFC as substrate after 30 mins,IC50,=,2500.0,nM,CCc1ccccc1C(C(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1)N(C)C,CHEMBL3352261,Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.,Bioorg. Med. Chem.,2014.0,22,17,4968,4997,10.1016/j.bmc.2014.06.027,25043312.0,
15008843,CHEMBL1951032,isopropyl 4-(5-methoxy-6-(2-methyl-6-(methylsulfonyl)pyridin-3-ylamino)pyrimidin-4-yloxy)piperidine-1-carboxylate,CHEMBL3374952,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5800.0,nM,COc1c(Nc2ccc(S(C)(=O)=O)nc2C)ncnc1OC1CCN(C(=O)OC(C)C)CC1,CHEMBL3352461,"Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.",Bioorg. Med. Chem. Lett.,2014.0,24,17,4332,4335,10.1016/j.bmcl.2014.06.071,25088191.0,
15008844,CHEMBL3325842,isopropyl 4-(5-fluoro-6-(2-methyl-6-(methylsulfonyl)pyridin-3-ylamino)pyrimidin-4-yloxy)piperidine-1-carboxylate,CHEMBL3374952,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5500.0,nM,Cc1nc(S(C)(=O)=O)ccc1Nc1ncnc(OC2CCN(C(=O)OC(C)C)CC2)c1F,CHEMBL3352461,"Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.",Bioorg. Med. Chem. Lett.,2014.0,24,17,4332,4335,10.1016/j.bmcl.2014.06.071,25088191.0,
15008845,CHEMBL3325843,isopropyl 4-(5-fluoro-6-(2-methyl-6-(methylsulfonyl)pyridin-3-yloxy)pyrimidin-4-yloxy)piperidine-1-carboxylate,CHEMBL3374952,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1nc(S(C)(=O)=O)ccc1Oc1ncnc(OC2CCN(C(=O)OC(C)C)CC2)c1F,CHEMBL3352461,"Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.",Bioorg. Med. Chem. Lett.,2014.0,24,17,4332,4335,10.1016/j.bmcl.2014.06.071,25088191.0,
15008846,CHEMBL3326667,1-methylcyclopropyl 4-(5-fluoro-6-(2-methyl-6-(methylsulfonyl)pyridin-3-yloxy)pyrimidin-4-yloxy)piperidine-1-carboxylate,CHEMBL3374952,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,25700.0,nM,Cc1nc(S(C)(=O)=O)ccc1Oc1ncnc(OC2CCN(C(=O)OC3(C)CC3)CC2)c1F,CHEMBL3352461,"Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.",Bioorg. Med. Chem. Lett.,2014.0,24,17,4332,4335,10.1016/j.bmcl.2014.06.071,25088191.0,
15010511,CHEMBL3311228,"(R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol",CHEMBL3373778,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,99000.0,nM,O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1,CHEMBL3351828,Design and optimization of highly-selective fungal CYP51 inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3455,3458,10.1016/j.bmcl.2014.05.068,24948565.0,
15022511,CHEMBL3329684,"N-(2-(Pyrrolidin-1-yl)ethyl)-5-((6-(3-(2-fluoro-4-methoxybenzoyl)ureido)-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide",CHEMBL3374449,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using Vivid OOMR substrate,IC50,>,10000.0,nM,COc1ccc(C(=O)NC(=O)Nc2ccc3c(c2)NC(=O)/C3=C\c2[nH]c(C)c(C(=O)NCCN3CCCC3)c2C)c(F)c1,CHEMBL3351479,Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.,Eur. J. Med. Chem.,2014.0,85,,268,288,10.1016/j.ejmech.2014.07.108,25089810.0,
15024481,CHEMBL3315061,"(S)-N-carbamoyl-2-(9-fluoro-2-(4-(morpholine-4-carbonyl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamide",CHEMBL3370909,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,14000.0,nM,CC(C)(C(=O)NC(N)=O)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21,CHEMBL3351663,Discovery of acylurea isosteres of 2-acylaminothiadiazole in the azaxanthene series of glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3268,3273,10.1016/j.bmcl.2014.06.010,24980053.0,
15024482,CHEMBL3315062,"(S)-2-(9-fluoro-2-(4-(morpholine-4-carbonyl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CHEMBL3370909,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,7000.0,nM,CC(C)(C(=O)Nc1nncs1)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21,CHEMBL3351663,Discovery of acylurea isosteres of 2-acylaminothiadiazole in the azaxanthene series of glucocorticoid receptor agonists.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3268,3273,10.1016/j.bmcl.2014.06.010,24980053.0,
15025388,CHEMBL3322590,"(Z)-N-(3-((1H-Pyrrol-2-yl)methylene)-2-oxoindolin-6-yl)-5-(2-fluorophenyl)-4-oxo-1,4-dihydropyridine-3-carboxamide",CHEMBL3362128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using Vivid OOMR substrate,IC50,=,40.0,nM,O=C1Nc2cc(NC(=O)c3c[nH]cc(-c4ccccc4F)c3=O)ccc2/C1=C/c1ccc[nH]1,CHEMBL3351387,Bioisosteric replacement of an acylureido moiety attached to an indolin-2-one scaffold with a malonamido or a 2/4-pyridinoylamido moiety produces a selectively potent Aurora-B inhibitor.,Eur. J. Med. Chem.,2014.0,84,,312,334,10.1016/j.ejmech.2014.07.033,25036791.0,
15026092,CHEMBL3321835,"tert-butyl 4-((7-(2-fluoro-4-(methylsulfonyl)phenyl)thieno[3,2-d]pyrimidin-4-yl)(methyl)amino)piperidine-1-carboxylate",CHEMBL3371035,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,76850.0,nM,CN(c1ncnc2c(-c3ccc(S(C)(=O)=O)cc3F)csc12)C1CCN(C(=O)OC(C)(C)C)CC1,CHEMBL3352639,Synthesis and biological evaluation of thienopyrimidine derivatives as GPR119 agonists.,Bioorg. Med. Chem. Lett.,2014.0,24,17,4281,4285,10.1016/j.bmcl.2014.07.020,25082125.0,
15026109,CHEMBL3321845,"(4-(2,5-dichlorophenoxy)pyrimidin-5-yl)(4-methyl-3,4-dihydroquinoxalin-1(2H)-yl)methanone",CHEMBL3367088,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome,IC50,=,1300.0,nM,CN1CCN(C(=O)c2cncnc2Oc2cc(Cl)ccc2Cl)c2ccccc21,CHEMBL3352618,Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists.,Bioorg. Med. Chem. Lett.,2014.0,24,17,4271,4275,10.1016/j.bmcl.2014.07.026,25082126.0,
15026110,CHEMBL3321846,"(4-(2,5-dichlorophenoxy)-2-hydroxypyrimidin-5-yl)(4-methyl-3,4-dihydroquinoxalin-1(2H)-yl)methanone",CHEMBL3367088,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome,IC50,=,1290.0,nM,CN1CCN(C(=O)c2cnc(O)nc2Oc2cc(Cl)ccc2Cl)c2ccccc21,CHEMBL3352618,Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists.,Bioorg. Med. Chem. Lett.,2014.0,24,17,4271,4275,10.1016/j.bmcl.2014.07.026,25082126.0,
15026111,CHEMBL3321850,"N-(2,5-dichlorophenyl)-1-(4-methyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)cyclopropanecarboxamide",CHEMBL3367088,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome,IC50,=,1540.0,nM,CN1CCN(C(=O)C2(C(=O)Nc3cc(Cl)ccc3Cl)CC2)c2ccccc21,CHEMBL3352618,Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists.,Bioorg. Med. Chem. Lett.,2014.0,24,17,4271,4275,10.1016/j.bmcl.2014.07.026,25082126.0,
15026112,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3367088,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome,IC50,=,180.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3352618,Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists.,Bioorg. Med. Chem. Lett.,2014.0,24,17,4271,4275,10.1016/j.bmcl.2014.07.026,25082126.0,
15033460,CHEMBL3318957,"(3S,4R,5R)-N3-cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-4-hydroxy-N3-(5-isopropylpyridin-2-yl)piperidine-3,5-dicarboxamide",CHEMBL3365835,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,CCOC[C@@H](CC(C)C)NC(=O)[C@@H]1CNC[C@H](C(=O)N(c2ccc(C(C)C)cn2)C2CC2)[C@@H]1O,CHEMBL3352242,Structure-based design of substituted piperidines as a new class of highly efficacious oral direct Renin inhibitors.,ACS Med. Chem. Lett.,2014.0,5,7,787,792,10.1021/ml500137b,25050166.0,
15038045,CHEMBL3318978,"3-(1-(4-chlorophenyl)cyclopropyl)-8-cyclopropyl-[1,2,4]triazolo[4,3-a]pyridine",CHEMBL3364423,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,Clc1ccc(C2(c3nnc4c(C5CC5)cccn34)CC2)cc1,CHEMBL3351978,"Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1).",ACS Med. Chem. Lett.,2014.0,5,7,803,808,10.1021/ml500144h,25050169.0,
15042640,CHEMBL3318997,"2-(1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-yl)-6-methyl-1H-benzo[d]imidazole-5-carbonitrile",CHEMBL3366660,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,COc1cnc2ccc(=O)n(CCN3CCC(c4nc5cc(C#N)c(C)cc5[nH]4)CC3)c2c1,CHEMBL3352071,Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing.,ACS Med. Chem. Lett.,2014.0,5,7,820,825,10.1021/ml5001728,25050172.0,
15042641,CHEMBL3318998,"2-(4-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperazin-1-yl)-6-methyl-1H-benzo[d]imidazole-5-carbonitrile",CHEMBL3366660,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,COc1cnc2ccc(=O)n(CCN3CCN(c4nc5cc(C#N)c(C)cc5[nH]4)CC3)c2c1,CHEMBL3352071,Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing.,ACS Med. Chem. Lett.,2014.0,5,7,820,825,10.1021/ml5001728,25050172.0,
15050241,CHEMBL3314850,4-chloro-N-(6-(pyrimidin-5-yloxy)pyrazin-2-yl)picolinamide,CHEMBL3363409,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in pooled human liver microsomes in presence of NADPH,IC50,>,30000.0,nM,O=C(Nc1cncc(Oc2cncnc2)n1)c1cc(Cl)ccn1,CHEMBL3352741,Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3307,3314,10.1016/j.bmcl.2014.06.003,24969015.0,
15051465,CHEMBL3318415,2-(2-chlorophenylthio)-3-hydroxy-5-phenylcyclohex-2-enone,CHEMBL3370222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,5000.0,nM,O=C1CC(c2ccccc2)CC(O)=C1Sc1ccccc1Cl,CHEMBL3352775,Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,2014.0,24,16,3764,3771,10.1016/j.bmcl.2014.06.076,25037916.0,
15051466,CHEMBL3318423,2-(2-hydroxy-6-oxo-4-phenylcyclohex-1-enylthio)benzonitrile,CHEMBL3370222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,5000.0,nM,N#Cc1ccccc1SC1=C(O)CC(c2ccccc2)CC1=O,CHEMBL3352775,Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,2014.0,24,16,3764,3771,10.1016/j.bmcl.2014.06.076,25037916.0,
15051467,CHEMBL3318469,"2-(2-chlorophenylthio)-5-(2,6-dichlorophenyl)-3-hydroxycyclohex-2-enone",CHEMBL3370222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,5000.0,nM,O=C1CC(c2c(Cl)cccc2Cl)CC(O)=C1Sc1ccccc1Cl,CHEMBL3352775,Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,2014.0,24,16,3764,3771,10.1016/j.bmcl.2014.06.076,25037916.0,
15051468,CHEMBL3318472,5-(2-chloro-6-(trifluoromethyl)phenyl)-2-(2-chlorophenylthio)-3-hydroxycyclohex-2-enone,CHEMBL3370222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,5000.0,nM,O=C1CC(c2c(Cl)cccc2C(F)(F)F)CC(O)=C1Sc1ccccc1Cl,CHEMBL3352775,Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,2014.0,24,16,3764,3771,10.1016/j.bmcl.2014.06.076,25037916.0,
15051469,CHEMBL3318477,"5-(2,6-bis(trifluoromethyl)phenyl)-2-(2-chlorophenylthio)-3-hydroxycyclohex-2-enone",CHEMBL3370222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,5000.0,nM,O=C1CC(c2c(C(F)(F)F)cccc2C(F)(F)F)CC(O)=C1Sc1ccccc1Cl,CHEMBL3352775,Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,2014.0,24,16,3764,3771,10.1016/j.bmcl.2014.06.076,25037916.0,
15051470,CHEMBL3318481,"2-(4-(2,6-dichlorophenyl)-2-hydroxy-6-oxocyclohex-1-enylthio)benzonitrile",CHEMBL3370222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,5000.0,nM,N#Cc1ccccc1SC1=C(O)CC(c2c(Cl)cccc2Cl)CC1=O,CHEMBL3352775,Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,2014.0,24,16,3764,3771,10.1016/j.bmcl.2014.06.076,25037916.0,
15051471,CHEMBL3318482,2-(4-(2-bromo-6-chlorophenyl)-2-hydroxy-6-oxocyclohex-1-enylthio)benzonitrile,CHEMBL3370222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,5000.0,nM,N#Cc1ccccc1SC1=C(O)CC(c2c(Cl)cccc2Br)CC1=O,CHEMBL3352775,Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.,Bioorg. Med. Chem. Lett.,2014.0,24,16,3764,3771,10.1016/j.bmcl.2014.06.076,25037916.0,
15061487,CHEMBL3353342,"(1R*,2S*)-2-(3-((E)-2-(Pyridin-3-yl)vinyl)-1H-indazol-6-yl)spiro-[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3364614,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC substrate after 45 mins by fluorescence assay,IC50,=,320.0,nM,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3cccnc3)n[nH]c2c1,CHEMBL3351767,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,2015.0,58,1,130,146,10.1021/jm5005336,24867403.0,
15061488,CHEMBL3353346,"(1R*,2S*)-5'-Methoxy-2-(3-((E)-2-(6-(piperidin-1-ylmethyl)-pyridin-3-yl)vinyl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3364614,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC substrate after 45 mins by fluorescence assay,IC50,=,1400.0,nM,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCCCC5)nc4)n[nH]c3c1)C(=O)N2,CHEMBL3351767,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,2015.0,58,1,130,146,10.1021/jm5005336,24867403.0,
15061489,CHEMBL3353348,"(1R*,2S*)-(E)-2-(3-(4-((Dimethylamino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3364614,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC substrate after 45 mins by fluorescence assay,IC50,=,850.0,nM,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN(C)C)cc4)n[nH]c3c1)C(=O)N2,CHEMBL3351767,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,2015.0,58,1,130,146,10.1021/jm5005336,24867403.0,
15061490,CHEMBL3353354,"(1R*,2S*)-(E)-2-(3-(4-(Morpholinomethyl)styryl)-1H-indazol-6-yl)-spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3364614,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC substrate after 45 mins by fluorescence assay,IC50,=,1400.0,nM,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1,CHEMBL3351767,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,2015.0,58,1,130,146,10.1021/jm5005336,24867403.0,
15061491,CHEMBL3353355,"(1R*,2S*)-(E)-5'-Methoxy-2-(3-(4-(morpholinomethyl)styryl)-1H-indazol-6-yl)spiro [cyclopropane-1,3'-indolin]-2'-one",CHEMBL3364614,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC substrate after 45 mins by fluorescence assay,IC50,=,1400.0,nM,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2,CHEMBL3351767,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,2015.0,58,1,130,146,10.1021/jm5005336,24867403.0,
15061492,CHEMBL3353356,"(1R,2S)-5'-Fluoro-2-(3-((E)-4-(morpholinomethyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3364614,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC substrate after 45 mins by fluorescence assay,IC50,=,500.0,nM,O=C1Nc2ccc(F)cc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1,CHEMBL3351767,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,2015.0,58,1,130,146,10.1021/jm5005336,24867403.0,
15061493,CHEMBL3353359,"(1R*,2S*)-(E)-2-(3-(4-((4-Methylpiperazin-1-yl)methyl)styryl)-1Hindazol-6-yl)spiro [cyclopropane-1,3'-indolin]-2'-one",CHEMBL3364614,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC substrate after 45 mins by fluorescence assay,IC50,>,1000.0,nM,CN1CCN(Cc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)CC1,CHEMBL3351767,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,2015.0,58,1,130,146,10.1021/jm5005336,24867403.0,
15061511,CHEMBL3353347,"(1R*,2S*)-(E)-2-(3-(4-((Dimethylamino)methyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3364614,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC substrate after 45 mins by fluorescence assay,IC50,>,1000.0,nM,CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)Nc4ccccc45)ccc23)cc1,CHEMBL3351767,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,2015.0,58,1,130,146,10.1021/jm5005336,24867403.0,
15061512,CHEMBL3353341,"(1R*,2S*)-5'-Methoxy-2-(3-((E)-2-(6-(4-methylpiperazin-1-yl)-pyridin-3-yl)vinyl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3364614,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC substrate after 45 mins by fluorescence assay,IC50,=,1600.0,nM,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2,CHEMBL3351767,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,2015.0,58,1,130,146,10.1021/jm5005336,24867403.0,
15061513,CHEMBL3353340,"(1R*,2S*)-(E)-2-(3-(2-(Pyridin-4-yl)vinyl)-1H-indazol-6-yl)spiro-[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3364614,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC substrate after 45 mins by fluorescence assay,IC50,=,30.0,nM,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccncc3)n[nH]c2c1,CHEMBL3351767,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,2015.0,58,1,130,146,10.1021/jm5005336,24867403.0,
15061515,CHEMBL3353338,"(1R*,2S*)-2-(1H-Indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3364614,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC substrate after 45 mins by fluorescence assay,IC50,>,10000.0,nM,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2cn[nH]c2c1,CHEMBL3351767,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,2015.0,58,1,130,146,10.1021/jm5005336,24867403.0,
15061516,CHEMBL3353337,indazol-6-ylmethyleneindolin-2-one,CHEMBL3364614,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC substrate after 45 mins by fluorescence assay,IC50,=,500.0,nM,O=C1Nc2ccccc2/C1=C/c1ccc2cn[nH]c2c1,CHEMBL3351767,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,2015.0,58,1,130,146,10.1021/jm5005336,24867403.0,
15061517,CHEMBL2407900,5-Methoxy-(E)-3-((3-((E)-2-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)vinyl)-1H-indazol-6-yl)methylene)indolin-2-one,CHEMBL3364614,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC substrate after 45 mins by fluorescence assay,IC50,=,1600.0,nM,COc1ccc2c(c1)/C(=C\c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2,CHEMBL3351767,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,2015.0,58,1,130,146,10.1021/jm5005336,24867403.0,
15061518,CHEMBL2407897,3-((3-((E)-4-((Dimethylamino)methyl)styryl)-1H-indazol-6-yl)-methylene)indolin-2-one,CHEMBL3364614,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC substrate after 45 mins by fluorescence assay,IC50,=,1400.0,nM,CN(C)Cc1ccc(/C=C/c2n[nH]c3cc(/C=C4/C(=O)Nc5ccccc54)ccc23)cc1,CHEMBL3351767,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,2015.0,58,1,130,146,10.1021/jm5005336,24867403.0,
15061519,CHEMBL2407749,(E)-3-((3-((E)-2-(Pyridin-4-yl)vinyl)-1H-indazol-6-yl)-methylene)-indolin-2-one,CHEMBL3364614,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC substrate after 45 mins by fluorescence assay,IC50,=,20.0,nM,O=C1Nc2ccccc2/C1=C\c1ccc2c(/C=C/c3ccncc3)n[nH]c2c1,CHEMBL3351767,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",J. Med. Chem.,2015.0,58,1,130,146,10.1021/jm5005336,24867403.0,
15062087,CHEMBL3298273,"2-((3-Fluorobenzyl)oxy)-7,8-dihydro-1,6-naphthyridin-5(6H)-one",CHEMBL3379149,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,O=C1NCCc2nc(OCc3cccc(F)c3)ccc21,CHEMBL3297742,Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu₅).,J. Med. Chem.,2014.0,57,13,5620,5637,10.1021/jm500259z,24914612.0,
15065202,CHEMBL3359854,"4-(9-(5-(5-chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-5-yl)butanoic acid",CHEMBL3381252,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC(C)Oc1ncc(-c2nc(-c3cccc4c3OCCNC4CCCC(=O)O)no2)cc1Cl,CHEMBL3352346,"Optimization of sphingosine-1-phosphate-1 receptor agonists: effects of acidic, basic, and zwitterionic chemotypes on pharmacokinetic and pharmacodynamic profiles.",J. Med. Chem.,2014.0,57,24,10424,10442,10.1021/jm5010336,25431977.0,
15065203,CHEMBL3359854,"4-(9-(5-(5-chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-5-yl)butanoic acid",CHEMBL3381252,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC(C)Oc1ncc(-c2nc(-c3cccc4c3OCCNC4CCCC(=O)O)no2)cc1Cl,CHEMBL3352346,"Optimization of sphingosine-1-phosphate-1 receptor agonists: effects of acidic, basic, and zwitterionic chemotypes on pharmacokinetic and pharmacodynamic profiles.",J. Med. Chem.,2014.0,57,24,10424,10442,10.1021/jm5010336,25431977.0,
15065204,CHEMBL3359847,"4-(7-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)butanoic acid",CHEMBL3381252,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC(C)Oc1ccc(-c2nc(-c3ccc4c(c3)CCN(CCCC(=O)O)CC4)no2)cc1C#N,CHEMBL3352346,"Optimization of sphingosine-1-phosphate-1 receptor agonists: effects of acidic, basic, and zwitterionic chemotypes on pharmacokinetic and pharmacodynamic profiles.",J. Med. Chem.,2014.0,57,24,10424,10442,10.1021/jm5010336,25431977.0,
15065205,CHEMBL3359844,"4-(9-(5-(3-chloro-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)butanoic acid",CHEMBL3381252,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,27000.0,nM,CC(C)Oc1ccc(-c2nc(-c3cccc4c3OCCN(CCCC(=O)O)C4)no2)cc1Cl,CHEMBL3352346,"Optimization of sphingosine-1-phosphate-1 receptor agonists: effects of acidic, basic, and zwitterionic chemotypes on pharmacokinetic and pharmacodynamic profiles.",J. Med. Chem.,2014.0,57,24,10424,10442,10.1021/jm5010336,25431977.0,
15065206,CHEMBL3360360,"sodium 3-(4-(5-(3-chloro-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-1H-indazol-1-yl)propanoate",CHEMBL3381252,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,7000.0,nM,CC(C)Oc1ccc(-c2nc(-c3cccc4c3cnn4CCC(=O)[O-])no2)cc1Cl.[Na+],CHEMBL3352346,"Optimization of sphingosine-1-phosphate-1 receptor agonists: effects of acidic, basic, and zwitterionic chemotypes on pharmacokinetic and pharmacodynamic profiles.",J. Med. Chem.,2014.0,57,24,10424,10442,10.1021/jm5010336,25431977.0,
15065251,CHEMBL2010601,IVACAFTOR,CHEMBL3385205,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O,CHEMBL3352164,"Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator.",J. Med. Chem.,2014.0,57,23,9776,9795,10.1021/jm5012808,25441013.0,
15069099,CHEMBL1515648,SID24394346,CHEMBL3388336,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate,IC50,>,20000.0,nM,COC(=O)c1ccc(CSc2nc3c(c(=O)[nH]2)CCC3)cc1,CHEMBL3352788,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,2014.0,57,22,9598,9611,10.1021/jm501284e,25330343.0,
15069134,CHEMBL514794,"pyrimidine-4,6-dicarboxylic acid bis(4-fluoro-3-methylbenzylamide)",CHEMBL3388336,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate,IC50,>,20000.0,nM,Cc1cc(CNC(=O)c2cc(C(=O)NCc3ccc(F)c(C)c3)ncn2)ccc1F,CHEMBL3352788,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,2014.0,57,22,9598,9611,10.1021/jm501284e,25330343.0,
15069167,CHEMBL496942,"4-((1-methyl-2,4-dioxo-6-(3-phenylprop-1-ynyl)-1,2-dihydroquinazolin-3(4H)-yl)methyl)benzoic acid",CHEMBL3388336,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate,IC50,>,2500.0,nM,Cn1c(=O)n(Cc2ccc(C(=O)O)cc2)c(=O)c2cc(C#CCc3ccccc3)ccc21,CHEMBL3352788,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,2014.0,57,22,9598,9611,10.1021/jm501284e,25330343.0,
15071399,CHEMBL3325526,"4-(((3R,4S)-4-(4-chlorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390678,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate,IC50,=,630.0,nM,O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@H]2CNCC[C@@H]2c2ccc(Cl)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071400,CHEMBL3325537,"4-(((3R,4S)-4-(4-chlorophenyl)-1-methylpiperidin-3-yl)methoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390678,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate,IC50,=,880.0,nM,CN1CC[C@H](c2ccc(Cl)cc2)[C@@H](COc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)C1,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071401,CHEMBL3325551,"4-(((3R,4S)-4-(4-chlorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(5-fluoropyrimidin-2-yl)benzenesulfonamide",CHEMBL3390678,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate,IC50,>,10000.0,nM,O=S(=O)(Nc1ncc(F)cn1)c1cc(F)c(OC[C@H]2CNCC[C@@H]2c2ccc(Cl)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15073578,CHEMBL3358006,"5-({2-Fluoro-4-[(methylsulfonyl)methyl]benzyl}oxy)-2-{(2R)-2-methyl-4-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]piperazin-1-yl}-pyrimidine",CHEMBL3383973,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by high throughput fluorescence assay,IC50,>,10000.0,nM,C[C@@H]1CN(c2nc(C(F)(F)F)no2)CCN1c1ncc(OCc2ccc(CS(C)(=O)=O)cc2F)cn1,CHEMBL3351317,Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.,J. Med. Chem.,2014.0,57,21,8984,8998,10.1021/jm5011012,25286150.0,
15075584,CHEMBL2023898,daclatasvir,CHEMBL3368246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9,IC50,=,59500.0,nM,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C,CHEMBL3351364,Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025).,J. Med. Chem.,2014.0,57,18,7716,7730,10.1021/jm500951r,25148100.0,
15075585,CHEMBL3341815,"Methyl [(S)-1-((S)-2-{5-[4-(4-{2-[(S)-1-((S)-2-(Methoxycarbonylamino)-3-methyl-butyryl)-pyrrolidin-2-yl]-3H-imidazol-4-yl}-buta-1,3-diynyl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methylpropyl]-carbamate Dihydrochloride",CHEMBL3368246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9,IC50,>,10000.0,nM,COC(=O)N[C@H](C(=O)N1CCC[C@@H]1c1ncc(C#CC#Cc2ccc(-c3cnc([C@H]4CCCN4C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]3)cc2)[nH]1)C(C)C.Cl,CHEMBL3351364,Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025).,J. Med. Chem.,2014.0,57,18,7716,7730,10.1021/jm500951r,25148100.0,
15079183,CHEMBL2181776,(E)-3-[4-({1-[(3-Cyclopentyl-1-methyl-2-pyridin-2-yl-1H-indole-6-carbonyl)amino]cyclobutanecarbonyl}amino)phenyl]-acrylic Acid,CHEMBL3383841,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3500.0,nM,Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21,CHEMBL3351932,"Discovery of BI 207524, an indole diamide NS5B thumb pocket 1 inhibitor with improved potency for the potential treatment of chronic hepatitis C virus infection.",J. Med. Chem.,2014.0,57,23,10130,10143,10.1021/jm501532z,25393851.0,
15079184,CHEMBL3355225,(E)-3-(4-(1-(2-(5-chloropyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutanecarboxamido)-2-ethoxyphenyl)acrylic acid,CHEMBL3383841,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,13500.0,nM,CCOc1cc(NC(=O)C2(NC(=O)c3ccc4c(C5CCCC5)c(-c5ncc(Cl)cn5)n(C)c4c3)CCC2)ccc1/C=C/C(=O)O,CHEMBL3351932,"Discovery of BI 207524, an indole diamide NS5B thumb pocket 1 inhibitor with improved potency for the potential treatment of chronic hepatitis C virus infection.",J. Med. Chem.,2014.0,57,23,10130,10143,10.1021/jm501532z,25393851.0,
15080899,CHEMBL3330442,"5-Chloro-N-(((3S,3aS)-1-oxo-7-(3-oxomorpholino)-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl)methyl)-thiophene-2-carboxamide",CHEMBL3384137,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,43230.0,nM,O=C(NC[C@@H]1OC(=O)N2c3ccc(N4CCOCC4=O)cc3OC[C@@H]12)c1ccc(Cl)s1,CHEMBL3351225,"Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.",J. Med. Chem.,2014.0,57,18,7770,7791,10.1021/jm501045e,25179681.0,
15082083,CHEMBL3338865,"N-((5,6-dimethoxypyridin-2-yl)methyl)-5'-methyl-5-(thiazol-2-yl)-2,3'-bipyridine-4-carboxamide",CHEMBL3387595,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,COc1ccc(CNC(=O)c2cc(-c3cncc(C)c3)ncc2-c2nccs2)nc1OC,CHEMBL3352684,Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,2014.0,24,20,4884,4890,10.1016/j.bmcl.2014.08.041,25248679.0,
15086971,CHEMBL3353992,"rac-cis-1-((2S*,4R*)-2-Methyl-4-(phenylamino)-6-(4-(piperidin-1-ylmethyl)phenyl)-3,4-dihydroquinolin-1(2H)-yl)ethanone",CHEMBL3382839,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) expressed in Escherichia coli bactosomes using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 10 mins by fluorescence assay,IC50,=,14000.0,nM,CC(=O)N1c2ccc(-c3ccc(CN4CCCCC4)cc3)cc2[C@H](Nc2ccccc2)C[C@@H]1C,CHEMBL3351476,"The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.",J. Med. Chem.,2014.0,57,19,8111,8131,10.1021/jm5010539,25249180.0,
15086972,CHEMBL2177300,"4-((2S,4R)-1-acetyl-4-(4-chlorophenylamino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid",CHEMBL3382839,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) expressed in Escherichia coli bactosomes using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 10 mins by fluorescence assay,IC50,=,13000.0,nM,CC(=O)N1c2ccc(-c3ccc(C(=O)O)cc3)cc2[C@H](Nc2ccc(Cl)cc2)C[C@@H]1C,CHEMBL3351476,"The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.",J. Med. Chem.,2014.0,57,19,8111,8131,10.1021/jm5010539,25249180.0,
15105308,CHEMBL3331469,N-(naphthalen-2-ylmethyl)-N-phenylazetidin-3-amine hydrochloride,CHEMBL3385973,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 5 mins by fluorescence assay,IC50,=,3130.0,nM,Cl.c1ccc(N(Cc2ccc3ccccc3c2)C2CNC2)cc1,CHEMBL3352820,Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.,ACS Med. Chem. Lett.,2014.0,5,9,999,1004,10.1021/ml500187a,25221656.0,
15105309,CHEMBL3331484,"N-cyclopropyl-N-(3,4-dichlorobenzyl)azetidin-3-amine",CHEMBL3385973,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 5 mins by fluorescence assay,IC50,=,12900.0,nM,Clc1ccc(CN(C2CC2)C2CNC2)cc1Cl,CHEMBL3352820,Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.,ACS Med. Chem. Lett.,2014.0,5,9,999,1004,10.1021/ml500187a,25221656.0,
15105310,CHEMBL3331502,"N-(azetidin-3-ylmethyl)-N-(2,3-dichlorobenzyl)aniline 2,2,2-trifluoroacetate",CHEMBL3385973,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 5 mins by fluorescence assay,IC50,=,440.0,nM,Clc1cccc(CN(CC2CNC2)c2ccccc2)c1Cl.O=C(O)C(F)(F)F,CHEMBL3352820,Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.,ACS Med. Chem. Lett.,2014.0,5,9,999,1004,10.1021/ml500187a,25221656.0,
15105311,CHEMBL3331503,"N-(azetidin-3-ylmethyl)-N-(3,4-dichlorobenzyl)propan-2-amine hydrochloride",CHEMBL3385973,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 5 mins by fluorescence assay,IC50,=,32700.0,nM,CC(C)N(Cc1ccc(Cl)c(Cl)c1)CC1CNC1.Cl,CHEMBL3352820,Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.,ACS Med. Chem. Lett.,2014.0,5,9,999,1004,10.1021/ml500187a,25221656.0,
15105312,CHEMBL1175,Methyl-[(S)-3-(naphthalen-1-yloxy)-3-thiophen-2-yl-propyl]-amine,CHEMBL3385973,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 5 mins by fluorescence assay,IC50,=,29100.0,nM,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,CHEMBL3352820,Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.,ACS Med. Chem. Lett.,2014.0,5,9,999,1004,10.1021/ml500187a,25221656.0,
15105313,CHEMBL3331504,N-(4-chlorobenzyl)-N-cyclohexylazetidin-3-amine,CHEMBL3385973,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 5 mins by fluorescence assay,IC50,=,6890.0,nM,Clc1ccc(CN(C2CCCCC2)C2CNC2)cc1,CHEMBL3352820,Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.,ACS Med. Chem. Lett.,2014.0,5,9,999,1004,10.1021/ml500187a,25221656.0,
15105314,CHEMBL3331506,N-(4-chlorobenzyl)-N-(2-fluorophenyl)azetidin-3-amine,CHEMBL3385973,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 5 mins by fluorescence assay,IC50,=,460.0,nM,Fc1ccccc1N(Cc1ccc(Cl)cc1)C1CNC1,CHEMBL3352820,Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.,ACS Med. Chem. Lett.,2014.0,5,9,999,1004,10.1021/ml500187a,25221656.0,
15105315,CHEMBL3331507,N-(3-chlorophenyl)-N-(naphthalen-2-ylmethyl)azetidin-3-amine,CHEMBL3385973,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 5 mins by fluorescence assay,IC50,=,3340.0,nM,Clc1cccc(N(Cc2ccc3ccccc3c2)C2CNC2)c1,CHEMBL3352820,Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.,ACS Med. Chem. Lett.,2014.0,5,9,999,1004,10.1021/ml500187a,25221656.0,
15105316,CHEMBL3331508,"N-(azetidin-3-ylmethyl)-N-(2-chlorobenzyl)aniline 2,2,2-trifluoroacetate",CHEMBL3385973,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 5 mins by fluorescence assay,IC50,=,360.0,nM,Clc1ccccc1CN(CC1CNC1)c1ccccc1.O=C(O)C(F)(F)F,CHEMBL3352820,Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.,ACS Med. Chem. Lett.,2014.0,5,9,999,1004,10.1021/ml500187a,25221656.0,
15105317,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3385973,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 incubated for 5 mins by fluorescence assay,IC50,=,4200.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3352820,Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.,ACS Med. Chem. Lett.,2014.0,5,9,999,1004,10.1021/ml500187a,25221656.0,
15107819,CHEMBL3357641,(Z)-(S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide,CHEMBL3385836,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatic microsomes after 20 mins by LC/MS/MS method,IC50,>,10000.0,nM,CN(C)C/C=C(\F)C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,CHEMBL3351667,A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.,J. Med. Chem.,2014.0,57,23,9889,9900,10.1021/jm5014659,25409491.0,
15107820,CHEMBL3357637,(Z)-N-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide,CHEMBL3385836,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatic microsomes after 20 mins by LC/MS/MS method,IC50,>,10000.0,nM,CCOc1cc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN(C)C,CHEMBL3351667,A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.,J. Med. Chem.,2014.0,57,23,9889,9900,10.1021/jm5014659,25409491.0,
15107821,CHEMBL3357635,(Z)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide,CHEMBL3385836,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatic microsomes after 20 mins by LC/MS/MS method,IC50,>,10000.0,nM,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN1CCCCC1,CHEMBL3351667,A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.,J. Med. Chem.,2014.0,57,23,9889,9900,10.1021/jm5014659,25409491.0,
15107822,CHEMBL3357634,(Z)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide,CHEMBL3385836,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatic microsomes after 20 mins by LC/MS/MS method,IC50,>,10000.0,nM,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN(C)C,CHEMBL3351667,A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.,J. Med. Chem.,2014.0,57,23,9889,9900,10.1021/jm5014659,25409491.0,
15114357,CHEMBL1230001,2-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carboxamido)benzoic acid,CHEMBL3380639,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,100000.0,nM,O=C(O)c1ccccc1NC(=O)N1CCC(c2ccccc2C(F)(F)F)CC1,CHEMBL3351344,"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,2014.0,57,18,7731,7757,10.1021/jm5010013,25210858.0,
15114358,CHEMBL3359014,"trans-2-((3aR,6aS)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[c]pyrrole-2-carboxamido)benzoic acid",CHEMBL3380639,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,340.0,nM,O=C(O)c1ccccc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1,CHEMBL3351344,"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,2014.0,57,18,7731,7757,10.1021/jm5010013,25210858.0,
15114359,CHEMBL3359017,"trans-5-fluoro-2-((3aR,6aS)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[c]pyrrole-2-carboxamido)benzoic acid",CHEMBL3380639,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,330.0,nM,O=C(O)c1cc(F)ccc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1,CHEMBL3351344,"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,2014.0,57,18,7731,7757,10.1021/jm5010013,25210858.0,
15114360,CHEMBL3359018,"trans-5-methoxy-2-((3aR,6aS)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[c]pyrrole-2-carboxamido)benzoic acid",CHEMBL3380639,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,13000.0,nM,COc1ccc(NC(=O)N2C[C@H]3C[C@@H](c4ccccc4C(F)(F)F)C[C@H]3C2)c(C(=O)O)c1,CHEMBL3351344,"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,2014.0,57,18,7731,7757,10.1021/jm5010013,25210858.0,
15114361,CHEMBL3359019,"trans-5-chloro-2-((3aR,6aS)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[c]pyrrole-2-carboxamido)benzoic acid",CHEMBL3380639,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,580.0,nM,O=C(O)c1cc(Cl)ccc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1,CHEMBL3351344,"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,2014.0,57,18,7731,7757,10.1021/jm5010013,25210858.0,
15114362,CHEMBL3359020,"trans-5-(methylsulfonyl)-2-((3aR,6aS)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[c]pyrrole-2-carboxamido)benzoic acid",CHEMBL3380639,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8700.0,nM,CS(=O)(=O)c1ccc(NC(=O)N2C[C@H]3C[C@@H](c4ccccc4C(F)(F)F)C[C@H]3C2)c(C(=O)O)c1,CHEMBL3351344,"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,2014.0,57,18,7731,7757,10.1021/jm5010013,25210858.0,
15114363,CHEMBL3359021,"trans-2-((3aR,6aS)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[c]pyrrole-2-carboxamido)nicotinic acid",CHEMBL3380639,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,27000.0,nM,O=C(O)c1cccnc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1,CHEMBL3351344,"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,2014.0,57,18,7731,7757,10.1021/jm5010013,25210858.0,
15114364,CHEMBL3359022,"trans-4-((3aR,6aS)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[c]pyrrole-2-carboxamido)nicotinic acid",CHEMBL3380639,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5600.0,nM,O=C(O)c1cnccc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1,CHEMBL3351344,"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,2014.0,57,18,7731,7757,10.1021/jm5010013,25210858.0,
15114365,CHEMBL3359023,"trans-6-methyl-4-((3aR,6aS)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[c]pyrrole-2-carboxamido)nicotinic acid",CHEMBL3380639,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1000.0,nM,Cc1cc(NC(=O)N2C[C@H]3C[C@@H](c4ccccc4C(F)(F)F)C[C@H]3C2)c(C(=O)O)cn1,CHEMBL3351344,"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,2014.0,57,18,7731,7757,10.1021/jm5010013,25210858.0,
15114366,CHEMBL3359024,"trans-5-((3aR,6aS)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[c]pyrrole-2-carboxamido)pyridazine-4-carboxylic acid",CHEMBL3380639,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,17000.0,nM,O=C(O)c1cnncc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1,CHEMBL3351344,"Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.",J. Med. Chem.,2014.0,57,18,7731,7757,10.1021/jm5010013,25210858.0,
15114692,CHEMBL3331521,"1-(5-butoxypyridin-3-yl)-4-methyl-8-(morpholin-4-ylmethyl)[1,2,4]triazolo[4,3-a]quinoxaline",CHEMBL3381172,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,CCCCOc1cncc(-c2nnc3c(C)nc4ccc(CN5CCOCC5)cc4n23)c1,CHEMBL3351311,"Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement.",ACS Med. Chem. Lett.,2014.0,5,9,1049,1053,10.1021/ml500262u,25221665.0,
15116716,CHEMBL3301607,SID174006711,CHEMBL3382751,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,70000.0,nM,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,CHEMBL3351789,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,J. Med. Chem.,2014.0,57,22,9323,9342,10.1021/jm501262q,25369270.0,
15118762,CHEMBL3330652,"8-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-7-carboxamide",CHEMBL3377164,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,7300.0,nM,O=C(NOCCO)c1ccn2cncc2c1Nc1ccc(I)cc1F,CHEMBL3351244,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,2014.0,24,19,4714,4723,10.1016/j.bmcl.2014.08.008,25193232.0,
15118763,CHEMBL3330651,"8-fluoro-5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide",CHEMBL3377164,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1200.0,nM,O=C(NOCCO)c1cc(F)c2cncn2c1Nc1ccc(I)cc1F,CHEMBL3351244,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,2014.0,24,19,4714,4723,10.1016/j.bmcl.2014.08.008,25193232.0,
15118764,CHEMBL3330650,"5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide",CHEMBL3377164,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,O=C(NOCCO)c1ccc2cncn2c1Nc1ccc(I)cc1F,CHEMBL3351244,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,2014.0,24,19,4714,4723,10.1016/j.bmcl.2014.08.008,25193232.0,
15118765,CHEMBL2087461,7-(2-Fluoro-4-iodo-phenylamino)-benzo[d]isothiazole-6-carboxylic acid(2-Hydroxy-ethoxy)-amide,CHEMBL3377164,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1300.0,nM,O=C(NOCCO)c1ccc2cnsc2c1Nc1ccc(I)cc1F,CHEMBL3351244,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,2014.0,24,19,4714,4723,10.1016/j.bmcl.2014.08.008,25193232.0,
15118766,CHEMBL3330649,"3-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)furo[3,2-c]pyridine-2-carboxamide",CHEMBL3377164,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,O=C(NOCCO)c1oc2ccncc2c1Nc1ccc(I)cc1F,CHEMBL3351244,"Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.",Bioorg. Med. Chem. Lett.,2014.0,24,19,4714,4723,10.1016/j.bmcl.2014.08.008,25193232.0,
15119290,CHEMBL3335537,(R)-4-((1H-benzo[d]imidazol-2-yl)methyl)-2-phenethylmorpholine,CHEMBL3383665,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by electrospray ionization,IC50,>,30000.0,nM,c1ccc(CC[C@@H]2CN(Cc3nc4ccccc4[nH]3)CCO2)cc1,CHEMBL3352711,"Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor with in Vivo Activity.",ACS Med. Chem. Lett.,2014.0,5,9,1060,1064,10.1021/ml500267c,25221667.0,
15119291,CHEMBL3335556,(R)-4-(4-chlorobenzyl)-2-phenethylmorpholine,CHEMBL3383665,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by electrospray ionization,IC50,=,4800.0,nM,Clc1ccc(CN2CCO[C@H](CCc3ccccc3)C2)cc1,CHEMBL3352711,"Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor with in Vivo Activity.",ACS Med. Chem. Lett.,2014.0,5,9,1060,1064,10.1021/ml500267c,25221667.0,
15122709,CHEMBL3326224,"trans-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine hydrochloride",CHEMBL3362486,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>=,5000.0,nM,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3ccccc3[nH]c12.Cl,CHEMBL3351750,"Discovery of Spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amines as Potent NOP and Opioid Receptor Agonists.",ACS Med. Chem. Lett.,2014.0,5,8,851,856,10.1021/ml500116x,25147602.0,
15140116,CHEMBL473326,"2-(4-chlorobenzylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol",CHEMBL3388336,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate,IC50,=,19000.0,nM,Oc1nc(SCc2ccc(Cl)cc2)nc2c1CCC2,CHEMBL3352788,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,2014.0,57,22,9598,9611,10.1021/jm501284e,25330343.0,
15140125,CHEMBL1371684,SID7972299,CHEMBL3388336,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate,IC50,=,8800.0,nM,Cc1ccc(CSc2nc(O)c3c(n2)CCC3)cc1,CHEMBL3352788,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,2014.0,57,22,9598,9611,10.1021/jm501284e,25330343.0,
15140689,CHEMBL3359270,"(S)-2-cyclopentyl-N-((1-ethylpyrrolidin-2-yl)methyl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrido[3,4-b]indole-4-carboxamide",CHEMBL3388524,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CCN1CCC[C@H]1CNC(=O)c1cn(C2CCCC2)c(=O)c2c1c1ccccc1n2C,CHEMBL3351313,"Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM).",J. Med. Chem.,2014.0,57,23,10192,10197,10.1021/jm501375c,25423411.0,
15140690,CHEMBL3359272,"(S)-2-cyclopentyl-N-((1-isopropylpyrrolidin-2-yl)methyl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrido[3,4-b]indole-4-carboxamide",CHEMBL3388524,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,CC(C)N1CCC[C@H]1CNC(=O)c1cn(C2CCCC2)c(=O)c2c1c1ccccc1n2C,CHEMBL3351313,"Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM).",J. Med. Chem.,2014.0,57,23,10192,10197,10.1021/jm501375c,25423411.0,
15141928,CHEMBL2144409,SID137275990,CHEMBL3395913,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1ccc(-c2ncn(-c3ccc(Nc4nccc(-c5cccc(N6CCOCC6)c5)n4)cc3)n2)cn1,CHEMBL3393060,Inhibitors of c-Jun N-terminal kinases: an update.,J. Med. Chem.,2015.0,58,1,72,95,10.1021/jm501212r,25415535.0,
15144978,CHEMBL3393730,"methyl N-[(2S)-1-[(2S,4S)-2-{5-[5-(4-{2-[(2S,4S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]-4-methylpyrrolidin-2-yl]-1H-imidazol-5-yl}phenyl)thiophen-2-yl]-1H-thieno[2,3-d]imidazol-2-yl}-4-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate",CHEMBL3396447,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,21000.0,nM,COC(=O)N[C@H](C(=O)N1C[C@@H](C)C[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cc5[nH]c([C@@H]6C[C@H](C)CN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5s4)s3)cc2)[nH]1)C(C)C,CHEMBL3393045,Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b.,Bioorg. Med. Chem. Lett.,2015.0,25,4,940,943,10.1016/j.bmcl.2014.12.044,25597006.0,
15144979,CHEMBL3120454,"methyl N-[(2S)-1-[(2S,4S)-2-{5-[4-(4-{2-[(2S,4S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]-4-methylpyrrolidin-2-yl]-1H-thieno[2,3-d]imidazol-5-yl}phenyl)phenyl]-1H-imidazol-2-yl}-4-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate",CHEMBL3396447,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,COC(=O)N[C@H](C(=O)N1C[C@@H](C)C[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cc5[nH]c([C@@H]6C[C@H](C)CN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5s4)cc3)cc2)[nH]1)C(C)C,CHEMBL3393045,Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b.,Bioorg. Med. Chem. Lett.,2015.0,25,4,940,943,10.1016/j.bmcl.2014.12.044,25597006.0,
15146586,CHEMBL3394719,"N-(4-(1-isobutylpiperidin-4-ylsulfonyl)benzyl)furo[2,3-c]pyridine-2-carboxamide",CHEMBL3396939,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes,IC50,=,190.0,nM,CC(C)CN1CCC(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1,CHEMBL3393056,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,2015.0,25,3,529,541,10.1016/j.bmcl.2014.12.026,25556090.0,
15146587,CHEMBL3394721,"N-(4-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-ylsulfonyl)benzyl)furo[2,3-c]pyridine-2-carboxamide",CHEMBL3396939,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes,IC50,=,300.0,nM,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2ccncc2o1,CHEMBL3393056,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,2015.0,25,3,529,541,10.1016/j.bmcl.2014.12.026,25556090.0,
15146588,CHEMBL3394722,"N-(4-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-ylsulfonyl)benzyl)-1H-pyrrolo[3,2-c]pyridine-2-carboxamide",CHEMBL3396939,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes,IC50,=,200.0,nM,O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2cnccc2[nH]1,CHEMBL3393056,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,2015.0,25,3,529,541,10.1016/j.bmcl.2014.12.026,25556090.0,
15146589,CHEMBL3394724,"rac-N-(4-(1-isobutylpiperidin-4-ylsulfinyl)benzyl)furo[2,3-c]pyridine-2-carboxamide",CHEMBL3396939,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes,IC50,=,1900.0,nM,CC(C)CN1CCC([S+]([O-])c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1,CHEMBL3393056,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,2015.0,25,3,529,541,10.1016/j.bmcl.2014.12.026,25556090.0,
15146590,CHEMBL3394729,"N-(4-(1-isopropyl-1H-pyrazol-4-ylsulfonyl)benzyl)furo[2,3-c]pyridine-2-carboxamide",CHEMBL3396939,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes,IC50,=,70.0,nM,CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1,CHEMBL3393056,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,2015.0,25,3,529,541,10.1016/j.bmcl.2014.12.026,25556090.0,
15146591,CHEMBL3394730,"N-(4-(1-propyl-1H-pyrazol-4-ylsulfonyl)benzyl)furo[2,3-c]pyridine-2-carboxamide",CHEMBL3396939,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes,IC50,=,70.0,nM,CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1,CHEMBL3393056,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,2015.0,25,3,529,541,10.1016/j.bmcl.2014.12.026,25556090.0,
15146592,CHEMBL3394734,"N-((5-(3,5-difluorophenylsulfonyl)pyridin-2-yl)methyl)furo[2,3-c]pyridine-2-carboxamide",CHEMBL3396939,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes,IC50,=,200.0,nM,O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1,CHEMBL3393056,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,2015.0,25,3,529,541,10.1016/j.bmcl.2014.12.026,25556090.0,
15146593,CHEMBL3394736,"rac-N-((5-(3,5-difluorophenylsulfinyl)pyridin-2-yl)methyl)furo[2,3-c]pyridine-2-carboxamide",CHEMBL3396939,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes,IC50,=,1000.0,nM,O=C(NCc1ccc([S+]([O-])c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1,CHEMBL3393056,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,2015.0,25,3,529,541,10.1016/j.bmcl.2014.12.026,25556090.0,
15146594,CHEMBL3394738,"N-((5-(1-isopropyl-1H-pyrazol-4-ylsulfonyl)pyridin-2-yl)methyl)furo[2,3-c]pyridine-2-carboxamide",CHEMBL3396939,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes,IC50,=,160.0,nM,CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1,CHEMBL3393056,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,2015.0,25,3,529,541,10.1016/j.bmcl.2014.12.026,25556090.0,
15146595,CHEMBL3394741,"N-((5-(1-propyl-1H-pyrazol-4-ylsulfonyl)pyridin-2-yl)methyl)furo[2,3-c]pyridine-2-carboxamide",CHEMBL3396939,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes,IC50,=,70.0,nM,CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1,CHEMBL3393056,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,2015.0,25,3,529,541,10.1016/j.bmcl.2014.12.026,25556090.0,
15147662,CHEMBL3394201,"5-Methoxy-2-(2-{2-[(1R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)benzamide",CHEMBL3396346,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,COc1ccc(CC(=O)N2CCC3(CC2)CN([C@@H]2CCc4cc(-c5cc(C)ncn5)ccc42)C3)c(C(N)=O)c1,CHEMBL3393021,Evaluation and synthesis of polar aryl- and heteroaryl spiroazetidine-piperidine acetamides as ghrelin inverse agonists.,ACS Med. Chem. Lett.,2015.0,6,2,156,161,10.1021/ml500414n,25699143.0,
15149333,CHEMBL3394842,"(2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-(8-fluoroquinolin-4-yloxy)-2-methylpiperidin-1-yl)methanone",CHEMBL3395413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,21400.0,nM,C[C@@H]1CC[C@@H](Oc2ccnc3c(F)cccc23)CN1C(=O)c1ccccc1-n1nccn1,CHEMBL3393034,Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.,Bioorg. Med. Chem. Lett.,2015.0,25,3,444,450,10.1016/j.bmcl.2014.12.056,25577040.0,
15149442,CHEMBL3394868,"((S)-1-{(2S,4S)-2-[4-(4'-{2-[(2S,4S)-1-((S)-2-Methoxycarbonylamino-3-methyl-butyryl)-4-methyl-pyrrolidin-2-yl]-1H-benzoimidazol-5-yl}-biphenyl-4-yl)-1H-imidazol-2-yl]-4-methyl-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester",CHEMBL3395550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,COC(=O)N[C@H](C(=O)N1C[C@@H](C)C[C@H]1c1nc(-c2ccc(-c3ccc(-c4ccc5[nH]c([C@@H]6C[C@H](C)CN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)cc3)cc2)c[nH]1)C(C)C,CHEMBL3393023,Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency.,Bioorg. Med. Chem. Lett.,2015.0,25,4,944,947,10.1016/j.bmcl.2014.12.045,25577041.0,
15160186,CHEMBL3398175,"(trans)-1-(2-hydroxyethyl)-4-(3-methoxy-4-(7-(2-methoxyphenyl)pyrrolo[1,2-f][1,2,4]triazin-2-ylamino)phenyl)piperidin-3-ol",CHEMBL3398766,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,19000.0,nM,COc1cc([C@H]2CCN(CCO)C[C@@H]2O)ccc1Nc1ncc2ccc(-c3ccccc3OC)n2n1,CHEMBL3396997,"Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinase.",Bioorg. Med. Chem. Lett.,2015.0,25,5,1047,1052,10.1016/j.bmcl.2015.01.019,25655723.0,
15160565,CHEMBL255930,"(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-(trifluoromethyl)pyrimidin-2-yl)pyrrolidine-3-carboxylic acid",CHEMBL3399117,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3200.0,nM,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2CN(c3nccc(C(F)(F)F)n3)C[C@@H]2C(=O)O)cc1,CHEMBL3396995,Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists.,Bioorg. Med. Chem. Lett.,2015.0,25,6,1196,1205,10.1016/j.bmcl.2015.01.066,25686852.0,
15166799,CHEMBL3402641,4-(3-methyl-5-morpholinopentanamido)-N-(thiazol-2-yl)benzamide,CHEMBL3406914,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,CC(CCN1CCOCC1)CC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1,CHEMBL3399957,"Synthesis and SAR studies of analogues of 4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-N-thiazol-2-yl-benzamide (Lu AA41063) as adenosine A2A receptor ligands with improved aqueous solubility.",Bioorg. Med. Chem. Lett.,2015.0,25,6,1212,1216,10.1016/j.bmcl.2015.01.062,25701253.0,
15167621,CHEMBL3401195,"6-(4-fluorophenyl)-2-(phenoxymethyl)-7,8-dihydroimidazo[1,2-c]pyrimidin-5(6H)-one",CHEMBL3404394,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=C1N(c2ccc(F)cc2)CCc2nc(COc3ccccc3)cn21,CHEMBL3399974,Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).,Bioorg. Med. Chem. Lett.,2015.0,25,6,1310,1317,10.1016/j.bmcl.2015.01.038,25683622.0,
15171121,CHEMBL3401541,rac-N-isopropyl-4-methoxy-3-(3-methoxypropoxy)-N-((4-(phenylmethylsulfonamido)pyrrolidin-3-yl)methyl)benzamide,CHEMBL3404903,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NS(=O)(=O)Cc2ccccc2)C(C)C)ccc1OC,CHEMBL3400139,"trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: prime site exploration using an amino linker.",Bioorg. Med. Chem. Lett.,2015.0,25,8,1782,1786,10.1016/j.bmcl.2015.02.039,25782742.0,
15178012,CHEMBL3403995,rac-(trans)-4-((N-isopropyl-4-methoxy-3-(3-methoxypropoxy)benzamido)methyl)pyrrolidin-3-yl benzylcarbamate,CHEMBL3406675,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OC(=O)NCc2ccccc2)C(C)C)ccc1OC,CHEMBL3400053,"trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: prime site exploration using an oxygen linker.",Bioorg. Med. Chem. Lett.,2015.0,25,8,1787,1791,10.1016/j.bmcl.2015.02.040,25754490.0,
15185169,CHEMBL3187348,SID160844222,CHEMBL3404119,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,COc1ccc(C(=O)NCc2csc(C)n2)cc1OC1CCN(C(C)C)CC1,CHEMBL3400059,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,2015.0,25,8,1757,1760,10.1016/j.bmcl.2015.02.058,25801932.0,
15185170,CHEMBL1872483,SID49818711,CHEMBL3404119,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OC1CCN(C(C)C)CC1,CHEMBL3400059,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,2015.0,25,8,1757,1760,10.1016/j.bmcl.2015.02.058,25801932.0,
15185171,CHEMBL3182315,SID160844216,CHEMBL3404119,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,CCn1nc(C)c(CNC(=O)c2ccc(OC)c(OC3CCN(C(C)C)CC3)c2)c1C,CHEMBL3400059,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,2015.0,25,8,1757,1760,10.1016/j.bmcl.2015.02.058,25801932.0,
15185172,CHEMBL3188567,SID160844212,CHEMBL3404119,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,COc1ccc(C(=O)NC(C)Cc2ccccn2)cc1OC1CCN(C(C)C)CC1,CHEMBL3400059,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,2015.0,25,8,1757,1760,10.1016/j.bmcl.2015.02.058,25801932.0,
15185173,CHEMBL3304438,N-((3-isopropylisoxazol-5-yl)methyl)-4-methoxy-3-(1-methylpiperidin-4-yloxy)benzamide,CHEMBL3404119,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OC1CCN(C)CC1,CHEMBL3400059,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,2015.0,25,8,1757,1760,10.1016/j.bmcl.2015.02.058,25801932.0,
15185174,CHEMBL3303792,N-((3-isopropylisoxazol-5-yl)methyl)-4-methoxy-3-(2-(piperidin-1-yl)ethoxy)benzamide,CHEMBL3404119,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OCCN1CCCCC1,CHEMBL3400059,Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,Bioorg. Med. Chem. Lett.,2015.0,25,8,1757,1760,10.1016/j.bmcl.2015.02.058,25801932.0,
15191565,CHEMBL3353341,"(1R*,2S*)-5'-Methoxy-2-(3-((E)-2-(6-(4-methylpiperazin-1-yl)-pyridin-3-yl)vinyl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,2000.0,nM,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191566,CHEMBL3408940,"(1R,2S)-1'-Methyl-2-(3-((E)-2-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)vinyl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,3800.0,nM,CN1CCN(c2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)N(C)c5ccccc56)ccc34)cn2)CC1,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191567,CHEMBL3408941,"(1R,2S)-(E)-2-(3-(4-(Piperazin-1-yl)styryl)-1H-indazol-6-yl)spiro-[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,1700.0,nM,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(N4CCNCC4)cc3)n[nH]c2c1,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191568,CHEMBL3353347,"(1R*,2S*)-(E)-2-(3-(4-((Dimethylamino)methyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,>,1000.0,nM,CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)Nc4ccccc45)ccc23)cc1,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191569,CHEMBL3353348,"(1R*,2S*)-(E)-2-(3-(4-((Dimethylamino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,3500.0,nM,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN(C)C)cc4)n[nH]c3c1)C(=O)N2,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191570,CHEMBL3408942,"(1R,2S)-(E)-2-(3-(4-((Dimethylamino)methyl)styryl)-1H-indazol-6-yl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,2600.0,nM,CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)N(C)c4ccccc45)ccc23)cc1,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191571,CHEMBL3408943,"(1R,2S)-(E)-2-(3-(4-(((R)-3-Fluoropyrrolidin-1-yl)methyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,900.0,nM,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CC[C@@H](F)C4)cc3)n[nH]c2c1,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191572,CHEMBL3408944,"(1R,2S)-(E)-5'-Methoxy-2-(3-(4-(piperidin-1-ylmethyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,3400.0,nM,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCCCC5)cc4)n[nH]c3c1)C(=O)N2,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191573,CHEMBL3353354,"(1R*,2S*)-(E)-2-(3-(4-(Morpholinomethyl)styryl)-1H-indazol-6-yl)-spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,700.0,nM,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191574,CHEMBL3353357,"(1R*,2S*)-(E)-5'-Methyl-2-(3-(4-(morpholinomethyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,1000.0,nM,Cc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191575,CHEMBL3353355,"(1R*,2S*)-(E)-5'-Methoxy-2-(3-(4-(morpholinomethyl)styryl)-1H-indazol-6-yl)spiro [cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,800.0,nM,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191576,CHEMBL3408945,"(1R,2S)-(E)-5'-Methoxy-1'-methyl-2-(3-(4-(morpholinomethyl)-styryl)-1H-indazol-6-yl)spiro-[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,1000.0,nM,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191577,CHEMBL3408946,"(1R,2S)-(E)-2-(3-(4-cis-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,800.0,nM,C[C@H]1CN(Cc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)C[C@@H](C)O1,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191578,CHEMBL3408947,"(1R,2S)-(E)-2-(3-(4-cis-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,940.0,nM,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191579,CHEMBL3408948,"(1R,2S)-2-(3-((E)-(4-cis-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxy-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,440.0,nM,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2C,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191580,CHEMBL3408951,"(1R,2S)-2-(3-((E)-4-((S)-1-Morpholinoethyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,440.0,nM,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc([C@H](C)N5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191581,CHEMBL3408955,"(1R,2S)-5'-Methoxy-2-(3-((E)-4-(((2R,6S)-2,4,6-trimethylpiperazin-1-yl)methyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,560.0,nM,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5[C@@H](C)CN(C)C[C@H]5C)cc4)n[nH]c3c1)C(=O)N2,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191582,CHEMBL3408957,"(1R,2S)-2-(3-((E)-4-((1-Isopropylpiperidin-4-yl)oxy)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL3411389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence assay,IC50,=,2400.0,nM,CC(C)N1CCC(Oc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)CC1,CHEMBL3407349,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",J. Med. Chem.,2015.0,58,1,147,169,10.1021/jm5005336,25723005.0,
15191915,CHEMBL3407774,"(1S,2R,3S,4R,5S)-2,3-Dihydroxy-N-methyl-4-(6-(methylamino)-2-(pyrazin-2-ylethynyl)-9H-purin-9-yl)bicyclo[3.1.0]hexane-1-carboxamide",CHEMBL3414382,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis,IC50,>,10000.0,nM,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4cnccn4)nc31)[C@H](O)[C@@H]2O,CHEMBL3407461,In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.,J. Med. Chem.,2014.0,57,23,9901,9914,10.1021/jm501021n,25422861.0,
15191967,CHEMBL3407778,"(1S,2R,3S,4R,5S)-4-(2-(Furan-2-ylethynyl)-6-(methylamino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide",CHEMBL3414382,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis,IC50,>,10000.0,nM,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4ccco4)nc31)[C@H](O)[C@@H]2O,CHEMBL3407461,In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.,J. Med. Chem.,2014.0,57,23,9901,9914,10.1021/jm501021n,25422861.0,
15192038,CHEMBL3407784,"(1S,2R,3S,4R,5S)-4-(2-((5-Chlorothiophen-2-yl)ethynyl)-6-(methylamino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]-hexane-1-carboxamide",CHEMBL3414382,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis,IC50,>,10000.0,nM,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4ccc(Cl)s4)nc31)[C@H](O)[C@@H]2O,CHEMBL3407461,In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.,J. Med. Chem.,2014.0,57,23,9901,9914,10.1021/jm501021n,25422861.0,
15193250,CHEMBL3407785,"(1S,2R,3S,4R,5S)-4-(2-((5-Bromothiophen-2-yl)ethynyl)-6-(methylamino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]-hexane-1-carboxamide",CHEMBL3414382,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis,IC50,>,7000.0,nM,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4ccc(Br)s4)nc31)[C@H](O)[C@@H]2O,CHEMBL3407461,In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.,J. Med. Chem.,2014.0,57,23,9901,9914,10.1021/jm501021n,25422861.0,
15199072,CHEMBL3409876,"(3R,5S)-1-(dibenzo[b,d]furan-2-ylmethyl)-5-(2-fluoro-6-methoxyphenyl)-3-hydroxypyrrolidin-2-one",CHEMBL3413706,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,9400.0,nM,COc1cccc(F)c1[C@@H]1C[C@@H](O)C(=O)N1Cc1ccc2oc3ccccc3c2c1,CHEMBL3407375,Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.,Bioorg. Med. Chem. Lett.,2015.0,25,9,1884,1891,10.1016/j.bmcl.2015.03.035,25838147.0,
15202773,CHEMBL3409588,(S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((tetrahydro-2H-pyran-4-ylamino))pyrimidin-4-yl)pyridin-2(1H)-one,CHEMBL3413962,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,O=c1cc(-c2ccnc(NC3CCOCC3)n2)ccn1[C@H](CO)c1ccc(Cl)c(F)c1,CHEMBL3407455,"Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.",J. Med. Chem.,2015.0,58,4,1976,1991,10.1021/jm501921k,25603482.0,
15205765,CHEMBL3408192,"8-(3-Chloro-5-(4-morpholin-4-ylphenyl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",CHEMBL3413218,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2900.0,nM,O=C1NCCC12CCN(c1c(Cl)cncc1-c1ccc(N3CCOCC3)cc1)CC2,CHEMBL3407438,"Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.",J. Med. Chem.,2015.0,58,4,1717,1735,10.1021/jm501436m,25680029.0,
15212818,CHEMBL2331699,"9-fluoro-7-(5-fluoropyridin-3-yl)-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline",CHEMBL3418347,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using diclofenac substrate by LC-MS/MS method,IC50,>,50000.0,nM,Cc1nnc2n1-c1c(F)cc(-c3cncc(F)c3)cc1CC2,CHEMBL3414516,"Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.",J. Med. Chem.,2015.0,58,5,2530,2537,10.1021/acs.jmedchem.5b00079,25711516.0,
15212819,CHEMBL3313969,"9-fluoro-1-methyl-7-(4-methylpyridin-3-yl)-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline",CHEMBL3418347,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using diclofenac substrate by LC-MS/MS method,IC50,>,50000.0,nM,Cc1ccncc1-c1cc(F)c2c(c1)CCc1nnc(C)n1-2,CHEMBL3414516,"Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.",J. Med. Chem.,2015.0,58,5,2530,2537,10.1021/acs.jmedchem.5b00079,25711516.0,
15215725,CHEMBL3415629,4-{[(3S)-1-(4-Chlorophenyl)-3-methyl-2-oxopyrrolidin-3-yl]amino}-benzenecarbohydroxamicAcid,CHEMBL3420786,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes preincubated for 10 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,C[C@]1(Nc2ccc(C(=O)NO)cc2)CCN(c2ccc(Cl)cc2)C1=O,CHEMBL3414430,Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.,J. Med. Chem.,2015.0,58,6,2809,2820,10.1021/jm502011f,25734520.0,
15222849,CHEMBL3417509,"5-[4-(1-{5-[1-(2-Dimethylamino-ethyl)-1H-pyrazol-4-yl]-[1,2,4]-oxadiazol-3-yl}-cyclobutyl)-phenyl]-pyrimidin-2-ylamine",CHEMBL3420843,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using dichlofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins,IC50,=,7000.0,nM,CN(C)CCn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CCC3)no2)cn1,CHEMBL3414472,"Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).",J. Med. Chem.,2015.0,58,4,1669,1690,10.1021/jm501185j,25671290.0,
15223448,CHEMBL3417504,"(+/-)-5-{4-[3-((R)-2-Methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one",CHEMBL3421055,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)C3CC23)cc1,CHEMBL3414489,"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,2015.0,95,,349,356,10.1016/j.ejmech.2015.03.054,25827402.0,
15223449,CHEMBL3417505,"(+/-)5-{4-[(S)-2-Methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one",CHEMBL3421055,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,C[C@H](COc1ccc(C2=NNC(=O)C3CC23)cc1)CN1CCC[C@H]1C,CHEMBL3414489,"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,2015.0,95,,349,356,10.1016/j.ejmech.2015.03.054,25827402.0,
15223450,CHEMBL3417585,"(1R,6S)-5-{4-[3-((R)-2-Methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4..0]hept-4-en-2-one",CHEMBL3421055,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@@H]3C[C@H]23)cc1,CHEMBL3414489,"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,2015.0,95,,349,356,10.1016/j.ejmech.2015.03.054,25827402.0,
15223451,CHEMBL3417586,"(1S,6R)-5-{4-[3-((R)-2-Methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one",CHEMBL3421055,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@H]3C[C@@H]23)cc1,CHEMBL3414489,"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,2015.0,95,,349,356,10.1016/j.ejmech.2015.03.054,25827402.0,
15224077,CHEMBL3417511,"1-[4-(3-{1-[4-(2-Amino-pyrimidin-5-yl)-phenyl]-cyclobutyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-2-methyl-propan-2-ol",CHEMBL3420843,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using dichlofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins,IC50,=,6000.0,nM,CC(C)(O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CCC3)no2)cn1,CHEMBL3414472,"Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).",J. Med. Chem.,2015.0,58,4,1669,1690,10.1021/jm501185j,25671290.0,
15224079,CHEMBL3417531,"1-[4-(3-{(R)-1-[4-(2-Amino-pyrimidin-5-yl)-phenyl]-1-cyclopropylethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-2-methyl-propan-2-ol",CHEMBL3420843,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using dichlofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins,IC50,=,4000.0,nM,CC(C)(O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1,CHEMBL3414472,"Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).",J. Med. Chem.,2015.0,58,4,1669,1690,10.1021/jm501185j,25671290.0,
15224081,CHEMBL3417525,"2-[4-(3-{(R)-1-[4-(2-Amino-pyrimidin-5-yl)-phenyl]-1-cyclopropylethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide",CHEMBL3420843,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using dichlofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins,IC50,>,30000.0,nM,CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1,CHEMBL3414472,"Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).",J. Med. Chem.,2015.0,58,4,1669,1690,10.1021/jm501185j,25671290.0,
15224083,CHEMBL3417530,"5-[4-((R)-1-Cyclopropyl-1-{5-[1-(2-dimethylamino-ethyl)-1H-pyrazol-4-yl]-[1,2,4]oxadiazol-3-yl}-ethyl)-phenyl]-pyrimidin-2-ylamin",CHEMBL3420843,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using dichlofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins,IC50,>,30000.0,nM,CN(C)CCn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1,CHEMBL3414472,"Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).",J. Med. Chem.,2015.0,58,4,1669,1690,10.1021/jm501185j,25671290.0,
15235865,CHEMBL3421982,2-(2-(4-(4-fluorobenzoyl)piperazin-1-yl)pyrimidin-4-yl)-2-(pyridin-2-yl)acetonitrile,CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,<,5000.0,nM,N#CC(c1ccccn1)c1ccnc(N2CCN(C(=O)c3ccc(F)cc3)CC2)n1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15235866,CHEMBL3421983,"(4-Fluorophenyl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,=,66000.0,nM,O=C(c1ccc(F)cc1)N1CCn2c(nnc2-c2ccccn2)C1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15235867,CHEMBL3422000,"(4-Fluorophenyl)(3-(6-methylpyridin-2-yl)-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,>,100000.0,nM,Cc1cccc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3)n1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15235868,CHEMBL3422004,"(4-Fluorophenyl)(3-(6-(trifluoromethyl)pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,>,100000.0,nM,O=C(c1ccc(F)cc1)N1CCn2c(nnc2-c2cccc(C(F)(F)F)n2)C1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15235869,CHEMBL3422005,"(R)-(4-Fluorophenyl)(8-methyl-3-(2-methylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,=,56000.0,nM,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)cs1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15235870,CHEMBL3422006,"(R)-(4-Fluorophenyl)(8-methyl-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,=,19000.0,nM,C[C@@H]1c2nnc(-c3csc(-c4ccccc4)n3)n2CCN1C(=O)c1ccc(F)cc1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15235871,CHEMBL3422007,"(R)-(8-Methyl-3-(6-methylpyridin-2-yl)-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,=,18000.0,nM,Cc1cccc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15235872,CHEMBL3422008,"(R)-(8-Methyl-3-(6-methylpyrazin-2-yl)-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,=,17000.0,nM,Cc1cncc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15235873,CHEMBL3422009,"[(8R)-3-[2-(2,4-Difluorophenyl)thiazol-4-yl]-8-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-[4-(2-thienyl)phenyl]-methanone",CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,=,3000.0,nM,C[C@@H]1c2nnc(-c3csc(-c4ccc(F)cc4F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15235874,CHEMBL3422010,"(R)-(8-Methyl-3-(2-methylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)-phenyl)methanone",CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,=,21000.0,nM,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)cs1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15235875,CHEMBL3422012,"(3-(2-Methylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]-pyrazin-7(8H)-yl)(4-(thiophen-2yl)phenyl)methanone",CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,=,19000.0,nM,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3)cs1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15235876,CHEMBL3422013,"(R)-(8-Methyl-3-(2-(trifluoromethyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,=,5000.0,nM,C[C@@H]1c2nnc(-c3csc(C(F)(F)F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15235877,CHEMBL3422014,"(R)-(3-(2-Isopropylthiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,=,4000.0,nM,CC(C)c1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)cs1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15235878,CHEMBL3422015,"(R)-(3-(2-Isopropyloxazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,=,14000.0,nM,CC(C)c1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)co1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15235879,CHEMBL3422016,"(R)-(8-Methyl-3-(4-methylthiazol-2-yl)-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,=,8000.0,nM,Cc1csc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15235880,CHEMBL3422017,"(R)-(8-Methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,=,40000.0,nM,Cc1noc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15235881,CHEMBL3422018,"(R)-(8-Methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",CHEMBL3425003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,IC50,=,13000.0,nM,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,CHEMBL3421625,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,J. Med. Chem.,2015.0,58,7,3060,3082,10.1021/jm5017413,25738882.0,
15252362,CHEMBL243876,"1-cyclopropyl-3-((1-(4-hydroxybutyl)-1H-benzo[d]imidazol-2-yl)methyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one",CHEMBL3428564,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,50000.0,nM,O=c1n(Cc2nc3ccccc3n2CCCCO)c2cnccc2n1C1CC1,CHEMBL3425470,Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors.,ACS Med. Chem. Lett.,2015.0,6,3,359,362,10.1021/acsmedchemlett.5b00008,25941547.0,
15252363,CHEMBL3427272,"3-(7-chloro-2-((1-cyclopropyl-2-oxo-1H-imidazo[4,5-c]pyridin-3(2H)-yl)methyl)imidazo[1,2-a]pyridin-3-yl)propanoic acid",CHEMBL3428564,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,50000.0,nM,O=C(O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12,CHEMBL3425470,Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors.,ACS Med. Chem. Lett.,2015.0,6,3,359,362,10.1021/acsmedchemlett.5b00008,25941547.0,
15252364,CHEMBL3427276,"3-((7-chloro-3-(2-(methylsulfonyl)ethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1-cyclopropyl-1H-imidazo[4,5-c]pyridin-2(3H)-one",CHEMBL3428564,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,50000.0,nM,CS(=O)(=O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12,CHEMBL3425470,Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors.,ACS Med. Chem. Lett.,2015.0,6,3,359,362,10.1021/acsmedchemlett.5b00008,25941547.0,
15252365,CHEMBL3427277,"3-((7-chloro-3-(2-(ethylsulfonyl)ethyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1-cyclopropyl-1H-imidazo[4,5-c]pyridin-2(3H)-one",CHEMBL3428564,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,50000.0,nM,CCS(=O)(=O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12,CHEMBL3425470,Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors.,ACS Med. Chem. Lett.,2015.0,6,3,359,362,10.1021/acsmedchemlett.5b00008,25941547.0,
15445879,CHEMBL480,"2-[3-Methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-1H-benzoimidazole",CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,=,19200.0,nM,Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445889,CHEMBL50,"2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one",CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,=,10200.0,nM,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445891,CHEMBL157101,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,=,8940.0,nM,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445897,CHEMBL1648,"3-isopropyl 5-methyl 4-(benzo[c][1,2,5]oxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate",CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,=,3660.0,nM,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc2nonc12,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445906,CHEMBL1479,"1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-7-oxa-8-aza-dicyclopenta[a,h]phenanthren-1-ol, danazol",CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,=,1440.0,nM,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445914,CHEMBL1484,"2,6-Dimethyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-[2-(benzyl-methyl-amino)-ethyl] ester 5-methyl ester",CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,=,378.0,nM,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445915,CHEMBL104,1-[(2-Chloro-phenyl)-diphenyl-methyl]-1H-imidazole,CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,=,136.0,nM,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445950,CHEMBL6966,"2-(3,4-Dimethoxy-phenyl)-5-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-2-isopropyl-pentanenitrile",CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445951,CHEMBL83,"{2-[4-(1,2-Diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine",CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445952,CHEMBL1064,"2,2-Dimethyl-butyric acid 8-[2-(4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester",CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445953,CHEMBL1423,"1-{1-[4,4-Bis-(4-fluoro-phenyl)-butyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one",CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445954,CHEMBL1708,Paroxetine.HCl,CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,Cl.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445955,CHEMBL900,Dimethyl-[2-(phenyl-o-tolyl-methoxy)-ethyl]-amine,CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,Cc1ccccc1C(OCCN(C)C)c1ccccc1,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445956,CHEMBL172,"(S)-(2,8-bis(trifluoromethyl)quinolin-4-yl)((R)-piperidin-2-yl)methanol",CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,O[C@@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@H]1CCCCN1,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445957,CHEMBL998,"4-(8-Chloro-5,6-dihydro-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-piperidine-1-carboxylic acid ethyl ester",CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445958,CHEMBL1200633,Ivermectin,CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445959,CHEMBL54,4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one (Haloperidol),CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445960,CHEMBL1008,Benzyl-(3-isobutoxy-2-pyrrolidin-1-yl-propyl)-phenyl-amine,CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15445981,CHEMBL296419,[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-yl}-amine,CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15447301,CHEMBL1483,(5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester,CHEMBL3530854,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15448839,CHEMBL451887,Carfilzomib,CHEMBL3533280,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 5 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,CHEMBL3526139,"Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.",Drug Metab. Dispos.,2013.0,41,1,230,237,10.1124/dmd.112.047662,23118326.0,
15450935,CHEMBL161,"(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-3-(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,>,50000.0,nM,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450936,CHEMBL71,[3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine,CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,>,50000.0,nM,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450937,CHEMBL6966,"2-(3,4-Dimethoxy-phenyl)-5-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-2-isopropyl-pentanenitrile",CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,>,50000.0,nM,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450938,CHEMBL833,"5-(2-Chloro-benzyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine",CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,=,31100.0,nM,Clc1ccccc1CN1CCc2sccc2C1,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450939,CHEMBL809,"[4-(3,4-Dichloro-phenyl)-1,2,3,4-tetrahydro-naphthalen-1-yl]-methyl-amine (Sertraline)",CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,>,50000.0,nM,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450940,CHEMBL42,"8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine",CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,=,21200.0,nM,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450941,CHEMBL1008,Benzyl-(3-isobutoxy-2-pyrrolidin-1-yl-propyl)-phenyl-amine,CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,=,4310.0,nM,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450942,CHEMBL567,2-{4-[3-(2-Chloro-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethanol,CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,=,21300.0,nM,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450943,CHEMBL1451,"9-Fluoro-11,16,17-trihydroxy-17-(2-hydroxy-acetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,>,50000.0,nM,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450944,CHEMBL13,1-Isopropylamino-3-[4-(2-methoxy-ethyl)-phenoxy]-propan-2-ol,CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,>,50000.0,nM,COCCc1ccc(OCC(O)CNC(C)C)cc1,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450945,CHEMBL54,4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one (Haloperidol),CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,>,50000.0,nM,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450946,CHEMBL388590,benzbromarone,CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,>,50000.0,nM,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450947,CHEMBL1428,"2,6-Dimethyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-isopropyl ester 5-(2-methoxy-ethyl) ester",CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,=,1690.0,nM,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450948,CHEMBL193,"2,6-Dimethyl-4-(2-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester",CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,=,4080.0,nM,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450949,CHEMBL9,"1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid",CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,>,50000.0,nM,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450950,CHEMBL45816,"Methoxy-acetic acid (1S,2S)-2-(2-{[3-(1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester",CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,=,28400.0,nM,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450951,CHEMBL1484,"2,6-Dimethyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-[2-(benzyl-methyl-amino)-ethyl] ester 5-methyl ester",CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,=,660.0,nM,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450952,CHEMBL682,AMODIAQUINE,CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,>,50000.0,nM,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450953,CHEMBL30008,1-[Bis-(4-fluoro-phenyl)-methyl]-4-(3-phenyl-allyl)-piperazine (Flunarizine),CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,>,50000.0,nM,Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15450954,CHEMBL1017,"4'-(1,7'-Dimethyl-2'-propyl-1H-[2,5']bibenzoimidazolyl-3'-ylmethyl)-biphenyl-2-carboxylic acid",CHEMBL3541096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,IC50,=,4780.0,nM,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,CHEMBL3526101,"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.",Drug Metab. Dispos.,2013.0,41,1,60,71,10.1124/dmd.112.048264,23033255.0,
15455075,CHEMBL3527048,"1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine",CHEMBL3532644,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of human CYP2C9 diclofenac 4'-hydroxylase activity,IC50,>,100000.0,nM,Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CC[C@H](N6CCCCC6)C5)c34)cnn2C)cc1,CHEMBL3526089,Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.,Drug Metab. Dispos.,2012.0,40,9,1686,1697,10.1124/dmd.112.045302,22645092.0,
15461258,CHEMBL1951575,2-(4-(4-(tert-butylcarbamoyl)-2-(4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid,CHEMBL3531866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 5 to 30 mins by LC-MS/MS analysis,IC50,>=,30000.0,nM,CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1,CHEMBL3526017,"Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors.",Drug Metab. Dispos.,2012.0,40,12,2239,2249,10.1124/dmd.112.047928,22930276.0,
15466661,CHEMBL1229211,DOLUTEGRAVIR,CHEMBL3529853,A,,Homo sapiens,Cytochrome P450 2C9,Metabolism-dependent inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 20 mins with NADPH prior to initiation of reaction with probe substrate by HPLC analysis,IC50,>,100000.0,nM,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,CHEMBL3526034,"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.",Drug Metab. Dispos.,2013.0,41,2,353,361,10.1124/dmd.112.048918,23132334.0,
15466675,CHEMBL1229211,DOLUTEGRAVIR,CHEMBL3527759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 20 mins with substrate prior to initiation of reaction with NADPH by HPLC analysis,IC50,>,100000.0,nM,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,CHEMBL3526034,"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.",Drug Metab. Dispos.,2013.0,41,2,353,361,10.1124/dmd.112.048918,23132334.0,
15467134,CHEMBL385517,(S)-2-[2-Amino-2-(3-hydroxy-adamantan-1-yl)-acetyl]-2-aza-bicyclo[3.1.0]hexane-3-carbonitrile,CHEMBL3528840,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as paclitaxel 6alpha-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH,IC50,>,50000.0,nM,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,CHEMBL3526095,Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.,Drug Metab. Dispos.,2012.0,40,7,1345,1356,10.1124/dmd.112.045450,22496391.0,
15467135,CHEMBL3350936,"(S)-2-[2-Amino-2-(3,5-dihydroxy-adamantan-1-yl)-acetyl]-2-aza-bicyclo[3.1.0]hexane-3-carbonitrile",CHEMBL3528840,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as paclitaxel 6alpha-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH,IC50,>,200000.0,nM,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(O)(CC(O)(C3)C1)C2,CHEMBL3526095,Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.,Drug Metab. Dispos.,2012.0,40,7,1345,1356,10.1124/dmd.112.045450,22496391.0,
15467154,CHEMBL385517,(S)-2-[2-Amino-2-(3-hydroxy-adamantan-1-yl)-acetyl]-2-aza-bicyclo[3.1.0]hexane-3-carbonitrile,CHEMBL3528850,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as paclitaxel 6alpha-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH,IC50,>,50000.0,nM,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,CHEMBL3526095,Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.,Drug Metab. Dispos.,2012.0,40,7,1345,1356,10.1124/dmd.112.045450,22496391.0,
15467155,CHEMBL3350936,"(S)-2-[2-Amino-2-(3,5-dihydroxy-adamantan-1-yl)-acetyl]-2-aza-bicyclo[3.1.0]hexane-3-carbonitrile",CHEMBL3528850,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as paclitaxel 6alpha-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH,IC50,>,200000.0,nM,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(O)(CC(O)(C3)C1)C2,CHEMBL3526095,Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.,Drug Metab. Dispos.,2012.0,40,7,1345,1356,10.1124/dmd.112.045450,22496391.0,
15608618,CHEMBL3577955,(4-isopropylpiperazin-1-yl)(4-(morpholinomethyl)phenyl)methanone bis-maleate,CHEMBL3578427,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,CC(C)N1CCN(C(=O)c2ccc(CN3CCOCC3)cc2)CC1.O=C(O)/C=C\C(=O)O,CHEMBL3576859,Novel benzamide-based histamine h3 receptor antagonists: the identification of two candidates for clinical development.,ACS Med. Chem. Lett.,2015.0,6,4,450,454,10.1021/ml5005156,25893048.0,
15613959,CHEMBL3582243,"methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate",CHEMBL3582738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 after 1 hr by LC-MS/MS analysis,IC50,=,8543.0,nM,CC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@](C)(CC[C@H]4C(C)(C)C(=O)C(C#N)=C[C@]34C)[C@]1(C)CC2,CHEMBL3580660,"Synthesis and Biological Evaluation of Novel Olean-28,13β-lactams as Potential Antiprostate Cancer Agents.",J. Med. Chem.,2015.0,58,11,4506,4520,10.1021/jm5020023,25992974.0,
15613960,CHEMBL3582240,"(1S,4S,5R,8R,13S,17S,18R)-24-cyclohexyl-4,5,9,9,13,20,20-heptamethyl-10,16,23-trioxo-24-azahexacyclo[15.5.2.0^{1,18}.0^{4,17}.0^{5,14}.0^{8,13}]tetracosa-11,14-diene-11-carbonitrile",CHEMBL3582738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 after 1 hr by LC-MS/MS analysis,IC50,>,100000.0,nM,CC1(C)CC[C@]23CC[C@]4(C)[C@](C(=O)C=C5[C@@]6(C)C=C(C#N)C(=O)C(C)(C)[C@@H]6CC[C@]54C)([C@@H]2C1)N(C1CCCCC1)C3=O,CHEMBL3580660,"Synthesis and Biological Evaluation of Novel Olean-28,13β-lactams as Potential Antiprostate Cancer Agents.",J. Med. Chem.,2015.0,58,11,4506,4520,10.1021/jm5020023,25992974.0,
15615057,CHEMBL3582336,"5-((1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one",CHEMBL3584054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCn1cc([C@@]2(c3nn(C)c(=O)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1,CHEMBL3580651,"Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.",ACS Med. Chem. Lett.,2015.0,6,5,513,517,10.1021/ml500514w,26005524.0,
15616629,CHEMBL3581693,BRILANESTRANT,CHEMBL3582529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2200.0,nM,CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl,CHEMBL3580562,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",J. Med. Chem.,2015.0,58,12,4888,4904,10.1021/acs.jmedchem.5b00054,25879485.0,
15620843,CHEMBL3580669,N-(4-(2-Fluoropyridin-4-yl)thiophen-2-yl)-2-(3-(methylsulfonamido)phenyl)acetamide,CHEMBL3585202,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,12000.0,nM,CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(F)c3)cs2)c1,CHEMBL3580640,"Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.",J. Med. Chem.,2015.0,58,12,5028,5037,10.1021/acs.jmedchem.5b00424,26039570.0,
15622412,CHEMBL3586436,"((3aR,6aS)-5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)methanone",CHEMBL3587717,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1cc(C)nc(N2C[C@H]3CN(C(=O)c4c(F)cccc4-n4nccn4)C[C@H]3C2)n1,CHEMBL3585263,"Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate.",J. Med. Chem.,2015.0,58,14,5620,5636,10.1021/acs.jmedchem.5b00742,26087021.0,
15623324,CHEMBL3343259,"Rac-(1R,2S)-N-(5-cyanopyridin-2-yl)-2-((3,4-dimethoxyphenoxy)methyl)-2-phenylcyclopropanecarboxamide",CHEMBL3588593,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as susbtrate incubated for 30 mins prior to substrate addition for 10 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,COc1ccc(OC[C@@]2(c3ccccc3)C[C@H]2C(=O)Nc2ccc(C#N)cn2)cc1OC,CHEMBL3585325,"Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist.",J. Med. Chem.,2015.0,58,11,4648,4664,10.1021/acs.jmedchem.5b00217,25953512.0,
15623325,CHEMBL3545367,LEMBOREXANT,CHEMBL3588593,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as susbtrate incubated for 30 mins prior to substrate addition for 10 mins by LC-MS/MS analysis,IC50,>,20000.0,nM,Cc1ncc(OC[C@@]2(c3cccc(F)c3)C[C@H]2C(=O)Nc2ccc(F)cn2)c(C)n1,CHEMBL3585325,"Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist.",J. Med. Chem.,2015.0,58,11,4648,4664,10.1021/acs.jmedchem.5b00217,25953512.0,
15642311,CHEMBL3589557,"(R)-4-chloro-2-fluoro-N-(2-fluorophenyl)-5-(octahydropyrrolo[1,2-a]pyrazine-2-carbonyl)benzenesulfonamide hydrochloride",CHEMBL3592807,A,,Homo sapiens,Cytochrome P450 2C9,Competitive inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cl.O=C(c1cc(S(=O)(=O)Nc2ccccc2F)c(F)cc1Cl)N1CCN2CCC[C@@H]2C1,CHEMBL3588745,"Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639.",ACS Med. Chem. Lett.,2015.0,6,6,641,644,10.1021/acsmedchemlett.5b00023,26101566.0,
15648952,CHEMBL3593759,"2-{[(1-Hydroxycyclohexyl)methyl]amino}-(1R)-(1-isopropyl-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethanone",CHEMBL3594644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 using 7-methoxy-4-trifluoromethylcoumarin as substrate after 45 mins by fluorescence-based assay,IC50,>,50000.0,nM,COc1ccc2c(c1)CCN(C(=O)CNCC1(O)CCCCC1)[C@@H]2C(C)C,CHEMBL3593157,Discovery of a 1-isopropyltetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain.,Bioorg. Med. Chem.,2015.0,23,15,4624,4637,10.1016/j.bmc.2015.05.030,26071371.0,
15648953,CHEMBL3593760,"2-{[(1-Hydroxycyclohexyl)methyl]amino}-(1S)-(1-isopropyl-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethanone",CHEMBL3594644,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 using 7-methoxy-4-trifluoromethylcoumarin as substrate after 45 mins by fluorescence-based assay,IC50,>,50000.0,nM,COc1ccc2c(c1)CCN(C(=O)CNCC1(O)CCCCC1)[C@H]2C(C)C,CHEMBL3593157,Discovery of a 1-isopropyltetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain.,Bioorg. Med. Chem.,2015.0,23,15,4624,4637,10.1016/j.bmc.2015.05.030,26071371.0,
15649342,CHEMBL3594232,"6-Methyl-2-((3aR,5r,6aS)-5-(2-(trifluoromethyl)phenyl)-hexahydrocydopenta[c]pyrrol-2(1H)-yl)pyrimidine-4-carboxylic Acid",CHEMBL3594975,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,34000.0,nM,Cc1cc(C(=O)O)nc(N2C[C@H]3C[C@@H](c4ccccc4C(F)(F)F)C[C@H]3C2)n1,CHEMBL3593175,Bicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease.,J. Med. Chem.,2015.0,58,15,5863,5888,10.1021/acs.jmedchem.5b00423,26181715.0,
15666748,CHEMBL3601185,"(1R,2S,3R,5R)-3-(2-(2,6-dimethylpyridin-4-ylamino)-5-(4-phenylthiazol-2-yl)pyrimidin-4-ylamino)-5-(hydroxymethyl)cyclopentane-1,2-diol",CHEMBL3603430,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1cc(Nc2ncc(-c3nc(-c4ccccc4)cs3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)cc(C)n1,CHEMBL3600286,Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,2015.0,25,16,3203,3207,10.1016/j.bmcl.2015.05.097,26115573.0,
15666749,CHEMBL3601186,"(1S,2R,3R,5R)-3-(hydroxymethyl)-5-(2-(2-methylpyridin-4-ylamino)-5-(4-phenylthiazol-2-yl)pyrimidin-4-ylamino)cyclopentane-1,2-diol",CHEMBL3603430,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1cc(Nc2ncc(-c3nc(-c4ccccc4)cs3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)ccn1,CHEMBL3600286,Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,2015.0,25,16,3203,3207,10.1016/j.bmcl.2015.05.097,26115573.0,
15666750,CHEMBL3601189,"(1S,2R,3R,5R)-3-(hydroxymethyl)-5-(2-(2-methoxypyridin-4-ylamino)-5-(quinolin-2-yl)pyrimidin-4-ylamino)cyclopentane-1,2-diol",CHEMBL3603430,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,COc1cc(Nc2ncc(-c3ccc4ccccc4n3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)ccn1,CHEMBL3600286,Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,2015.0,25,16,3203,3207,10.1016/j.bmcl.2015.05.097,26115573.0,
15666751,CHEMBL3601190,"(1R,2S,3R,5R)-3-(2-(2-cyclopropoxypyridin-4-ylamino)-5-(quinolin-2-yl)pyrimidin-4-ylamino)-5-(hydroxymethyl)cyclopentane-1,2-diol",CHEMBL3603430,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,OC[C@H]1C[C@@H](Nc2nc(Nc3ccnc(OC4CC4)c3)ncc2-c2ccc3ccccc3n2)[C@H](O)[C@@H]1O,CHEMBL3600286,Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,2015.0,25,16,3203,3207,10.1016/j.bmcl.2015.05.097,26115573.0,
15666752,CHEMBL3601070,"(1S,2R,3R,5R)-3-(hydroxymethyl)-5-(2-(2-isopropoxypyridin-4-ylamino)-5-(quinolin-2-yl)pyrimidin-4-ylamino)cyclopentane-1,2-diol",CHEMBL3603430,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC(C)Oc1cc(Nc2ncc(-c3ccc4ccccc4n3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)ccn1,CHEMBL3600286,Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,2015.0,25,16,3203,3207,10.1016/j.bmcl.2015.05.097,26115573.0,
15666753,CHEMBL3601192,"(1R,2S,3R,5R)-3-(2-(2,6-dimethylpyridin-4-ylamino)-5-(quinolin-2-yl)pyrimidin-4-ylamino)-5-(hydroxymethyl)cyclopentane-1,2-diol",CHEMBL3603430,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1cc(Nc2ncc(-c3ccc4ccccc4n3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)cc(C)n1,CHEMBL3600286,Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,2015.0,25,16,3203,3207,10.1016/j.bmcl.2015.05.097,26115573.0,
15666754,CHEMBL3601196,"(1R,2S,3R,5R)-3-(5-(benzo[d]thiazol-2-yl)-2-(2,6-dimethylpyridin-4-ylamino)pyridin-4-ylamino)-5-(hydroxymethyl)cyclopentane-1,2-diol",CHEMBL3603430,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1cc(Nc2cc(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)c(-c3nc4ccccc4s3)cn2)cc(C)n1,CHEMBL3600286,Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.,Bioorg. Med. Chem. Lett.,2015.0,25,16,3203,3207,10.1016/j.bmcl.2015.05.097,26115573.0,
15667774,CHEMBL3601411,"2,7-bis((3R,5S)-3,5-dimethylpiperidin-1-ylsulfonyl)anthracene-9,10-dione dioxime",CHEMBL3603637,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5620.0,nM,C[C@H]1C[C@@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@@H](C)C[C@@H](C)C4)ccc2C3=NO)C1,CHEMBL3600343,"Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway Inhibitors.",J. Med. Chem.,2015.0,58,15,5854,5862,10.1021/acs.jmedchem.5b00460,26182238.0,
15672037,CHEMBL3601260,"2-{[(2R)-2-Hydroxypropyl]amino}-1-[(1S)-8-methoxy-1-phenyl-3,4-dihydroisoquinolin-2(1H)-yl]ethanone",CHEMBL3603071,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence-based assay,IC50,>,50000.0,nM,COc1cccc2c1[C@H](c1ccccc1)N(C(=O)CNC[C@@H](C)O)CC2,CHEMBL3600316,Discovery of an 8-methoxytetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain without CYP inhibition liability.,Bioorg. Med. Chem.,2015.0,23,15,4638,4648,10.1016/j.bmc.2015.05.053,26078010.0,
15673265,CHEMBL3115074,4-((S)-1-((R)-1-(2-phenoxyethyl)piperidine-2-carboxamido)ethyl)benzoic acid hydrochloride,CHEMBL3602025,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,C[C@H](NC(=O)[C@H]1CCCCN1CCOc1ccccc1)c1ccc(C(=O)O)cc1.Cl,CHEMBL3600314,Discovery and characterization of a potent and selective EP4 receptor antagonist.,Bioorg. Med. Chem. Lett.,2015.0,25,16,3176,3178,10.1016/j.bmcl.2015.05.091,26091726.0,
15674495,CHEMBL3601377,2-(2-(4-((dimethylamino)methyl)-2-methylphenyl)-2-oxoethyl)-5-((5-methoxypyridin-2-yl)methoxy)pyridazin-3(2H)-one,CHEMBL3602771,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,COc1ccc(COc2cnn(CC(=O)c3ccc(CN(C)C)cc3C)c(=O)c2)nc1,CHEMBL3600349,"Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908.",Bioorg. Med. Chem. Lett.,2015.0,25,16,3275,3280,10.1016/j.bmcl.2015.05.065,26105194.0,
15674689,CHEMBL3605277,"(2-((3-fluorophenoxy)methyl)-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)-yl)(4-fluorophenyl)methanone",CHEMBL3607060,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,O=C(c1ccc(F)cc1)N1CCc2nc(COc3cccc(F)c3)oc2C1,CHEMBL3603827,Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3515,3519,10.1016/j.bmcl.2015.06.096,26183084.0,
15674690,CHEMBL3605296,"(2-(phenoxymethyl)-6,7-dihydrooxazolo[5,4-c]pyridin-5(4H)-yl)(1H-pyrazolo[3,4-b]pyridin-3-yl)methanone",CHEMBL3607060,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,14800.0,nM,O=C(c1n[nH]c2ncccc12)N1CCc2nc(COc3ccccc3)oc2C1,CHEMBL3603827,Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3515,3519,10.1016/j.bmcl.2015.06.096,26183084.0,
15676573,CHEMBL3604174,"N-(2,4-dichlorophenyl)-2H-1,2,3-triazole-4-carboxamide",CHEMBL3606432,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,500.0,nM,O=C(Nc1ccc(Cl)cc1Cl)c1cn[nH]n1,CHEMBL3603736,3-Substituted pyrazoles and 4-substituted triazoles as inhibitors of human 15-lipoxygenase-1.,Bioorg. Med. Chem. Lett.,2015.0,25,15,3024,3029,10.1016/j.bmcl.2015.05.004,26037322.0,
15678849,CHEMBL3605557,"(R)-6-Cyano-N-(1-(1-ethyl-6-(trifluoromethyl)-1H-imidazo-[4,5-c]pyridin-2-yl)ethyl)pyridine-3-sulfonamide",CHEMBL3607821,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes incubated for 5 mins in presence of NADPH and specific substrates by LC/MS/MS method,IC50,>,20000.0,nM,CCn1c([C@@H](C)NS(=O)(=O)c2ccc(C#N)nc2)nc2cnc(C(F)(F)F)cc21,CHEMBL3603779,Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity.,J. Med. Chem.,2015.0,58,17,7057,7075,10.1021/acs.jmedchem.5b01078,26291341.0,
15678877,CHEMBL3605558,"(R)-6-Cyano-N-(1-(6-cyclopropyl-1-ethyl-1H-imidazo[4,5-c]-pyridin-2-yl)ethyl)pyridine-3-sulfonamide",CHEMBL3607821,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes incubated for 5 mins in presence of NADPH and specific substrates by LC/MS/MS method,IC50,>,20000.0,nM,CCn1c([C@@H](C)NS(=O)(=O)c2ccc(C#N)nc2)nc2cnc(C3CC3)cc21,CHEMBL3603779,Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity.,J. Med. Chem.,2015.0,58,17,7057,7075,10.1021/acs.jmedchem.5b01078,26291341.0,
15686776,CHEMBL3603923,3-chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile,CHEMBL3606595,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,15848.93,nM,N#Cc1cc(Cl)cc(-c2cc(-c3ccc(F)cn3)ncn2)c1,CHEMBL3603801,Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile).,J. Med. Chem.,2015.0,58,16,6653,6664,10.1021/acs.jmedchem.5b00892,26225459.0,
15687848,CHEMBL3609819,"Isobutyric acid (1R,8R,12R)-12-(2-{[3-(4-methoxy-1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.02,7]trideca-2,4,6-trien-12-yl ester",CHEMBL3611374,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in diclofenac 4'-hydroxylation by LC-MS/MS method,IC50,=,32000.0,nM,COc1cccc2nc(CCCN(C)CC[C@]3(OC(=O)C(C)C)C[C@H]4CCC[C@@H]3c3ccccc34)[nH]c12,CHEMBL3608217,Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.,Bioorg. Med. Chem. Lett.,2015.0,25,18,3941,3946,10.1016/j.bmcl.2015.07.038,26231163.0,
15689442,CHEMBL3422009,"[(8R)-3-[2-(2,4-Difluorophenyl)thiazol-4-yl]-8-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-[4-(2-thienyl)phenyl]-methanone",CHEMBL3610075,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3000.0,nM,C[C@@H]1c2nnc(-c3csc(-c4ccc(F)cc4F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1,CHEMBL3608214,Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).,ACS Med. Chem. Lett.,2015.0,6,7,736,740,10.1021/acsmedchemlett.5b00117,26191358.0,
15689443,CHEMBL3422010,"(R)-(8-Methyl-3-(2-methylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)-phenyl)methanone",CHEMBL3610075,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,21000.0,nM,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)cs1,CHEMBL3608214,Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).,ACS Med. Chem. Lett.,2015.0,6,7,736,740,10.1021/acsmedchemlett.5b00117,26191358.0,
15689444,CHEMBL3608680,"(R)-(4-Fluorophenyl)(8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",CHEMBL3610075,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,42000.0,nM,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1,CHEMBL3608214,Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).,ACS Med. Chem. Lett.,2015.0,6,7,736,740,10.1021/acsmedchemlett.5b00117,26191358.0,
15689445,CHEMBL3422018,"(R)-(8-Methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",CHEMBL3610075,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,13000.0,nM,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,CHEMBL3608214,Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).,ACS Med. Chem. Lett.,2015.0,6,7,736,740,10.1021/acsmedchemlett.5b00117,26191358.0,
15689447,CHEMBL3608682,"(R)-(4-Fluorophenyl)(8-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",CHEMBL3610075,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,42000.0,nM,Cc1noc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1,CHEMBL3608214,Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).,ACS Med. Chem. Lett.,2015.0,6,7,736,740,10.1021/acsmedchemlett.5b00117,26191358.0,
15689448,CHEMBL3608683,"(R)-(4-Fluorophenyl)(3-(3-isopropyl-1,2,4-oxadiazol-5-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",CHEMBL3610075,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,64000.0,nM,CC(C)c1noc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1,CHEMBL3608214,Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).,ACS Med. Chem. Lett.,2015.0,6,7,736,740,10.1021/acsmedchemlett.5b00117,26191358.0,
15689449,CHEMBL3608684,"(4-Fluorophenyl)(3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",CHEMBL3610075,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,82000.0,nM,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3)n1,CHEMBL3608214,Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).,ACS Med. Chem. Lett.,2015.0,6,7,736,740,10.1021/acsmedchemlett.5b00117,26191358.0,
15689451,CHEMBL3608686,"(8,8-Dimethyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methanone",CHEMBL3610075,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,12000.0,nM,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3(C)C)n1,CHEMBL3608214,Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).,ACS Med. Chem. Lett.,2015.0,6,7,736,740,10.1021/acsmedchemlett.5b00117,26191358.0,
15689452,CHEMBL3608687,"(R)-(4-Chlorophenyl)(8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",CHEMBL3610075,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,7000.0,nM,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(Cl)cc2)[C@@H]3C)n1,CHEMBL3608214,Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).,ACS Med. Chem. Lett.,2015.0,6,7,736,740,10.1021/acsmedchemlett.5b00117,26191358.0,
15689453,CHEMBL3608688,"(R)-(4-Fluorophenyl)(8-methyl-3-(3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",CHEMBL3610075,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,45000.0,nM,C[C@@H]1c2nnc(-c3nc(C(F)(F)F)ns3)n2CCN1C(=O)c1ccc(F)cc1,CHEMBL3608214,Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).,ACS Med. Chem. Lett.,2015.0,6,7,736,740,10.1021/acsmedchemlett.5b00117,26191358.0,
15689454,CHEMBL3608740,"(R)-(8-Methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(phenyl)methanone",CHEMBL3610075,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,12000.0,nM,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccccc2)[C@@H]3C)n1,CHEMBL3608214,Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).,ACS Med. Chem. Lett.,2015.0,6,7,736,740,10.1021/acsmedchemlett.5b00117,26191358.0,
15689455,CHEMBL3608741,"(R)-(4-Fluorophenyl)(8-(2-hydroxyethyl)-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",CHEMBL3610075,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,77000.0,nM,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3CCO)n1,CHEMBL3608214,Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).,ACS Med. Chem. Lett.,2015.0,6,7,736,740,10.1021/acsmedchemlett.5b00117,26191358.0,
15690669,CHEMBL3609325,NA,CHEMBL3610821,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,CN[C@@H](C)C(=O)N[C@H](C(=O)N1C[C@@H]2C[C@H]1C(=O)N[C@@H](Cc1ccc3ccccc3c1)C(=O)N[C@H](C(=O)O)Cc1ccc(cc1)OCCCC[C@H]1C[C@@H](C(=O)N[C@@H](Cc3ccc4ccccc4c3)C(=O)N[C@H](NS(=O)(=O)C3CC3)Cc3ccc(cc3)OCc3cn2nn3)N(C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)C1)C(C)(C)C,CHEMBL3608248,Dimeric Macrocyclic Antagonists of Inhibitor of Apoptosis Proteins for the Treatment of Cancer.,ACS Med. Chem. Lett.,2015.0,6,7,770,775,10.1021/acsmedchemlett.5b00091,26191364.0,
15694634,CHEMBL3608458,"8-(2-((1R,3S,4S)-3-fluoro-4-hydroxycyclopentylamino)pyrimidin-4-yl)-2-((S)-2-hydroxy-1-phenylethyl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one",CHEMBL3611604,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,O=C1c2cc(-c3ccnc(N[C@@H]4C[C@H](O)[C@@H](F)C4)n3)cn2CCCN1[C@H](CO)c1ccccc1,CHEMBL3608240,Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase.,Bioorg. Med. Chem. Lett.,2015.0,25,18,3788,3792,10.1016/j.bmcl.2015.07.091,26259804.0,
15699377,CHEMBL3612810,"6-((S)-1-hydroxy-2-(4-((R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)piperazin-1-yl)ethyl)-4-methoxynicotinonitrile",CHEMBL3615708,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,COc1cc([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ncc1C#N,CHEMBL3612018,Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation.,ACS Med. Chem. Lett.,2015.0,6,7,747,752,10.1021/ml500440u,26191360.0,
15709928,CHEMBL3612341,"N-([1,1'-Biphenyl]-3-yl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide",CHEMBL3614362,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,O=C(Cn1cnc([N+](=O)[O-])n1)Nc1cccc(-c2ccccc2)c1,CHEMBL3611981,Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.,Bioorg. Med. Chem.,2015.0,23,19,6467,6476,10.1016/j.bmc.2015.08.014,26344593.0,
15720013,CHEMBL3618396,N-(4-(2-hydroxynicotinamido)butyl)-5-phenylisoxazole-3-carboxamide,CHEMBL3618673,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,O=C(NCCCCNC(=O)c1cccnc1O)c1cc(-c2ccccc2)on1,CHEMBL3616409,Optimization of a small molecule probe that restores e-cadherin expression.,Bioorg. Med. Chem. Lett.,2015.0,25,19,4260,4264,10.1016/j.bmcl.2015.07.104,26299347.0,
15727562,CHEMBL3617655,"(R)-2-(((5-Chloropyridin-2-yl)oxy)methyl)-5-(2-fluoropyridin-3-yl)-7-methyl-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one",CHEMBL3619188,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by cocktail assay,IC50,=,25600.0,nM,C[C@@H]1CN(c2cccnc2F)C(=O)c2cc(COc3ccc(Cl)cn3)nn21,CHEMBL3616441,Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents.,J. Med. Chem.,2015.0,58,18,7485,7500,10.1021/acs.jmedchem.5b01005,26335039.0,
15730153,CHEMBL3623127,"(3aalpha,4bet,5alpha,7beta,7aalpha)-4-(Octahydro-5-ethylsulfonamido-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-(trifluoromethyl)benzonitrile",CHEMBL3624810,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,40000.0,nM,CCS(=O)(=O)N[C@@H]1C[C@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,CHEMBL3621143,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",ACS Med. Chem. Lett.,2015.0,6,8,908,912,10.1021/acsmedchemlett.5b00173,26288692.0,
15739653,CHEMBL3623823,"(rac)-N-(4-(4-Cyanophenyl)-5,6,7,8-tetrahydroisoquinolin-8-yl)acetamide",CHEMBL3626124,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21,CHEMBL3621059,"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.",J. Med. Chem.,2015.0,58,20,8054,8065,10.1021/acs.jmedchem.5b00851,26403853.0,
15739654,CHEMBL3623824,"(rac)-N-(4-(4-Cyanophenyl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide",CHEMBL3626124,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCC(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21,CHEMBL3621059,"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.",J. Med. Chem.,2015.0,58,20,8054,8065,10.1021/acs.jmedchem.5b00851,26403853.0,
15739655,CHEMBL3623825,"(rac)-N-(4-(4-Cyanophenyl)-5,6,7,8-tetrahydroisoquinolin-8-yl)isobutyramide",CHEMBL3626124,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC(C)C(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21,CHEMBL3621059,"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.",J. Med. Chem.,2015.0,58,20,8054,8065,10.1021/acs.jmedchem.5b00851,26403853.0,
15739660,CHEMBL3623830,"(+)-(R)-N-(4-(4-Cyanophenyl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide",CHEMBL3626124,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCC(=O)N[C@@H]1CCCc2c(-c3ccc(C#N)cc3)cncc21,CHEMBL3621059,"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.",J. Med. Chem.,2015.0,58,20,8054,8065,10.1021/acs.jmedchem.5b00851,26403853.0,
15739661,CHEMBL3623831,"(-)-(S)-N-(4-(4-Cyanophenyl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide",CHEMBL3626124,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CCC(=O)N[C@H]1CCCc2c(-c3ccc(C#N)cc3)cncc21,CHEMBL3621059,"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.",J. Med. Chem.,2015.0,58,20,8054,8065,10.1021/acs.jmedchem.5b00851,26403853.0,
15745741,CHEMBL3623278,N-(3-Chloro-2-fluorophenyl)-7-methoxy-6-(morpholinomethyl)-quinazolin-4-amine,CHEMBL3624308,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,10000.0,nM,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCOCC1,CHEMBL3621142,"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",J. Med. Chem.,2015.0,58,20,8200,8215,10.1021/acs.jmedchem.5b01073,26313252.0,
15745916,CHEMBL3623290,"4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl (2R)-2,4-Dimethylpiperazine-1-carboxylate",CHEMBL3624605,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50.0,nM,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C,CHEMBL3621142,"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",J. Med. Chem.,2015.0,58,20,8200,8215,10.1021/acs.jmedchem.5b01073,26313252.0,
15748815,CHEMBL3627896,"(R)-2,6-dichloro-N-(2-(6-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-(3-fluorophenyl)ethyl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide",CHEMBL3630991,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,22380.0,nM,Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3nc4c(C)cc(Cl)cc4[nH]3)c(Cl)c2)n1,CHEMBL3627714,Development of a novel class of potent and selective FIXa inhibitors.,Bioorg. Med. Chem. Lett.,2015.0,25,21,4945,4949,10.1016/j.bmcl.2015.04.057,25978966.0,
15748832,CHEMBL3627899,"(R)-2,6-dichloro-N-(2-(8-fluoro-5-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(3-fluorophenyl)ethyl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide",CHEMBL3630991,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,42760.0,nM,Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3nc4c(F)ccc(C)c4c(=O)[nH]3)c(Cl)c2)n1,CHEMBL3627714,Development of a novel class of potent and selective FIXa inhibitors.,Bioorg. Med. Chem. Lett.,2015.0,25,21,4945,4949,10.1016/j.bmcl.2015.04.057,25978966.0,
15748839,CHEMBL3627895,"(R)-2,6-dichloro-N-(2-(6-chloro-1H-benzo[d]imidazol-2-yl)-2-(3-fluorophenyl)ethyl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide",CHEMBL3630991,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,19820.0,nM,Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3nc4ccc(Cl)cc4[nH]3)c(Cl)c2)n1,CHEMBL3627714,Development of a novel class of potent and selective FIXa inhibitors.,Bioorg. Med. Chem. Lett.,2015.0,25,21,4945,4949,10.1016/j.bmcl.2015.04.057,25978966.0,
15748856,CHEMBL3627897,"(R)-2,6-dichloro-N-(2-(3-fluorophenyl)-2-(2-methyl-1H-benzo[d]imidazol-5-yl)ethyl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide",CHEMBL3630991,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,24850.0,nM,Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3ccc4[nH]c(C)nc4c3)c(Cl)c2)n1,CHEMBL3627714,Development of a novel class of potent and selective FIXa inhibitors.,Bioorg. Med. Chem. Lett.,2015.0,25,21,4945,4949,10.1016/j.bmcl.2015.04.057,25978966.0,
15749454,CHEMBL3627894,"(R)-2,6-dichloro-N-(2-(6-chloro-5-methoxy-1H-benzo[d]imidazol-2-yl)-2-(3-fluorophenyl)ethyl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide",CHEMBL3630991,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,9089.0,nM,COc1cc2nc([C@@H](CNC(=O)c3c(Cl)cc(-n4cnc(C)n4)cc3Cl)c3cccc(F)c3)[nH]c2cc1Cl,CHEMBL3627714,Development of a novel class of potent and selective FIXa inhibitors.,Bioorg. Med. Chem. Lett.,2015.0,25,21,4945,4949,10.1016/j.bmcl.2015.04.057,25978966.0,
15749958,CHEMBL3628112,"N-(3-chloro-4-(5-chloro-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide",CHEMBL3631347,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,30000.0,nM,Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccc(Cl)cc3C2=O)c(Cl)c1,CHEMBL3627606,"Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.",J. Med. Chem.,2015.0,58,20,7959,7971,10.1021/acs.jmedchem.5b00727,26426481.0,
15749959,CHEMBL3628113,"N-(3-chloro-4-(4-fluoro-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide",CHEMBL3631347,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,=,6450.0,nM,Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3cccc(F)c3C2=O)c(Cl)c1,CHEMBL3627606,"Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.",J. Med. Chem.,2015.0,58,20,7959,7971,10.1021/acs.jmedchem.5b00727,26426481.0,
15749960,CHEMBL3628115,"N-(3-chloro-4-(1,3-dioxo-1H-pyrrolo[3,4-c]pyridin-2(3H)-yl)phenyl)-3-methylfuran-2-carboxamide",CHEMBL3631347,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,30000.0,nM,Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccncc3C2=O)c(Cl)c1,CHEMBL3627606,"Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.",J. Med. Chem.,2015.0,58,20,7959,7971,10.1021/acs.jmedchem.5b00727,26426481.0,
15749961,CHEMBL521982,N-(4-(trifluoromethyl)oxazol-2-yl)-9H-xanthene-9-carboxamide,CHEMBL3631347,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,=,600.0,nM,O=C(Nc1nc(C(F)(F)F)co1)C1c2ccccc2Oc2ccccc21,CHEMBL3627606,"Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.",J. Med. Chem.,2015.0,58,20,7959,7971,10.1021/acs.jmedchem.5b00727,26426481.0,
15749962,CHEMBL3628116,"3-chloro-N-(3-chloro-4-(4-chloro-1,3-dioxoisoindolin-2-yl)phenyl)picolinamide",CHEMBL3631347,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,30000.0,nM,O=C(Nc1ccc(N2C(=O)c3cccc(Cl)c3C2=O)c(Cl)c1)c1ncccc1Cl,CHEMBL3627606,"Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.",J. Med. Chem.,2015.0,58,20,7959,7971,10.1021/acs.jmedchem.5b00727,26426481.0,
15752389,CHEMBL372199,"N-((syn)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)trifluoromethanesulfonamide",CHEMBL3630423,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) co-incubated with substrate and protein,IC50,<,300.0,nM,O=S(=O)(N[C@H]1CC[C@@](c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752390,CHEMBL3629736,"((6aR,10aS)-10a-(4-chlorophenylsulfonyl)-1,4-difluoro-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromene-7,7-diyl)dimethanol",CHEMBL3630423,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) co-incubated with substrate and protein,IC50,=,23400.0,nM,O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCCC(CO)(CO)[C@@H]1COc1c(F)ccc(F)c12,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752391,CHEMBL3629738,"(3'S,6aR,10aS)-10a-(4-chlorophenylsulfonyl)-1,4-difluoro-4',5',6,6a,8,9,10,10a-octahydro-2'H-spiro[benzo[c]chromene-7,3'-furan]",CHEMBL3630423,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) co-incubated with substrate and protein,IC50,>,20000.0,nM,O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCC[C@]3(CCOC3)[C@@H]1COc1c(F)ccc(F)c12,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752392,CHEMBL3629740,"(6aR,7S,10aS)-10a-((4-Chlorophenyl)sulfonyl)-1,4-difluoro-4',5',6,6a,8,9,10,10a-octahydro-2'H-spiro[benzo-[c]chromene-7,3'-furan]-2'-one",CHEMBL3630423,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) co-incubated with substrate and protein,IC50,>,30000.0,nM,O=C1OCC[C@]12CCC[C@@]1(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]21,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752393,CHEMBL3629741,"(6aR,10aS)-10a-(4-chlorophenyl)sulfonyl-1,4-difluoro-spiro[6a,8,9,10-tetrahydro-6H-benzo[c]chromene-7,4'-thiane]1',1'-dioxide",CHEMBL3630423,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) co-incubated with substrate and protein,IC50,>,20000.0,nM,O=S1(=O)CCC2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CC1,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752394,CHEMBL3629743,"(3'S,6aR,10aS)-10a-(4-chlorophenylsulfonyl)-1,4-difluoro-1'-(trifluoromethylsulfonyl)-6,6a,8,9,10,10a-hexahydrospiro[benzo[c]chromene-7,3'-pyrrolidine]",CHEMBL3630423,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) co-incubated with substrate and protein,IC50,>,30000.0,nM,O=S(=O)(N1CC[C@]2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)C1)C(F)(F)F,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752395,CHEMBL3629744,"(6aR,10aS)-10a-((4-Chlorophenyl)sulfonyl)-1,4-difluoro-2'-methyl-6,6a,8,9,10,10a-hexahydrospiro[benzo[c]-chromene-7,5'-[1,3,2]dioxaphosphinane]-2'-Oxide",CHEMBL3630423,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) co-incubated with substrate and protein,IC50,>,20000.0,nM,CP1(=O)OCC2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CO1,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752396,CHEMBL3629745,"(5S,6'aR,10'aS)-10'a-(4-chlorophenyl)sulfonyl-1',4'-difluoro-2-methyl-spiro[1,3,2$l'5-dioxaphosphepane-5,7'-6a,8,9,10-tetrahydro-6H-benzo[c]chromene]-2-oxide",CHEMBL3630423,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) co-incubated with substrate and protein,IC50,>,20000.0,nM,CP1(=O)OCC[C@]2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CO1,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752397,CHEMBL1090209,"N-((6aR,8R,10aS)-10a-(4-chlorophenylsulfonyl)-1,4-difluoro-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-8-yl)-1,1,1-trifluoromethanesulfonamide",CHEMBL3630423,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) co-incubated with substrate and protein,IC50,<,300.0,nM,O=S(=O)(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@H]2C1)C(F)(F)F,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752398,CHEMBL3627955,"N-(((4R,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)methyl)-1,1,1-trifluoromethanesulfonamide",CHEMBL3630423,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) co-incubated with substrate and protein,IC50,=,2500.0,nM,O=S(=O)(NC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C(F)(F)F,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752399,CHEMBL372199,"N-((syn)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)trifluoromethanesulfonamide",CHEMBL3630424,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,IC50,<,300.0,nM,O=S(=O)(N[C@H]1CC[C@@](c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752400,CHEMBL3629736,"((6aR,10aS)-10a-(4-chlorophenylsulfonyl)-1,4-difluoro-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromene-7,7-diyl)dimethanol",CHEMBL3630424,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,IC50,=,21100.0,nM,O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCCC(CO)(CO)[C@@H]1COc1c(F)ccc(F)c12,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752401,CHEMBL3629738,"(3'S,6aR,10aS)-10a-(4-chlorophenylsulfonyl)-1,4-difluoro-4',5',6,6a,8,9,10,10a-octahydro-2'H-spiro[benzo[c]chromene-7,3'-furan]",CHEMBL3630424,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,IC50,>,20000.0,nM,O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCC[C@]3(CCOC3)[C@@H]1COc1c(F)ccc(F)c12,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752402,CHEMBL3629740,"(6aR,7S,10aS)-10a-((4-Chlorophenyl)sulfonyl)-1,4-difluoro-4',5',6,6a,8,9,10,10a-octahydro-2'H-spiro[benzo-[c]chromene-7,3'-furan]-2'-one",CHEMBL3630424,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,IC50,>,30000.0,nM,O=C1OCC[C@]12CCC[C@@]1(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]21,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752403,CHEMBL3629741,"(6aR,10aS)-10a-(4-chlorophenyl)sulfonyl-1,4-difluoro-spiro[6a,8,9,10-tetrahydro-6H-benzo[c]chromene-7,4'-thiane]1',1'-dioxide",CHEMBL3630424,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,IC50,>,20000.0,nM,O=S1(=O)CCC2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CC1,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752404,CHEMBL3629743,"(3'S,6aR,10aS)-10a-(4-chlorophenylsulfonyl)-1,4-difluoro-1'-(trifluoromethylsulfonyl)-6,6a,8,9,10,10a-hexahydrospiro[benzo[c]chromene-7,3'-pyrrolidine]",CHEMBL3630424,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,IC50,>,30000.0,nM,O=S(=O)(N1CC[C@]2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)C1)C(F)(F)F,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752405,CHEMBL3629744,"(6aR,10aS)-10a-((4-Chlorophenyl)sulfonyl)-1,4-difluoro-2'-methyl-6,6a,8,9,10,10a-hexahydrospiro[benzo[c]-chromene-7,5'-[1,3,2]dioxaphosphinane]-2'-Oxide",CHEMBL3630424,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,IC50,>,20000.0,nM,CP1(=O)OCC2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CO1,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752406,CHEMBL3629745,"(5S,6'aR,10'aS)-10'a-(4-chlorophenyl)sulfonyl-1',4'-difluoro-2-methyl-spiro[1,3,2$l'5-dioxaphosphepane-5,7'-6a,8,9,10-tetrahydro-6H-benzo[c]chromene]-2-oxide",CHEMBL3630424,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,IC50,>,20000.0,nM,CP1(=O)OCC[C@]2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CO1,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752407,CHEMBL1090209,"N-((6aR,8R,10aS)-10a-(4-chlorophenylsulfonyl)-1,4-difluoro-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-8-yl)-1,1,1-trifluoromethanesulfonamide",CHEMBL3630424,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,IC50,<,300.0,nM,O=S(=O)(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@H]2C1)C(F)(F)F,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15752408,CHEMBL3627955,"N-(((4R,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)methyl)-1,1,1-trifluoromethanesulfonamide",CHEMBL3630424,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,IC50,=,4900.0,nM,O=S(=O)(NC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C(F)(F)F,CHEMBL3627709,"Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.",J. Med. Chem.,2015.0,58,22,8806,8817,10.1021/acs.jmedchem.5b00774,26496070.0,
15763012,CHEMBL3634394,"(Z)-(1S,4R,6S,18S)-18-[7-Methoxy-8-methyl-2-(4-trifluoromethyl-thiazol-2-yl)-quinolin-4-yloxy]-13-methyl-N-(1-methyl-cyclopropanesulfonyl)-2,14-dioxo-3,13,15-triaza-tricyclo[13.4.0.04,6]nonadec-7-ene-4-carboxamide",CHEMBL3637618,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>=,10000.0,nM,COc1ccc2c(O[C@H]3CCN4C(=O)N(C)CCCC/C=C/[C@@H]5C[C@@]5(C(=O)NS(=O)(=O)C5(C)CC5)NC(=O)[C@@H]4C3)cc(-c3nc(C(F)(F)F)cs3)nc2c1C,CHEMBL3632591,Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320.,Bioorg. Med. Chem. Lett.,2015.0,25,22,5427,5436,10.1016/j.bmcl.2015.09.009,26410074.0,
15766268,CHEMBL3634101,1-(6-(3-chlorobenzyloxy)quinazolin-7-yl)-3-(naphthalen-1-yl)urea,CHEMBL3636858,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using luciferin tagged substrate preincubated for 10 mins before substrate addition,IC50,>,10000.0,nM,O=C(Nc1cc2ncncc2cc1OCc1cccc(Cl)c1)Nc1cccc2ccccc12,CHEMBL3632488,Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).,Eur. J. Med. Chem.,2015.0,103,,210,222,10.1016/j.ejmech.2015.08.001,26355532.0,
15766269,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3636858,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using luciferin tagged substrate preincubated for 10 mins before substrate addition,IC50,=,80.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3632488,Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).,Eur. J. Med. Chem.,2015.0,103,,210,222,10.1016/j.ejmech.2015.08.001,26355532.0,
15766464,CHEMBL3633184,"Ethyl (1R,5S)-3-{[(3R)-3-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)pyrrolidin-1-yl]methyl}-8-azabicyclo[3.2.1]octane-8-carboxylate",CHEMBL3635141,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,2000.0,nM,CCOC(=O)N1[C@H]2CC[C@@H]1C[C@@H](CN1CC[C@@H](N3Cc4ccccc4NC3=O)C1)C2,CHEMBL3632469,"Discovery of dihydroquinazolinone derivatives as potent, selective, and CNS-penetrant M(1) and M(4) muscarinic acetylcholine receptors agonists.",Bioorg. Med. Chem. Lett.,2015.0,25,22,5357,5361,10.1016/j.bmcl.2015.09.032,26428869.0,
15767919,CHEMBL3633320,"2-(3-Nitro-1H-1,2,4-triazol-1-yl)-1-(4-(4-(trifluoromethyl)benzyl)piperazin-1-yl)ethanone",CHEMBL3637653,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human Liver microsomes after 5 mins by LC-MS/MS method,IC50,>,20000.0,nM,O=C(Cn1cnc([N+](=O)[O-])n1)N1CCN(Cc2ccc(C(F)(F)F)cc2)CC1,CHEMBL3632593,3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.,Eur. J. Med. Chem.,2015.0,103,,325,334,10.1016/j.ejmech.2015.08.042,26363868.0,
15767920,CHEMBL3633321,"1-(4-(3,4-Dichlorobenzyl)piperazin-1-yl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)ethanone",CHEMBL3637653,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human Liver microsomes after 5 mins by LC-MS/MS method,IC50,>,20000.0,nM,O=C(Cn1cnc([N+](=O)[O-])n1)N1CCN(Cc2ccc(Cl)c(Cl)c2)CC1,CHEMBL3632593,3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.,Eur. J. Med. Chem.,2015.0,103,,325,334,10.1016/j.ejmech.2015.08.042,26363868.0,
15772162,CHEMBL3633460,"2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide",CHEMBL3636696,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,100000.0,nM,COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O,CHEMBL3632461,"Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases.",J. Med. Chem.,2015.0,58,21,8513,8528,10.1021/acs.jmedchem.5b00963,26509551.0,
15772169,CHEMBL3633460,"2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide",CHEMBL3637256,A,,Homo sapiens,Cytochrome P450 2C9,Time-dependent inhibition of CYP2C9 in human liver microsomes,IC50,>,100000.0,nM,COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O,CHEMBL3632461,"Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases.",J. Med. Chem.,2015.0,58,21,8513,8528,10.1021/acs.jmedchem.5b00963,26509551.0,
15775185,CHEMBL3633943,"1-(2-(phenoxymethyl)-6,7-dihydropyrazolo[1,5-a]pyrimidin-4(5H)-yl)ethanone",CHEMBL3636981,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,CC(=O)N1CCCn2nc(COc3ccccc3)cc21,CHEMBL3632544,"Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators.",Bioorg. Med. Chem. Lett.,2015.0,25,22,5115,5120,10.1016/j.bmcl.2015.10.009,26475522.0,
15775660,CHEMBL3634013,"(S)-N-(1-(4-methoxyphenyl)ethyl)-2-(1-methyl-3-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-6-yloxy)acetamide",CHEMBL3635621,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5000.0,nM,COc1ccc([C@H](C)NC(=O)COc2cc(C(F)(F)F)c3c(-c4ccccc4)nn(C)c3n2)cc1,CHEMBL3632504,"Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs).",Bioorg. Med. Chem. Lett.,2015.0,25,23,5555,5560,10.1016/j.bmcl.2015.10.055,26522950.0,
15775661,CHEMBL3634015,"(S)-N-(1-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl)-2-(1-methyl-3-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-6-yloxy)acetamide",CHEMBL3635621,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,Cc1n[nH]c(C)c1[C@H](C)NC(=O)COc1cc(C(F)(F)F)c2c(-c3ccccc3)nn(C)c2n1,CHEMBL3632504,"Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs).",Bioorg. Med. Chem. Lett.,2015.0,25,23,5555,5560,10.1016/j.bmcl.2015.10.055,26522950.0,
16259837,CHEMBL3645215,"US8546392, 19",CHEMBL3707849,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assay: Inhibition assay using P450 CYP enzymes.,IC50,=,1050.0,nM,CCOC(=O)/C=C/c1c(OC)ccc2cc(-c3cccc(OC)c3)ccc12,CHEMBL3638998,17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases,,2013.0,,,,,,,US-8546392-B2
16263986,CHEMBL157101,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",CHEMBL3707485,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.",IC50,=,40000.0,nM,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,CHEMBL3638942,Metalloenzyme inhibitor compounds,,2015.0,,,,,,,US-8987315-B2
16264677,CHEMBL3673964,"US9096593, P-2052",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,=,5000.0,nM,COc1ncccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16267777,CHEMBL3673982,"US9096593, P-2193",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,>,10000.0,nM,COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C#N)cc23)c(F)n1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16269038,CHEMBL3699081,"US8883797, 9",CHEMBL3706057,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 μM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 μM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 μM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 μM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.",IC50,=,13000.0,nM,OC(Cn1cnnc1)(c1ccc(F)cc1F)C(F)(F)c1ccc2cc(Br)ccc2n1,CHEMBL3638936,Metalloenzyme inhibitor compounds,,2014.0,,,,,,,US-8883797-B2
16269154,CHEMBL3673957,"US9096593, P-1562",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cc2F)cn1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16270120,CHEMBL3311223,"4-(6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)benzonitrile",CHEMBL3705202,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",IC50,>,60000.0,nM,N#Cc1ccc(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cc1,CHEMBL3638495,Metalloenzyme inhibitor compounds,,2014.0,,,,,,,US-8754227-B2
16272449,CHEMBL3680984,"US8754227, 17",CHEMBL3705202,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",IC50,=,40000.0,nM,OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1,CHEMBL3638495,Metalloenzyme inhibitor compounds,,2014.0,,,,,,,US-8754227-B2
16273161,CHEMBL3673937,"US9096593, P-2097",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(OC)n1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16274285,CHEMBL3673963,"US9096593, P-2048",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,>,10000.0,nM,COc1cnc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cc1F,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16275748,CHEMBL3682506,"US8987315, 3",CHEMBL3707485,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.",IC50,=,4800.0,nM,COc1cc2ccc(C(C(C)C)n3ncnn3)cc2cc1OC,CHEMBL3638942,Metalloenzyme inhibitor compounds,,2015.0,,,,,,,US-8987315-B2
16276013,CHEMBL3673979,"US9096593, P-2172",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,=,5000.0,nM,Fc1cc(Cc2c[nH]c3ncc(Cl)cc23)cnc1NCc1ccc(C(F)(F)F)nc1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16276933,CHEMBL3669004,"US9096593, P-2082",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCCC5)n4)nc3)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16277581,CHEMBL3680983,"US8754227, 16",CHEMBL3705202,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",IC50,=,4300.0,nM,OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(F)cc2)cn1,CHEMBL3638495,Metalloenzyme inhibitor compounds,,2014.0,,,,,,,US-8754227-B2
16279266,CHEMBL3264597,"rac-1-(6,7-dimethoxynaphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol",CHEMBL3707923,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target and clinical indication is critical. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available prostate anticancer agent ketoconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-imidazole to iron in the active site of CYP2C9, CYP2C19 and CYP3A4.",IC50,=,39000.0,nM,COc1cc2ccc(C(O)(c3cnn[nH]3)C(C)C)cc2cc1OC,CHEMBL3638860,Metalloenzyme inhibitor compounds,,2014.0,,,,,,,US-8623892-B2
16279781,CHEMBL3673960,"US9096593, P-2043",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,=,5000.0,nM,COc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4OC)nc3F)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16280715,CHEMBL3673936,"US9096593, P-2088",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16283774,CHEMBL3673978,"US9096593, P-2165",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,>,10000.0,nM,COc1ncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)cc1F,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16284400,CHEMBL3669003,"US9096593, P-2081",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCOCC5)n4)nc3)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16286786,CHEMBL3673947,"US9096593, P-2031",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3F)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16286822,CHEMBL1650646,6-(3-hydroxyphenyl)-1-(6-methoxypyridin-3-yl)naphthalen-2-ol,CHEMBL3707849,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assay: Inhibition assay using P450 CYP enzymes.,IC50,=,224.0,nM,COc1ccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)cn1,CHEMBL3638998,17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases,,2013.0,,,,,,,US-8546392-B2
16288764,CHEMBL3669005,"US9096593, P-2139",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,=,5000.0,nM,COc1ncccc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16289655,CHEMBL3673940,"US9096593, P-2131",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,Cc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)nc1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16290907,CHEMBL3311224,"2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)propan-2-ol",CHEMBL3705202,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",IC50,>,60000.0,nM,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(C(F)(F)F)cc2)cn1,CHEMBL3638495,Metalloenzyme inhibitor compounds,,2014.0,,,,,,,US-8754227-B2
16293957,CHEMBL3669002,"US9096593, P-2079",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,=,5000.0,nM,Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(C)n4)nc3)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16294316,CHEMBL3673953,"US9096593, P-1669",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(NC(C)=O)cc23)c(F)n1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16295255,CHEMBL3673934,"US9096593, P-2061",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,=,5000.0,nM,COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16297490,CHEMBL638,"(2R,3S)-2-(2,4-Difluoro-phenyl)-3-(5-fluoro-pyrimidin-4-yl)-1-[1,2,4]triazol-1-yl-butan-2-ol",CHEMBL3706057,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 μM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 μM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 μM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 μM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.",IC50,=,14000.0,nM,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,CHEMBL3638936,Metalloenzyme inhibitor compounds,,2014.0,,,,,,,US-8883797-B2
16297548,CHEMBL3673938,"US9096593, P-2103",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,Cc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4F)nc3F)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16298779,CHEMBL3264605,"rac-1-(6,7-bis(difluoromethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol",CHEMBL3707923,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target and clinical indication is critical. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available prostate anticancer agent ketoconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-imidazole to iron in the active site of CYP2C9, CYP2C19 and CYP3A4.",IC50,=,12000.0,nM,CC(C)C(O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1cnn[nH]1,CHEMBL3638860,Metalloenzyme inhibitor compounds,,2014.0,,,,,,,US-8623892-B2
16300060,CHEMBL3673946,"US9096593, P-2030",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(OC)nc4)nc3F)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16300498,CHEMBL3673976,"US9096593, P-2157",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,>,10000.0,nM,Cn1cc(F)cc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)c1=O,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16301450,CHEMBL3673966,"US9096593, P-2062",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,Cc1cnc2[nH]cc(Cc3ccc(NCc4cnccc4C(F)(F)F)nc3F)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16304064,CHEMBL3673945,"US9096593, P-2029",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cn1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16306934,CHEMBL3673965,"US9096593, P-2057",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,=,5000.0,nM,COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cn1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16308830,CHEMBL3673959,"US9096593, P-2038",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,=,5000.0,nM,COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16312360,CHEMBL3673973,"US9096593, P-2146",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,=,5000.0,nM,Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16312422,CHEMBL3645217,"US8546392, 59",CHEMBL3707849,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assay: Inhibition assay using P450 CYP enzymes.,IC50,=,150.0,nM,O=C(O)CCC(=O)Nc1ccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)cc1,CHEMBL3638998,17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases,,2013.0,,,,,,,US-8546392-B2
16313426,CHEMBL3673967,"US9096593, P-2063",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,>,10000.0,nM,FC(F)(F)c1ccncc1CNc1ccc(Cc2c[nH]c3ncc(Cl)cc23)cn1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16314011,CHEMBL3682507,"US8987315, 4",CHEMBL3707485,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.",IC50,=,15000.0,nM,CC(C)C(c1ccc2cc(OC(F)F)ccc2c1)n1ncnn1,CHEMBL3638942,Metalloenzyme inhibitor compounds,,2015.0,,,,,,,US-8987315-B2
16317224,CHEMBL3673952,"US9096593, P-2019",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16318103,CHEMBL3673943,"US9096593, P-2001",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,=,5000.0,nM,Fc1cncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16319167,CHEMBL3672841,"US9006242, 2",CHEMBL3707843,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: The potential inhibition of enzyme activities of human cytochromes P450 (CYP) of Compound 1, 2, or 105 was evaluated using pooled human liver microsomes.Methods: The competitive inhibition potential of Compounds 1, 2, and 105 was determined by assessing at multiple concentrations on probe CYP reactions near their respective Km values to create IC50 curves in human liver microsomes (HLM). The time-dependent inactivation (TDI) potential was also assessed for CYP3A4/5 by evaluating KI and kinact values when appropriate.A suspension containing PB, HLM, CYP-selective probe substrate, and the inhibitor being tested was added to a 96-well plate. The plates were preincubated in a 37Â° C. water bath for approximately 2 minutes. The reaction was initiated by the addition of NADPH to each well of the 96-well plate. The final concentrations for PB, HLM, and NADPH were 100 mmol/L (pH 7.4), 0.1 mg/mL, and 2.3 mmol/L, respectively. The CYP probe substrates and CYP inhibitors used as positive controls.",IC50,>,100000.0,nM,CCN(c1cc(C#CCN2CCOCC2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)[C@H]1CC[C@H](N(C)CCOC)CC1,CHEMBL3638403,Substituted benzene compounds,,2015.0,,,,,,,US-9006242-B2
16319816,CHEMBL3673958,"US9096593, P-2037",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,COc1ccnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c12,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16321558,CHEMBL3673935,"US9096593, P-2064",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,=,5000.0,nM,COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(Cl)cc23)cn1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16322031,CHEMBL3673980,"US9096593, P-2003",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,Clc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16322100,CHEMBL3673971,"US9096593, P-2073",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,COc1ncc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cc1F,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16322862,CHEMBL3682505,"US8987315, 2",CHEMBL3707485,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.",IC50,=,27000.0,nM,CC(C)C(c1ccc2cc(OCC(F)(F)F)ccc2c1)n1ncnn1,CHEMBL3638942,Metalloenzyme inhibitor compounds,,2015.0,,,,,,,US-8987315-B2
16323535,CHEMBL3673944,"US9096593, P-2028",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,COc1cnc2[nH]cc(Cc3ccc(NCc4cncc(F)c4)nc3F)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16325218,CHEMBL3673954,"US9096593, P-1679",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,CS(=O)(=O)Nc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16326678,CHEMBL3673941,"US9096593, P-2198",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,=,5000.0,nM,CCS(=O)(=O)Nc1ccccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16326695,CHEMBL3673974,"US9096593, P-2147",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,>,10000.0,nM,COc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16327244,CHEMBL1650658,N-{3-[2-Hydroxy-6-(3-hydroxyphenyl)-1-naphthyl]phenyl}-methanesulfonamide,CHEMBL3707849,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assay: Inhibition assay using P450 CYP enzymes.,IC50,=,1250.0,nM,CS(=O)(=O)Nc1cccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)c1,CHEMBL3638998,17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases,,2013.0,,,,,,,US-8546392-B2
16328674,CHEMBL3669001,"US9096593, P-2078",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(Cl)nc4)nc3)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16331591,CHEMBL3673948,"US9096593, P-2032",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16332502,CHEMBL3673970,"US9096593, P-2071",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,=,5000.0,nM,COc1cc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(F)cn1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16335821,CHEMBL3639728,"US9096593, P-2049",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,=,5000.0,nM,COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16335876,CHEMBL3699082,"US8883797, 10",CHEMBL3706057,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 μM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 μM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 μM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 μM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.",IC50,=,42000.0,nM,OC(Cn1cnnc1)(c1ccc(F)cc1F)C(F)(F)c1cnc2cc(Cl)ccc2n1,CHEMBL3638936,Metalloenzyme inhibitor compounds,,2014.0,,,,,,,US-8883797-B2
16336105,CHEMBL3689756,"US8623892, 2",CHEMBL3707923,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target and clinical indication is critical. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available prostate anticancer agent ketoconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-imidazole to iron in the active site of CYP2C9, CYP2C19 and CYP3A4.",IC50,=,33000.0,nM,COc1cc2cnc(C(O)(c3cnn[nH]3)C(C)C)cc2cc1OC,CHEMBL3638860,Metalloenzyme inhibitor compounds,,2014.0,,,,,,,US-8623892-B2
16336796,CHEMBL106,"2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol",CHEMBL3706057,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 μM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 μM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 μM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 μM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.",IC50,=,29000.0,nM,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,CHEMBL3638936,Metalloenzyme inhibitor compounds,,2014.0,,,,,,,US-8883797-B2
16337610,CHEMBL3672842,"US9006242, 105",CHEMBL3707843,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: The potential inhibition of enzyme activities of human cytochromes P450 (CYP) of Compound 1, 2, or 105 was evaluated using pooled human liver microsomes.Methods: The competitive inhibition potential of Compounds 1, 2, and 105 was determined by assessing at multiple concentrations on probe CYP reactions near their respective Km values to create IC50 curves in human liver microsomes (HLM). The time-dependent inactivation (TDI) potential was also assessed for CYP3A4/5 by evaluating KI and kinact values when appropriate.A suspension containing PB, HLM, CYP-selective probe substrate, and the inhibitor being tested was added to a 96-well plate. The plates were preincubated in a 37Â° C. water bath for approximately 2 minutes. The reaction was initiated by the addition of NADPH to each well of the 96-well plate. The final concentrations for PB, HLM, and NADPH were 100 mmol/L (pH 7.4), 0.1 mg/mL, and 2.3 mmol/L, respectively. The CYP probe substrates and CYP inhibitors used as positive controls.",IC50,=,75660.0,nM,CCN(c1cc(C#CC2CCN(C)CC2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,CHEMBL3638403,Substituted benzene compounds,,2015.0,,,,,,,US-9006242-B2
16339361,CHEMBL3673968,"US9096593, P-2067",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(C)c4)nc3F)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16341730,CHEMBL3673950,"US9096593, P-1622",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,=,5000.0,nM,COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(F)cc34)c(F)n2)cn1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16346632,CHEMBL3680985,"US8754227, 18",CHEMBL3705202,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",IC50,=,3100.0,nM,OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OC(F)(F)F)cc2)cn1,CHEMBL3638495,Metalloenzyme inhibitor compounds,,2014.0,,,,,,,US-8754227-B2
16349001,CHEMBL3673962,"US9096593, P-2045",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,>,10000.0,nM,COc1ncccc1CNc1ccc(Cc2c[nH]c3ncccc23)c(F)n1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16349840,CHEMBL3672840,"US9006242, 1",CHEMBL3707843,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: The potential inhibition of enzyme activities of human cytochromes P450 (CYP) of Compound 1, 2, or 105 was evaluated using pooled human liver microsomes.Methods: The competitive inhibition potential of Compounds 1, 2, and 105 was determined by assessing at multiple concentrations on probe CYP reactions near their respective Km values to create IC50 curves in human liver microsomes (HLM). The time-dependent inactivation (TDI) potential was also assessed for CYP3A4/5 by evaluating KI and kinact values when appropriate.A suspension containing PB, HLM, CYP-selective probe substrate, and the inhibitor being tested was added to a 96-well plate. The plates were preincubated in a 37Â° C. water bath for approximately 2 minutes. The reaction was initiated by the addition of NADPH to each well of the 96-well plate. The final concentrations for PB, HLM, and NADPH were 100 mmol/L (pH 7.4), 0.1 mg/mL, and 2.3 mmol/L, respectively. The CYP probe substrates and CYP inhibitors used as positive controls.",IC50,>,100000.0,nM,CCN(c1cc(-c2ccc(OCCOC)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)[C@H]1CC[C@H](N(C)C)CC1,CHEMBL3638403,Substituted benzene compounds,,2015.0,,,,,,,US-9006242-B2
16351118,CHEMBL3645225,"US8546392, 70",CHEMBL3707849,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assay: Inhibition assay using P450 CYP enzymes.,IC50,=,30.0,nM,CNC(=O)/C=C/c1cc(OC)cc(-c2ccc3cc(OC)ccc3c2)c1,CHEMBL3638998,17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases,,2013.0,,,,,,,US-8546392-B2
16352327,CHEMBL3673981,"US9096593, P-2004",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,Fc1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16352344,CHEMBL3673972,"US9096593, P-2075",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,<,5000.0,nM,Cc1cc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)ccn1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16352483,CHEMBL3682508,"US8987315, 1",CHEMBL3707485,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.",IC50,=,7000.0,nM,CC(C)C(O)c1ccc2cc(OCC(F)(F)F)ccc2c1,CHEMBL3638942,Metalloenzyme inhibitor compounds,,2015.0,,,,,,,US-8987315-B2
16357017,CHEMBL3673939,"US9096593, P-2118",CHEMBL3707726,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",IC50,=,5000.0,nM,Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(F)c4)nc3F)c2c1,CHEMBL3639021,"Compounds and methods for kinase modulation, and indications therefor",,2015.0,,,,,,,US-9096593-B2
16386278,CHEMBL3734797,"N-tert-butyl-8-(((trans)-2-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropanecarboxamido)methyl)-5-(3-(trifluoromethoxy)phenyl)-3,4-dihydroisoquinoline-2(1H)-carboxamide",CHEMBL3737864,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1500.0,nM,Cc1noc([C@H]2C[C@@H]2C(=O)NCc2ccc(-c3cccc(OC(F)(F)F)c3)c3c2CN(C(=O)NC(C)(C)C)CC3)n1,CHEMBL3734691,Discovery and Pharmacology of a Novel Class of Diacylglycerol Acyltransferase 2 Inhibitors.,J. Med. Chem.,2015.0,58,23,9345,9353,10.1021/acs.jmedchem.5b01345,26561979.0,
16387533,CHEMBL27,1-Isopropylamino-3-(naphthalen-1-yloxy)-propan-2-ol,CHEMBL3738823,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by LC-MS analysis,IC50,>,10000.0,nM,CC(C)NCC(O)COc1cccc2ccccc12,CHEMBL3734721,Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.,J. Med. Chem.,2015.0,58,23,9287,9295,10.1021/acs.jmedchem.5b01088,26565745.0,
16387534,CHEMBL3736433,"1-Isopropylamino-3-((2-methyl-1,2-dihydro-benzo[e][1,2]-azaborinin-8-yl)oxy)-propan-2-ol",CHEMBL3738823,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by LC-MS analysis,IC50,>,10000.0,nM,CB1C=Cc2cccc(OCC(O)CN(C)C)c2N1,CHEMBL3734721,Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.,J. Med. Chem.,2015.0,58,23,9287,9295,10.1021/acs.jmedchem.5b01088,26565745.0,
16387535,CHEMBL3736156,"1-Isopropyfamino-3-((2-methyl-1,2-dihydro-benzo[e][1,2]-azaborinin-5-yl)oxy)-propan-2-ol",CHEMBL3738823,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by LC-MS analysis,IC50,>,10000.0,nM,CB1C=Cc2c(cccc2OCC(O)CN(C)C)N1,CHEMBL3734721,Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.,J. Med. Chem.,2015.0,58,23,9287,9295,10.1021/acs.jmedchem.5b01088,26565745.0,
16402052,CHEMBL3740099,"2-(5,6-Dimethoxypyridin-3-yl)-4-(2,4,6-trifluorobenzyl)-2H-pyrido[2,3-e][1,2,4]thiadiazin-3(4H)-one 1,1-dioxide",CHEMBL3742906,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,COc1cc(N2C(=O)N(Cc3c(F)cc(F)cc3F)c3ncccc3S2(=O)=O)cnc1OC,CHEMBL3739366,"Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties",MedChemComm,2015.0,6,5,947,955,10.1039/C5MD00027K,,
16404953,CHEMBL3740684,"(S)-4-(4-Fluorophenyl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridine-3-carboxylic Acid [4-Fluoro-2-methyl-5-(2-methyl-3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-amide",CHEMBL3744574,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,32000.0,nM,Cc1cc(F)c(-c2ccnn(C)c2=O)cc1NC(=O)C1=CN(C)C(=O)C[C@H]1c1ccc(F)cc1,CHEMBL3739255,Novel Series of Dihydropyridinone P2X7 Receptor Antagonists.,J. Med. Chem.,2015.0,58,21,8413,8426,10.1021/acs.jmedchem.5b00365,26460788.0,
16405817,CHEMBL3739741,"(4S)-4-(4-Fluorophenyl)-N-[5-[4-[(2R)-2-hydroxy-3-methoxy-propyl]-3,5-dioxo-1,2,4-triazin-2-yl]-2-methyl-phenyl]-1-methyl-2-oxo-3,4-dihydropyridine-5-carboxamide",CHEMBL3744574,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence assay,IC50,>,50000.0,nM,COC[C@H](O)Cn1c(=O)cnn(-c2ccc(C)c(NC(=O)C3=CN(C)C(=O)C[C@H]3c3ccc(F)cc3)c2)c1=O,CHEMBL3739255,Novel Series of Dihydropyridinone P2X7 Receptor Antagonists.,J. Med. Chem.,2015.0,58,21,8413,8426,10.1021/acs.jmedchem.5b00365,26460788.0,
16406252,CHEMBL3597017,4-hydroxy-6-isobutyl-3-phenylpyridin-2(1H)-one,CHEMBL3743595,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(C)Cc1cc(O)c(-c2ccccc2)c(=O)[nH]1,CHEMBL3739268,Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents.,Eur. J. Med. Chem.,2015.0,106,,144,156,10.1016/j.ejmech.2015.10.008,26544629.0,
16406918,CHEMBL3741915,"(E)-4-(1-((3-Fluoro-N,4-dimethylphenyl)sulfonamido)-cyclopropane-1-carboxamido)adamantane-1-carboxamide",CHEMBL3744157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1ccc(S(=O)(=O)N(C)C2(C(=O)N[C@H]3C4CC5CC3C[C@](C(N)=O)(C5)C4)CC2)cc1F,CHEMBL3739263,Synthesis and biological evaluation of -sulfonamido-N-adamantanecarboxamide derivatives as 11-HSD1 inhibitors,MedChemComm,2015.0,6,7,1360,1369,10.1039/C5MD00096C,,
16410020,CHEMBL3740325,"3-(3-(3-chlorophenyl)-1-naphthamido)-2,4-dimethylbenzoic acid",CHEMBL3744270,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(C(=O)O)c(C)c1NC(=O)c1cc(-c2cccc(Cl)c2)cc2ccccc12,CHEMBL3739413,"Discovery of substituted-2,4-dimethyl-(naphthalene-4-carbonyl)amino-benzoic acid as potent and selective EP4 antagonists.",Bioorg. Med. Chem. Lett.,2016.0,26,1,105,109,10.1016/j.bmcl.2015.11.023,26608552.0,
16411243,CHEMBL3742347,7-Nitro-2-(piperidine-1-carbonyl)-5-(trifluoromethyl)benzo[d]thiazole 3-oxide,CHEMBL3742593,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by fluorescence assay,IC50,=,26600.0,nM,O=C(c1sc2c([N+](=O)[O-])cc(C(F)(F)F)cc2[n+]1[O-])N1CCCCC1,CHEMBL3739380,"Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.",Bioorg. Med. Chem.,2015.0,23,24,7694,7710,10.1016/j.bmc.2015.11.017,26643218.0,
16412426,CHEMBL3739863,"(S)-(2-(7-Nitro-5-(trifluoromethyl)benzo[d]thiazol-2-yl)-4,5-dihydrooxazol-4-yl)(pyrrolidin-1-yl)methanone",CHEMBL3742593,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by fluorescence assay,IC50,=,12400.0,nM,O=C([C@@H]1COC(c2nc3cc(C(F)(F)F)cc([N+](=O)[O-])c3s2)=N1)N1CCCC1,CHEMBL3739380,"Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.",Bioorg. Med. Chem.,2015.0,23,24,7694,7710,10.1016/j.bmc.2015.11.017,26643218.0,
16412446,CHEMBL3739831,"(S)-(2-(6-Methyl-7-nitro-5-(trifluoromethyl)benzo[d]thiazol-2-yl)-4,5-dihydrooxazol-4-yl)(pyrrolidin-1-yl)methanone",CHEMBL3742593,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 by fluorescence assay,IC50,=,22100.0,nM,Cc1c(C(F)(F)F)cc2nc(C3=N[C@H](C(=O)N4CCCC4)CO3)sc2c1[N+](=O)[O-],CHEMBL3739380,"Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.",Bioorg. Med. Chem.,2015.0,23,24,7694,7710,10.1016/j.bmc.2015.11.017,26643218.0,
16421553,CHEMBL3665949,"US8785467, 1-39",CHEMBL3750735,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5200.0,nM,Cc1c(Cl)nc(OC[C@H]2C[C@@H]2c2ccccn2)nc1NCc1cnn(C)c1,CHEMBL3745609,Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.,Bioorg. Med. Chem. Lett.,2016.0,26,1,126,132,10.1016/j.bmcl.2015.11.013,26602277.0,
16422258,CHEMBL3622898,"6-chloro-N-((2,4-dimethylthiazol-5-yl)methyl)-5-methyl-2-(3-(quinolin-2-yl)propoxy)pyrimidin-4-amine",CHEMBL3750735,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,300.0,nM,Cc1nc(C)c(CNc2nc(OCCCc3ccc4ccccc4n3)nc(Cl)c2C)s1,CHEMBL3745609,Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.,Bioorg. Med. Chem. Lett.,2016.0,26,1,126,132,10.1016/j.bmcl.2015.11.013,26602277.0,
16427056,CHEMBL3746457,"5-(5-fluoropyridin-2-yl)-2-(phenoxymethyl)-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one",CHEMBL3749960,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>=,30000.0,nM,O=C1c2cc(COc3ccccc3)nn2CCN1c1ccc(F)cn1,CHEMBL3745662,"Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia.",Bioorg. Med. Chem. Lett.,2016.0,26,2,429,434,10.1016/j.bmcl.2015.11.098,26684851.0,
16437967,CHEMBL3754085,"3-(6-(3-(hydroxymethyl)phenyl)-3-methylpicolinamido)-2,4-dimethylbenzoic acid",CHEMBL3754943,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(-c2cccc(CO)c2)nc1C(=O)Nc1c(C)ccc(C(=O)O)c1C,CHEMBL3751833,"Discovery of potent aryl-substituted 3-[(3-methylpyridine-2-carbonyl) amino]-2,4-dimethyl-benzoic acid EP4 antagonists with improved pharmacokinetic profile.",Bioorg. Med. Chem. Lett.,2016.0,26,3,931,935,10.1016/j.bmcl.2015.12.057,26764191.0,
16446799,CHEMBL3753341,"3-(5-Cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-4-amine",CHEMBL3756054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,CC(C)n1nc(-c2cc(C3CC3)on2)c2c(N)ncnc21,CHEMBL3751668,"A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.",J. Med. Chem.,2016.0,59,1,358,373,10.1021/acs.jmedchem.5b01522,26652860.0,
16456377,CHEMBL3758746,"N-(2-fluoro-4-(5-methyl-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide",CHEMBL3762442,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1ccc2c(c1)C(=O)N(c1ccc(NC(=O)c3occc3C)c(F)c1)C2=O,CHEMBL3758107,Lead optimization of the VU0486321 series of mGlu(1) PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool.,Bioorg. Med. Chem. Lett.,2016.0,26,3,751,756,10.1016/j.bmcl.2015.12.104,26778256.0,
16456378,CHEMBL3758305,"N-(2-fluoro-4-(4-methyl-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide",CHEMBL3762442,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3cccc(C)c3C2=O)cc1F,CHEMBL3758107,Lead optimization of the VU0486321 series of mGlu(1) PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool.,Bioorg. Med. Chem. Lett.,2016.0,26,3,751,756,10.1016/j.bmcl.2015.12.104,26778256.0,
16456379,CHEMBL3759901,"N-(4-(5-chloro-1,3-dioxoisoindolin-2-yl)-2-fluorophenyl)-3-methylfuran-2-carboxamide",CHEMBL3762442,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccc(Cl)cc3C2=O)cc1F,CHEMBL3758107,Lead optimization of the VU0486321 series of mGlu(1) PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool.,Bioorg. Med. Chem. Lett.,2016.0,26,3,751,756,10.1016/j.bmcl.2015.12.104,26778256.0,
16456380,CHEMBL3758435,"N-(2-fluoro-4-(5-fluoro-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide",CHEMBL3762442,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccc(F)cc3C2=O)cc1F,CHEMBL3758107,Lead optimization of the VU0486321 series of mGlu(1) PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool.,Bioorg. Med. Chem. Lett.,2016.0,26,3,751,756,10.1016/j.bmcl.2015.12.104,26778256.0,
16456381,CHEMBL3758465,"N-(2-fluoro-4-(4-fluoro-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide",CHEMBL3762442,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3cccc(F)c3C2=O)cc1F,CHEMBL3758107,Lead optimization of the VU0486321 series of mGlu(1) PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool.,Bioorg. Med. Chem. Lett.,2016.0,26,3,751,756,10.1016/j.bmcl.2015.12.104,26778256.0,
16457941,CHEMBL3759468,"N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide",CHEMBL3762414,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction of diclofenac metabolism after 8 mins,IC50,>,30000.0,nM,COc1cc(CNC(=O)c2cc(-c3nnn(C[C@H]4CO[C@H](CO)CO4)n3)nc(C)n2)ccc1F,CHEMBL3758105,"Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.",J. Med. Chem.,2016.0,59,1,313,327,10.1021/acs.jmedchem.5b01434,26653735.0,
16464551,CHEMBL111201,N-{4-[2-((R)-2-Hydroxy-2-pyridin-3-yl-ethylamino)-ethyl]-phenyl}-4-[4-(4-trifluoromethyl-phenyl)-thiazol-2-yl]-benzenesulfonamide,CHEMBL3767772,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac alpha'-hydroxylation,IC50,=,24000.0,nM,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1,CHEMBL3763146,Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,2016.0,59,2,609,623,10.1021/acs.jmedchem.5b01372,26709102.0,
16464552,CHEMBL1684585,"2-(2-aminothiazol-4-yl)-N-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)acetamide",CHEMBL3767772,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac alpha'-hydroxylation,IC50,>,100000.0,nM,Nc1nc(CC(=O)Nc2ccc(C[C@@H]3CC[C@H]([C@H](O)c4ccccc4)N3)cc2)cs1,CHEMBL3763146,Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,2016.0,59,2,609,623,10.1021/acs.jmedchem.5b01372,26709102.0,
16464553,CHEMBL3128178,"(R)-N-(4-(((2S,5R)-5-((R)-Hydroxy(pyridin-3-yl)methyl)-pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4H-cyclopenta[d]-thiazole-4-carboxamide",CHEMBL3767772,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac alpha'-hydroxylation,IC50,>,100000.0,nM,O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2scnc21,CHEMBL3763146,Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,2016.0,59,2,609,623,10.1021/acs.jmedchem.5b01372,26709102.0,
16464554,CHEMBL3128188,"(S)-N-(4-(((2S,5R)-5-((R)-Hydroxy(pyridin-3-yl)methyl)-pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]-pyrazole-6-carboxamide",CHEMBL3767772,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac alpha'-hydroxylation,IC50,>,100000.0,nM,O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2ccnn21,CHEMBL3763146,Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,2016.0,59,2,609,623,10.1021/acs.jmedchem.5b01372,26709102.0,
16464555,CHEMBL3764774,"N-(4-(((2S,5R)-5-((R)-Hydroxy(phenyl)methyl)pyrrolidin-2-yl)-methyl)phenyl)-2-(4-oxoquinazolin-3(4H)-yl)acetamide",CHEMBL3767772,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac alpha'-hydroxylation,IC50,>,100000.0,nM,O=C(Cn1cnc2ccccc2c1=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1,CHEMBL3763146,Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,2016.0,59,2,609,623,10.1021/acs.jmedchem.5b01372,26709102.0,
16464556,CHEMBL3764088,"N-(4-(((2S,5R)-5-((R)-Hydroxy(phenyl)methyl)pyrrolidin-2-yl)-methyl)phenyl)-2-(6-oxopyridazin-1(6H)-yl)acetamide",CHEMBL3767772,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac alpha'-hydroxylation,IC50,>,100000.0,nM,O=C(Cn1ncccc1=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1,CHEMBL3763146,Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,2016.0,59,2,609,623,10.1021/acs.jmedchem.5b01372,26709102.0,
16464557,CHEMBL3763594,"N-(4-(((2S,5R)-5-((R)-Hydroxy(phenyl)methyl)pyrrolidin-2-yl)-methyl)phenyl)-2-(2-oxopyrimidin-1(2H)-yl)acetamide",CHEMBL3767772,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac alpha'-hydroxylation,IC50,>,100000.0,nM,O=C(Cn1cccnc1=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1,CHEMBL3763146,Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,2016.0,59,2,609,623,10.1021/acs.jmedchem.5b01372,26709102.0,
16464558,CHEMBL2107826,VIBEGRON,CHEMBL3767772,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as diclofenac alpha'-hydroxylation,IC50,>,100000.0,nM,O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2nccc(=O)n21,CHEMBL3763146,Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.,J. Med. Chem.,2016.0,59,2,609,623,10.1021/acs.jmedchem.5b01372,26709102.0,
16480351,CHEMBL3765754,"(rac)-2-(4-fluorophenyl)-4-(3-(4-methyl-5-(4-methyloxazol-5-yl)-4H-1,2,4-triazol-3-ylthio)propyl)morpholine",CHEMBL3768216,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in bactosome,IC50,>,30000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CCOC(c3ccc(F)cc3)C2)n1C,CHEMBL3763143,Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists.,Bioorg. Med. Chem. Lett.,2016.0,26,4,1329,1332,10.1016/j.bmcl.2015.12.081,26786693.0,
16480352,CHEMBL3764557,"(rac)-4-(3-(4-methyl-5-(4-methyloxazol-5-yl)-4H-1,2,4-triazol-3-ylthio)propyl)-2-(4-(trifluoromethyl)phenyl)morpholine",CHEMBL3768216,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in bactosome,IC50,>,6000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)n1C,CHEMBL3763143,Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists.,Bioorg. Med. Chem. Lett.,2016.0,26,4,1329,1332,10.1016/j.bmcl.2015.12.081,26786693.0,
16480353,CHEMBL3765426,"(rac)-4-(4-methyl-5-(3-(2-(4-(trifluoromethyl)phenyl)morpholino)propylthio)-4H-1,2,4-triazol-3-yl)benzamide",CHEMBL3768216,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in bactosome,IC50,>,30000.0,nM,Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C(N)=O)cc1,CHEMBL3763143,Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists.,Bioorg. Med. Chem. Lett.,2016.0,26,4,1329,1332,10.1016/j.bmcl.2015.12.081,26786693.0,
16480354,CHEMBL3764143,"(rac)-2-(4-(trifluoromethyl)phenyl)-4-(3-(4-methyl-5-(4-(oxazol-2-yl)phenyl)-4H-1,2,4-triazol-3-ylthio)propyl)morpholine",CHEMBL3768216,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in bactosome,IC50,>,3000.0,nM,Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(-c2ncco2)cc1,CHEMBL3763143,Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists.,Bioorg. Med. Chem. Lett.,2016.0,26,4,1329,1332,10.1016/j.bmcl.2015.12.081,26786693.0,
16482164,CHEMBL3765022,2-(4-(Difluoromethoxy)-N-(1-(2'-(trifluoromethoxy)biphenyl-4-yl)cyclobutyl)phenylsulfonamido)acetic acid,CHEMBL3768881,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 10 mins by LC-MS analysis,IC50,=,27000.0,nM,O=C(O)CN(C1(c2ccc(-c3ccccc3OC(F)(F)F)cc2)CCC1)S(=O)(=O)c1ccc(OC(F)F)cc1,CHEMBL3763072,Structure activity relationship studies on chemically non-reactive glycine sulfonamide inhibitors of diacylglycerol lipase.,Bioorg. Med. Chem.,2016.0,24,7,1455,1468,10.1016/j.bmc.2016.02.006,26917221.0,
16482165,CHEMBL3764017,"2-(N-(1-(3',5'-Dichlorobiphenyl-3-yl)cyclobutyl)-2,2-dimethylchroman-6-sulfonamido)acetic acid",CHEMBL3768881,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 10 mins by LC-MS analysis,IC50,=,3000.0,nM,CC1(C)CCc2cc(S(=O)(=O)N(CC(=O)O)C3(c4cccc(-c5cc(Cl)cc(Cl)c5)c4)CCC3)ccc2O1,CHEMBL3763072,Structure activity relationship studies on chemically non-reactive glycine sulfonamide inhibitors of diacylglycerol lipase.,Bioorg. Med. Chem.,2016.0,24,7,1455,1468,10.1016/j.bmc.2016.02.006,26917221.0,
16482166,CHEMBL3764044,"2-(N-([1,1'-Biphenyl]-3-ylmethyl)-2,2-dimethylchroman-6-sulfonamido)acetic acid",CHEMBL3768881,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 10 mins by LC-MS analysis,IC50,=,23000.0,nM,CC1(C)CCc2cc(S(=O)(=O)N(CC(=O)O)Cc3cccc(-c4ccccc4)c3)ccc2O1,CHEMBL3763072,Structure activity relationship studies on chemically non-reactive glycine sulfonamide inhibitors of diacylglycerol lipase.,Bioorg. Med. Chem.,2016.0,24,7,1455,1468,10.1016/j.bmc.2016.02.006,26917221.0,
16482167,CHEMBL3764377,"2-(4-(Difluoromethoxy)-N-((2'-(trifluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)phenylsulfonamido)acetic acid",CHEMBL3768881,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 10 mins by LC-MS analysis,IC50,=,40000.0,nM,O=C(O)CN(Cc1cccc(-c2ccccc2OC(F)(F)F)c1)S(=O)(=O)c1ccc(OC(F)F)cc1,CHEMBL3763072,Structure activity relationship studies on chemically non-reactive glycine sulfonamide inhibitors of diacylglycerol lipase.,Bioorg. Med. Chem.,2016.0,24,7,1455,1468,10.1016/j.bmc.2016.02.006,26917221.0,
16484939,CHEMBL3771364,"(S)-2-[2-(2-Isopropyl-2H-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diaza-benzo[e]azulen-8-yloxy]-propionamide",CHEMBL3771680,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CC(C)n1ncnc1-c1cn2c(n1)-c1ccc(O[C@@H](C)C(N)=O)cc1OCC2,CHEMBL3769318,"The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).",J. Med. Chem.,2016.0,59,3,985,1002,10.1021/acs.jmedchem.5b01483,26741947.0,
16485856,CHEMBL3769933,"3-(2-(5-(3-Chloro-4-isopropoxyphenyl)-1,3,4-thiadiazol-2-yl)-3-methyl-6,7-dihydro-2H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-propanoic Acid",CHEMBL3772397,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) coexpressed in Escherichia coli with human NADPH reductase using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 10 mins by fluorescence assay,IC50,>,50000.0,nM,Cc1c2c(nn1-c1nnc(-c3ccc(OC(C)C)c(Cl)c3)s1)CCN(CCC(=O)O)C2,CHEMBL3769384,Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses.,J. Med. Chem.,2016.0,59,3,1003,1020,10.1021/acs.jmedchem.5b01512,26751273.0,
16487621,CHEMBL3771105,"2-(4-((5,6-Dichloro-2-methyl-4-nitro-1H-benzo[d]-imidazol-1-yl)methyl)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione",CHEMBL3772284,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis,IC50,=,1720.0,nM,Cc1nc2c([N+](=O)[O-])c(Cl)c(Cl)cc2n1Cc1ccc(B2OC(=O)CN(C)CC(=O)O2)cc1,CHEMBL3769365,Discovery of the First Potent and Selective Inhibitors of Human dCTP Pyrophosphatase 1.,J. Med. Chem.,2016.0,59,3,1140,1148,10.1021/acs.jmedchem.5b01741,26771665.0,
16496454,CHEMBL3775589,"rac-4-Methyl-3-(4-methyl-1,3-oxazol-5-yl)-5-[(3-{1-phenyloctahydropyrrolo[2,3-c]pyrrol-5-yl}propyl)sulfanyl]-4H-1,2,4-triazole",CHEMBL3776857,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by CYPEX assay,IC50,>,1000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccccc4)C3C2)n1C,CHEMBL3774368,"1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists.",Bioorg. Med. Chem.,2016.0,24,8,1619,1636,10.1016/j.bmc.2016.02.031,26951894.0,
16496458,CHEMBL3775226,"rac-3-[(3-{1-[2-Fluoro-4-(trifluoromethyl)phenyl]-octahydropyrrolo[2,3-c]pyrrol-5-yl}-propyl)sulfanyl]-4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazole",CHEMBL3776857,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by CYPEX assay,IC50,>,3000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4F)C3C2)n1C,CHEMBL3774368,"1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists.",Bioorg. Med. Chem.,2016.0,24,8,1619,1636,10.1016/j.bmc.2016.02.031,26951894.0,
16496528,CHEMBL3774588,"rac-3-({3-[1-(4-Fluorophenyl)-octahydropyrrolo[2,3-c]pyrrol-5-yl]propyl}sulfanyl)-4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazole",CHEMBL3776857,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by CYPEX assay,IC50,>,5000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)n1C,CHEMBL3774368,"1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists.",Bioorg. Med. Chem.,2016.0,24,8,1619,1636,10.1016/j.bmc.2016.02.031,26951894.0,
16496533,CHEMBL3774683,"rac-2-{4-Methyl-5-[(3-{1-[4-(trifluoromethyl)phenyl]-octahydropyrrolo[2,3-c]pyrrol-5-yl}propyl)sulfanyl]-4H-1,2,4-triazol-3-yl}pyrazine",CHEMBL3776857,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by CYPEX assay,IC50,>,2000.0,nM,Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cnccn1,CHEMBL3774368,"1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists.",Bioorg. Med. Chem.,2016.0,24,8,1619,1636,10.1016/j.bmc.2016.02.031,26951894.0,
16496536,CHEMBL3775598,"rac-2-{4-Methyl-5-[(3-{1-[2-(propan-2-yloxy)phenyl]-octahydropyrrolo[3,4-b]pyrrol-5-yl}propyl)sulfanyl]-4H-1,2,4-triazol-3-yl}pyrazine",CHEMBL3776857,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by CYPEX assay,IC50,>,1000.0,nM,CC(C)Oc1ccccc1N1CCC2CN(CCCSc3nnc(-c4cnccn4)n3C)CC21,CHEMBL3774368,"1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists.",Bioorg. Med. Chem.,2016.0,24,8,1619,1636,10.1016/j.bmc.2016.02.031,26951894.0,
16496539,CHEMBL3774591,"rac-2-[5-({3-[1-(2,4-Difluorophenyl)-octahydropyrrolo[2,3-c]pyrrol-5-yl]propyl}sulfanyl)-4-methyl-4H-1,2,4-triazol-3-yl]-pyrazine",CHEMBL3776857,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by CYPEX assay,IC50,>,1000.0,nM,Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4F)C3C2)nnc1-c1cnccn1,CHEMBL3774368,"1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists.",Bioorg. Med. Chem.,2016.0,24,8,1619,1636,10.1016/j.bmc.2016.02.031,26951894.0,
16496545,CHEMBL3775197,"rac-3-{4-Methyl-5-[(3-{1-[2-(trifluoromethyl)phenyl]-octahydropyrrolo[3,4-b]pyrrol-5-yl}propyl)sulfanyl]-4H-1,2,4-triazol-3-yl}pyridine",CHEMBL3776857,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by CYPEX assay,IC50,>,3000.0,nM,Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1cccnc1,CHEMBL3774368,"1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists.",Bioorg. Med. Chem.,2016.0,24,8,1619,1636,10.1016/j.bmc.2016.02.031,26951894.0,
16496550,CHEMBL3774411,"rac-4-{4-Methyl-5-[(3-{1-[4-(trifluoromethyl)phenyl]-octahydropyrrolo[2,3-c]pyrrol-5-yl}propyl)sulfanyl]-4H-1,2,4-triazol-3-yl}-1,2-dihydropyridin-2-one",CHEMBL3776857,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by CYPEX assay,IC50,>,20000.0,nM,Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cc[nH]c(=O)c1,CHEMBL3774368,"1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists.",Bioorg. Med. Chem.,2016.0,24,8,1619,1636,10.1016/j.bmc.2016.02.031,26951894.0,
16496551,CHEMBL3774769,"rac-1-Methyl-5-{4-methyl-5-[(3-{1-[4-(trifluoromethyl)phenyl]-octahydropyrrolo[3,4-b]pyrrol-5-yl}propyl)sulfanyl]-4H-1,2,4-triazol-3-yl}-1,2-dihydropyridin-2-one",CHEMBL3776857,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by CYPEX assay,IC50,>,16000.0,nM,Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccc(=O)n(C)c1,CHEMBL3774368,"1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists.",Bioorg. Med. Chem.,2016.0,24,8,1619,1636,10.1016/j.bmc.2016.02.031,26951894.0,
16496556,CHEMBL3774769,"rac-1-Methyl-5-{4-methyl-5-[(3-{1-[4-(trifluoromethyl)phenyl]-octahydropyrrolo[3,4-b]pyrrol-5-yl}propyl)sulfanyl]-4H-1,2,4-triazol-3-yl}-1,2-dihydropyridin-2-one",CHEMBL3776857,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by CYPEX assay,IC50,>,25000.0,nM,Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccc(=O)n(C)c1,CHEMBL3774368,"1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists.",Bioorg. Med. Chem.,2016.0,24,8,1619,1636,10.1016/j.bmc.2016.02.031,26951894.0,
16496558,CHEMBL3775350,"rac-1-Methyl-4-[4-methyl-5-({3-[1-(2,4,6-trifluorophenyl)-octahydropyrrolo[2,3-b]pyrrol-5-yl]propyl}sulfanyl)-1,2,4-triazol-3-yl]pyridin-2-one",CHEMBL3776857,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by CYPEX assay,IC50,>,15000.0,nM,Cn1c(SCCCN2CC3CCN(c4c(F)cc(F)cc4F)C3C2)nnc1-c1ccn(C)c(=O)c1,CHEMBL3774368,"1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists.",Bioorg. Med. Chem.,2016.0,24,8,1619,1636,10.1016/j.bmc.2016.02.031,26951894.0,
16496559,CHEMBL3774649,"rac-4-Methyl-3-(oxan-4-yl)-5-[(3-{1-phenyl-octahydropyrrolo[2,3-c]pyrrol-5-yl}propyl)sulfanyl]-4H-1,2,4-triazole",CHEMBL3776857,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate by CYPEX assay,IC50,>,17000.0,nM,Cn1c(SCCCN2CC3CCN(c4ccccc4)C3C2)nnc1C1CCOCC1,CHEMBL3774368,"1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists.",Bioorg. Med. Chem.,2016.0,24,8,1619,1636,10.1016/j.bmc.2016.02.031,26951894.0,
16503987,CHEMBL3774855,"(3R,4R)-1-acetyl-4-(4-cyclopropyl-5-(cis-3-isobutylcyclobutyl)-4H-1,2,4-triazol-3-yl)-N-(2,4-dimethylphenyl)pyrrolidine-3-carboxamide",CHEMBL3776833,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated with substrate for 5 mins followed by NADPH addition measured after 20 mins by HPLC analysis,IC50,>,50000.0,nM,CC(=O)N1C[C@H](C(=O)Nc2ccc(C)cc2C)[C@@H](c2nnc([C@H]3C[C@@H](CC(C)C)C3)n2C2CC2)C1,CHEMBL3774309,SAR Exploration Guided by LE and Fsp(3): Discovery of a Selective and Orally Efficacious RORγ Inhibitor.,ACS Med. Chem. Lett.,2016.0,7,1,23,27,10.1021/acsmedchemlett.5b00253,26819660.0,
16506624,CHEMBL3774871,"6-((3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)methyl)-1'-methylspiro[indoline-3,4'-piperidin]-2-one",CHEMBL3776779,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2828.0,nM,CN1CCC2(CC1)C(=O)Nc1cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc12,CHEMBL3774336,Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists.,Bioorg. Med. Chem.,2016.0,24,6,1384,1391,10.1016/j.bmc.2016.02.014,26897089.0,
16506625,CHEMBL3774852,"6-((3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)methyl)-1'-methyl-2-oxospiro[indoline-3,4'-piperidine]1'-oxide",CHEMBL3776779,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,16986.0,nM,C[N+]1([O-])CCC2(CC1)C(=O)Nc1cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc12,CHEMBL3774336,Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists.,Bioorg. Med. Chem.,2016.0,24,6,1384,1391,10.1016/j.bmc.2016.02.014,26897089.0,
16506626,CHEMBL3775464,"3-(6-((3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)methyl)-2-oxospiro[indoline-3,4'-piperidine]-1'-yl)propanoic acid",CHEMBL3776779,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,12572.0,nM,O=C(O)CCN1CCC2(CC1)C(=O)Nc1cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc12,CHEMBL3774336,Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists.,Bioorg. Med. Chem.,2016.0,24,6,1384,1391,10.1016/j.bmc.2016.02.014,26897089.0,
16506627,CHEMBL3775389,"1'-(2-(dimethylamino)acetyl)-6-((3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)methyl)spiro[indoline-3,4'-piperidin]-2-one",CHEMBL3776779,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3259.0,nM,CN(C)CC(=O)N1CCC2(CC1)C(=O)Nc1cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc12,CHEMBL3774336,Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists.,Bioorg. Med. Chem.,2016.0,24,6,1384,1391,10.1016/j.bmc.2016.02.014,26897089.0,
16506628,CHEMBL3775476,"6-((8-fluorodibenzo[b,e][1,4]oxazepin-5(11H)-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",CHEMBL3776779,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,649.0,nM,O=C1COc2ccc(CN3c4ccccc4COc4cc(F)ccc43)cc2N1,CHEMBL3774336,Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists.,Bioorg. Med. Chem.,2016.0,24,6,1384,1391,10.1016/j.bmc.2016.02.014,26897089.0,
16506629,CHEMBL3775370,"6-(8-fluorodibenzo[b,e][1,4]oxazepin-5(11H)-ylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",CHEMBL3776779,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1562.0,nM,O=C1COc2ccc(S(=O)(=O)N3c4ccccc4COc4cc(F)ccc43)cc2N1,CHEMBL3774336,Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists.,Bioorg. Med. Chem.,2016.0,24,6,1384,1391,10.1016/j.bmc.2016.02.014,26897089.0,
16506630,CHEMBL3775473,"6-(8-fluorodibenzo[b,e][1,4]oxazepin-5(11H)-ylsulfonyl)-4,4-dimethyl-1H-benzo[d][1,3]oxazine-2(4H)-thione",CHEMBL3776779,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,397.0,nM,CC1(C)OC(=S)Nc2ccc(S(=O)(=O)N3c4ccccc4COc4cc(F)ccc43)cc21,CHEMBL3774336,Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists.,Bioorg. Med. Chem.,2016.0,24,6,1384,1391,10.1016/j.bmc.2016.02.014,26897089.0,
16506631,CHEMBL3775798,"5-((3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)methyl)-1-((7R,8aR)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-7-yl)-1H-benzo[d]imidazol-2(3H)-one",CHEMBL3776779,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1600.0,nM,O=c1[nH]c2cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc2n1[C@@H]1C[C@@H]2COCCN2C1,CHEMBL3774336,Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists.,Bioorg. Med. Chem.,2016.0,24,6,1384,1391,10.1016/j.bmc.2016.02.014,26897089.0,
16523861,CHEMBL3684869,"US8604061, 292",CHEMBL3783773,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC[C@@H](C[C@H]1COC(N)=N1)c1ccccc1,CHEMBL3779872,"Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists.",ACS Med. Chem. Lett.,2016.0,7,2,192,197,10.1021/acsmedchemlett.5b00449,26985297.0,
16523862,CHEMBL3781694,"(S)-4-(3-Fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine",CHEMBL3783773,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1c(F)cccc1[C@H]1COC(N)=N1,CHEMBL3779872,"Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists.",ACS Med. Chem. Lett.,2016.0,7,2,192,197,10.1021/acsmedchemlett.5b00449,26985297.0,
16527347,CHEMBL3787247,"N-(4,4-Dimethylcyclohexyl)pyrido[1',2':1,5]pyrazolo[4,3-d]pyrimidin-4-amine",CHEMBL3789931,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH,IC50,>,30000.0,nM,CC1(C)CCC(Nc2ncnc3c2nn2ccccc32)CC1,CHEMBL3784934,"N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents.",Bioorg. Med. Chem. Lett.,2016.0,26,8,1894,1900,10.1016/j.bmcl.2016.03.026,26988308.0,
16541161,CHEMBL3785321,N-(3-chloro-4-(4-chloro-1-oxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide,CHEMBL3790238,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1ccoc1C(=O)Nc1ccc(N2Cc3c(Cl)cccc3C2=O)c(Cl)c1,CHEMBL3785002,Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 3. Engineering plasma stability by discovery and optimization of isoindolinone analogs.,Bioorg. Med. Chem. Lett.,2016.0,26,8,1869,1872,10.1016/j.bmcl.2016.03.031,26988302.0,
16555679,CHEMBL3794145,"1-(4-(5-(3-(pyridin-2-yl)-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylic acid",CHEMBL3795106,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,O=C(O)C1CN(Cc2ccc(-c3noc(-c4onc(-c5ccccn5)c4C(F)(F)F)n3)cc2)C1,CHEMBL3792331,Identification and synthesis of potent and selective pyridyl-isoxazole based agonists of sphingosine-1-phosphate 1 (S1P1).,Bioorg. Med. Chem. Lett.,2016.0,26,10,2470,2474,10.1016/j.bmcl.2016.03.105,27055941.0,
16556268,CHEMBL3692706,"US9056859, 72",CHEMBL3795958,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1c(CCN2CCN(C(=O)Cc3ccc(-n4cnnn4)nc3)CC2)ccc2c1COC2=O,CHEMBL3792353,Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation.,Bioorg. Med. Chem. Lett.,2016.0,26,9,2339,2343,10.1016/j.bmcl.2016.03.035,27017115.0,
16558266,CHEMBL3686863,"US8933098, 1::US8933099, 1",CHEMBL3795704,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1ccc(N2CCC(O)CC2)nc1C(=O)Nc1c(C)cc(C(=O)O)cc1C,CHEMBL3792364,Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists.,Bioorg. Med. Chem. Lett.,2016.0,26,9,2303,2307,10.1016/j.bmcl.2016.03.041,27020304.0,
16564893,CHEMBL3799831,"8-((8-fluoro-2H-benzo[b][1,4]oxazin-4(3H)-yl)methyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide",CHEMBL3802899,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,CN(C)C(=O)c1cc(CN2CCOc3c(F)cccc32)c2oc(N3CCOCC3)cc(=O)c2c1,CHEMBL3797054,"Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.",Bioorg. Med. Chem. Lett.,2016.0,26,9,2318,2323,10.1016/j.bmcl.2016.03.034,26996374.0,
16566261,CHEMBL521982,N-(4-(trifluoromethyl)oxazol-2-yl)-9H-xanthene-9-carboxamide,CHEMBL3804554,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,600.0,nM,O=C(Nc1nc(C(F)(F)F)co1)C1c2ccccc2Oc2ccccc21,CHEMBL3797099,Re-exploration of the mGlu₁ PAM Ro 07-11401 scaffold: Discovery of analogs with improved CNS penetration despite steep SAR.,Bioorg. Med. Chem. Lett.,2016.0,26,9,2289,2292,10.1016/j.bmcl.2016.03.044,27013388.0,
16566262,CHEMBL3797793,N-(4-cyanothiazol-2-yl)-9H-xanthene-9-carboxamide,CHEMBL3804554,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2900.0,nM,N#Cc1csc(NC(=O)C2c3ccccc3Oc3ccccc32)n1,CHEMBL3797099,Re-exploration of the mGlu₁ PAM Ro 07-11401 scaffold: Discovery of analogs with improved CNS penetration despite steep SAR.,Bioorg. Med. Chem. Lett.,2016.0,26,9,2289,2292,10.1016/j.bmcl.2016.03.044,27013388.0,
16566263,CHEMBL3799685,N-(4-isopropylthiazol-2-yl)-9H-xanthene-9-carboxamide,CHEMBL3804554,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2100.0,nM,CC(C)c1csc(NC(=O)C2c3ccccc3Oc3ccccc32)n1,CHEMBL3797099,Re-exploration of the mGlu₁ PAM Ro 07-11401 scaffold: Discovery of analogs with improved CNS penetration despite steep SAR.,Bioorg. Med. Chem. Lett.,2016.0,26,9,2289,2292,10.1016/j.bmcl.2016.03.044,27013388.0,
16569328,CHEMBL3794064,"1-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylic acid",CHEMBL3803544,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,O=C(O)C1CN(Cc2ccc(-c3noc(-c4onc(-c5ccccc5)c4C(F)(F)F)n3)cc2)C1,CHEMBL3797106,Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based Series.,J. Med. Chem.,2016.0,59,6,2820,2840,10.1021/acs.jmedchem.6b00089,26924461.0,
16577098,CHEMBL3797513,"6-(1-((2R,3S)-2-propyl-1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidine-3-carbonyl)piperidin-4-yloxy)picolinic acid",CHEMBL3802435,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1ccc(C(F)(F)F)cc1)C(=O)N1CCC(Oc2cccc(C(=O)O)n2)CC1,CHEMBL3797031,Structure-activity relationship study of 4-substituted piperidines at Leu26 moiety of novel p53-hDM2 inhibitors.,Bioorg. Med. Chem. Lett.,2016.0,26,11,2735,2738,10.1016/j.bmcl.2016.03.078,27080185.0,
16581552,CHEMBL3798234,"N-(3-chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-aminopicolinamide",CHEMBL3801265,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 4-hydroxydiclofenac as substrate,IC50,=,7200.0,nM,Nc1cccnc1C(=O)Nc1ccc(N2C(=O)c3ccccc3C2=O)c(Cl)c1,CHEMBL3797196,Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy.,Bioorg. Med. Chem. Lett.,2016.0,26,12,2915,2919,10.1016/j.bmcl.2016.04.041,27131990.0,
16581553,CHEMBL3798517,3-amino-N-(3-chloro-4-(5-ethylpyrimidin-2-yloxy)phenyl)picolinamide,CHEMBL3801265,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using 4-hydroxydiclofenac as substrate,IC50,>,30000.0,nM,CCc1cnc(Oc2ccc(NC(=O)c3ncccc3N)cc2Cl)nc1,CHEMBL3797196,Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy.,Bioorg. Med. Chem. Lett.,2016.0,26,12,2915,2919,10.1016/j.bmcl.2016.04.041,27131990.0,
16583906,CHEMBL3805852,"N-(3-((4S,6S)-2-amino-6-(3,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-4-yl)-4,5-difluorophenyl)-3,5-dimethoxypyrazine-2-carboxamide",CHEMBL3806685,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) expressed in baculovirus infected insect cells using MFC as susbtrate incubated for 45 mins by plate reader analysis in presence of NADP+,IC50,>,20000.0,nM,COc1cnc(C(=O)Nc2cc(F)c(F)c([C@]3(C)C[C@@H](c4c(C)noc4C)SC(N)=N3)c2)cn1,CHEMBL3804782,Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain Aβ Reduction in Rodents.,ACS Med. Chem. Lett.,2016.0,7,3,271,276,10.1021/acsmedchemlett.5b00432,26985314.0,
16583980,CHEMBL3341983,"4-(2-(3-aminobenzo[d]isoxazol-5-yl)-4-chlorophenoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3806758,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using warfarin as substrate after 30 mins by LC/MS/MS analysis,IC50,=,170.0,nM,Nc1noc2ccc(-c3cc(Cl)ccc3Oc3cc(F)c(S(=O)(=O)Nc4ncns4)cc3F)cc12,CHEMBL3804797,Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.,ACS Med. Chem. Lett.,2016.0,7,3,277,282,10.1021/acsmedchemlett.5b00447,26985315.0,
16583981,CHEMBL3804898,"4-(2-(3-Aminobenzo[d]isoxazol-5-yl)-4-chlorophenoxy)-2,5-difluoro-N-(pyrimidin-2-yl)benzenesulfonamide",CHEMBL3806758,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using warfarin as substrate after 30 mins by LC/MS/MS analysis,IC50,=,570.0,nM,Nc1noc2ccc(-c3cc(Cl)ccc3Oc3cc(F)c(S(=O)(=O)Nc4ncccn4)cc3F)cc12,CHEMBL3804797,Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.,ACS Med. Chem. Lett.,2016.0,7,3,277,282,10.1021/acsmedchemlett.5b00447,26985315.0,
16584257,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3807259,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using MFC as substrate incubated for 40 mins by fluorimetry,IC50,=,180.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3804820,"2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.",Eur. J. Med. Chem.,2016.0,117,,256,268,10.1016/j.ejmech.2016.03.083,27105029.0,
16584843,CHEMBL3805966,"(1S,2R,5S)-5-(2-methyl-6H-pyrazolo[1,5-a]pyrrolo[3,4-e]pyrimidin-7(8H)-yl)-2-(2,4,5-trifluorophenyl)cyclohexanamine",CHEMBL3807777,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1cc2ncc3c(n2n1)CN([C@H]1CC[C@H](c2cc(F)c(F)cc2F)[C@@H](N)C1)C3,CHEMBL3804801,"The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors.",Bioorg. Med. Chem. Lett.,2016.0,26,11,2622,2626,10.1016/j.bmcl.2016.04.020,27106708.0,
16584844,CHEMBL3806029,"(2R,3S,5R)-5-(2-methyl-6H-pyrazolo[1,5-a]pyrrolo[3,4-e]pyrimidin-7(8H)-yl)-2-(2,4,5-trifluorophenyl)tetrahydro-2H-pyran-3-amine",CHEMBL3807777,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1cc2ncc3c(n2n1)CN([C@H]1CO[C@H](c2cc(F)c(F)cc2F)[C@@H](N)C1)C3,CHEMBL3804801,"The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors.",Bioorg. Med. Chem. Lett.,2016.0,26,11,2622,2626,10.1016/j.bmcl.2016.04.020,27106708.0,
16584845,CHEMBL3806041,"(1S,2R,5S)-5-(1-cyclopropyl-6H-pyrrolo[3,4-e][1,2,4]triazolo[4,3-a]pyrimidin-7(8H)-yl)-2-(2,4,5-trifluorophenyl)cyclohexanamine",CHEMBL3807777,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,N[C@H]1C[C@@H](N2Cc3cnc4nnc(C5CC5)n4c3C2)CC[C@@H]1c1cc(F)c(F)cc1F,CHEMBL3804801,"The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors.",Bioorg. Med. Chem. Lett.,2016.0,26,11,2622,2626,10.1016/j.bmcl.2016.04.020,27106708.0,
16584846,CHEMBL3806003,"(1S,2R,5S)-5-(1H,3H-2,4,7a,8-Tetraaza-cyclopenta[a]inden-2-yl)-2-(2,4,5-trifluoro-phenyl)-cyclohexylamine",CHEMBL3807777,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,N[C@H]1C[C@@H](N2Cc3nn4cccnc4c3C2)CC[C@@H]1c1cc(F)c(F)cc1F,CHEMBL3804801,"The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors.",Bioorg. Med. Chem. Lett.,2016.0,26,11,2622,2626,10.1016/j.bmcl.2016.04.020,27106708.0,
16584847,CHEMBL3805400,"(2R,3S,5R)-2-(2,5-Difluoro-phenyl)-5-(5-methyl-1H,3H-2,4,7a,8-tetraaza-cyclopenta[a]inden-2-yl)-tetrahydro-pyran-3-ylamine",CHEMBL3807777,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1ccn2nc3c(c2n1)CN([C@H]1CO[C@H](c2cc(F)ccc2F)[C@@H](N)C1)C3,CHEMBL3804801,"The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors.",Bioorg. Med. Chem. Lett.,2016.0,26,11,2622,2626,10.1016/j.bmcl.2016.04.020,27106708.0,
16584848,CHEMBL3804950,"(2R,3S,5R)-2-(2,5-Difluoro-phenyl)-5-(7-methyl-1H,3H-2,4,7a,8-tetraaza-cyclopenta[a]inden-2-yl)-tetrahydro-pyran-3-ylamine",CHEMBL3807777,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1ccnc2c3c(nn12)CN([C@H]1CO[C@H](c2cc(F)ccc2F)[C@@H](N)C1)C3,CHEMBL3804801,"The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors.",Bioorg. Med. Chem. Lett.,2016.0,26,11,2622,2626,10.1016/j.bmcl.2016.04.020,27106708.0,
16584849,CHEMBL3806052,"(2R,3S,5R)-2-(2,5-Difluoro-phenyl)-5-(1H,3H-2,4,7,7a,8-pentaaza-cyclopenta[a]inden-2-yl)-tetrahydro-pyran-3-ylamine",CHEMBL3807777,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,N[C@H]1C[C@@H](N2Cc3nn4nccnc4c3C2)CO[C@@H]1c1cc(F)ccc1F,CHEMBL3804801,"The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors.",Bioorg. Med. Chem. Lett.,2016.0,26,11,2622,2626,10.1016/j.bmcl.2016.04.020,27106708.0,
16585217,CHEMBL3805372,"4-(2-(4-((2R,3S)-2-propyl-1-(4-(trifluoromethyl)nicotinoyl)-3-((5-(trifluoromethyl)thiophen-3-yl)oxy)piperidine-3-carbonyl)piperazin-1-yl)phenoxy)butanoic acid",CHEMBL3808004,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCCC(=O)O)CC1,CHEMBL3804796,"Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.",ACS Med. Chem. Lett.,2016.0,7,3,324,329,10.1021/acsmedchemlett.5b00472,26985323.0,
16585318,CHEMBL3806191,"4-(3'-amino-[1,1'-biphenyl]-3-yl)-1H-pyrazol-5-amine",CHEMBL3806592,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate by LC-MS/MS analysis,IC50,>,25000.0,nM,Nc1cccc(-c2cccc(-c3cn[nH]c3N)c2)c1,CHEMBL3804790,Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors.,J. Med. Chem.,2016.0,59,7,3272,3302,10.1021/acs.jmedchem.6b00007,27002486.0,
16585319,CHEMBL3806115,"4-(5-Amino-4-(3'-amino-[1,1'-biphenyl]-3-yl)-1H-pyrazol-3-yl)-phenol",CHEMBL3806592,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate by LC-MS/MS analysis,IC50,>,25000.0,nM,Nc1cccc(-c2cccc(-c3c(-c4ccc(O)cc4)n[nH]c3N)c2)c1,CHEMBL3804790,Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors.,J. Med. Chem.,2016.0,59,7,3272,3302,10.1021/acs.jmedchem.6b00007,27002486.0,
16585320,CHEMBL3805279,"4,4'-(5-((4-Hydroxybenzyl)-amino)-1H-pyrazole-3,4-diyl)diphenol",CHEMBL3806592,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate by LC-MS/MS analysis,IC50,>,25000.0,nM,Oc1ccc(CNc2[nH]nc(-c3ccc(O)cc3)c2-c2ccc(O)cc2)cc1,CHEMBL3804790,Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors.,J. Med. Chem.,2016.0,59,7,3272,3302,10.1021/acs.jmedchem.6b00007,27002486.0,
16602134,CHEMBL3809896,"N-(2-oxo-1-(1-(3-(trifluoromethyl)benzyl)-1H-imidazol-4-yl)-1,2-dihydropyridin-4-yl)thiazole-4-carboxamide",CHEMBL3813401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2100.0,nM,O=C(Nc1ccn(-c2cn(Cc3cccc(C(F)(F)F)c3)cn2)c(=O)c1)c1cscn1,CHEMBL3808290,"Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.",ACS Med. Chem. Lett.,2016.0,7,5,525,530,10.1021/acsmedchemlett.6b00064,27190604.0,
16602135,CHEMBL3808842,"N-(2-oxo-1-(1-(1-(3-(trifluoromethyl)phenyl)ethyl)-1H-imidazol-4-yl)-1,2-dihydropyridin-4-yl)thiazole-4-carboxamide",CHEMBL3813401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2100.0,nM,CC(c1cccc(C(F)(F)F)c1)n1cnc(-n2ccc(NC(=O)c3cscn3)cc2=O)c1,CHEMBL3808290,"Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.",ACS Med. Chem. Lett.,2016.0,7,5,525,530,10.1021/acsmedchemlett.6b00064,27190604.0,
16602136,CHEMBL3810245,"N-(2-oxo-1-(2-(1-(3-(trifluoromethyl)phenyl)ethyl)-1H-imidazol-4-yl)-1,2-dihydropyridin-4-yl)thiazole-4-carboxamide",CHEMBL3813401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,31.0,nM,CC(c1cccc(C(F)(F)F)c1)c1nc(-n2ccc(NC(=O)c3cscn3)cc2=O)c[nH]1,CHEMBL3808290,"Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.",ACS Med. Chem. Lett.,2016.0,7,5,525,530,10.1021/acsmedchemlett.6b00064,27190604.0,
16602137,CHEMBL3809890,"N-(1-(2-(hydroxy(3-(trifluoromethyl)phenyl)methyl)-1H-imidazol-4-yl)-2-oxo-1,2-dihydropyridin-4-yl)thiazole-4-carboxamide",CHEMBL3813401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,7300.0,nM,O=C(Nc1ccn(-c2c[nH]c(C(O)c3cccc(C(F)(F)F)c3)n2)c(=O)c1)c1cscn1,CHEMBL3808290,"Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.",ACS Med. Chem. Lett.,2016.0,7,5,525,530,10.1021/acsmedchemlett.6b00064,27190604.0,
16602138,CHEMBL3808805,"N-(1-(2-(1-hydroxy-1-(3-(trifluoromethyl)phenyl)ethyl)-1H-imidazol-4-yl)-2-oxo-1,2-dihydropyridin-4-yl)thiazole-4-carboxamide",CHEMBL3813401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3000.0,nM,CC(O)(c1cccc(C(F)(F)F)c1)c1nc(-n2ccc(NC(=O)c3cscn3)cc2=O)c[nH]1,CHEMBL3808290,"Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.",ACS Med. Chem. Lett.,2016.0,7,5,525,530,10.1021/acsmedchemlett.6b00064,27190604.0,
16602139,CHEMBL3810414,"N-(1-(2-(1-hydroxy-1-m-tolylethyl)-1H-imidazol-4-yl)-2-oxo-1,2-dihydropyridin-4-yl)thiazole-4-carboxamide",CHEMBL3813401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,13000.0,nM,Cc1cccc(C(C)(O)c2nc(-n3ccc(NC(=O)c4cscn4)cc3=O)c[nH]2)c1,CHEMBL3808290,"Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.",ACS Med. Chem. Lett.,2016.0,7,5,525,530,10.1021/acsmedchemlett.6b00064,27190604.0,
16602140,CHEMBL3809367,"N-(1-(2-(1-hydroxy-1-p-tolylethyl)-1H-imidazol-4-yl)-2-oxo-1,2-dihydropyridin-4-yl)thiazole-4-carboxamide",CHEMBL3813401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,14000.0,nM,Cc1ccc(C(C)(O)c2nc(-n3ccc(NC(=O)c4cscn4)cc3=O)c[nH]2)cc1,CHEMBL3808290,"Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.",ACS Med. Chem. Lett.,2016.0,7,5,525,530,10.1021/acsmedchemlett.6b00064,27190604.0,
16602141,CHEMBL3808401,"N-(1-(2-(1-hydroxy-3-methyl-1-(3-(trifluoromethyl)phenyl)butyl)-1H-imidazol-4-yl)-2-oxo-1,2-dihydropyridin-4-yl)thiazole-4-carboxamide",CHEMBL3813401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,150.0,nM,CC(C)CC(O)(c1cccc(C(F)(F)F)c1)c1nc(-n2ccc(NC(=O)c3cscn3)cc2=O)c[nH]1,CHEMBL3808290,"Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.",ACS Med. Chem. Lett.,2016.0,7,5,525,530,10.1021/acsmedchemlett.6b00064,27190604.0,
16602142,CHEMBL3810042,"N-(1-(2-(isopropoxy(3-(trifluoromethyl)phenyl)methyl)-1H-imidazol-4-yl)-2-oxo-1,2-dihydropyridin-4-yl)thiazole-4-carboxamide",CHEMBL3813401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1400.0,nM,CC(C)OC(c1cccc(C(F)(F)F)c1)c1nc(-n2ccc(NC(=O)c3cscn3)cc2=O)c[nH]1,CHEMBL3808290,"Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.",ACS Med. Chem. Lett.,2016.0,7,5,525,530,10.1021/acsmedchemlett.6b00064,27190604.0,
16605052,CHEMBL3109945,"tert-Butyl 6-(2-Chloro-4-(1-methyl-1H-imidazol-5-yl)phenylamino)-2-(1-methyl-1H-pyrazol-4-yl)-1Hpyrrolo[3,2-c]pyridine-1-carboxylate",CHEMBL3811850,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,<,1000.0,nM,Cn1cc(-c2cc3cnc(Nc4ccc(-c5cncn5C)cc4Cl)cc3n2C(=O)OC(C)(C)C)cn1,CHEMBL3808337,"Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach.",J. Med. Chem.,2016.0,59,8,3671,3688,10.1021/acs.jmedchem.5b01811,27055065.0,
16608404,CHEMBL1357034,SID57261322,CHEMBL3810542,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5800.0,nM,Cc1sc2ncnc(N3CCC(C(=O)Nc4ccc(S(N)(=O)=O)cc4)CC3)c2c1C,CHEMBL3808342,"Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core.",Bioorg. Med. Chem. Lett.,2016.0,26,13,3029,3033,10.1016/j.bmcl.2016.05.010,27185330.0,
16612410,CHEMBL3814206,(R)-(2-(4-(4-(hydroxymethyl)-3-(methylsulfonyl)phenyl)-2-isopropylpiperazin-1-yl)-4-(trifluoromethyl)pyrimidin-5-yl)methanol,CHEMBL3817094,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin),IC50,=,610.0,nM,CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3813625,"Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR) β Agonist.",J. Med. Chem.,2016.0,59,7,3264,3271,10.1021/acs.jmedchem.5b02029,26990539.0,
16612413,CHEMBL3814206,(R)-(2-(4-(4-(hydroxymethyl)-3-(methylsulfonyl)phenyl)-2-isopropylpiperazin-1-yl)-4-(trifluoromethyl)pyrimidin-5-yl)methanol,CHEMBL3817097,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,2200.0,nM,CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3813625,"Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR) β Agonist.",J. Med. Chem.,2016.0,59,7,3264,3271,10.1021/acs.jmedchem.5b02029,26990539.0,
16621034,CHEMBL3819185,"8-Ethoxy-5-methyl-8-phenyl-8H-[1,2,4]oxadiazolo[3,4-c][1,4]-thiazin-3-one",CHEMBL3821695,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 20 mins by LC-MS analysis,IC50,>,20000.0,nM,CCOC1(c2ccccc2)SC=C(C)n2c1noc2=O,CHEMBL3817843,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,2016.0,59,7,3340,3352,10.1021/acs.jmedchem.6b00030,26962886.0,
16621035,CHEMBL3819606,"5-Methyl-8-phenyl-8-(2,2,2-trifluoroethoxy)-8H-[1,2,4]-oxadiazolo[3,4-c][1,4]thiazin-3-one",CHEMBL3821695,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 20 mins by LC-MS analysis,IC50,=,18400.0,nM,CC1=CSC(OCC(F)(F)F)(c2ccccc2)c2noc(=O)n21,CHEMBL3817843,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,2016.0,59,7,3340,3352,10.1021/acs.jmedchem.6b00030,26962886.0,
16621036,CHEMBL3818643,"8-Ethoxy-8-(4-methoxyphenyl)-5-methyl-8H-[1,2,4]oxadiazolo-[3,4-c][1,4]thiazin-3-one",CHEMBL3821695,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 20 mins by LC-MS analysis,IC50,=,13600.0,nM,CCOC1(c2ccc(OC)cc2)SC=C(C)n2c1noc2=O,CHEMBL3817843,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,2016.0,59,7,3340,3352,10.1021/acs.jmedchem.6b00030,26962886.0,
16621037,CHEMBL3819226,"4-Ethoxy-4-phenyl-4H-[1,2,4]oxadiazolo[3,4-c][1,4]benzothiazin-1-one",CHEMBL3821695,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 20 mins by LC-MS analysis,IC50,=,19000.0,nM,CCOC1(c2ccccc2)Sc2ccccc2-n2c1noc2=O,CHEMBL3817843,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,2016.0,59,7,3340,3352,10.1021/acs.jmedchem.6b00030,26962886.0,
16621038,CHEMBL3818560,"4-Ethoxy-4-(4-methoxyphenyl)-4H-[1,2,4]oxadiazolo[3,4-c][1,4]-benzothiazin-1-one",CHEMBL3821695,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 20 mins by LC-MS analysis,IC50,=,11800.0,nM,CCOC1(c2ccc(OC)cc2)Sc2ccccc2-n2c1noc2=O,CHEMBL3817843,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,2016.0,59,7,3340,3352,10.1021/acs.jmedchem.6b00030,26962886.0,
16621039,CHEMBL3819349,"4-(4-Methoxyphenyl)-4-(2,2,2-trifluoroethoxy)-4H-[1,2,4]-oxadiazolo[3,4-c][1,4]benzothiazin-1-one",CHEMBL3821695,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 20 mins by LC-MS analysis,IC50,>,20000.0,nM,COc1ccc(C2(OCC(F)(F)F)Sc3ccccc3-n3c2noc3=O)cc1,CHEMBL3817843,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,2016.0,59,7,3340,3352,10.1021/acs.jmedchem.6b00030,26962886.0,
16621040,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3821695,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 20 mins by LC-MS analysis,IC50,=,740.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3817843,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,2016.0,59,7,3340,3352,10.1021/acs.jmedchem.6b00030,26962886.0,
16621041,CHEMBL211204,"8-(4-bromophenyl)-8-ethoxy-5-methyl-[1,2,4]oxadiazolo[3,4-c][1,4]thiazin-3(8H)-one",CHEMBL3821695,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 20 mins by LC-MS analysis,IC50,=,18400.0,nM,CCOC1(c2ccc(Br)cc2)SC=C(C)n2c1noc2=O,CHEMBL3817843,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,2016.0,59,7,3340,3352,10.1021/acs.jmedchem.6b00030,26962886.0,
16621042,CHEMBL3408523,"(rac)-8-(4-Bromophenyl)-5-methyl-8-(2,2,2-trifluoroethoxy)-8H-[1,2,4]oxadiazolo[3,4-c][1,4]thiazin-3-one",CHEMBL3821695,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 20 mins by LC-MS analysis,IC50,=,6600.0,nM,CC1=CSC(OCC(F)(F)F)(c2ccc(Br)cc2)c2noc(=O)n21,CHEMBL3817843,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,2016.0,59,7,3340,3352,10.1021/acs.jmedchem.6b00030,26962886.0,
16621043,CHEMBL3408526,"(rac)-4-(4-Bromophenyl)-4-ethoxy-4H-[1,2,4]oxadiazolo[3,4-c][1,4]benzothiazin-1-one",CHEMBL3821695,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 20 mins by LC-MS analysis,IC50,>,20000.0,nM,CCOC1(c2ccc(Br)cc2)Sc2ccccc2-n2c1noc2=O,CHEMBL3817843,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,2016.0,59,7,3340,3352,10.1021/acs.jmedchem.6b00030,26962886.0,
16621044,CHEMBL3408529,"(rac)-4-(4-Bromophenyl)-4-(2,2,2-trifluoroethoxy)-4H-[1,2,4]oxadiazolo[3,4-c][1,4]benzothiazin-1-one",CHEMBL3821695,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 20 mins by LC-MS analysis,IC50,>,20000.0,nM,O=c1onc2n1-c1ccccc1SC2(OCC(F)(F)F)c1ccc(Br)cc1,CHEMBL3817843,Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,J. Med. Chem.,2016.0,59,7,3340,3352,10.1021/acs.jmedchem.6b00030,26962886.0,
16627867,CHEMBL3819521,"N-{4-chloro-2-hydroxy-3-[(1-methyl-4-piperidinyl)sulfonyl]phenyl}-N'-(2,3-dichlorophenyl)urea",CHEMBL3821616,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1,CHEMBL3817840,Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.,ACS Med. Chem. Lett.,2016.0,7,4,397,402,10.1021/acsmedchemlett.5b00489,27096048.0,
16627868,CHEMBL3819512,1-(4-chloro-2-hydroxy-3-(1-methylpiperidin-4-ylsulfonyl)phenyl)-3-(2-chloro-3-fluorophenyl)urea,CHEMBL3821616,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1,CHEMBL3817840,Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.,ACS Med. Chem. Lett.,2016.0,7,4,397,402,10.1021/acsmedchemlett.5b00489,27096048.0,
16627869,CHEMBL3818331,1-(4-chloro-3-((1-ethylpiperidin-4-yl)sulfonyl)-2-hydroxyphenyl)-3-(2-chloro-3-fluorophenyl)urea,CHEMBL3821616,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1,CHEMBL3817840,Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.,ACS Med. Chem. Lett.,2016.0,7,4,397,402,10.1021/acsmedchemlett.5b00489,27096048.0,
16627870,CHEMBL3818179,"(S)-1-(4-chloro-2-hydroxy-3-((1-methylpyrrolidin-3-yl)sulfonyl)phenyl)-3-(2,3-dichlorophenyl)urea",CHEMBL3821616,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CN1CC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C1,CHEMBL3817840,Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.,ACS Med. Chem. Lett.,2016.0,7,4,397,402,10.1021/acsmedchemlett.5b00489,27096048.0,
16632220,CHEMBL3823832,"(S)-6-(2-methylbenzo[b]thiophen-3-yl)-1,6-dihydropyrimidine",CHEMBL3824848,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylation by LC-MS/MS analysis,IC50,=,6900.0,nM,Cc1sc2ccccc2c1[C@@H]1C=CN=CN1,CHEMBL3822388,In vivo phenotypic drug discovery: applying a behavioral assay to the discovery and optimization of novel antipsychotic agents,MedChemComm,2016.0,7,6,1093,1101,10.1039/C6MD00128A,,
16632221,CHEMBL3823354,"rac-6-(2,5-dimethylthiophen-3-yl)-1,6-dihydropyrimidine hydrochloride",CHEMBL3824848,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylation by LC-MS/MS analysis,IC50,>,25000.0,nM,Cc1cc(C2C=CN=CN2)c(C)s1.Cl,CHEMBL3822388,In vivo phenotypic drug discovery: applying a behavioral assay to the discovery and optimization of novel antipsychotic agents,MedChemComm,2016.0,7,6,1093,1101,10.1039/C6MD00128A,,
16633238,CHEMBL3823478,"4-(4-((dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one",CHEMBL3826665,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH using diclofenac as substrate measured within 2.5 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,COc1cc(-c2cn(C)c(=O)c3cnccc23)cc(OC)c1CN(C)C,CHEMBL3822369,Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.,J. Med. Chem.,2016.0,59,10,4462,4475,10.1021/acs.jmedchem.5b01865,26914985.0,
16633239,CHEMBL3823101,"4-{4-[(Dimethylamino)methyl]-2,5-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one",CHEMBL3826665,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH using diclofenac as substrate measured within 2.5 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,COc1cc(-c2cn(C)c(=O)c3cnccc23)c(OC)cc1CN(C)C,CHEMBL3822369,Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.,J. Med. Chem.,2016.0,59,10,4462,4475,10.1021/acs.jmedchem.5b01865,26914985.0,
16637026,CHEMBL3823873,2-(3-methoxyphenyl)quinazoline-4(3H)-thione,CHEMBL3825882,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 by P450-Glo luminescence assay,IC50,=,10990.0,nM,COc1cccc(-c2nc3ccccc3c(=S)[nH]2)c1,CHEMBL3822384,2-(3-Methoxyphenyl)quinazoline Derivatives: A New Class of Direct Constitutive Androstane Receptor (CAR) Agonists.,J. Med. Chem.,2016.0,59,10,4601,4610,10.1021/acs.jmedchem.5b01891,27145071.0,
16637027,CHEMBL3822473,4-Methoxy-2-(3-methoxyphenyl)quinazoline,CHEMBL3825882,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 by P450-Glo luminescence assay,IC50,=,5030.0,nM,COc1cccc(-c2nc(OC)c3ccccc3n2)c1,CHEMBL3822384,2-(3-Methoxyphenyl)quinazoline Derivatives: A New Class of Direct Constitutive Androstane Receptor (CAR) Agonists.,J. Med. Chem.,2016.0,59,10,4601,4610,10.1021/acs.jmedchem.5b01891,27145071.0,
16637028,CHEMBL3822867,2-(3-methoxyphenyl)-4-methylsulfanylquinazoline,CHEMBL3825882,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 by P450-Glo luminescence assay,IC50,=,4190.0,nM,COc1cccc(-c2nc(SC)c3ccccc3n2)c1,CHEMBL3822384,2-(3-Methoxyphenyl)quinazoline Derivatives: A New Class of Direct Constitutive Androstane Receptor (CAR) Agonists.,J. Med. Chem.,2016.0,59,10,4601,4610,10.1021/acs.jmedchem.5b01891,27145071.0,
16637029,CHEMBL106,"2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol",CHEMBL3825882,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 by P450-Glo luminescence assay,IC50,=,9210.0,nM,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,CHEMBL3822384,2-(3-Methoxyphenyl)quinazoline Derivatives: A New Class of Direct Constitutive Androstane Receptor (CAR) Agonists.,J. Med. Chem.,2016.0,59,10,4601,4610,10.1021/acs.jmedchem.5b01891,27145071.0,
16652088,CHEMBL3828718,N-(5-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)-2-fluorobenzyl)-N-(methoxycarbonyl)glycine,CHEMBL3831052,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,COC(=O)N(CC(=O)O)Cc1cc(OCc2nc(-c3ccc(Cl)cc3)oc2C)ccc1F,CHEMBL3826929,"Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist.",ACS Med. Chem. Lett.,2016.0,7,6,590,594,10.1021/acsmedchemlett.6b00033,27326332.0,
16652093,CHEMBL3828718,N-(5-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)-2-fluorobenzyl)-N-(methoxycarbonyl)glycine,CHEMBL3831058,A,TC5,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human TC5 cells,IC50,>,150000.0,nM,COC(=O)N(CC(=O)O)Cc1cc(OCc2nc(-c3ccc(Cl)cc3)oc2C)ccc1F,CHEMBL3826929,"Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist.",ACS Med. Chem. Lett.,2016.0,7,6,590,594,10.1021/acsmedchemlett.6b00033,27326332.0,
16663570,CHEMBL3688197,"US9067922, 247",CHEMBL3853455,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2000.0,nM,N#Cc1cc(S(=O)(=O)Nc2ccc(F)cn2)ccc1Oc1ccc(CO)c(Cl)c1,CHEMBL3853264,,MedChemComm,2016.0,7,8,1587,1595,10.1039/C6MD00190D,,
16663571,CHEMBL3683287,"US9067922, 1",CHEMBL3853455,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,4200.0,nM,N#Cc1ccc(Oc2ccc(S(=O)(=O)Nc3ccc(F)cn3)cc2C#N)cc1Cl,CHEMBL3853264,,MedChemComm,2016.0,7,8,1587,1595,10.1039/C6MD00190D,,
16663799,CHEMBL3924161,2-(Trifluoromethyl)-N-(5-(trifluoromethyl)pyridin-2-yl)-benzenesulfonamide,CHEMBL3853574,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1100.0,nM,O=S(=O)(Nc1ccc(C(F)(F)F)nc1)c1ccccc1C(F)(F)F,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16663880,CHEMBL3929544,2-(Trifluoromethyl)-N-(5-(trifluoromethyl)pyridin-3-yl)-benzenesulfonamide,CHEMBL3853574,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,350.0,nM,O=S(=O)(Nc1cncc(C(F)(F)F)c1)c1ccccc1C(F)(F)F,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16670098,CHEMBL3935692,"(rac)-(1R,3S/1S,3R)-5-(3-{[4-Methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]heptane",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,17000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670107,CHEMBL3913607,"(rac)-(1S,3S/1R,3R)-5-(3-{[4-Methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]heptane",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,17000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)n1C,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670112,CHEMBL3983937,"(1S,3R)-5-(3-{[4-Methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]-sulfanyl}propyl)-1-phenyl-5-azaspiro[2.4]heptane",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,50000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@H]3c3ccccc3)C2)n1C,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670228,CHEMBL3963783,"(1S,3R)-1-(4-Fluorophenyl)-5-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro-[2.4]heptane",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,17000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@H]3c3ccc(F)cc3)C2)n1C,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670233,CHEMBL3926847,"(1R,3R)-1-(2,4-Difluorophenyl)-5-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro-[2.4]heptane",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,17000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@H]3c3ccc(F)cc3F)C2)n1C,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670237,CHEMBL3901587,"(1S,3R)-1-[2-Fluoro-4-(trifluoromethyl)phenyl]-5-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}-propyl)-5-azaspiro[2.4]heptane",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,17000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3F)C2)n1C,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670287,CHEMBL3955505,"(1R,3R)-1-[2-Fluoro-4-(trifluoromethyl)phenyl]-5-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}-propyl)-5-azaspiro[2.4]heptane",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,17000.0,nM,Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@H]3c3ccc(C(F)(F)F)cc3F)C2)n1C,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670333,CHEMBL3899125,"4-[4-Methyl-5-({3-[(1R,3S)-1-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-benzamide",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,5000.0,nM,Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C(N)=O)cc1,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670334,CHEMBL3970323,"3-[4-Methyl-5-({3-[(1R,3S)-1-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-benzamide",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,3000.0,nM,Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccc(C(N)=O)c1,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670344,CHEMBL3981856,"2-{4-[4-Methyl-5-({3-[(1R,3S)-1-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-phenyl}acetamide",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,7000.0,nM,Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(CC(N)=O)cc1,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670356,CHEMBL3941818,"(1R,3S)-5-[3-({4-Methyl-5-[4-(1,3-oxazol-2-yl)phenyl]-4H-1,2,4-triazol-3-yl}sulfanyl)propyl]-1-[4-(trifluoromethyl)phenyl]-5-azaspiro-[2.4]heptane",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,3000.0,nM,Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(-c2ncco2)cc1,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670369,CHEMBL3949662,"(1S,3S)-1-[2-Fluoro-4-(trifluoromethyl)phenyl]-5-(3-{[4-methyl-5-(pyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]-heptane",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,7000.0,nM,Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3F)C2)nnc1-c1cccnc1,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670516,CHEMBL3912801,"N-{4-[4-Methyl-5-({3-[(1R,3S)-1-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-cyclohexyl}acetamide",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,6000.0,nM,CC(=O)NC1CCC(c2nnc(SCCCN3CC[C@]4(C[C@@H]4c4ccc(C(F)(F)F)cc4)C3)n2C)CC1,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670517,CHEMBL3948167,"(1R,3S)-5-(3-{[4-Methyl-5-(oxan-4-yl)-4H-1,2,4-triazol-3-yl]-sulfanyl}-propyl)-1-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]heptane",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,10000.0,nM,Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1CCOCC1,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670772,CHEMBL3968272,"(1R,3S)-5-(3-{[4-Methyl-5-(2-methylpyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]-heptane",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,7000.0,nM,Cc1ncccc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670777,CHEMBL3946313,"(1R,3S)-5-[3-({4-Methyl-5-[2-(trifluoromethyl)pyridin-3-yl]-4H-1,2,4-triazol-3-yl}sulfanyl)propyl]-1-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]heptane",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,6000.0,nM,Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccnc1C(F)(F)F,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670788,CHEMBL3950254,"(1R,3S)-5-[4-Methyl-5-({3-[(1R,3S)-1-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-pyridine-2-carboxamide",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,17000.0,nM,Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C(N)=O)nc1,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670799,CHEMBL3941520,"6-Methyl-5-[4-methyl-5-({3-[(1R,3S)-1-[4-(trifluoromethyl)-phenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyridine-2-carboxamide",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,10000.0,nM,Cc1nc(C(N)=O)ccc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670806,CHEMBL3964649,"6-Methyl-5-[4-methyl-5-({3-[(1R,3S)-1-[4-(trifluoromethyl)-phenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyridine-2-carboxylic Acid",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,38000.0,nM,Cc1nc(C(=O)O)ccc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670814,CHEMBL3964512,"5-[4-Methyl-5-({3-[(1R,3S/1S,3R)-1-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-1,2-dihydropyridin-2-one",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,5000.0,nM,Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1=CCC(=O)N=C1,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670829,CHEMBL3922838,"1-Methyl-5-[4-methyl-5-({3-[(1R,3S)-1-[4-(trifluoromethyl)-phenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-1,2-dihydropyridin-2-one",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,9000.0,nM,Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(=O)n(C)c1,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670836,CHEMBL3894853,"1-Methyl-4-[4-methyl-5-({3-[(1R,3S)-1-[4-(trifluoromethyl)-phenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-1,2-dihydropyridin-2-one",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,17000.0,nM,Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccn(C)c(=O)c1,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670847,CHEMBL3913849,"4-[4-Methyl-5-({3-[(1R,3S)-1-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-piperidin-2-one",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,21000.0,nM,Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1CCNC(=O)C1,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16670859,CHEMBL3963243,"1-{4-[4-Methyl-5-({3-[(1R,3S)-1-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-piperidin-1-yl}ethan-1-one",CHEMBL3855292,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in microsomes using FCA as substrate after 10 mins by P450 cypex assay,IC50,>,17000.0,nM,Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1CCN(C(N)=O)CC1,CHEMBL3853329,"1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.",J Med Chem,2016.0,59,18,8549,8576,10.1021/acs.jmedchem.6b00972,27564135.0,
16671027,CHEMBL3892579,"N,5-Bis(4-fluorophenyl)-3-(pyridin-4-yl)-4,5-dihydro-1H-pyrazole-1-carboxamide",CHEMBL3855343,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1800.0,nM,O=C(Nc1ccc(F)cc1)N1N=C(c2ccncc2)CC1c1ccc(F)cc1,CHEMBL3853331,"Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers.",J Med Chem,2016.0,59,18,8398,8411,10.1021/acs.jmedchem.6b00756,27579577.0,
16671291,CHEMBL3814206,(R)-(2-(4-(4-(hydroxymethyl)-3-(methylsulfonyl)phenyl)-2-isopropylpiperazin-1-yl)-4-(trifluoromethyl)pyrimidin-5-yl)methanol,CHEMBL3855413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,608.0,nM,CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,"Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.",Bioorg Med Chem Lett,2016.0,26,20,5044,5050,10.1016/j.bmcl.2016.08.089,27599745.0,
16671292,CHEMBL3978980,"(R)-(2-(2-(4-(hydroxymethyl)-3-(methylsulfonyl)phenyl)-6-isopropylpyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)-4-(trifluoromethyl)pyrimidin-5-yl)methanol",CHEMBL3855413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,493.0,nM,CC(C)[C@@H]1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,"Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.",Bioorg Med Chem Lett,2016.0,26,20,5044,5050,10.1016/j.bmcl.2016.08.089,27599745.0,
16671293,CHEMBL3932169,"(R)-(2-(6-isopropyl-2-(3-(methylsulfonyl)phenyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)-4-(trifluoromethyl)pyrimidin-5-yl)methanol",CHEMBL3855413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,373.0,nM,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,"Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.",Bioorg Med Chem Lett,2016.0,26,20,5044,5050,10.1016/j.bmcl.2016.08.089,27599745.0,
16671294,CHEMBL3959681,"(R)-6-isopropyl-2-(3-(methylsulfonyl)phenyl)-5-(4-(trifluoromethyl)pyrimidin-2-yl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole",CHEMBL3855413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2110.0,nM,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1nccc(C(F)(F)F)n1,CHEMBL3853334,"Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.",Bioorg Med Chem Lett,2016.0,26,20,5044,5050,10.1016/j.bmcl.2016.08.089,27599745.0,
16671295,CHEMBL3933543,"(R)-6-isopropyl-2-(3-(methylsulfonyl)phenyl)-5-(2-(trifluoromethyl)pyrimidin-4-yl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole",CHEMBL3855413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1867.0,nM,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ccnc(C(F)(F)F)n1,CHEMBL3853334,"Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.",Bioorg Med Chem Lett,2016.0,26,20,5044,5050,10.1016/j.bmcl.2016.08.089,27599745.0,
16671296,CHEMBL3960195,"(R)-6-isopropyl-2-(3-(methylsulfonyl)phenyl)-5-(6-(trifluoromethyl)pyrimidin-4-yl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole",CHEMBL3855413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5210.0,nM,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1cc(C(F)(F)F)ncn1,CHEMBL3853334,"Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.",Bioorg Med Chem Lett,2016.0,26,20,5044,5050,10.1016/j.bmcl.2016.08.089,27599745.0,
16671297,CHEMBL3985591,"(R)-6-isopropyl-5-(2-methyl-6-(trifluoromethyl)pyrimidin-4-yl)-2-(3-(methylsulfonyl)phenyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole",CHEMBL3855413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5043.0,nM,Cc1nc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C(F)(F)F)n1,CHEMBL3853334,"Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.",Bioorg Med Chem Lett,2016.0,26,20,5044,5050,10.1016/j.bmcl.2016.08.089,27599745.0,
16671298,CHEMBL3956923,"(R)-6-isopropyl-5-(2-methoxy-6-methylpyrimidin-4-yl)-2-(3-(methylsulfonyl)phenyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole",CHEMBL3855413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5752.0,nM,COc1nc(C)cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1,CHEMBL3853334,"Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.",Bioorg Med Chem Lett,2016.0,26,20,5044,5050,10.1016/j.bmcl.2016.08.089,27599745.0,
16671299,CHEMBL3914727,"(R)-6-isopropyl-5-(6-methoxy-2-methylpyrimidin-4-yl)-2-(3-(methylsulfonyl)phenyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole",CHEMBL3855413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,6616.0,nM,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)nc(C)n1,CHEMBL3853334,"Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.",Bioorg Med Chem Lett,2016.0,26,20,5044,5050,10.1016/j.bmcl.2016.08.089,27599745.0,
16671300,CHEMBL3972392,"(R)-5-(5-fluoro-2-methoxypyrimidin-4-yl)-6-isopropyl-2-(3-(methylsulfonyl)phenyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole",CHEMBL3855413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,858.0,nM,COc1ncc(F)c(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1,CHEMBL3853334,"Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.",Bioorg Med Chem Lett,2016.0,26,20,5044,5050,10.1016/j.bmcl.2016.08.089,27599745.0,
16671301,CHEMBL3905741,"(R)-5-(5-fluoro-6-methoxypyrimidin-4-yl)-6-isopropyl-2-(3-(methylsulfonyl)phenyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole",CHEMBL3855413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1445.0,nM,COc1ncnc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)c1F,CHEMBL3853334,"Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.",Bioorg Med Chem Lett,2016.0,26,20,5044,5050,10.1016/j.bmcl.2016.08.089,27599745.0,
16671302,CHEMBL3976470,"(R)-6-isopropyl-5-(2-methoxy-6-methylpyridin-4-yl)-2-(3-(methylsulfonyl)phenyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole",CHEMBL3855413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3815.0,nM,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C)n1,CHEMBL3853334,"Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.",Bioorg Med Chem Lett,2016.0,26,20,5044,5050,10.1016/j.bmcl.2016.08.089,27599745.0,
16671303,CHEMBL3913348,"(R)-6-isopropyl-5-(2-methoxypyridin-4-yl)-2-(3-(methylsulfonyl)phenyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole",CHEMBL3855413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5625.0,nM,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)ccn1,CHEMBL3853334,"Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.",Bioorg Med Chem Lett,2016.0,26,20,5044,5050,10.1016/j.bmcl.2016.08.089,27599745.0,
16671304,CHEMBL3940521,"(R)-6-(tert-butyl)-5-(2-methoxypyridin-4-yl)-2-(3-(methylsulfonyl)phenyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole",CHEMBL3855413,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8297.0,nM,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)(C)C)ccn1,CHEMBL3853334,"Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.",Bioorg Med Chem Lett,2016.0,26,20,5044,5050,10.1016/j.bmcl.2016.08.089,27599745.0,
16672477,CHEMBL3984425,"(S)-2-amino-N-(1-(8-((1-methyl-1H-pyrazol-4-yl)ethynyl)-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide",CHEMBL3855759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 5 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,20000.0,nM,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1,CHEMBL3853350,Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate.,ACS Med Chem Lett,2016.0,7,9,862,867,10.1021/acsmedchemlett.6b00238,27660692.0,
16744162,CHEMBL2064666,"(1S,2S,3R,4R)-3-[5-Chloro-2-((S)-1-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-ylamino)-pyrimidin-4-ylamino]bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Amide",CHEMBL3858247,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH by LC/MS/MS analysis,IC50,>,10000.0,nM,COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CC[C@@H](N1CCOCC1)CC2,CHEMBL3856231,"Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).",J Med Chem,2016.0,59,16,7478,7496,10.1021/acs.jmedchem.6b00487,27527804.0,
16744163,CHEMBL3936443,"(1S,2S,3R,4R)-3-[[5-Chloro-2-[[(6S)-1-methoxy-6-(4-methylpiperazin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]bicyclo-[2.2.1]hept-5-ene-2-carboxamide",CHEMBL3858247,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH by LC/MS/MS analysis,IC50,>,10000.0,nM,COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CCC[C@H](N1CCN(C)CC1)C2,CHEMBL3856231,"Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).",J Med Chem,2016.0,59,16,7478,7496,10.1021/acs.jmedchem.6b00487,27527804.0,
16744164,CHEMBL3980825,"(1S,2S,3R,4R)-3-[[5-Chloro-2-[[(6S)-1-methoxy-6-(4-methylpiperazin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]-amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide",CHEMBL3858247,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH by LC/MS/MS analysis,IC50,>,10000.0,nM,COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CCC[C@@H](N1CCN(C)CC1)C2,CHEMBL3856231,"Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).",J Med Chem,2016.0,59,16,7478,7496,10.1021/acs.jmedchem.6b00487,27527804.0,
16744165,CHEMBL3972653,"2-[[5-Chloro-2-[[(6R)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-amino]pyrimidin-4-yl]amino]-N-methylbenzamide",CHEMBL3858247,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH by LC/MS/MS analysis,IC50,>,5600.0,nM,CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCC[C@@H](N2CCN(CCO)CC2)C3)ncc1Cl,CHEMBL3856231,"Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).",J Med Chem,2016.0,59,16,7478,7496,10.1021/acs.jmedchem.6b00487,27527804.0,
16744166,CHEMBL3951811,"2-[[5-Chloro-2-[[(6S)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-amino]pyrimidin-4-yl]amino]-N-methylbenzamide",CHEMBL3858247,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH by LC/MS/MS analysis,IC50,>,5600.0,nM,CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCC[C@H](N2CCN(CCO)CC2)C3)ncc1Cl,CHEMBL3856231,"Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).",J Med Chem,2016.0,59,16,7478,7496,10.1021/acs.jmedchem.6b00487,27527804.0,
16744504,CHEMBL3904907,"(R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(4-fluorophenyl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone",CHEMBL3858386,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 15 mins by LC/MS/MS analysis,IC50,>,10000.0,nM,C[C@@H]1c2ncn(-c3ccc(F)cc3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl,CHEMBL3856233,"Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor.",J Med Chem,2016.0,59,18,8535,8548,10.1021/acs.jmedchem.6b00989,27548392.0,
16744505,CHEMBL3955145,"(R)-(2-Chloro-3-(trifluoromethyl)phenyl)(4-methyl-1-(pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone",CHEMBL3858386,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 15 mins by LC/MS/MS analysis,IC50,>,10000.0,nM,C[C@@H]1c2ncn(-c3ccccn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl,CHEMBL3856233,"Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor.",J Med Chem,2016.0,59,18,8535,8548,10.1021/acs.jmedchem.6b00989,27548392.0,
16744506,CHEMBL3895947,"(R)-(2-Chloro-3(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-methanone",CHEMBL3858386,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 15 mins by LC/MS/MS analysis,IC50,>,10000.0,nM,C[C@@H]1c2ncn(-c3ccc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl,CHEMBL3856233,"Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor.",J Med Chem,2016.0,59,18,8535,8548,10.1021/acs.jmedchem.6b00989,27548392.0,
16746127,CHEMBL3926416,"8-Trifluoromethyl-3-cyclopropylmethyl-7-[(4-(2,4-difluorophenyl)-1-piperazinyl)methyl]-1,2,4-triazolo[4,3-a]pyridine",CHEMBL3858880,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,Fc1ccc(N2CCN(Cc3ccn4c(CC5CC5)nnc4c3C(F)(F)F)CC2)c(F)c1,CHEMBL3856249,"Discovery of 8-Trifluoromethyl-3-cyclopropylmethyl-7-[(4-(2,4-difluorophenyl)-1-piperazinyl)methyl]-1,2,4-triazolo[4,3-a]pyridine (JNJ-46356479), a Selective and Orally Bioavailable mGlu2 Receptor Positive Allosteric Modulator (PAM).",J Med Chem,2016.0,59,18,8495,8507,10.1021/acs.jmedchem.6b00913,27579727.0,
16746281,CHEMBL3900554,"6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide",CHEMBL3858949,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,17100.0,nM,Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O,CHEMBL3856250,"Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers.",J Med Chem,2016.0,59,19,9173,9200,10.1021/acs.jmedchem.6b01088,27583770.0,
16752264,CHEMBL3972316,(R)-N-(1-(1-Acryloylazepan-3-yl)-7-methyl-1H-benzo[d]-imidazol-2-yl)-3-(trifluoromethyl)benzamide,CHEMBL3860381,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3400.0,nM,C=CC(=O)N1CCCC[C@@H](n2c(NC(=O)c3cccc(C(F)(F)F)c3)nc3cccc(C)c32)C1,CHEMBL3860038,"Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.",J Med Chem,2016.0,59,14,6671,6689,10.1021/acs.jmedchem.5b01985,27433829.0,
16752284,CHEMBL3951434,"(R,E)-N-(1-(1-(4-(Dimethylamino)but-2-enoyl)azepan-3-yl)-7-methyl-1H-benzo[d]imidazol-2-yl)-3-(trifluoromethyl)-benzamide",CHEMBL3860381,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,17600.0,nM,Cc1cccc2nc(NC(=O)c3cccc(C(F)(F)F)c3)n([C@@H]3CCCCN(C(=O)/C=C/CN(C)C)C3)c12,CHEMBL3860038,"Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.",J Med Chem,2016.0,59,14,6671,6689,10.1021/acs.jmedchem.5b01985,27433829.0,
16752299,CHEMBL3939913,"(R,E)-N-(1-(1-(4-(Dimethylamino)but-2-enoyl)azepan-3-yl)-7-methyl-1H-benzo[d]imidazol-2-yl)-2-(trifluoromethyl)-isonicotinamide",CHEMBL3860381,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,Cc1cccc2nc(NC(=O)c3ccnc(C(F)(F)F)c3)n([C@@H]3CCCCN(C(=O)/C=C/CN(C)C)C3)c12,CHEMBL3860038,"Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.",J Med Chem,2016.0,59,14,6671,6689,10.1021/acs.jmedchem.5b01985,27433829.0,
16752319,CHEMBL3960167,"(R,E)-N-(1-(1-(4-(Dimethylamino)but-2-enoyl)-azepan-3-yl)-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide",CHEMBL3860381,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,Cc1cc(C(=O)Nc2nc3cccc(C)c3n2[C@@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)ccn1,CHEMBL3860038,"Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.",J Med Chem,2016.0,59,14,6671,6689,10.1021/acs.jmedchem.5b01985,27433829.0,
16752414,CHEMBL3787344,NAZARTINIB,CHEMBL3860381,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,Cc1cc(C(=O)Nc2nc3cccc(Cl)c3n2[C@@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)ccn1,CHEMBL3860038,"Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.",J Med Chem,2016.0,59,14,6671,6689,10.1021/acs.jmedchem.5b01985,27433829.0,
16754088,CHEMBL3933906,4-chloro-N-((3-isopropylisoxazol-5-yl)methyl)-3-(1-methylpiperidin-4-yloxy)benzamide,CHEMBL3860696,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,CC(C)c1cc(CNC(=O)c2ccc(Cl)c(OC3CCN(C)CC3)c2)on1,CHEMBL3860045,"Optimization of the choline transporter (CHT) inhibitor ML352: Development of VU6001221, an improved in vivo tool compound.",Bioorg Med Chem Lett,2016.0,26,19,4637,4640,10.1016/j.bmcl.2016.08.062,27575469.0,
16754089,CHEMBL3304438,N-((3-isopropylisoxazol-5-yl)methyl)-4-methoxy-3-(1-methylpiperidin-4-yloxy)benzamide,CHEMBL3860696,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OC1CCN(C)CC1,CHEMBL3860045,"Optimization of the choline transporter (CHT) inhibitor ML352: Development of VU6001221, an improved in vivo tool compound.",Bioorg Med Chem Lett,2016.0,26,19,4637,4640,10.1016/j.bmcl.2016.08.062,27575469.0,
16756120,CHEMBL3892788,"(R)-1-{(1S,2S)-4,6-Dichloro-1-[4-(3,5-dimethyl-1,2,4-triazol-4-yl)-2-fluoro-phenoxy]-indan-2-yl}-pyrrolidin-3-ol hydrochloride",CHEMBL3861085,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in pooled human hepatic microsomes using diclofenac substrate in presence of NADPH,IC50,=,900.0,nM,Cc1nnc(C)n1-c1ccc(O[C@H]2c3cc(Cl)cc(Cl)c3C[C@@H]2N2CC[C@@H](O)C2)c(F)c1.Cl,CHEMBL3860060,"Discovery and Optimization of 1-Phenoxy-2-aminoindanes as Potent, Selective, and Orally Bioavailable Inhibitors of the Na+/H+ Exchanger Type 3 (NHE3).",J Med Chem,2016.0,59,19,8812,8829,10.1021/acs.jmedchem.6b00624,27606885.0,
16757307,CHEMBL1738980,6-chloro-2-methyl-4-phenylquinoline-3-carboxylic acid,CHEMBL3861363,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1nc2ccc(Cl)cc2c(-c2ccccc2)c1C(=O)O,CHEMBL3860074,"Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors.",Bioorg Med Chem Lett,2016.0,26,20,5092,5097,10.1016/j.bmcl.2016.08.071,27658368.0,
16757318,CHEMBL3947458,6-chloro-2-isopropyl-4-phenylquinoline-3-carboxylic acid,CHEMBL3861363,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC(C)c1nc2ccc(Cl)cc2c(-c2ccccc2)c1C(=O)O,CHEMBL3860074,"Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors.",Bioorg Med Chem Lett,2016.0,26,20,5092,5097,10.1016/j.bmcl.2016.08.071,27658368.0,
16757329,CHEMBL3941588,6-chloro-4-phenyl-2-(piperidin-1-yl)quinoline-3-carboxylic acid,CHEMBL3861363,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C(O)c1c(N2CCCCC2)nc2ccc(Cl)cc2c1-c1ccccc1,CHEMBL3860074,"Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors.",Bioorg Med Chem Lett,2016.0,26,20,5092,5097,10.1016/j.bmcl.2016.08.071,27658368.0,
16757340,CHEMBL3971182,"6,8-dichloro-4-phenyl-2-(piperidin-1-yl)quinoline-3-carboxylic acid",CHEMBL3861363,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,21000.0,nM,O=C(O)c1c(N2CCCCC2)nc2c(Cl)cc(Cl)cc2c1-c1ccccc1,CHEMBL3860074,"Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors.",Bioorg Med Chem Lett,2016.0,26,20,5092,5097,10.1016/j.bmcl.2016.08.071,27658368.0,
16757351,CHEMBL3950316,6-chloro-8-methyl-4-phenyl-2-(piperidin-1-yl)quinoline-3-carboxylic acid,CHEMBL3861363,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,12000.0,nM,Cc1cc(Cl)cc2c(-c3ccccc3)c(C(=O)O)c(N3CCCCC3)nc12,CHEMBL3860074,"Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors.",Bioorg Med Chem Lett,2016.0,26,20,5092,5097,10.1016/j.bmcl.2016.08.071,27658368.0,
16757362,CHEMBL3979347,6-chloro-2-(dimethylamino)-4-(3-isopropylphenyl)quinoline-3-carboxylic acid,CHEMBL3861363,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,9700.0,nM,CC(C)c1cccc(-c2c(C(=O)O)c(N(C)C)nc3ccc(Cl)cc23)c1,CHEMBL3860074,"Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors.",Bioorg Med Chem Lett,2016.0,26,20,5092,5097,10.1016/j.bmcl.2016.08.071,27658368.0,
16757373,CHEMBL3959018,6-chloro-4-phenyl-2-(piperidin-1-yl)-3-(1H-tetrazol-5-yl)quinoline,CHEMBL3861363,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,13000.0,nM,Clc1ccc2nc(N3CCCCC3)c(-c3nnn[nH]3)c(-c3ccccc3)c2c1,CHEMBL3860074,"Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors.",Bioorg Med Chem Lett,2016.0,26,20,5092,5097,10.1016/j.bmcl.2016.08.071,27658368.0,
16757391,CHEMBL3889982,"5-(6-chloro-4-phenyl-2-(piperidin-1-yl)quinolin-3-yl)-1,3,4-oxadiazol-2(3H)-one",CHEMBL3861363,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,11000.0,nM,O=c1[nH]nc(-c2c(N3CCCCC3)nc3ccc(Cl)cc3c2-c2ccccc2)o1,CHEMBL3860074,"Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors.",Bioorg Med Chem Lett,2016.0,26,20,5092,5097,10.1016/j.bmcl.2016.08.071,27658368.0,
16757402,CHEMBL3970105,"5-(6-chloro-4-phenyl-2-(piperidin-1-yl)quinolin-3-yl)-1,3,4-oxadiazole-2(3H)-thione",CHEMBL3861363,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3500.0,nM,S=c1[nH]nc(-c2c(N3CCCCC3)nc3ccc(Cl)cc3c2-c2ccccc2)o1,CHEMBL3860074,"Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors.",Bioorg Med Chem Lett,2016.0,26,20,5092,5097,10.1016/j.bmcl.2016.08.071,27658368.0,
16771246,CHEMBL3976121,"(1S,2R,3S,4R,5S)-4-(2-Chloro-6-((dicyclopropylmethyl)amino)-9Hpurin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide",CHEMBL3863893,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O,CHEMBL3862033,Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.,J Med Chem,2016.0,59,24,11006,11026,10.1021/acs.jmedchem.6b01183,27933810.0,
16771267,CHEMBL3970041,"Methyl (1S,2R,3S,4R,5S)-4-(2-Chloro-6-((dicyclopropylmethyl)-amino)-9H-purin-9-yl)-2,3-dihydroxybicyclo[3.1.0]hexane-1-carboxylate",CHEMBL3863893,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,20100.0,nM,COC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O,CHEMBL3862033,Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.,J Med Chem,2016.0,59,24,11006,11026,10.1021/acs.jmedchem.6b01183,27933810.0,
16792078,CHEMBL2420629,"N-{[4-(3,5-Difluorobenzenesulfonyl)phenyl]methyl}imidazo-[1,2-a]pyridine-6-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,200.0,nM,O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cc1)c1ccc2nccn2c1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792079,CHEMBL2391568,1-(4-{8-Oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea,CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,420.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792080,CHEMBL3260358,"N-(4-(3-(trifluoromethyl)phenylsulfonyl)benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,70.0,nM,O=C(NCc1ccc(S(=O)(=O)c2cccc(C(F)(F)F)c2)cc1)c1cnc2[nH]ncc2c1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792081,CHEMBL3127521,trans-N-(4-(Phenylsulfonyl)phenyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide,CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,720.0,nM,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@H]1C[C@@H]1c1cccnc1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792082,CHEMBL2419515,"N-(4-(6-methylpyridin-3-ylsulfonyl)benzyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,80.0,nM,Cc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792083,CHEMBL3394738,"N-((5-(1-isopropyl-1H-pyrazol-4-ylsulfonyl)pyridin-2-yl)methyl)furo[2,3-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,160.0,nM,CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792084,CHEMBL17289,N-[6-(4-chlorophenoxy)hexyl]-N''-cyano-N'-pyridin-4-ylguanidine,CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,120.0,nM,N#CN/C(=N\CCCCCCOc1ccc(Cl)cc1)Nc1ccncc1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792085,CHEMBL566757,N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide,CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,3600.0,nM,O=C(/C=C/c1cccnc1)NCCCCC1CCN(C(=O)c2ccccc2)CC1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792086,CHEMBL2391572,1-[4-(Benzenesulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea,CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,70.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)c2ccccc2)cc1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792087,CHEMBL2393174,1-((6-methylpyridin-3-yl)methyl)-3-(4-(phenylsulfonyl)phenyl)urea,CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1ccc(CNC(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792088,CHEMBL2393183,1-((6-aminopyridin-3-yl)methyl)-3-(4-(phenylsulfonyl)phenyl)urea,CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Nc1ccc(CNC(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792089,CHEMBL2393163,"rac-1-(4-(2,8-diazaspiro[4.5]decan-8-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N2CCC3(CCNC3)CC2)cc1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792090,CHEMBL3394734,"N-((5-(3,5-difluorophenylsulfonyl)pyridin-2-yl)methyl)furo[2,3-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,200.0,nM,O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792091,CHEMBL3897803,"N-((5-((S)-3,5-difluorophenylsulfinyl)pyridin-2-yl)methyl)-2,3-dihydrofuro[2,3-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,1000.0,nM,O=C(NCc1ccc([S@@+]([O-])c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792092,CHEMBL2420620,"N-{[4-(3,5-Difluorobenzenesulfonyl)phenyl]methyl}-1Hpyrrolo[3,2-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,60.0,nM,O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cc1)c1cc2cnccc2[nH]1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792093,CHEMBL3986623,"6-amino-N-(4-(3,5-difluorophenylsulfonyl)benzyl)-1H-pyrrolo[3,2-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Nc1cc2[nH]c(C(=O)NCc3ccc(S(=O)(=O)c4cc(F)cc(F)c4)cc3)cc2cn1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792094,CHEMBL2419505,"N-(4-(phenylsulfonyl)benzyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,50.0,nM,O=C(NCc1ccc(S(=O)(=O)c2ccccc2)cc1)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792095,CHEMBL2419506,"6-amino-N-(4-(phenylsulfonyl)benzyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Nc1cc2c(cn1)CN(C(=O)NCc1ccc(S(=O)(=O)c3ccccc3)cc1)C2,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792096,CHEMBL2419504,"N-(4-(phenylsulfonyl)benzyl)furo[2,3-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,50.0,nM,O=C(NCc1ccc(S(=O)(=O)c2ccccc2)cc1)c1cc2ccncc2o1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792097,CHEMBL3890621,"5-amino-N-(4-(phenylsulfonyl)benzyl)furo[2,3-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,3900.0,nM,Nc1cc2cc(C(=O)NCc3ccc(S(=O)(=O)c4ccccc4)cc3)oc2cn1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792098,CHEMBL3889557,"N-(4-(methylsulfonyl)benzyl)-1H-pyrrolo[3,2-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,200.0,nM,CS(=O)(=O)c1ccc(CNC(=O)c2cc3cnccc3[nH]2)cc1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792099,CHEMBL3959982,"N-(4-sulfamoylbenzyl)-1H-pyrrolo[3,2-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,340.0,nM,NS(=O)(=O)c1ccc(CNC(=O)c2cc3cnccc3[nH]2)cc1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792100,CHEMBL3978996,"N-benzyl-1H-pyrrolo[3,2-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,O=C(NCc1ccccc1)c1cc2cnccc2[nH]1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792101,CHEMBL3908644,"N-(4-(3-(dimethylcarbamoyl)benzyloxy)benzyl)-1H-pyrrolo[3,2-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,400.0,nM,CN(C)C(=O)c1cccc(COc2ccc(CNC(=O)c3cc4cnccc4[nH]3)cc2)c1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792102,CHEMBL3907541,"N-(4-(cyclopentanesulfonamido)benzyl)-1H-pyrrolo[3,2-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,360.0,nM,O=C(NCc1ccc(NS(=O)(=O)C2CCCC2)cc1)c1cc2cnccc2[nH]1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792103,CHEMBL3935485,"N-(4-(pyrrolidine-1-carbonyl)benzyl)-1H-pyrrolo[3,2-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,450.0,nM,O=C(NCc1ccc(C(=O)N2CCCC2)cc1)c1cc2cnccc2[nH]1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792104,CHEMBL3962066,"N-(cyclohexylmethyl)-1H-pyrrolo[3,2-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,O=C(NCC1CCCCC1)c1cc2cnccc2[nH]1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792105,CHEMBL3934566,"N-isobutyl-1H-pyrrolo[3,2-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)CNC(=O)c1cc2cnccc2[nH]1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792106,CHEMBL2417572,"N-(4-(cyclohexylsulfonyl)benzyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,80.0,nM,O=C(NCc1ccc(S(=O)(=O)C2CCCCC2)cc1)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792107,CHEMBL3943545,"(+/-)-tert-Butyl3-((1H-Pyrrolo[3,2-c]pyridine-2-carboxamido)-methyl)-2-oxa-9-azaspiro[5.5]undecane-9-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)(C)OC(=O)N1CCC2(CCC(CNC(=O)c3cc4cnccc4[nH]3)OC2)CC1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792108,CHEMBL3981065,"(+/-)-tert-Butyl1-((1H-Pyrrolo[3,2-c]pyridine-2-carboxamido)-methyl)-6-azaspiro[2.5]octane-6-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)(C)OC(=O)N1CCC2(CC1)CC2CNC(=O)c1cc2cnccc2[nH]1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792109,CHEMBL3952257,"tert-Butyl 4-(2-(1H-Pyrrolo[3,2-c]pyridine-2-carboxamido)-ethyl)piperidine-1-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)(C)OC(=O)N1CCC(CCNC(=O)c2cc3cnccc3[nH]2)CC1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792110,CHEMBL3891956,"(+/-)-tert-Butyl 3-(2-(1H-Pyrrolo[3,2-c]pyridine-2-carboxamido)-ethyl)piperidine-1-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,3400.0,nM,CC(C)(C)OC(=O)N1CCCC(CCNC(=O)c2cc3cnccc3[nH]2)C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792111,CHEMBL3960951,(+/-)-tert-Butyl1-((3-(Pyridin-3-ylmethyl)ureido)methyl)-6-azaspiro[2.5]octane-6-carboxylate,CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)(C)OC(=O)N1CCC2(CC1)CC2CNC(=O)NCc1cccnc1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792112,CHEMBL3972073,"(+/-)-tert-Butyl1-((Imidazo[1,2-a]pyrimidme-6-carboxamido)-methyl)-6-azaspiro[2.5]octane-6-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)(C)OC(=O)N1CCC2(CC1)CC2CNC(=O)c1cnc2nccn2c1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792113,CHEMBL3930818,"(+/-)-tert-Butyl1-((Imidazo[1,2-a]pyridine-6-carboxamido)-methyl)-6-azaspiro[2.5]octane-6-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)(C)OC(=O)N1CCC2(CC1)CC2CNC(=O)c1ccc2nccn2c1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792114,CHEMBL3902837,"(+/-)-tert-Butyl1-((Thieno[2,3-c]pyridine-2-carboxamidgo)-methyl)-6-azaspiro[2.5]octane-6-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,7200.0,nM,CC(C)(C)OC(=O)N1CCC2(CC1)CC2CNC(=O)c1cc2ccncc2s1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792115,CHEMBL3921880,"(+/-)-tert-Butyl1-((Furo[2,3-c]pyridine-2-carboxamido)-methyl)-6-azaspiro[2.5]octane-6-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)(C)OC(=O)N1CCC2(CC1)CC2CNC(=O)c1cc2ccncc2o1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792116,CHEMBL3893879,"(+/-)-tert-Butyl1-((2,3-Dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)(C)OC(=O)N1CCC2(CC1)CC2CNC(=O)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792117,CHEMBL3948584,"tert-Butyl (S)-1-((2,3-Dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)(C)OC(=O)N1CCC2(CC1)C[C@@H]2CNC(=O)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792118,CHEMBL3920776,"tert-Butyl(R)-1-((2,3-Dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)(C)OC(=O)N1CCC2(CC1)C[C@H]2CNC(=O)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792119,CHEMBL3963163,"(+/-)-N-((6-(3,3-Dimethylbutanoyl)-6-azaspiro[2.5]octan-1-yl)-methyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)(C)CC(=O)N1CCC2(CC1)CC2CNC(=O)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792120,CHEMBL3925878,"(+/-)-N-((6-(3-Methylbutanoyl)-6-azaspiro[2.5]octan-1-yl)-methyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)CC(=O)N1CCC2(CC1)CC2CNC(=O)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792121,CHEMBL3968268,"(+/-)-N-((6-(2-(4-methyltetrahydro-2H-pyran-4-yl)acetyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC1(CC(=O)N2CCC3(CC2)CC3CNC(=O)N2Cc3ccncc3C2)CCOCC1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792122,CHEMBL3889487,"(+/-)-N-((6-(3-(Tetrahydro-2H-pyran-4-yl)propanoyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1,3-dihydro-2H-pyrrolo[3,4-c]-pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,O=C(CCC1CCOCC1)N1CCC2(CC1)CC2CNC(=O)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792123,CHEMBL3904503,"(+/-)-N-((6-(2-(Tetrahydro-2H-pyran-4-yl)acetyl)-6-azaspiro-[2.5]octan-1-yl)methyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,O=C(CC1CCOCC1)N1CCC2(CC1)CC2CNC(=O)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792124,CHEMBL3932498,"(+/-)-N-((6-(2-(3-Hydroxy-3-methylcyclobutyl)acetyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1,3-dihydro-2H-pyrrolo[3,4-c]-pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC1(O)CC(CC(=O)N2CCC3(CC2)CC3CNC(=O)N2Cc3ccncc3C2)C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792125,CHEMBL3913503,"(+/-)-N-((6-(2-(3-Methyloxetan-3-yl)acetyl)-6-azaspiro[2.5]-octan-1-yl)methyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC1(CC(=O)N2CCC3(CC2)CC3CNC(=O)N2Cc3ccncc3C2)COC1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792126,CHEMBL3941475,"(+/-)-N-((6-(4,4,4-Trifluorobutanoyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,O=C(CCC(F)(F)F)N1CCC2(CC1)CC2CNC(=O)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792127,CHEMBL3984355,"(+/-)-N-((6-Benzoyl-6-azaspiro[2.5]octan-1-yl)methyl)-1Hpyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,O=C(NCC1CC12CCN(C(=O)c1ccccc1)CC2)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792128,CHEMBL3914526,"(+/-)-N-[[6-[4-(1-Methyl-4-piperidyl)benzoyl]-6-azaspiro[2.5]-octan-2-yl]methyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CN1CCC(c2ccc(C(=O)N3CCC4(CC3)CC4CNC(=O)N3Cc4ccncc4C3)cc2)CC1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792129,CHEMBL3895553,"(+/-)-N-((6-(2-(Pyrimidin-2-yl)acetyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,O=C(Cc1ncccn1)N1CCC2(CC1)CC2CNC(=O)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792130,CHEMBL3923552,"(+/-)-N-((6-(2,4-Dimethylthiazole-5-carbonyl)-6-azaspiro[2.5]-octan-1-yl)methyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1nc(C)c(C(=O)N2CCC3(CC2)CC3CNC(=O)N2Cc3ccncc3C2)s1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792131,CHEMBL3940454,"(+/-)-N-((6-(4-Methylnicotinoyl)-6-azaspiro[2.5]octan-1-yl)-methyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1ccncc1C(=O)N1CCC2(CC1)CC2CNC(=O)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792132,CHEMBL3974268,"(+/-)-N-((6-(1,5-Dimethyl-1H-pyrazole-4-carbonyl)-6-azaspiro-[2.5]octan-1-yl)methyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1c(C(=O)N2CCC3(CC2)CC3CNC(=O)N2Cc3ccncc3C2)cnn1C,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792133,CHEMBL3949594,"(+/-)-N-((6-(1,3,5-Trimethyl-1H-pyrazole-4-carbonyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1nn(C)c(C)c1C(=O)N1CCC2(CC1)CC2CNC(=O)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792134,CHEMBL3921809,"(+/-)-N-((6-(1,3-Dimethyl-1H-pyrazole-4-carbonyl)-6-azaspiro-[2.5]octan-1-yl)methyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1nn(C)cc1C(=O)N1CCC2(CC1)CC2CNC(=O)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792135,CHEMBL3958233,"(+/-)-N-((6-(2,4-Dimethyloxazole-5-carbonyl)-6-azaspiro[2.5]-octan-1-yl)methyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1nc(C)c(C(=O)N2CCC3(CC2)CC3CNC(=O)N2Cc3ccncc3C2)o1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792136,CHEMBL3930755,"(+/-)-N-((6-(tert-Butylcarbamoyl)-6-azaspiro[2.5]octan-1-yl)-methyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)(C)NC(=O)N1CCC2(CC1)CC2CNC(=O)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792137,CHEMBL3958520,"(+/-)-N-((6-Phenethyl-6-azaspiro[2.5]octan-1-yl)methyl)-1H-pyrrolo[3,4-c]pyridme-2(3H)-carboxamide",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,O=C(NCC1CC12CCN(CCc1ccccc1)CC2)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792138,CHEMBL3939767,"(+/-)-Isopropyl1-((2,3-Dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)OC(=O)N1CCC2(CC1)CC2CNC(=O)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792139,CHEMBL3977721,"(+/-)-Ethyl1-((2,3-Dihydro-1H-pyrrolo[3,4-c]pyridme-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CCOC(=O)N1CCC2(CC1)CC2CNC(=O)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792140,CHEMBL3948512,"(+/-)-1-Methylcyclobutyl1-((2,3-Dihydro-1H-pyrrolo[3,4-c]-pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC1(OC(=O)N2CCC3(CC2)CC3CNC(=O)N2Cc3ccncc3C2)CCC1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792141,CHEMBL3913883,"(+/-)-1-Methoxy-2-methylpropan-2-yl1-((2,3-dihydro-1Hpyrrolo[3,4-c]pyridine-2-carboxamido)methyl)-6-azaspiro-[2.5]octane-6-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,COCC(C)(C)OC(=O)N1CCC2(CC1)CC2CNC(=O)N1Cc2ccncc2C1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792142,CHEMBL3983716,"(+/-)-3-Methyloxetan-3-yl1-((2,3-Dihydro-1H-pyrrolo[3,4-c]-pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC1(OC(=O)N2CCC3(CC2)CC3CNC(=O)N2Cc3ccncc3C2)COC1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792143,CHEMBL3986197,"(+/-)-3-Methyloxetan-3-yl1-((2,3-Dihydro-1H-pyrrolo[3,4-c]-pyridine-2-carboxamido-1,1,3,3-d4)methyl)-6-azaspiro[2.5]-octane-6-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,[2H]C1([2H])c2ccncc2C([2H])([2H])N1C(=O)NCC1CC12CCN(C(=O)OC1(C)COC1)CC2,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792144,CHEMBL3916438,"(S)-3-Methyloxetan-3-yl1-((2,3-Dihydro-1H-pyrrolo[3,4-c]-pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate",CHEMBL3867191,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC1(OC(=O)N2CCC3(CC2)C[C@@H]3CNC(=O)N2Cc3ccncc3C2)COC1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792316,CHEMBL2420629,"N-{[4-(3,5-Difluorobenzenesulfonyl)phenyl]methyl}imidazo-[1,2-a]pyridine-6-carboxamide",CHEMBL3867236,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cc1)c1ccc2nccn2c1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16792317,CHEMBL3260358,"N-(4-(3-(trifluoromethyl)phenylsulfonyl)benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide",CHEMBL3867236,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,4800.0,nM,O=C(NCc1ccc(S(=O)(=O)c2cccc(C(F)(F)F)c2)cc1)c1cnc2[nH]ncc2c1,CHEMBL3865840,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,J Med Chem,2016.0,59,18,8345,8368,10.1021/acs.jmedchem.6b00697,27541271.0,
16798378,CHEMBL3968947,4-(2'-chloro-5'-(trifluoromethoxy)biphenyl-4-yloxy)butanoic acid,CHEMBL3868269,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,32970.0,nM,O=C(O)CCCOc1ccc(-c2cc(OC(F)(F)F)ccc2Cl)cc1,CHEMBL3867472,Discovery of benzofuran propanoic acid GPR120 agonists: From uHTS hit to mechanism-based pharmacodynamic effects.,Bioorg Med Chem Lett,2016.0,26,23,5724,5728,10.1016/j.bmcl.2016.10.054,27815121.0,
16798379,CHEMBL3909872,"4-(2'-chloro-3,5-dimethyl-5'-(trifluoromethoxy)biphenyl-4-yloxy)butanoic acid",CHEMBL3868269,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1cc(-c2cc(OC(F)(F)F)ccc2Cl)cc(C)c1OCCCC(=O)O,CHEMBL3867472,Discovery of benzofuran propanoic acid GPR120 agonists: From uHTS hit to mechanism-based pharmacodynamic effects.,Bioorg Med Chem Lett,2016.0,26,23,5724,5728,10.1016/j.bmcl.2016.10.054,27815121.0,
16798380,CHEMBL3896657,3-(5-(2-fluoro-5-(trifluoromethoxy)phenyl)benzofuran-2-yl)propanoic acid,CHEMBL3868269,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,38300.0,nM,O=C(O)CCc1cc2cc(-c3cc(OC(F)(F)F)ccc3F)ccc2o1,CHEMBL3867472,Discovery of benzofuran propanoic acid GPR120 agonists: From uHTS hit to mechanism-based pharmacodynamic effects.,Bioorg Med Chem Lett,2016.0,26,23,5724,5728,10.1016/j.bmcl.2016.10.054,27815121.0,
16799911,CHEMBL3928270,"2-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)-N,N-dimethylethanamine",CHEMBL3868457,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 secs by LC/MS/MS analysis,IC50,>,20000.0,nM,CN(C)CCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12,CHEMBL3867482,Design and synthesis of water soluble β-aminosulfone analogues of SCH 900229 as γ-secretase inhibitors.,Bioorg Med Chem Lett,2016.0,26,23,5836,5841,10.1016/j.bmcl.2016.04.095,27836402.0,
16799912,CHEMBL3903590,"1-(2-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)ethyl)piperazine",CHEMBL3868457,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 secs by LC/MS/MS analysis,IC50,>,20000.0,nM,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)CCN1CCNCC1,CHEMBL3867482,Design and synthesis of water soluble β-aminosulfone analogues of SCH 900229 as γ-secretase inhibitors.,Bioorg Med Chem Lett,2016.0,26,23,5836,5841,10.1016/j.bmcl.2016.04.095,27836402.0,
16799913,CHEMBL3920870,"4-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)-N,2-dimethylbutan-2-amine",CHEMBL3868457,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 secs by LC/MS/MS analysis,IC50,>,20000.0,nM,CNC(C)(C)CCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12,CHEMBL3867482,Design and synthesis of water soluble β-aminosulfone analogues of SCH 900229 as γ-secretase inhibitors.,Bioorg Med Chem Lett,2016.0,26,23,5836,5841,10.1016/j.bmcl.2016.04.095,27836402.0,
16799914,CHEMBL3916230,"2-((2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)methyl)-4,5-dihydro-1H-imidazole",CHEMBL3868457,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 secs by LC/MS/MS analysis,IC50,>,20000.0,nM,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)CC1=NCCN1,CHEMBL3867482,Design and synthesis of water soluble β-aminosulfone analogues of SCH 900229 as γ-secretase inhibitors.,Bioorg Med Chem Lett,2016.0,26,23,5836,5841,10.1016/j.bmcl.2016.04.095,27836402.0,
16799955,CHEMBL3966450,"2-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)ethanamine",CHEMBL3868457,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 secs by LC/MS/MS analysis,IC50,>,20000.0,nM,NCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12,CHEMBL3867482,Design and synthesis of water soluble β-aminosulfone analogues of SCH 900229 as γ-secretase inhibitors.,Bioorg Med Chem Lett,2016.0,26,23,5836,5841,10.1016/j.bmcl.2016.04.095,27836402.0,
16799956,CHEMBL3904067,"2-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)-N-methylethanamine",CHEMBL3868457,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 secs by LC/MS/MS analysis,IC50,>,20000.0,nM,CNCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12,CHEMBL3867482,Design and synthesis of water soluble β-aminosulfone analogues of SCH 900229 as γ-secretase inhibitors.,Bioorg Med Chem Lett,2016.0,26,23,5836,5841,10.1016/j.bmcl.2016.04.095,27836402.0,
16799957,CHEMBL3974964,"2-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)-N-ethylethanamine",CHEMBL3868457,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 secs by LC/MS/MS analysis,IC50,>,20000.0,nM,CCNCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12,CHEMBL3867482,Design and synthesis of water soluble β-aminosulfone analogues of SCH 900229 as γ-secretase inhibitors.,Bioorg Med Chem Lett,2016.0,26,23,5836,5841,10.1016/j.bmcl.2016.04.095,27836402.0,
16799958,CHEMBL3892856,"(R)-2-((2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)methyl)pyrrolidine",CHEMBL3868457,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 secs by LC/MS/MS analysis,IC50,>,20000.0,nM,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C[C@H]1CCCN1,CHEMBL3867482,Design and synthesis of water soluble β-aminosulfone analogues of SCH 900229 as γ-secretase inhibitors.,Bioorg Med Chem Lett,2016.0,26,23,5836,5841,10.1016/j.bmcl.2016.04.095,27836402.0,
16799959,CHEMBL3911925,"(S)-2-((2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)methyl)pyrrolidine",CHEMBL3868457,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 secs by LC/MS/MS analysis,IC50,>,20000.0,nM,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C[C@@H]1CCCN1,CHEMBL3867482,Design and synthesis of water soluble β-aminosulfone analogues of SCH 900229 as γ-secretase inhibitors.,Bioorg Med Chem Lett,2016.0,26,23,5836,5841,10.1016/j.bmcl.2016.04.095,27836402.0,
16799960,CHEMBL3981876,"(S)-3-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)pyrrolidine",CHEMBL3868457,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 secs by LC/MS/MS analysis,IC50,>,20000.0,nM,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)[C@H]1CCNC1,CHEMBL3867482,Design and synthesis of water soluble β-aminosulfone analogues of SCH 900229 as γ-secretase inhibitors.,Bioorg Med Chem Lett,2016.0,26,23,5836,5841,10.1016/j.bmcl.2016.04.095,27836402.0,
16799961,CHEMBL3902914,"(R)-3-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)pyrrolidine",CHEMBL3868457,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 30 secs by LC/MS/MS analysis,IC50,>,20000.0,nM,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)[C@@H]1CCNC1,CHEMBL3867482,Design and synthesis of water soluble β-aminosulfone analogues of SCH 900229 as γ-secretase inhibitors.,Bioorg Med Chem Lett,2016.0,26,23,5836,5841,10.1016/j.bmcl.2016.04.095,27836402.0,
16803993,CHEMBL3933749,"3-((3R,9aS)-8-(2-(5-(1H-tetrazol-1-yl)pyridin-2-yl)acetyl)octahydropyrazino[2,1-c][1,4]oxazin-3-yl)-6-fluoro-2-methylbenzonitrile",CHEMBL3869638,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1c([C@@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)cn4)C[C@H]3CO2)ccc(F)c1C#N,CHEMBL3868612,"Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold.",Bioorg Med Chem Lett,2016.0,26,23,5695,5702,10.1016/j.bmcl.2016.10.064,27839686.0,
16817297,CHEMBL1778663,(S)-2-(6-hydroxy-6-methylheptan-2-ylamino)-4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile,CHEMBL3871937,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1700.0,nM,Cc1cc(Nc2cc(C)c(C#N)c(N[C@@H](C)CCCC(C)(C)O)n2)n[nH]1,CHEMBL3871290,3-Cyano-6-(5-methyl-3-pyrazoloamino) pyridines (Part 2): A dual inhibitor of Aurora kinase and tubulin polymerization.,Bioorg Med Chem Lett,2016.0,26,24,5860,5862,10.1016/j.bmcl.2016.11.020,27884697.0,
16817300,CHEMBL3974799,2-(2-(2-chlorophenoxy)ethylamino)-4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile,CHEMBL3871937,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,<,200.0,nM,Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3ccccc3Cl)n2)n[nH]1,CHEMBL3871290,3-Cyano-6-(5-methyl-3-pyrazoloamino) pyridines (Part 2): A dual inhibitor of Aurora kinase and tubulin polymerization.,Bioorg Med Chem Lett,2016.0,26,24,5860,5862,10.1016/j.bmcl.2016.11.020,27884697.0,
16817304,CHEMBL3893914,4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)-2-(2-(6-methylpyridin-3-yloxy)ethylamino)nicotinonitrile,CHEMBL3871937,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,4900.0,nM,Cc1ccc(OCCNc2nc(Nc3cc(C)[nH]n3)cc(C)c2C#N)cn1,CHEMBL3871290,3-Cyano-6-(5-methyl-3-pyrazoloamino) pyridines (Part 2): A dual inhibitor of Aurora kinase and tubulin polymerization.,Bioorg Med Chem Lett,2016.0,26,24,5860,5862,10.1016/j.bmcl.2016.11.020,27884697.0,
16817305,CHEMBL3937431,4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)-2-(2-(2-methylpyridin-3-yloxy)ethylamino)nicotinonitrile,CHEMBL3871937,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2400.0,nM,Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3cccnc3C)n2)n[nH]1,CHEMBL3871290,3-Cyano-6-(5-methyl-3-pyrazoloamino) pyridines (Part 2): A dual inhibitor of Aurora kinase and tubulin polymerization.,Bioorg Med Chem Lett,2016.0,26,24,5860,5862,10.1016/j.bmcl.2016.11.020,27884697.0,
16817306,CHEMBL3967136,"2-(2-(2,6-dimethylpyridin-3-yloxy)ethylamino)-4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile",CHEMBL3871937,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3500.0,nM,Cc1ccc(OCCNc2nc(Nc3cc(C)[nH]n3)cc(C)c2C#N)c(C)n1,CHEMBL3871290,3-Cyano-6-(5-methyl-3-pyrazoloamino) pyridines (Part 2): A dual inhibitor of Aurora kinase and tubulin polymerization.,Bioorg Med Chem Lett,2016.0,26,24,5860,5862,10.1016/j.bmcl.2016.11.020,27884697.0,
16817307,CHEMBL3928420,2-(2-(6-ethylpyridin-3-yloxy)ethylamino)-4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile,CHEMBL3871937,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1400.0,nM,CCc1ccc(OCCNc2nc(Nc3cc(C)[nH]n3)cc(C)c2C#N)cn1,CHEMBL3871290,3-Cyano-6-(5-methyl-3-pyrazoloamino) pyridines (Part 2): A dual inhibitor of Aurora kinase and tubulin polymerization.,Bioorg Med Chem Lett,2016.0,26,24,5860,5862,10.1016/j.bmcl.2016.11.020,27884697.0,
16818534,CHEMBL3923127,"(S)-2-(5-(3-cyclopropyl-6-fluoroimidazo[1,2-a]pyridin-2-yl)pyridin-3-yl)-1,1,1-trifluoropropan-2-ol",CHEMBL3872124,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 (unknown origin),IC50,=,6000.0,nM,C[C@](O)(c1cncc(-c2nc3ccc(F)cn3c2C2CC2)c1)C(F)(F)F,CHEMBL3871305,Imidazopyridyl compounds as aldosterone synthase inhibitors.,Bioorg Med Chem Lett,2017.0,27,2,143,146,10.1016/j.bmcl.2016.12.003,27979595.0,
16818535,CHEMBL3951973,"6-chloro-3-cyclopropyl-7-fluoro-2-(5-fluoropyridin-3-yl)imidazo[1,2-a]pyridine",CHEMBL3872124,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 (unknown origin),IC50,>,25000.0,nM,Fc1cncc(-c2nc3cc(F)c(Cl)cn3c2C2CC2)c1,CHEMBL3871305,Imidazopyridyl compounds as aldosterone synthase inhibitors.,Bioorg Med Chem Lett,2017.0,27,2,143,146,10.1016/j.bmcl.2016.12.003,27979595.0,
16818801,CHEMBL3980898,"3-((R)-6-(2,3-difluoro-5-((1r,3R)-3-methoxycyclobutoxy)phenyl)chroman-2-yl)propanoic acid",CHEMBL3872169,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,50000.0,nM,CO[C@H]1C[C@H](Oc2cc(F)c(F)c(-c3ccc4c(c3)CC[C@H](CCC(=O)O)O4)n2)C1,CHEMBL3871307,Discovery of Chromane Propionic Acid Analogues as Selective Agonists of GPR120 with in Vivo Activity in Rodents.,ACS Med Chem Lett,2017.0,8,1,96,101,10.1021/acsmedchemlett.6b00394,28105282.0,
16821301,CHEMBL431701,"3,5,7-Trihydroxy-2-[3-(4-hydroxy-3-methoxy-phenyl)-2-hydroxymethyl-2,3-dihydro-benzo[1,4]dioxin-6-yl]-chroman-4-one",CHEMBL3872956,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate at after 30 mins by LC-MS/MS analysis,IC50,=,18000.0,nM,COc1cc([C@H]2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3O[C@@H]2CO)ccc1O,CHEMBL3872216,Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.,Eur J Med Chem,2016.0,123,,577,595,10.1016/j.ejmech.2016.07.070,27517806.0,
16821302,CHEMBL592675,Silybin B,CHEMBL3872956,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate at after 30 mins by LC-MS/MS analysis,IC50,=,8200.0,nM,COc1cc([C@@H]2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3O[C@H]2CO)ccc1O,CHEMBL3872216,Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.,Eur J Med Chem,2016.0,123,,577,595,10.1016/j.ejmech.2016.07.070,27517806.0,
16827992,CHEMBL3963788,"5-amino-N-(4-(difluoromethylsulfonyl)benzyl)-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxamide",CHEMBL3874703,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1nnc2sc(C(=O)NCc3ccc(S(=O)(=O)C(F)F)cc3)c(N)c2c1C,CHEMBL3872258,Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs.,Bioorg Med Chem Lett,2017.0,27,2,171,175,10.1016/j.bmcl.2016.11.086,27939174.0,
16827993,CHEMBL3915634,"5-amino-3,4-dimethyl-N-(4-(trifluoromethylsulfonyl)benzyl)thieno[2,3-c]pyridazine-6-carboxamide",CHEMBL3874703,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1nnc2sc(C(=O)NCc3ccc(S(=O)(=O)C(F)(F)F)cc3)c(N)c2c1C,CHEMBL3872258,Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs.,Bioorg Med Chem Lett,2017.0,27,2,171,175,10.1016/j.bmcl.2016.11.086,27939174.0,
16827994,CHEMBL3942511,"5-amino-3,4-dimethyl-N-[4-(pentafluoro-lambda~6~-sulfanyl)benzyl]thieno[2,3-c]pyridazine-6-carboxamide",CHEMBL3874703,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1nnc2sc(C(=O)NCc3ccc(S(F)(F)(F)(F)F)cc3)c(N)c2c1C,CHEMBL3872258,Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs.,Bioorg Med Chem Lett,2017.0,27,2,171,175,10.1016/j.bmcl.2016.11.086,27939174.0,
16828579,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3874791,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver using microsomes diclofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS method,IC50,=,704.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3872264,"Discovery of biphenyl imidazole derivatives as potent antifungal agents: Design, synthesis, and structure-activity relationship studies.",Bioorg Med Chem,2017.0,25,2,750,758,10.1016/j.bmc.2016.11.051,27955926.0,
16828753,CHEMBL3984743,"Isobutyl (S)-2-(2'-fluoro-[1,1'-biphenyl]-4-carboxamido)-3-(1H-imidazol-1-yl)propanoate",CHEMBL3874791,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver using microsomes diclofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS method,IC50,=,2360.0,nM,CC(C)COC(=O)[C@H](Cn1ccnc1)NC(=O)c1ccc(-c2ccccc2F)cc1,CHEMBL3872264,"Discovery of biphenyl imidazole derivatives as potent antifungal agents: Design, synthesis, and structure-activity relationship studies.",Bioorg Med Chem,2017.0,25,2,750,758,10.1016/j.bmc.2016.11.051,27955926.0,
16828754,CHEMBL3892576,"Isobutyl (R)-2-(2'-fluoro-[1,1'-biphenyl]-4-carboxamido)-3-(1H-1,2,4-triazol-1-yl)propanoate",CHEMBL3874791,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver using microsomes diclofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS method,IC50,=,3220.0,nM,CC(C)COC(=O)[C@@H](Cn1cncn1)NC(=O)c1ccc(-c2ccccc2F)cc1,CHEMBL3872264,"Discovery of biphenyl imidazole derivatives as potent antifungal agents: Design, synthesis, and structure-activity relationship studies.",Bioorg Med Chem,2017.0,25,2,750,758,10.1016/j.bmc.2016.11.051,27955926.0,
16830483,CHEMBL3910904,"(S)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile",CHEMBL3875097,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in diclofenac 4-hydroxylation at 1 to 25 uM by UPLC-MS/MS analysis,IC50,>,25000.0,nM,C[C@H](Nc1ncnc(N)c1C#N)c1nn2ccc(C#N)c2c(=O)n1-c1ccccc1,CHEMBL3872285,"Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases.",ACS Med Chem Lett,2017.0,8,1,118,123,10.1021/acsmedchemlett.6b00438,28105286.0,
16851612,CHEMBL3935883,"(6,7-Dihydrothieno[3,2-c]pyridin-5(4H)-yl)(2,4-dihydroxy-5-isopropylphenyl)methanone",CHEMBL3878502,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide 4-methylhydroxylation by LC/MS/MS analysis,IC50,>,50000.0,nM,CC(C)c1cc(C(=O)N2CCc3sccc3C2)c(O)cc1O,CHEMBL3877290,"Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.",Eur J Med Chem,2016.0,124,,1069,1080,10.1016/j.ejmech.2016.10.038,27783977.0,
16854085,CHEMBL3918431,"(2R)-N-(Isoquinolin-3-yl)-3'H-4-azaspiro[bicyclo[2.2.2]octane-2,2'-[1,4]oxazole]-5'-amine",CHEMBL3878951,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,40000.0,nM,c1ccc2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncc2c1,CHEMBL3877302,"Design and Synthesis of a New Series of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure-Activity Relationship.",J Med Chem,2016.0,59,24,11171,11181,10.1021/acs.jmedchem.6b01506,27958732.0,
16863256,CHEMBL3918722,"N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-2,5-difluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,O=C(c1c(F)ccc(NS(=O)(=O)c2cc(F)ccc2F)c1F)c1c[nH]c2ncc(Cl)cc12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863257,CHEMBL3971789,"N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-2,6-difluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,O=C(c1c(F)ccc(NS(=O)(=O)c2c(F)cccc2F)c1F)c1c[nH]c2ncc(Cl)cc12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863258,CHEMBL3903656,"N-[2,4-Difluoro-3-(5-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-2-fluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,COc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863259,CHEMBL3957835,"N-[2,4-Difluoro-3-(5-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-2,5-difluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,COc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863260,CHEMBL3941703,"N-[3-(5-Cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-2-fluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863261,CHEMBL3939013,"N-[2,4-Difluoro-3-(5-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-2-fluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863262,CHEMBL3986998,"N-[2,4-Difluoro-3-(5-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-2,5-difluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863263,CHEMBL3948750,"N-[2,4-Difluoro-3-(5-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-3-fluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,<,5000.0,nM,Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863264,CHEMBL3899101,"N-[3-(4-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-2-fluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,O=C(c1c(F)ccc(NS(=O)(=O)c2ccccc2F)c1F)c1c[nH]c2nccc(Cl)c12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863265,CHEMBL3896422,"N-[3-(4-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-2,5-difluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,O=C(c1c(F)ccc(NS(=O)(=O)c2cc(F)ccc2F)c1F)c1c[nH]c2nccc(Cl)c12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863266,CHEMBL3981313,"N-[3-(4-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-3-fluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,O=C(c1c(F)ccc(NS(=O)(=O)c2cccc(F)c2)c1F)c1c[nH]c2nccc(Cl)c12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863267,CHEMBL3934437,"N-[3-(4-Cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-2-fluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863268,CHEMBL3951586,"N-[2,4-Difluoro-3-(4-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-2-fluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863269,CHEMBL3949599,"N-[2,4-Difluoro-3-(4-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-2,5-difluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863270,CHEMBL3956565,"N-[2,4-Difluoro-3-(4-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-3-fluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863271,CHEMBL3904681,"N-[2,4-Difluoro-3-(5-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-2,6-difluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863272,CHEMBL3968497,"N-[3-(5-Cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-2,6-difluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863273,CHEMBL3966021,"N-[2,4-Difluoro-3-(4-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-2,6-difluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863274,CHEMBL3928847,"N-[3-(4-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-2,6-difluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,O=C(c1c(F)ccc(NS(=O)(=O)c2c(F)cccc2F)c1F)c1c[nH]c2nccc(Cl)c12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863275,CHEMBL3926189,"N-[3-(4-Cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-2,5-difluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863276,CHEMBL3890797,"N-[3-(4-Cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-2,6-difluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863277,CHEMBL3979607,"N-[3-(4-Cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-3-fluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863278,CHEMBL3895266,"N-{2,4-Difluoro-3-[5-(2-methoxy-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-2-fluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5ccccc5F)c4F)c3c2)cn1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863279,CHEMBL3904980,"N-{2,4-Difluoro-3-[5-(2-methoxy-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-2,5-difluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5cc(F)ccc5F)c4F)c3c2)cn1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863280,CHEMBL3940360,"N-{2,4-Difluoro-3-[5-(2-methoxy-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-2,6-difluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5c(F)cccc5F)c4F)c3c2)cn1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863281,CHEMBL3942988,"N-{2,4-Difluoro-3-[5-(2-methoxy-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-3-fluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5cccc(F)c5)c4F)c3c2)cn1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863282,CHEMBL3916725,"N-[3-(5-Cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,<,5000.0,nM,N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863283,CHEMBL3919462,"N-[3-(5-Cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]-2-fluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863284,CHEMBL3954395,"N-[3-(5-Cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]-2,5-difluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,<,5000.0,nM,N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863285,CHEMBL3956999,"N-[3-(5-Cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]-3-fluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cccc(F)c4)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863286,CHEMBL3944290,"N-[3-(5-Cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]-2,6-difluoro-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863287,CHEMBL3931676,"N-[3-(5-Cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4ccccc4)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863288,CHEMBL3977421,"Pyridine-3-sulfonic acid [2,4-difluoro-3-(5-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,<,5000.0,nM,Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863289,CHEMBL3968167,"Pyridine-3-sulfonic acid [3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,O=C(c1c(F)ccc(NS(=O)(=O)c2cccnc2)c1F)c1c[nH]c2ncc(Cl)cc12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863290,CHEMBL3967303,"Pyridine-3-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863291,CHEMBL3914107,"Pyridine-3-sulfonic acid [2,4-difluoro-3-(4-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863292,CHEMBL3893235,"Pyridine-3-sulfonic acid [3-(4-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,O=C(c1c(F)ccc(NS(=O)(=O)c2cccnc2)c1F)c1c[nH]c2nccc(Cl)c12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863293,CHEMBL3890467,"Pyridine-3-sulfonic acid [3-(4-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c12,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863294,CHEMBL3980636,"Pyridine-3-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cccnc4)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863295,CHEMBL3928507,"5-{3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-pyridine-2-carboxylic acid ethylamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C(=O)NCC)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863296,CHEMBL3912374,"Propane-1-sulfonic acid {3-[5-(6-chloro-pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863297,CHEMBL3964025,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(6-fluoro-pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(F)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863298,CHEMBL3921859,"Propane-1-sulfonic acid [2,4-difluoro-3-(5-pyrimidin-5-yl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cncnc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863299,CHEMBL3979361,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(4-methanesulfonylamino-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(NS(C)(=O)=O)cc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863300,CHEMBL3981784,"Propane-1-sulfonic acid (2,4-difluoro-3-{5-[4-(morpholine-4-sulfonyl)-phenyl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl}-phenyl)-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)N5CCOCC5)cc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863301,CHEMBL3904645,"4-{3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-N-methyl-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)NC)cc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863302,CHEMBL3907402,"N-Cyclopropyl-4-{3-[2,6-difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,<,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)NC5CC5)cc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863303,CHEMBL3968460,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,<,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cn[nH]c4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863304,CHEMBL3952336,"Propane-1-sulfonic acid (2,4-difluoro-3-{5-[1-(2-morpholin-4-yl-ethyl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl}-phenyl)-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,<,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnn(CCN5CCOCC5)c4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863305,CHEMBL3954978,"Propane-1-sulfonic acid (3-{5-[6-(3-dimethylamino-propoxy)-pyridin-3-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl}-2,4-difluoro-phenyl)-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCCN(C)C)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863306,CHEMBL3971807,"5-{3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-pyridine-2-carboxylic acid methylamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,<,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C(=O)NC)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863307,CHEMBL3969082,"5-{3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-pyridine-2-carboxylic acid cyclopropylamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,<,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C(=O)NC5CC5)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863308,CHEMBL3981425,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(4-methanesulfonyl-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(C)(=O)=O)cc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863309,CHEMBL3979042,"Propane-1-sulfonic acid {3-[5-(2,6-dimethoxy-pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OC)nc4OC)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863310,CHEMBL3935100,"4-{3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-N,N-dimethyl-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,<,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)N(C)C)cc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863311,CHEMBL3932389,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(6-methylsulfanyl-pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(SC)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863312,CHEMBL3968095,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(5-methanesulfonyl-pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cncc(S(C)(=O)=O)c4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863313,CHEMBL3985076,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(2-methylsulfanyl-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,<,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(SC)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863314,CHEMBL3913674,"Propane-1-sulfonic acid {3-[5-(1-benzyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,<,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnn(Cc5ccccc5)c4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863315,CHEMBL3920821,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(2-fluoro-pyridin-4-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccnc(F)c4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863316,CHEMBL3904333,"N-(5-{3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-pyridin-2-yl)-acetamid",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(NC(C)=O)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863317,CHEMBL3907089,"4-{3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-benzenesulfonamide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(N)(=O)=O)cc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863318,CHEMBL3942381,"Propane-1-sulfonic acid {3-[5-(2-dimethylamino-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(N(C)C)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863319,CHEMBL3945059,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(2-morpholin-4-yl-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(N5CCOCC5)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863320,CHEMBL3911079,"Propane-1-sulfonic acid {3-[5-(2,4-dimethoxy-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(OC)nc4OC)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863321,CHEMBL3899027,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(2-methyl-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(C)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863322,CHEMBL3933168,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(6-methyl-pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,<,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863323,CHEMBL3896589,"Propane-1-sulfonic acid {3-[5-(6-amino-pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(N)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863324,CHEMBL3899285,"Propane-1-sulfonic acid {3-[5-(4-ethanesulfonyl-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)CC)cc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863325,CHEMBL3928075,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(2-pyrrolidin-1-yl-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(N5CCCC5)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863326,CHEMBL3949992,"Propane-1-sulfonic acid (3-{5-[6-(3-diethylamino-prop-1-ynyl)-pyridin-3-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl}-2,4-difluoro-phenyl)-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C#CCN(CC)CC)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863327,CHEMBL3947313,"Propane-1-sulfonic acid (2,4-difluoro-3-{5-[4-(propane-2-sulfonyl)-phenyl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl}-phenyl)-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)C(C)C)cc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863328,CHEMBL3897700,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(6-propyl-pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCc1ccc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)CCC)c4F)c3c2)cn1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863329,CHEMBL3985717,"Propane-1-sulfonic acid (2,4-difluoro-3-{5-[6-(3-methoxy-propyl)-pyridin-3-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl}-phenyl)-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,<,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(CCCOC)cc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863330,CHEMBL3935744,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(3-methanesulfonyl-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cccc(S(C)(=O)=O)c4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863331,CHEMBL3955478,"Propane-1-sulfonic acid {3-[5-(6-dimethylamino-pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(N(C)C)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863332,CHEMBL3919966,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(6-pyrrolidin-1-yl-pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(N5CCCC5)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863333,CHEMBL3917210,"Propane-1-sulfonic acid (2,4-difluoro-3-{5-[6-(2-morpholin-4-yl-ethoxy)-pyridin-3-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl}-phenyl)-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCN5CCOCC5)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863334,CHEMBL3958968,"Propane-1-sulfonic acid (2,4-difluoro-3-{5-[6-(2-pyrrolidin-1-yl-ethoxy)-pyridin-3-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl}-phenyl)-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCN5CCCC5)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863335,CHEMBL3941565,"Propane-1-sulfonic acid (2,4-difluoro-3-{5-[6-(3-pyrrolidin-1-yl-propoxy)-pyridin-3-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl}-phenyl)-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCCN5CCCC5)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863336,CHEMBL3896039,"Propane-1-sulfonic acid (2,4-difluoro-3-{5-[6-(3-morpholin-4-yl-propoxy)-pyridin-3-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl}-phenyl)-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,<,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCCN5CCOCC5)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863337,CHEMBL3945707,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(3-methoxy-prop-1-ynyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(C#CCOC)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863338,CHEMBL3948349,"Propane-1-sulfonic acid [3-(5-ethynyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,C#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)CCC)c3F)c2c1,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863339,CHEMBL3917962,"Propane-1-sulfonic acid {2-fluoro-3-[5-(2-methoxy-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,>,10000.0,nM,CCCS(=O)(=O)Nc1cccc(C(=O)c2c[nH]c3ncc(-c4cnc(OC)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16863340,CHEMBL3923610,"Propane-1-sulfonic acid {3-[5-(2-dimethylamino-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2-fluoro-phenyl}-amide",CHEMBL3880167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using MFC as substrate after 45 mins,IC50,=,5000.0,nM,CCCS(=O)(=O)Nc1cccc(C(=O)c2c[nH]c3ncc(-c4cnc(N(C)C)nc4)cc23)c1F,CHEMBL3879902,"Compounds and methods for kinase modulation, and indications thereof",,2012.0,,,,,,,US-8198273-B2
16888323,CHEMBL3544960,AT-13148,CHEMBL3881293,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) expressed in baculosomes containing NADPH reductase by fluorescence based Pan-Vera VividC450 assay,IC50,>,10000.0,nM,NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1,CHEMBL3880434,Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases,,2013.0,,,,,,,US-8497294-B2
16888324,CHEMBL3942454,(R)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol,CHEMBL3881293,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) expressed in baculosomes containing NADPH reductase by fluorescence based Pan-Vera VividC450 assay,IC50,>,10000.0,nM,NC[C@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1,CHEMBL3880434,Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases,,2013.0,,,,,,,US-8497294-B2
17615354,CHEMBL3645534,"US8592410, 12",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)n2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615355,CHEMBL3645512,"US8592410, 13",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615356,CHEMBL3645513,"US8592410, 14",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,CCn1nc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615357,CHEMBL3645515,"US8592410, 16",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,13000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(CC(F)(F)F)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615358,CHEMBL3645516,"US8592410, 17",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,Cc1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)nn(C)c1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615359,CHEMBL3645517,"US8592410, 18",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,Cc1cc(=O)n(C)nc1-c1ccc([C@H](C)N2CC[C@](CC(C)(C)O)(c3ccccc3)OC2=O)cc1,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615360,CHEMBL3645518,"US8592410, 19",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,10700.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(CC3CC3)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615361,CHEMBL3645519,"US8592410, 20",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,28800.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C3CC3)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615362,CHEMBL1829763,"(S)-3-((S)-1-(2',4'-Difluoro-[1,1'-biphenyl]-4-yl)ethyl)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,4100.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615363,CHEMBL1829768,"(S)-3-((S)-1-(4'-fluorobiphenyl-4-yl)ethyl)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,5100.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615364,CHEMBL3645523,"US8575157, 194::US8592410, Comparator 6::US8598163, 64",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,2300.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615365,CHEMBL1829759,"(R)-3-((S)-1-(2',4'-difluorobiphenyl-4-yl)ethyl)-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,2400.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615366,CHEMBL1829761,"(R)-3-((S)-1-(4'-fluorobiphenyl-4-yl)ethyl)-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,3100.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615367,CHEMBL3645524,"US8575157, 199::US8592410, Comparator 11::US8598163, 69",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,6300.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCC(N)=O)(c2ccccc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615368,CHEMBL3645525,"US8575157, 200::US8592410, Comparator 12::US8598163, 70",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,4600.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615369,CHEMBL3645525,"US8575157, 200::US8592410, Comparator 12::US8598163, 70",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,3900.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615370,CHEMBL3645526,"US8575157, 201::US8592410, Comparator 13::US8598163, 71",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,5600.0,nM,C[C@@H](c1ccc(Br)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615371,CHEMBL3645527,"US8575157, 202::US8592410, Comparator 14::US8598163, 72",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,25900.0,nM,C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615372,CHEMBL3645528,"US8575157, 203::US8592410, Comparator 15::US8598163, 73",CHEMBL3705155,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,7700.0,nM,C[C@@H](c1ccc(Br)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615392,CHEMBL3645510,"US8592410, 10",CHEMBL3705153,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,14200.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)n2)cc1)N1CC[C@](CCCO)(c2ccc(F)cc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615393,CHEMBL3645520,"US8575157, 189::US8592410, Comparator 1::US8598163, 59",CHEMBL3705153,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,27000.0,nM,O=C1O[C@@](CCO)(c2ccccc2)CCN1c1cccc(-c2ccc(F)cc2F)c1,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615394,CHEMBL3645521,"US8575157, 190::US8592410, Comparator 2::US8598163, 60",CHEMBL3705153,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,1400.0,nM,O=C1OC(CCO)(c2ccccc2F)CCN1c1cccc(-c2ccc(F)cc2F)n1,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615395,CHEMBL1829763,"(S)-3-((S)-1-(2',4'-Difluoro-[1,1'-biphenyl]-4-yl)ethyl)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one",CHEMBL3705153,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,4900.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615396,CHEMBL3645522,"US8575157, 192::US8592410, Comparator 4::US8598163, 62",CHEMBL3705153,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,5100.0,nM,O=C1O[C@@](CCO)(c2ccccc2)CCN1c1cccc(-c2ccc(F)cc2)n1,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615397,CHEMBL1829768,"(S)-3-((S)-1-(4'-fluorobiphenyl-4-yl)ethyl)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one",CHEMBL3705153,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,3700.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615398,CHEMBL3645523,"US8575157, 194::US8592410, Comparator 6::US8598163, 64",CHEMBL3705153,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,5000.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615399,CHEMBL1829777,"3-((R)-3-((S)-1-(2',4'-difluorobiphenyl-4-yl)ethyl)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)propanamide",CHEMBL3705153,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,4000.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCC(N)=O)(c2ccc(F)cc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615400,CHEMBL1829759,"(R)-3-((S)-1-(2',4'-difluorobiphenyl-4-yl)ethyl)-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one",CHEMBL3705153,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,3000.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615401,CHEMBL1829761,"(R)-3-((S)-1-(4'-fluorobiphenyl-4-yl)ethyl)-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one",CHEMBL3705153,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,2500.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615402,CHEMBL1829782,"N-(3-((R)-3-((S)-1-(2',4'-difluorobiphenyl-4-yl)ethyl)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)propyl)methanesulfonamide",CHEMBL3705153,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,3600.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCNS(C)(=O)=O)(c2ccc(F)cc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615403,CHEMBL3645524,"US8575157, 199::US8592410, Comparator 11::US8598163, 69",CHEMBL3705153,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,5500.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCC(N)=O)(c2ccccc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615404,CHEMBL3645525,"US8575157, 200::US8592410, Comparator 12::US8598163, 70",CHEMBL3705153,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,2500.0,nM,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615405,CHEMBL3645526,"US8575157, 201::US8592410, Comparator 13::US8598163, 71",CHEMBL3705153,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,7300.0,nM,C[C@@H](c1ccc(Br)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615406,CHEMBL3645527,"US8575157, 202::US8592410, Comparator 14::US8598163, 72",CHEMBL3705153,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,24600.0,nM,C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615407,CHEMBL3645528,"US8575157, 203::US8592410, Comparator 15::US8598163, 73",CHEMBL3705153,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,9500.0,nM,C[C@@H](c1ccc(Br)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638832,Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8592410-B2
17615876,CHEMBL3664694,"US8575157, 3",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,38000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C3CC3)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615877,CHEMBL3664695,"US8575157, 4",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,17000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C(F)F)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615878,CHEMBL3664696,"US8575157, 5",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,37000.0,nM,C[C@@H](c1ccc(-c2ccn(C(F)F)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615879,CHEMBL3664643,"US8575157, 14",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,18000.0,nM,C[C@@H](c1ccc(-c2cc[nH]c(=O)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615880,CHEMBL3664706,"US8575157, 23",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2F)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615881,CHEMBL3664707,"US8575157, 25",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,30000.0,nM,C[C@@H](c1ccc(-c2ccn(CCF)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615882,CHEMBL3664646,"US8575157, 26",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2F)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615883,CHEMBL3664710,"US8575157, 30",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615884,CHEMBL3664711,"US8575157, 32",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615885,CHEMBL3664712,"US8575157, 33",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,43000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCCO)(c2ccc(F)cc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615886,CHEMBL3664715,"US8575157, 37",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,43000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615887,CHEMBL3664651,"US8575157, 40",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,CC[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCO)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615888,CHEMBL3664717,"US8575157, 48",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615889,CHEMBL3664657,"US8575157, 49",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,29000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615890,CHEMBL3639635,"US8575157, 50",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,11000.0,nM,C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615891,CHEMBL3664659,"US8575157, 52",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,14000.0,nM,CC[C@@H](c1ccc(-c2ccc(=O)n(CC)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615892,CHEMBL3664660,"US8575157, 53",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,CCn1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615893,CHEMBL3664661,"US8575157, 54",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,CC[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615894,CHEMBL3664662,"US8575157, 55",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,29000.0,nM,CC[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615895,CHEMBL3664665,"US8575157, 58",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,3000.0,nM,CC[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615896,CHEMBL3664718,"US8575157, 59",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,CC(C)n1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615897,CHEMBL3664667,"US8575157, 61",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,40000.0,nM,Cc1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cn(C)c1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615898,CHEMBL3664668,"US8575157, 62",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,CCn1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccc(F)cc4)OC3=O)cc2)ccc1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615899,CHEMBL3664670,"US8575157, 64",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,33000.0,nM,Cc1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc(=O)n1C,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615900,CHEMBL3664671,"US8575157, 65",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,CCn1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615901,CHEMBL3664672,"US8575157, 66",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,10000.0,nM,C[C@@H](c1ccc(-c2ccn(CC(F)(F)F)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615902,CHEMBL3664673,"US8575157, 67",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,41000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(CC(F)(F)F)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615903,CHEMBL3664674,"US8575157, 68",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,47000.0,nM,CC(C)n1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615904,CHEMBL3664675,"US8575157, 69",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,38000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccc(F)cc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615905,CHEMBL3664676,"US8575157, 70",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,CCn1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc(C)c1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615906,CHEMBL3664719,"US8575157, 230",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,17000.0,nM,C#CC(C)(C)C[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(-c3ccc(=O)[nH]c3)cc2)C(=O)O1,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615907,CHEMBL3664677,"US8575157, 72",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,35000.0,nM,CCn1c(C)cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615908,CHEMBL3664679,"US8575157, 75",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,19000.0,nM,C[C@@H](c1ccc(-c2ccn(C3CC3)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615909,CHEMBL3664680,"US8575157, 76",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,4000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(CC3CC3)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615910,CHEMBL3664681,"US8575157, 77",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,COC[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(-c3ccc(=O)n(C)c3)cc2)C(=O)O1,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615911,CHEMBL3664682,"US8575157, 78",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,39000.0,nM,COC[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(-c3ccn(C)c(=O)c3)cc2)C(=O)O1,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615912,CHEMBL3664683,"US8575157, 79",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,C[C@@H](c1ccc(-c2cc(=O)n(C)cc2F)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615913,CHEMBL3664684,"US8575157, 80",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,>,50000.0,nM,C[C@@H](c1ccc(-c2ccn(CC(C)(C)O)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615914,CHEMBL3664685,"US8575157, 81",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,30000.0,nM,COCC(C)Cn1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615915,CHEMBL3664686,"US8575157, 82",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,48000.0,nM,CC(CO)Cn1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615916,CHEMBL3664687,"US8575157, 83",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,14000.0,nM,COC(C)(C)Cn1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615917,CHEMBL3664689,"US8575157, 88",CHEMBL3705118,B,,Homo sapiens,Cytochrome P450 2C9,"Biological Assay Example 7: Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37° C. with human recombinant cytochrome P450 2C9.",IC50,=,28000.0,nM,C[C@@H](c1ccc(-c2ccn(C3CC3)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2F)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615960,CHEMBL3664640,"US8575157, 10",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,30000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)[nH]c2)cc1)N1CC[C@](CC(C)(C)NS(C)(=O)=O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615961,CHEMBL3664641,"US8575157, 11",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,16100.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)NS(C)(=O)=O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615962,CHEMBL3664642,"US8575157, 12",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,12100.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)N(C)S(C)(=O)=O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615963,CHEMBL3664709,"US8575157, 29",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,7500.0,nM,C[C@@H](c1ccc(-c2ccc(=O)[nH]c2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615964,CHEMBL3664710,"US8575157, 30",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,14300.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615965,CHEMBL3664711,"US8575157, 32",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,28700.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615966,CHEMBL3664712,"US8575157, 33",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,24600.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCCO)(c2ccc(F)cc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615967,CHEMBL3664715,"US8575157, 37",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,24800.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615968,CHEMBL3664649,"US8575157, 38",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,30000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCC(N)=O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615969,CHEMBL3664651,"US8575157, 40",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,27900.0,nM,CC[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCO)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615970,CHEMBL3664653,"US8575157, 43",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,10500.0,nM,CCn1cc(-c2ccc([C@H](C)N3CC[C@](CCCO)(c4ccccc4)OC3=O)cc2)ccc1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615971,CHEMBL3664655,"US8575157, 45",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,15200.0,nM,C[C@@H](c1ccc(-c2cc[nH]c(=O)c2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615972,CHEMBL3664716,"US8575157, 47",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,12100.0,nM,C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615973,CHEMBL3664717,"US8575157, 48",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,30000.0,nM,C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615974,CHEMBL3664657,"US8575157, 49",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,14800.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615975,CHEMBL3639635,"US8575157, 50",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,5100.0,nM,C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615976,CHEMBL3664659,"US8575157, 52",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,20300.0,nM,CC[C@@H](c1ccc(-c2ccc(=O)n(CC)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615977,CHEMBL3664660,"US8575157, 53",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,30000.0,nM,CCn1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615978,CHEMBL3664662,"US8575157, 55",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,24300.0,nM,CC[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615979,CHEMBL3664718,"US8575157, 59",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,17700.0,nM,CC(C)n1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17615980,CHEMBL3664691,"US8575157, 93",CHEMBL3705116,B,,Homo sapiens,Cytochrome P450 2C9,Biological Assay Example 9: The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859).,IC50,=,28500.0,nM,C[C@@H](c1ccc(-c2ccn(C3CC3)c(=O)c2)cc1)N1CCC(CC2CC2)(CC(C)(C)O)OC1=O,CHEMBL3638974,Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1,,2013.0,,,,,,,US-8575157-B2
17655876,CHEMBL157101,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",CHEMBL3887089,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: CYP17 activity was assayed according to the following procedure. Solutions of each test compound and isozyme inhibitor (ketoconazole) were separately prepared at concentrations of 2700, 540, 90, 18, 3, 0.6 and 0.1 uM by serial dilution with DMSO:ACN (50:50 v/v). The individual test compound and isozyme inhibitor solutions were then diluted 20-fold with deionized water (50:950 v/v) to concentrations of 135, 27, 4.5, 0.9, 0.15, 0.03 and 0.005 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture is 1%. Pooled rat testicular microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 1.25 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 2.5x. A stock solution of the substrate was prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution containing the substrate at 5 uM.",IC50,=,40000.0,nM,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,CHEMBL3886161,Metalloenzyme inhibitor compounds,,2015.0,,,,,,,US-9150527-B2
17692366,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3887120,B,,Homo sapiens,Cytochrome P450 2C9,"Fluorescent High Throughput P450 Assay: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5). Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths. Concentration-response curves performed in duplicate for known inhibitors for each isoenzyme were tested in ever",IC50,=,270.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3886173,Phospholipid drug analogs,,2015.0,,,,,,,US-9173935-B2
17709033,CHEMBL3264599,"rac-1-(6,7-dimethoxynaphthalen-2-yl)-2-methyl-1-(thiazol-5-yl)propan-1-ol",CHEMBL3887089,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: CYP17 activity was assayed according to the following procedure. Solutions of each test compound and isozyme inhibitor (ketoconazole) were separately prepared at concentrations of 2700, 540, 90, 18, 3, 0.6 and 0.1 uM by serial dilution with DMSO:ACN (50:50 v/v). The individual test compound and isozyme inhibitor solutions were then diluted 20-fold with deionized water (50:950 v/v) to concentrations of 135, 27, 4.5, 0.9, 0.15, 0.03 and 0.005 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture is 1%. Pooled rat testicular microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 1.25 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 2.5x. A stock solution of the substrate was prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution containing the substrate at 5 uM.",IC50,=,33000.0,nM,COc1cc2ccc(C(O)(c3cncs3)C(C)C)cc2cc1OC,CHEMBL3886161,Metalloenzyme inhibitor compounds,,2015.0,,,,,,,US-9150527-B2
17716971,CHEMBL4107005,"US9173935, SC12",CHEMBL3887120,B,,Homo sapiens,Cytochrome P450 2C9,"Fluorescent High Throughput P450 Assay: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5). Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths. Concentration-response curves performed in duplicate for known inhibitors for each isoenzyme were tested in ever",IC50,=,33400.0,nM,CCCCCCCCCCCC(=O)OCC(CCP(=O)(O)OCCNC(=O)c1ccc(Cn2c(=O)[nH]c3c(N)nc(OCCOC)nc32)cc1)OC(=O)CCCCCCCCCCC,CHEMBL3886173,Phospholipid drug analogs,,2015.0,,,,,,,US-9173935-B2
17718282,CHEMBL4106421,"US9180183, SC12",CHEMBL3887489,B,,Homo sapiens,Cytochrome P450 2C9,"Fluorescent High Throughput P450 Assays: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5).Materials and Methods: Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths.",IC50,=,33400.0,nM,CCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCNC(=O)c1ccc(Cn2c(=O)[nH]c3c(N)nc(OCCOC)nc32)cc1)OC(=O)CCCCCCCCCCC,CHEMBL3886338,Phospholipid drug analogs,,2015.0,,,,,,,US-9180183-B2
17718291,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3887489,B,,Homo sapiens,Cytochrome P450 2C9,"Fluorescent High Throughput P450 Assays: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5).Materials and Methods: Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths.",IC50,=,270.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3886338,Phospholipid drug analogs,,2015.0,,,,,,,US-9180183-B2
17729637,CHEMBL3891460,"US9221791, 4",CHEMBL3887760,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.",IC50,=,75000.0,nM,CCOC(=O)/C=C/c1ccc(C(F)(F)C(O)(Cn2cnnn2)c2ccc(F)cc2F)nc1,CHEMBL3886442,Metalloenzyme inhibitor compounds,,2015.0,,,,,,,US-9221791-B2
17729638,CHEMBL3954501,"US9221791, 6",CHEMBL3887760,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.",IC50,=,145000.0,nM,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(/C=C/COCC(F)(F)F)cn1,CHEMBL3886442,Metalloenzyme inhibitor compounds,,2015.0,,,,,,,US-9221791-B2
17729639,CHEMBL3918756,"US9221791, 30",CHEMBL3887760,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.",IC50,=,42000.0,nM,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(Cl)nc2)cn1,CHEMBL3886442,Metalloenzyme inhibitor compounds,,2015.0,,,,,,,US-9221791-B2
17729640,CHEMBL3945322,"US9221791, 31",CHEMBL3887760,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.",IC50,=,81000.0,nM,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(F)nc2)cn1,CHEMBL3886442,Metalloenzyme inhibitor compounds,,2015.0,,,,,,,US-9221791-B2
17729641,CHEMBL106,"2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol",CHEMBL3887760,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.",IC50,=,29000.0,nM,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,CHEMBL3886442,Metalloenzyme inhibitor compounds,,2015.0,,,,,,,US-9221791-B2
17729642,CHEMBL638,"(2R,3S)-2-(2,4-Difluoro-phenyl)-3-(5-fluoro-pyrimidin-4-yl)-1-[1,2,4]triazol-1-yl-butan-2-ol",CHEMBL3887760,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.",IC50,=,14000.0,nM,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,CHEMBL3886442,Metalloenzyme inhibitor compounds,,2015.0,,,,,,,US-9221791-B2
17734998,CHEMBL3969614,"US9242943, 27",CHEMBL3887875,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Inhibition of cytochromes P450 (CYPs) 2C9, 2D6 and 3A4 was assessed using human liver microsomes and CYP-selective substrate metabolism reactions. 50 μl incubations were made up containing (finally) 0.2 mg/ml pooled human liver microsomes, 5 μM substrate (diclofenac for CYP2C9 [4' hydroxylase], dextromethorphan for CYP2D6 [O-demethylase] or midazolam for CYP3A4 [1' hydroxylase]), 0.25 μl, DMSO containing test inhibitor and NADPH regenerating system. Test inhibitor concentrations of 50, 16.7, 5.6, 1.9, 0.6 and 0.2 μM were assessed in singlicate. Incubations were prewarmed to 37° C. for 10 minutes before initiation by addition of NADPH regenerating system. Incubations were quenched after 5 minutes (20 minutes for dextromethorphan) by addition of 50 μl cold acetonitrile containing 20 ng/ml 4-OH-diclofenac-13C6, 20 ng/mL dextrorphan-D3 and 20 ng/mL 1-OH-midazolam-D4. Quenched incubates were stored at -20° C. for at least 1 hour before centrifugation (20,000xg, 20 minutes). Supernatants were removed and diluted 1:1 with water prior to analysis using a RapidFire sample injector system and API4000 mass spectrometer.",IC50,>,50000.0,nM,C[C@@]1(c2cc(Nc3cc(Cl)cc4cc(Cl)cnc34)ccc2F)COCC(N)=N1,CHEMBL3886483,"1,4 oxazines as BACE1 and/or BACE2 inhibitors",,2016.0,,,,,,,US-9242943-B2
17734999,CHEMBL4111354,"US9242943, 34",CHEMBL3887875,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Inhibition of cytochromes P450 (CYPs) 2C9, 2D6 and 3A4 was assessed using human liver microsomes and CYP-selective substrate metabolism reactions. 50 μl incubations were made up containing (finally) 0.2 mg/ml pooled human liver microsomes, 5 μM substrate (diclofenac for CYP2C9 [4' hydroxylase], dextromethorphan for CYP2D6 [O-demethylase] or midazolam for CYP3A4 [1' hydroxylase]), 0.25 μl, DMSO containing test inhibitor and NADPH regenerating system. Test inhibitor concentrations of 50, 16.7, 5.6, 1.9, 0.6 and 0.2 μM were assessed in singlicate. Incubations were prewarmed to 37° C. for 10 minutes before initiation by addition of NADPH regenerating system. Incubations were quenched after 5 minutes (20 minutes for dextromethorphan) by addition of 50 μl cold acetonitrile containing 20 ng/ml 4-OH-diclofenac-13C6, 20 ng/mL dextrorphan-D3 and 20 ng/mL 1-OH-midazolam-D4. Quenched incubates were stored at -20° C. for at least 1 hour before centrifugation (20,000xg, 20 minutes). Supernatants were removed and diluted 1:1 with water prior to analysis using a RapidFire sample injector system and API4000 mass spectrometer.",IC50,=,6700.0,nM,Cn1nc(Nc2ccc(F)c([C@@]3(C)COCC(N)=N3)c2)c2ccc(Cl)cc21,CHEMBL3886483,"1,4 oxazines as BACE1 and/or BACE2 inhibitors",,2016.0,,,,,,,US-9242943-B2
17742398,CHEMBL4107824,"US9266853, 5514403",CHEMBL3888017,B,,Homo sapiens,Cytochrome P450 2C9,"CYP Inhibition Assay (Without Preincubation): Without Preincubation: To a 96 deep well plate was added 2.5 uL, of the test substance solution (x200 concentration), 442.5 uL of Incubation Mixture, and 5 uL of the substrate solution, and the solution was mixed and warmed to 37° C. for 5 minutes. To this incubation solution 50 uL of 10 mM NADPH was added to start the reaction, and incubated at 37° C. for 5 minutes. After the incubation, 100 uL of the Incubation Mixture was removed, added to 150 uL of isopropanol containing IS and mixed. This mixture was transferred onto a multi-screen filter, centrifuged at 500xg at 4° C. for 10 minutes. The filtrate was used for LC-MS/MS analysis.",IC50,=,7700.0,nM,CCCCCCCC(F)(F)CCCCCC/C=C/[C@H](C(O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)OC)[C@@](O)(CCOC)C(=O)O,CHEMBL3886540,Orally available viridiofungin derivative possessing anti-HCV activity,,2016.0,,,,,,,US-9266853-B2
17742399,CHEMBL4106646,"US9266853, 5526064",CHEMBL3888017,B,,Homo sapiens,Cytochrome P450 2C9,"CYP Inhibition Assay (Without Preincubation): Without Preincubation: To a 96 deep well plate was added 2.5 uL, of the test substance solution (x200 concentration), 442.5 uL of Incubation Mixture, and 5 uL of the substrate solution, and the solution was mixed and warmed to 37° C. for 5 minutes. To this incubation solution 50 uL of 10 mM NADPH was added to start the reaction, and incubated at 37° C. for 5 minutes. After the incubation, 100 uL of the Incubation Mixture was removed, added to 150 uL of isopropanol containing IS and mixed. This mixture was transferred onto a multi-screen filter, centrifuged at 500xg at 4° C. for 10 minutes. The filtrate was used for LC-MS/MS analysis.",IC50,=,12500.0,nM,CCCCCCCC(F)(F)CCCCCC/C=C/[C@H](C(O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)O)[C@@](O)(CCOC)C(=O)O,CHEMBL3886540,Orally available viridiofungin derivative possessing anti-HCV activity,,2016.0,,,,,,,US-9266853-B2
17742402,CHEMBL4107824,"US9266853, 5514403",CHEMBL3888019,B,,Homo sapiens,Cytochrome P450 2C9,"CYP Inhibition Assay (With Preincubation): With Preincubation: To a 96 deep well plate was added 2.5 uL of the test substance solution (x200 concentration), and 442.5 uL of Incubation Mixture, and the solution was mixed and warmed to 37° C. for 5 minutes. To this incubation solution 50 uL of 10 mM NADPH was added and preincubated at 37° C. for 30 minutes. After the preincubation, 5 uL of the substrate solution was added and the solution was mixed and further incubated at 37° C. for 5 minutes for the reaction. After the reaction, 100 uL of the Incubation Mixture was removed, added to 150 uL of isopropanol containing IS and mixed. This mixture was transferred onto a multi-screen filter, centrifuged at 500xg at 4° C. for 10 minutes. The filtrate was used for LC-MS/MS analysis.",IC50,=,19600.0,nM,CCCCCCCC(F)(F)CCCCCC/C=C/[C@H](C(O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)OC)[C@@](O)(CCOC)C(=O)O,CHEMBL3886540,Orally available viridiofungin derivative possessing anti-HCV activity,,2016.0,,,,,,,US-9266853-B2
17742403,CHEMBL4106646,"US9266853, 5526064",CHEMBL3888019,B,,Homo sapiens,Cytochrome P450 2C9,"CYP Inhibition Assay (With Preincubation): With Preincubation: To a 96 deep well plate was added 2.5 uL of the test substance solution (x200 concentration), and 442.5 uL of Incubation Mixture, and the solution was mixed and warmed to 37° C. for 5 minutes. To this incubation solution 50 uL of 10 mM NADPH was added and preincubated at 37° C. for 30 minutes. After the preincubation, 5 uL of the substrate solution was added and the solution was mixed and further incubated at 37° C. for 5 minutes for the reaction. After the reaction, 100 uL of the Incubation Mixture was removed, added to 150 uL of isopropanol containing IS and mixed. This mixture was transferred onto a multi-screen filter, centrifuged at 500xg at 4° C. for 10 minutes. The filtrate was used for LC-MS/MS analysis.",IC50,=,24400.0,nM,CCCCCCCC(F)(F)CCCCCC/C=C/[C@H](C(O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)O)[C@@](O)(CCOC)C(=O)O,CHEMBL3886540,Orally available viridiofungin derivative possessing anti-HCV activity,,2016.0,,,,,,,US-9266853-B2
17747918,CHEMBL3617971,"(R)-4-(2,5-dioxo-1-(3-(trifluoromethyl)phenyl)-2,3,4,5,6,7-hexahydro-1H-cyclopenta[d]pyrimidin-4-yl)benzonitrile",CHEMBL3888098,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 2C9 Inhibition Assay (Diclofenac): The inhibition of cytochrome P450 2C9-isoenzyme catalysed hydroxylation of Diclofenac by the test compound is assayed at 37° C. with human liver microsomes. All assays are carried out on a robotic system in 96 well plates. The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), human liver microsomes (0.1 mg/ml), Diclofenac (10 uM) and the test compound at five different concentrations or no compound (high control) in duplicate (e.g. highest concentration 10-50 uM with subsequent serial 1:4 dilutions). Following a short preincubation period, reactions are started with the cofactor (NADPH, 1 mM) and stopped by cooling the incubation down to 8° C. and subsequently by addition of one volume of acetonitrile.",IC50,>,50000.0,nM,N#Cc1ccc([C@H]2NC(=O)N(c3cccc(C(F)(F)F)c3)C3=C2C(=O)CC3)cc1,CHEMBL3886189,Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity,,2016.0,,,,,,,US-9290459-B1
17747919,CHEMBL4112385,"US9290459, 10A::US9290459, 47.21",CHEMBL3888098,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 2C9 Inhibition Assay (Diclofenac): The inhibition of cytochrome P450 2C9-isoenzyme catalysed hydroxylation of Diclofenac by the test compound is assayed at 37° C. with human liver microsomes. All assays are carried out on a robotic system in 96 well plates. The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), human liver microsomes (0.1 mg/ml), Diclofenac (10 uM) and the test compound at five different concentrations or no compound (high control) in duplicate (e.g. highest concentration 10-50 uM with subsequent serial 1:4 dilutions). Following a short preincubation period, reactions are started with the cofactor (NADPH, 1 mM) and stopped by cooling the incubation down to 8° C. and subsequently by addition of one volume of acetonitrile.",IC50,>,50000.0,nM,CS(=O)(=O)c1cc(C#N)ccc1[C@H]1NC(=O)N(c2cccc(C(F)(F)F)c2)C2=C1C(=O)CC2,CHEMBL3886189,Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity,,2016.0,,,,,,,US-9290459-B1
17747920,CHEMBL4107405,"US9290459, 9A",CHEMBL3888098,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 2C9 Inhibition Assay (Diclofenac): The inhibition of cytochrome P450 2C9-isoenzyme catalysed hydroxylation of Diclofenac by the test compound is assayed at 37° C. with human liver microsomes. All assays are carried out on a robotic system in 96 well plates. The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), human liver microsomes (0.1 mg/ml), Diclofenac (10 uM) and the test compound at five different concentrations or no compound (high control) in duplicate (e.g. highest concentration 10-50 uM with subsequent serial 1:4 dilutions). Following a short preincubation period, reactions are started with the cofactor (NADPH, 1 mM) and stopped by cooling the incubation down to 8° C. and subsequently by addition of one volume of acetonitrile.",IC50,>,50000.0,nM,CS(=O)(=O)N1C(=O)N(c2cccc(C(F)(F)F)c2)C2=C(C(=O)CC2)[C@H]1c1ccc(C#N)cc1,CHEMBL3886189,Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity,,2016.0,,,,,,,US-9290459-B1
17747921,CHEMBL4111285,"US9290459, 7.2A",CHEMBL3888098,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 2C9 Inhibition Assay (Diclofenac): The inhibition of cytochrome P450 2C9-isoenzyme catalysed hydroxylation of Diclofenac by the test compound is assayed at 37° C. with human liver microsomes. All assays are carried out on a robotic system in 96 well plates. The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), human liver microsomes (0.1 mg/ml), Diclofenac (10 uM) and the test compound at five different concentrations or no compound (high control) in duplicate (e.g. highest concentration 10-50 uM with subsequent serial 1:4 dilutions). Following a short preincubation period, reactions are started with the cofactor (NADPH, 1 mM) and stopped by cooling the incubation down to 8° C. and subsequently by addition of one volume of acetonitrile.",IC50,>,50000.0,nM,N#Cc1ccc([C@@H]2C3=C(CCC3=O)N(c3cccc(C(F)(F)F)c3)C(=O)N2C(=O)NCCO)cc1,CHEMBL3886189,Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity,,2016.0,,,,,,,US-9290459-B1
17747922,CHEMBL4112323,"US9290459, 41A",CHEMBL3888098,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 2C9 Inhibition Assay (Diclofenac): The inhibition of cytochrome P450 2C9-isoenzyme catalysed hydroxylation of Diclofenac by the test compound is assayed at 37° C. with human liver microsomes. All assays are carried out on a robotic system in 96 well plates. The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), human liver microsomes (0.1 mg/ml), Diclofenac (10 uM) and the test compound at five different concentrations or no compound (high control) in duplicate (e.g. highest concentration 10-50 uM with subsequent serial 1:4 dilutions). Following a short preincubation period, reactions are started with the cofactor (NADPH, 1 mM) and stopped by cooling the incubation down to 8° C. and subsequently by addition of one volume of acetonitrile.",IC50,>,50000.0,nM,CC(C)(O)CNC(=O)N1C(=O)N(c2cccc(C(F)(F)F)c2)C2=C(C(=O)CC2)[C@H]1c1ccc(C#N)cc1,CHEMBL3886189,Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity,,2016.0,,,,,,,US-9290459-B1
17747923,CHEMBL3617975,"(S)-4-(4-cyano-2-(methylsulfonyl)phenyl)-N-methyl-2,5-dioxo-1-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyrimidine-3(2H)-carboxamide",CHEMBL3888098,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 2C9 Inhibition Assay (Diclofenac): The inhibition of cytochrome P450 2C9-isoenzyme catalysed hydroxylation of Diclofenac by the test compound is assayed at 37° C. with human liver microsomes. All assays are carried out on a robotic system in 96 well plates. The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), human liver microsomes (0.1 mg/ml), Diclofenac (10 uM) and the test compound at five different concentrations or no compound (high control) in duplicate (e.g. highest concentration 10-50 uM with subsequent serial 1:4 dilutions). Following a short preincubation period, reactions are started with the cofactor (NADPH, 1 mM) and stopped by cooling the incubation down to 8° C. and subsequently by addition of one volume of acetonitrile.",IC50,>,50000.0,nM,CNC(=O)N1C(=O)N(c2cccc(C(F)(F)F)c2)C2=C(C(=O)CC2)[C@H]1c1ccc(C#N)cc1S(C)(=O)=O,CHEMBL3886189,Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity,,2016.0,,,,,,,US-9290459-B1
17747924,CHEMBL4110666,"US9290459, 47.2",CHEMBL3888098,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 2C9 Inhibition Assay (Diclofenac): The inhibition of cytochrome P450 2C9-isoenzyme catalysed hydroxylation of Diclofenac by the test compound is assayed at 37° C. with human liver microsomes. All assays are carried out on a robotic system in 96 well plates. The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), human liver microsomes (0.1 mg/ml), Diclofenac (10 uM) and the test compound at five different concentrations or no compound (high control) in duplicate (e.g. highest concentration 10-50 uM with subsequent serial 1:4 dilutions). Following a short preincubation period, reactions are started with the cofactor (NADPH, 1 mM) and stopped by cooling the incubation down to 8° C. and subsequently by addition of one volume of acetonitrile.",IC50,>,50000.0,nM,CCNC(=O)N1C(=O)N(c2cccc(C(F)(F)F)c2)C2=C(C(=O)CC2)[C@H]1c1ccc(C#N)cc1S(C)(=O)=O,CHEMBL3886189,Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity,,2016.0,,,,,,,US-9290459-B1
17748414,CHEMBL512283,(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide,CHEMBL3888114,B,,Homo sapiens,Cytochrome P450 2C9,"In Vitro CYP Inhibition Assay: P450 enzyme inhibition was measured using human cDNA-expressed CYP3A4, 2D6, 2C19, 2C9, and 1A2 recombinant enzymes and fluorogenic substrates (coumarin analogues) that are converted to fluorescent products. The analogues utilized for each isoenzyme are as follows: 7-benzyloxy-trifluoromethylcoumarin, (BFC) for 3A4; 3-[2-(N,N-diethyl-N-methyl amino)ethyl]7-methoxy-4-methylcoumarin, (AMMC) for 2D6; 3-cyano-7-ethoxycoumarin, (CEC) for 2C19 and 1 A2; and 7-methoxy-4-trifluoro-methylcoumarin, (MFC) for 2C9. These substrates were utilized at a single concentration (either 50 uM or 75 uM) at or near the apparent Km for each substrate. Fluorescence intensity was measured using a Wallac 1420 Victor3 Multi-label Counter Model (PerkinElmer, Wellesley, Mass.), with an excitation wavelength filter of 405 nm, and an emission filter of 460 nm (535 nm for the 3A4 and 2C9 substrates). Compound stocks (10 mM in a 4:1 ratio of acetonitrile:DMSO) were tested in this study using an 8-point dose response curve in duplicate (ranging from 0.15 uM-20.0 uM). The concentration of acetonitrile was kept constant at 0.4%, and the reaction was carried out at 37° C. for 30 minutes.",IC50,=,1300.0,nM,C[C@](O)(COc1ccc(Cl)c(F)c1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,CHEMBL3886583,SARMs and method of use thereof,,2016.0,,,,,,,US-9278914-B2
17748415,CHEMBL512283,(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide,CHEMBL3888114,B,,Homo sapiens,Cytochrome P450 2C9,"In Vitro CYP Inhibition Assay: P450 enzyme inhibition was measured using human cDNA-expressed CYP3A4, 2D6, 2C19, 2C9, and 1A2 recombinant enzymes and fluorogenic substrates (coumarin analogues) that are converted to fluorescent products. The analogues utilized for each isoenzyme are as follows: 7-benzyloxy-trifluoromethylcoumarin, (BFC) for 3A4; 3-[2-(N,N-diethyl-N-methyl amino)ethyl]7-methoxy-4-methylcoumarin, (AMMC) for 2D6; 3-cyano-7-ethoxycoumarin, (CEC) for 2C19 and 1 A2; and 7-methoxy-4-trifluoro-methylcoumarin, (MFC) for 2C9. These substrates were utilized at a single concentration (either 50 uM or 75 uM) at or near the apparent Km for each substrate. Fluorescence intensity was measured using a Wallac 1420 Victor3 Multi-label Counter Model (PerkinElmer, Wellesley, Mass.), with an excitation wavelength filter of 405 nm, and an emission filter of 460 nm (535 nm for the 3A4 and 2C9 substrates). Compound stocks (10 mM in a 4:1 ratio of acetonitrile:DMSO) were tested in this study using an 8-point dose response curve in duplicate (ranging from 0.15 uM-20.0 uM). The concentration of acetonitrile was kept constant at 0.4%, and the reaction was carried out at 37° C. for 30 minutes.",IC50,>,20000.0,nM,C[C@](O)(COc1ccc(Cl)c(F)c1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,CHEMBL3886583,SARMs and method of use thereof,,2016.0,,,,,,,US-9278914-B2
17751048,CHEMBL3545241,AC-430,CHEMBL3888165,B,,Homo sapiens,Cytochrome P450 2C9,"CYP450 Inhibition Assay: The ability of the R and S enantiomers of (4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol to inhibit the common drug metabolizing isoforms of cytochrome P450 (CYP) was evaluated against the following isoforms: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The compounds were incubated in duplicate with eight test compound concentrations (final DMSO concentration of 0.20%) with human liver microsomes (0.25 or 0.50 mg/mL) and NADPH (1 mM) in the presence of CYP isoform specific probe substrates (phenacetin, bupropion, taxol, diclofenac, mephenyloin, dextromethorphan, testosterone) at the Km for 10-20 minutes at 37° C. Selective CYP isoform inhibitors (furafulline, ticlopidine, quercetin, sulfaphenazole, ticlopidine, quinidine, ketoconazole) were screened alongside the test compounds as positive controls.",IC50,=,17400.0,nM,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1,CHEMBL3886191,"Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof",,2016.0,,,,,,,US-9295672-B2
17751055,CHEMBL3939800,"US9295672, (S)-(4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol",CHEMBL3888165,B,,Homo sapiens,Cytochrome P450 2C9,"CYP450 Inhibition Assay: The ability of the R and S enantiomers of (4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol to inhibit the common drug metabolizing isoforms of cytochrome P450 (CYP) was evaluated against the following isoforms: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The compounds were incubated in duplicate with eight test compound concentrations (final DMSO concentration of 0.20%) with human liver microsomes (0.25 or 0.50 mg/mL) and NADPH (1 mM) in the presence of CYP isoform specific probe substrates (phenacetin, bupropion, taxol, diclofenac, mephenyloin, dextromethorphan, testosterone) at the Km for 10-20 minutes at 37° C. Selective CYP isoform inhibitors (furafulline, ticlopidine, quercetin, sulfaphenazole, ticlopidine, quinidine, ketoconazole) were screened alongside the test compounds as positive controls.",IC50,=,24600.0,nM,Cc1cc(Nc2nc([C@@H](O)c3ccc(F)cc3)nc3ccccc23)n[nH]1,CHEMBL3886191,"Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof",,2016.0,,,,,,,US-9295672-B2
17751062,CHEMBL3962269,"US9295672, (R)-(4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol",CHEMBL3888165,B,,Homo sapiens,Cytochrome P450 2C9,"CYP450 Inhibition Assay: The ability of the R and S enantiomers of (4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol to inhibit the common drug metabolizing isoforms of cytochrome P450 (CYP) was evaluated against the following isoforms: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The compounds were incubated in duplicate with eight test compound concentrations (final DMSO concentration of 0.20%) with human liver microsomes (0.25 or 0.50 mg/mL) and NADPH (1 mM) in the presence of CYP isoform specific probe substrates (phenacetin, bupropion, taxol, diclofenac, mephenyloin, dextromethorphan, testosterone) at the Km for 10-20 minutes at 37° C. Selective CYP isoform inhibitors (furafulline, ticlopidine, quercetin, sulfaphenazole, ticlopidine, quinidine, ketoconazole) were screened alongside the test compounds as positive controls.",IC50,=,15200.0,nM,Cc1cc(Nc2nc([C@H](O)c3ccc(F)cc3)nc3ccccc23)n[nH]1,CHEMBL3886191,"Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof",,2016.0,,,,,,,US-9295672-B2
17763603,CHEMBL3942720,"US9333197, 4-Hydroxytolbutamide",CHEMBL3888372,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: Six test compound concentrations (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO; final DMSO concentration=0.25%) are incubated with human liver microsomes (1 mg/mL) and NADPH (1 mM) in the presence of the probe substrate tolbutamide (120 μM) for 60 min at 37° C. The selective CYP2C9 inhibitor, sulphaphenazole, is screened alongside the test compounds as a positive control.",IC50,>,25000.0,nM,CCCCNC(=O)NS(=O)(=O)c1ccc(CO)cc1,CHEMBL3886683,Apoptosis signal-regulating kinase inhibitor,,2016.0,,,,,,,US-9333197-B2
17774791,CHEMBL3975957,"US9359341, Formula B",CHEMBL3888576,B,,Homo sapiens,Cytochrome P450 2C9,"CYP Inhibition Assay: Incubation of phenacetin, diclofenac, dextromethorphan, mephenotoin, albendazole and testosterone with human liver microsomes in the presence of in each case eight different concentrations of a compound formula (B) (as potential inhibitor) is carried out on a incubator shaker at 37 C. Standard incubation mixtures comprise NADPH and substrates in 100 mM phosphate buffer (pH 7.4) in a total volume of 200 μl. Test compound are dissolved in acetonitrile. Incubated with pooled human liver microsomes at 37° C. for a defined time. The reactions are stopped by adding 100 μl of acetonitrile in which a suitable internal standard is always present. Precipitated proteins are removed by centrifugation, and the supernatants analyzed by LC-MS/MS.",IC50,=,22400.0,nM,O=CN(C[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)C(=O)c1ccc(Cl)s1,CHEMBL3886766,Aldehyde derivative of substitute oxazolidinones,,2016.0,,,,,,,US-9359341-B2
17774797,CHEMBL370614,5-Methyl-thiophene-2-carboxylic acid {(S)-2-oxo-3-[4-(3-oxo-morpholin-4-yl)-phenyl]-oxazolidin-5-ylmethyl}-amide,CHEMBL3888576,B,,Homo sapiens,Cytochrome P450 2C9,"CYP Inhibition Assay: Incubation of phenacetin, diclofenac, dextromethorphan, mephenotoin, albendazole and testosterone with human liver microsomes in the presence of in each case eight different concentrations of a compound formula (B) (as potential inhibitor) is carried out on a incubator shaker at 37 C. Standard incubation mixtures comprise NADPH and substrates in 100 mM phosphate buffer (pH 7.4) in a total volume of 200 μl. Test compound are dissolved in acetonitrile. Incubated with pooled human liver microsomes at 37° C. for a defined time. The reactions are stopped by adding 100 μl of acetonitrile in which a suitable internal standard is always present. Precipitated proteins are removed by centrifugation, and the supernatants analyzed by LC-MS/MS.",IC50,=,16700.0,nM,Cc1ccc(C(=O)NC[C@H]2CN(c3ccc(N4CCOCC4=O)cc3)C(=O)O2)s1,CHEMBL3886766,Aldehyde derivative of substitute oxazolidinones,,2016.0,,,,,,,US-9359341-B2
17777778,CHEMBL3916932,"US9394307, N-(2-{1H,3aH,7aH-pyrrolo[2,3-b]pyridine-4-carbonyl}-5-chloropyridin-3-yl)-4-chloro-3-(trifluoromethyl)benzene-1-sulfonamide",CHEMBL3888738,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: The test compounds were incubated with pooled human liver microsomes at 37° C. in the presence of NADPH and appropriate concentrations of substrates specific for CYP2C9 and 3A4. 120 μL of a mixture of human liver microsomes (HLM) in 50 mM potassium phosphate/5 mM MgCl2 buffer was added into all wells of row A in a 96-well plate. The concentration of microsomal protein was 2-fold the intended protein concentration for the particular isozyme assay recorded in Table 4. In addition, 80 μL of this human liver microsome preparation spiked with 1% DMSO was dispensed into all wells of rows B through H. 1.2 μL of each individual test compound in DMSO (10 mM) was added to the first 10 wells of row A (5 different test compounds each in duplicate). Additionally, 1.2 μL of the DMSO stock of the control inhibitor for the isozyme under study was added into the final two wells of row A to give a concentration two-fold above the highest final concentration. Three-fold serial dilutions were performed by taking 40 μL from each solution in wells of row A (wells 1-12, both compounds and controls) and diluting into the wells of row B. After thorough mixing, 40 μL from each solution in wells of row B were dispensed with a multichannel pipette (12 channels) into the wells of row C and the controls and test compounds hence further diluted. This process was repeated for rows D through G. After mixing, 40 μL was removed and discarded from the wells of row G. This procedure resulted in 80 μL of solution being present in all wells of all rows A through H, with protein concentrations being twice the final intended concentrations in all wells of rows, and test compound and control concentration being twice the final intended concentrations in rows A through G. Row H was not spiked with a test compound or positive control. The plate was covered and pre-incubated for 10 minutes in a 37° C. incubator. The reaction was initiated by adding 80 μL of a solution of the substrate for the isozyme under investigation in 50 mM potassium phosphate/5 mM MgCl2 buffer solution with 4 mM NADPH present, at a substrate concentration two-fold the intended final substrate concentrations using a multichannel pipette. The substrate solution was added to all wells rows A to H excluding wells 95 and 96 (microsomal blanks). The plate was covered and incubated at 37° C. for the time listed in Table 4 for the isoform under investigation. The reaction was stopped by dispensing 120 μL of internal standard (200 ng/mL CCX915-6A) in acetonitrile to all wells. 80 μL of the specific substrate/NADPH solution described above was added into the well 95 and 96 after stopping the reaction to provide the blank. The plate was vortexed for 10 min and spun in a centrifuge at 4,450 rpm and 4° C. for 10 min. With a multichannel pipette, 80 μL of the supernatant was transferred into a sample plate wells containing 80 μL of 0.1% formic acid/water and mixed well for analysis on LC-MS/MS as described in sections E and F.",IC50,=,3000.0,nM,O=C(C1=CC=NC2NC=CC12)c1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(C(F)(F)F)c1,CHEMBL3886812,Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation,,2016.0,,,,,,,US-9394307-B2
17777779,CHEMBL3948371,"US9394307, 4-chloro-N-(5-chloro-2-{7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl}pyridin-3-yl)-3-(trifluoromethyl)benzene-1-sulfonamide",CHEMBL3888738,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assay: The test compounds were incubated with pooled human liver microsomes at 37° C. in the presence of NADPH and appropriate concentrations of substrates specific for CYP2C9 and 3A4. 120 μL of a mixture of human liver microsomes (HLM) in 50 mM potassium phosphate/5 mM MgCl2 buffer was added into all wells of row A in a 96-well plate. The concentration of microsomal protein was 2-fold the intended protein concentration for the particular isozyme assay recorded in Table 4. In addition, 80 μL of this human liver microsome preparation spiked with 1% DMSO was dispensed into all wells of rows B through H. 1.2 μL of each individual test compound in DMSO (10 mM) was added to the first 10 wells of row A (5 different test compounds each in duplicate). Additionally, 1.2 μL of the DMSO stock of the control inhibitor for the isozyme under study was added into the final two wells of row A to give a concentration two-fold above the highest final concentration. Three-fold serial dilutions were performed by taking 40 μL from each solution in wells of row A (wells 1-12, both compounds and controls) and diluting into the wells of row B. After thorough mixing, 40 μL from each solution in wells of row B were dispensed with a multichannel pipette (12 channels) into the wells of row C and the controls and test compounds hence further diluted. This process was repeated for rows D through G. After mixing, 40 μL was removed and discarded from the wells of row G. This procedure resulted in 80 μL of solution being present in all wells of all rows A through H, with protein concentrations being twice the final intended concentrations in all wells of rows, and test compound and control concentration being twice the final intended concentrations in rows A through G. Row H was not spiked with a test compound or positive control. The plate was covered and pre-incubated for 10 minutes in a 37° C. incubator. The reaction was initiated by adding 80 μL of a solution of the substrate for the isozyme under investigation in 50 mM potassium phosphate/5 mM MgCl2 buffer solution with 4 mM NADPH present, at a substrate concentration two-fold the intended final substrate concentrations using a multichannel pipette. The substrate solution was added to all wells rows A to H excluding wells 95 and 96 (microsomal blanks). The plate was covered and incubated at 37° C. for the time listed in Table 4 for the isoform under investigation. The reaction was stopped by dispensing 120 μL of internal standard (200 ng/mL CCX915-6A) in acetonitrile to all wells. 80 μL of the specific substrate/NADPH solution described above was added into the well 95 and 96 after stopping the reaction to provide the blank. The plate was vortexed for 10 min and spun in a centrifuge at 4,450 rpm and 4° C. for 10 min. With a multichannel pipette, 80 μL of the supernatant was transferred into a sample plate wells containing 80 μL of 0.1% formic acid/water and mixed well for analysis on LC-MS/MS as described in sections E and F.",IC50,=,15000.0,nM,O=C(c1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(C(F)(F)F)c1)c1ncnc2[nH]ccc12,CHEMBL3886812,Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation,,2016.0,,,,,,,US-9394307-B2
17787779,CHEMBL4113903,"US9428492, A",CHEMBL3888973,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assay: Inhibition assay using CYP2C9,IC50,>,50000.0,nM,Cc1nc(C2C[C@H]2c2nc3ccccc3n2C)cc(-n2nc(C)nc2C(C)(C)O)n1,CHEMBL3886902,Secondary alcohol substituted triazoles as PDE10 inhibitors,,2016.0,,,,,,,US-9428492-B2
17787780,CHEMBL4110017,"US9428492, B",CHEMBL3888973,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assay: Inhibition assay using CYP2C9,IC50,=,10500.0,nM,CO[C@H](C)c1nc(C)nn1-c1cc(C2C[C@H]2c2nc3ccccc3n2C)nc(C)n1,CHEMBL3886902,Secondary alcohol substituted triazoles as PDE10 inhibitors,,2016.0,,,,,,,US-9428492-B2
17787781,CHEMBL4112279,"US9428492, C",CHEMBL3888973,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assay: Inhibition assay using CYP2C9,IC50,=,46000.0,nM,COCc1nc(C)nn1-c1cc(C2C[C@H]2c2nc3ccccc3n2C)nc(C)n1,CHEMBL3886902,Secondary alcohol substituted triazoles as PDE10 inhibitors,,2016.0,,,,,,,US-9428492-B2
17787782,CHEMBL4110385,"US9428492, 1::US9428492, 2",CHEMBL3888973,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assay: Inhibition assay using CYP2C9,IC50,>,50000.0,nM,Cc1nc(N2CC(c3nc4ccccc4n3C)C2)cc(-n2nc(C)nc2[C@@H](C)O)n1,CHEMBL3886902,Secondary alcohol substituted triazoles as PDE10 inhibitors,,2016.0,,,,,,,US-9428492-B2
17787783,CHEMBL4110385,"US9428492, 1::US9428492, 2",CHEMBL3888973,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assay: Inhibition assay using CYP2C9,IC50,>,50000.0,nM,Cc1nc(N2CC(c3nc4ccccc4n3C)C2)cc(-n2nc(C)nc2[C@@H](C)O)n1,CHEMBL3886902,Secondary alcohol substituted triazoles as PDE10 inhibitors,,2016.0,,,,,,,US-9428492-B2
17787784,CHEMBL3915808,"US9428492, 3::US9428492, 3a::US9428492, 3b",CHEMBL3888973,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assay: Inhibition assay using CYP2C9,IC50,>,50000.0,nM,Cc1nc(N2CC(c3nc4ccccc4n3C)C2)cc(-n2nc(C)nc2C(O)C(F)(F)F)n1,CHEMBL3886902,Secondary alcohol substituted triazoles as PDE10 inhibitors,,2016.0,,,,,,,US-9428492-B2
17787785,CHEMBL3909277,"US9428492, 4::US9428492, 4a::US9428492, 4b",CHEMBL3888973,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assay: Inhibition assay using CYP2C9,IC50,>,50000.0,nM,CCC(O)c1nc(C)nn1-c1cc(N2CC(c3nc4ccccc4n3C)C2)nc(C)n1,CHEMBL3886902,Secondary alcohol substituted triazoles as PDE10 inhibitors,,2016.0,,,,,,,US-9428492-B2
17787786,CHEMBL3929295,"US9428492, 6::US9428492, 6a::US9428492, 6b",CHEMBL3888973,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assay: Inhibition assay using CYP2C9,IC50,>,50000.0,nM,Cc1nc(N2CC(c3nc4ccccc4n3C)C2)cc(-n2nc(C)nc2C(O)C2CC2)n1,CHEMBL3886902,Secondary alcohol substituted triazoles as PDE10 inhibitors,,2016.0,,,,,,,US-9428492-B2
17787787,CHEMBL3962106,"US9428492, 13",CHEMBL3888973,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assay: Inhibition assay using CYP2C9,IC50,>,50000.0,nM,Cc1nc(C2C[C@H]2c2nc3ccccc3n2C)cc(-n2nc(C)nc2[C@H](C)O)n1,CHEMBL3886902,Secondary alcohol substituted triazoles as PDE10 inhibitors,,2016.0,,,,,,,US-9428492-B2
17787788,CHEMBL4107014,"US9428492, 14",CHEMBL3888973,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assay: Inhibition assay using CYP2C9,IC50,>,50000.0,nM,Cc1nc(C2C[C@H]2c2nc3ccccc3n2C)cc(-n2nc(C)nc2[C@@H](C)O)n1,CHEMBL3886902,Secondary alcohol substituted triazoles as PDE10 inhibitors,,2016.0,,,,,,,US-9428492-B2
17787789,CHEMBL4107580,"US9428492, 19::US9428492, 19a",CHEMBL3888973,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assay: Inhibition assay using CYP2C9,IC50,>,50000.0,nM,CCC(O)c1nc(C)nn1-c1cc(C2C[C@H]2c2nc3ccccc3n2C)nc(C)n1,CHEMBL3886902,Secondary alcohol substituted triazoles as PDE10 inhibitors,,2016.0,,,,,,,US-9428492-B2
17791722,CHEMBL3898132,"US9447092, Comparator 1, Example 56",CHEMBL3889069,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assays: Inhibition of CYP isozymes was determined using a mixture of probe substrates. The samples were incubated for 10 minutes followed by protein precipitation with methanol. The substrate metabolites in each sample were measured by LC/MS/MS using reverse-phase liquid chromatography and positive ion mode ESI with multiple reaction monitoring (MRM).,IC50,=,30.0,nM,Cn1cc(-c2nc3c(N4CCN(Cc5cccnc5)CC4)c(Br)cnc3[nH]2)cn1,CHEMBL3886141,Pharmaceutically active compounds,,2016.0,,,,,,,US-9447092-B2
17791723,CHEMBL3891461,"US9447092, Comparator 2, Example 57",CHEMBL3889069,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assays: Inhibition of CYP isozymes was determined using a mixture of probe substrates. The samples were incubated for 10 minutes followed by protein precipitation with methanol. The substrate metabolites in each sample were measured by LC/MS/MS using reverse-phase liquid chromatography and positive ion mode ESI with multiple reaction monitoring (MRM).,IC50,=,30.0,nM,Cc1nn(C)c(C)c1-c1nc2c(N3CCN(Cc4cccnc4)CC3)c(Br)cnc2[nH]1,CHEMBL3886141,Pharmaceutically active compounds,,2016.0,,,,,,,US-9447092-B2
17791724,CHEMBL2207503,"6-Chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine",CHEMBL3889069,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assays: Inhibition of CYP isozymes was determined using a mixture of probe substrates. The samples were incubated for 10 minutes followed by protein precipitation with methanol. The substrate metabolites in each sample were measured by LC/MS/MS using reverse-phase liquid chromatography and positive ion mode ESI with multiple reaction monitoring (MRM).,IC50,=,30.0,nM,Cc1nn(C)cc1-c1nc2c(N3CCN(Cc4ccc(Cl)cc4)CC3)c(Cl)cnc2[nH]1,CHEMBL3886141,Pharmaceutically active compounds,,2016.0,,,,,,,US-9447092-B2
17791725,CHEMBL2207500,"3-((4-(6-Chloro-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-1,2,4-oxadiazole",CHEMBL3889069,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assays: Inhibition of CYP isozymes was determined using a mixture of probe substrates. The samples were incubated for 10 minutes followed by protein precipitation with methanol. The substrate metabolites in each sample were measured by LC/MS/MS using reverse-phase liquid chromatography and positive ion mode ESI with multiple reaction monitoring (MRM).,IC50,=,30.0,nM,Cc1nn(C)cc1-c1nc2c(N3CCN(Cc4ncon4)CC3)c(Cl)cnc2[nH]1,CHEMBL3886141,Pharmaceutically active compounds,,2016.0,,,,,,,US-9447092-B2
17791726,CHEMBL2207501,"3-((4-(6-Chloro-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methyl-1,2,4-oxadiazole",CHEMBL3889069,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition Assays: Inhibition of CYP isozymes was determined using a mixture of probe substrates. The samples were incubated for 10 minutes followed by protein precipitation with methanol. The substrate metabolites in each sample were measured by LC/MS/MS using reverse-phase liquid chromatography and positive ion mode ESI with multiple reaction monitoring (MRM).,IC50,=,30.0,nM,Cc1nc(CN2CCN(c3c(Cl)cnc4[nH]c(-c5cn(C)nc5C)nc34)CC2)no1,CHEMBL3886141,Pharmaceutically active compounds,,2016.0,,,,,,,US-9447092-B2
17793007,CHEMBL3926686,"US9434724, 1",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccccc12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793008,CHEMBL3915393,"US9434724, 2::US9434724, 27",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccc(Cl)cc12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793009,CHEMBL3942519,"US9434724, 10::US9434724, 17",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,COc1ccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793010,CHEMBL3951269,"US9434724, 11",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(F)ccc12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793011,CHEMBL3927059,"US9434724, 12",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccc(F)cc12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793012,CHEMBL3926432,"US9434724, 13",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cccc(F)c12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793013,CHEMBL3900133,"US9434724, 14",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)ccc12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793014,CHEMBL3930161,"US9434724, 15",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccc(O)cc12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793015,CHEMBL3905553,"US9434724, 16",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,COc1cccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793016,CHEMBL3942519,"US9434724, 10::US9434724, 17",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,COc1ccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793017,CHEMBL3947939,"US9434724, 18",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793018,CHEMBL3941986,"US9434724, 19",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,Cc1cccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793019,CHEMBL3960725,"US9434724, 20",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,Cc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793020,CHEMBL3945113,"US9434724, 21",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,Cc1cccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793021,CHEMBL3934554,"US9434724, 22",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(Br)ccc12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793022,CHEMBL3957026,"US9434724, 23",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccc(Br)cc12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793023,CHEMBL3899367,"US9434724, 24",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cccc(Br)c12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793024,CHEMBL3889611,"US9434724, 25",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2c(Cl)cccc12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793025,CHEMBL3951766,"US9434724, 26",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(Cl)ccc12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793026,CHEMBL3915393,"US9434724, 2::US9434724, 27",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccc(Cl)cc12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793027,CHEMBL3923510,"US9434724, 28",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,N#Cc1ccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793028,CHEMBL3906058,"US9434724, 29",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(OC(F)(F)F)ccc12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793029,CHEMBL3930595,"US9434724, 30",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc3c(cc12)OCCO3,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793030,CHEMBL3932173,"US9434724, 31",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(OC(F)F)ccc12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793031,CHEMBL3907721,"US9434724, 32",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,COc1cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2cc1F,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793032,CHEMBL3923223,"US9434724, 33",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,COc1cc(F)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793033,CHEMBL3962437,"US9434724, 34",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1C,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793034,CHEMBL3910483,"US9434724, 35",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cccc(Cl)c12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793035,CHEMBL3895257,"US9434724, 36",CHEMBL3889092,B,,Homo sapiens,Cytochrome P450 2C9,Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.,IC50,>,10000.0,nM,COc1cccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793036,CHEMBL3969361,"US9434724, 37",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,COc1cc(C)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793037,CHEMBL3980571,"US9434724, 38",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,COc1cc(Cl)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793038,CHEMBL3917789,"US9434724, 39",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1Cl,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793039,CHEMBL3892761,"US9434724, 40",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1OC,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793040,CHEMBL3961768,"US9434724, 41",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(F)cc(Br)c12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793041,CHEMBL3916144,"US9434724, 42",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(Cl)cc(Br)c12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793042,CHEMBL3891650,"US9434724, 43",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,Cc1c(F)ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793043,CHEMBL3907175,"US9434724, 44",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,Cc1cc(F)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793044,CHEMBL3984048,"US9434724, 45",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,Cc1ccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793045,CHEMBL3910048,"US9434724, 46",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)cc(Cl)c12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793046,CHEMBL3977772,"US9434724, 47",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1Br,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793047,CHEMBL3967401,"US9434724, 48",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,COc1cc(Br)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793048,CHEMBL3906051,"US9434724, 49",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,Cc1cc(Br)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793049,CHEMBL3920876,"US9434724, 50",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,Cc1cc(Cl)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793050,CHEMBL3908841,"US9434724, 51",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(F)c(F)cc12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793051,CHEMBL3979166,"US9434724, 52",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(Cl)c(F)cc12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793052,CHEMBL3941189,"US9434724, 53",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)cc(Br)c12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793053,CHEMBL3945612,"US9434724, 54",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,Cc1cc(C)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793054,CHEMBL3898625,"US9434724, 55",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,Cc1cc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2cc1O,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793055,CHEMBL3973221,"US9434724, 56",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,COc1cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2cc1C,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793056,CHEMBL3939590,"US9434724, 57",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,COc1cc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2cc1F,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793057,CHEMBL3944958,"US9434724, 59",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)c(F)cc12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793058,CHEMBL3923319,"US9434724, 60",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,Cc1cc(C#N)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17793059,CHEMBL3918191,"US9434724, 83",CHEMBL3889093,B,,Homo sapiens,Cytochrome P450 2C9,"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration.",IC50,>,10000.0,nM,Cc1cc(O)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12,CHEMBL3886940,Quinuclidines for modulating alpha 7 activity,,2016.0,,,,,,,US-9434724-B2
17798397,CHEMBL3921669,"US9453031, 3",CHEMBL3889168,B,,Homo sapiens,Cytochrome P450 2C9,"Luciferase-Based P450-Glo Assay: Five CYP isoforms (0.5 pmol) were tested, namely 1A2, 2C9, 2C19, 2D6 and 3A4 (each isoform was assayed in a separate assay plate). Each assay plate contained several compounds at 2 concentrations (10 uM and 1 uM), with 2 replicates at each concentration or a small number of compounds per plate in dose response by duplicate (50, 16.5, 5.4, 1.8, 0.6, 0.2, 0.066, 0.022, 0.007 uM). In addition, each assay plate contained 8 different concentrations of an isoform-specific inhibitor (Furafylline, Sulfaphenazole, N-3-benzylnirvanol, Quinidine and Ketoconazole as inhibitors of CYP 1A2, 2C9, 2C19, 2D6 and 3A4, respectively), with two replicates at each concentration. The test compounds and the reference inhibitors were tested at a final DMSO concentration of 0.5%. The assay plate included also 8 replicates a vehicle control containing 0.5% DMSO/H2O. The membranes containing the CYPs, test compound and the probe substrate were pre-incubated 10 min at 37°C. in the absence of NADPH, NADPH was then added following incubation for 60 minutes at 37°C., the reaction was terminated by the addition of Luciferin detection reagent. After 20 min incubation at 37°C., the assay plate was read in the Envision 2104 Multilable reader. Values were normalized against the control activity included for each CYP. These values were plotted against the inhibitor concentration and were fitted to a sigmoid dose-response curve by using the model sigmoidal Four-Parameter Logistc inplement for Activity baseÂ  software.",IC50,>,50000.0,nM,CS(=O)(=O)C1(c2nc(-c3cccc4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CCOCC1,CHEMBL3886972,Chemical entities,,2016.0,,,,,,,US-9453031-B2
17798398,CHEMBL3985847,"US9453031, 11",CHEMBL3889168,B,,Homo sapiens,Cytochrome P450 2C9,"Luciferase-Based P450-Glo Assay: Five CYP isoforms (0.5 pmol) were tested, namely 1A2, 2C9, 2C19, 2D6 and 3A4 (each isoform was assayed in a separate assay plate). Each assay plate contained several compounds at 2 concentrations (10 uM and 1 uM), with 2 replicates at each concentration or a small number of compounds per plate in dose response by duplicate (50, 16.5, 5.4, 1.8, 0.6, 0.2, 0.066, 0.022, 0.007 uM). In addition, each assay plate contained 8 different concentrations of an isoform-specific inhibitor (Furafylline, Sulfaphenazole, N-3-benzylnirvanol, Quinidine and Ketoconazole as inhibitors of CYP 1A2, 2C9, 2C19, 2D6 and 3A4, respectively), with two replicates at each concentration. The test compounds and the reference inhibitors were tested at a final DMSO concentration of 0.5%. The assay plate included also 8 replicates a vehicle control containing 0.5% DMSO/H2O. The membranes containing the CYPs, test compound and the probe substrate were pre-incubated 10 min at 37°C. in the absence of NADPH, NADPH was then added following incubation for 60 minutes at 37°C., the reaction was terminated by the addition of Luciferin detection reagent. After 20 min incubation at 37°C., the assay plate was read in the Envision 2104 Multilable reader. Values were normalized against the control activity included for each CYP. These values were plotted against the inhibitor concentration and were fitted to a sigmoid dose-response curve by using the model sigmoidal Four-Parameter Logistc inplement for Activity baseÂ  software.",IC50,=,34000.0,nM,CNc1nc2ccccc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OC[C@@H]1COCCN21,CHEMBL3886972,Chemical entities,,2016.0,,,,,,,US-9453031-B2
17801515,CHEMBL3925961,"US9481673, 27",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,=,400.0,nM,CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc3ncccc3c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801516,CHEMBL3910478,"US9481673, 64",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,=,400.0,nM,CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc3nc(C)ccc3c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801517,CHEMBL3934839,"US9481673, 81",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,=,900.0,nM,CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(ccc(=O)n3C)c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801518,CHEMBL3969750,"US9481673, 82",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,=,400.0,nM,CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc(-c3ccon3)cc2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801519,CHEMBL3947193,"US9481673, 94",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,=,700.0,nM,CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(c2)OCC(=O)N3C)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801520,CHEMBL3970302,"US9481673, 185",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,=,4800.0,nM,CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccccc2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801596,CHEMBL3895473,"US9481673, (S)-1",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,=,38000.0,nM,CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cccnc3OC)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801597,CHEMBL3911035,"US9481673, (S)-2",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,>,50000.0,nM,CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccnc(C)c3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801598,CHEMBL3981054,"US9481673, (S)-3",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,>,50000.0,nM,CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cnn(C)c3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801599,CHEMBL3905467,"US9481673, (S)-4",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,=,27000.0,nM,CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cncn3C)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801600,CHEMBL3973040,"US9481673, (S)-5",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,>,50000.0,nM,CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cccnc3C)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801601,CHEMBL3896543,"US9481673, (S)-6",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,>,50000.0,nM,CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccc(C)nc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801602,CHEMBL3967713,"US9481673, (S)-7",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,>,50000.0,nM,CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cnc(C)nc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801603,CHEMBL3928571,"US9481673, (S)-8",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,>,50000.0,nM,CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccnc(OC)c3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801604,CHEMBL3964219,"US9481673, (S)-9",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,>,50000.0,nM,CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccc(OC)nc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801605,CHEMBL3930510,"US9481673, (S)-10",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,=,45000.0,nM,CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cccnc3OC)nc3cc(C)ccn23)c(C#Cc2ccc3c(ccc(=O)n3C)c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801606,CHEMBL3958007,"US9481673, (S)-11",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,>,50000.0,nM,CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccnc(C)c3)nc3cc(C)ccn23)c(C#Cc2ccccc2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801607,CHEMBL3935923,"US9481673, (S)-12",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,>,50000.0,nM,CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cnc(C)nc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(ccc(=O)n3C)c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801608,CHEMBL3969059,"US9481673, (S)-13",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,>,50000.0,nM,CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccnc(OC)c3)nc3cc(C)ccn23)c(C#Cc2ccc3c(ccc(=O)n3C)c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801609,CHEMBL3929505,"US9481673, (S)-14",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,>,50000.0,nM,CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccc(OC)nc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(ccc(=O)n3C)c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801610,CHEMBL3974300,"US9481673, (S)-15",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,=,19000.0,nM,CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cccnc3OC)nc3cc(Cl)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17801611,CHEMBL3956933,"US9481673, (S)-16",CHEMBL3889226,B,,Homo sapiens,Cytochrome P450 2C9,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",IC50,=,21000.0,nM,CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cccnc3OC)nc3ccccn23)c(C#Cc2ccc3c(C)nccc3c2)n1,CHEMBL3886996,6-alkynyl-pyridine derivatives,,2016.0,,,,,,,US-9481673-B2
17953179,CHEMBL4092421,"N-Benzyl-N-hydroxy-2,2-dimethylbutanamide",CHEMBL3993152,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCC(C)(C)C(=O)N(O)Cc1ccccc1,CHEMBL3992509,"Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome.",J Med Chem,2017.0,60,3,972,986,10.1021/acs.jmedchem.6b01196,27992216.0,
17957060,CHEMBL4095693,"1-(4-chlorophenyl)-7-(3-methoxyphenyl)-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL3993855,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,=,3780.0,nM,COc1cccc(C2=NC(C(F)(F)F)(C(F)(F)F)c3c(n(-c4ccc(Cl)cc4)c(=O)[nH]c3=O)N2)c1,CHEMBL3992536,"Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core.",J Med Chem,2017.0,60,4,1611,1616,10.1021/acs.jmedchem.6b01706,28103022.0,
17957061,CHEMBL4079193,"1,3-dimethyl-7-(3-nitrophenyl)-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL3993855,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,=,470.0,nM,Cn1c2c(c(=O)n(C)c1=O)C(C(F)(F)F)(C(F)(F)F)N=C(c1cccc([N+](=O)[O-])c1)N2,CHEMBL3992536,"Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core.",J Med Chem,2017.0,60,4,1611,1616,10.1021/acs.jmedchem.6b01706,28103022.0,
17957062,CHEMBL1341270,SID17416287,CHEMBL3993855,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,=,410.0,nM,Cn1c2c(c(=O)n(C)c1=O)C(C(F)(F)F)(C(F)(F)F)NC(c1ccc(Cl)cc1)=N2,CHEMBL3992536,"Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core.",J Med Chem,2017.0,60,4,1611,1616,10.1021/acs.jmedchem.6b01706,28103022.0,
17978109,CHEMBL4068784,(2-chloropyridin-4-yl)methanamine,CHEMBL3997555,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,NCc1ccnc(Cl)c1,CHEMBL3994667,Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.,ACS Med Chem Lett,2017.0,8,4,423,427,10.1021/acsmedchemlett.7b00014,28435530.0,
17981091,CHEMBL4071093,"(2E)-1-(2-hydroxy-4,5-dimethoxyphenyl)-3-(3-methoxyphenyl)prop-2-en-1-one",CHEMBL3998588,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect cells using Luciferin-H as substrate in presence of NADPH by P450-Glo luminescence assay,IC50,=,42100.0,nM,COc1cccc(/C=C/C(=O)c2cc(OC)c(OC)cc2O)c1,CHEMBL3997782,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,Eur J Med Chem,2017.0,126,,1129,1135,10.1016/j.ejmech.2016.12.017,28064141.0,
17981092,CHEMBL55,4-[(5-{4-[(Z)-amino(imino)methyl]phenoxy}pentyl)oxy]benzenecarboximidamide,CHEMBL3998588,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect cells using Luciferin-H as substrate in presence of NADPH by P450-Glo luminescence assay,IC50,>,100000.0,nM,N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1,CHEMBL3997782,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,Eur J Med Chem,2017.0,126,,1129,1135,10.1016/j.ejmech.2016.12.017,28064141.0,
17986306,CHEMBL4071864,"(S)-5-Benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide",CHEMBL3999267,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9,IC50,=,25000.0,nM,CN1C(=O)[C@@H](NC(=O)c2n[nH]c(Cc3ccccc3)n2)COc2ccccc21,CHEMBL3997808,Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.,J Med Chem,2017.0,60,4,1247,1261,10.1021/acs.jmedchem.6b01751,28151659.0,
17991352,CHEMBL3137332,FEVIPIPRANT,CHEMBL4000129,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1C(F)(F)F,CHEMBL3997855,"Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma.",ACS Med Chem Lett,2017.0,8,5,582,586,10.1021/acsmedchemlett.7b00157,28523115.0,
17995490,CHEMBL4097275,4'-(2-tert-butylphenoxy)-3'-(3-(4-(trifluoromethoxy)phenyl)ureido)biphenyl-3-carboxylic acid,CHEMBL4001255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2500.0,nM,CC(C)(C)c1ccccc1Oc1ccc(-c2cccc(C(=O)O)c2)cc1NC(=O)Nc1ccc(OC(F)(F)F)cc1,CHEMBL4000192,"Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors.",Bioorg Med Chem Lett,2017.0,27,3,582,585,10.1016/j.bmcl.2016.12.015,28003141.0,
17995491,CHEMBL4060679,"4-methoxy-4'-(5,6,7,8-tetrahydronaphthalen-1-yloxy)-3'-(3-m-tolylureido)biphenyl-3-carboxylic acid",CHEMBL4001255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,3000.0,nM,COc1ccc(-c2ccc(Oc3cccc4c3CCCC4)c(NC(=O)Nc3cccc(C)c3)c2)cc1C(=O)O,CHEMBL4000192,"Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors.",Bioorg Med Chem Lett,2017.0,27,3,582,585,10.1016/j.bmcl.2016.12.015,28003141.0,
17995492,CHEMBL4082553,"4-methoxy-4'-(5,6,7,8-tetrahydronaphthalen-1-yloxy)-3'-(3-o-tolylureido)biphenyl-3-carboxylic acid",CHEMBL4001255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,3000.0,nM,COc1ccc(-c2ccc(Oc3cccc4c3CCCC4)c(NC(=O)Nc3ccccc3C)c2)cc1C(=O)O,CHEMBL4000192,"Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors.",Bioorg Med Chem Lett,2017.0,27,3,582,585,10.1016/j.bmcl.2016.12.015,28003141.0,
17995493,CHEMBL4060089,"3'-(3-(2-chlorophenyl)ureido)-4-methoxy-4'-(5,6,7,8-tetrahydronaphthalen-1-yloxy)biphenyl-3-carboxylic acid",CHEMBL4001255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,3000.0,nM,COc1ccc(-c2ccc(Oc3cccc4c3CCCC4)c(NC(=O)Nc3ccccc3Cl)c2)cc1C(=O)O,CHEMBL4000192,"Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors.",Bioorg Med Chem Lett,2017.0,27,3,582,585,10.1016/j.bmcl.2016.12.015,28003141.0,
18001358,CHEMBL2105720,LESINURAD,CHEMBL4002423,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,100000.0,nM,O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12,CHEMBL4000255,Discovery and Assessment of Atropisomers of (±)-Lesinurad.,ACS Med Chem Lett,2017.0,8,3,299,303,10.1021/acsmedchemlett.6b00465,28337320.0,
18001359,CHEMBL2105720,LESINURAD,CHEMBL4002423,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,78700.0,nM,O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12,CHEMBL4000255,Discovery and Assessment of Atropisomers of (±)-Lesinurad.,ACS Med Chem Lett,2017.0,8,3,299,303,10.1021/acsmedchemlett.6b00465,28337320.0,
18001360,CHEMBL2105720,LESINURAD,CHEMBL4002423,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,31200.0,nM,O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12,CHEMBL4000255,Discovery and Assessment of Atropisomers of (±)-Lesinurad.,ACS Med Chem Lett,2017.0,8,3,299,303,10.1021/acsmedchemlett.6b00465,28337320.0,
18005543,CHEMBL4094462,2-((6-Methoxy-2-methylquinolin-4-yl)oxy)-N-(4-pentylphenyl)acetamide,CHEMBL4003199,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate by HPLC-MS/MS method,IC50,>,30000.0,nM,CCCCCc1ccc(NC(=O)COc2cc(C)nc3ccc(OC)cc23)cc1,CHEMBL4002573,New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis.,Eur J Med Chem,2017.0,126,,491,501,10.1016/j.ejmech.2016.11.048,27914363.0,
18015048,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4004666,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 5 to 15 mins,IC50,=,205.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4002644,"Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin.",ACS Med Chem Lett,2017.0,8,3,321,326,10.1021/acsmedchemlett.6b00491,28337324.0,
18015162,CHEMBL4101807,2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde,CHEMBL4004666,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 5 to 15 mins,IC50,=,8500.0,nM,CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,CHEMBL4002644,"Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin.",ACS Med Chem Lett,2017.0,8,3,321,326,10.1021/acsmedchemlett.6b00491,28337324.0,
18015294,CHEMBL3918431,"(2R)-N-(Isoquinolin-3-yl)-3'H-4-azaspiro[bicyclo[2.2.2]octane-2,2'-[1,4]oxazole]-5'-amine",CHEMBL4004719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 using fluorogenic substrate preincubated for 30 mins and measured after 20 to 60 mins in presence of NADPH regenerating system by fluorescence assay,IC50,>,40000.0,nM,c1ccc2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncc2c1,CHEMBL4002647,"BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.",ACS Med Chem Lett,2017.0,8,3,366,371,10.1021/acsmedchemlett.7b00032,28337332.0,
18015295,CHEMBL4084621,"(2R)-N-(6-(1H-Imidazol-1-yl)-4-pyrimidinyl)-4'H-spiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxazol]-2'-amine",CHEMBL4004719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 using fluorogenic substrate preincubated for 30 mins and measured after 20 to 60 mins in presence of NADPH regenerating system by fluorescence assay,IC50,>,30000.0,nM,c1cn(-c2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncn2)cn1,CHEMBL4002647,"BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.",ACS Med Chem Lett,2017.0,8,3,366,371,10.1021/acsmedchemlett.7b00032,28337332.0,
18017753,CHEMBL3301604,RALINEPAG,CHEMBL4005297,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C(O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2ccc(Cl)cc2)CC1,CHEMBL4004807,"Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.",J Med Chem,2017.0,60,3,913,927,10.1021/acs.jmedchem.6b00871,28072531.0,
18017754,CHEMBL3933704,2-(((trans)-4-(((3-fluorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid,CHEMBL4005297,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C(O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2cccc(F)c2)CC1,CHEMBL4004807,"Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.",J Med Chem,2017.0,60,3,913,927,10.1021/acs.jmedchem.6b00871,28072531.0,
18021197,CHEMBL4081497,N-Cyclopentyl-4-methyl-5-(2-((5-morpholinopyridin-2-yl)amino)-pyrimidin-4-yl)thiazol-2-amine,CHEMBL4005910,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate in presence of NADPH,IC50,>,25000.0,nM,Cc1nc(NC2CCCC2)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cn2)n1,CHEMBL4004830,"Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.",J Med Chem,2017.0,60,5,1892,1915,10.1021/acs.jmedchem.6b01670,28156111.0,
18033170,CHEMBL4093614,"(R,Z)-N-(5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrol-3-yl)pyrrolidine-2-carboxamide hydrochloride",CHEMBL4007978,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of microsomal CYP2C9 (unknown origin) using diclofenac as substrate preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis,IC50,>,33000.0,nM,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1NC(=O)[C@H]1CCCN1.Cl,CHEMBL4007390,"Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).",Eur J Med Chem,2017.0,127,,72,86,10.1016/j.ejmech.2016.12.038,28038328.0,
18037622,CHEMBL3765114,3-(4-(4-chlorophenyl)-7-fluoroquinolin-3-ylsulfonyl)benzonitrile,CHEMBL4008967,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,N#Cc1cccc(S(=O)(=O)c2cnc3cc(F)ccc3c2-c2ccc(Cl)cc2)c1,CHEMBL4007421,"Discovery and Preclinical Characterization of 3-((4-(4-Chlorophenyl)-7-fluoroquinoline-3-yl)sulfonyl)benzonitrile, a Novel Non-acetylenic Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator for Psychiatric Indications.",J Med Chem,2017.0,60,6,2470,2484,10.1021/acs.jmedchem.6b01858,28212015.0,
18037931,CHEMBL4082473,1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate,CHEMBL4009085,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br.CS(=O)(=O)O.O,CHEMBL4007422,"Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer's Disease.",J Med Chem,2017.0,60,5,1843,1859,10.1021/acs.jmedchem.6b01662,28212021.0,
18039761,CHEMBL427692,"1-(2,4-dimethoxyphenyl)-3-(pyridin-3-yl)prop-2-en-1-one",CHEMBL4009477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1ccc(C(=O)/C=C/c2cccnc2)c(OC)c1,CHEMBL4007432,Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.,Eur J Med Chem,2017.0,129,,159,174,10.1016/j.ejmech.2017.02.016,28222316.0,
18039762,CHEMBL4065284,(E)-1-(3-Chlorophenyl)-3-(3-pyridinyl)prop-2-en-1-one,CHEMBL4009477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1cccnc1)c1cccc(Cl)c1,CHEMBL4007432,Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.,Eur J Med Chem,2017.0,129,,159,174,10.1016/j.ejmech.2017.02.016,28222316.0,
18039763,CHEMBL4084977,(E)-1-(3-Bromophenyl)-3-(3-pyridinyl)prop-2-en-1-one,CHEMBL4009477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1cccnc1)c1cccc(Br)c1,CHEMBL4007432,Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.,Eur J Med Chem,2017.0,129,,159,174,10.1016/j.ejmech.2017.02.016,28222316.0,
18039764,CHEMBL4063333,(E)-1-(2-Naphthyl)-3-(3-pyridyl)prop-2-en-1-one,CHEMBL4009477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1cccnc1)c1ccc2ccccc2c1,CHEMBL4007432,Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.,Eur J Med Chem,2017.0,129,,159,174,10.1016/j.ejmech.2017.02.016,28222316.0,
18039765,CHEMBL4092737,(E)-1-(6-Methoxy-2-naphthyl)-3-(3-pyridyl)prop-2-en-1-one,CHEMBL4009477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1ccc2cc(C(=O)/C=C/c3cccnc3)ccc2c1,CHEMBL4007432,Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.,Eur J Med Chem,2017.0,129,,159,174,10.1016/j.ejmech.2017.02.016,28222316.0,
18039766,CHEMBL4071959,(E)-1-(1-Naphthyl)-3-(3-pyridyl)prop-2-en-1-one,CHEMBL4009477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1cccnc1)c1cccc2ccccc12,CHEMBL4007432,Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.,Eur J Med Chem,2017.0,129,,159,174,10.1016/j.ejmech.2017.02.016,28222316.0,
18039767,CHEMBL4080095,(E)-1-(3-Phenanthrenyl)-3-(3-pyridinyl)prop-2-en-1-one,CHEMBL4009477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1cccnc1)c1ccc2ccc3ccccc3c2c1,CHEMBL4007432,Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.,Eur J Med Chem,2017.0,129,,159,174,10.1016/j.ejmech.2017.02.016,28222316.0,
18039768,CHEMBL1413330,SID49648061,CHEMBL4009477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1ccc2c(c1)OCO2)c1cccnc1,CHEMBL4007432,Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.,Eur J Med Chem,2017.0,129,,159,174,10.1016/j.ejmech.2017.02.016,28222316.0,
18039769,CHEMBL4099058,(E)-3-(3-Methoxyphenyl)-1-(3-pyridyl)prop-2-en-1-one,CHEMBL4009477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1cccc(/C=C/C(=O)c2cccnc2)c1,CHEMBL4007432,Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.,Eur J Med Chem,2017.0,129,,159,174,10.1016/j.ejmech.2017.02.016,28222316.0,
18039770,CHEMBL4072091,(E)-3-(2-Methoxyphenyl)-1-(3-pyridyl)prop-2-en-1-one,CHEMBL4009477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1ccccc1/C=C/C(=O)c1cccnc1,CHEMBL4007432,Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.,Eur J Med Chem,2017.0,129,,159,174,10.1016/j.ejmech.2017.02.016,28222316.0,
18039771,CHEMBL4063471,"(E)-3-(3,4-Dimethoxyphenyl)-1-(3-pyridyl)prop-2-en-1-one",CHEMBL4009477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1ccc(/C=C/C(=O)c2cccnc2)cc1OC,CHEMBL4007432,Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.,Eur J Med Chem,2017.0,129,,159,174,10.1016/j.ejmech.2017.02.016,28222316.0,
18039772,CHEMBL2237709,"1-(pyridin-3-yl)-3-(2,3,4-trimethoxyphenyl)prop-2-en-1-one",CHEMBL4009477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1ccc(/C=C/C(=O)c2cccnc2)c(OC)c1OC,CHEMBL4007432,Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.,Eur J Med Chem,2017.0,129,,159,174,10.1016/j.ejmech.2017.02.016,28222316.0,
18039773,CHEMBL4068333,"(E)-3-(3, 4-Dichlorophenyl)-1-(3-pyridyl)prop-2-en-1-one",CHEMBL4009477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1ccc(Cl)c(Cl)c1)c1cccnc1,CHEMBL4007432,Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.,Eur J Med Chem,2017.0,129,,159,174,10.1016/j.ejmech.2017.02.016,28222316.0,
18039774,CHEMBL4059677,(E)-3-(2-Naphthyl)-1-(3-pyridyl)prop-2-en-1-one,CHEMBL4009477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1ccc2ccccc2c1)c1cccnc1,CHEMBL4007432,Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.,Eur J Med Chem,2017.0,129,,159,174,10.1016/j.ejmech.2017.02.016,28222316.0,
18039775,CHEMBL4087973,(E)-3-phenyl-1-(3-pyridyl)prop-2-en-1-one,CHEMBL4009477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1ccccc1)c1cccnc1,CHEMBL4007432,Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.,Eur J Med Chem,2017.0,129,,159,174,10.1016/j.ejmech.2017.02.016,28222316.0,
18040410,CHEMBL4101809,"(R)-5-(Benzofuran-2-yl)-3-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-5,6-dihydro-4H-1,2,4-oxadiazine",CHEMBL4009623,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8000.0,nM,COc1nc(C2=NOC[C@H](c3cc4ccccc4o3)N2)ccc1-n1cnc(C)c1,CHEMBL4007439,"Design, Synthesis, and Evaluation of a Novel Series of Oxadiazine Gamma Secretase Modulators for Familial Alzheimer's Disease.",J Med Chem,2017.0,60,6,2383,2400,10.1021/acs.jmedchem.6b01620,28230986.0,
18042657,CHEMBL4098877,"cis-2,6-Dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl)pyrimidin-4-yl)morpholine",CHEMBL4010131,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,50000.0,nM,C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1,CHEMBL4007454,"Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.",J Med Chem,2017.0,60,7,2983,2992,10.1021/acs.jmedchem.7b00045,28245354.0,
18044667,CHEMBL4075766,N-(2-Amino-1-(5-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(3-fluoro-4-methylphenyl)-1H-pyrrole-2-carboxamide,CHEMBL4010385,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 60 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,25000.0,nM,Cc1ccc(-c2ccc(C(=O)NC(CN)c3ncc(CO)s3)[nH]2)cc1F,CHEMBL4007461,"Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.",J Med Chem,2017.0,60,7,3124,3153,10.1021/acs.jmedchem.7b00179,28266845.0,
18044668,CHEMBL4083672,"N-(2-Amino-1-(5-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(4-chloro-3,5-difluorophenyl)-1H-pyrrole-2-carboxamide",CHEMBL4010385,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 60 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,25000.0,nM,NCC(NC(=O)c1ccc(-c2cc(F)c(Cl)c(F)c2)[nH]1)c1ncc(CO)s1,CHEMBL4007461,"Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.",J Med Chem,2017.0,60,7,3124,3153,10.1021/acs.jmedchem.7b00179,28266845.0,
18044669,CHEMBL4096918,5-(4-chlorophenyl)-N-((5-(hydroxymethyl)-4-methylthiazol-2-yl)(piperidin-2-yl)methyl)-1H-pyrrole-2-carboxamide,CHEMBL4010385,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 60 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,25000.0,nM,Cc1nc(C(NC(=O)c2ccc(-c3ccc(Cl)cc3)[nH]2)C2CCCCN2)sc1CO,CHEMBL4007461,"Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.",J Med Chem,2017.0,60,7,3124,3153,10.1021/acs.jmedchem.7b00179,28266845.0,
18044670,CHEMBL3301620,TEMSAVIR,CHEMBL4010385,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 60 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,25000.0,nM,COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12,CHEMBL4007461,"Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.",J Med Chem,2017.0,60,7,3124,3153,10.1021/acs.jmedchem.7b00179,28266845.0,
18045075,CHEMBL549472,10-gingerol,CHEMBL4010620,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 7 mins,IC50,=,7500.0,nM,CCCCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,CHEMBL4007467,"Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism.",Bioorg Med Chem Lett,2017.0,27,8,1826,1830,10.1016/j.bmcl.2017.02.047,28274629.0,
18045080,CHEMBL549472,10-gingerol,CHEMBL4010627,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes using Vivid OOMR substrate red measured every 30 sec for 30 mins by fluorescence assay,IC50,=,16300.0,nM,CCCCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,CHEMBL4007467,"Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism.",Bioorg Med Chem Lett,2017.0,27,8,1826,1830,10.1016/j.bmcl.2017.02.047,28274629.0,
18045089,CHEMBL402978,[1-(4'-hydroxy-3'-methoxyphenyl)-5-hydroxy-3-decanone],CHEMBL4010620,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 7 mins,IC50,=,27900.0,nM,CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,CHEMBL4007467,"Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism.",Bioorg Med Chem Lett,2017.0,27,8,1826,1830,10.1016/j.bmcl.2017.02.047,28274629.0,
18045092,CHEMBL402978,[1-(4'-hydroxy-3'-methoxyphenyl)-5-hydroxy-3-decanone],CHEMBL4010627,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes using Vivid OOMR substrate red measured every 30 sec for 30 mins by fluorescence assay,IC50,=,12100.0,nM,CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,CHEMBL4007467,"Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism.",Bioorg Med Chem Lett,2017.0,27,8,1826,1830,10.1016/j.bmcl.2017.02.047,28274629.0,
18045131,CHEMBL2071440,6-Paradol,CHEMBL4010519,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as enzyme-mediated metabolite formation using diclofenac as substrate incubated for 5 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis,IC50,=,13600.0,nM,CCCCCCCC(=O)CCc1ccc(O)c(OC)c1,CHEMBL4007467,"Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism.",Bioorg Med Chem Lett,2017.0,27,8,1826,1830,10.1016/j.bmcl.2017.02.047,28274629.0,
18045194,CHEMBL2071440,6-Paradol,CHEMBL4010582,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,9900.0,nM,CCCCCCCC(=O)CCc1ccc(O)c(OC)c1,CHEMBL4007467,"Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism.",Bioorg Med Chem Lett,2017.0,27,8,1826,1830,10.1016/j.bmcl.2017.02.047,28274629.0,
18045226,CHEMBL2071440,6-Paradol,CHEMBL4010614,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using diclofenac as substrate incubated for 5 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis,IC50,=,10500.0,nM,CCCCCCCC(=O)CCc1ccc(O)c(OC)c1,CHEMBL4007467,"Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism.",Bioorg Med Chem Lett,2017.0,27,8,1826,1830,10.1016/j.bmcl.2017.02.047,28274629.0,
18045236,CHEMBL25948,(E)-1-(4-Hydroxy-3-methoxy-phenyl)-dec-4-en-3-one,CHEMBL4010620,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 7 mins,IC50,=,3300.0,nM,CCCCC/C=C/C(=O)CCc1ccc(O)c(OC)c1,CHEMBL4007467,"Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism.",Bioorg Med Chem Lett,2017.0,27,8,1826,1830,10.1016/j.bmcl.2017.02.047,28274629.0,
18045244,CHEMBL25948,(E)-1-(4-Hydroxy-3-methoxy-phenyl)-dec-4-en-3-one,CHEMBL4010634,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate by HPLC analysis,IC50,=,29200.0,nM,CCCCC/C=C/C(=O)CCc1ccc(O)c(OC)c1,CHEMBL4007467,"Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism.",Bioorg Med Chem Lett,2017.0,27,8,1826,1830,10.1016/j.bmcl.2017.02.047,28274629.0,
18045250,CHEMBL1095671,8-Gingerol,CHEMBL4010620,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 7 mins,IC50,=,8700.0,nM,CCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,CHEMBL4007467,"Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism.",Bioorg Med Chem Lett,2017.0,27,8,1826,1830,10.1016/j.bmcl.2017.02.047,28274629.0,
18045256,CHEMBL1095671,8-Gingerol,CHEMBL4010627,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes using Vivid OOMR substrate red measured every 30 sec for 30 mins by fluorescence assay,IC50,=,6800.0,nM,CCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,CHEMBL4007467,"Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism.",Bioorg Med Chem Lett,2017.0,27,8,1826,1830,10.1016/j.bmcl.2017.02.047,28274629.0,
18051010,CHEMBL4064672,"(3S)-4-[[(4R)-4-(2-Chloro-4-fluorophenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic Acid",CHEMBL4011454,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,COC(=O)C1=C(CN2CCOC[C@H]2C(=O)O)NC(c2nccs2)=N[C@H]1c1ccc(F)cc1Cl,CHEMBL4007508,Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors.,J Med Chem,2017.0,60,8,3352,3371,10.1021/acs.jmedchem.7b00083,28339215.0,
18055656,CHEMBL4060568,"1-(2-Fluoro-5-methoxy-3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-N-(isoxazol-3-yl)isoquinoline-6-sulfonamide",CHEMBL4012229,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,430.0,nM,COc1cc(-c2cccc(C(F)(F)F)c2)c(F)cc1-c1nccc2cc(S(=O)(=O)Nc3ccon3)ccc12,CHEMBL4011598,Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities.,J Med Chem,2017.0,60,14,5969,5989,10.1021/acs.jmedchem.6b01851,28287723.0,
18056476,CHEMBL3983724,"US9346798, 182",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,250.0,nM,COc1cc(C(F)(F)F)ccc1N1CCOc2cc(S(=O)(=O)Nc3nccs3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056477,CHEMBL4073429,"1-(2,3'-Difluoro-5-methoxy-[1,1'-biphenyl]-4-yl)-N-(isoxazol-3-yl)-2-oxo-1,2-dihydroquinoline-6-sulfonamide",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,560.0,nM,COc1cc(-c2cccc(F)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056478,CHEMBL4073429,"1-(2,3'-Difluoro-5-methoxy-[1,1'-biphenyl]-4-yl)-N-(isoxazol-3-yl)-2-oxo-1,2-dihydroquinoline-6-sulfonamide",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,12000.0,nM,COc1cc(-c2cccc(F)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056479,CHEMBL4073429,"1-(2,3'-Difluoro-5-methoxy-[1,1'-biphenyl]-4-yl)-N-(isoxazol-3-yl)-2-oxo-1,2-dihydroquinoline-6-sulfonamide",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,760.0,nM,COc1cc(-c2cccc(F)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056480,CHEMBL3935302,"US9212182, 423::US9212182, 424",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,18000.0,nM,COc1cc(-c2cc(F)cc(F)c2)c(C)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056481,CHEMBL3928024,"US9212182, 455::US9212182, 456",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,4200.0,nM,COc1cc(-c2cccc(F)c2)c(Cl)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056482,CHEMBL4071624,"1-(2,3'-Difluoro-5-methoxy-[1,1'-biphenyl]-4-yl)-N-(isoxazol-3-yl)-2-oxo-1,2-dihydroquinazoline-6-sulfonamide",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,4000.0,nM,COc1cc(-c2cccc(F)c2)c(F)cc1-n1c(=O)ncc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056483,CHEMBL3902872,"US9212182, 652::US9212182, 653::US9212182, 654",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,2300.0,nM,COc1cc(-c2ccc(Cl)c(C)c2)c(F)cc1-n1c(=O)cnc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056484,CHEMBL3915688,"US9212182, 359::US9212182, 360",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,580.0,nM,COc1cc(-c2cccc(C(F)(F)F)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056485,CHEMBL3906185,"US9212182, 684",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,17000.0,nM,COc1cc(-c2cc(F)cc(F)c2)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056486,CHEMBL3983367,"US9212182, 457::US9212182, 458",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,1900.0,nM,COc1cc(-c2cc(F)cc(F)c2)c(Cl)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056487,CHEMBL3930653,"US9212182, 674",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,4000.0,nM,COc1cc(-c2ccc(F)c(F)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056488,CHEMBL3915688,"US9212182, 359::US9212182, 360",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,1900.0,nM,COc1cc(-c2cccc(C(F)(F)F)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056489,CHEMBL3967168,"US9212182, 673",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,2800.0,nM,COc1cc(-c2ccc(C(F)(F)F)cc2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056490,CHEMBL3903048,"US9212182, 955",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,510.0,nM,COc1cc(-c2ccccc2C(F)(F)F)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056491,CHEMBL3948535,"US9212182, 475::US9212182, 476",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,2600.0,nM,COc1cc(-c2cccc(Cl)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056492,CHEMBL3946521,"US9212182, 363::US9212182, 364",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,8200.0,nM,COc1cc(-c2cc(F)cc(F)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056493,CHEMBL3933527,"US9212182, 469::US9212182, 470",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,1300.0,nM,COc1cc(-c2ccc(Cl)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056494,CHEMBL3965976,"US9212182, 658",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,78.0,nM,COc1cc(-c2ccc(Cl)c(C)c2)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccncn3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056495,CHEMBL3935378,"US9212182, 683",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,6100.0,nM,COc1cc(-c2ccc(Cl)c(C)c2)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ncccn3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056496,CHEMBL3966606,"US9212182, 540::US9212182, 541",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,880.0,nM,COc1cc(-c2cc(F)cc(Cl)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccncn3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056497,CHEMBL4084372,"(P)-1-(4'-Fluoro-5-methoxy-2,3'-dimethyl-[1,1'-biphenyl]-4-yl)-N-(isoxazol-3-yl)-2-oxo-1,2-dihydroquinoline-6-sulfonamide",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,580.0,nM,COc1cc(-c2ccc(F)c(C)c2)c(C)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056498,CHEMBL3921690,"US9212182, 1054",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,2300.0,nM,COc1cc(-c2ccc(F)c(C)c2)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056499,CHEMBL3949600,"US9212182, 323::US9212182, 324",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,2100.0,nM,COc1cc(-c2cccc(C(F)(F)F)c2)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056500,CHEMBL3949474,"US9212182, 1053",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,1700.0,nM,COc1cc(-c2cc(C(F)(F)F)ccc2C)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056501,CHEMBL3956563,"US9212182, 419::US9212182, 420",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,850.0,nM,COc1cc(-c2cccc(C(F)(F)F)c2)c(C)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056502,CHEMBL3953660,"US9212182, 691",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,1200.0,nM,COc1cc(-c2ccc(Cl)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3cnccn3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056503,CHEMBL3941727,"US9212182, 696",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,4700.0,nM,COc1cc(-c2ccc(Cl)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ncccn3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056504,CHEMBL3921528,"US9212182, 632",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,2900.0,nM,COc1cc(-c2cccc(OC(F)F)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056505,CHEMBL3937744,"US9212182, 685",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,13000.0,nM,COc1cc(-c2cc(OC)c(-n3c(=O)ccc4cc(S(=O)(=O)Nc5ncccn5)ccc43)cc2F)ccc1Cl,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056506,CHEMBL3979498,"US9212182, 672",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,4600.0,nM,COc1cc(-c2cccc(C(F)(F)F)c2)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ncccn3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18056507,CHEMBL3961163,"US9212182, 512::US9212182, 513",CHEMBL4012330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH,IC50,=,1900.0,nM,COc1cc(-c2ccc(F)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,CHEMBL4011607,"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.",J Med Chem,2017.0,60,14,5990,6017,10.1021/acs.jmedchem.6b01850,28324649.0,
18061279,CHEMBL3908849,"US9085555, 124",CHEMBL4013312,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac as substrate,IC50,=,3400.0,nM,NC(=O)n1cc(NC(=O)N2CCC[C@H]2C(=O)Nc2cccc(OC(F)(F)F)c2)c2ccccc21,CHEMBL4011635,Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.,J Med Chem,2017.0,60,13,5717,5735,10.1021/acs.jmedchem.7b00425,28621538.0,
18061280,CHEMBL4065529,"(1R,3S,5R)-2-Aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic Acid-2-[(1-Carbamoyl-1H-indol-3-yl)-amide]-3-[(3-Trifluoromethoxy-phenyl)-amide]",CHEMBL4013312,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac as substrate,IC50,=,800.0,nM,NC(=O)n1cc(NC(=O)N2[C@H](C(=O)Nc3cccc(OC(F)(F)F)c3)C[C@H]3C[C@H]32)c2ccccc21,CHEMBL4011635,Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.,J Med Chem,2017.0,60,13,5717,5735,10.1021/acs.jmedchem.7b00425,28621538.0,
18061281,CHEMBL3668698,"US9085555, 191",CHEMBL4013312,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac as substrate,IC50,=,2500.0,nM,NC(=O)n1cc(NC(=O)N2C[C@H](F)C[C@H]2C(=O)Nc2cccc(OC(F)(F)F)c2)c2ccccc21,CHEMBL4011635,Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.,J Med Chem,2017.0,60,13,5717,5735,10.1021/acs.jmedchem.7b00425,28621538.0,
18061282,CHEMBL3668755,"US9085555, 249",CHEMBL4013312,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac as substrate,IC50,>,10000.0,nM,NC(=O)n1cc(NC(=O)N2C[C@@H](O)C[C@H]2C(=O)Nc2cccc(OC(F)(F)F)c2)c2ccccc21,CHEMBL4011635,Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.,J Med Chem,2017.0,60,13,5717,5735,10.1021/acs.jmedchem.7b00425,28621538.0,
18061283,CHEMBL3673825,"US9085555, 396",CHEMBL4013312,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac as substrate,IC50,>,10000.0,nM,NC(=O)n1cc(NC(=O)N2C[C@@H](N)C[C@H]2C(=O)Nc2cccc(OC(F)(F)F)c2)c2ccccc21,CHEMBL4011635,Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.,J Med Chem,2017.0,60,13,5717,5735,10.1021/acs.jmedchem.7b00425,28621538.0,
18061284,CHEMBL4094108,"(1R,3S,5R)-2-Aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic Acid-2-[(1-Carbamoyl-1H-indol-3-yl)-amide]-3-[(2-Fluoro-3-trifluoromethoxy-phenyl)-amide]",CHEMBL4013312,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac as substrate,IC50,=,250.0,nM,NC(=O)n1cc(NC(=O)N2[C@H](C(=O)Nc3cccc(OC(F)(F)F)c3F)C[C@H]3C[C@H]32)c2ccccc21,CHEMBL4011635,Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.,J Med Chem,2017.0,60,13,5717,5735,10.1021/acs.jmedchem.7b00425,28621538.0,
18061285,CHEMBL4070311,"(1R,3S,5R)-2-Aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic Acid-2-[(1-Carbamoyl-1H-indol-3-yl)-amide]-3-[(2-Fluoro-3-trifluoromethyl-phenyl)-amide]",CHEMBL4013312,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac as substrate,IC50,=,150.0,nM,NC(=O)n1cc(NC(=O)N2[C@H](C(=O)Nc3cccc(C(F)(F)F)c3F)C[C@H]3C[C@H]32)c2ccccc21,CHEMBL4011635,Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.,J Med Chem,2017.0,60,13,5717,5735,10.1021/acs.jmedchem.7b00425,28621538.0,
18061286,CHEMBL4098439,"(1R,3S,5R)-2-Azabicyclo[3.1.0]hexane-2,3-dicarboxylic Acid-2-[(1-Carbamoyl-1H-indol-3-yl)-amide]-3-[(6-Trifluoromethyl-pyridin-2-yl)-amide]",CHEMBL4013312,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac as substrate,IC50,=,4300.0,nM,NC(=O)n1cc(NC(=O)N2[C@H](C(=O)Nc3cccc(C(F)(F)F)n3)C[C@H]3C[C@H]32)c2ccccc21,CHEMBL4011635,Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.,J Med Chem,2017.0,60,13,5717,5735,10.1021/acs.jmedchem.7b00425,28621538.0,
18061287,CHEMBL3683737,"US9085555, 762",CHEMBL4013312,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac as substrate,IC50,=,4000.0,nM,NC(=O)n1cc(NC(=O)N2[C@H](C(=O)Nc3cccc(Br)n3)C[C@H]3C[C@H]32)c2ccccc21,CHEMBL4011635,Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.,J Med Chem,2017.0,60,13,5717,5735,10.1021/acs.jmedchem.7b00425,28621538.0,
18061288,CHEMBL3683753,"1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide (7)::US9085555, 727",CHEMBL4013312,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac as substrate,IC50,>,20000.0,nM,NC(=O)c1nn(CC(=O)N2[C@H](C(=O)Nc3cccc(Br)n3)C[C@H]3C[C@H]32)c2ccccc12,CHEMBL4011635,Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.,J Med Chem,2017.0,60,13,5717,5735,10.1021/acs.jmedchem.7b00425,28621538.0,
18064885,CHEMBL4099219,"3-(Benzo[d][1,3]dioxol-5-ylmethyl)-1-(thiazol-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one",CHEMBL4014091,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsomes in presence of NADPH,IC50,>,25000.0,nM,O=c1c2ccccc2oc2c(Cc3ccc4c(c3)OCO4)[nH]c(-c3nccs3)c12,CHEMBL4011656,"Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.",J Med Chem,2017.0,60,15,6622,6637,10.1021/acs.jmedchem.7b00523,28686445.0,
18068809,CHEMBL2058057,2-(4-bromophenyl)quinazolin-4(3H)-one,CHEMBL4014740,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay,IC50,>,50000.0,nM,O=c1[nH]c(-c2ccc(Br)cc2)nc2ccccc12,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068810,CHEMBL3289112,2-[3'-Hydroxy-4'-(methyloxy)phenyl]quinazolin-4(3H)-one,CHEMBL4014740,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay,IC50,>,50000.0,nM,COc1ccc(-c2nc3ccccc3c(=O)[nH]2)cc1O,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068811,CHEMBL4081914,(2-(4-hydroxy-3-methoxyphenyl)quinazolin-4(3H)-one),CHEMBL4014740,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay,IC50,>,50000.0,nM,COc1cc(-c2nc3ccccc3c(=O)[nH]2)ccc1O,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068812,CHEMBL4074105,2-(4-(prop-2-ynyloxy)phenyl)quinazolin-4(3H)-one,CHEMBL4014740,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay,IC50,>,50000.0,nM,C#CCOc1ccc(-c2nc3ccccc3c(=O)[nH]2)cc1,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068813,CHEMBL4100866,"2-(4-(2,4-dichlorophenoxy)phenyl)quinazolin-4(3H)-one",CHEMBL4014740,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay,IC50,>,50000.0,nM,O=c1[nH]c(-c2ccc(Oc3ccc(Cl)cc3Cl)cc2)nc2ccccc12,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068814,CHEMBL4084413,"2-(4-(2,4-difluorobenzyloxy)phenyl)quinazolin-4(3H)-one",CHEMBL4014740,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay,IC50,>,50000.0,nM,O=c1[nH]c(-c2ccc(OCc3ccc(F)cc3F)cc2)nc2ccccc12,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068815,CHEMBL283196,2-Phenyl-benzo[h]chromen-4-one,CHEMBL4014740,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay,IC50,>,10000.0,nM,O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18069841,CHEMBL4060768,"(R)-8-(1-(3,5-difluorophenyl)pyrrolidin-2-yl)-6-(morpholine-4-carbonyl)-2-morpholino-4H-chromen-4-one",CHEMBL4015068,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,O=C(c1cc([C@H]2CCCN2c2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1)N1CCOCC1,CHEMBL4014298,Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.,Bioorg Med Chem Lett,2017.0,27,9,1949,1954,10.1016/j.bmcl.2017.03.027,28347666.0,
18071701,CHEMBL4099807,5-phenyl-N-(pyridin-2-ylmethyl)-2-(pyridin-3-yl)quinazolin-4-amine,CHEMBL4015507,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,<,10000.0,nM,c1ccc(-c2cccc3nc(-c4cccnc4)nc(NCc4ccccn4)c23)cc1,CHEMBL4014310,Selective IKur Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide.,J Med Chem,2017.0,60,9,3795,3803,10.1021/acs.jmedchem.6b01889,28418664.0,
18076637,CHEMBL4080667,"(2R,6R)-1-(3-Hydroxy-azetidin-1-yl)-2-(6-hydroxy-2-phenyl-adamantan-2-yl)-ethanone",CHEMBL4016362,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,O=C(CC1(c2ccccc2)C2CC3CC1CC(C2)C3O)N1CC(O)C1,CHEMBL4014336,"Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.",J Med Chem,2017.0,60,12,4932,4948,10.1021/acs.jmedchem.7b00211,28537398.0,
18077754,CHEMBL4059848,"4-Acetyl-1-(3-(4-amino-5-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl)-3,3-dimethylpiperazin-2-one",CHEMBL4016550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(=O)N1CCN(c2cccc(-c3cc(-c4ccnn4CC(F)(F)F)c4c(N)ncnn34)c2)C(=O)C1(C)C,CHEMBL4014340,"Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders.",J Med Chem,2017.0,60,12,5193,5208,10.1021/acs.jmedchem.7b00618,28541707.0,
18077755,CHEMBL4064666,"2-(4-Acetyl-3,3-dimethyl-2-oxopiperazin-1-yl)-4-(4-amino-5-(trifluoromethyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)benzonitrile",CHEMBL4016550,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(=O)N1CCN(c2cc(-c3cc(C(F)(F)F)c4c(N)ncnn34)ccc2C#N)C(=O)C1(C)C,CHEMBL4014340,"Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders.",J Med Chem,2017.0,60,12,5193,5208,10.1021/acs.jmedchem.7b00618,28541707.0,
18078378,CHEMBL4066936,"methyl 4,6-diamino-2-(5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-ylcarbamate",CHEMBL4016810,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 using diclofenac as substrate,IC50,>,50000.0,nM,COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N,CHEMBL4014344,Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.,J Med Chem,2017.0,60,12,5146,5161,10.1021/acs.jmedchem.7b00449,28557445.0,
18079001,CHEMBL4090593,"4,6-dichloro-N-cycloheptyl-1H-indole-2-carboxamide",CHEMBL4017005,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,<=,20000.0,nM,O=C(NC1CCCCCC1)c1cc2c(Cl)cc(Cl)cc2[nH]1,CHEMBL4014347,Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections.,J Med Chem,2017.0,60,13,5876,5888,10.1021/acs.jmedchem.7b00582,28574259.0,
18080260,CHEMBL4081718,"(2S)-isopropyl 2-((((2R,3S,4R,5R)-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate",CHEMBL4017362,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using sulfaphenazole as substrate,IC50,=,25000.0,nM,CC(C)OC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](F)(Cl)[C@@H]1O)Oc1ccccc1,CHEMBL4014354,"2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.",J Med Chem,2017.0,60,13,5424,5437,10.1021/acs.jmedchem.7b00067,28595015.0,
18080261,CHEMBL1259059,"(S)-2-{[(1R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-(R)-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy]phenoxyphosphorylamino}propionic Acid (S)-Isopropyl Ester",CHEMBL4017362,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using sulfaphenazole as substrate,IC50,=,60000.0,nM,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CHEMBL4014354,"2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.",J Med Chem,2017.0,60,13,5424,5437,10.1021/acs.jmedchem.7b00067,28595015.0,
18082195,CHEMBL4102132,"(S)-5-chloro-2-fluoro-4-((3-(4-fluorophenyl)-1,2,5,6-tetrahydropyridin-2-yl)methylamino)-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4017779,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,33.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2NCCC=C2c2ccc(F)cc2)cc1F,CHEMBL4017456,The discovery of tetrahydropyridine analogs as hNav1.7 selective inhibitors for analgesia.,Bioorg Med Chem Lett,2017.0,27,10,2210,2215,10.1016/j.bmcl.2017.03.043,28385504.0,
18082196,CHEMBL4079748,"(S)-5-chloro-2-fluoro-4-((3-(4-fluorophenyl)-1,2,5,6-tetrahydropyridin-2-yl)methylamino)-N-(5-fluorothiazol-2-yl)benzenesulfonamide",CHEMBL4017779,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,710.0,nM,O=S(=O)(Nc1ncc(F)s1)c1cc(Cl)c(NC[C@H]2NCCC=C2c2ccc(F)cc2)cc1F,CHEMBL4017456,The discovery of tetrahydropyridine analogs as hNav1.7 selective inhibitors for analgesia.,Bioorg Med Chem Lett,2017.0,27,10,2210,2215,10.1016/j.bmcl.2017.03.043,28385504.0,
18082197,CHEMBL4090203,"(S)-5-chloro-N-(4-chlorothiazol-2-yl)-2-fluoro-4-((3-(4-fluorophenyl)-1,2,5,6-tetrahydropyridin-2-yl)methylamino)benzenesulfonamide",CHEMBL4017779,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,600.0,nM,O=S(=O)(Nc1nc(Cl)cs1)c1cc(Cl)c(NC[C@H]2NCCC=C2c2ccc(F)cc2)cc1F,CHEMBL4017456,The discovery of tetrahydropyridine analogs as hNav1.7 selective inhibitors for analgesia.,Bioorg Med Chem Lett,2017.0,27,10,2210,2215,10.1016/j.bmcl.2017.03.043,28385504.0,
18082448,CHEMBL4061793,5-chloro-2-fluoro-4-((hexahydro-1H-pyrrolizin-7a-yl)methylamino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4017826,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using warfarin as substrate after 30 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,50000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC23CCCN2CCC3)cc1F,CHEMBL4017458,"Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice.",Bioorg Med Chem Lett,2017.0,27,10,2087,2093,10.1016/j.bmcl.2017.03.085,28389149.0,
18082449,CHEMBL4062780,"(R)-5-chloro-4-((2,2-dimethylhexahydro-1H-pyrrolizin-7a-yl)methylamino)-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4017826,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using warfarin as substrate after 30 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,50000.0,nM,CC1(C)CN2CCC[C@]2(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)C1,CHEMBL4017458,"Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice.",Bioorg Med Chem Lett,2017.0,27,10,2087,2093,10.1016/j.bmcl.2017.03.085,28389149.0,
18083654,CHEMBL4096341,"2-chloro-N-((1R,4S,7S)-2-(4-chloroisoxazolo[5,4-c]pyridin-7-yl)-2-azabicyclo[2.2.1]heptan-7-yl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide",CHEMBL4018120,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in liver microsomes (unknown origin) assessed as formation of 4-hydroxydiclofenac from diclofenac in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1ncn(-c2ccc(C(=O)N[C@H]3[C@H]4CC[C@H]3N(c3ncc(Cl)c5cnoc35)C4)c(Cl)c2)n1,CHEMBL4017471,Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors.,Bioorg Med Chem Lett,2017.0,27,11,2622,2628,10.1016/j.bmcl.2017.03.002,28408226.0,
18084596,CHEMBL4068896,"N-(2-(6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-ylamino)-3-methylphenyl)acrylamide",CHEMBL4018318,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate pretreated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS method,IC50,=,900.0,nM,C=CC(=O)Nc1cccc(C)c1Nc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)ccc2n1,CHEMBL4017480,Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping.,Bioorg Med Chem Lett,2017.0,27,11,2420,2423,10.1016/j.bmcl.2017.04.014,28433531.0,
18084632,CHEMBL4089245,"N-(2-((5-((2,6-difluoro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylphenyl)acrylamide",CHEMBL4018318,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate pretreated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS method,IC50,=,3700.0,nM,C=CC(=O)Nc1cccc(C)c1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1,CHEMBL4017480,Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping.,Bioorg Med Chem Lett,2017.0,27,11,2420,2423,10.1016/j.bmcl.2017.04.014,28433531.0,
18084656,CHEMBL4077859,"N-((3R,4S)-4-((5-((2,6-difluoro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide",CHEMBL4018318,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate pretreated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS method,IC50,=,29100.0,nM,C=CC(=O)N[C@H]1COC[C@H]1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1,CHEMBL4017480,Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping.,Bioorg Med Chem Lett,2017.0,27,11,2420,2423,10.1016/j.bmcl.2017.04.014,28433531.0,
18109291,CHEMBL4065122,"2-{3'-Hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4']bipyridinyl-2'-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one",CHEMBL4023727,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,5000.0,nM,C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1,CHEMBL4020831,"Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.",J Med Chem,2018.0,61,6,2227,2245,10.1021/acs.jmedchem.7b01712,29457982.0,
18114159,CHEMBL4091875,"4-(4-amino-5-(trifluoromethyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)-2-((5S,6R)-2,2,5,6-tetramethyl-3-oxomorpholino)benzonitrile",CHEMBL4024918,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,C[C@H]1[C@@H](C)OC(C)(C)C(=O)N1c1cc(-c2cc(C(F)(F)F)c3c(N)ncnn23)ccc1C#N,CHEMBL4024705,Identification of highly potent and selective PI3Kδ inhibitors.,Bioorg Med Chem Lett,2017.0,27,13,2849,2853,10.1016/j.bmcl.2017.01.077,28209465.0,
18122263,CHEMBL4064608,"cis-N-((1r,4r)-4-Morpholinocyclohexyl)-5-(tetrahydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",CHEMBL4026994,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,c1nc(N[C@H]2CC[C@H](N3CCOCC3)CC2)c2c(C3CCOCC3)c[nH]c2n1,CHEMBL4024763,Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma.,J Med Chem,2017.0,60,24,10071,10091,10.1021/acs.jmedchem.7b01290,29172502.0,
18123955,CHEMBL4080228,"5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one",CHEMBL4027419,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,COc1cc(C)[nH]c(=O)c1CN1CCc2c(Cl)cc([C@H](OC)C3COC3)c(Cl)c2C1=O,CHEMBL4024771,"Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497).",J Med Chem,2018.0,61,3,650,665,10.1021/acs.jmedchem.7b01375,29211475.0,
18124735,CHEMBL3927519,"(S)-3-(4-((2-(2,6-dimethylphenyl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)methoxy)phenyl)hex-4-ynoic acid",CHEMBL4027555,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,60000.0,nM,CC#C[C@@H](CC(=O)O)c1ccc(OCc2ccc3nc(-c4c(C)cccc4C)nn3c2)cc1,CHEMBL4024777,Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.,J Med Chem,2018.0,61,3,934,945,10.1021/acs.jmedchem.7b01411,29236497.0,
18125086,CHEMBL4086008,"(E)-3-([1,1'-Biphenyl]-4-yl)-N-(benzofuran-3-ylmethyl)-N-methylprop-2-en-1-amine Hydrochloride",CHEMBL4027674,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate upto 10 uM after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,10000.0,nM,CN(C/C=C/c1ccc(-c2ccccc2)cc1)Cc1coc2ccccc12.Cl,CHEMBL4024779,Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.,J Med Chem,2018.0,61,1,224,250,10.1021/acs.jmedchem.7b01300,29243920.0,
18125087,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4027674,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate upto 10 uM after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,10000.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4024779,Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.,J Med Chem,2018.0,61,1,224,250,10.1021/acs.jmedchem.7b01300,29243920.0,
18127123,CHEMBL4064397,"(3-{4-[2-({1-[3-(3-Cyclohexylamino-propylamino)-propyl]-1H-[1,2,3]triazol-4-ylmethyl}-amino)-6-methyl-pyrimidin-4-ylamino]-piperidin-1-yl}-3-oxo-propylamino)-acetic Acid",CHEMBL4028366,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomal CYP2C9,IC50,>,100000.0,nM,Cc1cc(NC2CCN(C(=O)CCNCC(=O)O)CC2)nc(NCc2cn(CCCNCCCNC3CCCCC3)nn2)n1,CHEMBL4024793,Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.,J Med Chem,2018.0,61,3,818,833,10.1021/acs.jmedchem.7b01322,29314840.0,
18127503,CHEMBL4077296,"3-{[(5-Cyclopropyl-1,2-oxazol-3-yl)methyl]amino}adamantan-1-ol",CHEMBL4028474,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by LC-MS/MS analysis,IC50,>,100000.0,nM,OC12CC3CC(C1)CC(NCc1cc(C4CC4)on1)(C3)C2,CHEMBL4024798,In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses.,J Med Chem,2018.0,61,3,1074,1085,10.1021/acs.jmedchem.7b01536,29341607.0,
18128518,CHEMBL4085181,"3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid",CHEMBL4028663,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CCOC(=O)C1=C(CN2CCO[C@H](CCC(=O)O)C2)NC(c2nccs2)=N[C@H]1c1ccc(F)cc1Br,CHEMBL4024802,"3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4.",J Med Chem,2018.0,61,3,1355,1374,10.1021/acs.jmedchem.7b01914,29381358.0,
18136796,CHEMBL4098297,"(S)-1,1,1-trifluoro-2-(5-(3-methyl-1H-indazol-1-yl)pyridin-3-yl)propan-2-ol",CHEMBL4029980,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 (unknown origin),IC50,=,11000.0,nM,Cc1nn(-c2cncc([C@](C)(O)C(F)(F)F)c2)c2ccccc12,CHEMBL4028827,Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension.,Bioorg Med Chem Lett,2017.0,27,11,2384,2388,10.1016/j.bmcl.2017.04.021,28416132.0,
18136797,CHEMBL4080256,"(R)-1,1,1-trifluoro-2-(5-(3-methyl-1H-indazol-1-yl)pyridin-3-yl)propan-2-ol",CHEMBL4029980,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 (unknown origin),IC50,=,3800.0,nM,Cc1nn(-c2cncc([C@@](C)(O)C(F)(F)F)c2)c2ccccc12,CHEMBL4028827,Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension.,Bioorg Med Chem Lett,2017.0,27,11,2384,2388,10.1016/j.bmcl.2017.04.021,28416132.0,
18136798,CHEMBL4071689,"(S)-1,1,1-trifluoro-2-(5-(3-(trifluoromethyl)-1H-indazol-1-yl)pyridin-3-yl)propan-2-ol",CHEMBL4029980,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 (unknown origin),IC50,=,7200.0,nM,C[C@](O)(c1cncc(-n2nc(C(F)(F)F)c3ccccc32)c1)C(F)(F)F,CHEMBL4028827,Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension.,Bioorg Med Chem Lett,2017.0,27,11,2384,2388,10.1016/j.bmcl.2017.04.021,28416132.0,
18136799,CHEMBL4080420,2-(5-(4-fluoro-3-methyl-1H-indazol-1-yl)pyridin-3-yl)propan-2-ol,CHEMBL4029980,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 (unknown origin),IC50,=,4700.0,nM,Cc1nn(-c2cncc(C(C)(C)O)c2)c2cccc(F)c12,CHEMBL4028827,Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension.,Bioorg Med Chem Lett,2017.0,27,11,2384,2388,10.1016/j.bmcl.2017.04.021,28416132.0,
18136800,CHEMBL4067000,2-(5-(4-(trifluoromethyl)-1H-indazol-1-yl)pyridin-3-yl)propan-2-ol,CHEMBL4029980,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 (unknown origin),IC50,=,9100.0,nM,CC(C)(O)c1cncc(-n2ncc3c(C(F)(F)F)cccc32)c1,CHEMBL4028827,Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension.,Bioorg Med Chem Lett,2017.0,27,11,2384,2388,10.1016/j.bmcl.2017.04.021,28416132.0,
18137312,CHEMBL4069245,"(R)-8-(2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethyl)-2-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2,8-diazaspiro[4.5]decan-1-one",CHEMBL4030039,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(=O)n(C)n2)C3=O)ccc2c1COC2=O,CHEMBL4028831,Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores.,Bioorg Med Chem Lett,2017.0,27,11,2559,2566,10.1016/j.bmcl.2017.03.086,28431879.0,
18137943,CHEMBL4070692,"5-amino-3,4-dimethyl-N-(4-(pyridin-4-yl)benzyl)thieno[2,3-c]pyridazine-6-carboxamide",CHEMBL4030179,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2300.0,nM,Cc1nnc2sc(C(=O)NCc3ccc(-c4ccncc4)cc3)c(N)c2c1C,CHEMBL4028836,"Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology.",Bioorg Med Chem Lett,2017.0,27,11,2296,2301,10.1016/j.bmcl.2017.04.043,28442253.0,
18137944,CHEMBL4094439,"5-amino-N-(4-(2-fluoropyridin-4-yl)benzyl)-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxamide",CHEMBL4030179,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,25000.0,nM,Cc1nnc2sc(C(=O)NCc3ccc(-c4ccnc(F)c4)cc3)c(N)c2c1C,CHEMBL4028836,"Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology.",Bioorg Med Chem Lett,2017.0,27,11,2296,2301,10.1016/j.bmcl.2017.04.043,28442253.0,
18137945,CHEMBL4102040,"5-amino-N-(4-(6-fluoropyridin-3-yl)benzyl)-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxamide",CHEMBL4030179,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,26000.0,nM,Cc1nnc2sc(C(=O)NCc3ccc(-c4ccc(F)nc4)cc3)c(N)c2c1C,CHEMBL4028836,"Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology.",Bioorg Med Chem Lett,2017.0,27,11,2296,2301,10.1016/j.bmcl.2017.04.043,28442253.0,
18137946,CHEMBL4091821,"5-amino-N-(4-(2-fluoropyridin-3-yl)benzyl)-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxamide",CHEMBL4030179,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1nnc2sc(C(=O)NCc3ccc(-c4cccnc4F)cc3)c(N)c2c1C,CHEMBL4028836,"Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology.",Bioorg Med Chem Lett,2017.0,27,11,2296,2301,10.1016/j.bmcl.2017.04.043,28442253.0,
18139620,CHEMBL4103847,"4-((5-Methylisoxazol-3-yl)methoxy)-5-(pyridin-2-ylmethyl)-5H-pyrrolo[3,2-d]pyrimidin-2-amine",CHEMBL4030714,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 10 mins by LC/MS analysis,IC50,>,10000.0,nM,Cc1cc(COc2nc(N)nc3ccn(Cc4ccccn4)c23)no1,CHEMBL4028850,"Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B.",J Med Chem,2017.0,60,14,6137,6151,10.1021/acs.jmedchem.7b00365,28671847.0,
18147984,CHEMBL4095003,"1-((trans)-3-(4-(2-Chlorophenyl)-5-(pyrimidin-4-yl)-4H-1,2,4-triazol-3-yl)cyclobutyl)-2,3-dihydro-2-oxo-1H-benzo[d]imidazole-5-carbonitrile",CHEMBL4032844,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 30 mins by LC-MS/MS analysis,IC50,=,11900.0,nM,N#Cc1ccc2c(c1)[nH]c(=O)n2[C@H]1C[C@H](c2nnc(-c3ccncn3)n2-c2ccccc2Cl)C1,CHEMBL4028904,Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.,J Med Chem,2017.0,60,24,10013,10025,10.1021/acs.jmedchem.7b00883,29155568.0,
18148914,CHEMBL4066961,"2-(3,4-dimethoxyphenyl)-5-(3-methoxypropyl)benzofuran",CHEMBL4033110,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes preincubated for 5 mins followed by addition of NADPH generating system measured after 20 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,COCCCc1ccc2oc(-c3ccc(OC)c(OC)c3)cc2c1,CHEMBL4028909,Discovery of an Orally Bioavailable Benzofuran Analogue That Serves as a β-Amyloid Aggregation Inhibitor for the Potential Treatment of Alzheimer's Disease.,J Med Chem,2018.0,61,1,396,402,10.1021/acs.jmedchem.7b00844,29161514.0,
18149967,CHEMBL3938418,"US9464084, 288",CHEMBL4033433,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide or diclofenac as substrates,IC50,=,1600.0,nM,C[C@H]1Cc2c(nnn2-c2ccccc2)CN1C(=O)c1cccc(C(F)(F)F)c1Cl,CHEMBL4028916,"A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate.",J Med Chem,2018.0,61,1,207,223,10.1021/acs.jmedchem.7b01279,29211470.0,
18149968,CHEMBL3919664,"US9464084, 220",CHEMBL4033433,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide or diclofenac as substrates,IC50,>,10000.0,nM,C[C@H]1Cc2c(nnn2-c2ncc(F)cn2)CN1C(=O)c1cccc(C(F)(F)F)c1F,CHEMBL4028916,"A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate.",J Med Chem,2018.0,61,1,207,223,10.1021/acs.jmedchem.7b01279,29211470.0,
18149969,CHEMBL3931075,"US9464084, 118",CHEMBL4033433,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide or diclofenac as substrates,IC50,=,1200.0,nM,C[C@H]1Cc2c(nnn2-c2ccccn2)CN1C(=O)c1cccc(C(F)(F)F)c1Cl,CHEMBL4028916,"A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate.",J Med Chem,2018.0,61,1,207,223,10.1021/acs.jmedchem.7b01279,29211470.0,
18149970,CHEMBL3923283,"US9464084, 212",CHEMBL4033433,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide or diclofenac as substrates,IC50,=,5500.0,nM,C[C@H]1Cc2c(nnn2-c2cnccn2)CN1C(=O)c1cccc(C(F)(F)F)c1Cl,CHEMBL4028916,"A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate.",J Med Chem,2018.0,61,1,207,223,10.1021/acs.jmedchem.7b01279,29211470.0,
18149971,CHEMBL4077411,"(S)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(1-ethyl-1H-pyrazol-3-yl)-6-methyl-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)-methanone",CHEMBL4033433,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide or diclofenac as substrates,IC50,=,2500.0,nM,CCn1ccc(-n2nnc3c2C[C@H](C)N(C(=O)c2cccc(C(F)(F)F)c2Cl)C3)n1,CHEMBL4028916,"A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate.",J Med Chem,2018.0,61,1,207,223,10.1021/acs.jmedchem.7b01279,29211470.0,
18149972,CHEMBL4072525,"(S)-(2-Chloro-3-(trifluoromethyl)phenyl)(6-methyl-1-(thiophen-3-yl)-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone",CHEMBL4033433,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide or diclofenac as substrates,IC50,=,3700.0,nM,C[C@H]1Cc2c(nnn2-c2ccsc2)CN1C(=O)c1cccc(C(F)(F)F)c1Cl,CHEMBL4028916,"A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate.",J Med Chem,2018.0,61,1,207,223,10.1021/acs.jmedchem.7b01279,29211470.0,
18149973,CHEMBL3914857,"US9464084, 228",CHEMBL4033433,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide or diclofenac as substrates,IC50,>,10000.0,nM,C[C@H]1Cc2c(nnn2-c2ncc(F)cn2)CN1C(=O)c1ccnc(C(F)(F)F)c1F,CHEMBL4028916,"A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate.",J Med Chem,2018.0,61,1,207,223,10.1021/acs.jmedchem.7b01279,29211470.0,
18149974,CHEMBL3936866,"(S)-(1-(5-Fluoropyrimidin-2-yl)-6-methyl-6,7-dihydro-1H-[1,2,3]-triazolo[4,5-c]pyridin-5(4H)-yl)(3-methyl-2-(trifluoromethyl)pyridin-4-yl)methanone",CHEMBL4033433,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide or diclofenac as substrates,IC50,>,10000.0,nM,Cc1c(C(=O)N2Cc3nnn(-c4ncc(F)cn4)c3C[C@@H]2C)ccnc1C(F)(F)F,CHEMBL4028916,"A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate.",J Med Chem,2018.0,61,1,207,223,10.1021/acs.jmedchem.7b01279,29211470.0,
18160883,CHEMBL4062319,"5-amino-N-(1-(2,3-difluorophenyl)azetidin-3-yl)-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxamide",CHEMBL4035879,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3800.0,nM,Cc1nnc2sc(C(=O)NC3CN(c4cccc(F)c4F)C3)c(N)c2c1C,CHEMBL4033702,"Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides.",Bioorg Med Chem Lett,2017.0,27,13,2990,2995,10.1016/j.bmcl.2017.05.014,28522253.0,
18160884,CHEMBL4083081,"5-amino-3,4-dimethyl-N-(1-(6-(trifluoromethyl)pyridin-3-yl)azetidin-3-yl)thieno[2,3-c]pyridazine-6-carboxamide",CHEMBL4035879,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1nnc2sc(C(=O)NC3CN(c4ccc(C(F)(F)F)nc4)C3)c(N)c2c1C,CHEMBL4033702,"Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides.",Bioorg Med Chem Lett,2017.0,27,13,2990,2995,10.1016/j.bmcl.2017.05.014,28522253.0,
18163488,CHEMBL4072112,"(S)-3-((S)-1-(4-(2,6-dimethylpyridin-4-yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one",CHEMBL4036196,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,21400.0,nM,Cc1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc(C)n1,CHEMBL4033714,"Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.",Bioorg Med Chem,2017.0,25,14,3649,3657,10.1016/j.bmc.2017.04.033,28528082.0,
18163489,CHEMBL4069717,"(S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(6-methoxypyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one",CHEMBL4036196,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8000.0,nM,COc1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cn1,CHEMBL4033714,"Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.",Bioorg Med Chem,2017.0,25,14,3649,3657,10.1016/j.bmc.2017.04.033,28528082.0,
18163490,CHEMBL4096179,"(S)-3-((S)-1-(4-(5-fluoropyridin-2-yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one",CHEMBL4036196,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,20100.0,nM,C[C@@H](c1ccc(-c2ccc(F)cn2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL4033714,"Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.",Bioorg Med Chem,2017.0,25,14,3649,3657,10.1016/j.bmc.2017.04.033,28528082.0,
18163491,CHEMBL4090128,"6-(4-((S)-1-((S)-6-(2-hydroxy-2-methylpropyl)-2-oxo-6-phenyl-1,3-oxazinan-3-yl)ethyl)phenyl)nicotinonitrile",CHEMBL4036196,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,22200.0,nM,C[C@@H](c1ccc(-c2ccc(C#N)cn2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL4033714,"Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.",Bioorg Med Chem,2017.0,25,14,3649,3657,10.1016/j.bmc.2017.04.033,28528082.0,
18163492,CHEMBL4076599,"6-(4-((S)-1-((S)-6-(2-hydroxy-2-methylpropyl)-2-oxo-6-phenyl-1,3-oxazinan-3-yl)ethyl)phenyl)nicotinamide",CHEMBL4036196,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@@H](c1ccc(-c2ccc(C(N)=O)cn2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL4033714,"Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.",Bioorg Med Chem,2017.0,25,14,3649,3657,10.1016/j.bmc.2017.04.033,28528082.0,
18163493,CHEMBL4064441,"(S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(5-methylpyrazin-2-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one",CHEMBL4036196,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,33000.0,nM,Cc1cnc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cn1,CHEMBL4033714,"Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.",Bioorg Med Chem,2017.0,25,14,3649,3657,10.1016/j.bmc.2017.04.033,28528082.0,
18163494,CHEMBL4075178,"(S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(6-methylpyridazin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one",CHEMBL4036196,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)nn1,CHEMBL4033714,"Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.",Bioorg Med Chem,2017.0,25,14,3649,3657,10.1016/j.bmc.2017.04.033,28528082.0,
18163495,CHEMBL4105041,"(S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(2-methylpyrimidin-5-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one",CHEMBL4036196,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1ncc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cn1,CHEMBL4033714,"Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.",Bioorg Med Chem,2017.0,25,14,3649,3657,10.1016/j.bmc.2017.04.033,28528082.0,
18163496,CHEMBL3664715,"US8575157, 37",CHEMBL4036196,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,43000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL4033714,"Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.",Bioorg Med Chem,2017.0,25,14,3649,3657,10.1016/j.bmc.2017.04.033,28528082.0,
18163497,CHEMBL3664717,"US8575157, 48",CHEMBL4036196,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL4033714,"Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.",Bioorg Med Chem,2017.0,25,14,3649,3657,10.1016/j.bmc.2017.04.033,28528082.0,
18163498,CHEMBL4063121,"(S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one",CHEMBL4036196,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@@H](c1ccc(-c2ccc(=O)n(C)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL4033714,"Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.",Bioorg Med Chem,2017.0,25,14,3649,3657,10.1016/j.bmc.2017.04.033,28528082.0,
18163499,CHEMBL3660140,"US8598163, 3",CHEMBL4036196,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@@H](c1ccc(-c2ccc3ncnn3c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,CHEMBL4033714,"Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.",Bioorg Med Chem,2017.0,25,14,3649,3657,10.1016/j.bmc.2017.04.033,28528082.0,
18166825,CHEMBL4082366,N-(4-(1-(3-hydroxy-3-methylbutanoyl)piperidin-4-yl)phenyl)isoindoline-2-carboxamide,CHEMBL4036660,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8400.0,nM,CC(C)(O)CC(=O)N1CCC(c2ccc(NC(=O)N3Cc4ccccc4C3)cc2)CC1,CHEMBL4033748,SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).,Bioorg Med Chem Lett,2017.0,27,15,3317,3325,10.1016/j.bmcl.2017.06.018,28610984.0,
18166826,CHEMBL3929298,"US9302989, 411",CHEMBL4036660,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,O=C(NC[C@@H]1CCOC1)c1ccc(NC(=O)N2Cc3ccccc3C2)cc1,CHEMBL4033748,SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).,Bioorg Med Chem Lett,2017.0,27,15,3317,3325,10.1016/j.bmcl.2017.06.018,28610984.0,
18179415,CHEMBL4103707,6-Methyl-N-(6-methylpyridin-2-yl)-4-(pyrimidin-5-yloxy)-picolinamide,CHEMBL4039220,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,IC50,=,4100.0,nM,Cc1cccc(NC(=O)c2cc(Oc3cncnc3)cc(C)n2)n1,CHEMBL4038301,Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.,J Med Chem,2017.0,60,12,5072,5085,10.1021/acs.jmedchem.7b00410,28530802.0,
18179416,CHEMBL4076771,4-((5-Fluoropyridin-3-yl)oxy)-6-methyl-N-(6-methylpyridin-2-yl)-picolinamide,CHEMBL4039220,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,IC50,=,1300.0,nM,Cc1cccc(NC(=O)c2cc(Oc3cncc(F)c3)cc(C)n2)n1,CHEMBL4038301,Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.,J Med Chem,2017.0,60,12,5072,5085,10.1021/acs.jmedchem.7b00410,28530802.0,
18179417,CHEMBL2386772,N-(6-ethylpyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide,CHEMBL4039220,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,IC50,=,1800.0,nM,CCc1cccc(NC(=O)c2cc(Oc3cncnc3)cc(C)n2)n1,CHEMBL4038301,Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.,J Med Chem,2017.0,60,12,5072,5085,10.1021/acs.jmedchem.7b00410,28530802.0,
18179418,CHEMBL4095685,N-(6-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)-picolinamide,CHEMBL4039220,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,IC50,=,1800.0,nM,Cc1cc(Oc2cncnc2)cc(C(=O)Nc2cccc(F)n2)n1,CHEMBL4038301,Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.,J Med Chem,2017.0,60,12,5072,5085,10.1021/acs.jmedchem.7b00410,28530802.0,
18179419,CHEMBL4077672,N-(6-Fluoropyridin-2-yl)-4-((5-fluoropyridin-3-yl)oxy)-6-methylpicolinamide,CHEMBL4039220,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,IC50,=,1800.0,nM,Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2cccc(F)n2)n1,CHEMBL4038301,Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.,J Med Chem,2017.0,60,12,5072,5085,10.1021/acs.jmedchem.7b00410,28530802.0,
18179420,CHEMBL2386850,N-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide,CHEMBL4039220,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,IC50,=,12100.0,nM,Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(F)cn2)n1,CHEMBL4038301,Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.,J Med Chem,2017.0,60,12,5072,5085,10.1021/acs.jmedchem.7b00410,28530802.0,
18179421,CHEMBL2386849,N-(5-fluoropyridin-2-yl)-4-(5-fluoropyridin-3-yloxy)-6-methylpicolinamide,CHEMBL4039220,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,IC50,=,5400.0,nM,Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2ccc(F)cn2)n1,CHEMBL4038301,Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.,J Med Chem,2017.0,60,12,5072,5085,10.1021/acs.jmedchem.7b00410,28530802.0,
18179422,CHEMBL4082854,N-(5-Chloropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)-picolinamide,CHEMBL4039220,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,IC50,=,11000.0,nM,Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(Cl)cn2)n1,CHEMBL4038301,Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.,J Med Chem,2017.0,60,12,5072,5085,10.1021/acs.jmedchem.7b00410,28530802.0,
18179423,CHEMBL4100830,N-(5-Chloropyridin-2-yl)-4-((5-fluoropyridin-3-yl)oxy)-6-methylpicolinamide,CHEMBL4039220,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2ccc(Cl)cn2)n1,CHEMBL4038301,Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.,J Med Chem,2017.0,60,12,5072,5085,10.1021/acs.jmedchem.7b00410,28530802.0,
18179424,CHEMBL4090661,N-(4-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)-picolinamide,CHEMBL4039220,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,Cc1cc(Oc2cncnc2)cc(C(=O)Nc2cc(F)ccn2)n1,CHEMBL4038301,Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.,J Med Chem,2017.0,60,12,5072,5085,10.1021/acs.jmedchem.7b00410,28530802.0,
18179425,CHEMBL4062697,N-(4-Fluoropyridin-2-yl)-4-((5-fluoropyridin-3-yl)oxy)-6-methylpicolinamide,CHEMBL4039220,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,IC50,=,5700.0,nM,Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2cc(F)ccn2)n1,CHEMBL4038301,Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.,J Med Chem,2017.0,60,12,5072,5085,10.1021/acs.jmedchem.7b00410,28530802.0,
18179426,CHEMBL2386771,N-(5-fluoropyridin-2-yl)-6-methyl-4-(2-methylpyrimidin-5-yloxy)picolinamide,CHEMBL4039220,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,IC50,>,30000.0,nM,Cc1cc(Oc2cnc(C)nc2)cc(C(=O)Nc2ccc(F)cn2)n1,CHEMBL4038301,Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.,J Med Chem,2017.0,60,12,5072,5085,10.1021/acs.jmedchem.7b00410,28530802.0,
18179427,CHEMBL4096818,4-((5-Chloropyridin-3-yl)oxy)-N-(5-fluoropyridin-2-yl)-6-methylpicolinamide,CHEMBL4039220,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,IC50,=,21500.0,nM,Cc1cc(Oc2cncc(Cl)c2)cc(C(=O)Nc2ccc(F)cn2)n1,CHEMBL4038301,Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.,J Med Chem,2017.0,60,12,5072,5085,10.1021/acs.jmedchem.7b00410,28530802.0,
18179554,CHEMBL2386850,N-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide,CHEMBL4039272,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 15 mins measured after 8 mins in presence or absence of NADPH by LC/MS/MS analysis,IC50,=,29900.0,nM,Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(F)cn2)n1,CHEMBL4038301,Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation.,J Med Chem,2017.0,60,12,5072,5085,10.1021/acs.jmedchem.7b00410,28530802.0,
18183036,CHEMBL2324753,"4-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)-3-cyano-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,517.0,nM,Cn1nccc1-c1cc(Cl)ccc1Oc1ccc(S(=O)(=O)Nc2ncns2)cc1C#N,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183038,CHEMBL2325350,"4-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,39.0,nM,Cn1nccc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2ncns2)cc1F,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183040,CHEMBL2324755,"5-chloro-4-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)-2-fluoro-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide",CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,100.0,nM,Cn1nccc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2nncs2)cc1Cl,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183041,CHEMBL2322421,4-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)-3-cyano-N-(thiazol-4-yl)benzenesulfonamide,CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1368.0,nM,Cn1nccc1-c1cc(Cl)ccc1Oc1ccc(S(=O)(=O)Nc2cscn2)cc1C#N,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183042,CHEMBL2324405,5-chloro-4-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide,CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,37.0,nM,Cn1nccc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183044,CHEMBL2324391,5-chloro-4-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)-2-fluoro-N-(pyrimidin-4-yl)benzenesulfonamide,CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,184.0,nM,Cn1nccc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)cc1Cl,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183045,CHEMBL2324742,"4-(4-chloro-2-(1H-pyrazol-5-yl)phenoxy)-3-cyano-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,205.0,nM,N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(Cl)cc1-c1ccn[nH]1,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183046,CHEMBL2325330,"4-(4-chloro-2-(1H-pyrazol-4-yl)phenoxy)-3-cyano-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,83.0,nM,N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(Cl)cc1-c1cn[nH]c1,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183047,CHEMBL2325619,"3-cyano-4-(2-(5-methyl-1H-pyrazol-4-yl)-4-(trifluoromethyl)phenoxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,372.0,nM,Cc1[nH]ncc1-c1cc(C(F)(F)F)ccc1Oc1ccc(S(=O)(=O)Nc2ncns2)cc1C#N,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183048,CHEMBL2325038,"4-(2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy)-3-cyano-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,894.0,nM,N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(Cl)cc1-c1cn[nH]c1N,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183049,CHEMBL2325013,"4-(2-(2-aminopyridin-4-yl)-4-chlorophenoxy)-3-cyano-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,279.0,nM,N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(Cl)cc1-c1ccnc(N)c1,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183050,CHEMBL2323074,"3-cyano-4-(2-(pyrimidin-4-yl)-4-(trifluoromethyl)phenoxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,180.0,nM,N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(C(F)(F)F)cc1-c1ccncn1,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183051,CHEMBL2323073,"3-cyano-4-(2-(pyridazin-3-yl)-4-(trifluoromethyl)phenoxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,321.0,nM,N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(C(F)(F)F)cc1-c1cccnn1,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183052,CHEMBL2325021,"3-cyano-4-(2-(pyridazin-4-yl)-4-(trifluoromethyl)phenoxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2200.0,nM,N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(C(F)(F)F)cc1-c1ccnnc1,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183053,CHEMBL2325016,4-(4-chloro-2-(1H-pyrazol-4-yl)phenoxy)-3-cyano-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,36.0,nM,N#Cc1cc(S(=O)(=O)Nc2nccs2)ccc1Oc1ccc(Cl)cc1-c1cn[nH]c1,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183054,CHEMBL2324776,"5-chloro-2-fluoro-4-(2-(pyridazin-4-yl)-4-(trifluoromethyl)phenoxy)-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide",CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1101.0,nM,O=S(=O)(Nc1nncs1)c1cc(Cl)c(Oc2ccc(C(F)(F)F)cc2-c2ccnnc2)cc1F,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183055,CHEMBL2324396,5-chloro-2-fluoro-4-(2-(pyridazin-4-yl)-4-(trifluoromethyl)phenoxy)-N-(thiazol-4-yl)benzenesulfonamide,CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1365.0,nM,O=S(=O)(Nc1cscn1)c1cc(Cl)c(Oc2ccc(C(F)(F)F)cc2-c2ccnnc2)cc1F,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183056,CHEMBL2325627,"4-(2-(3-amino-1H-pyrazol-4-yl)-4-(trifluoromethyl)phenoxy)-5-chloro-2-fluoro-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide",CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,658.0,nM,Nc1n[nH]cc1-c1cc(C(F)(F)F)ccc1Oc1cc(F)c(S(=O)(=O)Nc2nncs2)cc1Cl,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183057,CHEMBL2325601,4-(2-(3-amino-1H-pyrazol-4-yl)-4-(trifluoromethyl)phenoxy)-5-chloro-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide,CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,552.0,nM,Nc1n[nH]cc1-c1cc(C(F)(F)F)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183058,CHEMBL2325014,4-(2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy)-5-chloro-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide,CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,299.0,nM,Nc1[nH]ncc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183059,CHEMBL2325622,"4-(4-chloro-2-(1-(1-methylazetidin-3-yl)-1H-pyrazol-5-yl)phenoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,264.0,nM,CN1CC(n2nccc2-c2cc(Cl)ccc2Oc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)C1,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183060,CHEMBL2324748,4-(4-chloro-2-(1-(1-ethylazetidin-3-yl)-1H-pyrazol-5-yl)phenoxy)-3-cyano-N-(thiazol-4-yl)benzenesulfonamide,CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,17992.0,nM,CCN1CC(n2nccc2-c2cc(Cl)ccc2Oc2ccc(S(=O)(=O)Nc3cscn3)cc2C#N)C1,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183061,CHEMBL2325317,"4-(4-chloro-2-(1-(1-methylazetidin-3-yl)-1H-pyrazol-5-yl)phenoxy)-2,5-difluoro-N-(thiazol-4-yl)benzenesulfonamide",CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1012.0,nM,CN1CC(n2nccc2-c2cc(Cl)ccc2Oc2cc(F)c(S(=O)(=O)Nc3cscn3)cc2F)C1,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18183062,CHEMBL2325020,"4-(4-chloro-2-(1-(1-ethylazetidin-3-yl)-1H-pyrazol-5-yl)phenoxy)-2,5-difluoro-N-(thiazol-4-yl)benzenesulfonamide",CHEMBL4040133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3234.0,nM,CCN1CC(n2nccc2-c2cc(Cl)ccc2Oc2cc(F)c(S(=O)(=O)Nc3cscn3)cc2F)C1,CHEMBL4038312,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",J Med Chem,2017.0,60,16,7029,7042,10.1021/acs.jmedchem.7b00598,28682065.0,
18187397,CHEMBL4105630,3alpha-hydroxy-3beta-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5beta-pregnan-20-one,CHEMBL4040871,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,C[C@]12CC[C@@H]3[C@H]4CC[C@@](C)(O)C[C@H]4CC[C@H]3[C@@H]1CC[C@@H]2C(=O)Cn1cc(C#N)cn1,CHEMBL4038335,Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor.,J Med Chem,2017.0,60,18,7810,7819,10.1021/acs.jmedchem.7b00846,28753313.0,
18213355,CHEMBL4061793,5-chloro-2-fluoro-4-((hexahydro-1H-pyrrolizin-7a-yl)methylamino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC23CCCN2CCC3)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213356,CHEMBL4104727,"5-chloro-2-fluoro-4-(((3as,6ar)-hexahydrofuro[2,3-b]furan-3a-yl)methylamino)-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@]23CCO[C@H]2OCC3)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213357,CHEMBL4080500,"5-chloro-2-fluoro-4-(((3ar,6ar)-6a-methylhexahydrofuro[2,3-b]furan-3a-yl)methylamino)-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,C[C@]12OCC[C@@]1(CNc1cc(F)c(S(=O)(=O)Nc3nccs3)cc1Cl)CCO2,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213358,CHEMBL4071860,"5-chloro-2-fluoro-4-(((3aS,7aR)-hexahydro-2H-furo[2,3-b]pyran-3a-yl)methylamino)-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@@]23CCCO[C@@H]2OCC3)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213359,CHEMBL4071736,"5-chloro-2-fluoro-4-(((3ar,6as)-6a-hydroxyoctahydropentalen-3a-yl)methylamino)-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@]23CCC[C@@]2(O)CCC3)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213360,CHEMBL4089301,"5-Chloro-2-fluoro-4-((((1S,3R,4s,5S,7S)-4-hydroxyadamantan-1-yl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC23CC4CC(C2)C(O)C(C4)C3)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213361,CHEMBL4061129,"5-Chloro-2-fluoro-4-(((1R,3S,5R,7)-3-hydroxyadamantan-1-yl)amino)-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC23CC4CC(CC(O)(C4)C2)C3)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213362,CHEMBL4097000,(+/-)-5-Chloro-2-fluoro-4-((tetrahydrofuran-3-yl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC2CCOC2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213363,CHEMBL4069801,(+/-)-4-(7-Oxabicyclo[2.2.1]heptan-2-ylamino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC2CC3CCC2O3)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213364,CHEMBL4101414,(+/-)-5-Chloro-2-fluoro-4-(((tetrahydrofuran-3-yl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CCOC2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213365,CHEMBL4076229,(+/-)-5-Chloro-2-fluoro-4-((2-(tetrahydrofuran-2-yl)ethyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCOC2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213366,CHEMBL4073353,(+/-)-5-Chloro-2-fluoro-4-((3-(tetrahydrofuran-3-yl)propyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCCC2CCOC2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213367,CHEMBL4100208,(+/-)-5-Chloro-2-fluoro-4-(((tetrahydrofuran-2-yl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CCCO2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213368,CHEMBL4083744,"4-(((1,3-Dioxolan-2-yl)methyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2OCCO2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213369,CHEMBL4062009,5-Chloro-2-fluoro-4-((tetrahydro-2H-pyran-4-yl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC2CCOCC2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213370,CHEMBL4102647,5-Chloro-2-fluoro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CCOCC2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213371,CHEMBL4084713,"5-Chloro-4-(((2,6-dimethyltetrahydro-2H-pyran-4-yl)methyl)amino)-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,CC1CC(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC(C)O1,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213372,CHEMBL4064762,5-Chloro-2-fluoro-4-((2-(tetrahydro-2H-pyran-4-yl)ethyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCOCC2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213373,CHEMBL4092463,(+/-)-5-Chloro-2-fluoro-4-(((tetrahydro-2H-pyran-2-yl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CCCCO2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213374,CHEMBL4087220,"(+/-)-4-(((1,4-Dioxan-2-yl)methyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2COCCO2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213375,CHEMBL4065798,(+/-)-5-Chloro-2-fluoro-4-((2-(tetrahydro-2H-pyran-2-yl)ethyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCCCO2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213376,CHEMBL4099769,(+/-)-5-Chloro-2-fluoro-4-((tetrahydro-2H-pyran-3-yl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC2CCCOC2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213377,CHEMBL4072883,(R)-5-Chloro-2-fluoro-4-(((tetrahydro-2H-pyran-3-yl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCCOC2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213378,CHEMBL4092025,(S)-5-Chloro-2-fluoro-4-(((tetrahydro-2H-pyran-3-yl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@@H]2CCCOC2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213379,CHEMBL4064295,"4-((((2SR,3RS)-2-(tert-Butyl)tetrahydro-2H-pyran-3-yl)methyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,CC(C)(C)[C@H]1OCCC[C@@H]1CNc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213380,CHEMBL4084268,"4-((((2SR,3SR)-2-(tert-Butyl)tetrahydro-2H-pyran-3-yl)methyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,CC(C)(C)[C@@H]1OCCC[C@@H]1CNc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213381,CHEMBL4102233,"5-Chloro-2-fluoro-4-((((2SR,3RS)-2-phenyltetrahydro-2H-pyran-3-yl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCCO[C@@H]2c2ccccc2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213382,CHEMBL4073933,"5-Chloro-2-fluoro-4-((((2RS,3RS)-2-phenyltetrahydro-2H-pyran-3-yl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCCO[C@H]2c2ccccc2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213383,CHEMBL4094490,(+/-)-5-Chloro-2-fluoro-4-((2-(tetrahydro-2H-pyran-3-yl)ethyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCCOC2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213384,CHEMBL4065325,5-Chloro-2-fluoro-4-(((3-methyloxetan-3-yl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,CC1(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)COC1,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213385,CHEMBL4086750,4-(2-Oxaspiro[3.3]heptan-6-ylamino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC2CC3(COC3)C2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213386,CHEMBL4102624,5-Chloro-2-fluoro-4-(((3-oxocyclohexyl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=C1CCCC(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)C1,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213387,CHEMBL4084685,"5-Chloro-2-fluoro-4-((((1SR,3SR)-3-hydroxycyclohexyl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCC[C@H](O)C2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213388,CHEMBL4094879,"5-Chloro-2-fluoro-4-((((1RS,3SR)-3-hydroxycyclohexyl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCC[C@@H](O)C2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213389,CHEMBL4074392,"4-((1,4-Dioxaspiro[4.5]decan-7-ylmethyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CCCC3(C2)OCCO3)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213390,CHEMBL4073324,5-Chloro-2-fluoro-4-(((4-oxocyclohexyl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=C1CCC(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213391,CHEMBL4100176,5-Chloro-2-fluoro-4-(((4-(methoxyimino)cyclohexyl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,CON=C1CCC(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213392,CHEMBL4064737,4-(((4-((Benzyloxy)imino)cyclohexyl)methyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide,CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CCC(=NOCc3ccccc3)CC2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213393,CHEMBL4092435,"5-Chloro-2-fluoro-4-((((1RS,4RS)-4-hydroxycyclohexyl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CC[C@H](O)CC2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213394,CHEMBL4068484,"5-Chloro-2-fluoro-4-((((1SR,4SR)-4-hydroxycyclohexyl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CC[C@@H](O)CC2)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213395,CHEMBL4095822,"4-((1,4-Dioxaspiro[4.5]decan-8-ylmethyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CCC3(CC2)OCCO3)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213396,CHEMBL4098747,"4-((2-(1,4-Dioxaspiro[4.5]decan-8-yl)ethyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCC3(CC2)OCCO3)cc1F,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213397,CHEMBL4071739,"5-Chloro-4-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino)-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S1(=O)CCC(Nc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213398,CHEMBL4075332,"5-Chloro-4-((2-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)ethyl)amino)-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S1(=O)CCC(CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18213399,CHEMBL4082252,"5-Chloro-4-(((1,1-dioxidotetrahydrothiophen-3-yl)methyl)amino)-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",CHEMBL4046480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,20000.0,nM,O=S1(=O)CCC(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)C1,CHEMBL4043185,Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.,Bioorg Med Chem,2017.0,25,20,5490,5505,10.1016/j.bmc.2017.08.012,28818462.0,
18214893,CHEMBL4060556,"{2-(5-Fluoropyridin-2-yl)-6,7-dihydro[1,3]oxazolo[4,5-c]pyridin-5(4H)-yl}(phenyl)methanone",CHEMBL4046789,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 10 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,O=C(c1ccccc1)N1CCc2oc(-c3ccc(F)cn3)nc2C1,CHEMBL4043199,"Synthesis and optimization of 4,5,6,7-tetrahydrooxazolo[4,5-c]pyridines as potent and orally-active metabotropic glutamate receptor 5 negative allosteric modulators.",Bioorg Med Chem Lett,2017.0,27,18,4331,4335,10.1016/j.bmcl.2017.08.030,28838696.0,
18214894,CHEMBL4102181,"(3-Fluorophenyl){2-(5-fluoropyridin-2-yl)-6,7-dihydro[1,3]oxazolo[4,5-c]pyridin-5(4H)-yl}methanone",CHEMBL4046789,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 10 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,O=C(c1cccc(F)c1)N1CCc2oc(-c3ccc(F)cn3)nc2C1,CHEMBL4043199,"Synthesis and optimization of 4,5,6,7-tetrahydrooxazolo[4,5-c]pyridines as potent and orally-active metabotropic glutamate receptor 5 negative allosteric modulators.",Bioorg Med Chem Lett,2017.0,27,18,4331,4335,10.1016/j.bmcl.2017.08.030,28838696.0,
18214895,CHEMBL4087545,"(3-Chloro-5-fluorophenyl){2-(5-fluoropyridin-2-yl)-6,7-dihydro[1,3]oxazolo[4,5-c]pyridin-5(4H)-yl}methanone",CHEMBL4046789,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 10 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,O=C(c1cc(F)cc(Cl)c1)N1CCc2oc(-c3ccc(F)cn3)nc2C1,CHEMBL4043199,"Synthesis and optimization of 4,5,6,7-tetrahydrooxazolo[4,5-c]pyridines as potent and orally-active metabotropic glutamate receptor 5 negative allosteric modulators.",Bioorg Med Chem Lett,2017.0,27,18,4331,4335,10.1016/j.bmcl.2017.08.030,28838696.0,
18214896,CHEMBL4098822,"(3-chloro-5-fluorophenyl)(2-(5-fluoropyridin-2-yl)-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)methanone",CHEMBL4046789,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 10 mins by LC-MS/MS analysis,IC50,>,40000.0,nM,O=C(c1cc(F)cc(Cl)c1)N1CCn2nc(-c3ccc(F)cn3)cc2C1,CHEMBL4043199,"Synthesis and optimization of 4,5,6,7-tetrahydrooxazolo[4,5-c]pyridines as potent and orally-active metabotropic glutamate receptor 5 negative allosteric modulators.",Bioorg Med Chem Lett,2017.0,27,18,4331,4335,10.1016/j.bmcl.2017.08.030,28838696.0,
18221356,CHEMBL4088036,N-(4-{4-[(6-Butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide dihydrochloride,CHEMBL4047774,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,31000.0,nM,CCCCc1cc(OC2CCN(CCCCNS(=O)(=O)CC)CC2)c2ncccc2c1.Cl.Cl,CHEMBL4043263,Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis.,Bioorg Med Chem Lett,2017.0,27,21,4914,4919,10.1016/j.bmcl.2017.09.020,28958623.0,
18221511,CHEMBL4089606,"6-(5-cyanopyridin-3-yloxy)-N-(5-fluoropyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide",CHEMBL4047825,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,=,20500.0,nM,N#Cc1cncc(Oc2cc(C(=O)Nc3ccc(F)cn3)c3ncnn3c2)c1,CHEMBL4043265,"Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.",Bioorg Med Chem Lett,2017.0,27,21,4858,4866,10.1016/j.bmcl.2017.09.042,28958625.0,
18221512,CHEMBL4081733,"6-(5,6-difluoropyridin-3-yloxy)-N-(5-fluoropyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide",CHEMBL4047825,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,O=C(Nc1ccc(F)cn1)c1cc(Oc2cnc(F)c(F)c2)cn2ncnc12,CHEMBL4043265,"Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.",Bioorg Med Chem Lett,2017.0,27,21,4858,4866,10.1016/j.bmcl.2017.09.042,28958625.0,
18221513,CHEMBL4092008,"6-(4,5-difluoropyridin-3-yloxy)-N-(5-fluoropyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide",CHEMBL4047825,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2F)cn2ncnc12,CHEMBL4043265,"Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.",Bioorg Med Chem Lett,2017.0,27,21,4858,4866,10.1016/j.bmcl.2017.09.042,28958625.0,
18221514,CHEMBL4085919,"N-(5-fluoropyridin-2-yl)-6-(pyrimidin-5-yloxy)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide",CHEMBL4047825,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,O=C(Nc1ccc(F)cn1)c1cc(Oc2cncnc2)cn2ncnc12,CHEMBL4043265,"Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.",Bioorg Med Chem Lett,2017.0,27,21,4858,4866,10.1016/j.bmcl.2017.09.042,28958625.0,
18221515,CHEMBL4089114,"N-(5-fluoropyridin-2-yl)-6-((5-fluoropyridin-3-yl)oxy)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide",CHEMBL4047825,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2)cn2ncnc12,CHEMBL4043265,"Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.",Bioorg Med Chem Lett,2017.0,27,21,4858,4866,10.1016/j.bmcl.2017.09.042,28958625.0,
18221516,CHEMBL4071447,"N-(5-Fluoropyridin-2-yl)-6-((5-fluoropyridin-3-yl)oxy)-[1,2,4]triazolo[4,3-a]pyridine-8-carboxamide",CHEMBL4047825,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2)cn2cnnc12,CHEMBL4043265,"Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.",Bioorg Med Chem Lett,2017.0,27,21,4858,4866,10.1016/j.bmcl.2017.09.042,28958625.0,
18221517,CHEMBL4104546,"6-(5-fluoropyridin-3-yloxy)-N-(5-methoxypyridin-2-yl)imidazo[1,2-a]pyridine-8-carboxamide",CHEMBL4047825,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,=,5700.0,nM,COc1ccc(NC(=O)c2cc(Oc3cncc(F)c3)cn3ccnc23)nc1,CHEMBL4043265,"Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.",Bioorg Med Chem Lett,2017.0,27,21,4858,4866,10.1016/j.bmcl.2017.09.042,28958625.0,
18221518,CHEMBL4080316,"6-(5-fluoropyridin-3-yloxy)-N-(5-methylpyridin-2-yl)imidazo[1,2-a]pyridine-8-carboxamide",CHEMBL4047825,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,=,6900.0,nM,Cc1ccc(NC(=O)c2cc(Oc3cncc(F)c3)cn3ccnc23)nc1,CHEMBL4043265,"Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.",Bioorg Med Chem Lett,2017.0,27,21,4858,4866,10.1016/j.bmcl.2017.09.042,28958625.0,
18221519,CHEMBL4066902,"N-(5-Fluoropyridin-2-yl)-6-((5-fluoropyridin-3-yl)oxy)imidazo[1,2-a]pyridine-8-carboxamide",CHEMBL4047825,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,=,5700.0,nM,O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2)cn2ccnc12,CHEMBL4043265,"Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.",Bioorg Med Chem Lett,2017.0,27,21,4858,4866,10.1016/j.bmcl.2017.09.042,28958625.0,
18221520,CHEMBL4088174,"6-(5-fluoropyridin-3-yloxy)-N-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-8-carboxamide",CHEMBL4047825,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,=,1000.0,nM,Cc1cccc(NC(=O)c2cc(Oc3cncc(F)c3)cn3ccnc23)n1,CHEMBL4043265,"Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.",Bioorg Med Chem Lett,2017.0,27,21,4858,4866,10.1016/j.bmcl.2017.09.042,28958625.0,
18221521,CHEMBL4077770,"N-(6-fluoropyridin-2-yl)-6-(5-fluoropyridin-3-yloxy)imidazo[1,2-a]pyridine-8-carboxamide",CHEMBL4047825,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,=,1600.0,nM,O=C(Nc1cccc(F)n1)c1cc(Oc2cncc(F)c2)cn2ccnc12,CHEMBL4043265,"Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.",Bioorg Med Chem Lett,2017.0,27,21,4858,4866,10.1016/j.bmcl.2017.09.042,28958625.0,
18221522,CHEMBL2386849,N-(5-fluoropyridin-2-yl)-4-(5-fluoropyridin-3-yloxy)-6-methylpicolinamide,CHEMBL4047825,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,=,5400.0,nM,Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2ccc(F)cn2)n1,CHEMBL4043265,"Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.",Bioorg Med Chem Lett,2017.0,27,21,4858,4866,10.1016/j.bmcl.2017.09.042,28958625.0,
18222435,CHEMBL4096279,"(+)-2-[3-(4-Chlorophenyl)ureido]-9-methyl-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[b]thiophene-3-carboxamide Hydrochloride",CHEMBL4048004,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,60000.0,nM,CN1[C@H]2CC[C@@H]1Cc1sc(NC(=O)Nc3ccc(Cl)cc3)c(C(N)=O)c12.Cl,CHEMBL4043273,"Phenotypic Optimization of Urea-Thiophene Carboxamides To Yield Potent, Well Tolerated, and Orally Active Protective Agents against Aminoglycoside-Induced Hearing Loss.",J Med Chem,2018.0,61,1,84,97,10.1021/acs.jmedchem.7b00932,28992413.0,
18224161,CHEMBL4079206,"(1'R,2'S)-2-(2,6-Dichlorostyryl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-4H-chromen-4-one",CHEMBL4048407,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using fluorogenic substrate preincubated with co-factor for 10 mins followed by enzyme-substrate addition by fluorometric method,IC50,>,20000.0,nM,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(/C=C/c4c(Cl)cccc4Cl)oc23)[C@H](O)C1,CHEMBL4043283,"Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor.",J Med Chem,2018.0,61,4,1664,1687,10.1021/acs.jmedchem.7b01765,29370702.0,
18226951,CHEMBL3917415,"US9290467, 23",CHEMBL4049063,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using MFC as substrate by fluorescence assay,IC50,=,16000.0,nM,N#CC1(NC(=O)[C@@H]2Cc3ccc(c(Cl)c3)OCCCCOc3cc(C(F)(F)F)ccc3C(=O)N2)CC1,CHEMBL4043299,Repurposing a Library of Human Cathepsin L Ligands: Identification of Macrocyclic Lactams as Potent Rhodesain and Trypanosoma brucei Inhibitors.,J Med Chem,2018.0,61,8,3350,3369,10.1021/acs.jmedchem.7b01869,29590750.0,
18227255,CHEMBL4104507,3-Chloro-N-(1-cyanocyclopropyl)-Nalpha-{[(2-(4-fluorophenyl)-2H-triazol-4-yl]carbonyl}-4-O-(trifluoromethyl)-L-tyrosinamide,CHEMBL4049109,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using MFC as substrate by fluorescence assay,IC50,=,9000.0,nM,N#CC1(NC(=O)[C@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)NC(=O)c2cnn(-c3ccc(F)cc3)n2)CC1,CHEMBL4043300,"2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.",J Med Chem,2018.0,61,8,3370,3388,10.1021/acs.jmedchem.7b01870,29590751.0,
18227256,CHEMBL4060895,N-(1-Cyanocyclopropyl)-3-chloro-4-O-(trifluoromethyl)-Nalpha-[(2-(6-fluoropyridin-3-yl)-2H-triazol-4-ylcarbonyl]-L-tyrosinamide,CHEMBL4049109,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using MFC as substrate by fluorescence assay,IC50,=,11000.0,nM,N#CC1(NC(=O)[C@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)NC(=O)c2cnn(-c3ccc(F)nc3)n2)CC1,CHEMBL4043300,"2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.",J Med Chem,2018.0,61,8,3370,3388,10.1021/acs.jmedchem.7b01870,29590751.0,
18227257,CHEMBL4081213,N-(1-Cyanocyclopropyl)-3-chloro-4-O-(trifluoromethyl)-Nalpha-[(2-(pyridin-3-yl)-2H-triazol-4-ylcarbonyl]-L-tyrosinamide,CHEMBL4049109,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using MFC as substrate by fluorescence assay,IC50,=,7000.0,nM,N#CC1(NC(=O)[C@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)NC(=O)c2cnn(-c3cccnc3)n2)CC1,CHEMBL4043300,"2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.",J Med Chem,2018.0,61,8,3370,3388,10.1021/acs.jmedchem.7b01870,29590751.0,
18227258,CHEMBL4093444,3-Chloro-N-(1-cyanocyclopropyl)-Nalpha-[(2-methyl-2H-triazol-4-ylcarbonyl]-4-O-(trifluoromethyl)-L-tyrosinamide,CHEMBL4049109,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using MFC as substrate by fluorescence assay,IC50,>,50000.0,nM,Cn1ncc(C(=O)N[C@@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)C(=O)NC2(C#N)CC2)n1,CHEMBL4043300,"2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.",J Med Chem,2018.0,61,8,3370,3388,10.1021/acs.jmedchem.7b01870,29590751.0,
18227260,CHEMBL4065483,N-(1-Cyanocyclopropyl)-3-chloro-4-O-(trifluoromethyl)-Nalpha-[(2-(tert-butyl)-2H-triazol-4-ylcarbonyl]-L-tyrosinamide,CHEMBL4049109,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using MFC as substrate by fluorescence assay,IC50,=,5000.0,nM,CC(C)(C)n1ncc(C(=O)N[C@@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)C(=O)NC2(C#N)CC2)n1,CHEMBL4043300,"2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.",J Med Chem,2018.0,61,8,3370,3388,10.1021/acs.jmedchem.7b01870,29590751.0,
18227261,CHEMBL4073014,"N-(1-Cyanocyclopropyl)-3,4-dichloro-Nalpha-[(2-(4-fluorophenyl)-2H-triazol-4-ylcarbonyl]-L-phenylalaninamide",CHEMBL4049109,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using MFC as substrate by fluorescence assay,IC50,=,4000.0,nM,N#CC1(NC(=O)[C@H](Cc2ccc(Cl)c(Cl)c2)NC(=O)c2cnn(-c3ccc(F)cc3)n2)CC1,CHEMBL4043300,"2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.",J Med Chem,2018.0,61,8,3370,3388,10.1021/acs.jmedchem.7b01870,29590751.0,
18231458,CHEMBL4081676,"1'-(5-(5-Chloro-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-5H-spiro-[furo[3,4-b]pyridine-7,4'-piperidin]-5-one",CHEMBL4050157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3400.0,nM,O=C1OC2(CCN(c3ccc(-c4nc5cc(Cl)ccc5[nH]4)cn3)CC2)c2ncccc21,CHEMBL4049398,Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.,J Med Chem,2017.0,60,9,3594,3605,10.1021/acs.jmedchem.6b01543,28252959.0,
18231459,CHEMBL4100640,2-(3-(5-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-3-azaspiro[5.5]undecan-9-yl)acetic acid,CHEMBL4050157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,10800.0,nM,O=C(O)CC1CCC2(CC1)CCN(c1ccc(-c3nc4cc(C(F)(F)F)ccc4[nH]3)cn1)CC2,CHEMBL4049398,Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.,J Med Chem,2017.0,60,9,3594,3605,10.1021/acs.jmedchem.6b01543,28252959.0,
18231460,CHEMBL4105361,"2-(9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-3,9-diazaspiro[5.5]undecan-3-yl)acetic Acid",CHEMBL4050157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C(O)CN1CCC2(CC1)CCN(c1ccc(-c3nc4cc(C(F)(F)F)ccc4[nH]3)cn1)CC2,CHEMBL4049398,Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.,J Med Chem,2017.0,60,9,3594,3605,10.1021/acs.jmedchem.6b01543,28252959.0,
18231462,CHEMBL4069786,9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-9-azaspiro[5.5]undecane-3-carboxylic Acid,CHEMBL4050157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C(O)C1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1,CHEMBL4049398,Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.,J Med Chem,2017.0,60,9,3594,3605,10.1021/acs.jmedchem.6b01543,28252959.0,
18231463,CHEMBL4075203,2-(9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-9-azaspiro[5.5]undecan-4-yl)acetic Acid,CHEMBL4050157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C(O)CC1CCOC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1,CHEMBL4049398,Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.,J Med Chem,2017.0,60,9,3594,3605,10.1021/acs.jmedchem.6b01543,28252959.0,
18231464,CHEMBL4060355,2-(9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-9-azaspiro[5.5]undecan-3-yl)acetic Acid,CHEMBL4050157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1,CHEMBL4049398,Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.,J Med Chem,2017.0,60,9,3594,3605,10.1021/acs.jmedchem.6b01543,28252959.0,
18231465,CHEMBL4082282,2-(8-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-8-azaspiro[4.5]decan-2-yl)acetic Acid,CHEMBL4050157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)O1,CHEMBL4049398,Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.,J Med Chem,2017.0,60,9,3594,3605,10.1021/acs.jmedchem.6b01543,28252959.0,
18231466,CHEMBL4087688,2-(8-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-8-azaspiro[4.5]decan-3-yl)acetic Acid,CHEMBL4050157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C(O)CC1COC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1,CHEMBL4049398,Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.,J Med Chem,2017.0,60,9,3594,3605,10.1021/acs.jmedchem.6b01543,28252959.0,
18231467,CHEMBL4066339,(R)-2-(8-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-8-azaspiro[4.5]decan-3-yl)acetic Acid,CHEMBL4050157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C(O)C[C@@H]1COC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1,CHEMBL4049398,Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.,J Med Chem,2017.0,60,9,3594,3605,10.1021/acs.jmedchem.6b01543,28252959.0,
18231468,CHEMBL4079801,(S)-2-(8-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-8-azaspiro[4.5]decan-3-yl)acetic Acid,CHEMBL4050157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C(O)C[C@H]1COC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1,CHEMBL4049398,Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.,J Med Chem,2017.0,60,9,3594,3605,10.1021/acs.jmedchem.6b01543,28252959.0,
18231469,CHEMBL4075203,2-(9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-9-azaspiro[5.5]undecan-4-yl)acetic Acid,CHEMBL4050157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,45200.0,nM,O=C(O)CC1CCOC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1,CHEMBL4049398,Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.,J Med Chem,2017.0,60,9,3594,3605,10.1021/acs.jmedchem.6b01543,28252959.0,
18231470,CHEMBL4075203,2-(9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-9-azaspiro[5.5]undecan-4-yl)acetic Acid,CHEMBL4050157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,35100.0,nM,O=C(O)CC1CCOC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1,CHEMBL4049398,Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.,J Med Chem,2017.0,60,9,3594,3605,10.1021/acs.jmedchem.6b01543,28252959.0,
18231471,CHEMBL4060355,2-(9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-9-azaspiro[5.5]undecan-3-yl)acetic Acid,CHEMBL4050157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,20400.0,nM,O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1,CHEMBL4049398,Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.,J Med Chem,2017.0,60,9,3594,3605,10.1021/acs.jmedchem.6b01543,28252959.0,
18231472,CHEMBL4060355,2-(9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-9-azaspiro[5.5]undecan-3-yl)acetic Acid,CHEMBL4050157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,25600.0,nM,O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1,CHEMBL4049398,Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.,J Med Chem,2017.0,60,9,3594,3605,10.1021/acs.jmedchem.6b01543,28252959.0,
18231474,CHEMBL4082282,2-(8-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-8-azaspiro[4.5]decan-2-yl)acetic Acid,CHEMBL4050157,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,39500.0,nM,O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)O1,CHEMBL4049398,Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.,J Med Chem,2017.0,60,9,3594,3605,10.1021/acs.jmedchem.6b01543,28252959.0,
18235931,CHEMBL4068611,RELACORILANT,CHEMBL4051183,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2000.0,nM,Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1,CHEMBL4049426,"Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist.",J Med Chem,2017.0,60,8,3405,3421,10.1021/acs.jmedchem.7b00162,28368581.0,
18237524,CHEMBL4070789,"(+)-(R)-2-(Butylsulfinyl)-4-(1,2-dimethyl-1H-imidazol-5-yl)-6-(thiazol-2-yl)thieno[2,3-b]pyridin-3-amine",CHEMBL4051511,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCCC[S@@+]([O-])c1sc2nc(-c3nccs3)cc(-c3cnc(C)n3C)c2c1N,CHEMBL4049436,Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.,J Med Chem,2017.0,60,9,3979,4001,10.1021/acs.jmedchem.7b00271,28398755.0,
18239839,CHEMBL4081789,"N-(6,8-Dimethylimidazo[1,2-a]pyrazin-2-yl)-4-(4-methylpiperazin-1-yl)benzamide",CHEMBL4052072,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1cn2cc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)nc2c(C)n1,CHEMBL4049449,Discovery of a Novel Class of Survival Motor Neuron 2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy.,J Med Chem,2017.0,60,10,4444,4457,10.1021/acs.jmedchem.7b00406,28441483.0,
18241929,CHEMBL4063337,"(R,R)-trans-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)-oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone Hydrochloride",CHEMBL4052353,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 human liver microsomes after 10 mins by LC-MS/MS analysis,IC50,=,1700.0,nM,Cl.NCc1ccnc(Oc2cccc(C(=O)N3C[C@@H](O)[C@H](F)C3)c2)c1,CHEMBL4049456,"Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).",J Med Chem,2017.0,60,10,4403,4423,10.1021/acs.jmedchem.7b00345,28471663.0,
18252206,CHEMBL4094806,"US9464084, 148",CHEMBL4054734,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 15 mins by LC-MS/MS analysis,IC50,=,2800.0,nM,C[C@@H]1c2nnn(-c3cc(F)ccn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl,CHEMBL4052642,"4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate.",J Med Chem,2017.0,60,11,4559,4572,10.1021/acs.jmedchem.7b00408,28493698.0,
18252207,CHEMBL4074304,"US9464084, 74",CHEMBL4054734,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 15 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@@H]1c2nnn(-c3cnccn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl,CHEMBL4052642,"4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate.",J Med Chem,2017.0,60,11,4559,4572,10.1021/acs.jmedchem.7b00408,28493698.0,
18252208,CHEMBL4068397,"US9464084, 88",CHEMBL4054734,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 15 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@@H]1c2nnn(-c3ncccn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl,CHEMBL4052642,"4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate.",J Med Chem,2017.0,60,11,4559,4572,10.1021/acs.jmedchem.7b00408,28493698.0,
18252209,CHEMBL4095741,"US9464084, 235",CHEMBL4054734,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 15 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1ccnc(-n2nnc3c2CCN(C(=O)c2cccc(C(F)(F)F)c2Cl)[C@@H]3C)n1,CHEMBL4052642,"4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate.",J Med Chem,2017.0,60,11,4559,4572,10.1021/acs.jmedchem.7b00408,28493698.0,
18252210,CHEMBL4079239,"US9464084, 158",CHEMBL4054734,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 15 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@@H]1c2nnn(-c3ncc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl,CHEMBL4052642,"4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate.",J Med Chem,2017.0,60,11,4559,4572,10.1021/acs.jmedchem.7b00408,28493698.0,
18261040,CHEMBL1397,Posaconazole,CHEMBL4056597,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatocyte microsomes using diclofenac substrate by HPLC/MS/MS method,IC50,=,109000.0,nM,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,CHEMBL4052712,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",Bioorg Med Chem Lett,2017.0,27,15,3243,3248,10.1016/j.bmcl.2017.06.037,28651982.0,
18261041,CHEMBL106,"2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol",CHEMBL4056597,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatocyte microsomes using diclofenac substrate by HPLC/MS/MS method,IC50,=,34000.0,nM,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,CHEMBL4052712,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",Bioorg Med Chem Lett,2017.0,27,15,3243,3248,10.1016/j.bmcl.2017.06.037,28651982.0,
18261042,CHEMBL1397,Posaconazole,CHEMBL4056598,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C19 in human hepatocyte microsomes using omeprazole substrate by HPLC/MS/MS method,IC50,=,7200.0,nM,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,CHEMBL4052712,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",Bioorg Med Chem Lett,2017.0,27,15,3243,3248,10.1016/j.bmcl.2017.06.037,28651982.0,
18261043,CHEMBL106,"2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol",CHEMBL4056598,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C19 in human hepatocyte microsomes using omeprazole substrate by HPLC/MS/MS method,IC50,=,13000.0,nM,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,CHEMBL4052712,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",Bioorg Med Chem Lett,2017.0,27,15,3243,3248,10.1016/j.bmcl.2017.06.037,28651982.0,
18261076,CHEMBL4077246,"4-((4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)ethynyl)phenoxy)methyl)benzonitrile",CHEMBL4056598,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C19 in human hepatocyte microsomes using omeprazole substrate by HPLC/MS/MS method,IC50,=,138000.0,nM,N#Cc1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)cc1,CHEMBL4052712,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",Bioorg Med Chem Lett,2017.0,27,15,3243,3248,10.1016/j.bmcl.2017.06.037,28651982.0,
18261077,CHEMBL4077246,"4-((4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)ethynyl)phenoxy)methyl)benzonitrile",CHEMBL4056597,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatocyte microsomes using diclofenac substrate by HPLC/MS/MS method,IC50,>,200000.0,nM,N#Cc1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)cc1,CHEMBL4052712,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",Bioorg Med Chem Lett,2017.0,27,15,3243,3248,10.1016/j.bmcl.2017.06.037,28651982.0,
18266488,CHEMBL1586994,SID14743891,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1cccc(/C=C/C(=O)c2ccc[nH]2)c1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266489,CHEMBL2299166,"(E)-3-(2,6-Dimethoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one",CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1cccc(OC)c1/C=C/C(=O)c1ccc[nH]1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266490,CHEMBL2299167,(E)-3-(2-Chloro-5-nitrophenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1cc([N+](=O)[O-])ccc1Cl)c1ccc[nH]1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266491,CHEMBL2236657,"3-(2,3-dimethoxy-phenyl)-1-(1H-pyrrol-2-yl)-propenone",CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1cccc(/C=C/C(=O)c2ccc[nH]2)c1OC,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266492,CHEMBL1477453,SID22414386,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1ccc2c(c1)OCO2)c1ccc[nH]1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266493,CHEMBL2299353,"(E)-3-(2,4-Dimethoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one",CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1ccc(/C=C/C(=O)c2ccc[nH]2)c(OC)c1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266494,CHEMBL4065261,"(2E,4E)-5-Phenyl-1-(1H-pyrrol-2-yl)penta-2,4-dien-1-one",CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/C=C/c1ccccc1)c1ccc[nH]1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266495,CHEMBL4086703,"(E)-3-(3,5-Dimethoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one",CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1cc(/C=C/C(=O)c2ccc[nH]2)cc(OC)c1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266496,CHEMBL4081406,(E)-3-(2-Fluorophenyl)-1-(1H-pyrrol-2yl)prop-2-en-1-one,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1ccccc1F)c1ccc[nH]1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266497,CHEMBL4105559,(E)-3-(2-Methoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1ccccc1/C=C/C(=O)c1ccc[nH]1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266498,CHEMBL3745717,"5-(4-methoxyphenyl)-1-(1H-pyrrol-2-yl)penta-2,4-dien-1-one",CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1ccc(/C=C/C=C/C(=O)c2ccc[nH]2)cc1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266499,CHEMBL2299165,(E)-3-(4-Dimethylaminophenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,CN(C)c1ccc(/C=C/C(=O)c2ccc[nH]2)cc1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266500,CHEMBL2299354,(E)-3-(4-Methoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1ccc(/C=C/C(=O)c2ccc[nH]2)cc1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266501,CHEMBL1335197,SID22404544,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1ccccc1Cl)c1ccc[nH]1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266502,CHEMBL4061752,(E)-3-(3-Bromophenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1cccc(Br)c1)c1ccc[nH]1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266503,CHEMBL4089828,(E)-3-(3-Bromo-4-methoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1ccc(/C=C/C(=O)c2ccc[nH]2)cc1Br,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266504,CHEMBL4076533,(E)-3-(5-Ethylfuran-2-yl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,CCc1ccc(/C=C/C(=O)c2ccc[nH]2)o1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266505,CHEMBL4090207,"(E)-1-(1H-Pyrrol-2-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one",CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1cc(/C=C/C(=O)c2ccc[nH]2)cc(OC)c1OC,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266506,CHEMBL4081017,(E)-3-(4-Trifluoromethoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1ccc(OC(F)(F)F)cc1)c1ccc[nH]1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266507,CHEMBL4105268,(E)-4-(3-Oxo-3-(1H-pyrrol-2-yl)prop-1-enyl)benzoic acid,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(O)c1ccc(/C=C/C(=O)c2ccc[nH]2)cc1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266508,CHEMBL4070384,(E)-3-(Anthracen-10-yl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1c2ccccc2cc2ccccc12)c1ccc[nH]1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266509,CHEMBL3735451,(2E)-3-(3-Chlorophenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1cccc(Cl)c1)c1ccc[nH]1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266510,CHEMBL2299352,(E)-3-(4-Bromophenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1ccc(Br)cc1)c1ccc[nH]1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266511,CHEMBL283196,2-Phenyl-benzo[h]chromen-4-one,CHEMBL4057738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 bound to yeast microsomal membrane using 3-cyano-7-ethoxycoumarin as substrate after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266576,CHEMBL4105559,(E)-3-(2-Methoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one,CHEMBL4057745,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in HEK293 cells using fluorogenic 3-cyano-7-ethoxycoumarin as preincubated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,10000.0,nM,COc1ccccc1/C=C/C(=O)c1ccc[nH]1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266577,CHEMBL1335197,SID22404544,CHEMBL4057745,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in HEK293 cells using fluorogenic 3-cyano-7-ethoxycoumarin as preincubated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,10000.0,nM,O=C(/C=C/c1ccccc1Cl)c1ccc[nH]1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18266578,CHEMBL4081017,(E)-3-(4-Trifluoromethoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one,CHEMBL4057745,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in HEK293 cells using fluorogenic 3-cyano-7-ethoxycoumarin as preincubated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1ccc(OC(F)(F)F)cc1)c1ccc[nH]1,CHEMBL4052762,"Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.",Bioorg Med Chem Lett,2017.0,27,16,3683,3687,10.1016/j.bmcl.2017.07.010,28711350.0,
18270980,CHEMBL4097025,"3-[7-(Difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2H-quinolin-1-yl]-N-methyl-1-tetrahydropyran-4-yl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxamide",CHEMBL4058661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CNC(=O)N1CCc2c(c(N3CCCc4cc(-c5cnn(C)c5)c(C(F)F)cc43)nn2C2CCOCC2)C1,CHEMBL4052814,"GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP).",J Med Chem,2017.0,60,22,9162,9183,10.1021/acs.jmedchem.7b00796,28892380.0,
18271432,CHEMBL4086143,"3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione",CHEMBL4058738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,100000.0,nM,O=C1CC(c2c[nH]c3ccc(F)cc23)C(=O)N1,CHEMBL4052817,"Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate.",J Med Chem,2017.0,60,23,9617,9629,10.1021/acs.jmedchem.7b00974,29111717.0,
18271433,CHEMBL4087106,"(R)-3-(1H-indol-3-yl)pyrrolidine-2,5-dione",CHEMBL4058738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,O=C1C[C@H](c2c[nH]c3ccccc23)C(=O)N1,CHEMBL4052817,"Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate.",J Med Chem,2017.0,60,23,9617,9629,10.1021/acs.jmedchem.7b00974,29111717.0,
18273680,CHEMBL4070320,"(E)-N1-((Tetrahydro-2H-pyran-4-yl)methyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)but-2-ene-1,4-diamine",CHEMBL4059175,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,<,5000.0,nM,C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNCC1CCOCC1,CHEMBL4052827,Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties.,J Med Chem,2018.0,61,3,946,979,10.1021/acs.jmedchem.7b01420,29350534.0,
18273681,CHEMBL4075205,"(E)-N1-(Tetrahydro-2H-pyran-4-yl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-but-2-ene-1,4-diamine",CHEMBL4059175,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,<,5000.0,nM,C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNC1CCOCC1,CHEMBL4052827,Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties.,J Med Chem,2018.0,61,3,946,979,10.1021/acs.jmedchem.7b01420,29350534.0,
18273682,CHEMBL4094400,"N1-(4,4-Difluorocyclohexyl)-2,2-dimethyl-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",CHEMBL4059175,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,<,5000.0,nM,CC(C)(CCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)CNC1CCC(F)(F)CC1,CHEMBL4052827,Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties.,J Med Chem,2018.0,61,3,946,979,10.1021/acs.jmedchem.7b01420,29350534.0,
18273683,CHEMBL4065224,"2,2-Dimethyl-N1-(tetrahydro-2H-pyran-4-yl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",CHEMBL4059175,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,<,5000.0,nM,CC(C)(CCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)CNC1CCOCC1,CHEMBL4052827,Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties.,J Med Chem,2018.0,61,3,946,979,10.1021/acs.jmedchem.7b01420,29350534.0,
18273684,CHEMBL4086662,"N1-(4,4-Dimethylcyclohexyl)-2,2-dimethyl-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",CHEMBL4059175,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,<,5000.0,nM,CC1(C)CCC(NCC(C)(C)CCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1,CHEMBL4052827,Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties.,J Med Chem,2018.0,61,3,946,979,10.1021/acs.jmedchem.7b01420,29350534.0,
18278400,CHEMBL4126548,Isobutyl (S)-2-(5-(2-fluorophenyl)isoxazole-3-carboxamido)-3-(1H-imidazol-1-yl)propanoate,CHEMBL4119500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS analysis,IC50,>,50000.0,nM,CC(C)COC(=O)[C@H](Cn1ccnc1)NC(=O)c1cc(-c2ccccc2F)on1,CHEMBL4118063,"Design, synthesis and evaluation of aromatic heterocyclic derivatives as potent antifungal agents.",Eur J Med Chem,2017.0,137,,96,107,10.1016/j.ejmech.2017.05.043,28558334.0,
18278401,CHEMBL4127941,Isopropyl (S)-2-(5-(2-fluorophenyl)isoxazole-3-carboxamido)-3-(1H-imidazol-1-yl)propanoate,CHEMBL4119500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS analysis,IC50,>,50000.0,nM,CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1cc(-c2ccccc2F)on1,CHEMBL4118063,"Design, synthesis and evaluation of aromatic heterocyclic derivatives as potent antifungal agents.",Eur J Med Chem,2017.0,137,,96,107,10.1016/j.ejmech.2017.05.043,28558334.0,
18278462,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4119500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS analysis,IC50,=,535.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4118063,"Design, synthesis and evaluation of aromatic heterocyclic derivatives as potent antifungal agents.",Eur J Med Chem,2017.0,137,,96,107,10.1016/j.ejmech.2017.05.043,28558334.0,
18289573,CHEMBL4126331,"5-(4-(4-amino-5-oxo-7,8-dihydropyrimido[5,4f][1,4]oxazepin-6(5H)-yl)-2,6-dimethylphenyl)-3,3-dimethylpent-4-ynoic acid",CHEMBL4122239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,100000.0,nM,Cc1cc(N2CCOc3ncnc(N)c3C2=O)cc(C)c1C#CC(C)(C)CC(=O)O,CHEMBL4118143,"Discovery of dimethyl pent-4-ynoic acid derivatives, as potent and orally bioavailable DGAT1 inhibitors that suppress body weight in diet-induced mouse obesity model.",Bioorg Med Chem Lett,2018.0,28,10,1686,1692,10.1016/j.bmcl.2018.04.051,29699923.0,
18290982,CHEMBL4128835,Evocalcet dihydrochloride,CHEMBL4122661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@@H](N[C@H]1CCN(c2ccc(CC(=O)O)cc2)C1)c1cccc2ccccc12.Cl.Cl,CHEMBL4118154,"Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism.",Bioorg Med Chem Lett,2018.0,28,11,2055,2060,10.1016/j.bmcl.2018.04.055,29724589.0,
18291509,CHEMBL4127978,"(R)-(1-Ethyl-4,5,6,7-tetrahydro-1H-indazol-5-yl)-[8-(4-fluoro-2-methylphenyl)-[1,2,4]triazolo[1,5-a]pyridine-2-yl]-amine",CHEMBL4122745,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH by LC-MS/MS analysis,IC50,=,25000.0,nM,CCn1ncc2c1CC[C@@H](Nc1nc3c(-c4ccc(F)cc4C)cccn3n1)C2,CHEMBL4118159,Discovery of tetrahydroindazoles as a novel class of potent and in vivo efficacious gamma secretase modulators.,Bioorg Med Chem,2018.0,26,12,3227,3241,10.1016/j.bmc.2018.04.053,29735425.0,
18295683,CHEMBL4127539,"4-{4-[(1''r,3''r,5''R,7''R)-dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo[3.3.1.1(3,7)]decan]-4-yl]benzyl}morpholine",CHEMBL4123554,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide methylhydroxylation after 4 to 40 mins in presence of NADPH by LCMS analysis,IC50,>,20000.0,nM,c1cc(C2CCC3(CC2)OOC2(OO3)C3CC4CC(C3)CC2C4)ccc1CN1CCOCC1,CHEMBL4118195,"Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.",Bioorg Med Chem,2018.0,26,11,2996,3005,10.1016/j.bmc.2018.05.006,29779669.0,
18295684,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4123554,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide methylhydroxylation after 4 to 40 mins in presence of NADPH by LCMS analysis,IC50,=,720.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4118195,"Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.",Bioorg Med Chem,2018.0,26,11,2996,3005,10.1016/j.bmc.2018.05.006,29779669.0,
18295841,CHEMBL4125752,"(R)-6-((1-(Cyclopropanecarbonyl)pyrrolidin-3-yl)methyl)-5-(4'-(1-methyl-1H-pyrazol-4-yl)-[1,1'-biphenyl]-4-yl)-4,6-diazaspiro[2.4]hept-4-en-7-one",CHEMBL4123634,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,7900.0,nM,Cn1cc(-c2ccc(-c3ccc(C4=NC5(CC5)C(=O)N4C[C@@H]4CCN(C(=O)C5CC5)C4)cc3)cc2)cn1,CHEMBL4118196,Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy.,Bioorg Med Chem Lett,2018.0,28,12,2159,2164,10.1016/j.bmcl.2018.05.014,29779975.0,
18295933,CHEMBL4126289,"N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide",CHEMBL4123665,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,40000.0,nM,CC1(C)OCCn2c1nc(C(=O)NCc1ccc(F)cc1)c(O)c2=O,CHEMBL4118197,"The discovery and preclinical evaluation of BMS-707035, a potent HIV-1 integrase strand transfer inhibitor.",Bioorg Med Chem Lett,2018.0,28,12,2124,2130,10.1016/j.bmcl.2018.05.027,29779976.0,
18300481,CHEMBL4109308,"US9227956, 16",CHEMBL4124693,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,O=C(c1ccc(-n2nnc3cccnc32)cc1)N(c1ncccc1Cl)[C@@H]1CCCNC1,CHEMBL4118248,Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents.,J Med Chem,2018.0,61,13,5704,5718,10.1021/acs.jmedchem.8b00650,29878763.0,
18300482,CHEMBL4127458,(R)-N-(3-Chloropyridin-2-yl)-4-(6-methylpyrazin-2-yl)-N-(piperidin-3-yl)benzamide,CHEMBL4124693,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1cncc(-c2ccc(C(=O)N(c3ncccc3Cl)[C@@H]3CCCNC3)cc2)n1,CHEMBL4118248,Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents.,J Med Chem,2018.0,61,13,5704,5718,10.1021/acs.jmedchem.8b00650,29878763.0,
18304215,CHEMBL4127317,"N-(3-(3-Isopropyl-7-((2-methoxy-4-(4-methylpiperazin-1-yl)-phenyl)amino)-2,4-dioxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",CHEMBL4125352,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 (unknown origin),IC50,>,50000.0,nM,C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,CHEMBL4118273,"Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.",J Med Chem,2018.0,61,13,5609,5622,10.1021/acs.jmedchem.8b00346,29906114.0,
18312490,CHEMBL4175440,2-(3-((4-methylacridin-9-yl)amino)phenyl)-1H-benzo[d]imidazole-4-carboxamide,CHEMBL4132431,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes preincubated for 5 mins followed by NADPH/substrate addition measured after 20 mins by LC-MS/MS analysis,IC50,=,2200.0,nM,Cc1cccc2c(Nc3cccc(-c4nc5c(C(N)=O)cccc5[nH]4)c3)c3ccccc3nc12,CHEMBL4130375,"Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.",Eur J Med Chem,2017.0,138,,1135,1146,10.1016/j.ejmech.2017.07.050,28763648.0,
18312715,CHEMBL4177457,"1-((5-chloro-1-(oxetan-3-ylmethyl)-1H-benzo[d]imidazol-2-yl)methyl)-3-(methylsulfonyl)-1H-pyrazolo[3,4-c]pyridine",CHEMBL4132511,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,100000.0,nM,CS(=O)(=O)c1nn(Cc2nc3cc(Cl)ccc3n2CC2COC2)c2cnccc12,CHEMBL4130376,Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors.,Eur J Med Chem,2017.0,138,,1147,1157,10.1016/j.ejmech.2017.07.032,28772235.0,
18319792,CHEMBL4164219,1-(4-fluorophenyl)-4-(2-phenoxypropoxy)pyridin-2(1H)-one,CHEMBL4134043,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 15 mins in presence of NADPH by LC/MS/MS analysis,IC50,>,30000.0,nM,CC(COc1ccn(-c2ccc(F)cc2)c(=O)c1)Oc1ccccc1,CHEMBL4130451,Design and Synthesis of N-Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu3 NAMs.,ACS Med Chem Lett,2017.0,8,9,925,930,10.1021/acsmedchemlett.7b00249,28947938.0,
18319793,CHEMBL4172540,(S)-1-(4-fluorophenyl)-4-(2-phenoxypropoxy)pyridin-2(1H)-one,CHEMBL4134043,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 15 mins in presence of NADPH by LC/MS/MS analysis,IC50,>,30000.0,nM,C[C@@H](COc1ccn(-c2ccc(F)cc2)c(=O)c1)Oc1ccccc1,CHEMBL4130451,Design and Synthesis of N-Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu3 NAMs.,ACS Med Chem Lett,2017.0,8,9,925,930,10.1021/acsmedchemlett.7b00249,28947938.0,
18335590,CHEMBL4165225,"N-{3-[(2R,3R)-5-Amino-3-methyl-2-(trifluoromethyl)-3,6-dihydro-2H-1,4-oxazin-3-yl]-4-fluorophenyl}-5-cyanopyridine-2-carboxamide",CHEMBL4137033,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of recombinant human CYP2C9 by fluorescence-based assay,IC50,>,30000.0,nM,C[C@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)N=C(N)CO[C@H]1C(F)(F)F,CHEMBL4130624,"Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate.",J Med Chem,2018.0,61,12,5292,5303,10.1021/acs.jmedchem.8b00304,29809004.0,
18336559,CHEMBL4164328,"N-((1S,2S)-1-(2-(Dimethylamino)ethylcarbamoyl)-2,3-dihydro-1H-inden-2-yl)-1H-indole-2-carboxamide",CHEMBL4137266,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,19952.62,nM,CN(C)CCNC(=O)[C@H]1c2ccccc2C[C@@H]1NC(=O)c1cc2ccccc2[nH]1,CHEMBL4130628,Identification and Pharmacological Profile of an Indane Based Series of Ghrelin Receptor Full Agonists.,J Med Chem,2018.0,61,14,5974,5987,10.1021/acs.jmedchem.8b00322,29909635.0,
18336751,CHEMBL3301620,TEMSAVIR,CHEMBL4137312,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12,CHEMBL4130629,Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.,J Med Chem,2018.0,61,14,6308,6327,10.1021/acs.jmedchem.8b00759,29920093.0,
18357486,CHEMBL2361777,SID103075273,CHEMBL4140834,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,COc1ccc(-c2c(C)nn3c(C(F)(F)F)cc(C)nc23)cc1,CHEMBL4138139,"Discovery of VU6005649, a CNS Penetrant mGlu7/8 Receptor PAM Derived from a Series of Pyrazolo[1,5-a]pyrimidines.",ACS Med Chem Lett,2017.0,8,10,1110,1115,10.1021/acsmedchemlett.7b00317,29057060.0,
18357487,CHEMBL4165248,"3-(3-Fluoro-4-methoxy-phenyl)-2,5-dimethyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine",CHEMBL4140834,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,=,27000.0,nM,COc1ccc(-c2c(C)nn3c(C(F)(F)F)cc(C)nc23)cc1F,CHEMBL4138139,"Discovery of VU6005649, a CNS Penetrant mGlu7/8 Receptor PAM Derived from a Series of Pyrazolo[1,5-a]pyrimidines.",ACS Med Chem Lett,2017.0,8,10,1110,1115,10.1021/acsmedchemlett.7b00317,29057060.0,
18357488,CHEMBL4168668,"3-(2,6-difluoro-4-methoxy-phenyl)-2,5-dimethyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine",CHEMBL4140834,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,COc1cc(F)c(-c2c(C)nn3c(C(F)(F)F)cc(C)nc23)c(F)c1,CHEMBL4138139,"Discovery of VU6005649, a CNS Penetrant mGlu7/8 Receptor PAM Derived from a Series of Pyrazolo[1,5-a]pyrimidines.",ACS Med Chem Lett,2017.0,8,10,1110,1115,10.1021/acsmedchemlett.7b00317,29057060.0,
18357489,CHEMBL4160748,"3-(2,3-Difluoro-4-methoxy-phenyl)-2,5-dimethyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine",CHEMBL4140834,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,=,24700.0,nM,COc1ccc(-c2c(C)nn3c(C(F)(F)F)cc(C)nc23)c(F)c1F,CHEMBL4138139,"Discovery of VU6005649, a CNS Penetrant mGlu7/8 Receptor PAM Derived from a Series of Pyrazolo[1,5-a]pyrimidines.",ACS Med Chem Lett,2017.0,8,10,1110,1115,10.1021/acsmedchemlett.7b00317,29057060.0,
18357490,CHEMBL4172016,"3-(2,5-Difluoro-4-methoxy-phenyl)-2,5-dimethyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine",CHEMBL4140834,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,COc1cc(F)c(-c2c(C)nn3c(C(F)(F)F)cc(C)nc23)cc1F,CHEMBL4138139,"Discovery of VU6005649, a CNS Penetrant mGlu7/8 Receptor PAM Derived from a Series of Pyrazolo[1,5-a]pyrimidines.",ACS Med Chem Lett,2017.0,8,10,1110,1115,10.1021/acsmedchemlett.7b00317,29057060.0,
18374341,CHEMBL4175981,OLORINAB,CHEMBL4144158,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC(C)(C)[C@@H](CO)NC(=O)c1nn(-c2c[n+]([O-])ccn2)c2c1C[C@@H]1C[C@H]21,CHEMBL4138258,Discovery of APD371: Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain.,ACS Med Chem Lett,2017.0,8,12,1309,1313,10.1021/acsmedchemlett.7b00396,29259753.0,
18374454,CHEMBL4166742,"(7-Hydroxy-5-phenethyl-[1,2,4]triazolo[1,5-a]pyridine-8-carbonyl)glycine hydrochloride",CHEMBL4144188,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,100000.0,nM,Cl.O=C(O)CNC(=O)c1c(O)cc(CCc2ccccc2)n2ncnc12,CHEMBL4138259,Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia.,ACS Med Chem Lett,2017.0,8,12,1320,1325,10.1021/acsmedchemlett.7b00404,29259755.0,
18375215,CHEMBL4174931,"N-(4-fluorobenzyl)-2-((R)-5-(3-methylureido)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-3'-yl)-N-((S)-1,1,1-trifluoropropan-2-yl)acetamide",CHEMBL4144347,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1600.0,nM,CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccccc2)[C@@H](C)C(F)(F)F)C1=O,CHEMBL4138268,"Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases.",ACS Med Chem Lett,2018.0,9,1,28,33,10.1021/acsmedchemlett.7b00395,29348807.0,
18377363,CHEMBL4173715,"(S)-2-(6-(5-(3-(3,4-Difluorophenyl)ureido)pyrazin-2-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydronaphthalen-2-yl)acetic acid",CHEMBL4144965,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac as substrate,IC50,>,10000.0,nM,O=C(O)C[C@]1(CC(F)(F)F)CCc2cc(-c3cnc(NC(=O)Nc4ccc(F)c(F)c4)cn3)ccc2C1=O,CHEMBL4138301,Discovery of Tetralones as Potent and Selective Inhibitors of Acyl-CoA:Diacylglycerol Acyltransferase 1.,ACS Med Chem Lett,2018.0,9,2,103,108,10.1021/acsmedchemlett.7b00450,29456796.0,
18379026,CHEMBL4159471,N-(4-Fluoro-3-methyl-phenyl)-3-[[(3S)-tetrahydrofuran-3-yl]-sulfamoyl]benzamide,CHEMBL4145272,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1cc(NC(=O)c2cccc(S(=O)(=O)N[C@H]3CCOC3)c2)ccc1F,CHEMBL4138314,Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV).,J Med Chem,2018.0,61,14,6247,6260,10.1021/acs.jmedchem.8b00654,29906396.0,
18398837,CHEMBL4166415,4-phenylisoxazol-5-amine,CHEMBL4149718,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Nc1oncc1-c1ccccc1,CHEMBL4145589,"Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2).",ACS Med Chem Lett,2018.0,9,5,417,421,10.1021/acsmedchemlett.7b00427,29795752.0,
18398838,CHEMBL4173485,4-(thiophen-3-yl)isoxazol-5-amine,CHEMBL4149718,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Nc1oncc1-c1ccsc1,CHEMBL4145589,"Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2).",ACS Med Chem Lett,2018.0,9,5,417,421,10.1021/acsmedchemlett.7b00427,29795752.0,
18398839,CHEMBL4168975,4-(1H-pyrazol-1-yl)isoxazol-5-amine,CHEMBL4149718,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Nc1oncc1-n1cccn1,CHEMBL4145589,"Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2).",ACS Med Chem Lett,2018.0,9,5,417,421,10.1021/acsmedchemlett.7b00427,29795752.0,
18398840,CHEMBL4166624,4-(4-fluoro-1H-pyrazol-1-yl)isoxazol-5-amine,CHEMBL4149718,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Nc1oncc1-n1cc(F)cn1,CHEMBL4145589,"Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2).",ACS Med Chem Lett,2018.0,9,5,417,421,10.1021/acsmedchemlett.7b00427,29795752.0,
18399824,CHEMBL3892956,"US9221796, 46, P-4",CHEMBL4149893,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,18000.0,nM,Cc1ccc(CN2CC[C@@H](N3CC[C@@H](c4ccc(O)cc4)[C@H](F)C3)C2=O)cc1,CHEMBL4145597,"BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder.",ACS Med Chem Lett,2018.0,9,5,472,477,10.1021/acsmedchemlett.8b00080,29795762.0,
18402586,CHEMBL4166144,"N-(5-(2-Amino-4-methyl-8-((tetrahydro-2H-pyran-4-yl)oxy)-quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide",CHEMBL4150481,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in 4-Hydroxydiclofenac formation using diclofenac as substrate after 10 to 20 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,COc1ncc(-c2cc(OC3CCOCC3)c3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4145625,Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment.,J Med Chem,2018.0,61,14,6087,6109,10.1021/acs.jmedchem.8b00416,29927604.0,
18402650,CHEMBL4176771,"(R)-N-(5-(2-Amino-4-methyl-8-((tetrahydrofuran-3-yl)oxy)-quinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide",CHEMBL4150481,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in 4-Hydroxydiclofenac formation using diclofenac as substrate after 10 to 20 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,COc1ncc(-c2cc(O[C@@H]3CCOC3)c3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4145625,Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment.,J Med Chem,2018.0,61,14,6087,6109,10.1021/acs.jmedchem.8b00416,29927604.0,
18402741,CHEMBL4166594,"2,4-Difluoro-N-(2-methoxy-5-(4-methyl-2-(methylamino)-8-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-6-yl)pyridin-3-yl)-benzenesulfonamide",CHEMBL4150481,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in 4-Hydroxydiclofenac formation using diclofenac as substrate after 10 to 20 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CNc1nc(C)c2cc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cc(OC3CCOCC3)c2n1,CHEMBL4145625,Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment.,J Med Chem,2018.0,61,14,6087,6109,10.1021/acs.jmedchem.8b00416,29927604.0,
18402816,CHEMBL4174909,"(R)-2,4-Difluoro-N-(2-methoxy-5-(4-methyl-2-(methylamino)-8-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)pyridin-3-yl)benzenesulfonamide",CHEMBL4150481,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in 4-Hydroxydiclofenac formation using diclofenac as substrate after 10 to 20 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CNc1nc(C)c2cc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cc(O[C@@H]3CCOC3)c2n1,CHEMBL4145625,Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment.,J Med Chem,2018.0,61,14,6087,6109,10.1021/acs.jmedchem.8b00416,29927604.0,
18405317,CHEMBL4171558,3-(pyridin-3-yl)prop-2-yn-1-amine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,30000.0,nM,Cl.Cl.NCC#Cc1cccnc1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405321,CHEMBL4164781,3-(6-Methylpyridin-3-yl)prop-2-yn-1-amine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,>,50000.0,nM,Cc1ccc(C#CCN)cn1.Cl.Cl,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405323,CHEMBL4173088,3-(4-Methylpyridin-3-yl)prop-2-yn-1-amine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,36000.0,nM,Cc1ccncc1C#CCN.Cl.Cl,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405325,CHEMBL4175429,3-(4-Ethylpyridin-3-yl)prop-2-yn-1-amine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,>,50000.0,nM,CCc1ccncc1C#CCN.Cl.Cl,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405326,CHEMBL4167560,3-(4-Methoxypyridin-3-yl)prop-2-yn-1-amine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,28000.0,nM,COc1ccncc1C#CCN.Cl.Cl,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405327,CHEMBL4171984,3-(4-Propylpyridin-3-yl)prop-2-yn-1-amine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,32000.0,nM,CCCc1ccncc1C#CCN.Cl.Cl,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405328,CHEMBL4164113,3-(4-Phenylpyridin-3-yl)prop-2-yn-1-amine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,3000.0,nM,Cl.Cl.NCC#Cc1cnccc1-c1ccccc1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405329,CHEMBL4163694,3-(4-Furan-2-yl-pyridin-3-yl)-prop-2-ynylamine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,2800.0,nM,Cl.Cl.NCC#Cc1cnccc1-c1ccco1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405330,CHEMBL4174365,3-(4-Furan-3-yl-pyridin-3-yl)-prop-2-ynylamine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,6300.0,nM,Cl.Cl.NCC#Cc1cnccc1-c1ccoc1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405331,CHEMBL4160326,"3-([4,4'-Bipyridin]-3'-yl)prop-2-yn-1-amine Trihydrochloride",CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,>,25000.0,nM,Cl.Cl.Cl.NCC#Cc1cnccc1-c1ccncc1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405332,CHEMBL4170930,"3-([3,4'-Bipyridin]-3'-yl)prop-2-yn-1-amine Trihydrochloride",CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,48000.0,nM,Cl.Cl.Cl.NCC#Cc1cnccc1-c1cccnc1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405333,CHEMBL4161777,3-(4-(Pyrimidin-5-yl)pyridin-3-yl)prop-2-yn-1-amine tetrahydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,>,25000.0,nM,Cl.Cl.Cl.Cl.NCC#Cc1cnccc1-c1cncnc1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405334,CHEMBL4172417,(5-(4-Methylpyridin-3-yl)furan-2-yl)methanamine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,36000.0,nM,Cc1ccncc1-c1ccc(CN)o1.Cl.Cl,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405335,CHEMBL4173133,(5-(4-Ethylpyridin-3-yl)furan-2-yl)methanamine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,59000.0,nM,CCc1ccncc1-c1ccc(CN)o1.Cl.Cl,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405336,CHEMBL4162449,(5-(4-Methoxypyridin-3-yl)furan-2-yl)methanamine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,>,50000.0,nM,COc1ccncc1-c1ccc(CN)o1.Cl.Cl,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405337,CHEMBL4169721,(5-(4-Propylpyridin-3-yl)furan-2-yl)methanamine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,19000.0,nM,CCCc1ccncc1-c1ccc(CN)o1.Cl.Cl,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405338,CHEMBL4159065,(5-(4-Phenylpyridin-3-yl)furan-2-yl)methanamine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,2600.0,nM,Cl.Cl.NCc1ccc(-c2cnccc2-c2ccccc2)o1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405339,CHEMBL4161400,(5-(4-(Furan-2-yl)pyridin-3-yl)furan-2-yl)methanamine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,2000.0,nM,Cl.Cl.NCc1ccc(-c2cnccc2-c2ccco2)o1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405340,CHEMBL4169324,(5-(4-(Furan-3-yl)pyridin-3-yl)furan-2-yl)methanamine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,4800.0,nM,Cl.Cl.NCc1ccc(-c2cnccc2-c2ccoc2)o1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405341,CHEMBL4176506,"(5-([4,4'-Bipyridin]-3'-yl)furan-2-yl)methanamine Trihydrochloride",CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,>,50000.0,nM,Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2ccncc2)o1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405342,CHEMBL4165895,"(5-([3,4'-Bipyridin]-3'-yl)furan-2-yl)methanamine Trihydrochloride",CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,28000.0,nM,Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2cccnc2)o1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405343,CHEMBL4168256,(5-(4-(Pyrimidin-5-yl)pyridin-3-yl)furan-2-yl)methanamine tetrahydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,>,25000.0,nM,Cl.Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2cncnc2)o1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405344,CHEMBL4176100,(5-(4-Methylpyridin-3-yl)thiophene-2-yl)methanamine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,28000.0,nM,Cc1ccncc1-c1ccc(CN)s1.Cl.Cl,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405345,CHEMBL4161819,(5-(4-Ethylpyridin-3-yl)thiophen-2-yl)methanamine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,16000.0,nM,CCc1ccncc1-c1ccc(CN)s1.Cl.Cl,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405346,CHEMBL4172462,(5-(4-Methoxypyridin-3-yl)thiophen-2-yl)methanamine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,>,50000.0,nM,COc1ccncc1-c1ccc(CN)s1.Cl.Cl,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405347,CHEMBL4165249,(5-(4-Propylpyridin-3-yl)thiophen-2-yl)methanamine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,8500.0,nM,CCCc1ccncc1-c1ccc(CN)s1.Cl.Cl,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405348,CHEMBL4175869,(5-(4-Phenylpyridin-3-yl)thiophen-2-yl)methanamine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,2900.0,nM,Cl.Cl.NCc1ccc(-c2cnccc2-c2ccccc2)s1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405349,CHEMBL4168669,(5-(4-(Furan-2-yl)pyridin-3-yl)thiophen-2-yl)methanamine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,4400.0,nM,Cl.Cl.NCc1ccc(-c2cnccc2-c2ccco2)s1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405350,CHEMBL4160749,(5-(4-(Furan-3-yl)pyridin-3-yl)thiophen-2-yl)methanamine Dihydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,6100.0,nM,Cl.Cl.NCc1ccc(-c2cnccc2-c2ccoc2)s1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405351,CHEMBL4172017,"(5-([4,4'-Bipyridin]-3'-yl)thiophen-2-yl)methanamine Trihydrochloride",CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,43000.0,nM,Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2ccncc2)s1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405352,CHEMBL4164142,"(5-([3,4'-Bipyridin]-3'-yl)thiophen-2-yl)methanamine Trihydrochloride",CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,=,23000.0,nM,Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2cccnc2)s1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18405353,CHEMBL4165094,(5-(4-(Pyrimidin-5-yl)pyridin-3-yl)thiophen-2-yl)methanamine tetrahydrochloride,CHEMBL4150904,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,IC50,>,50000.0,nM,Cl.Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2cncnc2)s1,CHEMBL4145649,Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.,J Med Chem,2018.0,61,16,7065,7086,10.1021/acs.jmedchem.8b00084,29995408.0,
18410157,CHEMBL1276308,"11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CHEMBL4151829,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using midazolam as substrate,IC50,=,4900.0,nM,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,CHEMBL4145686,Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).,J Med Chem,2018.0,61,17,7767,7784,10.1021/acs.jmedchem.8b00743,30091920.0,
18410158,CHEMBL4163069,"(8S,11R,13S,14S,17S)-11-(4-(Dimethylamino)phenyl)-17-(3,3-dimethylbut-1-yn-1-yl)-17-hydroxy-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]-phenanthren-3-one",CHEMBL4151829,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using midazolam as substrate,IC50,>,10000.0,nM,CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,CHEMBL4145686,Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).,J Med Chem,2018.0,61,17,7767,7784,10.1021/acs.jmedchem.8b00743,30091920.0,
18410159,CHEMBL4161754,"(8R,9S,10R,11S,13S,14S,17S)-17-(3,3-dimethylbut-1-ynyl)-17-hydroxy-11-(4-(isopropyl(methyl)amino)phenyl)-13-methyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one",CHEMBL4151829,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using midazolam as substrate,IC50,>,10000.0,nM,CC(C)N(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@@H]23)cc1,CHEMBL4145686,Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).,J Med Chem,2018.0,61,17,7767,7784,10.1021/acs.jmedchem.8b00743,30091920.0,
18420334,CHEMBL3960662,"US9428503, 1",CHEMBL4153800,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCOCC2)c(=O)n4C)cn1,CHEMBL4152224,"The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).",J Med Chem,2018.0,61,9,3823,3841,10.1021/acs.jmedchem.7b01896,29683659.0,
18431040,CHEMBL4160587,(3Z)-3-((1H-imidazole-2-yl)(phenyl)methylene)-N-((1S)-2-hydroxy-1-phenylethyl)-2-oxoindoline-5-carboxamide,CHEMBL4155721,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,21400.0,nM,O=C1Nc2ccc(C(=O)N[C@H](CO)c3ccccc3)cc2/C1=C(\c1ccccc1)c1ncc[nH]1,CHEMBL4152294,"Design, synthesis, structure-activity relationships study and X-ray crystallography of 3-substituted-indolin-2-one-5-carboxamide derivatives as PAK4 inhibitors.",Eur J Med Chem,2018.0,155,,197,209,10.1016/j.ejmech.2018.05.051,29886323.0,
18446609,CHEMBL4175320,"(R)-3-((4-(Difluoromethyl)-2,2-difluoro-3-hydroxy-1,1-dioxido-2,3-dihydrobenzo[b]thiophen-5-yl)oxy)-5-fluorobenzonitrile",CHEMBL4158407,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of of CYP2C9 in human liver microsomes using diclofenac as substrate after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,15700.0,nM,N#Cc1cc(F)cc(Oc2ccc3c(c2C(F)F)[C@@H](O)C(F)(F)S3(=O)=O)c1,CHEMBL4152377,"Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).",J Med Chem,2018.0,61,21,9691,9721,10.1021/acs.jmedchem.8b01196,30289716.0,
18446610,CHEMBL4173075,"(S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile",CHEMBL4158407,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of of CYP2C9 in human liver microsomes using diclofenac as substrate after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,23000.0,nM,CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)C(F)(F)C2,CHEMBL4152377,"Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).",J Med Chem,2018.0,61,21,9691,9721,10.1021/acs.jmedchem.8b01196,30289716.0,
18449463,CHEMBL3742114,"ethyl 4-(2-bromo-4-fluorophenyl)-6-(morpholinomethyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate",CHEMBL4177915,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CCOC(=O)C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccc(F)cc1Br,CHEMBL4177524,Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).,Bioorg Med Chem,2017.0,25,3,1042,1056,10.1016/j.bmc.2016.12.017,28082068.0,
18457909,CHEMBL4217988,"3-cyano-4-(3-(2-((2-(piperidin-4-yl)ethylamino)methyl)pyridin-4-yl)-3'-(trifluoromethyl)biphenyl-4-yloxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL4179805,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3750.0,nM,N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(-c2cccc(C(F)(F)F)c2)cc1-c1ccnc(CNCCC2CCNCC2)c1,CHEMBL4177603,Highly potent and selective NaV1.7 inhibitors for use as intravenous agents and chemical probes.,Bioorg Med Chem Lett,2017.0,27,21,4805,4811,10.1016/j.bmcl.2017.09.056,29029933.0,
18459058,CHEMBL4076061,"4-(((1R,6R)-6-amino-2-(4-fluorophenyl)cyclohex-2-enyl)methoxy)-5-chloro-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide",CHEMBL4180119,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,7500.0,nM,N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1COc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl,CHEMBL4177611,Discovery of aminocyclohexene analogues as selective and orally bioavailable hNav1.7 inhibitors for analgesia.,Bioorg Med Chem Lett,2017.0,27,22,4979,4984,10.1016/j.bmcl.2017.10.010,29037948.0,
18459059,CHEMBL4203948,(+/-)-5-chloro-4-((6-(ethylamino)-2-(4-fluorophenyl)cyclohex-2-enyl)methoxy)-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide hydrochloride,CHEMBL4180119,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,5700.0,nM,CCN[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1COc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl.Cl,CHEMBL4177611,Discovery of aminocyclohexene analogues as selective and orally bioavailable hNav1.7 inhibitors for analgesia.,Bioorg Med Chem Lett,2017.0,27,22,4979,4984,10.1016/j.bmcl.2017.10.010,29037948.0,
18459060,CHEMBL4210866,(-)-4-((6-amino-2-(4-fluorophenyl)cyclohex-2-enyl)methylamino)-5-chloro-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide hydrochloride,CHEMBL4180119,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,11800.0,nM,Cl.N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl,CHEMBL4177611,Discovery of aminocyclohexene analogues as selective and orally bioavailable hNav1.7 inhibitors for analgesia.,Bioorg Med Chem Lett,2017.0,27,22,4979,4984,10.1016/j.bmcl.2017.10.010,29037948.0,
18459061,CHEMBL4206499,(+/-)-4-((6-amino-2-(4-fluorophenyl)cyclohex-2-enyl)methoxy)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide hydrochloride,CHEMBL4180119,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,100.0,nM,Cl.N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1COc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl,CHEMBL4177611,Discovery of aminocyclohexene analogues as selective and orally bioavailable hNav1.7 inhibitors for analgesia.,Bioorg Med Chem Lett,2017.0,27,22,4979,4984,10.1016/j.bmcl.2017.10.010,29037948.0,
18459062,CHEMBL4209130,(-)-4-((6-amino-2-(4-fluorophenyl)cyclohex-2-enyl)methylamino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide hydrochloride,CHEMBL4180119,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,500.0,nM,Cl.N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1CNc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl,CHEMBL4177611,Discovery of aminocyclohexene analogues as selective and orally bioavailable hNav1.7 inhibitors for analgesia.,Bioorg Med Chem Lett,2017.0,27,22,4979,4984,10.1016/j.bmcl.2017.10.010,29037948.0,
18459063,CHEMBL4204264,(-)-4-((6-amino-2-(4-fluorophenyl)cyclohex-2-enyl)methylthio)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide hydrochloride,CHEMBL4180119,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,100.0,nM,Cl.N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1CSc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl,CHEMBL4177611,Discovery of aminocyclohexene analogues as selective and orally bioavailable hNav1.7 inhibitors for analgesia.,Bioorg Med Chem Lett,2017.0,27,22,4979,4984,10.1016/j.bmcl.2017.10.010,29037948.0,
18459064,CHEMBL4216985,(+/-)-5-chloro-4-((6-(ethylamino)-2-(4-fluorophenyl)cyclohex-2-enyl)methoxy)-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide hydrochloride,CHEMBL4180119,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,200.0,nM,CCN[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1COc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl.Cl,CHEMBL4177611,Discovery of aminocyclohexene analogues as selective and orally bioavailable hNav1.7 inhibitors for analgesia.,Bioorg Med Chem Lett,2017.0,27,22,4979,4984,10.1016/j.bmcl.2017.10.010,29037948.0,
18459065,CHEMBL4212007,(-)-5-chloro-4-((6-(ethylamino)-2-(4-fluorophenyl)cyclohex-2-enyl)methylamino)-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide hydrochloride,CHEMBL4180119,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,200.0,nM,CCN[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1CNc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl.Cl,CHEMBL4177611,Discovery of aminocyclohexene analogues as selective and orally bioavailable hNav1.7 inhibitors for analgesia.,Bioorg Med Chem Lett,2017.0,27,22,4979,4984,10.1016/j.bmcl.2017.10.010,29037948.0,
18466513,CHEMBL4217292,N-(1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl)-2-(4-(1-(trifluoromethyl)cyclopropyl)phenyl)acetamide,CHEMBL4181831,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,22000.0,nM,N#Cc1ccc(Cn2ccc(NC(=O)Cc3ccc(C4(C(F)(F)F)CC4)cc3)n2)nc1,CHEMBL4177680,"Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.",J Med Chem,2017.0,60,23,9769,9789,10.1021/acs.jmedchem.7b01236,29116786.0,
18467009,CHEMBL4205073,"(E)-3-(3-ethoxy-4,5-dimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one",CHEMBL4181960,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,10000.0,nM,CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OC,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467016,CHEMBL4218749,"(E)-1-(Pyridin-4-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one",CHEMBL4181951,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate measured after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OC,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467017,CHEMBL4202990,"(E)-3-(3,4-Dimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one",CHEMBL4181951,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate measured after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1ccc(/C=C/C(=O)c2ccncc2)cc1OC,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467018,CHEMBL4209004,(E)-3-(2-Methoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one,CHEMBL4181951,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate measured after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1ccccc1/C=C/C(=O)c1ccncc1,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467019,CHEMBL4212722,(E)-3-(3-Methoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one,CHEMBL4181951,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate measured after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1cccc(/C=C/C(=O)c2ccncc2)c1,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467020,CHEMBL2237704,3-(4-methoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one,CHEMBL4181951,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate measured after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1ccc(/C=C/C(=O)c2ccncc2)cc1,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467021,CHEMBL4210776,"(E)-3-(Benzo[d][1,3]dioxol-5-yl)-1-(pyridin-4-yl)prop-2-en-1-one",CHEMBL4181951,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate measured after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1ccc2c(c1)OCO2)c1ccncc1,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467022,CHEMBL1568243,SID17432603,CHEMBL4181951,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate measured after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=C(/C=C/c1cccc2ccccc12)c1ccncc1,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467023,CHEMBL4214111,"(E)-3-(3,5-Dimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one",CHEMBL4181951,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate measured after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467024,CHEMBL2237710,"1-(pyridin-4-yl)-3-(2,3,4-trimethoxyphenyl)prop-2-en-1-one",CHEMBL4181951,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate measured after 10 mins by fluorescence assay,IC50,>,20000.0,nM,COc1ccc(/C=C/C(=O)c2ccncc2)c(OC)c1OC,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467025,CHEMBL4213815,"(E)-3-(4-Ethoxy-3,5-Dimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one",CHEMBL4181951,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate measured after 10 mins by fluorescence assay,IC50,>,20000.0,nM,CCOc1c(OC)cc(/C=C/C(=O)c2ccncc2)cc1OC,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467026,CHEMBL4211876,"(E)-1-(pyridin-4-yl)-3-(3,4,5-triethoxyphenyl)prop-2-en-1-one",CHEMBL4181951,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate measured after 10 mins by fluorescence assay,IC50,>,20000.0,nM,CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OCC)c1OCC,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467027,CHEMBL4205073,"(E)-3-(3-ethoxy-4,5-dimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one",CHEMBL4181951,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate measured after 10 mins by fluorescence assay,IC50,>,20000.0,nM,CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OC,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467050,CHEMBL4210776,"(E)-3-(Benzo[d][1,3]dioxol-5-yl)-1-(pyridin-4-yl)prop-2-en-1-one",CHEMBL4181960,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,10000.0,nM,O=C(/C=C/c1ccc2c(c1)OCO2)c1ccncc1,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467054,CHEMBL4210137,"(E)-3-(3,4-diethoxy-5-methoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one",CHEMBL4181951,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate measured after 10 mins by fluorescence assay,IC50,>,20000.0,nM,CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OCC,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467055,CHEMBL283196,2-Phenyl-benzo[h]chromen-4-one,CHEMBL4181951,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes using 3-cyano-7-ethoxycoumarin as substrate measured after 10 mins by fluorescence assay,IC50,>,20000.0,nM,O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467158,CHEMBL4214111,"(E)-3-(3,5-Dimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one",CHEMBL4181960,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,10000.0,nM,COc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467159,CHEMBL2237710,"1-(pyridin-4-yl)-3-(2,3,4-trimethoxyphenyl)prop-2-en-1-one",CHEMBL4181960,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,10000.0,nM,COc1ccc(/C=C/C(=O)c2ccncc2)c(OC)c1OC,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467160,CHEMBL4213815,"(E)-3-(4-Ethoxy-3,5-Dimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one",CHEMBL4181960,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,10000.0,nM,CCOc1c(OC)cc(/C=C/C(=O)c2ccncc2)cc1OC,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467161,CHEMBL4211876,"(E)-1-(pyridin-4-yl)-3-(3,4,5-triethoxyphenyl)prop-2-en-1-one",CHEMBL4181960,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,10000.0,nM,CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OCC)c1OCC,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467176,CHEMBL1568243,SID17432603,CHEMBL4181960,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,10000.0,nM,O=C(/C=C/c1cccc2ccccc12)c1ccncc1,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467188,CHEMBL283196,2-Phenyl-benzo[h]chromen-4-one,CHEMBL4181960,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,10000.0,nM,O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467189,CHEMBL2237704,3-(4-methoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one,CHEMBL4181960,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,10000.0,nM,COc1ccc(/C=C/C(=O)c2ccncc2)cc1,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467200,CHEMBL4210137,"(E)-3-(3,4-diethoxy-5-methoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one",CHEMBL4181960,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,10000.0,nM,CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OCC,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467201,CHEMBL4212722,(E)-3-(3-Methoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one,CHEMBL4181960,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,10000.0,nM,COc1cccc(/C=C/C(=O)c2ccncc2)c1,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467227,CHEMBL4218749,"(E)-1-(Pyridin-4-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one",CHEMBL4181960,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,10000.0,nM,COc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OC,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467228,CHEMBL4202990,"(E)-3-(3,4-Dimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one",CHEMBL4181960,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,10000.0,nM,COc1ccc(/C=C/C(=O)c2ccncc2)cc1OC,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18467229,CHEMBL4209004,(E)-3-(2-Methoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one,CHEMBL4181960,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay,IC50,>,10000.0,nM,COc1ccccc1/C=C/C(=O)c1ccncc1,CHEMBL4177690,"(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.",Bioorg Med Chem Lett,2017.0,27,24,5409,5414,10.1016/j.bmcl.2017.11.009,29138024.0,
18478581,CHEMBL4215300,"(S)-N-(2-(diethylamino)propyl)-2-(3-methoxyazetidin-1-yl)-6-(5-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl)isonicotinamide",CHEMBL4184429,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CCN(CC)[C@@H](C)CNC(=O)c1cc(-c2cnn3ccc(-c4cccs4)nc23)nc(N2CC(OC)C2)c1,CHEMBL4184081,Discovery of potent and selective inhibitors of calmodulin-dependent kinase II (CaMKII).,Bioorg Med Chem Lett,2018.0,28,3,541,546,10.1016/j.bmcl.2017.10.040,29254643.0,
18480783,CHEMBL4210924,"4-(6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)-2-neopentyl-2,4-dihydro-3H-1,2,4-triazol-3-one",CHEMBL4184911,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate preincubated for 10 mins with substrate followed by NADPH addition measured after 15 mins by LC/MS/MS analysis,IC50,=,25000.0,nM,CC(C)(C)Cn1ncn(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)c1=O,CHEMBL4184109,"Design, synthesis, and structure-activity relationship studies of novel tetrazole antifungal agents with potent activity, broad antifungal spectrum and high selectivity.",Bioorg Med Chem Lett,2018.0,28,3,344,350,10.1016/j.bmcl.2017.12.040,29289430.0,
18480784,CHEMBL4211628,"(+/-)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol",CHEMBL4184911,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate preincubated for 10 mins with substrate followed by NADPH addition measured after 15 mins by LC/MS/MS analysis,IC50,=,11500.0,nM,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1,CHEMBL4184109,"Design, synthesis, and structure-activity relationship studies of novel tetrazole antifungal agents with potent activity, broad antifungal spectrum and high selectivity.",Bioorg Med Chem Lett,2018.0,28,3,344,350,10.1016/j.bmcl.2017.12.040,29289430.0,
18480785,CHEMBL4206432,"2-cyclopentyl-4-(6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one",CHEMBL4184911,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate preincubated for 10 mins with substrate followed by NADPH addition measured after 15 mins by LC/MS/MS analysis,IC50,=,11900.0,nM,O=c1n(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cnn1C1CCCC1,CHEMBL4184109,"Design, synthesis, and structure-activity relationship studies of novel tetrazole antifungal agents with potent activity, broad antifungal spectrum and high selectivity.",Bioorg Med Chem Lett,2018.0,28,3,344,350,10.1016/j.bmcl.2017.12.040,29289430.0,
18480786,CHEMBL4214518,"2-cyclohexyl-4-(6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one",CHEMBL4184911,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate preincubated for 10 mins with substrate followed by NADPH addition measured after 15 mins by LC/MS/MS analysis,IC50,=,16500.0,nM,O=c1n(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cnn1C1CCCCC1,CHEMBL4184109,"Design, synthesis, and structure-activity relationship studies of novel tetrazole antifungal agents with potent activity, broad antifungal spectrum and high selectivity.",Bioorg Med Chem Lett,2018.0,28,3,344,350,10.1016/j.bmcl.2017.12.040,29289430.0,
18488782,CHEMBL4202767,4-(3-Chloro-4-ethoxy-5-isopropoxybenzamido)-2-methylbenzoic acid,CHEMBL4187018,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,25000.0,nM,CCOc1c(Cl)cc(C(=O)Nc2ccc(C(=O)O)c(C)c2)cc1OC(C)C,CHEMBL4184197,"Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.",Bioorg Med Chem,2018.0,26,4,798,814,10.1016/j.bmc.2017.12.015,29288071.0,
18488783,CHEMBL107430,"4-[(4-Chloro-3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl)-amino]-2,6-difluoro-benzoic acid",CHEMBL4187018,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,=,25000.0,nM,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl,CHEMBL4184197,"Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.",Bioorg Med Chem,2018.0,26,4,798,814,10.1016/j.bmc.2017.12.015,29288071.0,
18493558,CHEMBL4209700,"5-(benzyloxy)-N4-butylquinazoline-2,4-diamine",CHEMBL4187760,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCCCNc1nc(N)nc2cccc(OCc3ccccc3)c12,CHEMBL4184225,"Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.",Bioorg Med Chem Lett,2018.0,28,4,711,719,10.1016/j.bmcl.2018.01.014,29366653.0,
18493559,CHEMBL4208231,"N4-butyl-5-(2-methoxybenzyloxy)quinazoline-2,4-diamine",CHEMBL4187760,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCCCNc1nc(N)nc2cccc(OCc3ccccc3OC)c12,CHEMBL4184225,"Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.",Bioorg Med Chem Lett,2018.0,28,4,711,719,10.1016/j.bmcl.2018.01.014,29366653.0,
18493560,CHEMBL4213155,(4-((2-amino-4-(butylamino)quinazolin-5-yloxy)methyl)-3-methoxyphenyl)methanol,CHEMBL4187760,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5000.0,nM,CCCCNc1nc(N)nc2cccc(OCc3ccc(CO)cc3OC)c12,CHEMBL4184225,"Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.",Bioorg Med Chem Lett,2018.0,28,4,711,719,10.1016/j.bmcl.2018.01.014,29366653.0,
18493561,CHEMBL4218074,"N4-butyl-5-(pyridin-2-ylmethoxy)quinazoline-2,4-diamine",CHEMBL4187760,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCCCNc1nc(N)nc2cccc(OCc3ccccn3)c12,CHEMBL4184225,"Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.",Bioorg Med Chem Lett,2018.0,28,4,711,719,10.1016/j.bmcl.2018.01.014,29366653.0,
18493562,CHEMBL4206363,"N4-butyl-5-(pyridin-3-ylmethoxy)quinazoline-2,4-diamine",CHEMBL4187760,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCCCNc1nc(N)nc2cccc(OCc3cccnc3)c12,CHEMBL4184225,"Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.",Bioorg Med Chem Lett,2018.0,28,4,711,719,10.1016/j.bmcl.2018.01.014,29366653.0,
18493563,CHEMBL4205861,"N4-butyl-5-((3,4-dimethoxypyridin-2-yl)methoxy)quinazoline-2,4-diamine",CHEMBL4187760,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCCCNc1nc(N)nc2cccc(OCc3nccc(OC)c3OC)c12,CHEMBL4184225,"Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.",Bioorg Med Chem Lett,2018.0,28,4,711,719,10.1016/j.bmcl.2018.01.014,29366653.0,
18493564,CHEMBL4210732,2-amino-4-(butylamino)-N-methylquinazoline-5-carboxamide,CHEMBL4187760,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8000.0,nM,CCCCNc1nc(N)nc2cccc(C(=O)NC)c12,CHEMBL4184225,"Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.",Bioorg Med Chem Lett,2018.0,28,4,711,719,10.1016/j.bmcl.2018.01.014,29366653.0,
18493565,CHEMBL4209289,2-amino-4-(butylamino)-N-isopropylquinazoline-5-carboxamide,CHEMBL4187760,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCCCNc1nc(N)nc2cccc(C(=O)NC(C)C)c12,CHEMBL4184225,"Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.",Bioorg Med Chem Lett,2018.0,28,4,711,719,10.1016/j.bmcl.2018.01.014,29366653.0,
18493567,CHEMBL4213687,2-amino-N-benzyl-4-(butylamino)quinazoline-5-carboxamide,CHEMBL4187760,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCCCNc1nc(N)nc2cccc(C(=O)NCc3ccccc3)c12,CHEMBL4184225,"Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.",Bioorg Med Chem Lett,2018.0,28,4,711,719,10.1016/j.bmcl.2018.01.014,29366653.0,
18493568,CHEMBL4218623,2-amino-N-benzyl-4-(butylamino)-N-methylquinazoline-5-carboxamide,CHEMBL4187760,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCCCNc1nc(N)nc2cccc(C(=O)N(C)Cc3ccccc3)c12,CHEMBL4184225,"Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.",Bioorg Med Chem Lett,2018.0,28,4,711,719,10.1016/j.bmcl.2018.01.014,29366653.0,
18493569,CHEMBL4202404,(R)-2-amino-4-(butylamino)-N-(1-phenylethyl)quinazoline-5-carboxamide,CHEMBL4187760,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCCCNc1nc(N)nc2cccc(C(=O)N[C@H](C)c3ccccc3)c12,CHEMBL4184225,"Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.",Bioorg Med Chem Lett,2018.0,28,4,711,719,10.1016/j.bmcl.2018.01.014,29366653.0,
18493570,CHEMBL4207296,(S)-2-amino-4-(butylamino)-N-(1-phenylethyl)quinazoline-5-carboxamide,CHEMBL4187760,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCCCNc1nc(N)nc2cccc(C(=O)N[C@@H](C)c3ccccc3)c12,CHEMBL4184225,"Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.",Bioorg Med Chem Lett,2018.0,28,4,711,719,10.1016/j.bmcl.2018.01.014,29366653.0,
18498082,CHEMBL4218848,6-(methylamino)nicotinamide,CHEMBL4188608,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CNc1ccc(C(N)=O)cn1,CHEMBL4184280,Novel nicotinamide analog as inhibitor of nicotinamide N-methyltransferase.,Bioorg Med Chem Lett,2018.0,28,5,922,925,10.1016/j.bmcl.2018.01.058,29433927.0,
18498179,CHEMBL4079324,N-(5-(3-cyclopropoxyphenyl)pyridin-2-yl)-2-methylpyrimidine-5-carboxamide,CHEMBL4188642,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1ncc(C(=O)Nc2ccc(-c3cccc(OC4CC4)c3)cn2)cn1,CHEMBL4184281,Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.,Bioorg Med Chem Lett,2018.0,28,5,934,941,10.1016/j.bmcl.2018.01.053,29433928.0,
18498180,CHEMBL4217112,2-methyl-N-(5-(thiophen-3-yl)pyridin-2-yl)pyrimidine-5-carboxamide,CHEMBL4188642,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1ncc(C(=O)Nc2ccc(-c3ccsc3)cn2)cn1,CHEMBL4184281,Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.,Bioorg Med Chem Lett,2018.0,28,5,934,941,10.1016/j.bmcl.2018.01.053,29433928.0,
18498181,CHEMBL4105066,N-(5-(3-(cyclopropylsulfonyl)phenyl)pyridin-2-yl)-2-methylpyrimidine-5-carboxamide,CHEMBL4188642,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1ncc(C(=O)Nc2ccc(-c3cccc(S(=O)(=O)C4CC4)c3)cn2)cn1,CHEMBL4184281,Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.,Bioorg Med Chem Lett,2018.0,28,5,934,941,10.1016/j.bmcl.2018.01.053,29433928.0,
18499843,CHEMBL4205617,"4-(5-((5r,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl)pentyloxy)-N,N-dimethylbenzamide",CHEMBL4189054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CN(C)C(=O)c1ccc(OCCCCC[C@H]2CC[C@]3(CC2)COC(C)(C)C3)cc1,CHEMBL4184304,Design and synthesis of novel and potent GPR119 agonists with a spirocyclic structure.,Bioorg Med Chem Lett,2018.0,28,7,1228,1233,10.1016/j.bmcl.2018.02.044,29519733.0,
18499844,CHEMBL4215560,isopropyl 4-(5-(4-(dimethylcarbamoyl)phenoxy)pentyl)piperidine-1-carboxylate,CHEMBL4189054,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,<,10000.0,nM,CC(C)OC(=O)N1CCC(CCCCCOc2ccc(C(=O)N(C)C)cc2)CC1,CHEMBL4184304,Design and synthesis of novel and potent GPR119 agonists with a spirocyclic structure.,Bioorg Med Chem Lett,2018.0,28,7,1228,1233,10.1016/j.bmcl.2018.02.044,29519733.0,
18504622,CHEMBL4211068,"triethylamine 4'-carbamoyl-5-(4-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)biphenyl-3-carboxylate",CHEMBL4189978,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>=,30000.0,nM,CCN(CC)CC.NC(=O)c1ccc(-c2cc(C(=O)O)cc(-n3cc(-c4ccc(C(F)(F)F)cc4)nn3)c2)cc1,CHEMBL4184336,Structure-Guided Modification of Heterocyclic Antagonists of the P2Y14 Receptor.,J Med Chem,2018.0,61,11,4860,4882,10.1021/acs.jmedchem.8b00168,29767967.0,
18505061,CHEMBL4206892,1-(6-Fluoro-3-(4-(methylsulfonyl)piperazine-1-carbonyl)-quinolin-4-yl)-4-phenylpiperidine-4-carbonitrile,CHEMBL4190049,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,10000.0,nM,CS(=O)(=O)N1CCN(C(=O)c2cnc3ccc(F)cc3c2N2CCC(C#N)(c3ccccc3)CC2)CC1,CHEMBL4184337,"Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity.",J Med Chem,2018.0,61,11,4883,4903,10.1021/acs.jmedchem.8b00270,29767973.0,
18505062,CHEMBL4206272,1-(4-(6-Fluoro-3-(4-(methylsulfonyl)piperazine-1-carbonyl)-quinolin-4-yl)phenyl)cyclopropanecarbonitrile,CHEMBL4190049,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,10000.0,nM,CS(=O)(=O)N1CCN(C(=O)c2cnc3ccc(F)cc3c2-c2ccc(C3(C#N)CC3)cc2)CC1,CHEMBL4184337,"Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity.",J Med Chem,2018.0,61,11,4883,4903,10.1021/acs.jmedchem.8b00270,29767973.0,
18506833,CHEMBL4208555,(R)-1-(4-chlorophenyl)-N-(2-(4-hydroxy-4-(trifluoromethyl)piperidin-1-yl)-3-phenylpropyl)cyclopentanecarboxamide,CHEMBL4190654,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,11405.0,nM,O=C(NC[C@@H](Cc1ccccc1)N1CCC(O)(C(F)(F)F)CC1)C1(c2ccc(Cl)cc2)CCCC1,CHEMBL4190175,,MedChemComm,2016.0,7,11,2145,2158,10.1039/C6MD00387G,,
18520801,CHEMBL4215754,"5-Amino-3-[2-[4-[3-fluoro-4-(2-methoxyethoxy)phenyl]piperazin-1-yl]ethyl]-1-methyl-8-thiazol-2-yl-[1,2,4]triazolo[5,1-f]purin-2-one",CHEMBL4193756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,COCCOc1ccc(N2CCN(CCn3c(=O)n(C)c4c3nc(N)n3nc(-c5nccs5)nc43)CC2)cc1F,CHEMBL4190330,Discovery of Potent and Selective A2A Antagonists with Efficacy in Animal Models of Parkinson's Disease and Depression.,ACS Med Chem Lett,2017.0,8,8,835,840,10.1021/acsmedchemlett.7b00175,28835798.0,
18529099,CHEMBL4205817,6-(Difluoro(pyrimidin-5-yl)methyl)-N-(4-methylthiazol-2-yl)quinoline-8-carboxamide,CHEMBL4195061,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH by LC/MS/MS analysis,IC50,=,5300.0,nM,Cc1csc(NC(=O)c2cc(C(F)(F)c3cncnc3)cc3cccnc23)n1,CHEMBL4190386,Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.,Bioorg Med Chem Lett,2018.0,28,10,1679,1685,10.1016/j.bmcl.2018.04.053,29705142.0,
18529100,CHEMBL2386850,N-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide,CHEMBL4195061,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH by LC/MS/MS analysis,IC50,=,12100.0,nM,Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(F)cn2)n1,CHEMBL4190386,Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.,Bioorg Med Chem Lett,2018.0,28,10,1679,1685,10.1016/j.bmcl.2018.04.053,29705142.0,
18529101,CHEMBL4089114,"N-(5-fluoropyridin-2-yl)-6-((5-fluoropyridin-3-yl)oxy)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide",CHEMBL4195061,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH by LC/MS/MS analysis,IC50,>,30000.0,nM,O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2)cn2ncnc12,CHEMBL4190386,Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.,Bioorg Med Chem Lett,2018.0,28,10,1679,1685,10.1016/j.bmcl.2018.04.053,29705142.0,
18530610,CHEMBL4213486,"(S)-N-(3-(2-Amino-6-(fluoromethyl)-4-methyl-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide",CHEMBL4195226,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 15 mins in presence of NADPH by LC/MS/MS analysis,IC50,>,20000.0,nM,C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C=C(CF)OC(N)=N1,CHEMBL4190390,"Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain.",J Med Chem,2018.0,61,12,5122,5137,10.1021/acs.jmedchem.8b00002,29733614.0,
18532065,CHEMBL4210484,"5-(5-Methanesulfonyl-2-{[(2S)-1,1,1-trifluoropropan-2-yl]-oxy}benzoyl)-2-phenyl-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(-c3ccccc3)nc2C1)C(F)(F)F,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532066,CHEMBL4211012,"2-(2-Fluorophenyl)-5-(5-methanesulfonyl-2-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzoyl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(-c3ccccc3F)nc2C1)C(F)(F)F,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532067,CHEMBL4206122,"5-(5-Methanesulfonyl-2-{[(2S)-1,1,1-trifluoropropan-2-yl]-oxy}benzoyl)-2-(3-methylphenyl)-2H,4H,5H,6H-pyrrolo[3,4-c]-pyrazole",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1cccc(-n2cc3c(n2)CN(C(=O)c2cc(S(C)(=O)=O)ccc2O[C@@H](C)C(F)(F)F)C3)c1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532068,CHEMBL4206639,"3-Fluoro-5-[5-(5-methanesulfonyl-2-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}-benzoyl)-2H,4H,5H,6H-pyrrolo[3,4-c]-pyrazol-2-yl]pyridine",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(-c3cncc(F)c3)nc2C1)C(F)(F)F,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532069,CHEMBL4218366,"4-[5-(5-Methanesulfonyl-2-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzoyl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazol-2-yl]-2-methylpyridine",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(S(C)(=O)=O)ccc2O[C@@H](C)C(F)(F)F)C3)ccn1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532070,CHEMBL4218894,"2-Cyclopentyl-5-(5-methanesulfonyl-2-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzoyl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(C3CCCC3)nc2C1)C(F)(F)F,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532071,CHEMBL4213968,"2-(2-Fluorophenyl)-5-[5-methanesulfonyl-2-(propan-2-yloxy)benzoyl]-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(-c3ccccc3F)nc2C1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532072,CHEMBL4216391,"5-[2-(2,2-Dimethylpropoxy)-5-methanesulfonylbenzoyl]-2-(2-fluorophenyl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)(C)Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(-c3ccccc3F)nc2C1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532073,CHEMBL4211426,"5-[2-(Cyclopropylmethoxy)-5-methanesulfonylbenzoyl]-2-(2-fluorophenyl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CS(=O)(=O)c1ccc(OCC2CC2)c(C(=O)N2Cc3cn(-c4ccccc4F)nc3C2)c1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532074,CHEMBL4205471,"4,4-Difluoro-1-{2-[2-(2-fluorophenyl)-2H,4H,5H,6H-pyrrolo-[3,4-c]pyrazole-5-carbonyl]-4-methanesulfonylphenyl}-piperidine",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CS(=O)(=O)c1ccc(N2CCC(F)(F)CC2)c(C(=O)N2Cc3cn(-c4ccccc4F)nc3C2)c1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532075,CHEMBL4210353,"3-{5-[2-(4,4-Difluoropiperidin-1-yl)-5-methanesulfonylbenzoyl]-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazol-2-yl}-5-fluoropyridine",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CS(=O)(=O)c1ccc(N2CCC(F)(F)CC2)c(C(=O)N2Cc3cn(-c4cncc(F)c4)nc3C2)c1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532076,CHEMBL4217712,"4-{5-[2-(4,4-Difluoropiperidin-1-yl)-5-methanesulfonylbenzoyl]-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazol-2-yl}-2-methylpyridine",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(S(C)(=O)=O)ccc2N2CCC(F)(F)CC2)C3)ccn1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532077,CHEMBL4205995,"2-(2-Fluorophenyl)-5-[2-(3-fluorophenyl)-5-methanesulfonylbenzoyl]-2H,4H,5H,6H-pyrrolo[3,4-c]-pyrazole",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CS(=O)(=O)c1ccc(-c2cccc(F)c2)c(C(=O)N2Cc3cn(-c4ccccc4F)nc3C2)c1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532078,CHEMBL4214250,"3-Fluoro-5-{5-[2-(3-fluorophenyl)-5-methanesulfonylbenzoyl]-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazol-2-yl}pyridine",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CS(=O)(=O)c1ccc(-c2cccc(F)c2)c(C(=O)N2Cc3cn(-c4cncc(F)c4)nc3C2)c1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532079,CHEMBL4202565,"4-{5-[2-(3-Fluorophenyl)-5-methanesulfonylbenzoyl]-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazol-2-yl}-2-methylpyridine",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(S(C)(=O)=O)ccc2-c2cccc(F)c2)C3)ccn1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532080,CHEMBL4209849,"5-[5-(Ethanesulfonyl)-2-{[(2S)-1,1,1-trifluoropropan-2-yl]-oxy}benzoyl]-2-(2-fluorophenyl)-2H,4H,5H,6H-pyrrolo[3,4-c]-pyrazole",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CCS(=O)(=O)c1ccc(O[C@@H](C)C(F)(F)F)c(C(=O)N2Cc3cn(-c4ccccc4F)nc3C2)c1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532081,CHEMBL4214756,"3-{5-[5-(Ethanesulfonyl)-2-{[(2S)-1,1,1-trifluoropropan-2-yl]-oxy}benzoyl]-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazol-2-yl}-5-fluoropyridine",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CCS(=O)(=O)c1ccc(O[C@@H](C)C(F)(F)F)c(C(=O)N2Cc3cn(-c4cncc(F)c4)nc3C2)c1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532082,CHEMBL4206403,"4-{5-[5-(Ethanesulfonyl)-2-{[(2S)-1,1,1-trifluoropropan-2-yl]-oxy}benzoyl]-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazol-2-yl}-2-methylpyridine",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CCS(=O)(=O)c1ccc(O[C@@H](C)C(F)(F)F)c(C(=O)N2Cc3cn(-c4ccnc(C)c4)nc3C2)c1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532083,CHEMBL4211293,"2-Phenyl-5-[5-(propane-2-sulfonyl)-2-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzoyl]-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)S(=O)(=O)c1ccc(O[C@@H](C)C(F)(F)F)c(C(=O)N2Cc3cn(-c4ccccc4)nc3C2)c1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532084,CHEMBL4210589,"3-[2-(2-Fluorophenyl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole-5-carbonyl]-4-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}-benzonitrile",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@H](Oc1ccc(C#N)cc1C(=O)N1Cc2cn(-c3ccccc3F)nc2C1)C(F)(F)F,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532085,CHEMBL4205726,"3-[2-(5-Fluoropyridin-3-yl)-2H,4H,5H,6H-pyrrolo[3,4-c]-pyrazole-5-carbonyl]-4-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}-benzonitrile",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@H](Oc1ccc(C#N)cc1C(=O)N1Cc2cn(-c3cncc(F)c3)nc2C1)C(F)(F)F,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532086,CHEMBL4215015,"3-[2-(2-Methylpyridin-4-yl)-2H,4H,5H,6H-pyrrolo[3,4-c]-pyrazole-5-carbonyl]-4-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}-benzonitrile",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2O[C@@H](C)C(F)(F)F)C3)ccn1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532087,CHEMBL4210095,"3-{2-Cyclopentyl-F-pyrrolo[3,4-c]pyrazole-5-carbonyl}-4-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzonitrile",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@H](Oc1ccc(C#N)cc1C(=O)N1Cc2cn(C3CCCC3)nc2C1)C(F)(F)F,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532088,CHEMBL4202824,"3-{2-Phenyl-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole-5-carbonyl}-4-(propan-2-yloxy)-benzonitrile",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)Oc1ccc(C#N)cc1C(=O)N1Cc2cn(-c3ccccc3)nc2C1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532089,CHEMBL4214486,"3-[2-(5-Fluoropyridin-3-yl)-2H,4H,5H,6H-pyrrolo[3,4-c]-pyrazole-5-carbonyl]-4-(propan-2-yloxy)benzonitrile",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CC(C)Oc1ccc(C#N)cc1C(=O)N1Cc2cn(-c3cncc(F)c3)nc2C1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532090,CHEMBL4207171,"3-[2-(2-Methylpyridin-4-yl)-2H,4H,5H,6H-pyrrolo[3,4-c]-pyrazole-5-carbonyl]-4-(propan-2-yloxy)benzonitrile",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2OC(C)C)C3)ccn1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532091,CHEMBL4218903,"4-(Cyclopropylmethoxy)-3-[2-(2-methylpyridin-4-yl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole-5-carbonyl]benzonitrile",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2OCC2CC2)C3)ccn1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532092,CHEMBL4211535,"4-(4,4-Difluoropiperidin-1-yl)-3-[2-(2-methylpyridin-4-yl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole-5-carbonyl]benzonitrile",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2N2CCC(F)(F)CC2)C3)ccn1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532093,CHEMBL4206650,"4-(3-Fluorophenyl)-3-[2-(5-fluoropyridin-3-yl)-2H,4H,5H,6Hpyrrolo[3,4-c]pyrazole-5-carbonyl]benzonitrile",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,N#Cc1ccc(-c2cccc(F)c2)c(C(=O)N2Cc3cn(-c4cncc(F)c4)nc3C2)c1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18532094,CHEMBL4212425,"4-(3-Fluorophenyl)-3-[2-(2-methylpyridin-4-yl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole-5-carbonyl]benzonitrile",CHEMBL4195545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2-c2cccc(F)c2)C3)ccn1,CHEMBL4190397,Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.,J Med Chem,2018.0,61,14,6018,6033,10.1021/acs.jmedchem.8b00372,29886732.0,
18536136,CHEMBL55,4-[(5-{4-[(Z)-amino(imino)methyl]phenoxy}pentyl)oxy]benzenecarboximidamide,CHEMBL4196411,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay,IC50,>,100000.0,nM,N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18536137,CHEMBL110,N-Benzyl-2-(2-nitro-imidazol-1-yl)-acetamide,CHEMBL4196411,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay,IC50,>,100000.0,nM,O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18536138,CHEMBL125,hexadecyloxy-2-trimethylammonioethylphosphorate,CHEMBL4196411,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay,IC50,>,100000.0,nM,CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18536139,CHEMBL267345,"33-(4-Amino-3,5-dihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxa-bicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid (amphotericin B)",CHEMBL4196411,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay,IC50,>,100000.0,nM,C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18538819,CHEMBL4203179,"6-(1-ethylpiperidin-4-yl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine",CHEMBL4197071,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes preincubated for 10 mins followed by NADPH/substrate addition by LC-MS/MS analysis,IC50,>,50000.0,nM,CCN1CCC(N2CCc3nc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)ccc3C2)CC1,CHEMBL4196019,"Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy.",Eur J Med Chem,2018.0,148,,140,153,10.1016/j.ejmech.2018.02.022,29459274.0,
18551533,CHEMBL4215835,(-)-3-(6-(2-carbamoyl-6-(trifluoromethoxy)-1H-indol-1-yl)pyridin-2-yl)butanoic acid,CHEMBL4199533,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9,IC50,>,20000.0,nM,CC(CC(=O)O)c1cccc(-n2c(C(N)=O)cc3ccc(OC(F)(F)F)cc32)n1,CHEMBL4196112,Design of Selective sPLA2-X Inhibitor (-)-2-{2-[Carbamoyl-6-(trifluoromethoxy)-1H-indol-1-yl]pyridine-2-yl}propanoic Acid.,ACS Med Chem Lett,2018.0,9,7,600,605,10.1021/acsmedchemlett.7b00507,30034586.0,
18552038,CHEMBL4078588,"3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-methylpyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one",CHEMBL4199658,A,,Homo sapiens,Cytochrome P450 2C9,Competitive reversible inhibition of CYP2C9 (unknown origin),IC50,=,13300.0,nM,Cc1ccc(Cc2cc3c(=O)n([C@H]4CCCC[C@@H]4O)cnc3c3ccccc23)cn1,CHEMBL4196115,MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate.,ACS Med Chem Lett,2018.0,9,7,652,656,10.1021/acsmedchemlett.8b00095,30034595.0,
18553336,CHEMBL4211915,(S)-4-Fluoro-5-(2-(3-methylmorpholino)-6-(1-(methylsulfonyl)cyclopropyl)pyrimidin-4-yl)pyridin-2-amine,CHEMBL4199853,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate pretreated for 5 mins followed by NADPH addition and measured after 10 mins by LC-MS analysis,IC50,>,10000.0,nM,C[C@H]1COCCN1c1nc(-c2cnc(N)cc2F)cc(C2(S(C)(=O)=O)CC2)n1,CHEMBL4196123,Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines.,ACS Med Chem Lett,2018.0,9,7,719,724,10.1021/acsmedchemlett.8b00167,30034607.0,
18553833,CHEMBL4213970,"(S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide",CHEMBL4199990,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) co-incubated with substrate,IC50,>,5000.0,nM,CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc(OC(C)C)nc4)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncn(C)n4)cc3)CC2)C1,CHEMBL4196128,MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.,ACS Med Chem Lett,2018.0,9,7,761,767,10.1021/acsmedchemlett.8b00220,30034615.0,
18553834,CHEMBL4213970,"(S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide",CHEMBL4199991,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) preincubated followed by substrate addition,IC50,>,5000.0,nM,CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc(OC(C)C)nc4)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncn(C)n4)cc3)CC2)C1,CHEMBL4196128,MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.,ACS Med Chem Lett,2018.0,9,7,761,767,10.1021/acsmedchemlett.8b00220,30034615.0,
18556367,CHEMBL4217549,6-{6-[3-(Dimethylamino)propoxy]-3-pyridinyl}-4-{[(1S)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-cinnolinecarboxamide,CHEMBL4200500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,C[C@H](Nc1c(C(N)=O)nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc12)C1CCOCC1,CHEMBL4196159,"Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.",ACS Med Chem Lett,2018.0,9,8,809,814,10.1021/acsmedchemlett.8b00200,30128072.0,
18556368,CHEMBL4218854,6-{6-[3-(Dimethylamino)propoxy]-3-pyridinyl}-N-methyl-4-{[(1S)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-cinnolinecarboxamide,CHEMBL4200500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,CNC(=O)c1nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc2c1N[C@@H](C)C1CCOCC1,CHEMBL4196159,"Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.",ACS Med Chem Lett,2018.0,9,8,809,814,10.1021/acsmedchemlett.8b00200,30128072.0,
18557411,CHEMBL4208229,ASCIMINIB,CHEMBL4200796,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1,CHEMBL4196169,"Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.",J Med Chem,2018.0,61,18,8120,8135,10.1021/acs.jmedchem.8b01040,30137981.0,
18558017,CHEMBL4218772,"3-(benzo[d][1,3]dioxol-5-ylmethyl)-8-hydroxy-6-(2-methoxyethylamino)-1-(thiazol-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one",CHEMBL4200937,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH,IC50,=,135.0,nM,COCCNc1cc(O)c2c(=O)c3c(-c4nccs4)[nH]c(Cc4ccc5c(c4)OCO5)c3oc2c1,CHEMBL4196172,"Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.",J Med Chem,2018.0,61,18,8468,8473,10.1021/acs.jmedchem.8b01209,30148362.0,
18558321,CHEMBL4205724,1-(1H-indol-3-yl)-2-(5-methoxypyridin-3-ylamino)-2-phenylethanone,CHEMBL4200993,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3300.0,nM,COc1cncc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)c1,CHEMBL4196174,Discovery of Indole Derivatives as Novel and Potent Dengue Virus Inhibitors.,J Med Chem,2018.0,61,18,8390,8401,10.1021/acs.jmedchem.8b00913,30149709.0,
18558322,CHEMBL4203720,2-(benzo[d]oxazol-2-yl)-1-(1H-indol-3-yl)-2-(3-methoxyphenylamino)ethanone,CHEMBL4200993,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,6100.0,nM,COc1cccc(NC(C(=O)c2c[nH]c3ccccc23)c2nc3ccccc3o2)c1,CHEMBL4196174,Discovery of Indole Derivatives as Novel and Potent Dengue Virus Inhibitors.,J Med Chem,2018.0,61,18,8390,8401,10.1021/acs.jmedchem.8b00913,30149709.0,
18558323,CHEMBL4203293,rac-2-((3-(2-Hydroxyethoxy)-5-methoxyphenyl)amino)-1-(1H-indol-3-yl)-2-phenylethanone,CHEMBL4200993,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3100.0,nM,COc1cc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)cc(OCCO)c1,CHEMBL4196174,Discovery of Indole Derivatives as Novel and Potent Dengue Virus Inhibitors.,J Med Chem,2018.0,61,18,8390,8401,10.1021/acs.jmedchem.8b00913,30149709.0,
18558324,CHEMBL4212403,"rac-2-((3,5-Dimethoxyphenyl)amino)-1-(1H-indol-3-yl)-2-phenylethanone",CHEMBL4200993,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3200.0,nM,COc1cc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)cc(OC)c1,CHEMBL4196174,Discovery of Indole Derivatives as Novel and Potent Dengue Virus Inhibitors.,J Med Chem,2018.0,61,18,8390,8401,10.1021/acs.jmedchem.8b00913,30149709.0,
18558325,CHEMBL4212403,"rac-2-((3,5-Dimethoxyphenyl)amino)-1-(1H-indol-3-yl)-2-phenylethanone",CHEMBL4200993,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3000.0,nM,COc1cc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)cc(OC)c1,CHEMBL4196174,Discovery of Indole Derivatives as Novel and Potent Dengue Virus Inhibitors.,J Med Chem,2018.0,61,18,8390,8401,10.1021/acs.jmedchem.8b00913,30149709.0,
18558326,CHEMBL4212403,"rac-2-((3,5-Dimethoxyphenyl)amino)-1-(1H-indol-3-yl)-2-phenylethanone",CHEMBL4200993,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,4800.0,nM,COc1cc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)cc(OC)c1,CHEMBL4196174,Discovery of Indole Derivatives as Novel and Potent Dengue Virus Inhibitors.,J Med Chem,2018.0,61,18,8390,8401,10.1021/acs.jmedchem.8b00913,30149709.0,
18572736,CHEMBL4227731,Propan-2-yl 2-{3-[3-fluoro-4-(pyrrolidine-1-carbonyl)phenoxy]propyl}-7-azaspiro[3.5]nonane-7-carboxylate,CHEMBL4221404,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,<,10000.0,nM,CC(C)OC(=O)N1CCC2(CC1)CC(CCCOc1ccc(C(=O)N3CCCC3)c(F)c1)C2,CHEMBL4219099,"Design, synthesis and biological evaluation of novel 7-azaspiro[3.5]nonane derivatives as GPR119 agonists.",Bioorg Med Chem,2018.0,26,8,1832,1847,10.1016/j.bmc.2018.02.032,29486951.0,
18572741,CHEMBL4226885,Propan-2-yl 2-{3-[4-(azetidine-1-carbonyl)-3-fluorophenoxy]propyl}-7-azaspiro[3.5]nonane-7-carboxylate,CHEMBL4221404,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,<,10000.0,nM,CC(C)OC(=O)N1CCC2(CC1)CC(CCCOc1ccc(C(=O)N3CCC3)c(F)c1)C2,CHEMBL4219099,"Design, synthesis and biological evaluation of novel 7-azaspiro[3.5]nonane derivatives as GPR119 agonists.",Bioorg Med Chem,2018.0,26,8,1832,1847,10.1016/j.bmc.2018.02.032,29486951.0,
18572746,CHEMBL4226586,Propan-2-yl 2-{3-[3-fluoro-4-(3-hydroxyazetidine-1-carbonyl)phenoxy]propyl}-7-azaspiro[3.5]nonane-7-carboxylate,CHEMBL4221404,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,<,10000.0,nM,CC(C)OC(=O)N1CCC2(CC1)CC(CCCOc1ccc(C(=O)N3CC(O)C3)c(F)c1)C2,CHEMBL4219099,"Design, synthesis and biological evaluation of novel 7-azaspiro[3.5]nonane derivatives as GPR119 agonists.",Bioorg Med Chem,2018.0,26,8,1832,1847,10.1016/j.bmc.2018.02.032,29486951.0,
18578835,CHEMBL4227082,"N-(6-methyl-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl)-3-(pyridin-2-ylmethyl)isothiazol-5-amine",CHEMBL4222470,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,20000.0,nM,Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(Cc3ccccn3)ns2)n1,CHEMBL4219148,"Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitor.",Bioorg Med Chem Lett,2018.0,28,8,1397,1403,10.1016/j.bmcl.2018.02.037,29545102.0,
18578836,CHEMBL4225923,"rac-3-((tert-butylamino)(pyridin-2-yl)methyl)-N-(6-methyl-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl)isothiazol-5-amine",CHEMBL4222470,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,6000.0,nM,Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(C(NC(C)(C)C)c3ccccn3)ns2)n1,CHEMBL4219148,"Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitor.",Bioorg Med Chem Lett,2018.0,28,8,1397,1403,10.1016/j.bmcl.2018.02.037,29545102.0,
18579404,CHEMBL4227228,"N-((R)-1-(5-fluoropyridin-2-yl)ethyl)-3-(5-methylpyridin-2-yl)-5-((S)-5-(pyridin-2-yl)-4,5-dihydroisoxazol-3-yl)benzamide",CHEMBL4222586,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5700.0,nM,Cc1ccc(-c2cc(C(=O)N[C@H](C)c3ccc(F)cn3)cc(C3=NO[C@H](c4ccccn4)C3)c2)nc1,CHEMBL4219153,Identification of second-generation P2X3 antagonists for treatment of pain.,Bioorg Med Chem Lett,2018.0,28,8,1392,1396,10.1016/j.bmcl.2018.02.039,29548573.0,
18579405,CHEMBL4227222,(R)-3-(2-hydroxypropan-2-yl)-5-(5-methylpyridin-2-yl)-N-(1-(6-(trifluoromethyl)pyridin-3-yl)ethyl)benzamide,CHEMBL4222586,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,19000.0,nM,Cc1ccc(-c2cc(C(=O)N[C@H](C)c3ccc(C(F)(F)F)nc3)cc(C(C)(C)O)c2)nc1,CHEMBL4219153,Identification of second-generation P2X3 antagonists for treatment of pain.,Bioorg Med Chem Lett,2018.0,28,8,1392,1396,10.1016/j.bmcl.2018.02.039,29548573.0,
18579406,CHEMBL4227903,(R)-5-(1-(3-(2-hydroxypropan-2-yl)-5-(5-methylpyridin-2-yl)benzamido)ethyl)-2-(trifluoromethyl)pyridine 1-oxide,CHEMBL4222586,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1ccc(-c2cc(C(=O)N[C@H](C)c3ccc(C(F)(F)F)[n+]([O-])c3)cc(C(C)(C)O)c2)nc1,CHEMBL4219153,Identification of second-generation P2X3 antagonists for treatment of pain.,Bioorg Med Chem Lett,2018.0,28,8,1392,1396,10.1016/j.bmcl.2018.02.039,29548573.0,
18579407,CHEMBL4229237,(R)-5-(1-(3-(5-chloropyridin-2-yl)-5-(2-hydroxypropan-2-yl)benzamido)ethyl)-2-(trifluoromethyl)pyridine 1-oxide,CHEMBL4222586,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,82000.0,nM,C[C@@H](NC(=O)c1cc(-c2ccc(Cl)cn2)cc(C(C)(C)O)c1)c1ccc(C(F)(F)F)[n+]([O-])c1,CHEMBL4219153,Identification of second-generation P2X3 antagonists for treatment of pain.,Bioorg Med Chem Lett,2018.0,28,8,1392,1396,10.1016/j.bmcl.2018.02.039,29548573.0,
18586326,CHEMBL4224936,"2-(4-(4,9-diethoxy-1,3-dioxo-1H-benzo[f]isoindol-2(3H)-yl)phenyl)acetic acid",CHEMBL4223494,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,100000.0,nM,CCOc1c2c(c(OCC)c3ccccc13)C(=O)N(c1ccc(CC(=O)O)cc1)C2=O,CHEMBL4219215,"Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP4 receptor partial agonist for the treatment of pain.",Bioorg Med Chem Lett,2018.0,28,10,1892,1896,10.1016/j.bmcl.2018.03.091,29636218.0,
18590812,CHEMBL4227117,"Isopropyl (S)-2-(4,5-dihydronaphtho[2,1-d]isoxazole-3-carboxamido)-3-(1H-imidazol-1-yl)propanoate",CHEMBL4224400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1noc2c1CCc1ccccc1-2,CHEMBL4219262,"Design, synthesis and evaluation of benzoheterocycle analogues as potent antifungal agents targeting CYP51.",Bioorg Med Chem,2018.0,26,12,3242,3253,10.1016/j.bmc.2018.04.054,29748145.0,
18590813,CHEMBL4227911,"Isopropyl (S)-3-(1H-imidazol-1-yl)-2-(naphtho[2,1-d]isoxazole-3-carboxamido)propanoate",CHEMBL4224400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1noc2c1ccc1ccccc12,CHEMBL4219262,"Design, synthesis and evaluation of benzoheterocycle analogues as potent antifungal agents targeting CYP51.",Bioorg Med Chem,2018.0,26,12,3242,3253,10.1016/j.bmc.2018.04.054,29748145.0,
18590814,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4224400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,462.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4219262,"Design, synthesis and evaluation of benzoheterocycle analogues as potent antifungal agents targeting CYP51.",Bioorg Med Chem,2018.0,26,12,3242,3253,10.1016/j.bmc.2018.04.054,29748145.0,
18592038,CHEMBL4226756,"Methyl (S,E)-(4-(2-(4-isopropoxyphenoxy)thiazol-5-yl)but-3-en-2-yl)carbamate",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2700.0,nM,COC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OC(C)C)cc2)s1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592039,CHEMBL4225651,"(S,E)-N-(4-(2-(4-isopropoxyphenoxy)thiazol-5-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,4400.0,nM,CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OC(C)C)cc2)s1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592040,CHEMBL4226491,"(S,E)-N-(4-(2-(4-ethoxyphenoxy)thiazol-5-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8600.0,nM,CCOc1ccc(Oc2ncc(/C=C/[C@H](C)NC(C)=O)s2)cc1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592041,CHEMBL4225397,"(S,E)-N-(4-(2-(4-(cyclopropylmethoxy)phenoxy)thiazol-5-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8200.0,nM,CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OCC3CC3)cc2)s1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592042,CHEMBL4226229,"(S,E)-N-(4-(2-(2-chloro-4-(cyclopropylmethoxy)phenoxy)thiazol-5-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3500.0,nM,CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OCC3CC3)cc2Cl)s1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592043,CHEMBL4225124,"(S,E)-N-(4-(5-(2-chloro-4-(cyclopropylmethoxy)phenoxy)-1,3,4-thiadiazol-2-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,15000.0,nM,CC(=O)N[C@@H](C)/C=C/c1nnc(Oc2ccc(OCC3CC3)cc2Cl)s1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592044,CHEMBL4225976,"(S,E)-N-(4-(2-(2-chloro-4-(cyclopropylmethoxy)phenoxy)-1-methyl-1H-imidazol-5-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,10000.0,nM,CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OCC3CC3)cc2Cl)n1C,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592045,CHEMBL4224858,"(S,E)-N-(4-(6-(2-chloro-4-(cyclopropylmethoxy)phenoxy)pyridin-3-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,9500.0,nM,CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc(OCC3CC3)cc2Cl)nc1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592046,CHEMBL4226182,"(S,E)-N-(4-(5-(2-chloro-4-(cyclopropylmethoxy)phenoxy)pyrazin-2-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OCC3CC3)cc2Cl)cn1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592047,CHEMBL4227288,"(S,E)-N-(4-(6-(2-chloro-4-(cyclopropylmethoxy)phenoxy)pyridazin-3-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc(OCC3CC3)cc2Cl)nn1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592049,CHEMBL4226442,"(S,E)-N-(4-(2-(2-chloro-4-(cyclopropylmethoxy)phenoxy)pyrimidin-5-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OCC3CC3)cc2Cl)nc1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592050,CHEMBL4227033,"(S,E)-N-(4-(6-(2-chloro-4-ethoxyphenoxy)pyridin-3-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CCOc1ccc(Oc2ccc(/C=C/[C@H](C)NC(C)=O)cn2)c(Cl)c1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592051,CHEMBL4226186,"(S,E)-N-(4-(6-(2-chloro-4-(2-fluoroethoxy)phenoxy)pyridin-3-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc(OCCF)cc2Cl)nc1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592052,CHEMBL4224836,"(S,E)-N-(4-(6-(2-chloro-4-(2,2-difluoroethoxy)phenoxy)pyridin-3-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc(OCC(F)F)cc2Cl)nc1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592053,CHEMBL4225924,"(S,E)-N-(4-(6-((7-chloro-2-methylbenzothiazol-6-yl)oxy)pyridin-3-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C)sc3c2Cl)nc1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592054,CHEMBL4226500,"(S,E)-N-(4-(6-((5-chloro-2-methylbenzo[d]thiazol-6-yl)oxy)pyridin-3-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2cc3sc(C)nc3cc2Cl)nc1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592055,CHEMBL4225659,"(S,E)-N-(4-(6-((7-chloro-2-isopropylbenzothiazol-6-yl)oxy)pyridin-3-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,13000.0,nM,CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C(C)C)sc3c2Cl)nc1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592056,CHEMBL4224749,"(S,E)-N-(4-(6-((7-chloro-2-(2-hydroxypropan-2-yl)benzothiazol-6-yl)oxy)pyridin-3-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,17000.0,nM,CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C(C)(C)O)sc3c2Cl)nc1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592057,CHEMBL4225405,"(S,E)-N-(4-(6-((7-chloro-2-ethoxybenzo[d]thiazol-6-yl)oxy)pyridin-3-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,13000.0,nM,CCOc1nc2ccc(Oc3ccc(/C=C/[C@H](C)NC(C)=O)cn3)c(Cl)c2s1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592058,CHEMBL4228805,"(S,E)-N-(4-(6-((4-chloro-2-isopropylbenzothiazol-5-yl)oxy)pyridin-3-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,14000.0,nM,CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3sc(C(C)C)nc3c2Cl)nc1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592059,CHEMBL4226825,"(S,E)-N-(4-(6-((2-isopropyl-7-(trifluoromethyl)benzothiazol-6-yl)oxy)pyridin-3-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,14000.0,nM,CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C(C)C)sc3c2C(F)(F)F)nc1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18592060,CHEMBL4229067,"(S,E)-N-(4-(6-((7-fluoro-2-isopropylbenzothiazol-6-yl)oxy)pyridin-3-yl)but-3-en-2-yl)acetamide",CHEMBL4224648,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C(C)C)sc3c2F)nc1,CHEMBL4219273,Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.,Bioorg Med Chem Lett,2018.0,28,14,2498,2503,10.1016/j.bmcl.2018.05.055,29903660.0,
18652768,CHEMBL4239823,(S)-4-((2-(2-(4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)pyrrolidin-1-yl)sulfonyl)isoquinoline,CHEMBL4229930,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human supersome CYP2C9 using diclofenac as substrate assessed as diclofenac 4'-hydroxylation after 30 mins by HPLC-UV detection,IC50,>,100000.0,nM,O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCN(c2cccc3sccc23)CC1,CHEMBL4229332,Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects.,Eur J Med Chem,2018.0,145,,790,804,10.1016/j.ejmech.2018.01.002,29407591.0,
18652769,CHEMBL4246655,"(S)-3-(4-(2-(1-(Isoquinolin-4-ylsulfonyl)pyrrolidin-2-yl)ethyl)piperazin-1-yl)-1,2-benzothiazole",CHEMBL4229930,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human supersome CYP2C9 using diclofenac as substrate assessed as diclofenac 4'-hydroxylation after 30 mins by HPLC-UV detection,IC50,=,100000.0,nM,O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCN(c2nsc3ccccc23)CC1,CHEMBL4229332,Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects.,Eur J Med Chem,2018.0,145,,790,804,10.1016/j.ejmech.2018.01.002,29407591.0,
18678845,CHEMBL4063810,"(2H)-3-benzylidene-6-(1-(5-tert-butyl-1H-imidazol-4-yl)ethylidene)piperazine-2,5-dione",CHEMBL4236080,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,560.0,nM,[2H]/C(c1nc[nH]c1C(C)(C)C)=c1/[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O,CHEMBL4229536,"In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.",Bioorg Med Chem,2018.0,26,16,4687,4692,10.1016/j.bmc.2018.08.009,30119994.0,
18678846,CHEMBL1096380,Plinabulin,CHEMBL4236080,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,530.0,nM,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O,CHEMBL4229536,"In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.",Bioorg Med Chem,2018.0,26,16,4687,4692,10.1016/j.bmc.2018.08.009,30119994.0,
18679217,CHEMBL1873475,SID124898784,CHEMBL4236267,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8500.0,nM,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,CHEMBL4229542,"Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.",Bioorg Med Chem Lett,2018.0,28,17,2939,2944,10.1016/j.bmcl.2018.07.008,30122225.0,
18683445,CHEMBL4244935,"4,4-Difluoro-N-((S)-3-((1R,3R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(thiophen-2-yl)-propyl)cyclohexane-1-carboxamide",CHEMBL4237148,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1cccs1,CHEMBL4229569,"Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.",J Med Chem,2018.0,61,21,9621,9636,10.1021/acs.jmedchem.8b01077,30234300.0,
18683446,CHEMBL4248282,"4,4-Difluoro-N-((S)-3-((1R,3R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(5-methylthiophen-2-yl)propyl)cyclohexane-1-carboxamide",CHEMBL4237148,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,Cc1ccc([C@H](CCN2[C@H]3CC[C@@H]2C[C@@H](n2c(C)nnc2C(C)C)C3)NC(=O)C2CCC(F)(F)CC2)s1,CHEMBL4229569,"Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.",J Med Chem,2018.0,61,21,9621,9636,10.1021/acs.jmedchem.8b01077,30234300.0,
18683447,CHEMBL4242114,"N-((S)-3-(exo-3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(thiophen-2-yl)propyl)cyclohexane Carboxamide",CHEMBL4237148,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCCCC1)c1cccs1,CHEMBL4229569,"Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.",J Med Chem,2018.0,61,21,9621,9636,10.1021/acs.jmedchem.8b01077,30234300.0,
18683448,CHEMBL4238063,"N-((S)-3-(exo-3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(thiophen-2-yl)propyl)cyclopentaneCarboxamide",CHEMBL4237148,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCCC1)c1cccs1,CHEMBL4229569,"Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.",J Med Chem,2018.0,61,21,9621,9636,10.1021/acs.jmedchem.8b01077,30234300.0,
18683449,CHEMBL4249798,"4,4-Difluoro-N-(3-((1R,3S,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(thiophen-3-yl)-propyl)cyclohexane-1-carboxamide",CHEMBL4237148,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccsc1,CHEMBL4229569,"Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.",J Med Chem,2018.0,61,21,9621,9636,10.1021/acs.jmedchem.8b01077,30234300.0,
18684349,CHEMBL4280986,"2-(((1aS,7bS)-2,2-dimethyl-6-(trifluoromethyl)-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7b-yl)methyl)-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-1H-pyrido[1,2-a]pyrazine-1,6(2H)-dione",CHEMBL4251798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,22700.0,nM,Cc1cn(-c2ccc3n(c2=O)CCN(C[C@@]24C[C@@H]2C(C)(C)Oc2ccc(C(F)(F)F)cc24)C3=O)cn1,CHEMBL4251542,"Discovery of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators with robust central efficacy.",MedChemComm,2017.0,8,4,730,743,10.1039/C6MD00406G,30108792.0,
18690085,CHEMBL4289811,"2,4-Dihydroxy-5-isopropyl-N-methyl-N-(4-(propylcarbamoyl)benzyl)-benzamide",CHEMBL4252957,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human pooled human liver microsomes using tolbutamide as substrate assessed as tolbutamide 4-methylhydroxylation preincubated for 5 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis,IC50,=,5300.0,nM,CCCNC(=O)c1ccc(CN(C)C(=O)c2cc(C(C)C)c(O)cc2O)cc1,CHEMBL4251579,"Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.",Eur J Med Chem,2018.0,143,,390,401,10.1016/j.ejmech.2017.11.054,29202402.0,
18708820,CHEMBL4279238,"N-(7-(Adamantan-1-ylmethoxy)-6-cyclopropyl-[1,2,4]-triazolo[4,3-a]pyridin-3-yl)methanesulfonamide",CHEMBL4256605,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using warfarin as substrate after 30 mins by LC-MS/MS method,IC50,>,10000.0,nM,CS(=O)(=O)Nc1nnc2cc(OCC34CC5CC(CC(C5)C3)C4)c(C3CC3)cn12,CHEMBL4251746,"Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3- a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNaV1.7 Inhibitors for the Treatment of Pain.",J Med Chem,2018.0,61,11,4810,4831,10.1021/acs.jmedchem.7b01826,29737846.0,
18708821,CHEMBL4290579,"N-(7-(Adamantan-1-ylmethoxy)-6-cyclopropyl-[1,2,4]-triazolo[4,3-a]-pyridin-3-yl)cyclo-propanesulfonamide",CHEMBL4256605,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using warfarin as substrate after 30 mins by LC-MS/MS method,IC50,>,10000.0,nM,O=S(=O)(Nc1nnc2cc(OCC34CC5CC(CC(C5)C3)C4)c(C3CC3)cn12)C1CC1,CHEMBL4251746,"Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3- a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNaV1.7 Inhibitors for the Treatment of Pain.",J Med Chem,2018.0,61,11,4810,4831,10.1021/acs.jmedchem.7b01826,29737846.0,
18708822,CHEMBL4285790,"N-(6-Cyclopropyl-7-((3,5-dichlorophenoxy)methyl)-[1,2,4]-triazolo[4,3-a]pyridin-3-yl)methanesulfonamide",CHEMBL4256605,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using warfarin as substrate after 30 mins by LC-MS/MS method,IC50,>,10000.0,nM,CS(=O)(=O)Nc1nnc2cc(COc3cc(Cl)cc(Cl)c3)c(C3CC3)cn12,CHEMBL4251746,"Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3- a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNaV1.7 Inhibitors for the Treatment of Pain.",J Med Chem,2018.0,61,11,4810,4831,10.1021/acs.jmedchem.7b01826,29737846.0,
18720648,CHEMBL4294195,6-Methoxy chelerythrine,CHEMBL4257976,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control,IC50,>,10000.0,nM,COc1ccc2c(c1OC)C(OC)N(C)c1c-2ccc2cc3c(cc12)OCO3,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720649,CHEMBL44541,4-(5-Bromo-1H-indol-3-yl)-pyrimidin-2-ylamine,CHEMBL4257976,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control,IC50,>,10000.0,nM,Nc1nccc(-c2c[nH]c3ccc(Br)cc23)n1,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720650,CHEMBL4282750,Karanjin,CHEMBL4257976,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control,IC50,>,10000.0,nM,COc1c(-c2ccccc2)oc2c(ccc3ccoc32)c1=O,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720651,CHEMBL44746,"4,9-Dimethoxy-7-methyl-furo[3,2-g]chromen-5-one",CHEMBL4257976,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control,IC50,>,10000.0,nM,COc1c2occc2c(OC)c2c(=O)cc(C)oc12,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720652,CHEMBL226508,"5-hydroxy-6,7,3',4'-tetramethoxyflavone",CHEMBL4257976,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control,IC50,>,10000.0,nM,COc1ccc(-c2cc(=O)c3c(O)c(OC)c(OC)cc3o2)cc1OC,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720653,CHEMBL4285296,Pongamol,CHEMBL4257976,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control,IC50,>,10000.0,nM,COc1c(C(=O)CC(=O)c2ccccc2)ccc2occc12,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720654,CHEMBL24171,"4-Methoxy-furo[3,2-g]chromen-7-one",CHEMBL4257976,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control,IC50,>,10000.0,nM,COc1c2ccoc2cc2oc(=O)ccc12,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720655,CHEMBL452751,phellopterin,CHEMBL4257976,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control,IC50,>,10000.0,nM,COc1c2ccoc2c(OCC=C(C)C)c2oc(=O)ccc12,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720656,CHEMBL140796,"4,9-Dimethoxy-furo[3,2-g]chromen-7-one",CHEMBL4257976,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control,IC50,>,10000.0,nM,COc1c2ccoc2c(OC)c2oc(=O)ccc12,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720657,CHEMBL295316,"5-Hydroxy-2-methyl-[1,4]naphthoquinone",CHEMBL4257976,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control,IC50,>,10000.0,nM,CC1=CC(=O)c2c(O)cccc2C1=O,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720658,CHEMBL274056,"5,8-Dihydroxy-[1,4]naphthoquinone",CHEMBL4257976,A,HEK293,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control,IC50,>,10000.0,nM,O=C1C=CC(=O)c2c(O)ccc(O)c21,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18746302,CHEMBL4282403,"5-(2,4,5-trichlorophenoxy)pyridin-2-amine",CHEMBL4263019,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,<,100.0,nM,Nc1ccc(Oc2cc(Cl)c(Cl)cc2Cl)cn1,CHEMBL4261550,Triazolopyrimidines identified as reversible myeloperoxidase inhibitors.,MedChemComm,2017.0,8,11,2093,2099,10.1039/C7MD00268H,30108726.0,
18749255,CHEMBL4293810,Rac-4-(4-Hydroxyphenyl)cycloheptanemethanol,CHEMBL4263507,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using luciferin-H as substrate preincubated for 10 mins followed by NADPH regeneration system addition and measured after 30 mins by Promega P450-GloScreening assay,IC50,=,2700.0,nM,OCC1CCCC(c2ccc(O)cc2)CC1,CHEMBL4261581,Synthesis and evaluation of 4-cycloheptylphenols as selective Estrogen receptor-β agonists (SERBAs).,Eur J Med Chem,2018.0,157,,791,804,10.1016/j.ejmech.2018.08.006,30144697.0,
18755894,CHEMBL4288001,"(S)-3-(4-(((S)-7-chloro-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methoxy)phenyl)hex-4-ynoic acid",CHEMBL4265242,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,60500.0,nM,CC#C[C@@H](CC(=O)O)c1ccc(OC[C@H]2COc3ccc(Cl)cc3O2)cc1,CHEMBL4261634,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.",Bioorg Med Chem,2018.0,26,22,5780,5791,10.1016/j.bmc.2018.10.019,30392954.0,
18756929,CHEMBL4285867,"N-(1-Methylcyclopropyl)-3-[(1-methylpyrazol-4-yl)methyl]-1-(oxetan-3-ylmethyl)-2,4-dioxo-quinazoline-6-sulfonamide",CHEMBL4265339,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cn1cc(Cn2c(=O)c3cc(S(=O)(=O)NC4(C)CC4)ccc3n(CC3COC3)c2=O)cn1,CHEMBL4261639,Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides.,J Med Chem,2018.0,61,23,10767,10792,10.1021/acs.jmedchem.8b01407,30403352.0,
18756930,CHEMBL4283898,"N-(1-Methylcyclopropyl)-3-[(3-methylisoxazol-5-yl)methyl]-1(oxetan-3-ylmethyl)-2,4-dioxo-quinazoline-6-sulfonamide",CHEMBL4265339,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,Cc1cc(Cn2c(=O)c3cc(S(=O)(=O)NC4(C)CC4)ccc3n(CC3COC3)c2=O)on1,CHEMBL4261639,Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides.,J Med Chem,2018.0,61,23,10767,10792,10.1021/acs.jmedchem.8b01407,30403352.0,
18758331,CHEMBL4291468,"5-[[4-[2-(4-Methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-2,4-thiazolidinedione",CHEMBL4265670,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,23000.0,nM,COc1cccc(C(=O)COc2ccc(CC3SC(=O)NC3=O)cc2)c1,CHEMBL4261653,"PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development.",Bioorg Med Chem,2018.0,26,22,5870,5884,10.1016/j.bmc.2018.10.033,30429097.0,
18758332,CHEMBL146624,"5-{4-[2-(5-Ethyl-pyridin-2-yl)-2-oxo-ethoxy]-benzyl}-thiazolidine-2,4-dione",CHEMBL4265670,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,22000.0,nM,CCc1ccc(C(=O)COc2ccc(CC3SC(=O)NC3=O)cc2)nc1,CHEMBL4261653,"PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development.",Bioorg Med Chem,2018.0,26,22,5870,5884,10.1016/j.bmc.2018.10.033,30429097.0,
18763399,CHEMBL4276988,"[2-amino-4-[[(1S)-1-(2-hydroxyethyl)butyl]amino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-(2-methylthiazol-4-yl)methanone",CHEMBL4266946,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCC[C@@H](CCO)Nc1nc(N)nc2c1CN(C(=O)c1csc(C)n1)CC2,CHEMBL4265889,Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonists.,Bioorg Med Chem Lett,2018.0,28,19,3216,3221,10.1016/j.bmcl.2018.08.015,30143425.0,
18764306,CHEMBL4292052,"3,5-dimethyl-N-(6-(trifluoromethyl)benzo[d]thiazol-2-yl)cyclohexanecarboxamide",CHEMBL4267019,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC1CC(C)CC(C(=O)Nc2nc3ccc(C(F)(F)F)cc3s2)C1,CHEMBL4265897,Discovery of benzothiazole amides as potent antimycobacterial agents.,Bioorg Med Chem Lett,2018.0,28,19,3177,3181,10.1016/j.bmcl.2018.08.026,30172617.0,
18764307,CHEMBL4281073,"N-(6-bromobenzo[d]thiazol-2-yl)-3,3,5-trimethylcyclohexanecarboxamide",CHEMBL4267019,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC1CC(C(=O)Nc2nc3ccc(Br)cc3s2)CC(C)(C)C1,CHEMBL4265897,Discovery of benzothiazole amides as potent antimycobacterial agents.,Bioorg Med Chem Lett,2018.0,28,19,3177,3181,10.1016/j.bmcl.2018.08.026,30172617.0,
18764308,CHEMBL4295138,"N-(6-chlorobenzo[d]thiazol-2-yl)-3,3,5-trimethylcyclohexanecarboxamide",CHEMBL4267019,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC1CC(C(=O)Nc2nc3ccc(Cl)cc3s2)CC(C)(C)C1,CHEMBL4265897,Discovery of benzothiazole amides as potent antimycobacterial agents.,Bioorg Med Chem Lett,2018.0,28,19,3177,3181,10.1016/j.bmcl.2018.08.026,30172617.0,
18764309,CHEMBL4287884,"3,3,5-trimethyl-N-(6-(trifluoromethoxy)benzo[d]thiazol-2-yl)cyclohexanecarboxamide",CHEMBL4267019,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC1CC(C(=O)Nc2nc3ccc(OC(F)(F)F)cc3s2)CC(C)(C)C1,CHEMBL4265897,Discovery of benzothiazole amides as potent antimycobacterial agents.,Bioorg Med Chem Lett,2018.0,28,19,3177,3181,10.1016/j.bmcl.2018.08.026,30172617.0,
18772727,CHEMBL4276719,Sodium 2-(2-(5-(((2-butylphenyl)amino)methyl)thiophene-2-carboxamido)thiazol-4-yl)acetate,CHEMBL4268624,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCCCc1ccccc1NCc1ccc(C(=O)Nc2nc(CC(=O)O)cs2)s1,CHEMBL4265954,"Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.",Eur J Med Chem,2018.0,158,,832,852,10.1016/j.ejmech.2018.09.003,30248655.0,
18775779,CHEMBL4283853,"(6S)-(+)-10-Methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic Acid",CHEMBL4269034,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,COCCCOc1cc2c(cc1OC)-c1cc(=O)c(C(=O)O)cn1[C@H](C(C)C)C2,CHEMBL4265974,Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action.,J Med Chem,2018.0,61,23,10619,10634,10.1021/acs.jmedchem.8b01245,30286292.0,
18779434,CHEMBL2325697,4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)-cyclopropyl]pyrimidi-2-yl}-1H-indole,CHEMBL4269688,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis,IC50,>,10000.0,nM,C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1,CHEMBL4266018,"Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.",J Med Chem,2018.0,61,22,9889,9907,10.1021/acs.jmedchem.8b01187,30346772.0,
18779435,CHEMBL4285417,CERALASERTIB,CHEMBL4269688,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis,IC50,>,10000.0,nM,C[C@@H]1COCCN1c1cc(C2([S@](C)(=N)=O)CC2)nc(-c2cc[nH]c3nccc2-3)n1,CHEMBL4266018,"Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.",J Med Chem,2018.0,61,22,9889,9907,10.1021/acs.jmedchem.8b01187,30346772.0,
18779444,CHEMBL4281240,"4-{4-[1-(Methanesulfonyl)cyclopropyl]-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-yl}-1H-pyrrolo[2,3-c]pyridine",CHEMBL4269688,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis,IC50,>,10000.0,nM,C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cncc3[nH]ccc23)n1,CHEMBL4266018,"Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.",J Med Chem,2018.0,61,22,9889,9907,10.1021/acs.jmedchem.8b01187,30346772.0,
18779445,CHEMBL4291436,N-Methyl-1-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1Hbenzimidazol-2-amine,CHEMBL4269688,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis,IC50,>,10000.0,nM,CNc1nc2ccccc2n1-c1nc(N2CCOC[C@H]2C)cc(C2(S(C)(=O)=O)CC2)n1,CHEMBL4266018,"Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.",J Med Chem,2018.0,61,22,9889,9907,10.1021/acs.jmedchem.8b01187,30346772.0,
18779446,CHEMBL3648329,"US8552004, 2.03",CHEMBL4269688,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis,IC50,>,10000.0,nM,CNc1nc2ccccc2n1-c1nc(N2CCOC[C@H]2C)cc(C2([S@](C)(=N)=O)CC2)n1,CHEMBL4266018,"Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.",J Med Chem,2018.0,61,22,9889,9907,10.1021/acs.jmedchem.8b01187,30346772.0,
18781672,CHEMBL4282052,"4-{8-[(2,6-diethoxy-4'-fluorobiphenyl-4-yl)methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl}benzoic acid trifluoromethyl acetate",CHEMBL4270277,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,50000.0,nM,CCOc1cc(CN2CCC3(CC2)CC(=O)N(c2ccc(C(=O)O)cc2)C3)cc(OCC)c1-c1ccc(F)cc1.O=C(O)C(F)(F)F,CHEMBL4266056,Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition.,ACS Med Chem Lett,2018.0,9,11,1082,1087,10.1021/acsmedchemlett.8b00305,30429949.0,
18782461,CHEMBL4284170,"N-(4-(3-(6-(difluoromethyl)pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)pyridin-2-yl)acetamide",CHEMBL4270426,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(=O)Nc1cc(-c2[nH]c3cccnc3c2-c2cccc(C(F)F)n2)ccn1,CHEMBL4266061,Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents.,ACS Med Chem Lett,2018.0,9,11,1117,1122,10.1021/acsmedchemlett.8b00357,30429955.0,
18782462,CHEMBL4280731,"N-[4-[3-[5-(trideuteriomethoxy)-2-pyridyl]-1H-pyrrolo[3,2-b]pyridin-2-yl]-2-pyridyl]acetamide",CHEMBL4270426,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,[2H]C([2H])([2H])Oc1ccc(-c2c(-c3ccnc(NC(C)=O)c3)[nH]c3cccnc23)nc1,CHEMBL4266061,Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents.,ACS Med Chem Lett,2018.0,9,11,1117,1122,10.1021/acsmedchemlett.8b00357,30429955.0,
18812405,CHEMBL3921520,"US9266835, 41",CHEMBL4276269,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 10 to 30 mins by LC/MS analysis,IC50,>,10000.0,nM,O=c1cc(NC2CCN(S(=O)(=O)C(F)(F)F)CC2)c2cc(C(c3ccc(Cl)cc3)c3nccs3)ccc2[nH]1,CHEMBL4270663,6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB1) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity.,J Med Chem,2018.0,61,22,10276,10298,10.1021/acs.jmedchem.8b01467,30339387.0,
18812423,CHEMBL3962890,"US9266835, 28",CHEMBL4276269,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 10 to 30 mins by LC/MS analysis,IC50,>,10000.0,nM,O=c1cc(/C=C/c2ccc(C(F)(F)F)cc2)c2cc(C(c3ccc(Cl)cc3)c3nccs3)ccc2[nH]1,CHEMBL4270663,6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB1) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity.,J Med Chem,2018.0,61,22,10276,10298,10.1021/acs.jmedchem.8b01467,30339387.0,
18812438,CHEMBL3945880,"US9266835, 44",CHEMBL4276269,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 10 to 30 mins by LC/MS analysis,IC50,>,10000.0,nM,O=c1cc(NC2CCN(S(=O)(=O)C(F)(F)F)CC2)c2cc(C(c3ccc(Cl)cc3)c3ccc(Cl)cc3)ccc2[nH]1,CHEMBL4270663,6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB1) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity.,J Med Chem,2018.0,61,22,10276,10298,10.1021/acs.jmedchem.8b01467,30339387.0,
18847588,CHEMBL3261573,2-(3-(4-bromophenylethylaminocarbonyl)phenyl)-3-(2-methoxyphenyl)-4-thiazolidinone,CHEMBL4305000,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by LC-MS/MS analysis,IC50,=,5350.0,nM,COc1ccccc1N1C(=O)CSC1c1cccc(C(=O)NCCc2ccc(Br)cc2)c1,CHEMBL4304741,"Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin.",J Med Chem,2019.0,62,10,4949,4966,10.1021/acs.jmedchem.9b00059,31026162.0,
18847589,CHEMBL4528087,"3-(5-(4-Methoxyphenyl)-3-methyl-1H-1,2,4-triazolyl)-N-(4-phenylbutyl)benzamide",CHEMBL4305000,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by LC-MS/MS analysis,IC50,=,3930.0,nM,COc1ccc(-c2nc(C)nn2-c2cccc(C(=O)NCCCCc3ccccc3)c2)cc1,CHEMBL4304741,"Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin.",J Med Chem,2019.0,62,10,4949,4966,10.1021/acs.jmedchem.9b00059,31026162.0,
18847590,CHEMBL4582168,"3-(3-Ethyl-5-(5-methoxy-2-pyrimidinyl)-1H-1,2,4-triazolyl)-N-(4-phenylbutyl)benzamide",CHEMBL4305000,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by LC-MS/MS analysis,IC50,=,20480.0,nM,CCc1nc(-c2ncc(OC)cn2)n(-c2cccc(C(=O)NCCCCc3ccccc3)c2)n1,CHEMBL4304741,"Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin.",J Med Chem,2019.0,62,10,4949,4966,10.1021/acs.jmedchem.9b00059,31026162.0,
18847591,CHEMBL4587127,"3-(1-(4-Methoxyphenyl)-3-methyl-1H-1,2,4-triazol-5-yl)-N-(4-phenylbutyl)benzamide",CHEMBL4305000,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by LC-MS/MS analysis,IC50,=,3380.0,nM,COc1ccc(-n2nc(C)nc2-c2cccc(C(=O)NCCCCc3ccccc3)c2)cc1,CHEMBL4304741,"Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin.",J Med Chem,2019.0,62,10,4949,4966,10.1021/acs.jmedchem.9b00059,31026162.0,
18848823,CHEMBL4463039,"3-(4-(2-(Trifluoromethyl)phenyl)piperidine-1-carbonyl)-[1,2,4]-triazolo[4,3-a]pyridine-6-carbonitrile",CHEMBL4305290,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in insect cell microsomes in presence of NADPH-regenerating system after 15 to 45 mins by fluorescence probe substrate-based assay,IC50,=,4700.0,nM,N#Cc1ccc2nnc(C(=O)N3CCC(c4ccccc4C(F)(F)F)CC3)n2c1,CHEMBL4304746,"Design, Synthesis, and Preclinical Efficacy of Novel Nonretinoid Antagonists of Retinol-Binding Protein 4 in the Mouse Model of Hepatic Steatosis.",J Med Chem,2019.0,62,11,5470,5500,10.1021/acs.jmedchem.9b00352,31079449.0,
18848824,CHEMBL3954871,"US9434727, 65",CHEMBL4305290,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in insect cell microsomes in presence of NADPH-regenerating system after 15 to 45 mins by fluorescence probe substrate-based assay,IC50,=,11000.0,nM,N#Cc1ccc2nnc(C(=O)N3CCC(c4cccc(F)c4C(F)(F)F)CC3)n2c1,CHEMBL4304746,"Design, Synthesis, and Preclinical Efficacy of Novel Nonretinoid Antagonists of Retinol-Binding Protein 4 in the Mouse Model of Hepatic Steatosis.",J Med Chem,2019.0,62,11,5470,5500,10.1021/acs.jmedchem.9b00352,31079449.0,
18854469,CHEMBL4470753,"2-(4-((5-(4-bromophenyl)isoxazol-3-yl)methyl)-2,6-dimethylphenoxy)-2-methylpropanoic acid",CHEMBL4307163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 10 mins followed by substrate addition further incubated for 10 mins by LC-MS/MS analysis,IC50,=,20000.0,nM,Cc1cc(Cc2cc(-c3ccc(Br)cc3)on2)cc(C)c1OC(C)(C)C(=O)O,CHEMBL4304783,Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.,ACS Med Chem Lett,2019.0,10,7,1068,1073,10.1021/acsmedchemlett.9b00189,31312410.0,
18861529,CHEMBL4452972,"(E)-3-(3,5-difluoro-4-((6R,10R)-12-(2-fluoro-2-methylpropyl)-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indol-6-yl)phenyl)acrylic acid",CHEMBL4308803,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,CC(C)(F)CN1[C@@H]2CCC[C@@]1(c1c(F)cc(/C=C/C(=O)O)cc1F)c1[nH]c3ccccc3c1C2,CHEMBL4304838,Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry.,ACS Med Chem Lett,2019.0,10,10,1492,1497,10.1021/acsmedchemlett.9b00370,31620239.0,
18862110,CHEMBL4483344,1-{[6-(4-Chloro-2-fluorophenyl)pyridin-3-yl]methyl}-1H-benzotriazole,CHEMBL4309078,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,6600.0,nM,Fc1cc(Cl)ccc1-c1ccc(Cn2nnc3ccccc32)cn1,CHEMBL4308828,Fragment Based Optimization of Metabotropic Glutamate Receptor 2 (mGluR2) Positive Allosteric Modulators in the Absence of Structural Information.,J Med Chem,2018.0,62,1,234,246,10.1021/acs.jmedchem.8b00161,29505715.0,
18862111,CHEMBL4460927,1-(Cyclopropylmethyl)-4-(trifluoromethyl)-1H-benzotriazole,CHEMBL4309078,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,FC(F)(F)c1cccc2c1nnn2CC1CC1,CHEMBL4308828,Fragment Based Optimization of Metabotropic Glutamate Receptor 2 (mGluR2) Positive Allosteric Modulators in the Absence of Structural Information.,J Med Chem,2018.0,62,1,234,246,10.1021/acs.jmedchem.8b00161,29505715.0,
18870658,CHEMBL3945728,"US9133148, 9aq",CHEMBL4309882,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9,IC50,>,50000.0,nM,O=C(OC(C(F)(F)F)C(F)(F)F)N1CCN(Cc2ccc(C(F)(F)F)cc2N2CCCC2)CC1,CHEMBL4308843,"Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders.",J Med Chem,2018.0,61,20,9062,9084,10.1021/acs.jmedchem.8b00951,30067909.0,
18871500,CHEMBL4588443,"6-((1H-Pyrazolo[4,3-b]pyridin-3-yl)amino)-N-(3,3-difluorocyclobutyl)benzo[d]isothiazole-3-carboxamide",CHEMBL4310065,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 15 mins followed by substrate addition and measured after 8 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,O=C(NC1CC(F)(F)C1)c1nsc2cc(Nc3n[nH]c4cccnc34)ccc12,CHEMBL4308847,"Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu<sub>4</sub>).",J Med Chem,2018.0,62,1,342,358,10.1021/acs.jmedchem.8b00994,30247901.0,
18885273,CHEMBL463783,4-(6-chloro-2-methoxyacridin-9-ylamino)-2-((4-methylpiperazin-1-yl)methyl)phenol,CHEMBL4313173,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,10000.0,nM,COc1ccc2nc3cc(Cl)ccc3c(Nc3ccc(O)c(CN4CCN(C)CC4)c3)c2c1,CHEMBL4311953,Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF.,J Med Chem,2019.0,62,17,7684,7696,10.1021/acs.jmedchem.9b00326,31369707.0,
18885274,CHEMBL4470176,4-((6-Chloro-2-methoxyacridin-9-yl)amino)-2-((4-(2-(dimethylamino)ethyl)piperazin-1-yl)methyl)phenol,CHEMBL4313173,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,1000.0,nM,COc1ccc2nc3cc(Cl)ccc3c(Nc3ccc(O)c(CN4CCN(CCN(C)C)CC4)c3)c2c1,CHEMBL4311953,Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF.,J Med Chem,2019.0,62,17,7684,7696,10.1021/acs.jmedchem.9b00326,31369707.0,
18903831,CHEMBL4533341,"rel-(2R,4S,4aS)-11-Fluoro-2,4-dimethyl-8-(5-oxo-4-oxa-6-azaspiro[2.4]heptan-6-yl)-1,2,4,4a-tetrahydro-2'H,6H-spiro-[isoxazolo[4,5-g][1,4]oxazino[4,3-a]quinoline-5,5'-pyrimidine]-2',4',6'(1'H,3'H)-trione",CHEMBL4316972,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate preincubated for 10 mins followed by NADPH addition and measured for 15 mins by LC-MS/MS analysis,IC50,>,25000.0,nM,C[C@@H]1O[C@H](C)CN2c3c(cc4c(N5CC6(CC6)OC5=O)noc4c3F)CC3(C(=O)NC(=O)NC3=O)[C@@H]12,CHEMBL4316588,"Design, Synthesis, and Biological Evaluation of Novel DNA Gyrase-Inhibiting Spiropyrimidinetriones as Potent Antibiotics for Treatment of Infections Caused by Multidrug-Resistant Gram-Positive Bacteria.",J Med Chem,2019.0,62,6,2950,2973,10.1021/acs.jmedchem.8b01750,30698430.0,
18920015,CHEMBL4557670,"N-(3-((4R,5R,6R)-2-Amino-5-fluoro-4,6-dimethyl-5,6-dihydro-4H-1,3-thiazin-4-yl)-4-fluorophenyl)-5-(fluoromethoxy)pyrazine-2-carboxamide",CHEMBL4322988,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate incubated for 15 mins in presence of NADPH by LC/MS/MS analysis,IC50,=,3500.0,nM,C[C@H]1SC(N)=N[C@](C)(c2cc(NC(=O)c3cnc(OCF)cn3)ccc2F)[C@H]1F,CHEMBL4321815,Discovery of an Extremely Potent Thiazine-Based β-Secretase Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose.,J Med Chem,2019.0,62,20,9331,9337,10.1021/acs.jmedchem.9b01140,31549838.0,
18920112,CHEMBL4557670,"N-(3-((4R,5R,6R)-2-Amino-5-fluoro-4,6-dimethyl-5,6-dihydro-4H-1,3-thiazin-4-yl)-4-fluorophenyl)-5-(fluoromethoxy)pyrazine-2-carboxamide",CHEMBL4323079,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate incubated for 15 mins in presence of NADPH by fluorescence method,IC50,=,3500.0,nM,C[C@H]1SC(N)=N[C@](C)(c2cc(NC(=O)c3cnc(OCF)cn3)ccc2F)[C@H]1F,CHEMBL4321815,Discovery of an Extremely Potent Thiazine-Based β-Secretase Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose.,J Med Chem,2019.0,62,20,9331,9337,10.1021/acs.jmedchem.9b01140,31549838.0,
18922721,CHEMBL4537998,"(5S)-5-(4-Chlorophenyl)-N-[4-(4-fluorophenoxy)phenyl]-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxamide",CHEMBL4323815,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate by LC-MS/MS analysis,IC50,=,4400.0,nM,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@@H]1c1ccc(Cl)cc1,CHEMBL4321836,"Discovery of BAY-298 and BAY-899: Tetrahydro-1,6-naphthyridine-Based, Potent, and Selective Antagonists of the Luteinizing Hormone Receptor Which Reduce Sex Hormone Levels in Vivo.",J Med Chem,2019.0,62,22,10321,10341,10.1021/acs.jmedchem.9b01382,31670515.0,
18922722,CHEMBL4458424,"(5S)-N-[2-(4-Fluorophenoxy)pyrimidin-5-yl]-5-(4-fluorophenyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxamide",CHEMBL4323815,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate by LC-MS/MS analysis,IC50,=,9900.0,nM,O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1,CHEMBL4321836,"Discovery of BAY-298 and BAY-899: Tetrahydro-1,6-naphthyridine-Based, Potent, and Selective Antagonists of the Luteinizing Hormone Receptor Which Reduce Sex Hormone Levels in Vivo.",J Med Chem,2019.0,62,22,10321,10341,10.1021/acs.jmedchem.9b01382,31670515.0,
18923194,CHEMBL4447631,2-((1-(2-Fluoro-4-((4-(1-isopropyl-1H-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)phenyl)piperidin-4-yl)(methyl)-amino)ethan-1-ol,CHEMBL4323965,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,78100.0,nM,Cc1cnc(Nc2ccc(N3CCC(N(C)CCO)CC3)c(F)c2)nc1-c1cnn(C(C)C)c1,CHEMBL4321837,Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.,J Med Chem,2019.0,62,22,10305,10320,10.1021/acs.jmedchem.9b01348,31670517.0,
18924698,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4324280,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in pooled human liver microsomes pre-incubated for 5 mins before NADPH addition and measured after 10 mins by UPLC-MS/MS analysis relative to control,IC50,=,685.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4321845,Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.,J Med Chem,2019.0,62,23,10563,10582,10.1021/acs.jmedchem.9b01562,31710479.0,
18926313,CHEMBL4521594,N-[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide,CHEMBL4324763,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate by LC-MS/MS analysis,IC50,=,4600.0,nM,NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1,CHEMBL4321858,Discovery and Characterization of the Potent and Selective P2X4 Inhibitor <i>N</i>-[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and Structure-Guided Amelioration of Its CYP3A4 Induction Profile.,J Med Chem,2019.0,62,24,11194,11217,10.1021/acs.jmedchem.9b01304,31746599.0,
18927993,CHEMBL4590564,"(2R)-4-[6-[4-(1-aminocyclopropyl)buta-1,3-diynyl]-3-oxo-1H-pyrrolo[1,2-c]imidazol-2-yl]-2-methyl-2-methylsulfonyl-butanehydroxamic acid",CHEMBL4325064,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@@](CCN1Cc2cc(C#CC#CC3(N)CC3)cn2C1=O)(C(=O)NO)S(C)(=O)=O,CHEMBL4321867,Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.,J Med Chem,2020.0,63,1,88,102,10.1021/acs.jmedchem.9b01605,31804829.0,
18927994,CHEMBL4520045,"(2R)-N-Hydroxy-2-methyl-4-(6-((1-methylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-(methylsulfonyl)butanamide",CHEMBL4325064,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CN1CC(C#CC#Cc2cc3n(c2)C(=O)N(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C3)C1,CHEMBL4321867,Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.,J Med Chem,2020.0,63,1,88,102,10.1021/acs.jmedchem.9b01605,31804829.0,
18927995,CHEMBL4457739,"(2R)-4-(6-((1-(2-Fluoroethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide",CHEMBL4325064,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@@](CCN1Cc2cc(C#CC#CC3CN(CCF)C3)cn2C1=O)(C(=O)NO)S(C)(=O)=O,CHEMBL4321867,Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.,J Med Chem,2020.0,63,1,88,102,10.1021/acs.jmedchem.9b01605,31804829.0,
18927996,CHEMBL4437135,"(2R)-N-Hydroxy-4-(6-((1-(2-hydroxyethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide",CHEMBL4325064,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@@](CCN1Cc2cc(C#CC#CC3CN(CCO)C3)cn2C1=O)(C(=O)NO)S(C)(=O)=O,CHEMBL4321867,Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.,J Med Chem,2020.0,63,1,88,102,10.1021/acs.jmedchem.9b01605,31804829.0,
18927997,CHEMBL4438243,"(2R)-N-Hydroxy-4-(6-(((1S,2S)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2(methylsulfonyl)butanamide",CHEMBL4325064,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@@](CCN1Cc2cc(C#CC#C[C@H]3C[C@@H]3CO)cn2C1=O)(C(=O)NO)S(C)(=O)=O,CHEMBL4321867,Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.,J Med Chem,2020.0,63,1,88,102,10.1021/acs.jmedchem.9b01605,31804829.0,
18927998,CHEMBL3754389,"(R)-4-(6-(((1S,2S)-2-fluoro-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide",CHEMBL4325064,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@@](CCN1Cc2cc(C#CC#C[C@@H]3C[C@@]3(F)CO)cn2C1=O)(C(=O)NO)S(C)(=O)=O,CHEMBL4321867,Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.,J Med Chem,2020.0,63,1,88,102,10.1021/acs.jmedchem.9b01605,31804829.0,
18927999,CHEMBL4456704,"(2R)-4-(6-(((1S,2S)-2-((R)-1,2-Dihydroxyethyl)cyclopropyl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide",CHEMBL4325064,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@@](CCN1Cc2cc(C#CC#C[C@H]3C[C@@H]3[C@@H](O)CO)cn2C1=O)(C(=O)NO)S(C)(=O)=O,CHEMBL4321867,Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.,J Med Chem,2020.0,63,1,88,102,10.1021/acs.jmedchem.9b01605,31804829.0,
18932360,CHEMBL3707245,OMIDENEPAG,CHEMBL4326161,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 using 7-methoxy-4-(trifluoromethyl)coumarin fluorescent substrate in presence of NADPH-generating system after 15 mins,IC50,>,20000.0,nM,O=C(O)CNc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)n1,CHEMBL4325826,"Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl.",J Med Chem,2018.0,61,15,6869,6891,10.1021/acs.jmedchem.8b00808,29995405.0,
18939380,CHEMBL2006299,SID103904582,CHEMBL4328673,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of C-terminal 4His-tagged CYP2C9 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,IC50,=,120.0,nM,COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1,CHEMBL4325872,Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.,J Med Chem,2018.0,61,24,11074,11100,10.1021/acs.jmedchem.8b01098,30384606.0,
18939381,CHEMBL4454552,N-(3-Ethoxybenzyl)-4-(pyridin-4-yl)benzamide,CHEMBL4328673,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of C-terminal 4His-tagged CYP2C9 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,IC50,=,480.0,nM,CCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1,CHEMBL4325872,Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.,J Med Chem,2018.0,61,24,11074,11100,10.1021/acs.jmedchem.8b01098,30384606.0,
18939382,CHEMBL4476761,N-(3-Propoxybenzyl)-4-(pyridin-4-yl)benzamide,CHEMBL4328673,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of C-terminal 4His-tagged CYP2C9 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,IC50,=,260.0,nM,CCCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1,CHEMBL4325872,Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.,J Med Chem,2018.0,61,24,11074,11100,10.1021/acs.jmedchem.8b01098,30384606.0,
18939383,CHEMBL4522042,"N-((2,3-Dihydrobenzo[b][1,4]dioxin-5-yl)methyl)-4-(pyridin-4-yl)benzamide",CHEMBL4328673,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of C-terminal 4His-tagged CYP2C9 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,IC50,=,2040.0,nM,O=C(NCc1cccc2c1OCCO2)c1ccc(-c2ccncc2)cc1,CHEMBL4325872,Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.,J Med Chem,2018.0,61,24,11074,11100,10.1021/acs.jmedchem.8b01098,30384606.0,
18939384,CHEMBL4436040,N-(3-(3-(Dimethylamino)propoxy)benzyl)-4-(pyridin-4-yl)-benzamide,CHEMBL4328673,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of C-terminal 4His-tagged CYP2C9 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,IC50,=,16000.0,nM,CN(C)CCCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1,CHEMBL4325872,Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.,J Med Chem,2018.0,61,24,11074,11100,10.1021/acs.jmedchem.8b01098,30384606.0,
18939385,CHEMBL4448806,(R)-N-(1-(3-Methoxyphenyl)ethyl)-4-(pyridin-4-yl)-benzamide,CHEMBL4328673,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of C-terminal 4His-tagged CYP2C9 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,IC50,=,640.0,nM,COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2)c1,CHEMBL4325872,Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.,J Med Chem,2018.0,61,24,11074,11100,10.1021/acs.jmedchem.8b01098,30384606.0,
18939386,CHEMBL4474946,(R)-4-(2-Aminopyridin-4-yl)-N-(1-(3-methoxyphenyl)ethyl)-benzamide,CHEMBL4328673,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of C-terminal 4His-tagged CYP2C9 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,IC50,>,20000.0,nM,COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(N)c3)cc2)c1,CHEMBL4325872,Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.,J Med Chem,2018.0,61,24,11074,11100,10.1021/acs.jmedchem.8b01098,30384606.0,
18939387,CHEMBL4459800,(R)-4-(2-Fluoropyridin-4-yl)-N-(1-(3-methoxyphenyl)ethyl)-benzamide,CHEMBL4328673,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of C-terminal 4His-tagged CYP2C9 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,IC50,=,18100.0,nM,COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(F)c3)cc2)c1,CHEMBL4325872,Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.,J Med Chem,2018.0,61,24,11074,11100,10.1021/acs.jmedchem.8b01098,30384606.0,
18939388,CHEMBL4472858,(R)-4-(3-Fluoropyridin-4-yl)-N-(1-(3-methoxyphenyl)ethyl)-benzamide,CHEMBL4328673,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of C-terminal 4His-tagged CYP2C9 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,IC50,=,7700.0,nM,COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3F)cc2)c1,CHEMBL4325872,Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.,J Med Chem,2018.0,61,24,11074,11100,10.1021/acs.jmedchem.8b01098,30384606.0,
18939389,CHEMBL4460511,(R)-N-(1-(3-Methoxyphenyl)ethyl)-4-(pyrimidin-4-yl)-benzamide,CHEMBL4328673,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of C-terminal 4His-tagged CYP2C9 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,IC50,=,6000.0,nM,COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2)c1,CHEMBL4325872,Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.,J Med Chem,2018.0,61,24,11074,11100,10.1021/acs.jmedchem.8b01098,30384606.0,
18939390,CHEMBL4584824,(R)-N-(1-(3-Methoxyphenyl)ethyl)-4-(pyridazin-4-yl)-benzamide,CHEMBL4328673,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of C-terminal 4His-tagged CYP2C9 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,IC50,>,20000.0,nM,COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnnc3)cc2)c1,CHEMBL4325872,Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.,J Med Chem,2018.0,61,24,11074,11100,10.1021/acs.jmedchem.8b01098,30384606.0,
18945543,CHEMBL4301600,"2-(3-(1-(4-Chlorophenyl)cyclopropyl)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)propan-2-ol",CHEMBL4329715,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,30000.0,nM,CC(C)(O)c1cccn2c(C3(c4ccc(Cl)cc4)CC3)nnc12,CHEMBL4325920,Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1).,ACS Med Chem Lett,2018.0,9,12,1170,1174,10.1021/acsmedchemlett.8b00307,30613321.0,
18954201,CHEMBL4445670,"[2-Amino-4-(trifluoromethoxy)phenyl]{4-[7-(4-methylpiperazin-1-yl)pyrido[3,2-d]pyrimidin-4-yl]piperidin-1-yl}methanone",CHEMBL4332043,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate by LC-MS/MS analysis,IC50,>,20000.0,nM,CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1,CHEMBL4330097,"Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.",J Med Chem,2019.0,62,2,928,940,10.1021/acs.jmedchem.8b01606,30563338.0,
18954318,CHEMBL4591100,"N4-((5s,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl)-N6-(2-fluoro-4-(methylsulfonyl)phenyl)pyrimidine-4,6-diamine",CHEMBL4332063,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC1(C)C[C@]2(CC[C@H](Nc3cc(Nc4ccc(S(C)(=O)=O)cc4F)ncn3)CC2)CO1,CHEMBL4330099,Lead generation and optimization of novel GPR119 agonists with a spirocyclic cyclohexane structure.,Bioorg Med Chem Lett,2019.0,29,3,373,379,10.1016/j.bmcl.2018.12.041,30587450.0,
18954817,CHEMBL4449687,"2-(4-ethoxy-4'-(3-(4-(2-fluorophenyl)-5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)biphenyl-3-yl)acetic acid",CHEMBL4332170,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8200.0,nM,CCOc1ccc(-c2ccc(CCCc3nn(-c4ccc(C(F)(F)F)cc4)c(=O)n3-c3ccccc3F)cc2)cc1CC(=O)O,CHEMBL4330102,Discovery of potent and selective PPARα/δ dual antagonists and initial biological studies.,Bioorg Med Chem Lett,2019.0,29,3,503,508,10.1016/j.bmcl.2018.12.045,30594433.0,
18957630,CHEMBL4471264,"1-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)anthracene-9,10-dione hydrochloride",CHEMBL4333060,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylation by tandem mass spectrometry analysis,IC50,>,50000.0,nM,Cl.O=C1c2ccccc2C(=O)c2c1cccc2-c1cnn(C2CCNCC2)c1,CHEMBL4330127,Discovery of Novel Pyruvate Dehydrogenase Kinase 4 Inhibitors for Potential Oral Treatment of Metabolic Diseases.,J Med Chem,2019.0,62,2,575,588,10.1021/acs.jmedchem.8b01168,30623649.0,
18959930,CHEMBL4447340,(S)-2-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-3-(3-hydroxyphenyl)-4-methyl-2H-chromen-6-ol,CHEMBL4333869,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3200.0,nM,CC1=C(c2cccc(O)c2)[C@H](c2ccc(OCCN3CC(CF)C3)cc2)Oc2ccc(O)cc21,CHEMBL4330143,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,ACS Med Chem Lett,2019.0,10,1,50,55,10.1021/acsmedchemlett.8b00414,30655946.0,
18975620,CHEMBL4463581,"((3aR,9bR)-9b-((4-Fluorophenyl)sulfonyl)-7-(perfluoropropan-2-yl)-1,2,3a,4,5,9b-hexahydro-3H-benzo[e]indol-3-yl) (4-hydroxy-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methanone",CHEMBL4338086,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin),IC50,=,10000.0,nM,O=C(N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12)C1(O)CCS(=O)(=O)CC1,CHEMBL4334512,"Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy.",J Med Chem,2019.0,62,21,9931,9946,10.1021/acs.jmedchem.9b01369,31638797.0,
18980179,CHEMBL4463663,"2-amino-4-fluoro-5-((4-hydroxypiperidin-1-yl)sulfonyl)-N-(3,4,5-trifluorophenyl)benzamide",CHEMBL4338997,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using tolubutamide as substrate by LC/MS/MS analysis,IC50,=,17020.0,nM,Nc1cc(F)c(S(=O)(=O)N2CCC(O)CC2)cc1C(=O)Nc1cc(F)c(F)c(F)c1,CHEMBL4334551,Discovery of a New Sulfonamide Hepatitis B Capsid Assembly Modulator.,ACS Med Chem Lett,2020.0,11,2,166,171,10.1021/acsmedchemlett.9b00550,32071684.0,
18980268,CHEMBL4514379,"6-[5-(3-chloro-4-fluoro-phenyl)-3-(2-hydroxyethyl)imidazol-4-yl]imidazo[1,2-b]pyridazine-3-carbonitrile",CHEMBL4339057,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin),IC50,>,20000.0,nM,N#Cc1cnc2ccc(-c3c(-c4ccc(F)c(Cl)c4)ncn3CCO)nn12,CHEMBL4334552,"Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent.",ACS Med Chem Lett,2020.0,11,2,172,178,10.1021/acsmedchemlett.9b00552,32071685.0,
18980477,CHEMBL4585089,"(Z)-N-(2-((4-(N-(3-chlorophenyl)-N'-hydroxycarbamimidoyl)-1,2,5-oxadiazol-3-yl)thio)ethyl)-2-sulfamoylacetamide",CHEMBL4339126,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,NS(=O)(=O)CC(=O)NCCSc1nonc1/C(=N/O)Nc1cccc(Cl)c1,CHEMBL4334553,Discovery of Hydroxyamidine Based Inhibitors of IDO1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation.,ACS Med Chem Lett,2020.0,11,2,179,187,10.1021/acsmedchemlett.9b00572,32071686.0,
18980481,CHEMBL4549976,"N-(2-((4-(N-(3-(Difluoromethyl)-4-fluorophenyl)-N'-hydroxycarbamimidoyl)-1,2,5-oxadiazol-3-yl)thio)ethyl)-2-(sulfamoylamino)acetamide",CHEMBL4339126,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,NS(=O)(=O)NCC(=O)NCCSc1nonc1/C(=N/O)Nc1ccc(F)c(C(F)F)c1,CHEMBL4334553,Discovery of Hydroxyamidine Based Inhibitors of IDO1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation.,ACS Med Chem Lett,2020.0,11,2,179,187,10.1021/acsmedchemlett.9b00572,32071686.0,
18983848,CHEMBL4443868,"1-(azetidin-1-yl)-2-(6-(4-fluoro-3-methylphenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)ethanone",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,Cc1cc(-c2cnc3ccn(CC(=O)N4CCC4)c3c2)ccc1F,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983849,CHEMBL4588774,"2-(6-(4-fluoro-3-methylphenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-1-(piperidin-1-yl)ethanone",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,1200.0,nM,Cc1cc(-c2cnc3ccn(CC(=O)N4CCCCC4)c3c2)ccc1F,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983850,CHEMBL4550955,"2-(6-(4-fluoro-3-methylphenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-1-(pyrrolidin-1-yl)ethanone",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,2700.0,nM,Cc1cc(-c2cnc3ccn(CC(=O)N4CCCC4)c3c2)ccc1F,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983851,CHEMBL4445829,"2-(6-(4-fluoro-3-methylphenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-1-(3-fluoroazetidin-1-yl)ethanone",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,8700.0,nM,Cc1cc(-c2cnc3ccn(CC(=O)N4CC(F)C4)c3c2)ccc1F,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983852,CHEMBL4302264,"2-(6-(4-fluoro-3-methylphenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-N,N-dimethylacetamide",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,Cc1cc(-c2cnc3ccn(CC(=O)N(C)C)c3c2)ccc1F,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983853,CHEMBL4539619,"6-(4-fluoro-3-methylphenyl)-1-(pyridin-2-ylmethyl)-1H-pyrrolo[3,2-b]pyridine",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,3200.0,nM,Cc1cc(-c2cnc3ccn(Cc4ccccn4)c3c2)ccc1F,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983854,CHEMBL4590530,"2-((6-(4-fluoro-3-methylphenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)methyl)-5-methyl-1,3,4-oxadiazole",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,Cc1nnc(Cn2ccc3ncc(-c4ccc(F)c(C)c4)cc32)o1,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983855,CHEMBL4471014,"5-((6-(4-fluoro-3-methylphenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)methyl)-3-methyl-1,2,4-oxadiazole",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,2900.0,nM,Cc1noc(Cn2ccc3ncc(-c4ccc(F)c(C)c4)cc32)n1,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983856,CHEMBL4526512,"2-((6-(4-fluoro-3-methylphenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)methyl)oxazole",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,7100.0,nM,Cc1cc(-c2cnc3ccn(Cc4ncco4)c3c2)ccc1F,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983857,CHEMBL4446706,"6-(4-fluoro-3-methylphenyl)-1-((tetrahydrofuran-3-yl)methyl)-1H-pyrrolo[3,2-b]pyridine",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,3400.0,nM,Cc1cc(-c2cnc3ccn(CC4CCOC4)c3c2)ccc1F,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983858,CHEMBL4537967,"1-(cyclobutylmethyl)-6-(4-fluoro-3-methylphenyl)-1H-pyrrolo[3,2-b]pyridine",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,2600.0,nM,Cc1cc(-c2cnc3ccn(CC4CCC4)c3c2)ccc1F,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983859,CHEMBL4571666,"N,N-dimethyl-2-(6-(3-(trifluoromethyl)phenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)acetamide",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,CN(C)C(=O)Cn1ccc2ncc(-c3cccc(C(F)(F)F)c3)cc21,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983860,CHEMBL4515350,"1-(azetidin-1-yl)-2-(6-(3-(trifluoromethyl)phenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)ethanone",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,5900.0,nM,O=C(Cn1ccc2ncc(-c3cccc(C(F)(F)F)c3)cc21)N1CCC1,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983861,CHEMBL4462073,"N,N-dimethyl-2-(6-(6-(trifluoromethyl)pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)acetamide",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,CN(C)C(=O)Cn1ccc2ncc(-c3cccc(C(F)(F)F)n3)cc21,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983862,CHEMBL4451099,"2-(6-(3-chlorophenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-N,N-dimethylacetamide",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,CN(C)C(=O)Cn1ccc2ncc(-c3cccc(Cl)c3)cc21,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983863,CHEMBL4474982,"N,N-dimethyl-2-(6-m-tolyl-1H-pyrrolo[3,2-b]pyridin-1-yl)acetamide",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,Cc1cccc(-c2cnc3ccn(CC(=O)N(C)C)c3c2)c1,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983864,CHEMBL4593473,"2-(6-(3-chloro-4-fluorophenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-N,N-dimethylacetamide",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,CN(C)C(=O)Cn1ccc2ncc(-c3ccc(F)c(Cl)c3)cc21,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983865,CHEMBL4547576,"2-(6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-N,N-dimethylacetamide",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,CN(C)C(=O)Cn1ccc2ncc(-c3ccc(F)c(C(F)F)c3)cc21,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983866,CHEMBL4591770,"2-(6-(3,4-difluorophenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-N,N-dimethylacetamide",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,CN(C)C(=O)Cn1ccc2ncc(-c3ccc(F)c(F)c3)cc21,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983867,CHEMBL4531750,"N,N-dimethyl-2-(6-(5-(trifluoromethyl)thiophen-2-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)acetamide",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,CN(C)C(=O)Cn1ccc2ncc(-c3ccc(C(F)(F)F)s3)cc21,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983868,CHEMBL4575739,"N,N-dimethyl-2-(6-(5-methylthiophen-2-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)acetamide",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,Cc1ccc(-c2cnc3ccn(CC(=O)N(C)C)c3c2)s1,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983869,CHEMBL4529810,"N,N-dimethyl-2-(6-(4-methylthiophen-2-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)acetamide",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,Cc1csc(-c2cnc3ccn(CC(=O)N(C)C)c3c2)c1,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983870,CHEMBL4211247,"2-(6-(5-chlorothiophen-2-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-N,N-dimethylacetamide",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,10000.0,nM,CN(C)C(=O)Cn1ccc2ncc(-c3ccc(Cl)s3)cc21,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983871,CHEMBL4451514,"2-(6-(4-chloro-3-methylphenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-N,N-dimethylacetamide",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,9300.0,nM,Cc1cc(-c2cnc3ccn(CC(=O)N(C)C)c3c2)ccc1Cl,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18983872,CHEMBL4475155,"N-cyclopropyl-2-(6-(3-(trifluoromethyl)phenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)acetamide",CHEMBL4339661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,1800.0,nM,O=C(Cn1ccc2ncc(-c3cccc(C(F)(F)F)c3)cc21)NC1CC1,CHEMBL4339196,"1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.",ACS Med Chem Lett,2019.0,10,3,261,266,10.1021/acsmedchemlett.8b00542,30891123.0,
18984042,CHEMBL4443161,"5-(2-(4-fluorophenyl)-8-morpholinoimidazo[1,2-a]pyrazin-3-yl)indolin-2-one",CHEMBL4339692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 15 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,500.0,nM,O=C1Cc2cc(-c3c(-c4ccc(F)cc4)nc4c(N5CCOCC5)nccn34)ccc2N1,CHEMBL4339197,"Discovery of Imidazo[1,2-a]pyrazines and Pyrazolo[1,5-c]pyrimidines as TARP γ-8 Selective AMPAR Negative Modulators.",ACS Med Chem Lett,2019.0,10,3,267,272,10.1021/acsmedchemlett.8b00599,30891124.0,
18984079,CHEMBL4439877,"4-(2-(4-fluorophenyl)-3-(1H-indazol-5-yl)imidazo[1,2-a]pyrazin-8-yl)morpholine",CHEMBL4339692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 15 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,500.0,nM,Fc1ccc(-c2nc3c(N4CCOCC4)nccn3c2-c2ccc3[nH]ncc3c2)cc1,CHEMBL4339197,"Discovery of Imidazo[1,2-a]pyrazines and Pyrazolo[1,5-c]pyrimidines as TARP γ-8 Selective AMPAR Negative Modulators.",ACS Med Chem Lett,2019.0,10,3,267,272,10.1021/acsmedchemlett.8b00599,30891124.0,
18984080,CHEMBL4436028,"5-(2-(4-fluorophenyl)-7-(4-hydroxypiperidin-1-yl)pyrazolo[1,5-c]pyrimidin-3-yl)indolin-2-one",CHEMBL4339692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 15 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,1900.0,nM,O=C1Cc2cc(-c3c(-c4ccc(F)cc4)nn4c(N5CCC(O)CC5)nccc34)ccc2N1,CHEMBL4339197,"Discovery of Imidazo[1,2-a]pyrazines and Pyrazolo[1,5-c]pyrimidines as TARP γ-8 Selective AMPAR Negative Modulators.",ACS Med Chem Lett,2019.0,10,3,267,272,10.1021/acsmedchemlett.8b00599,30891124.0,
18984555,CHEMBL3934548,"US9458171, 95",CHEMBL4339788,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4339200,"Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse Agonists.",ACS Med Chem Lett,2019.0,10,3,367,373,10.1021/acsmedchemlett.9b00010,30891142.0,
19000090,CHEMBL4560579,"N-(3-((1S,5S,6S)-3-Amino-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-(prop-2-yn-1-yloxy)pyrazine-2-carboxamide",CHEMBL4343473,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,25000.0,nM,C#CCOc1cnc(C(=O)Nc2cc(F)c(F)c([C@@]3(C)N=C(N)S[C@@]4(COC)C[C@H]43)c2)cn1,CHEMBL4342420,Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2.,J Med Chem,2020.0,63,5,2263,2281,10.1021/acs.jmedchem.9b01034,31589043.0,
19010878,CHEMBL4449082,"6-(cis-2,6-Dimethylmorpholino)-4-fluoro-1-methyl-1'-(8-methyl-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-2-yl)spiro[indoline-3,4'-piperidin]-2-one",CHEMBL4345454,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition and measured for 10 to 30 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@H]1CN(c2cc(F)c3c(c2)N(C)C(=O)C32CCN(c3nc4c(c(=O)[nH]3)CCCN4C)CC2)C[C@@H](C)O1,CHEMBL4342498,Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.,J Med Chem,2020.0,63,8,4183,4204,10.1021/acs.jmedchem.0c00045,32202790.0,
19032763,CHEMBL4454027,"4-[3-(2,6-dichlorobenzoyl)indol-1-yl]benzoic acid",CHEMBL4349922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,3800.0,nM,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3ccccc32)cc1,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19032764,CHEMBL3609407,"N-(2,6-dichloro-2'-(trifluoromethoxy)biphenyl-4-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide",CHEMBL4349922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,2100.0,nM,CCS(=O)(=O)c1ccc(CC(=O)Nc2cc(Cl)c(-c3ccccc3OC(F)(F)F)c(Cl)c2)cc1,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19032765,CHEMBL4570491,"4-[3-(2,6-dichlorobenzoyl)indol-1-yl]-3-fluoro-benzoic acid",CHEMBL4349922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,5900.0,nM,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3ccccc32)c(F)c1,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19032776,CHEMBL4520100,4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indol-1-yl]benzoic acid,CHEMBL4349922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,16000.0,nM,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3ccccc32)cc1,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19032777,CHEMBL4475634,4-(3-(2-chloro-6-fluorobenzoyl)-1H-indol-1-yl)benzoic acid,CHEMBL4349922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,9000.0,nM,O=C(O)c1ccc(-n2cc(C(=O)c3c(F)cccc3Cl)c3ccccc32)cc1,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19032781,CHEMBL4476185,4-[3-(2-chloro-6-methyl-benzoyl)indol-1-yl]benzoic acid,CHEMBL4349922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,13500.0,nM,Cc1cccc(Cl)c1C(=O)c1cn(-c2ccc(C(=O)O)cc2)c2ccccc12,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19032783,CHEMBL4446695,"4-[3-(2,6-dichlorobenzoyl)-4-fluoro-indol-1-yl]benzoic acid",CHEMBL4349922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3c(F)cccc32)cc1,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19032793,CHEMBL4567440,4-(3-(2-chloro-6-(trifluoromethyl)benzoyl)-7-fluoro-1H-indol-1-yl)benzoic acid,CHEMBL4349922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,9900.0,nM,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3cccc(F)c32)cc1,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19032794,CHEMBL4455132,"4-(3-(2,6-dichlorobenzoyl)-7-fluoro-1H-indol-1-yl)-3-fluorobenzoic acid",CHEMBL4349922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,6400.0,nM,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccc(F)c32)c(F)c1,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19032796,CHEMBL4438970,"4-(3-(2,6-dichlorobenzoyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-fluorobenzoic acid",CHEMBL4349922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,16000.0,nM,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccnc32)c(F)c1,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19032798,CHEMBL4466120,4-(3-(2-chloro-6-methylbenzoyl)-7-fluoro-1H-indol-1-yl)benzoic acid,CHEMBL4349922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,31970.0,nM,Cc1cccc(Cl)c1C(=O)c1cn(-c2ccc(C(=O)O)cc2)c2c(F)cccc12,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19032801,CHEMBL4452714,"4-(3-(2,6-dichlorobenzoyl)-4-fluoro-1H-indol-1-yl)-3-fluorobenzoic acid",CHEMBL4349922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,8010.0,nM,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3c(F)cccc32)c(F)c1,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19032802,CHEMBL4577020,4-(3-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indol-1-yl)benzoic acid,CHEMBL4349922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,22600.0,nM,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3c(F)cccc32)cc1,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19032803,CHEMBL4577409,4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoro-indol-1-yl]-3-fluoro-benzoic acid,CHEMBL4349922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,20300.0,nM,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3c(F)cccc32)c(F)c1,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19032805,CHEMBL4556521,"4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]pyrrolo[2,3-b]pyridin-1-yl]-3-fluoro-benzoic acid",CHEMBL4349922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,17200.0,nM,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3cccnc32)c(F)c1,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19032806,CHEMBL4578385,"4-(3-(2,6-dichlorobenzoyl)-7-fluoro-1H-indol-1-yl)benzoic acid",CHEMBL4349922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,IC50,=,11100.0,nM,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccc(F)c32)cc1,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19033386,CHEMBL4578385,"4-(3-(2,6-dichlorobenzoyl)-7-fluoro-1H-indol-1-yl)benzoic acid",CHEMBL4350028,A,,Homo sapiens,Cytochrome P450 2C9,Time-dependent inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate in presence of NADPH measured after 30 mins by LC-MS/MS analysis,IC50,>,17000.0,nM,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccc(F)c32)cc1,CHEMBL4346735,Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.,Bioorg Med Chem Lett,2019.0,29,16,2208,2217,10.1016/j.bmcl.2019.06.044,31272795.0,
19036492,CHEMBL4437341,N-(4-(4-(3-cyanophenyl)piperazin-1-yl)butyl)-4-(thiophen-3-yl)benzamide,CHEMBL4350900,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,N#Cc1cccc(N2CCN(CCCCNC(=O)c3ccc(-c4ccsc4)cc3)CC2)c1,CHEMBL4346764,"Design, synthesis, and evaluation of N-(4-(4-phenyl piperazin-1-yl)butyl)-4-(thiophen-3-yl)benzamides as selective dopamine D<sub>3</sub> receptor ligands.",Bioorg Med Chem Lett,2019.0,29,18,2690,2694,10.1016/j.bmcl.2019.07.020,31387791.0,
19037158,CHEMBL4450838,"1-Methyl-4-({(1R,2R)-2-[4-(5-methyl-1H-pyrazol-3-yl)benzoyl]cyclohexane-1-carbonyl}amino)-1H-pyrazole-3-carboxamide",CHEMBL4351255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in Escherichia coli assessed as maximum reduction in metabolite formation using coumarin based substrate by fluorescence assay,IC50,=,10000.0,nM,Cc1cc(-c2ccc(C(=O)[C@@H]3CCCC[C@H]3C(=O)Nc3cn(C)nc3C(N)=O)cc2)[nH]n1,CHEMBL4350955,Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease.,J Med Chem,2019.0,62,9,4325,4349,10.1021/acs.jmedchem.8b02012,30929436.0,
19037159,CHEMBL4555790,"(1R,2R)-N-(3-Cyano-1-methyl-1H-pyrazol-4-yl)-2-[4-(5-methyl-1H-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide",CHEMBL4351255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in Escherichia coli assessed as maximum reduction in metabolite formation using coumarin based substrate by fluorescence assay,IC50,=,7943.28,nM,Cc1cc(-c2ccc(C(=O)[C@@H]3CCCC[C@H]3C(=O)Nc3cn(C)nc3C#N)cc2)n[nH]1,CHEMBL4350955,Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease.,J Med Chem,2019.0,62,9,4325,4349,10.1021/acs.jmedchem.8b02012,30929436.0,
19037160,CHEMBL4534060,"(1R,2R)-N-[1-Methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]-2-[4-(1H-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide",CHEMBL4351255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in Escherichia coli assessed as maximum reduction in metabolite formation using coumarin based substrate by fluorescence assay,IC50,=,6309.57,nM,Cn1ncc(NC(=O)[C@@H]2CCCC[C@H]2C(=O)c2ccc(-c3cc[nH]n3)cc2)c1C(F)(F)F,CHEMBL4350955,Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease.,J Med Chem,2019.0,62,9,4325,4349,10.1021/acs.jmedchem.8b02012,30929436.0,
19037219,CHEMBL4472842,"1-Methyl-4-({(1R,2R)-2-[6-(5-methyl-1H-pyrazol-3-yl)-1,2-benzoxazol-3-yl]cyclohexane-1-carbonyl}amino)-1H-pyrazole-3-carboxamide",CHEMBL4351255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in Escherichia coli assessed as maximum reduction in metabolite formation using coumarin based substrate by fluorescence assay,IC50,=,7943.28,nM,Cc1cc(-c2ccc3c([C@@H]4CCCC[C@H]4C(=O)Nc4cn(C)nc4C(N)=O)noc3c2)n[nH]1,CHEMBL4350955,Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease.,J Med Chem,2019.0,62,9,4325,4349,10.1021/acs.jmedchem.8b02012,30929436.0,
19037220,CHEMBL4527700,"(1S,3R,4R,6R)-N-[1-Methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]-4-[4-(1H-pyrazol-3-yl)benzoyl]bicyclo[4.1.0]heptane-3-carboxamide",CHEMBL4351255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in Escherichia coli assessed as maximum reduction in metabolite formation using coumarin based substrate by fluorescence assay,IC50,=,5011.87,nM,Cn1ncc(NC(=O)[C@@H]2C[C@@H]3C[C@@H]3C[C@H]2C(=O)c2ccc(-c3cc[nH]n3)cc2)c1C(F)(F)F,CHEMBL4350955,Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease.,J Med Chem,2019.0,62,9,4325,4349,10.1021/acs.jmedchem.8b02012,30929436.0,
19037221,CHEMBL4528662,"(1R,2R)-N-(6-Methoxypyrimidin-4-yl)-2-[4-(1H-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide",CHEMBL4351255,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in Escherichia coli assessed as maximum reduction in metabolite formation using coumarin based substrate by fluorescence assay,IC50,=,5011.87,nM,COc1cc(NC(=O)[C@@H]2CCCC[C@H]2C(=O)c2ccc(-c3cc[nH]n3)cc2)ncn1,CHEMBL4350955,Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease.,J Med Chem,2019.0,62,9,4325,4349,10.1021/acs.jmedchem.8b02012,30929436.0,
19039536,CHEMBL3647536,"US8952008, 4",CHEMBL4351546,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,11000.0,nM,CCn1cnc2c(-c3ccc(F)c(-c4ccc(S(=O)(=O)CC)cc4OC)c3)cnnc21,CHEMBL4350959,"Design and Identification of a Novel, Functionally Subtype Selective GABA<sub>A</sub> Positive Allosteric Modulator (PF-06372865).",J Med Chem,2019.0,62,12,5773,5796,10.1021/acs.jmedchem.9b00322,30964988.0,
19039537,CHEMBL4545044,"5-[5-(7-Ethyl-7H-imidazo[4,5-c]pyridazin-4-yl)-2-fluorophenyl]-6-methoxy-2-methyl-2,3-dihydro-1H-isoindol-1-one",CHEMBL4351546,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,14500.0,nM,CCn1cnc2c(-c3ccc(F)c(-c4cc5c(cc4OC)C(=O)N(C)C5)c3)cnnc21,CHEMBL4350959,"Design and Identification of a Novel, Functionally Subtype Selective GABA<sub>A</sub> Positive Allosteric Modulator (PF-06372865).",J Med Chem,2019.0,62,12,5773,5796,10.1021/acs.jmedchem.9b00322,30964988.0,
19042456,CHEMBL3989870,BERZOSERTIB,CHEMBL4352774,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,CNCc1ccc(-c2cc(-c3nc(-c4ccc(S(=O)(=O)C(C)C)cc4)cnc3N)on2)cc1,CHEMBL4350970,"Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.",J Med Chem,2019.0,62,11,5547,5561,10.1021/acs.jmedchem.9b00426,31074988.0,
19042457,CHEMBL3989870,BERZOSERTIB,CHEMBL4352775,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2D6 (unknown origin),IC50,>,30000.0,nM,CNCc1ccc(-c2cc(-c3nc(-c4ccc(S(=O)(=O)C(C)C)cc4)cnc3N)on2)cc1,CHEMBL4350970,"Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.",J Med Chem,2019.0,62,11,5547,5561,10.1021/acs.jmedchem.9b00426,31074988.0,
19053582,CHEMBL1213603,thiamet-G,CHEMBL4355804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1,CHEMBL4354805,"Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.",J Med Chem,2019.0,62,22,10062,10097,10.1021/acs.jmedchem.9b01090,31487175.0,
19053583,CHEMBL4570378,"(3aR,5R,6S,7R,7aR)-2-(Ethylamino)-5-(methoxymethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d]-thiazole-6,7-diol",CHEMBL4355804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCNC1=N[C@H]2[C@H](O[C@H](COC)[C@@H](O)[C@@H]2O)S1,CHEMBL4354805,"Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.",J Med Chem,2019.0,62,22,10062,10097,10.1021/acs.jmedchem.9b01090,31487175.0,
19053584,CHEMBL4577980,"(3aR,5R,6S,7R,7aR)-2-(Ethylamino)-5-(hydroxymethyl)-6-methoxy-5,6,7,7a-tetrahydro-3aH-pyrano-[3,2-d]thiazol-7-ol",CHEMBL4355804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](OC)[C@@H]2O)S1,CHEMBL4354805,"Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.",J Med Chem,2019.0,62,22,10062,10097,10.1021/acs.jmedchem.9b01090,31487175.0,
19053585,CHEMBL4519186,"(3aR,5R,6S,7R,7aR)-2-(Ethylamino)-5-(hydroxymethyl)-7-methoxy-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d]thiazol-6-ol",CHEMBL4355804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2OC)S1,CHEMBL4354805,"Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.",J Med Chem,2019.0,62,22,10062,10097,10.1021/acs.jmedchem.9b01090,31487175.0,
19053586,CHEMBL4483089,"(3aR,5R,6S,7R,7aR)-2-(Ethyl(methyl)-amino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3aH-pyrano-[3,2-d]thiazole-6,7-diol",CHEMBL4355804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCN(C)C1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1,CHEMBL4354805,"Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.",J Med Chem,2019.0,62,22,10062,10097,10.1021/acs.jmedchem.9b01090,31487175.0,
19053587,CHEMBL4110677,"US9243020, 1",CHEMBL4355804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCNC1=N[C@H]2[C@H](O[C@H](C)[C@@H](O)[C@@H]2O)S1,CHEMBL4354805,"Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.",J Med Chem,2019.0,62,22,10062,10097,10.1021/acs.jmedchem.9b01090,31487175.0,
19053588,CHEMBL4520749,"(3aR,5S,7S,7aR)-2-(Ethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d]thiazol-7-ol",CHEMBL4355804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCNC1=N[C@@H]2[C@@H](O)C[C@@H](CO)O[C@@H]2S1,CHEMBL4354805,"Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.",J Med Chem,2019.0,62,22,10062,10097,10.1021/acs.jmedchem.9b01090,31487175.0,
19053589,CHEMBL4107048,"US9243020, 2",CHEMBL4355804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCNC1=N[C@@H]2C[C@H](O)[C@@H](CO)O[C@@H]2S1,CHEMBL4354805,"Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.",J Med Chem,2019.0,62,22,10062,10097,10.1021/acs.jmedchem.9b01090,31487175.0,
19053590,CHEMBL4543991,"(3aR,5S,6S,7R,7aR)-2-(Ethylamino)-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d]thiazole-6,7-diol",CHEMBL4355804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCNC1=N[C@H]2[C@H](O[C@H](CF)[C@@H](O)[C@@H]2O)S1,CHEMBL4354805,"Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.",J Med Chem,2019.0,62,22,10062,10097,10.1021/acs.jmedchem.9b01090,31487175.0,
19053591,CHEMBL4554360,"(3aR,5R,7R,7aR)-2-(Ethylamino)-6-fluoro-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3aH-pyrano-[3,2-d]thiazol-7-ol",CHEMBL4355804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCNC1=N[C@H]2[C@H](O[C@H](CO)C(F)[C@@H]2O)S1,CHEMBL4354805,"Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.",J Med Chem,2019.0,62,22,10062,10097,10.1021/acs.jmedchem.9b01090,31487175.0,
19053592,CHEMBL4448352,"(3aR,5R,6R,7R,7aR)-2-(Ethylamino)-7-fluoro-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d]thiazol-6-ol",CHEMBL4355804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2F)S1,CHEMBL4354805,"Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.",J Med Chem,2019.0,62,22,10062,10097,10.1021/acs.jmedchem.9b01090,31487175.0,
19054881,CHEMBL4441731,4-(3-(Propylamino)azetidin-1-yl)pyrimidin-2-amine Fumarate Hydrate,CHEMBL4356399,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,CCCNC1CN(c2ccnc(N)n2)C1.O.O=C(O)/C=C/C(=O)O,CHEMBL4354817,4-(3-Aminoazetidin-1-yl)pyrimidin-2-amines as High-Affinity Non-imidazole Histamine H3 Receptor Agonists with in Vivo Central Nervous System Activity.,J Med Chem,2019.0,62,23,10848,10866,10.1021/acs.jmedchem.9b01462,31675226.0,
19061170,CHEMBL4483575,Remibrutinib; N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide,CHEMBL4358507,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>=,5000.0,nM,C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C,CHEMBL4354855,"Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.",J Med Chem,2020.0,63,10,5102,5118,10.1021/acs.jmedchem.9b01916,32083858.0,
19063367,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4359424,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate incubated for 10 mins in presence of NADPH,IC50,=,660.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4354878,Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties.,J Med Chem,2020.0,63,9,4837,4848,10.1021/acs.jmedchem.0c00117,32293182.0,
19063368,CHEMBL175691,"4-{4-[4-((E)-2-Cyano-vinyl)-2,6-dimethyl-phenylamino]-pyrimidin-2-ylamino}-benzonitrile",CHEMBL4359424,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate incubated for 10 mins in presence of NADPH,IC50,=,346.0,nM,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,CHEMBL4354878,Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties.,J Med Chem,2020.0,63,9,4837,4848,10.1021/acs.jmedchem.0c00117,32293182.0,
19063369,CHEMBL4094163,"(E)-4-((4-((4-(4-(2-Cyanovinyl)-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzenesulfonamide",CHEMBL4359424,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate incubated for 10 mins in presence of NADPH,IC50,=,13200.0,nM,Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(S(N)(=O)=O)cc3)CC2)nc2ccsc12,CHEMBL4354878,Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties.,J Med Chem,2020.0,63,9,4837,4848,10.1021/acs.jmedchem.0c00117,32293182.0,
19063370,CHEMBL4526732,"(E)-4-((4-((4-(4-(2-Cyanovinyl)-2,6-dimethylphenoxy)thieno[2,3-d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzenesulfonamide",CHEMBL4359424,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate incubated for 10 mins in presence of NADPH,IC50,=,8370.0,nM,Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(S(N)(=O)=O)cc3)CC2)nc2sccc12,CHEMBL4354878,Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties.,J Med Chem,2020.0,63,9,4837,4848,10.1021/acs.jmedchem.0c00117,32293182.0,
19067802,CHEMBL4459856,"6-fluoro-5-(1-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)-5H-imidazo[5,1-a]isoindole",CHEMBL4360765,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis,IC50,>,10000.0,nM,Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)cc2)cn1,CHEMBL4359827,"Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-dioxygenase Inhibitors.",ACS Med Chem Lett,2019.0,10,6,949,953,10.1021/acsmedchemlett.9b00114,31223453.0,
19067803,CHEMBL4471614,"6-fluoro-5-(1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)-5H-imidazo[5,1-a]isoindole",CHEMBL4360765,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis,IC50,=,940.0,nM,Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)c(F)c2)cn1,CHEMBL4359827,"Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-dioxygenase Inhibitors.",ACS Med Chem Lett,2019.0,10,6,949,953,10.1021/acsmedchemlett.9b00114,31223453.0,
19067804,CHEMBL4445809,"6-fluoro-5-(1-(3-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)-5H-imidazo[5,1-a]isoindole",CHEMBL4360765,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis,IC50,=,7400.0,nM,Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)cc2F)cn1,CHEMBL4359827,"Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-dioxygenase Inhibitors.",ACS Med Chem Lett,2019.0,10,6,949,953,10.1021/acsmedchemlett.9b00114,31223453.0,
19067805,CHEMBL4443301,"6-fluoro-5-(1-(3-methyl-4-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)-5H-imidazo[5,1-a]isoindole",CHEMBL4360765,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis,IC50,=,300.0,nM,Cc1cc(N2CCC(C3c4c(F)cccc4-c4cncn43)CC2)ccc1-c1cnn(C)c1,CHEMBL4359827,"Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-dioxygenase Inhibitors.",ACS Med Chem Lett,2019.0,10,6,949,953,10.1021/acsmedchemlett.9b00114,31223453.0,
19067806,CHEMBL4522927,"(S)-6-fluoro-5-(1-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)-5H-imidazo[5,1-a]isoindole",CHEMBL4360765,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis,IC50,>,30000.0,nM,Cn1cc(-c2ccc(N3CCC([C@H]4c5c(F)cccc5-c5cncn54)CC3)cc2)cn1,CHEMBL4359827,"Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-dioxygenase Inhibitors.",ACS Med Chem Lett,2019.0,10,6,949,953,10.1021/acsmedchemlett.9b00114,31223453.0,
19074782,CHEMBL4475126,"2-(4-((4-(methoxyimino)cyclohexyl)methyl)piperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one",CHEMBL4362469,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CON=C1CCC(CN2CCN(c3nc(=O)c4cc(C(F)(F)F)cc([N+](=O)[O-])c4s3)CC2)CC1,CHEMBL4359877,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,Eur J Med Chem,2019.0,181,,111595,111595,10.1016/j.ejmech.2019.111595,31408806.0,
19074783,CHEMBL4571987,"2-(4-((4-(ethoxyimino)cyclohexyl)methyl)piperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one",CHEMBL4362469,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCON=C1CCC(CN2CCN(c3nc(=O)c4cc(C(F)(F)F)cc([N+](=O)[O-])c4s3)CC2)CC1,CHEMBL4359877,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,Eur J Med Chem,2019.0,181,,111595,111595,10.1016/j.ejmech.2019.111595,31408806.0,
19074784,CHEMBL3330226,"2-(4-(cyclohexylmethyl)piperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one",CHEMBL4362469,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,O=c1nc(N2CCN(CC3CCCCC3)CC2)sc2c([N+](=O)[O-])cc(C(F)(F)F)cc12,CHEMBL4359877,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,Eur J Med Chem,2019.0,181,,111595,111595,10.1016/j.ejmech.2019.111595,31408806.0,
19082543,CHEMBL3109802,"N-(2-Hydroxyethyl)-1-((6-methoxy-5-methylpyrimidin-4-yl)-methyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide",CHEMBL4364030,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc32)c1C,CHEMBL4359928,Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity.,ACS Med Chem Lett,2019.0,10,10,1480,1485,10.1021/acsmedchemlett.9b00343,31620237.0,
19082544,CHEMBL4473847,N-(2-fluoroethyl)-1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-1H-benzo[d]imidazole-4-carboxamide,CHEMBL4364030,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,COc1ncnc(Cn2cnc3c(C(=O)NCCF)cccc32)c1C,CHEMBL4359928,Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity.,ACS Med Chem Lett,2019.0,10,10,1480,1485,10.1021/acsmedchemlett.9b00343,31620237.0,
19082545,CHEMBL4515785,1-((6-(dimethylamino)-5-methylpyrimidin-4-yl)methyl)-N-(2-fluoroethyl)-6-methoxy-1H-benzo[d]imidazole-4-carboxamide,CHEMBL4364030,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,COc1cc(C(=O)NCCF)c2ncn(Cc3ncnc(N(C)C)c3C)c2c1,CHEMBL4359928,Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity.,ACS Med Chem Lett,2019.0,10,10,1480,1485,10.1021/acsmedchemlett.9b00343,31620237.0,
19084186,CHEMBL4541269,"rac-trans-4-(3-((5-chloro-2-methoxyphenylamino)methyl)-2,2-dimethylcyclopropyl)benzenesulfonamide",CHEMBL4364375,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,COc1ccc(Cl)cc1NCC1C(c2ccc(S(N)(=O)=O)cc2)C1(C)C,CHEMBL4364238,"Discovery of BNC375, a Potent, Selective, and Orally Available Type I Positive Allosteric Modulator of α7 nAChRs.",ACS Med Chem Lett,2019.0,10,5,754,760,10.1021/acsmedchemlett.9b00001,31097995.0,
19089981,CHEMBL4436895,4-(2-Bromo-6-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide,CHEMBL4365555,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,5000.0,nM,O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1,CHEMBL4364269,Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.,Eur J Med Chem,2019.0,178,,530,543,10.1016/j.ejmech.2019.05.057,31212132.0,
19090968,CHEMBL4591825,"(1S,5R)-1-(2-chloro-4-fluorophenyl)-3-(5-(methoxymethyl)-4-(6-methoxypyridin-3-yl)-4H-1,2,4-triazol-3-yl)-3-azabicyclo[3.1.0]hexane",CHEMBL4366139,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,30000.0,nM,COCc1nnc(N2C[C@@H]3C[C@]3(c3ccc(F)cc3Cl)C2)n1-c1ccc(OC)nc1,CHEMBL4364273,"Discovery of SHR1653, a Highly Potent and Selective OTR Antagonist with Improved Blood-Brain Barrier Penetration.",ACS Med Chem Lett,2019.0,10,6,996,1001,10.1021/acsmedchemlett.9b00186,31223461.0,
19094304,CHEMBL4558456,"1-((R)-1-(2,4-Dichlorophenyl)ethyl)-6-((3R,4S)-4-((S)-2-(hydroxymethyl)pyrrolidin-1-yl)-3-methylpiperidin-1-yl)-1H-pyrazolo[3,4-b]pyrazine-3-carbonitrile",CHEMBL4367195,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,C[C@@H]1CN(c2cnc3c(C#N)nn([C@H](C)c4ccc(Cl)cc4Cl)c3n2)CC[C@@H]1N1CCC[C@H]1CO,CHEMBL4364292,Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment.,J Med Chem,2019.0,62,13,6190,6213,10.1021/acs.jmedchem.9b00506,31259550.0,
19094305,CHEMBL4459231,"1-((R)-1-(2,4-Dichlorophenyl)ethyl)-6-((4S,5R)-4-((S)-2-(hydroxymethyl)pyrrolidin-1-yl)-5-methylcyclohex-1-en-1-yl)-1H-pyrazolo[3,4-b]pyrazine-3-carbonitrile",CHEMBL4367195,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,C[C@@H]1CC(c2cnc3c(C#N)nn([C@H](C)c4ccc(Cl)cc4Cl)c3n2)=CC[C@@H]1N1CCC[C@H]1CO,CHEMBL4364292,Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment.,J Med Chem,2019.0,62,13,6190,6213,10.1021/acs.jmedchem.9b00506,31259550.0,
19095040,CHEMBL3989951,NAVOXIMOD,CHEMBL4367277,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,100000.0,nM,O[C@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@H](O)CC1,CHEMBL4364294,"Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1.",J Med Chem,2019.0,62,14,6705,6733,10.1021/acs.jmedchem.9b00662,31264862.0,
19108359,CHEMBL2012686,"(1R,2R,3S,4R,5S)-4-(2-Chloro-6-(dicyclopropylmethylamino)-9H-purin-9-yl)bicyclo[3.1.0]hexane-2,3-diol",CHEMBL4369968,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using tolbutamide as substrate,IC50,>,25000.0,nM,O[C@@H]1[C@H](O)[C@@H]2C[C@@H]2[C@H]1n1cnc2c(NC(C3CC3)C3CC3)nc(Cl)nc21,CHEMBL4368904,Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.,J Med Chem,2019.0,62,3,1502,1522,10.1021/acs.jmedchem.8b01662,30605331.0,
19109593,CHEMBL4514678,"4-((4-((4-(4-Cyano-2,6-dimethylphenoxy)-5,7-dihydrofuro-[3,4-d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzamide",CHEMBL4370109,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 10 mins in presence of NADPH,IC50,=,46600.0,nM,Cc1cc(C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(C(N)=O)cc3)CC2)nc2c1COC2,CHEMBL4368909,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",J Med Chem,2019.0,62,3,1484,1501,10.1021/acs.jmedchem.8b01656,30624934.0,
19109594,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4370109,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 10 mins in presence of NADPH,IC50,=,660.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4368909,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",J Med Chem,2019.0,62,3,1484,1501,10.1021/acs.jmedchem.8b01656,30624934.0,
19110172,CHEMBL4593911,N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride,CHEMBL4370244,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,45000.0,nM,Cl.Cl.O=C(CN1CCOCC1)Nc1ccc(OC2CCN(C3CCC3)CC2)cc1,CHEMBL4368912,"Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H<sub>3</sub> Receptor Inverse Agonist with Robust Wake-Promoting Activity.",J Med Chem,2019.0,62,3,1203,1217,10.1021/acs.jmedchem.8b01280,30629436.0,
19110532,CHEMBL4448852,"(E)-3-[3,5-Difluoro-4-[(6S,8R)-7-(2-fluoro-2-methyl-propyl)-8-methyl-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]phenyl]-prop-2-enoic Acid",CHEMBL4370357,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,2500.0,nM,C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2c(F)cc(/C=C/C(=O)O)cc2F)N1CC(C)(C)F,CHEMBL4368914,Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.,J Med Chem,2019.0,62,3,1593,1608,10.1021/acs.jmedchem.8b01837,30640465.0,
19110533,CHEMBL4436187,"(E)-3-(4-((6S,8R)-7-(2,2-Difluoropropyl)-8-methyl-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)-3,5-difluorophenyl)acrylic Acid",CHEMBL4370357,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,6600.0,nM,C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2c(F)cc(/C=C/C(=O)O)cc2F)N1CC(C)(F)F,CHEMBL4368914,Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.,J Med Chem,2019.0,62,3,1593,1608,10.1021/acs.jmedchem.8b01837,30640465.0,
19111621,CHEMBL4453186,"(E)-3-(3,5-dimethyl-4-(2-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylonitrile",CHEMBL4370561,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 10 mins in presence of NADP by LC-MS/MS analysis,IC50,=,22300.0,nM,Cc1cc(/C=C/C#N)cc(C)c1Oc1ccnc(Nc2ccc(CN3CCN(S(C)(=O)=O)CC3)cc2)n1,CHEMBL4368923,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,J Med Chem,2019.0,62,4,2083,2098,10.1021/acs.jmedchem.8b01729,30721060.0,
19111622,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4370561,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 10 mins in presence of NADP by LC-MS/MS analysis,IC50,=,847.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4368923,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,J Med Chem,2019.0,62,4,2083,2098,10.1021/acs.jmedchem.8b01729,30721060.0,
19113336,CHEMBL4576867,"(3-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl)phenyl)methanol",CHEMBL4370897,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8600.0,nM,OCc1cccc(-c2ccc3nc(-c4ccc(Cl)cc4)cn3c2)c1,CHEMBL4368940,Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.,Bioorg Med Chem Lett,2019.0,29,7,929,932,10.1016/j.bmcl.2019.01.024,30773432.0,
19113337,CHEMBL4472621,"N-phenyl-6-(pyridin-2-yl)imidazo[1,2-a]pyridine-2-carboxamide",CHEMBL4370897,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8600.0,nM,O=C(Nc1ccccc1)c1cn2cc(-c3ccccn3)ccc2n1,CHEMBL4368940,Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.,Bioorg Med Chem Lett,2019.0,29,7,929,932,10.1016/j.bmcl.2019.01.024,30773432.0,
19114448,CHEMBL4447540,"ethyl 2-(thiazolo[4,5-c]pyridine-2-carboxamido)thiophene-3-carbonylcarbamate",CHEMBL4371339,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 30 mins by in presence of NADPH by LC-MS/MS analysis,IC50,=,100.0,nM,CCOC(=O)NC(=O)c1ccsc1NC(=O)c1nc2cnccc2s1,CHEMBL4371005,Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.,J Med Chem,2018.0,61,19,8563,8593,10.1021/acs.jmedchem.8b00281,29851474.0,
19114449,CHEMBL4475286,"ethyl 2-([1,2,4]triazolo[4,3-a]pyridine-7-carboxamido)thiophene-3-carbonylcarbamate",CHEMBL4371339,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 30 mins by in presence of NADPH by LC-MS/MS analysis,IC50,=,1830.0,nM,CCOC(=O)NC(=O)c1ccsc1NC(=O)c1ccn2cnnc2c1,CHEMBL4371005,Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.,J Med Chem,2018.0,61,19,8563,8593,10.1021/acs.jmedchem.8b00281,29851474.0,
19114450,CHEMBL4453252,"N-(3-(4-methylpyrimidin-2-ylcarbamoyl)thiophen-2-yl)-[1,2,4]triazolo[4,3-a]pyridine-7-carboxamide",CHEMBL4371339,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 30 mins by in presence of NADPH by LC-MS/MS analysis,IC50,>,50000.0,nM,Cc1ccnc(NC(=O)c2ccsc2NC(=O)c2ccn3cnnc3c2)n1,CHEMBL4371005,Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.,J Med Chem,2018.0,61,19,8563,8593,10.1021/acs.jmedchem.8b00281,29851474.0,
19116669,CHEMBL4593464,(R)-N-(4-(3-(5-(trifluoromethyl)pyridin-2-yloxy)benzylidene)cyclohexyl)nicotinamide,CHEMBL4371967,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis,IC50,=,2.7,nM,O=C(NC1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1)c1cccnc1,CHEMBL4371025,Discovery and evaluation of novel FAAH inhibitors in neuropathic pain model.,Bioorg Med Chem Lett,2019.0,29,2,238,243,10.1016/j.bmcl.2018.11.048,30503633.0,
19116670,CHEMBL4557596,(R)-6-Amino-N-[4-[[3-[[5-(trifluoromethyl)-2-pyridyl]oxy]phenyl]methylene]cyclohexyl]pyridine-3-carboxamide,CHEMBL4371967,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis,IC50,=,3.4,nM,Nc1ccc(C(=O)NC2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1,CHEMBL4371025,Discovery and evaluation of novel FAAH inhibitors in neuropathic pain model.,Bioorg Med Chem Lett,2019.0,29,2,238,243,10.1016/j.bmcl.2018.11.048,30503633.0,
19116671,CHEMBL4474161,(R)-6-Amino-5-methyl-N-[4-[[3-[[5-(trifluoromethyl)-2-pyridyl]oxy]phenyl]methylene]cyclohexyl]pyridine-3-carboxamide,CHEMBL4371967,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis,IC50,=,9.2,nM,Cc1cc(C(=O)NC2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cnc1N,CHEMBL4371025,Discovery and evaluation of novel FAAH inhibitors in neuropathic pain model.,Bioorg Med Chem Lett,2019.0,29,2,238,243,10.1016/j.bmcl.2018.11.048,30503633.0,
19116672,CHEMBL4438972,(R)-2-Amino-N-[4-[[3-[[5-(trifluoromethyl)-2-pyridyl]oxy]phenyl]methylene]cyclohexyl]pyrimidine-5-carboxamide,CHEMBL4371967,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis,IC50,=,6.5,nM,Nc1ncc(C(=O)NC2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1,CHEMBL4371025,Discovery and evaluation of novel FAAH inhibitors in neuropathic pain model.,Bioorg Med Chem Lett,2019.0,29,2,238,243,10.1016/j.bmcl.2018.11.048,30503633.0,
19118438,CHEMBL4455896,"4-amino-N-(3-bromo-1-(pyridin-3-ylmethyl)-1H-indazol-4-yl)thieno[3,2-d]pyrimidine-7-carboxamide",CHEMBL4372342,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,=,1380.0,nM,Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3cccnc3)csc12,CHEMBL4371041,"Synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel FMS inhibitors.",Bioorg Med Chem Lett,2019.0,29,2,271,275,10.1016/j.bmcl.2018.11.037,30522957.0,
19118498,CHEMBL4483816,"4-amino-N-(3-methyl-1-((6-methylpyridin-2-yl)methyl)-1H-indazol-4-yl)thieno[3,2-d]pyrimidine-7-carboxamide",CHEMBL4372342,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,20000.0,nM,Cc1cccc(Cn2nc(C)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)n1,CHEMBL4371041,"Synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel FMS inhibitors.",Bioorg Med Chem Lett,2019.0,29,2,271,275,10.1016/j.bmcl.2018.11.037,30522957.0,
19123774,CHEMBL4279180,3-(5-chloro-6-isobutoxypyridin-3-yl)-1-methyl-N-(methylsulfonyl)-1H-indole-6-carboxamide,CHEMBL4373234,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,9900.0,nM,CC(C)COc1ncc(-c2cn(C)c3cc(C(=O)NS(C)(=O)=O)ccc23)cc1Cl,CHEMBL4371076,Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective NaV1.7 Inhibitors for the Treatment of Pain.,J Med Chem,2019.0,62,2,831,856,10.1021/acs.jmedchem.8b01550,30576602.0,
19123778,CHEMBL4550045,5-Fluoro-3-(6-isobutoxypyridin-3-yl)-1-methyl-N-(methylsulfonyl)-1H-indole-6-carboxamide,CHEMBL4373234,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,27000.0,nM,CC(C)COc1ccc(-c2cn(C)c3cc(C(=O)NS(C)(=O)=O)c(F)cc23)cn1,CHEMBL4371076,Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective NaV1.7 Inhibitors for the Treatment of Pain.,J Med Chem,2019.0,62,2,831,856,10.1021/acs.jmedchem.8b01550,30576602.0,
19124242,CHEMBL4576513,"(7-Chloro-1,6,8-trimethyl-1H-pyrazolo[3',4':4,5]thieno[2,3-b]pyridin-3-yl)-furan-2-ylmethyl-amine",CHEMBL4373349,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1000.0,nM,Cc1nc2sc3c(NCc4ccco4)nn(C)c3c2c(C)c1Cl,CHEMBL4371085,Novel M<sub>4</sub> positive allosteric modulators derived from questioning the role and impact of a presumed intramolecular hydrogen-bonding motif in β-amino carboxamide-harboring ligands.,Bioorg Med Chem Lett,2019.0,29,3,362,366,10.1016/j.bmcl.2018.12.039,30580918.0,
19124243,CHEMBL4522777,"(7-Chloro-1,6,8-trimethyl-1H-pyrazolo[3',4':4,5]thieno[2,3-b]pyridin-3-yl)-cyclopropylmethyl-amine",CHEMBL4373349,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1000.0,nM,Cc1nc2sc3c(NCC4CC4)nn(C)c3c2c(C)c1Cl,CHEMBL4371085,Novel M<sub>4</sub> positive allosteric modulators derived from questioning the role and impact of a presumed intramolecular hydrogen-bonding motif in β-amino carboxamide-harboring ligands.,Bioorg Med Chem Lett,2019.0,29,3,362,366,10.1016/j.bmcl.2018.12.039,30580918.0,
19132673,CHEMBL4451346,"N-((5Sa)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-ethylthieno[2,3-d]pyrimidin-4-yl)-D-phenylalanine",CHEMBL4375126,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>=,20000.0,nM,CCc1sc2ncnc(N[C@H](Cc3ccccc3)C(=O)O)c2c1-c1ccc(OCCN2CCN(C)CC2)c(Cl)c1C,CHEMBL4373699,Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity.,J Med Chem,2019.0,62,15,6913,6924,10.1021/acs.jmedchem.9b00134,31339316.0,
19132674,CHEMBL4472351,"(2R)-2-[((5Sa)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-ethylthieno[2,3-d]pyrimidin-4-yl)oxy]-3-phenylpropanoic acid",CHEMBL4375126,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>=,20000.0,nM,CCc1sc2ncnc(O[C@H](Cc3ccccc3)C(=O)O)c2c1-c1ccc(OCCN2CCN(C)CC2)c(Cl)c1C,CHEMBL4373699,Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity.,J Med Chem,2019.0,62,15,6913,6924,10.1021/acs.jmedchem.9b00134,31339316.0,
19143945,CHEMBL4435170,"6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide",CHEMBL4377411,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,CHEMBL4376812,Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.,J Med Chem,2019.0,62,20,8973,8995,10.1021/acs.jmedchem.9b00444,31318208.0,
19145385,CHEMBL4454609,"(1S,2S)-2-{5-[(4-Chloronaphthalen-1-yl)(cyclopropylmethyl)amino]-3-methoxypyridine-2-carbonyl}cyclopropane-1-carboxylic acid",CHEMBL4378204,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in Escherichia coli using coumarin based substrate by fluorescence assay,IC50,>,20000.0,nM,COc1cc(N(CC2CC2)c2ccc(Cl)c3ccccc23)cnc1C(=O)[C@H]1C[C@@H]1C(=O)O,CHEMBL4376816,"Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1<i>S</i>,2<i>S</i>)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma.",J Med Chem,2019.0,62,17,7769,7787,10.1021/acs.jmedchem.9b00555,31415176.0,
19145386,CHEMBL3961833,"(1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid::US20160326143, 62",CHEMBL4378204,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in Escherichia coli using coumarin based substrate by fluorescence assay,IC50,>,30000.0,nM,COc1nc(N(CC(C)(C)F)c2cc(Cl)c(F)cc2F)cnc1C(=O)[C@H]1C[C@@H]1C(=O)O,CHEMBL4376816,"Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1<i>S</i>,2<i>S</i>)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma.",J Med Chem,2019.0,62,17,7769,7787,10.1021/acs.jmedchem.9b00555,31415176.0,
19153247,CHEMBL4537673,"1-(4-{(1R)-1-[2-({6-[6-(Dimethylamino)pyrimidin-4-yl]-1H-benzimidazol-2-yl}amino)pyridin-4-yl]ethyl}piperazin-1-yl)-3,3,3-trifluoropropan-1-one",CHEMBL4380537,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,17000.0,nM,C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1,CHEMBL4376867,"Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.",J Med Chem,2020.0,63,2,601,612,10.1021/acs.jmedchem.9b01460,31859507.0,
19156561,CHEMBL4442726,"(E)-4-((4-(4-(2-Cyanovinyl)-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl)amino)-2-fluorobenzonitrile",CHEMBL4381393,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate in presence of NADPH incubated for 10 mins,IC50,=,1990.0,nM,Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)c(F)c2)nc2ccsc12,CHEMBL4376885,Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.,J Med Chem,2020.0,63,3,1298,1312,10.1021/acs.jmedchem.9b01769,31935327.0,
19156604,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4381393,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate in presence of NADPH incubated for 10 mins,IC50,=,609.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4376885,Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.,J Med Chem,2020.0,63,3,1298,1312,10.1021/acs.jmedchem.9b01769,31935327.0,
19156963,CHEMBL4514031,(3R)-4-[8-(1H-indol-4-yl)-2-[(3S)-3-methylmorpholin-4-yl]-9H-purin-6-yl]-3-methylmorpholine,CHEMBL4381562,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1980.0,nM,C[C@H]1COCCN1c1nc(N2CCOC[C@H]2C)c2nc(-c3cccc4[nH]ccc34)[nH]c2n1,CHEMBL4376889,Discovery of a Brain-Penetrant ATP-Competitive Inhibitor of the Mechanistic Target of Rapamycin (mTOR) for CNS Disorders.,J Med Chem,2020.0,63,3,1068,1083,10.1021/acs.jmedchem.9b01398,31955578.0,
19156964,CHEMBL4518369,"(S)-3-Methyl-4-(7-((R)-3-methylmorpholino)-2-(1H-pyrazol-3-yl)thiazolo[5,4-d]pyrimidin-5-yl)morpholine",CHEMBL4381562,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@H]1COCCN1c1nc(N2CCOC[C@H]2C)c2nc(-c3cc[nH]n3)sc2n1,CHEMBL4376889,Discovery of a Brain-Penetrant ATP-Competitive Inhibitor of the Mechanistic Target of Rapamycin (mTOR) for CNS Disorders.,J Med Chem,2020.0,63,3,1068,1083,10.1021/acs.jmedchem.9b01398,31955578.0,
19158748,CHEMBL4467408,"(R)-3,4-Dihydroxy-1-(1-hydroxy-3-phenylpropan-2-yl)-2-methylpyridin-1-ium Chloride",CHEMBL4382123,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,200000.0,nM,Cc1c(O)c(O)cc[n+]1[C@@H](CO)Cc1ccccc1.[Cl-],CHEMBL4376902,CN128: A New Orally Active Hydroxypyridinone Iron Chelator.,J Med Chem,2020.0,63,8,4215,4226,10.1021/acs.jmedchem.0c00137,32208614.0,
19162160,CHEMBL4586075,2-[4-(Cyclohexylmethyl)piperazin-1-yl]-8-nitro-6-(trifluoromethyl)-4H-thiochromen-4-one,CHEMBL4383588,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 20 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,O=c1cc(N2CCN(CC3CCCCC3)CC2)sc2c([N+](=O)[O-])cc(C(F)(F)F)cc12,CHEMBL4382210,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,Eur J Med Chem,2018.0,160,,157,170,10.1016/j.ejmech.2018.09.042,30336450.0,
19174878,CHEMBL4580164,"1-Cyclopentyl-6-(((R)-1-((S)-3-fluoropyrrolidin-1-yl)-1-oxopropan-2-yl)amino)-1,5-dihydro-4H-pyrazolo[3,4-d]-pyrimidin-4-one",CHEMBL4385838,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using [14C]-naproxen as substrate preincubated for 2 mins in presence of NADPH followed by substrate addition and measured after 30 mins by liquid scintillation counting method,IC50,>,10000.0,nM,C[C@@H](Nc1nc2c(cnn2C2CCCC2)c(=O)[nH]1)C(=O)N1CC[C@H](F)C1,CHEMBL4385597,"Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.",J Med Chem,2019.0,62,8,4218,4224,10.1021/acs.jmedchem.8b01041,30916555.0,
19185985,CHEMBL97797,6-Methoxy-benzothiazol-2-ylamine,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,COc1ccc2nc(N)sc2c1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19185986,CHEMBL744,6-Trifluoromethoxy-benzothiazol-2-ylamine (Riluzole),CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2ccc(OC(F)(F)F)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19185987,CHEMBL2386433,"6-(Benzyloxy)-1,3-benzothiazol-2-amine",CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2ccc(OCc3ccccc3)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19185988,CHEMBL4465714,"6-((3,4-Dichlorobenzyl)oxy)benzo[d]thiazol-2-amine",CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2ccc(OCc3ccc(Cl)c(Cl)c3)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19185989,CHEMBL4468228,4-(((2-Aminobenzo[d]thiazol-6-yl)oxy)methyl)benzonitrile,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,N#Cc1ccc(COc2ccc3nc(N)sc3c2)cc1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19185990,CHEMBL4540341,Methyl 4-(((2-Aminobenzo[d]thiazol-6-yl)oxy)methyl)benzoate,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,COC(=O)c1ccc(COc2ccc3nc(N)sc3c2)cc1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19185991,CHEMBL4566383,Methyl 1-(4-(((2-Aminobenzo[d]thiazol-6-yl)oxy)methyl)-benzoyl)piperidine-4-carboxylate,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,<,10000.0,nM,COC(=O)C1CCN(C(=O)c2ccc(COc3ccc4nc(N)sc4c3)cc2)CC1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19185992,CHEMBL4592124,6-(Methylthio)benzo[d]thiazol-2-amine,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,CSc1ccc2nc(N)sc2c1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19185993,CHEMBL95463,6-Trifluoromethylsulfanyl-benzothiazol-2-ylamine,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2ccc(SC(F)(F)F)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19185994,CHEMBL4475811,6-(Benzylthio)benzo[d]thiazol-2-amine,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2ccc(SCc3ccccc3)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19185995,CHEMBL4439011,"6-((3,4-Dichlorobenzyl)thio)benzo[d]thiazol-2-amine",CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2ccc(SCc3ccc(Cl)c(Cl)c3)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19185996,CHEMBL4564287,4-(((2-Aminobenzo[d]thiazol-6-yl)thio)methyl)benzonitrile,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,=,10000.0,nM,N#Cc1ccc(CSc2ccc3nc(N)sc3c2)cc1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19185997,CHEMBL4577695,Methyl 4-(((2-Aminobenzo[d]thiazol-6-yl)thio)methyl)benzoate,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,<,10000.0,nM,COC(=O)c1ccc(CSc2ccc3nc(N)sc3c2)cc1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19185998,CHEMBL4441552,Methyl 1-(4-(((2-Aminobenzo[d]thiazol-6-yl)thio)-methyl)benzoyl)piperidine-4-carboxylate,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,COC(=O)C1CCN(C(=O)c2ccc(CSc3ccc4nc(N)sc4c3)cc2)CC1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19185999,CHEMBL4562350,4-(((2-Aminobenzo[d]thiazol-6-yl)thio)methyl)-N-benzylbenzamide,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,<,10000.0,nM,Nc1nc2ccc(SCc3ccc(C(=O)NCc4ccccc4)cc3)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186000,CHEMBL432942,6-Methanesulfonyl-benzothiazol-2-ylamine,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,CS(=O)(=O)c1ccc2nc(N)sc2c1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186001,CHEMBL4440584,6-(Benzylsulfonyl)benzo[d]thiazol-2-amine,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2ccc(S(=O)(=O)Cc3ccccc3)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186002,CHEMBL4581441,"6-((3,4-Dichlorobenzyl)sulfonyl)benzo[d]thiazol-2-amine",CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2ccc(S(=O)(=O)Cc3ccc(Cl)c(Cl)c3)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186003,CHEMBL4464690,4-(((2-Aminobenzo[d]thiazol-6-yl)sulfonyl)methyl)benzonitrile,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,N#Cc1ccc(CS(=O)(=O)c2ccc3nc(N)sc3c2)cc1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186004,CHEMBL4446494,Methyl 4-(((2-Aminobenzo[d]thiazol-6-yl)sulfonyl)methyl)-benzoate,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,=,10000.0,nM,COC(=O)c1ccc(CS(=O)(=O)c2ccc3nc(N)sc3c2)cc1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186005,CHEMBL4476655,Methyl 1-(4-(((2-Aminobenzo[d]thiazol-6-yl)sulfonyl)methyl)-benzoyl)piperidine-4-carboxylate,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,<,10000.0,nM,COC(=O)C1CCN(C(=O)c2ccc(CS(=O)(=O)c3ccc4nc(N)sc4c3)cc2)CC1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186006,CHEMBL4469761,2-amino-N-benzylbenzo[d]thiazole-6-carboxamide,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2ccc(C(=O)NCc3ccccc3)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186007,CHEMBL4458858,"2-Amino-N-(3,4-dichlorobenzyl)benzo[d]thiazole-6-carboxamide",CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2ccc(C(=O)NCc3ccc(Cl)c(Cl)c3)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186008,CHEMBL4561783,2-Amino-N-(4-cyanobenzyl)benzo[d]thiazole-6-carboxamide,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,N#Cc1ccc(CNC(=O)c2ccc3nc(N)sc3c2)cc1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186009,CHEMBL4579215,Methyl 4-((2-Aminobenzo[d]thiazole-6-carboxamido)methyl)-benzoate,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,=,10000.0,nM,COC(=O)c1ccc(CNC(=O)c2ccc3nc(N)sc3c2)cc1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186010,CHEMBL4452155,methyl 1-(4-((2-aminobenzo[d]thiazole-6-carboxamido)methyl)benzoyl)piperidine-4-carboxylate,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,COC(=O)C1CCN(C(=O)c2ccc(CNC(=O)c3ccc4nc(N)sc4c3)cc2)CC1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186011,CHEMBL4581650,2-amino-N-(4-(benzylcarbamoyl)benzyl)benzo[d]thiazole-6-carboxamide,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,=,10000.0,nM,Nc1nc2ccc(C(=O)NCc3ccc(C(=O)NCc4ccccc4)cc3)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186012,CHEMBL4554726,"2-Amino-N-(3,4,5-trimethoxybenzyl)benzo[d]thiazole-6-carboxamide",CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,COc1cc(CNC(=O)c2ccc3nc(N)sc3c2)cc(OC)c1OC,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186013,CHEMBL4582026,2-Amino-N-(2-nitrobenzyl)benzo[d]thiazole-6-carboxamide,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2ccc(C(=O)NCc3ccccc3[N+](=O)[O-])cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186014,CHEMBL4460492,2-amino-N-(2-aminobenzyl)benzo[d]thiazole-6-carboxamide,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2ccc(C(=O)NCc3ccccc3N)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186015,CHEMBL4435791,2-Amino-N-benzhydrylbenzo[d]thiazole-6-carboxamide,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,<,10000.0,nM,Nc1nc2ccc(C(=O)NC(c3ccccc3)c3ccccc3)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186016,CHEMBL4545398,Methyl 1-(2-Aminobenzo[d]thiazole-6-carbonyl)piperidine-4-carboxylate,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,=,10000.0,nM,COC(=O)C1CCN(C(=O)c2ccc3nc(N)sc3c2)CC1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186017,CHEMBL4554707,2-Amino-N-(2-(thiophen-2-yl)ethyl)benzo[d]thiazole-6-carboxamide,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2ccc(C(=O)NCCc3cccs3)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186018,CHEMBL4528355,N-(2-(1H-Indol-3-yl)ethyl)-2-aminobenzo[d]thiazole-6-carboxamide,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2ccc(C(=O)NCCc3c[nH]c4ccccc34)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186019,CHEMBL4444333,"2-Amino-N-benzyl-N-(3,4-dichlorobenzyl)benzo[d]thiazole-6-carboxamide",CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,<,10000.0,nM,Nc1nc2ccc(C(=O)N(Cc3ccccc3)Cc3ccc(Cl)c(Cl)c3)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186020,CHEMBL4452773,2-Amino-N-benzyl-N-(2-hydroxyethyl)benzo[d]thiazole-6-carboxamide,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2ccc(C(=O)N(CCO)Cc3ccccc3)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186021,CHEMBL4462566,"2-Amino-N-(3,4-dichlorobenzyl)-N-(3,4-dimethoxybenzyl)benzo-[d]thiazole-6-carboxamide",CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,<,10000.0,nM,COc1ccc(CN(Cc2ccc(Cl)c(Cl)c2)C(=O)c2ccc3nc(N)sc3c2)cc1OC,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186022,CHEMBL4552119,2-Amino-N-benzyl-4-hydroxybenzo[d]thiazole-6-carboxamide,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2c(O)cc(C(=O)NCc3ccccc3)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186023,CHEMBL4549839,"2-Amino-N-(3,4-dichlorobenzyl)-4-hydroxybenzo[d]thiazole-6-carboxamide",CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2c(O)cc(C(=O)NCc3ccc(Cl)c(Cl)c3)cc2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186024,CHEMBL4583705,"2-Amino-N-benzyl-N-(3,4-dichlorobenzyl)-6,7-dihydroxybenzo-[d]thiazole-4-carboxamide",CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,<,10000.0,nM,Nc1nc2c(C(=O)N(Cc3ccccc3)Cc3ccc(Cl)c(Cl)c3)cc(O)c(O)c2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186025,CHEMBL4453795,"2-Amino-N-(3,4-dichlorobenzyl)-6,7-dihydroxybenzo[d]thiazole-4-carboxamide",CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2c(C(=O)NCc3ccc(Cl)c(Cl)c3)cc(O)c(O)c2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186026,CHEMBL4456198,"2-Amino-N-benzyl-6,7-dihydroxybenzo[d]thiazole-4-carboxamide",CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,Nc1nc2c(C(=O)NCc3ccccc3)cc(O)c(O)c2s1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19186027,CHEMBL55,4-[(5-{4-[(Z)-amino(imino)methyl]phenoxy}pentyl)oxy]benzenecarboximidamide,CHEMBL4388239,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,IC50,>,25000.0,nM,N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1,CHEMBL4387708,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,J Med Chem,2019.0,62,8,3989,4012,10.1021/acs.jmedchem.8b02021,30908048.0,
19187569,CHEMBL4457447,"N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(1,2-dithiolan-3-yl)acetamide",CHEMBL4388570,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)CC1CCSS1,CHEMBL4387720,"Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors.",Bioorg Med Chem Lett,2019.0,29,12,1435,1439,10.1016/j.bmcl.2019.04.029,31023512.0,
19190706,CHEMBL4451760,"(S)-2-[8-(3-fluoro-2-methyl-phenyl)-6,8-dihydro-5H-imidazo[2,1-c][1,4]oxazin-2-yl]-4-methoxy-1H-indole-5-carbonitrile",CHEMBL4388916,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5900.0,nM,COc1c(C#N)ccc2[nH]c(-c3cn4c(n3)[C@H](c3cccc(F)c3C)OCC4)cc12,CHEMBL4387734,Design and synthesis of a novel series of cyanoindole derivatives as potent γ-secretase modulators.,Bioorg Med Chem Lett,2019.0,29,14,1737,1745,10.1016/j.bmcl.2019.05.023,31122869.0,
19190707,CHEMBL4466805,"N-(3-fluoro-5-(trifluoromethyl)phenyl)-3-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-1-methyl-1H-1,2,4-triazol-5-amine",CHEMBL4388916,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,12300.0,nM,COc1nc(-c2nc(Nc3cc(F)cc(C(F)(F)F)c3)n(C)n2)ccc1-n1cnc(C)c1,CHEMBL4387734,Design and synthesis of a novel series of cyanoindole derivatives as potent γ-secretase modulators.,Bioorg Med Chem Lett,2019.0,29,14,1737,1745,10.1016/j.bmcl.2019.05.023,31122869.0,
19191224,CHEMBL4555459,"(R)-1-(3-(1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)phenyl)-3-(2-(pyrrolidin-1-yl)phenyl)urea",CHEMBL4389553,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1800.0,nM,O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1,CHEMBL4387741,Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens.,Bioorg Med Chem,2019.0,27,13,2905,2913,10.1016/j.bmc.2019.05.021,31138459.0,
19191273,CHEMBL4564973,"(R)-1-(2-Fluoro-6-(pyrrolidin-1-yl)phenyl)-3-(3-(1-(2-hydroxyethyl)-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazin-2-yl)phenyl)urea",CHEMBL4389553,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,5000.0,nM,O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1,CHEMBL4387741,Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens.,Bioorg Med Chem,2019.0,27,13,2905,2913,10.1016/j.bmc.2019.05.021,31138459.0,
19195559,CHEMBL3965066,"US9458171, 387",CHEMBL4390472,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CC[C@]1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC[C@H](C(=O)O)CC1,CHEMBL4387773,"Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists.",Bioorg Med Chem Lett,2019.0,29,16,2265,2269,10.1016/j.bmcl.2019.06.036,31257087.0,
19195560,CHEMBL3964587,"US9458171, 392",CHEMBL4390472,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,O=C(O)C12CCC(C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)(CC1)CC2,CHEMBL4387773,"Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists.",Bioorg Med Chem Lett,2019.0,29,16,2265,2269,10.1016/j.bmcl.2019.06.036,31257087.0,
19196055,CHEMBL4548931,"5-((R)-1-((6S,9s)-3,3-difluoro-1-oxaspiro[5.5]undecan-9-yloxy)ethyl)-3-(3,5-difluoro-4-(methylsulfonylmethyl)phenyl)-1,2,4-oxadiazole",CHEMBL4390532,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@@H](O[C@H]1CC[C@]2(CCC(F)(F)CO2)CC1)c1nc(-c2cc(F)c(CS(C)(=O)=O)c(F)c2)no1,CHEMBL4387781,Optimization of oxadiazole derivatives with a spirocyclic cyclohexane structure as novel GPR119 agonists.,Bioorg Med Chem Lett,2019.0,29,16,2100,2106,10.1016/j.bmcl.2019.07.004,31288965.0,
19197661,CHEMBL3121193,4-((N-(5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)methyl)-2-fluorophenylboronic acid,CHEMBL4390908,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition and measured by LC-MS/MS analysis,IC50,=,4900.0,nM,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(Cc3ccc(B(O)O)c(F)c3)S(C)(=O)=O)c(C3CC3)cc12,CHEMBL4390640,Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.,J Med Chem,2019.0,62,7,3254,3267,10.1021/acs.jmedchem.8b01719,30763090.0,
19197662,CHEMBL4451904,"(4-(1-(5-Cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)-1H-1,2,4-triazol-5-yl)-2-fluorophenyl)boronic acid",CHEMBL4390908,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition and measured by LC-MS/MS analysis,IC50,=,2700.0,nM,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(-n3ncnc3-c3ccc(B(O)O)c(F)c3)c(C3CC3)cc12,CHEMBL4390640,Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.,J Med Chem,2019.0,62,7,3254,3267,10.1021/acs.jmedchem.8b01719,30763090.0,
19197663,CHEMBL4439082,(4-(1-(5-Cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)-1H-pyrazol-5-yl)-2-fluorophenyl)boronic acid,CHEMBL4390908,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition and measured by LC-MS/MS analysis,IC50,=,1500.0,nM,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(-n3nccc3-c3ccc(B(O)O)c(F)c3)c(C3CC3)cc12,CHEMBL4390640,Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.,J Med Chem,2019.0,62,7,3254,3267,10.1021/acs.jmedchem.8b01719,30763090.0,
19197664,CHEMBL4528447,(2-Chloro-4-(N-(5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)phenyl)boronic acid,CHEMBL4390908,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition and measured by LC-MS/MS analysis,IC50,=,2600.0,nM,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3ccc(B(O)O)c(Cl)c3)S(C)(=O)=O)c(C3CC3)cc12,CHEMBL4390640,Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.,J Med Chem,2019.0,62,7,3254,3267,10.1021/acs.jmedchem.8b01719,30763090.0,
19197665,CHEMBL4467259,"6-(N-(7-Chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide",CHEMBL4390908,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition and measured by LC-MS/MS analysis,IC50,=,22000.0,nM,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3cc(Cl)c4c(c3)COB4O)S(C)(=O)=O)c(C3CC3)cc12,CHEMBL4390640,Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.,J Med Chem,2019.0,62,7,3254,3267,10.1021/acs.jmedchem.8b01719,30763090.0,
19214656,CHEMBL4563459,"N-tert-butoxy-1-methyl-4-((1R,2R)-2-(4-(3-methyl-1H-pyrazol-5-yl)benzoyl)cyclohexanecarboxamido)-1H-pyrazole-5-carboxamide",CHEMBL4393800,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in Escherichia coli using 7MFC as substrate by fluorescence assay,IC50,>,20000.0,nM,Cc1cc(-c2ccc(C(=O)[C@@H]3CCCC[C@H]3C(=O)Nc3cnn(C)c3C(=O)NOC(C)(C)C)cc2)[nH]n1,CHEMBL4393654,Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.,J Med Chem,2019.0,62,9,4312,4324,10.1021/acs.jmedchem.8b02004,30869888.0,
19214657,CHEMBL4474619,"(1R,2R)-2-(4-(5-methyl-1H-pyrazol-3-yl)benzoyl)-N-(1-methyl-5-sulfamoyl-1H-pyrazol-4-yl)cyclohexanecarboxamide",CHEMBL4393800,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in Escherichia coli using 7MFC as substrate by fluorescence assay,IC50,>,20000.0,nM,Cc1cc(-c2ccc(C(=O)[C@@H]3CCCC[C@H]3C(=O)Nc3cnn(C)c3S(N)(=O)=O)cc2)n[nH]1,CHEMBL4393654,Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.,J Med Chem,2019.0,62,9,4312,4324,10.1021/acs.jmedchem.8b02004,30869888.0,
19214658,CHEMBL4542281,"(1R,2R)-2-(4-(5-methyl-1H-pyrazol-3-yl)benzoyl)-N-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)cyclohexanecarboxamide",CHEMBL4393800,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in Escherichia coli using 7MFC as substrate by fluorescence assay,IC50,>,20000.0,nM,Cc1cc(-c2ccc(C(=O)[C@@H]3CCCC[C@H]3C(=O)Nc3cnn4c3C(=O)NCC4)cc2)n[nH]1,CHEMBL4393654,Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.,J Med Chem,2019.0,62,9,4312,4324,10.1021/acs.jmedchem.8b02004,30869888.0,
19231130,CHEMBL4573171,2-(4-((2-(3-Chlorophenyl)-6-ethylpyrimidin-4-yl)methyl)phenyl)acetamide,CHEMBL4397224,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence-based assay,IC50,>,100000.0,nM,CCc1cc(Cc2ccc(CC(N)=O)cc2)nc(-c2cccc(Cl)c2)n1,CHEMBL4396869,Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.,J Med Chem,2019.0,62,10,4884,4901,10.1021/acs.jmedchem.9b00193,31013090.0,
19231131,CHEMBL4541964,ZATOLMILAST,CHEMBL4397224,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) by fluorescence-based assay,IC50,>,51000.0,nM,O=C(O)Cc1ccc(Cc2cc(-c3cccc(Cl)c3)nc(C(F)(F)F)c2)cc1,CHEMBL4396869,Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.,J Med Chem,2019.0,62,10,4884,4901,10.1021/acs.jmedchem.9b00193,31013090.0,
19235827,CHEMBL4465111,N-(5-((6-((2-Methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-3-(pyrrolidin-1-yl)pyridin-2-yl)oxy)-2-methylphenyl)acrylamide,CHEMBL4398528,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,C=CC(=O)Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ccc2N2CCCC2)ccc1C,CHEMBL4396895,Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors.,J Med Chem,2019.0,62,12,5901,5919,10.1021/acs.jmedchem.9b00631,31145622.0,
19235828,CHEMBL4540948,N-(5-((6-((2-Methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-3-(piperidin-1-yl)pyridin-2-yl)oxy)-2-methylphenyl)acrylamide,CHEMBL4398528,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,C=CC(=O)Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ccc2N2CCCCC2)ccc1C,CHEMBL4396895,Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors.,J Med Chem,2019.0,62,12,5901,5919,10.1021/acs.jmedchem.9b00631,31145622.0,
19235829,CHEMBL4464752,N-(5-((6-((2-Methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-3-morpholinopyridin-2-yl)oxy)-2-methylphenyl)acrylamide,CHEMBL4398528,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,C=CC(=O)Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ccc2N2CCOCC2)ccc1C,CHEMBL4396895,Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors.,J Med Chem,2019.0,62,12,5901,5919,10.1021/acs.jmedchem.9b00631,31145622.0,
19244844,CHEMBL4446981,rac-2-cyano-2-(6-(6-fluoropyridin-3-yl)benzo[d]thiazol-2-yl)-N-(2-(oxetan-3-ylamino)-2-oxoethyl)acetamide,CHEMBL4400379,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,18000.0,nM,N#CC(C(=O)NCC(=O)NC1COC1)c1nc2ccc(-c3ccc(F)nc3)cc2s1,CHEMBL4396970,Benzothiazole-based compounds as potent endothelial lipase inhibitors.,Bioorg Med Chem Lett,2019.0,29,20,126673,126673,10.1016/j.bmcl.2019.126673,31519373.0,
19244845,CHEMBL4438345,rac-2-cyano-N-(2-(cyclopropylamino)-2-oxoethyl)-2-(6-(4-(4-methylpiperazine-1-carbonyl)phenyl)benzo[d]thiazol-2-yl)acetamide,CHEMBL4400379,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,18000.0,nM,CN1CCN(C(=O)c2ccc(-c3ccc4nc(C(C#N)C(=O)NCC(=O)NC5CC5)sc4c3)cc2)CC1,CHEMBL4396970,Benzothiazole-based compounds as potent endothelial lipase inhibitors.,Bioorg Med Chem Lett,2019.0,29,20,126673,126673,10.1016/j.bmcl.2019.126673,31519373.0,
19244846,CHEMBL4557424,"rac-3-(2-(1-cyano-2-(2-(cyclopropylamino)-2-oxoethylamino)-2-oxoethyl)benzo[d]thiazol-6-yl)-N,N-dimethylbenzamide",CHEMBL4400379,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,18000.0,nM,CN(C)C(=O)c1cccc(-c2ccc3nc(C(C#N)C(=O)NCC(=O)NC4CC4)sc3c2)c1,CHEMBL4396970,Benzothiazole-based compounds as potent endothelial lipase inhibitors.,Bioorg Med Chem Lett,2019.0,29,20,126673,126673,10.1016/j.bmcl.2019.126673,31519373.0,
19244847,CHEMBL4545633,rac-2-cyano-N-(2-(cyclopropylamino)-2-oxoethyl)-2-(6-(4-(morpholine-4-carbonyl)phenyl)benzo[d]thiazol-2-yl)acetamide,CHEMBL4400379,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,18000.0,nM,N#CC(C(=O)NCC(=O)NC1CC1)c1nc2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)cc2s1,CHEMBL4396970,Benzothiazole-based compounds as potent endothelial lipase inhibitors.,Bioorg Med Chem Lett,2019.0,29,20,126673,126673,10.1016/j.bmcl.2019.126673,31519373.0,
19244848,CHEMBL4587475,rac-2-cyano-N-(2-(cyclopropylamino)-2-oxoethyl)-2-(6-phenylbenzo[d]thiazol-2-yl)acetamide,CHEMBL4400379,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,18000.0,nM,N#CC(C(=O)NCC(=O)NC1CC1)c1nc2ccc(-c3ccccc3)cc2s1,CHEMBL4396970,Benzothiazole-based compounds as potent endothelial lipase inhibitors.,Bioorg Med Chem Lett,2019.0,29,20,126673,126673,10.1016/j.bmcl.2019.126673,31519373.0,
19245075,CHEMBL4513792,3-[[4-[(1S)-3-Methyl-1-[6-methyl-5-[2-methyl-4-(trifluoromethyl)phenyl]indazol-1-yl]butyl]benzoyl]amino]propanoic acid,CHEMBL4400440,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using tolbutamide as substrate,IC50,>,10000.0,nM,Cc1cc(C(F)(F)F)ccc1-c1cc2cnn([C@@H](CC(C)C)c3ccc(C(=O)NCCC(=O)O)cc3)c2cc1C,CHEMBL4396971,Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes.,Bioorg Med Chem Lett,2019.0,29,20,126668,126668,10.1016/j.bmcl.2019.126668,31519374.0,
19245076,CHEMBL4589676,3-[[4-[(1S)-3-methyl-1-[6-methyl-5-[2-methyl-4-(trifluoromethyl)phenyl]indazol-2-yl]butyl]benzoyl]amino]propanoic acid,CHEMBL4400440,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using tolbutamide as substrate,IC50,>,10000.0,nM,Cc1cc(C(F)(F)F)ccc1-c1cc2cn([C@@H](CC(C)C)c3ccc(C(=O)NCCC(=O)O)cc3)nc2cc1C,CHEMBL4396971,Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes.,Bioorg Med Chem Lett,2019.0,29,20,126668,126668,10.1016/j.bmcl.2019.126668,31519374.0,
19245077,CHEMBL4468579,3-[[4-[(1S)-1-[5-[2-Chloro-4-(trifluoromethyl)phenyl]-6-methyl-indazol-1-yl]-3-methylbutyl]benzoyl]amino]propanoic acid,CHEMBL4400440,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using tolbutamide as substrate,IC50,>,10000.0,nM,Cc1cc2c(cnn2[C@@H](CC(C)C)c2ccc(C(=O)NCCC(=O)O)cc2)cc1-c1ccc(C(F)(F)F)cc1Cl,CHEMBL4396971,Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes.,Bioorg Med Chem Lett,2019.0,29,20,126668,126668,10.1016/j.bmcl.2019.126668,31519374.0,
19245078,CHEMBL4582082,3-[[4-[(1S)-1-[5-[2-Chloro-4-(trifluoromethyl)phenyl]-4-methyl-indazol-2-yl]-3-methylbutyl]benzoyl]amino]propanoic acid,CHEMBL4400440,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using tolbutamide as substrate,IC50,>,10000.0,nM,Cc1c(-c2ccc(C(F)(F)F)cc2Cl)ccc2nn([C@@H](CC(C)C)c3ccc(C(=O)NCCC(=O)O)cc3)cc12,CHEMBL4396971,Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes.,Bioorg Med Chem Lett,2019.0,29,20,126668,126668,10.1016/j.bmcl.2019.126668,31519374.0,
19250734,CHEMBL4452711,"5-(3,4-dichlorobenzyl)-4-oxo-1-(piperidin-4-yl)-N-(pyridin-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridine-7-carboxamide",CHEMBL4401549,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5900.0,nM,O=C(Nc1ccncc1)c1cn(Cc2ccc(Cl)c(Cl)c2)c(=O)c2cnn(C3CCNCC3)c12,CHEMBL4400540,"Structure-based design, synthesis and biological evaluation of a novel series of isoquinolone and pyrazolo[4,3-c]pyridine inhibitors of fascin 1 as potential anti-metastatic agents.",Bioorg Med Chem Lett,2019.0,29,8,1023,1029,10.1016/j.bmcl.2019.01.035,30773430.0,
19252215,CHEMBL4459692,"4-(5-(4,7-Dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid",CHEMBL4401922,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis,IC50,>,25000.0,nM,Cc1ccc(C)c2oc(-c3nc(-c4ccc(C(=O)O)cc4)no3)cc12,CHEMBL4400551,"Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury.",Bioorg Med Chem Lett,2019.0,29,8,995,1000,10.1016/j.bmcl.2019.02.011,30792038.0,
19257447,CHEMBL4540811,"N-(4-(Dimethylcarbamoyl)phenyl)-2,4-dihydroxy-N-(4-hydroxybenzyl)benzamide",CHEMBL4403280,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,13400.0,nM,CN(C)C(=O)c1ccc(N(Cc2ccc(O)cc2)C(=O)c2ccc(O)cc2O)cc1,CHEMBL4402524,Identification of Novel Resorcinol Amide Derivatives as Potent and Specific Pyruvate Dehydrogenase Kinase (PDHK) Inhibitors.,J Med Chem,2019.0,62,18,8461,8479,10.1021/acs.jmedchem.9b00565,31469962.0,
19257448,CHEMBL4575355,"N-((5-Bromofuran-2-yl)methyl)-N-(4-(dimethylcarbamoyl)phenyl)-2,4-dihydroxybenzamide",CHEMBL4403280,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CN(C)C(=O)c1ccc(N(Cc2ccc(Br)o2)C(=O)c2ccc(O)cc2O)cc1,CHEMBL4402524,Identification of Novel Resorcinol Amide Derivatives as Potent and Specific Pyruvate Dehydrogenase Kinase (PDHK) Inhibitors.,J Med Chem,2019.0,62,18,8461,8479,10.1021/acs.jmedchem.9b00565,31469962.0,
19257449,CHEMBL4591977,"N-((4-Bromothiophen-2-yl)methyl)-N-(4-(dimethylcarbamoyl)phenyl)-2,4-dihydroxybenzamide",CHEMBL4403280,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,18000.0,nM,CN(C)C(=O)c1ccc(N(Cc2cc(Br)cs2)C(=O)c2ccc(O)cc2O)cc1,CHEMBL4402524,Identification of Novel Resorcinol Amide Derivatives as Potent and Specific Pyruvate Dehydrogenase Kinase (PDHK) Inhibitors.,J Med Chem,2019.0,62,18,8461,8479,10.1021/acs.jmedchem.9b00565,31469962.0,
19262087,CHEMBL4447583,(S)-N-(2-Amino-1-(5-(hydroxymethyl)thiazol-2-yl)ethyl)-3-methyl-5-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrrole-2-carboxamide,CHEMBL4404459,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH addition and measured for 10 to 30 mins by LC-MS/MS analysis,IC50,>,100000.0,nM,Cc1cc(-c2ccc(C(F)(F)F)cn2)[nH]c1C(=O)N[C@@H](CN)c1ncc(CO)s1,CHEMBL4402563,"Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.",J Med Chem,2020.0,63,4,1724,1749,10.1021/acs.jmedchem.9b02149,32031803.0,
19262788,CHEMBL4435674,N-(1-(tert-Butyl)piperidin-4-yl)-2-chloro-4-(trifluoromethyl)benzamide,CHEMBL4404591,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,100000.0,nM,CC(C)(C)N1CCC(NC(=O)c2ccc(C(F)(F)F)cc2Cl)CC1,CHEMBL4402569,Optimization of 4-Aminopiperidines as Inhibitors of Influenza A Viral Entry That Are Synergistic with Oseltamivir.,J Med Chem,2020.0,63,6,3120,3130,10.1021/acs.jmedchem.9b01900,32069052.0,
19263247,CHEMBL4471352,"7-((5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2H,6H-pyrano[3,2-b]xanthen-9-yl)oxy)heptanoic Acid",CHEMBL4404738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,>,10000.0,nM,COc1c(OCCCCCCC(=O)O)cc2oc3cc4c(c(O)c3c(=O)c2c1CC=C(C)C)C=CC(C)(C)O4,CHEMBL4402573,Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.,J Med Chem,2020.0,63,6,3370,3380,10.1021/acs.jmedchem.0c00060,32115956.0,
19265578,CHEMBL4440098,"6-(2-(2,4-Difluorophenoxy)-5-((ethylsulfonyl)methyl)pyridin-3-yl)-8-methylpyrrolo[1,2-a]pyrazin-1(2H)-one",CHEMBL4405096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate preincubated for 10 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis,IC50,>,20000.0,nM,CCS(=O)(=O)Cc1cnc(Oc2ccc(F)cc2F)c(-c2cc(C)c3c(=O)[nH]ccn23)c1,CHEMBL4402585,"Discovery of 8-Methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives as Highly Potent and Selective Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitors.",J Med Chem,2020.0,63,8,3956,3975,10.1021/acs.jmedchem.9b01784,32208600.0,
19266986,CHEMBL4438144,"4-((5-(4-Fluoro-1-(1H-indazol-6-yl)-1H-benzo[d][1,2,3]triazol-6-yl)-1H-pyrazol-1-yl)methyl)benzonitrile",CHEMBL4405664,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using diclofenac as substrate incubated for 5 to 20 mins by LC-MS/MS analysis,IC50,>,40000.0,nM,N#Cc1ccc(Cn2nccc2-c2cc(F)c3nnn(-c4ccc5cn[nH]c5c4)c3c2)cc1,CHEMBL4402588,Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.,J Med Chem,2020.0,63,8,3935,3955,10.1021/acs.jmedchem.9b01713,32212732.0,
19266993,CHEMBL4467828,"4-((5-(4-Chloro-1-(1H-indazol-6-yl)-1H-benzo[d][1,2,3]triazol-6-yl)-1H-pyrazol-1-yl)methyl)benzonitrile",CHEMBL4405664,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using diclofenac as substrate incubated for 5 to 20 mins by LC-MS/MS analysis,IC50,=,4000.0,nM,N#Cc1ccc(Cn2nccc2-c2cc(Cl)c3nnn(-c4ccc5cn[nH]c5c4)c3c2)cc1,CHEMBL4402588,Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.,J Med Chem,2020.0,63,8,3935,3955,10.1021/acs.jmedchem.9b01713,32212732.0,
19267000,CHEMBL4581829,"6-((5-(1-(1H-Indazol-6-yl)-1H-benzo[d][1,2,3]triazol-6-yl)-1H-pyrazol-1-yl)methyl)nicotinonitrile",CHEMBL4405664,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using diclofenac as substrate incubated for 5 to 20 mins by LC-MS/MS analysis,IC50,=,17800.0,nM,N#Cc1ccc(Cn2nccc2-c2ccc3nnn(-c4ccc5cn[nH]c5c4)c3c2)nc1,CHEMBL4402588,Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.,J Med Chem,2020.0,63,8,3935,3955,10.1021/acs.jmedchem.9b01713,32212732.0,
19267007,CHEMBL4527606,"6-(1-(2,4-Dichlorobenzyl)-1H-pyrazol-5-yl)-1-(1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine",CHEMBL4405664,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using diclofenac as substrate incubated for 5 to 20 mins by LC-MS/MS analysis,IC50,>,40000.0,nM,Nc1nn(-c2ccc3cn[nH]c3c2)c2cc(-c3ccnn3Cc3ccc(Cl)cc3Cl)cnc12,CHEMBL4402588,Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.,J Med Chem,2020.0,63,8,3935,3955,10.1021/acs.jmedchem.9b01713,32212732.0,
19267014,CHEMBL4454039,"4-Chloro-6-(1-((5-chloropyridin-2-yl)methyl)-1H-pyrazol-5-yl)-1-(1H-indazol-6-yl)-1H-benzo[d][1,2,3]triazole",CHEMBL4405664,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using diclofenac as substrate incubated for 5 to 20 mins by LC-MS/MS analysis,IC50,=,15900.0,nM,Clc1ccc(Cn2nccc2-c2cc(Cl)c3nnn(-c4ccc5cn[nH]c5c4)c3c2)nc1,CHEMBL4402588,Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.,J Med Chem,2020.0,63,8,3935,3955,10.1021/acs.jmedchem.9b01713,32212732.0,
19267021,CHEMBL4516795,"4-((5-(4-Fluoro-1-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-1H-benzo[d][1,2,3]triazol-6-yl)-1H-pyrazol-1-yl)methyl)benzonitrile",CHEMBL4405664,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using diclofenac as substrate incubated for 5 to 20 mins by LC-MS/MS analysis,IC50,>,40000.0,nM,N#Cc1ccc(Cn2nccc2-c2cc(F)c3nnn(-c4ccc5[nH]c(=O)[nH]c5c4)c3c2)cc1,CHEMBL4402588,Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.,J Med Chem,2020.0,63,8,3935,3955,10.1021/acs.jmedchem.9b01713,32212732.0,
19267028,CHEMBL4454426,"3-Chloro-4-((5-(1-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-1H-[1,2,3]triazolo[4,5-c]pyridin-6-yl)-1H-pyrazol-1-yl)methyl)benzonitrile",CHEMBL4405664,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using diclofenac as substrate incubated for 5 to 20 mins by LC-MS/MS analysis,IC50,>,40000.0,nM,N#Cc1ccc(Cn2nccc2-c2cc3c(cn2)nnn3-c2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1,CHEMBL4402588,Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.,J Med Chem,2020.0,63,8,3935,3955,10.1021/acs.jmedchem.9b01713,32212732.0,
19267035,CHEMBL4527142,"5-(6-(1-(2,4-Dichlorobenzyl)-1H-pyrazol-5-yl)-1H-[1,2,3]triazolo[4,5-c]pyridin-1-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one",CHEMBL4405664,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using diclofenac as substrate incubated for 5 to 20 mins by LC-MS/MS analysis,IC50,>,40000.0,nM,O=c1[nH]c2ccc(-n3nnc4cnc(-c5ccnn5Cc5ccc(Cl)cc5Cl)cc43)cc2[nH]1,CHEMBL4402588,Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.,J Med Chem,2020.0,63,8,3935,3955,10.1021/acs.jmedchem.9b01713,32212732.0,
19267042,CHEMBL4522718,"5-(4-Chloro-6-(1-((5-chloropyridin-2-yl)methyl)-1H-pyrazol-5-yl)-1H-benzo[d][1,2,3]triazol-1-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one",CHEMBL4405664,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using diclofenac as substrate incubated for 5 to 20 mins by LC-MS/MS analysis,IC50,>,40000.0,nM,O=c1[nH]c2ccc(-n3nnc4c(Cl)cc(-c5ccnn5Cc5ccc(Cl)cn5)cc43)cc2[nH]1,CHEMBL4402588,Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.,J Med Chem,2020.0,63,8,3935,3955,10.1021/acs.jmedchem.9b01713,32212732.0,
19267049,CHEMBL4456158,"6-((5-(4-Chloro-1-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-1H-benzo[d][1,2,3]triazol-6-yl)-1H-pyrazol-1-yl)methyl)nicotinonitrile",CHEMBL4405664,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using diclofenac as substrate incubated for 5 to 20 mins by LC-MS/MS analysis,IC50,>,40000.0,nM,N#Cc1ccc(Cn2nccc2-c2cc(Cl)c3nnn(-c4ccc5[nH]c(=O)[nH]c5c4)c3c2)nc1,CHEMBL4402588,Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.,J Med Chem,2020.0,63,8,3935,3955,10.1021/acs.jmedchem.9b01713,32212732.0,
19267990,CHEMBL4571380,"(1R,2R,3S,4R,5S)-4-(6-((4-Hydroxy-3-methoxyphenethyl)amino)-2-(phenylethynyl)-9H-purin-9-yl)bicyclo[3.1.0]hexane-2,3-diol",CHEMBL4406047,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using tolbutamide as substrate,IC50,=,14400.0,nM,COc1cc(CCNc2nc(C#Cc3ccccc3)nc3c2ncn3[C@H]2[C@H](O)[C@H](O)[C@@H]3C[C@@H]32)ccc1O,CHEMBL4402597,Truncated (N)-Methanocarba Nucleosides as Partial Agonists at Mouse and Human A3 Adenosine Receptors: Affinity Enhancement by N6-(2-Phenylethyl) Substitution.,J Med Chem,2020.0,63,8,4334,4348,10.1021/acs.jmedchem.0c00235,32271569.0,
19269738,CHEMBL4442292,"6-[(1H-1,2,3-Benzotriazol-1-yl)amino]hexanoic Acid",CHEMBL4406412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human pooled liver microsomes using tolbutamide as substrate after 10 mins by UPLC-MS/MS analysis,IC50,>,3000000.0,nM,O=C(O)CCCCCNn1nnc2ccccc21,CHEMBL4402606,Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1.,J Med Chem,2020.0,63,9,4824,4836,10.1021/acs.jmedchem.0c00101,32302132.0,
19269739,CHEMBL4557940,"8-[(1H-1,2,3-Benzotriazol-1-yl)amino]octanoic Acid",CHEMBL4406412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human pooled liver microsomes using tolbutamide as substrate after 10 mins by UPLC-MS/MS analysis,IC50,=,343000.0,nM,O=C(O)CCCCCCCNn1nnc2ccccc21,CHEMBL4402606,Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1.,J Med Chem,2020.0,63,9,4824,4836,10.1021/acs.jmedchem.0c00101,32302132.0,
19269752,CHEMBL4442292,"6-[(1H-1,2,3-Benzotriazol-1-yl)amino]hexanoic Acid",CHEMBL4406407,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human pooled liver microsomes using tolbutamide as substrate preincubated with NADPH for 30 mins followed by substrate addition and measured after 10 mins by UPLC-MS/MS analysis,IC50,=,1940000.0,nM,O=C(O)CCCCCNn1nnc2ccccc21,CHEMBL4402606,Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1.,J Med Chem,2020.0,63,9,4824,4836,10.1021/acs.jmedchem.0c00101,32302132.0,
19269753,CHEMBL4557940,"8-[(1H-1,2,3-Benzotriazol-1-yl)amino]octanoic Acid",CHEMBL4406407,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human pooled liver microsomes using tolbutamide as substrate preincubated with NADPH for 30 mins followed by substrate addition and measured after 10 mins by UPLC-MS/MS analysis,IC50,=,330000.0,nM,O=C(O)CCCCCCCNn1nnc2ccccc21,CHEMBL4402606,Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1.,J Med Chem,2020.0,63,9,4824,4836,10.1021/acs.jmedchem.0c00101,32302132.0,
19271797,CHEMBL4575655,2-Fluoro-6-methoxy-4-(4-methyl-5-(4-(4-methylpiperazin-1-yl)phenyl)pyridin-3-yl)benzamide,CHEMBL4406781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate incubated for 40 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,30000.0,nM,COc1cc(-c2cncc(-c3ccc(N4CCN(C)CC4)cc3)c2C)cc(F)c1C(N)=O,CHEMBL4402613,Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.,J Med Chem,2020.0,63,9,4978,4996,10.1021/acs.jmedchem.0c00395,32369358.0,
19271798,CHEMBL4548795,2-Fluoro-4-(5-(4-(4-isopropylpiperazin-1-yl)phenyl)-4-methylpyridin-3-yl)-6-methoxybenzamide,CHEMBL4406781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate incubated for 40 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,30000.0,nM,COc1cc(-c2cncc(-c3ccc(N4CCN(C(C)C)CC4)cc3)c2C)cc(F)c1C(N)=O,CHEMBL4402613,Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.,J Med Chem,2020.0,63,9,4978,4996,10.1021/acs.jmedchem.0c00395,32369358.0,
19271799,CHEMBL4434717,"2-Fluoro-6-methoxy-4-(4-methyl-5-(4-((3R,5S)-3,4,5-trimethylpiperazin-1-yl)phenyl)pyridin-3-yl)benzamide",CHEMBL4406781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate incubated for 40 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,30000.0,nM,COc1cc(-c2cncc(-c3ccc(N4C[C@H](C)N(C)[C@H](C)C4)cc3)c2C)cc(F)c1C(N)=O,CHEMBL4402613,Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.,J Med Chem,2020.0,63,9,4978,4996,10.1021/acs.jmedchem.0c00395,32369358.0,
19296339,CHEMBL4586372,"1-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(4-(8-(cyclopropylamino)imidazo[1,2-a]pyrazin-5-yl)-3-methylphenyl)urea",CHEMBL4412515,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in liver microsomes (unknown origin) using sulfaphenazole as substrate preincubated for 5 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis,IC50,=,3500.0,nM,Cc1cc(NC(=O)Nc2cc(C(C)(C)C)nn2-c2ccccc2)ccc1-c1cnc(NC2CC2)c2nccn12,CHEMBL4411291,Synthesis and anti-tumor activity of imidazopyrazines as TAK1 inhibitors.,Eur J Med Chem,2019.0,163,,660,670,10.1016/j.ejmech.2018.12.025,30576901.0,
19300626,CHEMBL4551786,Ethyl (3E)-3-[3-(6-Methylpyridin-2-yl)prop-2-yn-1-ylidene]-pyrrolidine-1-carboxylate,CHEMBL4413477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9,IC50,>,20000.0,nM,CCOC(=O)N1CC/C(=C\C#Cc2cccc(C)n2)C1,CHEMBL4411314,"Evaluation of Amides, Carbamates, Sulfonamides, and Ureas of 4-Prop-2-ynylidenecycloalkylamine as Potent, Selective, and Bioavailable Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5.",J Med Chem,2019.0,62,3,1246,1273,10.1021/acs.jmedchem.8b01226,30624919.0,
19300627,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4413477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9,IC50,>,20000.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4411314,"Evaluation of Amides, Carbamates, Sulfonamides, and Ureas of 4-Prop-2-ynylidenecycloalkylamine as Potent, Selective, and Bioavailable Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5.",J Med Chem,2019.0,62,3,1246,1273,10.1021/acs.jmedchem.8b01226,30624919.0,
19303122,CHEMBL4546378,"6-Amino-2-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-((2,3-dichlorophenyl)thio)-3-methylpyrimidin-4(3H)-one",CHEMBL4414048,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@@H]1OCC2(CCN(c3nc(N)c(Sc4cccc(Cl)c4Cl)c(=O)n3C)CC2)[C@@H]1N,CHEMBL4411331,"6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors.",J Med Chem,2019.0,62,4,1793,1802,10.1021/acs.jmedchem.8b01726,30688459.0,
19303317,CHEMBL4439006,"6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(3-chloro-2-(cyclopropylamino)pyridin-4-yl)-5-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one",CHEMBL4414114,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@@H]1OCC2(CCN(c3nc4[nH]nc(-c5ccnc(NC6CC6)c5Cl)c4c(=O)n3C)CC2)[C@@H]1N,CHEMBL4411333,Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors.,J Med Chem,2019.0,62,4,1781,1792,10.1021/acs.jmedchem.8b01725,30688462.0,
19306122,CHEMBL3936761,"US9447106, 27b (peak 2)",CHEMBL4414953,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM by LC-MS/MS analysis,IC50,=,5700.0,nM,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,CHEMBL4414549,"Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.",J Med Chem,2019.0,62,17,7923,7940,10.1021/acs.jmedchem.9b00687,31381333.0,
19309092,CHEMBL4460028,"4-((2-((2,2-Dimethylazetidin-1-yl)methyl)-6-fluorobenzyl)-amino)-2,6-difluoro-N-(thiazol-4-yl)benzenesulfonamide",CHEMBL4415873,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,23000.0,nM,CC1(C)CCN1Cc1cccc(F)c1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)c(F)c1,CHEMBL4414586,Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective Na<sub>V</sub>1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy.,J Med Chem,2019.0,62,21,9618,9641,10.1021/acs.jmedchem.9b01032,31525968.0,
19309093,CHEMBL4471825,"4-((2-((tert-Butyl(methyl)amino)methyl)-6-fluorobenzyl)amino)-2,6-difluoro-N-(thiazol-4-yl)benzenesulfonamide",CHEMBL4415873,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,29000.0,nM,CN(Cc1cccc(F)c1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)c(F)c1)C(C)(C)C,CHEMBL4414586,Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective Na<sub>V</sub>1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy.,J Med Chem,2019.0,62,21,9618,9641,10.1021/acs.jmedchem.9b01032,31525968.0,
19309094,CHEMBL4435054,"2,6-Difluoro-4-((2-fluoro-6-((isopropyl(methyl)amino)methyl)-benzyl)amino)-N-(thiazol-4-yl)benzenesulfonamide",CHEMBL4415873,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,14000.0,nM,CC(C)N(C)Cc1cccc(F)c1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)c(F)c1,CHEMBL4414586,Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective Na<sub>V</sub>1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy.,J Med Chem,2019.0,62,21,9618,9641,10.1021/acs.jmedchem.9b01032,31525968.0,
19309190,CHEMBL4580996,"(S)-5-Chloro-4-((1-(2,5-difluorophenyl)ethyl)amino)-2-fluoro-N-(thiazol-4-yl)benzene-sulfonamide",CHEMBL4415873,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,3000.0,nM,C[C@H](Nc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl)c1cc(F)ccc1F,CHEMBL4414586,Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective Na<sub>V</sub>1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy.,J Med Chem,2019.0,62,21,9618,9641,10.1021/acs.jmedchem.9b01032,31525968.0,
19309191,CHEMBL4466858,"(S)-2,6-Difluoro-4-((1-(2-fluorophenyl)ethyl)amino)-N-(thiazol-4-yl)benzenesulfonamide",CHEMBL4415873,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,4400.0,nM,C[C@H](Nc1cc(F)c(S(=O)(=O)Nc2cscn2)c(F)c1)c1ccccc1F,CHEMBL4414586,Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective Na<sub>V</sub>1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy.,J Med Chem,2019.0,62,21,9618,9641,10.1021/acs.jmedchem.9b01032,31525968.0,
19315061,CHEMBL4473988,2-[(13-(2-(methylamino)-2-oxoacetamido)tridec-8(Z)-en-1-yl)oxy]acetic acid,CHEMBL4416917,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence method,IC50,>,50000.0,nM,CNC(=O)C(=O)NCCCC/C=C\CCCCCCCOCC(=O)O,CHEMBL4414645,"Development of Robust 17(R),18(S)-Epoxyeicosatetraenoic Acid (17,18-EEQ) Analogues as Potential Clinical Antiarrhythmic Agents.",J Med Chem,2019.0,62,22,10124,10143,10.1021/acs.jmedchem.9b00952,31693857.0,
19315062,CHEMBL4463477,N1-(15-(1H-tetrazol-5-yl)pentadec-5(Z)-enyl)-N2-methyloxalamide,CHEMBL4416917,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence method,IC50,=,5400.0,nM,CNC(=O)C(=O)NCCCC/C=C\CCCCCCCCCc1nnn[nH]1,CHEMBL4414645,"Development of Robust 17(R),18(S)-Epoxyeicosatetraenoic Acid (17,18-EEQ) Analogues as Potential Clinical Antiarrhythmic Agents.",J Med Chem,2019.0,62,22,10124,10143,10.1021/acs.jmedchem.9b00952,31693857.0,
19315063,CHEMBL1802692,(Z)-16-(2-(methylamino)-2-oxoacetamido)hexadec-11-enoic acid,CHEMBL4416917,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence method,IC50,>,50000.0,nM,CNC(=O)C(=O)NCCCC/C=C\CCCCCCCCCC(=O)O,CHEMBL4414645,"Development of Robust 17(R),18(S)-Epoxyeicosatetraenoic Acid (17,18-EEQ) Analogues as Potential Clinical Antiarrhythmic Agents.",J Med Chem,2019.0,62,22,10124,10143,10.1021/acs.jmedchem.9b00952,31693857.0,
19315064,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4416917,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 by fluorescence method,IC50,=,280.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4414645,"Development of Robust 17(R),18(S)-Epoxyeicosatetraenoic Acid (17,18-EEQ) Analogues as Potential Clinical Antiarrhythmic Agents.",J Med Chem,2019.0,62,22,10124,10143,10.1021/acs.jmedchem.9b00952,31693857.0,
19359985,CHEMBL369285,Methyl-(5-pyridin-3-yl-thiophen-2-ylmethyl)-amine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,67700.0,nM,CNCc1ccc(-c2cccnc2)s1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19359986,CHEMBL179621,2-Fluoro-5-(3-methyl-thiophen-2-yl)-pyridine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,>,400000.0,nM,Cc1ccsc1-c1ccc(F)nc1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19359987,CHEMBL361153,3-Thiophen-3-yl-pyridine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,96300.0,nM,c1cncc(-c2ccsc2)c1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19359988,CHEMBL368883,3-(2-Methyl-imidazol-1-yl)-pyridine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,>,300000.0,nM,Cc1nccn1-c1cccnc1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19359989,CHEMBL178516,3-(1H-Imidazol-4-yl)-pyridine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,41800.0,nM,c1cncc(-c2c[nH]cn2)c1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19359990,CHEMBL178938,Methyl-(5-pyridin-3-yl-furan-2-ylmethyl)-amine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,76100.0,nM,CNCc1ccc(-c2cccnc2)o1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19359991,CHEMBL179704,3-(4-Methyl-thiophen-3-yl)-pyridine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,123000.0,nM,Cc1cscc1-c1cccnc1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19359992,CHEMBL359657,C-(5-Pyridin-3-yl-thiophen-2-yl)-methylamine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,8900.0,nM,NCc1ccc(-c2cccnc2)s1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19359994,CHEMBL178090,C-(5-Pyridin-3-yl-furan-2-yl)-methylamine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,11700.0,nM,NCc1ccc(-c2cccnc2)o1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19359996,CHEMBL179669,3-(3-Methyl-thiophen-2-yl)-pyridine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,93100.0,nM,Cc1ccsc1-c1cccnc1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19359997,CHEMBL360998,Dimethyl-(5-pyridin-3-yl-furan-2-ylmethyl)-amine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,222000.0,nM,CN(C)Cc1ccc(-c2cccnc2)o1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19359998,CHEMBL360999,3-(1-Methyl-1H-imidazol-4-yl)-pyridine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,79500.0,nM,Cn1cnc(-c2cccnc2)c1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19359999,CHEMBL361969,Dimethyl-(5-pyridin-3-yl-thiophen-2-ylmethyl)-amine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,206000.0,nM,CN(C)Cc1ccc(-c2cccnc2)s1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360001,CHEMBL178708,5-Pyridin-3-yl-furan-2-carbaldehyde,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,2600.0,nM,O=Cc1ccc(-c2cccnc2)o1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360002,CHEMBL386124,S-(5-(Pyridin-3-yl)furan-2-yl)methyl ethanethioate,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,5700.0,nM,CC(=O)SCc1ccc(-c2cccnc2)o1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360003,CHEMBL214784,(5-pyridin-3-yl-furan-2-yl)methanethiol,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,730.0,nM,SCc1ccc(-c2cccnc2)o1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360004,CHEMBL214990,3-(5-((methylthio)methyl)furan-2-yl)pyridine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,28200.0,nM,CSCc1ccc(-c2cccnc2)o1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360495,CHEMBL178780,3-(1-Benzyl-1H-imidazol-4-yl)-pyridine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,26900.0,nM,c1ccc(Cn2cnc(-c3cccnc3)c2)cc1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360501,CHEMBL178534,5-Pyridin-3-yl-thiophene-2-carbaldehyde oxime,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,223000.0,nM,O/N=C/c1ccc(-c2cccnc2)s1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360506,CHEMBL361364,3-(1-Ethyl-1H-imidazol-4-yl)-pyridine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,75200.0,nM,CCn1cnc(-c2cccnc2)c1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360511,CHEMBL3640762,"US8609708, 21",CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,2100.0,nM,Nc1ccc(-c2cccnc2)s1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360516,CHEMBL179398,5-Pyridin-3-yl-thiophene-2-carbaldehyde,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,55200.0,nM,O=Cc1ccc(-c2cccnc2)s1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360521,CHEMBL179763,"[3,3'']Bipyridinyl",CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,>,300000.0,nM,c1cncc(-c2cccnc2)c1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360526,CHEMBL178711,Bis-(5-pyridin-3-yl-thiophen-2-ylmethyl)-amine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,710.0,nM,c1cncc(-c2ccc(CNCc3ccc(-c4cccnc4)s3)s2)c1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360531,CHEMBL179618,3-Thiophen-2-yl-pyridine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,99200.0,nM,c1cncc(-c2cccs2)c1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360536,CHEMBL362702,1-(5-Pyridin-3-yl-thiophen-2-yl)-ethanone,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,98200.0,nM,CC(=O)c1ccc(-c2cccnc2)s1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360541,CHEMBL178547,5-Pyridin-3-yl-furan-2-carbaldehyde oxime,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,86200.0,nM,O/N=C/c1ccc(-c2cccnc2)o1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360546,CHEMBL425519,2-Fluoro-5-(4-methyl-thiophen-3-yl)-pyridine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,>,400000.0,nM,Cc1cscc1-c1ccc(F)nc1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360551,CHEMBL178330,5-Pyridin-3-yl-furan-2-carbaldehyde oxime,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,398000.0,nM,O/N=C\c1ccc(-c2cccnc2)o1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360558,CHEMBL4466954,(cis/trans)-5-(pyridin-3-yl)furan-2-carbaldehyde oxime,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,=,141000.0,nM,ON=Cc1ccc(-c2cccnc2)o1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19360648,CHEMBL179005,2-Fluoro-5-thiophen-3-yl-pyridine,CHEMBL4422412,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as reduction in specific vivid-blue substrate O-dealkylation by modified PanVera vivid assay protocol based method,IC50,>,400000.0,nM,Fc1ccc(-c2ccsc2)cn1,CHEMBL4421730,Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer,,,,,,,,,US-8609708-B2
19362070,CHEMBL4451942,"5-methyl-3-phenethyl-1-((tetrahydrofuran-2-yl)methyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL4422958,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 15 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,8300.0,nM,Cc1csc2c1c(=O)n(CCc1ccccc1)c(=O)n2CC1CCCO1,CHEMBL4422615,Novel non-xanthine antagonist of the A<sub>2B</sub> adenosine receptor: From HTS hit to lead structure.,Eur J Med Chem,2019.0,163,,763,778,10.1016/j.ejmech.2018.11.045,30576906.0,
19362402,CHEMBL4522981,"3-Ethyl-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",CHEMBL4422958,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 15 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,20000.0,nM,CCn1c(=O)c2c(C)c(C(=O)N3CCC(O)CC3)sc2n(CCC(F)(F)F)c1=O,CHEMBL4422615,Novel non-xanthine antagonist of the A<sub>2B</sub> adenosine receptor: From HTS hit to lead structure.,Eur J Med Chem,2019.0,163,,763,778,10.1016/j.ejmech.2018.11.045,30576906.0,
19364680,CHEMBL4455140,"6-(((1,3-Dihydroxypropan-2-yl)amino)methyl)-5-iodopyrimidine-2,4(1H,3H)-dione",CHEMBL4423607,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by HPLC-MS/MS analysis,IC50,>,100000.0,nM,O=c1[nH]c(CNC(CO)CO)c(I)c(=O)[nH]1,CHEMBL4422632,"Design of Novel Inhibitors of Human Thymidine Phosphorylase: Synthesis, Enzyme Inhibition, in Vitro Toxicity, and Impact on Human Glioblastoma Cancer.",J Med Chem,2019.0,62,3,1231,1245,10.1021/acs.jmedchem.8b01305,30615449.0,
19368484,CHEMBL4592045,"1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine",CHEMBL4424350,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 15 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,CCc1cc(F)c2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)c(C)c2c1,CHEMBL4422661,Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140).,J Med Chem,2019.0,62,4,1761,1780,10.1021/acs.jmedchem.8b01679,30707578.0,
19369962,CHEMBL4439812,"sodium (R)-4-isobutyryl-5-(2-methoxyphenyl)-2-oxo-1-(4-(thiophen-3-yl)phenyl)-2,5-dihydro-1H-pyrrol-3-olate",CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,19000.0,nM,COc1ccccc1[C@@H]1C(C(=O)C(C)C)=C([O-])C(=O)N1c1ccc(-c2ccsc2)cc1.[Na+],CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19369963,CHEMBL4437131,3-hydroxy-4-isobutyryl-5-(2-(2-(methylsulfinyl)ethoxy)phenyl)-1-(4-(thiophen-3-yl)phenyl)-1H-pyrrol-2(5H)-one,CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccsc3)cc2)C1c1ccccc1OCC[S+](C)[O-],CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19369964,CHEMBL4537290,3-hydroxy-5-(2-(2-hydroxyethoxy)phenyl)-4-isobutyryl-1-(4-(thiophen-3-yl)phenyl)-1H-pyrrol-2(5H)-one,CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,9000.0,nM,CC(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccsc3)cc2)C1c1ccccc1OCCO,CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19369965,CHEMBL4454941,3-hydroxy-4-isobutyryl-5-(2-methoxyphenyl)-1-(4-(thiophen-3-yl)phenyl)-1H-pyrrol-2(5H)-one,CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,18000.0,nM,COc1ccccc1C1C(C(=O)C(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1,CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19369966,CHEMBL4459015,"2-(2-(4-hydroxy-5-oxo-3-pivaloyl-1-(4-(thiophen-3-yl)phenyl)-2,5-dihydro-1H-pyrrol-2-yl)phenoxy)-N,N-dimethylacetamide",CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,18000.0,nM,CN(C)C(=O)COc1ccccc1C1C(C(=O)C(C)(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1,CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19369967,CHEMBL4445659,"2-(2-(4-hydroxy-5-oxo-3-pivaloyl-1-(4-(thiophen-3-yl)phenyl)-2,5-dihydro-1H-pyrrol-2-yl)phenoxy)acetic acid",CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(C)(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccsc3)cc2)C1c1ccccc1OCC(=O)O,CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19369968,CHEMBL4459391,3-hydroxy-5-(2-(2-(methylsulfinyl)ethoxy)phenyl)-4-pivaloyl-1-(4-(thiophen-3-yl)phenyl)-1H-pyrrol-2(5H)-one,CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,18000.0,nM,C[S+]([O-])CCOc1ccccc1C1C(C(=O)C(C)(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1,CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19369969,CHEMBL4572081,5-(2-(2-(dimethylamino)ethoxy)phenyl)-3-hydroxy-4-pivaloyl-1-(4-(thiophen-3-yl)phenyl)-1H-pyrrol-2(5H)-one,CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CN(C)CCOc1ccccc1C1C(C(=O)C(C)(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1,CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19369970,CHEMBL4592312,3-hydroxy-5-(2-(2-methoxyethoxy)phenyl)-4-pivaloyl-1-(4-(thiophen-3-yl)phenyl)-1H-pyrrol-2(5H)-one,CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5000.0,nM,COCCOc1ccccc1C1C(C(=O)C(C)(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1,CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19369971,CHEMBL4457637,3-hydroxy-5-(2-methoxyphenyl)-4-pivaloyl-1-(4-(thiophen-3-yl)phenyl)-1H-pyrrol-2(5H)-one,CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8000.0,nM,COc1ccccc1C1C(C(=O)C(C)(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1,CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19369972,CHEMBL4465467,3-hydroxy-5-(2-(2-hydroxyethoxy)phenyl)-4-pivaloyl-1-(4-(thiophen-2-yl)phenyl)-1H-pyrrol-2(5H)-one,CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8000.0,nM,CC(C)(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3cccs3)cc2)C1c1ccccc1OCCO,CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19369973,CHEMBL4466252,3-hydroxy-5-(2-(2-hydroxyethoxy)phenyl)-4-pivaloyl-1-(4-(thiophen-3-yl)phenyl)-1H-pyrrol-2(5H)-one,CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8000.0,nM,CC(C)(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccsc3)cc2)C1c1ccccc1OCCO,CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19369974,CHEMBL4562022,1-(4-(furan-3-yl)phenyl)-3-hydroxy-5-(2-(2-hydroxyethoxy)phenyl)-4-pivaloyl-1H-pyrrol-2(5H)-one,CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,15000.0,nM,CC(C)(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccoc3)cc2)C1c1ccccc1OCCO,CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19369975,CHEMBL4526549,"3-hydroxy-5-(2-(2-hydroxyethoxy)phenyl)-1-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)-4-pivaloyl-1H-pyrrol-2(5H)-one",CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,17000.0,nM,Cc1noc(-c2ccc(N3C(=O)C(O)=C(C(=O)C(C)(C)C)C3c3ccccc3OCCO)cc2)n1,CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19369976,CHEMBL4456152,"3-hydroxy-5-(2-(2-hydroxyethoxy)phenyl)-1-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)-4-pivaloyl-1H-pyrrol-2(5H)-one",CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,Cc1nc(-c2ccc(N3C(=O)C(O)=C(C(=O)C(C)(C)C)C3c3ccccc3OCCO)cc2)no1,CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19369977,CHEMBL4459785,3-hydroxy-5-(2-(2-hydroxyethoxy)phenyl)-1-(4-(3-methylisoxazol-5-yl)phenyl)-4-pivaloyl-1H-pyrrol-2(5H)-one,CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,4000.0,nM,Cc1cc(-c2ccc(N3C(=O)C(O)=C(C(=O)C(C)(C)C)C3c3ccccc3OCCO)cc2)on1,CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19369978,CHEMBL4565775,3-hydroxy-5-(2-(2-hydroxyethoxy)phenyl)-1-(4-(isoxazol-3-yl)phenyl)-4-pivaloyl-1H-pyrrol-2(5H)-one,CHEMBL4424686,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,13000.0,nM,CC(C)(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccon3)cc2)C1c1ccccc1OCCO,CHEMBL4422675,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.,Bioorg Med Chem Lett,2019.0,29,5,688,693,10.1016/j.bmcl.2019.01.039,30728111.0,
19405545,CHEMBL4458575,"2-((R)-1-((S)-2-Hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)-isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)-acetic Acid",CHEMBL4426272,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,O=C(O)C[C@H]1CCCN(C[C@@H](O)c2ccc(-c3noc(-c4onc(-c5ccccc5)c4C(F)(F)F)n3)cc2)C1,CHEMBL4425115,Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1).,J Med Chem,2016.0,59,13,6248,6264,10.1021/acs.jmedchem.6b00373,27309907.0,
19406035,CHEMBL4447846,"7-{[5-Methoxy-3-(1,2,3,6-tetrahydropyridin-4yl)-1H-indol-1-yl]sulfonyl}quinoline",CHEMBL4426371,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in supersomes assessed as diclofenac 4'-hydroxylation after 15 mins by HPLC analysis,IC50,>,100000.0,nM,COc1ccc2c(c1)c(C1=CCNCC1)cn2S(=O)(=O)c1ccc2cccnc2c1,CHEMBL4425120,N1-Azinylsulfonyl-1H-indoles: 5-HT6 Receptor Antagonists with Procognitive and Antidepressant-Like Properties.,ACS Med Chem Lett,2016.0,7,6,618,622,10.1021/acsmedchemlett.6b00056,27326337.0,
19406036,CHEMBL4469309,"4-{[5-Methoxy-3-(1,2,3,6-tetrahydropyridin-4yl)-1H-indol-1-yl]sulfonyl}isoquinoline",CHEMBL4426371,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in supersomes assessed as diclofenac 4'-hydroxylation after 15 mins by HPLC analysis,IC50,>,100000.0,nM,COc1ccc2c(c1)c(C1=CCNCC1)cn2S(=O)(=O)c1cncc2ccccc12,CHEMBL4425120,N1-Azinylsulfonyl-1H-indoles: 5-HT6 Receptor Antagonists with Procognitive and Antidepressant-Like Properties.,ACS Med Chem Lett,2016.0,7,6,618,622,10.1021/acsmedchemlett.6b00056,27326337.0,
19409443,CHEMBL4098822,"(3-chloro-5-fluorophenyl)(2-(5-fluoropyridin-2-yl)-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)methanone",CHEMBL4427253,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 10 mins in presence of NADPH by LC/MS/MS analysis,IC50,>,40000.0,nM,O=C(c1cc(F)cc(Cl)c1)N1CCn2nc(-c3ccc(F)cn3)cc2C1,CHEMBL4425158,"Synthesis, structure-activity relationships and biological evaluation of 4,5,6,7-tetrahydropyrazolopyrazines as metabotropic glutamate receptor 5 negative allosteric modulators.",Bioorg Med Chem Lett,2016.0,26,16,3866,3869,10.1016/j.bmcl.2016.07.019,27432763.0,
19409483,CHEMBL4554361,"phenyl{2-(pyridin-2-yl)-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl}methanone",CHEMBL4427253,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 10 mins in presence of NADPH by LC/MS/MS analysis,IC50,>,50000.0,nM,O=C(c1ccccc1)N1CCn2nc(-c3ccccn3)cc2C1,CHEMBL4425158,"Synthesis, structure-activity relationships and biological evaluation of 4,5,6,7-tetrahydropyrazolopyrazines as metabotropic glutamate receptor 5 negative allosteric modulators.",Bioorg Med Chem Lett,2016.0,26,16,3866,3869,10.1016/j.bmcl.2016.07.019,27432763.0,
19410497,CHEMBL4469414,"N-cyclopropyl-4-(7-((cis-3-hydroxy-3-methylcyclobutyl)methylamino)-5-(pyridin-3-yloxy)pyrazolo[1,5-a]pyrimidin-3-yl)-2-methylbenzamide",CHEMBL4427400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) preincubated for 10 mins followed by addition of MFC as substrate measured after 45 mins in presence of NADP by fluorescence analysis,IC50,=,13000.0,nM,Cc1cc(-c2cnn3c(NC[C@H]4C[C@@](C)(O)C4)cc(Oc4cccnc4)nc23)ccc1C(=O)NC1CC1,CHEMBL4425165,"Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent.",ACS Med Chem Lett,2016.0,7,7,671,675,10.1021/acsmedchemlett.5b00485,27437075.0,
19410517,CHEMBL4546441,"N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(2'-fluoro-3-methyl-2,4'-bipyridin-5-yl)acetamide",CHEMBL4427426,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CC(=O)N1CCN(c2ccc(NC(=O)Cc3cnc(-c4ccnc(F)c4)c(C)c3)nc2)CC1,CHEMBL4425166,"Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors.",ACS Med Chem Lett,2016.0,7,7,676,680,10.1021/acsmedchemlett.6b00038,27437076.0,
19410901,CHEMBL3696475,"US9018211, 2A",CHEMBL4427526,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of human CYP2C9,IC50,>,50000.0,nM,Cc1c([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O,CHEMBL4425169,"Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure.",ACS Med Chem Lett,2016.0,7,7,697,701,10.1021/acsmedchemlett.6b00122,27437080.0,
19430210,CHEMBL4438330,N-(3-(Tert-butyl)-1-ethyl-1H-pyrazol-5-yl)-4-(3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)thiazol-2-amine,CHEMBL4428773,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,>,100000.0,nM,CCn1nc(C(C)(C)C)cc1Nc1nc(-c2ccc(-n3cnc(C)c3)c(F)c2)cs1,CHEMBL4428049,Design and synthesis of aminothiazole modulators of the gamma-secretase enzyme.,Bioorg Med Chem Lett,2016.0,26,16,3928,3937,10.1016/j.bmcl.2016.07.011,27426299.0,
19430854,CHEMBL4462738,1-((5-Chloro-6-isobutoxypyridin-3-yl)oxy)-N-(methylsulfonyl)isoquinoline-6-carboxamide,CHEMBL4428893,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsomes using diclofenac as substrate coincubated with substrate for 30 mins measured after 5 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,9400.0,nM,CC(C)COc1ncc(Oc2nccc3cc(C(=O)NS(C)(=O)=O)ccc23)cc1Cl,CHEMBL4428053,Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors.,J Med Chem,2016.0,59,17,7818,7839,10.1021/acs.jmedchem.6b00425,27441383.0,
19430855,CHEMBL4470763,"4-(5-Chloro-6-isobutoxypyridin-3-yl)-2,5-difluoro-N-(methylsulfonyl)benzamide",CHEMBL4428893,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsomes using diclofenac as substrate coincubated with substrate for 30 mins measured after 5 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,34100.0,nM,CC(C)COc1ncc(-c2cc(F)c(C(=O)NS(C)(=O)=O)cc2F)cc1Cl,CHEMBL4428053,Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors.,J Med Chem,2016.0,59,17,7818,7839,10.1021/acs.jmedchem.6b00425,27441383.0,
19430856,CHEMBL4469805,"4-(5-Chloro-6-(2,5-difluorophenoxy)-3-pyridinyl)-2-fluoro-5-methoxy-N-(methylsulfonyl)benzamide",CHEMBL4428893,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsomes using diclofenac as substrate coincubated with substrate for 30 mins measured after 5 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,45300.0,nM,COc1cc(C(=O)NS(C)(=O)=O)c(F)cc1-c1cnc(Oc2cc(F)ccc2F)c(Cl)c1,CHEMBL4428053,Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors.,J Med Chem,2016.0,59,17,7818,7839,10.1021/acs.jmedchem.6b00425,27441383.0,
19430863,CHEMBL4462738,1-((5-Chloro-6-isobutoxypyridin-3-yl)oxy)-N-(methylsulfonyl)isoquinoline-6-carboxamide,CHEMBL4428896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsomes using diclofenac as substrate incubated with enzyme and NADPH prior to substrate addition by LC-MS/MS analysis,IC50,=,11100.0,nM,CC(C)COc1ncc(Oc2nccc3cc(C(=O)NS(C)(=O)=O)ccc23)cc1Cl,CHEMBL4428053,Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors.,J Med Chem,2016.0,59,17,7818,7839,10.1021/acs.jmedchem.6b00425,27441383.0,
19430864,CHEMBL4470763,"4-(5-Chloro-6-isobutoxypyridin-3-yl)-2,5-difluoro-N-(methylsulfonyl)benzamide",CHEMBL4428896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsomes using diclofenac as substrate incubated with enzyme and NADPH prior to substrate addition by LC-MS/MS analysis,IC50,=,34700.0,nM,CC(C)COc1ncc(-c2cc(F)c(C(=O)NS(C)(=O)=O)cc2F)cc1Cl,CHEMBL4428053,Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors.,J Med Chem,2016.0,59,17,7818,7839,10.1021/acs.jmedchem.6b00425,27441383.0,
19430865,CHEMBL4469805,"4-(5-Chloro-6-(2,5-difluorophenoxy)-3-pyridinyl)-2-fluoro-5-methoxy-N-(methylsulfonyl)benzamide",CHEMBL4428896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsomes using diclofenac as substrate incubated with enzyme and NADPH prior to substrate addition by LC-MS/MS analysis,IC50,=,49600.0,nM,COc1cc(C(=O)NS(C)(=O)=O)c(F)cc1-c1cnc(Oc2cc(F)ccc2F)c(Cl)c1,CHEMBL4428053,Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors.,J Med Chem,2016.0,59,17,7818,7839,10.1021/acs.jmedchem.6b00425,27441383.0,
19432619,CHEMBL3918580,7-(2-hydroxypropan-2-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-9H-carbazole-1-carboxamide,CHEMBL4429416,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 after 30 mins in presence of NADPH,IC50,>,8000.0,nM,Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O,CHEMBL4428066,"Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177).",J Med Chem,2016.0,59,17,7915,7935,10.1021/acs.jmedchem.6b00722,27531604.0,
19434016,CHEMBL4448986,"(+/-)-2-Chloro-N-(1-(4,4-difluoro-1-(4-((1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl)piperazin-1-yl)cyclohexyl)ethyl)-4-(trifluoromethyl)-benzamide Hydrochloride",CHEMBL4429887,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,7200.0,nM,CC(NC(=O)c1ccc(C(F)(F)F)cc1Cl)C1(N2CCN(S(=O)(=O)c3cn(C)nn3)CC2)CCC(F)(F)CC1.Cl,CHEMBL4428077,Synthesis and Biological Evaluation of N-((1-(4-(Sulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide Inhibitors of Glycine Transporter-1.,J Med Chem,2016.0,59,18,8473,8494,10.1021/acs.jmedchem.6b00914,27559615.0,
19434226,CHEMBL4444341,"(4S,6S)-4-(2,4-Difluorophenyl)-4-methyl-6-(pyrimidin-5-yl)-5,6-dihydro-4H-1,3-thiazin-2-amine",CHEMBL4430016,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 preincubated for 10 mins followed by addition of MFC as substrate measured after 45 mins,IC50,>,20000.0,nM,C[C@@]1(c2ccc(F)cc2F)C[C@@H](c2cncnc2)SC(N)=N1,CHEMBL4428078,"Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine β-Site APP Cleaving Enzyme-1 (BACE1) Inhibitors.",J Med Chem,2016.0,59,18,8593,8600,10.1021/acs.jmedchem.6b01012,27559936.0,
19434673,CHEMBL4545710,"(2S)-2-tert-butoxy-2-(4-(4,5-dimethyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2,5-dimethyl-6-((trans)-4-methylcyclohexylcarbamoyl)pyridin-3-yl)acetic acid",CHEMBL4430199,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1nc(C(=O)N[C@H]2CC[C@H](C)CC2)c(C)c(-c2ccc3c(c2C)N(C)CCO3)c1[C@H](OC(C)(C)C)C(=O)O,CHEMBL4428082,Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs.,ACS Med Chem Lett,2016.0,7,8,797,801,10.1021/acsmedchemlett.6b00194,27563405.0,
19439682,CHEMBL4457557,3-(5'-Benzyl-2'-carbamoylbiphenyl-3-yl)propanoic acid,CHEMBL4431172,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9,IC50,>,20000.0,nM,NC(=O)c1ccc(Cc2ccccc2)cc1-c1cccc(CCC(=O)O)c1,CHEMBL4428134,Discovery of AZD2716: A Novel Secreted Phospholipase A<sub>2</sub> (sPLA<sub>2</sub>) Inhibitor for the Treatment of Coronary Artery Disease.,ACS Med Chem Lett,2016.0,7,10,884,889,10.1021/acsmedchemlett.6b00188,27774123.0,
19442539,CHEMBL4464764,"3,6-dihydroxy-2-(3-hydroxyphenyl)-4H-chromen-4-one",CHEMBL4432028,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay,IC50,>,10000.0,nM,O=c1c(O)c(-c2cccc(O)c2)oc2ccc(O)cc12,CHEMBL4431321,Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.,J Med Chem,2016.0,59,16,7598,7616,10.1021/acs.jmedchem.6b00698,27411733.0,
19442971,CHEMBL4541225,"(2S)-4,4-Difluoro-1-[[(4S)-4-(4-fluorophenyl)-5-methoxycarbonyl-4-methyl-2-thiazol-2-yl-1H-pyrimidin-6-yl]methyl]pyrrolidine-2-carboxylic Acid",CHEMBL4432119,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using substrate preincubated for 10 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,COC(=O)C1=C(CN2CC(F)(F)C[C@H]2C(=O)O)NC(c2nccs2)=N[C@@]1(C)c1ccc(F)cc1,CHEMBL4431325,Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.,J Med Chem,2016.0,59,16,7651,7666,10.1021/acs.jmedchem.6b00879,27458651.0,
19451142,CHEMBL4450031,"2-(benzo[d][1,3]dioxol-5-yl)-3-hydroxy-7-methoxy-4H-chromen-4-one",CHEMBL4433759,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cell microsomes using CYP/Luciferin as substrate pre-incubated for 30 mins followed by NADPH regeneration mixture addition and measured after 30 mins by Promega P450-Glo assay,IC50,=,1600.0,nM,COc1ccc2c(=O)c(O)c(-c3ccc4c(c3)OCO4)oc2c1,CHEMBL4433215,SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-<i>Trypanosoma brucei</i> Agent.,ACS Med Chem Lett,2019.0,10,4,528,533,10.1021/acsmedchemlett.8b00565,30996791.0,
19454362,CHEMBL4443920,"isopropyl (S)-2-(2-fluoro-[1,1'-biphenyl]-4-carboxamido)-3-(1H-imidazol-1-yl)propanoate",CHEMBL4434602,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac pre-incubated for 10 mins before NADPH addition and measured after 10 mins by LC/MS/MS analysis,IC50,>,50000.0,nM,CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1ccc(-c2ccccc2)c(F)c1,CHEMBL4433269,"Design, synthesis and evaluation of biphenyl imidazole analogues as potent antifungal agents.",Bioorg Med Chem Lett,2019.0,29,17,2448,2451,10.1016/j.bmcl.2019.07.037,31358467.0,
19454363,CHEMBL4514676,"isopropyl (S)-2-(3-fluoro-[1,1'-biphenyl]-4-carboxamido)-3-(1H-imidazol-1-yl)propanoate",CHEMBL4434602,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac pre-incubated for 10 mins before NADPH addition and measured after 10 mins by LC/MS/MS analysis,IC50,=,4490.0,nM,CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1ccc(-c2ccccc2)cc1F,CHEMBL4433269,"Design, synthesis and evaluation of biphenyl imidazole analogues as potent antifungal agents.",Bioorg Med Chem Lett,2019.0,29,17,2448,2451,10.1016/j.bmcl.2019.07.037,31358467.0,
19471421,CHEMBL4513257,"3-(3-(4-(Aminomethyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]-pyridin-2-yl)pyridin-2-amine Hydrochloride",CHEMBL4478670,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 10 mins by LC/MS/MS analysis,IC50,<,1000.0,nM,Cl.NCc1ccc(-n2c(-c3cccnc3N)nc3ccc(-c4ccccc4)nc32)cc1,CHEMBL4477217,"Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.",J Med Chem,2016.0,59,13,6455,6469,10.1021/acs.jmedchem.6b00619,27305487.0,
19471422,CHEMBL4546484,"N-(3-(3-(4-(Aminomethyl)phenyl)-2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-5-yl)phenyl)acetamide Hydrochloride",CHEMBL4478670,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 10 mins by LC/MS/MS analysis,IC50,=,100.0,nM,CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CN)cc4)c3n2)c1.Cl,CHEMBL4477217,"Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.",J Med Chem,2016.0,59,13,6455,6469,10.1021/acs.jmedchem.6b00619,27305487.0,
19471423,CHEMBL4523032,"3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo-[4,5-b]pyridin-2-yl)pyridin-2-amine Hydrochloride",CHEMBL4478670,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 10 mins by LC/MS/MS analysis,IC50,=,7900.0,nM,Cl.Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1,CHEMBL4477217,"Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.",J Med Chem,2016.0,59,13,6455,6469,10.1021/acs.jmedchem.6b00619,27305487.0,
19471424,CHEMBL4519558,"N-(3-(3-(4-(1-Aminocyclobutyl)phenyl)-2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-5-yl)phenyl)acetamide Hydrochloride",CHEMBL4478670,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 10 mins by LC/MS/MS analysis,IC50,=,1000.0,nM,CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1.Cl,CHEMBL4477217,"Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.",J Med Chem,2016.0,59,13,6455,6469,10.1021/acs.jmedchem.6b00619,27305487.0,
19471425,CHEMBL4574111,"3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-(3-aminophenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine Hydrochloride",CHEMBL4478670,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 10 mins by LC/MS/MS analysis,IC50,>,20000.0,nM,Cl.Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1,CHEMBL4477217,"Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.",J Med Chem,2016.0,59,13,6455,6469,10.1021/acs.jmedchem.6b00619,27305487.0,
19471426,CHEMBL4544109,"3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-(pyridin-3-yl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine Hydrochloride",CHEMBL4478670,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 10 mins by LC/MS/MS analysis,IC50,=,10000.0,nM,Cl.Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(C2(N)CCC2)cc1,CHEMBL4477217,"Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.",J Med Chem,2016.0,59,13,6455,6469,10.1021/acs.jmedchem.6b00619,27305487.0,
19471879,CHEMBL4584780,4-(1-(6-(Pyridin-3-yl)-2-(pyridin-4-yl)pyrimidin-4-yl)-piperidin-4-yl)morpholine,CHEMBL4478738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate by fluorescence assay,IC50,=,1900.0,nM,c1cncc(-c2cc(N3CCC(N4CCOCC4)CC3)nc(-c3ccncc3)n2)c1,CHEMBL4477219,Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials.,J Med Chem,2016.0,59,13,6101,6120,10.1021/acs.jmedchem.6b00028,27314305.0,
19471880,CHEMBL4569641,4-((1-(6-(Pyridin-3-yl)-2-(pyridin-4-yl)pyrimidin-4-yl)-piperidin-4-yl)methyl)morpholine,CHEMBL4478738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate by fluorescence assay,IC50,=,3500.0,nM,c1cncc(-c2cc(N3CCC(CN4CCOCC4)CC3)nc(-c3ccncc3)n2)c1,CHEMBL4477219,Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials.,J Med Chem,2016.0,59,13,6101,6120,10.1021/acs.jmedchem.6b00028,27314305.0,
19471881,CHEMBL4570567,"4-(1-(2-(2,6-Dimethylpyridin-4-yl)-6-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-yl)morpholine",CHEMBL4478738,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using 7-methoxy-4-(trifluoromethyl)-coumarin as substrate by fluorescence assay,IC50,=,82000.0,nM,Cc1cc(-c2nc(-c3cccnc3)cc(N3CCC(N4CCOCC4)CC3)n2)cc(C)n1,CHEMBL4477219,Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials.,J Med Chem,2016.0,59,13,6101,6120,10.1021/acs.jmedchem.6b00028,27314305.0,
19476046,CHEMBL4557930,(1-(2-chlorobenzyl)-3-(6-methoxypyridin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanol,CHEMBL4479546,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes incubated for 15 mins using diclofenac substrate in presence of NADPH by LC-MS/MS method,IC50,=,6800.0,nM,COc1ccc(-c2c(CO)n(Cc3ccccc3Cl)c3ccc(OC(F)(F)F)cc23)cn1,CHEMBL4477245,Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin.,J Med Chem,2016.0,59,16,7690,7695,10.1021/acs.jmedchem.6b00928,27482618.0,
19476047,CHEMBL4528799,(1-(2-chlorobenzyl)-3-(2-(methylthio)pyrimidin-5-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanol,CHEMBL4479546,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes incubated for 15 mins using diclofenac substrate in presence of NADPH by LC-MS/MS method,IC50,=,6100.0,nM,CSc1ncc(-c2c(CO)n(Cc3ccccc3Cl)c3ccc(OC(F)(F)F)cc23)cn1,CHEMBL4477245,Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin.,J Med Chem,2016.0,59,16,7690,7695,10.1021/acs.jmedchem.6b00928,27482618.0,
19476048,CHEMBL4566669,"(1-(2-chlorobenzyl)-3-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanol",CHEMBL4479546,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes incubated for 15 mins using diclofenac substrate in presence of NADPH by LC-MS/MS method,IC50,=,11200.0,nM,COc1nn2cc(-c3c(CO)n(Cc4ccccc4Cl)c4ccc(OC(F)(F)F)cc34)nc2s1,CHEMBL4477245,Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin.,J Med Chem,2016.0,59,16,7690,7695,10.1021/acs.jmedchem.6b00928,27482618.0,
19476422,CHEMBL3919436,"US9193736, 40",CHEMBL4479645,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin),IC50,>,10000.0,nM,O=C(O)c1ccc(-c2c(/C=C/c3ccc4ccccc4n3)nc3c(N4CCOCC4)ccnn23)cc1,CHEMBL4477250,"Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors.",Bioorg Med Chem Lett,2016.0,26,17,4216,4222,10.1016/j.bmcl.2016.07.054,27491708.0,
19486014,CHEMBL4537625,"sodium (S)-4-(4'-cyclopropyl-5-neopentyl-3,5'-biisoxazol-3'-yl)-6-(2,4-dichlorophenylamino)-6-oxohexanoate",CHEMBL4481576,A,,Homo sapiens,Cytochrome P450 2C9,Time-dependent inhibition of human CYP2C9,IC50,>,50000.0,nM,CC(C)(C)Cc1cc(-c2onc([C@@H](CCC(=O)[O-])CC(=O)Nc3ccc(Cl)cc3Cl)c2C2CC2)no1.[Na+],CHEMBL4480411,Discovery of Second Generation RORγ Inhibitors Composed of an Azole Scaffold.,J Med Chem,2019.0,62,5,2837,2842,10.1021/acs.jmedchem.8b01567,30776227.0,
20600312,CHEMBL4634634,"3-(1-methyl-1H-pyrazol-4-yl)-5-((R)-3-methyl-4-((1R,2R)-2-methylcyclopropane-1-carbonyl)piperazin-1-yl)pyrazine-2-carbonitrile",CHEMBL4603263,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C,CHEMBL4602617,Discovery and optimization of heteroaryl piperazines as potent and selective PI3Kδ inhibitors.,Bioorg Med Chem Lett,2020.0,30,1,126715,126715,10.1016/j.bmcl.2019.126715,31757666.0,
20606232,CHEMBL4640031,"(2S,6R)-N-(4-(1-((1s,4s)-4-Hydroxy-4-methylcyclohexyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl)-2,6-dimethylmorpholine-4-carboxamide",CHEMBL4604979,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,C[C@H]1CN(C(=O)Nc2cc(-c3cn([C@H]4CC[C@@](C)(O)CC4)c4cnccc34)ccn2)C[C@@H](C)O1,CHEMBL4602691,Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133.,J Med Chem,2020.0,63,6,2958,2973,10.1021/acs.jmedchem.9b01624,32077280.0,
20606233,CHEMBL4636064,"4-Ethyl-N-(4-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl)piperazine-1-carboxamide",CHEMBL4604979,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,CCN1CCN(C(=O)Nc2cc(-c3cn(C4CCOCC4)c4cnccc34)ccn2)CC1,CHEMBL4602691,Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133.,J Med Chem,2020.0,63,6,2958,2973,10.1021/acs.jmedchem.9b01624,32077280.0,
20606880,CHEMBL4647703,N-(3-((5-Chloro-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)amino)phenyl)acetamide,CHEMBL4605186,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C)CC4)cn3)ncc2Cl)c1,CHEMBL4602695,"Discovery and SARs of 5-Chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity.",J Med Chem,2020.0,63,6,3327,3347,10.1021/acs.jmedchem.9b02121,32129996.0,
20608184,CHEMBL4633246,N-Cyclopropyl-3-methyl-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1H-pyrrole-2-carboxamide,CHEMBL4605438,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate measured for 10 to 30 mins in presence of NADPH regenerating system by UPLC-MS analysis,IC50,>,20000.0,nM,Cc1c(Cc2ccc(C(F)(F)F)nc2)c[nH]c1C(=O)NC1CC1,CHEMBL4602703,Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.,J Med Chem,2020.0,63,9,4929,4956,10.1021/acs.jmedchem.0c00311,32248693.0,
20608945,CHEMBL4643577,"N-(6-(4-Isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-3-methoxy-1-methyl-1H-pyrazole-4-carboxamide",CHEMBL4605641,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using tolbutamide as substrate,IC50,=,10000.0,nM,COc1nn(C)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1,CHEMBL4602708,Discovery of CNS-Penetrant Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitors.,ACS Med Chem Lett,2020.0,11,4,485,490,10.1021/acsmedchemlett.9b00611,32292554.0,
20608946,CHEMBL4641666,N-(6-(1-Isopropyl-1H-imidazol-5-yl)pyridin-2-yl)-3-methoxy-1-methyl-1H-pyrazole-4-carboxamide,CHEMBL4605641,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using tolbutamide as substrate,IC50,=,700.0,nM,COc1nn(C)cc1C(=O)Nc1cccc(-c2cncn2C(C)C)n1,CHEMBL4602708,Discovery of CNS-Penetrant Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitors.,ACS Med Chem Lett,2020.0,11,4,485,490,10.1021/acsmedchemlett.9b00611,32292554.0,
20608947,CHEMBL4632672,"N-(6-(4-Isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-3-methoxy-1-(pyrazin-2-yl)-1H-pyrazole-4-carboxamide",CHEMBL4605641,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using tolbutamide as substrate,IC50,>,10000.0,nM,COc1nn(-c2cnccn2)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1,CHEMBL4602708,Discovery of CNS-Penetrant Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitors.,ACS Med Chem Lett,2020.0,11,4,485,490,10.1021/acsmedchemlett.9b00611,32292554.0,
20610875,CHEMBL4642567,"2-(Isopentylamino)naphthalene-1,4-dione",CHEMBL4606254,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using isoform-specific probe substrates incubated for 15 to 30 mins by by LC-MS/MS analysis,IC50,=,29300.0,nM,CC(C)CCNC1=CC(=O)c2ccccc2C1=O,CHEMBL4602726,Discovery of the First Vitamin K Analogue as a Potential Treatment of Pharmacoresistant Seizures.,J Med Chem,2020.0,63,11,5865,5878,10.1021/acs.jmedchem.0c00168,32390424.0,
20612221,CHEMBL4640366,N-Phenyl-N'-(trityloxy)octanediamide,CHEMBL4606402,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 45 mins by LC-MS/MS analysis,IC50,=,2520.0,nM,O=C(CCCCCCC(=O)Nc1ccccc1)NOC(c1ccccc1)(c1ccccc1)c1ccccc1,CHEMBL4602729,O-Alkyl Hydroxamates Display Potent and Selective Antileishmanial Activity.,J Med Chem,2020.0,63,11,5734,5751,10.1021/acs.jmedchem.9b02016,32392053.0,
20631825,CHEMBL473417,2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide,CHEMBL4610900,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,CHEMBL4610013,"Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).",Bioorg Med Chem,2020.0,28,2,115227,115227,10.1016/j.bmc.2019.115227,31862310.0,
20631851,CHEMBL4632769,"N-[5-(lH-imidazol-2-yl)-2,4-dimethylphenyl]-4-(pyridin-2-yl-methoxy)benzamide",CHEMBL4610900,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,Cc1cc(C)c(-c2ncc[nH]2)cc1NC(=O)c1ccc(OCc2ccccn2)cc1,CHEMBL4610013,"Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).",Bioorg Med Chem,2020.0,28,2,115227,115227,10.1016/j.bmc.2019.115227,31862310.0,
20631877,CHEMBL4637222,"N-[2,4-dimethyl-5-(l-methyl-lH-imidazol-4-yl)phenyl]-4-(pyr-idin-2-ylmethoxy)benzamide",CHEMBL4610900,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,4500.0,nM,Cc1cc(C)c(-c2cn(C)cn2)cc1NC(=O)c1ccc(OCc2ccccn2)cc1,CHEMBL4610013,"Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).",Bioorg Med Chem,2020.0,28,2,115227,115227,10.1016/j.bmc.2019.115227,31862310.0,
20632166,CHEMBL4633059,"3-methyl-1-[2-[5-methyl-6-(trifluoromethyl)furo[2,3-d]pyrimidin-4-yl]sulfanylacetyl]imidazolidin-4-one",CHEMBL4610965,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1c(C(F)(F)F)oc2ncnc(SCC(=O)N3CC(=O)N(C)C3)c12,CHEMBL4610015,"Scaffold-hopping identifies furano[2,3-d]pyrimidine amides as potent Notum inhibitors.",Bioorg Med Chem Lett,2020.0,30,3,126751,126751,10.1016/j.bmcl.2019.126751,31862412.0,
20634622,CHEMBL4643134,"(S)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(2-(2,3,5,6-tetramethylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)propanoic acid",CHEMBL4611430,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCn1nnc2c(C)c([C@@H](CC(=O)O)c3ccc4c(c3)CN(C(=O)c3c(C)c(C)cc(C)c3C)CC4)ccc21,CHEMBL4610043,"Design, synthesis and identification of novel, orally bioavailable non-covalent Nrf2 activators.",Bioorg Med Chem Lett,2020.0,30,4,126852,126852,10.1016/j.bmcl.2019.126852,31898999.0,
20639586,CHEMBL4647810,"2-[(3R)-3-Methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine",CHEMBL4612736,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate by LC-MS/MS analysis,IC50,=,11000.0,nM,C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1,CHEMBL4610117,"Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.",J Med Chem,2020.0,63,13,7293,7325,10.1021/acs.jmedchem.0c00369,32502336.0,
20640766,CHEMBL4635331,"N-((R)-3-(7-Methyl-1H-indazol-5-yl)-1-oxo-1-(((S)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)-amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine4,4'-pyrido[2,3-d][1,3]oxazine]-1-carboxamide",CHEMBL4613014,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50118.72,nM,Cc1cc(C[C@@H](NC(=O)N2CCC3(CC2)OC(=O)Nc2ncccc23)C(=O)N[C@@H](CC2CCNCC2)C(=O)N2CCN(c3ccncc3)CC2)cc2cn[nH]c12,CHEMBL4610123,"Structure-Based Drug Discovery of <i>N</i>-((<i>R</i>)-3-(7-Methyl-1<i>H</i>-indazol-5-yl)-1-oxo-1-(((<i>S</i>)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-<i>d</i>][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine.",J Med Chem,2020.0,63,14,7906,7920,10.1021/acs.jmedchem.0c01003,32558564.0,
20641209,CHEMBL4636208,"(R)-N-(1-(1-(1H-Indazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide",CHEMBL4613096,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,10400.0,nM,CC(C)[C@@H](NC(=O)c1cc(C(F)(F)F)ccc1F)C(=O)N1CCC2(CC1)C(=O)N(C)C(=O)N2c1ccc2[nH]ncc2c1,CHEMBL4610127,Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry.,J Med Chem,2020.0,63,14,7840,7856,10.1021/acs.jmedchem.0c00688,32584034.0,
20641322,CHEMBL4644729,"(R)-1-(tert-Butyl)-6-((1-(4-chlorophenyl)ethyl)amino)-5-(4-fluorobenzyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one",CHEMBL4613178,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,6600.0,nM,C[C@@H](Nc1nc2c(cnn2C(C)(C)C)c(=O)n1Cc1ccc(F)cc1)c1ccc(Cl)cc1,CHEMBL4610129,Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis.,J Med Chem,2020.0,63,14,7867,7879,10.1021/acs.jmedchem.0c00711,32603117.0,
20647889,CHEMBL2103870,LUMACAFTOR,CHEMBL4614957,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as reduction in diclofenac 4-hydroxylation,IC50,=,32000.0,nM,Cc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1,CHEMBL4613261,Metabolic and Pharmaceutical Aspects of Fluorinated Compounds.,J Med Chem,2020.0,63,12,6315,6386,10.1021/acs.jmedchem.9b01877,32182061.0,
20653321,CHEMBL4646510,"(2R,3S,5R,6S)-2-(2,5-Difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)-6-(trifluoromethyl)-tetrahydro-2H-pyran-3-amine",CHEMBL4616444,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9,IC50,>,100000.0,nM,CS(=O)(=O)n1cc2c(n1)CN([C@@H]1C[C@H](N)[C@@H](c3cc(F)ccc3F)O[C@@H]1C(F)(F)F)C2,CHEMBL4613324,"Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.",J Med Chem,2020.0,63,13,7108,7126,10.1021/acs.jmedchem.0c00374,32452679.0,
20653333,CHEMBL4646510,"(2R,3S,5R,6S)-2-(2,5-Difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)-6-(trifluoromethyl)-tetrahydro-2H-pyran-3-amine",CHEMBL4616432,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9,IC50,>,100000.0,nM,CS(=O)(=O)n1cc2c(n1)CN([C@@H]1C[C@H](N)[C@@H](c3cc(F)ccc3F)O[C@@H]1C(F)(F)F)C2,CHEMBL4613324,"Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.",J Med Chem,2020.0,63,13,7108,7126,10.1021/acs.jmedchem.0c00374,32452679.0,
20653345,CHEMBL4646510,"(2R,3S,5R,6S)-2-(2,5-Difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)-6-(trifluoromethyl)-tetrahydro-2H-pyran-3-amine",CHEMBL4616420,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9,IC50,>,100000.0,nM,CS(=O)(=O)n1cc2c(n1)CN([C@@H]1C[C@H](N)[C@@H](c3cc(F)ccc3F)O[C@@H]1C(F)(F)F)C2,CHEMBL4613324,"Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.",J Med Chem,2020.0,63,13,7108,7126,10.1021/acs.jmedchem.0c00374,32452679.0,
20656893,CHEMBL4645774,"7,7-dimethyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole",CHEMBL4617373,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC1(C)CN2CCNCc3cccc1c32,CHEMBL4616608,Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.,Bioorg Med Chem Lett,2020.0,30,5,126929,126929,10.1016/j.bmcl.2019.126929,31952960.0,
20656894,CHEMBL4636196,"2,3,4,6-tetrahydro-1H-spiro[[1,4]diazepino[6,7,1-hi]indole-7,1'-cyclobutane]",CHEMBL4617373,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,c1cc2c3c(c1)C1(CCC1)CN3CCNC2,CHEMBL4616608,Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.,Bioorg Med Chem Lett,2020.0,30,5,126929,126929,10.1016/j.bmcl.2019.126929,31952960.0,
20662352,CHEMBL4648137,N-(trans-4-Hydroxycyclohexyl)-6-phenylhexanamide,CHEMBL4618624,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,O=C(CCCCCc1ccccc1)N[C@H]1CC[C@H](O)CC1,CHEMBL4616675,Discovery of 6-Phenylhexanamide Derivatives as Potent Stereoselective Mitofusin Activators for the Treatment of Mitochondrial Diseases.,J Med Chem,2020.0,63,13,7033,7051,10.1021/acs.jmedchem.0c00366,32506913.0,
20663149,CHEMBL4641568,"6-Chloro-3-methyl-2-(3-pyridyl)-3,4-dihydroisoquinolin-1-one",CHEMBL4618750,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC1Cc2cc(Cl)ccc2C(=O)N1c1cccnc1,CHEMBL4616681,"Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors.",J Med Chem,2020.0,63,13,6876,6897,10.1021/acs.jmedchem.0c00233,32530624.0,
20663152,CHEMBL4644373,"6-Chloro-4-methyl-2-(3-pyridyl)-3,4-dihydroisoquinolin-1-one",CHEMBL4618750,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC1CN(c2cccnc2)C(=O)c2ccc(Cl)cc21,CHEMBL4616681,"Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors.",J Med Chem,2020.0,63,13,6876,6897,10.1021/acs.jmedchem.0c00233,32530624.0,
20663155,CHEMBL4638042,"6-Chloro-4,4-dimethyl-2-(3-pyridyl)-3H-isoquinolin-1-one",CHEMBL4618750,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CC1(C)CN(c2cccnc2)C(=O)c2ccc(Cl)cc21,CHEMBL4616681,"Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors.",J Med Chem,2020.0,63,13,6876,6897,10.1021/acs.jmedchem.0c00233,32530624.0,
20664184,CHEMBL4634542,"(1R,3S,4R)-4-((3aR,9bR)-9b-((4-fluorophenyl)sulfonyl)-7-(perfluoropropan-2-yl)-3a,4,5,9b-tetrahydro-1H-benzo[e]indole-3-carbonyl)-3-methylcyclohexane-1-carboxylic acid",CHEMBL4618970,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin),IC50,>,20000.0,nM,C[C@H]1C[C@H](C(=O)O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12,CHEMBL4616702,"Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist.",ACS Med Chem Lett,2020.0,11,6,1221,1227,10.1021/acsmedchemlett.0c00063,32551004.0,
20665277,CHEMBL4641354,(R)-2-(((S)-2-(4-cyanophenyl)propyl)amino)-N-(5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)-2-phenylacetamide,CHEMBL4619289,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,6600.0,nM,C[C@H](CN[C@@H](C(=O)Nc1ccc(-c2cnn(C)c2)cn1)c1ccccc1)c1ccc(C#N)cc1,CHEMBL4616714,"Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor.",ACS Med Chem Lett,2020.0,11,6,1324,1329,10.1021/acsmedchemlett.0c00155,32551019.0,
20671571,CHEMBL4634571,"5-(2,3-dichloro-4-(N-((S)-1,1,1-trifluoropropan-2-yl)sulfamoyl)phenyl)-N-(2-hydroxy-2-methylpropyl)-4-((S)-2-methylpiperidine-1-carbonyl)thiazole-2-carboxamide",CHEMBL4620724,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3700.0,nM,C[C@H]1CCCCN1C(=O)c1nc(C(=O)NCC(C)(C)O)sc1-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)c(Cl)c1Cl,CHEMBL4619752,Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.,Bioorg Med Chem Lett,2020.0,30,12,127205,127205,10.1016/j.bmcl.2020.127205,32336498.0,
20671572,CHEMBL4646118,"5-(2,3-dichloro-4-(N-((S)-1,1,1-trifluoropropan-2-yl)sulfamoyl)phenyl)-4-(4,4-difluoropiperidine-1-carbonyl)-N-(2-hydroxy-2-methylpropyl)thiazole-2-carboxamide",CHEMBL4620724,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,9600.0,nM,C[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N2CCC(F)(F)CC2)c(Cl)c1Cl)C(F)(F)F,CHEMBL4619752,Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.,Bioorg Med Chem Lett,2020.0,30,12,127205,127205,10.1016/j.bmcl.2020.127205,32336498.0,
20671573,CHEMBL4643996,"5-(2,3-dichloro-4-(N-((S)-1,1,1-trifluoropropan-2-yl)sulfamoyl)phenyl)-4-(4-fluoropiperidine-1-carbonyl)-N-(2-hydroxy-2-methylpropyl)thiazole-2-carboxamide",CHEMBL4620724,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,C[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N2CCC(F)CC2)c(Cl)c1Cl)C(F)(F)F,CHEMBL4619752,Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.,Bioorg Med Chem Lett,2020.0,30,12,127205,127205,10.1016/j.bmcl.2020.127205,32336498.0,
20671574,CHEMBL4634281,"5-(2,3-dichloro-4-(N-((S)-1,1,1-trifluoropropan-2-yl)sulfamoyl)phenyl)-4-((2S,4S)-4-fluoro-2-methylpiperidine-1-carbonyl)-N-(2-hydroxy-2-methylpropyl)thiazole-2-carboxamide",CHEMBL4620724,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3800.0,nM,C[C@H]1C[C@@H](F)CCN1C(=O)c1nc(C(=O)NCC(C)(C)O)sc1-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)c(Cl)c1Cl,CHEMBL4619752,Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.,Bioorg Med Chem Lett,2020.0,30,12,127205,127205,10.1016/j.bmcl.2020.127205,32336498.0,
20671575,CHEMBL4647147,"5-(2,3-dichloro-4-(N-((S)-1,1,1-trifluoropropan-2-yl)sulfamoyl)phenyl)-4-(3,3-difluoropyrrolidine-1-carbonyl)-N-(2-hydroxy-2-methylpropyl)thiazole-2-carboxamide",CHEMBL4620724,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,9100.0,nM,C[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N2CCC(F)(F)C2)c(Cl)c1Cl)C(F)(F)F,CHEMBL4619752,Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.,Bioorg Med Chem Lett,2020.0,30,12,127205,127205,10.1016/j.bmcl.2020.127205,32336498.0,
20671576,CHEMBL4644553,"5-(2,3-dichloro-4-(N-((S)-1,1,1-trifluoropropan-2-yl)sulfamoyl)phenyl)-4-((S)-4,4-difluoro-2-methylpyrrolidine-1-carbonyl)-N-(2-hydroxy-2-methylpropyl)thiazole-2-carboxamide",CHEMBL4620724,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,6300.0,nM,C[C@H]1CC(F)(F)CN1C(=O)c1nc(C(=O)NCC(C)(C)O)sc1-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)c(Cl)c1Cl,CHEMBL4619752,Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.,Bioorg Med Chem Lett,2020.0,30,12,127205,127205,10.1016/j.bmcl.2020.127205,32336498.0,
20671577,CHEMBL4643735,"5-(2,3-dichloro-4-(N-((S)-1,1,1-trifluoropropan-2-yl)sulfamoyl)phenyl)-N4,N4-diethyl-N2-(2-hydroxy-2-methylpropyl)thiazole-2,4-dicarboxamide",CHEMBL4620724,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CCN(CC)C(=O)c1nc(C(=O)NCC(C)(C)O)sc1-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)c(Cl)c1Cl,CHEMBL4619752,Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.,Bioorg Med Chem Lett,2020.0,30,12,127205,127205,10.1016/j.bmcl.2020.127205,32336498.0,
20671578,CHEMBL4645439,"5-(2,3-dichloro-4-(N-((S)-1,1,1-trifluorobutan-2-yl)sulfamoyl)phenyl)-4-(4-fluoropiperidine-1-carbonyl)-N-(2-hydroxy-2-methylpropyl)thiazole-2-carboxamide",CHEMBL4620724,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8400.0,nM,CC[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N2CCC(F)CC2)c(Cl)c1Cl)C(F)(F)F,CHEMBL4619752,Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.,Bioorg Med Chem Lett,2020.0,30,12,127205,127205,10.1016/j.bmcl.2020.127205,32336498.0,
20671579,CHEMBL4648138,"N-(5-(2,3-dichloro-4-(N-((S)-1,1,1-trifluoropropan-2-yl)sulfamoyl)phenyl)-4-(4-fluoropiperidine-1-carbonyl)thiazol-2-yl)-3-hydroxy-3-methylbutanamide",CHEMBL4620724,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,7900.0,nM,C[C@H](NS(=O)(=O)c1ccc(-c2sc(NC(=O)CC(C)(C)O)nc2C(=O)N2CCC(F)CC2)c(Cl)c1Cl)C(F)(F)F,CHEMBL4619752,Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.,Bioorg Med Chem Lett,2020.0,30,12,127205,127205,10.1016/j.bmcl.2020.127205,32336498.0,
20671580,CHEMBL4639653,"5-(2,3-dichloro-4-(N-((S)-1,1,1-trifluorobutan-2-yl)sulfamoyl)phenyl)-N4,N4-diethyl-N2-(2-hydroxy-2-methylpropyl)thiazole-2,4-dicarboxamide",CHEMBL4620724,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,6400.0,nM,CC[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N(CC)CC)c(Cl)c1Cl)C(F)(F)F,CHEMBL4619752,Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.,Bioorg Med Chem Lett,2020.0,30,12,127205,127205,10.1016/j.bmcl.2020.127205,32336498.0,
20671581,CHEMBL4646215,"5-(2-(difluoromethyl)-3-fluoro-4-(N-((S)-1,1,1-trifluorobutan-2-yl)sulfamoyl)phenyl)-N-(2-hydroxy-2-methylpropyl)-4-((S)-2-methylpiperidine-1-carbonyl)thiazole-2-carboxamide",CHEMBL4620724,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CC[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N2CCCC[C@@H]2C)c(C(F)F)c1F)C(F)(F)F,CHEMBL4619752,Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.,Bioorg Med Chem Lett,2020.0,30,12,127205,127205,10.1016/j.bmcl.2020.127205,32336498.0,
20671582,CHEMBL4129202,5-(4-(N-tert-butylsulfamoyl)naphthalen-1-yl)-4-(cyclohexylmethyl)-N-(2-hydroxy-2-methylpropyl)thiazole-2-carboxamide,CHEMBL4620724,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,5000.0,nM,CC(C)(O)CNC(=O)c1nc(CC2CCCCC2)c(-c2ccc(S(=O)(=O)NC(C)(C)C)c3ccccc23)s1,CHEMBL4619752,Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.,Bioorg Med Chem Lett,2020.0,30,12,127205,127205,10.1016/j.bmcl.2020.127205,32336498.0,
20673518,CHEMBL4638872,N-(4-(4-Methylpiperidin-1-yl)-3-(trifluoromethyl)phenyl)-4-(morpholinomethyl)benzamide,CHEMBL4621299,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculovirus infected insect cell microsomes using fluorescent substrate in presence of NADPH by fluorescence assay,IC50,=,4980.0,nM,CC1CCN(c2ccc(NC(=O)c3ccc(CN4CCOCC4)cc3)cc2C(F)(F)F)CC1,CHEMBL4619772,Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.,J Med Chem,2020.0,63,13,7211,7225,10.1021/acs.jmedchem.0c00463,32490678.0,
20673521,CHEMBL4634276,N-(3-Chloro-4-((trifluoromethyl)thio)phenyl)-4-(piperidin-1-ylmethyl)benzamide,CHEMBL4621294,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculovirus infected insect cell microsomes using vivid BOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of NAD+ by fluorescence assay,IC50,=,4490.0,nM,O=C(Nc1ccc(SC(F)(F)F)c(Cl)c1)c1ccc(CN2CCCCC2)cc1,CHEMBL4619772,Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.,J Med Chem,2020.0,63,13,7211,7225,10.1021/acs.jmedchem.0c00463,32490678.0,
20673522,CHEMBL4640955,"N-(2,4-Di-tert-butylphenyl)-4-(piperidin-1-ylmethyl)benzamide",CHEMBL4621294,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculovirus infected insect cell microsomes using vivid BOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of NAD+ by fluorescence assay,IC50,=,18600.0,nM,CC(C)(C)c1ccc(NC(=O)c2ccc(CN3CCCCC3)cc2)c(C(C)(C)C)c1,CHEMBL4619772,Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.,J Med Chem,2020.0,63,13,7211,7225,10.1021/acs.jmedchem.0c00463,32490678.0,
20673523,CHEMBL4644544,"N-(4-((1R,3R,5S)-Adamantan-1-yl)phenyl)-4-(piperidin-1-ylmethyl)benzamide",CHEMBL4621294,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculovirus infected insect cell microsomes using vivid BOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of NAD+ by fluorescence assay,IC50,>,100000.0,nM,O=C(Nc1ccc(C23CC4CC(CC(C4)C2)C3)cc1)c1ccc(CN2CCCCC2)cc1,CHEMBL4619772,Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.,J Med Chem,2020.0,63,13,7211,7225,10.1021/acs.jmedchem.0c00463,32490678.0,
20673526,CHEMBL4640931,(5-(tert-Butyl)indolin-1-yl)(4-(1-(piperidin-1-yl)ethyl)phenyl)methanone,CHEMBL4621294,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculovirus infected insect cell microsomes using vivid BOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of NAD+ by fluorescence assay,IC50,=,7940.0,nM,CC(c1ccc(C(=O)N2CCc3cc(C(C)(C)C)ccc32)cc1)N1CCCCC1,CHEMBL4619772,Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.,J Med Chem,2020.0,63,13,7211,7225,10.1021/acs.jmedchem.0c00463,32490678.0,
20673543,CHEMBL4647732,"N-(4-((1R,3R,5S)-Adamantan-1-yl)phenyl)-4-(morpholinomethyl)benzamide",CHEMBL4621299,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculovirus infected insect cell microsomes using fluorescent substrate in presence of NADPH by fluorescence assay,IC50,=,3140.0,nM,O=C(Nc1ccc(C23CC4CC(CC(C4)C2)C3)cc1)c1ccc(CN2CCOCC2)cc1,CHEMBL4619772,Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.,J Med Chem,2020.0,63,13,7211,7225,10.1021/acs.jmedchem.0c00463,32490678.0,
20673703,CHEMBL4643449,"(S)-2-(2-((3-(3-Amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylbenzyl)oxy)phenyl)acetic Acid",CHEMBL4621409,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(C)c1cc(COc2ccccc2CC(=O)O)cc(-c2ccc3c(c2)[C@H](N)CO3)c1,CHEMBL4619774,Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach.,J Med Chem,2020.0,63,15,8088,8113,10.1021/acs.jmedchem.0c00279,32551603.0,
20677510,CHEMBL4632970,"(R)-3-(6-(5-(2-chloro-4-fluorophenylsulfonamido)-6-methoxypyridin-3-yl)-4-oxoquinazolin-3(4H)-yl)-N,2-dimethylpropanamide",CHEMBL4621967,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition and measured after 10 mins by LC-MS/MS analysis,IC50,=,6100.0,nM,CNC(=O)[C@H](C)Cn1cnc2ccc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4Cl)c3)cc2c1=O,CHEMBL4619796,"Discovery of 3-Quinazolin-4(3<i>H</i>)-on-3-yl-2,<i>N</i>-dimethylpropanamides as Orally Active and Selective PI3Kα Inhibitors.",ACS Med Chem Lett,2020.0,11,7,1463,1469,10.1021/acsmedchemlett.0c00239,32676155.0,
20678976,CHEMBL4645216,4-(4-(Quinuclidin-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-naphthoic Acid,CHEMBL4622333,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,O=C(O)c1cc(-c2ccc(C34CCN(CC3)CC4)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1,CHEMBL4619807,Exploration of Alternative Scaffolds for P2Y<sub>14</sub> Receptor Antagonists Containing a Biaryl Core.,J Med Chem,2020.0,63,17,9563,9589,10.1021/acs.jmedchem.0c00745,32787142.0,
20678977,CHEMBL4646514,"4'-(Quinuclidin-4-yl)-5-(4-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)-[1,1'-biphenyl]-3-carboxylic Acid",CHEMBL4622333,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,O=C(O)c1cc(-c2ccc(C34CCN(CC3)CC4)cc2)cc(-n2cc(-c3ccc(C(F)(F)F)cc3)nn2)c1,CHEMBL4619807,Exploration of Alternative Scaffolds for P2Y<sub>14</sub> Receptor Antagonists Containing a Biaryl Core.,J Med Chem,2020.0,63,17,9563,9589,10.1021/acs.jmedchem.0c00745,32787142.0,
20681414,CHEMBL4640376,"5-{8-[(3,4'-Difluoro[1,1'-biphenyl]-4-yl)methoxy]-2-methylimidazo[1,2-a]pyridin-3-yl}-N-methylpyridine-2-carboxamide hydrogen chloride",CHEMBL4623240,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 assessed as reduction in metabolite formation using MFC as substrate incubated for 30 mins by fluorescence assay,IC50,>,10000.0,nM,CNC(=O)c1ccc(-c2c(C)nc3c(OCc4ccc(-c5ccc(F)cc5)cc4F)cccn23)cn1.Cl,CHEMBL4622842,Optimization and biological evaluation of imidazopyridine derivatives as a novel scaffold for γ-secretase modulators with oral efficacy against cognitive deficits in Alzheimer's disease model mice.,Bioorg Med Chem,2020.0,28,11,115455,115455,10.1016/j.bmc.2020.115455,32307259.0,
20682271,CHEMBL4641138,"3-[4-(cyclobutylmethyl)-5-[2-(difluoromethyl)-3-fluoro-4-[[(1S)-1-(trifluoromethyl)propyl]sulfamoyl]phenyl]thiazol-2-yl]-2,2-dimethyl-propanoic acid",CHEMBL4623396,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,6300.0,nM,CC[C@H](NS(=O)(=O)c1ccc(-c2sc(CC(C)(C)C(=O)O)nc2CC2CCC2)c(C(F)F)c1F)C(F)(F)F,CHEMBL4622850,Discovery and optimization of new oxadiazole substituted thiazole RORγt inverse agonists through a bioisosteric amide replacement approach.,Bioorg Med Chem Lett,2020.0,30,12,127174,127174,10.1016/j.bmcl.2020.127174,32334912.0,
20682313,CHEMBL4632490,"3-[5-[4-(cyclobutylmethyl)-5-[2,3-dichloro-4-[[(1S)-2,2,2-trifluoro-1-methyl-ethyl]sulfamoyl]phenyl]thiazol-2-yl]-1,3,4-thiadiazol-2-yl]-2,2-dimethyl-propanoic acid",CHEMBL4623396,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,900.0,nM,C[C@H](NS(=O)(=O)c1ccc(-c2sc(-c3nnc(CC(C)(C)C(=O)O)s3)nc2CC2CCC2)c(Cl)c1Cl)C(F)(F)F,CHEMBL4622850,Discovery and optimization of new oxadiazole substituted thiazole RORγt inverse agonists through a bioisosteric amide replacement approach.,Bioorg Med Chem Lett,2020.0,30,12,127174,127174,10.1016/j.bmcl.2020.127174,32334912.0,
20684949,CHEMBL4633566,"rac-5-Chloro-2-fluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclohexyl]oxy]-N-(pyrimidin-4-yl)benzene-1-sulfonamide",CHEMBL4623875,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,4900.0,nM,Cn1nccc1[C@H]1CCCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)cc1Cl,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20686755,CHEMBL4636716,4-(5-hydroxy-6-p-tolylpyrimidin-4-ylamino)benzimidamide,CHEMBL4624401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1ccc(-c2ncnc(Nc3ccc(C(=N)N)cc3)c2O)cc1,CHEMBL4622895,Discovery of hydroxy pyrimidine Factor IXa inhibitors.,Bioorg Med Chem Lett,2020.0,30,15,127279,127279,10.1016/j.bmcl.2020.127279,32527459.0,
20686756,CHEMBL4643810,3-chloro-4-(5-hydroxy-6-p-tolylpyrimidin-4-ylamino)benzimidamide,CHEMBL4624401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,Cc1ccc(-c2ncnc(Nc3ccc(C(=N)N)cc3Cl)c2O)cc1,CHEMBL4622895,Discovery of hydroxy pyrimidine Factor IXa inhibitors.,Bioorg Med Chem Lett,2020.0,30,15,127279,127279,10.1016/j.bmcl.2020.127279,32527459.0,
20686757,CHEMBL4632936,4-(4-(aminomethyl)phenylamino)-6-p-tolylpyrimidin-5-ol,CHEMBL4624401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1700.0,nM,Cc1ccc(-c2ncnc(Nc3ccc(CN)cc3)c2O)cc1,CHEMBL4622895,Discovery of hydroxy pyrimidine Factor IXa inhibitors.,Bioorg Med Chem Lett,2020.0,30,15,127279,127279,10.1016/j.bmcl.2020.127279,32527459.0,
20686758,CHEMBL4648414,4-(1-iminoisoindolin-5-ylamino)-6-p-tolylpyrimidin-5-ol,CHEMBL4624401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,Cc1ccc(-c2ncnc(Nc3ccc4c(c3)CNC4=N)c2O)cc1,CHEMBL4622895,Discovery of hydroxy pyrimidine Factor IXa inhibitors.,Bioorg Med Chem Lett,2020.0,30,15,127279,127279,10.1016/j.bmcl.2020.127279,32527459.0,
20686759,CHEMBL4637996,4-(4-chloro-1-iminoisoindolin-5-ylamino)-6-p-tolylpyrimidin-5-ol,CHEMBL4624401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,Cc1ccc(-c2ncnc(Nc3ccc4c(c3Cl)CNC4=N)c2O)cc1,CHEMBL4622895,Discovery of hydroxy pyrimidine Factor IXa inhibitors.,Bioorg Med Chem Lett,2020.0,30,15,127279,127279,10.1016/j.bmcl.2020.127279,32527459.0,
20693492,CHEMBL4647963,"5-Methyl-N-((3R,4S)-1-(phenylsulfonyl)-4-((S)-piperidin-3-ylcarbamoyl)pyrrolidin-3-yl)-1H-indole-2-carboxamide",CHEMBL4626023,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1ccc2[nH]c(C(=O)N[C@H]3CN(S(=O)(=O)c4ccccc4)C[C@@H]3C(=O)N[C@H]3CCCNC3)cc2c1,CHEMBL4622972,Identification and Optimization of Pyrrolidine Derivatives as Highly Potent Ghrelin Receptor Full Agonists.,J Med Chem,2020.0,63,17,9705,9730,10.1021/acs.jmedchem.0c00828,32787075.0,
20694132,CHEMBL4517408,"1-[4-[4-methyl-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenyl]piperazine",CHEMBL4626214,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate incubated for 20 mins in presence of NADPH by LC/MS/MS analysis,IC50,>,30000.0,nM,COc1cc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2C)cc(OC)c1OC,CHEMBL4622974,Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma.,J Med Chem,2020.0,63,17,10061,10085,10.1021/acs.jmedchem.0c01199,32787083.0,
20694302,CHEMBL4636120,"1-(4-(5-(4-Fluoro-3,5-dimethoxyphenyl)-4-methylpyridin-3-yl)phenyl)piperazine",CHEMBL4626214,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate incubated for 20 mins in presence of NADPH by LC/MS/MS analysis,IC50,=,7300.0,nM,COc1cc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2C)cc(OC)c1F,CHEMBL4622974,Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma.,J Med Chem,2020.0,63,17,10061,10085,10.1021/acs.jmedchem.0c01199,32787083.0,
20697870,CHEMBL3544912,RAXATRIGINE HYDROCHLORIDE,CHEMBL4627229,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,100000.0,nM,Cl.NC(=O)[C@@H]1CC[C@H](c2ccc(OCc3ccccc3F)cc2)N1,CHEMBL4622996,Discovery of Vixotrigine: A Novel Use-Dependent Sodium Channel Blocker for the Treatment of Trigeminal Neuralgia.,ACS Med Chem Lett,2020.0,11,9,1678,1687,10.1021/acsmedchemlett.0c00263,32945812.0,
20704383,CHEMBL4634061,"1'-(tetrahydropyran-4-ylmethyl)-5-(trifluoromethyl)spiro[indoline-2,4'-piperidine]-3-one",CHEMBL4628003,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,18000.0,nM,O=C1c2cc(C(F)(F)F)ccc2NC12CCN(CC1CCOCC1)CC2,CHEMBL4627279,Discovery and structure-activity relationships of spiroindolines as novel inducers of oligodendrocyte progenitor cell differentiation.,Bioorg Med Chem,2020.0,28,6,115348,115348,10.1016/j.bmc.2020.115348,32046916.0,
20706826,CHEMBL4643511,"N-[3-[(2S)-6-amino-5,5-difluoro-2-(fluoromethyl)-3,4-dihydropyridin-2-yl]-4-fluoro-phenyl]-5-(fluoromethoxy)pyrazine-2-carboxamide",CHEMBL4628360,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,NC1=N[C@](CF)(c2cc(NC(=O)c3cnc(OCF)cn3)ccc2F)CCC1(F)F,CHEMBL4627305,"3,3-Difluoro-3,4,5,6-tetrahydropyridin-2-amines: Potent and permeable BACE-1 inhibitors.",Bioorg Med Chem Lett,2020.0,30,8,126999,126999,10.1016/j.bmcl.2020.126999,32089426.0,
20714489,CHEMBL4640712,"(S)-2-(3-Aminopiperidin-1-yl)-4-((3,5-bis(2-cyanopropan-2-yl)phenyl)amino)pyrimidine-5-carboxamide",CHEMBL4629910,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,6000.0,nM,CC(C)(C#N)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)(C)C#N)c1,CHEMBL4627396,Discovery of Highly Selective Inhibitors of Calmodulin-Dependent Kinases That Restore Insulin Sensitivity in the Diet-Induced Obesity <i>in Vivo</i> Mouse Model.,J Med Chem,2020.0,63,13,6784,6801,10.1021/acs.jmedchem.9b01803,32433887.0,
20714490,CHEMBL4635883,"(S)-2-(3-Aminopiperidin-1-yl)-4-((2,6-diisopropylpyridin-4-yl)amino)pyrimidine-5-carboxamide",CHEMBL4629910,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,6000.0,nM,CC(C)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)C)n1,CHEMBL4627396,Discovery of Highly Selective Inhibitors of Calmodulin-Dependent Kinases That Restore Insulin Sensitivity in the Diet-Induced Obesity <i>in Vivo</i> Mouse Model.,J Med Chem,2020.0,63,13,6784,6801,10.1021/acs.jmedchem.9b01803,32433887.0,
20717081,CHEMBL4634054,"2-((R)-3-(1-(1-((R)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1H-pyrazolo[3,4-b]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethan-1-ol",CHEMBL4630448,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac sodium salt as substrate incubated for 20 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,40000.0,nM,Cc1nn([C@H](C)c2ccc(Cl)cc2Cl)c2nc(N3CC([C@H]4CCCN(CCO)C4)C3)cnc12,CHEMBL4627411,Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors.,J Med Chem,2020.0,63,15,8584,8607,10.1021/acs.jmedchem.0c00988,32667798.0,
20717082,CHEMBL4637143,"1-((R)-1-(2,4-Dichlorophenyl)ethyl)-6-(3-((R)-1-(2-hydroxyethyl)piperidin-3-yl)azetidin-1-yl)-1H-pyrazolo[3,4-b]pyrazine-3-carbonitrile",CHEMBL4630448,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac sodium salt as substrate incubated for 20 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,40000.0,nM,C[C@H](c1ccc(Cl)cc1Cl)n1nc(C#N)c2ncc(N3CC([C@H]4CCCN(CCO)C4)C3)nc21,CHEMBL4627411,Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors.,J Med Chem,2020.0,63,15,8584,8607,10.1021/acs.jmedchem.0c00988,32667798.0,
20717366,CHEMBL4643105,"(3R,4S)-3-(3,5-Difluorophenyl)-9-((E)-3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)-4-methyl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]oxadiazine",CHEMBL4630552,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,33000.0,nM,COc1cc(/C=C2\CCCN3C2=NO[C@H](c2cc(F)cc(F)c2)[C@@H]3C)ccc1-n1cnc(C)c1,CHEMBL4627416,Generation of Leads for γ-Secretase Modulation.,J Med Chem,2020.0,63,15,8216,8230,10.1021/acs.jmedchem.0c00446,32786237.0,
20717367,CHEMBL4634921,"(3R,4S)-9-((E)-3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)-benzylidene)-4-methyl-3-(3,4,5-trifluorophenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]oxadiazine",CHEMBL4630552,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,37000.0,nM,COc1cc(/C=C2\CCCN3C2=NO[C@H](c2cc(F)c(F)c(F)c2)[C@@H]3C)ccc1-n1cnc(C)c1,CHEMBL4627416,Generation of Leads for γ-Secretase Modulation.,J Med Chem,2020.0,63,15,8216,8230,10.1021/acs.jmedchem.0c00446,32786237.0,
20717368,CHEMBL4634696,"(R)-9-(3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-3-(3,4,5-trifluorophenyl)-3,4,7,8-tetrahydro-6H-[1,2,4]oxadiazino[4,3-a]azepine",CHEMBL4630552,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,18000.0,nM,COc1cc(C2=CC3=NO[C@H](c4cc(F)c(F)c(F)c4)CN3CCC2)ccc1-n1cnc(C)c1,CHEMBL4627416,Generation of Leads for γ-Secretase Modulation.,J Med Chem,2020.0,63,15,8216,8230,10.1021/acs.jmedchem.0c00446,32786237.0,
20717369,CHEMBL4642697,"(S)-9-(3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-4-(3,4,5-trifluorophenyl)-3,4,7,8-tetrahydro-6H-[1,2,4]oxadiazino[4,3-a]azepine",CHEMBL4630552,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8000.0,nM,COc1cc(C2=CC3=NOC[C@H](c4cc(F)c(F)c(F)c4)N3CCC2)ccc1-n1cnc(C)c1,CHEMBL4627416,Generation of Leads for γ-Secretase Modulation.,J Med Chem,2020.0,63,15,8216,8230,10.1021/acs.jmedchem.0c00446,32786237.0,
22385558,CHEMBL4784617,"6-(1H-pyrazolo[4,3-b]pyridin-3-ylamino)isoquinolin-1(2H)-one",CHEMBL4665926,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,O=c1[nH]ccc2cc(Nc3n[nH]c4cccnc34)ccc12,CHEMBL4665621,"The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu PAM development candidate.",Bioorg Med Chem Lett,2019.0,29,2.0,342,346,10.1016/j.bmcl.2018.10.050,30503632.0,
22385559,CHEMBL4783372,"N-(1H-pyrazolo[4,3-b]pyridin-3-yl)isoquinolin-6-amine",CHEMBL4665926,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1350.0,nM,c1cnc2c(Nc3ccc4cnccc4c3)n[nH]c2c1,CHEMBL4665621,"The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu PAM development candidate.",Bioorg Med Chem Lett,2019.0,29,2.0,342,346,10.1016/j.bmcl.2018.10.050,30503632.0,
22385560,CHEMBL4787268,"1-(1H-pyrazol-1-yl)-N-(1H-pyrazolo[4,3-b]pyridin-3-yl)isoquinolin-6-amine",CHEMBL4665926,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,7300.0,nM,c1cnc2c(Nc3ccc4c(-n5cccn5)nccc4c3)n[nH]c2c1,CHEMBL4665621,"The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu PAM development candidate.",Bioorg Med Chem Lett,2019.0,29,2.0,342,346,10.1016/j.bmcl.2018.10.050,30503632.0,
22385561,CHEMBL4779331,"1-(difluoromethyl)-N-(1H-pyrazolo[4,3-b]pyridin-3-yl)isoquinolin-6-amine",CHEMBL4665926,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,30000.0,nM,FC(F)c1nccc2cc(Nc3n[nH]c4cccnc34)ccc12,CHEMBL4665621,"The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu PAM development candidate.",Bioorg Med Chem Lett,2019.0,29,2.0,342,346,10.1016/j.bmcl.2018.10.050,30503632.0,
22392908,CHEMBL4795177,"5-amino-3-methoxy-4-methyl-N-[1-[5-(trifluoromethyl)pyrimidin-2-yl]azetidin-3-yl]thieno[2,3-c]pyridazine-6-carboxamide",CHEMBL4667456,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,COc1nnc2sc(C(=O)NC3CN(c4ncc(C(F)(F)F)cn4)C3)c(N)c2c1C,CHEMBL4665653,"VU6005806/AZN-00016130, an advanced M positive allosteric modulator (PAM) profiled as a potential preclinical development candidate.",Bioorg Med Chem Lett,2019.0,29,14.0,1714,1718,10.1016/j.bmcl.2019.05.026,31113706.0,
22394546,CHEMBL4750688,"(-)-2-(4-(Dimethylamino)phenyl)-N-((3S,4R)-4-(4-(trifluoromethyl)phenyl)pyrrolidin-3-yl)acetamide",CHEMBL4667944,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculovirus infected insect cells using tolbutamide as substrate incubated for 30 mins in presence of NADPH-regenerating system by fluorescence based assay,IC50,=,98100.0,nM,CN(C)c1ccc(CC(=O)N[C@@H]2CNC[C@H]2c2ccc(C(F)(F)F)cc2)cc1,CHEMBL4665665,4-Aryl Pyrrolidines as Novel Orally Efficacious Antimalarial Agents. Part 2: 2-Aryl-N-(4-arylpyrrolidin-3-yl)acetamides.,ACS Med Chem Lett,2019.0,10,6.0,966,971,10.1021/acsmedchemlett.9b00123,31223456.0,
22394547,CHEMBL4755729,"(-)-2-[4-(dimethylamino)phenyl]-N-[(3S,4R)-4-[4-(pentafluoro-lambda6-sulfanyl)phenyl]pyrrolidin-3-yl]acetamide",CHEMBL4667944,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculovirus infected insect cells using tolbutamide as substrate incubated for 30 mins in presence of NADPH-regenerating system by fluorescence based assay,IC50,=,36600.0,nM,CN(C)c1ccc(CC(=O)N[C@@H]2CNC[C@H]2c2ccc(S(F)(F)(F)(F)F)cc2)cc1,CHEMBL4665665,4-Aryl Pyrrolidines as Novel Orally Efficacious Antimalarial Agents. Part 2: 2-Aryl-N-(4-arylpyrrolidin-3-yl)acetamides.,ACS Med Chem Lett,2019.0,10,6.0,966,971,10.1021/acsmedchemlett.9b00123,31223456.0,
22394548,CHEMBL4759278,"(-)-N-[(3S,4R)-4-[4-(1,1-difluoroethyl)phenyl]pyrrolidin-3-yl]-2-[4-(dimethylamino)phenyl]acetamide",CHEMBL4667944,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculovirus infected insect cells using tolbutamide as substrate incubated for 30 mins in presence of NADPH-regenerating system by fluorescence based assay,IC50,>,100000.0,nM,CN(C)c1ccc(CC(=O)N[C@@H]2CNC[C@H]2c2ccc(C(C)(F)F)cc2)cc1,CHEMBL4665665,4-Aryl Pyrrolidines as Novel Orally Efficacious Antimalarial Agents. Part 2: 2-Aryl-N-(4-arylpyrrolidin-3-yl)acetamides.,ACS Med Chem Lett,2019.0,10,6.0,966,971,10.1021/acsmedchemlett.9b00123,31223456.0,
22401439,CHEMBL4162752,2-(5-(3-(4-chlorophenoxy)prop-1-ynyl)-3-hydroxypicolinamido)acetic acid,CHEMBL4669705,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac as substrate preincubated for 5 mins followed by addition of NADPH measured after 20 mins by LC-MS/MS analysis,IC50,>,30000.0,nM,O=C(O)CNC(=O)c1ncc(C#CCOc2ccc(Cl)cc2)cc1O,CHEMBL4665751,"Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.",J Med Chem,2020.0,63,17.0,10045,10060,10.1021/acs.jmedchem.0c01161,32787144.0,
22401881,CHEMBL4778342,"6-(3-chloro-5-methylphenyl)-3-(3-fluoro-5-hydroxyphenyl)-5-({methyl[(2S)-pyrrolidin-2-ylmethyl]amino}methyl)-3H,4H-pyrido[2,3-d]pyrimidin-4-one",CHEMBL4669853,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1cc(Cl)cc(-c2cnc3ncn(-c4cc(O)cc(F)c4)c(=O)c3c2CN(C)C[C@@H]2CCCN2)c1,CHEMBL4665759,"Discovery of substituted 3H-pyrido[2,3-d]pyrimidin-4-ones as potent, biased, and orally bioavailable sst2 agonist.",Bioorg Med Chem Lett,2020.0,30,21.0,127496,127496,10.1016/j.bmcl.2020.127496,32805408.0,
22402030,CHEMBL4567446,"4-[4-(1-isopropyl-7-oxo-spiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-6-methoxy-2-pyridyl]benzoic acid",CHEMBL4669909,A,,Homo sapiens,Cytochrome P450 2C9,inhibition of CYP2C9 in human liver microsomes,IC50,>,50000.0,nM,COc1cc(C(=O)N2CCC3(CC2)CC(=O)c2c(cnn2C(C)C)C3)cc(-c2ccc(C(=O)O)cc2)n1,CHEMBL4665761,Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting.,J Med Chem,2020.0,63,19.0,10879,10896,10.1021/acs.jmedchem.0c00640,32809824.0,
22403516,CHEMBL4755842,"5-[2-Amino-3-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]-pyrimidin-5-yl]-2-[(1S)-1-cyclopropylethyl]-7-methyl-2,3-dihydro-1H-isoindol-1-one",CHEMBL4670200,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 5 to 20 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,2400.0,nM,Cc1cc(-c2ccn3nc(N)c(-c4cnn(C)c4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,Discovery of Potent and Selective PI3Kγ Inhibitors.,J Med Chem,2020.0,63,19.0,11235,11257,10.1021/acs.jmedchem.0c01203,32865410.0,
22403517,CHEMBL4785086,"N-(5-{2-[(1S)-1-Cyclopropylethyl]-1-oxo-7-(trifluoromethyl)-2,3-dihydro-1H-isoindol-5-yl}pyrazolo[1,5-a]pyrimidin-2-yl)acetamide",CHEMBL4670200,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 5 to 20 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,40000.0,nM,CC(=O)Nc1cc2nc(-c3cc4c(c(C(F)(F)F)c3)C(=O)N([C@@H](C)C3CC3)C4)ccn2n1,CHEMBL4665778,Discovery of Potent and Selective PI3Kγ Inhibitors.,J Med Chem,2020.0,63,19.0,11235,11257,10.1021/acs.jmedchem.0c01203,32865410.0,
22403519,CHEMBL4782083,"5-[2-amino-3-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl]-2-[(1S)-1-cyclopropylethyl]-7-(trifluoromethyl)-2,3-dihydro-1H-isoindol-1-one",CHEMBL4670200,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 5 to 20 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,40000.0,nM,C[C@@H](C1CC1)N1Cc2cc(-c3ccn4nc(N)c(-c5cnn(C)c5)c4n3)cc(C(F)(F)F)c2C1=O,CHEMBL4665778,Discovery of Potent and Selective PI3Kγ Inhibitors.,J Med Chem,2020.0,63,19.0,11235,11257,10.1021/acs.jmedchem.0c01203,32865410.0,
22405885,CHEMBL4759016,"rac-2-((1-(4-Cyclopropylnaphthalen-1-yl)-1H-imidazo[4,5-b]pyridin-2-yl)thio)propanoic Acid",CHEMBL4670647,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome using probe substrate measured after 20 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,20000.0,nM,CC(Sc1nc2ncccc2n1-c1ccc(C2CC2)c2ccccc12)C(=O)O,CHEMBL4665798,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,J Med Chem,2020.0,63,19.0,10829,10854,10.1021/acs.jmedchem.0c00223,32897699.0,
22405886,CHEMBL4750462,"rac-2-((1-(4-Cyclopropylnaphthalen-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)thio)propanoic Acid",CHEMBL4670647,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome using probe substrate measured after 20 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,2390.0,nM,CC(Sc1nc2cnccc2n1-c1ccc(C2CC2)c2ccccc12)C(=O)O,CHEMBL4665798,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,J Med Chem,2020.0,63,19.0,10829,10854,10.1021/acs.jmedchem.0c00223,32897699.0,
22405887,CHEMBL4756866,"2-((5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)-N-((4-bromophenyl)sulfonyl)acetamide",CHEMBL4670647,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome using probe substrate measured after 20 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,636.0,nM,O=C(CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12)NS(=O)(=O)c1ccc(Br)cc1,CHEMBL4665798,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,J Med Chem,2020.0,63,19.0,10829,10854,10.1021/acs.jmedchem.0c00223,32897699.0,
22405888,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4670647,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsome using probe substrate measured after 20 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,609.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4665798,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,J Med Chem,2020.0,63,19.0,10829,10854,10.1021/acs.jmedchem.0c00223,32897699.0,
22411128,CHEMBL4789100,4-{[(6-Bromo-3-methyl-2-phenylquinolin-4-yl)carbonyl]amino}bicyclo[2.2.2]octane-1-carboxylic acid,CHEMBL4671494,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 15 mins in presence of NADPH generating system by LC-MS/MS analysis,IC50,>,10000.0,nM,Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NC12CCC(C(=O)O)(CC1)CC2,CHEMBL4665834,Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).,J Med Chem,2020.0,63,20.0,11639,11662,10.1021/acs.jmedchem.0c00834,32969660.0,
22411129,CHEMBL4643852,BAY_6672,CHEMBL4671494,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 15 mins in presence of NADPH generating system by LC-MS/MS analysis,IC50,>,20000.0,nM,Cc1c(N2CCCC2)nc2ccc(Br)cc2c1C(=O)NC[C@H](CCC(=O)O)c1ccccc1Cl,CHEMBL4665834,Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).,J Med Chem,2020.0,63,20.0,11639,11662,10.1021/acs.jmedchem.0c00834,32969660.0,
22412476,CHEMBL4758823,"4-amino-2-[5-chloro-3-(3,3,3-trifluoropropyl)indazol-1-yl]-5,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-6-one",CHEMBL4671744,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,7000.0,nM,CC1(C)C(=O)Nc2nc(-n3nc(CCC(F)(F)F)c4cc(Cl)ccc43)nc(N)c21,CHEMBL4665837,Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947.,Bioorg Med Chem Lett,2020.0,30,21.0,127574,127574,10.1016/j.bmcl.2020.127574,32980512.0,
22417768,CHEMBL4741218,"5-(Difluoromethyl)-7-[(3S,4R)-4-methyl-1-(4-phenyl-2-pyridyl)-3-piperidyl]-[1,2,4]triazolo[1,5-a]pyrimidine",CHEMBL4672652,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS analysis,IC50,=,9000.0,nM,C[C@@H]1CCN(c2cc(-c3ccccc3)ccn2)C[C@H]1c1cc(C(F)F)nc2ncnn12,CHEMBL4665888,"[1,2,4]Triazolo[1,5-a]pyrimidine Phosphodiesterase 2A Inhibitors: Structure and Free-Energy Perturbation-Guided Exploration.",J Med Chem,2020.0,63,21.0,12887,12910,10.1021/acs.jmedchem.0c01272,33105987.0,
22418543,CHEMBL3928976,"US9334290, 32",CHEMBL4672852,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5700.0,nM,Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O,CHEMBL4665894,Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK.,ACS Med Chem Lett,2020.0,11,11.0,2195,2203,10.1021/acsmedchemlett.0c00335,33214829.0,
22419893,CHEMBL4750385,"(3S)-5-[9-Ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]-3-[(2-fluoro-2-methyl-propyl)amino]-3-methyl-1H-pyrrolo[2,3-b]pyridin-2-one",CHEMBL4673102,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,CCn1c(-c2cnc(C)nc2)nc2c(-c3cnc4c(c3)[C@](C)(NCC(C)(C)F)C(=O)N4)ncnc21,CHEMBL4665917,Optimization of Versatile Oxindoles as Selective PI3Kδ Inhibitors.,ACS Med Chem Lett,2020.0,11,12.0,2461,2469,10.1021/acsmedchemlett.0c00441,33335668.0,
22419894,CHEMBL4776201,"(3S)-1'-(Cyclopropanecarbonyl)-1-methyl-5-[9-methyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]spiro[indoline-3,2'-pyrrolidine]-2-one",CHEMBL4673102,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Cc1ncc(-c2nc3c(-c4ccc5c(c4)[C@@]4(CCCN4C(=O)C4CC4)C(=O)N5C)ncnc3n2C)cn1,CHEMBL4665917,Optimization of Versatile Oxindoles as Selective PI3Kδ Inhibitors.,ACS Med Chem Lett,2020.0,11,12.0,2461,2469,10.1021/acsmedchemlett.0c00441,33335668.0,
22420003,CHEMBL4782326,"(3R,5S)-3-Fluoro-5-((3aR,9bR)-9b-((4-fluorophenyl)sulfonyl)-7-(perfluoropropan-2-yl)-2,3,3a,4,5,9b-hexahydro-1H-benzo[e]indole-3-carbonyl)-1-(2-hydroxy-2-methylpropyl)pyrrolidin-2-one",CHEMBL4673128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,4900.0,nM,CC(C)(O)CN1C(=O)[C@H](F)C[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12,CHEMBL4665919,Novel Tricyclic Pyroglutamide Derivatives as Potent RORγt Inverse Agonists Identified using a Virtual Screening Approach.,ACS Med Chem Lett,2020.0,11,12.0,2510,2518,10.1021/acsmedchemlett.0c00496,33335675.0,
22426650,CHEMBL577397,Pongapin,CHEMBL4675246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Sacchrosomes using 3-cyano-7-ethoxycoumarin as substrate by fluorescence based assay,IC50,>,20000.0,nM,COc1c(-c2ccc3c(c2)OCO3)oc2c(ccc3occc32)c1=O,CHEMBL4673221,Furanoflavones pongapin and lanceolatin B blocks the cell cycle and induce senescence in CYP1A1-overexpressing breast cancer cells.,Bioorg Med Chem,2018.0,26,23-24,6076,6086,10.1016/j.bmc.2018.11.013,30448188.0,
22426651,CHEMBL224157,"2-phenyl-furo[2,3-h]chromen-4-one",CHEMBL4675246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in Sacchrosomes using 3-cyano-7-ethoxycoumarin as substrate by fluorescence based assay,IC50,>,20000.0,nM,O=c1cc(-c2ccccc2)oc2c1ccc1occc12,CHEMBL4673221,Furanoflavones pongapin and lanceolatin B blocks the cell cycle and induce senescence in CYP1A1-overexpressing breast cancer cells.,Bioorg Med Chem,2018.0,26,23-24,6076,6086,10.1016/j.bmc.2018.11.013,30448188.0,
22429428,CHEMBL3716365,"9-cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-yl-methoxy)-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one",CHEMBL4675899,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using probe substrate and in presence of co-factor preincubated for 20 mins followed by substrate addition by LC-MS/MS analysis,IC50,>,100000.0,nM,O=c1nc(OC[C@@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2,CHEMBL4673243,"Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial.",J Med Chem,2020.0,63,22,13526,13545,10.1021/acs.jmedchem.0c00272,32902984.0,
22429429,CHEMBL3717363,"9-cyclopropylethynyl-2-((R)-1-[1,4]dioxan-2-yl-methoxy)-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one",CHEMBL4675899,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using probe substrate and in presence of co-factor preincubated for 20 mins followed by substrate addition by LC-MS/MS analysis,IC50,=,31600.0,nM,O=c1nc(OC[C@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2,CHEMBL4673243,"Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial.",J Med Chem,2020.0,63,22,13526,13545,10.1021/acs.jmedchem.0c00272,32902984.0,
22429724,CHEMBL4549658,"2-[(1S,5R)-3-[2-[(2S)-2-methylazetidin-1-yl]-6-(trifluoromethyl)pyrimidin-4-yl]-3-azabicyclo[3.1.0]hexan-6-yl]acetic acid",CHEMBL4676030,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,100000.0,nM,C[C@H]1CCN1c1nc(N2C[C@H]3[C@H](CC(=O)O)[C@H]3C2)cc(C(F)(F)F)n1,CHEMBL4673244,Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose.,J Med Chem,2020.0,63,22,13546,13560,10.1021/acs.jmedchem.0c00944,32910646.0,
22429804,CHEMBL4650365,CAMIZESTRANT,CHEMBL4676091,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,>,30000.0,nM,C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2ccc(NC3CN(CCCF)C3)cn2)N1CC(F)(F)F,CHEMBL4673245,"Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.",J Med Chem,2020.0,63,23,14530,14559,10.1021/acs.jmedchem.0c01163,32910656.0,
22430566,CHEMBL4537788,BAY_784,CHEMBL4676227,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate by LC-MS/MS analysis,IC50,>,10000.0,nM,O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1,CHEMBL4673248,"Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women.",J Med Chem,2020.0,63,20,11854,11881,10.1021/acs.jmedchem.0c01076,32960053.0,
22432347,CHEMBL4741924,"(R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)Pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide",CHEMBL4676596,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 10 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,10000.0,nM,CNC(=O)c1cn(C[C@H](F)CCc2ccc(NC(=O)Cc3cc(OC4CC(F)(F)C4)cc(C)n3)nn2)nn1,CHEMBL4673258,"Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.",J Med Chem,2020.0,63,21,12957,12977,10.1021/acs.jmedchem.0c01398,33118821.0,
22433450,CHEMBL3684611,"US8575197, II-204",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,6000.0,nM,COc1ccccc1C1c2c(n[nH]c2C(C)(C)C)C(=O)N1c1ccc(-c2ccsc2)cc1,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22433451,CHEMBL4799974,"3-tert-butyl-4-(2-methoxyphenyl)-5-(4-(thiazol-2-yl)phenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2000.0,nM,COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2nccs2)cc1,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22433452,CHEMBL4762641,"3-tert-butyl-4-(2-methoxyphenyl)-5-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5000.0,nM,COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2nnc(C)o2)cc1,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22433453,CHEMBL4745262,"3-tert-butyl-4-(2-methoxyphenyl)-5-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,2000.0,nM,COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2nc(C)no2)cc1,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22433454,CHEMBL4745598,"3-tert-butyl-4-(2-methoxyphenyl)-5-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1000.0,nM,COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2noc(C)n2)cc1,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22433455,CHEMBL3684614,"US8575197, II-209",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,4000.0,nM,COc1ccccc1C1c2c(n[nH]c2C(C)(C)C)C(=O)N1c1ccc(-c2ncco2)cc1,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22433456,CHEMBL4750518,"3-tert-butyl-4-(2-methoxyphenyl)-5-(4-(3-methylisoxazol-5-yl)phenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,1000.0,nM,COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2cc(C)no2)cc1,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22433457,CHEMBL4743161,"4-(3-tert-butyl-4-(2-methoxyphenyl)-6-oxopyrrolo[3,4-c]pyrazol-5(1H,4H,6H)-yl)-N,N-dimethylbenzamide",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(C(=O)N(C)C)cc1,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22433458,CHEMBL3679906,"US8575197, II-057",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,4000.0,nM,CCOC(=O)c1ccc(N2C(=O)c3n[nH]c(C(C)(C)C)c3C2c2ccccc2OC)cc1,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22433459,CHEMBL4745595,"3-tert-butyl-5-(4-fluorophenyl)-4-(2-methoxyphenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,7000.0,nM,COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(F)cc1,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22433460,CHEMBL4765176,"3-tert-butyl-5-(4-(isoxazol-3-yl)phenyl)-4-(2-methoxyphenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,10000.0,nM,COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2ccon2)cc1,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22433461,CHEMBL3679944,"US8575197, II-100",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,11000.0,nM,CC(C)(C)c1[nH]nc2c1C(c1ccccc1OCCO)N(c1ccc(-c3ccon3)cc1)C2=O,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22433462,CHEMBL4758458,"3-tert-butyl-5-(4-(isoxazol-3-yl)phenyl)-4-(2-(2-(methylsulfonyl)ethoxy)phenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(C)(C)c1n[nH]c2c1C(c1ccccc1OCCS(C)(=O)=O)N(c1ccc(-c3ccon3)cc1)C2=O,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22433463,CHEMBL3679880,"US8575197, II-029",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(C)(C)c1[nH]nc2c1C(c1ccccc1OCC(=O)O)N(c1ccc(-c3ccon3)cc1)C2=O,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22433464,CHEMBL4741951,"3-(2-hydroxyethyl)-5-(4-(isoxazol-3-yl)phenyl)-4-(2-methoxyphenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,15000.0,nM,COc1ccccc1C1c2c(CCO)n[nH]c2C(=O)N1c1ccc(-c2ccon2)cc1,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22433465,CHEMBL4797432,"3-(1-hydroxy-2-methylpropan-2-yl)-5-(4-(isoxazol-3-yl)phenyl)-4-(2-methoxyphenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,16000.0,nM,COc1ccccc1C1c2c(C(C)(C)CO)n[nH]c2C(=O)N1c1ccc(-c2ccon2)cc1,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22433466,CHEMBL3684655,"US8575197, II-258",CHEMBL4677099,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,COc1ccccc1C1c2c(n[nH]c2C(C)(CO)CO)C(=O)N1c1ccc(-c2ccon2)cc1,CHEMBL4673267,Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.,Bioorg Med Chem Lett,2020.0,30,24,127636,127636,10.1016/j.bmcl.2020.127636,33132115.0,
22436042,CHEMBL4741417,"(+)-N-(5-((7-(2-methylquinolin-4-yl)-2,7-diazaspiro[4.4]nonan-2-yl)methyl)thiazol-2-yl)acetamide",CHEMBL4677548,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using isoform-specific probe substrates by LC/MS analysis,IC50,>,10000.0,nM,CC(=O)Nc1ncc(CN2CCC3(CCN(c4cc(C)nc5ccccc45)C3)C2)s1,CHEMBL4673290,Diazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders.,J Med Chem,2020.0,63,22,14017,14044,10.1021/acs.jmedchem.0c01479,33197187.0,
22439048,CHEMBL4791626,N-[2-[2-(dimethylamino)ethyl]-6-(1-hydroxy-1-methylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide,CHEMBL4678091,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,CN(C)CCn1cc2cc(NC(=O)c3cccc(C(F)(F)F)n3)c(C(C)(C)O)cc2n1,CHEMBL4673322,Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors.,Bioorg Med Chem Lett,2021.0,31,,127686,127686,10.1016/j.bmcl.2020.127686,33242574.0,
22440886,CHEMBL4112930,"US9260440, 69",CHEMBL4678511,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,C[C@]12CCCN1CC1=NNC(=O)c3cc(F)cc4[nH]c2c1c34,CHEMBL4673340,"Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.",J Med Chem,2020.0,63,24,15541,15563,10.1021/acs.jmedchem.0c01346,33264017.0,
22441452,CHEMBL4778736,"(1s,4s)-4-[1-methyl-2-(m-tolylmethyl)benzimidazol-5-yl]oxycyclohexanecarboxylic acid",CHEMBL4678685,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,Cc1cccc(Cc2nc3cc(O[C@H]4CC[C@@H](C(=O)O)CC4)ccc3n2C)c1,CHEMBL4673346,Discovery of a benzimidazole series as the first highly potent and selective ACSL1 inhibitors.,Bioorg Med Chem Lett,2021.0,33,,127722,127722,10.1016/j.bmcl.2020.127722,33285268.0,
22442273,CHEMBL4786038,1-[(4-Cyanobenzyl)oxy]-2-(3-cyanophenyl)-4-methyl-1H-imidazole-5-carboxylic acid,CHEMBL4678933,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate preincubated for 5 mins followed by NADPH generating system addition and measured after 120 mins by LC-MS/MS,IC50,>,10000.0,nM,Cc1nc(-c2cccc(C#N)c2)n(OCc2ccc(C#N)cc2)c1C(=O)O,CHEMBL4673353,Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y and P2Y as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor.,J Med Chem,2020.0,63,24,15752,15772,10.1021/acs.jmedchem.0c01524,33307675.0,
22442463,CHEMBL2086892,3-(3-Imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-(N-butyloxy carbonyl)sulfonamide,CHEMBL4678998,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 3 mins followed by NADPH addition by LC-MS/MS analysis,IC50,=,2000.0,nM,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1cccc(Cn2ccnc2)c1,CHEMBL4673354,N-(Methyloxycarbonyl)thiophene sulfonamides as high affinity AT2 receptor ligands.,Bioorg Med Chem,2021.0,29,,115859,115859,10.1016/j.bmc.2020.115859,33309749.0,
22442464,CHEMBL4788892,Methyl ((3-(3-(2-(2-(tert-butyl)-1H-imidazol-1-yl)acetyl)phenyl)-5-isobutylthiophen-2-yl)sulfonyl)carbamate,CHEMBL4678998,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 3 mins followed by NADPH addition by LC-MS/MS analysis,IC50,>,15000.0,nM,COC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1cccc(C(=O)Cn2ccnc2C(C)(C)C)c1,CHEMBL4673354,N-(Methyloxycarbonyl)thiophene sulfonamides as high affinity AT2 receptor ligands.,Bioorg Med Chem,2021.0,29,,115859,115859,10.1016/j.bmc.2020.115859,33309749.0,
22442860,CHEMBL4763375,"(S)-N-(4-chlorophenyl)-2-((1'R,4's)-6-(trifluoromethyl)-2H-spiro[benzofuran-3,1'-cyclohexane]-4'-yl)propanamide",CHEMBL4679078,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,C[C@H](C(=O)Nc1ccc(Cl)cc1)[C@H]1CC[C@]2(CC1)COc1cc(C(F)(F)F)ccc12,CHEMBL4673358,Discovery of highly potent heme-displacing IDO1 inhibitors based on a spirofused bicyclic scaffold.,Bioorg Med Chem Lett,2021.0,33,,127738,127738,10.1016/j.bmcl.2020.127738,33316404.0,
22442861,CHEMBL4751227,"Rac-(S)-N-(4-chlorophenyl)-2-(6-(trifluoromethyl)-2H-spiro[benzofuran-3,4'-piperidine]-1'-yl)butanamide",CHEMBL4679078,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5000.0,nM,CC[C@@H](C(=O)Nc1ccc(Cl)cc1)N1CCC2(CC1)COc1cc(C(F)(F)F)ccc12,CHEMBL4673358,Discovery of highly potent heme-displacing IDO1 inhibitors based on a spirofused bicyclic scaffold.,Bioorg Med Chem Lett,2021.0,33,,127738,127738,10.1016/j.bmcl.2020.127738,33316404.0,
22445039,CHEMBL4161733,"(R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide",CHEMBL4679363,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,730.0,nM,C[C@@H](C(=O)Nc1ccc(Cl)cc1)[C@H]1CC[C@@H](c2ccnc3ccc(F)cc32)CC1,CHEMBL4673373,Discovery and optimization of substituted oxalamides as novel heme-displacing IDO1 inhibitors.,Bioorg Med Chem Lett,2021.0,33,,127744,127744,10.1016/j.bmcl.2020.127744,33333163.0,
22445040,CHEMBL4753967,"N-(4-chlorophenyl)-2-((3R*,4R*)-4-(6-fluoroquinolin-4-yl)-3-hydroxypiperidin-1-yl)-2-oxoacetamide",CHEMBL4679363,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,O=C(Nc1ccc(Cl)cc1)C(=O)N1CC[C@H](c2ccnc3ccc(F)cc23)[C@@H](O)C1,CHEMBL4673373,Discovery and optimization of substituted oxalamides as novel heme-displacing IDO1 inhibitors.,Bioorg Med Chem Lett,2021.0,33,,127744,127744,10.1016/j.bmcl.2020.127744,33333163.0,
22445041,CHEMBL4746699,N-(4-chlorophenyl)-2-(4-(6-fluoroquinolin-4-yl)piperidin-1-yl)-2-oxoacetamide,CHEMBL4679363,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,6100.0,nM,O=C(Nc1ccc(Cl)cc1)C(=O)N1CCC(c2ccnc3ccc(F)cc23)CC1,CHEMBL4673373,Discovery and optimization of substituted oxalamides as novel heme-displacing IDO1 inhibitors.,Bioorg Med Chem Lett,2021.0,33,,127744,127744,10.1016/j.bmcl.2020.127744,33333163.0,
22446921,CHEMBL4795990,"1-(2-(1-(2,2-Difluoroethyl)-1H imidazol-4-yl)ethyl)-3-(4-methyl-5-(2-(pyridin-3-yl)ethynyl)thiazol-2-yl)urea",CHEMBL4679701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,490.0,nM,Cc1nc(NC(=O)NCCc2cn(CC(F)F)cn2)sc1C#Cc1cccnc1,CHEMBL4673392,Discovery of a Novel Series of Potent and Selective Alkynylthiazole-Derived PI3Kγ Inhibitors.,ACS Med Chem Lett,2021.0,12,1,129,135,10.1021/acsmedchemlett.0c00573,33488974.0,
22446922,CHEMBL4759283,"1-(2-(Cyclopropylmethoxy)ethyl)-3-(5-((5,6-dimethoxypyridin-3-yl)ethynyl)-4-methylthiazol-2-yl)urea",CHEMBL4679701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,7000.0,nM,COc1cc(C#Cc2sc(NC(=O)NCCOCC3CC3)nc2C)cnc1OC,CHEMBL4673392,Discovery of a Novel Series of Potent and Selective Alkynylthiazole-Derived PI3Kγ Inhibitors.,ACS Med Chem Lett,2021.0,12,1,129,135,10.1021/acsmedchemlett.0c00573,33488974.0,
22446923,CHEMBL4764646,"1-(2-(Cyclopropylmethoxy)ethyl)-3-(5-(imidazo[1,2-a]pyridin-6-ylethynyl)-4-methylthiazol-2-yl)urea",CHEMBL4679701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,11000.0,nM,Cc1nc(NC(=O)NCCOCC2CC2)sc1C#Cc1ccc2cncn2c1,CHEMBL4673392,Discovery of a Novel Series of Potent and Selective Alkynylthiazole-Derived PI3Kγ Inhibitors.,ACS Med Chem Lett,2021.0,12,1,129,135,10.1021/acsmedchemlett.0c00573,33488974.0,
22446924,CHEMBL4784202,(S)-1-(2-(Cyclopropylmethoxy)propyl)-3-(5-((5-methoxypyridin-3-yl)ethynyl)-4-methylthiazol-2-yl)urea,CHEMBL4679701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,11000.0,nM,Cc1cncc(C#Cc2sc(NC(=O)NC[C@H](C)OCC3CC3)nc2C)c1,CHEMBL4673392,Discovery of a Novel Series of Potent and Selective Alkynylthiazole-Derived PI3Kγ Inhibitors.,ACS Med Chem Lett,2021.0,12,1,129,135,10.1021/acsmedchemlett.0c00573,33488974.0,
22446925,CHEMBL4756664,"(S)-1-(2-(cyclopropylmethoxy)propyl)-3-(5-((5,6-dimethoxypyridin-3-yl)ethynyl)-4-methylthiazol-2-yl)urea",CHEMBL4679701,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,15000.0,nM,Cc1cc(C#Cc2sc(NC(=O)NC[C@H](C)OCC3CC3)nc2C)cnc1C,CHEMBL4673392,Discovery of a Novel Series of Potent and Selective Alkynylthiazole-Derived PI3Kγ Inhibitors.,ACS Med Chem Lett,2021.0,12,1,129,135,10.1021/acsmedchemlett.0c00573,33488974.0,
22447416,CHEMBL4790083,"6-(3-(3-(benzo[d]thiazol-7-ylsulfonyl)propanoyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)nicotinonitrile",CHEMBL4679791,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 in pooled human liver microsomes using diclofenac as substrate incubated for 5 mins by LC-MS/MS,IC50,>,10000.0,nM,N#Cc1ccc(N2C3CCC2CN(C(=O)CCS(=O)(=O)c2cccc4ncsc24)C3)nc1,CHEMBL4673395,"Discovery of PIPE-359, a Brain-Penetrant, Selective M Receptor Antagonist with Robust Efficacy in Murine MOG-EAE.",ACS Med Chem Lett,2021.0,12,1,155,161,10.1021/acsmedchemlett.0c00626,33488977.0,
22448183,CHEMBL4786690,cis-4-chloro-N-[(1R)-1-[4-(6-fluoro-4-quinolyl)cyclohexyl]ethyl]benzamide,CHEMBL4679983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,IC50,=,740.0,nM,C[C@@H](NC(=O)c1ccc(Cl)cc1)[C@H]1CC[C@@H](c2ccnc3ccc(F)cc32)CC1,CHEMBL4673406,"Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1.",ACS Med Chem Lett,2021.0,12,2,288,294,10.1021/acsmedchemlett.0c00668,33603977.0,
22451665,CHEMBL3959509,"US9216972, 7",CHEMBL4681150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,O=C(O)C1CN(Cc2ccc3c(c2)CCc2c-3noc2-c2onc(-c3ccccc3)c2C(F)(F)F)C1,CHEMBL4680083,Identification of Tricyclic Agonists of Sphingosine-1-phosphate Receptor 1 (S1P) Employing Ligand-Based Drug Design.,J Med Chem,2016.0,59,21,9837,9854,10.1021/acs.jmedchem.6b01099,27726358.0,
22453036,CHEMBL4747534,6-[(R)-4-(4-Methanesulfonyl-phenyl)-2-methyl-piperazin-1-yl]-pyridine-2-carboxylic acid (5-hydroxy-adamantan-2-yl)-amide,CHEMBL4681497,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in pooled human liver microsomes using diclofenac as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@@H]1CN(c2ccc(S(C)(=O)=O)cc2)CCN1c1cccc(C(=O)NC2C3CC4CC2CC(O)(C4)C3)n1,CHEMBL4680093,"Discovery of 2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1).",J Med Chem,2016.0,59,22,10176,10189,10.1021/acs.jmedchem.6b01122,27798827.0,
22453037,CHEMBL4779054,"N-((1R,2s,3S,5S,7S)-5-Hydroxyadamantan-2-yl)-6-((R)-2-methyl-4-(6-(methylcarbamoyl)pyridin-3-yl)piperazin-1-yl)picolinamide",CHEMBL4681497,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in pooled human liver microsomes using diclofenac as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,CNC(=O)c1ccc(N2CCN(c3cccc(C(=O)NC4C5CC6CC4CC(O)(C6)C5)n3)[C@H](C)C2)cn1,CHEMBL4680093,"Discovery of 2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1).",J Med Chem,2016.0,59,22,10176,10189,10.1021/acs.jmedchem.6b01122,27798827.0,
22453038,CHEMBL4746745,"N-((1R,2s,3S,5S,7S)-5-Hydroxyadamantan-2-yl)-6-((R)-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-2-methylpiperazin-1-yl)picolinamide",CHEMBL4681497,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in pooled human liver microsomes using diclofenac as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@@H]1CN(c2ccc(C(C)(C)O)nc2)CCN1c1cccc(C(=O)NC2C3CC4CC2CC(O)(C4)C3)n1,CHEMBL4680093,"Discovery of 2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1).",J Med Chem,2016.0,59,22,10176,10189,10.1021/acs.jmedchem.6b01122,27798827.0,
22453039,CHEMBL4788862,"N-((1R,2s,3S,5S,7S)-5-Hydroxyadamantan-2-yl)-2-((R)-2-methyl-4-(4-(methylsulfonyl)phenyl)piperazin-1-yl)pyrimidine-4-carboxamide",CHEMBL4681497,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in pooled human liver microsomes using diclofenac as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@@H]1CN(c2ccc(S(C)(=O)=O)cc2)CCN1c1nccc(C(=O)NC2C3CC4CC2CC(O)(C4)C3)n1,CHEMBL4680093,"Discovery of 2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1).",J Med Chem,2016.0,59,22,10176,10189,10.1021/acs.jmedchem.6b01122,27798827.0,
22453040,CHEMBL4748750,"2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide",CHEMBL4681497,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in pooled human liver microsomes using diclofenac as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@@H]1CN(c2ccc(S(C)(=O)=O)cc2F)CCN1c1nccc(C(=O)NC2C3CC4CC2CC(O)(C4)C3)n1,CHEMBL4680093,"Discovery of 2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1).",J Med Chem,2016.0,59,22,10176,10189,10.1021/acs.jmedchem.6b01122,27798827.0,
22455709,CHEMBL3754515,"5-(4-Chlorophenyl)-[3,3'-bipyridine]-6,6'-diamine",CHEMBL4681983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,3000.0,nM,Nc1ccc(-c2cnc(N)c(-c3ccc(Cl)cc3)c2)cn1,CHEMBL4680107,2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety.,J Med Chem,2018.0,61,7,3114,3125,10.1021/acs.jmedchem.8b00152,29570292.0,
22455710,CHEMBL4746566,2-{4-[6-Amino-5-(4-chlorophenyl)pyridin-3-yl]phenoxy}-2-methylpropanoic Acid,CHEMBL4681983,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,3000.0,nM,CC(C)(Oc1ccc(-c2cnc(N)c(-c3ccc(Cl)cc3)c2)cc1)C(=O)O,CHEMBL4680107,2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety.,J Med Chem,2018.0,61,7,3114,3125,10.1021/acs.jmedchem.8b00152,29570292.0,
22466986,CHEMBL4784137,"(3S,11aR)-N-(benzo[c](1,2,5)oxadiazol-5-ylmethyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide",CHEMBL4684404,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate incubated for 30 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc5nonc5c4)c(=O)c(O)c3C(=O)N12,CHEMBL4680174,"Synthesis, biological evaluation and in silico modeling of novel integrase strand transfer inhibitors (INSTIs).",Eur J Med Chem,2020.0,189,,112064,112064,10.1016/j.ejmech.2020.112064,31972393.0,
22466987,CHEMBL4744587,"(3S,11aR)-N-[(2,6-difluoropyridin-3-yl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide",CHEMBL4684404,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate incubated for 30 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)nc4F)c(=O)c(O)c3C(=O)N12,CHEMBL4680174,"Synthesis, biological evaluation and in silico modeling of novel integrase strand transfer inhibitors (INSTIs).",Eur J Med Chem,2020.0,189,,112064,112064,10.1016/j.ejmech.2020.112064,31972393.0,
22484371,CHEMBL4779059,"2-(5-(3-Chloro-4-((2,5-dimethylphenyl)amino)quinolin-6-yl)-pyrimidin-2-yl)propan-2-ol",CHEMBL4688266,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin),IC50,=,600.0,nM,Cc1ccc(C)c(Nc2c(Cl)cnc3ccc(-c4cnc(C(C)(C)O)nc4)cc23)c1,CHEMBL4680302,Biologic-like In Vivo Efficacy with Small Molecule Inhibitors of TNFα Identified Using Scaffold Hopping and Structure-Based Drug Design Approaches.,J Med Chem,2020.0,63,23,15050,15071,10.1021/acs.jmedchem.0c01732,33261314.0,
22484373,CHEMBL4764418,"2-(5-(3-Chloro-4-((2,5-dimethylphenyl)amino)-2-methylquinolin-6-yl)pyrimidin-2-yl)propan-2-ol",CHEMBL4688266,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin),IC50,=,2800.0,nM,Cc1ccc(C)c(Nc2c(Cl)c(C)nc3ccc(-c4cnc(C(C)(C)O)nc4)cc23)c1,CHEMBL4680302,Biologic-like In Vivo Efficacy with Small Molecule Inhibitors of TNFα Identified Using Scaffold Hopping and Structure-Based Drug Design Approaches.,J Med Chem,2020.0,63,23,15050,15071,10.1021/acs.jmedchem.0c01732,33261314.0,
22484379,CHEMBL4777447,"(R)-3-(1-((3-Chloro-7-fluoro-6-(2-(2-hydroxypropan-2-yl)-pyrimidin-5-yl)-2-methyl-1,5-naphthyridin-4-yl)amino)ethyl)-4-fluorobenzonitrile",CHEMBL4688266,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin),IC50,=,2000.0,nM,Cc1nc2cc(F)c(-c3cnc(C(C)(C)O)nc3)nc2c(N[C@H](C)c2cc(C#N)ccc2F)c1Cl,CHEMBL4680302,Biologic-like In Vivo Efficacy with Small Molecule Inhibitors of TNFα Identified Using Scaffold Hopping and Structure-Based Drug Design Approaches.,J Med Chem,2020.0,63,23,15050,15071,10.1021/acs.jmedchem.0c01732,33261314.0,
22490865,CHEMBL4798111,"N-((R)-1-((S)-2-methylpyrrolidin-1-yl)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide",CHEMBL4689628,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 15 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,C[C@H]1CCCN1C[C@@H](C)NC(=O)c1ccc(-c2noc(C(F)(F)F)n2)cc1,CHEMBL4680373,"Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.",ACS Med Chem Lett,2021.0,12,3,380,388,10.1021/acsmedchemlett.0c00532,33738065.0,
22491070,CHEMBL4779920,"(R)-4-fluoro-N-(1-(5-(pyrimidin-4-yl)-5,6,7,8-tetrahydro-1,5-naphthyridin-2-yl)ethyl)benzamide",CHEMBL4689688,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,175.0,nM,C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2c1ccncn1,CHEMBL4680374,Carbamate and N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors.,ACS Med Chem Lett,2021.0,12,3,389,396,10.1021/acsmedchemlett.0c00525,33738066.0,
22491071,CHEMBL4744727,"(R)-N-(1-(5-(3-chlorobenzoyl)-5,6,7,8-tetrahydro-1,5-naphthyridin-2-yl)ethyl)-4-fluorobenzamide",CHEMBL4689688,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,12000.0,nM,C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2C(=O)c1cccc(Cl)c1,CHEMBL4680374,Carbamate and N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors.,ACS Med Chem Lett,2021.0,12,3,389,396,10.1021/acsmedchemlett.0c00525,33738066.0,
22491072,CHEMBL4749009,"cyclopropyl (R)-6-(1-(4-fluorobenzamido)ethyl)-3,4-dihydro-1,5-naphthyridine-1(2H)-carboxylate",CHEMBL4689688,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,6200.0,nM,C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2C(=O)OC1CC1,CHEMBL4680374,Carbamate and N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors.,ACS Med Chem Lett,2021.0,12,3,389,396,10.1021/acsmedchemlett.0c00525,33738066.0,
22491073,CHEMBL4783395,"(R)-4-fluoro-N-(1-(5-(2-(trifluoromethyl)pyrimidin-4-yl)-5,6,7,8-tetrahydro-1,5-naphthyridin-2-yl)ethyl)benzamide",CHEMBL4689688,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,18000.0,nM,C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2c1ccnc(C(F)(F)F)n1,CHEMBL4680374,Carbamate and N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors.,ACS Med Chem Lett,2021.0,12,3,389,396,10.1021/acsmedchemlett.0c00525,33738066.0,
22754325,CHEMBL4747990,"7-(4-amino-2,5-difluorophenyl)-5-cyclopropyl-6-methyloxazolo[4,5-c]quinolin-4-one",CHEMBL4700470,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,Cc1c(-c2cc(F)c(N)cc2F)ccc2c3ocnc3c(=O)n(C3CC3)c12,CHEMBL4699432,"Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 1",RSC Med Chem,2020.0,11,12,1366,1378,10.1039/d0md00174k,34095844.0,
22754326,CHEMBL4764598,"7-(4-amino-2,5-difluorophenyl)-2-(aminomethyl)-5-cyclopropyl-6-methyloxazolo[4,5-c]quinolin-4-one",CHEMBL4700470,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,300.0,nM,Cc1c(-c2cc(F)c(N)cc2F)ccc2c3oc(CN)nc3c(=O)n(C3CC3)c12,CHEMBL4699432,"Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 1",RSC Med Chem,2020.0,11,12,1366,1378,10.1039/d0md00174k,34095844.0,
22754327,CHEMBL4787847,"2-(aminomethyl)-5-cyclopropyl-6-methyl-7-(1H-pyrazolo[3,4-b]pyridin-5-yl)oxazolo[4,5-c]quinolin-4-one",CHEMBL4700470,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,800.0,nM,Cc1c(-c2cnc3[nH]ncc3c2)ccc2c3oc(CN)nc3c(=O)n(C3CC3)c12,CHEMBL4699432,"Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 1",RSC Med Chem,2020.0,11,12,1366,1378,10.1039/d0md00174k,34095844.0,
22754328,CHEMBL4743440,"2-(aminomethyl)-5-cyclopropyl-7-(1H-indazol-5-yl)-6-methyloxazolo[4,5-c]quinolin-4(5H)-one",CHEMBL4700470,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,200.0,nM,Cc1c(-c2ccc3[nH]ncc3c2)ccc2c3oc(CN)nc3c(=O)n(C3CC3)c12,CHEMBL4699432,"Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 1",RSC Med Chem,2020.0,11,12,1366,1378,10.1039/d0md00174k,34095844.0,
22754468,CHEMBL4786331,"7-((R)-3-((S)-1-aminoethyl)pyrrolidin-1-yl)-6-chloro-5-cyclopropyl-8-fluoro-2-methyloxazolo[4,5-c]quinolin-4(5H)-one",CHEMBL4700508,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,16400.0,nM,Cc1nc2c(=O)n(C3CC3)c3c(Cl)c(N4CC[C@@H]([C@H](C)N)C4)c(F)cc3c2o1,CHEMBL4699433,"Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 2",RSC Med Chem,2020.0,11,12,1379,1385,10.1039/d0md00175a,34095845.0,
22756163,CHEMBL4209316,"(S)-7-(4-fluorophenyl)-N2-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine",CHEMBL4700811,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,7400.0,nM,CNc1nc(Nc2ccc(-n3cnc(C)n3)c(OC)c2)nc2c1CC[C@H]2c1ccc(F)cc1,CHEMBL4699441,Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481.,ACS Med Chem Lett,2019.0,10,3,312,317,10.1021/acsmedchemlett.8b00541,30891132.0,
22757287,CHEMBL4744041,3-isopropoxy-N-(2-methyl-4-(2-(1-methyl-1H-pyrazol-4-ylamino)pyrimidin-4-yl)benzyl)azetidine-1-carboxamide,CHEMBL4701144,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate measured after 15 mins in presence of NADPH by LC-MS/MS analysis,IC50,>,25000.0,nM,Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1,CHEMBL4699451,"Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.",J Med Chem,2020.0,63,21,12526,12541,10.1021/acs.jmedchem.0c00702,32696648.0,
22759037,CHEMBL4763134,"(1R,3S,4R)-4-((3aR,9bR)-8-fluoro-7-(perfluoropropan-2-yl)-9b-(phenylsulfonyl)-2,3,3a,4,5,9b-hexahydro-1H-benzo[e]indole-3-carbonyl)-3-methylcyclohexanecarboxylic acid",CHEMBL4701590,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin),IC50,>,20000.0,nM,C[C@H]1C[C@H](C(=O)O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccccc3)c3cc(F)c(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12,CHEMBL4699477,"Tricyclic sulfones as potent, selective and efficacious RORγt inverse agonists - Exploring C6 and C8 SAR using late-stage functionalization.",Bioorg Med Chem Lett,2020.0,30,23,127521,127521,10.1016/j.bmcl.2020.127521,32882417.0,
22765647,CHEMBL4445443,"N-(2-ethyl-4,5,6,7-tetrahydro-2H-indazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,=,9000.0,nM,CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCCC2,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765648,CHEMBL4754724,"N-(2-(tert-butyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,=,47000.0,nM,COc1nc(-c2csc(Nc3c4c(nn3C(C)(C)C)CCCC4)n2)ccc1-n1cnc(C)c1,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765649,CHEMBL4795963,"N-(2-cyclobutyl-4,5,6,7-tetrahydro-2H-indazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,=,660.0,nM,COc1nc(-c2csc(Nc3c4c(nn3C3CCC3)CCCC4)n2)ccc1-n1cnc(C)c1,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765650,CHEMBL4750723,"N-(2-(2-fluoroethyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,=,6800.0,nM,COc1nc(-c2csc(Nc3c4c(nn3CCF)CCCC4)n2)ccc1-n1cnc(C)c1,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765651,CHEMBL4741060,"2-(3-((4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-yl)amino)-4,5,6,7-tetrahydro-2H-indazol-2-yl)ethanol",CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,>,100000.0,nM,COc1nc(-c2csc(Nc3c4c(nn3CCO)CCCC4)n2)ccc1-n1cnc(C)c1,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765652,CHEMBL4777113,"3-(3-((4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-yl)amino)-4,5,6,7-tetrahydro-2H-indazol-2-yl)propan-1-ol",CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,>,100000.0,nM,COc1nc(-c2csc(Nc3c4c(nn3CCCO)CCCC4)n2)ccc1-n1cnc(C)c1,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765653,CHEMBL4760389,"1-(3-((4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-yl)amino)-4,5,6,7-tetrahydro-2H-indazol-2-yl)-2-methylpropan-2-ol",CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,=,9000.0,nM,COc1nc(-c2csc(Nc3c4c(nn3CC(C)(C)O)CCCC4)n2)ccc1-n1cnc(C)c1,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765654,CHEMBL4794750,N-(3-(tert-butyl)-1-isopropyl-1H-pyrazol-5-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine,CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,=,14000.0,nM,COc1nc(-c2csc(Nc3cc(C(C)(C)C)nn3C(C)C)n2)ccc1-n1cnc(C)c1,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765655,CHEMBL4786740,N-(3-(tert-butyl)-1-(2-fluoroethyl)-1H-pyrazol-5-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine,CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,=,4100.0,nM,COc1nc(-c2csc(Nc3cc(C(C)(C)C)nn3CCF)n2)ccc1-n1cnc(C)c1,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765656,CHEMBL4751736,"N-(3-(tert-butyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,=,20000.0,nM,COc1nc(-c2csc(Nc3cc(C(C)(C)C)nn3CC(F)(F)F)n2)ccc1-n1cnc(C)c1,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765657,CHEMBL4749020,N-(1-ethyl-3-(1-methylcyclopropyl)-1H-pyrazol-5-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine,CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,>,100000.0,nM,CCn1nc(C2(C)CC2)cc1Nc1nc(-c2ccc(-n3cnc(C)c3)c(OC)n2)cs1,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765658,CHEMBL4763513,N-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine,CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,=,47000.0,nM,CCn1nc(C(F)(F)F)cc1Nc1nc(-c2ccc(-n3cnc(C)c3)c(OC)n2)cs1,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765659,CHEMBL4741605,"4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-N-(2-methyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)thiazol-2-amine",CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,>,100000.0,nM,COc1nc(-c2csc(Nc3c4c(nn3C)CCC4)n2)ccc1-n1cnc(C)c1,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765660,CHEMBL4758131,"N-(2-ethyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,>,100000.0,nM,CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCC2,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765661,CHEMBL4759910,"N-(2-(2-fluoroethyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,>,100000.0,nM,COc1nc(-c2csc(Nc3c4c(nn3CCF)CCC4)n2)ccc1-n1cnc(C)c1,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765662,CHEMBL4777391,"4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-N-(2-(2,2,2-trifluoroethyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)thiazol-2-amine",CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,=,11000.0,nM,COc1nc(-c2csc(Nc3c4c(nn3CC(F)(F)F)CCC4)n2)ccc1-n1cnc(C)c1,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765663,CHEMBL4761020,"2-(3-((4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-yl)amino)-5,6-dihydrocyclopenta[c]pyrazol-2(4H)-yl)ethanol",CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,=,50000.0,nM,COc1nc(-c2csc(Nc3c4c(nn3CCO)CCC4)n2)ccc1-n1cnc(C)c1,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765664,CHEMBL4747572,"N-(2-ethyl-6,6-dimethyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,=,48000.0,nM,CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCC2(C)C,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765665,CHEMBL4798079,"(+/-)-N-(2-ethyl-4,6,6-trimethyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,=,35000.0,nM,CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)C(C)CC2(C)C,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22765666,CHEMBL4745955,"N-(2-ethyl-2,4,5,6,7,8-hexahydrocyclohepta[c]pyrazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",CHEMBL4703150,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) by fluorescence-based assay,IC50,=,37000.0,nM,CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCCCC2,CHEMBL4699542,Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.,Bioorg Med Chem,2020.0,28,22,115734,115734,10.1016/j.bmc.2020.115734,33007551.0,
22771968,CHEMBL4788846,"5-(4-Chloro-3-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2(3H)-one",CHEMBL4704620,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,25000.0,nM,O=c1[nH]nc(-c2ccc(Cl)c(C(F)(F)F)c2)o1,CHEMBL4699601,"5-Phenyl-1,3,4-oxadiazol-2(3H)-ones Are Potent Inhibitors of Notum Carboxylesterase Activity Identified by the Optimization of a Crystallographic Fragment Screening Hit.",J Med Chem,2020.0,63,21,12942,12956,10.1021/acs.jmedchem.0c01391,33124429.0,
22775233,CHEMBL4781849,"(S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo-[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one",CHEMBL4705438,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) incubated for 20 to 30 mins by P450-Glo assay,IC50,>,10000.0,nM,CC[C@@H](c1nc2cccc(F)c2c(=O)n1C1CC1)n1nc(-c2ccc(OC)c(F)c2)c2c(N)ncnc21,CHEMBL4699641,"Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease.",J Med Chem,2020.0,63,22,13973,13993,10.1021/acs.jmedchem.0c01544,33180507.0,
22776989,CHEMBL4748253,"(S)-1-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)urea",CHEMBL4705937,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CO[C@@H](C)c1c(NC(=O)Nc2cnc(-n3nccn3)c(Cl)c2)cnc2cc(Cl)nn12,CHEMBL4699655,Optimization of the In Vivo Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole Blood.,J Med Chem,2020.0,63,23,14594,14608,10.1021/acs.jmedchem.0c01246,33216547.0,
22776990,CHEMBL4746044,"1-[2-chloro-7-[(1S)-1-methoxyethyl]pyrazolo[1,5-a]pyrimidin-6-yl]-3-[2-(trifluoromethyl)-4-pyridyl]urea",CHEMBL4705937,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CO[C@@H](C)c1c(NC(=O)Nc2ccnc(C(F)(F)F)c2)cnc2cc(Cl)nn12,CHEMBL4699655,Optimization of the In Vivo Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole Blood.,J Med Chem,2020.0,63,23,14594,14608,10.1021/acs.jmedchem.0c01246,33216547.0,
22777213,CHEMBL4743610,"1-(4-(2-((1-(3,4-Difluorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone hydrochloride",CHEMBL4706015,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,100000.0,nM,CC(=O)N1CCN(CCOCc2ccn(-c3ccc(F)c(F)c3)n2)CC1.Cl,CHEMBL4699658,EST64454: a Highly Soluble σ Receptor Antagonist Clinical Candidate for Pain Management.,J Med Chem,2020.0,63,23,14979,14988,10.1021/acs.jmedchem.0c01575,33237785.0,
22778143,CHEMBL4762103,"(S)-2-chloro-9-(1-(4-(2,2-difluoroethoxy)pyridin-2-yl)ethyl)-9H-purin-6-amine",CHEMBL4706257,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH,IC50,>,25000.0,nM,C[C@@H](c1cc(OCC(F)F)ccn1)n1cnc2c(N)nc(Cl)nc21,CHEMBL4699664,Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors.,J Med Chem,2020.0,63,24,15852,15863,10.1021/acs.jmedchem.0c01573,33291877.0,
22778380,CHEMBL4753698,"Sodium (2R,5R)-2-Fluoro-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl Sulfate",CHEMBL4706317,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH by LC-MS/MS analysis,IC50,>,50000.0,nM,O=C1N2C[C@@H](CC[C@H]2F)N1OS(=O)(=O)[O-].[Na+],CHEMBL4699665,"Discovery of ANT3310, a Novel Broad-Spectrum Serine β-Lactamase Inhibitor of the Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter baumannii.",J Med Chem,2020.0,63,24,15802,15820,10.1021/acs.jmedchem.0c01535,33306385.0,
22778778,CHEMBL4782111,"(3S,4S)-1-Cyclopropylmethyl-4-([5-(2,4-difluoro-phenyl)isoxazole-3-carbonyl]-amino)-piperidine-3-carboxylic acid (1-Pyrimidin-2-yl-cyclopropyl)-amide",CHEMBL4706368,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac substrate by LC-MS/MS analysis,IC50,>,50000.0,nM,O=C(N[C@H]1CCN(CC2CC2)C[C@@H]1C(=O)NC1(c2ncccn2)CC1)c1cc(-c2ccc(F)cc2F)on1,CHEMBL4699667,"Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239.",J Med Chem,2020.0,63,24,15864,15882,10.1021/acs.jmedchem.0c01588,33314938.0,
22779069,CHEMBL4761666,"2-(1,1-Difluoroethyl)-N-(6-chloro-1,2,3,4-tetrahydronaphthalen-2-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",CHEMBL4706777,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using isoform-specific probe substrates in presence of NADPH-generating system by LC-MS analysis,IC50,=,10200.0,nM,Cc1cc(NC2CCc3cc(Cl)ccc3C2)n2nc(C(C)(F)F)nc2n1,CHEMBL4706474,Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.,J Med Chem,2016.0,59,11.0,5416,5431,10.1021/acs.jmedchem.6b00275,27127993.0,
22779070,CHEMBL4751920,"(S)-N-(7-Chloro-1,2,3,4-tetrahydronaphthalen-2-yl)-2-(1,1-difluoroethyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",CHEMBL4706777,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using isoform-specific probe substrates in presence of NADPH-generating system by LC-MS analysis,IC50,=,2100.0,nM,Cc1cc(N[C@H]2CCc3ccc(Cl)cc3C2)n2nc(C(C)(F)F)nc2n1,CHEMBL4706474,Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.,J Med Chem,2016.0,59,11.0,5416,5431,10.1021/acs.jmedchem.6b00275,27127993.0,
22779071,CHEMBL4747214,"2-(1,1-Difluoroethyl)-N-(6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",CHEMBL4706777,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using isoform-specific probe substrates in presence of NADPH-generating system by LC-MS analysis,IC50,=,8700.0,nM,Cc1cc(NC2CCc3cc(Br)ccc3C2)n2nc(C(C)(F)F)nc2n1,CHEMBL4706474,Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.,J Med Chem,2016.0,59,11.0,5416,5431,10.1021/acs.jmedchem.6b00275,27127993.0,
22779072,CHEMBL4753862,"2-(1,1-Difluoroethyl)-N-(7-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",CHEMBL4706777,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using isoform-specific probe substrates in presence of NADPH-generating system by LC-MS analysis,IC50,=,3100.0,nM,Cc1cc(NC2CCc3ccc(Br)cc3C2)n2nc(C(C)(F)F)nc2n1,CHEMBL4706474,Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.,J Med Chem,2016.0,59,11.0,5416,5431,10.1021/acs.jmedchem.6b00275,27127993.0,
22779073,CHEMBL4794107,"N-(5,6-Difluoro-2,3-dihydro-1H-inden-2-yl)-2-(1,1-difluoroethyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",CHEMBL4706777,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using isoform-specific probe substrates in presence of NADPH-generating system by LC-MS analysis,IC50,=,18500.0,nM,Cc1cc(NC2Cc3cc(F)c(F)cc3C2)n2nc(C(C)(F)F)nc2n1,CHEMBL4706474,Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.,J Med Chem,2016.0,59,11.0,5416,5431,10.1021/acs.jmedchem.6b00275,27127993.0,
22779813,CHEMBL4793954,(S)-5-((5-(3-Hydroxy-3-methylbut-1-yn-1-yl)-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile,CHEMBL4706943,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,CC(C)(O)C#Cc1cnc(Nc2cnc(C#N)cn2)cc1NC[C@@H]1CNCCO1,CHEMBL4706475,Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).,J Med Chem,2016.0,59,11.0,5221,5237,10.1021/acs.jmedchem.5b01938,27167172.0,
22779814,CHEMBL4740741,(S)-5-((5-Ethynyl-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile,CHEMBL4706943,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,C#Cc1cnc(Nc2cnc(C#N)cn2)cc1NC[C@@H]1CNCCO1,CHEMBL4706475,Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).,J Med Chem,2016.0,59,11.0,5221,5237,10.1021/acs.jmedchem.5b01938,27167172.0,
22779815,CHEMBL4792322,(S)-5-((5-Cyclopropyl-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile,CHEMBL4706943,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,N#Cc1cnc(Nc2cc(NC[C@@H]3CNCCO3)c(C3CC3)cn2)cn1,CHEMBL4706475,Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).,J Med Chem,2016.0,59,11.0,5221,5237,10.1021/acs.jmedchem.5b01938,27167172.0,
22779816,CHEMBL4754960,(R)-5-(5-Chloro-4-(morpholin-2-ylmethylamino)pyridin-2-ylamino)pyrazine-2-carbonitrile,CHEMBL4706943,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,N#Cc1cnc(Nc2cc(NC[C@H]3CNCCO3)c(Cl)cn2)cn1,CHEMBL4706475,Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).,J Med Chem,2016.0,59,11.0,5221,5237,10.1021/acs.jmedchem.5b01938,27167172.0,
22779817,CHEMBL4169078,(R)-5-(4-(morpholin-2-ylmethylamino)-5-(trifluoromethyl)pyridin-2-ylamino)pyrazine-2-carbonitrile,CHEMBL4706943,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,N#Cc1cnc(Nc2cc(NC[C@H]3CNCCO3)c(C(F)(F)F)cn2)cn1,CHEMBL4706475,Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).,J Med Chem,2016.0,59,11.0,5221,5237,10.1021/acs.jmedchem.5b01938,27167172.0,
22791501,CHEMBL4740287,"2-((4-(N-(carboxymethyl)-2,4,6-trimethylphenylsulfonamido)naphthalen-1-yl)oxy)-2-(4-methoxyphenyl)acetic acid",CHEMBL4709594,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes preincubated for 10 mins followed by NADPH addition by LC-MS/MS analysis,IC50,>,10000.0,nM,COc1ccc(C(Oc2ccc(N(CC(=O)O)S(=O)(=O)c3c(C)cc(C)cc3C)c3ccccc23)C(=O)O)cc1,CHEMBL4706544,Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions.,Eur J Med Chem,2020.0,207,,112734,112734,10.1016/j.ejmech.2020.112734,32866756.0,
22816798,CHEMBL4751832,"4-((3-(2-Cyclopropoxypyridin-4-yl)-5-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)oxy)-2-methylbutan-2-ol",CHEMBL4715005,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes,IC50,=,7800.0,nM,Cn1cc(-c2nc3c(-c4ccnc(OC5CC5)c4)cnn3cc2OCCC(C)(C)O)cn1,CHEMBL4706744,Discovery of Selective Transforming Growth Factor β Type II Receptor Inhibitors as Antifibrosis Agents.,ACS Med Chem Lett,2021.0,12,5.0,745,751,10.1021/acsmedchemlett.0c00679,34055221.0,
22817505,CHEMBL4750756,"N-((6aS,7R,9aS)-9a-((4-Fluorophenyl)sulfonyl)-3-(perfluoropropan-2-yl)-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[f]quinolin-7-yl)-2-hydroxy-2-methylpropanamide",CHEMBL4715128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,3200.0,nM,CC(C)(O)C(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12,CHEMBL4706752,Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis.,ACS Med Chem Lett,2021.0,12,5.0,827,835,10.1021/acsmedchemlett.1c00112,34055233.0,
22817506,CHEMBL4800380,"N-((6aS,7R,9aS)-9a-((4-Fluorophenyl)sulfonyl)-3-(perfluoropropan-2-yl)-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[f]quinolin-7-yl)-3-hydroxy-3-methylbutanamide",CHEMBL4715128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,8500.0,nM,CC(C)(O)CC(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12,CHEMBL4706752,Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis.,ACS Med Chem Lett,2021.0,12,5.0,827,835,10.1021/acsmedchemlett.1c00112,34055233.0,
22817507,CHEMBL4744956,"N-((6aS,7R,9aS)-9a-((4-Fluorophenyl)sulfonyl)-3-(perfluoropropan-2-yl)-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[f]quinolin-7-yl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide",CHEMBL4715128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,9500.0,nM,O=C(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12)C1CCS(=O)(=O)CC1,CHEMBL4706752,Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis.,ACS Med Chem Lett,2021.0,12,5.0,827,835,10.1021/acsmedchemlett.1c00112,34055233.0,
22817508,CHEMBL4760466,"(S)-N-((6aS,7R,9aS)-9a-((4-Fluorophenyl)sulfonyl)-3-(perfluoropropan-2-yl)-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[f]quinolin-7-yl)-2-hydroxy-2-methyl-3-(methylsulfonyl)propanamide",CHEMBL4715128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,C[C@@](O)(CS(C)(=O)=O)C(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12,CHEMBL4706752,Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis.,ACS Med Chem Lett,2021.0,12,5.0,827,835,10.1021/acsmedchemlett.1c00112,34055233.0,
22817509,CHEMBL4784900,"N-((3R,3aS,9bS)-9b-(4-fluorophenylsulfonyl)-7-(perfluoropropan-2-yl)-2,3,3a,4,5,9b-hexahydro-1H-cyclopenta[a]naphthalen-3-yl)-3-hydroxy-3-methylbutanamide",CHEMBL4715128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,12000.0,nM,CC(C)(O)CC(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12,CHEMBL4706752,Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis.,ACS Med Chem Lett,2021.0,12,5.0,827,835,10.1021/acsmedchemlett.1c00112,34055233.0,
22817510,CHEMBL4796103,"1,1-Dioxo-hexahydro-1lambda*6*-thiopyran-4-carboxylic acid [(3R,3aS,9bS)-9b-(4-fluoro-benzenesulfonyl)-7-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-2,3,3a,4,5,9b-hexahydro-1H-cyclopenta[a]naphthalen-3-yl]-amide",CHEMBL4715128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5500.0,nM,O=C(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12)C1CCS(=O)(=O)CC1,CHEMBL4706752,Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis.,ACS Med Chem Lett,2021.0,12,5.0,827,835,10.1021/acsmedchemlett.1c00112,34055233.0,
22817511,CHEMBL4741364,"(R)-N-((3R,3aS,9bS)-9b-((4-Fluorophenyl)sulfonyl)-7-(perfluoropropan-2-yl)-2,3,3a,4,5,9b-hexahydro-1H-cyclopenta[a]naphthalen-3-yl)-2-hydroxy-2-methyl-3-(methylsulfonyl)propanamide",CHEMBL4715128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,9200.0,nM,C[C@](O)(CS(C)(=O)=O)C(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12,CHEMBL4706752,Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis.,ACS Med Chem Lett,2021.0,12,5.0,827,835,10.1021/acsmedchemlett.1c00112,34055233.0,
22817512,CHEMBL4779994,"(S)-N-((3R,3aS,9bS)-9b-((4-fluorophenyl)sulfonyl)-7-(perfluoropropan-2-yl)-2,3,3a,4,5,9b-hexahydro-1H-cyclopenta[a]naphthalen-3-yl)-2-hydroxy-2-methyl-3-(methylsulfonyl)propanamide",CHEMBL4715128,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,12000.0,nM,C[C@@](O)(CS(C)(=O)=O)C(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12,CHEMBL4706752,Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis.,ACS Med Chem Lett,2021.0,12,5.0,827,835,10.1021/acsmedchemlett.1c00112,34055233.0,
22818282,CHEMBL4760098,"N-((1R,2S,5R)-5-(methylamino)-2-((S)-2-oxo-3-((6-(trifluoromethyl)quinazolin-4-yl)amino)pyrrolidin-1-yl)cyclohexyl)acetamide",CHEMBL4715411,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,CN[C@@H]1CC[C@H](N2CC[C@H](Nc3ncnc4ccc(C(F)(F)F)cc34)C2=O)[C@H](NC(C)=O)C1,CHEMBL4706769,Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2.,ACS Med Chem Lett,2021.0,12,6.0,969,975,10.1021/acsmedchemlett.1c00082,34141082.0,
22818283,CHEMBL4781426,"N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-((6-(trifluoromethyl)quinazolin-4-yl)amino)pyrrolidin-1-yl)cyclohexyl)acetamide",CHEMBL4715411,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3ccc(C(F)(F)F)cc23)C1=O,CHEMBL4706769,Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2.,ACS Med Chem Lett,2021.0,12,6.0,969,975,10.1021/acsmedchemlett.1c00082,34141082.0,
22818284,CHEMBL4746510,"N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-((6-(trifluoromethoxy)quinazolin-4-yl)amino)pyrrolidin-1-yl)cyclohexyl)acetamide",CHEMBL4715411,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3ccc(OC(F)(F)F)cc23)C1=O,CHEMBL4706769,Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2.,ACS Med Chem Lett,2021.0,12,6.0,969,975,10.1021/acsmedchemlett.1c00082,34141082.0,
22818583,CHEMBL4761298,"trans-4-[(1-{[2-Cyano-3-(trifluoromethyl)phenyl]methyl}-5-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl)methyl]cyclohexane-1-carboxylic acid",CHEMBL4715563,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,84000.0,nM,Cc1cccc2c1c(=O)n(C[C@H]1CC[C@H](C(=O)O)CC1)c(=O)n2Cc1cccc(C(F)(F)F)c1C#N,CHEMBL4706771,Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors.,ACS Med Chem Lett,2021.0,12,6.0,1005,1010,10.1021/acsmedchemlett.1c00160,34141085.0,
22818785,CHEMBL4747709,"(S)-5-chloro-4-((4,4-dimethyl-2-(methylamino)pentyl)amino)-2-fluoro-N-(5-fluorothiazol-2-yl)benzenesulfonamide hydrochloride",CHEMBL4715643,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,28000.0,nM,CN[C@H](CNc1cc(F)c(S(=O)(=O)Nc2ncc(F)s2)cc1Cl)CC(C)(C)C.Cl,CHEMBL4706775,"Discovery of Arylsulfonamide Na1.7 Inhibitors: IVIVC, MPO Methods, and Optimization of Selectivity Profile.",ACS Med Chem Lett,2021.0,12,6.0,1038,1049,10.1021/acsmedchemlett.1c00218,34141090.0,
22825237,CHEMBL4439903,(R)-N-(1-(2-(4-chlorophenyl)-1-hydroxybutan-2-yl)-1H-indol-4-yl)methanesulfonamide,CHEMBL4717263,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,13000.0,nM,CC[C@](CO)(c1ccc(Cl)cc1)n1ccc2c(NS(C)(=O)=O)cccc21,CHEMBL4715716,Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists.,Bioorg Med Chem Lett,2016.0,26,12.0,2866,2869,10.1016/j.bmcl.2016.04.052,27161805.0,
22825775,CHEMBL4746135,"3-(3-chloro-2-fluorophenoxy)-10-(2-methylpyridin-4-yl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepine",CHEMBL4717443,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 using diclofenac as substrate by MUX-MS/MS analysis,IC50,=,5260.0,nM,Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4cccc(Cl)c4F)n2CCO3)ccn1,CHEMBL4715723,"Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.",Bioorg Med Chem Lett,2016.0,26,12.0,2947,2951,10.1016/j.bmcl.2016.04.018,27240550.0,
22825776,CHEMBL4759692,"3-(2-chlorophenoxy)-10-(2-methylpyridin-4-yl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepine",CHEMBL4717443,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 using diclofenac as substrate by MUX-MS/MS analysis,IC50,>,50000.0,nM,Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4ccccc4Cl)n2CCO3)ccn1,CHEMBL4715723,"Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.",Bioorg Med Chem Lett,2016.0,26,12.0,2947,2951,10.1016/j.bmcl.2016.04.018,27240550.0,
22825777,CHEMBL4743615,"10-(2-methylpyridin-4-yl)-3-(2-(trifluoromethoxy)phenoxy)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepine",CHEMBL4717443,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 using diclofenac as substrate by MUX-MS/MS analysis,IC50,=,26100.0,nM,Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4ccccc4OC(F)(F)F)n2CCO3)ccn1,CHEMBL4715723,"Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.",Bioorg Med Chem Lett,2016.0,26,12.0,2947,2951,10.1016/j.bmcl.2016.04.018,27240550.0,
22825778,CHEMBL4751613,"10-(2-methylpyridin-4-yl)-3-(3-(trifluoromethoxy)phenoxy)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepine",CHEMBL4717443,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 using diclofenac as substrate by MUX-MS/MS analysis,IC50,=,14300.0,nM,Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4cccc(OC(F)(F)F)c4)n2CCO3)ccn1,CHEMBL4715723,"Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.",Bioorg Med Chem Lett,2016.0,26,12.0,2947,2951,10.1016/j.bmcl.2016.04.018,27240550.0,
22825779,CHEMBL4761139,"3-(3-chlorophenoxy)-10-(2-methylpyridin-4-yl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepine",CHEMBL4717443,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 using diclofenac as substrate by MUX-MS/MS analysis,IC50,>,50000.0,nM,Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4cccc(Cl)c4)n2CCO3)ccn1,CHEMBL4715723,"Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.",Bioorg Med Chem Lett,2016.0,26,12.0,2947,2951,10.1016/j.bmcl.2016.04.018,27240550.0,
22825780,CHEMBL4744842,"3-(3-chlorobenzyl)-10-(2-methylpyridin-4-yl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepine",CHEMBL4717443,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 using diclofenac as substrate by MUX-MS/MS analysis,IC50,=,1450.0,nM,Cc1cc(-c2ccc3c(c2)-c2nnc(Cc4cccc(Cl)c4)n2CCO3)ccn1,CHEMBL4715723,"Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.",Bioorg Med Chem Lett,2016.0,26,12.0,2947,2951,10.1016/j.bmcl.2016.04.018,27240550.0,
22825781,CHEMBL4798957,"10-(2-methylpyridin-4-yl)-N-(3-(trifluoromethoxy)phenyl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepin-3-amine",CHEMBL4717443,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 using diclofenac as substrate by MUX-MS/MS analysis,IC50,=,1390.0,nM,Cc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(OC(F)(F)F)c4)n2CCO3)ccn1,CHEMBL4715723,"Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.",Bioorg Med Chem Lett,2016.0,26,12.0,2947,2951,10.1016/j.bmcl.2016.04.018,27240550.0,
22825782,CHEMBL4755454,"10-(pyridin-4-yl)-N-(3-(trifluoromethoxy)phenyl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepin-3-amine",CHEMBL4717443,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 using diclofenac as substrate by MUX-MS/MS analysis,IC50,=,934.0,nM,FC(F)(F)Oc1cccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)c1,CHEMBL4715723,"Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.",Bioorg Med Chem Lett,2016.0,26,12.0,2947,2951,10.1016/j.bmcl.2016.04.018,27240550.0,
22825783,CHEMBL4752684,"10-(2-ethylpyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepin-3-amine",CHEMBL4717443,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 using diclofenac as substrate by MUX-MS/MS analysis,IC50,=,3540.0,nM,CCc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(C(F)(F)F)c4)n2CCO3)ccn1,CHEMBL4715723,"Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.",Bioorg Med Chem Lett,2016.0,26,12.0,2947,2951,10.1016/j.bmcl.2016.04.018,27240550.0,
22825784,CHEMBL4788072,"10-(2-methylpyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepin-3-amine",CHEMBL4717443,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 using diclofenac as substrate by MUX-MS/MS analysis,IC50,=,1960.0,nM,Cc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(C(F)(F)F)c4)n2CCO3)ccn1,CHEMBL4715723,"Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.",Bioorg Med Chem Lett,2016.0,26,12.0,2947,2951,10.1016/j.bmcl.2016.04.018,27240550.0,
22825785,CHEMBL4790150,"10-(pyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepin-3-amine",CHEMBL4717443,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 using diclofenac as substrate by MUX-MS/MS analysis,IC50,=,531.0,nM,FC(F)(F)c1cccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)c1,CHEMBL4715723,"Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.",Bioorg Med Chem Lett,2016.0,26,12.0,2947,2951,10.1016/j.bmcl.2016.04.018,27240550.0,
22825786,CHEMBL4750179,"N-(3-chlorophenyl)-10-(2-methylpyridin-4-yl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepin-3-amine",CHEMBL4717443,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 using diclofenac as substrate by MUX-MS/MS analysis,IC50,=,3440.0,nM,Cc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(Cl)c4)n2CCO3)ccn1,CHEMBL4715723,"Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.",Bioorg Med Chem Lett,2016.0,26,12.0,2947,2951,10.1016/j.bmcl.2016.04.018,27240550.0,
22825787,CHEMBL4755668,"N-(3,4-dichlorophenyl)-7-(pyridin-4-yl)-2,3-dihydrobenzo[f][1,4]oxazepine-4(5H)-carboxamide",CHEMBL4717443,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 using diclofenac as substrate by MUX-MS/MS analysis,IC50,=,326000.0,nM,O=C(Nc1ccc(Cl)c(Cl)c1)N1CCOc2ccc(-c3ccncc3)cc2C1,CHEMBL4715723,"Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.",Bioorg Med Chem Lett,2016.0,26,12.0,2947,2951,10.1016/j.bmcl.2016.04.018,27240550.0,
22825788,CHEMBL4787638,"N-(3-chlorophenyl)-7-(pyridin-4-yl)-2,3-dihydrobenzo[f][1,4]oxazepine-4(5H)-carboxamide",CHEMBL4717443,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 using diclofenac as substrate by MUX-MS/MS analysis,IC50,=,232000.0,nM,O=C(Nc1cccc(Cl)c1)N1CCOc2ccc(-c3ccncc3)cc2C1,CHEMBL4715723,"Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.",Bioorg Med Chem Lett,2016.0,26,12.0,2947,2951,10.1016/j.bmcl.2016.04.018,27240550.0,
22841767,CHEMBL4750944,"2-amino-2-(2-(6-octyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethyl)propane-1,3-diol",CHEMBL4719899,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,10700.0,nM,CCCCCCCCC1CCc2cc(CCC(N)(CO)CO)ccc2C1,CHEMBL4715806,"Asymmetric Hydroboration Approach to the Scalable Synthesis of ((1R,3S)-1-Amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) as a Potent S1P Receptor Modulator.",J Med Chem,2016.0,59,24.0,11138,11147,10.1021/acs.jmedchem.6b01433,28002964.0,
22841768,CHEMBL3806158,"((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol",CHEMBL4719899,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CCCCCC[C@@H]1CCc2cc([C@H]3CC[C@](N)(CO)C3)ccc2C1,CHEMBL4715806,"Asymmetric Hydroboration Approach to the Scalable Synthesis of ((1R,3S)-1-Amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) as a Potent S1P Receptor Modulator.",J Med Chem,2016.0,59,24.0,11138,11147,10.1021/acs.jmedchem.6b01433,28002964.0,
22843161,CHEMBL4755698,"1-(4-((4-Amino-5-(benzo[d][1,3]dioxol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl)piperidin-1-yl)prop-2-en-1-one",CHEMBL4720199,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using tolbutamide as substrate incubated for 5 mins followed by NADPH addition and further incubated for 10 mins in shaking water bath by LC-MS/MS analysis,IC50,=,3540.0,nM,C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1,CHEMBL4715815,"Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.",Eur J Med Chem,2018.0,145,,96,112,10.1016/j.ejmech.2017.12.079,29324347.0,
22844172,CHEMBL4750196,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide,CHEMBL4721158,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using diclofenac as substrate,IC50,>,50000.0,nM,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F,CHEMBL4715818,Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.,Bioorg Med Chem,2018.0,26,8.0,1740,1750,10.1016/j.bmc.2018.02.022,29523467.0,
22845421,CHEMBL3301620,TEMSAVIR,CHEMBL4721724,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using diclofenac as substrate incubated for 20 mins by LC-MS/MS analysis,IC50,=,25000.0,nM,COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12,CHEMBL4715822,Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.,Eur J Med Chem,2018.0,154,,367,391,10.1016/j.ejmech.2018.04.062,29860061.0,
22845422,CHEMBL4533529,(S)-N-(2-amino-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(3-fluoro-4-(trifluoromethyl)phenyl)-1H-pyrrole-2-carboxamide,CHEMBL4721724,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using diclofenac as substrate incubated for 20 mins by LC-MS/MS analysis,IC50,>,25000.0,nM,NC[C@H](NC(=O)c1ccc(-c2ccc(C(F)(F)F)c(F)c2)[nH]1)c1nc(CO)cs1,CHEMBL4715822,Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.,Eur J Med Chem,2018.0,154,,367,391,10.1016/j.ejmech.2018.04.062,29860061.0,
22845423,CHEMBL4761836,"(S)-N-(2-Amino-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(4-chloro-3,5-difluorophenyl)-1H-pyrrole-2-carboxamide",CHEMBL4721724,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using diclofenac as substrate incubated for 20 mins by LC-MS/MS analysis,IC50,>,25000.0,nM,NC[C@H](NC(=O)c1ccc(-c2cc(F)c(Cl)c(F)c2)[nH]1)c1nc(CO)cs1,CHEMBL4715822,Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.,Eur J Med Chem,2018.0,154,,367,391,10.1016/j.ejmech.2018.04.062,29860061.0,
22848293,CHEMBL4780781,"2-[3-(4-trifluoromethoxyphenoxy)butyl]-3,4-dihydropyrazino[1,2-a]benzimidazol-1(2H)-one",CHEMBL4722655,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,7000.0,nM,O=C1c2nc3ccccc3n2CCN1CCCCOc1ccc(OC(F)(F)F)cc1,CHEMBL4715841,Discovery of dihydropyrazino-benzimidazole derivatives as metabotropic glutamate receptor-2 (mGluR2) positive allosteric modulators (PAMs).,Eur J Med Chem,2020.0,186,,111881,111881,10.1016/j.ejmech.2019.111881,31780081.0,
22851109,CHEMBL4789776,"(S,S,2S)-N,N'-(4,4'-(hexa-2,4-diyne-1,6-diylbis(oxy))bis(7-methoxyquinazoline-6,4-diyl))bis(1-((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-carboxamide)",CHEMBL4723656,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,12600.0,nM,CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(OCC#CC#CCOc3ncnc4cc(OC)c(NC(=O)[C@@H]5CCCN5C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc34)ncnc2cc1OC)C(C)(C)C,CHEMBL4715861,"Design, synthesis and biological evaluation of new bivalent quinazoline analogues as IAP antagonists.",Bioorg Med Chem Lett,2021.0,34,,127676,127676,10.1016/j.bmcl.2020.127676,33166687.0,
22851110,CHEMBL4753756,"(S,S,2S,2'S)-N,N'-(4,4'-(1r,4r)-cyclohexane-1,4-diylbis(azanediyl)bis(7-methoxyquinazoline-6,4-diyl))bis(1-((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-carboxamide)",CHEMBL4723656,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,43600.0,nM,CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(N[C@H]3CC[C@H](Nc4ncnc5cc(OC)c(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc45)CC3)ncnc2cc1OC)C(C)(C)C,CHEMBL4715861,"Design, synthesis and biological evaluation of new bivalent quinazoline analogues as IAP antagonists.",Bioorg Med Chem Lett,2021.0,34,,127676,127676,10.1016/j.bmcl.2020.127676,33166687.0,
22852085,CHEMBL4781892,"5-Amino-2-(2,6-difluorophenyl)-N-(4-((1R,3R,4R,5S)-4-(fluoromethyl)-3,4-dihydroxy-5-methylcyclohexyl)-pyridin-3-yl)pyrimidine-4-carboxamide",CHEMBL4723899,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,30000.0,nM,C[C@H]1C[C@@H](c2ccncc2NC(=O)c2nc(-c3c(F)cccc3F)ncc2N)C[C@@H](O)[C@@]1(O)CF,CHEMBL4715870,Synthesis and Structure-Activity Relationship of Tetra-Substituted Cyclohexyl Diol Inhibitors of Proviral Insertion of Moloney Virus (PIM) Kinases.,J Med Chem,2020.0,63,23.0,14885,14904,10.1021/acs.jmedchem.0c01279,33258605.0,
22852086,CHEMBL4758068,"5-Amino-2-(2,6-difluorophenyl)-N-(4-((1R,3R,4R,5S)-3,4-dihydroxy-4,5-dimethylcyclohexyl)pyridin-3-yl)pyrimidine-4-carboxamide",CHEMBL4723899,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,9800.0,nM,C[C@H]1C[C@@H](c2ccncc2NC(=O)c2nc(-c3c(F)cccc3F)ncc2N)C[C@@H](O)[C@]1(C)O,CHEMBL4715870,Synthesis and Structure-Activity Relationship of Tetra-Substituted Cyclohexyl Diol Inhibitors of Proviral Insertion of Moloney Virus (PIM) Kinases.,J Med Chem,2020.0,63,23.0,14885,14904,10.1021/acs.jmedchem.0c01279,33258605.0,
22856885,CHEMBL4754334,2-amino-N-(3-(difluoromethyl)-4-fluorophenyl)-4-fluoro-5-((4-hydroxypiperidin-1-yl)sulfonyl)benzamide,CHEMBL4725048,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using tolbutamide as substrate incubated for 20 mins by LC-MS/MS with HPLC analysis,IC50,=,25200.0,nM,Nc1cc(F)c(S(=O)(=O)N2CCC(O)CC2)cc1C(=O)Nc1ccc(F)c(C(F)F)c1,CHEMBL4715925,Sulfamoylbenzamide-based Capsid Assembly Modulators for Selective Inhibition of Hepatitis B Viral Replication.,ACS Med Chem Lett,2021.0,12,2.0,242,248,10.1021/acsmedchemlett.0c00606,33603970.0,
22856886,CHEMBL4761323,"2-amino-N-(3,4-difluorophenyl)-4-fluoro-5-((4-hydroxypiperidin-1-yl)sulfonyl)benzamide",CHEMBL4725048,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using tolbutamide as substrate incubated for 20 mins by LC-MS/MS with HPLC analysis,IC50,=,25000.0,nM,Nc1cc(F)c(S(=O)(=O)N2CCC(O)CC2)cc1C(=O)Nc1ccc(F)c(F)c1,CHEMBL4715925,Sulfamoylbenzamide-based Capsid Assembly Modulators for Selective Inhibition of Hepatitis B Viral Replication.,ACS Med Chem Lett,2021.0,12,2.0,242,248,10.1021/acsmedchemlett.0c00606,33603970.0,
22857215,CHEMBL4748198,"1-((2-((1r,4r)-4-tert-butylcyclohexyloxy)-4-methylnaphthalen-1-yl)methyl)piperidine-4-carboxylic acid",CHEMBL4725124,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,Cc1cc(O[C@H]2CC[C@H](C(C)(C)C)CC2)c(CN2CCC(C(=O)O)CC2)c2ccccc12,CHEMBL4715931,Novel Potent Selective Orally Active S1P5 Receptor Antagonists.,ACS Med Chem Lett,2021.0,12,3.0,351,355,10.1021/acsmedchemlett.0c00631,33738061.0,
22857781,CHEMBL4756822,"4-((cis)-4-(1-(6-Chloro-1H-imidazo[4,5-b]pyridin-2-yl)propyl)cyclohexyl)-6-(trifluoromethyl)quinoline",CHEMBL4725203,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9,IC50,=,242.0,nM,CCC(c1nc2ncc(Cl)cc2[nH]1)[C@H]1CC[C@@H](c2ccnc3ccc(C(F)(F)F)cc32)CC1,CHEMBL4715934,"Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy.",ACS Med Chem Lett,2021.0,12,3.0,494,501,10.1021/acsmedchemlett.1c00014,33738077.0,
22879835,CHEMBL4791225,"(+/-)-trans-N-((-8-Fluoro-1-oxo-7-thiomorpholino-3a,4-dihydro-1H,3H-benzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl)methyl)acetamide",CHEMBL4726706,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 20 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,CC(=O)NC[C@@H]1OC(=O)N2c3cc(F)c(N4CCSCC4)cc3OC[C@@H]12,CHEMBL4725282,Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis.,J Med Chem,2020.0,63,17,9316,9339,10.1021/acs.jmedchem.0c00500,32666789.0,
22879836,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4726706,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes after 20 mins by LC-MS/MS analysis,IC50,=,770.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4725282,Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis.,J Med Chem,2020.0,63,17,9316,9339,10.1021/acs.jmedchem.0c00500,32666789.0,
22881575,CHEMBL4792347,N-cyclopropyl-4-methyl-3-(3-(2-(2-(2-(methylamino)ethoxy)phenyl)propan-2-ylamino)-2-oxopyrazin-1(2H)-yl)benzamide,CHEMBL4727228,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50118.72,nM,CNCCOc1ccccc1C(C)(C)Nc1nccn(-c2cc(C(=O)NC3CC3)ccc2C)c1=O,CHEMBL4725297,The discovery and evaluation of 3-amino-2(1H)-pyrazinones as a novel series of selective p38α MAP kinase inhibitors.,Bioorg Med Chem Lett,2020.0,30,18,127412,127412,10.1016/j.bmcl.2020.127412,32717614.0,
22888952,CHEMBL4779889,"1-(2-(Azetidin-1-yl)-2-oxoethyl)-3-methyl-6-(5-(trifluoromethyl)thiophen-2-yl)-1,3-dihydro-imidazo[4,5-b]pyridin-2-one",CHEMBL4728839,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate measured after 15 mins by LC-MS/MS analysis,IC50,<,50000.0,nM,Cn1c(=O)n(CC(=O)N2CCC2)c2cc(-c3ccc(C(F)(F)F)s3)cnc21,CHEMBL4725355,"Design, Synthesis, and Preclinical Evaluation of 3-Methyl-6-(5-thiophenyl)-1,3-dihydro-imidazo[4,5-b]pyridin-2-ones as Selective GluN2B Negative Allosteric Modulators for the Treatment of Mood Disorders.",J Med Chem,2020.0,63,17,9181,9196,10.1021/acs.jmedchem.9b02113,32787105.0,
22890541,CHEMBL4745832,"(S)-4,11-Dimethoxy-14-methyl-7,8,13b,14-tetrahydroindolo-[2',3':3,4]pyrido[2,1-b]quinazolin-5(13H)-one",CHEMBL4729285,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,10000.0,nM,COc1ccc2c3c([nH]c2c1)[C@@H]1N(CC3)C(=O)c2c(OC)cccc2N1C,CHEMBL4725363,Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket.,J Med Chem,2020.0,63,17,9828,9837,10.1021/acs.jmedchem.0c00983,32794708.0,
22891045,CHEMBL4764602,"(1r,3r)-1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-7-(3-hydroxycyclobutyl)-4-oxo-quinoline-3-carboxylic acid",CHEMBL4729396,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,41700.0,nM,Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c([C@H]4C[C@H](O)C4)c(Cl)c32)c(F)cc1F,CHEMBL4725368,Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.,Bioorg Med Chem Lett,2020.0,30,20,127428,127428,10.1016/j.bmcl.2020.127428,32799032.0,
22891046,CHEMBL4800257,"(1s,3s)-1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-7-(3-hydroxycyclobutyl)-4-oxo-quinoline-3-carboxylic acid",CHEMBL4729396,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c([C@H]4C[C@@H](O)C4)c(Cl)c32)c(F)cc1F,CHEMBL4725368,Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.,Bioorg Med Chem Lett,2020.0,30,20,127428,127428,10.1016/j.bmcl.2020.127428,32799032.0,
22891047,CHEMBL4746307,"7-(3-aminoazetidin-1-yl)-1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-4-oxo-quinoline-3-carboxylic acid",CHEMBL4729396,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,12700.0,nM,Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(N)C4)c(Cl)c32)c(F)cc1F,CHEMBL4725368,Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.,Bioorg Med Chem Lett,2020.0,30,20,127428,127428,10.1016/j.bmcl.2020.127428,32799032.0,
22891048,CHEMBL8,"1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid",CHEMBL4729396,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,CHEMBL4725368,Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.,Bioorg Med Chem Lett,2020.0,30,20,127428,127428,10.1016/j.bmcl.2020.127428,32799032.0,
22891049,CHEMBL2105637,DELAFLOXACIN,CHEMBL4729396,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,50000.0,nM,Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(O)C4)c(Cl)c32)c(F)cc1F,CHEMBL4725368,Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.,Bioorg Med Chem Lett,2020.0,30,20,127428,127428,10.1016/j.bmcl.2020.127428,32799032.0,
22893247,CHEMBL4764985,"[(2R)-2-({(2R,3S,4R,5R)-5-[6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}-methoxy)-1-hydroxy-3-methoxypropan-2-yl]phosphonic Acid",CHEMBL4730019,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,COC[C@](CO)(OC[C@H]1O[C@@H](n2ncc3c(NC4CCCC4)nc(Cl)nc32)[C@H](O)[C@@H]1O)P(=O)(O)O,CHEMBL4725392,Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production.,J Med Chem,2020.0,63,18,10433,10459,10.1021/acs.jmedchem.0c01086,32865411.0,
22897100,CHEMBL4754834,"(R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one",CHEMBL4730751,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using diclofenac as substrate preincubated for 10 mins followed by substrate and NADPH addition and measured after 10 mins by LC-MS/MS analysis,IC50,=,39600.0,nM,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c(=O)c32)C1,CHEMBL4725429,"Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor.",ACS Med Chem Lett,2020.0,11,10,1863,1868,10.1021/acsmedchemlett.9b00395,33062165.0,
22897101,CHEMBL1873475,SID124898784,CHEMBL4730751,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 using diclofenac as substrate preincubated for 10 mins followed by substrate and NADPH addition and measured after 10 mins by LC-MS/MS analysis,IC50,=,9690.0,nM,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,CHEMBL4725429,"Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor.",ACS Med Chem Lett,2020.0,11,10,1863,1868,10.1021/acsmedchemlett.9b00395,33062165.0,
22898987,CHEMBL388590,benzbromarone,CHEMBL4731282,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,41.0,nM,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,CHEMBL4725450,"Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity.",ACS Med Chem Lett,2020.0,11,10,2017,2023,10.1021/acsmedchemlett.0c00176,33062187.0,
22898988,CHEMBL4740995,"3-(3-Cyano-5-cyclopropyl-4-hydroxy-benzoyl)-1,1-dioxo-1,2-dihydro-3H-1,3-benzothiazole",CHEMBL4731282,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,57000.0,nM,N#Cc1cc(C(=O)N2CS(=O)(=O)c3ccccc32)cc(C2CC2)c1O,CHEMBL4725450,"Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity.",ACS Med Chem Lett,2020.0,11,10,2017,2023,10.1021/acsmedchemlett.0c00176,33062187.0,
22899581,CHEMBL4743180,(R)-N-((R)-6-amino-1-(4-(3-methylureido)piperidin-1-yl)-1-oxohexan-2-yl)-4-methyl-2-((R)-3-phenyl-2-(2-(((R)-2-phenylpropyl)amino)acetamido)propanamido)pentanamide,CHEMBL4731394,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human pooled liver microsomes using tolbutamide as substrate measured up to 20 mins by UHPLC-MS/MS analysis,IC50,>,30000.0,nM,CNC(=O)NC1CCN(C(=O)[C@@H](CCCCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)CNC[C@H](C)c2ccccc2)CC1,CHEMBL4725465,"Discovery of SHR0687, a Highly Potent and Peripheral Nervous System-Restricted KOR Agonist.",ACS Med Chem Lett,2020.0,11,11,2151,2155,10.1021/acsmedchemlett.0c00287,33214823.0,
22900686,CHEMBL4779873,"2-[(1S)-1-Cyclopropylethyl]-7-methyl-5-[3-(pyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,3-dihydro-1H-isoindol-1-one",CHEMBL4731661,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac as substrate measured after 5 to 20 mins in presence of NADPH by LC-MS/MS analysis,IC50,=,300.0,nM,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3Kγ Inhibitors.,ACS Med Chem Lett,2020.0,11,11,2244,2252,10.1021/acsmedchemlett.0c00387,33214836.0,
22920162,CHEMBL4784911,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(methyl-d3)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide-3,3-d2 methanesulfonate",CHEMBL4736471,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins in presence of NADPH generating system followed by substrate addition and measured after 10 mins by LC-MS/MS analysis,IC50,>,50000.0,nM,CS(=O)(=O)O.[2H]C([2H])=CC(=O)Nc1cc(Nc2nccc(-c3cn(C([2H])([2H])[2H])c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4732150,"Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer.",J Med Chem,2021.0,64,2.0,925,937,10.1021/acs.jmedchem.0c02005,33459024.0,
22923698,CHEMBL3985699,"US9150546, I-364",CHEMBL4737220,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,CC(C)Oc1ccc(Nc2nc(=O)n(CC(C)(C)C(=O)O)c(=O)n2Cc2ccc(Cl)cc2)cc1F,CHEMBL4732178,Dioxotriazine derivatives as a new class of P2X receptor antagonists: Identification of a lead and initial SAR studies.,Bioorg Med Chem Lett,2021.0,37,,127833,127833,10.1016/j.bmcl.2021.127833,33540044.0,
22923699,CHEMBL4748113,"3-(4-(3-chloro-4-isopropoxyphenylamino)-5-(4-methylbenzyl)-2,6-dioxo-5,6-dihydro-1,3,5-triazin-1(2H)-yl)propanoic acid",CHEMBL4737220,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,20000.0,nM,Cc1ccc(Cn2c(Nc3ccc(OC(C)C)c(Cl)c3)nc(=O)n(CCC(=O)O)c2=O)cc1,CHEMBL4732178,Dioxotriazine derivatives as a new class of P2X receptor antagonists: Identification of a lead and initial SAR studies.,Bioorg Med Chem Lett,2021.0,37,,127833,127833,10.1016/j.bmcl.2021.127833,33540044.0,
22926901,CHEMBL4777349,"8-(3-(Benzofuran-2-yl)-5-chloropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",CHEMBL4737756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide 4-hydroxylation as substrate by LC-MS/MS analysis,IC50,>,25000.0,nM,O=C1NCCC12CCN(c1c(Cl)cncc1-c1cc3ccccc3o1)CC2,CHEMBL4732199,"Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.",Eur J Med Chem,2021.0,214,,113248,113248,10.1016/j.ejmech.2021.113248,33571827.0,
22926902,CHEMBL4791586,"8-(3-(Benzo[b]thiophen-2-yl)-5-chloropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",CHEMBL4737756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide 4-hydroxylation as substrate by LC-MS/MS analysis,IC50,>,25000.0,nM,O=C1NCCC12CCN(c1c(Cl)cncc1-c1cc3ccccc3s1)CC2,CHEMBL4732199,"Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.",Eur J Med Chem,2021.0,214,,113248,113248,10.1016/j.ejmech.2021.113248,33571827.0,
22934391,CHEMBL388590,benzbromarone,CHEMBL4739222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,41.0,nM,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,CHEMBL4732254,Novel monocyclic amide-linked phenol derivatives without mitochondrial toxicity have potent uric acid-lowering activity.,Bioorg Med Chem Lett,2021.0,40,,127900,127900,10.1016/j.bmcl.2021.127900,33684442.0,
22934392,CHEMBL4744272,"5-(2,5-dihydro-1H-pyrrole-1-carbonyl)-2-hydroxy-3-(trifluoromethyl)benzonitrile",CHEMBL4739222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,52000.0,nM,N#Cc1cc(C(=O)N2CC=CC2)cc(C(F)(F)F)c1O,CHEMBL4732254,Novel monocyclic amide-linked phenol derivatives without mitochondrial toxicity have potent uric acid-lowering activity.,Bioorg Med Chem Lett,2021.0,40,,127900,127900,10.1016/j.bmcl.2021.127900,33684442.0,
22934393,CHEMBL4751546,"2-hydroxy-5-(3-methyl-2,5-dihydro-1H-pyrrole-1-carbonyl)-3-(trifluoromethyl)benzonitrile",CHEMBL4739222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,94000.0,nM,CC1=CCN(C(=O)c2cc(C#N)c(O)c(C(F)(F)F)c2)C1,CHEMBL4732254,Novel monocyclic amide-linked phenol derivatives without mitochondrial toxicity have potent uric acid-lowering activity.,Bioorg Med Chem Lett,2021.0,40,,127900,127900,10.1016/j.bmcl.2021.127900,33684442.0,
22934394,CHEMBL4794079,2-hydroxy-5-(thiazolidine-3-carbonyl)-3-(trifluoromethyl)benzonitrile,CHEMBL4739222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,100000.0,nM,N#Cc1cc(C(=O)N2CCSC2)cc(C(F)(F)F)c1O,CHEMBL4732254,Novel monocyclic amide-linked phenol derivatives without mitochondrial toxicity have potent uric acid-lowering activity.,Bioorg Med Chem Lett,2021.0,40,,127900,127900,10.1016/j.bmcl.2021.127900,33684442.0,
22934395,CHEMBL4594446,DOTINURAD,CHEMBL4739222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,5700.0,nM,O=C(c1cc(Cl)c(O)c(Cl)c1)N1CS(=O)(=O)c2ccccc21,CHEMBL4732254,Novel monocyclic amide-linked phenol derivatives without mitochondrial toxicity have potent uric acid-lowering activity.,Bioorg Med Chem Lett,2021.0,40,,127900,127900,10.1016/j.bmcl.2021.127900,33684442.0,
22934680,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4739296,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,630.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4732257,The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition.,Bioorg Med Chem Lett,2021.0,40,,127924,127924,10.1016/j.bmcl.2021.127924,33705901.0,
22934681,CHEMBL4778117,4-amino-N-(1-(4-methoxyphenyl)-1H-pyrazol-5-yl)benzenesulfonamide,CHEMBL4739296,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,11500.0,nM,COc1ccc(-n2nccc2NS(=O)(=O)c2ccc(N)cc2)cc1,CHEMBL4732257,The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition.,Bioorg Med Chem Lett,2021.0,40,,127924,127924,10.1016/j.bmcl.2021.127924,33705901.0,
22950020,CHEMBL3707392,ELECLAZINE,CHEMBL4765963,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,10000.0,nM,O=C1c2cc(-c3ccc(OC(F)(F)F)cc3)ccc2OCCN1Cc1ncccn1,CHEMBL4765231,"Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late Ii), a Phase II Agent with Demonstrated Preclinical Anti-Ischemic and Antiarrhythmic Properties.",J Med Chem,2016.0,59,19.0,9005,9017,10.1021/acs.jmedchem.6b00939,27690427.0,
22951592,CHEMBL4783524,N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide,CHEMBL4766458,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,60000.0,nM,COc1ccc(C(NC(=O)c2cnc(-c3cccnn3)nc2O)c2ccc(OC)cc2)cc1,CHEMBL4765235,"Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.",J Med Chem,2016.0,59,24.0,11039,11049,10.1021/acs.jmedchem.6b01242,28002958.0,
22953962,CHEMBL4649457,"[(1R,3S)-1-amino-3-[(2S)-2-[2-(2-methoxyphenyl)ethyl]tetralin-6-yl]cyclopentyl]methanol",CHEMBL4767252,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,14000.0,nM,COc1ccccc1CC[C@@H]1CCc2cc([C@H]3CC[C@](N)(CO)C3)ccc2C1,CHEMBL4765241,"Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P) Modulator Advanced into Clinical Trials.",J Med Chem,2019.0,62,5.0,2265,2285,10.1021/acs.jmedchem.8b01695,30785748.0,
22971656,CHEMBL4797998,N-(2-(dimethylamino)ethyl)-6-methoxybenzofuran-2-carboxamide methanesulfonate,CHEMBL4770838,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 5 mins followed by NADPH addition and measured after 20 mins by LC-MS/MS analysis,IC50,>,10000.0,nM,COc1ccc2cc(C(=O)NCCN(C)C)oc2c1.CS(=O)(=O)O,CHEMBL4765342,"Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.",Eur J Med Chem,2020.0,200,,112465,112465,10.1016/j.ejmech.2020.112465,32480301.0,
22971657,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4770838,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate incubated for 5 mins followed by NADPH addition and measured after 20 mins by LC-MS/MS analysis,IC50,=,893.0,nM,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4765342,"Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.",Eur J Med Chem,2020.0,200,,112465,112465,10.1016/j.ejmech.2020.112465,32480301.0,
22992075,CHEMBL4785484,"(S)-3-(1-((2-Amino-6,8-difluoroquinolin-3-yl)oxy)ethyl)-4-(1H-pyrazol-1-yl)benzoic acid",CHEMBL4775404,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,20600.0,nM,C[C@H](Oc1cc2cc(F)cc(F)c2nc1N)c1cc(C(=O)O)ccc1-n1cccn1,CHEMBL4765473,PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.,J Med Chem,2021.0,64,1.0,326,342,10.1021/acs.jmedchem.0c01518,33356244.0,
22992076,CHEMBL4650304,PF-07059013,CHEMBL4775404,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,=,24900.0,nM,C[C@H](Oc1cc2cc(F)ccc2nc1N)c1[nH]c(=O)ccc1-n1cccn1,CHEMBL4765473,PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.,J Med Chem,2021.0,64,1.0,326,342,10.1021/acs.jmedchem.0c01518,33356244.0,
22992626,CHEMBL4789639,6-(cyclopropanecarbonylamino)-4-[3-(5-fluoropyrimidin-2-yl)-2-methoxy-anilino]-N-(trideuteriomethyl)pyridine-3-carboxamide,CHEMBL4775577,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),IC50,>,40000.0,nM,[2H]C([2H])([2H])NC(=O)c1cnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncc(F)cn2)c1OC,CHEMBL4765480,Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2.,J Med Chem,2021.0,64,1.0,677,694,10.1021/acs.jmedchem.0c01698,33370104.0,
